{
  "responseHeader":{
    "status":0,
    "QTime":254,
    "params":{
      "q":"(Doc_abstract: head and neck squamous cell carcinoma OR HNSCC OR Doc_title: head and neck squamous cell carcinoma OR HNSCC) AND (Doc_abstract: CDKN2A OR \"ARF\" OR \"MLM\" OR \"P14\" OR \"P16\" OR \"P19\" OR \"CMM2\" OR \"INK4\" OR \"MTS1\" OR \"TP16\" OR \"CDK4I\" OR \"CDKN2\" OR \"INK4A\" OR \"MTS-1\" OR \"P14ARF\" OR \"P19ARF\" OR \"P16INK4\" OR \"P16INK4A\" OR \"P16-INK4A\" OR Doc_title: CDKN2A OR \"ARF\" OR \"MLM\" OR \"P14\" OR \"P16\" OR \"P19\" OR \"CMM2\" OR \"INK4\" OR \"MTS1\" OR \"TP16\" OR \"CDK4I\" OR \"CDKN2\" OR \"INK4A\" OR \"MTS-1\" OR \"P14ARF\" OR \"P19ARF\" OR \"P16INK4\" OR \"P16INK4A\" OR \"P16-INK4A\")"}},
  "response":{"numFound":13126,"start":0,"docs":[
      {
        "Doc_abstract":"The INK4a-ARF (CDKN2A) locus, located on chromosome 9p21, encodes two functionally distinct tumor suppressor genes, p14(ARF) and p16(INK4a), that play active roles in the p53 and Rb tumor suppressive pathways, respectively. We analyzed the alterations of p14(ARF), p16(INK4a) and p53 to study the contribution of each pathway in tumorigenesis of 29 patients with primary and consecutive (second primary) squamous cell carcinoma of the head and neck (HNSCC), with a total of 68 carcinomas.;After microdissection, the DNA of 29 primary and 39 consecutive squamous cell carcinomas was analyzed for INK4a-ARF inactivation and p53 mutation by means of DNA sequence analysis, methylation-specific polymerase chain reaction (MSP), restriction-enzyme-related polymerase chain reaction (RE-PCR), multiplex RT-PCR and immunohistochemistry. In addition, microdeletions of p14(ARF) and p16(INK4a) were assessed using differential PCR.;Altogether inactivation (methylation, loss of heterozygosity and mutation of exon 1beta) of p14(ARF) was found in 29 of all 68 (43%) carcinomas, with a significant difference in primary [8 of 29 (28%)] relative to second primary carcinomas [21 of 39 (54%)]. Methylation of p16(INK4a) occurred in 22 of 68 (32%) carcinomas with an even distribution among primary and consecutive tumors. Only two (secondary) carcinomas showed simultaneous promoter methylation of p14(ARF) and p16 (INK4a). Mutations of p53 were found in 32 of 68 HNSCCs (44%), evenly distributed among primary and recurrent carcinomas. p14(ARF) alterations showed no relationship to p53 mutations.;Our data indicate that the INK4a-ARF-/p53 pathway was disrupted in 58 of 68 (84%) primary and recurrent tumors, either by p53 mutations or by INK4a-ARF inactivation. p14(ARF) methylation occurred independently of p16(INK4a) alterations and showed no correlation to p53 mutations. The significantly higher rate of p14(ARF) alterations in recurrent (respective second primary) carcinomas suggests a further acquired genetic aberration during the development of the recurrent carcinomas.",
        "Doc_title":"INK4a-ARF alterations and p53 mutations in primary and consecutive squamous cell carcinoma of the head and neck.",
        "Journal":"Virchows Archiv : an international journal of pathology",
        "Do_id":"12189502",
        "Doc_ChemicalList":"Biomarkers, Tumor;Cyclin-Dependent Kinase Inhibitor p16;DNA Primers;DNA, Neoplasm;RNA, Messenger;RNA, Neoplasm;Tumor Suppressor Protein p14ARF",
        "Doc_meshdescriptors":"Biomarkers, Tumor;Carcinoma, Squamous Cell;Cyclin-Dependent Kinase Inhibitor p16;DNA Methylation;DNA Primers;DNA, Neoplasm;Genes, p53;Head and Neck Neoplasms;Humans;Immunohistochemistry;Mutation;Neoplasm Recurrence, Local;Neoplasms, Second Primary;RNA, Messenger;RNA, Neoplasm;Reverse Transcriptase Polymerase Chain Reaction;Tumor Suppressor Protein p14ARF",
        "Doc_meshqualifiers":"analysis;chemistry;genetics;secondary;analysis;genetics;chemistry;analysis;chemistry;genetics;pathology;chemistry;genetics;pathology;analysis;analysis;analysis;genetics",
        "_version_":1605852094702551040},
      {
        "Doc_abstract":"To understand the association of candidate tumour suppressor genes SH3GL2, p16(INK4a), p14(ARF), and p15(INK4b) in the pathogenesis of head and neck squamous cell carcinoma (HNSCC), we studied the deletion, mutation, and methylation of these genes in 61 dysplastic lesions and 94 HNSCC samples. In mild dysplasia, SH3GL2, p16(INK4a), and p14(ARF) showed a higher frequency of overall alterations (60-70%) than in p15(INK4b) (40%). However, in subsequent stages of tumour progression, the alteration frequency of these genes did not change significantly. One novel mutation in common exon 2 of p16(INK4a)/p14(ARF) and three in exon 9 of SH3GL2 were seen. Concordance was seen in the expression of these genes with their molecular alterations. Deletions of INK4A-ARF and p15(INK4b) have a significant poor patient outcome. The alterations of p16(INK4a), p14(ARF), and p15(INK4b) were positively correlated with tobacco and inversely with HPV, while SH3GL2 alterations were independent of these factors. Based on aetiological factors, four tumour subtypes were recognized: HPV(-)tobacco(-) (I), HPV(+)tobacco(-) (II), HPV(-)tobacco(+) (III), and HPV(+)tobacco(+) (IV). Groups III and IV showed a high frequency of p16(INK4a)/p14(ARF)/p15(INK4b) alterations with significant poor patient outcome in comparison to group II. Our findings suggest that deregulation of SH3GL2-associated signalling and p16(INK4a)/p14(ARF)/p15(INK4b)-mediated G1-S/G2-M checkpoints of cell cycle are independent pathways for the development of early dysplastic lesions of the head and neck.",
        "Doc_title":"SH3GL2 and CDKN2A/2B loci are independently altered in early dysplastic lesions of head and neck: correlation with HPV infection and tobacco habit.",
        "Journal":"The Journal of pathology",
        "Do_id":"19023882",
        "Doc_ChemicalList":"Adaptor Proteins, Signal Transducing;Cyclin-Dependent Kinase Inhibitor p15;RNA, Messenger;SH3GL2 protein, human",
        "Doc_meshdescriptors":"Adaptor Proteins, Signal Transducing;Carcinoma, Squamous Cell;Cell Line, Tumor;Cyclin-Dependent Kinase Inhibitor p15;DNA Mutational Analysis;Gene Expression Regulation, Neoplastic;Genes, p16;Head and Neck Neoplasms;Human papillomavirus 16;Human papillomavirus 18;Humans;Papillomavirus Infections;Precancerous Conditions;RNA, Messenger;Smoking;Survival Rate",
        "Doc_meshqualifiers":"analysis;genetics;genetics;pathology;virology;genetics;genetics;pathology;virology;complications;metabolism;pathology;virology;analysis;adverse effects",
        "_version_":1605752323342073856},
      {
        "Doc_abstract":"p16(INK4a) immunohistochemical overexpression is an overall reliable surrogate marker of human papillomavirus (HPV)-associated head and neck squamous cell carcinomas (HNSCC). However, cases of ambiguous p16(INK4a) overexpression are regularly detected in the head and neck: p16(INK4a) expression can be observed in non-malignant tissue, such as tonsillar crypt epithelium and a proportion of branchial cleft cysts. Additionally, diverse patterns of p16(INK4) expression can complicate interpretation of \"p16(INK4a) -positivity\". These aspects impede the unrestricted application of p16(INK4a) as a diagnostic marker in the head and neck. We hypothesized that combined detection of p16(INK4a) and the proliferation marker Ki-67 could support clarification of ambiguous p16(INK4a) expression in the head and neck by specifically indicating p16(INK4a) -expressing cells with proliferative activity. p16(INK4a) /Ki-67 co-expression in a combined staining procedure was correlated to distinct p16(INK4a) expression patterns and HPV status (HPV DNA followed by E6*I oncogene mRNA detection) in 147 HNSCC and 50 non-malignant head and neck samples. p16(INK4a) /Ki-67 co-expression only occurred in transformed cells of the head and neck. Co-expression was never detected in non-transformed cells. Combined p16(INK4a) /Ki-67 expression was stringently associated with a diffuse p16(INK4a) expression pattern. All HPV oncogene-expressing HNSCC showed p16(INK4a) /Ki-67 co-expression. We demonstrate that p16(INK4a) /Ki-67 co-expression occurs exclusively in transformed cells of the head and neck. Our findings indicate a substantial impact of combined p16(INK4a) /Ki-67 expression in the assessment of ambiguous p16(INK4a) expression in the head and neck by specifically identifying p16(INK4a) -expressing cells with proliferative activity. This property will be of considerable significance for head and neck histo- and cytopathology. ",
        "Doc_title":"p16(INK4a) /Ki-67 co-expression specifically identifies transformed cells in the head and neck region.",
        "Journal":"International journal of cancer",
        "Do_id":"25104331",
        "Doc_ChemicalList":"Biomarkers, Tumor;Cyclin-Dependent Kinase Inhibitor p16;DNA, Viral;E6 protein, Human papillomavirus type 16;Ki-67 Antigen;Oncogene Proteins, Viral;Repressor Proteins",
        "Doc_meshdescriptors":"Biomarkers, Tumor;Carcinoma, Squamous Cell;Cell Line, Transformed;Cyclin-Dependent Kinase Inhibitor p16;DNA, Viral;Gene Expression;Head and Neck Neoplasms;Humans;Immunohistochemistry;Ki-67 Antigen;Oncogene Proteins, Viral;Papillomaviridae;Papillomavirus Infections;Repressor Proteins",
        "Doc_meshqualifiers":"genetics;diagnosis;genetics;virology;genetics;metabolism;genetics;diagnosis;genetics;virology;genetics;metabolism;genetics;metabolism;genetics;complications;genetics;metabolism",
        "_version_":1605747546757529602},
      {
        "Doc_abstract":"A number of genetic aberrations have been reported in end-stage squamous cell carcinoma of the head and neck, including p16(INK4a) and p14(ARF) (INK4a/ARF) inactivation rates of 70-85%. Still, the cell cycle-regulatory genes p16(INK4a) and p14(ARF) remain poorly understood in oral cavity premalignant lesions. This study evaluated INK4a/ARF locus alterations in 26 patients (28 samples) deemed to be at increased risk for malignant transformation to squamous cell carcinoma due to the diagnosis of severe oral epithelial dysplasia. Microscopically confirmed dysplastic oral epithelium and matching normal tissue were laser capture-microdissected from paraffin sections, DNA was isolated, and molecular techniques were used to evaluate p16(INK4a) and p14(ARF) gene deletion, mutation, loss of heterozygosity (LOH), and hypermethylation events. Deletion of exon 1beta, 1alpha, or 2 was detected in 3.8%, 11.5%, and 7.7% of patients, respectively. INK4a and ARF mutations were detected in 15.4% and 11.5% of patients with severe dysplasia of the oral epithelium. All identified mutations occurred in the INK4a/ARF conserved exon 2. Allelic imbalance was assessed using three markers previously reported to show high LOH rates in head and neck tumors. LOH was found in 42.1%, 35.0%, and 82.4% of patients for the markers IFNalpha, D9S1748, and D9S171, respectively. Hypermethylation of p16(INK4a) and p14(ARF) was detected in 57.7% and 3.8% of patients, respectively, using nested, two-stage methylation-specific PCR. The highest rates of p16(INK4a) hypermethylation occurred in lesions of the tongue and floor of the mouth. In addition, p16(INK4a) hypermethylation was significantly linked to LOH in two or more markers. These data support that INK4a/ARF locus alterations are frequent events preceding the development of oral cancer and that p16(INK4a) inactivation occurs to a greater extent in oral dysplasia than does p14(ARF) inactivation.",
        "Doc_title":"Alterations of p16(INK4a) and p14(ARF) in patients with severe oral epithelial dysplasia.",
        "Journal":"Cancer research",
        "Do_id":"12234999",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;Tumor Suppressor Protein p14ARF",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Allelic Imbalance;Biopsy;Chromosomes, Human, Pair 9;Cyclin-Dependent Kinase Inhibitor p16;DNA Methylation;DNA Mutational Analysis;Female;Gene Deletion;Gene Silencing;Humans;Loss of Heterozygosity;Male;Middle Aged;Mouth Mucosa;Mouth Neoplasms;Precancerous Conditions;Tumor Suppressor Protein p14ARF",
        "Doc_meshqualifiers":"genetics;pathology;genetics;pathology;genetics;pathology;genetics",
        "_version_":1605752733348921344},
      {
        "Doc_abstract":"The INK4a gene locus on chromosome 9p21 encodes two proteins, p16(INK4a) and p14(ARF), which influence cell cycle control regulated by pRb and p53. The objective of this study was to use different methods for the analysis of the incidence of changes at the INK4a locus in head and neck cancer (HNSCC). Primary tumours were analysed for allelic imbalances (AI) with microsatellite markers for chromosome 9, by immunohistochemistry (IHC) and IHC with enhanced sensitivity by tyramide signal amplification (TSA-IHC), and by RT-PCR. No homozygous deletions at 9p21 were detected. AI at 9p21, which was found in approximately 60% of the tumours, completely failed to indicate the functional inactivation of the two INK4a gene products. Immunostaining of normal squamous epithelia revealed very low levels of p16(INK4a), whereas p14(ARF) was readily detectable. In 160 tumours, IHC suggested a loss of p16(INK4a) expression in 90%. However, by TSA-IHC, only 53.7% showed loss of p16(INK4a) expression, and this was consistent with the RT-PCR analyses. In 100 tumours analysed for both proteins, selective loss of p16(INK4a) occurred in 37%; loss of p14(ARF) was found in only 15%, and selective loss in only 4%; 11% of the tumours had lost both proteins. We conclude that only IHC with high sensitivity and the combined expression analysis of mRNAs and proteins is suitable for studying the role of INK4a in HNSCC. The INK4a gene expression defects are frequent but not universal and primarily affect p16(INK4a). Their clinical impact is still not clear.",
        "Doc_title":"Detailed gene expression analysis but not microsatellite marker analysis of 9p21 reveals differential defects in the INK4a gene locus in the majority of head and neck cancers.",
        "Journal":"The Journal of pathology",
        "Do_id":"11439363",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;Genetic Markers;Proteins;Tumor Suppressor Protein p14ARF",
        "Doc_meshdescriptors":"Carcinoma, Squamous Cell;Chromosomes, Human, Pair 9;Cyclin-Dependent Kinase Inhibitor p16;Gene Deletion;Gene Expression;Genetic Markers;Head and Neck Neoplasms;Humans;Hypopharyngeal Neoplasms;Immunohistochemistry;Laryngeal Neoplasms;Mouth Neoplasms;Oropharyngeal Neoplasms;Proteins;Reverse Transcriptase Polymerase Chain Reaction;Tumor Suppressor Protein p14ARF",
        "Doc_meshqualifiers":"genetics;genetics;genetics;genetics;genetics;genetics;genetics;genetics",
        "_version_":1605851681327677440},
      {
        "Doc_abstract":"The CDKN2A locus encodes two tumor suppressor proteins, p16(ink4) and p14(arf), through use of alternative first exons. CDKN2A mutations detected in melanoma families are usually missense or nonsense changes which mainly impair p16(ink4) function. Large genomic deletions spanning the entire locus have been observed in two pedigrees with melanomas and nervous tumors. We have detected a novel splice site mutation in a family with melanomas, neurofibromas, and multiple dysplastic nevi. Both alternative mRNAs produced by the mutant allele lacked shared sequences from exon 2, which encodes a substantial portion (>50%) of both p16(ink4) and p14(arf) proteins. The development of neurofibromas can be explained by cooperative effects of combined inactivation of p16(ink4) and p14(arf) or, alternatively, of p14(arf) alone.",
        "Doc_title":"CDKN2A germline splicing mutation affecting both p16(ink4) and p14(arf) RNA processing in a melanoma/neurofibroma kindred.",
        "Journal":"Genes, chromosomes & cancer",
        "Do_id":"11433531",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;Proteins;Tumor Suppressor Protein p14ARF",
        "Doc_meshdescriptors":"Adolescent;Adult;Aged;Alternative Splicing;Cyclin-Dependent Kinase Inhibitor p16;Female;Genes, Tumor Suppressor;Genes, p16;Germ-Line Mutation;Humans;Male;Melanoma;Middle Aged;Neurofibroma;Pedigree;Proteins;RNA Processing, Post-Transcriptional;Tumor Suppressor Protein p14ARF",
        "Doc_meshqualifiers":"genetics;genetics;genetics;genetics;genetics;genetics;genetics;genetics;genetics",
        "_version_":1605882782675894272},
      {
        "Doc_abstract":"The INK4a (MTS1, CDKN2) gene encodes an inhibitor (p16INK4a) of the cyclin D-dependent kinases CDK4 and CDK6 that blocks them from phosphorylating the retinoblastoma protein (pRB) and prevents exit from the G1 phase of the cell cycle. Deletions and mutations involving INK4a occur frequently in cancers, implying that p16INK4a, like pRB, suppresses tumor formation. An unrelated protein (p19ARF) arises in major part from an alternative reading frame of the mouse INK4a gene, and its ectopic expression in the nucleus of rodent fibroblasts induces G1 and G2 phase arrest. Economical reutilization of coding sequences in this manner is practically without precedent in mammalian genomes, and the unitary inheritance of p16INK4a and p19ARF may underlie their dual requirement in cell cycle control.",
        "Doc_title":"Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest.",
        "Journal":"Cell",
        "Do_id":"8521522",
        "Doc_ChemicalList":"Carrier Proteins;Cyclin-Dependent Kinase Inhibitor p16;Proteins;RNA, Messenger;Tumor Suppressor Protein p14ARF",
        "Doc_meshdescriptors":"3T3 Cells;Amino Acid Sequence;Animals;Base Sequence;Carrier Proteins;Cell Cycle;Cell Nucleus;Cloning, Molecular;Cyclin-Dependent Kinase Inhibitor p16;Exons;Genes, Tumor Suppressor;Humans;Mice;Molecular Sequence Data;Mutation;Organ Specificity;Protein Biosynthesis;Proteins;RNA, Messenger;Reading Frames;Sequence Homology, Amino Acid;Tumor Suppressor Protein p14ARF",
        "Doc_meshqualifiers":"genetics;genetics;chemistry;genetics;genetics;genetics;analysis;genetics;physiology;analysis;genetics",
        "_version_":1605928363956895744},
      {
        "Doc_abstract":"The INK4a/ARF locus encodes p16INK4a and p14ARF, both of which are crucial for two tumor suppressor pathways, retinoblastoma (RB)/p16INK4a and p53/ARF. Inactivation of RB/p16INK4a was frequently reported, but alterations of the p14ARF gene in hepatocellular carcinoma (HCC) in the Japanese population have been insufficiently analyzed.;To determine the role of p53/ARF alteration in hepatocarcinogenesis, we examined 44 HCCs for mRNA expression, deletion, mutation, and promoter hypermethylation of the p14(ARF) gene; alterations of p53 were also analyzed in the same series of HCCs.;Homozygous deletion, spanning from exon 1 beta to exon 2, was found in 1 HCC mutations within exon 2 were found in 2 HCCs, but no promoter hypermethylation was detected. All 3 HCCs with p14(ARF) alteration were well differentiated. Twelve of the 44 HCCs (27.2%) showed immunohistochemical evidence of p53 alteration; however, only 1 of the tumors with p53 alteration was well differentiated. TaqMan polymarase chain reaction (PCR) indicated that the expression of p14(ARF) in HCCs was higher than in that in all but three of the corresponding non-tumorous tissues ( P < 0.0001), and increased expression of p14(ARF) seemed to be associated with poorly differentiated phenotype. Absence of p14(ARF) expression was seen in only one HCC, with homozygous deletion of the p14(ARF) gene.;Compared with p53 alteration, p14(ARF) alteration does not occur frequently, but may play a role in a subset of Japanese HCCs in the early stage of hepatocarcinogenesis. On the other hand, overexpression of p14(ARF) was frequently observed in HCC, especially in poorly differentiated tumors, probably reflecting oncogenic stimuli in these tumors. The INK4a/ARF locus encodes p16(INK4a) and p14(ARF), both of which are crucial for two tumor suppressor pathways, retinoblastoma (RB)/p16(INK4a) and p53/ARF. Inactivation of RB/p16(INK4a) was frequently reported, but alterations of the p14(ARF) gene in hepatocellular carcinoma (HCC) in the Japanese population have been insufficiently analyzed.",
        "Doc_title":"Alteration of the p14(ARF) gene and p53 status in human hepatocellular carcinomas.",
        "Journal":"Journal of gastroenterology",
        "Do_id":"15168247",
        "Doc_ChemicalList":"Tumor Suppressor Protein p14ARF",
        "Doc_meshdescriptors":"Adult;Aged;Carcinoma, Hepatocellular;Cell Transformation, Neoplastic;Female;Genes, p53;Humans;Liver Neoplasms;Male;Middle Aged;Mutation;Tumor Suppressor Protein p14ARF",
        "Doc_meshqualifiers":"genetics;genetics;genetics;genetics;genetics;genetics",
        "_version_":1605846736373284864},
      {
        "Doc_abstract":"The signal transduction pathway regulated by the retinoblastoma tumor suppressor protein, pRB, is abrogated in the majority of human cancers. Using a series of cell lines derived from oral squamous cell carcinomas (SCCs) that were not subjected to radiation or chemotherapy treatment, we detected specific hyperactivity of cyclin dependent kinase (cdk) 6 but not cdk4. Subcellular localization studies showed a predominant nuclear localization of cdk6, demonstrating that this kinase was biologically active. The molecular basis for this aberration are mutations in the MTS1 locus of chromosome 9p21. This locus encodes two partially overlapping genes, the cdk inhibitor p16(ink4a), and p14(ARF), an inhibitor of mdm2-mediated degradation of p53. Our analysis demonstrates that the mutations of the MTS1 locus in oral SCC specifically target expression of the p16(ink4a) gene but less frequently affect p14(ARF). These results suggest that hyperactivity of cdk6 represents a distinct mechanism for pRB inactivation in oral SCC.",
        "Doc_title":"Aberrations in the MTS1 tumor suppressor locus in oral squamous cell carcinoma lines preferentially affect the INK4A gene and result in increased cdk6 activity.",
        "Journal":"Oral oncology",
        "Do_id":"11854066",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;Neoplasm Proteins;RNA, Messenger;RNA, Neoplasm;Tumor Suppressor Protein p14ARF;Protein-Serine-Threonine Kinases;CDK6 protein, human;Cyclin-Dependent Kinase 6;Cyclin-Dependent Kinases",
        "Doc_meshdescriptors":"Carcinoma, Squamous Cell;Cell Nucleus;Cyclin-Dependent Kinase 6;Cyclin-Dependent Kinase Inhibitor p16;Cyclin-Dependent Kinases;Genes, p16;Humans;Mouth Neoplasms;Mutation;Neoplasm Proteins;Protein-Serine-Threonine Kinases;RNA, Messenger;RNA, Neoplasm;Tumor Cells, Cultured;Tumor Suppressor Protein p14ARF",
        "Doc_meshqualifiers":"genetics;metabolism;metabolism;genetics;metabolism;genetics;metabolism;metabolism;metabolism;genetics;genetics;genetics;metabolism",
        "_version_":1605790088039497728},
      {
        "Doc_abstract":"The pathophysiology underlying the chromosome (Chr) 9p21 locus of atherosclerosis susceptibility is presently unknown. Here, we sought to determine whether protein coding genes in the Chr9p21 region, i.e. cyclin-dependent kinase inhibitors CDKN2B (p15(INK4b)), CDKN2A (p16(INK4a), p14(ARF)) and methylthioadenosine phosphorylase (MTAP) were expressed in human atherosclerotic lesions and whether expression was correlated with lesion composition.;Protein expression of p15(INK4b), p16(INK4a), p14(ARF) and MTAP was demonstrated by immunostaining in normal and atherosclerotic coronary arteries and co-localized with CD68 and smooth muscle alpha-actin positive cells. Quantitative RT-PCR in human endarteryectomy specimens (n = 57) revealed increased p16(INK4a) and decreased MTAP expression in macrophage-rich lesions (P<0.001 and P = 0.007, respectively). Functional studies suggest that decreased MTAP expression in macrophage-rich lesions might be mediated through down-regulation by TNF-alpha. No clear association of p15(INK4b), p16(INK4a), p14(ARF), and MTAP expression in plaque tissue with Chr9p21 haplotypes was found. The latter finding was corroborated by the lack of correlation of RNA expression of 9p21-regulated transcripts EU741058 and NR_003529 of antisense non-coding RNA in the INK4 locus (ANRIL) with mRNA expression of these genes. In contrast, ANRIL DQ485454 which is not genetically determined by the 9p21 genotype was significantly correlated with MTAP expression (P = 0.01).;CDKN2B (p15(INK4b)), CDKN2A (p16(INK4a), p14(ARF)), and MTAP are abundantly expressed in atherosclerotic lesions. While expression levels showed no clear association with Chr9p21 genotype, association of high p16(INK4a) and low MTAP expression with a less stable plaque phenotype suggests a more general role of these proteins in atherogenesis.",
        "Doc_title":"Expression of Chr9p21 genes CDKN2B (p15(INK4b)), CDKN2A (p16(INK4a), p14(ARF)) and MTAP in human atherosclerotic plaque.",
        "Journal":"Atherosclerosis",
        "Do_id":"20637465",
        "Doc_ChemicalList":"Actins;Antigens, CD;Antigens, Differentiation, Myelomonocytic;CD68 antigen, human;CDKN2B protein, human;Cyclin-Dependent Kinase Inhibitor p15;Cyclin-Dependent Kinase Inhibitor p16;RNA, Messenger;Tumor Necrosis Factor-alpha;Tumor Suppressor Protein p14ARF;Purine-Nucleoside Phosphorylase;5'-methylthioadenosine phosphorylase",
        "Doc_meshdescriptors":"Actins;Antigens, CD;Antigens, Differentiation, Myelomonocytic;Autopsy;Chromosomes, Human, Pair 9;Coronary Artery Disease;Cyclin-Dependent Kinase Inhibitor p15;Cyclin-Dependent Kinase Inhibitor p16;Endarterectomy;Genetic Predisposition to Disease;HEK293 Cells;Haplotypes;Humans;Immunohistochemistry;Macrophages;Phenotype;Purine-Nucleoside Phosphorylase;RNA, Messenger;Reverse Transcriptase Polymerase Chain Reaction;Tumor Necrosis Factor-alpha;Tumor Suppressor Protein p14ARF",
        "Doc_meshqualifiers":"analysis;analysis;analysis;enzymology;genetics;pathology;surgery;analysis;genetics;analysis;genetics;chemistry;analysis;genetics;analysis;analysis;analysis;genetics",
        "_version_":1605876000222085120},
      {
        "Doc_abstract":"The p16(INK4a) and p14(ARF) tumor suppressor genes (TSGs) are encoded within the CDKN2A locus on chromosome 9p21 and function as cell cycle regulatory proteins in the p53 and RB pathways. Inactivation of these genes by genetic and epigenetic changes has been described in some human cancers, but their importance in cutaneous squamous cell carcinoma (SCC) has not been established. Our detailed examination of 40 cutaneous SCC revealed loss of heterozygosity of 9p21 markers in 32.5% of cases. Mutational analysis confirmed five point mutations in four of 40 SCCs. These mutations changed the amino acid sequence of p16(INK4a) in four tumors and p14(ARF) in three tumors. Promoter methylation of p16(INK4a) and p14(ARF) was detected in 13 of 36 (36%) and 16 of 38 (42%) cases, respectively. Absent protein expression was confirmed by immunohistochemistry in 13 of 16 (82%) of the tumors with biallelic inactivating events. Overall, the frequency of 9p21 alterations was 76% and for both p16(INK4a) and p14(ARF), promoter methylation is the commonest mechanism of gene inactivation. Alterations at this locus were significantly more common in tumors from immunocompetent compared with immunosuppressed individuals. These data confirm the importance of inactivation of p16(INK4a) and p14(ARF) TSGs in the pathogenesis of cutaneous SCCs.",
        "Doc_title":"p16INK4a and p14ARF tumor suppressor genes are commonly inactivated in cutaneous squamous cell carcinoma.",
        "Journal":"The Journal of investigative dermatology",
        "Do_id":"15140233",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;Tumor Suppressor Protein p14ARF",
        "Doc_meshdescriptors":"Carcinoma, Squamous Cell;Cyclin-Dependent Kinase Inhibitor p16;DNA Methylation;Female;Gene Expression Regulation, Neoplastic;Gene Silencing;Humans;Immunohistochemistry;Loss of Heterozygosity;Male;Point Mutation;Skin Neoplasms;Tumor Suppressor Protein p14ARF",
        "Doc_meshqualifiers":"genetics;immunology;physiopathology;genetics;metabolism;genetics;immunology;physiopathology;genetics;metabolism",
        "_version_":1605837114005520384},
      {
        "Doc_abstract":"The INK4a-ARF (CDKN2A) locus on chromosome 9p21 encodes two tumour suppressor proteins, p16(INK4a) and p14(ARF), whose functions are inactivated in many human cancers.;To evaluate p14(ARF) and p16(INK4a) alterations in liver cell adenoma.;After microdissection, DNA from 25 liver cell adenomas and corresponding normal liver tissue were analysed for INK4-ARF inactivation by DNA sequence analysis, methylation specific polymerase chain reaction, restriction enzyme related-polymerase chain reaction (RE-PCR), mRNA expression, microsatellite analysis, and immunohistochemistry. In addition, microdeletion of p14(ARF) and p16(INK4a) were assessed by differential PCR.;Methylation of p14(ARF) was found in 3/25 cases (12%) and alterations in p16(INK4a) occurred in 6/25 liver cell adenomas (24%) which correlated with loss of mRNA transcription. We failed to detect microdeletions or specific mutations of both exons. p16(INK4a) methylation appeared in the context of an unmethylated p14(ARF) promoter in six cases. In normal liver tissue, p14(ARF) or p16(INK4a) alterations were not observed.;Our data suggest that p14(ARF) methylation occurs independently of p16(INK4a) alterations in liver cell adenomas. Furthermore, methylation of p14(ARF) and p16(INK4a) may be a result of cell cycle deregulation and does not seem to be a prerequisite of malignancy.",
        "Doc_title":"INK4a-ARF alterations in liver cell adenoma.",
        "Journal":"Gut",
        "Do_id":"12117890",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;Helminth Proteins;Muscle Proteins;calponin homolog protein, Schistosoma japonicum",
        "Doc_meshdescriptors":"Adenoma, Liver Cell;Alleles;Cyclin-Dependent Kinase Inhibitor p16;DNA Methylation;Female;Gene Dosage;Genes, p16;Helminth Proteins;Humans;Immunohistochemistry;Liver Neoplasms;Male;Muscle Proteins;Retrospective Studies;Reverse Transcriptase Polymerase Chain Reaction;Sequence Analysis, DNA",
        "Doc_meshqualifiers":"genetics;analysis;analysis;genetics;genetics;analysis;genetics",
        "_version_":1605742748971827201},
      {
        "Doc_abstract":"The INK4A-ARF locus at chromosome 9p21 is frequently altered in head and neck squamous cell carcinoma (SCC) and encodes two distinct tumor suppressors, p16(INK4A) and p14(ARF). This study addressed the role of p14(ARF) as a potential prognostic marker in this disease.;p14(ARF) protein expression was assessed by immunohistochemistry in a cohort of 140 patients with SCC of the anterior tongue. Using univariate and multivariate Cox's proportional hazards models, the outcomes examined were time to disease recurrence or death, with or without clinicopathologic covariates, including nodal status, disease stage, treatment status, Ki-67 staining, and molecular markers with known functional or genetic relationships with p14(ARF) (p16(INK4A), p53, pRb, p21(WAF1/CIP1), E2F-1).;On multivariate analysis, p14(ARF) positivity (nucleolar p14(ARF) staining and/or nuclear p14(ARF) staining in >/=30% of tumor cells) was an independent predictor of improved disease-free survival (DFS; P = 0.002) and overall survival (OS; P = 0.002). This was further enhanced when p14(ARF) positivity was cosegregated with positive (>/=1%) p16(INK4A) staining (DFS, P < 0.001; OS, P < 0.001). Patients whose cancers were p14(ARF) negative and p53 positive (>50%) had the poorest outcome (DFS, P < 0.001; OS, P < 0.001) of any patient subgroup analyzed.;These data show that in patients with SCC of the tongue, combined nuclear and nucleolar expression of p14(ARF) protein predicts for improved DFS and OS independent of established prognostic markers.",
        "Doc_title":"p14ARF protein expression is a predictor of both relapse and survival in squamous cell carcinoma of the anterior tongue.",
        "Journal":"Clinical cancer research : an official journal of the American Association for Cancer Research",
        "Do_id":"15930346",
        "Doc_ChemicalList":"CDKN1A protein, human;Cell Cycle Proteins;Cyclin-Dependent Kinase Inhibitor p16;Cyclin-Dependent Kinase Inhibitor p21;DNA-Binding Proteins;E2F Transcription Factors;E2F1 Transcription Factor;E2F1 protein, human;Ki-67 Antigen;Retinoblastoma Protein;Transcription Factors;Tumor Suppressor Protein p14ARF;Tumor Suppressor Protein p53;Cyclin D1",
        "Doc_meshdescriptors":"Carcinoma, Squamous Cell;Cell Cycle Proteins;Cohort Studies;Cyclin D1;Cyclin-Dependent Kinase Inhibitor p16;Cyclin-Dependent Kinase Inhibitor p21;DNA-Binding Proteins;E2F Transcription Factors;E2F1 Transcription Factor;Humans;Immunohistochemistry;Ki-67 Antigen;Multivariate Analysis;Neoplasm Recurrence, Local;Neoplasm Staging;Predictive Value of Tests;Prognosis;Proportional Hazards Models;Retinoblastoma Protein;Survival Analysis;Tongue Neoplasms;Transcription Factors;Tumor Suppressor Protein p14ARF;Tumor Suppressor Protein p53",
        "Doc_meshqualifiers":"metabolism;pathology;analysis;analysis;biosynthesis;analysis;analysis;analysis;metabolism;pathology;analysis;biosynthesis;analysis",
        "_version_":1605883602104483840},
      {
        "Doc_abstract":"The p14(ARF), p15(INK4B) and p16(INK4A) genes were localized to 9p21, where genetic alterations have been reported frequently in various human tumors. We performed a molecular analysis of the mechanism of inactivation in cell lines and 32 oral squamous cell carcinoma (OSCC), using deletion screening, PCR-SSCP, methylation-specific-PCR and cycle sequencing. We detected homozygous deletion of p14(ARF)-1Ebeta in 9 (26.5%), of p15(INK4B) in one (3.1%), and of p16(INK4A) in 22 (56.3%) tumor samples. Three mutations were detected in the p16(INK4A) genes. We detected aberrant methylation of the p14(ARF) genes in 14 (43.8%), of the p15(INK4B) gene in 9 (28.1%), and of the p16(INK4A) gene in 16 (50.0%) tumor samples. Altogether, 87.5% of the samples harbored at least one of the alterations in the p14(ARF), p15(INK4B), and p16(INK4A) genes, indicating that the frequent inactivation of these genes may be an important mechanism during OSCC development.",
        "Doc_title":"Inactivation of the p14(ARF), p15(INK4B) and p16(INK4A) genes is a frequent event in human oral squamous cell carcinomas.",
        "Journal":"Oral oncology",
        "Do_id":"11435176",
        "Doc_ChemicalList":"CDKN2B protein, human;Carrier Proteins;Cell Cycle Proteins;Cyclin-Dependent Kinase Inhibitor p15;Cyclin-Dependent Kinase Inhibitor p16;Proteins;Tumor Suppressor Protein p14ARF;Tumor Suppressor Proteins",
        "Doc_meshdescriptors":"Carcinoma, Squamous Cell;Carrier Proteins;Cell Cycle Proteins;Cyclin-Dependent Kinase Inhibitor p15;Cyclin-Dependent Kinase Inhibitor p16;DNA Methylation;Gene Deletion;Gene Silencing;Homozygote;Humans;Mouth Neoplasms;Point Mutation;Polymerase Chain Reaction;Proteins;Tumor Cells, Cultured;Tumor Suppressor Protein p14ARF;Tumor Suppressor Proteins",
        "Doc_meshqualifiers":"genetics;genetics;genetics;genetics;genetics",
        "_version_":1605813027742941184},
      {
        "Doc_abstract":"Analysis of the INK4A/ARF locus in human T-ALL patients revealed frequent deletions in exon 2, the exon common to both p16(INK4A) and p14(ARF). Other studies have described selective deletion of exon 1beta of p14(ARF) or methylation of the p16(INK4A) promoter. Therefore, it is unclear from these studies whether loss of p16(INK4A) and/or p14(ARF) contributes to the development of T-ALL. To elucidate the relative contribution of the ink4a/arf locus to T-cell leukemogenesis, we mated our tal1 transgenic mice to ink4a/arf-/-, p16(ink4a)-/-, and p19(arf)-/- mice and generated tal1/ink4a/arf+/-, tal1/p16(ink4a)+/-, and tal1/p19(arf)+/- mice. Each of these mice developed T-cell leukemia rapidly, indicating that loss of either p16(ink4a) or p19(arf) cooperates with Tal1 to induce leukemia in mice. Preleukemic studies reveal that Tal1 expression stimulates entry into the cell cycle and thymocyte apoptosis in vivo. Interestingly, mice expressing a DNA-binding mutant of Tal1 do not exhibit increases in S phase cells. The S phase induction is accompanied by an increase in thymocyte apoptosis in tal1 transgenic mice. Whereas apoptosis is reduced to wild-type levels in tal1/ink4a/arf-/- mice, S phase induction remains unaffected. Thus, Tal1 stimulates cell cycle entry independent of the ink4a/arf locus, but its ability to induce apoptosis is Ink4a/Arf-dependent.",
        "Doc_title":"p16Ink4a or p19Arf loss contributes to Tal1-induced leukemogenesis in mice.",
        "Journal":"Oncogene",
        "Do_id":"16407836",
        "Doc_ChemicalList":"Antigens, CD;Antigens, Neoplasm;Basic Helix-Loop-Helix Transcription Factors;Cdkn2a protein, mouse;Cyclin-Dependent Kinase Inhibitor p16;Glycoproteins;Neoplasm Proteins;Notch1 protein, mouse;Proto-Oncogene Proteins;Receptor, Notch1;Tal1 protein, mouse;Transcription Factors;Tumor Suppressor Protein p14ARF;Wnt Proteins;Wnt5b protein, mouse;DNA",
        "Doc_meshdescriptors":"Animals;Antigens, CD;Antigens, Neoplasm;Apoptosis;Basic Helix-Loop-Helix Transcription Factors;Cell Cycle;Cell Transformation, Neoplastic;Cyclin-Dependent Kinase Inhibitor p16;DNA;Exons;Gene Deletion;Gene Expression Regulation;Gene Expression Regulation, Leukemic;Genes, p16;Glycoproteins;Immunophenotyping;Leukemia-Lymphoma, Adult T-Cell;Mice;Mice, Transgenic;Neoplasm Proteins;Preleukemia;Protein Binding;Protein Structure, Tertiary;Proto-Oncogene Proteins;Receptor, Notch1;S Phase;T-Lymphocyte Subsets;Transcription Factors;Tumor Suppressor Protein p14ARF;Wnt Proteins",
        "Doc_meshqualifiers":"analysis;analysis;genetics;physiology;genetics;genetics;deficiency;physiology;metabolism;genetics;physiology;genetics;genetics;physiology;genetics;metabolism;physiology;physiology;genetics;pathology;physiology;deficiency;genetics;physiology;physiology",
        "_version_":1605752923737817088},
      {
        "Doc_abstract":"The Ink4a/Arf locus encodes two structurally unrelated tumor suppressor proteins, p16(INK4a) and p14(ARF) (murine p19(ARF)). Invariant inactivation of either the p16(INK4a)-cyclin D/CDK-pRb pathway and/or p53-p14(ARF) pathway occurs in most human tumors. Cyclin D1 is frequently overexpressed in breast cancer cells contributing an alternate mechanism inactivating the p16(INK4a)/pRb pathway. Targeted overexpression of cyclin D1 to the mammary gland is sufficient for tumorigenesis, and cyclin D1-/- mice are resistant to Ras-induced mammary tumors. Recent studies suggest cyclin D1 and p16(INK4a) expression are reciprocal in human breast cancers. Herein, reciprocal regulation of cyclin D1 and p16(INK4a) was observed in tissues of mice mutant for the Ink4a/Arf locus. p16(INK4a) and p19(ARF) inhibited DNA synthesis in MCF7 cells. p16(INK4a) repressed cyclin D1 expression and transcription. Repression of cyclin D1 by p16(INK4a) occurred independently of the p16(INK4a)-cdk4-binding function and required a cAMP-response element/activating transcription factor-2-binding site. p19(ARF) repressed cyclin D1 through a novel distal cis-element at -1137, which bound p53 in chromatin-immunoprecipitation assays. Transcriptional repression of the cyclin D1 gene through distinct DNA sequences may contribute to the tumor suppressor function of the Ink4a/Arf locus.",
        "Doc_title":"The inhibitor of cyclin-dependent kinase 4a/alternative reading frame (INK4a/ARF) locus encoded proteins p16INK4a and p19ARF repress cyclin D1 transcription through distinct cis elements.",
        "Journal":"Cancer research",
        "Do_id":"15205322",
        "Doc_ChemicalList":"Cdkn2a protein, mouse;Cyclin-Dependent Kinase Inhibitor p16;DNA, Neoplasm;Repressor Proteins;Tumor Suppressor Protein p14ARF;Cyclin D1",
        "Doc_meshdescriptors":"Animals;Apoptosis;Breast Neoplasms;Cell Line, Tumor;Cyclin D1;Cyclin-Dependent Kinase Inhibitor p16;DNA, Neoplasm;Fibroblasts;Humans;Mice;Mice, Knockout;Promoter Regions, Genetic;Repressor Proteins;Transcription, Genetic;Transfection;Tumor Suppressor Protein p14ARF",
        "Doc_meshqualifiers":"genetics;genetics;metabolism;pathology;biosynthesis;genetics;biosynthesis;genetics;antagonists & inhibitors;biosynthesis;metabolism;biosynthesis;genetics;biosynthesis;genetics",
        "_version_":1605795850612637696},
      {
        "Doc_abstract":"To determine the effects of adenovirus-mediated transfer of p14(ARF) and p16(INK4a) on growth and apoptosis of human pancreatic carcinoma cell lines.;Pancreatic carcinoma cell lines, PC-7, PANC-1 and MIA PaCa-2 (p14(ARF)-/- and p16(INK4a)-/-), were used. PC-7 (p53 wt) and MIA PaCa-2 (p53 mt) cells infected with recombinant adenovirus vector expressing p14(ARF) gene (Adp14) showed significant inhibition of cell growth compared with control vector in vitro and in vivo, whereas PANC-1 cells (p53 mt) did not show such effects. Those three cell lines exhibited growth retardation and senescence phenotype after infected with the adenovirus vector containing p16(INK4a) gene (Adp16) in vivo and in vitro.;Adenovirus-mediated transfer of p14(ARF) and p16(INK4a) produces significant growth suppression of pancreatic carcinoma cells in vitro and in vivo. The effects of Adp14 partly depend on the status of p53 gene in those cells.",
        "Doc_title":"Adenovirus-mediated Ink4a/ARF gene transfer significantly suppressed the growth of pancreatic carcinoma cells.",
        "Journal":"Cancer biology & therapy",
        "Do_id":"16258260",
        "Doc_ChemicalList":"Tumor Suppressor Protein p14ARF",
        "Doc_meshdescriptors":"Adenoviridae;Apoptosis;Carcinoma;Cell Division;Cell Line, Tumor;Gene Transfer Techniques;Genes, p16;Genetic Vectors;Humans;Pancreatic Neoplasms;Transgenes;Tumor Suppressor Protein p14ARF",
        "Doc_meshqualifiers":"genetics;genetics;metabolism;pathology;genetics;metabolism;pathology;metabolism",
        "_version_":1605907569337958400},
      {
        "Doc_abstract":"The INK4a locus encodes two structurally unrelated tumor suppressor proteins, p16(INK4a) and p14(ARF). Although the former is one of the most common targets for inactivation in human neoplasia, the frequency of p14(ARF) abrogation is not established. We have developed an immunohistochemical assay that allows the evaluation of p14(ARF) expression in formalin-fixed, paraffin-embedded tissues, using commercially available antibodies. p14(ARF) positive cells showed nuclear/nucleolar staining, which was absent in all cell lines and tumors with homozygous deletions of the INK4a gene. The assay was applied to 34 paraffin-embedded cell buttons, 30 non-small cell lung cancers and 28 pancreatic carcinomas, and the staining results were correlated with p16(INK4a) expression. Loss of p14(ARF) expression was common but less frequent than down-regulation of p16(INK4a) (53% versus 76% of all specimens). The p14(ARF) and p16(INK4a) expression pattern was concordant in 65 of 92 cases (71%). Significantly, 24 cases were p16(INK4a)-/p14(ARF)+, while the opposite staining pattern was observed in three cases, consistent with the notion that the two proteins have nonredundant functions. The immunohistochemical assay described here may facilitate studies on the prevalence and significance of aberrant p14(ARF) expression in human tumors.",
        "Doc_title":"Immunohistochemical [corrected] detection of the alternate INK4a-encoded tumor suppressor protein p14(ARF) in archival human cancers and cell lines using commercial antibodies: correlation with p16(INK4a) expression.",
        "Journal":"Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc",
        "Do_id":"11706079",
        "Doc_ChemicalList":"DNA, Neoplasm;Tumor Suppressor Protein p14ARF;Tumor Suppressor Proteins",
        "Doc_meshdescriptors":"Adenocarcinoma;DNA, Neoplasm;Gene Deletion;Gene Expression Regulation, Neoplastic;Humans;Immunohistochemistry;Mutation;Neoplasms;Pancreatic Neoplasms;Tumor Cells, Cultured;Tumor Suppressor Protein p14ARF;Tumor Suppressor Proteins",
        "Doc_meshqualifiers":"genetics;metabolism;pathology;genetics;methods;genetics;metabolism;pathology;genetics;metabolism;pathology;analysis;genetics;analysis;genetics",
        "_version_":1605742150699450368},
      {
        "Doc_abstract":"We determined inactivation of the CDKN2A (p16(INK4a) and p14(ARF)) gene in 21 cases of oesophageal squamous cell carcinoma (OSCC). The tumours were also analysed for mutations in exons 5-8 and allelic losses in the p53 gene. In addition, we screened the CDKN2B (p15 INK4b), CDKN2C (p18 INK4c), CDK4 and p53R2 genes for mutations in the tumour tissues. Besides concomitant alterations in the CDKN2A and p53 loci in more than half of the cases, our results showed that in 18 OSCC (86%) the CDKN2A (p16(INK4a) and p14(ARF) ) gene was affected through mutations, homozygous/hemizygous deletions and promoter hypermethylation. Eight out of 10 tumours with mutations or promoter hypermethylation specific to the CDKN2A/p16 INK4a gene showed loss of the wild-type allele. One tumour with a single base deletion in the N-terminus (codon 8) of the CDKN2A/p16(INK4a) gene carried a novel germ-line mutation or a rare polymorphism (Ile51Met) in exon 2 of the CDK4 gene. Promoter hypermethylation in the CDKN2A/p14 ARF gene was detected in 11 tumours. In the p53 gene 15 mutations were detected in 14 tumours. We detected an inverse relationship between CDKN2A/p16 INK4a inactivation and frequency of loss of heterozygosity at the p53 locus (OR 0.09, 95% CI 0.01-0.98; Fisher exact test, P-value approximately 0.03). Screening of nine exons of the p53R2 [Human Genome Organisation (HUGO) official name RRM2B] gene resulted in identification of a novel polymorphism in the 5' untranslated region, which was detected in four cases. Our results suggest that the CDKN2A (p16(INK4a) and p14(ARF) ) and p53 genes involved in the two cell cycle pathways are major and independent targets of inactivation in OSCC.",
        "Doc_title":"Genetic status of cell cycle regulators in squamous cell carcinoma of the oesophagus: the CDKN2A (p16(INK4a) and p14(ARF) ) and p53 genes are major targets for inactivation.",
        "Journal":"Carcinogenesis",
        "Do_id":"11960918",
        "Doc_ChemicalList":"5' Untranslated Regions;Codon;Cyclin-Dependent Kinase Inhibitor p16;Sulfites;Tumor Suppressor Protein p14ARF;Tumor Suppressor Protein p53",
        "Doc_meshdescriptors":"5' Untranslated Regions;Adult;Aged;Aged, 80 and over;Alleles;Carcinoma, Squamous Cell;Cell Cycle;Codon;Cyclin-Dependent Kinase Inhibitor p16;DNA Mutational Analysis;Esophageal Neoplasms;Exons;Gene Deletion;Genes, p53;Homozygote;Humans;Loss of Heterozygosity;Middle Aged;Models, Genetic;Mutation;Polymorphism, Genetic;Promoter Regions, Genetic;Protein Structure, Tertiary;Sequence Analysis, DNA;Sulfites;Tumor Suppressor Protein p14ARF;Tumor Suppressor Protein p53",
        "Doc_meshqualifiers":"enzymology;genetics;biosynthesis;genetics;genetics;metabolism;pharmacology;biosynthesis;genetics;biosynthesis",
        "_version_":1605766038459252736},
      {
        "Doc_abstract":"A locus for familial melanoma, MLM, has been mapped within the same interval on chromosome 9p21 as the gene for a putative cell cycle regulator, p16INK4 (CDKN2) MTS1. This gene is homozygously deleted from many tumour cell lines including melanomas, suggesting that CDKN2 is a good candidate for MLM. We have analysed CDKN2 coding sequences in pedigrees segregating 9p melanoma susceptibility and 38 other melanoma-prone families. In only two families were potential predisposing mutations identified. No evidence was found for heterozygous deletions of CDKN2 in the germline of melanoma-prone individuals. The low frequency of potential predisposing mutations detected suggests that either the majority of mutations fall outside the CDKN2 coding sequence or that CDKN2 is not MLM.",
        "Doc_title":"Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus.",
        "Journal":"Nature genetics",
        "Do_id":"7987388",
        "Doc_ChemicalList":"Carrier Proteins;Cyclin-Dependent Kinase Inhibitor p16",
        "Doc_meshdescriptors":"Base Sequence;Blotting, Southern;Carrier Proteins;Chromosomes, Human, Pair 9;Cyclin-Dependent Kinase Inhibitor p16;Gene Frequency;Germ-Line Mutation;Humans;Melanoma;Molecular Sequence Data;Pedigree;Skin Neoplasms",
        "Doc_meshqualifiers":"genetics;genetics;genetics",
        "_version_":1605831842638856192},
      {
        "Doc_abstract":"The two products of the Ink4a-Arf locus, p16(Ink4a) and p19(Arf) (p14(ARF) in humans), are potent tumor suppressors that regulate the activities of the retinoblastoma protein and the p53 transcription factor. These proteins form part of a signaling network that is disrupted in most, if not all, cancer cells. The Ink4a-Arf locus responds to stress signals, limiting cell proliferation and modulating oncogene-induced apoptosis. Recent evidence emerging from mouse tumor models distinguishes the activities of p16(Ink4a) and p19(Arf) in regulating tumor onset and identifies differences in their responsiveness to drugs.",
        "Doc_title":"Tumor suppression by Ink4a-Arf: progress and puzzles.",
        "Journal":"Current opinion in genetics & development",
        "Do_id":"12573439",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;Retinoblastoma Protein;Tumor Suppressor Protein p53;ADP-Ribosylation Factors",
        "Doc_meshdescriptors":"ADP-Ribosylation Factors;Animals;Cyclin-Dependent Kinase Inhibitor p16;Feedback, Physiological;Humans;Lymphoma;Mice;Neoplasms;Rats;Retinoblastoma Protein;Tumor Suppressor Protein p53",
        "Doc_meshqualifiers":"physiology;physiology;physiology;metabolism;prevention & control;physiology;physiology",
        "_version_":1605929080628183040},
      {
        "Doc_abstract":"Epstein-Barr virus (EBV) nuclear antigen 3C (EBNA3C) and EBNA3A are each essential for EBV conversion of primary human B lymphocytes into continuously proliferating lymphoblast cell lines (LCLs) and for maintaining LCL growth. We now find that EBNA3C and EBNA3A's essential roles are to repress p16(INK4A) and p14(ARF). In the absence of EBNA3C or EBNA3A, p16(INK4A) and p14(ARF) expression increased and cell growth ceased. EBNA3C inactivation did not alter p16(INK4A) promoter CpG methylation, but reduced already low H3K27me3, relative to resting B cells, and increased H3K4me3 and H3-acetylation, linking EBNA3C inactivation to histone modifications associated with increased transcription. Importantly, knockdown of p16(INK4A) or p14(ARF) partially rescued LCLs from EBNA3C or EBNA3A inactivation-induced growth arrest and knockdown of both rescued LCL growth, confirming central roles for p16(INK4A) and p14(ARF) in LCL growth arrest following EBNA3C or EBNA3A inactivation. Moreover, blockade of p16(INK4A) and p14(ARF) effects on pRb and p53 by human papilloma virus type 16 E7 and E6 expression, sustained LCL growth after EBNA3C or EBNA3A inactivation. These data indicate that EBNA3C and EBNA3A joint repression of CDKN2A p16(INK4A) and p14(ARF) is essential for LCL growth.",
        "Doc_title":"Epstein-Barr virus nuclear antigens 3C and 3A maintain lymphoblastoid cell growth by repressing p16INK4A and p14ARF expression.",
        "Journal":"Proceedings of the National Academy of Sciences of the United States of America",
        "Do_id":"21245331",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;Epstein-Barr Virus Nuclear Antigens;Tumor Suppressor Protein p14ARF",
        "Doc_meshdescriptors":"Cell Division;Cell Line;CpG Islands;Cyclin-Dependent Kinase Inhibitor p16;DNA Methylation;Epstein-Barr Virus Nuclear Antigens;Gene Knockdown Techniques;Humans;Promoter Regions, Genetic;Tumor Suppressor Protein p14ARF",
        "Doc_meshqualifiers":"physiology;genetics;physiology;physiology;genetics;physiology",
        "_version_":1605784202288037888},
      {
        "Doc_abstract":"The INK4a-ARF (CDKN2A)- locus on chromosome 9p21 encodes for two tumour suppressor proteins, p16(INK4a) and p14(ARF), that act as upstream regulators of the Rb-CDK4 and p53 pathways. To study the contribution of each pathway in tumorigenesis of hepatocellular carcinoma (HCC), we analysed the alterations of p14(ARF), p16(INC4a) and p53. After microdissection, DNA of 71 hepatocellular carcinomas was analysed for INK4-ARF inactivation and p53 mutation by DNA sequence analysis, methylation-specific PCR (MSP), restriction-enzyme related polymerase chain reaction (RE-PCR), mRNA expression and immunohistochemistry. In addition, microdeletion of p14(ARF) and p16(INC4a) were assessed by differential PCR. Inactivation of p14(ARF) was found in 11/71 cases (15%), alterations of p16(INK4a) occurred in 47/71 carcinomas (66%), which correlated with loss of mRNA transcription. Five tumours (7%) had homozygous deletions of the INK4a-ARF locus. We failed to detect specific mutations of both exons. P16(INK4a) methylation with an unmethylated p14(ARF) promotor appeared in 39 cases. Mutations of p53 were found in 30 of 71 HCC (42%), and only one of them harboured p14(ARF) inactivation. We failed to establish alterations of the INK4a-ARF locus or p53 status as independent prognostic factor in these tumours. Our data indicate, that p14(ARF) methylation occurs independently of p16(INK4a) alterations in a subset of HCC together with wild type p53. The INK4a-ARF-/p53-pathway was disrupted in 86% of HCC, either by p53 mutations or by INK4a-ARF inactivation, and may have co-operative effects in hepatocarcinogenesis.",
        "Doc_title":"INK4a-ARF alterations and p53 mutations in hepatocellular carcinomas.",
        "Journal":"Oncogene",
        "Do_id":"11704835",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;DNA, Neoplasm;RNA, Messenger;RNA, Neoplasm;Tumor Suppressor Protein p14ARF;Tumor Suppressor Protein p53",
        "Doc_meshdescriptors":"Adult;Carcinoma, Hepatocellular;Chromosomes, Human, Pair 9;CpG Islands;Cyclin-Dependent Kinase Inhibitor p16;DNA Methylation;DNA Mutational Analysis;DNA, Neoplasm;Exons;Female;Gene Silencing;Genes, p16;Genes, p53;Humans;Liver Cirrhosis;Liver Neoplasms;Male;Middle Aged;Mutation;Neoplasm Staging;Polymerase Chain Reaction;Polymorphism, Single-Stranded Conformational;Prognosis;Promoter Regions, Genetic;RNA, Messenger;RNA, Neoplasm;Sequence Deletion;Survival Analysis;Tumor Suppressor Protein p14ARF;Tumor Suppressor Protein p53",
        "Doc_meshqualifiers":"complications;genetics;mortality;pathology;genetics;physiology;genetics;genetics;complications;genetics;complications;genetics;mortality;pathology;biosynthesis;biosynthesis;genetics;physiology;physiology",
        "_version_":1605818579417038848},
      {
        "Doc_abstract":"p14(ARF), p15(INK4b), and p16(INK4a) are tumor suppressor genes that are located closely at 9p21 and are often coinactivated by genetic or epigenetic alterations. Malignant peripheral nerve sheath tumor (MPNST) is a rare sarcoma with poor prognosis. However, the prognostic implications of inactivation of p14(ARF), p15(INK4b), and p16(INK4a) in MPNSTs have not been adequately investigated. Here we carried out a genetic, epigenetic, and expression analysis of p14(ARF), p15(INK4b), and p16(INK4a), and clarified the prognostic significance of their inactivation in MPNSTs.;p14(ARF), p15(INK4b), and p16(INK4a) protein expressions were assessed by immunohistochemistry in 129 formalin-fixed samples of MPNST including 85 primary tumors. Thirty-nine samples, for which frozen material was available, were also investigated by Western blotting and quantitative reverse transcription PCR (RT-PCR) to detect p14(ARF), p15(INK4b), and p16(INK4a) protein and mRNA expression, and by multiplex real-time PCR, PCR single strand conformation polymorphism and methylation-specific PCR to detect p14(ARF), p15(INK4b), and p16(INK4a) gene alterations.;Immunohistochemically decreased expressions of p14(ARF), p15(INK4b), and p16(INK4a) were observed in 48%, 54%, and 49% of primary MPNSTs, respectively, and were significantly correlated with their concordant mRNA levels. As for gene alterations, homozygous deletion of CDKN2A was detected in one third of the cases. Inactivation of p14(ARF) and p16(INK4a) was associated with poor prognosis by both univariate and multivariate analyses. Furthermore, cases with inactivation of all p14(ARF), p15(INK4b), and p16(INK4a) genes showed the worst prognosis in a combined prognostic assessment.;A comprehensive analysis of p14(ARF), p15(INK4b), and p16(INK4a) inactivation status provides useful prognostic information in MPNSTs.",
        "Doc_title":"Prognostic significance of p14ARF, p15INK4b, and p16INK4a inactivation in malignant peripheral nerve sheath tumors.",
        "Journal":"Clinical cancer research : an official journal of the American Association for Cancer Research",
        "Do_id":"21262917",
        "Doc_ChemicalList":"CDKN2B protein, human;Cyclin-Dependent Kinase Inhibitor p15;Cyclin-Dependent Kinase Inhibitor p16;Tumor Suppressor Protein p14ARF",
        "Doc_meshdescriptors":"Adolescent;Adult;Aged;Aged, 80 and over;Child;Child, Preschool;Cyclin-Dependent Kinase Inhibitor p15;Cyclin-Dependent Kinase Inhibitor p16;Female;Genes, p16;Humans;Infant;Male;Middle Aged;Nerve Sheath Neoplasms;Prognosis;Tumor Suppressor Protein p14ARF",
        "Doc_meshqualifiers":"genetics;metabolism;genetics;metabolism;diagnosis;genetics;metabolism;genetics;metabolism",
        "_version_":1605837212865265664},
      {
        "Doc_abstract":"Basal cell carcinoma (BCC) is a locally aggressive slowly growing tumour that rarely metastasizes and is mostly seen in older members of the population.;To determine the involvement of the tumour suppressor genes p14(ARF), p15(INK4b), p16(INK4a) and p53 in BCC.;We investigated the integrity of the CDKN2A locus in 15 BCC samples by analysing the presence of allelic imbalance/loss of heterozygosity (LOH). Moreover, we studied the mRNA expression levels of the tumour suppressor genes p14(ARF), p15(INK4b), p16(INK4a) and p53 in the BCC samples and compared them with mRNA levels in the corresponding normal tissue. The presence of mutations was examined by sequencing for exons 1a and 2 of p16(INK4a).;We found LOH in one BCC sample for the marker D9S1748. A polymorphism (G442A) of exon 2 was detected in three cases. p14(ARF), p15(INK4b) and p53 presented high expression levels, whereas p16(INK4a) exhibited low mRNA levels compared with the corresponding normal tissue. Significant correlations were detected among the genes studied.;Our results demonstrate a different expression profile between p16(INK4a) and p14(ARF), p15(INK4b) and p53 in BCC. Moreover, we found a low percentage of LOH and of a polymorphic sequence variant (Ala148Thr) for the CDKN2A locus.",
        "Doc_title":"Deregulation of the tumour suppressor genes p14(ARF), p15(INK4b), p16(INK4a) and p53 in basal cell carcinoma.",
        "Journal":"The British journal of dermatology",
        "Do_id":"19298278",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p15;RNA, Messenger;Tumor Suppressor Protein p14ARF;Tumor Suppressor Proteins",
        "Doc_meshdescriptors":"Aged;Aged, 80 and over;Carcinoma, Basal Cell;Cyclin-Dependent Kinase Inhibitor p15;DNA Mutational Analysis;Female;Gene Expression Regulation, Neoplastic;Genes, Tumor Suppressor;Genes, p16;Genes, p53;Heterozygote;Humans;Loss of Heterozygosity;Male;Microsatellite Instability;Microsatellite Repeats;Polymerase Chain Reaction;RNA, Messenger;Skin Neoplasms;Statistics as Topic;Tumor Suppressor Protein p14ARF;Tumor Suppressor Proteins",
        "Doc_meshqualifiers":"genetics;genetics;methods;genetics;physiology;genetics;methods;metabolism;genetics;genetics;genetics",
        "_version_":1605758504842297344},
      {
        "Doc_abstract":"The INK4A locus encodes two independent but overlapping genes, p16INK4A and p19ARF, and is frequently inactivated in human cancers. The unusual structure of this locus has lead to ambiguity regarding the biological role of each gene. Here we express, in primary mouse embryonic fibroblasts (MEFs), antisense RNA constructs directed specifically towards either p16INK4A or p19 ARF. Such constructs induce extended lifespan in primary MEFs; this lifespan extension is reversed upon subsequent elimination of the p16INK4A or p19ARF antisense constructs. In immortal derivatives of cell lines expressing antisense p16INK4A or p19ARF RNA, growth arrest induced by recovery of p16INK4A expression is bypassed by compromising the function of the retinoblastoma protein (Rb), whereas growth arrest induced by re-expression of p19ARF is overcome only by simultaneous inactivation of both the Rb and the p53 pathways. Thus, the physically overlapping p16INK4A and p19ARF genes act in partly overlapping pathways.",
        "Doc_title":"p16INK4A and p19ARF act in overlapping pathways in cellular immortalization.",
        "Journal":"Nature cell biology",
        "Do_id":"10707085",
        "Doc_ChemicalList":"Antigens, Viral, Tumor;Cyclin-Dependent Kinase Inhibitor p16;Nuclear Proteins;Oncogene Proteins, Viral;Papillomavirus E7 Proteins;Proteins;Proto-Oncogene Proteins;RNA, Antisense;Retinoblastoma Protein;Tumor Suppressor Protein p14ARF;Tumor Suppressor Protein p53;Viral Proteins;oncogene protein E7, Human papillomavirus type 16;Mdm2 protein, mouse;Proto-Oncogene Proteins c-mdm2;Cre recombinase;Integrases",
        "Doc_meshdescriptors":"Animals;Antigens, Viral, Tumor;Cell Aging;Cell Death;Cell Division;Cells, Cultured;Cyclin-Dependent Kinase Inhibitor p16;Embryo, Mammalian;Fibroblasts;Gene Expression;Integrases;Mice;Nuclear Proteins;Oncogene Proteins, Viral;Papillomavirus E7 Proteins;Protein Biosynthesis;Proteins;Proto-Oncogene Proteins;Proto-Oncogene Proteins c-mdm2;RNA, Antisense;Retinoblastoma Protein;Signal Transduction;Tumor Suppressor Protein p14ARF;Tumor Suppressor Protein p53;Viral Proteins",
        "Doc_meshqualifiers":"biosynthesis;pharmacology;physiology;physiology;drug effects;genetics;antagonists & inhibitors;biosynthesis;genetics;cytology;drug effects;metabolism;drug effects;biosynthesis;genetics;pharmacology;biosynthesis;pharmacology;antagonists & inhibitors;genetics;metabolism;pharmacology;antagonists & inhibitors;metabolism;genetics;antagonists & inhibitors;metabolism",
        "_version_":1605877140785463296},
      {
        "Doc_abstract":"Human papillomavirus is involved in the carcinogenesis of tonsillar squamous cell carcinomas. Here, we investigated the expression and the prognostic value of key cell cycle proteins in the pRb and p53 pathways in both human papillomavirus type 16-positive and -negative tonsillar squamous cell carcinomas. Using immunohistochemistry, 77 tonsillar squamous cell carcinomas with known human papillomavirus type 16 status and clinical outcome were analyzed for expression of Ki67, p16(INK4A,) cyclin D1, pRb, p14(ARF), MDM2, p53, p21(Cip1/WAF1), and p27(KIP1). Results were correlated with each other and with clinical and demographic patient data. A total of 35% of tonsillar carcinomas harbored integrated human papillomavirus type 16 DNA and p16(INK4A) overexpression, both being considered essential features for human papillomavirus association. These tumors also showed the overexpression of p14(ARF) (P<0.0001) and p21(Cip1/WAF1) (P=0.001), and downregulation of pRb (P<0.0001) and cyclin D1 (P=0.027) compared with the human papillomavirus-negative cases. Univariate Cox regression analyses revealed a favorable survival rate for non-smokers (P=0.006), as well as for patients with T1-2 tumors (P<0.0001) or tumors showing low expression of cyclin D1 (P=0.028), presence of human papillomavirus and overexpression of p16(INK4A) (P=0.01), p14(ARF) (P=0.02) or p21(Cip1/WAF1) (P=0.004). In multivariate regression analyses, smoking and tumor size, as well as expression of cyclin D1 and p21(Cip1/WAF1), were found to be independent prognostic markers. We conclude that human papillomavirus positivity in tonsillar squamous cell carcinomas strongly correlates with p21(Cip1/WAF1) and p14(ARF) overexpression and downregulation of pRb and cyclin D1. In particular p21(Cip1/WAF1) overexpression is an excellent favorable prognosticator in tonsillar squamous cell carcinomas.",
        "Doc_title":"P21 Cip1/WAF1 expression is strongly associated with HPV-positive tonsillar carcinoma and a favorable prognosis.",
        "Journal":"Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc",
        "Do_id":"19305381",
        "Doc_ChemicalList":"Biomarkers, Tumor;CDKN1A protein, human;Cell Cycle Proteins;Cyclin-Dependent Kinase Inhibitor p21;Retinoblastoma Protein;Tumor Suppressor Protein p14ARF;Cyclin D1",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Biomarkers, Tumor;Carcinoma, Squamous Cell;Cell Cycle Proteins;Cyclin D1;Cyclin-Dependent Kinase Inhibitor p21;Female;Gene Expression;Humans;Immunohistochemistry;Kaplan-Meier Estimate;Male;Middle Aged;Papillomaviridae;Papillomavirus Infections;Prognosis;Retinoblastoma Protein;Smoking;Tonsillar Neoplasms;Tumor Suppressor Protein p14ARF",
        "Doc_meshqualifiers":"analysis;metabolism;mortality;virology;biosynthesis;biosynthesis;biosynthesis;metabolism;mortality;biosynthesis;adverse effects;metabolism;mortality;virology;biosynthesis",
        "_version_":1605904029946216448},
      {
        "Doc_abstract":"Two separate pathways leading to vulvar carcinoma have been suggested. First, a human papillomavirus (HPV)-dependent pathway, in which premalignant stages of vulvar cancer are the classic vulvar intraepithelial neoplasia (VIN) lesions. Second, an HPV-independent pathway, associated with differentiated VIN III lesions and/or lichen sclerosus. To obtain insight into the mechanisms underlying these pathways, we determined the relationship between HPV DNA and the expression of p14(ARF) and p16(INK4A) in non- and (pre)malignant vulvar lesions. Seventy-three archival samples of non- and (pre)neoplastic vulvar lesions were selected and tested for hr-HPV DNA using a broad-spectrum HPV detection/genotyping assay (SPF(10)-LiPA) and the expression of p14(ARF) and p16(INK4A). The prevalence of HPV increased with the severity of the classic VIN lesions; in VIN I no hr-HPV was detected, in VIN II 43%, and in VIN III 71% of the samples were hr-HPV-positive. Roughly the same was true for the expression of p14(ARF) and p16(INK4A). The simultaneous expression of p14(ARF) and p16(INK4A) was highly associated with the presence of hr-HPV DNA. Hr-HPV was detected in only a single case of the differentiated VIN III lesions, whereas no expression of p14(ARF) was found and 16(INK4A) was present in only two cases. All 16 samples of vulvar cancer were hr-HPV DNA- negative, although in respectively 63% and 25%, p14(ARF) and p16(INK4A) was expressed. No relation was found between hr-HPV and the expression of p14(ARF) and p16(INK4A) in the 20 nonneoplastic vulvar lesions. Our results provide further evidence that vulvar squamous cell carcinoma is a multifactorial disease that develops from two different pathways. First, an HPV-dependent pathway with a remarkable resemblance to CIN lesions and cervical carcinoma and second, an HPV-independent pathway in which differentiated VIN III lesions that are hr-HPV-negative may be precursors.",
        "Doc_title":"Vulvar squamous cell carcinoma is a multifactorial disease following two separate and independent pathways.",
        "Journal":"International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists",
        "Do_id":"16306780",
        "Doc_ChemicalList":"Biomarkers, Tumor;Cyclin-Dependent Kinase Inhibitor p16;DNA, Viral;Tumor Suppressor Protein p14ARF",
        "Doc_meshdescriptors":"Adolescent;Adult;Aged;Aged, 80 and over;Biomarkers, Tumor;Carcinoma in Situ;Carcinoma, Squamous Cell;Child;Cyclin-Dependent Kinase Inhibitor p16;DNA, Viral;Female;Humans;Middle Aged;Papillomaviridae;Papillomavirus Infections;Precancerous Conditions;Tumor Suppressor Protein p14ARF;Vulvar Lichen Sclerosus;Vulvar Neoplasms",
        "Doc_meshqualifiers":"metabolism;etiology;metabolism;pathology;etiology;metabolism;pathology;metabolism;isolation & purification;isolation & purification;complications;pathology;complications;pathology;metabolism;complications;pathology;etiology;metabolism;pathology",
        "_version_":1605761178713194496},
      {
        "Doc_abstract":"In many human cancers, the INK4A locus is frequently mutated by homozygous deletions. By alternative splicing this locus encodes two non-related tumor suppressor genes, p16(INK4A) and p14(ARF) (p19(ARF) in mice), which regulate cell cycle and cell survival in the retinoblastoma protein (pRb) and p53 pathways, respectively. In mice, the role of p16(INK4A) as the critical tumor suppressor gene at the INK4A locus was challenged when it was found that p19(ARF) only knock-out mice developed tumors, including gliomas. We have analysed the genetic status of the INK4A locus in 105 primary gliomas using both microsatellite mapping (MSM) and quantitative real-time PCR (QRT-PCR). Comparison of the results of the two methods revealed agreement in 67% of the tumors examined. In discordant cases, fluorescence in situ hybridization (FISH) analysis was always found to support QRT-PCR classification. Direct assessment of p14(ARF) exon 1beta, p16(INK4A) exon 1alpha and exon 2 by QRT-PCR revealed 43 (41%) homozygous and eight (7%) hemizygous deletions at the INK4A locus. In 49 (47%) gliomas, both alleles were retained. In addition, QRT-PCR, but not MSM, detected hyperploidy in five (5%) tumors. Deletion of p14(ARF) was always associated with co-deletion of p16(INK4A) and increased in frequency upon progression from low to high grade gliomas. Shorter survival was associated with homozygous deletions of INK4A in the subgroup of glioblastoma patients older than 50 years of age (P=0.025, Anova test single factor, alpha=0.05).",
        "Doc_title":"Quantitative real-time PCR does not show selective targeting of p14(ARF) but concomitant inactivation of both p16(INK4A) and p14(ARF) in 105 human primary gliomas.",
        "Journal":"Oncogene",
        "Do_id":"11314047",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;DNA Primers;Proteins;Tumor Suppressor Protein p14ARF",
        "Doc_meshdescriptors":"Chromosome Mapping;Cyclin-Dependent Kinase Inhibitor p16;DNA Mutational Analysis;DNA Primers;Gene Deletion;Gene Expression;Glioma;Homozygote;Humans;In Situ Hybridization, Fluorescence;Microsatellite Repeats;Middle Aged;Polymerase Chain Reaction;Proteins;Survival Analysis;Tumor Cells, Cultured;Tumor Suppressor Protein p14ARF",
        "Doc_meshqualifiers":"genetics;chemistry;genetics;pathology;methods;genetics",
        "_version_":1605837456004874240},
      {
        "Doc_abstract":"CDKN2A encodes proteins such as p16 (INK4a), which negatively regulate the cell-cycle. Molecular genetic studies have revealed that deletions in CDKN2A occur frequently in cancer. Although p16 (INK4a) may be involved in tumor progression, the clinical impact and prognostic implications in head and neck squamous cell carcinoma (HNSCC) are controversial. The objective of this study was to evaluate the frequency of the immunohistochemical expression of p16 (INK4a) in 40 oropharynx and 35 larynx from HNSCC patients treated in a single institution and followed-up at least for 10 years in order to explore potential associations with clinicopathological outcomes and prognostic implications. Forty cases (53.3%) were positive for p16 (INK4a) and this expression was more intense in non-smoking patients (P = 0.050), whose tumors showed negative vascular embolization (P = 0.018), negative lymphatic permeation (P = 0.002), and clear surgical margins (P = 0.050). Importantly, on the basis of negative p16 (INK4a) expression, it was possible to predict a probability of lower survival (P = 0.055) as well as tumors presenting lymph node metastasis (P = 0.050) and capsular rupture (P = 0.0010). Furthermore, increased risk of recurrence was observed in tumors presenting capsular rupture (P = 0.0083). Taken together, the alteration in p16 (INK4a) appears to be a common event in patients with oropharynx and larynx squamous cell carcinoma and the negative expression of this protein correlated with poor prognosis.",
        "Doc_title":"p16 (INK4a) has clinicopathological and prognostic impact on oropharynx and larynx squamous cell carcinoma.",
        "Journal":"Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas",
        "Do_id":"22948376",
        "Doc_ChemicalList":"Biomarkers, Tumor;Cyclin-Dependent Kinase Inhibitor p16",
        "Doc_meshdescriptors":"Adult;Aged;Biomarkers, Tumor;Carcinoma, Squamous Cell;Cyclin-Dependent Kinase Inhibitor p16;Disease Progression;Female;Humans;Immunohistochemistry;Laryngeal Neoplasms;Male;Middle Aged;Oropharyngeal Neoplasms;Prognosis;Retrospective Studies;Survival Analysis",
        "Doc_meshqualifiers":"metabolism;metabolism;metabolism;metabolism;metabolism",
        "_version_":1605830667960057856},
      {
        "Doc_abstract":"Head and neck squamous cell carcinoma (HNSCC) patients with human papillomavirus (HPV) infection have better prognosis than those without HPV infection. Although p16(INK4a) expression is used as a surrogate marker for HPV infection, there is controversy as to whether p16(INK4a) reliably indicates HPV infection. Here, to evaluate the accuracy of p16(INK4a) expression for determining HPV infection and the prognostic value of HPV infection and p16(INK4a) expression for HNSCC survival, especially oropharyngeal squamous cell carcinoma (OPSCC) survival, 150 fresh-frozen HNSCC samples were analyzed for HPV DNA, E6/E7 mRNA and p16(INK4a) expression by polymerase chain reaction and immunohistochemistry. p16(INK4a) expression was scored from 0 to 4 according to the percentage of p16(INK4a)-positive cells, with overexpression defined as >40% positive cells. Of the 150 tumor samples tested, 10 tumors were nasopharyngeal, 53 oropharyngeal, 39 hypopharyngeal, 24 laryngeal and 24 were located in the oral cavity. HPV DNA was detected in 47 (31.3%) samples, but only 21 also exhibited HPV mRNA expression. Inter-rater agreement was low between p16(INK4a) expression and HPV DNA presence and between p16(INK4a) expression and HPV mRNA expression, but was good between the combination of HPV DNA status and p16(INK4a) overexpression and HPV mRNA expression. Three-year recurrence-free survival was significantly higher for OPSCC patients who were HPV DNA-positive than for OPSCC patients who were HPV DNA-negative (P=0.008) and for OPSCC patients overexpressing p16(INK4a) than for without overexpressing p16(INK4a) (P=0.034). Multivariate analysis revealed that T1-3 stage and the combination of HPV DNA positivity and p16(INK4a) overexpression predicted significantly better recurrence-free survival. This combination is a more accurate marker for active HPV infection in HNSCC than HPV DNA status or general p16(INK4a)-positive status alone and offers a useful and reliable method for detecting and determining the prognosis of HPV-related HNSCC.",
        "Doc_title":"A comprehensive evaluation of human papillomavirus positive status and p16INK4a overexpression as a prognostic biomarker in head and neck squamous cell carcinoma.",
        "Journal":"International journal of oncology",
        "Do_id":"24820457",
        "Doc_ChemicalList":"Biomarkers, Tumor;Cyclin-Dependent Kinase Inhibitor p16;DNA, Viral;RNA, Messenger;RNA, Viral",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Biomarkers, Tumor;Carcinoma, Squamous Cell;Cell Line, Tumor;Cyclin-Dependent Kinase Inhibitor p16;DNA, Viral;Female;Head and Neck Neoplasms;Human Papillomavirus DNA Tests;Humans;Male;Middle Aged;Papillomaviridae;Papillomavirus Infections;Prognosis;RNA, Messenger;RNA, Viral;Survival Analysis",
        "Doc_meshqualifiers":"analysis;diagnosis;pathology;virology;genetics;metabolism;analysis;diagnosis;pathology;virology;genetics;complications;diagnosis;virology;analysis;analysis",
        "_version_":1605811091228590080},
      {
        "Doc_abstract":"The aim of this study was hypermethylation of multiple genes for papillary thyroid carcinomas (PTCs).;We examined 39 lesions using methylation-specific PCR to assess hypermethylation in genes, including p16(INK4a), p14(ARF), RB1, p27(Kip1)and 0(6)-MGMT. Homozygous deletions of p16(INK4a) and p14(ARF) were investigated by differential PCR, all with reference to clinicopathological factors.;We found methylation of p16(INK4a) in 35.9% (14/39); p14(ARF) in 2.6% (1/39); RB1 in 23.1% (9/39); p27(Kip1) in 15.4% (6/39),and 0(6)-MGMT in 15.4% (6/39). Hypermethylation of at least one of these genes was apparent in 66.7% (26/39). Homozygous deletions of p14(ARF) and p16(INK4a) were detected in 7.7 (3/39) and 2.6% (1/39), respectively. In cases with p16(INK4a) alterations, tumors were significantly increased. A history of chronic thyroid disease and lymphocytic infiltration was significantly associated with p14(ARF) alterations, without regional lymph node metastases.;Our data suggest that alterations in p16(INK4a), mainly hypermethylation, may be linked to tumor growth but not tumor development, while alterations in p14(ARF) may contribute to the induction of chronic inflammation-related PTCs.",
        "Doc_title":"DNA hypermethylation status of multiple genes in papillary thyroid carcinomas.",
        "Journal":"Pathobiology : journal of immunopathology, molecular and cellular biology",
        "Do_id":"18087199",
        "Doc_ChemicalList":"Tumor Suppressor Protein p14ARF",
        "Doc_meshdescriptors":"Adolescent;Adult;Aged;Carcinoma, Papillary;Child;CpG Islands;DNA Methylation;Female;Genes, p16;Humans;Immunohistochemistry;Male;Middle Aged;Polymerase Chain Reaction;Thyroid Neoplasms;Tumor Suppressor Protein p14ARF",
        "Doc_meshqualifiers":"genetics;pathology;genetics;genetics;pathology;genetics",
        "_version_":1605756140239454208},
      {
        "Doc_abstract":"The CDKN2A gene, which encodes the proteins p16(INK4a) and p14(ARF), is located on chromosome 9p21. Germline mutations at this locus increase susceptibility to cutaneous malignant melanoma (CMM). In general, missense and nonsense mutations are primarily responsible for defective p16(INK4a) and possibly p14(ARF) protein function and account for approximately 20% of inherited CMM cases. We report a G>T transversion mutation in the last nucleotide of exon 2, affecting the aspartic acid residue at position 153 of CDKN2A-p16(INK4a) in a proband with melanoma. If splicing were unaffected, this mutation would change Asp to Tyr. RT-PCR analysis, however, revealed that this mutation, which we have termed D153spl(c.457G>T), and a previously described mutation at the next nucleotide, IVS2+1G>T, result in identical aberrant splicing affecting both p16(INK4a) and p14(ARF). The two main alternate splice products for each of the two normal transcripts includes a 74 bp deletion in exon 2, revealing a cryptic splice site, and the complete skipping of exon 2. The dual inactivation of p16(INK4a) and p14(ARF) may contribute to the CMM in these families.",
        "Doc_title":"CDKN2A point mutations D153spl(c.457G>T) and IVS2+1G>T result in aberrant splice products affecting both p16INK4a and p14ARF.",
        "Journal":"Oncogene",
        "Do_id":"12853981",
        "Doc_ChemicalList":"3' Untranslated Regions;Cyclin-Dependent Kinase Inhibitor p16;Tumor Suppressor Protein p14ARF",
        "Doc_meshdescriptors":"3' Untranslated Regions;Amino Acid Sequence;Base Sequence;Cyclin-Dependent Kinase Inhibitor p16;Genes, p16;Humans;Melanoma;Molecular Sequence Data;Point Mutation;RNA Splicing;Skin Neoplasms;Tumor Suppressor Protein p14ARF",
        "Doc_meshqualifiers":"genetics;genetics;genetics;genetics",
        "_version_":1605805965550026752},
      {
        "Doc_abstract":"The INK4a/ARF locus encodes two cell cycle-regulatory proteins, p16(INK4a)and p14(ARF). Inactivation of the p16(INK4a)(MTS1) tumor suppressor gene by mutations, promoter methylation or gene deletions is a common event in the development of many different human tumors. The present report describes a novel polyA mononucleotide repeat situated 7.2 kb on the telomeric side of the INK4a/ARF locus. This highly polymorphic microsatellite marker (heterozygote frequency: 0.78) proved to be efficient for p16 allele loss and microsatellite instability analyses in human colon cancer.",
        "Doc_title":"A novel highly informative polyA microsatellite on the telomeric side of the INK4a/ARF locus.",
        "Journal":"Molecular and cellular probes",
        "Do_id":"11352600",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;Proteins;Tumor Suppressor Protein p14ARF;Poly A",
        "Doc_meshdescriptors":"Adenocarcinoma;Alleles;Colon;Colonic Neoplasms;Cyclin-Dependent Kinase Inhibitor p16;Heterozygote;Humans;Loss of Heterozygosity;Microsatellite Repeats;Mucous Membrane;Poly A;Polymorphism, Genetic;Proteins;Telomere;Tumor Suppressor Protein p14ARF",
        "Doc_meshqualifiers":"genetics;pathology;genetics;genetics;pathology;genetics;genetics;ultrastructure",
        "_version_":1605853616215687168},
      {
        "Doc_abstract":"The CDKN2A locus on human chromosome 9p21 encodes two tumor suppressors, p14(ARF) and p16(INK4A), which enhance the growth-suppressive functions of the retinoblastoma (Rb) and the p53 proteins, respectively. Conversely, the E6 and E7 oncoproteins of the high-risk human papillomaviruses (HPVs) causally associated with carcinogenesis of the uterine cervix contributes to tumor development by inactivating p53 and Rb. Nevertheless, a correlation between expression of p14(ARF)/p16(INK4A) and HPV infection in uterine cervix is less clear. To clarify this, we examined 25 cervical cancers and 11 normal uterine cervixes. HPV was detected in 21 of 25 cervical cancers (84%) and their subtype was determined by PCR-RFLP. Quantitative real-time RT-PCR assays showed overexpression of p14(ARF) mRNA in all 21 HPV-positive cases (100%). p16(INK4A) mRNA was overexpressed in 17 cases of the HPV-positive cases (81%). In four HPV-negative cancers, reduced expression of p14(ARF) mRNA was detected in two cases (50%) and reduced p16(INK4A) mRNA in three cases (75%). Our data indicate that the overexpression of p14(ARF) and p16(INK4A) strongly associates with HPV-positive cervical cancers and that reduced expression of p14(ARF) and p16(INK4A) correlates with HPV-negative cervical cancers. These findings may indicate that impaired p14(ARF) and p16(INK4A) mRNA expression contribute to tumor development in HPV-negative cervical cancers by failure to support p53 and Rb instead of their inactivation by HPV E6 and E7.",
        "Doc_title":"Correlation between p14(ARF)/p16(INK4A) expression and HPV infection in uterine cervical cancer.",
        "Journal":"Cancer letters",
        "Do_id":"15312681",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;DNA Primers;RNA, Messenger;Retinoblastoma Protein;Tumor Suppressor Protein p14ARF;Tumor Suppressor Protein p53",
        "Doc_meshdescriptors":"Carcinoma, Squamous Cell;Cell Transformation, Neoplastic;Chromosomes, Human, Pair 9;Cyclin-Dependent Kinase Inhibitor p16;DNA Primers;Female;Humans;Papillomaviridae;Papillomavirus Infections;Polymerase Chain Reaction;Polymorphism, Restriction Fragment Length;RNA, Messenger;Retinoblastoma Protein;Risk Factors;Tumor Suppressor Protein p14ARF;Tumor Suppressor Protein p53;Uterine Cervical Neoplasms",
        "Doc_meshqualifiers":"genetics;virology;biosynthesis;pathogenicity;complications;biosynthesis;biosynthesis;metabolism;biosynthesis;biosynthesis;metabolism;genetics;virology",
        "_version_":1605764883548209152},
      {
        "Doc_abstract":"Pleomorphic adenomas of the parotid gland are benign tumours composed of epithelial and mesenchymal cells. The INK4a-ARF (CDKN2A) locus on chromosome 9p21 encodes two tumour suppressor proteins, p16(INK4a) and p14(ARF), which act as upstream regulators of the Rb-CDK4 and p53 pathways. To study the contribution of each pathway in pleomorphic adenomas, this study analysed alterations of p14(ARF), p16(INK4a), p53, and pRb in these tumours. After microdissecting the different histological components, 42 pleomorphic adenomas of the parotid gland were analysed for INK4a-ARF inactivation by DNA sequence analysis, methylation-specific PCR (MSP), restriction enzyme-related polymerase chain reaction (RE-PCR), mRNA expression, microsatellite analysis, and immunohistochemistry. In addition, microdeletion of p14(ARF) and p16(INK4a) were assessed by differential PCR. The status of p53 and Rb was examined by direct sequencing and immunohistochemistry. Using microdissection, it was possible to examine the tumour components, i.e. epithelial, mesenchymal, and transitional, separately after immunohistochemical identification. Methylation of p14(ARF) was found in 1/42 cases and alterations of p16(INK4a) occurred in 12/42 of pleomorphic adenomas, which correlated with loss of mRNA transcription. Microdeletions or specific mutations of either exon were not detected. Methylation was detected exclusively in the epithelial and transitional components and not within the mesenchymal part of the tumour. p53 mutations were detected in 4/42 adenomas, also occurring solely in the epithelial components of the tumours. pRb was detected immunohistochemically in 40/42 adenomas. In normal, corresponding parotid tissue, p14(ARF), p16(INK4a), p53, and pRb alterations were not observed. The observation that alterations of p14(ARF) and p16(INK4a), and also p53 mutations, occurred exclusively in the epithelial and transitional components of pleomorphic adenoma supports the theory that these areas are prone to malignant transformation to carcinoma in adenoma.",
        "Doc_title":"Alterations of the INK4a-ARF gene locus in pleomorphic adenoma of the parotid gland.",
        "Journal":"The Journal of pathology",
        "Do_id":"12375265",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;DNA, Neoplasm;Neoplasm Proteins;RNA, Messenger;RNA, Neoplasm;Retinoblastoma Protein;Tumor Suppressor Protein p14ARF",
        "Doc_meshdescriptors":"Adenoma, Pleomorphic;Chromosomes, Human, Pair 9;Cyclin-Dependent Kinase Inhibitor p16;DNA Methylation;DNA Mutational Analysis;DNA, Neoplasm;Genes, p53;Humans;Microsatellite Repeats;Mutation;Neoplasm Proteins;Parotid Neoplasms;RNA, Messenger;RNA, Neoplasm;Retinoblastoma Protein;Retrospective Studies;Reverse Transcriptase Polymerase Chain Reaction;Tumor Suppressor Protein p14ARF",
        "Doc_meshqualifiers":"genetics;metabolism;genetics;genetics;genetics;metabolism;genetics;metabolism;genetics;genetics;metabolism;genetics",
        "_version_":1605840759624302592},
      {
        "Doc_abstract":"The INK4a tumor suppressor locus encodes p16INK4a, an inhibitor of cyclin D-dependent kinases, and p19ARF, an alternative reading frame protein that also blocks cell proliferation. Surprisingly, mice lacking p19ARF but expressing functional p16INK4a develop tumors early in life. Their embryo fibroblasts (MEFs) do not senesce and are transformed by oncogenic Ha-ras alone. Conversion of ARF+/+ or ARF+/- MEF strains to continuously proliferating cell lines involves loss of either p19ARF or p53. p53-mediated checkpoint control is unperturbed in ARF-null fibroblast strains, whereas p53-negative cell lines are resistant to p19ARF-induced growth arrest. Therefore, INK4a encodes growth inhibitory proteins that act upstream of the retinoblastoma protein and p53. Mutations and deletions targeting this locus in cancer cells are unlikely to be functionally equivalent.",
        "Doc_title":"Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF.",
        "Journal":"Cell",
        "Do_id":"9393858",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;Proteins;Tumor Suppressor Protein p14ARF;Tumor Suppressor Protein p53",
        "Doc_meshdescriptors":"3T3 Cells;Animals;Cell Division;Cyclin-Dependent Kinase Inhibitor p16;Exons;Female;G1 Phase;Gene Deletion;Gene Expression Regulation, Neoplastic;Humans;Kidney;Leukemia, Erythroblastic, Acute;Male;Mice;Mice, Inbred C57BL;Mice, Mutant Strains;Mutagenesis;Neoplasms, Experimental;Open Reading Frames;Phenotype;Proteins;Tumor Suppressor Protein p14ARF;Tumor Suppressor Protein p53",
        "Doc_meshqualifiers":"genetics;genetics;genetics;physiology;physiology;cytology;physiology;genetics;genetics;genetics;physiology",
        "_version_":1605805212344254464},
      {
        "Doc_abstract":"The human INK4a locus encodes two structurally unrelated tumor suppressor proteins, p16 INK4a and p14 ARF (p19 ARF in the mouse), which are frequently inactivated in human cancer. Both the proapoptotic and cell cycle-regulatory functions of p14 ARF were initially proposed to be strictly dependent on a functional p53/mdm-2 tumor suppressor pathway. However, a number of recent reports have implicated p53-independent mechanisms in the regulation of cell cycle arrest and apoptosis induction by p14 ARF. Here, we show that the G1 cell cycle arrest induced by p14 ARF entirely depends on both p53 and p21 in human HCT116 and DU145 carcinoma cells. In contrast, neither loss of p53 nor p21 impaired apoptosis induction by p14 ARF as evidenced by nuclear DNA fragmentation, phosphatidyl serine exposure, and caspase activation, which included caspase-3/7- and caspase-9-like activities. However, lack of functional p21 resulted in the accumulation of cells in G2/M phase of the cell cycle and markedly enhanced p14 ARF-induced apoptosis that was, nevertheless, efficiently inhibited by the cell permeable broad-spectrum caspase inhibitor zVAD-fmk (valyl-alanyl-aspartyl-(O)-methyl)-fluoromethylketone). Thus, loss of cell cycle restriction point control in the absence of p21 may interfere with p14 ARF-induced apoptosis. Finally, these data indicate that the signaling events required for G1 cell cycle arrest and apoptosis induction by p14 ARF dissociate upstream of p53.",
        "Doc_title":"Loss of p21 disrupts p14 ARF-induced G1 cell cycle arrest but augments p14 ARF-induced apoptosis in human carcinoma cells.",
        "Journal":"Oncogene",
        "Do_id":"15750619",
        "Doc_ChemicalList":"CDKN1A protein, human;Cell Cycle Proteins;Cyclin-Dependent Kinase Inhibitor p21;Tumor Suppressor Protein p14ARF;Caspases;Bromodeoxyuridine",
        "Doc_meshdescriptors":"Adenoviridae;Apoptosis;Bromodeoxyuridine;Carcinoma;Caspases;Cell Cycle;Cell Cycle Proteins;Cell Line;Cell Line, Tumor;Colorectal Neoplasms;Cyclin-Dependent Kinase Inhibitor p21;G1 Phase;Gene Deletion;Genetic Vectors;Humans;Kidney;Tumor Suppressor Protein p14ARF",
        "Doc_meshqualifiers":"genetics;physiology;metabolism;physiology;genetics;physiology;physiology",
        "_version_":1605841295533670400},
      {
        "Doc_abstract":"Tumor suppressor gene CDKN2 (also called MTS1, CDK4I and p16INK4) is located in 9p21 and deleted homozygously in a high percentage of tumor cell lines. We have examined the sequence of CDKN2 in 154 tumor cell lines that are not homozygously deleted for CDKN2. Overall, 18% (27/154) of the cell lines carried mutations in CDKN2. These mutations were found in cell lines derived from melanoma, bladder, lung and prostate cancers, as well as sarcomas of various origin. The spectrum of the CDKN2 mutations found in melanoma cell lines indicated a major role for ultraviolet light in generating the mutations, suggesting the mutations occurred in vivo. The frequency of loss of heterozygosity in 9p21 in this set of lines is only slightly higher than the background rate of aneuploidy, suggesting that a second 9p21 tumor suppressor gene, if it exists, must lie near CDKN2.",
        "Doc_title":"CDKN2 (MTS1) tumor suppressor gene mutations in human tumor cell lines.",
        "Journal":"Oncogene",
        "Do_id":"7700630",
        "Doc_ChemicalList":"Carrier Proteins;Cyclin-Dependent Kinase Inhibitor p16;DNA, Neoplasm",
        "Doc_meshdescriptors":"Amino Acid Sequence;Base Sequence;Carrier Proteins;Chromosome Deletion;Chromosomes, Human, Pair 9;Cyclin-Dependent Kinase Inhibitor p16;DNA, Neoplasm;Genes, Tumor Suppressor;Heterozygote;Humans;Molecular Sequence Data;Point Mutation;Tumor Cells, Cultured",
        "Doc_meshqualifiers":"genetics",
        "_version_":1605876864048431104},
      {
        "Doc_abstract":"Deletion of 9p21 is a common event in many human tumors, including head and neck squamous cell carcinoma (HNSCC). The gene CDKN2, which encodes the protein p16, a cyclin-dependent kinase-4 inhibitor, maps to 9p21. The role of CDKN2 as the tumor suppressor gene in these neoplasms is unclear. The role of loss of heterozygosity (LOH) as a prognostic tool has not been described in HNSCC.;We performed deletion mapping using Southern and PCR-based LOH analysis and prospective survival analysis.;We demonstrate that LOH of 9p and, specifically, the interferon (IFN) gene cluster correlates with recurrence of HNSCC. We also demonstrate two separate areas of deletion on 9p, one centromeric to IFNbeta and telomeric to CDKN2 and the other centromeric to CDKN2 and telomeric to the polymorphic marker D9S19. All the deletions involve either the markers IFNalpha and/or D9S171 and D9S126 but not necessarily CDKN2.;These results suggest another tumor suppressor gene (TSG) may be involved in HNSCC carcinogenesis and may play a role in aggressive disease as manifest by local, regional, or distant recurrence.",
        "Doc_title":"9p21 deletion correlates with recurrence in head and neck cancer.",
        "Journal":"Head & neck",
        "Do_id":"9484941",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;Genetic Markers;Interferon-beta;Interferons",
        "Doc_meshdescriptors":"Aged;Blotting, Southern;Carcinoma, Squamous Cell;Centromere;Chromosome Mapping;Chromosomes, Human, Pair 9;Cyclin-Dependent Kinase Inhibitor p16;Female;Follow-Up Studies;Gene Deletion;Genes, Tumor Suppressor;Genes, p16;Genetic Markers;Head and Neck Neoplasms;Humans;Interferon-beta;Interferons;Loss of Heterozygosity;Male;Middle Aged;Neoplasm Recurrence, Local;Polymerase Chain Reaction;Polymorphism, Genetic;Prognosis;Prospective Studies;Survival Analysis;Telomere",
        "Doc_meshqualifiers":"genetics;genetics;genetics;genetics;genetics;genetics;genetics;genetics;genetics;genetics;genetics;genetics;genetics;genetics",
        "_version_":1605742647575576577},
      {
        "Doc_abstract":"TGFbeta1 acts as a potent negative regulator of the cell cycle and tumor suppressor in part through induction of cyclin dependent kinase inhibitors p15(ink4b), p21, and p57. We previously showed that primary mouse epidermal keratinocytes (MEK) expressing a v-ras(Ha) oncogene undergo hyperproliferation followed by growth arrest and senescence that was dependent on TGFbeta1 signaling and associated with increased levels of p16(ink4a) and p19(ARF). Here we show that the induction of both p16(ink4a) and p19(ARF) in v-ras(Ha) expressing keratinocytes is dependent on TGFbeta1 signaling, as TGFbeta1 treatment or Smad3 overexpression induces both p16(ink4a) and p19(ARF) protein and mRNA, while Smad3 depletion or Smad7 overexpression blocks induction. Genetic ablation of the cdkn2a (ink4a/arf) locus reduced sensitivity to TGFbeta1 mediated cell cycle arrest and induction of senescence suggesting that alteration of TGFbeta1 responses may be an additional pathway impacted by the inactivation of cdkn2a locus during tumor development.",
        "Doc_title":"Induction of p16ink4a and p19ARF by TGFbeta1 contributes to growth arrest and senescence response in mouse keratinocytes.",
        "Journal":"Molecular carcinogenesis",
        "Do_id":"18655107",
        "Doc_ChemicalList":"Cdkn2a protein, mouse;Cyclin-Dependent Kinase Inhibitor p16;Cyclin-Dependent Kinase Inhibitor p21;Extracellular Matrix Proteins;Smad2 Protein;Smad2 protein, mouse;Smad3 Protein;Smad3 protein, mouse;Smad4 Protein;Smad4 protein, mouse;Smad7 Protein;Smad7 protein, mouse;Transforming Growth Factor beta;betaIG-H3 protein",
        "Doc_meshdescriptors":"Adenoviridae;Animals;Animals, Newborn;Cell Aging;Cell Cycle;Cell Differentiation;Cell Proliferation;Cell Transformation, Viral;Cyclin-Dependent Kinase Inhibitor p16;Cyclin-Dependent Kinase Inhibitor p21;Epidermis;Extracellular Matrix Proteins;Genes, ras;Keratinocytes;Mice;Mice, Inbred BALB C;Mice, Inbred C57BL;Mice, Knockout;Signal Transduction;Smad2 Protein;Smad3 Protein;Smad4 Protein;Smad7 Protein;Transforming Growth Factor beta",
        "Doc_meshqualifiers":"genetics;physiology;biosynthesis;metabolism;cytology;pharmacology;drug effects;metabolism;genetics;metabolism;physiology;genetics;metabolism;genetics;metabolism;pharmacology",
        "_version_":1605755710340071424},
      {
        "Doc_abstract":"p63 is critical for squamous epithelial development, and elevated levels of the Np63 isoform are seen in squamous cell cancers of various organ sites. However, significant controversy exists regarding the role of p63 isoforms as oncoproteins or tumor suppressors. Here, lentiviruses were developed to drive long-term overexpression of Np63 in primary keratinocytes. Elevated levels of Np63 in vitro promote long-term survival and block both replicative and oncogene-induced senescence in primary keratinocytes, as evidenced by the expression of SA--gal and the presence of nuclear foci of heterochromatin protein 1. The contribution of Np63 to cancer development was assessed using an in vivo grafting model of experimental skin tumorigenesis that allows distinction between benign and malignant tumors. Grafted lenti-Np63 keratinocytes do not form tumors, whereas lenti-GFP/v-ras(Ha) keratinocytes develop well-differentiated papillomas. Lenti-Np63/v-ras(Ha) keratinocytes form undifferentiated carcinomas. The average volume of lenti-Np63/v-ras(Ha) tumors was significantly higher than those in the lenti-GFP/v-ras(Ha) group, consistent with increased BrdU incorporation detected by immunohistochemistry. The block in oncogene-induced senescence corresponds to sustained levels of E2F1 and phosphorylated AKT, and is associated with loss of induction of p16(ink4a)/p19(arf). The relevance of p16(ink4a)/p19(arf) loss was demonstrated in grafting studies of p19(arf)-null keratinocytes, which develop malignant carcinomas in the presence of v-ras(Ha) similar to those arising in wildtype keratinocytes that express lenti-Np63 and v-ras(Ha). Our findings establish that Np63 has oncogenic activity and its overexpression in human squamous cell carcinomas contributes to the malignant phenotype, and implicate its ability to regulate p16(ink4a)/p19(arf) in the process.",
        "Doc_title":"Dysregulated Np63 inhibits expression of Ink4a/arf, blocks senescence, and promotes malignant conversion of keratinocytes.",
        "Journal":"PloS one",
        "Do_id":"21789189",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;Cyclin-Dependent Kinase Inhibitor p19;TP63 protein, human;Transcription Factors;Tumor Suppressor Proteins;ras Proteins",
        "Doc_meshdescriptors":"Animals;Cell Aging;Cell Survival;Cell Transformation, Neoplastic;Cells, Cultured;Cyclin-Dependent Kinase Inhibitor p16;Cyclin-Dependent Kinase Inhibitor p19;Gene Expression;Gene Expression Regulation;HEK293 Cells;Humans;Keratinocytes;Lentivirus;Mice;Phenotype;Time Factors;Transcription Factors;Tumor Suppressor Proteins;Up-Regulation;ras Proteins",
        "Doc_meshqualifiers":"metabolism;pathology;antagonists & inhibitors;metabolism;antagonists & inhibitors;metabolism;metabolism;pathology;genetics;metabolism;metabolism;genetics;metabolism",
        "_version_":1605877232220241920},
      {
        "Doc_abstract":"Stem cells persist throughout life in diverse tissues by undergoing self-renewing divisions. Self-renewal capacity declines with age, partly because of increasing expression of the tumor suppressor p16(Ink4a). We discovered that the Hmga2 transcriptional regulator is highly expressed in fetal neural stem cells but that expression declines with age. This decrease is partly caused by the increasing expression of let-7b microRNA, which is known to target HMGA2. Hmga2-deficient mice show reduced stem cell numbers and self-renewal throughout the central and peripheral nervous systems of fetal and young-adult mice but not old-adult mice. Furthermore, p16(Ink4a) and p19(Arf) expression were increased in Hmga2-deficient fetal and young-adult stem cells, and deletion of p16(Ink4a) and/or p19(Arf) partially restored self-renewal capacity. let-7b overexpression reduced Hmga2 and increased p16(Ink4a)/p19(Arf) expression. Hmga2 thus promotes fetal and young-adult stem cell self-renewal by decreasing p16(Ink4a)/p19(Arf) expression. Changes in let-7 and Hmga2 expression during aging contribute to the decline in neural stem cell function.",
        "Doc_title":"Hmga2 promotes neural stem cell self-renewal in young but not old mice by reducing p16Ink4a and p19Arf Expression.",
        "Journal":"Cell",
        "Do_id":"18957199",
        "Doc_ChemicalList":"Cdkn2a protein, mouse;Cyclin-Dependent Kinase Inhibitor p16;HMGA2 Protein;MicroRNAs",
        "Doc_meshdescriptors":"Aging;Animals;Cyclin-Dependent Kinase Inhibitor p16;HMGA2 Protein;Mice;Mice, Inbred C57BL;MicroRNAs;Nervous System;Neurons;Stem Cells",
        "Doc_meshqualifiers":"metabolism;genetics;metabolism;metabolism;embryology;metabolism;metabolism",
        "_version_":1605826787755950080},
      {
        "Doc_abstract":"The susceptibility of BALB/c mice to pristane-induced plasmacytomas is a complex genetic trait involving multiple loci, while DBA/2 and C57BL/6 strains are genetically resistant to the plasmacytomagenic effects of pristane. In this model system for human B-cell neoplasia, one of the BALB/c susceptibility and modifier loci, Pctr1, was mapped to a 5.7-centimorgan (cM) chromosomal region that included Cdkn2a, which encodes p16(INK4a) and p19(ARF), and the coding sequences for the BALB/c p16(INK4a) and p19(ARF) alleles were found to be polymorphic with respect to their resistant Pctr1 counterparts in DBA/2 and C57BL/6 mice (45). In the present study, alleles of Pctr1, Cdkn2a, and D4Mit15 from a resistant strain (BALB/cDAG) carrying DBA/2 chromatin were introgressively backcrossed to the susceptible BALB/c strain. The resultant C.DAG-Pctr1 Cdkn2a D4Mit15 congenic was more resistant to plasmacytomagenesis than BALB/c, thus narrowing Pctr1 to a 1.5-cM interval. Concomitantly, resistant C57BL/6 mice, from which both gene products of the Cdkn2a gene have been eliminated, developed pristane-induced plasma cell tumors over a shorter latency period than the traditionally susceptible BALB/cAn strain. Biological assays of the p16(INK4a) and p19(ARF) alleles from BALB/c and DBA/2 indicated that the BALB/c p16(INK4a) allele was less active than its DBA/2 counterpart in inducing growth arrest of mouse plasmacytoma cell lines and preventing ras-induced transformation of NIH 3T3 cells, while the two p19(ARF) alleles displayed similar potencies in both assays. We propose that the BALB/c susceptibility/modifier locus, Pctr1, is an \"efficiency\" allele of the p16(INK4a) gene.",
        "Doc_title":"Efficiency alleles of the Pctr1 modifier locus for plasmacytoma susceptibility.",
        "Journal":"Molecular and cellular biology",
        "Do_id":"11113205",
        "Doc_ChemicalList":"Carrier Proteins;Cyclin-Dependent Kinase Inhibitor p16;Proteins;Terpenes;Tumor Suppressor Protein p14ARF;pristane",
        "Doc_meshdescriptors":"3T3 Cells;Alleles;Animals;Carrier Proteins;Cell Division;Cell Transformation, Neoplastic;Chromosome Mapping;Cyclin-Dependent Kinase Inhibitor p16;Flow Cytometry;G1 Phase;Genes, p16;Genes, ras;Genetic Predisposition to Disease;Genetic Variation;Histocytochemistry;Mice;Mice, Congenic;Mice, Inbred BALB C;Mice, Inbred DBA;Mice, Knockout;Plasmacytoma;Proteins;Terpenes;Tumor Stem Cell Assay;Tumor Suppressor Protein p14ARF",
        "Doc_meshqualifiers":"genetics;chemically induced;genetics;pathology;genetics;genetics;genetics;genetics;chemically induced;genetics;pathology;genetics;pharmacology",
        "_version_":1605840876299354112},
      {
        "Doc_abstract":"The INK4a gene, one of the most frequently disrupted tumor suppressor loci in human cancer, encodes two unrelated proteins, p16INK4a and p19ARF, each of which is capable of inducing cell cycle arrest. Splicing of alternative first exons (1 alpha vs. 1 beta) to a common second exon within INK4a generates mRNAs in which exon 2 sequences are translated in two different reading frames. One of the products, the cyclin D-dependent kinase inhibitor p16INK4a, is functionally inactivated by mutations or deletions in a wide variety of cancers. However, because many such mutations reside in exon 2, they also affect the alternative reading frame (ARF) protein. To determine whether such mutations disrupt p19ARF function, we introduced naturally occurring missense mutations into mouse INK4a exon 2 sequences and tested mutant p16INK4a and p19ARF proteins for their ability to inhibit cell cycle progression. Six p19ARF point mutants remained fully active in mediating cell cycle arrest in NIH 3T3 fibroblasts, whereas two of the corresponding mutations within p16INK4a resulted in complete loss of activity. Analysis of p19ARF deletion mutants indicated that the unique aminoterminal domain encoded by exon 1 beta was both necessary and sufficient for inducing G1 arrest. Therefore, cancer-associated mutations within exon 2 of the INK4a gene specifically target p16INK4a, and not p19ARF, for inactivation.",
        "Doc_title":"Cancer-associated mutations at the INK4a locus cancel cell cycle arrest by p16INK4a but not by the alternative reading frame protein p19ARF.",
        "Journal":"Proceedings of the National Academy of Sciences of the United States of America",
        "Do_id":"9012842",
        "Doc_ChemicalList":"Carrier Proteins;Cyclin-Dependent Kinase Inhibitor p16;DNA, Neoplasm;Proteins;Tumor Suppressor Protein p14ARF",
        "Doc_meshdescriptors":"3T3 Cells;Alternative Splicing;Animals;Carrier Proteins;Cell Cycle;Cyclin-Dependent Kinase Inhibitor p16;DNA, Neoplasm;Exons;Genes, Tumor Suppressor;Mice;Mutation;Proteins;Sequence Deletion;Tumor Cells, Cultured;Tumor Suppressor Protein p14ARF",
        "Doc_meshqualifiers":"genetics;genetics;genetics;cytology",
        "_version_":1605908420390551552},
      {
        "Doc_abstract":"The two distinct proteins encoded by the CDKN2A locus are specified by translating the common second exon in alternative reading frames. The product of the alpha transcript, p16(INK4a), is a recognized tumour suppressor that induces a G1 cell cycle arrest by inhibiting the phosphorylation of the retinoblastoma protein by the cyclin-dependent kinases, CDK4 and CDK6. In contrast, the product of the human CDKN2A beta transcript, p14(ARF), activates a p53 response manifest in elevated levels of MDM2 and p21(CIP1) and cell cycle arrest in both G1 and G2/M. As a consequence, p14(ARF)-induced cell cycle arrest is p53 dependent and can be abrogated by the co-expression of human papilloma virus E6 protein. p14(ARF) acts by binding directly to MDM2, resulting in the stabilization of both p53 and MDM2. Conversely, p53 negatively regulates p14(ARF) expression and there is an inverse correlation between p14(ARF) expression and p53 function in human tumour cell lines. However, p14(ARF) expression is not involved in the response to DNA damage. These results place p14(ARF) in an independent pathway upstream of p53 and imply that CDKN2A encodes two proteins that are involved in tumour suppression.",
        "Doc_title":"The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2.",
        "Journal":"The EMBO journal",
        "Do_id":"9724636",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;Nuclear Proteins;Proteins;Proto-Oncogene Proteins;Tumor Suppressor Protein p14ARF;Tumor Suppressor Protein p53;MDM2 protein, human;Proto-Oncogene Proteins c-mdm2",
        "Doc_meshdescriptors":"Alternative Splicing;Amino Acid Sequence;Cell Cycle;Cyclin-Dependent Kinase Inhibitor p16;Feedback;Gene Expression Regulation, Neoplastic;Humans;Models, Genetic;Molecular Sequence Data;Nuclear Proteins;Protein Binding;Proteins;Proto-Oncogene Proteins;Proto-Oncogene Proteins c-mdm2;Sequence Homology, Amino Acid;Tumor Suppressor Protein p14ARF;Tumor Suppressor Protein p53",
        "Doc_meshqualifiers":"physiology;genetics;metabolism;genetics;metabolism;metabolism;metabolism",
        "_version_":1605873965870350336},
      {
        "Doc_abstract":"The presence of RD(INK4/ARF) (RD) enhancer in the INK4-ARF locus provides a novel mechanism to simultaneously increase the transcription of p15(INK4b) (p15), p14ARF (p14), and p16(INK4a) (p16). While such upregulation can be repressed through interactions between RD and oncoproteins CDC6 and BMI1, little is known about the involvement of RD in cancer. In this study we investigated RD deletions in 30 squamous cell carcinoma of the head and neck (SCCHN) and the patient-matched High At-Risk Mucosa specimens (HARM, \"phenotypically normal\" tissues neighboring SCCHN foci but beyond the surgical resection margin). RD was deleted (homozygously/heterozygously) in SCCHN and HARM at the incidence of 36.7% (11/30) and 13.3% (4/30), respectively. In comparison, no RD deletion was detected in 26 oral buccal brush biopsy specimens from healthy donors. Both p16 and p14 were lowly expressed in SCCHN and HARM, and their mRNA expression levels were positively associated with each other (P<0.01). Moreover, BMI1 was highly expressed in both SCCHN and HARM, and BMI1 overexpression was associated with p16 downregulation in SCCHN (P<0.05). These results indicate that RD deletion and BMI1 overexpression frequently occur in the early stage of oral carcinogenesis and BMI1 overexpression may downregulate the transcription of p16 and p14 through interfering with RD.",
        "Doc_title":"Alterations in RD(INK4/ARF) -mediated en bloc regulation of the INK4-ARF locus in human squamous cell carcinoma of the head and neck.",
        "Journal":"Molecular carcinogenesis",
        "Do_id":"24302590",
        "Doc_ChemicalList":"BMI1 protein, human;Cyclin-Dependent Kinase Inhibitor p15;Cyclin-Dependent Kinase Inhibitor p16;Tumor Suppressor Protein p14ARF;Polycomb Repressive Complex 1",
        "Doc_meshdescriptors":"Carcinoma, Squamous Cell;Cyclin-Dependent Kinase Inhibitor p15;Cyclin-Dependent Kinase Inhibitor p16;Female;Gene Deletion;Gene Expression Regulation, Neoplastic;Genetic Loci;Head and Neck Neoplasms;Humans;Male;Middle Aged;Polycomb Repressive Complex 1;Tumor Suppressor Protein p14ARF",
        "Doc_meshqualifiers":"genetics;genetics;genetics;genetics;genetics;genetics",
        "_version_":1605741919097323520},
      {
        "Doc_abstract":"Expression of high-risk HPV oncogenes results in a strong overexpression of cellular protein p16(INK4a). Immunohistochemical staining for p16(INK4a) is widely used as diagnostic marker. However, p16(INK4a) upregulation was also described as a biomarker of age. Here we analyzed p16(INK4a) expression in cervical smears to investigate if patient age may influence p16(INK4a)-based cervical cancer diagnosis. p14(ARF) was analyzed as a related supportive biomarker. Cervical scrapes were taken and stored in RNAlater. Total RNA was extracted, and cDNA was analyzed for expression of p16(INK4a) and p14(ARF) relative to -actin, by real-time reverse transcriptase PCR SYBR-Green I assays. Patient-derived smears referred as HSIL (n=45) had 6.27-fold higher p16(INK4a) mRNA expression than smears of cytologically normal and HPV-negative persons (n=48). Expression of p14(ARF) was 4.87-fold higher. When women with normal diagnoses were stratified for age, a significantly enhanced p16(INK4a) (2.88-fold) and p14(ARF) (1.9-fold) expression was observed as a consequence of ageing. A significant age-dependent upregulation was also observed in older HSIL patients (2.54-fold). Our study revealed significantly enhanced expression of p16(INK4a)/p14(ARF) mRNA in cervical scrapes referred to as HSIL compared with normal women. An age-dependent bias has to be considered when quantifying these tumor suppressor genes, with respect to cervical cancer development.",
        "Doc_title":"p16INKa and p14ARF mRNA expression in Pap smears is age-related.",
        "Journal":"Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc",
        "Do_id":"22080060",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;RNA, Messenger;Tumor Suppressor Protein p14ARF",
        "Doc_meshdescriptors":"Adult;Age Factors;Aged;Aged, 80 and over;Aging;Alphapapillomavirus;Cervical Intraepithelial Neoplasia;Cyclin-Dependent Kinase Inhibitor p16;Female;Gene Expression;Humans;Middle Aged;Papillomavirus Infections;RNA, Messenger;Tumor Suppressor Protein p14ARF;Uterine Cervical Neoplasms;Young Adult",
        "Doc_meshqualifiers":"physiology;isolation & purification;genetics;metabolism;virology;genetics;metabolism;complications;pathology;analysis;genetics;metabolism;genetics;metabolism;virology",
        "_version_":1605765949395304448},
      {
        "Doc_abstract":"Early detection of breast cancer increases the chances of cure, but the reliable identification of impalpable lesions is still a challenge. In spite of the advances in breast cancer detection, the molecular basis of impalpable lesions and the corresponding circulating biomarkers are not well understood. Impalpable lesions, classified by radiologists according to the Breast Imaging Reporting and Data System in the categories 3 and 4, can be either benign or malignant (slow growing or aggressive). In this article, we report the DNA methylation pattern in CDKN2A (p14(ARF)/p16(INK4a)) and in ATM gene promoters from 62 impalpable lesions, 39 peripheral blood samples, and 39 saliva samples, assessed by methylation-specific polymerase chain reaction method. ATM showed the greatest percentage of methylation in DNA from lesions (benign and malignant), blood (even with p16(INK4a)), and saliva, followed by p16(INK4a) and p14(ARF). Among the malignant cases, ATM promoter was the most hypermethylated in lesion DNA and in blood and saliva DNAs, and p14(ARF), the least. The highest percentage of p16(INK4a) methylation was found in the blood. Finally, our data are relevant because they were obtained using impalpable breast lesions from patients who were carefully recruited in 2 public hospitals of Rio de Janeiro. ",
        "Doc_title":"CDKN2A (p14(ARF)/p16(INK4a)) and ATM promoter methylation in patients with impalpable breast lesions.",
        "Journal":"Human pathology",
        "Do_id":"26255234",
        "Doc_ChemicalList":"Biomarkers, Tumor;ATM protein, human;Ataxia Telangiectasia Mutated Proteins",
        "Doc_meshdescriptors":"Adolescent;Adult;Aged;Aged, 80 and over;Ataxia Telangiectasia Mutated Proteins;Biomarkers, Tumor;Breast Neoplasms;DNA Methylation;Early Detection of Cancer;Female;Genes, p16;Humans;Middle Aged;Polymerase Chain Reaction;Promoter Regions, Genetic;Young Adult",
        "Doc_meshqualifiers":"analysis;biosynthesis;analysis;diagnosis;genetics;genetics;methods;genetics",
        "_version_":1605902053006114816},
      {
        "Doc_abstract":"It is known that the pRb pathway cell-cycle inhibitor p16(INK4A) plays a significant role in cutaneous melanoma and that alteration of p16(INK4A), which resides within the 9p21-22 locus that also contains p15(INK4B) and p14(ARF), may occur in up to one third of uveal melanomas. The absence of TGFbeta responsiveness noted in cultured uveal melanoma cells also suggests that the TGFbeta pathway plays a role in the formation of this tumor. Therefore, mutational screening was performed in several key genes in tumor-suppressor pathways that are known to be altered in some uveal melanomas.;Using denaturing high-performance liquid chromatography (DHPLC) analysis and DNA sequencing, a series of 67 uveal melanomas were screened for inactivating mutations in the TGFbeta pathway members Smad4 and TGFbeta receptor type 2 (TGFbetaR2), the downstream cell-cycle inhibitor p15(INK4B), and the cell-cycle inhibitors p14(ARF) and p16(INK4A). p16(INK4A) was also investigated for promoter hypermethylation. Mutational analysis was also performed on the Wnt pathway gene beta-catenin, known to be mutated in approximately one quarter of cutaneous melanoma cell lines.;Polymorphisms in p16(INK4A) were detected in 3 of 50 samples, but no inactivating mutations were detected in any of the genes screened. Promoter hypermethylation of p16(INK4A) was detected in 5 of 55 tumors, and loss of heterozygosity of the p16(INK4A) locus was detected in 5 of 16 tumors.;Most primary uveal melanomas do not appear to contain somatic mutations in Smad4, TGFbetaR2, p14(ARF), p15(INK4B), p16(INK4A), or beta-catenin. However, methylation of the p16(INK4A) promoter and loss of heterozygosity of the p14(ARF)-p16(INK4A) locus occurs in some tumors.",
        "Doc_title":"Mutational analysis of selected genes in the TGFbeta, Wnt, pRb, and p53 pathways in primary uveal melanoma.",
        "Journal":"Investigative ophthalmology & visual science",
        "Do_id":"12202501",
        "Doc_ChemicalList":"CDKN2B protein, human;Cell Cycle Proteins;Cyclin-Dependent Kinase Inhibitor p15;Cyclin-Dependent Kinase Inhibitor p16;DNA, Neoplasm;Neoplasm Proteins;Proto-Oncogene Proteins;Transforming Growth Factor beta;Tumor Suppressor Protein p14ARF;Tumor Suppressor Protein p53;Tumor Suppressor Proteins;Wnt Proteins;Zebrafish Proteins",
        "Doc_meshdescriptors":"Cell Cycle Proteins;Chromatography, High Pressure Liquid;Cyclin-Dependent Kinase Inhibitor p15;Cyclin-Dependent Kinase Inhibitor p16;DNA Methylation;DNA Mutational Analysis;DNA, Neoplasm;Female;Humans;Loss of Heterozygosity;Male;Melanoma;Middle Aged;Mutation;Neoplasm Proteins;Polymerase Chain Reaction;Polymorphism, Genetic;Proto-Oncogene Proteins;Signal Transduction;Transforming Growth Factor beta;Tumor Suppressor Protein p14ARF;Tumor Suppressor Protein p53;Tumor Suppressor Proteins;Uveal Neoplasms;Wnt Proteins;Zebrafish Proteins",
        "Doc_meshqualifiers":"genetics;genetics;analysis;genetics;genetics;genetics;genetics;genetics;genetics;genetics;genetics",
        "_version_":1605907757239631872},
      {
        "Doc_abstract":"Expression of p14(ARF) and p16(INK4a) tumor suppressor genes was investigated in 109 patients with chronic myeloid leukemia (CML). The p14(ARF) and p16(INK4a) mRNA levels were significantly low in patients in chronic phase (CP) at presentation and high in patients treated with interferon-alpha (IFN-alpha), especially in non-responders. A moderate overexpression of p14(ARF) with a normal expression of p16(INK4a) was observed in imatinib-resistant patients. Although protein expression did not consistently match mRNA levels, a role for the two cell cycle regulators in the IFN-alpha signaling pathway is suggested as well as a relation with the resistance to IFN-alpha or imatinib therapy.",
        "Doc_title":"Expression of the cell cycle regulators p14(ARF) and p16(INK4a) in chronic myeloid leukemia.",
        "Journal":"Leukemia research",
        "Do_id":"16533530",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;RNA, Messenger;Tumor Suppressor Protein p14ARF",
        "Doc_meshdescriptors":"Cell Cycle;Cyclin-Dependent Kinase Inhibitor p16;Gene Expression Regulation, Neoplastic;Humans;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;RNA, Messenger;Reference Values;Retrospective Studies;Signal Transduction;Tumor Suppressor Protein p14ARF",
        "Doc_meshqualifiers":"genetics;genetics;blood;genetics;genetics;genetics",
        "_version_":1605801937597366272},
      {
        "Doc_abstract":"Mortality for black males with head and neck squamous cell carcinoma (HNSCC) is twice that of white males or females. Human papillomavirus (HPV)-active HNSCC, defined by the concurrent presence of high-risk type HPV DNA and host cell p16(INK4a) expression, is associated with decreased mortality. We hypothesized that prevalence of this HPV-active disease class would be lower in black HNSCC patients compared to white patients.;Multi-institutional retrospective cohort analysis.;Real-time polymerase chain reaction was used to evaluate for high-risk HPV DNA presence. Immunohistochemistry for p16(INK4a) protein was used as a surrogate marker for HPV oncoprotein activity. Patients were classified as HPV-negative (HPV DNA-negative, p16(INK4a) low), HPV-inactive (HPV DNA-positive, p16(INK4a) low), and HPV-active (HPV DNA-positive, p16(INK4a) high). Overall survival and recurrence rates were compared by Fisher exact test and Kaplan-Meier analysis.;There were 140 patients with HNSCC who met inclusion criteria. Self-reported ethnicity was white (115), black (25), and other (0). Amplifiable DNA was recovered from 102/140 patients. The presence of HPV DNA and the level of p16(INK4a) expression were determined, and the results were used to classify these patients as HPV-negative (44), HPV-inactive (33), and HPV-active (25). Patients with HPV-active HNSCC had improved overall 5-year survival (59.7%) compared to HPV-negative and HPV-inactive patients (16.9%) (P = .003). Black patients were less likely to have HPV-active disease (0%) compared to white patients (21%) (P = .017).;The favorable HPV-active disease class is less common in black than in white patients with HNSCC, which appears to partially explain observed ethnic health disparities.",
        "Doc_title":"Human papillomavirus-active head and neck cancer and ethnic health disparities.",
        "Journal":"The Laryngoscope",
        "Do_id":"20564751",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Adult;African Americans;Aged;Carcinoma, Squamous Cell;European Continental Ancestry Group;Female;Head and Neck Neoplasms;Healthcare Disparities;Humans;Male;Middle Aged;Papillomaviridae;Survival Analysis;Tumor Virus Infections;United States",
        "Doc_meshqualifiers":"epidemiology;mortality;virology;epidemiology;mortality;virology;epidemiology;virology",
        "_version_":1605873745309728768},
      {
        "Doc_abstract":"Aberrant methylation of cytosines in CpG islands of the promoter regions of tumor suppressor genes is found in human tumors as a common mechanism of gene silencing. We investigated the methylation status of the chromosome 9p21 gene cluster (p14(ARF), p15(INK4b) and p16(INK4a) genes) by methylation-specific polymerase chain reaction in 20 central and 40 peripheral types of pulmonary squamous cell carcinoma (SqCC) in order to determine the differences between the pathogeneses of the central and peripheral types of SqCC. The frequencies of methylation were 30% for the p14(ARF) gene, 20% for the p15(INK4b) gene and 40% for the p16(INK4a) gene in the central type and 25% for the p14(ARF) gene, 10% for the p15(INK4b) gene and 38% for the p16(INK4a) gene in the peripheral type. Cases in which there was methylation of the p16(INK4a) gene had a higher smoking index in the peripheral type (P = 0.007). This trend was not detected in the central type. Methylation of two or three genes was observed in 55% of methylation in at least one gene of the central type but in only 17% of the peripheral type. This overlap methylation of the chromosome 9p21 gene cluster was found more frequently in the central type (P = 0.02). These findings suggest one of the epigenetic differences between the central and peripheral types of SqCC.",
        "Doc_title":"Aberrant methylation of p14(ARF), p15(INK4b) and p16(INK4a) genes and location of the primary site in pulmonary squamous cell carcinoma.",
        "Journal":"Pathology international",
        "Do_id":"15260845",
        "Doc_ChemicalList":"CDKN2B protein, human;Cell Cycle Proteins;Cyclin-Dependent Kinase Inhibitor p15;Cyclin-Dependent Kinase Inhibitor p16;Tumor Suppressor Protein p14ARF;Tumor Suppressor Proteins;DNA-Directed DNA Polymerase",
        "Doc_meshdescriptors":"Aged;Carcinoma, Squamous Cell;Cell Cycle Proteins;Cyclin-Dependent Kinase Inhibitor p15;Cyclin-Dependent Kinase Inhibitor p16;DNA Methylation;DNA-Directed DNA Polymerase;Gene Silencing;Humans;Immunoenzyme Techniques;Lung Neoplasms;Tumor Suppressor Protein p14ARF;Tumor Suppressor Proteins",
        "Doc_meshqualifiers":"genetics;metabolism;pathology;genetics;metabolism;genetics;metabolism;metabolism;genetics;metabolism;pathology;genetics;metabolism;genetics;metabolism",
        "_version_":1605799177210560512},
      {
        "Doc_abstract":"Lung tumors from AC3F1 mice treated with aflatoxin B(1) (AFB(1)), were examined for loss of alleles, point mutations and hypermethylation of CpG sites within the promoters of the two genes in the Ink4a/Arf gene locus. Loss of microsatellite alleles in the Ink4a/Arf region occurred in 22 of 74 (30%) AFB(1)-induced lung tumors. Fifty-one of 61 (83%) tumors had at least partial methylation of CpG sites within the p16Ink4a promoter-exon 1alpha region. At least partial methylation of CpG sites was observed in 43 of 49 (88%) tumors analyzed for p19Arf promoter hypermethylation, with methylation of identified transcription factor binding sites or consensus sequences occurring in 21 tumors (DMP1/Ets in two tumors, CTCF in four tumors, E2F in three tumors, Sp1 in 16 tumors). Two tumors contained point mutations in the p19Arf promoter. Nuclear staining for p19(Arf) was decreased by 80-100% in 41 of 71 (58%) tumors. The concordance between p19Arf molecular perturbations and altered protein expression was 63%. However, upon comparing p19Arf promoter perturbations (i.e. methylation of functional transcription factor binding sites and point mutations) and altered p19(Arf) expression, the concordance was 86%, suggesting a mechanism for changes in protein expression in some tumors. There was an absence of a mutually exclusive relationship between disruption of p53 and p19(Arf), since the concordance was 62%. Similarly, no evidence was found of inverse relationships between perturbation of p16Ink4a and p19(Arf) (43% concordance) or p16Ink4(a) and p53 (37% concordance), suggesting that inactivation of these genes occurs independently and provides evidence that, although these genes may participate in cooperative cellular pathways, they also have functions in independent pathways that are important in mouse lung tumorigenesis.",
        "Doc_title":"Perturbations of the Ink4a/Arf gene locus in aflatoxin B1-induced mouse lung tumors.",
        "Journal":"Carcinogenesis",
        "Do_id":"12538357",
        "Doc_ChemicalList":"Cdkn2a protein, mouse;Cyclin-Dependent Kinase Inhibitor p16;Tumor Suppressor Protein p14ARF;Tumor Suppressor Protein p53;Aflatoxin B1",
        "Doc_meshdescriptors":"Aflatoxin B1;Animals;CpG Islands;Cyclin-Dependent Kinase Inhibitor p16;DNA Methylation;Gene Expression Regulation, Neoplastic;Loss of Heterozygosity;Lung Neoplasms;Mice;Promoter Regions, Genetic;Tumor Suppressor Protein p14ARF;Tumor Suppressor Protein p53",
        "Doc_meshqualifiers":"pharmacology;genetics;genetics;drug effects;genetics;chemically induced;genetics;genetics;genetics;genetics",
        "_version_":1605762129980293120},
      {
        "Doc_abstract":"The CDKN2A locus encodes two distinct proteins, p16INK4a and p14ARF, both of which are implicated in replicative senescence and tumor suppression in different contexts. Here, we describe the characterization of a novel strain of human diploid fibroblasts (designated Milan HDFs) from an individual who is homozygous for the R24P mutation in p16INK4a. As this mutation occurs in the first exon of INK4a (exon 1alpha), it has no effect on the primary sequence of p14(ARF). Based on both in vitro and in vivo analyses, the R24P variant is specifically defective for binding to CDK4 but remains able to associate with CDK6. Nevertheless, Milan HDFs behave as if they are p16INK4a deficient, in terms of sensitivity to spontaneous and oncogene-induced senescence, and the R24P variant has little effect on proliferation when ectopically expressed in normal fibroblasts. It can, however, impair the proliferation of U20S cells, presumably because they express more CDK6 than primary fibroblasts. These observations suggest that CDK4 and CDK6 are not functionally redundant and underscore the importance of CDK4 in the development of melanoma.",
        "Doc_title":"A CDKN2A mutation in familial melanoma that abrogates binding of p16INK4a to CDK4 but not CDK6.",
        "Journal":"Cancer research",
        "Do_id":"17909018",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;CDK6 protein, human;Cyclin-Dependent Kinase 4;Cyclin-Dependent Kinase 6",
        "Doc_meshdescriptors":"Cell Aging;Cell Growth Processes;Cyclin-Dependent Kinase 4;Cyclin-Dependent Kinase 6;Cyclin-Dependent Kinase Inhibitor p16;Diploidy;Fibroblasts;Genes, p16;Genetic Predisposition to Disease;Germ-Line Mutation;Humans;Melanoma;Pedigree;Protein Binding",
        "Doc_meshqualifiers":"genetics;genetics;metabolism;metabolism;genetics;metabolism;pathology;physiology;enzymology;genetics;metabolism;pathology",
        "_version_":1605795984898523136},
      {
        "Doc_abstract":"Homozygous chromosome 9p deletions in gliomas commonly include the CDKN2A and CDKN2B genes, which code for the structurally highly homologous cdk inhibitors/tumor suppressors p16 and p15, respectively. Alternative splicing of the CDKN2A gene results in the expression of p14(ARF). Interestingly, not only p16 and p15, but also the structurally unrelated p14(ARF) appear to function as negative cell cycle regulators. Concerted inactivation of p16, p15 and p14(ARF) could be demonstrated in seven of nine glioblastoma cell lines. Strong suppression of tumorigenicity after transfection with p16 and p15 alone or in combination was seen in cell lines containing neither endogenous p16 nor p15 but functional pRB. Significantly weaker growth suppression was observed in tumors either retaining expression of both p16 and p15 or p15 only. p14(ARF) proved to be a potent tumor suppressor in the presence of wild-type p53, while mutant p53 substantially reduced growth inhibition by p14(ARF). No differences between p16 and p15 effects could be observed, suggesting a largely overlapping function of p16 and p15. To facilitate further research into p16/p15 effects, three cell lines with conditional, tetracycline-controlled p16 expression were established. Reversible growth suppression mediated by p16 was observed in these models. Combined inactivation of CDKN2A and CDKN2B, i.e., loss of both p16 and p15 as well as p14(ARF), results in disruption of two major growth control pathways involving pRB and p53 in malignant gliomas. Therefore, homozygous co-deletions of CDKN2A and CDKN2B rather than mutations targeting individual transcripts are frequently selected for in these tumors.",
        "Doc_title":"Functional evidence for a role of combined CDKN2A (p16-p14(ARF))/CDKN2B (p15) gene inactivation in malignant gliomas.",
        "Journal":"Acta neuropathologica",
        "Do_id":"10541865",
        "Doc_ChemicalList":"DNA, Neoplasm;Proteins;Tumor Suppressor Protein p14ARF;Tetracycline",
        "Doc_meshdescriptors":"Base Sequence;Brain Neoplasms;DNA, Neoplasm;Gene Silencing;Genes, p16;Glioma;Humans;Molecular Sequence Data;Mutation;Proteins;Tetracycline;Tumor Cells, Cultured;Tumor Suppressor Protein p14ARF",
        "Doc_meshqualifiers":"genetics;analysis;physiology;genetics;genetics;genetics;genetics;pharmacology",
        "_version_":1605904915840892928},
      {
        "Doc_abstract":"The INK4a locus encodes two different, cell cycle-regulating proteins, p16INK4a and p19ARF. In this study, we screened mutations in all coding regions of the INK4a locus (exons 1 beta, 1 alpha, 2, and 3) in 21 squamous cell carcinomas (SCCs) of human skin by polymerase chain reaction-single strand conformation polymorphism analysis. Mutations were detected in 3 SCCs in exon 2, which is common to both p16INK4a and p19ARF. These included an in-frame deletion of 21 base pairs from codon 84 to 90, a frameshift mutation of CCC-->TC at codon 75, and a nonsense mutation of CGA-->TGA at codon 80 of the p16INK4a gene. These results suggest that inactivation of the INK4a locus has some relevance to the carcinogenesis in at least some of SCCs of human skin. This is the first demonstration of aberrations in the INK4a locus in SCCs of human skin.",
        "Doc_title":"Mutations of the INK4a locus in squamous cell carcinomas of human skin.",
        "Journal":"Biochemical and biophysical research communications",
        "Do_id":"9125147",
        "Doc_ChemicalList":"Carrier Proteins;Cyclin-Dependent Kinase Inhibitor p16;Proteins;Tumor Suppressor Protein p14ARF",
        "Doc_meshdescriptors":"Carcinoma, Squamous Cell;Carrier Proteins;Cyclin-Dependent Kinase Inhibitor p16;Humans;Mutation;Polymerase Chain Reaction;Polymorphism, Single-Stranded Conformational;Proteins;Skin Neoplasms;Tumor Suppressor Protein p14ARF",
        "Doc_meshqualifiers":"genetics;genetics;genetics;genetics",
        "_version_":1605806168878350336},
      {
        "Doc_abstract":"The INK4A locus encodes two tumor suppressor genes, p16(INK4A) and p14(ARF), transcribed using alternative exons 1alpha or 1beta spliced onto the same exons 2 and 3. Both p16(INK4A) and p14(ARF) are capable of inhibiting the cell-cycle progression, albeit in different manner; p16(INK4A) is phosphorylation of retinoblastoma (pRB) dependent while p14(ARF) is p53-dependent. In this study, we report the discovery of a novel variant of p16(INK4A), termed p16gamma, in a primary T-cell acute lymphoblastic leukemia (T-ALL) patient sample and a neuroblastoma cell line, which was expressed at both the transcriptional and translational levels. Cloning and sequencing of the p16gamma cDNA revealed that p16gamma was identical to p16(INK4A), except that it contained an in-frame insertion of 197 bp between exons 2 and 3. p16gamma expression was detected in the majority of p16(INK4A)-expressing primary T-ALL and B-ALL patient samples and other p16(INK4A)-expressing tumor samples, but was only barely detectable in some normal mononuclear cells and other non-tumor samples. Structural analysis by nuclear magnetic resonance and circular dichroism confirmed that p16gamma, like p16(INK4A), is also an ankyrin-repeat protein. Functional analysis of p16gamma revealed that p16gamma protein interacted with cyclin D-dependent kinase4 and inhibited its kinase activity. Using a luciferase reporter assay, the transfection of p16gamma repressed the E2F response, the downstream target of pRB, with an efficacy equivalent to that of p16(INK4A). Moreover p16gamma, like p16(INK4A), induced cell-cycle arrest at G(0)/G(1), and inhibited cell growth in colony formation assay.",
        "Doc_title":"Human p16gamma, a novel transcriptional variant of p16(INK4A), coexpresses with p16(INK4A) in cancer cells and inhibits cell-cycle progression.",
        "Journal":"Oncogene",
        "Do_id":"17486064",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;E2F Transcription Factors;Luciferases;Cyclin-Dependent Kinase 4",
        "Doc_meshdescriptors":"Alternative Splicing;Blotting, Western;Burkitt Lymphoma;Circular Dichroism;Colony-Forming Units Assay;Cyclin-Dependent Kinase 4;Cyclin-Dependent Kinase Inhibitor p16;E2F Transcription Factors;G1 Phase;Humans;Immunoprecipitation;Leukemia-Lymphoma, Adult T-Cell;Luciferases;Neuroblastoma;Resting Phase, Cell Cycle;Two-Hybrid System Techniques",
        "Doc_meshqualifiers":"genetics;metabolism;metabolism;genetics;metabolism;metabolism;genetics;metabolism;metabolism;genetics;metabolism",
        "_version_":1605893174252797952},
      {
        "Doc_abstract":"CDKN2A and CDK4 are the only known high-penetrant genes conferring proneness to cutaneous melanoma. The CDKN2A locus consists of four exons and encodes several alternate transcripts, two of which are p16(INK4a) and p14(ARF), and originate from different open reading frames. Exon 1alpha is specific for p16(INK4a), while exon 1beta characterizes p14(ARF). Most CDKN2A mutations are located in exons 1alpha and 2, while exon 1beta variations have been identified in rare melanoma-prone pedigrees. In a previous study, we investigated 155 Italian melanoma cases, including 94 familial melanomas (FAMs) and 61 sporadic multiple primary melanomas (MPMs), for p16(INK4a)/CDK4 germline alterations and identified 15 p16(INK4a) and 1 CDK4 point mutations. In the present work, we extended our search to p14(ARF) mutations and CDKN2A deletions in the remaining samples. We identified the recurrent g.193+1G> A mutation in two FAM cases, while an additional pedigree displayed the previously undescribed variant g.161G> A. Multiplex ligation-dependent probe amplification (MLPA) screening for copy variations resulted negative in all cases. In Italy, the overall frequency of p14(ARF) mutations is 3.2% in FAM and 0% in sporadic MPM. Re-evaluation of our patients' cohort emphasizes that the chance of identifying CDKN2A/CDK4 mutations in FAM is mainly influenced by the number of affected family members and the presence of one or more MPM cases. Accordingly, mutation rate rises to 61% in selected cases. Further studies are expected in order to investigate CDKN2A rarer mutations, including atypical deletions and inherited epimutations.",
        "Doc_title":"Novel and recurrent p14 mutations in Italian familial melanoma.",
        "Journal":"Clinical genetics",
        "Do_id":"20132244",
        "Doc_ChemicalList":"Tumor Suppressor Protein p14ARF",
        "Doc_meshdescriptors":"Amino Acid Sequence;Cohort Studies;Family;Genes, p16;Humans;Italy;Melanoma;Molecular Sequence Data;Mutation;Pedigree;Skin Neoplasms;Tumor Suppressor Protein p14ARF",
        "Doc_meshqualifiers":"genetics;genetics;genetics",
        "_version_":1605837641159278592},
      {
        "Doc_abstract":"The cyclin-dependent kinase inhibitor 2a (Cdkn2a) locus encodes two distinct tumor suppressors, p16INK4a and p19ARF, whose functions interrelate in the regulation of cell proliferation as key components of the retinoblastoma and p53 pathways, respectively. In many types of cancer, alterations of Cdkn2a abrogate the functions of both suppressors, implying that both are integral to the genesis of certain cancer types. While this has been observed in mouse lung adenocarcinogenesis, recent observations also suggested that naturally occurring variation at the Cdkn2a locus is probably operative in the development of these tumors. Firstly, two common haplotypes of mouse Cdkn2a have been identified, each of which encodes cosegregating variants of p16INK4a and p19ARF. The p16INK4a variants differ at amino acids 18 (histidine or proline) and 51 (valine or isoleucine), whereas the p19ARF variants differ only at amino acid 72 (histidine or arginine). Secondly, genetic resistance to lung tumor formation appears to segregate with one particular haplotype, which also is deleted preferentially in lung adenocarcinomas of Cdkn2a heterozygous mice. Here we attempt to explain these observations and to characterize further the roles of p16INK4 and p19ARF in mouse lung tumorigenesis by examining the function and expression of each of the variants of Cdkn2a. Functional analysis showed that the proline 18/isoleucine 51 p16INK4a variant was diminished in cdk6 binding, cdk6 inhibition and NIH/3T3 fibroblast growth suppression compared with the histidine 18/valine 51 variant, whereas both of the p19ARF variants suppressed growth with similar potencies. Also, the different alleles for p16INK4a and p19ARF were transcribed equally in the normal lungs of Cdkn2a heterozygotes, as determined by comparative reverse transcription-polymerase chain reaction-single-stranded conformation polymorphism analysis. These results indicate that strain-specific variation in p16INK4a function is exploited in mouse lung tumorigenesis and strongly implicate a role for p16INK4a in lung cancer predisposition and development.",
        "Doc_title":"Cdkn2a encodes functional variation of p16INK4a but not p19ARF, which confers selection in mouse lung tumorigenesis.",
        "Journal":"Molecular carcinogenesis",
        "Do_id":"10365910",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;Proteins;Tumor Suppressor Protein p14ARF",
        "Doc_meshdescriptors":"Adenocarcinoma;Animals;Cell Transformation, Neoplastic;Cyclin-Dependent Kinase Inhibitor p16;Humans;Jurkat Cells;Lung Neoplasms;Mice;Mutation;Polymorphism, Single-Stranded Conformational;Proteins;Reverse Transcriptase Polymerase Chain Reaction;Tumor Suppressor Protein p14ARF",
        "Doc_meshqualifiers":"genetics;genetics;genetics;genetics;genetics",
        "_version_":1605810531962191872},
      {
        "Doc_abstract":"Actinic keratosis (AK) is a well-established pre-cancerous skin lesion that has the potential to progress to squamous cell carcinoma (SCC). We investigated the involvement of the CDKN2A, CDKN2B and p53 genes in AK and in the progression of AK to SCC. Mutational analysis on exons 1a, 1b and 2 of the CDKN2A locus and exon 1 of the CDKN2B locus as well as allelic imbalance was performed in 26 AK specimens. Expression levels of the genes p14(ARF), p15(INK4b), p16(INK4a) and p53 were examined in 16 AKs and 12 SCCs by real-time RT-PCR. A previously described polymorphism of p16(INK4a) (Ala148Thr) was detected at an allelic frequency of 12%. Six samples carried novel mutations at codon 71 of the CDKN2A locus and one sample presented an additional mutation at codon 65. Two AK samples carried a not-previously described non-UV type missense mutation at codon 184 (Val184Glu) of exon 1b in the p14(ARF) gene. Regarding the CDKN2B locus a new mutation at codon 50 (Ala50Thr) and another at codon 24 (Arg24Arg), were detected. Microsatellite instability (MSI) was found in 15% of AKs in at least one marker, indicating that genetic instability has some implication in the development of AK. Down-regulation of p16(INK4a) and p53 mRNA levels was noted in SCC compared to AK. TSGs expression levels in sun-exposed morphologically normal-appearing skin, suggests that abnormal growth stimuli might exist in these tissues as well. Furthermore, we suggest a possible role of p15(INK4b), independently from the intracellular pathway mediated by p16(INK4a), and of p14(ARF) in AK development, as well as in the progression of AK to SCC. The deregulation of the expression profiles of the CDKN2A, CDKN2B and p53 genes may, independently of mutations and LOH at 9p21, play a significant role in AK and progression of AK to SCC.",
        "Doc_title":"Genomic instability, mutations and expression analysis of the tumour suppressor genes p14(ARF), p15(INK4b), p16(INK4a) and p53 in actinic keratosis.",
        "Journal":"Cancer letters",
        "Do_id":"18331779",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p15;Cyclin-Dependent Kinase Inhibitor p16;RNA, Messenger;Tumor Suppressor Protein p14ARF;Tumor Suppressor Protein p53;Tumor Suppressor Proteins",
        "Doc_meshdescriptors":"Aged;Aged, 80 and over;Base Sequence;Carcinoma, Squamous Cell;Cyclin-Dependent Kinase Inhibitor p15;Cyclin-Dependent Kinase Inhibitor p16;DNA Mutational Analysis;Female;Genomic Instability;Humans;Keratosis;Loss of Heterozygosity;Male;Middle Aged;Molecular Sequence Data;Mutation;Polymorphism, Single-Stranded Conformational;Precancerous Conditions;RNA, Messenger;Reverse Transcriptase Polymerase Chain Reaction;Tumor Suppressor Protein p14ARF;Tumor Suppressor Protein p53;Tumor Suppressor Proteins",
        "Doc_meshqualifiers":"genetics;genetics;metabolism;genetics;metabolism;genetics;metabolism;genetics;metabolism;biosynthesis;genetics;metabolism;genetics;metabolism;genetics;metabolism",
        "_version_":1605819362052145152},
      {
        "Doc_abstract":"The aim of this study was to determine the methylation status of the p16(INK4a), p14(ARF) and p15(INK4b) genes and the subsequent effect of hypermethylation on the expression of these genes in cervical cancer patients. Methylation-specific PCR (MSP) was performed to analyse the methylation status of p16(INK4a), p14(ARF) and p15(INK4b) genes and was confirmed by sequencing. Reverse transcription PCR (RT-PCR) was carried out to determine changes in the expression of the genes due to hypermethylation. Hypermethylation of the p16(INK4a), p14(ARF) and p15(INK4b) gene promoters was observed in 36, 8.8 and 11.2%, respectively, of 125 cervical cancer samples from a north Indian population. Methylation of p16(INK4a) was significantly (P<0.001) associated with the cervical cancer cases. Significant association of p16(INK4a) hypermethylation with passive smoking and oral contraceptive use was also observed. Methylation of p15(INK4b) was also found to be significant (P<0.05). Our findings did not reveal any correlation between the promoter methylation of p16(INK4a), p14(ARF) and p15(INK4b) with factors, including age and human papillomavirus infection. mRNA expression was significantly reduced in patients with a methylated promoter (P<0.001) of p16(INK4a) compared to patients with an unmethylated promoter. In conclusion, this is the first study demonstrating significant hypermethylation of p15(INK4b) and p16(INK4a) genes among cervical cancer patients in a north Indian population, and a significant association of p16(INK4a) hypermethylation with passive smoking and oral contraceptive use.",
        "Doc_title":"p16(INK4a) and p15(INK4b) gene promoter methylation in cervical cancer patients.",
        "Journal":"Oncology letters",
        "Do_id":"22783444",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605841475975774208},
      {
        "Doc_abstract":"Ink4a/Arf inactivation and epidermal growth factor receptor (EGFR) activation are signature lesions in high-grade gliomas. How these mutations mediate the biological features of these tumors is poorly understood. Here, we demonstrate that combined loss of p16(INK4a) and p19(ARF), but not of p53, p16(INK4a), or p19(ARF), enables astrocyte dedifferentiation in response to EGFR activation. Moreover, transduction of Ink4a/Arf(-/-) neural stem cells (NSCs) or astrocytes with constitutively active EGFR induces a common high-grade glioma phenotype. These findings identify NSCs and astrocytes as equally permissive compartments for gliomagenesis and provide evidence that p16(INK4a) and p19(ARF) synergize to maintain terminal astrocyte differentiation. These data support the view that dysregulation of specific genetic pathways, rather than cell-of-origin, dictates the emergence and phenotype of high-grade gliomas.",
        "Doc_title":"Epidermal growth factor receptor and Ink4a/Arf: convergent mechanisms governing terminal differentiation and transformation along the neural stem cell to astrocyte axis.",
        "Journal":"Cancer cell",
        "Do_id":"12086863",
        "Doc_ChemicalList":"Cdkn2a protein, mouse;Cyclin-Dependent Kinase Inhibitor p16;Luminescent Proteins;Tumor Suppressor Protein p14ARF;Tumor Suppressor Protein p53;Green Fluorescent Proteins;Receptor, Epidermal Growth Factor",
        "Doc_meshdescriptors":"Animals;Astrocytes;Blotting, Western;Cell Differentiation;Cells, Cultured;Cyclin-Dependent Kinase Inhibitor p16;Green Fluorescent Proteins;Homozygote;Humans;Immunoenzyme Techniques;Infusion Pumps, Implantable;Luminescent Proteins;Magnetic Resonance Imaging;Mice;Mice, SCID;Neoplasms, Experimental;Neurons;Receptor, Epidermal Growth Factor;Retroviridae;Stem Cells;Transformation, Genetic;Tumor Suppressor Protein p14ARF;Tumor Suppressor Protein p53",
        "Doc_meshqualifiers":"cytology;physiology;physiology;cytology;metabolism;metabolism;metabolism;pathology;cytology;physiology;genetics;cytology;physiology;physiology;metabolism;metabolism",
        "_version_":1605810857789358080},
      {
        "Doc_abstract":"Mouse and human cells have most frequently been used for studies that have led to the elucidation of various molecular pathways involved in senescence. The ARF-p53 pathway has been assigned as one of the major protagonists in these phenomena. ARF is an alternative reading frame protein encoded along with p16INK4A by the INK4a locus on human chromosome 9p21 and the corresponding locus on mouse chromosome 4. Whereas the mouse ARF (p19ARF) consists of 169 amino acids, the human ARF (p14ARF) consists of 132 amino acids, truncated at the C-terminus. Molecular studies on the regulation of ARF activity by its binding partners have revealed that mouse ARF protein, but not human ARF protein, interacts with a cytoplasmic protein, Pex19p. This interaction of mouse ARF with Pex19p results in its milder p53 activation function in mouse cells as compared to human cells and thus accounts, at least in part, for the weaker tumor surveillance and frequent immortalization of mouse cells.",
        "Doc_title":"The ARF-p53 senescence pathway in mouse and human cells.",
        "Journal":"Histology and histopathology",
        "Do_id":"14702199",
        "Doc_ChemicalList":"Cdkn2a protein, mouse;Cyclin-Dependent Kinase Inhibitor p16;Tumor Suppressor Protein p14ARF;Tumor Suppressor Protein p53",
        "Doc_meshdescriptors":"Animals;Cell Aging;Cell Lineage;Cells, Cultured;Cyclin-Dependent Kinase Inhibitor p16;Humans;Mice;Mice, Knockout;Mice, Transgenic;Open Reading Frames;Tumor Suppressor Protein p14ARF;Tumor Suppressor Protein p53",
        "Doc_meshqualifiers":"metabolism;genetics;metabolism;genetics;metabolism",
        "_version_":1605747019268227074},
      {
        "Doc_abstract":"The INK4A gene, a candidate tumor suppressor gene located on chromosome 9p21, encodes two protein products, p16 and p19(ARF). p16 is a negative cell cycle regulator capable of arresting cells in the G1 phase by inhibiting cyclin-dependent kinases 4 (Cdk4) and 6 (Cdk6), thus preventing pRB phosphorylation. p19(ARF) prevents Mdm2-mediated neutralization of p53. Loss of INK4A is a frequent molecular alteration involved in the genesis of several neoplasms, including tumors of neuroectodermal origin. This study investigated the frequency of INK4A gene alterations in a series of malignant peripheral nerve sheath tumors (MPNSTs) and neurofibromas (NFs). INK4A gene and the p19(ARF)-specific exon 1beta were studied in 11 MPNST samples from 8 patients and 7 neurofibromas. Presence of INK4A deletions was assessed by Southern blotting hybridization and by a multiplex polymerase chain reaction (mPCR). INK4A point mutations were examined by single-strand conformation polymorphism (SSCP) and sequencing. The p16 promoter methylation status was determined by PCR amplification of bisulfite-treated DNA. Homozygous deletions of exon 2, thus affecting both p16 and p19(ARF), were identified in MPNSTs from 4 of 8 patients. Deletions, mutations, or silencing by methylation were not identified in the neurofibromas analyzed. Based on our results, we conclude that INK4A deletions are frequent events in MPNSTs and may participate in tumor progression. Silencing of p16 by methylation, which occurs often in several tumor types, is uncommon in MPNSTs.",
        "Doc_title":"Deletions of the INK4A gene occur in malignant peripheral nerve sheath tumors but not in neurofibromas.",
        "Journal":"The American journal of pathology",
        "Do_id":"10595915",
        "Doc_ChemicalList":"DNA, Neoplasm;Proteins;Tumor Suppressor Protein p14ARF;Cyclin-Dependent Kinases",
        "Doc_meshdescriptors":"Blotting, Southern;Cell Cycle;Cyclin-Dependent Kinases;DNA Methylation;DNA, Neoplasm;Exons;Gene Deletion;Genes, Tumor Suppressor;Genes, p16;Humans;Nerve Sheath Neoplasms;Neurofibroma;Point Mutation;Polymerase Chain Reaction;Polymorphism, Single-Stranded Conformational;Proteins;Tumor Suppressor Protein p14ARF",
        "Doc_meshqualifiers":"antagonists & inhibitors;analysis;genetics;pathology;genetics;pathology;genetics",
        "_version_":1605748127149588480},
      {
        "Doc_abstract":"Germline mutations at the INK4a/p16 locus are implicated in several human cancer syndromes, including familial atypical multiple mole melanoma (FAMMM) syndrome, FAMMM-pancreatic cancer (FAMMM-PC) syndrome, and in familial head and neck cancer syndrome.;We present an individual with a family history of melanoma and pancreatic cancer who had multiple dysplastic nevi, squamous cell carcinoma of the tongue at age 22, multiple melanomas, a second squamous cell cancer of the tongue at age 40, and ultimately a pancreatic cancer.;We demonstrate a germline mutation in INK4a and loss of heterozygosity at this locus in his HNSCC tissue.;This report suggests that INK4a germline mutations associated with FAMMM/FAMMM-PC can also be associated with HNSCC. We conclude that HNSCC in young individuals should prompt clinicians to obtain a family history and consider that the patient may have a germline p16 defect that could predispose them to other cancers, including melanoma and pancreatic cancer.",
        "Doc_title":"Head and neck squamous cell carcinoma in FAMMM syndrome.",
        "Journal":"Head & neck",
        "Do_id":"19360740",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Adult;Carcinoma, Squamous Cell;Dysplastic Nevus Syndrome;Head and Neck Neoplasms;Humans;Male;Melanoma;Pancreatic Neoplasms;Pedigree;Young Adult",
        "Doc_meshqualifiers":"genetics;pathology;therapy;genetics;pathology;therapy;genetics;pathology;therapy;genetics;pathology;therapy;genetics;pathology;therapy",
        "_version_":1605801463095754752},
      {
        "Doc_abstract":"A fraction of head and neck squamous cell carcinomas (HNSCC) reveal overexpression of the p53 protein although sequence analysis failed to detect mutations in the core region of the protein. The functional and clinical status of p53 in these tumors is unclear.;In 31 HNSCC, allelic imbalances (AI) at TP53 and other chromosome 17 loci were analyzed by microsatellite marker analysis. Expression of p16(INK4a) protein was analyzed by immunohistochemistry. Seven tumors were re-examined for sequence alterations by the Affymetrix p53 GeneChip.;About 54.8% of these tumors showed AI at TP53; 41.9% showed loss of p16, an overlapping fraction of 35.5% demonstrated AI and p16 loss. Six of seven such tumors revealed heterozygous missense mutations.;A large proportion of HNSCC with presumed wild-type p53 overexpression are false-negative cases. These results strengthen the established strong association of p53 protein overexpression with missense mutations. AI at TP53 and p16 loss are useful surrogate markers for genetic alterations of TP53 in HNSCC.",
        "Doc_title":"Refined characterization of head and neck squamous cell carcinomas expressing a seemingly wild-type p53 protein.",
        "Journal":"Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology",
        "Do_id":"16393249",
        "Doc_ChemicalList":"Tumor Suppressor Protein p53",
        "Doc_meshdescriptors":"Allelic Imbalance;Carcinoma, Squamous Cell;Chromosomes, Human, Pair 17;Gene Expression Regulation, Neoplastic;Genes, p16;Genes, p53;Head and Neck Neoplasms;Humans;Loss of Heterozygosity;Microsatellite Repeats;Mutation, Missense;Sequence Analysis, Protein;Tumor Suppressor Protein p53",
        "Doc_meshqualifiers":"genetics;genetics;genetics;genetics;genetics;genetics;genetics;genetics;genetics;genetics",
        "_version_":1605801835312971776},
      {
        "Doc_abstract":"Aberrant promoter methylation is an important mechanism for gene silencing. In the present study, 50 Barrett's esophagus-associated esophageal adenocarcinomas (ADC), 50 cardiac ADC and 50 gastric ADC were investigated by means of methylation-specific real-time PCR for hypermethylation in the tumor suppressor genes APC, p16(INk4A) and p14(ARF). Additionally, expression of p16(INK4A) protein in the carcinomas was assessed using immunohistochemistry. Marked differences in hypermethylation were found between esophageal, cardiac and gastric ADC in the APC gene (78% vs. 32% vs. 84%) and in the p16(INK4A) gene (54% vs. 36% vs. 10%). Hypermethylation of p14(ARF) was absent from esophageal ADC and present infrequently in cardiac (2%) and gastric ADC (10%). Complete loss of p16(INK4A) protein expression was detectable in 45% of all tumors and was significantly associated with hypermethylation of the p16(INK4A) gene (p<0.0001, chi(2)-test). Our results suggest that hypermethylation of p16(INK4A) and APC are frequent findings in esophageal, cardiac and gastric ADC. Additionally, the data point to a tumor specific methylation pattern in upper gastrointestinal ADC.",
        "Doc_title":"Hypermethylation of tumor suppressor genes (p16INK4A, p14ARF and APC) in adenocarcinomas of the upper gastrointestinal tract.",
        "Journal":"International journal of cancer",
        "Do_id":"15197775",
        "Doc_ChemicalList":"Tumor Suppressor Protein p14ARF",
        "Doc_meshdescriptors":"Adenocarcinoma;Adult;Aged;Aged, 80 and over;Barrett Esophagus;Cardia;DNA Methylation;Esophageal Neoplasms;Female;Gene Expression Profiling;Genes, APC;Genes, p16;Humans;Immunohistochemistry;Male;Middle Aged;Stomach Neoplasms;Tumor Suppressor Protein p14ARF",
        "Doc_meshqualifiers":"genetics;physiopathology;complications;pathology;genetics;physiopathology;genetics;physiopathology;genetics",
        "_version_":1605746985088843778},
      {
        "Doc_abstract":"The INK4a/ARF locus encodes two different proteins involved in cell cycle control. Both molecules, p16(INK4a) and p19(ARF), inhibit cell cycle progression and have been shown to act as tumor suppressors in a variety of models. Their expression is controlled by separate promoters responding to different stimuli and they therefore show independent transcriptional regulation. We have cloned and characterized a 2.5 kb region upstream of the murine p19(ARF) gene to determine the role of DNA methylation in suppressing p19(ARF) transcription in a wide panel of murine primary T cell lymphomas. This region contains a DNA fragment with the characteristics of a CpG island similar to those described for the murine p16(INK4a) and p15(INK4b) genes. Expression of p19(ARF) is decreased in a significant number (20%) of the murine lymphomas analyzed. Overexpression of the p19(ARF) transcript is also frequent, suggesting alterations in molecules of the retinoblastoma or p53 pathways that are involved in p19(ARF) regulation. Although hypermethylation of the INK4a and INK4b promoters is frequently involved in murine lymphomas, the p19(ARF) CpG island is infrequently methylated in the murine primary lymphomas studied in this work. Since loss of p19(ARF) expression cannot be explained as the result of homozygous deletions or hypermethylation of the ARF gene, other regulatory mechanisms seem to be altered in these malignancies.",
        "Doc_title":"Characterization of the murine p19(ARF) promoter CpG island and its methylation pattern in primary lymphomas.",
        "Journal":"Carcinogenesis",
        "Do_id":"10753221",
        "Doc_ChemicalList":"Carrier Proteins;Cyclin-Dependent Kinase Inhibitor p16;Proteins;Tumor Suppressor Protein p14ARF",
        "Doc_meshdescriptors":"Animals;Carrier Proteins;CpG Islands;Cyclin-Dependent Kinase Inhibitor p16;DNA Methylation;Female;Lymphoma;Male;Mice;Mice, Inbred BALB C;Mice, Inbred C57BL;Promoter Regions, Genetic;Proteins;Tumor Suppressor Protein p14ARF",
        "Doc_meshqualifiers":"genetics;genetics;genetics",
        "_version_":1605830376585953280},
      {
        "Doc_abstract":"To elucidate the role of p53/p16(INK4a)/RB1 pathways in prostate carcinogenesis, we analyzed the p14(ARF), p16(INK4a), RB1, p21(Waf1), p27(Kip1), PTEN, p73, p53, and MDM2 gene status of multiple areas within 16 histologically heterogeneous prostate carcinomas using methylation-specific polymerase chain reaction, differential polymerase chain reaction, and immunohistochemistry. All focal areas examined had Gleason scores ranging from 1 to 5. Methylation of either PTEN or p73 was undetected in any sample, whereas expression of MDM2 seemed to be an independent event within small foci of 4 of 16 tumors. Loss of p14(ARF), p16(INK4a), RB1, and p27(Kip1) expression correlated with homozygous deletion or promoter hypermethylation. One carcinoma showed co-deletion of both p14(ARF) and p16(INK4a) in two of five areas examined; two areas within another tumor demonstrated concurrent hypermethylation of the promoter regions of the same genes. Focal hypermethylation of RB1, p21(Waf1), and p27(Kip1) was detected within two, two, and three tumors, respectively. These findings indicate that both genetic and epigenetic events occur independently in intratumor foci and further suggest hypermethylation-induced loss of gene function may be as critical as specific genetic mutations in prostate carcinogenesis.",
        "Doc_title":"Heterogeneous methylation and deletion patterns of the INK4a/ARF locus within prostate carcinomas.",
        "Journal":"The American journal of pathology",
        "Do_id":"11943705",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;Neoplasm Proteins;Tumor Suppressor Protein p14ARF;Tumor Suppressor Protein p53",
        "Doc_meshdescriptors":"Aged;Carcinoma;Cyclin-Dependent Kinase Inhibitor p16;DNA Methylation;Gene Deletion;Humans;Immunohistochemistry;Male;Mutation;Neoplasm Proteins;Prostatic Neoplasms;Tumor Suppressor Protein p14ARF;Tumor Suppressor Protein p53",
        "Doc_meshqualifiers":"genetics;metabolism;pathology;genetics;metabolism;genetics;metabolism;genetics;metabolism;pathology;genetics;metabolism;genetics",
        "_version_":1605874988328419328},
      {
        "Doc_abstract":"The 9p21 region of human chromosome 9 is a hot spot for chromosomal aberrations in both cultured cell lines and primary tumors. This region contains a gene, P16 (also called MTS1, CDKN2 and p16INK4), that encodes a presumptive negative cell cycle regulator called p16. P16 is deleted or mutated at high frequency in a variety of tumor cell lines including melanoma and bladder carcinoma lines. As such, it is likely to be a tumor suppressor gene. Here we show that P16 is mutated in primary bladder carcinomas (3 of 33) and melanomas (5 of 34). These findings support studies that show P16 mutations are not solely a product of growth in tissue culture but rather are involved in formation of tumors in viva. Some bladder primary tumors and some bladder and melanoma tumor cell lines contain mutations in both P16 and P53 at frequencies that suggest that p53 and p16 function in different pathways, each of which is important in suppressing malignant transformation.",
        "Doc_title":"Genetic evidence in melanoma and bladder cancers that p16 and p53 function in separate pathways of tumor suppression.",
        "Journal":"The American journal of pathology",
        "Do_id":"7747814",
        "Doc_ChemicalList":"Carrier Proteins;Cyclin-Dependent Kinase Inhibitor p16;DNA, Neoplasm",
        "Doc_meshdescriptors":"Amino Acid Sequence;Base Sequence;Carcinoma, Transitional Cell;Carrier Proteins;Cyclin-Dependent Kinase Inhibitor p16;DNA, Neoplasm;Genes, Tumor Suppressor;Genes, p53;Humans;Melanoma;Molecular Sequence Data;Mutation;Skin Neoplasms;Urinary Bladder Neoplasms",
        "Doc_meshqualifiers":"genetics;genetics;genetics;genetics;genetics;genetics;genetics;genetics;genetics",
        "_version_":1605764555284152320},
      {
        "Doc_abstract":"We have previously shown that the disruption/deletion of the MTS(MTS1-MTS2) locus due to illegitimate V(D)J recombinase activity is a genetic event characteristic of T-cell acute lymphoblastic leukemia (T-ALL). Inactivation of the p16INK4a tumor suppressor protein, encoded by MTS1, is thought to be the major functional consequence of these chromosomal rearrangements. The two other cell cycle inhibitors encoded by genes identified in the locus (p19ARF by MTS1 and p15INK4b by MTS2), also represent possible candidates for inactivating events. By analyzing p16INK4a expression in three cases in which an identical 36-kb deletion had deleted MTS2 and disrupted the p19ARF, but spared the p16INK4a MTS1 encoding exons, we have excluded p16INK4a and pinpointed p19ARF and/or p15INK4b as the functional target(s) of this rearrangement. Moreover, by the study of the MTS genomic configuration of 149 rearranged alleles from a large series of T-ALL cases, we have shown that p19ARF encoding exons were always disrupted or deleted, whereas p16INK4a and p15INK4b encoding exons were spared in four and 21 cases, respectively. These results suggest that p19ARF may be targeted by the genetic events that occur in the MTS locus in the majority of T-ALLs.",
        "Doc_title":"Genomic alterations of the p19ARF encoding exons in T-cell acute lymphoblastic leukemia.",
        "Journal":"Blood",
        "Do_id":"9446664",
        "Doc_ChemicalList":"Proteins;RNA, Messenger;Tumor Suppressor Protein p14ARF;RNA-Directed DNA Polymerase",
        "Doc_meshdescriptors":"Adolescent;Adult;Alleles;Blotting, Southern;Child;Female;Gene Deletion;Humans;Leukemia-Lymphoma, Adult T-Cell;Male;Polymerase Chain Reaction;Proteins;RNA, Messenger;RNA-Directed DNA Polymerase;Recombination, Genetic;Thymus Gland;Tumor Suppressor Protein p14ARF",
        "Doc_meshqualifiers":"genetics;genetics;analysis;chemistry",
        "_version_":1605747078904938498},
      {
        "Doc_abstract":"The MTS1 (Multiple Tumor Suppressor 1) locus is a very original one as its organization results in the expression of two alternative transcripts that encode two structurally and functionally different proteins: INK4a and ARF (also designated p19ARF in mouse and p14ARF in man). Recent findings indicate that the latter is a major component of a regulatory pathway of oncogenic signals culminating in p53 activation by stabilisation of the protein. While the importance of this pathway has been overtly established in animal experimental oncology, it still has to be further documented in human oncology in order for this gene to acquire its full biological significance.",
        "Doc_title":"[The ARF-p53 pathway: a line of defence against oncogenic signals].",
        "Journal":"Pathologie-biologie",
        "Do_id":"10858963",
        "Doc_ChemicalList":"Proteins;Tumor Suppressor Protein p14ARF;Tumor Suppressor Protein p53",
        "Doc_meshdescriptors":"Animals;Cell Division;Gene Expression Regulation;Humans;Neoplasms;Oncogenes;Proteins;Signal Transduction;Tumor Suppressor Protein p14ARF;Tumor Suppressor Protein p53",
        "Doc_meshqualifiers":"genetics;genetics;physiology;physiology",
        "_version_":1605844258143600640},
      {
        "Doc_abstract":"We studied the expression of p16(INK4a) in a series of HPV-negative laryngeal squamous cell carcinomas and assessed its association with prognosis. Forty-five patients with laryngeal carcinoma were included in the study. Clinicopathological features and prognosis were reviewed. p16(INK4a) protein expression was analysed through immunohistochemistry. We analysed messenger RNA (mRNA) in 25 cases through quantitative reverse transcription polymerase chain reaction. HPV status was assessed by PCR using three different protocols based on MY09/11 and GP5/6 primers. Four out of 45 (9 %) cases overexpressed p16(INK4a) protein and showed a tendency to worse survival that was significant for stages I-III (log-rank p value=0.001). Expression of p16(INK4a) mRNA was high in 12 out of 25 (48 %) cases using an arbitrary cut-off level. All tumours were HPV negative with all three detection methods. A CDKN2A mutation was found in eight cases. One case with a missense and one with a frameshift mutation showed p16(INK4a) protein expression by immunohistochemistry. Six out of seven (86 %) mutated but only 6 out of 18 (33 %) non-mutated cases presented p16(INK4a) mRNA overexpression (p=0.03). Our findings suggest that p16(INK4a) overexpression, both at protein and mRNA levels, may reflect CDKN2A genetic alterations in HPV-negative laryngeal squamous cell carcinomas.",
        "Doc_title":"P16(INKa) overexpression is associated with CDKN2A mutation and worse prognosis in HPV-negative laryngeal squamous cell carcinomas.",
        "Journal":"Virchows Archiv : an international journal of pathology",
        "Do_id":"25652585",
        "Doc_ChemicalList":"Biomarkers, Tumor;Cyclin-Dependent Kinase Inhibitor p16",
        "Doc_meshdescriptors":"Aged;Biomarkers, Tumor;Carcinoma, Squamous Cell;Cyclin-Dependent Kinase Inhibitor p16;DNA Mutational Analysis;Female;Head and Neck Neoplasms;Humans;Immunohistochemistry;Kaplan-Meier Estimate;Laryngeal Neoplasms;Male;Middle Aged;Mutation;Papillomavirus Infections;Prognosis;Reverse Transcriptase Polymerase Chain Reaction",
        "Doc_meshqualifiers":"analysis;genetics;mortality;pathology;biosynthesis;genetics;genetics;mortality;pathology;genetics;mortality;pathology",
        "_version_":1605853368873385985},
      {
        "Doc_abstract":"The four members of the INK4 gene family (p16(INK4a), p15(INK4b), p18(INK4c) and p19(INK4d)) inhibit the closely related cyclin-dependent kinases CDK4 and CDK6 as part of the regulation of the G1-->S transition in the cell-division cycle. Loss of INK4 gene product function, particularly that of p16(INK4a), is found in 10-60% of human tumors, suggesting that broadly applicable anticancer therapies might be based on restoration of p16(INK4a) CDK inhibitory function. Although much less frequent, defects of p19(INK4d) have also been associated with human cancer (osteosarcomas). The protein structures of some INK4 family members, determined by nuclear magnetic resonance (NMR) spectroscopy and X-ray techniques, have begun to clarify the functional role of p16(INK4a) and the dysfunction introduced by the mutations associated with human tumors.;The crystal structure of human p19(INK4d) has been determined at 1.8 A resolution using multiple isomorphous replacement methods. The fold of p19(INK4d) produces an oblong molecule comprising five approximately 32-residue ankyrin-like repeats. The architecture of the protein demonstrates the high structural similarity within the INK4 family. Comparisons to other ankyrin-repeat-containing proteins (GABPbeta, 53BP2 and myotrophin) show similar structures with comparable hydrogen-bonding patterns and hydrophobic interactions. Such comparisons highlight the splayed beta-loop geometry that is specific to INK4 inhibitors. This geometry is the result of a modified ankyrin structure in the second repeat.;Among the INK4 inhibitors, the highest amino acid sequence conservation is found in the helical stacks; this conservation creates a conserved beta-loop geometry specific to INK4 inhibitors. Therefore, in addition to models which predict that the conserved helix alpha6 is responsible for CDK inhibition, a binding mode whereby the loops of INK4 proteins bind to the CDKs should also be considered. A similar loop-based interaction is seen in the complex formed between the ankyrin-repeat-containing protein GABPbeta and_GABPalpha. This mode of binding would be consistent with the observation that p16(INK4a) is sensitive to deleterious mutations found throughout this tumor suppressor protein; these mutations probably destabilize the three-dimensional structure.",
        "Doc_title":"Structure of human cyclin-dependent kinase inhibitor p19INK4d: comparison to known ankyrin-repeat-containing structures and implications for the dysfunction of tumor suppressor p16INK4a.",
        "Journal":"Structure (London, England : 1993)",
        "Do_id":"9782052",
        "Doc_ChemicalList":"Ankyrins;CDKN2D protein, human;Carrier Proteins;Cell Cycle Proteins;Cyclin-Dependent Kinase Inhibitor p16;Cyclin-Dependent Kinase Inhibitor p19;Enzyme Inhibitors;Cyclin-Dependent Kinases",
        "Doc_meshdescriptors":"Amino Acid Sequence;Ankyrins;Carrier Proteins;Cell Cycle;Cell Cycle Proteins;Cell Division;Computer Graphics;Crystallography, X-Ray;Cyclin-Dependent Kinase Inhibitor p16;Cyclin-Dependent Kinase Inhibitor p19;Cyclin-Dependent Kinases;Enzyme Inhibitors;Humans;Models, Molecular;Molecular Sequence Data;Mutation;Neoplasms;Protein Structure, Secondary;Repetitive Sequences, Amino Acid;Sequence Alignment;Sequence Homology, Amino Acid",
        "Doc_meshqualifiers":"chemistry;chemistry;genetics;genetics;genetics;chemistry;genetics;antagonists & inhibitors;chemistry;genetics;metabolism",
        "_version_":1605805334736142336},
      {
        "Doc_abstract":"Malignant rhabdoid tumors (MRTs) are aggressive tumors associated with mutations in the SMARCB1 gene. In experimental systems, the loss of SMARCB1 is hypothesized to alter p16(INK4A) pathways resulting in the repression of tumor suppressors. To determine whether these pathways are deregulated in human MRT, we used immunohistochemistry on tissue microarrays to evaluate p16(INK4A)/E2F1/RB and p14(ARF)/MDM2/p53 pathways in 25 atypical teratoid/rhabdoid tumors (AT/RT) and 11 non-CNS MRT. p16(INK4A) was negative or showed focal weak expression. p16(INK4A) downstream targets CDK4/cyclin D1/ppRB were variably expressed at moderate to low levels; E2F1 was negative. Unexpectedly, p14(ARF) expression was seen in many cases, which correlated positively with p53 and inversely with MDM2 immunostaining in AT/RT. TP53 mutational analysis in 19 of 25 AT/RT and in 8 of 11 non-CNS MRT cases showed point mutations in only 3 AT/RT cases, suggesting that p53 expression was driven mainly by p14(ARF). Finally, nucleophosmin, a protein that stabilizes p53, was positive in most cases and colocalized with p53. Together, these data suggest that, in MRT, there is deregulation not only of p16(INK4A) but also of the p14(ARF) pathway. These results provide insights into cell cycle deregulation in the pathogenesis of human MRT and may aid in the design and evaluation of potential therapies for these tumors.",
        "Doc_title":"p16INK4A and p14ARF tumor suppressor pathways are deregulated in malignant rhabdoid tumors.",
        "Journal":"Journal of neuropathology and experimental neurology",
        "Do_id":"21666498",
        "Doc_ChemicalList":"Chromosomal Proteins, Non-Histone;Cyclin-Dependent Kinase Inhibitor p16;DNA-Binding Proteins;SMARCB1 Protein;SMARCB1 protein, human;Transcription Factors;Tumor Suppressor Protein p14ARF;Tumor Suppressor Protein p53",
        "Doc_meshdescriptors":"Child, Preschool;Chromosomal Proteins, Non-Histone;Cyclin-Dependent Kinase Inhibitor p16;DNA Mutational Analysis;DNA-Binding Proteins;Female;Gene Expression Regulation, Neoplastic;Humans;Infant;Male;Microarray Analysis;SMARCB1 Protein;Severity of Illness Index;Signal Transduction;Statistics, Nonparametric;Teratoma;Transcription Factors;Tumor Suppressor Protein p14ARF;Tumor Suppressor Protein p53",
        "Doc_meshqualifiers":"genetics;metabolism;genetics;metabolism;genetics;metabolism;physiology;genetics;physiology;genetics;metabolism;physiopathology;genetics;metabolism;genetics;metabolism;genetics",
        "_version_":1605903947716886528},
      {
        "Doc_abstract":"Human papilloma virus (HPV) infection is a powerful prognostic biomarker in head and neck squamous cell carcinoma (HNSCC). Increased epidermal growth factor receptor (EGFR) gene copy number and protein expression have been reported to be negative predictors of outcome. This study examined the relationship between HPV status, EGFR gene copy number, EGFR protein expression, and clinical outcome in HNSCC patients treated with chemoradiation.;HPV status was determined using p16(INK4A) immunohistochemistry (IHC), EGFR gene copy number was evaluated with FISH, and EGFR protein expression by IHC in 212 subjects.;EGFR FISH was positive in 41 of 204 (20%) patients and was negatively correlated with failure-free survival (FFS; HR = 1.84, P = 0.027) and overall survival (OS; HR = 1.78, P = 0.082). For p16(INK4A), 85 of 200 (42.5%) patients were found to be p16 positive, including 75 of 131 (57%) with oropharyngeal cancer. Patients with p16-positive oropharyngeal cancer had significantly improved FFS (HR = 0.28, P < 0.001) and OS (HR = 0.31, P = 0.002). Only 2 of 126 (1.6%) oropharyngeal cancer patients were found to be p16+/EGFR FISH+. EGFR IHC was positive in 81 of 93 (87%) of patients and was associated with poorer FFS (HR = 1.98, P = 0.35) and OS (HR = 2.52, P = 0.22).;Increased EGFR gene copy number is largely restricted to p16(INK4A)-negative oropharyngeal cancer. Although p16(INK4A) and EGFR FISH are both predictive of outcome in univariate analyses, only p16(INK4A) remains independently predictive.;Knowledge of HPV and EGFR status can have implications for treatment options and prognosis in HNSCC.",
        "Doc_title":"Relationship between epidermal growth factor receptor status, p16(INK4A), and outcome in head and neck squamous cell carcinoma.",
        "Journal":"Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology",
        "Do_id":"21467228",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;EGFR protein, human;Receptor, Epidermal Growth Factor",
        "Doc_meshdescriptors":"Adult;Aged;Carcinoma, Squamous Cell;Clinical Trials, Phase I as Topic;Clinical Trials, Phase II as Topic;Clinical Trials, Phase III as Topic;Cyclin-Dependent Kinase Inhibitor p16;Female;Gene Dosage;Head and Neck Neoplasms;Humans;Immunoenzyme Techniques;In Situ Hybridization, Fluorescence;Male;Middle Aged;Prognosis;Receptor, Epidermal Growth Factor;Survival Rate;Young Adult",
        "Doc_meshqualifiers":"genetics;metabolism;metabolism;genetics;metabolism;genetics;metabolism",
        "_version_":1605746466843787264},
      {
        "Doc_abstract":"Oncogenic Ras induces two products of the INK4a/ARF tumor suppressor locus (p16(INK4a) and p19(ARF)) in primary human and rodent fibroblasts, ultimately leading to a permanent state of cell cycle arrest resembling replicative senescence. Whereas p16(INK4a) antagonizes the activities of cyclin D-dependent kinases, p19(ARF) activates the p53 transcription factor. Immortalized rodent fibroblast cell lines that lack INK4a/ARF function, ARF alone, or p53 are resistant to the growth inhibitory effects of oncogenic Ras and instead continue to proliferate and undergo morphological transformation. Primary mouse embryo fibroblasts lacking Cip1 and Kip1 genes encoding inhibitors of cyclin-dependent kinase-2 were used to further explore the effects of oncogenic Ras on arrest of the cell division cycle. Although early passage primary fibroblast strains that lack both p21(Cip1) and p27(Kip1) fail to assemble cyclin D-dependent kinases, oncogenic Ras retained its ability to induce p19(ARF), but not p16(INK4a), protecting Cip/Kip-null cells from proliferating and undergoing transformation. Under these conditions, Ras did not induce G(1) phase arrest but instead triggered DNA synthesis, abnormal nuclear divisions, failure of cytokinesis, and emergence of polyploid cells. Therefore, in the absence of p16(INK4a), p21(Cip1), and p27(Kip1), oncogenic Ras affects the functions of genes required for completion of the cell cycle.",
        "Doc_title":"Oncogenic Ras induces p19ARF and growth arrest in mouse embryo fibroblasts lacking p21Cip1 and p27Kip1 without activating cyclin D-dependent kinases.",
        "Journal":"The Journal of biological chemistry",
        "Do_id":"10842176",
        "Doc_ChemicalList":"CDKN1A protein, human;Cdkn1a protein, mouse;Cdkn1b protein, mouse;Cell Cycle Proteins;Cyclin-Dependent Kinase Inhibitor p21;Cyclins;Microtubule-Associated Proteins;Tumor Suppressor Protein p14ARF;Tumor Suppressor Proteins;Cyclin D1;Cyclin-Dependent Kinase Inhibitor p27;Cyclin-Dependent Kinases;Oncogene Protein p21(ras)",
        "Doc_meshdescriptors":"3T3 Cells;Animals;Cell Cycle;Cell Cycle Proteins;Cell Division;Cyclin D1;Cyclin-Dependent Kinase Inhibitor p21;Cyclin-Dependent Kinase Inhibitor p27;Cyclin-Dependent Kinases;Cyclins;Embryo, Mammalian;Enzyme Activation;Fibroblasts;Humans;Mice;Microtubule-Associated Proteins;Oncogene Protein p21(ras);Protein Biosynthesis;Tumor Suppressor Protein p14ARF;Tumor Suppressor Proteins",
        "Doc_meshqualifiers":"physiology;biosynthesis;metabolism;metabolism;metabolism;cytology;metabolism;cytology;metabolism;metabolism;physiology",
        "_version_":1605820331001380864},
      {
        "Doc_abstract":"The multi tumor suppressor genes MTS1 (CDKN2, p16INK4A) and MTS2 (CDKN1, p15INK4B) located at 9p21-22 are inactivated in some human cancers via several mechanisms including deletion and hypermethylation. In hematological malignancies, deletion of p16/p15 locus has been shown to be highly specific to lymphoid malignancies, and more particularly to T-cell acute lymphoblastic leukemia (TALL). We have investigated the deletion, methylation and p16 protein expression status of MTS1 in Tcell childhood acute lymphoblastic leukemia (19 cases) and cell lines[11]. On Southern blot homozygous deletions or hemizygous deletion with rearangement were detected in 4/19 T-ALL. The expression of p16 protein was not observed on Western blot in 4/15 T-ALL with intact p16 gene. The p16 gene was methylated 3/15 in T-ALL. Only one of three expressed p16 protein. The other 11/15 T-ALL had p16 protein expression but different level. Loss of MTS1 was observed in 3/11 cell lines. Cell line with MTS1 gene had p16 protein expression in 6/8. After treatment with the demethylating agent (5-AzoCyt) RD cell line showed p16 expression. This has not been observed with the other cell lines. Thus hypermethylation of MTS1 is rare in childhood T-ALL. Although inactivation of MTS1 by deletion is common in T-ALL and cell lines. Furthermore our data show that the p16 gene inactivation by hypermethylation and deletion may play a role in the leukemogenesis. ",
        "Doc_title":"Variable Expression and Hypermethylation of p16 Gene in Patients with T-ALL and Cell Lines.",
        "Journal":"Turkish journal of haematology : official journal of Turkish Society of Haematology",
        "Do_id":"27264975",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605875050668359680},
      {
        "Doc_abstract":"Senescence and apoptosis are two key mechanisms that protect against cancer development. Many cell cycle regulators, such as p14(ARF), p15(INK4b) and p16(INK4a), are important in G1 cell cycle arrest and oncogene-induced senescence. The bcl-2 protein is one of the key components that control apoptosis, while the p53 protein plays key roles in both mechanisms. The genes of these key regulator proteins are often mutated or deleted in various malignancies. It is unknown how senescence and apoptosis are regulated in one of the most common tumors of the female genital tract, cervical squamous cell carcinoma (SCC). In this study the, expression of senescence, apoptosis and proliferation markers in normal cervical epithelium, cervical intraepithelial neoplasia (CIN) and SCC are characterized via immunohistochemical staining for p14(ARF), p15(INK4b), p16(INK4a), bcl-2, p53 and Ki-67 in tissue microarray blocks containing 20 samples each of normal cervix, moderate-to-severe cervical dysplasia (CIN II-III) and invasive SCC. Samples are derived from 60 total cases of cervical biopsies and cervical conizations. Results showed that the proliferation marker, Ki-67, is markedly increased, and the senescence markers, p15(INK4b), p16(INK4a) and p14(ARF) are overexpressed in both dysplasia and carcinoma. P53 immunostain is negative in all normal cervical tissue, and positive in dysplasia and carcinoma. Although the expression of bcl-2 is increased in dysplasia, this marker is negative in approximately half of SCC cases. These results suggest that some senescence pathways are activated and are still maintained in cervical dysplasia and carcinoma. However proliferation is increased and carcinogenesis is not thwarted, leading to eventual development of cervical cancer. Other mechanisms, such as those that account for the apparent overexpression of p53 and paradoxical loss of bcl-2 expression in some SCC cases, as well as additional senescence and apoptotic pathways, may play key roles carcinogenesis of cervical SCC.",
        "Doc_title":"Senescence and apoptosis in carcinogenesis of cervical squamous carcinoma.",
        "Journal":"Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc",
        "Do_id":"17632454",
        "Doc_ChemicalList":"Biomarkers, Tumor;Cyclin-Dependent Kinase Inhibitor p15;Cyclin-Dependent Kinase Inhibitor p16;Ki-67 Antigen;Proto-Oncogene Proteins c-bcl-2;TP53 protein, human;Tumor Suppressor Protein p14ARF;Tumor Suppressor Protein p53",
        "Doc_meshdescriptors":"Apoptosis;Biomarkers, Tumor;Carcinoma, Squamous Cell;Cell Aging;Cell Proliferation;Cell Transformation, Neoplastic;Cervical Intraepithelial Neoplasia;Cyclin-Dependent Kinase Inhibitor p15;Cyclin-Dependent Kinase Inhibitor p16;Diagnosis, Differential;Female;Humans;Immunohistochemistry;Ki-67 Antigen;Neoplasm Staging;Proto-Oncogene Proteins c-bcl-2;Retrospective Studies;Tissue Array Analysis;Tumor Suppressor Protein p14ARF;Tumor Suppressor Protein p53;Uterine Cervical Neoplasms",
        "Doc_meshqualifiers":"analysis;chemistry;diagnosis;pathology;chemistry;pathology;chemistry;diagnosis;pathology;analysis;analysis;analysis;analysis;analysis;analysis;chemistry;diagnosis;pathology",
        "_version_":1605846218823434240},
      {
        "Doc_abstract":"p16(INK4a), p15(INK4b), p18(INK4c) and p19(INK4d) comprise a family of cyclin-dependent kinase inhibitors and tumor suppressors. We report that the INK4 proteins share the ability to arrest cells in G1, and interact with CDK4 or CDK6 with similar avidity. In contrast, only p18 and particularly p19 are phosphorylated in vivo, and each of the human INK4 proteins shows unique expression patterns dependent on cell and tissue type, and differentiation stage. Thus, the INK4 proteins harbor redundant as well as non-overlapping properties, suggesting distinct regulatory modes, and diverse roles for the individual INK4 family members in cell cycle control, cellular differentiation, and multistep oncogenesis.",
        "Doc_title":"Distinct versus redundant properties among members of the INK4 family of cyclin-dependent kinase inhibitors.",
        "Journal":"FEBS letters",
        "Do_id":"10734227",
        "Doc_ChemicalList":"CDKN2B protein, human;CDKN2C protein, human;CDKN2D protein, human;Carrier Proteins;Cell Cycle Proteins;Cyclin-Dependent Kinase Inhibitor p15;Cyclin-Dependent Kinase Inhibitor p16;Cyclin-Dependent Kinase Inhibitor p18;Cyclin-Dependent Kinase Inhibitor p19;Enzyme Inhibitors;Proto-Oncogene Proteins;Recombinant Fusion Proteins;Tumor Suppressor Proteins;Tretinoin;Protein-Serine-Threonine Kinases;CDK4 protein, human;CDK6 protein, human;Cyclin-Dependent Kinase 4;Cyclin-Dependent Kinase 6;Cyclin-Dependent Kinases",
        "Doc_meshdescriptors":"Binding, Competitive;Carrier Proteins;Cell Cycle Proteins;Cell Differentiation;Cyclin-Dependent Kinase 4;Cyclin-Dependent Kinase 6;Cyclin-Dependent Kinase Inhibitor p15;Cyclin-Dependent Kinase Inhibitor p16;Cyclin-Dependent Kinase Inhibitor p18;Cyclin-Dependent Kinase Inhibitor p19;Cyclin-Dependent Kinases;Enzyme Inhibitors;G1 Phase;Gene Expression Profiling;Gene Expression Regulation, Neoplastic;Genes, p16;Humans;Multigene Family;Organ Specificity;Phosphorylation;Protein Binding;Protein-Serine-Threonine Kinases;Proto-Oncogene Proteins;Recombinant Fusion Proteins;Teratocarcinoma;Tretinoin;Tumor Cells, Cultured;Tumor Suppressor Proteins",
        "Doc_meshqualifiers":"genetics;metabolism;drug effects;antagonists & inhibitors;metabolism;drug effects;genetics;physiology;genetics;antagonists & inhibitors;metabolism;genetics;metabolism;metabolism;pathology;pharmacology",
        "_version_":1605789523302678528},
      {
        "Doc_abstract":"The p16INK4a protein is a principal cyclin-dependent kinase inhibitor that decelerates the cell cycle. Abnormally high levels of p16INK4a are commonly observed in human papillomavirus (HPV)-positive head and neck squamous cell carcinomas (HNSCC). We and others found that p16INK4a overexpression is associated with improved therapy response and survival of patients with HNSCC treated with radiotherapy. However, the functional role of p16INK4a in HNSCC remains unexplored. Our results implicate p16INK4a in regulation of homologous recombination-mediated DNA damage response independently from its role in control of the cell cycle. We found that expression of p16INK4a dramatically affects radiation sensitivity of HNSCC cells. p16INK4a overexpression impairs the recruitment of RAD51 to the site of DNA damage in HPV-positive cells by downregulating of cyclin D1 protein expression. Consistent with the in vitro findings, immunostaining of HNSCC patient samples revealed that high levels p16INK4a expression significantly correlated with decreased cyclin D1 expression. In summary, these findings reveal an unexpected function of p16INK4a in homologous recombination-mediated DNA repair response and imply p16INK4a status as an independent marker to predict response of patients with HNSCC to radiotherapy.",
        "Doc_title":"p16INK4a impairs homologous recombination-mediated DNA repair in human papillomavirus-positive head and neck tumors.",
        "Journal":"Cancer research",
        "Do_id":"24473065",
        "Doc_ChemicalList":"CCND1 protein, human;Cyclin-Dependent Kinase Inhibitor p16;Cyclin D1;CDK4 protein, human;CDK6 protein, human;Cyclin-Dependent Kinase 4;Cyclin-Dependent Kinase 6;RAD51 protein, human;Rad51 Recombinase",
        "Doc_meshdescriptors":"Carcinoma, Squamous Cell;Cell Line, Tumor;Chemoradiotherapy;Cyclin D1;Cyclin-Dependent Kinase 4;Cyclin-Dependent Kinase 6;Cyclin-Dependent Kinase Inhibitor p16;DNA Damage;Head and Neck Neoplasms;Humans;Kaplan-Meier Estimate;Papillomavirus Infections;Rad51 Recombinase;Radiation Tolerance;Recombinational DNA Repair;Treatment Outcome",
        "Doc_meshqualifiers":"genetics;mortality;therapy;virology;metabolism;metabolism;metabolism;physiology;genetics;mortality;therapy;virology;genetics;mortality;therapy;virology;metabolism",
        "_version_":1605812021638463488},
      {
        "Doc_abstract":"The INK4A and INK4B loci are located at 9p21 and have been implicated in the tumorigenesis of various human malignancies. The INK4A gene encodes two cell cycle regulators, p16(INK4A) and ARF, while INK4B encodes p15(INK4B). Previously, we have shown that the p16(INK4) tumor suppressor was not mutated or deleted in primary breast carcinomas. However, primary and metastatic breast carcinomas exhibited a relative hypomethylation of p16(INK4A), which is associated with expression, compared to normal breast tissue. The present study was conducted to determine if inactivation of p15(INK4B) and INK4A exon 1beta (ARF) are common events in breast carcinoma. Mutational analysis was performed by PCR-SSCP, and mRNA expression was evaluated by RT-PCR. Methylation-specific PCR was used to determine the methylation status of the p15(INK4B) promoter. Our results demonstrate that the p15(INK4B) gene was altered in 3 (21%) of the 14 breast cell lines; one had a silent mutation and two had homozygous deletion of the gene. None of the cell lines showed methylation of p15(INK4B). Two (14%) cell lines had homozygous deletion of INK4A exon 1beta. All normal and malignant breast tissue samples were wild-type and non-methylated for p15(INK4B) and wild-type for exon 1beta. Our results show that these structurally and functionally related genes are not invariably affected together, and the most frequently observed alteration at the INK4A and INK4B loci in breast carcinoma appears to be p16(INK4A) hypomethylation.",
        "Doc_title":"Molecular analysis of the INK4A and INK4B gene loci in human breast cancer cell lines and primary carcinomas.",
        "Journal":"Cancer genetics and cytogenetics",
        "Do_id":"11369056",
        "Doc_ChemicalList":"CDKN2B protein, human;Carrier Proteins;Cell Cycle Proteins;Cyclin-Dependent Kinase Inhibitor p15;Cyclin-Dependent Kinase Inhibitor p16;DNA, Neoplasm;Neoplasm Proteins;RNA, Messenger;RNA, Neoplasm;Tumor Suppressor Proteins;Viral Proteins;arf protein, Enterobacteria phage P22",
        "Doc_meshdescriptors":"Blotting, Southern;Breast;Breast Neoplasms;Carcinoma;Carrier Proteins;Cell Cycle Proteins;Chromosomes, Human, Pair 9;CpG Islands;Cyclin-Dependent Kinase Inhibitor p15;Cyclin-Dependent Kinase Inhibitor p16;DNA Methylation;DNA Mutational Analysis;DNA, Neoplasm;Exons;Female;Gene Expression Profiling;Gene Expression Regulation, Neoplastic;Gene Silencing;Genes, Tumor Suppressor;Genes, p16;Humans;Neoplasm Proteins;Polymorphism, Single-Stranded Conformational;RNA, Messenger;RNA, Neoplasm;Reverse Transcriptase Polymerase Chain Reaction;Sequence Deletion;Tumor Cells, Cultured;Tumor Suppressor Proteins;Viral Proteins",
        "Doc_meshqualifiers":"metabolism;genetics;pathology;genetics;pathology;biosynthesis;genetics;genetics;biosynthesis;genetics;genetics;biosynthesis;genetics;biosynthesis;biosynthesis;biosynthesis;genetics",
        "_version_":1605902263389257728},
      {
        "Doc_abstract":"The p16 gene encodes a 16-kDa cyclin kinase inhibitor, and the p14ARF gene a 14-kDa protein, which acts as a cell cycle regulator or tumor suppressor in human cancer cells. Both genes are mapped on chromosome 9p21. Previous studies have suggested that the p16 gene has important roles in head and neck squamous cell carcinoma. To clarify carcinogenesis in oral squamous cell carcinoma (OSCC), we examined 44 primary OSCCs for alterations of p16 and p14ARF mRNA expression, the methylation status of the p16 gene promoter, the loss of heterozygosity (LOH) at the 9p21 locus, and p16 and p14ARF gene mutations. Alterations of p16 and p14ARF mRNA expression were seen in 27 (61.4%) of 44 and 10 (22.7%) of 44 of OSCC samples, respectively. Methylation of the p16 gene promoter region was detected in 28 (63.6%) of 44 samples, and LOH at 9p21 locus was found in 30 (68.2%) of 44. p16 and p14ARF gene mutations were observed in 4 (9.0%) of 44 and 2 (4.5%) of 44 samples, respectively. Suspected homozygous deletion (HD) was seen in 9 (20.5%) of 44. All cases except one (97.7%) showed alterations in p16, p14ARF, and their locus. These data indicate that the status of p16 and p14ARF genes in OSCC is frequently influenced by methylation, gene mutation, and allelic deletions. Furthermore, these genes and their 9p21 locus have various roles in the pathogenesis of OSCC.",
        "Doc_title":"Alterations of p16 and p14ARF genes and their 9p21 locus in oral squamous cell carcinoma.",
        "Journal":"Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics",
        "Do_id":"19101490",
        "Doc_ChemicalList":"Neoplasm Proteins;P16 protein, human;RNA, Messenger;Tumor Suppressor Protein p14ARF",
        "Doc_meshdescriptors":"Carcinoma, Squamous Cell;Chromosomes, Human, Pair 9;DNA Methylation;DNA Mutational Analysis;Gene Deletion;Gene Silencing;Genes, p16;Humans;Loss of Heterozygosity;Mouth Neoplasms;Neoplasm Proteins;Polymorphism, Single-Stranded Conformational;Promoter Regions, Genetic;RNA, Messenger;Reverse Transcriptase Polymerase Chain Reaction;Tumor Suppressor Protein p14ARF",
        "Doc_meshqualifiers":"genetics;genetics;genetics;biosynthesis;genetics",
        "_version_":1605826834573819904},
      {
        "Doc_abstract":"To explore the role of p16(INK4a) as an intrinsic barrier to B cell transformation by EBV, we transformed primary B cells from an individual homozygous for a deletion in the CDKN2A locus encoding p16(INK4a) and p14(ARF). Using recombinant EBV-BAC viruses expressing conditional EBNA3C (3CHT), we developed a system that allows inactivation of EBNA3C in lymphoblastoid cell lines (LCLs) lacking active p16(INK4a) protein but expressing a functional 14(ARF)-fusion protein (p14/p16). The INK4a locus is epigenetically repressed by EBNA3C--in cooperation with EBNA3A--despite the absence of functional p16(INK4a). Although inactivation of EBNA3C in LCLs from normal B cells leads to an increase in p16(INK4a) and growth arrest, EBNA3C inactivation in the p16(INK4a)-null LCLs has no impact on the rate of proliferation, establishing that the repression of INK4a is a major function of EBNA3C in EBV-driven LCL proliferation. This conditional LCL system allowed us to use microarray analysis to identify and confirm genes regulated specifically by EBNA3C, independently of proliferation changes modulated by the p16(INK4a)-Rb-E2F axis. Infections of normal primary B cells with recombinant EBV-BAC virus from which EBNA3C is deleted or with 3CHT EBV in the absence of activating ligand 4-hydroxytamoxifen, revealed that EBNA3C is necessary to overcome an EBV-driven increase in p16(INK4a) expression and concomitant block to proliferation 2-4 weeks post-infection. If cells are p16(INK4a)-null, functional EBNA3C is dispensable for the outgrowth of LCLs.",
        "Doc_title":"Induction of p16(INK4a) is the major barrier to proliferation when Epstein-Barr virus (EBV) transforms primary B cells into lymphoblastoid cell lines.",
        "Journal":"PLoS pathogens",
        "Do_id":"23436997",
        "Doc_ChemicalList":"Antigens, Viral;Cyclin-Dependent Kinase Inhibitor p16;EBNA-3A antigen;EBNA-3C, epstein-barr virus;Epstein-Barr Virus Nuclear Antigens",
        "Doc_meshdescriptors":"Antigens, Viral;B-Lymphocytes;Cell Line;Cell Proliferation;Cell Survival;Cyclin-Dependent Kinase Inhibitor p16;Epigenetic Repression;Epstein-Barr Virus Infections;Epstein-Barr Virus Nuclear Antigens;Genetic Loci;Herpesvirus 4, Human;Humans;Lymphocyte Activation;Oligonucleotide Array Sequence Analysis;Phosphorylation;Primary Cell Culture;Virus Latency",
        "Doc_meshqualifiers":"genetics;metabolism;virology;genetics;metabolism;genetics;immunology;virology;genetics;metabolism;immunology;physiology",
        "_version_":1605929418544381952},
      {
        "Doc_abstract":"There is increasing recognition of familial propensity to glioma as a distinct clinical entity beyond a few rare syndromes; however its genetic basis is poorly understood. The role of p16(INK4A)/p14(ARF) and p53 mutations in sporadic glioma provides a strong rationale for investigating germline mutations in these genes as a cause of familial glioma. To survey the familial glioma phenotype and examine the contribution of germline mutation in p16(INK4A)/p14(ARF) and p53 to the disease we have analyzed a series of 101 index familial cases collected through the GLIOGENE Consortium (http://braintumor.epigenetic.org/). There was little evidence for within family correlations for tumour histology, suggesting generic susceptibility to glial tumors. We did not detect any functional mutations in p16(INK4A) or p14(ARF). One index case with glioblastoma multiforme (GBM) diagnosed at age 54 and had a family history comprised of a paternal aunt with GBM at age 55, carried the p53 R158H mutation, which is predicted to be functional and has previously been implicated as a cause of Li-Fraumeni syndrome. Our findings provide no evidence that p16(INK4A)/p14(ARF) and p53 mutations contribute significantly to familial glioma.",
        "Doc_title":"Survey of familial glioma and role of germline p16INK4A/p14ARF and p53 mutation.",
        "Journal":"Familial cancer",
        "Do_id":"20455025",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Adolescent;Adult;Aged;Brain Neoplasms;Child;Child, Preschool;DNA Mutational Analysis;Female;Genes, p16;Genes, p53;Genetic Predisposition to Disease;Germ-Line Mutation;Glioma;Humans;Male;Middle Aged;Pedigree;Polymerase Chain Reaction;Young Adult",
        "Doc_meshqualifiers":"genetics;genetics",
        "_version_":1605851878476742656},
      {
        "Doc_abstract":"Ataxia-Telangiectasia-Mutated (ATM) gene loss has been associated with poor prognosis and treatment resistance in head and neck squamous cell carcinomas (HNSCC). We investigated the relationship between ATM loss detected by fluorescence in-situ hybridisation (FISH) with patient outcome, and its relationship with Human Papillomavirus (HPV)/p16(INK4A) status.;Copy number of the ATM gene and chromosome 11 were determined by FISH and HPV status was determined using p16(INK4A) immunohistochemistry in 87 paraffin embedded tumour samples from patients with HNSCC treated with chemoradiation at a single institution. ATM loss was correlated with patient outcome as both a continuous and dichotomous variable.;Of 73 evaluable patients, 44 (60.3%) demonstrated loss of the ATM gene. There was no correlation between ATM loss (defined as a mean ratio of ATM: chromosome 11<0.75) and overall survival (OS, p=0.67) or time to locoregional failure (TTLRF, p=0.72). Similarly, when evaluated as a continuous variable there was no significant relationship between ATM loss and patient outcome (OS, p=0.89; TTLRF, p=0.21). No significant relationship was found between p16(INK4A) status and ATM loss, for patient outcome. We found 35.6% (n=26) of patients demonstrated polysomy of chromosome 11 (defined as the presence of a mean >2.5 copies of chromosome 11) which was significantly associated with p16(INK4A) negative status (p=0.0004), but did not influence outcome.;ATM loss is a frequent event in HNSCC, however it does not impact outcome after treatment with chemoradiation. Polysomy of chromosome 11 was significantly associated with p16(INK4A) negative status but also lacks prognostic significance.",
        "Doc_title":"Correlation of Ataxia-Telangiectasia-Mutated (ATM) gene loss with outcome in head and neck squamous cell carcinoma.",
        "Journal":"Oral oncology",
        "Do_id":"22410096",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Ataxia Telangiectasia;Carcinoma, Squamous Cell;Chromosomes, Human, Pair 11;Clinical Trials, Phase I as Topic;Clinical Trials, Phase II as Topic;Clinical Trials, Phase III as Topic;Female;Human papillomavirus 16;Humans;In Situ Hybridization, Fluorescence;Male;Middle Aged;Mouth Neoplasms;Treatment Outcome",
        "Doc_meshqualifiers":"genetics;genetics;therapy;genetics;genetics;genetics;therapy",
        "_version_":1605842062988541952},
      {
        "Doc_abstract":"To identify altered gene targets that characterize disease progression in squamous cell carcinoma (SCC) of the head and neck (HNSCC). Genetic alterations in HNSCC cell lines reflect the tumor in vivo and can serve as valuable tools to study the development and progression of HNSCC. Identification of key molecular events may be useful for more accurate distinction of prognostic groups for selection and targeting of therapy.;Individual gene loci were analyzed for genetic alterations using a novel genomewide strategy.;Head and neck squamous cell carcinoma primary (A) and recurrent or metastatic (B) cell lines UMSCC-11A/11B, UMSCC-17A/17B (previously karyotyped), and UMSCC-81A/81B are described.;At the genome level, loss and gain of genetic loci concurred with tumor karyotypes. Several abnormal gene loci not apparent by cytogenetics were also identified. All except 11B indicated loss of CDKN2A (encodes p14 and p16), with concomitant loss of CDKN2B (encodes p15) in 11A, 17B, and 81A. All 6 cell lines showed gain of PIK3CA (encodes a PI3 kinase) located at 3q26.3.;We provide evidence for the role of 3 critical pathways in the development and progression of HNSCC. The CDKN2A/B genes encode various components of the Rb and p53 pathways, and the PIK3CA gene makes a catalytic subunit of the protein phosphatidylinositol 3-OH kinase (PI3K), which is known to be involved in the PI3K/ATK signaling pathways. Molecular events may ultimately serve to achieve genomic alterations that set off an interplay among key gene loci along discrete genetic pathways used by tumor cells in HNSCC.",
        "Doc_title":"Delineating genetic pathways of disease progression in head and neck squamous cell carcinoma.",
        "Journal":"Archives of otolaryngology--head & neck surgery",
        "Do_id":"12874067",
        "Doc_ChemicalList":"Oligonucleotide Probes;Phosphatidylinositol 3-Kinases",
        "Doc_meshdescriptors":"Carcinoma, Squamous Cell;DNA Mutational Analysis;Disease Progression;Genes, p16;Head and Neck Neoplasms;Humans;Oligonucleotide Probes;Phosphatidylinositol 3-Kinases;Tumor Cells, Cultured",
        "Doc_meshqualifiers":"genetics;physiology;genetics",
        "_version_":1605831644942434304},
      {
        "Doc_abstract":"The cyclin-dependent kinase (CDK) inhibitor p16(INK4a) and the MDM2 ubiquitin ligase inhibitor p19(ARF) are critical to the regulation of cell cycle progression. Their loss by deletion, mutation or epigenetic silencing is a common molecular alteration in many human cancers. To investigate the role of p16(INK4a)/p19(ARF) deficiency in CNS tumor pathogenesis, pregnant mice bearing p16(-/-)/p19(-/-), p16(+/-)/p19(+/-), and p16(+/+)/p19(+/+) embryos were exposed transplacentally on gestation day 14 to a single dose of the potent carcinogen, ethylnitrosourea (ENU). p16(+/-)/p19(+/-) male mice treated with ENU developed meningial proliferative lesions with a high incidence (5/10). The incidence was lower in other ENU-treated animals of both sexes and none occurred in saline-treated control animals. The lesions ranged from widespread meningeal proliferation and plaque-like thickening by neoplastic spindle cells consistent with meningiomatosis to a larger discrete mass consistent with a meningioma. Ultrastructural analysis revealed the presence of intercellular junctions between cells, supporting a meningothelial histogenesis. Spontaneous meningiomas occur rarely in wild-type mice but are a common neoplasm afflicting humans, accounting for between 13 and 26% of primary intracranial neoplasms. This ENU inducible meningeal lesion in p16(+/-)/p19(+/-) mice may provide additional insight into the pathogenesis of meningeal neoplasia and aid the development of therapeutics.",
        "Doc_title":"N-ethyl-N-nitrosourea (ENU)-induced meningiomatosis and meningioma in p16(INK4a)/p19(ARF) tumor suppressor gene-deficient mice.",
        "Journal":"Toxicologic pathology",
        "Do_id":"17943659",
        "Doc_ChemicalList":"Cdkn2a protein, mouse;Cyclin-Dependent Kinase Inhibitor p16;Ethylnitrosourea",
        "Doc_meshdescriptors":"Animals;Cyclin-Dependent Kinase Inhibitor p16;Ethylnitrosourea;Female;Fetus;Genes, Tumor Suppressor;Genes, p16;Male;Meningeal Neoplasms;Meningioma;Mice;Mice, Inbred C57BL;Pregnancy",
        "Doc_meshqualifiers":"genetics;physiology;toxicity;drug effects;physiology;chemically induced;pathology;chemically induced;pathology",
        "_version_":1605843980060196864},
      {
        "Doc_abstract":"Recurrent deletion on a chromosomal location in tumor cells can be detected by frequent allelic loss and generally is considered to be an indication of the existence of a tumor suppressor gene (TSG) in the region. In the current study, using fluorescent-labeled, high-density microsatellite markers for allelotyping, the authors pinpointed three minimal deleted regions (MDRs) and screened mutations of putative TSGs on chromosomes 3, 9, and 11 in nasopharyngeal carcinoma (NPC) cases occurring in Taiwan.;A total of 133 informative microsatellite markers were used on chromosomes 3, 9, and 11 with an average marker density of 4 centimorgans (cM) for the allelotyping of genomic DNAs isolated from NPC tissues and their corresponding lymphocytes in 48 patients. The correlation between allelic loss and the clinicopathologic parameters of NPC tissues was examined. In addition, putative TSGs including FHIT, p16(INK4a), and p19(ARF) were selected for mutation screening to investigate their potential participation in NPC tumorigenesis.;Of 3787 informative allelotyping data, 25 frequent allelic losses (or loss of heterozygosity [LOH]) in 13 cytogenetic loci were identified based on a deletion frequency that was greater than the average of allelic loss on that particular chromosome. Several significant associations were determined after statistical analysis of the correlation between allelic loss and clinicopathologic parameters. The allelic losses by D9S318 and D11S1304 were associated with N2/N3 (P = 0.035 and P = 0.005, respectively), and those by D9S905 and D11S1304 were associated with grouped American Joint Committee on Cancer (AJCC) Stage III/IV samples (P = 0.022 and P = 0.017, respectively) of NPC tissues. In addition, three MDRs were revealed on 3p25.3-24.1 (< 19 cM), 3p23-21.31 (< 9 cM), and 11q22.1-23.2 (< 8 cM). To examine somatic mutations in previously reported TSGs located near these frequent LOH loci, three candidate genes, p16(INK4a), p19(ARF), and FHIT, were analyzed. Point mutations in the coding region of FHIT and in the intron 1 splicing acceptor site of both p16(INK4a) and p19(ARF) were detected in NPC cell lines. Sequence analysis of both p16(INK4a) and p19(ARF) transcripts revealed that the point mutation resulted in skipping of exon 2 and the generation of shorter transcripts.;High-density allelotyping permitted the discovery of 3 MDRs on 3p25.3-24.1 (< 19 cM), 3p23-21.31 (< 9 cM), and 11q22.1-23.2 (< 8 cM) and a correlation was determined between allelic loss and clinicopathologic parameters of NPC tissues. More important, one somatic mutation in NPC cell lines on the intron 1/exon 2 splicing acceptor site of the INK4a/ARF locus was found to result in exon 2 skipping both p16(INK4a) and p19(ARF) transcripts, which presumably inactivates the functions of both the p16(INK4a) and p19(ARF) proteins.",
        "Doc_title":"Definition of three minimal deleted regions by comprehensive allelotyping and mutational screening of FHIT,p16(INK4A), and p19(ARF) genes in nasopharyngeal carcinoma.",
        "Journal":"Cancer",
        "Do_id":"11932901",
        "Doc_ChemicalList":"Cdkn2a protein, mouse;Cyclin-Dependent Kinase Inhibitor p16;DNA, Neoplasm;Neoplasm Proteins;Tumor Suppressor Protein p14ARF;fragile histidine triad protein;Acid Anhydride Hydrolases",
        "Doc_meshdescriptors":"Acid Anhydride Hydrolases;Alleles;Chromosome Aberrations;Chromosome Deletion;Chromosomes, Human, Pair 11;Chromosomes, Human, Pair 3;Chromosomes, Human, Pair 9;Cyclin-Dependent Kinase Inhibitor p16;DNA Mutational Analysis;DNA, Neoplasm;Genes, Tumor Suppressor;Humans;Loss of Heterozygosity;Microsatellite Repeats;Nasopharyngeal Neoplasms;Neoplasm Proteins;Neoplasm Recurrence, Local;Neoplasm Staging;Polymerase Chain Reaction;Reverse Transcriptase Polymerase Chain Reaction;Tumor Suppressor Protein p14ARF",
        "Doc_meshqualifiers":"genetics;genetics;genetics;genetics;analysis;genetics;genetics;pathology;genetics;genetics;pathology;genetics",
        "_version_":1605747059527254016},
      {
        "Doc_abstract":"The p16(INK4A) gene encodes 2 cell cycle regulator proteins, p16 and p14(ARF), by alternative splicing. This genetic locus also contains another cell cycle regulator gene, p15(INK4B), which encodes p15. The inactivation of the p16 protein has been demonstrated in some hepatocellular carcinomas (HCCs); however, the inactivation of the other 2 cell regulator proteins and their inactivation patterns are not well characterized.;To characterize the role of the above 3 cell cycle regulator proteins in HCCs, the authors examined the genomic status of the p16(INK4A) and p15(INK4B) genes and their RNA products in 20 HCC tissues and 7 human HCC cell lines. Homozygous deletions in each exon of p16(INK4A) and p15(INK4B) were evaluated by comparative multiplex polymerase chain reaction (PCR), and the methylation status of the p16(INK4A) and p15(INK4B) promoter region was analyzed by methylation specific PCR.;Homozygous deletions were found in 6 of 20 HCCs (30%) and 2 of 7 HCC cell lines (29%). In 20 HCCs, the frequency of homozygous deletions was 20% in exon 1 of p15(INK4B), 20% in exon 2 of p15(INK4B), 10% in exon 1beta of p16(INK4A), 25% in exon 1alpha of p16(INK4A), 15% in exon 2 of p16(INK4A), and 15% in exon 3 of p16(INK4A). The authors found hypermethylation of the p16(INK4A) promoter region in 7 HCCs (35%) and 3 HCC cell lines (43%). The overall frequency of p16 alterations in HCCs, including hypermethylation and homozygous deletions, was 60% (12 of 20 cases). According to reverse transcriptase-PCR analysis, the absence of RNA expression was most frequent in p16 (11 of 20 cases, 55%) and less frequent in p15 (7 of 20 cases, 35%) and p14(ARF) (5 of 20 cases, 25%).;Among the 3 cell cycle regulator proteins encoded at the 9p21 genetic locus, inactivation of p16 is the most frequent event in HCCs in which promoter hypermethylation and homozygous deletions are the common mechanisms.",
        "Doc_title":"p16 is a major inactivation target in hepatocellular carcinoma.",
        "Journal":"Cancer",
        "Do_id":"10897001",
        "Doc_ChemicalList":"CDKN2B protein, human;Cell Cycle Proteins;Cyclin-Dependent Kinase Inhibitor p15;Cyclin-Dependent Kinase Inhibitor p16;DNA, Neoplasm;Proteins;Transcription Factors;Tumor Suppressor Protein p14ARF;Tumor Suppressor Proteins;RNA",
        "Doc_meshdescriptors":"Carcinoma, Hepatocellular;Cell Cycle Proteins;Cell Transformation, Neoplastic;Cyclin-Dependent Kinase Inhibitor p15;Cyclin-Dependent Kinase Inhibitor p16;DNA, Neoplasm;Gene Deletion;Genes, p16;Humans;Liver Neoplasms;Methylation;Promoter Regions, Genetic;Proteins;RNA;Transcription Factors;Tumor Suppressor Protein p14ARF;Tumor Suppressor Proteins",
        "Doc_meshqualifiers":"genetics;genetics;genetics;genetics;genetics;genetics;genetics;genetics;genetics",
        "_version_":1605839308916260864},
      {
        "Doc_abstract":"p14(ARF) is a putative tumor suppressor gene thought to modify the levels of p53. CpG sites within the 5'-flanking region and exon 1beta of p14(ARF) are targets of aberrant methylation and transcriptional silencing in human colorectal cancer (CRC). Here we have developed methylation-specific polymerase chain reaction (MSPCR) methods to detect methylation of CpG sites in p14(ARF) in CRC cell lines and primary CRC tumors, and correlated p14(ARF) mRNA expression with methylation in CRC cell lines using competitive quantitative reverse transcription-polymerase chain reaction methods. Ten CRC cell lines were studied; three (DLD-1, HCT15 and SW48) showed extensive methylation and six (Colo320, SW480, HT29, Caco2, SW837 and WiDr) were unmethylated; the other cell line, LoVo, showed partial methylation that affected exon 1beta but not the immediate upstream CpG sites. p14(ARF) mRNA was expressed at extremely low levels in fully methylated cell lines and at 10(4)- to 10(5)-fold higher levels in unmethylated cell lines. p14(ARF) expression in the partially methylated LoVo cell line was intermediate. Treatment of LoVo cells with 2 microM 5-aza-2'-deoxycytidine for 72 h was associated with marked (100-fold) induction of mRNA levels. Of 119 primary CRCs, 18% contained p14(ARF) methylation, although partial methylation was the most common pattern observed (in 67% of methylated tumors). Methylation of p14(ARF) was often accompanied by p16(INK4a) methylation; however, 50% of p14(ARF) methylated tumors contained unmethylated p16(INK4a). Methylation at p14(ARF) was associated with female gender, greater age, proximal anatomic location and poor differentiation, but not stage at diagnosis. A two-step MSPCR method for assaying p14(ARF) methylation in human tumors is described.",
        "Doc_title":"Correlations of partial and extensive methylation at the p14(ARF) locus with reduced mRNA expression in colorectal cancer cell lines and clinicopathological features in primary tumors.",
        "Journal":"Carcinogenesis",
        "Do_id":"11062168",
        "Doc_ChemicalList":"DNA, Neoplasm;Proteins;RNA, Messenger;Sulfites;Tumor Suppressor Protein p14ARF;hydrogen sulfite",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Base Sequence;Colorectal Neoplasms;CpG Islands;DNA Methylation;DNA, Neoplasm;Exons;Female;Humans;Male;Middle Aged;Molecular Sequence Data;Polymerase Chain Reaction;Proteins;RNA, Messenger;Sequence Analysis, DNA;Sulfites;Tumor Cells, Cultured;Tumor Suppressor Protein p14ARF",
        "Doc_meshqualifiers":"genetics;metabolism;pathology;genetics;genetics;metabolism;methods;genetics;biosynthesis;genetics",
        "_version_":1605826874270810112},
      {
        "Doc_abstract":"The retinoblastoma (Rb), cyclin-dependent kinase (CDK), and CDK inhibitor genes regulate cell generation, and deregulation can produce increased cell growth and tumorigenesis. Polycythemia vera (PV) is a clonal myeloproliferative disease where the mechanism producing increased hematopoiesis is still unknown. To investigate possible defects in cell-cycle regulation in PV, the expression of Rb and CDK inhibitor gene messenger RNAs (mRNAs) in highly purified human erythroid colony-forming cells (ECFCs) was screened using an RNase protection assay (RPA) and 11 gene probes. It was found that RNA representing exon 2 of p16(INK4a) and p14(ARF) was enhanced by 2.8- to 15.9-fold in 11 patients with PV. No increase of exon 2 mRNA was evident in the T cells of patients with PV, or in the ECFCs and T cells from patients with secondary polycythemia. p27 also had elevated mRNA expression in PV ECFCs, but to a lesser degree. Because the INK4a/ARF locus encodes 2 tumor suppressors, p16(INK4a) and p14(ARF) with the same exon 2 sequence, the increased mRNA fragment could represent either one. To clarify this, mRNA representing the unique first exons of INK4a and ARF were analyzed by semiquantitative reverse transcription-polymerase chain reaction. This demonstrated that mRNAs from the first exons of both genes were increased in erythroid and granulocyte-macrophage cells and Western blot analysis showed that the INK4a protein (p16(INK4a)) was increased in PV ECFCs. Sequencing revealed no mutations of INK4a or ARF in 10 patients with PV. p16(INK4a) is an important negative cell-cycle regulator, but in contrast with a wide range of malignancies where inactivation of the INK4a gene is one of the most common carcinogenetic events, in PV p16( INK4a) expression was dramatically increased without a significant change in ECFC cell cycle compared with normal ECFCs. It is quite likely that p16(INK4a) and p14(ARF) are not the pathogenetic cause of PV, but instead represent a cellular response to an abnormality of a downstream regulator of proliferation such as cyclin D, CDK4/CDK6, Rb, or E2F. Further work to delineate the function of these genes in PV is in progress. (Blood. 2001;97:3424-3432)",
        "Doc_title":"Increased expression of the INK4a/ARF locus in polycythemia vera.",
        "Journal":"Blood",
        "Do_id":"11369633",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;Proteins;RNA, Messenger;Tumor Suppressor Protein p14ARF;Cyclin-Dependent Kinases",
        "Doc_meshdescriptors":"Aged;Cell Cycle;Cell Division;Cyclin-Dependent Kinase Inhibitor p16;Cyclin-Dependent Kinases;DNA Mutational Analysis;Erythroid Precursor Cells;Exons;Female;Gene Expression;Granulocytes;Hematopoietic Stem Cells;Humans;Macrophages;Male;Middle Aged;Polycythemia Vera;Proteins;RNA, Messenger;Reverse Transcriptase Polymerase Chain Reaction;T-Lymphocytes;Tumor Suppressor Protein p14ARF",
        "Doc_meshqualifiers":"genetics;antagonists & inhibitors;metabolism;pathology;chemistry;chemistry;chemistry;genetics;genetics;analysis;chemistry;metabolism",
        "_version_":1605804768901464064},
      {
        "Doc_abstract":"Melanoma genomes contain thousands of alterations including: mutations, copy number alterations, structural aberrations, and methylation changes. The bulk of this variation is stochastic and functionally neutral, with only a small minority representing \"drivers\" that contribute to the genesis and maintenance of tumors. Drivers are often directly or inversely correlated across tumors, reflecting the molecular and regulatory signaling pathways in which they operate. Here, a profile of genetic and epigenetic drivers in 110 human melanoma cell lines was generated and searched for non-random distribution patterns. Statistically significant mutual exclusivity was revealed among components of each of the p16(INK4A)-CDK4-RB, RAS-RAF-MEK-ERK and PI3K-AKT signaling pathways. In addition, an inverse correlation was observed between promoter hypermethylation of retinoic acid receptor  (RARB) and CDKN2A alterations affecting p14(ARF) (P < 0.0001), suggesting a functional link between RAR signaling and the melanoma-suppressive activities of p14(ARF). Mechanistically, all-trans retinoic acid (ATRA) treatment increased the expression of p14(ARF) in primary human melanocytes and the steady-state levels of p14(ARF) in these cells were shown to be regulated via RAR. Furthermore, the ability of ATRA to induce senescence is reduced in p14(ARF)-depleted melanocytes, and we provide proof-of-concept that ATRA can induce irreversible growth arrest in melanoma cells with an intact RAR-p14(ARF) signaling axis, independent of p16(INK4A) and p53 status.;These data highlight the power of mutual exclusivity analysis of cancer drivers to unravel molecular pathways and establish a previously unrecognized cross-talk between RAR and p14(ARF) with potential implications for melanoma treatment.",
        "Doc_title":"Mutual exclusivity analysis of genetic and epigenetic drivers in melanoma identifies a link between p14 ARF and RAR signaling.",
        "Journal":"Molecular cancer research : MCR",
        "Do_id":"23851445",
        "Doc_ChemicalList":"Receptors, Retinoic Acid;Tumor Suppressor Protein p14ARF;retinoic acid receptor beta;Tretinoin",
        "Doc_meshdescriptors":"Cell Line, Tumor;Epigenesis, Genetic;Gene Expression Profiling;Gene Expression Regulation, Neoplastic;Humans;Melanoma;Receptors, Retinoic Acid;Signal Transduction;Tretinoin;Tumor Suppressor Protein p14ARF",
        "Doc_meshqualifiers":"genetics;pathology;genetics;metabolism;genetics;pharmacology;genetics;metabolism",
        "_version_":1605742790754435073},
      {
        "Doc_abstract":"A newly recognized class of INK4 family of cyclin-dependent kinase inhibitors CDKIs) include its prototype, p16 (INK4A/MTS1/CDKN2), and three others, p15 (INK4B/MTS2), p18 (INK4C), and p19 (INK4D). The putative tumor suppressor gene, p16 is frequently altered in certain neoplasms and many cell lines. The potential role of INK4 CDKIs in pathogenesis of prostate carcinoma was studied.;Thirty-two primary prostate cancer samples and two prostate cancer cell lines were examined for alterations of the p16, p15, p18, and p19 genes by polymerase chain reaction-single strand conformation polymorphism (PCR-SSCP) and Southern blot analysis.;Alteration of the p16 gene was found in one of 32 primary prostate cancer samples by PCR-SSCP. DNA sequencing of the sample showed a 24-basepair insertion in exon 1 of the p16 gene at codon 11. No other mutations were found in p15, p18, or p19 genes by PCR-SSCP. Furthermore, none of the p16, p15, p18, or p19 genes had alterations by Southern blot analysis.;These results indicate that structural abnormalities of the INK4 CDKIs is a rare event in prostate carcinoma, and the loss of function of INK4 CDKIs by other mechanisms, such as methylation should be further explored.",
        "Doc_title":"Molecular analysis of the INK4 family of genes in prostate carcinomas.",
        "Journal":"The Journal of urology",
        "Do_id":"9112579",
        "Doc_ChemicalList":"CDKN2B protein, human;Carrier Proteins;Cell Cycle Proteins;Cyclin-Dependent Kinase Inhibitor p15;Cyclin-Dependent Kinase Inhibitor p16;Tumor Suppressor Proteins",
        "Doc_meshdescriptors":"Base Sequence;Carrier Proteins;Cell Cycle Proteins;Cyclin-Dependent Kinase Inhibitor p15;Cyclin-Dependent Kinase Inhibitor p16;Genes, Tumor Suppressor;Humans;Male;Prostatic Neoplasms;Tumor Suppressor Proteins",
        "Doc_meshqualifiers":"genetics;genetics;genetics",
        "_version_":1605765151624003584},
      {
        "Doc_abstract":"The p16(INK4A-ARF) locus plays a crucial role in the control of cellular proliferation via both the Rb and P53 pathways. We previously demonstrated that this locus is altered in human skin carcinomas. In the present study we have studied the expression of the p16(INK4A-ARF) locus following UVB irradiation of normal human keratinocytes both at the mRNA (RT-PCR) and at the protein (Western blotting) levels. Our data confirmed that P16(INK4A) protein is induced by UVB at low (30 mJ cm(2)) and high (100 mJ cm(2)) doses and is observed after a single or repeated exposure implying that this response is involved in both the immediate and adaptative response to UVB. The apparent absence of induction p16(INK4A) mRNA suggested that P16(INK4A) protein is upregulated at the post-transcriptional level. Analysis by flow cytometry and BrdU staining indicated that the highest protein level of P16(INK4A) in the cells was associated with a G(2) cell cycle arrest. Comparative analysis of P16(INK4A) and P53 showed that they were differentially modulated in keratinocytes according to the UVB dose and regimen. Low, acute or repeated UVB exposures led to accumulation of both P16(INK4A) and p53, whereas at high UVB doses, P53 and P53-dependent genes were not induced or even downregulated and only a slight but reproducible stabilization of P16(INK4A) protein was observed. In our conditions, P14(ARF) did not seem to participate in the UV response in these cells as P14(ARF) protein did not vary. These results infer that P16(INK4A) plays a role in cell cycle regulation of keratinocytes submitted to UVB irradiation. They also reinforce our previous demonstration of the importance of inactivation of this gene in UV-induced skin carcinogenesis.",
        "Doc_title":"P16(INK4A) is implicated in both the immediate and adaptative response of human keratinocytes to UVB irradiation.",
        "Journal":"Oncogene",
        "Do_id":"11965538",
        "Doc_ChemicalList":"CDKN1A protein, human;Cyclin-Dependent Kinase Inhibitor p16;Cyclin-Dependent Kinase Inhibitor p21;Cyclins;DNA Primers;Nuclear Proteins;Proto-Oncogene Proteins;Proto-Oncogene Proteins c-bcl-2;RNA, Messenger;Tumor Suppressor Protein p14ARF;Tumor Suppressor Protein p53;bcl-2-Associated X Protein;MDM2 protein, human;Proto-Oncogene Proteins c-mdm2;Bromodeoxyuridine",
        "Doc_meshdescriptors":"Blotting, Western;Bromodeoxyuridine;Cells, Cultured;Cyclin-Dependent Kinase Inhibitor p16;Cyclin-Dependent Kinase Inhibitor p21;Cyclins;DNA Primers;Dose-Response Relationship, Radiation;Flow Cytometry;Gene Expression Regulation;Humans;Immunoblotting;Keratinocytes;Nuclear Proteins;Proto-Oncogene Proteins;Proto-Oncogene Proteins c-bcl-2;Proto-Oncogene Proteins c-mdm2;RNA, Messenger;Radiation Dosage;Reverse Transcriptase Polymerase Chain Reaction;Tumor Suppressor Protein p14ARF;Tumor Suppressor Protein p53;Ultraviolet Rays;Up-Regulation;bcl-2-Associated X Protein",
        "Doc_meshqualifiers":"genetics;metabolism;genetics;metabolism;chemistry;radiation effects;metabolism;radiation effects;genetics;metabolism;metabolism;genetics;metabolism;genetics;metabolism",
        "_version_":1605741943624564738},
      {
        "Doc_abstract":"Promoter methylation is an important pathway in transcriptional silencing of known and candidate tumor suppressor genes in Head and Neck Squamous Cell Carcinoma (HNSCC). In order to study the association of tumor suppressor gene promoter methylation in HNSCC with patient clinical characteristics, especially alcohol consumption and tobacco smoking, we examined promoter methylation of the p16(INK4a), DAP-kinase, E-Cadherin, and RASSF1A genes using methylation-specific PCR (MSP) in 80 patients. The prevalence of p16(INK4a), DAP-kinase, E-Cadherin, and RASSF1A promoter methylation was 26/80 (32.5%), 19/80 (23.8%), 29/80 (36.3%), 6/80 (7.5%) respectively. In 48 cases (60%), at least one of these promoters was methylated. There was a significant association of methylation of any of these genes and ever smoking (P=0.006). p16(INK4a) gene promoter methylation was associated with a younger age of smoking initiation (P<0.03); E-Cadherin promoter methylation was associated with an increased number of pack years smoked (P<0.03). We also found an association of methylation of any gene and T status (OR=2.7, P<0.05). Tumors with p16(INK4a) methylation were significantly less likely to show lymph node metastasis (P<0.001). DAP-kinase promoter methylation was significantly associated with lymph node metastasis and this relationship was dependent upon p16(INK4a) promoter methylation status. Our results suggest that, in HNSCC, promoter methylation of these four genes accumulates with increasing tumor size. This may reflect distinct pathways of somatic inactivation leading to cancer; additional larger studies are needed to further investigate this possibility. Tobacco smoking may play an important role in both the occurrence of promoter methylation as well as delineating the precise pathway that eventually results in a tumorigenic phenotype.",
        "Doc_title":"Patterns of gene promoter methylation in squamous cell cancer of the head and neck.",
        "Journal":"Oncogene",
        "Do_id":"12082610",
        "Doc_ChemicalList":"Apoptosis Regulatory Proteins;Cadherins;DNA, Neoplasm;Neoplasm Proteins;RASSF1 protein, human;Tumor Suppressor Proteins;Death-Associated Protein Kinases;Calcium-Calmodulin-Dependent Protein Kinases",
        "Doc_meshdescriptors":"Adult;Aged;Alcohol Drinking;Apoptosis Regulatory Proteins;Cadherins;Calcium-Calmodulin-Dependent Protein Kinases;Carcinoma, Squamous Cell;Cell Transformation, Neoplastic;DNA Methylation;DNA, Neoplasm;Death-Associated Protein Kinases;Disease Progression;Female;Gene Expression Regulation, Neoplastic;Gene Silencing;Genes, Tumor Suppressor;Genes, p16;Head and Neck Neoplasms;Humans;Lymphatic Metastasis;Male;Middle Aged;Neoplasm Proteins;Promoter Regions, Genetic;Smoking;Time Factors;Tumor Suppressor Proteins",
        "Doc_meshqualifiers":"genetics;genetics;genetics;complications;genetics;pathology;genetics;chemistry;genetics;complications;genetics;pathology;genetics;genetics;genetics",
        "_version_":1605747008101941248},
      {
        "Doc_abstract":"The hSNF5 chromatin-remodeling factor is a tumor suppressor that is inactivated in malignant rhabdoid tumors (MRTs). A number of studies have shown that hSNF5 re-expression blocks MRT cell proliferation. However, the pathway through which hSNF5 acts remains unknown. To address this question, we generated MRT-derived cell lines in which restoration of hSNF5 expression leads to an accumulation in G(0)/G(1), induces cellular senescence and increased apoptosis. Following hSNF5 expression, we observed transcriptional activation of the tumor suppressor p16(INK4a) but not of p14(ARF), repression of several cyclins and CD44, a cell surface glycoprotein implicated in metastasis. Chromatin immunoprecipitations indicated that hSNF5 activates p16(INK4a) transcription and CD44 down-regulation by mediating recruitment of the SWI/SNF complex. Thus, hSNF5 acts as a dualistic co-regulator that, depending on the promoter context, can either mediate activation or repression. Three lines of evidence established that p16(INK4a) is an essential effector of hSNF5-induced cell cycle arrest. 1) Overexpression of p16(INK4a) mimics the effect of hSNF5 induction and leads to cellular senescence. 2) Expression of a p16(INK4a)-insensitive form of CDK4 obstructs hSNF5-induced cell cycle arrest. 3) Inhibition of p16(INK4a) activation by siRNA blocks hSNF5-mediated cellular senescence. Collectively, these results indicate that in human MRT cells, the p16(INK4a)/pRb, rather than the p14(ARF)/p53 pathway, mediates hSNF5-induced cellular senescence.",
        "Doc_title":"P16INK4a is required for hSNF5 chromatin remodeler-induced cellular senescence in malignant rhabdoid tumor cells.",
        "Journal":"The Journal of biological chemistry",
        "Do_id":"14604992",
        "Doc_ChemicalList":"Antigens, CD44;Chromatin;Chromosomal Proteins, Non-Histone;Cyclin-Dependent Kinase Inhibitor p16;DNA-Binding Proteins;RNA, Messenger;RNA, Small Interfering;Retinoblastoma Protein;SMARCB1 Protein;SMARCB1 protein, human;Transcription Factors;Tumor Suppressor Protein p14ARF;Tumor Suppressor Protein p53;Cyclin D1",
        "Doc_meshdescriptors":"Antigens, CD44;Apoptosis;Cell Aging;Cell Cycle;Cell Division;Cell Line, Tumor;Chromatin;Chromosomal Proteins, Non-Histone;Cyclin D1;Cyclin-Dependent Kinase Inhibitor p16;DNA-Binding Proteins;Down-Regulation;Electrophoresis, Polyacrylamide Gel;G1 Phase;HeLa Cells;Humans;Immunoblotting;Lentivirus;Neoplasm Metastasis;Precipitin Tests;Promoter Regions, Genetic;RNA, Messenger;RNA, Small Interfering;Resting Phase, Cell Cycle;Retinoblastoma Protein;Rhabdoid Tumor;SMARCB1 Protein;Time Factors;Transcription Factors;Transcriptional Activation;Tumor Suppressor Protein p14ARF;Tumor Suppressor Protein p53",
        "Doc_meshqualifiers":"biosynthesis;metabolism;metabolism;physiology;metabolism;genetics;metabolism;metabolism;metabolism;metabolism;metabolism;metabolism",
        "_version_":1605825972210237440},
      {
        "Doc_abstract":"The tumor suppressor proteins p15(INK4B), p16(INK4A), and p14(ARF), encoded by the INK4AB/ARF locus, are crucial regulators of cellular senescence. The locus is epigenetically silenced by the repressive Polycomb complexes in growing cells but is activated in response to oncogenic stress. Here we show that the mitogen- and stress-activated kinase (MSK1) is up-regulated after RAF1 oncogenic stress and that the phosphorylated (activated) form of MSK1 is significantly increased in the nucleus and recruited to the INK4AB/ARF locus. We show that MSK1 mediates histone H3S28 phosphorylation at the INK4AB/ARF locus and contributes to the rapid transcriptional activation of p15(INK4B) and p16(INK4A) in human cells despite the presence of the repressive H3K27me3 mark. Furthermore, we show that upon MSK1 depletion in oncogenic RAF1-expressing cells, H3S28ph presence at the INK4 locus and p15(INK4B) and p16(INK4A) expression are reduced. Finally, we show that H3S28-MSK-dependent phosphorylation functions in response to RAF1 signaling and that ERK and p38 contribute to MSK1 activation in oncogene-induced senescence. ",
        "Doc_title":"MSK1 triggers the expression of the INK4AB/ARF locus in oncogene-induced senescence.",
        "Journal":"Molecular biology of the cell",
        "Do_id":"27385346",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605742104906039296},
      {
        "Doc_abstract":"The INK4a proteins p16(INK4a) and p19(ARF) regulate cell cycle arrest and senescence. However, the role of these proteins in controlling these processes in the normal kidney and following injury is unknown. We performed unilateral ureteral obstruction (UUO) to induce fibrosis in 2- to 3-mo-old wild-type (WT) C57/B6 and INK4a knockout mice. By quantitative RT-PCR, p16(INK4a) levels were increased sixfold in WT mice 7 days after UUO and p19(ARF) remained undetectable. Kidney sections were examined to determine levels and localization of p16(INK4a), apoptosis, fibrosis, and senescent cells. INK4a knockout mice displayed mesangial cell proliferation, increased matrix deposition, and myofibroblast differentiation under normal conditions. Following UUO, INK4a knockout mice displayed 10-fold increased tubular and interstitial cell proliferation, 75% decreased collecting duct apoptosis, 2-fold greater collagen and fibronectin deposition, and no cell senescence by senescence-associated -galactosidase staining compared with WT mice. Both INK4a knockout mesangial cells and kidney lysates from knockout mice following injury showed elevated levels of IL-6 by ELISA compared with WT samples. INK4a knockout epithelial cell cultures displayed increased mesenchymal cell markers when exposed to transforming growth factor-. These results confirm that p16(INK4a) controls cell proliferation and matrix production and mitigates fibrosis following injury and suggest that the mechanism involves a role in limiting inflammation and cell proliferation.",
        "Doc_title":"INK4a knockout mice exhibit increased fibrosis under normal conditions and in response to unilateral ureteral obstruction.",
        "Journal":"American journal of physiology. Renal physiology",
        "Do_id":"20861074",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16",
        "Doc_meshdescriptors":"Animals;Apoptosis;Cell Aging;Cell Proliferation;Cyclin-Dependent Kinase Inhibitor p16;Fibrosis;Kidney;Male;Mice;Mice, Knockout;Ureteral Obstruction",
        "Doc_meshqualifiers":"genetics;physiology;metabolism;pathology;pathology",
        "_version_":1605800847995830272},
      {
        "Doc_abstract":"Inactivation of the CDKN2 genes that encode the p16(INK4A) and p14(ARF) proteins occurs in the majority of human T-cell acute lymphoblastic leukemias (T-ALLs). Ectopic expression of TAL1 and LMO1 genes is linked to the development of T-ALL in humans. In TAL1xLMO1 mice, leukemia develops in 100% of mice at 5 months. To identify the molecular events crucial to leukemic transformation, we produced several mouse models. We report here that expression of P16(INK4A) in developing TAL1xLMO1 thymocytes blocks leukemogenesis in the majority of the mice, and the leukemias that eventually develop show P16(INK4A) loss of expression. Events related to the T-cell receptor beta selection process are thought to be important for leukemic transformation. We show here that the absence of the pTalpha chain only slightly delays the appearance of TAL1xLMO1-induced T-ALL, which indicates a minor role of the pTalpha chain. We also show that the CD3epsilon-mediated signal transduction pathway is essential for this transformation process, since the TAL1xLMO1xCD3epsilon-deficient mice do not develop T-ALL for up to 1 year.",
        "Doc_title":"p16INK4A tumor suppressor gene expression and CD3epsilon deficiency but not pre-TCR deficiency inhibit TAL1-linked T-lineage leukemogenesis.",
        "Journal":"Blood",
        "Do_id":"17507663",
        "Doc_ChemicalList":"Antigens, CD3;Basic Helix-Loop-Helix Transcription Factors;CCND3 protein, human;CD3E protein, human;Ccnd3 protein, mouse;Cyclin D3;Cyclin-Dependent Kinase Inhibitor p16;Cyclins;LIM Domain Proteins;Lmo1 protein, mouse;Nuclear Proteins;Proto-Oncogene Proteins;RNA, Messenger;Receptor, Notch1;Receptors, Antigen, T-Cell;Tal1 protein, mouse;Transcription Factors;TAL1 protein, human",
        "Doc_meshdescriptors":"Animals;Antigens, CD3;Basic Helix-Loop-Helix Transcription Factors;Cell Differentiation;Cell Lineage;Cell Transformation, Neoplastic;Cyclin D3;Cyclin-Dependent Kinase Inhibitor p16;Cyclins;Gene Expression Regulation, Neoplastic;Humans;LIM Domain Proteins;Leukemia;Mice;Mice, Transgenic;Mutation;Nuclear Proteins;Proto-Oncogene Proteins;RNA, Messenger;Receptor, Notch1;Receptors, Antigen, T-Cell;Survival Rate;Thymus Gland;Transcription Factors",
        "Doc_meshqualifiers":"genetics;metabolism;genetics;metabolism;genetics;metabolism;pathology;genetics;metabolism;metabolism;genetics;metabolism;pathology;genetics;genetics;metabolism;genetics;metabolism;genetics;genetics;metabolism;deficiency;genetics;metabolism;cytology;metabolism;genetics;metabolism",
        "_version_":1605881267911393280},
      {
        "Doc_abstract":"The methylation status of p15(INK4b) (MTS2), p16(INK4a) (MTS1) and p14(ARF) (p16beta) was analyzed in 56 lymphomas by restriction-enzyme related polymerase chain reaction (PCR) (REP), methylation-specific PCR (MSP), and bisulfite genomic sequencing (BGS). Methylation of the p15 and p16 genes was detected, respectively, in 64% and 32% of the B-cell lymphomas, in 44% and 22% of the T-cell lymphomas, and in none of the 5 reactive lymph nodes analyzed. Both p15 and p16 genes were methylated more often in the high-grade (78% and 50%, respectively) than in the low-grade B-cell lymphomas (55% and 21%, respectively). For 5 cases, mapping of the methylated CpGs of the p16 promoter region confirmed the results of REP and MSP. In addition, a large variation in the methylation patterns of p16 exon 1 was observed, not only from one lymphoma to another, but also within a given tumor. Methylation of p15 and p16 was associated with an absence of gene expression, as assessed by reverse transcription-PCR. The p14 gene was unmethylated and normally expressed in all 56 tumors. We found no mutations of p15, p16, or p14 in any of the 56 lymphomas. Our results suggest a role for p15 and p16 gene methylation during lymphomagenesis and a possible association between p15 and p16 inactivation and aggressive transformation in B-cell and T-cell lymphomas.",
        "Doc_title":"Frequent methylation silencing of p15(INK4b) (MTS2) and p16(INK4a) (MTS1) in B-cell and T-cell lymphomas.",
        "Journal":"Blood",
        "Do_id":"10477703",
        "Doc_ChemicalList":"CDKN2B protein, human;Carrier Proteins;Cell Cycle Proteins;Cyclin-Dependent Kinase Inhibitor p15;Cyclin-Dependent Kinase Inhibitor p16;DNA, Neoplasm;Tumor Suppressor Proteins",
        "Doc_meshdescriptors":"Carrier Proteins;Cell Cycle Proteins;Cyclin-Dependent Kinase Inhibitor p15;Cyclin-Dependent Kinase Inhibitor p16;DNA Methylation;DNA, Neoplasm;Genes, Tumor Suppressor;Humans;Lymphoma, B-Cell;Lymphoma, T-Cell;Polymerase Chain Reaction;Tumor Suppressor Proteins",
        "Doc_meshqualifiers":"genetics;genetics;genetics;genetics;metabolism;genetics;metabolism",
        "_version_":1605763312597860352},
      {
        "Doc_abstract":"The purpose of this study was to report associations between p16 status, clinicopathologic characteristics, and outcomes for head and neck squamous cell carcinoma of unknown primary (CUP).;Specimens of squamous cell CUP were reanalyzed. Human papillomavirus (HPV) status was determined by p16 stain. A tissue microarray (TMA) was constructed to evaluate biomarkers potentially prognostic in head and neck squamous cell carcinoma (HNSCC).;A majority of the population (n=26; 74%) was p16 positive (+). Prognostic factors benefiting survival were p16+ status (p<.0001), absence of macroscopic extracapsular extension (ECE; p=.004), younger age (p=.01), and higher grade (p=0.007). The prognostic implication of worse overall survival (OS) with macroscopic ECE (p = .009) remained significant when limited to patients who were p16+ (p=.002). Exploratory TMA between unknown primary and controls suggested a biomolecular difference between squamous cell CUP and known-primary cancer.;The majority of patients with squamous cell CUP were p16+, indicative of HPV association. P16 staining and ECE seem to be the most prognostic features in squamous cell CUP.",
        "Doc_title":"p16 status, pathologic and clinical characteristics, biomolecular signature, and long-term outcomes in head and neck squamous cell carcinomas of unknown primary.",
        "Journal":"Head & neck",
        "Do_id":"24115269",
        "Doc_ChemicalList":"Biomarkers, Tumor;Neoplasm Proteins;P16 protein, human",
        "Doc_meshdescriptors":"Age Factors;Biomarkers, Tumor;Carcinoma, Squamous Cell;Female;Head and Neck Neoplasms;Humans;Male;Neoplasm Proteins;Neoplasms, Unknown Primary;Papillomavirus Infections;Survival Analysis;Tissue Array Analysis",
        "Doc_meshqualifiers":"metabolism;metabolism;mortality;pathology;metabolism;mortality;pathology;metabolism;metabolism;mortality;pathology",
        "_version_":1605832221903552512},
      {
        "Doc_abstract":"The tumor suppressor gene p16 (CDKN2/MTS-1/INK4A) can be inactivated by multiple genetic mechanisms. We analyzed 29 invasive primary head and neck squamous cell carcinomas (HNSCC) for p16 inactivation with immunohistochemistry utilizing a new monoclonal antibody (mAb), DCS-50. p16 staining of the primary lesions was correlated with genetic analysis including: (a) detailed microsatellite analysis of markers at the p16 locus to detect homozygous deletion; (b) sequence analysis of p16; and (c) Southern blot analysis to determine the methylation status of the 5' CpG island of p16. Twenty-four of 29 (83%) head and neck squamous cell carcinoma tumors displayed an absence of p16 nuclear staining using immunohistochemistry. Of these 24 tumors, we found that 16 (67%) harbored homozygous deletions, 5 (21%) were methylated, 1 displayed a rearrangement at the p16 locus, and 1 displayed a frameshift mutation in exon 1. These data suggest that: (a) inactivation of the p16 tumor suppressor gene is a frequent event in squamous cell carcinomas of the head and neck; (b) p16 is inactivated by several distinct and exclusive events including homozygous deletion, point mutation, and promoter methylation; and (c) immunohistochemical analysis for expression of the p16 gene product is an accurate and relatively simple method for evaluating p16 gene inactivation.",
        "Doc_title":"High frequency of p16 (CDKN2/MTS-1/INK4A) inactivation in head and neck squamous cell carcinoma.",
        "Journal":"Cancer research",
        "Do_id":"8705996",
        "Doc_ChemicalList":"Carrier Proteins;Cyclin-Dependent Kinase Inhibitor p16;DNA, Neoplasm",
        "Doc_meshdescriptors":"Blotting, Southern;Carcinoma, Squamous Cell;Carrier Proteins;Cyclin-Dependent Kinase Inhibitor p16;DNA, Neoplasm;Exons;Genes, Tumor Suppressor;Head and Neck Neoplasms;Humans;Immunohistochemistry;Methylation;Mutation",
        "Doc_meshqualifiers":"genetics;analysis;genetics;analysis;genetics",
        "_version_":1605755353391169536},
      {
        "Doc_abstract":"Head and neck squamous cell carcinoma (HNSCC) is the fifth most frequent cancer in the US. Several genetic and epigenetic alterations are associated with HNSCC tumorigenesis, including inactivation of CDKN2A, which encodes the p16 tumor suppressor, in cell lines and primary tumors by DNA methylation. Reactivation of tumor suppressor genes by DNA-demethylating agents and histone deacetylase (HDAC) inhibitors shows therapeutic promise for other cancers. Therefore, we investigated the ability of these agents to reactivate p16 in Tu159 HNSCC cells. Treatment of cells with 5-aza-2'deoxycytidine (5-aza-dC) increases CDKN2A expression and slightly increases histone H3 acetylation at this gene. No reactivation of CDKN2A is observed upon treatment with the HDAC inhibitor trichostatin A (TSA), but synergistic reactivation of CDKN2A is observed upon sequential treatment of Tu159 cells with both 5-aza-dC and TSA. Silencing of CDKN2A in Tu159 cells is correlated with increased methylation of histone H3 at lysine 9 and decreased methylation at lysine 4 relative to the upstream p15 gene promoter. Interestingly, global levels of H3-K9 methylation are decreased upon treatment with 5-aza-dC. Together these data indicate that DNA methylation is a dominant epigenetic mark for silencing of CDKN2A in Tu159 tumor cells. Moreover, changes in DNA methylation can reset the histone code by impacting multiple H3 modifications.",
        "Doc_title":"Resetting the histone code at CDKN2A in HNSCC by inhibition of DNA methylation.",
        "Journal":"Oncogene",
        "Do_id":"14654786",
        "Doc_ChemicalList":"Antimetabolites, Antineoplastic;Histone Deacetylase Inhibitors;Histones;Hydroxamic Acids;trichostatin A;decitabine;Azacitidine",
        "Doc_meshdescriptors":"Animals;Antimetabolites, Antineoplastic;Azacitidine;Carcinoma, Squamous Cell;DNA Methylation;Gene Silencing;Genes, p16;Head and Neck Neoplasms;Histone Deacetylase Inhibitors;Histones;Humans;Hydroxamic Acids",
        "Doc_meshqualifiers":"pharmacology;analogs & derivatives;pharmacology;genetics;metabolism;drug effects;physiology;genetics;metabolism;metabolism;pharmacology",
        "_version_":1605897077904113664},
      {
        "Doc_abstract":"When treated by radiotherapy, patients with squamous cell carcinomas of the head and neck (HNSCC) positive for HPV and p16(INK4a) possess a clearly favorable prognosis as compared to those with HPV-negative HNSCC. The aim of this work was to study whether the better outcomes might be caused by an enhanced cellular radiosensitivity.;The radiation response of five HPV/p16(INK4a)-positive and five HPV-negative cell lines was characterized with regard to cellular radiosensitivity by colony formation assay. Furthermore G1- and G2-arrest, apoptosis and residual DNA double-strand breaks (DSB) were analyzed by the colcemid-based G1-efflux assay, propidium iodide staining, the detection of PARP cleavage, the fluorescence-based detection of caspase activity and the immunofluorescence staining of H2AX and 53BP1 foci.;On average, the cellular radiosensitivity of the HNSCC cell lines positive for HPV and p16(INK4a) was higher as compared to the sensitivity of a panel of five HPV-negative HNSCC cell lines (SF3=0.2827 vs. 0.4455). The higher sensitivity does not result from increased apoptosis or the execution of a permanent G1-arrest, but is rather associated with both, elevated levels of residual DSBs and extensive G2-arrest.;Increased cellular radiosensitivity due to compromised DNA repair capacity is likely to contribute to the improved outcome of patients with HPV/p16(INK4a)-positive tumors when treated by radiotherapy.",
        "Doc_title":"HNSCC cell lines positive for HPV and p16 possess higher cellular radiosensitivity due to an impaired DSB repair capacity.",
        "Journal":"Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology",
        "Do_id":"23602369",
        "Doc_ChemicalList":"Neoplasm Proteins;P16 protein, human",
        "Doc_meshdescriptors":"Apoptosis;Carcinoma, Squamous Cell;Cell Line, Tumor;DNA Breaks, Double-Stranded;DNA Repair;G1 Phase;Head and Neck Neoplasms;Humans;Neoplasm Proteins;Papillomaviridae;Radiation Tolerance",
        "Doc_meshqualifiers":"chemistry;genetics;radiotherapy;virology;chemistry;genetics;radiotherapy;virology;analysis;isolation & purification",
        "_version_":1605810127969976320},
      {
        "Doc_abstract":"It has been proposed that p16(INK4A) qualifies as a surrogate marker for viral oncogene activity in head and neck cancer (HNSCC). By analyzing 78 HNSCC we sought to validate the accuracy of p16(INK4A) as a reliable marker of active HPV infections in HNSCC. To this end we determined HPV DNA (HPVD) and E6*I mRNA (HPVR) expression status and correlated these results with p16(INK4A) staining. In tonsillar SCC 12/20 were HPVD+ and 12/12 of these showed active HPV infections whereas in non-tonsillar SCC 10/58 were HPVD+ and 5/10 showed active HPV infections. Thus, we prove about 8% of non-tonsillar SCC to be also correlated with HPV-associated carcinogenesis. Strikingly, 3/14 (21.4%) of tonsillar and non-tonsillar HPVD+/HPVR+ cases did not show p16(INK4A) overexpression and these cases would have been missed when applying initial p16(INK4A) staining only. However, in 13 cases negative for HPV, DNA p16(INK4A) was overexpressed. In conclusion, our data confirm tonsillar SCC to be predominantly but not only associated with active HPV infections. Furthermore, our data show that p16(INK4A) overexpression is not evident in a subgroup of HNSCC with active HPV infection. Definitive HPV data should therefore be utilized in diagnostics and treatment modalities of HPV positive and HPV negative HNSCC patients, resulting in a paradigm shift regarding these obviously different tumor entities.",
        "Doc_title":"HPV DNA, E6*I-mRNA expression and p16INK4A immunohistochemistry in head and neck cancer - how valid is p16INK4A as surrogate marker?",
        "Journal":"Cancer letters",
        "Do_id":"22484467",
        "Doc_ChemicalList":"Biomarkers;Cyclin-Dependent Kinase Inhibitor p16;DNA, Viral;E6 protein, human papillomavirus type 1;Oncogene Proteins, Viral;RNA, Messenger",
        "Doc_meshdescriptors":"Adult;Aged;Biomarkers;Carcinoma, Squamous Cell;Cyclin-Dependent Kinase Inhibitor p16;DNA, Viral;Female;Head and Neck Neoplasms;Humans;Immunohistochemistry;Male;Middle Aged;Multiplex Polymerase Chain Reaction;Oncogene Proteins, Viral;Papillomavirus Infections;RNA, Messenger;Tonsillar Neoplasms",
        "Doc_meshqualifiers":"analysis;metabolism;virology;analysis;analysis;metabolism;virology;analysis;complications;diagnosis;analysis;metabolism;virology",
        "_version_":1605897896372207616},
      {
        "Doc_abstract":"To demonstrate the roles of p16(INK4a) in the senescence of human chondrocytes and the progression of osteoarthritis (OA).;Immunohistochemistry and reverse transcriptase polymerase chain reaction (RT-PCR) were performed to examine p16(INK4a) expression in fetal, normal age-matched and OA cartilage, and Western blot was used in primary cultured chondrocytes from different origins. To explore a functional p16(INK4a) knockdown in OA chondrocytes, the primary cultured cells were treated with p16(INK4a)-specific small interfering ribonucleic acids (siRNAs). Expression of p16(INK4a), p14(ARF) and p53 was observed by Western blot and RT-PCR. The phosphorylation status of pRb, senescence-associated beta-galactosidase (SA-beta-gal), cell G1/S transition and cell proliferation were studied by Western blot, histological staining, 3H-thymidine incorporation and cell counts respectively. Expression of the collagen I, collagen II and aggrecan genes was measured by semiquantitative RT-PCR. To establish the response of chondrocytes to cytokines, cells were treated with transforming growth factor-beta1 (TGF-beta1) or interleukin-1alpha (IL-1alpha) and examined for incorporation of 3H-thymidine, 3H-proline and 35S-sulphate respectively.;A significant increase of p16(INK4a) was detected in OA chondrocytes compared with normal age-matched and fetal chondrocytes (P<0.01) in vivo and in vitro. Treated with p16(INK4a)-specific siRNAs, OA chondrocytes displayed a significant decrease in p16(INK4a) expression with an increase of phosphorylated pRb, but no alteration of p14(ARF) and p53 expression, followed by decreases of senescent features and increases in the expression of some chondrocyte-specific genes and overall repair capacity.;p16(INK4a) is instrumental in the senescence of human articular chondrocytes or OA. The reduction of p16(INK4a) by RNA interference (RNAi) contributed to the recovery of osteoarthritic chondrocytes, suggesting that p16(INK4a) may be a viable future therapeutic candidate.",
        "Doc_title":"Recovery of function in osteoarthritic chondrocytes induced by p16INK4a-specific siRNA in vitro.",
        "Journal":"Rheumatology (Oxford, England)",
        "Do_id":"15026580",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;Cytokines;RNA, Small Interfering;Tumor Suppressor Protein p14ARF;Tumor Suppressor Protein p53",
        "Doc_meshdescriptors":"Aged;Aged, 80 and over;Cartilage, Articular;Cell Aging;Cells, Cultured;Chondrocytes;Cyclin-Dependent Kinase Inhibitor p16;Cytokines;Disease Progression;Gene Expression Regulation;Humans;Middle Aged;Osteoarthritis, Knee;RNA, Small Interfering;Reverse Transcriptase Polymerase Chain Reaction;Transfection;Tumor Suppressor Protein p14ARF;Tumor Suppressor Protein p53",
        "Doc_meshqualifiers":"metabolism;pathology;physiology;physiology;genetics;metabolism;physiology;pharmacology;metabolism;pathology;genetics;metabolism;metabolism",
        "_version_":1605818686169415680},
      {
        "Doc_abstract":"Detection of hypermethylated circulating tumor DNA has the potential to be a minimally invasive, low cost, and reproducible method for cancer detection.;We evaluated serum from 100 patients with known head and neck squamous cell carcinoma (HNSCC) and 50 healthy control patients for 3 previously described methylation targets, endothelin receptor type B (EDNRB), cyclin-dependent kinase inhibitor 2A (CDKN2A or p16), and deleted in colorectal carcinoma (DCC), using quantitative methylation specific polymerase chain reaction (qMSPCR).;EDNRB hypermethylation was identified in the serum of 10% of the patients with HNSCC but in none of the control patients. DCC hypermethylation was detected in 2 serum samples from patients with cancer that also amplified EDNRB and one of these samples also had p16 hypermethylation. EDNRB hypermethylation was statistically significant by Fisher's exact test (p=.03) when comparing HNSCC to controls.;Serum EDNRB hypermethylation is a highly specific but not sensitive serum biomarker for HNSCC.",
        "Doc_title":"Serum biomarkers for detection of head and neck squamous cell carcinoma.",
        "Journal":"Head & neck",
        "Do_id":"24995714",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605756588160712704},
      {
        "Doc_abstract":"The INK4a gene, one of the most frequently disrupted loci in human cancer, encodes two unrelated proteins, p16INK4a and p19ARF, that both block cell proliferation. p16INK4a is a component of the Rb regulatory pathway, while p19ARF has been functionally related to p53. Moreover, p16INK4a is inactivated in many human tumors, while it has been very recently reported that p19ARF null mice develop tumors early in life. We show here that p19ARF is able to inhibit the formation of G418-resistant colonies when transfected into human and mouse cell lines expressing wild-type p53, regardless of p16 status. Moreover its amino terminal domain encoded by exon 1beta is still sufficient to obtain the same effect. We have analysed the ability of p19ARF to interfere with Ras-mediated cellular transformation in the NIH3T3 cell line. Cotransfection of p19ARF together with activated ras potently inhibited the formation of transformed foci in a dose-dependent manner. We have also isolated stable NIH3T3 transfectants expressing p19ARF and we have measured their growth properties as well as their efficiency of transformation by activated ras. Our results suggest that p19ARF can interfere with oncogene-mediated transformation, without significantly affecting NIH3T3 cell growth, at least at the levels of expression achieved in these experiments.",
        "Doc_title":"Suppression of Ras-mediated NIH3T3 transformation by p19ARF does not involve alterations of cell growth properties.",
        "Journal":"Oncogene",
        "Do_id":"10321741",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;Gentamicins;Proteins;Tumor Suppressor Protein p14ARF;antibiotic G 418;ras Proteins",
        "Doc_meshdescriptors":"3T3 Cells;Animals;Cell Transformation, Neoplastic;Cyclin-Dependent Kinase Inhibitor p16;Gentamicins;Humans;Mice;Proteins;Suppression, Genetic;Tumor Suppressor Protein p14ARF;ras Proteins",
        "Doc_meshqualifiers":"genetics;genetics;pharmacology;genetics;genetics",
        "_version_":1605813145561989120},
      {
        "Doc_abstract":"The frequent loss of the INK4a/ARF locus, encoding for both p16(INK4a)and p19(ARF)in human melanoma, raises the question as to which INK4a/ARF gene product functions to suppress melanoma-genesis in vivo. Studies in the mouse have shown that activated RAS mutation can cooperate with INK4a(Delta 2/3)deficiency (null for both p16(INK4a)and p19(ARF)) to promote development of melanoma, and these melanomas retain wild-type p53. Given the functional link between p19(ARF)and p53, we have now shown that activated RAS can also cooperate with p53 deficiency to produce melanoma in the mouse. Moreover, genome-wide analysis of RAS-induced p53 mutant melanomas reveals alterations of key components governing RB-regulated G1/S transition, such as c-Myc. These experimental findings suggest that both RB and p53 pathways function to suppress melanocyte transformation in vivo in the mouse.",
        "Doc_title":"Genetic dissection of melanoma pathways in the mouse.",
        "Journal":"Seminars in cancer biology",
        "Do_id":"11407950",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;Microtubule Proteins;Phosphoproteins;STMN1 protein, human;Stathmin;Stmn1 protein, mouse;Tumor Suppressor Protein p53",
        "Doc_meshdescriptors":"Animals;Cyclin-Dependent Kinase Inhibitor p16;Disease Models, Animal;Gene Deletion;Genes, Tumor Suppressor;Humans;Melanoma;Mice;Microtubule Proteins;Phosphoproteins;Stathmin;Tumor Suppressor Protein p53",
        "Doc_meshqualifiers":"genetics;genetics;genetics;genetics",
        "_version_":1605875698034016256},
      {
        "Doc_abstract":"Recent identification of an enhancer element, RD(INK4/ARF) (RD), in the prominent INK4/ARF locus provides a novel mechanism to simultaneously regulate the transcription of p15(INK4B) (p15), p14(ARF) , and p16(INK4A) (p16) tumor suppressor genes. While genetic inactivation of p15, p14(ARF) , and p16 in human tumors has been extensively studied, little is known about genetic alterations of RD and its impact on p15, p14(ARF) , and p16 in human cancer. The purpose of this study was to investigate the potential existence of genetic alterations of RD in human cancer cells. DNAs extracted from 17 different cancer cell lines and 31 primary pheochromocytoma tumors were analyzed for deletion and mutation of RD using real-time PCR and direct DNA sequencing. We found that RD was deleted in human cancer cell lines and pheochromocytoma tumors at frequencies of 41.2% (7/17) and 13.0% (4/31), respectively. While some of these RD deletion events occurred along with deletions of the entire INK4/ARF locus, other RD deletion events were independent of genetic alterations in p15, p14(ARF) , and p16. Furthermore, the status of RD was poorly associated with the expression of p15, p14(ARF) , and p16 in tested cancer cell lines and tumors. This study demonstrates for the first time that deletion of the RD enhancer is a prevalent event in human cancer cells. Its implication in carcinogenesis remains to be further explored.",
        "Doc_title":"Genetic alterations of RD(INK4/ARF) enhancer in human cancer cells.",
        "Journal":"Molecular carcinogenesis",
        "Do_id":"23065809",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p15;Cyclin-Dependent Kinase Inhibitor p16;Tumor Suppressor Protein p14ARF",
        "Doc_meshdescriptors":"Adrenal Gland Neoplasms;Cyclin-Dependent Kinase Inhibitor p15;Cyclin-Dependent Kinase Inhibitor p16;DNA Methylation;Enhancer Elements, Genetic;Gene Deletion;Humans;Neoplasms;Pheochromocytoma;Point Mutation;Tumor Cells, Cultured;Tumor Suppressor Protein p14ARF",
        "Doc_meshqualifiers":"genetics;genetics;genetics;genetics;genetics;genetics;genetics;genetics",
        "_version_":1605766336390103040},
      {
        "Doc_abstract":"To assess the anti-tumor effect of p16(INK4A) gene transfer and the combined effect of this gene therapy and ionizing radiation in the treatment of laryngeal squamous cell carcinoma.;A Complete p16(INK4A) gene was inserted into a replication-defective recombinant adenovirus, and the tumor cells were infected with Adenovinus-p16 (Ad-p16) and irradiated with X-rays. Confirmation of P16(INK4A) protein expression after Ad-p16 infection was performed by Western blotting. The therapeutic effects were evaluated both in vitro and in vivo.;The replication-defective recombinant adenovirus could direct a high level of P16INK4A protein expression in laryngeal squamous cell carcinoma. Studies both in vitro and in vivo demonstrated that Ad-p16 treatment significantly inhibited the cell growth and the established tumors in mude mice when compared with the control treatments (P < 0.05). The combination of Ad-p16 and radiation group resulted in greater inhibition of tumor growth, compared with any other treatment groups and controls (P < 0.05). No significant difference was observed between Adenovirus-LacZ (Ad-LacZ) and PBS groups.;These results demonstrate a significant antitumor effect of Ad-p16 against human laryngeal squamous cell carcinoma and also demonstrate for the first time a combined effect of radiation and Ad-p16 gene transfer in p16 deficient human laryngeal squamous cell carcinoma.",
        "Doc_title":"[Combination of adenovirus p16(INK4A) gene therapy and ionizing radiation for laryngeal squamous cell carcinoma].",
        "Journal":"Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition",
        "Do_id":"15071918",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16",
        "Doc_meshdescriptors":"Adenoviridae;Animals;Carcinoma, Squamous Cell;Cyclin-Dependent Kinase Inhibitor p16;Gene Transfer Techniques;Genes, p16;Genetic Therapy;Laryngeal Neoplasms;Mice;Mice, Nude;Neoplasm Transplantation;Radiotherapy, Adjuvant;Transfection;Tumor Cells, Cultured",
        "Doc_meshqualifiers":"metabolism;radiotherapy;therapy;genetics;metabolism;methods;metabolism;radiotherapy;therapy",
        "_version_":1605806778163920896},
      {
        "Doc_abstract":"To explore the mechanism underlying the aging of hematopoietic stem/progenitor cells (HSC/HPC) induced by radiation stress.;Male C57BL/6J mice were divided randomly into radiation group and control group. The radiation group were treated with total 6.5 Gy X-ray radiation for 24 h; the control group received the same treatment except radiation. Thereafter, Sca-1(+);HSC/HPC were isolated by magnetic-activated cell sorting (MACS) from bone marrow of all the mice. The distributions of cell cycle were tested by flow cytometry. The percentage of aging cells was detected by SA--Gal staining. The potentials of self-renewal and multi-differentiation were measured by CFU-Mix assay. DNA damages of Sca-1(+);HSC/HPC were analyzed by single cell gel electrophoresis technique (SCGE). The expressions of senescence-associated genes p16(INK4a);, p19(Arf);, p53, p21(Cip1/Waf1); mRNA were detected by RT-PCR. Western blotting was performed to analyze the expressions of p16(INK4a); and p21(Cip1/Waf1); proteins.;The purity of Sca-1(+);HSC/HPC reached 94% after MACS. Compared with control group cells, after radiation, the number of Sca-1(+);HSC/HPC per femur and CFU-Mix sharply decreased (P<0.05), Sca-1(+);HSC/HPC apparently showed G1 arrest and elevated percentage of SA--Gal positive cells (P<0.05), cell trailing had a prolonged time, and the expressions of senescence-associated genes (p16(INK4a);, p19(Arf);, p53, p21(Cip1/Waf1);) and relevant proteins (p16(INK4a);, p21(Cip1/Waf1);) were up-regulated significantly (P<0.05).;DNA damage and senescence-associated biological changes of Sca-1(+);HSC/HPC can be achieved by X-ray radiation, which may be involved in p16(INK4a);-Rb and p19(Arf);-p53-p21(Cip1/Waf1); signal pathways.",
        "Doc_title":"[Mechanism of hematopoietic stem/progenitor cell aging induced by radiation damage].",
        "Journal":"Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology",
        "Do_id":"23643076",
        "Doc_ChemicalList":"Antigens, Ly;Cdkn1a protein, mouse;Cdkn2a protein, mouse;Cyclin-Dependent Kinase Inhibitor p16;Cyclin-Dependent Kinase Inhibitor p21;Ly6a protein, mouse;Membrane Proteins;Tumor Suppressor Protein p53;beta-Galactosidase",
        "Doc_meshdescriptors":"Animals;Antigens, Ly;Cell Aging;Cell Count;Cyclin-Dependent Kinase Inhibitor p16;Cyclin-Dependent Kinase Inhibitor p21;DNA Damage;Gene Expression Regulation;Hematopoietic Stem Cells;Male;Membrane Proteins;Mice;Mice, Inbred C57BL;Signal Transduction;Stress, Physiological;Tumor Suppressor Protein p53;beta-Galactosidase",
        "Doc_meshqualifiers":"metabolism;radiation effects;metabolism;metabolism;radiation effects;cytology;enzymology;metabolism;radiation effects;metabolism;radiation effects;genetics;radiation effects;metabolism;metabolism",
        "_version_":1605818757903548416},
      {
        "Doc_abstract":"Development of squamous cell cancer of head and neck (SCCHN) is associated with human papillomavirus (HPV) infection, which in turn is closely related with expression of p16 INK4A. Loss of p16 INK4A expression by deletion, mutation, or hypermethylation is common in SCCHN. We here evaluated p16 INK4A as a prognostic marker of treatment response and survival in our SCCHN patients with laryngeal, hypopharyngeal or nasopharyngeal cancers.;131 patients diagnosed with SCCHN between January 2,2006 and July 17, 2010 were examined for p16 INK4A. The median age was 60 years (15-82 years). Fifty one patients were stage I-II and 80 were stage III-IV. Immunohistochemical expression of p16 INK4A was analyzed in pretreatment paraffin-embedded tumor blocks. The influence of p16 INK4A status on disease-free survival, and overall survival after treatment was evaluated.;P16 INK4A positivity was found in 58 patients (44%). Tumor-positivity for p16INK4A was correlated with improved disease free survival (70.1 months vs 59 months) and improved overall survival (2, 3 and 5-year values; 77% vs 72%, 70% vs 63% and, 63% vs 55%; respectively). On multivariate analysis, stage was determined as independent prognostic factor for disease-free survival.;Stage was the major prognostic factor on treatment response and survival in our patients. P16 INK4A status predicts better outcome in laryngeal, hypopharyngeal or nasopharyngeal cancer cases treated with surgery plus adjuvant radiochemotherapy as well as with definitive radiation therapy and/or chemotherapy.",
        "Doc_title":"HPV-associated p16 INK4A expression and response to therapy and survival in selected head and neck cancers.",
        "Journal":"Asian Pacific journal of cancer prevention : APJCP",
        "Do_id":"25640361",
        "Doc_ChemicalList":"Biomarkers, Tumor;Cyclin-Dependent Kinase Inhibitor p16",
        "Doc_meshdescriptors":"Adolescent;Adult;Aged;Aged, 80 and over;Biomarkers, Tumor;Carcinoma, Squamous Cell;Cyclin-Dependent Kinase Inhibitor p16;Disease-Free Survival;Female;Gene Deletion;Head and Neck Neoplasms;Humans;Hypopharyngeal Neoplasms;Laryngeal Neoplasms;Male;Middle Aged;Nasopharyngeal Neoplasms;Neoplasm Staging;Papillomaviridae;Papillomavirus Infections;Retrospective Studies;Young Adult",
        "Doc_meshqualifiers":"genetics;genetics;therapy;virology;biosynthesis;genetics;genetics;therapy;virology;genetics;therapy;virology;genetics;therapy;virology;genetics;therapy;virology;genetics;complications;virology",
        "_version_":1605846084457857024},
      {
        "Doc_abstract":"Head and neck squamous cell carcinoma (HNSCC) represents 5.5% of malignancies worldwide, with approximately 30,000 new cases and approximately 11,000 deaths reported in the United States annually. The opioid growth factor (OGF; [Met(5)]-enkephalin) and the OGF receptor (OGFr) form an endogenous growth regulating system; the OGF-OGFr axis influences the G(0)-G(1) phase of the cell cycle in HNSCC. Cells treated with small interfering RNA (siRNA) for OGFr no longer responded to the growth inhibitory effects of OGF or the growth stimulatory effects of naltrexone, indicating that these activities are entirely mediated by OGFr. In this investigation, we examined the precise target of OGF in the cell cycle. Using SCC-1 cells, OGF decreased the phosphorylation of retinoblastoma protein. This change was correlated with reduced Cdk4, but not Cdk2, kinase activity. OGF treatment increased cyclin-dependent kinase inhibitor p16 protein expression. Importantly, p16 complexed with Cdk4 was increased by OGF treatment at all time points, consistent with the hypothesis that OGF mediated growth inhibition through p16. Blockade of OGF-OGFr interactions with naloxone abolished the increased expression of p16 protein by OGF. Inhibition of p16 (INK4a) activation by p16-specific siRNA blocked OGF's repressive action on proliferation of SCC-1, CAL-27, and SCC-4 HNSCC cells. These data are the first to reveal that the target of cell proliferative inhibitory action of OGF in human HNSCC is a cyclin-dependent kinase inhibitory pathway, and this may be useful in the diagnosis and treatment of HNSCC.",
        "Doc_title":"The opioid growth factor (OGF)-OGF receptor axis uses the p16 pathway to inhibit head and neck cancer.",
        "Journal":"Cancer research",
        "Do_id":"17974995",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;Receptors, Opioid;Retinoblastoma Protein;methionine-enkephalin receptor;Cyclin D1;Enkephalin, Methionine;CDK4 protein, human;Cyclin-Dependent Kinase 4",
        "Doc_meshdescriptors":"Carcinoma, Squamous Cell;Cell Cycle;Cell Line, Tumor;Cell Proliferation;Cyclin D1;Cyclin-Dependent Kinase 4;Cyclin-Dependent Kinase Inhibitor p16;Enkephalin, Methionine;Head and Neck Neoplasms;Humans;Phosphorylation;Receptors, Opioid;Retinoblastoma Protein",
        "Doc_meshqualifiers":"drug therapy;pathology;drug effects;drug effects;metabolism;metabolism;physiology;pharmacology;drug therapy;pathology;physiology;analysis",
        "_version_":1605846077775282176},
      {
        "Doc_abstract":"CDKN2 (p16(INK4A)/MTS1) is found to be mutated in a variety of human tumor types. To explore the involvement of CDKN2 in prostate carcinogenesis, alterations of CDKN2 were examined in 116 human prostate tissues and cell lines and xenografts. Markedly reduced expression of CDKN2 mRNA was found in 43% (26 of 60) of untreated primary carcinomas, whereas no alteration was observed in 10 benign prostatic hyperplasias. In 17 matched sets from individual patients, 41% of cancerous tissues in contrast to 6% of noncancerous tissues expressed low levels of CDKN2 mRNA, supporting the role of CDKN2 as a tumor suppressor in prostate cancer. Alteration of CDKN2 was observed in each prostate tumor cell line, including one with a missense mutation, and in one of three xenograft tumor tissues derived from primary carcinomas. Two cell lines (PC-3 and TSU-Pr1) expressed only CDKN2 E1beta transcripts, indicating that the expression of CDKN2 E1alpha and E1beta are under separate control in the prostate. A high level of CDKN2 expression was related to abnormal RB1 in one primary tumor and in the DU145 cell line, which expressed the mutated CDKN2 allele. Analysis of genomic DNA indicated that altered CDKN2 expression in primary carcinomas of the prostate was more frequently due to down-regulation of transcription (five of seven) than deletion of the gene (two of seven). Additionally, CDKN2 mRNA was induced in nonexpressor cell lines by treatment with 5-aza-2'-deoxycytidine. This study demonstrates that alteration of CDKN2 is one of the most frequent genetic abnormalities in prostate cancer and may contribute to prostate carcinogenesis.",
        "Doc_title":"Frequent alteration of CDKN2 (p16(INK4A)/MTS1) expression in human primary prostate carcinomas.",
        "Journal":"Clinical cancer research : an official journal of the American Association for Cancer Research",
        "Do_id":"9815578",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;Neoplasm Proteins;RNA, Messenger;RNA, Neoplasm;Retinoblastoma Protein;decitabine;Azacitidine",
        "Doc_meshdescriptors":"Adenocarcinoma;Animals;Azacitidine;Blotting, Western;Cyclin-Dependent Kinase Inhibitor p16;Gene Expression Regulation, Neoplastic;Genes, Retinoblastoma;Genes, p16;Humans;Male;Mice;Mice, Nude;Neoplasm Proteins;Neoplasm Transplantation;Polymerase Chain Reaction;Polymorphism, Single-Stranded Conformational;Prostatic Hyperplasia;Prostatic Neoplasms;RNA, Messenger;RNA, Neoplasm;Retinoblastoma Protein;Transcription, Genetic;Tumor Cells, Cultured",
        "Doc_meshqualifiers":"genetics;metabolism;pathology;analogs & derivatives;pharmacology;biosynthesis;deficiency;genetics;drug effects;biosynthesis;deficiency;genetics;genetics;metabolism;pathology;genetics;metabolism;pathology;biosynthesis;genetics;biosynthesis;genetics;biosynthesis;genetics;drug effects;drug effects",
        "_version_":1605928657239408640},
      {
        "Doc_abstract":"Head and neck squamous cell carcinoma (HNSCC) is considered a serious public health problem in many countries. Recently, genetic variations have been considered as important factors to cancer susceptibility and prognosis. More specifically, genetic polymorphisms have been associated with the development and prognosis of HNSCC. The purpose of the current study was to investigate an association among p16 (CDKN2A) gene polymorphism at rs11515, age, and HNSCC aggressiveness. PCR-RFLP analysis was used to investigate the p16 (CDKN2A) gene in 96 patients with HNSCC and in 100 individuals without HNSCC. A case group was categorized by age in younger (<60 years) and older ( 60 years) patients. Differences between the case and control groups were determined using Fisher and chi-squared tests. Time of survival was calculated from the date of diagnosis to the date of last follow-up visit or to the date of death using the Kaplan-Meier estimator and comparing this to the log-rank test. Statistical significance was set at p<0.05. In the present study, no association was established between HNSCC and rs11515 polymorphism, as indicated in a previous study. We found that HNSCC individuals with large-sized tumors and with metastatic disease presented worse overall survival, consistent with fundamental concepts that establish the effects of tumor size and lymph node metastasis to HNSCC outcomes. This study identified that there is no difference in the distribution of rs11515 between the control and HNSCC groups. In addition, no differences between rs11515 genotypes and clinicopathological parameters were observed.",
        "Doc_title":"p16 (CDKN2A) SNP rs11515 was not associated with head and neck carcinoma.",
        "Journal":"Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine",
        "Do_id":"24633888",
        "Doc_ChemicalList":"Neoplasm Proteins;P16 protein, human",
        "Doc_meshdescriptors":"Adult;Aged;Carcinoma, Squamous Cell;Female;Head and Neck Neoplasms;Humans;Male;Middle Aged;Neoplasm Proteins;Polymorphism, Single Nucleotide",
        "Doc_meshqualifiers":"genetics;mortality;pathology;genetics;mortality;pathology;genetics",
        "_version_":1605774944891830272},
      {
        "Doc_abstract":"The polycomb group (PcG) protein Bmi1 plays an essential role in the self-renewal of hematopoietic and neural stem cells. Derepression of the Ink4a/Arf gene locus has been largely attributed to Bmi1-deficient phenotypes in the nervous system. However, its role in hematopoietic stem cell (HSC) self-renewal remained undetermined. In this study, we show that derepressed p16(Ink4a) and p19(Arf) in Bmi1-deficient mice were tightly associated with a loss of self-renewing HSCs. The deletion of both Ink4a and Arf genes substantially restored the self-renewal capacity of Bmi1(-/-) HSCs. Thus, Bmi1 regulates HSCs by acting as a critical failsafe against the p16(Ink4a)- and p19(Arf)-dependent premature loss of HSCs. We further identified a novel role for Bmi1 in the organization of a functional bone marrow (BM) microenvironment. The BM microenvironment in Bmi1(-/-) mice appeared severely defective in supporting hematopoiesis. The deletion of both Ink4a and Arf genes did not considerably restore the impaired BM microenvironment, leading to a sustained postnatal HSC depletion in Bmi1(-/-)Ink4a-Arf(-/-) mice. Our findings unveil a differential role of derepressed Ink4a and Arf on HSCs and their BM microenvironment in Bmi1-deficient mice. Collectively, Bmi1 regulates self-renewing HSCs in both cell-autonomous and nonautonomous manners.",
        "Doc_title":"Differential impact of Ink4a and Arf on hematopoietic stem cells and their bone marrow microenvironment in Bmi1-deficient mice.",
        "Journal":"The Journal of experimental medicine",
        "Do_id":"16954369",
        "Doc_ChemicalList":"BMI1 protein, human;Cdkn2a protein, mouse;Cyclin-Dependent Kinase Inhibitor p16;DNA Primers;Nuclear Proteins;Proto-Oncogene Proteins;Repressor Proteins;Polycomb Repressive Complex 1",
        "Doc_meshdescriptors":"Animals;Bone Marrow;Cyclin-Dependent Kinase Inhibitor p16;DNA Primers;Hematopoietic Stem Cells;Mice;Mice, Mutant Strains;Nuclear Proteins;Polycomb Repressive Complex 1;Proto-Oncogene Proteins;Repressor Proteins;Reverse Transcriptase Polymerase Chain Reaction",
        "Doc_meshqualifiers":"metabolism;metabolism;cytology;deficiency;deficiency",
        "_version_":1605846836362346496},
      {
        "Doc_abstract":"Lung cancer commonly displays a number of recurrent genetic abnormalities, and about 30% of lung adenocarcinomas carry activating mutations in the Kras gene, often concomitantly with inactivation of tumor suppressor genes p16(INK4A) and p14(ARF) of the CDKN2AB locus. However, little is known regarding the function of p15INK4B translated from the same locus. To determine the frequency of CDKN2AB loss in human mutant KRAS lung cancer, The Cancer Genome Atlas (TCGA) database was interrogated. Two-hit inactivation of CDKN2A and CDKN2B occurs frequently in patients with mutant KRAS lung adenocarcinoma. Moreover, p15INK4B loss occurs in the presence of biallelic inactivation of p16(INK4A) and p14(ARF), suggesting that p15INK4B loss confers a selective advantage to mutant KRAS lung cancers that are p16(INK4A) and p14(ARF) deficient. To determine the significance of CDKN2AB loss in vivo, genetically engineered lung cancer mouse models that express mutant Kras in the respiratory epithelium were utilized. Importantly, complete loss of CDKN2AB strikingly accelerated mutant Kras-driven lung tumorigenesis, leading to loss of differentiation, increased metastatic disease, and decreased overall survival. Primary mutant Kras lung epithelial cells lacking Cdkn2ab had increased clonogenic potential. Furthermore, comparative analysis of mutant Kras;Cdkn2a null with Kras;Cdkn2ab null mice and experiments with mutant KRAS;CDKN2AB-deficient human lung cancer cells indicated that p15INK4B is a critical tumor suppressor. Thus, the loss of CDKN2AB is of biologic significance in mutant KRAS lung tumorigenesis by fostering cellular proliferation, cancer cell differentiation, and metastatic behavior.;These findings indicate that mutant Kras;Cdkn2ab null mice provide a platform for accurately modeling aggressive lung adenocarcinoma and testing therapeutic modalities.",
        "Doc_title":"Nullifying the CDKN2AB locus promotes mutant K-ras lung tumorigenesis.",
        "Journal":"Molecular cancer research : MCR",
        "Do_id":"24618618",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p15;Cyclin-Dependent Kinase Inhibitor p16",
        "Doc_meshdescriptors":"Adenocarcinoma;Animals;Carcinogenesis;Carcinoma, Non-Small-Cell Lung;Cell Line, Tumor;Cyclin-Dependent Kinase Inhibitor p15;Cyclin-Dependent Kinase Inhibitor p16;Disease Models, Animal;Genes, ras;Humans;Lung Neoplasms;Mice;Mice, Transgenic;Microarray Analysis;Plasmids",
        "Doc_meshqualifiers":"genetics;pathology;genetics;genetics;pathology;genetics;genetics;genetics;pathology",
        "_version_":1605806479729754112},
      {
        "Doc_abstract":"The human CDKN2A locus encodes 2 distinct proteins, p16(INK4A) and p14(ARF) [mouse p19(Arf)], designated INK4A (inhibitor of cyclin dependent kinase 4) and ARF (alternative reading frame) here, that are translated from alternatively spliced mRNAs. Human ARF is implicated as a tumor suppressor gene, mainly in association with the simultaneous deletion of INK4A. However, questions remain as to whether loss of ARF alone is sufficient to drive tumorigenesis. Here, we report that mice deficient for Arf are susceptible to accelerated asbestos-induced malignant mesothelioma (MM). MMs arising in Arf (+/-) mice consistently exhibit biallelic inactivation of Arf, but, unexpectedly, do not acquire additional recurrent genetic alterations that we previously identified in asbestos-induced MMs arising in Nf2 (+/-) mice. Array CGH analysis was used to detect a recurrent deletion at chromosome 4C6 in MMs from Arf (+/-) mice. A candidate gene in this region, Faf1 (FAS-associated factor 1), was further explored, because it encodes a protein implicated in tumor cell survival and in the pathogenesis of some human tumor types. We confirmed hemizygous loss of Faf1 and down-regulation of Faf1 protein in a series of MMs from Arf (+/-) mice, and we then showed that Faf1 regulates TNF-alpha-mediated NF-kappaB signaling, a pathway previously implicated in asbestos-induced oncogenesis of human mesothelial cells. Collectively, these data indicate that Arf inactivation has a significant role in driving MM pathogenesis, and implicate Faf1 as a key component in the TNF-alpha/NF-kappaB signaling node that has now been independently implicated in asbestos-induced oncogenesis.",
        "Doc_title":"Activated TNF-alpha/NF-kappaB signaling via down-regulation of Fas-associated factor 1 in asbestos-induced mesotheliomas from Arf knockout mice.",
        "Journal":"Proceedings of the National Academy of Sciences of the United States of America",
        "Do_id":"19223589",
        "Doc_ChemicalList":"Carrier Proteins;Cdkn2a protein, mouse;Cyclin-Dependent Kinase Inhibitor p16;Faf1 protein, mouse;NF-kappa B;Tumor Necrosis Factor-alpha",
        "Doc_meshdescriptors":"Animals;Carrier Proteins;Cyclin-Dependent Kinase Inhibitor p16;Down-Regulation;Mesothelioma;Mice;Mice, Knockout;NF-kappa B;Signal Transduction;Tumor Cells, Cultured;Tumor Necrosis Factor-alpha",
        "Doc_meshqualifiers":"genetics;metabolism;deficiency;genetics;metabolism;genetics;metabolism;pathology;metabolism;metabolism",
        "_version_":1605746308320067585},
      {
        "Doc_abstract":"The chromosome 9p21 region harbors three tumor suppressor genes, p14(ARF), p15(INK4b), and p16(INK4a), all of which can be targets for hypermethylation-associated inactivation in low-grade gliomas. p16(INK4a) and p15(INK4b) are critically involved in the RB1 pathway, whereas p14(ARF) acts as an upstream regulator of the TP53 pathway. The role of each tumor suppressor pathway in low-grade diffuse astrocytomas and their relationships with clinical behavior remain to be elucidated.;We assessed the alterations of the RB1/CDK4/p16(INK4a)/p15(INK4b) and the TP53/MDM2/p14(ARF) pathways in 46 WHO grade II astrocytomas and analyzed their impact on prognosis.;The TP53/MDM2/p14(ARF) pathway was altered in 32 of 46 cases (70%) by either TP53 mutation (25 cases) or p14(ARF) methylation (9 cases). The RB1/CDK4/p16(INK4a)/p15(INK4b) pathway was disrupted in 6 of 46 cases (13%) by either RB1 methylation (1 case), p16(INK4a) methylation (3 cases), or p15(INK4b) methylation or homozygous deletion (3 cases). Generally speaking, individual tumors thus tended to display alteration of only one component from both pathways. Any independently analyzed genetic alteration failed to provide statistically prognostic information. The alternate or simultaneous presence of TP53 mutation and p14(ARF) methylation emerged as a univariate predictor of a shorter progression-free survival (P = 0.0456) but was not statistically significant when age and extent of surgery were included in the analysis.;Alternative disruption of the TP53/p14(ARF) pathway represents a frequent event in low-grade diffuse astrocytomas and correlates with an unfavorable clinical course. However, its value is unlikely to include prognostic utility that is independent of other conventional prognostic factors.",
        "Doc_title":"Deregulation of the TP53/p14ARF tumor suppressor pathway in low-grade diffuse astrocytomas and its influence on clinical course.",
        "Journal":"Clinical cancer research : an official journal of the American Association for Cancer Research",
        "Do_id":"14581362",
        "Doc_ChemicalList":"CDKN2B protein, human;Cell Cycle Proteins;Codon;Cyclin-Dependent Kinase Inhibitor p15;Cyclin-Dependent Kinase Inhibitor p16;Nuclear Proteins;Proto-Oncogene Proteins;Retinoblastoma Protein;Tumor Suppressor Protein p14ARF;Tumor Suppressor Protein p53;Tumor Suppressor Proteins;MDM2 protein, human;Proto-Oncogene Proteins c-mdm2;CDK4 protein, human;Cyclin-Dependent Kinase 4;Cyclin-Dependent Kinases",
        "Doc_meshdescriptors":"Adult;Astrocytoma;Brain Neoplasms;Cell Cycle Proteins;Cell Line, Tumor;Codon;CpG Islands;Cyclin-Dependent Kinase 4;Cyclin-Dependent Kinase Inhibitor p15;Cyclin-Dependent Kinase Inhibitor p16;Cyclin-Dependent Kinases;DNA Methylation;Disease-Free Survival;Exons;Female;Gene Deletion;Homozygote;Humans;Male;Middle Aged;Mutation;Nuclear Proteins;Polymerase Chain Reaction;Prognosis;Proto-Oncogene Proteins;Proto-Oncogene Proteins c-mdm2;Retinoblastoma Protein;Time Factors;Treatment Outcome;Tumor Suppressor Protein p14ARF;Tumor Suppressor Protein p53;Tumor Suppressor Proteins",
        "Doc_meshqualifiers":"metabolism;metabolism;pathology;metabolism;metabolism;metabolism;metabolism;metabolism;metabolism;metabolism;metabolism;metabolism",
        "_version_":1605792711588184064},
      {
        "Doc_abstract":"The microsatellite instability and CpG island hypermethylation of p14 ( ARF ) and p16 ( INK4a ) are related to the pathogenesis of neoplasia in ulcerative colitis. This study was designed to assess the significance of those genetic or epigenetic alterations for cancer surveillance in ulcerative colitis.;During surveillance colonoscopy in 39 patients with ulcerative colitis, biopsy specimens were obtained from the cecum and the rectum as well as from any other areas suspected of being neoplasia by chromoscopy. Using DNA extracts, the methylation status of p14 ( ARF ) and p16 ( INK4a ) and the microsatellite status were determined.;Microsatellite instability was positive in one of five dysplasias, but it was negative in the cecum and the rectum. The incidence of hypermethylation of p14 ( ARF ) was 0 percent in the cecum, 26 percent in the rectum, and 100 percent in dysplasia, whereas that of p16 ( INK4a ) was 10, 10, and 0 percent, respectively. Patients who were positive for the hypermethylation of p14 ( ARF )in the rectum had a longer duration of ulcerative colitis than those who were negative for such hypermethylation. Two of 10 patients who were positive for p14 ( ARF ) hypermethylation in the rectum and 1 of 29 patients who were negative for the hypermethylation had dysplasia. During the subsequent surveillance of 36 patients, dysplasia was detected in 2 of 8 patients with p14 ( ARF ) hypermethylation and in none of 28 patients without hypermethylation (P = 0.044).;In patients with ulcerative colitis, hypermethylation of p14 ( ARF ) seems to be associated with an early stage of dysplasia. The hypermethylation may be one of candidates for potential biomarker to identify patients at a high risk of dysplasia.",
        "Doc_title":"Hypermethylation of p14 (ARF) may be predictive of colitic cancer in patients with ulcerative colitis.",
        "Journal":"Diseases of the colon and rectum",
        "Do_id":"17665255",
        "Doc_ChemicalList":"Biomarkers, Tumor;DNA, Neoplasm;Tumor Suppressor Protein p14ARF",
        "Doc_meshdescriptors":"Adolescent;Adult;Aged;Biomarkers, Tumor;Biopsy;Colitis, Ulcerative;Colonic Neoplasms;Colonoscopy;DNA, Neoplasm;Female;Follow-Up Studies;Genes, p16;Humans;Male;Methylation;Microsatellite Instability;Middle Aged;Prognosis;Rectum;Retrospective Studies;Tumor Suppressor Protein p14ARF",
        "Doc_meshqualifiers":"genetics;metabolism;complications;metabolism;pathology;etiology;metabolism;pathology;genetics;physiology;metabolism;pathology;genetics;metabolism",
        "_version_":1605903206717587456},
      {
        "Doc_abstract":"Superior treatment response and survival for patients with human papilloma virus (HPV)-positive head and neck cancer (HNSCC) are documented in clinical studies. However, the relevance of high-grade acute organ toxicity (HGAOT), which has also been correlated with improved prognosis, has attracted scant attention in HPV-positive HNSCC patients. Hence we tested the hypothesis that both parameters, HPV and HGAOT, are positive prognostic factors in patients with HNSCC treated with definite radiotherapy (RT) or radiochemotherapy (RCT).;Pretreatment tumor tissue and clinical records were available from 233 patients receiving definite RT (62 patients) or RCT (171 patients). HPV infection was analysed by means of HPV DNA detection or p16(INK4A) expression; HGAOT was defined as the occurrence of acute organ toxicity >grade 2 according to the Common Toxicity Criteria. Both variables were correlated with overall survival (OS) using Cox proportional hazards regression.;Positivity for HPV DNA (44 samples, 18.9%) and p16(INK4A) expression (102 samples, 43.8%) were significantly correlated (p<0.01), and HGAOT occurred in 77 (33%) patients. Overall, the 5-year OS was 23%; stratified for p16(INK4A) expression and HGAOT, OS rates were 47%, 42%, 20% and 10% for patients with p16(INK4A) expression and HGAOT, patients with HGAOT only, patients with p16(INK4A) expression only, and patients without p16(INK4A) expression or HGAOT, respectively. After multivariate testing p16(INK4A) expression (p=0.003) and HGAOT (p<0.001) were significantly associated with OS.;P16(INK4A) expression and HGAOT are independent prognostic factors for OS of patients with HNSCC, whereas p16(INK4A) expression is particularly important for patients without HGAOT.",
        "Doc_title":"High-grade acute organ toxicity and p16(INK4A) expression as positive prognostic factors in primary radio(chemo)therapy for patients with head and neck squamous cell carcinoma.",
        "Journal":"Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]",
        "Do_id":"25575976",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16",
        "Doc_meshdescriptors":"Adult;Aged;Carcinoma, Squamous Cell;Chemoradiotherapy;Cyclin-Dependent Kinase Inhibitor p16;Female;Human Papillomavirus DNA Tests;Humans;Male;Middle Aged;Neoplasm Grading;Neoplasm Staging;Otorhinolaryngologic Neoplasms;Prognosis;Radiation Injuries;Radiotherapy Dosage",
        "Doc_meshqualifiers":"genetics;therapy;genetics;genetics;therapy;etiology",
        "_version_":1605741939404046336},
      {
        "Doc_abstract":"Proliferation of pancreatic islet beta cells is an important mechanism for self-renewal and for adaptive islet expansion. Increased expression of the Ink4a/Arf locus, which encodes the cyclin-dependent kinase inhibitor p16(INK4a) and tumor suppressor p19(Arf), limits beta-cell regeneration in aging mice, but the basis of beta-cell Ink4a/Arf regulation is poorly understood. Here we show that Enhancer of zeste homolog 2 (Ezh2), a histone methyltransferase and component of a Polycomb group (PcG) protein complex, represses Ink4a/Arf in islet beta cells. Ezh2 levels decline in aging islet beta cells, and this attrition coincides with reduced histone H3 trimethylation at Ink4a/Arf, and increased levels of p16(INK4a) and p19(Arf). Conditional deletion of beta-cell Ezh2 in juvenile mice also reduced H3 trimethylation at the Ink4a/Arf locus, leading to precocious increases of p16(INK4a) and p19(Arf). These mutant mice had reduced beta-cell proliferation and mass, hypoinsulinemia, and mild diabetes, phenotypes rescued by germline deletion of Ink4a/Arf. beta-Cell destruction with streptozotocin in controls led to increased Ezh2 expression that accompanied adaptive beta-cell proliferation and re-establishment of beta-cell mass; in contrast, mutant mice treated similarly failed to regenerate beta cells, resulting in lethal diabetes. Our discovery of Ezh2-dependent beta-cell proliferation revealed unique epigenetic mechanisms underlying normal beta-cell expansion and beta-cell regenerative failure in diabetes pathogenesis.",
        "Doc_title":"Polycomb protein Ezh2 regulates pancreatic beta-cell Ink4a/Arf expression and regeneration in diabetes mellitus.",
        "Journal":"Genes & development",
        "Do_id":"19390090",
        "Doc_ChemicalList":"Antibiotics, Antineoplastic;Cdkn2a protein, mouse;Cyclin-Dependent Kinase Inhibitor p16;Histones;Streptozocin;Enhancer of Zeste Homolog 2 Protein;Ezh2 protein, mouse;Histone-Lysine N-Methyltransferase;Polycomb Repressive Complex 2",
        "Doc_meshdescriptors":"Aging;Animals;Antibiotics, Antineoplastic;Cell Proliferation;Cells, Cultured;Cyclin-Dependent Kinase Inhibitor p16;Diabetes Mellitus;Enhancer of Zeste Homolog 2 Protein;Female;Gene Deletion;Gene Expression Regulation;Histone-Lysine N-Methyltransferase;Histones;Humans;Insulin-Secreting Cells;Male;Mice;Mice, Inbred C57BL;Polycomb Repressive Complex 2;Streptozocin",
        "Doc_meshqualifiers":"metabolism;pharmacology;drug effects;genetics;metabolism;metabolism;drug effects;metabolism;metabolism;cytology;drug effects;metabolism;pharmacology",
        "_version_":1605757154942255104},
      {
        "Doc_abstract":"The cell-cycle regulatory gene INK4A-ARF (CDKN2A) has two alternative transcripts that produce entirely different proteins, namely p14(ARF) and p16, which have complementary functions as regulators of p53 and pRB tumor suppressor pathways, respectively. The unusual organization of INK4A-ARF has long led to speculation of a need for coordinated regulation of p14(ARF) and p16. We now show that p14(ARF) (ARF) regulates the stability of p16 protein in human cancer cell lines, as well as in mouse embryonic fibroblasts (MEFs). In particular, ARF promotes rapid degradation of p16 protein, which is mediated by the proteasome and, more specifically, by interaction of ARF with one of its subunits, REG. Furthermore, this ARF-dependent destabilization of p16 can be abrogated by knockdown of REG or by pharmacologic blockade of its nuclear export. Thus, our findings have uncovered a novel crosstalk of 2 key tumor suppressors mediated by a REG-dependent mechanism. The ability of ARF to control p16 stability may influence cell-cycle function.;The ability of ARF to control p16 stability may influence cell cycle function. Visual Overview: http://mcr.aacrjournals.org/content/current.",
        "Doc_title":"ARF regulates the stability of p16 protein via REG-dependent proteasome degradation.",
        "Journal":"Molecular cancer research : MCR",
        "Do_id":"23817020",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;Tumor Suppressor Protein p14ARF;Tumor Suppressor Protein p53;Proteasome Endopeptidase Complex",
        "Doc_meshdescriptors":"Active Transport, Cell Nucleus;Animals;Cell Cycle;Cell Line, Tumor;Cell Nucleus;Cells, Cultured;Cyclin-Dependent Kinase Inhibitor p16;Gene Expression Regulation, Neoplastic;Humans;Male;Mice;Prostatic Neoplasms;Proteasome Endopeptidase Complex;Protein Stability;Signal Transduction;Tumor Suppressor Protein p14ARF;Tumor Suppressor Protein p53;Urinary Bladder Neoplasms",
        "Doc_meshqualifiers":"genetics;physiology;metabolism;genetics;metabolism;genetics;metabolism;metabolism;antagonists & inhibitors;genetics;metabolism;genetics;metabolism;genetics;metabolism",
        "_version_":1605920191847333888},
      {
        "Doc_abstract":"Cellular senescence is a terminal growth phase characteristic of normal human diploid fibroblasts. Altered gene expression during cellular senescence is numerous compared to that of younger proliferative cells in culture. We have previously reported that the levels and activities of hnRNP A1 and A2 RNA binding proteins are decreased in senescent human fibroblasts. Both proteins are multifunctional and may influence the expression of mRNA isoforms during development. In this study, we tested whether overexpression of either protein could modulate the mRNA isoforms of the INK4a locus, specifically p14(ARF) and p16(INK4a). Both INK4a mRNA isoforms have been shown to be growth suppressors and deletions of this locus allow cells to escape cellular senescence. We have found that increasing the ratio of either hnRNP A1 or A2 over that of splicing factor SF2/ASF results in the preferential generation of the p14(ARF) isoform. Overexpression of A1 or A2 RNA binding proteins also appear to increase the steady state mRNA levels of both isoforms, suggesting that in addition to alternative splicing, A1 and A2 may effect p14(ARF) and p16(INK4a) mRNA stability. A constitutive decrease in the ratio of hnRNP A1 or A2 to SF2/ASF in senescent fibroblasts is typically accompanied by an increase in the level of p16(INK4a) isoform. Our studies suggest that hnRNP A1 and A2 may exert an important role during replicative senescence by altering expression of cell cycle regulatory proteins through mRNA metabolism.",
        "Doc_title":"Modulation of the expression of p16INK4a and p14ARF by hnRNP A1 and A2 RNA binding proteins: implications for cellular senescence.",
        "Journal":"Journal of cellular physiology",
        "Do_id":"12209876",
        "Doc_ChemicalList":"Cell Cycle Proteins;Cyclin-Dependent Kinase Inhibitor p16;Heterogeneous-Nuclear Ribonucleoprotein Group A-B;Heterogeneous-Nuclear Ribonucleoproteins;Luminescent Proteins;RNA, Messenger;Recombinant Fusion Proteins;Ribonucleoproteins;Tumor Suppressor Protein p14ARF;hnRNP A1;hnRNP A2",
        "Doc_meshdescriptors":"Cell Aging;Cell Cycle Proteins;Cell Line;Cyclin-Dependent Kinase Inhibitor p16;Fibroblasts;Gene Expression Regulation;Heterogeneous-Nuclear Ribonucleoprotein Group A-B;Heterogeneous-Nuclear Ribonucleoproteins;Humans;Luminescent Proteins;Microscopy, Fluorescence;RNA, Messenger;Recombinant Fusion Proteins;Ribonucleoproteins;Transfection;Tumor Suppressor Protein p14ARF",
        "Doc_meshqualifiers":"physiology;genetics;metabolism;genetics;metabolism;cytology;drug effects;metabolism;drug effects;physiology;genetics;metabolism;genetics;metabolism;genetics;metabolism;pharmacology;genetics;metabolism",
        "_version_":1605841898931486720},
      {
        "Doc_abstract":"We have determined the promoter CpG island methylation status of O(6)-methylguanine-DNA methyltransferase (MGMT), glutathione-S-transferase P1 (GSTP1), death-associated protein kinase (DAPK), p14(ARF), thrombospondin-1 (THBS1), tissue inhibitor of metalloproteinase-3 gene (TIMP-3), p73, p16(INK4A), RB1, and TP53 genes in three primary central nervous system lymphomas (PCNSL). Five genes (GSTP1, DAPK, TIMP-3, p16(INK4A), and RB1) were hypermethylated in two samples, whereas MGMT, THBS1, and p73 were aberrantly methylated in only one sample. No case presented CpG island methylation for the p14(ARF) and TP53 genes. These findings concur with previous data suggesting a frequent inactivation of p16(INK4A) and very limited involvement of TP53 in PCNSL and also provide insights into the epigenetic molecular involvement of other tumor-related genes in this neoplasm.",
        "Doc_title":"CpG island methylation of tumor-related genes in three primary central nervous system lymphomas in immunocompetent patients.",
        "Journal":"Cancer genetics and cytogenetics",
        "Do_id":"12660028",
        "Doc_ChemicalList":"Apoptosis Regulatory Proteins;Cyclin-Dependent Kinase Inhibitor p16;DNA-Binding Proteins;Isoenzymes;Nuclear Proteins;Retinoblastoma Protein;Thrombospondin 1;Tissue Inhibitor of Metalloproteinase-3;Tumor Protein p73;Tumor Suppressor Protein p14ARF;Tumor Suppressor Proteins;p73 protein, human;O(6)-Methylguanine-DNA Methyltransferase;GSTP1 protein, human;Glutathione S-Transferase pi;Glutathione Transferase;Death-Associated Protein Kinases;Calcium-Calmodulin-Dependent Protein Kinases",
        "Doc_meshdescriptors":"Aged;Apoptosis Regulatory Proteins;Brain;Calcium-Calmodulin-Dependent Protein Kinases;Central Nervous System Neoplasms;CpG Islands;Cyclin-Dependent Kinase Inhibitor p16;DNA Methylation;DNA-Binding Proteins;Death-Associated Protein Kinases;Female;Genes, Tumor Suppressor;Genes, p53;Glutathione S-Transferase pi;Glutathione Transferase;Humans;Immunocompetence;Isoenzymes;Lymphoma;Male;Middle Aged;Nuclear Proteins;O(6)-Methylguanine-DNA Methyltransferase;Promoter Regions, Genetic;Reference Values;Retinoblastoma Protein;Thrombospondin 1;Tissue Inhibitor of Metalloproteinase-3;Tumor Protein p73;Tumor Suppressor Protein p14ARF;Tumor Suppressor Proteins",
        "Doc_meshqualifiers":"physiology;genetics;genetics;genetics;genetics;genetics;genetics;genetics;genetics;genetics;genetics;genetics;genetics;genetics",
        "_version_":1605905484572786688},
      {
        "Doc_abstract":"The nuclear envelope can regulate gene expression through its interaction with chromatin and by the sequestration of specific transcription factors. In this study, we show that such regulation can be achieved via microRNA regulation. We identify a set of miRNAs that are dysregulated in the absence of a fully functional nuclear lamina. We then focus on miRNA-31 and experimentally confirm its targets. The target set identified is significantly enriched in genes involved in controlling progress through the cell cycle such as Cdkn2a. Normalizing miRNA-31 levels, either using a specific inhibitor or by restoration of the nuclear lamina, also normalizes cell cycle distribution and cell proliferation rates. We show that the 3'UtR of p16(Ink4a)/p19(Arf) has a functional miRNA-31 binding site which contributes to the observed regulation of cell cycle progression. Our findings are the first demonstration that the nuclear envelope can control gene expression by regulating specific miRNA levels, and that miRNA-31 is involved in the regulation of cell proliferation and progress through the cell cycle at least in part by regulating the levels of p16(Ink4a)/p19(Arf).",
        "Doc_title":"The nuclear envelope can control gene expression and cell cycle progression via miRNA regulation.",
        "Journal":"Cell cycle (Georgetown, Tex.)",
        "Do_id":"20081371",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;Cyclin-Dependent Kinase Inhibitor p19;MicroRNAs;Mirn31 microRNA, mouse",
        "Doc_meshdescriptors":"Animals;Base Sequence;Cell Cycle;Cell Proliferation;Cyclin-Dependent Kinase Inhibitor p16;Cyclin-Dependent Kinase Inhibitor p19;Fibroblasts;Gene Expression Regulation;Mice;MicroRNAs;Models, Biological;Molecular Sequence Data;Nuclear Envelope",
        "Doc_meshqualifiers":"genetics;genetics;metabolism;genetics;metabolism;cytology;metabolism;genetics;metabolism;genetics;metabolism",
        "_version_":1605893809560879104},
      {
        "Doc_abstract":"Infection with human papillomaviruses (HPVs) characterizes a distinct subset of head and neck squamous cell cancers (HNSCCs). HPV-positive HNSCC preferentially affect the oropharynx and tonsils. Localized HPV-positive HNSCCs have a favorable prognosis and treatment outcome. However, the impact of HPV in advanced or metastatic HNSCC remains to be defined. In particular, it is unclear whether HPV modulates the response to cetuximab, an antibody targeting the epidermal growth factor receptor (EGFR), which is a mainstay of treatment of advanced HNSCC. To this end, we have examined the sensitivity of HPV-positive and -negative HNSCC models to cetuximab and cytotoxic drugs in vitro and in vivo. In addition, we have stably expressed the HPV oncogenes E6 and E7 in cetuximab-sensitive cancer cell lines to specifically investigate their role in the antibody response. The endogenous HPV status or the expression of HPV oncogenes had no significant impact on cetuximab-mediated suppression of EGFR signaling and proliferation in vitro. Cetuximab effectively inhibited the growth of E6- and E7-expressing tumors grafted in NOD/SCID mice. In support, formalin-fixed, paraffin-embedded tumor samples from cetuximab-treated patients with recurrent or metastatic HNSCC were probed for p16(INK4a) expression, an established biomarker of HPV infection. Response rates (45.5% versus 45.5%) and median progression-free survival (97 versus 92 days) following cetuximab-based therapy were similar in patients with p16(INK4A)-positive and p16(INK4A)-negative tumors. In conclusion, HPV oncogenes do not modulate the anti-EGFR antibody response in HSNCC. Cetuximab treatment should be administered independently of HPV status. ",
        "Doc_title":"Impact of human papilloma virus infection on the response of head and neck cancers to anti-epidermal growth factor receptor antibody therapy.",
        "Journal":"Cell death & disease",
        "Do_id":"24577089",
        "Doc_ChemicalList":"Antibodies, Monoclonal, Humanized;Antineoplastic Agents;Cyclin-Dependent Kinase Inhibitor p16;E6 protein, Human papillomavirus type 16;Oncogene Proteins, Viral;Papillomavirus E7 Proteins;Repressor Proteins;oncogene protein E7, Human papillomavirus type 16;EGFR protein, human;Receptor, Epidermal Growth Factor;Cetuximab",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Animals;Antibodies, Monoclonal, Humanized;Antineoplastic Agents;Carcinoma, Squamous Cell;Cell Line, Tumor;Cell Proliferation;Cetuximab;Cyclin-Dependent Kinase Inhibitor p16;Dose-Response Relationship, Drug;Female;Head and Neck Neoplasms;Human papillomavirus 16;Humans;Kaplan-Meier Estimate;Male;Mice;Mice, Inbred NOD;Mice, SCID;Middle Aged;Oncogene Proteins, Viral;Papillomavirus E7 Proteins;Papillomavirus Infections;Receptor, Epidermal Growth Factor;Repressor Proteins;Time Factors;Transfection;Tumor Burden;Xenograft Model Antitumor Assays",
        "Doc_meshqualifiers":"pharmacology;pharmacology;drug therapy;genetics;metabolism;mortality;virology;drug effects;metabolism;drug therapy;genetics;metabolism;mortality;virology;genetics;metabolism;pathogenicity;genetics;metabolism;genetics;metabolism;genetics;metabolism;mortality;virology;antagonists & inhibitors;immunology;metabolism;genetics;metabolism;drug effects",
        "_version_":1605783284223049728},
      {
        "Doc_abstract":"Deregulation of tumor suppressor gene function and abrogation of cell cycle control are common features of malignant neoplasms, but corresponding data on Ewing sarcomas and primitive neuroectodermal tumors are relatively scarce. We studied the expression of 4 tumor suppressor proteins in the Ewing family of tumors (EFTs).;We examined a series of 20 pediatric EFTs for abnormal expression of p16(INK4a), p14(ARF), p21(WAF1), and pRB by immunohistochemical analysis of pretreatment, nondecalcified archival specimens. Clinical follow up was available in all cases (median, 21 months; range, 5-103 months). Five patients presented with metastatic disease, 8 had no evidence of disease at last follow up, and 12 had an adverse outcome (death or progressive tumor posttherapy).;Twelve cases (60%) demonstrated abnormal expression of at least one tumor suppressor protein. There were 11 cases (55%) with loss of p21(WAF1) expression, 4 (20%) with down-regulation of p16(INK4a), 2 (10%) with absence of pRB, and one case (5%) with loss of p14(ARF) expression. Loss of p16(INK4a) expression correlated with metastatic disease at presentation (P =.026), and showed a trend toward shortened survival (P =.20). The p21(WAF1), p14(ARF), and pRB status was not significantly correlated with either metastatic disease at presentation or outcome.;Abrogation of the G1 checkpoint was common in this series of EFTs, and down-regulation of p21(WAF1) and p16(INK4a) were the most frequent findings. Loss of p16(INK4a) expression may identify a subset of cases with a more aggressive phenotype.",
        "Doc_title":"Aberrant expression of tumor suppressor proteins in the Ewing family of tumors.",
        "Journal":"Archives of pathology & laboratory medicine",
        "Do_id":"11520274",
        "Doc_ChemicalList":"Biomarkers, Tumor;CDKN1A protein, human;Cyclin-Dependent Kinase Inhibitor p16;Cyclin-Dependent Kinase Inhibitor p21;Cyclins;Enzyme Inhibitors;Retinoblastoma Protein",
        "Doc_meshdescriptors":"Adolescent;Biomarkers, Tumor;Bone Neoplasms;Child;Child, Preschool;Cyclin-Dependent Kinase Inhibitor p16;Cyclin-Dependent Kinase Inhibitor p21;Cyclins;Enzyme Inhibitors;Female;Follow-Up Studies;Genes, Tumor Suppressor;Humans;Immunohistochemistry;Male;Neoplasm Staging;Prognosis;Retinoblastoma Protein;Retrospective Studies;Sarcoma, Ewing;Survival Rate",
        "Doc_meshqualifiers":"analysis;genetics;mortality;pathology;surgery;analysis;analysis;analysis;analysis;genetics;mortality;pathology;surgery",
        "_version_":1605747500681003011},
      {
        "Doc_abstract":"Reports suggest that a subset of uveal melanoma is familial. The association of uveal melanoma with breast and ovarian cancer and the increased risk in BRCA2-linked families implicates germline BRCA2 mutations as the cause of a subset of uveal melanomas. Similarly, the association between cutaneous and uveal melanomas in some families, coupled with the high frequency of somatic deletions of the INK4A-ARF locus in uveal melanomas, strongly suggests that mutations in P16(INK4A) and P15 account for a proportion of uveal melanomas.;To examine this proposition, a systematically ascertained series of 385 patients with uveal melanoma were screened for germline mutations in BRCA2, P16(INK4A), P14(ARF), and P15.;One patient was found to harbor a Gly35Ala substitution in exon 1alpha of P16(INK4A), which has previously been reported to be pathogenic. No mutations were detected in P14(ARF) or P15. None of the patients harbored germline nucleotide changes that lead to truncation or that create or disrupt consensus splice sites of BRCA2 or missense variants with clear pathogenic potential.;These findings suggest that less than 2% of cases of uveal melanoma can be ascribed to germline mutations in BRCA2, P16(INK4A), P14(ARF), or P15. It is likely that mutations in other genes contribute to an inherited predisposition to uveal melanoma.",
        "Doc_title":"Contribution of germline mutations in BRCA2, P16(INK4A), P14(ARF) and P15 to uveal melanoma.",
        "Journal":"Investigative ophthalmology & visual science",
        "Do_id":"12556369",
        "Doc_ChemicalList":"BRCA2 Protein;CDKN2B protein, human;Cell Cycle Proteins;Cyclin-Dependent Kinase Inhibitor p15;Cyclin-Dependent Kinase Inhibitor p16;DNA, Neoplasm;Transcription Factors;Tumor Suppressor Protein p14ARF;Tumor Suppressor Proteins",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;BRCA2 Protein;Cell Cycle Proteins;Cyclin-Dependent Kinase Inhibitor p15;Cyclin-Dependent Kinase Inhibitor p16;DNA Mutational Analysis;DNA, Neoplasm;Female;Germ-Line Mutation;Humans;Incidence;Male;Melanoma;Middle Aged;Polymerase Chain Reaction;Transcription Factors;Tumor Suppressor Protein p14ARF;Tumor Suppressor Proteins;Uveal Neoplasms",
        "Doc_meshqualifiers":"genetics;genetics;genetics;genetics;genetics;genetics;genetics",
        "_version_":1605755773752705024},
      {
        "Doc_abstract":"Cell cycle progression and arrest of renal tubular cells after acute injury is a reactive process of renal regeneration. The p16(INK4a)/p19(ARF) (alternative reading frame) locus encodes two proteins involved in cell cycle regulation. We investigated the transcriptional regulation and tissue distribution of p19(ARF) in ischemic acute renal failure (ARF).;We examined the time course and immunohistochemistry of p19(ARF) in rat kidneys following the induction of ischemic ARF. We also examined the effect of p19(ARF) overexpression on p53 levels and cell cycle progression in MDCK cells.;The protein expression of p19(ARF) strongly increased 72 h after the ischemia. Immunohistochemical studies showed that the renal tubular cells in the outer medulla expressed p19(ARF) protein 72 h after ischemic injury. The time course of E2F1 induction was observed at 6-24 h, and it was found to precede p19(ARF) expression. In MDCK cells, the overexpression of E2F1 increased promoter activity and the protein level of p19(ARF) and induced apoptosis. Transfection of the p19(ARF) expression vector caused an increase in p53 protein, cell cycle arrest and apoptosis.;These data support the hypothesis that the E2F1-p19(ARF)-p53 pathway forms a negative feedback loop to regulate the cell cycle of renal tubular cells in the ischemic ARF.",
        "Doc_title":"Role of the E2F1-p19-p53 pathway in ischemic acute renal failure.",
        "Journal":"Nephron. Physiology",
        "Do_id":"15990448",
        "Doc_ChemicalList":"Cell Cycle Proteins;E2F1 Transcription Factor;E2f1 protein, rat;Tumor Suppressor Protein p14ARF;Tumor Suppressor Protein p53;p19(ARF) protein, rat",
        "Doc_meshdescriptors":"Acute Kidney Injury;Animals;Cell Cycle;Cell Cycle Proteins;E2F1 Transcription Factor;Kidney;Male;Rats;Rats, Sprague-Dawley;Reperfusion Injury;Signal Transduction;Tissue Distribution;Tumor Suppressor Protein p14ARF;Tumor Suppressor Protein p53",
        "Doc_meshqualifiers":"etiology;metabolism;pathology;metabolism;metabolism;metabolism;pathology;complications;metabolism;pathology;metabolism;metabolism",
        "_version_":1605812357538250752},
      {
        "Doc_abstract":"Mantle cell lymphoma (MCL) is characterized by the chromosomal translocation t(11;14)(q13;q32), resulting in overexpression of CCND1 in the vast majority of cases. In addition, alterations of other cell-cycle-regulating signal pathways (CDKN2B/CDKN2A-CCND1 and ARF-MDM2-TP53) are frequently observed. However, the hierarchy of promoter methylations and genomic alterations as well as the interaction with other cell-cycle regulator CDKN1A is poorly understood. A complete methylation-specific PCR coupled with direct sequencing of 71 MCL patient samples previously characterized for TP53 alterations, Ki67 expression by immunohistochemistry, and other genomic alterations was performed. In contrast to rare p16(INK4a) promoter methylation (9%), frequent p15(INK4b) (62%) and p14(ARF) (70%) promoter methylation was detectable in MCL. In an additional 16% of MCL cases, LOH for p16(INK4a) was detected. However, MCL cases with p15(INK4b) methylation tended to have lower proliferation (73% vs. 57%), and p15(INK4b) and p14(ARF) promoter methylation was also detected in normal stem cells. Therefore, epigenetic changes of those genes seem not to represent primary oncogenic mechanisms but physiological mechanisms of cell regulation. The rare p16(INK4a) promoter methylation and p16(INK4a) genetic alterations were directly correlated to cell proliferation and therefore are regarded as additional molecular alterations involved in the cell-cycle dysregulation of MCL.",
        "Doc_title":"Differential effect of epigenetic alterations and genomic deletions of CDK inhibitors [p16(INK4a), p15(INK4b), p14(ARF)] in mantle cell lymphoma.",
        "Journal":"Genes, chromosomes & cancer",
        "Do_id":"16258956",
        "Doc_ChemicalList":"CDKN2B protein, human;Cyclin-Dependent Kinase Inhibitor p15;Cyclin-Dependent Kinase Inhibitor p16;DNA Primers;Tumor Suppressor Protein p14ARF",
        "Doc_meshdescriptors":"Base Sequence;Chromosomes, Human, Pair 9;Cyclin-Dependent Kinase Inhibitor p15;Cyclin-Dependent Kinase Inhibitor p16;DNA Primers;Epigenesis, Genetic;Gene Deletion;Humans;Immunohistochemistry;Loss of Heterozygosity;Lymphoma, Mantle-Cell;Promoter Regions, Genetic;Tumor Suppressor Protein p14ARF",
        "Doc_meshqualifiers":"genetics;genetics;genetics;genetics",
        "_version_":1605754794389012480},
      {
        "Doc_abstract":"Tumors often display unrestricted cell cycling attributable to a dysfunctional G(1)-S checkpoint. One of the mechanisms leading to such a defect is the inactivation of the cyclin-dependent kinase inhibitor p16(INK4a). Although inactivation of p16(INK4a) is observed in a wide range of tumors, including cutaneous melanoma, genetic alteration of p16(INK4a) is reportedly uncommon in uveal melanoma. Here we show that the p16(INK4a) promoter is hypermethylated in 6 of 12 uveal melanoma cell lines and in 7 of 22 primary uveal melanomas analyzed. Five of seven patients with a methylated primary tumor died of metastatic disease compared with 2 of 15 patients with a nonmethylated primary tumor. We also show that all uveal melanoma cell lines with a hypermethylated p16(INK4a) promoter have lost p16(INK4a) expression but have maintained the expression of p14(ARF). Treatment of uveal melanoma cell lines with 5-aza-2'-deoxycytidine results in demethylation of p16(INK4a) and in reexpression of p16(INK4a) mRNA, which is maintained upon withdrawal of the 5-aza-2'-deoxycytidine. In conclusion, p16(INK4a) promoter methylation appears to be a common event in uveal melanoma and is accompanied by the loss of p16(INK4a) expression.",
        "Doc_title":"Promoter hypermethylation: a common cause of reduced p16(INK4a) expression in uveal melanoma.",
        "Journal":"Cancer research",
        "Do_id":"11431374",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;DNA, Neoplasm;RNA, Messenger;decitabine;Azacitidine",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Azacitidine;CpG Islands;Cyclin-Dependent Kinase Inhibitor p16;DNA Methylation;DNA, Neoplasm;Female;Gene Expression Regulation, Neoplastic;Gene Silencing;Humans;Male;Melanoma;Middle Aged;Promoter Regions, Genetic;RNA, Messenger;Reverse Transcriptase Polymerase Chain Reaction;Tumor Cells, Cultured;Uveal Neoplasms",
        "Doc_meshqualifiers":"analogs & derivatives;pharmacology;physiology;biosynthesis;genetics;drug effects;genetics;metabolism;genetics;metabolism;pathology;biosynthesis;genetics;drug effects;genetics;metabolism;pathology",
        "_version_":1605759734241034240},
      {
        "Doc_abstract":"The INK4a-ARF [CDKN2A]- locus on chromosome 9p21 encodes for two tumour suppressor proteins, p16INK4a and p14ARF, which act as upstream regulators of the Rb-CDK4 and p53 pathways. To study the contribution of each pathway to the carcinogenesis of Barrett's adenocarcinoma, we analysed the alterations of p14ARF and p16INK4a in preneoplastic and neoplastic lesions of this disease.;After microdissection, DNA of 15 Barrett's adenocarcinomas, 40 Barrett's intraepithelial neoplasms (n=20 low- and n=20 high-grade) and 15 Barrett's mucosa without neoplasia was analysed for INK4-ARF inactivation using DNA sequence and loss of heterozygosity (LOH) analysis, methylation-specific polymerase chain reaction, restriction-enzyme-related polymerase chain reaction and immunohistochemistry.;We detected 9p21 LOH, p16INK4a methylation and p16INK4a mutations in Barrett's adenocarcinomas in 5 of 15 (33%), 8 of 15 (53%) and 1 of 15 (7%) patients, respectively. P14ARF was methylated in 3 of 15 (20%) adenocarcinomas. In Barrett's intraepithelial neoplasia, p16INK4a was altered in 12 of 20 (60%) high-grade and in 4 of 20 (20%) low-grade intraepithelial neoplasms. In Barrett's mucosa without intraepithelial neoplasia p16(INK4a) was methylated in one case (7%). P14ARF was intact in Barrett's mucosa without intraepithelial neoplasia.;We conclude that most Barrett's intraepithelial neoplasms contain genetic and/or epigenetic INK4a-ARF alterations. Methylation of p16INK4a appears to be the most frequent epigenetic defect in the neoplastic progression of Barrett's tumourigenesis.",
        "Doc_title":"INK4a-ARF alterations in Barrett's epithelium, intraepithelial neoplasia and Barrett's adenocarcinoma.",
        "Journal":"Virchows Archiv : an international journal of pathology",
        "Do_id":"15185075",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;DNA, Neoplasm;Tumor Suppressor Protein p14ARF",
        "Doc_meshdescriptors":"Barrett Esophagus;Carcinoma in Situ;Cyclin-Dependent Kinase Inhibitor p16;DNA Methylation;DNA, Neoplasm;Disease Progression;Esophageal Neoplasms;Gene Silencing;Humans;Immunohistochemistry;Loss of Heterozygosity;Microdissection;Polymerase Chain Reaction;Prognosis;Promoter Regions, Genetic;Tumor Suppressor Protein p14ARF",
        "Doc_meshqualifiers":"genetics;genetics;genetics;genetics;genetics;genetics;genetics",
        "_version_":1605791491215589376},
      {
        "Doc_abstract":"Patients with head and neck squamous cell carcinoma (HNSCC) may initially present with neck metastases diagnosed by fine-needle aspiration (FNA). In these patients, it is critical to locate the primary site so that targeted therapy can be administered. Nearly a quarter of HNSCC are associated with human papillomavirus (HPV) infection. The great majority of HPV-related primaries originate in the oropharynx. p16INKa (p16) functions as a surrogate marker of HPV infection. We sought to determine if expression of p16 by immunocytochemistry (ICC) in neck metastases could assist in localizing the primary site to the oropharynx.;Diagnostic FNA cytology smears of neck metastases from 90 patients with biopsy-proven primary HNSCC were reviewed. Papanicolaou-stained slides were directly subjected to ICC, using p16 antibody.;Twenty-seven (30%) tumors expressed p16 by ICC; 74% of these p16-positive tumors were metastases from oropharynx. There was a significantly higher proportion of p16 expression in patients with primary oropharyngeal carcinoma (47%) versus those whose primary tumor was non-oropharyngeal (15%; p = 0.0013).;p16 expression in FNA cytology smears of metastatic HNSCC is a useful indicator of oropharyngeal origin and can be used to help localize the primary site in cases where this is not clinically evident.",
        "Doc_title":"p16INKa immunocytochemistry in fine-needle aspiration cytology smears of metastatic head and neck squamous cell carcinoma.",
        "Journal":"Acta cytologica",
        "Do_id":"23221169",
        "Doc_ChemicalList":"Biomarkers, Tumor;Cyclin-Dependent Kinase Inhibitor p16",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Biomarkers, Tumor;Biopsy, Fine-Needle;Carcinoma, Squamous Cell;Cyclin-Dependent Kinase Inhibitor p16;Female;Head and Neck Neoplasms;Humans;Immunohistochemistry;Male;Middle Aged;Oropharyngeal Neoplasms;Papillomavirus Infections",
        "Doc_meshqualifiers":"analysis;metabolism;secondary;virology;analysis;biosynthesis;metabolism;pathology;virology;metabolism;pathology;virology;complications;diagnosis",
        "_version_":1605747018879205379},
      {
        "Doc_abstract":"In the current study, we evaluated p16 expression in rare subtypes of endometrial carcinomas, whose HPV status has been previously examined in order to establish the role of this protein in their pathogenesis. These rare subtypes of endometrial carcinomas are primary squamous endometrial carcinoma (ESCC), endometrial mucinous microglandular adenocarcinoma (EMMA), and endometrial transitional cell carcinoma (ETCC). All tissues, obtained at the time of hysterectomy, were fixed in 10% phosphate-buffered formalin and embedded in paraffin. Serial sections were made for hematoxylin and eosin staining and for immunohistochemistry. Although a previous PCR study has demonstrated that none of these neoplasms showed any signal for HPV DNA, these malignancies did display immunoreactivity for P16(INK4a). In ESCC, P16(INK4a) immunoreactivity was diffuse in 100% of neoplastic cells. In two cases of EMMA, positivity for P16INK4a was zonal. In ETCC, scattered cells were positive for P16INK4a protein. These findings suggest that alteration of p16 could play an etiologic role, without any association to HPV infections, in these rare endometrial carcinomas. However, in our view, other cases of these rare malignancies should be investigated in order to confirm this hypothesis.",
        "Doc_title":"P16(INK4a) overexpression independent of Human Papilloma Virus (HPV) infection in rare subtypes of endometrial carcinomas.",
        "Journal":"Pathology, research and practice",
        "Do_id":"17498885",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16",
        "Doc_meshdescriptors":"Adenocarcinoma, Mucinous;Aged;Aged, 80 and over;Carcinoma, Squamous Cell;Carcinoma, Transitional Cell;Cyclin-Dependent Kinase Inhibitor p16;Endometrial Neoplasms;Female;Humans;Immunohistochemistry;Middle Aged;Papillomaviridae;Papillomavirus Infections;Polymerase Chain Reaction",
        "Doc_meshqualifiers":"metabolism;virology;metabolism;virology;metabolism;virology;biosynthesis;metabolism;virology;complications",
        "_version_":1605827264787775488},
      {
        "Doc_abstract":"Human papillomavirus (HPV) positive head and neck squamous cell carcinoma (HNSCC) accounts for 25% of HNSCCs and frequently presents with neck lymph node metastases. We investigated utilizing cytology needle rinse material for HPV DNA testing by Hybrid Capture 2 molecular testing (HC2) as an alternative to p16 immunohistochemistry.;Twenty-two cases of HNSCC presenting with neck lymph node metastasis were prospectively identified by assessment of Diff Quik stained cytology smears. An aliquot of the needle rinse material from the lymph node was analyzed for HPV status using standard HC2 protocol. P16 status was determined with immunohistochemistry on the cell block and/or surgically obtained tumor.;The mean age of patients with p16 negative HNSCC was 7 years older than p16 positive disease (Table ). Primary tumor subsites were as follows: 17 oropharynx, 1 hypophayrnx, 3 larynx, and 1 oral cavity (Table ). All ten p16 negative patients had a history of smoking compared with 33% of p16 positive. Only 3 (25%) of p16 positive tumors demonstrated keratinization, whereas 90% of the p16 negative tumors keratinized (Fig. 1). Twelve of 22 HNSCC cases (55%) were p16 positive, of which 7 (58%) tested positive for HPV by HC2. Ten cases (45%) were negative for p16, all of which were negative for HPV by HC2 (Table ).;Molecular testing for HPV using HC2 on needle rinse material of FNA of HNSCC is a useful method of determining HPV status in HNSCC.",
        "Doc_title":"Hybrid Capture 2 human papillomavirus testing of fine needle aspiration cytology of head and neck squamous cell carcinomas.",
        "Journal":"Diagnostic cytopathology",
        "Do_id":"25964135",
        "Doc_ChemicalList":"Azure Stains;DNA, Viral;Diff Quik;Neoplasm Proteins;P16 protein, human;Xanthenes;Methylene Blue",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Azure Stains;Biopsy, Fine-Needle;Carcinoma, Squamous Cell;DNA, Viral;Female;Head and Neck Neoplasms;Human Papillomavirus DNA Tests;Humans;In Situ Hybridization;Lymph Nodes;Lymphatic Metastasis;Male;Methylene Blue;Middle Aged;Molecular Diagnostic Techniques;Neoplasm Proteins;Papillomaviridae;Papillomavirus Infections;Prospective Studies;Xanthenes",
        "Doc_meshqualifiers":"diagnosis;genetics;virology;diagnosis;genetics;virology;methods;methods;pathology;pathology;analysis;genetics;diagnosis;virology",
        "_version_":1605811166092722176},
      {
        "Doc_abstract":"The aim of this study was to investigate the role of human papillomaviruses (HPVs) and alterations of p16INK4A in different squamous cell carcinomas (SCCs) of the head and neck region by screening these carcinomas for alterations in exon 2 of p16INK4A and for HPV DNA. A total of 42 samples of different SCCs of the head and neck were collected by biopsy or surgical resection. After DNA isolation, exon 2 of p16 was amplified and sequenced. HPV DNA was detected by applying a broad-spectrum polymerase chain reaction system. Mutations were found in 4 of our 42 samples. A total of 27 biopsies showed the presence of HPV DNA. All of the biopsies showing a mutation in exon 2 of CDK4 were HPV-positive, except the first biopsy of an oropharyngeal carcinoma. It might be possible that HPV infection and mutations in the exon 2 of CDK4 play a causal role in malignant transformation in a small number of squamous carcinomas of the head and neck region.",
        "Doc_title":"Analysis of exon 2 of MTS1 in HPV-positive and HPV-negative tumors of the head and neck region.",
        "Journal":"European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery",
        "Do_id":"17340131",
        "Doc_ChemicalList":"Biomarkers, Tumor;DNA, Neoplasm;DNA, Viral",
        "Doc_meshdescriptors":"Biomarkers, Tumor;Biopsy;Carcinoma, Squamous Cell;DNA, Neoplasm;DNA, Viral;Diagnosis, Differential;Exons;Genes, p16;Head and Neck Neoplasms;Human papillomavirus 11;Humans;Mutation;Oropharyngeal Neoplasms;Papillomavirus Infections;Polymerase Chain Reaction",
        "Doc_meshqualifiers":"genetics;diagnosis;genetics;genetics;genetics;genetics;pathology;virology;genetics;diagnosis;genetics;pathology;virology",
        "_version_":1605747534684225538},
      {
        "Doc_abstract":"The INK4a/ARF locus (9p21) encodes two unique and unrelated cell cycle regulators, p16INK4a and p14ARF. This study was performed to evaluate the methylation status of p16INK4a and p14ARF genes, as well as its association with p16 and p53 expression, microsatellite instability (MI) status, and various clinicopathologic parameters in sporadic colorectal cancer. Sixty-five cases of primary colorectal adenocarcinoma with a series of clinicopathological parameters were obtained. We performed methylation-specific PCR of p16INK4a and p14ARF genes in colorectal cancer paraffin blocks with its paired normal samples, as well as immunohistochemical stainings for p16 and p53, and MI analysis. Aberrant methylations of p16INK4a and p14ARF gene were present in 21 (32.3%) and 33 (50.8%) out of 65 cases, respectively. p16INK4a aberrant methylation was correlated with p16 negativity (P=0.021) and p53 overexpression (P=0.007). p16INK4a aberrant methylation was more frequently present in poorly differentiated adenocarcinomas (P=0.002). Aberrant methylation of p14ARF gene occurred more frequently in patients under 50 years of age and in left-sided colon cancers, and was not statistically significant. Compared with the group with simultaneous absence of methylation in both promoters, the group showing concomitant alterations in both p16INK4a and p14ARF genes (n=10) more frequently presented lymph node metastasis (P=0.020) and higher tumor grade (P=0.014). There was no correlation between p16INK4a and p14ARF gene hypermethylation or MI status. This study suggests that simultaneous hypermethylation of both p16INK4a and p14ARF genes is greater prognostic value in sporadic human colorectal cancer.",
        "Doc_title":"Prognostic value of p16INK4a and p14ARF gene hypermethylation in human colon cancer.",
        "Journal":"Pathology, research and practice",
        "Do_id":"16675157",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;Tumor Suppressor Protein p14ARF",
        "Doc_meshdescriptors":"Adenocarcinoma;Adult;Aged;Aged, 80 and over;Colonic Neoplasms;Cyclin-Dependent Kinase Inhibitor p16;DNA Methylation;Female;Humans;Loss of Heterozygosity;Male;Microsatellite Repeats;Middle Aged;Prognosis;Tumor Suppressor Protein p14ARF",
        "Doc_meshqualifiers":"genetics;metabolism;secondary;genetics;metabolism;pathology;genetics;metabolism;genetics;metabolism",
        "_version_":1605741986861547520},
      {
        "Doc_abstract":"The cell cycle inhibitor p15(INK4B) is frequently inactivated by homozygous deletions together with p16(INK4a)/p14(ARF) in many tumour types. Although it is now well established that p16(INK4a) and p14(ARF) act as tumour suppressor genes, the role of p15(INK4b) remains to be well defined. In order to explore the possibility of a selective deregulation of p15(INK4b) in human lung carcinogenesis, we studied p15(INK4b) status in neuroendocrine (NE) lung tumours where homozygous deletions of the p16(INK4a)/p14(ARF) locus are rarely observed. Expressions of p15 and p15.5 protein isoforms were analysed in a series of eight control normal lung, 12 tumour-associated normal lung, five low grade and 15 high grade neuroendocrine (NE) lung tumours and relationship with a specific p15(INK4b) methylation status was studied. Using Western blot analysis, we showed that p15 and p15.5 isoforms displayed a high heterogeneous pattern of expression in both normal and tumour tissues. P15 and p15.5 expressions were correlated in control normal lung (P<0.04) whereas they were not in tumours and associated normal lung. The level of p15.5 was significantly higher in associated normal lung and in tumours (P<0.02 respectively), specially in low grade tumours (P<0.01), than in control normal lung. Furthermore, p15.5 expression was more variable in tumours than in normal lung (P<0.01) and in low grade than in high grade NE lung tumours (P<0.02). Levels of p15 and p15.5 were distinct (up- or downregulated) from those observed in paired normal lung in 4/12 (33%) and 10/12 (83%) tumours respectively. Aberrant methylation at the 5' end of p15(INK4b) gene was observed in 15% of NE lung tumours using PCR-based assay, in a region proximal to the translation start where methylation did not occur in control and associated normal lung. However, no correlation could be assessed with protein status. MSP analysis of CpG islands proximal to the transcription start revealed methylation in all normal and tumour samples. No correlation was found between p15(INK4b) and p16(INK4a) or p14(ARF) status. These data suggest that complex deregulation of p15.5 is implicated in the carcinogenesis of human NE lung tumours independently of p16(INK4a) and p14(ARF) status.",
        "Doc_title":"Expression of p15 and p15.5 products in neuroendocrine lung tumours: relationship with p15(INK4b) methylation status.",
        "Journal":"Oncogene",
        "Do_id":"11641784",
        "Doc_ChemicalList":"CDKN2B protein, human;Carrier Proteins;Cell Cycle Proteins;Cyclin-Dependent Kinase Inhibitor p15;Cyclin-Dependent Kinase Inhibitor p16;Protein Isoforms;Proteins;Tumor Suppressor Protein p14ARF;Tumor Suppressor Proteins",
        "Doc_meshdescriptors":"Carcinoma, Neuroendocrine;Carrier Proteins;Cell Cycle Proteins;Cyclin-Dependent Kinase Inhibitor p15;Cyclin-Dependent Kinase Inhibitor p16;DNA Methylation;Gene Expression Regulation, Neoplastic;Humans;Lung;Lung Neoplasms;Polymerase Chain Reaction;Protein Biosynthesis;Protein Isoforms;Proteins;Tumor Suppressor Protein p14ARF;Tumor Suppressor Proteins",
        "Doc_meshqualifiers":"genetics;metabolism;genetics;metabolism;genetics;metabolism;metabolism;genetics;metabolism;metabolism;metabolism",
        "_version_":1605790050827632640},
      {
        "Doc_abstract":"Variants of p16(INK4a) and p14(ARF), encoded by the CDKN2A locus, may respond differently to the presence of human papillomavirus (HPV). We investigated the potential association of two CDKN2A polymorphisms, 500C>G (rs11515) and 540C>T (rs3088440), with cervical neoplasia in patients with cervical lesions and healthy controls (n=492). Polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP), single-strand conformation polymorphism (SSCP) and/or DNA sequencing techniques were employed for genotyping. The 500G allele was found higher, whereas the 540T/T genotype was less frequent in patients with more severe lesions. The CDKN2A variants may have the potential to be markers for the management of patients with cervical neoplasia.",
        "Doc_title":"Association of CDKN2A polymorphisms with the severity of cervical neoplasia in a Brazilian population.",
        "Journal":"Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals",
        "Do_id":"24491138",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16",
        "Doc_meshdescriptors":"Adolescent;Adult;Aged;Aged, 80 and over;Brazil;Case-Control Studies;Cervical Intraepithelial Neoplasia;Cyclin-Dependent Kinase Inhibitor p16;Female;Genetic Association Studies;Genetic Predisposition to Disease;Haplotypes;Humans;Middle Aged;Polymorphism, Restriction Fragment Length;Polymorphism, Single Nucleotide;Polymorphism, Single-Stranded Conformational;Sequence Analysis, DNA;Severity of Illness Index;Uterine Cervical Neoplasms;Young Adult",
        "Doc_meshqualifiers":"genetics;pathology;genetics;genetics;pathology",
        "_version_":1605755399676362752},
      {
        "Doc_abstract":"Promoter hypermethylation represents a primary mechanism in the inactivation of tumor suppressor genes during tumorigenesis. We analyzed the promoter methylation status of eight tumor-associated genes (p14 ARF, p15 INK4B, p16 INK4A, Rb, hMLH1, hMSH2, APC, and DAPK) in 30 patients with myelofibrosis with myeloid metaplasia (MMM) by methylation specific PCR. The study showed no hypermethylation of the promoters of p16(INK4A), Rb, hMLH1, hMSH2, APC, and DAPK genes. The p14 ARF, p15 INK4B promoters were hypermethylated in only one patient each. This study indicates that, although methylation of these genes is important in other cancers, it is rare in MMM and causation of this disease should be focused elsewhere.",
        "Doc_title":"Methylation analysis of the cell cycle control genes in myelofibrosis with myeloid metaplasia.",
        "Journal":"Leukemia research",
        "Do_id":"15755503",
        "Doc_ChemicalList":"Cell Cycle Proteins",
        "Doc_meshdescriptors":"Adult;Aged;Cell Cycle Proteins;DNA Methylation;Female;Genes, Tumor Suppressor;Humans;Male;Middle Aged;Primary Myelofibrosis;Promoter Regions, Genetic",
        "Doc_meshqualifiers":"genetics;physiology;genetics;genetics",
        "_version_":1605746394490994692},
      {
        "Doc_abstract":"Four INK4 proteins can prevent cell proliferation by specifically inhibiting cyclin D-dependent kinases. Both p18INK4c and p19INK4d were widely expressed during mouse embryogenesis, but p16INK4a and p15INK4b were not readily detected prenatally. Although p15INK4b, p18INK4c and p19INK4d were demonstrated in many tissues by 4 weeks after birth, p16INK4a protein expression was restricted to the lung and spleen of older mice, with increased, more widespread mRNA expression during aging. Transcripts encoding the INK4a alternative reading frame product p19ARF were not detected before birth but were ubiquitous postnatally. Expression of p16INK4a and p15INK4b was induced when mouse embryos were disrupted and cultured as mouse embryo 'fibroblasts' (MEFs). The levels of p16INK4a and p18INK4c, but not p15INK4b or p19INK4d, further increased as MEFs approached senescence. Following crisis and establishment, three of four independently-derived cell lines became polyploid and expressed higher levels of functional p16INK4a. In contrast, one MEF line that sustained bi-allelic deletions of INK4a initially remained diploid. Therefore, loss of p16INK4a and other events predisposing to polyploidy may represent alternative processes contributing to cell immortalization. Whereas p18INK4c and p19INK4d may regulate pre- and postnatal development, p16INK4a more likely plays a checkpoint function during cell senescence that underscores its selective role as a tumor suppressor.",
        "Doc_title":"Expression of the p16INK4a tumor suppressor versus other INK4 family members during mouse development and aging.",
        "Journal":"Oncogene",
        "Do_id":"9244355",
        "Doc_ChemicalList":"Carrier Proteins;Cdkn2b protein, mouse;Cdkn2c protein, mouse;Cell Cycle Proteins;Cyclin-Dependent Kinase Inhibitor p15;Cyclin-Dependent Kinase Inhibitor p16;Cyclin-Dependent Kinase Inhibitor p18;Enzyme Inhibitors;RNA, Messenger;Tumor Suppressor Proteins",
        "Doc_meshdescriptors":"Aging;Amino Acid Sequence;Animals;Carrier Proteins;Cell Cycle Proteins;Cells, Cultured;Cyclin-Dependent Kinase Inhibitor p15;Cyclin-Dependent Kinase Inhibitor p16;Cyclin-Dependent Kinase Inhibitor p18;Embryonic and Fetal Development;Enzyme Inhibitors;Gene Expression Regulation;Mice;Molecular Sequence Data;RNA, Messenger;Tumor Suppressor Proteins",
        "Doc_meshqualifiers":"metabolism;analysis;genetics;analysis",
        "_version_":1605742681892323328},
      {
        "Doc_abstract":"We tested the expression of known (p16(ink4), Ki67, p53, EGFR) and a new immunohistochemical (collagen XVII/BP180) biomarker in head and neck squamous cell carcinomas (SCC) of diverse anatomical localization. Tissue microarrays (TMA) of 124 SCC were created, immunostained, and analyzed following whole slide digitalization using the Pannoramic Scan and the TMA Module software (3DHISTECH Kft, Budapest, Hungary). Statistical analysis of scoring results was carried out using Pearson's chi-square test. We observed the significant elevation of p16(ink4) and Ki67 expression in supraglottic, tonsillar and tonsillo-lingual SCCs compared to those affecting the oral cavity, oropharynx without tonsils, larynx without supraglottis and the hypopharynx. This differential antigen expression may reflect the diverse route of embryologic differentiation followed by the affected regions except those of the tonsils and the supraglottis which show similar antigenic pattern but diverse developmental path. All the other biomarkers tested including p53, collagen XVII and EGFR were detected in the majority of cancers including high grade cases, but did not reveal any significant regional difference. Based on our results oropharyngeal squamous cell carcinomas may not be regarded as one entity. Concerning the oral cavity and the oropharynx, cancers affecting the tonsils (palatine and lingual) show significantly elevated p16(ink4) and Ki67 expression; so as the cancers of the supraglottis compared to the rest of larynx. Consequently, tonsillar and supraglottic cancers show similar biomarker profiles. Correlation of differential biomarker expression with diverse biological behavior in head and neck cancers need further investigations.",
        "Doc_title":"Differential biomarker expression in head and neck cancer correlates with anatomical localization.",
        "Journal":"Pathology oncology research : POR",
        "Do_id":"21487776",
        "Doc_ChemicalList":"Biomarkers, Tumor;Cyclin-Dependent Kinase Inhibitor p16;Ki-67 Antigen;TP53 protein, human;Tumor Suppressor Protein p53;EGFR protein, human;Receptor, Epidermal Growth Factor",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Biomarkers, Tumor;Carcinoma, Squamous Cell;Cyclin-Dependent Kinase Inhibitor p16;Female;Head and Neck Neoplasms;Humans;Hypopharyngeal Neoplasms;Immunoenzyme Techniques;Ki-67 Antigen;Laryngeal Neoplasms;Male;Middle Aged;Oropharyngeal Neoplasms;Prognosis;Receptor, Epidermal Growth Factor;Survival Rate;Tissue Array Analysis;Tumor Suppressor Protein p53",
        "Doc_meshqualifiers":"metabolism;metabolism;pathology;metabolism;metabolism;pathology;metabolism;pathology;metabolism;metabolism;pathology;metabolism;pathology;metabolism;metabolism",
        "_version_":1605898362022789120},
      {
        "Doc_abstract":"Squamous cell carcinomas of head and neck (HNSCC) are a result of multiple genetic and epigenetic alterations. Epigenetic inactivation of tumor suppressor genes is an important event in head and neck carcinogenesis. Here we analyzed the promoter methylation of 15 genes (RASSF1A, p16, MGMT, DAPK, RARbeta, MLH1, CDH1, GSTP1, RASSF2, RASSF4, RASSF5, MST1, MST2, LATS1, LATS2) in 54 HNSCC and in matching 23 normal tissues. Methylation of these tumor-related genes (TRG) was significantly more frequent in HNSCC (42%) compared to normal samples (23%; p<0.05). Particularly, methylation of p16 (60%), MGMT (53%), DAPK (67%), RARbeta (75%), MLH1 (69%), CDH1 (43%), RASSF5 and MST1 (96%) was often found in HNSCC. Methylation of RASSF1A (18%), GSTP1 (4%), RASSF4 (13%), MST2 (4%), LATS1 (24%) and LATS2 (8%) was less frequently detected. A trend of increased TRG methylation in more advanced tumor stages and less differentiated HNSCC was observed. Methylation of p16 was significantly higher in poorly differentiated HNSCC (p=0.037) and RASSF5 methylation occurred preferentially in advanced tumor stages (p<0.05). Methylation of RASSF4 was higher in patients with recurrent HNSCC (23%) than patients without relapse (0%; p=0.033). Methylation of TRG in head and neck cancer cell lines was observed at similar frequency as in primary HNSCC. In summary, frequent hyper-methylation of tumor-related genes in HNSCC was detected and this epigenetic silencing event may have an essential role in head and neck carcinogenesis.",
        "Doc_title":"Frequent promoter hypermethylation of tumor-related genes in head and neck squamous cell carcinoma.",
        "Journal":"Oncology reports",
        "Do_id":"19885608",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Adult;Aged;Carcinoma, Squamous Cell;Cell Line, Tumor;DNA Methylation;Epigenesis, Genetic;Female;Gene Expression Profiling;Gene Expression Regulation, Neoplastic;Gene Silencing;Head and Neck Neoplasms;Humans;Male;Middle Aged;Promoter Regions, Genetic",
        "Doc_meshqualifiers":"genetics;metabolism;genetics;metabolism",
        "_version_":1605904154492928000},
      {
        "Doc_abstract":"The INK4 family of proteins p15INK4b, p14ARF and p16INK4a function as cell cycle inhibitors where they are involved in the inhibition of G1 phase progression. Methylation of the p15INK4b promoter never seems to occur in solid tumors but is a major gene silencing mechanism in hematological malignancies. p14ARF and p16INK4a promoter methylation often occurs in solid tumors but also in leukemias and lymphomas. In chronic myelogenous leukemia (CML), only a few reports have been published regarding INK4 methylation and the results of the literature are discordant. Thus clearly, more works on large series have to be performed independently.",
        "Doc_title":"p14ARF, p15INK4b and p16INK4a methylation status in chronic myelogenous leukemia.",
        "Journal":"Leukemia & lymphoma",
        "Do_id":"15370242",
        "Doc_ChemicalList":"CDKN2B protein, human;Cell Cycle Proteins;Cyclin-Dependent Kinase Inhibitor p15;Cyclin-Dependent Kinase Inhibitor p16;Tumor Suppressor Protein p14ARF;Tumor Suppressor Proteins",
        "Doc_meshdescriptors":"Cell Cycle Proteins;Cyclin-Dependent Kinase Inhibitor p15;Cyclin-Dependent Kinase Inhibitor p16;DNA Methylation;Humans;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Tumor Suppressor Protein p14ARF;Tumor Suppressor Proteins",
        "Doc_meshqualifiers":"genetics;genetics;genetics;genetics;genetics",
        "_version_":1605753024260603904},
      {
        "Doc_abstract":"Chemically induced skin carcinomas in mice are a paradigm for epithelial neoplasia, where oncogenic ras mutations precede p53 and INK4a/ARF mutations during the progression toward malignancy. To explore the biological basis for these genetic interactions, we studied cellular responses to oncogenic ras in primary murine keratinocytes. In wild-type keratinocytes, ras induced a cell-cycle arrest that displayed some features of terminal differentiation and was accompanied by increased expression of the p19(ARF), p16(INK4a), and p53 tumor suppressors. In ARF-null keratinocytes, ras was unable to promote cell-cycle arrest, induce differentiation markers, or properly activate p53. Although oncogenic ras produced a substantial increase in both nucleolar and nucleoplasmic p19(ARF), Mdm2 did not relocalize to the nucleolus or to nuclear bodies but remained distributed throughout the nucleoplasm. This result suggests that p19(ARF) can activate p53 without overtly affecting Mdm2 subcellular localization. Nevertheless, like p53-null keratinocytes, ARF-null keratinocytes were transformed by oncogenic ras and rapidly formed carcinomas in vivo. Thus, oncogenic ras can activate the ARF-p53 program to suppress epithelial cell transformation. Disruption of this program may be important during skin carcinogenesis and the development of other carcinomas.",
        "Doc_title":"Oncogenic ras activates the ARF-p53 pathway to suppress epithelial cell transformation.",
        "Journal":"Proceedings of the National Academy of Sciences of the United States of America",
        "Do_id":"11309506",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;Nuclear Proteins;Proteins;Proto-Oncogene Proteins;Tumor Suppressor Protein p14ARF;Tumor Suppressor Protein p53;DNA;Mdm2 protein, mouse;Proto-Oncogene Proteins c-mdm2;Oncogene Protein p21(ras);Calcium",
        "Doc_meshdescriptors":"Animals;Animals, Newborn;Calcium;Carcinoma, Squamous Cell;Cell Cycle;Cell Differentiation;Cell Size;Cell Transformation, Neoplastic;Cells, Cultured;Cyclin-Dependent Kinase Inhibitor p16;DNA;Gene Deletion;Keratinocytes;Mice;Mice, Nude;Neoplasm Transplantation;Nuclear Matrix;Nuclear Proteins;Oncogene Protein p21(ras);Protein Transport;Proteins;Proto-Oncogene Proteins;Proto-Oncogene Proteins c-mdm2;Signal Transduction;Tumor Suppressor Protein p14ARF;Tumor Suppressor Protein p53",
        "Doc_meshqualifiers":"pharmacology;genetics;metabolism;pathology;drug effects;drug effects;metabolism;biosynthesis;cytology;drug effects;metabolism;pathology;metabolism;metabolism;genetics;metabolism;metabolism;deficiency;genetics;metabolism",
        "_version_":1605880265569206272},
      {
        "Doc_abstract":"Recent works aimed at clarifying the respective roles of p16INKa and p14ARF (both located on the same INK4a locus on chromosome 9p21 in man) in malignant transformation come to the conclusion that p16INK4a is the true tumor suppressor gene in man. In mouse, it is the p19ARF knockout that suppresses the barrier protecting cells from malignant transformation. This situation is in agreement with p19ARF- and p16-mediated senescence induced by oncogenic mutated ras (Ras*) in mouse and man respectively. Other results have shown that senescence in human diploid fibroblasts is associated with heterochromatin occurrence that maintains in repressed state E2F1-induced gens required for G1 to S phases transition. Since RB protein is responsible for this chromatin modification, cells with any impaired RB pathway cannot enter into senescence.",
        "Doc_title":"[pRB, p53, p16INK4a, senescence and malignant transformation].",
        "Journal":"Bulletin du cancer",
        "Do_id":"15281278",
        "Doc_ChemicalList":"Cdkn2a protein, mouse;Cyclin-Dependent Kinase Inhibitor p16;Tumor Suppressor Protein p14ARF",
        "Doc_meshdescriptors":"Animals;Cell Aging;Cell Transformation, Neoplastic;Cyclin-Dependent Kinase Inhibitor p16;Genes, Retinoblastoma;Genes, p16;Genes, p53;Humans;Mice;Tumor Suppressor Protein p14ARF",
        "Doc_meshqualifiers":"genetics;genetics;physiology;physiology;genetics",
        "_version_":1605898720693452800},
      {
        "Doc_abstract":"Cyclin-dependent kinase (CDK) inhibitors represented by the INK4 family (including p16(INK4a, CDKN2A), p15(INK4b, CDKN2B), p18(INK4c, CDKN2C), and p19(INK4d, CDKN2D)) are regulators of the cell cycle shown to be aberrant in many types of human cancer. We tested the hypothesis that these CDK inhibitors are a target for altered gene expression in Wilms tumor. Using RT-PCR, gene expression of the INK4 family was found to be decreased in 9 of 38 Wilms tumor samples obtained from the National Wilms Tumor Study Group (NWTSG) tissue bank. All the affected tumor samples were of favorable histology. Methylation-specific PCR revealed that methylation in the p16 promoter region may be responsible for altered expression. The incidence of loss of p16 expression may increase with increasing tumor stage, i.e., 1/10 (10%) with stage I/II FH Wilms tumor, 2/10 (20%) with stage III FH Wilms tumor, and 4/10 (40%) with stage IV FH Wilms tumor. Thus, determining the expression status of the INK4 family may have potential prognostic value in the management of Wilms tumor.",
        "Doc_title":"Decreased expression of the INK4 family of cyclin-dependent kinase inhibitors in Wilms tumor.",
        "Journal":"Genes, chromosomes & cancer",
        "Do_id":"10918395",
        "Doc_ChemicalList":"CDKN2B protein, human;Carrier Proteins;Cell Cycle Proteins;Cyclin-Dependent Kinase Inhibitor p15;Cyclin-Dependent Kinase Inhibitor p16;Tumor Suppressor Proteins;Cyclin-Dependent Kinases",
        "Doc_meshdescriptors":"Carrier Proteins;Cell Cycle Proteins;Child;Cyclin-Dependent Kinase Inhibitor p15;Cyclin-Dependent Kinase Inhibitor p16;Cyclin-Dependent Kinases;Gene Expression Regulation, Neoplastic;Genes, Tumor Suppressor;Genes, p16;HeLa Cells;Humans;Multigene Family;Pilot Projects;Prognosis;Tumor Suppressor Proteins;Wilms Tumor",
        "Doc_meshqualifiers":"biosynthesis;genetics;antagonists & inhibitors;genetics;genetics;genetics;genetics;genetics;metabolism",
        "_version_":1605884220628008960},
      {
        "Doc_abstract":"The INK4a/ARF locus encodes the cyclin dependent kinase inhibitor, p16(INK4a) and the p53 activator, p14ARF. These two proteins have an independent first exon (exon 1alpha and exon 1beta, respectively) but share exons 2 and 3 and are translated in different reading frames. Germline mutations in this locus are associated with melanoma susceptibility in 20-40% of multiple case melanoma families. Although most of these mutations specifically inactivate p16(INK4a), more than 40% of the INK4a/ARF alterations located in exon 2, affect both p16(INK4a) and p14ARF. We now report a 16 base pair exon 1beta germline insertion specifically altering p14ARF, but not p16(INK4a), in an individual with multiple primary melanomas. This mutant p14ARF, 60ins16, was restricted to the cytoplasm, did not stabilize p53 and was unable to arrest the growth of a p53 expressing melanoma cell line. This is the first example of an exon 1beta mutation that inactivates p14ARF, and thus implicates a role for this tumour suppressor in melanoma predisposition.",
        "Doc_title":"A melanoma-associated germline mutation in exon 1beta inactivates p14ARF.",
        "Journal":"Oncogene",
        "Do_id":"11571653",
        "Doc_ChemicalList":"Proteins;Tumor Suppressor Protein p14ARF;Tumor Suppressor Protein p53",
        "Doc_meshdescriptors":"Adult;Amino Acid Sequence;Base Sequence;Cell Division;Cytoplasm;Exons;Female;Genetic Predisposition to Disease;Germ-Line Mutation;Humans;Melanoma;Molecular Sequence Data;Mutagenesis, Insertional;Pedigree;Proteins;Tumor Cells, Cultured;Tumor Suppressor Protein p14ARF;Tumor Suppressor Protein p53",
        "Doc_meshqualifiers":"metabolism;genetics;metabolism;pathology;genetics;metabolism;metabolism",
        "_version_":1605800236941312000},
      {
        "Doc_abstract":"The objective of this study was to evaluate the effect of p16 expression on response to chemoradiation in stage IVa/b head and neck squamous cell carcinoma (HNSCC) patients.;We retrospectively identified 64 patients with stage IVa/b HNSCC who received chemoradiation. Eligibility criteria included presence of biopsy-proven stage IVa/b HNSCC without a prior history of chemotherapy or radiotherapy. Immunohistochemistry was used to assess p16 protein expression in pretreatment biopsy specimens.;Of the 64 patients, 38 showed high p16 expression, and 50 patients responded to chemoradiotherapy, 32 exhibiting a complete and 18 a partial response. Response was significantly associated with p16 expression (P < 0.001) and multivariate analysis indicated that that p16 expression (HR: 2.62, 95%C.I.: 1.14-6.06; P=0.024) was an independent prognostic factor for overall survival.;High p16 expression predicts a better response to chemoradiation in patients with stage IVa/b HNSCC.",
        "Doc_title":"High p16 expression predicts a positive response to chemoradiotherapy in stage IVa/b head and neck squamous cell carcinoma.",
        "Journal":"Asian Pacific journal of cancer prevention : APJCP",
        "Do_id":"21627359",
        "Doc_ChemicalList":"Biomarkers, Tumor;Cyclin-Dependent Kinase Inhibitor p16;Cisplatin;Fluorouracil",
        "Doc_meshdescriptors":"Adult;Aged;Antineoplastic Combined Chemotherapy Protocols;Biomarkers, Tumor;Brachytherapy;Carcinoma, Squamous Cell;Cisplatin;Cohort Studies;Combined Modality Therapy;Cyclin-Dependent Kinase Inhibitor p16;Female;Fluorouracil;Follow-Up Studies;Head and Neck Neoplasms;Humans;Immunoenzyme Techniques;Male;Middle Aged;Prognosis;Retrospective Studies;Survival Rate",
        "Doc_meshqualifiers":"therapeutic use;metabolism;metabolism;therapy;administration & dosage;metabolism;administration & dosage;metabolism;therapy",
        "_version_":1605913531544240128},
      {
        "Doc_abstract":"It is well established that p16(INK4A) protein acts as a cell cycle inhibitor in the nucleus. Therefore, cytoplasmic localization of p16 (INK4A) usually is disregarded by investigators as nonspecific. Three recent studies reported findings that differ from the current view concerning p16(INK4A) immunohistochemical localization. All three demonstrated that breast and colon cancers expressing cytoplasmic p16(INK4) represent distinct biological subsets. We previously detected in a percentage of non-small cell lung carcinomas simultaneous nuclear and cytoplasmic p16(INK4A) staining. In view of the reports concerning breast and colon carcinomas, we conducted an ultrastructural re-evaluation of our cases to clarify the specificity of p16(INK4A) cytoplasmic expression. We observed p16 (INK4A) immunolocalization in both the nucleus and the cytoplasm of a proportion of tumor cells. Diffuse dense nuclear staining was detected in the nucleoplasm, whereas weaker granular immunoreactivity was observed in the cytoplasm near the rough endoplasmic reticulum. Negative tumor cells also were visible. In the tumor-associated stromal, cells p16(INK4A) immunoreactivity was detected only in the nuclei. We have demonstrated that p16(INK4A) cytoplasmic staining is specific and suggest that it represents a mechanism of p16(INK4A) inactivation similar to that observed in other tumor suppressor genes.",
        "Doc_title":"Electron microscopy evidence that cytoplasmic localization of the p16(INK4A) \"nuclear\" cyclin-dependent kinase inhibitor (CKI) in tumor cells is specific and not an artifact. A study in non-small cell lung carcinomas.",
        "Journal":"Biotechnic & histochemistry : official publication of the Biological Stain Commission",
        "Do_id":"15223748",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;Nuclear Proteins",
        "Doc_meshdescriptors":"Artifacts;Carcinoma, Non-Small-Cell Lung;Cell Nucleus;Cyclin-Dependent Kinase Inhibitor p16;Cytoplasm;Humans;Immunohistochemistry;Microscopy, Electron, Transmission;Nuclear Proteins;Tumor Cells, Cultured",
        "Doc_meshqualifiers":"metabolism;pathology;ultrastructure;metabolism;ultrastructure;metabolism;ultrastructure;metabolism;ultrastructure;metabolism;ultrastructure",
        "_version_":1605928668099510272},
      {
        "Doc_abstract":"To clarify the roles of Bmi-1 in colorectal carcinoma, we examined the expression of Bmi-1 in 41 samples out of 46 colorectal carcinomas by reverse transcription-PCR, whereas all 46 were analyzed by immunostaining. In addition, we analyzed the expression patterns of Bmi-1 in association with p16INK4a and p14ARF (in mouse p19ARF) in a series of colorectal carcinomas. The level of Bmi-1 mRNA in the carcinoma tissues was significantly higher than those of the adjacent non-neoplastic colonic mucosal tissues. Immunohistochemistry for Bmi-1 showed moderate or strong expression levels in 65% (30/46) of colorectal carcinomas. Colorectal carcinomas with moderate or strong Bmi-1 expression were more likely to have low levels of the INK4 locus proteins (p16INK4a/p14ARF) (P<0.07). These results suggested that modulation of Bmi-1 protein might be involved in human colorectal carcinogenesis by repressing the INK4a/ARF proteins.",
        "Doc_title":"The Bmi-1 oncoprotein is overexpressed in human colorectal cancer and correlates with the reduced p16INK4a/p14ARF proteins.",
        "Journal":"Cancer letters",
        "Do_id":"14732230",
        "Doc_ChemicalList":"BMI1 protein, human;Bmi1 protein, mouse;Cyclin-Dependent Kinase Inhibitor p16;Nuclear Proteins;Proto-Oncogene Proteins;RNA, Messenger;Repressor Proteins;Tumor Suppressor Protein p14ARF;Polycomb Repressive Complex 1",
        "Doc_meshdescriptors":"Adult;Carcinoma;Cell Differentiation;Colon;Colorectal Neoplasms;Cyclin-Dependent Kinase Inhibitor p16;Female;Humans;Immunohistochemistry;Male;Middle Aged;Mucous Membrane;Neoplasms;Nuclear Proteins;Polycomb Repressive Complex 1;Proto-Oncogene Proteins;RNA, Messenger;Repressor Proteins;Reverse Transcriptase Polymerase Chain Reaction;Tumor Suppressor Protein p14ARF;Up-Regulation;Zinc Fingers",
        "Doc_meshqualifiers":"metabolism;pathology;metabolism;biosynthesis;pathology;pathology;biosynthesis;biosynthesis;metabolism;biosynthesis",
        "_version_":1605842085146001408},
      {
        "Doc_abstract":"The aetiology of squamous cell carcinomas of the head and neck (HNSCC) is multifactorial. Oncogenic human papillomaviruses (HPVs), a causative agent in uterine cervical cancer, have also been repeatedly detected in HNSCC, especially in squamous cell carcinomas of tonsils. Approximately half the HPV DNA-positive HNSCC contain detectable E6/E7 transcripts with wild-type p53, reduced pRb and overexpressed p16 in the tumours. HPV-16 is the predominant type and exists in episomal, integrated, or mixed forms. Tonsillar carcinomas have a remarkably higher viral load than carcinomas at other sites of the head and neck region. HPV-16 DNA has also been detected in tumour-free tonsils. Infection by oncogenic HPVs is a necessary but not a sufficient cause of cancers. Studies on the molecular mechanisms underlying HPV-associated carcinogenesis are difficult, because HPV is not easy to propagate in vitro. HPV-immortalised human tonsillar epithelial cell lines may provide an in vitro model to study co-factors for the HPV-associated tonsillar cancers and to test the effects of anti-viral and anti-tumour agents.",
        "Doc_title":"Human papillomavirus type 16 in head and neck carcinogenesis.",
        "Journal":"Reviews in medical virology",
        "Do_id":"15942978",
        "Doc_ChemicalList":"E6 protein, Human papillomavirus type 16;Oncogene Proteins, Viral;Papillomavirus E7 Proteins;RNA, Messenger;Repressor Proteins;oncogene protein E7, Human papillomavirus type 16",
        "Doc_meshdescriptors":"Carcinoma, Squamous Cell;Genes, p16;Head and Neck Neoplasms;Human papillomavirus 16;Humans;Oncogene Proteins, Viral;Palatine Tonsil;Papillomavirus E7 Proteins;Papillomavirus Infections;RNA, Messenger;Repressor Proteins",
        "Doc_meshqualifiers":"metabolism;virology;physiology;metabolism;virology;genetics;isolation & purification;metabolism;biosynthesis;genetics;virology;complications;genetics;biosynthesis;genetics",
        "_version_":1605802154148233216},
      {
        "Doc_abstract":"Cervical cancer is the second most common cancer affecting Malaysian women. Despite the implementation of pap smear screening, many women are still diagnosed only in the advanced stage of cervical cancer. This could partly be due to failure of detection of its precursor lesions; hence the need to search for novel biomarkers to assist in the screening and diagnosis of cervical neoplasia. This study aims to determine the expression of p16INK4A and survivin as possible predictive biomarkers in cervical squamous neoplasm.;This is a retrospective study on 201 cases of cervical neoplasm comprising of 129 cervical intraepithelial neoplasia (CIN) and 72 squamous cell carcinoma (SCC). All samples were evaluated by two independent observers using p16INK4A and survivin monoclonal antibodies. The p16 INK4A expression was graded as negative, focal and diffuse positivity. The intensity for survivin expression was graded as weak, moderate and intense.;It is seen that p16 INK4A expression in CIN 1, CIN 2 and CIN 3 were 25.4%, 42.9% and 95.9% respectively. Majority of SCC (98.6%) showed p16 INK4A expression. Survivin expressions in CIN 1, CIN 2, CIN 3 and SCC were 56.7%, 33.4%, 87.5% and 98.6%. There was a linear relationship between increasing grade of CIN and p16 INK4A expressions.;Our study showed that p16 INK4A expressions correlate well with the increasing grade of CIN. Although survivin does not correlate well to the increasing grade of CIN, it could be useful in differentiating CIN 3 from SCC.",
        "Doc_title":"Immunohistochemical study of p16 INK4A and survivin expressions in cervical squamous neoplasm.",
        "Journal":"Indian journal of pathology & microbiology",
        "Do_id":"20090212",
        "Doc_ChemicalList":"BIRC5 protein, human;Biomarkers, Tumor;Cyclin-Dependent Kinase Inhibitor p16;Inhibitor of Apoptosis Proteins;Microtubule-Associated Proteins",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Biomarkers, Tumor;Carcinoma, Squamous Cell;Cervical Intraepithelial Neoplasia;Cyclin-Dependent Kinase Inhibitor p16;Female;Humans;Immunohistochemistry;Inhibitor of Apoptosis Proteins;Malaysia;Microtubule-Associated Proteins;Middle Aged;Retrospective Studies;Severity of Illness Index;Statistics as Topic;Uterine Neoplasms;Young Adult",
        "Doc_meshqualifiers":"analysis;diagnosis;pathology;diagnosis;pathology;biosynthesis;methods;biosynthesis;diagnosis;pathology",
        "_version_":1605746482758025217},
      {
        "Doc_abstract":"In man, the MTS1 (multiple tumor suppressor 1) locus has been located on chromosome band 9p21 and encodes two unrelated genes, p16INK4a and p19ARF that both act, through different mechanisms, as cell proliferation inhibitors. The inhibitory mechanism of p19ARF has begun to be elucidated by the finding that the protein has the ability to bind the mdm2 oncoprotein. mdm2 is implicated in the degradation of p53 and its functional inactivation. While this result provides an opportunity for understanding the tumor suppression role of p19ARF, it allows to define a new cell cycle regulatory pathway, the p19ARF-p53 pathway. In this respect, MTS1 is unique in its ability to control two crucial pathways that regulate the cell cycle. For this reason, it will be crucial to investigate the status of p19ARF in a variety human tumors.",
        "Doc_title":"[When p19ARF finds a partner or new \"dangerous liaisons\"].",
        "Journal":"Bulletin du cancer",
        "Do_id":"9752279",
        "Doc_ChemicalList":"Neoplasm Proteins;Nuclear Proteins;Proteins;Proto-Oncogene Proteins;Tumor Suppressor Protein p14ARF;Tumor Suppressor Protein p53;MDM2 protein, human;Mdm2 protein, mouse;Proto-Oncogene Proteins c-mdm2",
        "Doc_meshdescriptors":"Animals;Cell Cycle;Humans;Mice;Mutation;Neoplasm Proteins;Nuclear Proteins;Proteins;Proto-Oncogene Proteins;Proto-Oncogene Proteins c-mdm2;Transcriptional Activation;Tumor Suppressor Protein p14ARF;Tumor Suppressor Protein p53",
        "Doc_meshqualifiers":"physiology;genetics;metabolism;physiology;metabolism;physiology;metabolism;physiology;genetics;metabolism",
        "_version_":1605913143711629312},
      {
        "Doc_abstract":"Many human tumors harbor mutations that result in deregulation of Cdk4 activity. Most of these mutations involve overexpression of D-type cyclins and inactivation of INK4 inhibitors. In addition, a mutation in the Cdk4 protein has been described in patients with familial melanoma (Wolfel, T., Hauer, M., Schneider, J., Serrano, M., Wolfel, C., et al. (1995) Science 269, 1281-1284; Zuo, L., Weger, J., Yang, Q., Goldstein, A. M., Tucker, M. A., et al. (1996) Nat. Genet. 12, 97-99). This mutation, R24C, renders the Cdk4 protein insensitive to inhibition by INK4 proteins including p16(INK4a), a major candidate for the melanoma susceptibility locus. Here we show that knock-in mice expressing a Cdk4 R24C allele are highly susceptible to melanoma development after specific carcinogenic treatments. These tumors do not have mutations in the p19(ARF)/p53 pathway, suggesting a specific involvement of the p16(INK4a)/Cdk4/Rb pathway in melanoma development. Moreover, by using targeted mice deficient for other INK4 inhibitors, we show that deletion of p18(INK4c) but not of p15(INK4b) confers proliferative advantage to melanocytic tumor growth. These results provide an experimental scenario to study the role of Cdk4 regulation in melanoma and to develop novel therapeutic approaches to control melanoma progression.",
        "Doc_title":"Invasive melanoma in Cdk4-targeted mice.",
        "Journal":"Proceedings of the National Academy of Sciences of the United States of America",
        "Do_id":"11606789",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;Proto-Oncogene Proteins;Cdk4 protein, mouse;Cyclin-Dependent Kinase 4;Cyclin-Dependent Kinases",
        "Doc_meshdescriptors":"Animals;Cyclin-Dependent Kinase 4;Cyclin-Dependent Kinase Inhibitor p16;Cyclin-Dependent Kinases;Genes, Tumor Suppressor;Genetic Predisposition to Disease;Melanoma, Experimental;Mice;Mice, Inbred C57BL;Mice, Mutant Strains;Neoplasm Invasiveness;Proto-Oncogene Proteins",
        "Doc_meshqualifiers":"antagonists & inhibitors;genetics;genetics;physiology;genetics;pathology",
        "_version_":1605905912127553536},
      {
        "Doc_abstract":"To test the safety of the CDK4/6 inhibitor palbociclib with cetuximab in patients with recurrent/metastatic head and neck squamous cell carcinoma (HNSCC).;A phase I trial using 3+3 design was performed to determine the dose limiting toxicity (DLT) and maximum tolerated dose (MTD) of palbociclib with standard dose weekly cetuximab. Palbociclib was administered orally days 1-21 every 28days: dose level 1 (100mg/d) and 2 (125mg/d; approved monotherapy dose). Pharmacokinetic assessments were performed on cycle 2, day 15. Cyclin D1, p16(INK4a), and Rb protein expression were measured on pre-treatment tumor. Tumor response was assessed using RECIST1.1.;Nine patients (five p16(INK4a) negative; four positive) were enrolled across dose levels 1 (n=3) and 2 (n=6) and none experienced a DLT. A MTD of palbociclib was not reached. Myelosuppression was the most common adverse event. Six of nine patients had cetuximab-resistant and 4/9 had platin-resistant disease. Disease control (DC) occurred in 89%, including partial response (PR) in two (22%) and stable disease in six (67%) patients. PRs occurred in p16(INK4a) negative HNSCC. Five patients (56%) had measurable decreases in tumor target lesions. In cetuximab-resistant HNSCC, best tumor response was PR in 1 and DC in 5 and median TTP was 112days (range: 28-168). In platin-resistant HNSCC, best tumor response: PR in 1, DC in 3 and median TTP was 112days (range: 28-112). The Cmax and AUC0-24h appeared comparable in patients receiving 125 vs 100mg dose of palbociclib.;This trial, the first to evaluate a CDK4/6 inhibitor in HNSCC, determined that palbociclib 125mg/day on days 1-21 every 28days with cetuximab was safe. Tumor responses were observed, even in cetuximab- or platin-resistant disease.",
        "Doc_title":"Phase I trial of palbociclib, a selective cyclin dependent kinase 4/6 inhibitor, in combination with cetuximab in patients with recurrent/metastatic head and neck squamous cell carcinoma.",
        "Journal":"Oral oncology",
        "Do_id":"27311401",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605846160414605312},
      {
        "Doc_abstract":"p16(INK4a) is a tumor suppressor gene frequently inactivated by aberrant promoter hypermethylation. In the present study, p16(INK4a) methylation was evaluated in non-small cell lung cancer (NSCLC) using a quantitative assay and the clinical significance of the methylation was explored.;A total of 244 tumor samples from formalin-fixed paraffin-embedded archives were examined in this study. p16(INK4a) methylation was analyzed by the fluorescence-based, real-time methylation-specific PCR assay, MethyLight. The quantitative methylation value was expressed as the percentage of methylated reference (PMR).;The median level of p16(INK4) methylation was 0.55 PMR (range 0.00-503.4). The p16(INK4) methylation value was significantly higher in males (p = 0.005) and in squamous cell carcinoma (p = 0.018). Prognostic analysis using the Cox proportional hazard model showed that the p16(INK4a) methylation value was a significant prognostic factor (odds ratio, 1.005; 95% CI, 1.003 to 1.008; p < 0.0001). The p16(INK4a) methylation value remained a significant prognostic factor (p = 0.0004) in multivariate analysis including age, gender, histological type and clinical stage. Specimens were then classified into hypermethylated or non-hypermethylated groups based on the p16(INK4a) methylation value using various cut-offs from 1 to 100 PMR. There was no significant difference in prognosis between the two groups using a cut-off value of 1 PMR. On the other hand, there was a significant difference using 6 PMR or more as the cut-off value (p < 0.01).;These results provide clear evidence for the prognostic significance of p16(INK4a) methylation in NSCLC using quantitative DNA methylation analysis. Careful assessment of DNA methylation is needed because qualitative methylation analysis may overestimate low levels of methylation, which have less clinical significance.",
        "Doc_title":"Prognostic significance of p16(INK4a) hypermethylation in non-small cell lung cancer is evident by quantitative DNA methylation analysis.",
        "Journal":"Anticancer research",
        "Do_id":"17094392",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16",
        "Doc_meshdescriptors":"Aged;Carcinoma, Non-Small-Cell Lung;Cyclin-Dependent Kinase Inhibitor p16;DNA Methylation;Female;Humans;Lung Neoplasms;Male;Middle Aged;Prognosis;Promoter Regions, Genetic;Survival Analysis",
        "Doc_meshqualifiers":"genetics;pathology;genetics;genetics;pathology",
        "_version_":1605808189030268928},
      {
        "Doc_abstract":"The transcription factor CCAAT/enhancer binding protein beta (C/EBPbeta) is involved in cellular responses to oncogenic and physiologic Ras signals. C/EBPbeta is required for premature senescence of primary mouse fibroblasts induced by expression of H-Ras(V12), demonstrating its role in oncogene-induced senescence. Here, we have investigated the mechanisms by which Ras inhibits proliferation of normal cells but transforms immortalized cells. We show that oncogenic Ras down-regulates C/EBPbeta expression in NIH 3T3 cells, which are immortalized by a deletion of the CDKN2A locus and, therefore, lack the p16(Ink4a) and p19(Arf) tumor suppressors. Ras(V12)-induced silencing of C/EBPbeta occurred at the mRNA level and involved both the Raf-mitogen-activated protein/extracellular signal-regulated kinase (ERK) kinase-ERK and phosphatidylinositol 3-kinase signaling pathways. Oncogenic Ras decreased C/EBPbeta expression in Ink4a/Arf(-/-) mouse embryo fibroblasts (MEF) but increased C/EBPbeta levels in wild-type MEFs. C/EBPbeta down-regulation in NIH 3T3 cells was reversed by expression of p19(Arf), but not of p53 or p16(Ink4a), highlighting a critical role for p19(Arf) in sustaining C/EBPbeta levels. Ectopic expression of p34 C/EBPbeta (LAP) inhibited Ras(V12)-mediated transformation of NIH 3T3 cells, suppressed their tumorigenicity in nude mice, and reactivated expression of the proapoptotic Fas receptor, which is also down-regulated by Ras. Our findings indicate that Cebpb gene silencing eliminates a growth inhibitory transcription factor that would otherwise restrain oncogenesis. We propose that C/EBPbeta is part of a p53-independent, p19(Arf)-mediated network that enforces Ras-induced cell cycle arrest and tumor suppression in primary fibroblasts.",
        "Doc_title":"RasV12-mediated down-regulation of CCAAT/enhancer binding protein beta in immortalized fibroblasts requires loss of p19Arf and facilitates bypass of oncogene-induced senescence.",
        "Journal":"Cancer research",
        "Do_id":"19276382",
        "Doc_ChemicalList":"Antigens, CD95;CCAAT-Enhancer-Binding Protein-beta;Cdkn2a protein, mouse;Cyclin-Dependent Kinase Inhibitor p16;Tumor Suppressor Protein p53;ras Proteins",
        "Doc_meshdescriptors":"Animals;Antigens, CD95;CCAAT-Enhancer-Binding Protein-beta;Cell Aging;Cell Transformation, Neoplastic;Cyclin-Dependent Kinase Inhibitor p16;Down-Regulation;Fibroblasts;Genes, ras;Humans;Mice;NIH 3T3 Cells;Tumor Suppressor Protein p53;ras Proteins",
        "Doc_meshqualifiers":"genetics;biosynthesis;genetics;genetics;genetics;metabolism;genetics;metabolism;metabolism;physiology;genetics;genetics;metabolism",
        "_version_":1605791770876051456},
      {
        "Doc_abstract":"to investigate p16(INK4a) and p14(ARF) tumor suppressor gene methylation status, determine telomere length and assess the importance of these epigenetic and genetic parameters in the development of pleomorphic adenoma and carcinoma ex pleomorphic adenoma of the parotid salivary glands.;Genomic DNA from paraffin-embedded samples of 50 pleomorphic adenomas and 10 carcinomas ex pleomorphic adenoma was subjected to methylation specific polymerase chain reaction for hypermethylation analyses and real time polymerase chain reaction for the relative telomere length calculations.;Promoter hypermethylation of the two genes was a very frequent event in both neoplasms - between 60% and 90% of samples were hypermethylated - but without significant difference between the groups. The mean relative telomere length in the pleomorphic adenoma group was significantly increased in comparison to the control group (P=0.00), and significantly decreased in comparison to the carcinoma group (P=0.05). Telomeres were also longer in myxoid and cellular histological subtypes of adenomas than in the classic type (P=0.044 and P=0.018, respectively). Longer telomeres were more frequent in tumors with hypermethylated p14(ARF) alleles (P=0.013).;Promoter hypermethylations seems to be an important mechanism of p16(INK4a) and p14(ARF) inactivation in parotid gland tumors. Telomeric lengthening appears to be involved in the pathogenesis of both benign and malignant tumors of the parotid glands.",
        "Doc_title":"High frequency of p16 and p14 promoter hypermethylation and marked telomere instability in salivary gland tumors.",
        "Journal":"Archives of oral biology",
        "Do_id":"26351750",
        "Doc_ChemicalList":"CDK2AP2 protein, human;Cyclin-Dependent Kinase Inhibitor p16;Oncogene Proteins",
        "Doc_meshdescriptors":"Adenoma, Pleomorphic;Adult;Aged;Cyclin-Dependent Kinase Inhibitor p16;DNA Methylation;Female;Genes, Tumor Suppressor;Genes, p16;Humans;Male;Middle Aged;Neoplasm Grading;Oncogene Proteins;Parotid Neoplasms;Promoter Regions, Genetic;Telomere;Telomere Homeostasis;Young Adult",
        "Doc_meshqualifiers":"genetics;metabolism;pathology;genetics;metabolism;genetics;metabolism;genetics;metabolism;pathology;genetics;metabolism",
        "_version_":1605747090420400129},
      {
        "Doc_abstract":"p16 (CDKN2/MTS1/p16INK4a) is frequently deleted, methylated, or mutated in many malignancies including squamous cell carcinoma of the head and neck (HNSCC). p16 beta is an alternative transcript derived from a newly described exon (exon 1 beta) located more than 15 kb 5' to exon 1 of p16. Moreover, the p16 beta transcript theoretically encodes a protein distinct from p16 derived from a divergent reading frame putatively initiated in exon 1 beta. To test the contribution of both of these transcripts in carcinogenesis, full-length cDNA of p16 and p16 beta were cloned in separate vector constructs and then transfected into HNSCC cell lines characterized for p16 status (p16[+/+], p16[mut/-], and p16[methylated]). Transfection of either p16 or p16 beta resulted in marked growth inhibition in all three HNSCC lines tested, regardless of p16 status. However, p16 beta but not p16 inhibited the growth of HeLa cells, a cell line with inactive pRB due to expression of E7 papillomavirus protein. Moreover, transfection of all three HNSCC lines with either p16 or p16 beta resulted in a marked increase in cells in G0-G1 consistent with a cell cycle arrest in G1. These data are consistent with the hypothesis that p16 and p16 beta are growth-inhibitory genes active in HNSCC and that both act by blocking progression through the G1-S transition of the cell cycle. Furthermore, the suppressive effects of p16 beta on HeLa growth suggest that p16 beta mediates its effect independently from pRB.",
        "Doc_title":"p16 and p16 beta are potent growth suppressors of head and neck squamous carcinoma cells in vitro.",
        "Journal":"Cancer research",
        "Do_id":"8797577",
        "Doc_ChemicalList":"Carrier Proteins;Cyclin-Dependent Kinase Inhibitor p16;DNA Primers;Enzyme Inhibitors;Protein Kinase Inhibitors",
        "Doc_meshdescriptors":"Alternative Splicing;Base Sequence;Blotting, Western;Carrier Proteins;Cell Cycle;Cell Line;Cell Survival;Cyclin-Dependent Kinase Inhibitor p16;DNA Primers;Enzyme Inhibitors;Exons;Genes, Tumor Suppressor;Head and Neck Neoplasms;Humans;Molecular Sequence Data;Polymerase Chain Reaction;Protein Kinase Inhibitors;Transcription, Genetic;Transfection;Tumor Cells, Cultured",
        "Doc_meshqualifiers":"biosynthesis;physiology;pathology",
        "_version_":1605747087193931777},
      {
        "Doc_abstract":"Alterations of the candidate tumor suppressor gene PTEN/MMAC1 and the cell cycle control gene p16((CDKN2/MTS-1/INK4a)) have been detected in many types of human cancer. Here, we wanted to study the role of PTEN/MMAC1 in head and neck squamous cell carcinomas (HNSCC) in correlation to mutation and methylation of p16 and to previous in situ hybridization results concerning loss of chromosomes 9 and 10. We screened for alterations of PTEN/MMAC1 and p16 in 52 HNSCC of different sites. Mutations of PTEN/MMAC1 were found in 23% of tumor samples (missense mutations in 7 carcinomas, 13%). A loss of chromosome 10 was detected in five carcinomas with missense PTEN/MMAC1 mutations (71%). The missense mutations of PTEN/MMAC1 occurred in exons 5 (five different mutations in the neighborhood of the protein tyrosine phosphatase domain), 6, 7, and 8. Only one of these mutations had been described before. In addition, in three laryngeal carcinomas (6%), missense mutations of p16 (in exon 2) were detected and 14% of carcinomas showed a methylation of p16. Our results focus on the essential but not solitary role of PTEN/MMAC1 in the tumorigenesis or progression of a subset of HNSCC.",
        "Doc_title":"Detection of new PTEN/MMAC1 mutations in head and neck squamous cell carcinomas with loss of chromosome 10.",
        "Journal":"Cancer genetics and cytogenetics",
        "Do_id":"11801303",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;DNA Primers;DNA, Neoplasm;Tumor Suppressor Proteins;Phosphoric Monoester Hydrolases;PTEN Phosphohydrolase;PTEN protein, human",
        "Doc_meshdescriptors":"Carcinoma, Squamous Cell;Chromosomes, Human, Pair 10;Chromosomes, Human, Pair 9;Cyclin-Dependent Kinase Inhibitor p16;DNA Methylation;DNA Mutational Analysis;DNA Primers;DNA, Neoplasm;Exons;Female;Gene Deletion;Genes, Tumor Suppressor;Head and Neck Neoplasms;Humans;In Situ Hybridization, Fluorescence;Male;Mutation, Missense;PTEN Phosphohydrolase;Phosphoric Monoester Hydrolases;Polymerase Chain Reaction;Tumor Suppressor Proteins",
        "Doc_meshqualifiers":"blood;genetics;pathology;genetics;genetics;genetics;metabolism;chemistry;analysis;blood;genetics;pathology;genetics;genetics;genetics",
        "_version_":1605841903957311488},
      {
        "Doc_abstract":"The tumor-suppressor genes p14(ARF), p16(INK4a) and Tp53 are commonly inactivated in many tumors. We investigated their role in the pathogenesis of 9 bile tract cancer cell lines and 21 primary sporadic extrahepatic bile duct carcinomas. p53 and p16 protein expression was examined by Western blot analysis and immunohistochemistry. Mutation screening of p53 was done by SSCP and direct sequencing. Inactivating mechanisms of p14 and p16 were addressed by screening for mutations, homozygous deletions, chromosomal loss of 9p21 (loss of heterozygosity [LOH] analysis) and promoter hypermethylation of the p14/p16 genes. p53 overexpression could be detected in 7 of 9 cell lines and 7 of 21 primary tumors, but mutations were found in 3 cell lines only. p16 expression was absent in all cell lines, due to homozygous deletion of the gene in 8 of 9 cell lines and hypermethylation of the p16 promoter in one cell line (CC-LP-1). p14 exon 1beta was homozygously deleted in 6 of 9 cell lines, while retained in CC-LP-1 and 2 additional lines. No p14 promoter hypermethylation could be detected. p16 expression was lost in 11 of 21 primary tumors. p16 promoter hypermethylation was present in 9 of 21 primary tumors, all with lost p16 expression. Allelic loss at 9p21 was detected in 13 of 21 primary tumors, 10 of 11 with lost p16 expression and 8 of 9 with methylated p16 promoter. No p14 promoter hypermethylation or p14/p16 mutations could be detected. Neither Tp53 nor p16 alterations showed obvious association with histopathologic or clinical characteristics. In conclusion, inactivation of the p16 gene is a frequent event in primary sporadic extrahepatic bile duct cancers, 9p21 LOH and promoter hypermethylation being the principal inactivating mechanisms. Therefore, p16, but not p14, seems to be the primary target of inactivation at the INK4a locus in bile duct cancers. Other mechanisms than Tp53 mutations seems to be predominantly responsible for stabilization of nuclear p53 protein in bile duct cancers.",
        "Doc_title":"Inactivation of the INK4a/ARF locus and p53 in sporadic extrahepatic bile duct cancers and bile tract cancer cell lines.",
        "Journal":"International journal of cancer",
        "Do_id":"11802210",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;Neoplasm Proteins;Tumor Suppressor Protein p14ARF;Tumor Suppressor Protein p53",
        "Doc_meshdescriptors":"Bile Duct Neoplasms;Bile Ducts, Extrahepatic;Biliary Tract Neoplasms;Blotting, Western;Carcinoma;Cyclin-Dependent Kinase Inhibitor p16;DNA Methylation;DNA Mutational Analysis;Gallbladder Neoplasms;Gene Deletion;Gene Expression Profiling;Gene Expression Regulation, Neoplastic;Genes, Tumor Suppressor;Genes, p16;Genes, p53;Humans;Loss of Heterozygosity;Neoplasm Proteins;Polymerase Chain Reaction;Polymorphism, Single-Stranded Conformational;Promoter Regions, Genetic;Tumor Cells, Cultured;Tumor Suppressor Protein p14ARF;Tumor Suppressor Protein p53",
        "Doc_meshqualifiers":"genetics;genetics;pathology;genetics;pathology;deficiency;genetics;pathology;deficiency;genetics;deficiency;genetics;deficiency",
        "_version_":1605825500336357376},
      {
        "Doc_abstract":"We have previously shown TP16 MTS1/CDK41 gene deletion in more than 50% of a cohort of squamous cell carcinoma of the head and neck (SCCHN) patients using polymerase chain reaction (PCR). We have performed fluorescence in situ hybridization (FISH) on paraffin-embedded SCCHN specimens from the same cohort to identify the deletion of TP16 MTS1/CDK41CDK41gene. Twenty normal and 19 SCCHN specimens were studied. An alpha-satellite DNA probe specific for chromosome 9 and a cosmid probe for the TP16 MTS1/CDK41CDK41gene were used. Of the 19 tumors examined by FISH, 6 had homozygous deletions, 7 were hemizygously deleted, and the remaining 6 showed no evidence of deletion of the TP16 MTS1/CDK41 gene. None of the normal specimens showed TP16 gene deletion. Data obtained from FISH highly correlated with the PCR results for the identification of TP16 MTS1/CDK41 gene deletions. Patients with deletion of the TP16 MTS1/CDK41 gene show a greater tendency toward the development of recurrence and metastasis.",
        "Doc_title":"Fluorescence in situ hybridization for detecting TP16 MTS1/CDK41 gene deletions in squamous cell carcinoma of the head and neck.",
        "Journal":"Cancer genetics and cytogenetics",
        "Do_id":"12581898",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Adult;Aged;Chromosomes, Human, Pair 9;Female;Gene Deletion;Genes, p16;Head and Neck Neoplasms;Humans;In Situ Hybridization, Fluorescence;Male;Middle Aged;Neoplasm Metastasis;Neoplasm Recurrence, Local;Neoplasms, Squamous Cell;Prognosis;Risk Factors",
        "Doc_meshqualifiers":"genetics;genetics;pathology;methods;genetics;pathology",
        "_version_":1605896400621535232},
      {
        "Doc_abstract":"Human papillomavirus (HPV)-positive oropharyngeal squamous cell carcinoma (OPSCC) is recognized as a distinct disease entity associated with improved survival. DNA hypermethylation profiles differ significantly by HPV status suggesting that a specific subset of methylated CpG loci could give mechanistic insight into HPV-driven OPSCC. We analyzed genome-wide DNA methylation of primary tumor samples and adjacent normal mucosa from 46 OPSCC patients undergoing treatment at Montefiore Medical Center, Bronx, NY using the Illumina HumanMethylation27 beadchip. For each matched tissue set, we measured differentially methylated CpG loci using a change in methylation level (M value). From these analyses, we identified a 22 CpG loci panel for HPV+ OPSCC that included four CDKN2A loci downstream of the p16(INK4A) and p14(ARF) transcription start sites. This panel was significantly associated with overall HPV detection (P < 0.05; ROC area under the curve = 0.96, 95% CI: 0.91-1.0) similar to the subset of four CDKN2A-specific CpG loci (0.90, 95% CI: 0.82-0.99) with equivalence to the full 22 CpG panel. DNA hypermethylation correlated with a significant increase in alternative open reading frame (ARF) expression in HPV+ OPSCC primary tumors, but not to the other transcript variant encoded by the CDKN2A locus. Overall, this study provides evidence of epigenetic changes to the downstream region of the CDKN2A locus in HPV+ oropharyngeal cancer that are associated with changes in expression of the coded protein products.",
        "Doc_title":"Epigenetic changes in the CDKN2A locus are associated with differential expression of P16INK4A and P14ARF in HPV-positive oropharyngeal squamous cell carcinoma.",
        "Journal":"Cancer medicine",
        "Do_id":"25619363",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;RNA, Messenger;Tumor Suppressor Protein p14ARF",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Carcinoma, Squamous Cell;CpG Islands;Cyclin-Dependent Kinase Inhibitor p16;DNA Methylation;Epigenesis, Genetic;Female;Humans;Male;Middle Aged;Oropharyngeal Neoplasms;Papillomaviridae;Papillomavirus Infections;RNA, Messenger;Tumor Suppressor Protein p14ARF",
        "Doc_meshqualifiers":"genetics;metabolism;genetics;metabolism;genetics;metabolism;genetics;metabolism;metabolism;genetics;metabolism",
        "_version_":1605897464882135040},
      {
        "Doc_abstract":"The INK4a-ARF locus encodes two tumor suppressor proteins, p16(INK4a) and p14(ARF), that act through the Rb-CDK4 and p53 pathways, respectively. Data from murine models and sporadic human skin carcinomas implicate p16(INK4a) and p14(ARF) in the development of skin carcinomas. We examined the frequency of INK4a-ARF, p53, and CDK4 mutations in skin carcinomas from patients with xeroderma pigmentosum (XP), a rare autosomal disease that is associated with a defect in DNA repair and that predisposes patients to skin cancer.;DNA from skin cancers of 28 unrelated XP patients was screened for mutations in p53, INK4a-ARF, and CDK4 coding exons by single-strand conformation polymorphism analysis and automated sequencing. Data were evaluated with the use of the exact unconditional test derived from Fisher's test. All statistical tests were two-sided.;Eight of 28 XP-associated tumors had mutations in the INK4a-ARF locus. Three XP-associated tumors had multiple mutations at this locus. In all, 13 mutations in the INK4a-ARF locus were detected in XP-associated tumors, of which seven (54%) were signature UV radiation-induced mutations, i.e., tandem CC : GG-->TT : AA transitions. p53 mutations, mostly of the type induced by UV radiation, were present in 12 tumors (43%). Statistically significant positive associations were found between the frequency of mutations in p53 and in p16(INK4a) (P =.008) and between the frequency of mutations in p53 and in p14(ARF) (P<.001). No mutations were detected within the CDK4 gene.;We have demonstrated for the first time the occurrence of UV radiation-induced mutations in INK4a-ARF in XP-associated skin carcinomas. The simultaneous inactivation of p53 and INK4a-ARF may be linked to the genetic instability caused by XP and could be advantageous for tumor progression.",
        "Doc_title":"Association between INK4a-ARF and p53 mutations in skin carcinomas of xeroderma pigmentosum patients.",
        "Journal":"Journal of the National Cancer Institute",
        "Do_id":"11078762",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;DNA, Neoplasm;Proteins;Tumor Suppressor Protein p14ARF;Cyclin-Dependent Kinases",
        "Doc_meshdescriptors":"Africa, Northern;Carcinoma;Cyclin-Dependent Kinase Inhibitor p16;Cyclin-Dependent Kinases;DNA Damage;DNA, Neoplasm;European Continental Ancestry Group;Genes, Tumor Suppressor;Genes, p53;Humans;Mutation;Polymorphism, Single-Stranded Conformational;Proteins;Sequence Analysis, DNA;Skin Neoplasms;Tumor Suppressor Protein p14ARF;Ultraviolet Rays;Xeroderma Pigmentosum",
        "Doc_meshqualifiers":"ethnology;genetics;genetics;antagonists & inhibitors;radiation effects;genetics;genetics;genetics;genetics;genetics;genetics;adverse effects;genetics",
        "_version_":1605795970887450624},
      {
        "Doc_abstract":"Human papillomavirus (HPV)-positive head and neck squamous cell carcinomas (HNSCC) have been shown to have a significantly better prognosis and response to current treatment modalities. Current guidelines recommend systematic HPV-DNA and/or p16 testing on HNSCCs, although treatment approach should not be directed by test results. The objectives of this study were to (1) assess whether HPV-DNA and/or p16 status are systematically evaluated across North American otolaryngologists-head and neck surgeons and (2) whether the status is used to direct treatment approach.;A 15-question online survey was sent to three associations: the Association of Oto-rhino-laryngology-Head and Neck Surgery of Quebec, the Canadian Society of Otolaryngology-Head and Neck Surgery, and the American Head and Neck Society.;Sixty-seven percent of respondents systematically test for HPV-DNA and/or p16 on HNSCC sites, while 58.3% report using test results to direct treatment for oropharyngeal cancers. A lack of official guidelines was the primary reason (81.8%) physicians did not use test results to direct treatment. Academic centre physicians (83.3%) and physicians with 50% oncologic practice (87.6%) were more likely to test for HPV-DNA and/or p16 in HNSCC compared to non-academic centre physicians (39.7%) and physicians with <50% oncologic practices (51.4%) (p<0.001). Cost of the tests (69.2%), lack of relevance (46.1%) and time constraints (30.8%) were the primary reasons HPV-DNA and/or p16 were not tested.;The majority of North American respondents in this survey systematically test for HPV-DNA and/or p16 in HNSCC sites, and most indicate that test results influence their treatment approach for oropharyngeal cancers.",
        "Doc_title":"North-American survey on HPV-DNA and p16 testing for head and neck squamous cell carcinoma.",
        "Journal":"Oral oncology",
        "Do_id":"25096827",
        "Doc_ChemicalList":"DNA, Viral",
        "Doc_meshdescriptors":"Alphapapillomavirus;Canada;Carcinoma, Squamous Cell;DNA, Viral;Data Collection;Genes, p16;Head and Neck Neoplasms;Humans;In Situ Hybridization;Polymerase Chain Reaction",
        "Doc_meshqualifiers":"genetics;isolation & purification;virology;genetics;virology",
        "_version_":1605852685254262784},
      {
        "Doc_abstract":"Recently, the p16/CDKN2/MTS1 gene in the 9p21-22 region has been offered as a candidate tumor suppressor gene. We examined the frequency of hemizygous and homozygous deletions of p16/CDKN2 in head and neck squamous cell carcinoma (HNSCC) using a quantitative polymerase chain reaction (PCR) method.;Twenty-one HNSCC and 12 corresponding normal DNA samples were examined for deletion of p16/ CDKN2 using PCR amplification and fluorescent quantification of DNA. All tumor and normal DNA samples were also amplified with fluorescein-labeled primers for a control DNA marker on chromosome 8p (D8S265). The ratios of the observed fluorescence of the p16/CDKN2 and 8p PCR products were compared.;Patients with HNSCC scheduled to undergo surgical resection of their tumors were recruited. After the specimen was removed, a portion of the tissue was snap frozen for further DNA extraction.;Eight tumors (38%) had p16/CDKN2-D8S265 ratios of greater than 0.75; 8 tumors (38%), from 0.25 to 0.75; and 5 tumors (24%), of less than 0.25, the average ratio in this last group being 0.06.;These ratios suggest a higher rate of homozygous deletion than previously reported and significant probable hemizygous deletion of the p16/CDKN2 gene in HNSCC.",
        "Doc_title":"Deletion analysis of the p16/CDKN2 gene in head and neck squamous cell carcinoma using quantitative polymerase chain reaction method.",
        "Journal":"Archives of otolaryngology--head & neck surgery",
        "Do_id":"9260553",
        "Doc_ChemicalList":"Carrier Proteins;Cyclin-Dependent Kinase Inhibitor p16;DNA Primers;DNA, Neoplasm;Fluorescent Dyes",
        "Doc_meshdescriptors":"Carcinoma, Squamous Cell;Carrier Proteins;Chromosomes, Human, Pair 8;Chromosomes, Human, Pair 9;Cyclin-Dependent Kinase Inhibitor p16;DNA Primers;DNA, Neoplasm;Fluorescent Dyes;Gene Deletion;Genes, Tumor Suppressor;Head and Neck Neoplasms;Humans;Polymerase Chain Reaction",
        "Doc_meshqualifiers":"genetics;genetics;analysis;genetics;genetics",
        "_version_":1605807945967206400},
      {
        "Doc_abstract":"Frequencies as high as 60% of overexpressed p16(INK4) were recently reported in lichen planus (LP). Because p16(INK4) overexpression may be a feature of human papilloma virus (HPV)-induced cancer, it has been postulated that LP may be somehow related to HPV. The present study is the first to evaluate both high p16(INK4) expression and HPV in patients with LP.;Thirty-five consecutive biopsy specimens from patients with LP constituted the basis of the present study. Level of p16(INK4A) expression was evaluated in each sample by immunohistochemical analysis, and the presence of HPV DNA was tested by real-time polymerase chain reaction (PCR).;p16(INK4) expression was detected in 26 specimens, whereas HPV was found in 4 lesions: 3 low-risk HPV and 1 high-risk HPV. All HPV-positive lesions also indicated p16(INK4A) overexpression, whereas 22 cases of overexpressed p16(INK4A) were HPV negative (Chi square 2.6; ns).;p16(INK4) overexpression is not correlated with HPV in patients with LP.",
        "Doc_title":"p16(INK4) expression is not associated with human papillomavirus in oral lichen planus.",
        "Journal":"Oral surgery, oral medicine, oral pathology and oral radiology",
        "Do_id":"25457887",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;DNA, Viral",
        "Doc_meshdescriptors":"Biopsy;Cyclin-Dependent Kinase Inhibitor p16;DNA, Viral;Female;Humans;Immunohistochemistry;Lichen Planus, Oral;Male;Papillomavirus Infections;Real-Time Polymerase Chain Reaction",
        "Doc_meshqualifiers":"metabolism;analysis;metabolism;metabolism",
        "_version_":1605884132699668480},
      {
        "Doc_abstract":"Cytogenetic/molecular abnormalities significantly influence the prognosis of patients with acute leukemia. Recently, two genes, p16INK4a and p15INK4b, encoding two cyclin-dependent kinase inhibitor proteins of the INK4 family of Mr 15,000 and 16,000, respectively, have been localized to 9p21. Remarkably, the p16INK4a locus has been found to encode a second protein, p14ARF, known as p19ARF in mice, with a distinct reading frame. Like p16INK4a, p14ARF is involved in cell cycle regulation, blocking cells at the G1 restriction point through the activity of MDM-2 and p53. We studied bone marrow samples of 42 newly diagnosed and untreated patients with acute lymphoblastic leukemia for the incidence of deletions of p16INK4a/p14ARF and p15INK4b using Southern blot analysis and determined the clinical outcome with regard to complete remission (CR) duration, event-free survival, and overall survival. We found deletions of p16INK4a/p14ARF in 17 of 42 patients (40%), with homozygous deletions in 11 of 42 patients (26%) and hemizygous deletions in 6 of 42 patients (14%). The gene for p15INK4b was codeleted in most, but not all, cases and was never deleted without deletion of p16INK4a/ p14ARF. No correlation was observed between molecular studies and karyotype abnormalities as determined by conventional cytogenetics. Furthermore, no difference was found in the CR rate, CR duration, event-free survival, and overall survival in patients with homozygous gene deletions compared to patients with no deletions or loss of only one allele.",
        "Doc_title":"The prognostic significance of p16INK4a/p14ARF and p15INK4b deletions in adult acute lymphoblastic leukemia.",
        "Journal":"Clinical cancer research : an official journal of the American Association for Cancer Research",
        "Do_id":"10430092",
        "Doc_ChemicalList":"CDKN2B protein, human;Carrier Proteins;Cell Cycle Proteins;Cyclin-Dependent Kinase Inhibitor p15;Cyclin-Dependent Kinase Inhibitor p16;Genetic Markers;Proteins;Tumor Suppressor Protein p14ARF;Tumor Suppressor Proteins",
        "Doc_meshdescriptors":"Adolescent;Adult;Age Factors;Aged;Carrier Proteins;Cell Cycle Proteins;Chromosome Mapping;Chromosomes, Human, Pair 9;Cyclin-Dependent Kinase Inhibitor p15;Cyclin-Dependent Kinase Inhibitor p16;Female;Gene Deletion;Genes, p16;Genetic Markers;Humans;Male;Middle Aged;Philadelphia Chromosome;Precursor Cell Lymphoblastic Leukemia-Lymphoma;Prognosis;Proteins;Tumor Suppressor Protein p14ARF;Tumor Suppressor Proteins",
        "Doc_meshqualifiers":"genetics;genetics;genetics;genetics",
        "_version_":1605783427891593216},
      {
        "Doc_abstract":"INK4a/ARF locus encodes at least two products, P16(INK4a) and P19(ARF), which are very important in controlling cell-cycle arrest and apoptosis. Many human cancers have been found to be highly related to the mutations at this locus. Here is a review of its structure, function and role in tumor suppression.",
        "Doc_title":"[Cyclin-dependent kinase 4 inhibitor a and tumor].",
        "Journal":"Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics",
        "Do_id":"11402455",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;Proteins;Tumor Suppressor Protein p14ARF",
        "Doc_meshdescriptors":"Animals;Cyclin-Dependent Kinase Inhibitor p16;Genes, p16;Genes, p53;Humans;Neoplasms;Proteins;Tumor Suppressor Protein p14ARF",
        "Doc_meshqualifiers":"chemistry;physiology;prevention & control;genetics;physiology",
        "_version_":1605746811703656449},
      {
        "Doc_abstract":"Genes of the polycomb group function by silencing homeotic selector genes that regulate embryogenesis. In mice, downregulation of one of the polycomb genes, bmi-1, leads to neurological alterations and severe proliferative defects in lymphoid cells, whilst bmi-1 overexpression, together with upregulation of myc-1, induces lymphoma. An oncogenic function has been further supported in primary fibroblast studies where bmi-1 overexpression induces immortalization due to repression of p16/p19ARF, and where together with H-ras, it readily transforms MEFs. It was the aim of this study to assess the expression of bmi-1 in resectable non-small cell lung cancer (NSCLC) in association with p16 and p14ARF (=human p19ARF). Tumours (48 resectable NSCLC (32 squamous, 9 adeno-, 2 large cell, 4 undifferentiated carcinomas and 1 carcinoid); stage I, 29, II, 7, III, 12; T1, 18, T2, 30; differentiation: G1 12, G2 19, G3 17) were studied by immunohistochemistry for protein expression and by comparative multiplex PCR for gene amplification analysis. In tumour-free, normal lung tissue from patients, weak - moderate bmi-1 staining was seen in some epithelial cells, lymphocytes, glandular cells and in fibroblasts, whereas blood, endothelial, chondrocytes, muscle cells and adipocytes did not exhibit any bmi-1 expression. In tumours, malignant cells were negative/weakly, moderately and strongly positive in 20, 22 and 6 cases, respectively. As assessed by multiplex PCR, bmi-1 gene amplification was not the reason for high-level bmi-1 expression. Tumours with moderate or strong bmi-1 expression were more likely to have low levels of p16 and p14ARF (P = 0.02). Similarly, tumours negative for both, p16 and p14ARF, exhibit moderate-strong bmi-1 staining. 58% of resectable NSCLC exhibit moderate-high levels of bmi-1 protein. The inverse correlation of bmi-1 and the INK4 locus proteins expression (p16/p14ARF) supports a possible role for bmi-1 misregulation in lung carcinogenesis.",
        "Doc_title":"The bmi-1 oncoprotein is differentially expressed in non-small cell lung cancer and correlates with INK4A-ARF locus expression.",
        "Journal":"British journal of cancer",
        "Do_id":"11355949",
        "Doc_ChemicalList":"BMI1 protein, human;Biomarkers, Tumor;Cyclin-Dependent Kinase Inhibitor p16;Nuclear Proteins;Proteins;Proto-Oncogene Proteins;Repressor Proteins;Tumor Suppressor Protein p14ARF;Polycomb Repressive Complex 1",
        "Doc_meshdescriptors":"Aged;Biomarkers, Tumor;Carcinoma, Non-Small-Cell Lung;Cell Line;Cyclin-Dependent Kinase Inhibitor p16;Female;Humans;Lung;Lung Neoplasms;Male;Middle Aged;Nuclear Proteins;Organ Specificity;Polycomb Repressive Complex 1;Polymerase Chain Reaction;Proteins;Proto-Oncogene Proteins;Repressor Proteins;Survival Rate;Tumor Cells, Cultured;Tumor Suppressor Protein p14ARF;Zinc Fingers",
        "Doc_meshqualifiers":"genetics;mortality;pathology;surgery;genetics;cytology;metabolism;genetics;mortality;pathology;surgery;analysis;genetics;genetics;analysis;genetics",
        "_version_":1605751893142798336},
      {
        "Doc_abstract":"We have recently shown that the multiple tumor suppressor gene 1 (MTS1 ) encoding the p16(INK4a) and p19(ARF) cell-cycle inhibitors is inactivated by deletion or disruption in most human T-cell acute lymphoblastic leukemias (T-ALLs), representing the most frequent genetic event thus far described in this disease. To analyze the mechanism of these chromosomal events, we used cloning, sequencing, and/or polymerase chain reaction mapping to study 15 rearrangements occurring in the MTS1 locus. We found that these breakpoints occur in two clusters (MTS1(bcralpha) and MTS1(bcrbeta) ). The three rearrangements occurring in MTS1(bcralpha) correspond to a recurrent recombination juxtaposing 5' MTS2 exon 1 and 5' MTS1 exon 1alpha sequences. Breakpoints for 10 of 12 rearrangements within MTS1(bcrbeta) are located at a polymorphic (CA) repeat, suggesting that this sequence might play a role in the clustering. For both MTS1(bcralpha) and MTS1(bcrbeta), sequence analyses and PCR mapping experiments show that the tightly clustered breakpoints are located in the vicinity of heptamers whose sequence is similar to those involved in the V(D)J recombination. Moreover, short deletions, GC-rich random nucleotide additions, and clone-specific junctional sequences are present in all cases, further suggesting that the rearrangements are due to illegitimate V(D)J recombinase activity. These data are the first demonstration that a tumor suppressor gene can be inactivated by the V(D)J recombinational mechanism. Moreover, they reinforce the view that this process, normally required for T-cell differentiation, plays a crucial role in the pathogenesis of T-ALL.",
        "Doc_title":"Disruption of the multiple tumor suppressor gene MTS1/p16(INK4a)/CDKN2 by illegitimate V(D)J recombinase activity in T-cell acute lymphoblastic leukemias.",
        "Journal":"Blood",
        "Do_id":"9345058",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;DNA Nucleotidyltransferases;VDJ Recombinases",
        "Doc_meshdescriptors":"Base Sequence;Cyclin-Dependent Kinase Inhibitor p16;DNA Nucleotidyltransferases;Gene Deletion;Gene Rearrangement, T-Lymphocyte;Humans;Leukemia-Lymphoma, Adult T-Cell;Molecular Sequence Data;Multigene Family;VDJ Recombinases",
        "Doc_meshqualifiers":"genetics;genetics;metabolism;enzymology;genetics",
        "_version_":1605818720921321473},
      {
        "Doc_abstract":"Molecular genetic alterations that disturb cell cycle regulation in tumor cells can affect their response to chemotherapeutic agents and radiation. Many genes that regulate the critical cell cycle checkpoint at G1S are altered in human tumors. These genetic changes can result in uncontrolled cellular proliferation, genetic instability, and altered response to radiation and chemotherapy. The p53 tumor suppressor gene serves a critical role at the G1S transition, where it can either block entry into S phase or activate programmed cell death (apoptosis) in response to DNA damage. p53 Gene mutations are common in human tumors and interfere with the activation of apoptosis in response to most chemotherapeutic agents. Paclitaxel is a potent chemotherapeutic agent that interferes with mitotic spindle function to block cells at G2M, the most radiosensitive phase of the cell cycle. Utilization of paclitaxel as a radiation sensitizer in vivo to treat aggressive, locally advanced neoplasms has resulted in high response rates and acceptable toxicity in protocols for non-small cell lung carcinoma, upper gastrointestinal tract carcinoma, and other malignancies. Recent evidence suggests that paclitaxel is unique in its ability to activate apoptosis in tumor cells with p53 mutations in vitro and in vivo. The p16(INK4a) (MTS-1, CDKN2) gene product acts in the same pathway as p53 to inhibit cell cycle progression at G1/S. p16(INK4a) is deleted and/or mutated in a significant fraction of human tumors, including pancreatic carcinoma. The effects of p16(INK4a) alterations in response to paclitaxel/radiation and the risk of systemic relapse are currently being evaluated. Information about molecular genetic alterations in individual tumors ultimately may be a critical factor in choosing between therapeutic options.",
        "Doc_title":"Role of p53 and p16 gene alterations in determining response to concurrent paclitaxel and radiation in solid tumor.",
        "Journal":"Seminars in radiation oncology",
        "Do_id":"10210535",
        "Doc_ChemicalList":"Antineoplastic Agents, Phytogenic;Radiation-Sensitizing Agents;Paclitaxel",
        "Doc_meshdescriptors":"Animals;Antineoplastic Agents, Phytogenic;Apoptosis;Carcinoma, Non-Small-Cell Lung;Cell Cycle;Combined Modality Therapy;Genes, cdc;Genes, p16;Genes, p53;Humans;Lung Neoplasms;Mutation;Paclitaxel;Pancreatic Neoplasms;Radiation-Sensitizing Agents;Stomach Neoplasms",
        "Doc_meshqualifiers":"therapeutic use;drug therapy;genetics;radiotherapy;physiology;genetics;genetics;genetics;drug therapy;genetics;radiotherapy;therapeutic use;drug therapy;genetics;radiotherapy;therapeutic use;drug therapy;genetics;radiotherapy",
        "_version_":1605837002372022272},
      {
        "Doc_abstract":"The tumor suppressor gene p16 encodes a cyclin-dependent kinase inhibitor that normally inhibits cell proliferation by causing a G1 cell cycle arrest. The p16 gene is frequently mutated in a variety of somatic tumors, as well as in familial melanoma and familial pancreatic carcinoma. We identified a family with a high incidence of head and neck squamous cell carcinoma (HNSCC) and melanoma. Molecular analyses of the p16 gene locus in blood and tumor DNA from this family was performed to determine whether an association between germline p16 gene mutation and HNSCC exists.;Molecular pedigree analyses.;Exon 2 of p16 was polymerase chain reaction amplified from blood, tumor, or nontumor DNA isolated from affected and unaffected members, then directly sequenced and compared with consensus p16 sequence. Cell cycle position of cells expressing wild-type or mutant p16 was determined by flow cytometry.;Molecular analyses revealed a nonfunctional germline point mutation within exon 2 of the p16 gene that encodes a mutant p16 protein substituting proline at amino acid position 87 for the wild-type arginine (p16R87P). Relative to wild-type p16, p16R87P lost ability to cause a growth arrest following ectopic expression. The mutant (p16R87P) allele segregated with cancer predisposition in tested family members, and analyses of HNSCC tumor tissues demonstrated universal loss of wild-type allele.;Significance of the mutant p16 (p16R87P) in HNSCC tumorigenesis is strongly suggested by its loss of cell cycle arrest activity and its retention in tumor tissue with simultaneous loss of the wild-type allele. Further, the germline p16 mutation segregated with cancer predisposition within the family. In aggregate, these data suggest that there is a direct causal relationship between the germline p16 mutation in this family and HNSCC tumorigenesis. Based on our observations, the spectrum of familial cancers associated with p16 mutations should include a new clinical entity, familial HNSCC.",
        "Doc_title":"Familial head and neck cancer: molecular analysis of a new clinical entity.",
        "Journal":"The Laryngoscope",
        "Do_id":"12352668",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16",
        "Doc_meshdescriptors":"Alleles;Amino Acid Substitution;Carcinoma, Squamous Cell;Cyclin-Dependent Kinase Inhibitor p16;Exons;Family Health;Flow Cytometry;Gene Expression;Genes, Tumor Suppressor;Genetic Predisposition to Disease;Germ-Line Mutation;Head and Neck Neoplasms;Humans;Melanoma;Pedigree;Polymerase Chain Reaction",
        "Doc_meshqualifiers":"genetics;genetics;genetics",
        "_version_":1605915896560222208},
      {
        "Doc_abstract":"Approximately 8-12% of melanoma is inherited in an autosomal dominant fashion with variable penetrance. A chromosome 9p21 locus has been linked to this disease in 50-80% of affected families. CDKN2A (also known as P16, INK4, p16INK4A and MTS1) is allelic to this locus and encodes a cdk4/cdk6 kinase inhibitor that constrains cells from progressing through the G1 restriction point. Although germline CDKN2A coding mutations cosegregate with melanoma in 25-60% of families predisposed to the disease, there remains a number of mutation-negative families that demonstrate linkage of inherited melanoma to 9p21 markers. We show here that a subset of these kindreds possess a G-->T transversion at base -34 of CDKN2A, designated G-34T. This mutation gives rise to a novel AUG translation initiation codon that decreases translation from the wild-type AUG. The G-34T mutation is not seen in controls, segregates with melanoma in families and, on the basis of haplotyping studies, probably arose from a common founder in the United Kingdom. Characterization of this and other CDKN2A non-coding mutations should have an impact on current efforts to identify susceptible melanoma-prone families and individuals.",
        "Doc_title":"Mutation of the CDKN2A 5' UTR creates an aberrant initiation codon and predisposes to melanoma.",
        "Journal":"Nature genetics",
        "Do_id":"9916806",
        "Doc_ChemicalList":"5' Untranslated Regions;Codon, Initiator;Cyclin-Dependent Kinase Inhibitor p16;Guanine;Thymine",
        "Doc_meshdescriptors":"5' Untranslated Regions;Alleles;Cell Line, Transformed;Codon, Initiator;Cyclin-Dependent Kinase Inhibitor p16;Female;Genetic Predisposition to Disease;Guanine;Humans;Male;Melanoma;Mutation;Pedigree;Protein Biosynthesis;Thymine;Transcription, Genetic",
        "Doc_meshqualifiers":"genetics;genetics",
        "_version_":1605824180425588736},
      {
        "Doc_abstract":"Head and neck cancer is a frequent malignancy with a complex, and up to now not clear etiology. The reactivation of telomerase activity and losses or gains of specific chromosomal regions, which point to deletions of tumor suppressor genes or amplification of oncogenes are supposed to be the molecular processes during the development and progression of head and neck cancer. Therefore, we analyzed telomerase activity and microsatellite markers using a genome wide panel of 28 microsatellite markers in 38 head and neck squamous-cell carcinomas (HNSCC). Our microsatellite marker set included distinct chromosomal areas that all likely harbor genes contributing to the carcinogenesis of HNSCC. DNA or protein lysates were obtained from primary tumors and compared to peripheral lymphocytes or corresponding normal tissue. At least one genomic alteration [loss of heterozygosity (LOH), or microsatellite instability (MSI)] was found in 31 of the 38 cases (82%). Most frequently we detected an LOH in the chromosomal region 9p12-21 where at least the tumor suppressor genes (TSG) p16INK4A, p14ARF and p15INKB are localized. The comparison between grade two and grade three tumors showed a highly changed frequency of LOH in the chromosomal region 7q31, where a putative TSG is predicted. Telomerase activity was present in 31/37 (83.8%) tumor samples independent of the histopathological staging and grading of the tumors. These molecular characterizations of HNSCC may be a further hint for the involvement of additional, so far unknown, TSGs in the tumor progression and will elucidate the regulation of telomerase.",
        "Doc_title":"Molecular characterization of head and neck tumors by analysis of telomerase activity and a panel of microsatellite markers.",
        "Journal":"International journal of molecular medicine",
        "Do_id":"11891539",
        "Doc_ChemicalList":"Genetic Markers;Telomerase",
        "Doc_meshdescriptors":"Carcinoma, Squamous Cell;Genetic Markers;Head and Neck Neoplasms;Humans;Loss of Heterozygosity;Lymphocytes;Microsatellite Repeats;Telomerase",
        "Doc_meshqualifiers":"genetics;metabolism;genetics;metabolism;genetics;metabolism;genetics;metabolism",
        "_version_":1605824838792904704},
      {
        "Doc_abstract":"Although genetic alterations of chromosome band 9p21-22 occur frequently in head and neck squamous cell carcinoma (HNSCC) cell lines, alterations of the cyclin-dependent kinase inhibitor p16INK4a located in this region are less common in corresponding primary tumors. To further investigate genetic alterations at 9p21-22 and p16INK4a in primary HNSCC, a paired set of 21 tumors and blood specimens that were shown previously to exhibit allelic loss at 3p and elsewhere, were tested for LOH at 9p21-22 using eight different highly polymorphic marker. Sixteen of the samples (81%) exhibited LOH for at least one marker. Frequent LOH was found surrounding p16INK4a and at three additional non-contiguous regions of 9p21-22. No homozygous deletions were identified. SSCP screening and direct sequence analysis led to the identification of mutations the p16INK4a gene in two tumors. p16INK4a was not hypermethylated in any of the samples studied. Furthermore, there was no correlation between LOH at 9p21-22 and the RB1 tumor suppressor gene. These findings indicate that in the set of tumors that we tested, LOH at 9p21-22 is common in primary HNSCC but that genetic alterations of p16INK4a located in this region are unusual. Additional tumor suppressor genes at 9p21-22 may therefore be involved in the pathogenesis of this tumor.",
        "Doc_title":"Genetic alterations of chromosome band 9p21-22 in head and neck cancer are not restricted to p16INK4a.",
        "Journal":"Oncogene",
        "Do_id":"9349503",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;Retinoblastoma Protein",
        "Doc_meshdescriptors":"Carcinoma, Squamous Cell;Chromosome Mapping;Chromosomes, Human, Pair 9;Cyclin-Dependent Kinase Inhibitor p16;DNA Methylation;Head and Neck Neoplasms;Humans;Loss of Heterozygosity;Microsatellite Repeats;Polymorphism, Single-Stranded Conformational;Retinoblastoma Protein",
        "Doc_meshqualifiers":"genetics;genetics;genetics;genetics",
        "_version_":1605747055608725505},
      {
        "Doc_abstract":"The INK4A locus is often inactivated in human cancer. INK4A encodes for p14ARF and p16INK4A that inhibit growth through p53 and pRb, respectively. We used RNA interference vectors in transformation assays of human primary cells to analyze tumor-suppressive functions. We first show that a concerted inactivation of pRb and p53 is required for transformation. We then demonstrate that loss of p14ARF enhances growth in a p53-dependent manner but has little tumorigenic effect. In contrast, suppression of p16INK4A expression does not affect cellular proliferation but synergizes with p53 loss to accelerate growth and cause transformation. Our results delineate the functions of the human INK4A genes in normal and tumorigenic growth.",
        "Doc_title":"The tumor-suppressive functions of the human INK4A locus.",
        "Journal":"Cancer cell",
        "Do_id":"14585358",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;RNA, Small Interfering;Retinoblastoma Protein;Tumor Suppressor Protein p14ARF;Tumor Suppressor Protein p53",
        "Doc_meshdescriptors":"Cell Division;Cells, Cultured;Cyclin-Dependent Kinase Inhibitor p16;Fibroblasts;Gene Deletion;Genes, ras;HeLa Cells;Humans;Mutation;RNA, Small Interfering;Retinoblastoma Protein;Skin;Tumor Suppressor Protein p14ARF;Tumor Suppressor Protein p53",
        "Doc_meshqualifiers":"physiology;genetics;metabolism;metabolism;genetics;physiology;metabolism;metabolism;metabolism;genetics;metabolism;metabolism",
        "_version_":1605808558037794816},
      {
        "Doc_abstract":"The INK4 family of cyclin-dependent kinase inhibitors (CKI) encode important cell cycle regulators that tightly control cell cycle during G1 to S phase. These related genes are considered tumor suppressors as loss of function contributes to the malignant phenotype. Expression of CKIs p16, p14ARF, or p15 were defective in six different canine mammary tumor (CMT) cell lines compared to normal thoracic canine fibroblasts. This suggests CKI defects are frequently responsible for neoplastic transformation in canine mammary carcinomas. p16 and p14ARF are two alternatively spliced products derived from the canine p16/INK4A/p14ARF gene locus. Despite omissions in the published p16 transcript and canine genome and the presence of GC-rich repeats, we determined the complete coding sequence of canine p16 revealing a deletion and frameshift mutation in p16 exon 1 in CMT28 cells. In addition, we determined canine p14ARF mRNA and protein sequences. Mapping of these mutations uncovered important aspects of p16 and p14ARF expression and defects in CMT28 cells shifting the p16 reading frame into p14ARF making a fusion protein that was predicted to be truncated, unstable and devoid of structural and functional integrity. This data describes an important neoplastic mechanism in the p16/INK4A/p14ARF locus in a spontaneous canine model of breast cancer.",
        "Doc_title":"Novel frameshift mutation in the p16/INK4A tumor suppressor gene in canine breast cancer alters expression from the p16/INK4A/p14ARF locus.",
        "Journal":"Journal of cellular biochemistry",
        "Do_id":"22833492",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;Oncogene Proteins, Fusion;Tumor Suppressor Protein p14ARF",
        "Doc_meshdescriptors":"Alternative Splicing;Amino Acid Sequence;Animals;Carcinoma;Cell Line, Tumor;Cyclin-Dependent Kinase Inhibitor p16;Dogs;Exons;Female;Frameshift Mutation;Gene Expression;Genes, p16;Genetic Loci;Humans;Mammary Glands, Animal;Mammary Neoplasms, Experimental;Models, Molecular;Molecular Sequence Data;Oncogene Proteins, Fusion;Open Reading Frames;Sequence Homology, Amino Acid;Tumor Suppressor Protein p14ARF",
        "Doc_meshqualifiers":"genetics;metabolism;pathology;genetics;metabolism;metabolism;pathology;genetics;metabolism;pathology;genetics;metabolism;genetics;metabolism",
        "_version_":1605811317172600832},
      {
        "Doc_abstract":"In normal cells, p53 protein is maintained at low levels, but the levels increase after stress or inappropriate growth signals to coordinate growth arrest or apoptosis. Human mammary epithelial cells (HMECs) are unusual in that they exhibit two phases of growth. The second growth phase, referred to as post-selection, follows a period of temporary growth arrest and is characterized by the absence of p16(INK4a) (also known as CDK4I and p16-INK4a) expression. Previously, we observed that post-selection HMECs have elevated levels of p53. Exogenous p16(INK4a) expression decreased levels of both p53 transcript and protein, and this effect was inhibited by nutlin-3a, indicating that p16(INK4a) can regulate p53 expression by affecting both p53 transcription and Mdm2-dependent degradation of p53. The p53 in post-selection HMECs was wild type and, as expected, increased p53 expression was associated with elevated p21(WAF1/CIP1) and Mdm2 levels; the p53 response to DNA damage seemed normal. Despite elevated levels of wild-type p53 and p21(WAF1/CIP1), post-selection cells grew more rapidly than their pre-selection HMEC precursors. We found that the post-selection HMECs contain a truncated Mdm2 protein (p60), which presumably lacks the p53 ubiquitylation domain. We propose that the increased levels of p53 in post-selection HMECs are due to the presence of an Mdm2 fragment that binds p53 but does not result in its degradation.",
        "Doc_title":"Normal human mammary epithelial cells proliferate rapidly in the presence of elevated levels of the tumor suppressors p53 and p21(WAF1/CIP1).",
        "Journal":"Journal of cell science",
        "Do_id":"19638413",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;Cyclin-Dependent Kinase Inhibitor p21;Tumor Suppressor Protein p53;MDM2 protein, human;Proto-Oncogene Proteins c-mdm2",
        "Doc_meshdescriptors":"Cell Division;Cell Proliferation;Cyclin-Dependent Kinase Inhibitor p16;Cyclin-Dependent Kinase Inhibitor p21;DNA Damage;Epithelial Cells;Humans;Mammary Glands, Human;Models, Biological;Protein Processing, Post-Translational;Protein Stability;Proto-Oncogene Proteins c-mdm2;Transcription, Genetic;Tumor Suppressor Protein p53",
        "Doc_meshqualifiers":"metabolism;metabolism;cytology;metabolism;cytology;metabolism;genetics;metabolism",
        "_version_":1605775222799073280},
      {
        "Doc_abstract":"The ability to identify individuals at increased risk of cancer is of immediate clinical relevance. Germline mutations in the CDKN2A locus, encoding the key tumor suppressor proteins p16/INK4A and p14/ARF, are frequently present in kindreds with hereditary cutaneous melanoma but have seldom been reported in families with genetic susceptibility to head and neck squamous cell carcinomas (HNSCC).;We report the pedigree of a patient with an unusually high incidence of HNSCC and melanomas. CDKN2A mutation analysis was performed with standard capillary sequencing and multiplex ligation-dependent probe amplification.;A previously unreported germline CDKN2A mutation affecting only the p16/INK4A open reading frame, c.106delG (p.Ala36ArgfsX17), was detected in the proband. This mutation causes a premature termination codon.;Our report emphasizes the need to consider germinal CDKN2A mutations in the differential diagnosis of familial HNSCC and the importance of awareness of these tumors in carriers of CDKN2A mutations.",
        "Doc_title":"Novel germline CDKN2A mutation associated with head and neck squamous cell carcinomas and melanomas.",
        "Journal":"Head & neck",
        "Do_id":"22083977",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;Tumor Suppressor Proteins",
        "Doc_meshdescriptors":"Carcinoma, Squamous Cell;Cyclin-Dependent Kinase Inhibitor p16;Genes, p16;Genetic Testing;Germ-Line Mutation;Head and Neck Neoplasms;Humans;Male;Melanoma;Middle Aged;Pedigree;Tumor Suppressor Proteins",
        "Doc_meshqualifiers":"genetics;genetics;genetics;genetics;genetics",
        "_version_":1605928633071828992},
      {
        "Doc_abstract":"Epigenetic mechanisms such as DNA methylation play important role in cancer. Epigenetic alterations involved in the onset and progression of breast cancer may serve as biomarkers for early detection and prediction of disease prognosis. Furthermore, using body fluids such as serum offers a non-invasive method to procure multiple samples for biomarker analyses. The aim of this study is to determine the correlation between methylation status of multiple cancer genes, p16(INK4A), p14(ARF), Cyclin D2 and Slit2 in invasive ductal carcinoma of the breast and paired serum DNA and clinicopathological parameters. Of the 36 breast cancer patients investigated, 31 (86%) tumors and 30 (83%) paired sera showed methylation of at least one of these 4 genes. Methylation frequencies varied from 27% for CyclinD2, 44% for p16(INK4A), 47% for p14(ARF) to 58% for Slit2. There was concordance between DNA methylation in tumor and paired serum DNA of each gene. This study underscores the potential utility of DNA methylation based screening of serum as a surrogate marker for tumor DNA methylation status of these genes in breast cancer. Further, expression profile of p16(INK4A) could be linked to epigenetic events, thus suggesting this pathway as a potential target for therapeutic strategies based on reversal of epigenetic silencing.",
        "Doc_title":"Promoter hypermethylation of p16INK4A, p14ARF, CyclinD2 and Slit2 in serum and tumor DNA from breast cancer patients.",
        "Journal":"Life sciences",
        "Do_id":"17383681",
        "Doc_ChemicalList":"Biomarkers, Tumor;Cyclin-Dependent Kinase Inhibitor p16;DNA, Neoplasm;Intercellular Signaling Peptides and Proteins;Nerve Tissue Proteins;Slit homolog 2 protein;Tumor Suppressor Protein p14ARF;Cyclin-Dependent Kinase 2",
        "Doc_meshdescriptors":"Adult;Aged;Biomarkers, Tumor;Breast Neoplasms;Cyclin-Dependent Kinase 2;Cyclin-Dependent Kinase Inhibitor p16;DNA Methylation;DNA, Neoplasm;Female;Humans;Immunohistochemistry;Intercellular Signaling Peptides and Proteins;Middle Aged;Nerve Tissue Proteins;Promoter Regions, Genetic;Serum;Tumor Suppressor Protein p14ARF",
        "Doc_meshqualifiers":"blood;genetics;blood;diagnosis;genetics;metabolism;genetics;metabolism;metabolism;methods;genetics;metabolism;genetics;metabolism;physiology;chemistry;genetics;metabolism",
        "_version_":1605907308602195968},
      {
        "Doc_abstract":"Cell cycle progression from G(1) to S phase depends on phosphorylation of pRb by complexes containing a cyclin (D type or E type) and cyclin-dependent kinase (e.g., cdk2, cdk4, or cdk6). Ink4 proteins function to oppose the action of cdk4/6-cyclin D complexes by inhibiting cdk4/6. We employed genetic and pharmacologic approaches to study the interplay among Ink4 proteins and cdk4/6 activity in vivo. Mouse embryo fibroblasts (MEF) lacking p16(Ink4a) and p18(Ink4c) showed similar growth kinetics as wild-type MEFs despite increased cdk4 activity. In vivo, germline deficiency of p16(Ink4a) and p18(Ink4c) resulted in increased proliferation in the intermediate pituitary and pancreatic islets of adult mice, and survival of p16(Ink4a-/-);p18(Ink4c-/-) mice was significantly reduced due to aggressive pituitary tumors. Compensation among the Ink4 proteins was observed both in vivo in p18(Ink4c-/-) mice and in MEFs from p16(Ink4a-/-), p18(Ink4c-/-), or p16(Ink4a-/-);p18(Ink4c-/-) mice. Treatment with PD 0332991, a specific cdk4/6 kinase inhibitor, abrogated proliferation in those compartments where Ink4 deficiency was associated with enhanced proliferation (i.e., islets, pituitary, and B lymphocytes) but had no effect on proliferation in other tissues such as the small bowel. These data suggest that p16(Ink4a) and p18(Ink4c) coordinately regulate the in vivo catalytic activity of cdk4/6 in specific compartments of adult mice.",
        "Doc_title":"Expression of p16Ink4a compensates for p18Ink4c loss in cyclin-dependent kinase 4/6-dependent tumors and tissues.",
        "Journal":"Cancer research",
        "Do_id":"17510401",
        "Doc_ChemicalList":"Cdkn2c protein, mouse;Cyclin-Dependent Kinase Inhibitor p16;Cyclin-Dependent Kinase Inhibitor p18;Piperazines;Pyridines;Cyclin-Dependent Kinase 5;Cyclin-Dependent Kinase 6;palbociclib",
        "Doc_meshdescriptors":"Animals;Cell Growth Processes;Cell Transformation, Neoplastic;Cyclin-Dependent Kinase 5;Cyclin-Dependent Kinase 6;Cyclin-Dependent Kinase Inhibitor p16;Cyclin-Dependent Kinase Inhibitor p18;Embryo, Mammalian;Fibroblasts;Mice;Mice, Transgenic;Piperazines;Pituitary Neoplasms;Pyridines",
        "Doc_meshqualifiers":"physiology;genetics;metabolism;antagonists & inhibitors;metabolism;antagonists & inhibitors;metabolism;biosynthesis;deficiency;genetics;metabolism;deficiency;genetics;metabolism;cytology;enzymology;physiology;pharmacology;enzymology;genetics;pathology;pharmacology",
        "_version_":1605746809297174528},
      {
        "Doc_abstract":"The INK4A gene which codes for the cyclin-dependent kinase (CDK) inhibitor INK4A or p16 underlies susceptibility to melanoma in some families. Germline mutations in the gene that codes for the target protein of p16, CDK4, underlie susceptibility in very rare families. We report mutation screening of the INK4A and CDK4 genes in 42 UK families. A total of nine families were identified with INK4A mutations and none with CDK4 exon 2 mutations. These mutations were in 8/22 (35%) families with three or more cases of melanoma and 1/20 (5%) families with only two cases. In one of these nine families a novel single base pair substitution was identified, Gly67Arg. In an attempt to identify another melanoma susceptibility gene, a member of the INK4 family, the p19 INK4D gene has been studied. The p19 gene was sequenced in DNA from the 42 UK families and six additional US families. No mutations were identified.",
        "Doc_title":"Mutation testing in melanoma families: INK4A, CDK4 and INK4D.",
        "Journal":"British journal of cancer",
        "Do_id":"10390011",
        "Doc_ChemicalList":"CDKN2D protein, human;Carrier Proteins;Cell Cycle Proteins;Cyclin-Dependent Kinase Inhibitor p16;Cyclin-Dependent Kinase Inhibitor p19;Proto-Oncogene Proteins;CDK4 protein, human;Cyclin-Dependent Kinase 4;Cyclin-Dependent Kinases",
        "Doc_meshdescriptors":"Carrier Proteins;Cell Cycle Proteins;Cyclin-Dependent Kinase 4;Cyclin-Dependent Kinase Inhibitor p16;Cyclin-Dependent Kinase Inhibitor p19;Cyclin-Dependent Kinases;Humans;Melanoma;Mutation;Pedigree;Proto-Oncogene Proteins",
        "Doc_meshqualifiers":"genetics;genetics;antagonists & inhibitors;genetics;genetics",
        "_version_":1605801187109502976},
      {
        "Doc_abstract":"Androgen receptor (AR) signaling is essential for prostate cancer (PCa) development in humans. The initiation of prostate malignancy and progression to a castration-resistant stage are largely contributed by the modulation of AR activity through its coregulatory proteins. We and others previously reported that p14 alternative reading frame (ARF) expression is positively correlated with the disease progression and severity of PCa. Here, we provide evidence that p14ARF physically interacts with AR and functions as an AR corespressor in both an androgen-dependent and androgen-independent manner. Endogenous ARF (p14ARF in human and p19ARF in mouse) and AR colocalize in both human PCa cells in vitro and PCa tissues of mouse and human in vivo. Overexpression of p14ARF in PCa cells significantly attenuates the activities of androgen response region (ARR2)-probasin and prostate-specific antigen (PSA) promoters. The forced expression of p14ARF in cells resulted in a suppression of PSA and NK transcription factor locus 1 (NKX3.1) expression. Conversely, knockdown of endogenous p14ARF in human PCa cells with short hairpin RNA enhanced AR transactivation activities in a dose-dependent and p53-independent manner. Furthermore, we demonstrated that p14ARF binds to both the N-terminal domain and the ligand-binding domain of AR, and the human double minute 2 (HDM2)-binding motif of p14ARF is required for the interaction of p14ARF and AR proteins. p14ARF perturbs the androgen-induced interaction between the N terminus and C terminus of AR. Most importantly, we observed that the expression of PSA is reversely correlated with p14ARF in human prostate tissues. Taken together, our results reveal a novel function of ARF in modulation of AR transactivation in PCa.",
        "Doc_title":"ARF represses androgen receptor transactivation in prostate cancer.",
        "Journal":"Molecular endocrinology (Baltimore, Md.)",
        "Do_id":"23449888",
        "Doc_ChemicalList":"Homeodomain Proteins;Receptors, Androgen;Repressor Proteins;Tumor Suppressor Protein p14ARF;Prostate-Specific Antigen",
        "Doc_meshdescriptors":"Amino Acid Motifs;Amino Acid Sequence;Animals;Cell Line, Tumor;Cell Nucleus;Down-Regulation;Gene Expression Regulation, Neoplastic;Gene Knockdown Techniques;HEK293 Cells;Homeodomain Proteins;Humans;Male;Mice;Molecular Sequence Data;Prostate;Prostate-Specific Antigen;Prostatic Neoplasms;Protein Binding;Protein Transport;Receptors, Androgen;Repressor Proteins;Transcriptional Activation;Tumor Suppressor Protein p14ARF",
        "Doc_meshqualifiers":"metabolism;genetics;metabolism;metabolism;pathology;metabolism;genetics;pathology;chemistry;genetics;metabolism;metabolism;genetics;chemistry;metabolism",
        "_version_":1605812142697611264},
      {
        "Doc_abstract":"p16(INK4A) expression has been used as a surrogate marker for human papillomavirus (HPV) infection in cervical cancer and head and neck cancer. p53 has also been reported as a feasible marker to identify HPV-positive oropharyngeal carcinoma and penile lesions. This study aimed to investigate p16(INK4A) and p53 expression levels and their correlation with HPV status and clinical parameters in Kazakh patients with esophageal squamous cell carcinoma.;Immunohistochemical expression of p16 (INK4A) and p53 were evaluated in 163 cases of esophageal squamous cell carcinoma in Kazakh patients. The presence of HPV DNA was detected by polymerase chain reaction.;p16 (INK4A) -positive expression was detected in 19.0% of patients, and its expression was significantly correlated with a lower frequency of lymph node metastasis (p=0.038). By contrast no significant association was found between p16 (INK4A) -positive expression and HPV status (correlation coefficient=-0.062, p=0.499). p16 (INK4A) -positive expression did not affect the odds of tumors being HPV positive (odds ratio [OR]=0.727 with 95% confidence interval [CI]=0.288-1.836). The sensitivity of p16 (INK4A) -positive expression as an HPV marker was 0.164, with a specificity of 0.788 and a positive predictive value of 0.391. p53-positive expression was present in 88.3% of all cases. Although no significant correlation with available clinical parameters was found, a significantly inverse correlation was observed between p53 expression and HPV status (correlation coefficient=-0.186, p=0.039). Moreover, p53-positive expression decreased the odds of tumors being HPV positive (OR=0.292 with 95% CI=0.086-0.990). The sensitivity of p53-negative expression as an HPV marker was 0.179, with a specificity of 0.940 and a positive predictive value of 0.714. The overall HPV prevalence was high (45.5%) in Kazakh patients, with no significant association between HPV positivity and available clinical parameters or combined p16 (INK4A) /p53 expression.;p16 (INK4A) -positive expression was associated with lymph node metastasis. Results indicate that p53-negative expression and not p16 (INK4A) -positive expression may be used as a marker for HPV status in ESCC; however, this finding requires further studies for validation.",
        "Doc_title":"p53 expression but not p16(INK4A) correlates with human papillomavirus-associated esophageal squamous cell carcinoma in Kazakh population.",
        "Journal":"Infectious agents and cancer",
        "Do_id":"27076841",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605808012392398848},
      {
        "Doc_abstract":"Inactivation of the P16 (INK4A)/retinoblastoma (RB) or TP53 biochemical pathway is frequent event in most human cancers. Recent evidence has shown that P14ARF binds to MDM2 leading to an increased availability of wild type TP53 protein. Functional studies also support a putative tumor suppressor gene function for p14ARF suggesting that p14ARF or p53 inactivation may be functionally equivalent in tumorigenesis. To study the relative contribution of each pathway in tumorigenesis, we analysed and compared alterations of the p16, p14ARF and p53 genes in 38 primary non-small cell lung cancers (NSCLCs) (19 adenocarcinomas and 19 squamous carcinoma). The p16 tumor suppressor gene was inactivated in 22 of 38 (58%) tumors. Twelve of these samples (31%) had homozygous deletions by microsatellite analysis; eight of them (21%) had p16 promoter hypermethylation detected by Methylation Specific PCR (MSP) and the remaining two (5%) harbored a point mutation in exon 2 by sequence analysis. The absence of P16 protein in every case was confirmed by immunohistochemistry. Fourteen of the 22 tumors with p16 inactivation also inactivated the p14ARF gene (12 with homozygous deletions extending into INK4a/ARF and two with exon 2 mutations). Mutations of p53 were found in 18 (47%) of the tumors and nine of them (50%) harbored p14ARF inactivation. Thus, an inverse correlation was not found between p14ARF and p53 genetic alterations (P=0.18; Fisher Exact Test). Our data confirm that the p16 gene is frequently inactivated in NSCLC. Assuming that 9p deletion occurs first, the common occurrence of p53 and p14ARF alterations suggests that p14ARF inactivation is not functionally equivalent to abrogation of the TP53 pathway by p53 mutation.",
        "Doc_title":"Inactivation of the INK4A/ARF locus frequently coexists with TP53 mutations in non-small cell lung cancer.",
        "Journal":"Oncogene",
        "Do_id":"10557071",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;Proteins;Tumor Suppressor Protein p14ARF;Tumor Suppressor Protein p53",
        "Doc_meshdescriptors":"Carcinoma, Non-Small-Cell Lung;Cyclin-Dependent Kinase Inhibitor p16;Humans;Lung Neoplasms;Mutation;Proteins;Tumor Suppressor Protein p14ARF;Tumor Suppressor Protein p53",
        "Doc_meshqualifiers":"genetics;pathology;genetics;genetics;pathology;genetics;genetics",
        "_version_":1605818658183970816},
      {
        "Doc_abstract":"The tumor suppressor gene CDKN2A (p16/MTS1/INK4A), which encodes the cyclin-dependent kinase inhibitor p16(INK4a), is a target of 9p21 deletions during the malignant progression of human gliomas. This gene also encodes a second protein product (human p16beta, murine p19ARF), which originates from an unrelated exon of CDKN2A (exon 1beta) spliced onto exon 2 in an alternate reading frame. Cell cycle arrest by p16beta is caused by an as yet unidentified pathway. In order to test the candidacy of p16beta as a glioma suppressor, we replaced p16(INK4a), p15(INK4b) and p16beta wild-type as well as a series of seven glioma-derived p16beta alleles (R87H, A112V, R120H, A121V, G125R, A128A and A128V), into glioma cell lines that had either CDKN2A-/RB+ (U-87MG and U-251MG) or CDKN2A+/RB- (LN-319) endogenous backgrounds and demonstrated that p16beta can act as a functional glioma cell growth suppressor. Moreover, p16beta, but not p16(INK4a) or p15(INK4b) inhibited the growth of RB-negative LN-319 cells, indicating that p16beta likely exerts its effects through an RB-independent pathway. In vitro and in vivo assays of pRB phosphorylation were consistent with this interpretation. Since none of the glioma-derived p16beta mutations inactivated their growth suppressive activities, it appears that mutations in CDKN2A exon 2 (which is shared in the coding sequences of p16(INK4a) and p16beta) likely exclusively target p16(INK4a).",
        "Doc_title":"Functional analysis of wild-type and malignant glioma derived CDKN2Abeta alleles: evidence for an RB-independent growth suppressive pathway.",
        "Journal":"Oncogene",
        "Do_id":"9366518",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;Retinoblastoma Protein",
        "Doc_meshdescriptors":"Alleles;Cell Division;Chromosome Deletion;Chromosomes, Human, Pair 9;Cyclin-Dependent Kinase Inhibitor p16;Genes, Tumor Suppressor;Genetic Vectors;Glioma;Humans;Phosphorylation;Point Mutation;Retinoblastoma Protein;Transfection;Tumor Cells, Cultured",
        "Doc_meshqualifiers":"genetics;genetics;antagonists & inhibitors;genetics;physiology;genetics;physiology;genetics;genetics;pathology;genetics;metabolism",
        "_version_":1605909330808274944},
      {
        "Doc_abstract":"Oral squamous cell carcinoma is a major cause of death throughout the developed world. It is associated with smoking and alcohol consumption. Human papillomavirus (HPV) type 16 has also been suggested to play a role in etiology of head and neck squamous cell carcinoma (HNSCC). p16 expression is now being used as a surrogate marker of HPV infection in squamous cell carcinoma and provides important prognostic information and future therapy planning.;In this prospective study, total of 75 cases of HNSCC were taken. Tumor grade was determined according to World Health Organization (WHO) criteria. p16 expression was determined by immunohistochemical staining. The obtained results were analyzed and evaluated using Chi-square test (Statistical Package for Social Sciences (SPSS) version 20), value of P <0.05 was taken significant.;Out of 75 cases, 78.7% cases were positive for p16 (inclusive of all grades), while 21.3% cases were negative. Expression of p16 was higher in nonsmokers and nonalcohol consumers and significantly associated with paan chewing habit. No significant correlation was seen with history of abnormal sexual habits, but p16 expression was significantly correlated in cases with multiple sexual partners (P = 0.003), with increasing histological grade (P = 0.045) and in cases with lymph node metastasis (P = 0.03).;As HPV integration with transcription of viral oncoprotein induces overexpression of p16, immunohistochemical expression of p16 can be used as a surrogate marker of HPV. This approach can be implemented in diagnostic laboratories and can provide support for vaccination program in high risk group.",
        "Doc_title":"Assessment and clinicopathological correlation of p16 expression in head and neck squamous cell carcinoma.",
        "Journal":"Journal of cancer research and therapeutics",
        "Do_id":"27072243",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605892178985353216},
      {
        "Doc_abstract":"Hypoxia-inducible factor-1 (HIF1), a master transcriptional regulator of the cellular and systemic hypoxia response, is essential for the maintenance of self-renewal capacity of normal HSCs. It is still unknown whether HIF1 has a role in survival regulation of leukemia stem cells (LSCs) in chronic myeloid leukemia (CML). Using a mouse model of CML, here we report that HIF1 plays a crucial role in survival maintenance of LSCs. Deletion of HIF1 impairs the propagation of CML through impairing cell-cycle progression and inducing apoptosis of LSCs. Deletion of HIF1 results in elevated expression of p16(Ink4a) and p19(Arf) in LSCs, and knockdown of p16(Ink4a) and p19(Arf) rescues the defective colony-forming ability of HIF1(-/-) LSCs. Compared with normal HSCs, LSCs appear to be more dependent on the HIF1 pathway. Together, these results demonstrate that HIF1 represents a critical pathway in LSCs and inhibition of the HIF1 pathway provides a therapeutic strategy for eradicating LSCs in CML.",
        "Doc_title":"HIF1 is required for survival maintenance of chronic myeloid leukemia stem cells.",
        "Journal":"Blood",
        "Do_id":"22275380",
        "Doc_ChemicalList":"Biomarkers;Cdkn2a protein, mouse;Cyclin-Dependent Kinase Inhibitor p16;Hif1a protein, mouse;Hypoxia-Inducible Factor 1, alpha Subunit;RNA, Messenger",
        "Doc_meshdescriptors":"Animals;Apoptosis;Biomarkers;Blotting, Western;Bone Marrow Transplantation;Cell Cycle;Cell Proliferation;Cyclin-Dependent Kinase Inhibitor p16;Flow Cytometry;Gene Expression Profiling;Hypoxia;Hypoxia-Inducible Factor 1, alpha Subunit;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Mice;Mice, Inbred C57BL;Mice, Knockout;Neoplastic Stem Cells;Oligonucleotide Array Sequence Analysis;RNA, Messenger;Real-Time Polymerase Chain Reaction;Reverse Transcriptase Polymerase Chain Reaction;Survival Rate",
        "Doc_meshqualifiers":"metabolism;antagonists & inhibitors;genetics;metabolism;metabolism;pathology;physiology;metabolism;mortality;pathology;metabolism;pathology;genetics",
        "_version_":1605842674138480640},
      {
        "Doc_abstract":"Although the exact molecular mechanisms of Merkel cell carcinoma (MCC) tumorigenesis are unknown, they likely involve complex genetic alterations and mutations similar to those seen in many other cancers. In this study, we obtained MCCs from 21 elderly patients (19 women, 2 men) and analyzed their DNA for mutation of exons of interest in several tumor-suppressor genes or oncogenes known to be frequently mutated in skin cancer: p53 (exons 4-8), Ras (exons 1 and 2), c-Kit (exon 11), and the INK4a-ARF locus (encoding p14 and p16) (exons 1 and 2). Direct sequence analysis revealed p53 mutations (that is, at codons 224, 234, and 294) in three tumors (14%) and p16INK4a mutations (that is, at codon 6) in one (5%). No mutations were detected in Ha-Ras, Ki-Ras, N-Ras, c-Kit, or p14ARF. On the other hand, methylation-specific PCR revealed methylation of p14ARF promoter DNA in eight of 19 analyzable tumor samples (42%) and p16INK4a promoter DNA in one of 19 analyzable tumor samples (5%). Together, these findings suggest that p14ARF silencing may be an important mechanism in MCC tumorigenesis, and thus a potential target for therapeutic intervention in this highly aggressive tumor type.",
        "Doc_title":"p14ARF hypermethylation is common but INK4a-ARF locus or p53 mutations are rare in Merkel cell carcinoma.",
        "Journal":"The Journal of investigative dermatology",
        "Do_id":"18219279",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;Tumor Suppressor Protein p14ARF;Proto-Oncogene Proteins c-kit",
        "Doc_meshdescriptors":"Aged;Aged, 80 and over;Carcinoma, Merkel Cell;Chromosome Mapping;Cyclin-Dependent Kinase Inhibitor p16;DNA Methylation;Female;Genes, p53;Genes, ras;Humans;Immunohistochemistry;Male;Mutation;Promoter Regions, Genetic;Proto-Oncogene Proteins c-kit;Skin Neoplasms;Tumor Suppressor Protein p14ARF",
        "Doc_meshqualifiers":"genetics;analysis;genetics;genetics;genetics;analysis;genetics",
        "_version_":1605798341813207040},
      {
        "Doc_abstract":"Unknown mechanisms govern degradation of the p19Arf tumor suppressor, an activator of p53 and inhibitor of ribosomal RNA processing. Kinetic metabolic labeling of cells with [3H]-leucine indicated that p19Arf is a relatively stable protein (half-life approximately 6 h) whose degradation depends upon the ubiquitin-proteasome pathway. Although p19Arf binds to the Mdm2 E3 ubiquitin protein ligase to activate p53, neither of these molecules regulates p19Arf turnover. In contrast, the nucleolar protein nucleophosmin/B23, which binds to p19Arf with high stoichiometry, retards its turnover, and Arf mutants that do not efficiently associate with nucleophosmin/B23 are unstable and functionally impaired. Mouse p19Arf, although highly basic (22% arginine content), contains only a single lysine residue absent from human p14ARF, and substitution of arginine for lysine in mouse p19Arf had no effect on its rate of degradation. Mouse p19Arf (either wild-type or lacking lysine) and human p14ARF undergo N-terminal polyubiquitination, a process that has not as yet been documented in naturally occurring lysine-less proteins. Re-engineering of the p19Arf N terminus to provide consensus sequences for N-acetylation limited Arf ubiquitination and decelerated its turnover.",
        "Doc_title":"N-terminal polyubiquitination and degradation of the Arf tumor suppressor.",
        "Journal":"Genes & development",
        "Do_id":"15289458",
        "Doc_ChemicalList":"Cdkn2a protein, mouse;Cyclin-Dependent Kinase Inhibitor p16;Multienzyme Complexes;Nuclear Proteins;Proto-Oncogene Proteins;Tumor Suppressor Protein p14ARF;Tumor Suppressor Protein p53;Ubiquitin;nucleophosmin;MDM2 protein, human;Mdm2 protein, mouse;Proto-Oncogene Proteins c-mdm2;Ubiquitin-Protein Ligases;Cysteine Endopeptidases;Proteasome Endopeptidase Complex;Leucine",
        "Doc_meshdescriptors":"Acetylation;Amino Acid Sequence;Animals;Cyclin-Dependent Kinase Inhibitor p16;Cysteine Endopeptidases;Genes, Tumor Suppressor;Genes, p16;Humans;Leucine;Mice;Molecular Sequence Data;Multienzyme Complexes;Mutation;NIH 3T3 Cells;Nuclear Proteins;Proteasome Endopeptidase Complex;Proto-Oncogene Proteins;Proto-Oncogene Proteins c-mdm2;Tumor Suppressor Protein p14ARF;Tumor Suppressor Protein p53;Ubiquitin;Ubiquitin-Protein Ligases",
        "Doc_meshqualifiers":"metabolism;physiology;physiology;metabolism;metabolism;genetics;metabolism;metabolism;metabolism;metabolism;metabolism;metabolism",
        "_version_":1605747528256454656},
      {
        "Doc_abstract":"The p16(INK4a) protein inhibits cyclin-dependent kinase 4, a key regulator of progression through the G(1) phase of the cell cycle. Methylation of CpG islands in the promoter region is an important avenue for inactivation of p16. The mechanism of methylation of the p16 promoter region, however, has not been elucidated. Recent reports investigating p16 methylation in non-small cell lung cancer (NSCLC) suggest that carcinogens in tobacco smoke induce the DNA methylation process. We investigated the association between methylation of the p16 promoter region and exposure to tobacco smoke in 185 primary NSCLCS: We also studied the relationship of p16 methylation with mutation of the K-ras and p53 genes, as well as with methylation at the DAP-kinase and p14(ARF) loci. Finally, we evaluated the prognostic significance of p16 methylation in NSCLC. The prevalence of p16 methylation was greater in squamous cell carcinoma (41%) compared with adenocarcinoma (22%; P = 0.03; Fisher's exact test). Methylation of p16 was significantly associated with pack-years smoked (P = 0.007; Wilcoxon rank sum test), duration of smoking (P = 0.0009; Wilcoxon rank sum test), and negatively with the time since quitting smoking (P = 0.03; Wilcoxon rank sum test). No methylation of the nearby p14(ARF) locus was detected, and methylation of the DAP-kinase locus was not associated with either p16 methylation or with exposure to tobacco smoke. In patients with stage 1 adenocarcinoma, p16 methylation was an independent risk factor predicting significantly shorter postsurgery survival (P = 0.03), controlling for the significant effects of other factors, including K-ras mutation. These findings suggest that methylation of CpG islands in tobacco-associated cancers occurs in a gene- and tissue-specific manner and is induced directly or indirectly by exposure to tobacco smoke in NSCLC.",
        "Doc_title":"p16(INK4a) and histology-specific methylation of CpG islands by exposure to tobacco smoke in non-small cell lung cancer.",
        "Journal":"Cancer research",
        "Do_id":"11309302",
        "Doc_ChemicalList":"Apoptosis Regulatory Proteins;Cyclin-Dependent Kinase Inhibitor p16;Proteins;Tumor Suppressor Protein p14ARF;Death-Associated Protein Kinases;Calcium-Calmodulin-Dependent Protein Kinases",
        "Doc_meshdescriptors":"Aged;Apoptosis Regulatory Proteins;Calcium-Calmodulin-Dependent Protein Kinases;Carcinoma, Non-Small-Cell Lung;CpG Islands;Cyclin-Dependent Kinase Inhibitor p16;DNA Methylation;Death-Associated Protein Kinases;Female;Gene Expression Regulation, Neoplastic;Gene Silencing;Genes, p16;Genes, p53;Genes, ras;Humans;Lung Neoplasms;Male;Polymerase Chain Reaction;Polymorphism, Single-Stranded Conformational;Prognosis;Promoter Regions, Genetic;Proteins;Smoking;Tumor Suppressor Protein p14ARF",
        "Doc_meshqualifiers":"genetics;genetics;pathology;genetics;pathology;genetics;adverse effects;genetics",
        "_version_":1605742746660765696},
      {
        "Doc_abstract":"Human papillomavirus (HPV) is a basic risk factor for head and neck squamous cell carcinoma (HNSCC). Little knowledge exists about the impact of HPV on clinical diagnostic and therapy of patients with HNSCC.;We evaluated the evidence of HPV16 in 131 retrospectively collected HNSCC and associated cervical lymph node metastases by HPV16 real-time polymerase chain reaction (PCR) and p16 immunohistochemistry and its impact on clinicopathological characteristics.;HPV16-DNA and p16 overexpression were present in 27% of HNSCCs. All cervical lymph node metastases of HPV16-positive HNSCC showed HPV16-DNA. HPV16 was strongly associated with tumors arising from the oropharyngeal site (p < .000001), favorable outcome after standard therapy in univariate (p = .001) and multivariate (p = .0004) analysis, and cervical lymph node metastases before primary detection.;HPV16-diagnostic in cervical lymph node metastases can predict the site of tumor origin in case of carcinoma of unknown primary (CUP) and favorable outcome and should, therefore, be included in routine diagnostic workup.",
        "Doc_title":"Prevalence and impact on clinicopathological characteristics of human papillomavirus-16 DNA in cervical lymph node metastases of head and neck squamous cell carcinoma.",
        "Journal":"Head & neck",
        "Do_id":"20737490",
        "Doc_ChemicalList":"DNA, Viral",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Carcinoma;Carcinoma, Squamous Cell;Cohort Studies;DNA, Viral;Female;Head and Neck Neoplasms;Human papillomavirus 16;Humans;Immunohistochemistry;Kaplan-Meier Estimate;Lymph Nodes;Lymphatic Metastasis;Male;Middle Aged;Neck;Neoplasms, Squamous Cell;Papillomavirus Infections;Prevalence;Prognosis;Proportional Hazards Models;Retrospective Studies;Reverse Transcriptase Polymerase Chain Reaction;Risk Assessment;Statistics, Nonparametric;Survival Analysis;Tumor Cells, Cultured",
        "Doc_meshqualifiers":"epidemiology;pathology;secondary;virology;analysis;epidemiology;mortality;pathology;secondary;virology;genetics;isolation & purification;pathology;virology;epidemiology;pathology;secondary;virology;diagnosis;epidemiology",
        "_version_":1605766937837568000},
      {
        "Doc_abstract":"The tumor suppressor p16(INK4a) has been shown to be inactivated in numerous cancer lines and primary tumors. Recently, we reported loss of heterozygosity of the region in which p16(INK4a) is located in more than one-half of primary breast tumors. However, mutational analysis of these same tumors revealed mutation of p16(INK4a) to be infrequent. Other possible modes of inactivation, such as de novo methylation and homozygous deletion, have since been shown to occur in numerous neoplasias. Furthering the complexity of this locus, a transcript overlapping the p16(INK4a) coding sequence and encoding a novel peptide with growth-suppressive activity, p19(ARF), has been described. To clearly elucidate the target of aberrations affecting this subchromosomal region and approximate frequency in breast cancer, we performed a comprehensive study including p16 deletion analysis by means of interphase chromosomal fluorescence in situ hybridization, methylation analysis of the first exon encoding p16(INK4a) (exon 1alpha), mutational analysis of exon 1beta by single-strand conformational polymorphism analysis of p19(ARF) transcripts, and expression of both alpha and beta transcripts by reverse transcription PCR. Homozygous deletion of p16, as determined by interphase chromosomal fluorescence in situ hybridization, was observed in 3 of 18 (17%) tumors analyzed, whereas de novo methylation of exon 1alpha was observed in an additional 17% (4 of 23). Reduced expression of p16(INK4a) was observed in 11 tumors (48%), including all those in which homozygous deletion or complete methylation was observed. No mutations of exon 1 beta were detected, and expression of its transcript was variable, with 13% demonstrating decreased expression and 17% demonstrating overexpression. These results further support p16(INK4a) as a target of inactivation in the 9p21 region for breast cancer.",
        "Doc_title":"Preferential loss of expression of p16(INK4a) rather than p19(ARF) in breast cancer.",
        "Journal":"Clinical cancer research : an official journal of the American Association for Cancer Research",
        "Do_id":"9816158",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;Proteins;RNA, Messenger;Tumor Suppressor Protein p14ARF",
        "Doc_meshdescriptors":"Breast Neoplasms;Cyclin-Dependent Kinase Inhibitor p16;DNA Methylation;DNA Mutational Analysis;Exons;Female;Gene Dosage;Gene Expression Regulation, Neoplastic;Humans;In Situ Hybridization, Fluorescence;Loss of Heterozygosity;Polymorphism, Single-Stranded Conformational;Proteins;RNA, Messenger;Reverse Transcriptase Polymerase Chain Reaction;Tumor Suppressor Protein p14ARF",
        "Doc_meshqualifiers":"genetics;genetics;genetics;genetics;metabolism",
        "_version_":1605800804565909504},
      {
        "Doc_abstract":"Human papillomavirus (HPV)-associated head and neck squamous cell carcinoma (HNSCC) accounts for up to 25% of all HNSCCs. These tumors largely arise from the oropharynx, particularly the tonsil and base of tongue. The first manifestation of HPV-associated HNSCC is frequently as metastasis to cervical lymph nodes that can be documented by fine-needle aspiration. These metastases are often cystic with a predominantly non-keratinizing, basaloid morphology. Knowledge of the HPV status of metastatic HNSCC has significant treatment and prognostic implications as HPV-associated tumors have a more favorable prognosis than conventional HNSCC. Accordingly, HPV testing should be performed on any squamous cell carcinoma of unknown primary identified in neck lymph nodes. HPV detection may be performed using a variety of methods including p16 as a surrogate immunohistochemical marker, in situ hybridization and/or polymerase chain reaction detection of viral DNA or RNA. Further investigation is needed to determine the optimal method for HPV detection in fine-needle aspiration specimens. Cytology screening for HPV-associated HNSCC does not appear to be effective. Greater understanding of the natural history of oral HPV infections is needed before knowing if oral HPV testing may be useful as a screening test.",
        "Doc_title":"Role of cytology in the diagnosis and management of HPV-associated head and neck carcinoma.",
        "Journal":"Acta cytologica",
        "Do_id":"23406782",
        "Doc_ChemicalList":"DNA, Viral;RNA, Viral",
        "Doc_meshdescriptors":"Biopsy, Fine-Needle;Carcinoma, Squamous Cell;Cytodiagnosis;DNA, Viral;Female;Head and Neck Neoplasms;Human Papillomavirus DNA Tests;Humans;Immunohistochemistry;In Situ Hybridization;Lymph Nodes;Lymphatic Metastasis;Male;Papillomaviridae;Papillomavirus Infections;Polymerase Chain Reaction;Predictive Value of Tests;Prognosis;RNA, Viral",
        "Doc_meshqualifiers":"diagnosis;secondary;virology;methods;isolation & purification;diagnosis;pathology;virology;pathology;virology;genetics;isolation & purification;diagnosis;virology;isolation & purification",
        "_version_":1605759021661290496},
      {
        "Doc_abstract":"Cyclin-dependent kinase inhibitors p16(INK4a), p21(Cip1), and p27(Kip1) are regarded as key effectors of cellular senescence. In this review, we describe three senescence-inducing pathways involving these inhibitors, namely, the p16(INK4a)/Rb pathway, the p19(ARF)/p53/p21(Cip1) pathway, and the PTEN/p27(Kip1) pathway. We emphasize the participation of tumor suppressors and oncogenes in the regulation of these senescence-inducing pathways. Finally, we discuss the impact of the Ras and Myc oncogenes on the above-mentioned pathways.",
        "Doc_title":"Tumor suppressors and oncogenes in cellular senescence.",
        "Journal":"Experimental gerontology",
        "Do_id":"10832053",
        "Doc_ChemicalList":"CDKN1A protein, human;Cell Cycle Proteins;Cyclin-Dependent Kinase Inhibitor p16;Cyclin-Dependent Kinase Inhibitor p21;Cyclins;Enzyme Inhibitors;Microtubule-Associated Proteins;Proteins;Retinoblastoma Protein;Tumor Suppressor Protein p14ARF;Tumor Suppressor Protein p53;Tumor Suppressor Proteins;Cyclin-Dependent Kinase Inhibitor p27;Cyclin-Dependent Kinases;Phosphoric Monoester Hydrolases;PTEN Phosphohydrolase;PTEN protein, human",
        "Doc_meshdescriptors":"Animals;Apoptosis;Cell Aging;Cell Cycle Proteins;Cyclin-Dependent Kinase Inhibitor p16;Cyclin-Dependent Kinase Inhibitor p21;Cyclin-Dependent Kinase Inhibitor p27;Cyclin-Dependent Kinases;Cyclins;Enzyme Inhibitors;Genes, Retinoblastoma;Genes, Tumor Suppressor;Genes, myc;Genes, p53;Genes, ras;Humans;Microtubule-Associated Proteins;Oncogenes;PTEN Phosphohydrolase;Phosphoric Monoester Hydrolases;Proteins;Retinoblastoma Protein;Tumor Suppressor Protein p14ARF;Tumor Suppressor Protein p53;Tumor Suppressor Proteins",
        "Doc_meshqualifiers":"genetics;genetics;physiology;physiology;antagonists & inhibitors;physiology;metabolism;physiology;physiology;physiology;physiology;physiology",
        "_version_":1605799611664957440},
      {
        "Doc_abstract":"Human papillomavirus (HPV) is a risk factor for the development of benign and malignant mucosal head and neck lesions. P16(INK4A) is often used as a surrogate marker for HPV-infection, although there is still controversy with respect its reliability. Our aim was to determine if p16(INK4A) overexpression can accurately predict both high-risk and low-risk-HPV-presence in (pre)malignant and benign head and neck lesions. P16(INK4A) immunohistochemistry was performed on paraffin-embedded tissue sections of 162 oropharyngeal squamous cell carcinomas (OPSCC), 14 tonsillar and 23 laryngeal dysplasias, and 20 tonsillar and 27 laryngeal papillomas. PCR, enzyme-immunoassay and FISH analysis were used to assess HPV-presence and type. Of the 162 OPSCC and 14 tonsillar dysplasias, 51 (31%) and 10 (71%) were HPV16-positive, respectively. All tonsillar papillomas were HPV-negative and four laryngeal dysplasias and 26 laryngeal papillomas were positive for HPV6 or -11. P16(INK4A) immunohistochemistry revealed a strong nuclear and cytoplasmic staining in 50 out of 51 HPV16-positive and 5 out of 111 HPV-negative OPSCC (p < 0.0001) and in all HPV16-positive tonsillar dysplasias, whereas highly variable staining patterns were detected in the papillomas and laryngeal dysplasias, irrespective of the HPV-status. In addition, the latter lesions generally showed a higher nuclear than cytoplasmic p16(INK4A) immunostaining intensity. In conclusion, our data show that strong nuclear and cytoplasmic p16(INK4A) overexpression is a reliable surrogate indicator for HPV16 in OPSCC and (adjacent) dysplasias. For HPV6 or -11-positive and HPV-negative benign and premalignant lesions of the tonsil and larynx, however, p16(INK4A) immunostaining is highly variable and cannot be recommended to predict HPV-presence.",
        "Doc_title":"P16(INK4A) immunostaining is a strong indicator for high-risk-HPV-associated oropharyngeal carcinomas and dysplasias, but is unreliable to predict low-risk-HPV-infection in head and neck papillomas and laryngeal dysplasias.",
        "Journal":"International journal of cancer",
        "Do_id":"24127203",
        "Doc_ChemicalList":"Biomarkers, Tumor;Cyclin-Dependent Kinase Inhibitor p16",
        "Doc_meshdescriptors":"Adolescent;Adult;Aged;Aged, 80 and over;Biomarkers, Tumor;Carcinoma, Squamous Cell;Child;Child, Preschool;Cyclin-Dependent Kinase Inhibitor p16;Female;Head and Neck Neoplasms;Humans;Immunohistochemistry;In Situ Hybridization, Fluorescence;Infant;Laryngeal Neoplasms;Male;Middle Aged;Oropharyngeal Neoplasms;Papilloma;Papillomavirus Infections;Precancerous Conditions;Risk Factors;Young Adult",
        "Doc_meshqualifiers":"analysis;metabolism;virology;metabolism;metabolism;virology;metabolism;virology;metabolism;virology;metabolism;virology;complications;diagnosis;diagnosis;metabolism;virology",
        "_version_":1605784792176001024},
      {
        "Doc_abstract":"Head and neck squamous cell carcinoma (HNSCC) is a heterogeneous group of tumours with a typical 5year survival rate of <40%. DNA methylation in tumour-suppressor genes often occurs at an early stage of tumorigenesis, hence DNA methylation can be used as an early tumour biomarker. Saliva is an ideal diagnostic medium to detect early HNSCC tumour activities due to its proximity to tumour site, non-invasiveness and ease of sampling. We test the hypothesis that the surveillance of DNA methylation in five tumour-suppressor genes (RASSF1, p16 ",
        "Doc_title":"Salivary DNA methylation panel to diagnose HPV-positive and HPV-negative head and neck cancers.",
        "Journal":"BMC cancer",
        "Do_id":"27663357",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605746394413400064},
      {
        "Doc_abstract":"p14(ARF), the alternative product from the human INK4a/ARF locus, antagonizes Hdm2 and mediates p53 activation in response to oncogenic stimuli. An immunohistochemical study of p14(ARF) expression in 74 samples of aggressive B-cell lymphomas was performed, demonstrating an array of different abnormalities. A distinct nucleolar expression pattern was detected in nontumoral tissue and a subset of lymphomas (50/74). In contrast, a group of cases (8/74) showed absence of p14(ARF) expression, dependent either on promoter hypermethylation or gene loss. Additionally, 16 out of 74 cases displayed an abnormal nuclear p14(ARF) overexpression not confined to the nucleoli, as confirmed by confocal microscopy, and that was associated with high levels of p53 and Hdm2. A genetic study of these cases failed to show any alteration in the p14(ARF) gene, but revealed the presence of p53 mutations in over 50% of these cases. An increased growth fraction and a more aggressive clinical course, with a shortened survival time, also characterized the group of tumors with p14(ARF) nuclear overexpression. Moreover, this p14(ARF) expression pattern was more frequent in tumors displaying accumulated alterations in the p53, p16(INK4a), and p27(KIP1) tumor supressors. These observations, together with the consideration of the central role of p14(ARF) in cell cycle control, suggest that p14(ARF) abnormal nuclear overexpression is a sensor of malfunction of the major cell cycle regulatory pathways, and consequently a marker of a high tumor aggressivity.",
        "Doc_title":"p14(ARF) nuclear overexpression in aggressive B-cell lymphomas is a sensor of malfunction of the common tumor suppressor pathways.",
        "Journal":"Blood",
        "Do_id":"11830494",
        "Doc_ChemicalList":"Biomarkers, Tumor;Nuclear Proteins;Proto-Oncogene Proteins;Tumor Suppressor Protein p14ARF;Tumor Suppressor Protein p53;Tumor Suppressor Proteins;MDM2 protein, human;Proto-Oncogene Proteins c-mdm2",
        "Doc_meshdescriptors":"Biomarkers, Tumor;Cell Cycle;Cell Nucleus;DNA Mutational Analysis;Frozen Sections;Gene Expression;Humans;Lymphoma;Lymphoma, B-Cell;Nuclear Proteins;Prognosis;Proto-Oncogene Proteins;Proto-Oncogene Proteins c-mdm2;Survival Rate;Tumor Cells, Cultured;Tumor Suppressor Protein p14ARF;Tumor Suppressor Protein p53;Tumor Suppressor Proteins",
        "Doc_meshqualifiers":"metabolism;drug effects;chemistry;metabolism;mortality;pathology;metabolism;mortality;pathology;metabolism;genetics;physiology;genetics;metabolism;metabolism",
        "_version_":1605818601500049409},
      {
        "Doc_abstract":"JDP2 (Jun dimerization protein 2, an AP-1 transcription factor) is involved in the regulation of the differentiation and proliferation of cells. We report here that JDP2-deficient mouse embryonic fibroblasts (Jdp2(-/-) MEF) are resistant to replicative senescence. In the absence of JDP2, the level of expression of p16(Ink4a), which is known to rise as normal fibroblasts age, fell significantly when cells were cultured for more than 2 months. Conversely, the overexpression of JDP2 induced the expression of genes for p16(Ink4a) and p19(Arf). Moreover, at the promoter of the gene for p16(Ink4a) in Jdp2(-/-) MEF, the extent of methylation of lysine 27 of histone H3 (H3K27), which is important for gene silencing, increased. Polycomb-repressive complexes (PRC-1 and PRC-2), which are responsible for histone methylation, bound efficiently to the promoter to repress the expression of the gene for p16(Ink4a). As a result, JDP2-deficient MEF became resistant to replicative senescence. Our results indicate that JDP2 is involved in the signaling pathway for senescence via epigenetic regulation of the expression of the gene for p16(Ink4a).",
        "Doc_title":"JDP2 (Jun Dimerization Protein 2)-deficient mouse embryonic fibroblasts are resistant to replicative senescence.",
        "Journal":"The Journal of biological chemistry",
        "Do_id":"19233846",
        "Doc_ChemicalList":"Cdkn2a protein, mouse;Chromatin;Cyclin-Dependent Kinase Inhibitor p16;Histones;Jundp2 protein, mouse;RNA, Small Interfering;Repressor Proteins",
        "Doc_meshdescriptors":"Animals;Cell Aging;Cell Cycle;Cell Proliferation;Cells, Cultured;Chromatin;Cyclin-Dependent Kinase Inhibitor p16;Epigenesis, Genetic;Fibroblasts;Gene Expression Regulation;Histones;Methylation;Mice;Mice, Knockout;Promoter Regions, Genetic;RNA, Small Interfering;Repressor Proteins;Signal Transduction;Time Factors",
        "Doc_meshqualifiers":"physiology;physiology;metabolism;genetics;metabolism;cytology;physiology;metabolism;genetics;metabolism;genetics;metabolism;physiology",
        "_version_":1605742083202613249},
      {
        "Doc_abstract":"p14(ARF), generated through an alternative splicing process that replaces the first exon, 1alpha, of p16(INK4a) with exon 1beta, located >15 kb upstream of exon 1alpha, has been shown to function as a growth suppressor. We examined 11 gastric cancer cell lines for mRNA expression, homozygous deletion, mutation, and promoter methylation of the p14(ARF) gene. No mRNA expression was detected in 5 of the 7 diffuse-type cell lines. All intestinal cell lines displayed normal levels of expression except for one with a low level of expression. Of the 5 cell lines without expression, 3 (MKN45, NUGC-2, and NUGC-4) and 1 (KATO III) displayed homozygous deletion and methylation of the p14(ARF) gene, respectively. No mutation was found in the whole coding region of the p14(ARF) gene in 8 cell lines without homozygous deletion. Our results indicate that the p14(ARF) gene is more frequently inactivated by homozygous deletion or methylation in diffuse-type gastric cancer cell lines (5/7, 71.4%) than in intestinal ones (0/4, P = 0.022). When we also analyzed 62 primary gastric cancers for the methylation status of the p14(ARF) promoter region, the methylation frequency tended to be higher in diffuse-type gastric cancers (15/33, 45.5%) than in intestinal ones (7/28, 25%). Thus, p14(ARF) alterations might be involved in diffuse-type gastric carcinogenesis.",
        "Doc_title":"Alterations and hypermethylation of the p14(ARF) gene in gastric cancer.",
        "Journal":"International journal of cancer",
        "Do_id":"10925358",
        "Doc_ChemicalList":"Carrier Proteins;Cyclin-Dependent Kinase Inhibitor p16;Proteins;RNA, Messenger;Tumor Suppressor Protein p14ARF;Tumor Suppressor Protein p53",
        "Doc_meshdescriptors":"Carrier Proteins;Cyclin-Dependent Kinase Inhibitor p16;DNA Methylation;Gene Deletion;Gene Expression;Homozygote;Humans;Immunohistochemistry;Mutation;Promoter Regions, Genetic;Protein Biosynthesis;Proteins;RNA, Messenger;Reverse Transcriptase Polymerase Chain Reaction;Stomach Neoplasms;Tumor Cells, Cultured;Tumor Suppressor Protein p14ARF;Tumor Suppressor Protein p53",
        "Doc_meshqualifiers":"genetics;physiology;genetics;biosynthesis;genetics;genetics;biosynthesis;genetics",
        "_version_":1605907148540215296},
      {
        "Doc_abstract":"Exposure to ionizing radiation (IR) and certain chemotherapeutic agents not only causes acute bone marrow (BM) suppression but also leads to long-term residual hematopoietic injury. This latter effect has been attributed to damage to hematopoietic stem cell (HSC) self-renewal. Using a mouse model, we investigated whether IR induces senescence in HSCs, as induction of HSC senescence can lead to the defect in HSC self-renewal. It was found that exposure of C57BL/6 mice to a sublethal dose (6.5 Gy) of total body irradiation (TBI) resulted in a sustained quantitative and qualitative reduction of LKS+ HSCs. In addition, LKS+ HSCs from irradiated mice exhibited an increased expression of the 2 commonly used biomarkers of cellular senescence, p16(Ink4a) and SA-beta-gal. In contrast, no such changes were observed in irradiated LKS- hematopoietic progenitor cells. These results provide the first direct evidence demonstrating that IR exposure can selectively induce HSC senescence. Of interest, the induction of HSC senescence was associated with a prolonged elevation of p21(Cip1/Waf1), p19(Arf), and p16(Ink4a) mRNA expression, while the expression of p27(Kip1) and p18(Ink4c) mRNA was not increased following TBI. This suggests that p21(Cip1/Waf1), p19(Arf), and p16(Ink4a) may play an important role in IR-induced senescence in HSCs.",
        "Doc_title":"Total body irradiation selectively induces murine hematopoietic stem cell senescence.",
        "Journal":"Blood",
        "Do_id":"16150936",
        "Doc_ChemicalList":"Cdkn1a protein, mouse;Cdkn2d protein, mouse;Cyclin-Dependent Kinase Inhibitor p16;Cyclin-Dependent Kinase Inhibitor p19;Cyclin-Dependent Kinase Inhibitor p21;RNA, Messenger",
        "Doc_meshdescriptors":"Animals;Cell Aging;Cyclin-Dependent Kinase Inhibitor p16;Cyclin-Dependent Kinase Inhibitor p19;Cyclin-Dependent Kinase Inhibitor p21;Hematopoietic Stem Cells;Male;Mice;Mice, Inbred C57BL;RNA, Messenger;Up-Regulation;Whole-Body Irradiation",
        "Doc_meshqualifiers":"radiation effects;genetics;genetics;genetics;radiation effects;analysis;radiation effects",
        "_version_":1605800411886780416},
      {
        "Doc_abstract":"p14(ARF) tumor suppressor protein regulates p53 by interfering with mdm2-p53 interaction. p14(ARF) is activated in response to oncogenic stimuli but little is known of the responses of endogenous p14(ARF) to different types of cellular stress or DNA damage. Azidothymidine (AZT) is being tested in several clinical trials as an enhancer of anticancer chemotherapy. However, the knowledge of the relationship between AZT and cellular pathways, e.g. p53 pathway, is very limited. In this study, we show that AZT, cisplatin (CDDP) and docetaxel (DTX) all induce unique molecular responses in OVCAR-3 ovarian carcinoma cells carrying a mutated p53, while in A2780, ovarian carcinoma and MCF-7 breast carcinoma cells with wild type p53, all of these drugs cause similar p53 responses. We found that endogenous p14(ARF) protein in OVCAR-3 cells is down-regulated by DTX but induced by AZT and a short CDDP pulse treatment. In HT-29 colon carcinoma cells with a mutated p53, all treatments down-regulated p14(ARF) protein. Both CDDP and AZT increased the expression of p14ARF mRNA in OVCAR-3 cells. Differences in cell death induced by these drugs did not explain the differences in protein and mRNA expressions. No increase in the level of either c-Myc or H-ras oncoproteins was seen in OVCAR-3 cells after AZT or CDDP-treatment. These results suggest that p14(ARF) can respond to DNA damage without oncogene activation in cell lines without functional p53.",
        "Doc_title":"Azidothymidine and cisplatin increase p14ARF expression in OVCAR-3 ovarian cancer cell line.",
        "Journal":"Toxicology and applied pharmacology",
        "Do_id":"16797627",
        "Doc_ChemicalList":"Antineoplastic Agents;DNA-Binding Proteins;GADD45 protein;Intracellular Signaling Peptides and Proteins;RNA, Messenger;Reverse Transcriptase Inhibitors;Taxoids;Transcription Factors;Tumor Suppressor Protein p14ARF;Tumor Suppressor Protein p53;docetaxel;Zidovudine;Proto-Oncogene Proteins c-mdm2;Amy1 protein, mouse;Salivary alpha-Amylases;ras Proteins;Cisplatin",
        "Doc_meshdescriptors":"Antineoplastic Agents;Apoptosis;Blotting, Western;Cell Line, Tumor;Cisplatin;DNA-Binding Proteins;Dose-Response Relationship, Drug;Female;Gene Expression Regulation, Neoplastic;HT29 Cells;Humans;Intracellular Signaling Peptides and Proteins;Ovarian Neoplasms;Proto-Oncogene Proteins c-mdm2;RNA, Messenger;Reverse Transcriptase Inhibitors;Salivary alpha-Amylases;Taxoids;Transcription Factors;Tumor Suppressor Protein p14ARF;Tumor Suppressor Protein p53;Zidovudine;ras Proteins",
        "Doc_meshqualifiers":"pharmacology;drug effects;pharmacology;genetics;metabolism;drug effects;genetics;metabolism;genetics;metabolism;pathology;genetics;metabolism;genetics;metabolism;pharmacology;pharmacology;genetics;metabolism;genetics;metabolism;genetics;metabolism;pharmacology;genetics;metabolism",
        "_version_":1605809503406653440},
      {
        "Doc_abstract":"We show here that histone deacetylase inhibitors (HDACIs) sodium dibutyrate (SDB) and trichostatin A (TSA) induce a phenotype that has similarities to replicative senescence in human fibroblasts. There was no evidence that SDB accelerated a constitutive cell division counting mechanism as previously suggested because cells pretreated with SDB for three mean population doublings (MPDs) exhibited a similar overall proliferative life span to controls once SDB was withdrawn. SDB-treated cells upregulated the cell cycle inhibitors p21(WAF1) and p16(INK4A), but not p14(ARF), in the same sequential order as in senescence and the cells developed biochemical markers of senescence. However, the mechanism of senescence did not involve telomere dysfunction and there was no evidence for any posttranslational modification of p53. The expression of human papillomavirus (HPV) 16 E6 in human fibroblasts or targeted disruption of the p53 and p21(WAF) genes only weakly antagonized HDACI-induced senescence. However, expression of the E7 gene, which inhibits the function of pRb, cooperated with E6 to block SDB-induced senescence completely and human cells deficient in p16(INK4A) (but not p14(ARF)) were also resistant to SDB-induced senescence, suggesting that the p16(INK4A)/pRb pathway is the major mediator of HDACI-induced senescence in human cells. However, p53-/- mouse fibroblasts were resistant to HDACI-induced senescence, identifying p53 as the major pathway to senescence in this species.",
        "Doc_title":"Histone deacetylase inhibitors induce a senescence-like state in human cells by a p16-dependent mechanism that is independent of a mitotic clock.",
        "Journal":"Experimental cell research",
        "Do_id":"15093749",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;Enzyme Inhibitors;Histone Deacetylase Inhibitors;Hydroxamic Acids;Retinoblastoma Protein;Tumor Suppressor Protein p53;Butyric Acid;trichostatin A;Histone Deacetylases",
        "Doc_meshdescriptors":"Animals;Butyric Acid;Cell Aging;Cell Division;Cell Line;Cyclin-Dependent Kinase Inhibitor p16;Diploidy;Enzyme Inhibitors;Fetus;Fibroblasts;Gene Expression Regulation;Histone Deacetylase Inhibitors;Histone Deacetylases;Humans;Hydroxamic Acids;Karyotyping;Mice;Papillomaviridae;Precipitin Tests;Retinoblastoma Protein;Signal Transduction;Skin;Species Specificity;Tumor Suppressor Protein p53;Up-Regulation",
        "Doc_meshqualifiers":"pharmacology;physiology;physiology;deficiency;metabolism;pharmacology;enzymology;metabolism;drug effects;metabolism;pharmacology;metabolism;genetics;metabolism;cytology;genetics;metabolism",
        "_version_":1605804244265336832},
      {
        "Doc_abstract":"The cyclin-dependent kinase inhibitor 2A (CDKN2A) gene on chromosome 9p21 encodes p16 (INK4A), the inhibitor of the CDK4/retinoblastoma (Rb) cell proliferation pathway, as well as p14 (ARF), which controls p53-dependent pathways. Inactivation of p16 has previously been associated with the prognostically unfavourable primary cutaneous diffuse large B-cell lymphoma, leg type (PCLBCL, LT). In this work, we analysed 22 tumors [nine primary cutaneous follicle centre lymphomas (PCFCL), seven primary cutaneous marginal zone lymphomas (PCMZL) and six PCLBCL, LT] not only for alterations of the p16 gene but also for p14, p53 and Rb by fluorescence in situ hybridization (FISH) and immunohistochemistry. In most PCLBCL, LT (4/6) alterations of CDKN2A (two biallelic deletions, one monoallelic deletion and one trisomy 9) and in addition the highest frequency of deletions of p53 (3/6) and Rb (3/6) were detected. p16 was not expressed but very high levels of phosphorylated Rb, indicating a functional effect of genomic CDKN2A alterations on the protein level in PCLBCL, LT. Regarding the p14/p53 axis, PCLBCL, LT showed a variable expression. Neither PCFCL nor PCMZL showed alterations of CDKN2A and also deletions of p53 or Rb were extremely rare in these subtypes. Exclusively in PCMZL, p53 protein was consistently lacking. In conclusion, only PCLBCL, LT is characterized by a high frequency of aberrations of the CDKN2A network components in both important tumor suppressor pathways regulated by the CDKN2A gene. Moreover, PCLBCL, LT appears to be distinguishable from PCMZL not only by its level of p53 expression but also by its stage of Rb phosphorylation. The latter may also apply to a subgroup of PCFCL.",
        "Doc_title":"Simultaneous aberrations of single CDKN2A network components and a high Rb phosphorylation status can differentiate subgroups of primary cutaneous B-cell lymphomas.",
        "Journal":"Experimental dermatology",
        "Do_id":"21410763",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;Tumor Suppressor Protein p14ARF",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Alleles;Chromosomes, Human, Pair 13;Chromosomes, Human, Pair 17;Chromosomes, Human, Pair 9;Cyclin-Dependent Kinase Inhibitor p16;DNA Mutational Analysis;Female;Genes, Retinoblastoma;Genes, p16;Genes, p53;Humans;In Situ Hybridization, Fluorescence;Lymphoma, B-Cell, Marginal Zone;Lymphoma, Follicular;Lymphoma, Large B-Cell, Diffuse;Male;Middle Aged;Phosphorylation;Sequence Deletion;Skin Neoplasms;Trisomy;Tumor Suppressor Protein p14ARF;Young Adult",
        "Doc_meshqualifiers":"genetics;metabolism;genetics;metabolism;genetics;metabolism;genetics;metabolism;genetics;genetics;metabolism;genetics;metabolism;genetics;metabolism;genetics;genetics;genetics;metabolism",
        "_version_":1605742637647659010},
      {
        "Doc_abstract":"The role of high-risk human papillomavirus (HPV) in the pathogenesis of esophageal squamous cell carcinoma (ESCC) remains unclear. p16(INK4) is used as a surrogate marker to detect HPV-related tumors but has had discrepant results in ESCC. In this study, 32 cases of ESCC were examined to determine the relationship between p16(INK4) expression and high-risk HPV. All the tumors were stained by immunohistochemistry for p16(INK4). Tumors having p16(INK4) nuclear and/or nuclear and cytoplasmic expression were considered positive. Tumors positive for p16(INK4) expression were tested for high-risk HPV by in situ hybridization (ISH). In all, 20 cases of ESCC (63%) showed only cytoplasmic staining for p16(INK4), and 11 cases (34%) showed both cytoplasmic and nuclear staining for p16(INK4); 4 cases (13%) showed no staining for p16(INK4). None of the p16(INK4) -positive cases were positive for high-risk HPV by ISH. These results indicate that p16(INK4) expression in ESCC does not correlate with the presence of high-risk HPV DNA by ISH. High-risk HPV does not seem to play a major role in the carcinogenesis of ESCC in low-risk areas.",
        "Doc_title":"Assessment of immunohistochemistry for p16INK4 and high-risk HPV DNA by in situ hybridization in esophageal squamous cell carcinoma.",
        "Journal":"International journal of surgical pathology",
        "Do_id":"21087981",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;DNA, Viral",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Carcinoma, Squamous Cell;Cyclin-Dependent Kinase Inhibitor p16;DNA, Viral;Esophageal Neoplasms;Female;Humans;Immunohistochemistry;In Situ Hybridization;Male;Middle Aged;Papillomaviridae;Precancerous Conditions;Risk Factors",
        "Doc_meshqualifiers":"genetics;metabolism;virology;genetics;metabolism;genetics;metabolism;genetics;metabolism;virology;genetics;metabolism;genetics;metabolism;virology",
        "_version_":1605742780329492480},
      {
        "Doc_abstract":"Type 2 diabetes, fuelled by the obesity epidemic, is an escalating worldwide cause of personal hardship and public cost. Diabetes incidence increases with age, and many studies link the classic senescence and ageing protein p16(INK4A) to diabetes pathophysiology via pancreatic islet biology. Genome-wide association studies (GWASs) have unequivocally linked the CDKN2A/B locus, which encodes p16 inhibitor of cyclin-dependent kinase (p16(INK4A)) and three other gene products, p14 alternate reading frame (p14(ARF)), p15(INK4B) and antisense non-coding RNA in the INK4 locus (ANRIL), with human diabetes risk. However, the mechanism by which the CDKN2A/B locus influences diabetes risk remains uncertain. Here, we weigh the evidence that CDKN2A/B polymorphisms impact metabolic health via islet biology vs effects in other tissues. Structured in a bedside-to-bench-to-bedside approach, we begin with a summary of the evidence that the CDKN2A/B locus impacts diabetes risk and a brief review of the basic biology of CDKN2A/B gene products. The main emphasis of this work is an in-depth look at the nuanced roles that CDKN2A/B gene products and related proteins play in the regulation of beta cell mass, proliferation and insulin secretory function, as well as roles in other metabolic tissues. We finish with a synthesis of basic biology and clinical observations, incorporating human physiology data. We conclude that it is likely that the CDKN2A/B locus influences diabetes risk through both islet and non-islet mechanisms. ",
        "Doc_title":"Islet biology, the CDKN2A/B locus and type 2 diabetes risk.",
        "Journal":"Diabetologia",
        "Do_id":"27155872",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605812558067924992},
      {
        "Doc_abstract":"Human papillomavirus (HPV)-positive oropharyngeal cancer is associated with improved survival and treatment response as compared to HPV-negative cancers. P16 overexpression is widely accepted as a surrogate marker for HPV positivity.;A total of 92 serum samples from 75 head and neck squamous cell carcinoma (HNSCC) patients were examined for HPV16 and 18 E7 antibodies by ELISA. Available tissue was tested for HPV-DNA by PCR, and p16 immunohistochemistry was obtained from a deidentified database.;Of 75 HNSCC patients, 25 were HPV E7 seropositive. Seropositivity was strongly associated with cancers of the oropharynx, and correlated with positive p16 immunohistochemistry (IHC) and HPV-DNA. Post-treatment serum was available in a limited subset of patients, revealing a decrease in antibody titers following response to treatment.;HPV E7 seropositivity correlated with positive tumor HPV-DNA and p16 expression, and was strongly associated with cancers of the oropharynx. E7 serology warrants further study as a potential biomarker in HPV-positive HNSCC.",
        "Doc_title":"Human papillomavirus E7 serology and association with p16 immunohistochemistry in squamous cell carcinoma of the head and neck.",
        "Journal":"Experimental and molecular pathology",
        "Do_id":"26116154",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;DNA, Viral;Papillomavirus E7 Proteins",
        "Doc_meshdescriptors":"Adult;Aged;Carcinoma, Squamous Cell;Cyclin-Dependent Kinase Inhibitor p16;DNA, Viral;Enzyme-Linked Immunosorbent Assay;Female;Head and Neck Neoplasms;Human papillomavirus 16;Humans;Immunoenzyme Techniques;Male;Middle Aged;Neoplasm Staging;Papillomavirus E7 Proteins;Papillomavirus Infections;Polymerase Chain Reaction;Prognosis;Seroepidemiologic Studies",
        "Doc_meshqualifiers":"metabolism;pathology;virology;metabolism;genetics;metabolism;pathology;virology;genetics;isolation & purification;blood;metabolism;pathology;virology",
        "_version_":1605842832496525312},
      {
        "Doc_abstract":"The p16 gene (CDKN2) which is localized on chromosome 9p21, is deleted in a significant number of sporadic cancers. Moreover, germline mutations identified in some melanoma-prone kindreds last year suggested that CDKN2 is identical to the 9p21-linked melanoma susceptibility gene (MLM); however, failure to identify p16 mutations in all melanoma kindreds putatively linked to 9p21 left some doubts. We have analysed CDKN2 coding sequences in 15 Dutch familial atypical multiple mole-melanoma (FAMMM) syndrome pedigrees, and identified a 19 basepair (bp) germline deletion in 13 of them. All 13 families originate from an endogamous population. The deletion causes a reading frame shift, predicted to result in a severely truncated p16 protein. Interestingly, two family members are homozygous for the deletion, one of whom shows no obvious signs of disease. This surprising finding demonstrates that homozygotes for this CDKN2 mutation are viable, and suggests the presence of a genetic mechanism that can compensate for the functional loss of p16. Our results also greatly strengthen the notion that p16 is indeed MLM.",
        "Doc_title":"Homozygotes for CDKN2 (p16) germline mutation in Dutch familial melanoma kindreds.",
        "Journal":"Nature genetics",
        "Do_id":"7670475",
        "Doc_ChemicalList":"DNA Primers",
        "Doc_meshdescriptors":"Amino Acid Sequence;Chromosomes, Human, Pair 9;DNA Primers;Female;Germ-Line Mutation;Homozygote;Humans;Male;Melanoma;Molecular Sequence Data;Neoplasms, Multiple Primary;Netherlands;Pedigree;Phenotype;Polymerase Chain Reaction;Sequence Deletion;Syndrome",
        "Doc_meshqualifiers":"genetics;genetics;genetics",
        "_version_":1605755254919397376},
      {
        "Doc_abstract":"Combined multi-point linkage analysis in seven Dutch families with FAMMM syndrome confirmed the location of a melanoma susceptibility (MLM) gene in the 9p21 area. The occurrence of a shared high-risk haplotype in six of the families strongly suggests a founder effect in the Leiden region. No indication for locus heterogeneity was observed. Recently, the CDKN2 (p16) gene, an important regulator of the cell cycle, was isolated from the 9p21 region. A 19-bp germline deletion in the CDKN2 gene was detected in the high-risk haplotype, suggesting CDKN2 to be identical to MLM. Loss of heterozygosity studies in melanoma and pancreatic carcinoma from gene carriers strongly support the view that CDKN2 is a general tumour suppressor gene predisposing not only to melanoma but also to other malignancies. Interestingly, the occurrence of apparent clinical FAMMM cases with melanoma but without the high-risk deletion haplotype suggests the necessity of additional (naevus) genes to explain the complete FAMMM phenotype.",
        "Doc_title":"CDKN2 explains part of the clinical phenotype in Dutch familial atypical multiple-mole melanoma (FAMMM) syndrome families.",
        "Journal":"Melanoma research",
        "Do_id":"7640518",
        "Doc_ChemicalList":"Carrier Proteins;Cyclin-Dependent Kinase Inhibitor p16;DNA",
        "Doc_meshdescriptors":"Adolescent;Adult;Aged;Amino Acid Sequence;Base Sequence;Carrier Proteins;Child;Child, Preschool;Chromosome Mapping;Cyclin-Dependent Kinase Inhibitor p16;DNA;Female;Founder Effect;Genes, Tumor Suppressor;Germ-Line Mutation;Haplotypes;Humans;Infant;Male;Melanoma;Middle Aged;Molecular Sequence Data;Netherlands;Pedigree;Phenotype",
        "Doc_meshqualifiers":"genetics;analysis;genetics",
        "_version_":1605741924044505088},
      {
        "Doc_abstract":"The p16 (CDKN2a/INK4a) gene is an important tumor-suppressor gene, involved in the p16/cyclin-dependent kinase/retinoblastoma gene pathway of cell cycle control. The p16 protein is considered to be a negative regulator of the pathway. The gene encodes an inhibitor of cyclin-dependent kinases 4 and 6, which regulate the phosphorylation of retinoblastoma gene and the G1 to S phase transition of the cell cycle. In the present study, p16 gene promoter hypermethylation patterns and p16 protein expression were analyzed in 100 consecutive untreated cases of primary head and neck squamous cell carcinoma by methylation-specific PCR and immunohistochemical staining. The p16 promoter hypermethylation and apparent loss of p16 protein expression were detected in 27% and 74% of head and neck squamous cell carcinoma, respectively. By chi(2) test, history of alcohol or tobacco use was significantly correlated with the loss of p16 protein expression (P =.005 and.05, respectively). When patient follow-up data were correlated with various clinical and molecular parameters, tumor size and nodal and clinical stage were the strongest prognostic predictors for disease-free survival (tumor recurrence) and for cause-specific and overall survival in patients with head and neck squamous cell carcinoma. Neither p16 promoter hypermethylation nor apparent loss of p16 protein expression appears to be an independent prognostic factor, although loss of p16 protein may be used to predict overall patient survival in early-stage head and neck squamous cell carcinoma.",
        "Doc_title":"The p16 (CDKN2a/INK4a) tumor-suppressor gene in head and neck squamous cell carcinoma: a promoter methylation and protein expression study in 100 cases.",
        "Journal":"Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc",
        "Do_id":"13679459",
        "Doc_ChemicalList":"Biomarkers, Tumor;DNA, Neoplasm",
        "Doc_meshdescriptors":"Adult;Aged;Alcohol Drinking;Biomarkers, Tumor;Carcinoma, Squamous Cell;DNA Methylation;DNA, Neoplasm;Genes, p16;Head and Neck Neoplasms;Humans;Immunohistochemistry;Middle Aged;Polymerase Chain Reaction;Prognosis;Promoter Regions, Genetic;Risk Factors;Smoking",
        "Doc_meshqualifiers":"analysis;genetics;mortality;pathology;analysis;genetics;mortality;pathology",
        "_version_":1605792375387455488},
      {
        "Doc_abstract":"Head and neck squamous cell cancer (HNSCC) includes tumors of various anatomical sites sharing common etiological factors. Serum levels of MMP1, MMP2, and MMP9 were analyzed in patients with oropharyngeal, laryngeal, and hypopharyngeal carcinomas in an effort to elucidate the pathobiology and in order to find useful biomarkers of site-specific HNSCC.;The study group comprised of 46 patients with HNSCC (21 with oropharyngeal, 21 with laryngeal and 4 with hypopharyngeal cancer). Serum levels of MMP1, -2, and -9 were determined by the MAGPIX multiplex method. P16 protein was detected by immunohistochemistry. Serum levels of matrix metalloproteinases (MMPs) were correlated with clinicopathological features of carcinomas and were compared with respect to tumor site.;Significant correlations were confirmed between p16 positivity and oropharyngeal cancer, MMP1 and p16 positivity, and recurrence and smoking. Statistically significant differences in serum levels of MMPs between cancer of different locations were not found.;MMP1 expression is significantly affected by smoking habit and by p16 and might mediate etiopathogenetical process in cancerogenesis of HNSCC. Our pilot study did not establish any utility of MMP1, -2, or -9 in clinical practice as diagnostic/prognostic markers.",
        "Doc_title":"Analysis of preoperative serum levels of MMP1, -2, and -9 in patients with site-specific head and neck squamous cell cancer.",
        "Journal":"Anticancer research",
        "Do_id":"25503184",
        "Doc_ChemicalList":"Biomarkers, Tumor;Cyclin-Dependent Kinase Inhibitor p16;MMP2 protein, human;Matrix Metalloproteinase 2;MMP9 protein, human;Matrix Metalloproteinase 9;MMP1 protein, human;Matrix Metalloproteinase 1",
        "Doc_meshdescriptors":"Alcoholism;Biomarkers, Tumor;Carcinoma, Squamous Cell;Cyclin-Dependent Kinase Inhibitor p16;Female;Gene Expression Regulation, Neoplastic;Head and Neck Neoplasms;Humans;Hypopharyngeal Neoplasms;Immunohistochemistry;Laryngeal Neoplasms;Male;Matrix Metalloproteinase 1;Matrix Metalloproteinase 2;Matrix Metalloproteinase 9;Middle Aged;Neoplasm Recurrence, Local;Oropharyngeal Neoplasms;Pilot Projects;Preoperative Period;Prognosis;Smoking",
        "Doc_meshqualifiers":"blood;blood;biosynthesis;genetics;blood;blood;blood;blood;blood;blood;blood;adverse effects",
        "_version_":1605841434587430912},
      {
        "Doc_abstract":"Lymph node involvement is prognostically the most determinant clinical factor for patients with head and neck squamous cell carcinomas (HNSCCs). Ultrasound of the neck and fine-needle aspiration (FNA) cytology is one of the first diagnostic procedures and the most accurate diagnostic staging tool for the neck. Patients with HPV-positive oropharyngeal carcinomas (OPSCC) show a significantly better prognosis when compared with HPV-negative OPSCC. P16 overexpression is accepted as surrogate marker for HPV-positive in OPSCC. These HPV/p16-positive OPSCC are localized either in the palatal tonsils or the base of tongue and frequently present with lymph node metastases. We analyzed the correlation and reliability of p16 expression of the FNA of the lymph node metastasis with the immunohistochemical expression of p16 of the same lymph node metastasis and its corresponding primary tumor, as it could be of importance for determining the localization and different prognosis of the primary tumor. 54 HNSCC patients were evaluated, p16 expression of the primary tumors and their lymph node metastases correlated precisely. In 25 of the 54 HNSCC patients, a FNA of the lymph node metastases was taken before the treatment. The positive cytological and immunohistochemical p16 staining correlated exactly. Of the 17 histologically p16-negative lymph node metastases 15 FNA were p16-negative, whereas two samples were p16-positive. In our view, a cytological p16 analysis of cervical lymph node metastasis can facilitate the correct localization of the primary tumor and discriminate reliably HPV-positive OPSCC from HPV-negative HNSCC with their significantly diverse prognosis.",
        "Doc_title":"The clinical impact of p16 status in fine-needle aspirates of cervical lymph node metastasis of head and neck squamous cell carcinomas.",
        "Journal":"European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery",
        "Do_id":"22588195",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Biopsy, Fine-Needle;Carcinoma, Squamous Cell;Female;Human papillomavirus 16;Humans;Lymph Nodes;Lymphatic Metastasis;Male;Middle Aged;Neck;Oropharyngeal Neoplasms",
        "Doc_meshqualifiers":"pathology;virology;isolation & purification;pathology;virology;pathology;virology",
        "_version_":1605746976672972800},
      {
        "Doc_abstract":"The objective of this study is to establish the aging model of murine hematopoietic stem cell (HSC) ex vitro and investigate its relative biological mechanism, aimed to build the foundation for searching the methods to delaying HSC aging. Sca-1(+)HSC were isolated and purified from murine bone marrow mono-nucleated cell by magnetic-activated cell sorting. The purity of separated cells was analyzed by flow cytometry (FCM) and the expression of Sca-1 was detected by immunofluorescence. Sca-1(+)HSC induced aging by tert-butylhydroperoxide (t-BHP, final concentration of 100mol/L) for 6h to establish the murine HSC aging model in vitro. Biological characteristics of aging HSC were evaluated by mixed hematopoietic progenitor cell culture in vitro, cell cycle assay and senescence-associated -galactosidase (SA--gal) cytochemical staining. Telomere length and telomerase activity were detected by southern blotting and telomere repeat amplification protocol-polymerase chain reaction (TRAP-PCR) augmentation. The expressions of p16(INK4a), P19(Arf), P53, P21(Cip1/Waf1) mRNA were detected by reverse transcription (RT)-PCR. The purity of separated Sca-1(+) HSC was 87.2% and the survival of Sca-1(+) HSC was 96~99%. After 6h cocultured with 100mol/Lt-BHP, the ability of aging Sca-1(+) HSC to form mixed hematopoietic progenitor colony, self-renewal and multi-differentiation were decreased significantly. The number of aging Sca-1(+) HSC entered G1 phase of the cell cycle and the percentage of positive cells expressed SA--gal increased significantly. The telomere length shortened and the telomerase activity decreased. The expression of p16(INK4a), p19(Arf), p53, P21(Cip1/Waf1) mRNA increased. The t-BHP can induce Sca-1(+) HSC senescence in vitro. The signal transduction pathways of p16(INK4a)-retinoblastoma and P19(Arf)-Mdm2-P53-P21(Cip1/Waf1) may play key roles in the Sca-1(+) HSC senescence induced by t-BHP.",
        "Doc_title":"Establishment of an aging model of Sca-1+ hematopoietic stem cell and studies on its relative biological mechanisms.",
        "Journal":"In vitro cellular & developmental biology. Animal",
        "Do_id":"21132465",
        "Doc_ChemicalList":"Antigens, Ly;Ly6a protein, mouse;Membrane Proteins;Telomerase;beta-Galactosidase",
        "Doc_meshdescriptors":"Aging;Animals;Antigens, Ly;Cell Aging;Cell Cycle;Hematopoietic Stem Cells;Membrane Proteins;Mice;Models, Animal;Telomerase;beta-Galactosidase",
        "Doc_meshqualifiers":"genetics;physiology;analysis;genetics;physiology;genetics;cytology;physiology;analysis;analysis;analysis",
        "_version_":1605800082662227968},
      {
        "Doc_abstract":"Transforming growth factor 1 gene (TGF1) genotype is a potential p16 independent prognostic factor predicting response to chemoradiotherapy in head and neck squamous cell carcinoma (HNSCC).;Expression of p16 and epidermal growth factor receptor (EGFR) has been reported to be associated with survival in HNSCC. We have previously reported that genetic polymorphism of TGF1 is linked with survival in HNSCC patients who have undergone chemoradiotherapy. We evaluate here whether TGFB1 genotype can serve as a prognostic factor independent of tumor p16 and EGFR expression.;Expression of p16 and EGFR was studied by immunohistochemistry in tumors from 130 HNSCC patients. Peripheral blood DNA was used to genotype 95 patients for single nucleotide polymorphism rs1800470 within the TGF1 gene. The minimum follow-up time was 31 months.;p16 overexpression was associated with an improved disease-free survival (hazard ratio (HR) = 0.39, 95% CI 0.19-0.78), whereas no evident association was observed between EGFR expression and disease-free survival (HR = 0.90, 95% CI 0.68-1.19). Among the 37 patients who had received chemoradiotherapy, TGF1 genotype was associated with disease-free (HR = 0.44, 95% CI 0.19-1.02) and overall survival (HR = 0.31, 95% CI 0.12-0.80) independent of tumor p16 expression.",
        "Doc_title":"Transforming growth factor beta 1 genotype and p16 as prognostic factors in head and neck squamous cell carcinoma.",
        "Journal":"Acta oto-laryngologica",
        "Do_id":"22667340",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;Transforming Growth Factor beta1;EGFR protein, human;Receptor, Epidermal Growth Factor",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Alleles;Carcinoma, Squamous Cell;Chemoradiotherapy, Adjuvant;Cyclin-Dependent Kinase Inhibitor p16;Disease-Free Survival;Female;Follow-Up Studies;Gene Expression Regulation, Neoplastic;Genotype;Humans;Male;Middle Aged;Otorhinolaryngologic Neoplasms;Polymorphism, Single Nucleotide;Prognosis;Receptor, Epidermal Growth Factor;Transforming Growth Factor beta1",
        "Doc_meshqualifiers":"genetics;mortality;therapy;genetics;genetics;mortality;therapy;genetics;genetics;genetics",
        "_version_":1605907037800103936},
      {
        "Doc_abstract":"Human papillomavirus (HPV) is one of the most common causes of sexually transmitted infection in the world. France and Belgium present one of the highest incidence of head and neck squamous cell carcinomas (HNSCC) worldwide. Besides, considering only the male population, HNSCCs represent the fourth most frequent cancer after prostate, lung and colon cancers. Although the causal link between high-risk HPVs and cervical carcinoma is well established, the implication of this viral infection in HNSCC remains debatable. Here, we discuss current knowledge concerning the HPV implication in HNSCCs. Based on our literature review, 20 to 25% of HNSCCs could be associated with oncogenic HPVs, in particular HPV type 16. The oropharynx--more precisely the tonsil--is the head and neck location presenting the highest incidence of HPV infection. Moreover, a clear increase of tonsillar carcinoma incidence has been described. As observed in cervical carcinomas, HPV positive HNSCCs are sexually transmitted and characterized by alterations of p53 and pRb signalling pathways. Several studies have shown that HPV positive subgroup presented better prognosis particularly if these patients overexpressed p16INK4. New studies regarding HPV status in HNSCCs are warranted to provide a rationale for large scale HPV vaccination in young male populations.",
        "Doc_title":"[Involvement of human papillomavirus in upper aero-digestive tracts cancers].",
        "Journal":"Bulletin du cancer",
        "Do_id":"19744917",
        "Doc_ChemicalList":"Tumor Suppressor Protein p53",
        "Doc_meshdescriptors":"Carcinoma, Squamous Cell;Female;Head and Neck Neoplasms;Human papillomavirus 16;Humans;Laryngeal Neoplasms;Male;Mouth Neoplasms;Nose Neoplasms;Papillomaviridae;Papillomavirus Infections;Pharyngeal Neoplasms;Prevalence;Prognosis;Salivary Gland Neoplasms;Sexual Behavior;Signal Transduction;Tumor Suppressor Protein p53;Virus Integration",
        "Doc_meshqualifiers":"epidemiology;prevention & control;virology;epidemiology;prevention & control;virology;genetics;physiology;epidemiology;virology;epidemiology;virology;epidemiology;virology;genetics;physiology;complications;epidemiology;prevention & control;transmission;epidemiology;virology;epidemiology;virology;genetics;physiology;physiology",
        "_version_":1605907386738933760},
      {
        "Doc_abstract":"To investigate the relationship between FDG-PET maximum standard uptake value (SUVmax), p16, EGFR, GLUT1 and HK2 expression in head and neck squamous cell carcinomas (HNSCC).;Immunohistochemical staining of p16, EGFR, GLUT1 and HK2 was performed on primary tumor tissue from 97 locally advanced HNSCC patients treated with definitive chemoradiation. SUVmax along with p16, EGFR, GLUT1 and HK2 expression were analyzed for associations including local control, locoregional control and disease free survival.;Pretreatment SUVmax in primary tumors did not differ when stratified by p16, EGFR or GLUT1 expression but SUVmax was significantly higher in HK2 expressing tumors (p=0.021) and in tumors with higher T-stage (p=0.022). GLUT1 expression was significantly higher in p16 negative (p<0.001) and EGFR positive tumors (p<0.01). HK2 expressing tumors were associated with EGFR positive tumors (p=0.022) but not with p16 or GLUT1 expression. EGFR positive, p16 negative and high GLUT1 expressing tumors were associated with worse local control and disease free survival on univariate analyses. After adjusting for patient and treatment characteristics p16 status was the only factor that predicted for outcome on multivariate analysis.;High GLUT1 expression was associated with EGFR positive and p16 negative HNSCC tumors. GLUT1 maybe an important biomarker in HNSCC but its expression appears dependent on p16 status.",
        "Doc_title":"The association of (18)F-FDG PET and glucose metabolism biomarkers GLUT1 and HK2 in p16 positive and negative head and neck squamous cell carcinomas.",
        "Journal":"Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology",
        "Do_id":"26328941",
        "Doc_ChemicalList":"Biomarkers, Tumor;Glucose Transporter Type 1;KIF2A protein, human;SLC2A1 protein, human;Fluorodeoxyglucose F18;Receptor, Epidermal Growth Factor;Kinesin;Glucose",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Biomarkers, Tumor;Carcinoma, Squamous Cell;Chemoradiotherapy;Disease-Free Survival;Female;Fluorodeoxyglucose F18;Glucose;Glucose Transporter Type 1;Head and Neck Neoplasms;Human papillomavirus 16;Humans;Kinesin;Male;Middle Aged;Papillomavirus Infections;Positron-Emission Tomography;Prognosis;Receptor, Epidermal Growth Factor;Treatment Outcome",
        "Doc_meshqualifiers":"metabolism;diagnosis;therapy;virology;metabolism;metabolism;diagnosis;therapy;virology;isolation & purification;metabolism;complications;metabolism;methods;metabolism",
        "_version_":1605906599460732928},
      {
        "Doc_abstract":"Germ-line mutations of the tumor-suppressor gene CDKN2A predispose individuals to melanoma in families worldwide. However, coding mutations of CDKN2A have not been detected in a significant proportion of those affected. The identification of a disease-associated intronic mutation of CDKN2A in UK families, which has proved to be the most common CDKN2A mutation as yet identified in this population, has highlighted the possibility that additional causal mutations may lie within the intronic sequence of the gene. In this article, we describe the comprehensive screening of 109 English and 26 Australian melanoma pedigrees for intronic mutations of CDKN2A. In total, 24 sequence variants were identified across the two introns of the gene. We show evidence that two of the CDKN2A intronic variants (IVS1 + 1104 C > A and IVS1 - 1104 C > G) predispose to melanoma. IVS1 + 1104 was shown to result in the aberrant splicing of both p16(INK4a) and p14(ARF) mRNA. Overall, however, the proportion of English melanoma families with these variants is small.",
        "Doc_title":"Intronic sequence variants of the CDKN2A gene in melanoma pedigrees.",
        "Journal":"Genes, chromosomes & cancer",
        "Do_id":"15761864",
        "Doc_ChemicalList":"DNA Primers",
        "Doc_meshdescriptors":"Base Sequence;DNA Primers;Female;Genes, p16;Germ-Line Mutation;Humans;Introns;Male;Melanoma;Pedigree;RNA Splicing;Reverse Transcriptase Polymerase Chain Reaction",
        "Doc_meshqualifiers":"genetics",
        "_version_":1605742783562252289},
      {
        "Doc_abstract":"Inhalation of radon is closely associated with an increased risk of lung cancers. While the involvement of Ink4a in lung tumor development has been widely described, the tumor suppressor gene has not been studied in radon-induced lung tumors. In this study, loss of heterozygosity (LOH) analysis of the Cdkn2a locus, common to the Ink4a and Arf genes, was performed on 33 radon-induced rat lung tumors and showed a DNA loss in 50% of cases. The analysis of p16(Ink4a) protein expression by immunohistochemistry revealed that 50% of the tumors were negative for this protein. Looking for the origin of this lack of expression, we observed a low frequency of homozygous deletion (6%), a lack of mutation, an absence of correlation between promoter methylation and Ink4a mRNA expression and no correlation between LOH and protein expression. However, a tendency for an inverse correlation between p16(Ink4a) and pRb protein expression was observed. The expressions of p19Arf, Mmd2 and Mdm4 were not deregulated and only 14% of the tumors were mutated for Tp53. These results indicated that Ink4a/Cdk4/Rb1 pathway deregulation, more than Arf/Mdm2/Tp53 pathway, has a major role in the development of these tumors through p16(Ink4a) deregulation. However, all known mechanisms of inactivation of the pathway do not play a recurrent role in these tumors and the actual origin of the lack of p16(Ink4a) protein expression remains to be established.",
        "Doc_title":"Molecular analysis of the Ink4a/Rb1-Arf/Tp53 pathways in radon-induced rat lung tumors.",
        "Journal":"Lung cancer (Amsterdam, Netherlands)",
        "Do_id":"18656278",
        "Doc_ChemicalList":"Carcinogens, Environmental;Cyclin-Dependent Kinase Inhibitor p16;RNA, Neoplasm;Retinoblastoma Protein;Tumor Suppressor Protein p14ARF;Tumor Suppressor Protein p53;Radon",
        "Doc_meshdescriptors":"Animals;Carcinogens, Environmental;Cyclin-Dependent Kinase Inhibitor p16;DNA Methylation;Gene Expression Regulation, Neoplastic;Immunohistochemistry;Lung Neoplasms;Mutation;Neoplasms, Experimental;Polymerase Chain Reaction;RNA, Neoplasm;Radon;Rats;Rats, Inbred F344;Rats, Inbred WF;Rats, Sprague-Dawley;Retinoblastoma Protein;Tumor Suppressor Protein p14ARF;Tumor Suppressor Protein p53",
        "Doc_meshqualifiers":"toxicity;analysis;genetics;chemically induced;chemistry;genetics;chemically induced;chemistry;genetics;analysis;genetics;toxicity;analysis;genetics;analysis;genetics;analysis;genetics",
        "_version_":1605759147555422208},
      {
        "Doc_abstract":"P16(INK4A) (also known as P16 and MTS1), a protein consisting exclusively of four ankyrin repeats, is recognized as a tumor suppressor mainly because of the prevalence of genetic inactivation of the p16(INK4A) (or CDKN2A) gene in virtually all types of human cancers. However, it has also been shown that an elevated level of expression (upregulation) of P16 is involved in cellular senescence, aging, and cancer progression, indicating that the regulation of P16 is critical for its function. Here, we discuss the regulatory mechanisms of P16 function at the DNA level, the transcription level, and the posttranscriptional level, as well as their implications for the structure-function relationship of P16 and for human cancers.",
        "Doc_title":"Regulatory mechanisms of tumor suppressor P16(INK4A) and their relevance to cancer.",
        "Journal":"Biochemistry",
        "Do_id":"21619050",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16",
        "Doc_meshdescriptors":"Amino Acid Sequence;Cyclin-Dependent Kinase Inhibitor p16;Drug Delivery Systems;Gene Expression Regulation, Neoplastic;Genetic Loci;Humans;Molecular Sequence Data;Mutation;Neoplasms;Structure-Activity Relationship;Transcription, Genetic",
        "Doc_meshqualifiers":"chemistry;genetics;physiology;methods;genetics;chemistry;genetics;therapy",
        "_version_":1605742754532425731},
      {
        "Doc_abstract":"Head and neck squamous cell carcinoma (HNSCC) includes both morphological and functional cellular heterogeneity, as would be expected if it arose from dysregulated stem or progenitor cells as opposed to the simple clonal expansion of a mutated cell; however, stemness molecule expression levels and distribution in HNSCC remain unclear. To clarify this, stemness molecule expressions were determined in HNSCC, as well as their properties and prognosis. Two proto-oncogenic chromatin regulators, Bmi-1 and high-mobility-group A2 (Hmga2), were identified in 12 pair cases of HNSCC tumor regions by comparison with their non-cancerous background tissues using cDNA microarray. Both Bmi-1 and Hmga2 are known to promote stem cell self-renewal by negatively regulating the expressions of Ink4a and Arf tumor suppressors. Despite similar targets, Bmi-1 protein was expressed in an early cancerous region and HMGA2 protein was expressed in a region showing more progression. Similarly, Bmi1 expression had no significance with regard to overall survival (P=0.67), whereas HMGA2 expression was associated with decreased overall survival (P=0.05). Quantitative real-time reverse transcription polymerase chain reaction analyses also correlated with protein levels. These findings suggest that Bmi-1 is an early detection marker to distinguish cancerous from non-cancerous regions, whereas HMGA2 is presumed to be a tumor prognosis marker. Among our HNSCC analyses, these stemness molecules expressed fewer primitive rare cells in the tumor than all other cells in the tumor. HNSCC cells with high expression of stemness molecules partly behave like stem cells.",
        "Doc_title":"Stem cell self-renewal factors Bmi1 and HMGA2 in head and neck squamous cell carcinoma: clues for diagnosis.",
        "Journal":"Laboratory investigation; a journal of technical methods and pathology",
        "Do_id":"24145240",
        "Doc_ChemicalList":"BMI1 protein, human;Biomarkers, Tumor;HMGA2 Protein;Polycomb Repressive Complex 1",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Biomarkers, Tumor;Carcinoma, Squamous Cell;Female;Gene Expression Profiling;HMGA2 Protein;Humans;Male;Middle Aged;Mouth;Mouth Neoplasms;Oligonucleotide Array Sequence Analysis;Polycomb Repressive Complex 1",
        "Doc_meshqualifiers":"metabolism;diagnosis;metabolism;pathology;metabolism;pathology;diagnosis;metabolism;pathology;metabolism",
        "_version_":1605846868353351680},
      {
        "Doc_abstract":"Senescence is now understood to be the final phenotypic state adopted by a cell in response to several distinct cell physiological processes, including proliferation, oncogene activation and oxygen free radical toxicity. The role of telomere maintenance in immortalization and the roles of p16(INK4A), p19(ARF), p53 and other genes in senescence are being further elucidated. Significant progress continues to be made in our understanding of cellular senescence and immortalization.",
        "Doc_title":"Genes involved in senescence and immortalization.",
        "Journal":"Current opinion in cell biology",
        "Do_id":"11063935",
        "Doc_ChemicalList":"Proteins;Reactive Oxygen Species;Tumor Suppressor Protein p14ARF",
        "Doc_meshdescriptors":"Animals;Cell Aging;Cell Division;Gene Expression Regulation;Genes, p16;Humans;Mice;Oncogenes;Oxidative Stress;Proteins;Reactive Oxygen Species;Signal Transduction;Telomere;Tumor Suppressor Protein p14ARF",
        "Doc_meshqualifiers":"genetics;genetics;genetics;genetics;genetics;genetics;metabolism;genetics;genetics;metabolism",
        "_version_":1605746395530133505},
      {
        "Doc_abstract":"The cell cycle inhibitor p15(INK4b) is frequently inactivated by homozygous deletion together with p16(INK4a) and p19(ARF) in some types of tumors. Although the tumor suppressor capability of p15(INK4b) is still questioned, it has been found to be specifically inactivated by hypermethylation in hematopoietic malignancies in the absence of p16(INK4a) alterations. Here we show that, in vitro, p15(INK4b) is a strong inhibitor of cellular transformation by Ras. Surprisingly, p15(INK4b) is induced in cultured cells by oncogenic Ras to an extent similar to that of p16(INK4a), and their expression is associated with premature G(1) arrest and senescence. Ras-dependent induction of these two INK4 genes is mediated mainly by the Raf-Mek-Erk pathway. Studies with activated and dominant negative forms of Ras effectors indicate that the Raf-Mek-Erk pathway is essential for induction of both the p15(INK4b) and p16(INK4a) promoters, although other Ras effector pathways can collaborate, giving rise to a stronger response. Our results indicate that p15(INK4b), by itself, is able to stop cell transformation by Ras and other oncogenes such as Rgr (a new oncogene member of the Ral-GDS family, whose action is mediated through Ras). In fact, embryonic fibroblasts isolated from p15(INK4b) knockout mice are susceptible to transformation by the Ras or Rgr oncogene whereas wild-type embryonic fibroblasts are not. Similarly, p15(INK4b)-deficient mouse embryo fibroblasts are more sensitive than wild-type cells to transformation by a combination of the Rgr and E1A oncogenes. The cell cycle inhibitor p15(INK4b) is therefore involved, at least in some cell types, in the tumor suppressor activity triggered after inappropriate oncogenic Ras activation in the cell.",
        "Doc_title":"Cellular response to oncogenic ras involves induction of the Cdk4 and Cdk6 inhibitor p15(INK4b).",
        "Journal":"Molecular and cellular biology",
        "Do_id":"10733595",
        "Doc_ChemicalList":"Carrier Proteins;Cdkn2b protein, mouse;Cell Cycle Proteins;Cyclin-Dependent Kinase Inhibitor p15;Cyclin-Dependent Kinase Inhibitor p16;Proto-Oncogene Proteins;Tumor Suppressor Proteins;Protein-Serine-Threonine Kinases;Cdk4 protein, mouse;Cdk6 protein, mouse;Cyclin-Dependent Kinase 4;Cyclin-Dependent Kinase 6;Cyclin-Dependent Kinases;ras Proteins",
        "Doc_meshdescriptors":"3T3 Cells;Animals;Carrier Proteins;Cell Cycle;Cell Cycle Proteins;Cell Transformation, Neoplastic;Cyclin-Dependent Kinase 4;Cyclin-Dependent Kinase 6;Cyclin-Dependent Kinase Inhibitor p15;Cyclin-Dependent Kinase Inhibitor p16;Cyclin-Dependent Kinases;Enzyme Activation;Gene Expression Regulation;Mice;Protein-Serine-Threonine Kinases;Proto-Oncogene Proteins;Signal Transduction;Tumor Suppressor Proteins;ras Proteins",
        "Doc_meshqualifiers":"physiology;physiology;physiology;physiology;physiology;physiology;physiology;physiology",
        "_version_":1605757962632036352},
      {
        "Doc_abstract":"To evaluate the prognostic and predictive value of molecular and immunohistochemical markers related to cell-cycle control in terms of recurrence, progression, and survival in urothelial neoplasms of the bladder (UNB).;Clinical and pathological findings of 84 patients with UNB were assessed. Homozygous deletion (HD) and promoter methylation of p14ARF, p15INK4B, p16INK4A, loss of heterozygosity of the locus 9p21, p53 mutations, and immunohistochemical expression of p53, p16, p14, p21, p27, pRb, Ki67, MDM2, and cyclin D1 proteins were evaluated in relation to overall survival (OS), recurrence-free survival (RFS), and progression-free survival (PFS).;In the univariate analysis, RFS was shorter in cases with p14ARF (p=0.006), p15INK4B (p=0.003), p16INK4A (p=0.03) HD, low p14 immunoreactivity index (IRI) (p=0.01) and high Ki67 IRI (p=0.04); HD of the 9p21 locus genes and p14 IRI remained as independent prognostic factors for early UNB recurrence (p=0.006) whereas tumour stage (p=0.00001) and cyclin D1 IRI (p=0.049) were related to worse PFS in the multivariate analysis. In the univariate analysis, IRI for Ki67 (p=0.002), cyclin D1 (p=0.06), p53 (p=0.00008), p16 (p=0.02), p27 (p=0.0005) MDM2 (p=0.01) and p53 mutations (p=0.03) were related to poor OS, and only the Ki67 IRI retained their independent value in the multivariate analysis.;9p21 HD and p14 IRI constitute independent predictive factors for UNB recurrence and cyclin D1 IRI and tumour stage for progression. In addition, Ki67 IRI and tumour stage are independent prognostic factors for overall survival in UNB.",
        "Doc_title":"Molecular and immunohistochemical analysis of the prognostic value of cell-cycle regulators in urothelial neoplasms of the bladder.",
        "Journal":"European urology",
        "Do_id":"16624482",
        "Doc_ChemicalList":"Biomarkers, Tumor;Cell Cycle Proteins;Cyclin-Dependent Kinase Inhibitor p15;Cyclin-Dependent Kinase Inhibitor p16;Ki-67 Antigen;Tumor Suppressor Protein p14ARF;Tumor Suppressor Protein p53;Cyclin-Dependent Kinase Inhibitor p27;MDM2 protein, human;Proto-Oncogene Proteins c-mdm2",
        "Doc_meshdescriptors":"Biomarkers, Tumor;Carcinoma;Cell Cycle Proteins;Cyclin-Dependent Kinase Inhibitor p15;Cyclin-Dependent Kinase Inhibitor p16;Cyclin-Dependent Kinase Inhibitor p27;Disease Progression;Female;Humans;Immunohistochemistry;Ki-67 Antigen;Male;Molecular Diagnostic Techniques;Neoplasm Recurrence, Local;Predictive Value of Tests;Prognosis;Proto-Oncogene Proteins c-mdm2;Retinoblastoma;Survival Analysis;Tumor Suppressor Protein p14ARF;Tumor Suppressor Protein p53;Urinary Bladder Neoplasms;Urothelium",
        "Doc_meshqualifiers":"metabolism;diagnosis;metabolism;mortality;metabolism;metabolism;metabolism;metabolism;methods;metabolism;methods;diagnosis;metabolism;mortality;metabolism;metabolism;metabolism;metabolism;diagnosis;metabolism;mortality;pathology",
        "_version_":1605765302816079872},
      {
        "Doc_abstract":"p16INK4a is a tumor suppressor gene playing a critical role. Researches have indicated the gene to be altered in oral squamous cell carcinoma. Present studies have tried to assess the correlation between p16INK4a expression and INK4a locus mutation in relation to grades and stages of this tumor.;Expression of p16INK4a was studied immunohistochemically in 58 oral squamous sell carcinoma samples and INK4a locus mutation was determined by polymerase chain reaction (PCR) and conformation sensitive gel electrophoresis (CSGE).;Expression of p16INK4a was higher in stage1 compared to stage 2, 3, and 4 (P = 0.234). The difference was not significant in grade 1, 2, and 3 (P = 0.671). The average values of total score (TS) were significantly higher in stage1 compared to stage 2, 3, and 4 (P = 0.035). The average values of complete score (CS) were higher in stage 1 compared to stage 2, 3, and 4 (P = 0.061). The research did not show a significant correlation between lymph node involvement and p16INK4a expression (P = 0.491). It seems that 5.1% (3/58) of samples have mutation in INK4a locus.;Loss of p16INK4a expression occurred in initial stages of oral squamous cell carcinoma. Evaluation of TS and CS for p16INK4a might be a useful clinical indicator concerning the tumor. However, gene mutation is believed to have minor rate of genetic alteration in carcinogenesis.",
        "Doc_title":"The correlation between p16 expression and INK4a locus mutation with grades and stages in oral squamous cell carcinoma.",
        "Journal":"Indian journal of pathology & microbiology",
        "Do_id":"24739827",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16",
        "Doc_meshdescriptors":"Carcinoma, Squamous Cell;Cyclin-Dependent Kinase Inhibitor p16;Electrophoresis;Female;Humans;Immunohistochemistry;Male;Middle Aged;Mouth Neoplasms;Mutation;Polymerase Chain Reaction;Severity of Illness Index",
        "Doc_meshqualifiers":"genetics;biosynthesis;genetics;genetics",
        "_version_":1605741926705790976},
      {
        "Doc_abstract":"The current study aimed to evaluate the significance of the cell-cycle-control proteins cyclin D1 and p16 as prognostic markers in head and neck squamous cell carcinoma (HNSCC) patients treated with docetaxel and radiotherapy.;Cyclin D1 and/or p16 protein expression was retrospectively evaluated by immunohistochemistry in 53 patients with stage T1-3N0-2M0 (except T1N0 glottis) HNSCC who were treated with 10 mg/m(2)/week docetaxel 4 to 6 times and received concurrent chemoradiotherapy.;Kaplan-Meier univariate analysis revealed that patients with cyclin D1-positive tumors or p16-negative tumors had a worse prognosis compared with those with cyclin D1-negative tumors or p16-positive tumors (p = .0004 and p = .025, respectively). The prognostic significance of cyclin D1 expression, not p16 expression, was confirmed using a proportional hazard regression model.;An assessment of cyclin D1 and p16 levels might be of clinical use in defining subgroups of patients with poor prognosis.",
        "Doc_title":"Prognostic significance of cyclin D1 and p16 in patients with intermediate-risk head and neck squamous cell carcinoma treated with docetaxel and concurrent radiotherapy.",
        "Journal":"Head & neck",
        "Do_id":"17563903",
        "Doc_ChemicalList":"Antineoplastic Agents;Biomarkers, Tumor;Cyclin-Dependent Kinase Inhibitor p16;Taxoids;Cyclin D1;docetaxel",
        "Doc_meshdescriptors":"Adult;Aged;Antineoplastic Agents;Biomarkers, Tumor;Carcinoma, Squamous Cell;Cyclin D1;Cyclin-Dependent Kinase Inhibitor p16;Female;Head and Neck Neoplasms;Humans;Male;Middle Aged;Prognosis;Proportional Hazards Models;Radiotherapy, Adjuvant;Taxoids",
        "Doc_meshqualifiers":"therapeutic use;metabolism;metabolism;mortality;therapy;metabolism;metabolism;metabolism;mortality;therapy;therapeutic use",
        "_version_":1605882723772137472},
      {
        "Doc_abstract":"The INK4 family of cyclin-dependent kinase (CDK) inhibitors includes four 15- to 19-kDa polypeptides (p16(INK4a), p15(INK4b), p18(INK4c), and p19(INK4d)) that bind to CDK4 and CDK6. By disrupting cyclin D-dependent holoenzymes, INK4 proteins prevent phosphorylation of the retinoblastoma protein and block entry into the DNA-synthetic phase of the cell division cycle. The founding family member, p16(INK4a), is a potent tumor suppressor in humans, whereas involvement, if any, of other INK4 proteins in tumor surveillance is less well documented. INK4c and INK4d are expressed during mouse embryogenesis in stereotypic tissue-specific patterns and are also detected, together with INK4b, in tissues of young mice. INK4a is expressed neither before birth nor at readily appreciable levels in young animals, but its increased expression later in life suggests that it plays some checkpoint function in response to cell stress, genotoxic damage, or aging per se. We used targeted gene disruption to generate mice lacking INK4d. These animals developed into adulthood, had a normal life span, and did not spontaneously develop tumors. Tumors did not arise at increased frequency in animals neonatally exposed to ionizing radiation or the carcinogen dimethylbenzanthrene. Mouse embryo fibroblasts, bone marrow-derived macrophages, and lymphoid T and B cells isolated from these animals proliferated normally and displayed typical lineage-specific differentiation markers. Males exhibited marked testicular atrophy associated with increased apoptosis of germ cells, although they remained fertile. The absence of tumors in INK4d-deficient animals demonstrates that, unlike INK4a, INK4d is not a tumor suppressor but is instead involved in spermatogenesis.",
        "Doc_title":"INK4d-deficient mice are fertile despite testicular atrophy.",
        "Journal":"Molecular and cellular biology",
        "Do_id":"10594039",
        "Doc_ChemicalList":"Carrier Proteins;Cdkn2d protein, mouse;Cell Cycle Proteins;Cyclin-Dependent Kinase Inhibitor p16;Cyclin-Dependent Kinase Inhibitor p19;Cyclin-Dependent Kinases",
        "Doc_meshdescriptors":"Animals;Carrier Proteins;Cell Cycle Proteins;Cyclin-Dependent Kinase Inhibitor p16;Cyclin-Dependent Kinase Inhibitor p19;Cyclin-Dependent Kinases;Fertility;Gene Expression Regulation;Male;Mice;Mice, Knockout;Testis",
        "Doc_meshqualifiers":"genetics;antagonists & inhibitors;genetics;physiology;pathology;physiology",
        "_version_":1605821054970757120},
      {
        "Doc_abstract":"The molecular mechanisms of hepatocarcinogenesis are poorly understood. Only very recently has there been a suggestion of familial hepatocellular carcinoma (HCC). We have analyzed the status of the p16INK4(MTS1) gene, a cyclin-dependent kinase inhibitor, in 26 patients with HCC of different etiologies. Four patients carried hemizygous germ-line point mutations of the p16INK4(MTS1) gene, suggesting the existence of familial HCC involving this gene. The wild-type allele was lost in the tumor in 2 of these 4 patients. Three of the patients carrying a germ-line mutation had non-cirrhosis-associated HCC. No somatic mutations of p16INK4(MTS1) were observed in the 26 cases of HCC. The most common somatic alteration of the p16INK4(MTS1) gene in HCC was de novo methylation, which was detected in 48% of the cases. Low levels (21%) of p16INK4(MTS1) gene allele loss were observed. Altogether, these results indicate that alteration of the p16INK4(MTS1) gene plays an important role in the genesis of HCC.",
        "Doc_title":"Germ-line mutations of the p16INK4(MTS1) gene occur in a subset of patients with hepatocellular carcinoma.",
        "Journal":"Hepatology (Baltimore, Md.)",
        "Do_id":"9185756",
        "Doc_ChemicalList":"Carrier Proteins;Cyclin-Dependent Kinase Inhibitor p16;Proteins;Tumor Suppressor Protein p14ARF",
        "Doc_meshdescriptors":"Adult;Aged;Alleles;Carcinoma, Hepatocellular;Carrier Proteins;Cyclin-Dependent Kinase Inhibitor p16;DNA Methylation;Exons;Female;Genes, Tumor Suppressor;Germ-Line Mutation;Humans;Liver Neoplasms;Male;Middle Aged;Pedigree;Polymorphism, Single-Stranded Conformational;Promoter Regions, Genetic;Proteins;Tumor Suppressor Protein p14ARF",
        "Doc_meshqualifiers":"genetics;genetics;genetics;genetics",
        "_version_":1605746811539030016},
      {
        "Doc_abstract":"To further characterize the biological and clinical role of molecular alterations involved in oral squamous carcinogenesis, the immunohistochemical expression level of two tumor suppressor genes, fragile histidine triad and p16INK4a, in non-carcinomatous squamous epithelia and head and neck squamous cell carcinoma was determined. In addition, human papillomavirus infection determined by PCR assay and the use of alcohol and cigarettes were evaluated. In this study 28 non-carcinomatous squamous epithelia and 57 head and neck squamous cell carcinoma were considered. The expression levels of fragile histidine triad were lower in head and neck squamous cell carcinoma than in non-carcinomatous squamous epithelia. In contrast, p16INK4a is expressed in malignant lesions (51% of the cases analyzed), but not in non-carcinomatous squamous epithelia. No correlation between gene expression alterations of the two tumor suppressors was observed. PCR analysis showed that HPV DNA was present in 5 of the 57 malignant lesions analyzed (8.8%). None of the factors described above, despite changes in gene expression and HPV infection, appears to be associated with alcohol use and/or tobacco smoking and clinical outcome. Our data showed that fragile histidine triad and p16INK4a expression are altered in malignant lesions. Most likely, the decreasing levels of fragile histidine triad is directly involved in cancer development, while the accumulation of p16INK4a in head and neck squamous cell carcinoma may be the consequence of loss of functional tumor suppressor retinoblastoma pathway.",
        "Doc_title":"Altered p16INK4a and Fhit expression in carcinogenesis and progression of human oral cancer.",
        "Journal":"International journal of oncology",
        "Do_id":"14719099",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;Neoplasm Proteins;Retinoblastoma Protein;fragile histidine triad protein;Acid Anhydride Hydrolases",
        "Doc_meshdescriptors":"Acid Anhydride Hydrolases;Aged;Alcohol Drinking;Carcinoma, Squamous Cell;Cyclin-Dependent Kinase Inhibitor p16;Disease Progression;Epithelium;Female;Genes, Tumor Suppressor;Genes, p16;Head and Neck Neoplasms;Humans;Immunohistochemistry;Male;Middle Aged;Mouth Neoplasms;Neoplasm Proteins;Papillomavirus Infections;Polymerase Chain Reaction;Retinoblastoma Protein;Smoking;Time Factors",
        "Doc_meshqualifiers":"biosynthesis;metabolism;pathology;biosynthesis;pathology;metabolism;pathology;metabolism;pathology;biosynthesis;diagnosis;metabolism",
        "_version_":1605875988058603520},
      {
        "Doc_abstract":"The incidence of distal gastric adenocarcinoma has significantly decreased, but gastric cardia adenocarcinoma has been on the rise. Cardia adenocarcinoma might be a specific entity distinct from the carcinoma of the rest stomach. The aim was to explore putative differences in p16(INK) (4a) -retinoblastoma (Rb) pathway and INK4a/ARF methylation between gastric cardia and distal adenocarcinomas.;Ninety-six cardia adenocarcinomas and 79 distal samples were analyzed for comparing p16(INK) (4a) -Rb expressions, INK4a/ARF deletion, and methylation using immunohistochemistry, polymerase chain reaction, and methylation-specific polymerase chain reaction.;The expression of p16(INK) (4a) in cardia adenocarcinoma (43.2%) was significantly lower than in distal cases (75.0%, P<0.05). As well, cardia adenocarcinoma showed lower expression of p14(ARF) compared with distal cases (34.1% vs 57.5%, P<0.05). The incidence of p16(INK) (4a) deletion was 20.5% and 15.0%, while p14(ARF) deletion was 18.2% and 10.0% in cardia and distal adenocarcinomas, respectively, showing no significant differences between two entities. However, the incidences of p14(ARF) and p16(INK) (4a) methylation in cardia adenocarcinoma were significantly higher than in distal samples (p14(ARF) : 61.5% vs 43.6%; p16(INK) (4a) : 73.1% vs 51.3%, P<0.05). INK4a/ARF methylations were more prevalent in poorly differentiated cardia carcinoma compared with poorly differentiated distal cases.;There were differences in p16(INK) (4a) -Rb immunotypes and INK4a/ARF methylation between two entities, indicating that cardia adenocarcinoma may be different in cell proliferation, differentiation, and gene biomarkers compared with distal gastric adenocarcinoma.",
        "Doc_title":"Different roles for p16(INK) (4a) -Rb pathway and INK4a/ARF methylation between adenocarcinomas of gastric cardia and distal stomach.",
        "Journal":"Journal of gastroenterology and hepatology",
        "Do_id":"25123601",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;Retinoblastoma Protein",
        "Doc_meshdescriptors":"Adenocarcinoma;Aged;Cell Proliferation;Cell Transformation, Neoplastic;Cyclin-Dependent Kinase Inhibitor p16;Humans;Male;Methylation;Middle Aged;Retinoblastoma Protein;Signal Transduction;Stomach;Stomach Neoplasms",
        "Doc_meshqualifiers":"genetics;pathology;genetics;physiology;genetics;physiology;genetics;physiology;anatomy & histology;genetics;pathology",
        "_version_":1605884343980392448},
      {
        "Doc_abstract":"Some of the mechanisms involved in neoplastic transformation and progression of laryngeal squamous cell carcinoma (LSCC) are discussed. Although tumor suppressor inactivation of p53 and p16 is common in these tumors (about 50% each), oncogenic activation is less well characterized. Cyclin D1 and epidermal growth factor receptor amplification have been reported in one-third and one-quarter of LSCCs, respectively, both related to advanced stages, whereas c-myc could be amplified in 13% of cases although without associated overexpression. The role of ras in LSCC is, at most, exceptional, and the role of human papillomavirus infection in these neoplasms could have been largely overestimated. The AIS (amplified in squamous carcinoma) gene has been recently proposed as the main oncogenic target in head and neck squamous carcinomas and is a promising line of investigation. This, along with the link that exists between p53 and INK4 suppressor pathways through ARF and MDM-2, and the role of the universal cdk inhibitors (the Cip/Kip family) in these neoplasms deserve further investigation. Not forgotten are the mechanisms leading to cell immortalization and invasive capabilities acquisition, some of which are also briefly described.",
        "Doc_title":"Molecular biology of laryngeal squamous cell carcinoma.",
        "Journal":"Virchows Archiv : an international journal of pathology",
        "Do_id":"12536308",
        "Doc_ChemicalList":"DNA, Neoplasm;Cyclin D1;Telomerase",
        "Doc_meshdescriptors":"Carcinoma, Squamous Cell;Cell Transformation, Neoplastic;Cyclin D1;DNA, Neoplasm;Disease Progression;Genes, p16;Genes, p53;Humans;Laryngeal Neoplasms;Molecular Biology;Proto-Oncogenes;Telomerase",
        "Doc_meshqualifiers":"enzymology;genetics;pathology;genetics;pathology;genetics;analysis;enzymology;genetics;pathology",
        "_version_":1605813081619824640},
      {
        "Doc_abstract":"The purpose of this research was to examine the DNA methylation profile of meningiomas. Accordingly, we examined the DNA methylation status of ten tumor-related genes (RB1, p16(INK4a), p73, MGMT, ER, DAPK, TIMP-3, p14(ARF), THBS1, and Caspase-8) in 98 meningiomas (68 grade I; 27 grade II; and 3 grade III samples) using methylation-specific PCR and sequencing. The most frequently methylated genes were THBS1 (30%), TIMP-3 (24%), p16(INK4a) (17%), MGMT (16%), p73 (15%), ER (15%), and p14(ARF) (13%), whereas methylation was relatively rare in the other genes (<10%). Methylation occurred in at least one gene in 77.5% of the cases and in three or more genes in 25.5%. Methylation was tumor specific since it was absent in the controls: two non-neoplastic meningeal samples and two non-neoplastic brain samples. The frequency of aberrant gene methylation in grade I versus grade II-III tumors showed some differences for TIMP-3, THBS1, MGMT, p16(INK4a) and p73; these differences reached statistical significance for TIMP-3: 18% in grade I versus 40% in grade II-III (P < 0.02). Our previous loss of heterozygosity studies provided the allelic constitution at 1p and 22q for 60 of the 98 meningiomas included in this report. The level of aberrant promoter methylation increased in tumors (30 samples) displaying 1p loss (either isolated or as concurrent deletion at 1p/22q; P = 0.014). These meningiomas primarily accumulated the epigenetic changes of THBS1 (14/30; 47%; P < 0.005), TIMP-3 (12/30; 40%; P < 0.05), p73 (10/30; 26%; P < 0.02) and p14(ARF) /p16(INK4a)(7/30 each one; 23%; not significant). Our findings indicate that aberrant DNA methylation of promoter-associated CpG islands in meningiomas contributes to the development of these tumors.",
        "Doc_title":"DNA methylation of multiple promoter-associated CpG islands in meningiomas: relationship with the allelic status at 1p and 22q.",
        "Journal":"Acta neuropathologica",
        "Do_id":"15365725",
        "Doc_ChemicalList":"DNA, Neoplasm",
        "Doc_meshdescriptors":"Adolescent;Adult;Aged;Aged, 80 and over;Alleles;CpG Islands;DNA Methylation;DNA, Neoplasm;Female;Humans;Loss of Heterozygosity;Male;Meningeal Neoplasms;Meningioma;Middle Aged;Polymerase Chain Reaction;Promoter Regions, Genetic",
        "Doc_meshqualifiers":"genetics;genetics;genetics;genetics",
        "_version_":1605750886817071104},
      {
        "Doc_abstract":"Recently, the p14 ARF gene has emerged as a new putative tumor suppressor gene, and the alteration of p14 ARF gene is closely related to development of multiple human tumors. The aberrant promoter methylation as a mechanism of inactivation of p14 ARF gene might participate in tumorigenesis. The aim of this study is to investigate promoter methylation status and protein expression of p14 ARF gene in pulmonary squamous cell carcinoma and adenocarcinoma, and to value the role of p14 ARF promoter methylation in carcinogenesis of non-small cell lung cancer.;Promoter methylation status and protein expression of p14 ARF gene were analyzed in 40 cases of pulmonary squamous cell carcinoma and adenocarcinoma by methylation specific polymerase chain reaction (MSP), restriction enzyme-related polymerase chain reaction (RE-PCR) and immunohistochemistry (IHC).;The positive rate of p14 ARF promoter methylation in tumor tissues and normal tissues adjacent to cancer was 17.5% (7/40) and 2.5% (1/40) respectively (P= 0.025 ). The results of RE-PCR were consistent with the above. The positive rate of p14 ARF protein in tumor tissues was significantly lower than that in normal tissues adjacent to cancer (P=0.003). Promoter methylation and protein expression of p14 ARF gene showed a significantly negative correlation (r=-0.56, P= 0.001 ), and both of them did not correlate statistically with the clinicopathologic characteristics of patients such as histological classification, TNM stages, differentiation grade and lymph node involvement.;Promoter methylation is a crucial mechanism of inactivation of p14 ARF gene. Promoter methylation of p14 ARF gene might be involved in carcinogenesis of non-small cell lung cancer, and it is an early event in development process of non-small cell lung cancer.",
        "Doc_title":"[Promoter methylation status and protein expression of p14ARF gene in squamous cell carcinoma and adenocarcinoma of the lung].",
        "Journal":"Zhongguo fei ai za zhi = Chinese journal of lung cancer",
        "Do_id":"21144280",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605799199366971392},
      {
        "Doc_abstract":"The aim of this study was to determine p16INK4a point mutations and promoter hypermethylation in tumour cells and bronchial preneoplastic lesions in 32 surgically resected lungs due to primary squamous cell carcinoma. P16 point mutations were detected in 1 (3%) and promoter hypermethylation in 12 (31%) of 32 squamous cell carcinomas. The status of p16 was further characterized in 38 premalignant lesions including squamous metaplasias without dysplasia, squamous metaplasias with mild, moderate and severe dysplasias and 4 carcinomas in situ. No p16 point mutations have been found in premalignant or CIS lesions. Methylation of p16 was detected in 1 of 8 (12.5%) cases of squamous metaplasias without dysplasia, in 1 of 10 (10%) cases of squamous metaplasias with mild dysplasia, in 1 of 9 (11%) cases of squamous metaplasia with moderate dysplasia and in 2 of 7 (28.5%) cases of severe dysplasias, as well as in 1 of 4 (25%) carcinomas in situ. This investigation indicates that P16INK4a supressor gene point mutations are rather late event and inactivation of this gene by promoter hypermethylation is early and likely critical in bronchial cancerogenesis.",
        "Doc_title":"P16INK4a point mutations and promoter hypermetylation in bronchial preneoplastic lesions.",
        "Journal":"Folia histochemica et cytobiologica",
        "Do_id":"11820618",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16",
        "Doc_meshdescriptors":"Bronchial Neoplasms;Carcinoma, Squamous Cell;Cyclin-Dependent Kinase Inhibitor p16;DNA Methylation;DNA Mutational Analysis;Humans;Point Mutation;Precancerous Conditions;Promoter Regions, Genetic",
        "Doc_meshqualifiers":"genetics;pathology;genetics;pathology;genetics;genetics;pathology;physiology",
        "_version_":1605842379242209280},
      {
        "Doc_abstract":"Pheochromocytomas and abdominal extra-adrenal paragangliomas are related to endocrine tumors of the sympathetic nervous system. Studies in animal models have shown that inactivation of the products of the cyclin dependent kinase inhibitor 2A (CDKN2A) gene locus, p16INK4A and p14ARF, promotes the development of pheochromocytoma, especially in malignant form. The present study evaluated the involvement of CDKN2A in human pheochromocytomas and abdominal extra-adrenal paragangliomas from 55 patients. Promoter methylation was assessed using quantitative Pyrosequencing and methylation-specific PCR, and mRNA expression was measured by quantitative real-time PCR. For p16, western blot analysis and sequencing were also performed. succinate dehydrogenase complex subunit B (SDHB) sequencing analysis included extra-adrenal paragangliomas, all tumors classified as malignant, and cases diagnosed at 30 years or younger. The p16INK4A promoter was heavily methylated in a subset of paragangliomas, and this was significantly associated with malignancy (P<0.0043) and SDHB mutation (P<0.002). p16INK4A mRNA expression showed moderate suppression in malignant cases (P<0.05). In contrast, very little p14ARF promoter methylation was seen and there was no significant difference in p14ARF expression between tumors and normal samples. The p16 protein expression was reduced in 16 tumors, and sequence variations were observed in four tumors including the missense mutation A57V and the single nucleotide polymorphism (SNP) A148T. The results suggest that p16INK4A, and not p14ARF, is a subject of frequent involvement in these tumors. Importantly, hypermethylation of the p16INK4A promoter was significantly associated with malignancy and metastasis, and SDHB gene mutations. This finding suggests an etiological link and could provide a clinical utility for diagnostic purposes.",
        "Doc_title":"Methylation of the p16INK4A promoter is associated with malignant behavior in abdominal extra-adrenal paragangliomas but not pheochromocytomas.",
        "Journal":"Endocrine-related cancer",
        "Do_id":"18509008",
        "Doc_ChemicalList":"Tumor Suppressor Protein p14ARF;SDHB protein, human;Succinate Dehydrogenase",
        "Doc_meshdescriptors":"Breast Neoplasms;Cell Line, Tumor;DNA Methylation;Gene Expression Regulation, Neoplastic;Genes, p16;Genetic Variation;Humans;Mutation, Missense;Osteosarcoma;Paraganglioma, Extra-Adrenal;Peripheral Nervous System Neoplasms;Pheochromocytoma;Polymorphism, Single Nucleotide;Promoter Regions, Genetic;Reverse Transcriptase Polymerase Chain Reaction;Succinate Dehydrogenase;Suppression, Genetic;Sympathetic Nervous System;Tumor Suppressor Protein p14ARF",
        "Doc_meshqualifiers":"physiology;genetics;pathology;genetics;pathology;genetics;pathology;physiology;genetics;genetics;pathology;genetics",
        "_version_":1605846006749986816},
      {
        "Doc_abstract":"The INK4A locus codes for two independent tumor suppressors, p14ARF and p16/CDKN2A, and is frequently mutated in many cancers. Here we report a novel deletion/substitution from CC to T in the shared exon 2 of p14ARF/p16 in a melanoma cell line. This mutation aligns the reading frames of p14ARF and p16 mid-transcript, producing one protein which is half p14ARF and half p16, chimera ARF (chARF), and another which is half p16 and half non-p14ARF/non-p16 amino acids, p16-Alternate Carboxyl Terminal (p16-ACT). In an effort to understand the cellular impact of this novel mutation and others like it, we expressed the two protein products in a tumor cell line and analyzed common p14ARF and p16 pathways, including the p53/p21 and CDK4/cyclin D1 pathways, as well as the influence of the two proteins on growth and the cell cycle. We report that chARF mimicked wild-type p14ARF by inducing the p53/p21 pathway, inhibiting cell growth through G2/M arrest and maintaining a certain percentage of cells in G1 during nocodazole-induced G2 arrest. chARF also demonstrated p16 activity by binding CDK4. However, rather than preventing cyclin D1 from binding CDK4, chARF stabilized this interaction through p21 which bound CDK4. p16-ACT had no p16-related function as it was unable to inhibit cyclin D1/CDK4 complex formation and was unable to arrest the cell cycle, though it did inhibit colony formation. We conclude that these novel chimeric proteins, which are very similar to predicted p16/p14ARF chimeric proteins found in other primary cancers, result in maintained p14ARF-p53-p21 signaling while p16-dependent CDK4 inhibition is lost. ",
        "Doc_title":"Chimeras of p14ARF and p16: functional hybrids with the ability to arrest growth.",
        "Journal":"PloS one",
        "Do_id":"24505435",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;Mutant Chimeric Proteins;Tumor Suppressor Protein p14ARF;Tumor Suppressor Protein p53;Cyclin D1;Cyclin-Dependent Kinase 4",
        "Doc_meshdescriptors":"Base Sequence;Cell Cycle;Cell Line, Tumor;Cell Proliferation;Cyclin D1;Cyclin-Dependent Kinase 4;Cyclin-Dependent Kinase Inhibitor p16;Exons;Humans;Melanoma;Mutant Chimeric Proteins;Mutation;Tumor Suppressor Protein p14ARF;Tumor Suppressor Protein p53",
        "Doc_meshqualifiers":"metabolism;metabolism;genetics;metabolism;genetics;metabolism;pathology;genetics;metabolism;genetics;metabolism;metabolism",
        "_version_":1605844292685791232},
      {
        "Doc_abstract":"The cyclin-dependent kinase inhibitor known as p16 (CDK41, CDKN2, INK4A, MTS1) has been proposed as a tumor suppressor gene on chromosome segment 9p21. We have evaluated CDKN2 alterations in 34 non-small cell lung cancers (NSCLCs) with matched normal tissue controls and in 9 NSCLC cell lines by Southern blotting, single-strand conformation polymorphism (SSCP) with the polymerase chain reaction, and direct sequencing. In addition, loss of heterozygosity at chromosome segment 9p21, with the use of the microsatellite marker D9S171, was studied in these samples. Whereas CDKN2 was either deleted or mutated in NSCLC cell lines at a high frequency (6/9, 67%), alterations were much less frequent (7/34, 21%) in primary tumor samples. Only one sample contained a point mutation in exon 1 of CDKN2. In addition, two samples had homozygous deletions of CDKN2 in exon 1; one had a homozygous and three a hemizygous deletion of exon 2. Possibly normal tissue contaminating our tumor samples may have masked homozygous deletions in these cases. Four patient samples had LOH in the region of CDKN2 on chromosome segment 9p21; two of these samples had potentially inactivating alterations of CDKN2; one sample had a mutation of CDKN2, and the other had a homozygous deletion of exon 1. In summary, inactivation of CDKN2 is implicated in the development of about 20% of NSCLC, but the possibility of another tumor suppressor gene on chromosome segment 9p21 important in lung cancer cannot be eliminated.",
        "Doc_title":"Alterations of CDKN2 (p16) in non-small cell lung cancer.",
        "Journal":"Genes, chromosomes & cancer",
        "Do_id":"8589032",
        "Doc_ChemicalList":"Carrier Proteins;Cyclin-Dependent Kinase Inhibitor p16;DNA, Neoplasm",
        "Doc_meshdescriptors":"Base Sequence;Blotting, Southern;Carcinoma, Non-Small-Cell Lung;Carrier Proteins;Chromosomes, Human, Pair 9;Cyclin-Dependent Kinase Inhibitor p16;DNA Mutational Analysis;DNA, Neoplasm;Genes, Tumor Suppressor;Humans;Lung Neoplasms;Microsatellite Repeats;Molecular Sequence Data;Polymorphism, Single-Stranded Conformational;Sequence Deletion",
        "Doc_meshqualifiers":"genetics;genetics;genetics;genetics;genetics",
        "_version_":1605830583843291136},
      {
        "Doc_abstract":"p16(INK4a) is known to play a critical role as a negative regulator of cell cycle progression and differentiation by controlling the activity of the tumor-suppressor protein pRb. The present study evaluated the expression of p16(INK4a) and pRb in cervical squamous and glandular neoplasia. Immunohistochemical staining was performed for p16(INK4a) and pRb in formalin-fixed, paraffin-embedded tissue sections of the uterine cervix using an indirect immunoperoxidase method. p16(INK4a) staining was detected in 7 of 108 sections (6.5%) of normal squamous mucosa, in scattered ciliated columnar cells in 33 of 88 sections (37.5%) of normal endocervical glands, in 9 of 30 sections (30%) with Nabothian cysts, and in 4 of 4 areas (100%) of tubal metaplasia. In contrast, strong p16(INK4a) staining was found in 13 of 18 cases (72.2%) of cervical intraepithelial neoplasia (CIN) I and in all cases of CIN II/III (n = 46), squamous cell carcinoma (n = 18), endocervical glandular dysplasia (n = 10), adenocarcinoma in situ (n = 23), and invasive adenocarcinoma (n = 12). pRb expression was detected in each diagnostic category; however, the proportion of pRb-positive cells was relatively decreased in high-grade premalignant and malignant lesions of the squamous and endocervical mucosa and showed a generally inverse correlation with the expression of p16(INK4a) at the tissue level. These findings confirm a correlation between the expression of p16(INK4a) and pRb in cervical neoplasias and indicate that p16(INK4a) is a specific marker for premalignant and malignant lesions of the squamous and endocervical mucosa.",
        "Doc_title":"Evaluation of p16INK4a and pRb expression in cervical squamous and glandular neoplasia.",
        "Journal":"Human pathology",
        "Do_id":"15188135",
        "Doc_ChemicalList":"Biomarkers, Tumor;Cyclin-Dependent Kinase Inhibitor p16;Retinoblastoma Protein",
        "Doc_meshdescriptors":"Adenocarcinoma;Adolescent;Adult;Aged;Aged, 80 and over;Biomarkers, Tumor;Carcinoma, Squamous Cell;Cervical Intraepithelial Neoplasia;Cyclin-Dependent Kinase Inhibitor p16;Female;Humans;Immunohistochemistry;Middle Aged;Retinoblastoma Protein;Uterine Cervical Neoplasms",
        "Doc_meshqualifiers":"metabolism;pathology;analysis;metabolism;pathology;metabolism;pathology;biosynthesis;biosynthesis;metabolism;pathology",
        "_version_":1605809138763300864},
      {
        "Doc_abstract":"Loss of CDKN2A expression was demonstrated by immunohistochemistry in 87% of oral and oropharyngeal squamous cell carcinoma (OSCC) primary tumor samples. By contrast, DNA studies showed a much lower frequency of loss of the CDKN2A gene. Point mutations and promoter methylation of CDKN2A were seen in 7% and 23%, respectively, of primary tumors. Loss of heterozygosity analysis using a dense set of 9p markers showed allelic imbalance that included CDKN2A in only 31% of samples, but a further 47% showed loss at loci near CDKN2A with apparent retention of CDKN2A. No tumor with any allelic imbalance expressed CDKN2A, whether or not the imbalance appeared to involve the CDKN2A locus. We interpret these data as showing partially overlapping deletions on the two 9p homologues, with homozygous deletion of CDKN2A masked by amplification of contaminating stromal material. Our data show that inactivation of the CDKN2A gene products is a near-universal step in the development of oral and oropharyngeal squamous cell carcinomas, and we suggest that homozygous deletion is the most common mechanism of inactivation. The CDKN2A locus may be particularly prone to deletion because it encodes two unrelated tumor suppressor proteins, CDKN2A (p16INK4a) and p19ARF, and deletion, but not point mutation or methylation, would inactivate both gene products. However, our results also suggest that complex patterns of allelic imbalance in primary squamous carcinomas in general may not provide reliable evidence for the existence of multiple tumor suppressor genes within a single chromosomal region.",
        "Doc_title":"DNA studies underestimate the major role of CDKN2A inactivation in oral and oropharyngeal squamous cell carcinomas.",
        "Journal":"Genes, chromosomes & cancer",
        "Do_id":"10221335",
        "Doc_ChemicalList":"5' Untranslated Regions;DNA, Neoplasm",
        "Doc_meshdescriptors":"5' Untranslated Regions;Carcinoma, Squamous Cell;Chromosomes, Human, Pair 9;CpG Islands;DNA Methylation;DNA Mutational Analysis;DNA, Neoplasm;Gene Expression Regulation, Neoplastic;Genes, p16;Humans;Loss of Heterozygosity;Mouth Neoplasms;Oropharyngeal Neoplasms",
        "Doc_meshqualifiers":"genetics;genetics;genetics;genetics;analysis;genetics;physiology;genetics;physiology;genetics;genetics",
        "_version_":1605901803152474112},
      {
        "Doc_abstract":"A role for the transcription factor JunB in proliferation control was investigated in genetically modified mouse fibroblasts. Increased JunB expression induced high levels of the cyclin-dependent kinase inhibitor p16(INK4a), leading to premature senescence in primary cells and reduced proliferation in 3T3 cells, whereas lack of JunB expression results in decreased p16 levels. Furthermore, JunB-mediated p16 induction in 3T3 cells completely abolished cyclin D-associated kinase activity, resulting in reduced pRb hyperphosphorylation and G(1)-phase extension. Moreover, three AP1-like binding sites were identified in the p16 promoter through which JunB directly activates p16 transcription. Elevated JunB expression in 3T3 cells also inhibited Ras- and Src-mediated transformation and tumour growth in vivo. The suppressive effect of JunB on cell proliferation was shown to be dependent on p16 since it did not occur in INK4a(-/-) fibroblasts that lack both p16 and p19(ARF). These results demonstrate that p16 is a direct transcriptional target gene of JunB and identify JunB as a negative regulator of cell proliferation.",
        "Doc_title":"JunB suppresses cell proliferation by transcriptional activation of p16(INK4a) expression.",
        "Journal":"The EMBO journal",
        "Do_id":"10856241",
        "Doc_ChemicalList":"Carrier Proteins;Cyclin D;Cyclin-Dependent Kinase Inhibitor p16;Cyclins;Proto-Oncogene Proteins c-jun;Transcription Factor AP-1;Protein Kinases;Oncogene Protein pp60(v-src);Cyclin-Dependent Kinases;Oncogene Protein p21(ras)",
        "Doc_meshdescriptors":"Animals;Carrier Proteins;Cell Aging;Cell Cycle;Cell Transformation, Neoplastic;Cells, Cultured;Cyclin D;Cyclin-Dependent Kinase Inhibitor p16;Cyclin-Dependent Kinases;Cyclins;Fibroblasts;G1 Phase;Mice;Mice, Transgenic;Oncogene Protein p21(ras);Oncogene Protein pp60(v-src);Promoter Regions, Genetic;Protein Kinases;Proto-Oncogene Proteins c-jun;Transcription Factor AP-1;Transcriptional Activation",
        "Doc_meshqualifiers":"biosynthesis;genetics;physiology;antagonists & inhibitors;cytology;genetics;metabolism;metabolism",
        "_version_":1605908143457435648},
      {
        "Doc_abstract":"The hallmark of Burkitt lymphoma (BL) is a constitutively activated c-myc gene that drives tumor cell growth. A majority of BL-derived cell lines also carry mutant p53. In addition, the p16INK4a promoter is hypermethylated in most BL biopsies and BL cell lines, leading to silencing of this gene. Activation of c-myc and/or cell cycle dysregulation can induce ARF expression and p53-dependent apoptosis. We therefore investigated the p14ARF-MDM2-p53 pathway in BL cell lines. p14ARF was expressed and localized to nucleoli in all BL carrying mutant p53. Three out of seven BL carrying wt p53 had a homozygous deletion of the CDKN2A locus that encodes both p14ARF and p16INK4a. Three BL carrying wild type p53 retained the CDKN2A locus and overexpressed MDM2. DNA sequencing revealed a point mutation in CDKN2A exon 2 in one of these BL, Seraphine. However, this point mutation did not affect p14ARF's nucleolar localization or ability to induce p53. The Bmi-1 protein that negatively regulates the p14ARF promoter and co-operates with c-myc in tumorigenesis was expressed at low to moderate levels in all BL analysed. Our results indicate that inactivation of the ARF-MDM2-p53 pathway is an essential step during the development of Burkitt lymphoma, presumably as a mechanism to escape c-myc induced apoptosis.",
        "Doc_title":"p14ARF homozygous deletion or MDM2 overexpression in Burkitt lymphoma lines carrying wild type p53.",
        "Journal":"Oncogene",
        "Do_id":"11360201",
        "Doc_ChemicalList":"BMI1 protein, human;Nuclear Proteins;Proteins;Proto-Oncogene Proteins;RNA, Messenger;Repressor Proteins;Tumor Suppressor Protein p14ARF;MDM2 protein, human;Polycomb Repressive Complex 1;Proto-Oncogene Proteins c-mdm2",
        "Doc_meshdescriptors":"Burkitt Lymphoma;Gene Deletion;Gene Expression Regulation, Neoplastic;Genes, p16;Genes, p53;Humans;Nuclear Proteins;Point Mutation;Polycomb Repressive Complex 1;Proteins;Proto-Oncogene Proteins;Proto-Oncogene Proteins c-mdm2;RNA, Messenger;Repressor Proteins;Reverse Transcriptase Polymerase Chain Reaction;Tumor Cells, Cultured;Tumor Suppressor Protein p14ARF",
        "Doc_meshqualifiers":"genetics;metabolism;genetics;genetics;biosynthesis;genetics;genetics;biosynthesis;genetics;biosynthesis;genetics",
        "_version_":1605792593259528192},
      {
        "Doc_abstract":"Two functionally and structurally different proteins, p16(INK4a) and p14(ARF), encoded by the gene INK4a/ARF located at 9p21 are cyclin-dependent kinase (cdk) inhibitors and important cell cycle regulators. More and more evidences have been accumulated to show that the exogenous p16(INK4a) or p14(ARF) can inhibit the cell growth and/or induce the apoptosis. But it is still unclear if they can play positive role when combine with the conventional chemotherapy in cancer treatment. Here we show that cationic liposome-mediated gene transfection of INK4a/ARF into lung cancer cell line A549, in which the INK4a/ARF locus was lost, suppressed the growth and induced apoptosis. When treated with five different chemotherapy drugs with different mechanism after the transfection, A549 got an increased chemosensitivity for adriamycin and cisplatin and an unchanged result for topotecan, taxol or vinorelbine. The results indicated that cell cycle redistribution and increased apoptosis index after transfection might be the main explanation for the enhanced chemosensitivity. The combination of gene therapy with conventional chemotherapy is not always better than single chemotherapy. This trial will be of benefit to the treatment of lung cancer when combine the conventional chemotherapy and gene therapy in the future.",
        "Doc_title":"The co-transfection of p16(INK4a) and p14(ARF) genes into human lung cancer cell line A549 and the effects on cell growth and chemosensitivity.",
        "Journal":"Colloids and surfaces. B, Biointerfaces",
        "Do_id":"16337111",
        "Doc_ChemicalList":"Antineoplastic Agents;Cyclin-Dependent Kinase Inhibitor p16;Tumor Suppressor Protein p14ARF",
        "Doc_meshdescriptors":"Antineoplastic Agents;Apoptosis;Cell Cycle;Cell Division;Cell Line, Tumor;Cyclin-Dependent Kinase Inhibitor p16;Drug Screening Assays, Antitumor;Humans;Lung Neoplasms;Plasmids;Transfection;Tumor Suppressor Protein p14ARF",
        "Doc_meshqualifiers":"pharmacology;genetics;genetics;genetics;pathology;genetics",
        "_version_":1605758874847019008},
      {
        "Doc_abstract":"For evaluating the diagnostic significance of p16(INK4A) over-expression in the uterine cervical intraepithelial neoplasm and in invasive carcinoma, human papillomavirus (HPV) was detected and genotyped by oligonucleotide microarray in archival tissues of 117 cervical specimens, including 47 invasive squamous cell carcinomas (SCC), 30 cases of cervical intraepithelial neoplasia (CIN), 20 adenocarcinomas, and 20 cases of non-neoplastic cervix. The expression of p16(INK4A) protein was immunohistochemically studied in these cases and in five HPV-positive and one HPV-negative cervical cancer cell lines. HPV was detected in 50% of CIN, 61.7% of SCC, and 45.5% of adenocarcinomas. p16(INK4A) expression was seen in all 20 cases of adenocarcinoma, 78.7% (37/47) of SCC, and 96.7% (29/30) of CIN, but not in any cases of the non-neoplastic cervix. There was no difference in p16(INK4A) expression between the HPV-positive and HPV-negative cervical lesions. All HPV-positive and -negative cervical cancer cell lines expressed p16(INK4A) protein. In conclusion, the presence of p16(INK4A) expression in cervical squamous and glandular epithelium indicates the existence of dysplasia or malignancy in the uterine cervix, regardless of HPV infection.",
        "Doc_title":"Human papillomavirus genotyping by oligonucleotide microarray and p16 expression in uterine cervical intraepithelial neoplasm and in invasive carcinoma in Korean women.",
        "Journal":"Pathology international",
        "Do_id":"15998377",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16",
        "Doc_meshdescriptors":"Adenocarcinoma;Carcinoma, Squamous Cell;Cell Line, Tumor;Cervical Intraepithelial Neoplasia;Cyclin-Dependent Kinase Inhibitor p16;Female;Gene Expression Regulation, Neoplastic;Genotype;HeLa Cells;Humans;Korea;Neoplasm Invasiveness;Oligonucleotide Array Sequence Analysis;Papillomaviridae;Papillomavirus Infections;Polymerase Chain Reaction;Uterine Cervical Neoplasms",
        "Doc_meshqualifiers":"genetics;metabolism;virology;genetics;metabolism;virology;genetics;metabolism;virology;biosynthesis;genetics;methods;genetics;genetics;metabolism;virology;methods;genetics;metabolism;virology",
        "_version_":1605819955205373952},
      {
        "Doc_abstract":"p16(INK4a), an indirect marker of cell cycle dysregulation, is commonly expressed in cervical dysplasias and carcinomas associated with high risk human papillomavirus (HR-HPV) infections. Although p16(INK4a) immunohistology is routinely used as a cost effective surrogate marker, many of the published articles are confusing and contradictory. The discrepancies can be ascribed to a multitude of factors operating at the molecular, technical and interpretative levels. In the first place, our simplistic model of viral mediated oncogenesis is speculative and fails to account for all the known biomolecular changes. Unresolved technical issues include the variables of tissue fixation, antibody dilution, antibody isotype and clone, and the sensitivity of the particular detection method. Within any controlled staining method, strong diffuse or 'block' immunoreactivity in squamous cells may be found in moderate/severe dysplasia (CIN 2/3) and invasive squamous carcinoma. In contrast, focal or multifocal reactivity in squamous cells may be artefactual, related to low risk or HR-HPV. p16(INK4a) is less reliable when dealing with glandular lesions since considerable overlap exists between reactive and dysplastic lesions. In addition not all glandular dysplasias/carcinomas are HR-HPV related, nor are all p16(INK4a) immunoreactive lesions associated with HR-HPV. We conclude that p16(INK4a) immunoperoxidase shows greater specificity than sensitivity for squamous lesions; in comparison, glandular dysplasias/carcinomas show reduced specificity and sensitivity. Like all cell cycle regulatory proteins, the future diagnostic role of p16(INK4a) is limited. The ideal diagnostic molecular test for cervical dysplasias will detect a HR-HPV related product after, but not before, cell transformation and will reliably predict those cases yet to experience disease progression.",
        "Doc_title":"Diagnostic utility of p16INK4a: a reappraisal of its use in cervical biopsies.",
        "Journal":"Pathology",
        "Do_id":"18446622",
        "Doc_ChemicalList":"Biomarkers, Tumor;Cyclin-Dependent Kinase Inhibitor p16;DNA, Viral",
        "Doc_meshdescriptors":"Biomarkers, Tumor;Biopsy;Cervical Intraepithelial Neoplasia;Cyclin-Dependent Kinase Inhibitor p16;DNA, Viral;Female;Humans;Immunoenzyme Techniques;Papillomaviridae;Papillomavirus Infections;Precancerous Conditions;Uterine Cervical Neoplasms",
        "Doc_meshqualifiers":"metabolism;metabolism;virology;metabolism;genetics;methods;genetics;isolation & purification;diagnosis;metabolism;metabolism;virology;metabolism;virology",
        "_version_":1605796648166883328},
      {
        "Doc_abstract":"To conduct high-throughput mutational analysis in 6 commonly used head and neck cancer cell lines. Comprehensive mutation analysis of primary head and neck squamous cell carcinoma (HNSCC) tumors has recently been reported, and mutations in the NOTCH receptors, TP53 and CDKN2A, were key findings. Established cell lines are valuable tools to study cancer in vitro. Similar high-throughput mutational analysis of head and neck cancer cell lines is necessary to confirm their mutational profile.;DNA was extracted from American Type Culture Collection (ATCC) cell lines Cal27, Detroit562, FaDu, SCC4, SCC15, and SCC25. Cell line identity was confirmed by short tandem repeat (STR) analysis, and human papillomavirus (HPV) infection status was assessed by real-time polymerase chain reaction. A total of 535 cancer-associated genes were sequenced through a limited exome capture on the Illumina HiSeq system.;London Regional Cancer Program.;The identity of the 6 cell lines was confirmed by STR analysis, and all lines tested negative for HPV infection. We achieved an average of 129-fold coverage with paired-end 100 base-pair reads. Sequencing revealed an average of 38 damaging mutations in each cell line (range, 30-45). The TP53 mutations, predicted to confer loss of function, were noted in all cell lines, and damaging CDKN2A mutations were found in all lines except SCC15.;High-throughput sequencing of head and neck cancer cell lines revealed similar mutations to those observed in primary tumors. Thus, these lines reflect the tumor biology of HNSCC and can serve as valuable models to study HNSCC in vitro.",
        "Doc_title":"Frequent mutations in TP53 and CDKN2A found by next-generation sequencing of head and neck cancer cell lines.",
        "Journal":"Archives of otolaryngology--head & neck surgery",
        "Do_id":"22911296",
        "Doc_ChemicalList":"TP53 protein, human;Tumor Suppressor Protein p53",
        "Doc_meshdescriptors":"Carcinoma, Squamous Cell;Cell Line, Tumor;DNA Mutational Analysis;Genes, p16;Genotype;Head and Neck Neoplasms;Humans;Microsatellite Repeats;Papillomaviridae;Papillomavirus Infections;Real-Time Polymerase Chain Reaction;Tumor Suppressor Protein p53",
        "Doc_meshqualifiers":"genetics;virology;genetics;virology;genetics;isolation & purification;virology;genetics",
        "_version_":1605844121178603520},
      {
        "Doc_abstract":"Two distinct etiologies of head and neck squamous cell carcinoma (HNSCC) have been proposed, DNA damage owing to tobacco and alcohol exposure and human papillomavirus (HPV) oncogene-mediated transformation. Common genetic alterations in HNSCC include TP53 mutations, 11q13 amplification (amp) and CDKN2A/p16 mutations or promoter methlyation. However, in HPV+ HNSCC it is frequent to observe wild-type TP53 and expression of p16. The relationship of this unusual pattern with 11q13 amp has not been tested. In a retrospective study on 125 HNSCC patients, only 17% (five out of 30) of HPV+ vs 44% (39 out of 89) of HPV - tumours expressed 11q13 amp (adjusted odds ratio (OR)=0.2, 95% confidence interval (CI)=0.1-0.6). A subpopulation of tumours (n=69) were classified according to the three molecular markers, TP53, p16 and 11q13 amp. In addition to wild-type TP53, and p16 expression, HPV+ tumours were more likely not to be amplified at 11q13 (OR=6.5, 95% CI=1.8-23.9). As HPV+ HNSCC lack the genetic alterations which are common in other tumours, we hypothesise that HPV infection may represent an early event in the HNSCC carcinogenic process, thus suggesting a distinct molecular pathway.",
        "Doc_title":"11q13 amplification status and human papillomavirus in relation to p16 expression defines two distinct etiologies of head and neck tumours.",
        "Journal":"British journal of cancer",
        "Do_id":"17003776",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;DNA, Viral;Tumor Suppressor Protein p53",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Carcinoma, Squamous Cell;Chromosomes, Human, Pair 11;Cyclin-Dependent Kinase Inhibitor p16;DNA, Viral;Female;Gene Amplification;Head and Neck Neoplasms;Humans;Male;Middle Aged;Papillomaviridae;Papillomavirus Infections;Retrospective Studies;Sequence Analysis, DNA;Survival Rate;Tumor Cells, Cultured;Tumor Suppressor Protein p53",
        "Doc_meshqualifiers":"genetics;virology;genetics;genetics;chemistry;genetics;genetics;virology;genetics;isolation & purification;genetics;virology;genetics",
        "_version_":1605746284939968513},
      {
        "Doc_abstract":"p16 is known to be an excellent surrogate marker of human papillomavirus infection in squamous cell carcinoma of the cervix. Recent studies have demonstrated a link between human papillomavirus infection and a subset of head and neck squamous cell carcinomas, especially from the oropharynx. The aims of this study were to determine the incidence of p16 expression in squamous cell carcinomas of noncervical origin and to assess its utility as a surrogate marker of human papillomavirus infection in various noncervical primary sites. One hundred thirty-seven squamous cell carcinomas from 5 primary sites, including 34 from the oropharynx (tonsil and base of tongue), 43 cases from nonoropharyngeal head and neck sites, and 20 cases each from the lung, esophagus, and skin, were retrieved from our surgical pathology archives. Immunohistochemistry for p16 was performed on each case. All p16-positive cases and 21 p16-negative cases were further tested for both high-risk and low-risk human papillomavirus by in situ hybridization. p16 expression was detected in 54 cases overall, including 25 (74%) of 34 oropharyngeal squamous cell carcinomas, 8 (19%) of 43 nonoropharyngeal head and neck squamous cell carcinomas including 3 of 4 from the sinonasal cavity, 6 (30%) of 20 esophageal squamous cell carcinomas, 7 (35%) of 20 lung squamous cell carcinomas, and 8 (40%) of 20 skin squamous cell carcinomas. Of the 54 p16-positive cases, 30 were positive for high-risk human papillomavirus, including 24 (96%) of 25 from the oropharynx, 5 (63%) of 8 from nonoropharyngeal head and neck sites, and 1 (17%) of 6 from the esophagus. All 7 lung and 8 skin cases tested were negative. All p16-positive cases were negative for low-risk human papillomavirus. In selected head and neck squamous cell carcinomas, mainly from the oropharynx and sinonasal cavity, p16 positivity correlates well with high-risk human papillomavirus infection. p16 is not a reliable indicator of high-risk human papillomavirus infection in squamous cell carcinomas of the lung, skin, and esophagus.",
        "Doc_title":"The relationship between p16 expression and high-risk human papillomavirus infection in squamous cell carcinomas from sites other than uterine cervix: a study of 137 cases.",
        "Journal":"Human pathology",
        "Do_id":"21840041",
        "Doc_ChemicalList":"Biomarkers, Tumor;Cyclin-Dependent Kinase Inhibitor p16",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Biomarkers, Tumor;Carcinoma, Squamous Cell;Cyclin-Dependent Kinase Inhibitor p16;Female;Head and Neck Neoplasms;Human papillomavirus 16;Humans;Male;Middle Aged;Oropharyngeal Neoplasms;Papillomavirus Infections;Young Adult",
        "Doc_meshqualifiers":"metabolism;metabolism;pathology;virology;metabolism;metabolism;pathology;virology;isolation & purification;metabolism;pathology;virology;complications;metabolism;pathology",
        "_version_":1605789943762780160},
      {
        "Doc_abstract":"Data indicate a better prognosis for human papillomavirus (HPV)-associated head and neck squamous cell carcinoma (HNSCC). HPV and p16 detection are established markers for HPV-related HNSCC. Both are accepted as survival-independent predictors. Previous studies investigating the survival in HNSCC patients depending on HPV(+/-) and p16(+/-) status consistently found discordant results with p16(-)/HPV(+) and p16(+)/HPV(-). However, no meta-analysis regarding the survival according to combined HPV/p16 status has been performed yet. The objective of this study was to discriminate the impact of combined HPV(+/-) and p16(+/-) status on survival. Data sources were identification and review of publications assessing survival of the distinct subgroups with both p16 and HPV investigated in HNSCC until February, 2015. A meta-analysis was performed to classify survival and clinical outcomes. 18 out of 397 articles (4424 patients) were eligible for the meta-analysis. The percent proportion of the subgroups was 25% for HPV(+)/p16(+), 61.2% for HPV(-)/p16(-), 7.1% for HPV(-)/p16(+) and 6.8% for HPV(+)/P16(-). The meta-analysis showed a significantly improved 5-year overall survival (OS), 5-year disease-free survival and their corresponding hazard ratio for HPV(+)/p16(+) HNSCC in comparison to HPV(-)/p16(-), HPV(+)/p16(-) and HPV(-)/p16(+). The 5-year OS of the HPV(-)/p16(+) subgroup was intermediate while HPV(+)/p16(-) and HPV(-)/p16(-) HNSCC had the shortest survival. With current therapeutic strategies, survival of patients with HNSCC is better if associated with HPV(+)/p16(+) or HPV(-)/p16(+). Clinical trials are needed to confirm the distinct survival pattern and to investigate possible differences in survival for HPV(+)/p16(-) and HPV(-)/p16(+) HNSCC. To further differentiate p16(+) HNSCC, HPV testing may be advisable. ",
        "Doc_title":"Meta-analysis of survival in patients with HNSCC discriminates risk depending on combined HPV and p16 status.",
        "Journal":"European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery",
        "Do_id":"26227616",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605746283765563393},
      {
        "Doc_abstract":"There is increasing evidence that predisposition to some cancers has a genetic component. There is a high incidence of loss of heterozygosity on chromosome 9, in the region of tumour suppressor gene, CDKN2A (also known as p16), in sporadic squamous cell cancer of the head and neck (SCCHN). To investigate the possibility that CDKN2A may be involved in the inherited susceptibility to SCCHN, the 3 coding exons of CDKN2A were sequenced in 40 patients who had developed a second primary cancer after an index squamous cell cancer of the head and neck. No mutations were found and we conclude that CDKN2A mutations do not play a major role in cancer susceptibility in this group.",
        "Doc_title":"No germline mutations in CDKN2A (p16) in patients with squamous cell cancer of the head and neck and second primary tumours.",
        "Journal":"British journal of cancer",
        "Do_id":"11720478",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16",
        "Doc_meshdescriptors":"Aged;Carcinoma, Squamous Cell;Chromosomes, Human, Pair 9;Cyclin-Dependent Kinase Inhibitor p16;Female;Genetic Predisposition to Disease;Germ-Line Mutation;Head and Neck Neoplasms;Humans;Loss of Heterozygosity;Male;Middle Aged;Neoplasms, Second Primary",
        "Doc_meshqualifiers":"genetics;pathology;genetics;analysis;genetics;genetics;genetics;pathology;genetics",
        "_version_":1605821881547489280},
      {
        "Doc_abstract":"Seven tumour suppressor genes (Chk1, Chk2, Apaf1, Rb1, p53, p16(INK4a) and p14(ARF)) and two oncogenes (N-ras and BRAF) were screened in nine human malignant melanoma (HMM) cell lines for point mutations or small deletions/insertions by DGGE, TGGE and SCCP analysis. For the first time in human mesothelioma, Chk1 gene mutations were detected in two of the nine investigated HMM cell lines. P53 gene mutations were found in three cell lines and p16(INK4a) mutations in 5. Mutation of the Chk1 gene implies a novel disruption mechanism of the p53 pathway in HMM, without affecting p53 itself. According to our knowledge, this is the first mutation screening of Chk1, Chk2, Apaf1 and Rb1 in human malignant mesothelioma.",
        "Doc_title":"Mutational analysis of 9 different tumour-associated genes in human malignant mesothelioma cell lines.",
        "Journal":"Oncology reports",
        "Do_id":"16077986",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;Oncogene Proteins;Tumor Suppressor Protein p53;Tumor Suppressor Proteins;Protein Kinases;CHEK1 protein, human;Checkpoint Kinase 1",
        "Doc_meshdescriptors":"Base Sequence;Cell Line, Tumor;Checkpoint Kinase 1;Cyclin-Dependent Kinase Inhibitor p16;DNA Mutational Analysis;Humans;Mesothelioma;Mutation;Oncogene Proteins;Protein Kinases;Sequence Homology, Nucleic Acid;Tumor Suppressor Protein p53;Tumor Suppressor Proteins",
        "Doc_meshqualifiers":"genetics;genetics;pathology;genetics;genetics;genetics;genetics",
        "_version_":1605802697080963072},
      {
        "Doc_abstract":"Ionizing radiation leads to rapid stabilization and activation of the p53 tumor suppressor. Previous reports demonstrate that murine p19ARF cooperates with p53 in the cellular response to gamma irradiation. Here, we show that endogenous ARF sequentially interacts with p53 and MDM2 following irradiation of primary human and mouse embryonic fibroblasts. Shortly after irradiation, p14ARF binds p53 independently of MDM2. As nuclear pools of p53 decline, endogenous p14ARF co-immunoprecipitates with MDM2 and is localized within the nucleolus. Interestingly, p14ARF nucleolar localization during this response is abrogated in cells lacking functional p53. Taken together, our data suggest that human and murine ARF contribute to the mammalian DNA damage response.",
        "Doc_title":"p14ARF is a component of the p53 response following ionizing irradiation of normal human fibroblasts.",
        "Journal":"Oncogene",
        "Do_id":"15195142",
        "Doc_ChemicalList":"Cdkn2a protein, mouse;Cyclin-Dependent Kinase Inhibitor p16;Nuclear Proteins;Proto-Oncogene Proteins;Tumor Suppressor Protein p14ARF;Tumor Suppressor Protein p53;MDM2 protein, human;Mdm2 protein, mouse;Proto-Oncogene Proteins c-mdm2",
        "Doc_meshdescriptors":"Animals;Cell Line;Cell Nucleolus;Cyclin-Dependent Kinase Inhibitor p16;DNA Damage;Fibroblasts;Humans;Mice;Nuclear Proteins;Proto-Oncogene Proteins;Proto-Oncogene Proteins c-mdm2;Radiation, Ionizing;Tumor Suppressor Protein p14ARF;Tumor Suppressor Protein p53",
        "Doc_meshqualifiers":"chemistry;metabolism;radiation effects;metabolism;metabolism;analysis;metabolism;physiology;analysis;metabolism",
        "_version_":1605898380867796992},
      {
        "Doc_abstract":"Overexpression of p16(INK4a) has been observed when retinoblastoma protein is inactivated by high-risk human papillomavirus (HPV) oncoprotein E7. We investigated overexpression of p16(INK4a) and HPV infection in cervical squamous neoplasia to evaluate the oncogenic potential among various HPV subtypes. The high-risk HPV was detected by PCR in 69.8% (37/53), 97.5% (39/40), 91.7% (44/48), and 100% (16/16) of cervical intraepithelial neoplasia (CIN)1, CIN2, CIN3, and squamous cell carcinoma (SCC), respectively. The p16(INK4a) overexpression was investigated immunohistochemically using a p16(INK4a)-specific monoclonal antibody (clone E6H4). In high-risk HPV positive cases, 32.4% (12/37) of CIN1, 82.1% (32/39) of CIN2, 93.2% (41/44) of CIN3, and all (16/16) SCC showed p16(INK4a) overexpression. The incidence of p16(INK4a) overexpression was significantly different between CIN1 and CIN2, suggesting that the disorder of cell cycle regulation by HPV frequently occurred from CIN2. As for CIN1 cases, p16(INK4a) overexpression was observed more frequently in HPV16 and HPV52 than in HPV51 and HPV35. Using p16(INK4a) as a bio marker of HPV oncogenic activity, we demonstrate that the level of pRb dysfunction by high-risk HPV varied from subtypes and was getting more frequent from CIN2.",
        "Doc_title":"Overexpression of p16 INK4a as an indicator for human papillomavirus oncogenic activity in cervical squamous neoplasia.",
        "Journal":"International journal of gynecological cancer : official journal of the International Gynecological Cancer Society",
        "Do_id":"16445657",
        "Doc_ChemicalList":"Biomarkers, Tumor;Cyclin-Dependent Kinase Inhibitor p16",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Biomarkers, Tumor;Biopsy, Needle;Carcinoma, Squamous Cell;Cohort Studies;Cyclin-Dependent Kinase Inhibitor p16;Female;Gene Expression Regulation, Neoplastic;Humans;Immunohistochemistry;Middle Aged;Papillomaviridae;Papillomavirus Infections;Polymerase Chain Reaction;Prognosis;Sensitivity and Specificity;Tissue Culture Techniques;Uterine Cervical Neoplasms",
        "Doc_meshqualifiers":"analysis;pathology;virology;analysis;genetics;pathogenicity;genetics;pathology;pathology;virology",
        "_version_":1605747072339804161},
      {
        "Doc_abstract":"Point mutations in the tumor suppressor gene p16(INK4a) (also known as p16, CDKN2, MTS1, and INK4a) are found in many tumor types. Because the function of the products of these naturally occurring mutants has not been fully explored, we investigated the functional activities of a wide range of naturally occurring p16 mutant proteins.;Sixteen cancer-associated p16 mutant proteins, resulting from missense mutations, were characterized for their ability to bind and inhibit the cyclin-dependent kinases (CDK4 and CDK6) and to induce cell cycle arrest in G(1) phase.;Among 16 mutants analyzed, nine had detectable functional defects. Three mutants (D84V, D84G, and R87P) had defects in CDK binding, kinase inhibition, and cell cycle arrest. The corresponding mutations are located in the third ankyrin repeat in a highly conserved region believed to form the CDK binding cleft. Three mutants (P48L, D74N, and R87L) had defects in kinase inhibition and cell cycle arrest. Among the 10 mutants with normal CDK binding and inhibitory activity, three mutants (N71S, R80L, and H83Y) had defects only in their ability to induce cell cycle arrest. Thus, p16 mutant proteins that retain CDK4 and CDK6 binding may have more subtle functional defects. All nine mutations leading to functional impairments mapped to the central portion of the p16 protein. Ankyrin repeats II and III appear more critical to p16 function, and mutations in ankyrin repeats I and IV are less likely to disrupt p16 function.",
        "Doc_title":"Biologic and biochemical analyses of p16(INK4a) mutations from primary tumors.",
        "Journal":"Journal of the National Cancer Institute",
        "Do_id":"10491434",
        "Doc_ChemicalList":"Ankyrins;Cyclin-Dependent Kinase Inhibitor p16;Proto-Oncogene Proteins;Glutathione Transferase;Protein-Serine-Threonine Kinases;CDK4 protein, human;CDK6 protein, human;Cyclin-Dependent Kinase 4;Cyclin-Dependent Kinase 6;Cyclin-Dependent Kinases",
        "Doc_meshdescriptors":"Amino Acid Sequence;Ankyrins;Cyclin-Dependent Kinase 4;Cyclin-Dependent Kinase 6;Cyclin-Dependent Kinase Inhibitor p16;Cyclin-Dependent Kinases;G1 Phase;Genes, p16;Glutathione Transferase;Humans;Molecular Sequence Data;Mutation, Missense;Protein Binding;Protein-Serine-Threonine Kinases;Proto-Oncogene Proteins",
        "Doc_meshqualifiers":"genetics;chemistry;genetics;metabolism;antagonists & inhibitors;metabolism;genetics;genetics;antagonists & inhibitors;metabolism",
        "_version_":1605852418733506560},
      {
        "Doc_abstract":"The p16INK4a is an important tumor suppressor gene (TSG) and aberrant methylation of promoter is known to be a major inactivation mechanism of the tumor suppressor and tumor-related genes. Aberrant TSG methylation was considered an important epigenetic silencing mechanism in the progression of head and neck squamous cell carcinoma (HNSCC). However, some studies have reported differences in the methylation frequencies of P16INK4a promoter between cancer and the corresponding control group. Therefore, we conducted a meta-analysis to better identify the association.;PubMed, Ovid, ISI Web of Science, and EMBASE were searched to identify eligible studies to evaluate the association of p16INK4a promoter methylation and HNSCC. Odds ratio (ORs) and 95% confidence intervals (95%CI) were calculated to evaluate the strength of association between p16INK4a promoter methylation and HNSCC.;A total of twenty-one studies with 1155 cases and 1017 controls were included in the meta-analysis. The frequencies of p16INK4a promoter methylation in the cancer group were significantly higher than those in the control group (cancer group: median: 46.67%, range = 7.84%-95.12%; control group: median: 18.37%, range = 0-83.33%; respectively). The pooled odds ratio was 3.37 (95%CI = 2.32-4.90) in the cancer group versus the corresponding control group under the random-effects model.;This meta-analysis of 21 published studies identified that aberrant methylation of p16INK4a promoter was found to be significantly associated with HNSCC.",
        "Doc_title":"Association between P16INK4a promoter methylation and HNSCC: a meta-analysis of 21 published studies.",
        "Journal":"PloS one",
        "Do_id":"25835498",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16",
        "Doc_meshdescriptors":"Carcinoma, Squamous Cell;Case-Control Studies;Cyclin-Dependent Kinase Inhibitor p16;DNA Methylation;Epigenesis, Genetic;Head and Neck Neoplasms;Humans;Neoplasm Staging;Odds Ratio;Promoter Regions, Genetic",
        "Doc_meshqualifiers":"genetics;metabolism;pathology;genetics;metabolism;genetics;metabolism;pathology",
        "_version_":1605759942666485760},
      {
        "Doc_abstract":"Loss of the INK4a/ARF/INK4b locus on chromosome 9p21 is among the most frequent cytogenetic events in human cancer. The products of the locus--p15(INK4b), p16(INK4a), and ARF--play widespread and independent roles in tumor suppression. Recent data also suggest that expression of p16(INK4a) induces an age-dependent decrease in the proliferative capacity of certain tissue-specific stem cells and unipotent progenitors. Here, we discuss the regulation and role of p16(INK4a), ARF, and p15(INK4b) in cancer and aging.",
        "Doc_title":"The regulation of INK4/ARF in cancer and aging.",
        "Journal":"Cell",
        "Do_id":"17055429",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor Proteins;Cyclin-Dependent Kinase Inhibitor p15;Cyclin-Dependent Kinase Inhibitor p16;ADP-Ribosylation Factors",
        "Doc_meshdescriptors":"ADP-Ribosylation Factors;Aging;Animals;Cell Aging;Cell Transformation, Neoplastic;Cyclin-Dependent Kinase Inhibitor Proteins;Cyclin-Dependent Kinase Inhibitor p15;Cyclin-Dependent Kinase Inhibitor p16;Gene Expression Regulation, Neoplastic;Gene Silencing;Humans",
        "Doc_meshqualifiers":"genetics;metabolism;metabolism;metabolism;genetics;metabolism;metabolism;metabolism",
        "_version_":1605766593292271616},
      {
        "Doc_abstract":"The tumor suppressor gene CDKN2A generates at least three different transcriptional variants, each of which is thought to encode a tumor suppressor. However, the inhibitory activities of these variants have not yet been compared in the same cells. Protein therapy is known to have several advantages over gene therapy. Thus, investigation of the exogenous protein molecule of the most effective suppressor may yield meaningful information regarding protein-based cancer therapy.;The inhibitory effects of p16INK4a, p14ARF and p12 were studied in the human lung cancer cell line A549 which lacks the CDKN2A locus. The eukaryotic expression plasmids of the three transcriptional variants were constructed and stably transfected into the cells. RNA and protein expression by the plasmids was confirmed using RT-PCR and fluorescence immunocytochemistry, respectively. Cell growth inhibition and cell-cycle redistribution after transfection were investigated based on growth curve and flow cytometry analyses. An exogenous His-tag fusion p16INK4a protein was obtained and purified by affinity chromatography. Cell growth inhibition and cell cycle arrest induced by the expression of p16INK4a protein were measured in A549 cells transduced with the exogenous protein.;While all three variants suppressed cell growth, p16INK4a had the strongest effect. Marked G1-phase accumulation and S-phase inhibition were induced by p16INK4a and p14ARF but not by p12. Exogenous p16INK4a protein was successfully expressed and purified and transduction of the fusion protein into A549 cells inhibited cell growth by G1-->S arrest.;Among the three transcript variants, p16INK4a has a greater inhibitory effect than p14ARF and p12; exogenous p16INK4a protein should be further investigated for use in cancer therapy as a protein agent.",
        "Doc_title":"Comparison of the inhibitory effects of three transcriptional variants of CDKN2A in human lung cancer cell line A549.",
        "Journal":"Journal of experimental & clinical cancer research : CR",
        "Do_id":"20565749",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;RNA, Messenger",
        "Doc_meshdescriptors":"Alternative Splicing;Blotting, Western;Cell Cycle;Cell Proliferation;Cyclin-Dependent Kinase Inhibitor p16;Flow Cytometry;Genetic Variation;Humans;Immunoenzyme Techniques;Lung Neoplasms;RNA, Messenger;Reverse Transcriptase Polymerase Chain Reaction;Tumor Cells, Cultured",
        "Doc_meshqualifiers":"genetics;metabolism;genetics;genetics;pathology;prevention & control;genetics",
        "_version_":1605897777603149825},
      {
        "Doc_abstract":"Dilantin sodium (phenytoin) is an antiepileptic drug, which is routinely used to control generalized tonic clonic seizure and partial seizure episodes. A few case reports of oral squamous cell carcinomas arising from regions of phenytoin induced gingival overgrowth (GO), and overexpression of mitogenic factors and p53 have presented this condition as a pathology with potential to transform into malignancy. We recently investigated the genetic status of p53 and H-ras, which are known to be frequently mutated in Indian oral carcinomas in GO tissues and found them to only contain wild type sequences, which suggested a non-neoplastic nature of phenytoin induced GO. However, besides p53 and H-ras, other oncogenes and tumor suppressors such as PIK3CA, p14ARF, p16INK4a and p21Waf1/Cip1, are frequently altered in oral squamous cell carcinoma, and hence are required to be analyzed in phenytoin induced GO tissues to be affirmative of its non-neoplastic nature.;100ng of chromosomal DNA isolated from twenty gingival overgrowth tissues were amplified with primers for exons 9 and 20 of PIK3CA, exons 1, 1 and 2 of p16INK4a and p14ARF, and exon 2 of p21Waf1/Cip1, in independent reactions. PCR amplicons were subsequently gel purified and eluted products were sequenced.;Sequencing analysis of the twenty samples of phenytoin induced gingival growth showed no mutations in the analyzed exons of PIK3CA, p14ARF, p16INK4a and p21Waf1/Cip1.;The present data indicate that the mutational alterations of genes, PIK3CA, p14ARF, p16INK4a and p21Waf1/Cip1 that are frequently mutated in oral squamous cell carcinomas are rare in phenytoin induced gingival growth. Thus the findings provide further evidence that phenytoin induced gingival overgrowth as a non-neoplastic lesion, which may be considered as clinically significant given the fact that the epileptic patients are routinely administered with phenytoin for the rest of their lives to control seizure episodes.",
        "Doc_title":"Comprehensive mutation analysis of PIK3CA, p14ARF, p16INK4a and p21Waf1/Cip1 genes is suggestive of a non- neoplastic nature of phenytoin induced gingival overgrowth.",
        "Journal":"Asian Pacific journal of cancer prevention : APJCP",
        "Do_id":"23803025",
        "Doc_ChemicalList":"CDKN1A protein, human;Cyclin-Dependent Kinase Inhibitor p16;Cyclin-Dependent Kinase Inhibitor p21;Tumor Suppressor Protein p14ARF;Tumor Suppressor Protein p53;Phenytoin;Phosphatidylinositol 3-Kinases;PIK3CA protein, human;Proto-Oncogene Proteins p21(ras)",
        "Doc_meshdescriptors":"Base Sequence;Carcinoma, Squamous Cell;Cross-Sectional Studies;Cyclin-Dependent Kinase Inhibitor p16;Cyclin-Dependent Kinase Inhibitor p21;DNA Mutational Analysis;Gingival Overgrowth;Humans;Mouth Neoplasms;Mutation;Phenytoin;Phosphatidylinositol 3-Kinases;Proto-Oncogene Proteins p21(ras);Sequence Analysis, DNA;Tumor Suppressor Protein p14ARF;Tumor Suppressor Protein p53",
        "Doc_meshqualifiers":"chemically induced;genetics;genetics;genetics;chemically induced;adverse effects;genetics;genetics;genetics;genetics",
        "_version_":1605847086812626944},
      {
        "Doc_abstract":"The tumor suppressor protein p16(INK4a) is a member of the INK4 family of cyclin-dependent kinase (Cdk) inhibitors, which are involved in the regulation of the eukaryotic cell cycle. However, the mechanisms underlying the anti-proliferative effects of p16(INK4a) have not been fully elucidated. Using yeast two-hybrid screening, we identified the eukaryotic elongation factor (eEF)1A2 as a novel interacting partner of p16(INK4a). eEF1A2 is thought to function as an oncogene in cancers. The p16(INK4a) protein interacted with all but the D2 (250-327 aa) domain of eEF1A2. Ectopic expression of p16(INK4a) decreased the expression of eEF1A2 and inhibited cancer cell growth. Furthermore, suppression of protein synthesis by expression of p16(INK4a) ex vivo was verified by luciferase reporter activity. Microinjection of p16(INK4a) mRNA into the cytoplasm of Xenopus embryos suppressed the luciferase mRNA translation, whereas the combination of p16(INK4a) and morpholino-eEF1A2 resulted in a further reduction in translational activity. We conclude that the interaction of p16(INK4a) with eEF1A2, and subsequent downregulation of the expression and function of eEF1A2 is a novel mechanism explaining the anti-proliferative effects of p16(INK4a).",
        "Doc_title":"Tumor suppressor p16(INK4a) inhibits cancer cell growth by downregulating eEF1A2 through a direct interaction.",
        "Journal":"Journal of cell science",
        "Do_id":"23444377",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;EEF1A2 protein, human;Peptide Elongation Factor 1",
        "Doc_meshdescriptors":"Animals;Blotting, Western;CHO Cells;COS Cells;Cell Line, Tumor;Cell Proliferation;Cercopithecus aethiops;Cricetinae;Cricetulus;Cyclin-Dependent Kinase Inhibitor p16;HeLa Cells;Humans;Immunoprecipitation;Peptide Elongation Factor 1;Protein Binding;Two-Hybrid System Techniques;Xenopus laevis",
        "Doc_meshqualifiers":"metabolism;metabolism",
        "_version_":1605899083301519360},
      {
        "Doc_abstract":"Much of the current literature regarding the molecular pathophysiology of human papillomavirus (HPV) in head and neck squamous cell carcinoma (HNSCC) has focused on the virus's effect on cell cycle modulation and cell proliferation. A second mechanism of pathogenicity employed by HPV, dysregulation of cellular DNA repair processes, has been more sparsely studied. The purpose of this review is to describe current understanding about the effect of HPV on DNA repair in HNSCC, taking cues from cervical cancer literature. HPV affects DNA-damage response pathways by interacting with many proteins, including ATM, ATR, MRN, -H2AX, Chk1, Chk2, p53, BRCA1, BRCA2, RAD51, Rb-related proteins 107 and 130, Tip60, and p16INK4A. Further elucidation of these pathways could lead to development of targeted therapies and improvement of current treatment protocols. ",
        "Doc_title":"The effect of human papillomavirus on DNA repair in head and neck squamous cell carcinoma.",
        "Journal":"Oral oncology",
        "Do_id":"27688101",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605818726780764160},
      {
        "Doc_abstract":"Long-term survival of head and neck squamous cell carcinoma (HNSCC) patients has not improved significantly during the last 20 years and recurrent disease is frequently observed. In this study, the potential presence of pre-malignant cells or rare malignant cells at the time of diagnosis in HNSCC was investigated.;Fifty-nine biopsies obtained from 41 HNSCC patients were analysed. Eighteen of these biopsies were normal mucosal tissue, located at least 5 cm from the tumour margin. DNA content and DNA methylation of p16, DAPK and RASSF1A was examined.;Thirty-nine out of 41 (95%) tumour biopsies showed p16 methylation and 21 (51%) of them displayed aneuploidy. Of 18 distant normal mucosal biopsies, 6 (33%) of these showed evidence of aneuploidy and 15(83%) of them showed methylated p16 genes. Among paired samples, the highest frequencies of DNA methylation were found in tumours with aneuploidy. Regardless of DNA content, methylation at DAPK, RASSF1A or p16 were found in the corresponding distant mucosal biopsies.;The cells with abnormal DNA content or DNA methylation in mucosal tissue were not detected clinically or by pathological macroscopic and microscopic examination. Thus, distant mucosal tissue DNA content and DNA methylation analyses in combination with histopathology will provide a better prognostic base for the evaluation and treatment of HNSCC patients.",
        "Doc_title":"DNA content and methylation of p16, DAPK and RASSF1A gene in tumour and distant, normal mucosal tissue of head and neck squamous cell carcinoma patients.",
        "Journal":"Anticancer research",
        "Do_id":"21115918",
        "Doc_ChemicalList":"Apoptosis Regulatory Proteins;DNA, Neoplasm;Neoplasm Proteins;P16 protein, human;RASSF1 protein, human;Tumor Suppressor Proteins;Death-Associated Protein Kinases;Calcium-Calmodulin-Dependent Protein Kinases",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Aneuploidy;Apoptosis Regulatory Proteins;Calcium-Calmodulin-Dependent Protein Kinases;Carcinoma, Squamous Cell;CpG Islands;DNA Methylation;DNA, Neoplasm;Death-Associated Protein Kinases;Female;Head and Neck Neoplasms;Humans;Male;Middle Aged;Mucous Membrane;Neoplasm Proteins;Polymerase Chain Reaction;Prognosis;Promoter Regions, Genetic;Survival Rate;Tumor Suppressor Proteins",
        "Doc_meshqualifiers":"genetics;genetics;genetics;pathology;genetics;genetics;pathology;metabolism;pathology;genetics;genetics;genetics",
        "_version_":1605893865240264704},
      {
        "Doc_abstract":"CDKN2A (p16) disruption is reported as a frequent event in head and neck squamous cell carcinomas that confers poor prognosis. We investigated the frequency of different potential mechanisms of CDKN2A inactivation in oral tongue squamous cell carcinomas (OTSCC) and their impact on patient outcome. From a cohort of 153 OTSCC patients, 131 formalin fixed paraffin embedded blocks of pre-treatment primary tumours were suitable for further molecular analysis. We assessed CDKN2A (p16) levels by immunohistochemistry (IHC), promoter methylation status by methylation-sensitive high resolution melting, mutation status by Sanger sequencing, gene copy number variation by fluorescence in situ hybridisation, and correlated these with patient outcome. We found that the majority of OTSCC did not overexpress p16 (110/116, 95%), assessed by IHC. The frequency of CDKN2A mutations was 20% (21/103), homozygous loss was 7% (7/97), hemizygous loss 31% (30/97), and promoter methylation was 18% (20/113). We found no evidence of these mechanisms in 24/106 (23%) p16 IHC negative tumours. No significant correlation was identified between any potential mechanism of CDKN2A inactivation and clinical features, including smoking status and age. There was a non-significant trend for worse overall survival for p16 IHC negative patients versus positive patients (HR = 1.81, 95% CI = 0.44-7.47, p = 0.40). No relationship was found between mechanisms of CDKN2A disruption and patient outcome. In conclusion, we demonstrate that CDKN2A alteration is a frequent event in OTSCC tumourigenesis. However, no correlation was identified between different potential mechanisms of CDKN2A disruption and clinical characteristics or patient outcome. ",
        "Doc_title":"Differential mechanisms of CDKN2A (p16) alteration in oral tongue squamous cell carcinomas and correlation with patient outcome.",
        "Journal":"International journal of cancer",
        "Do_id":"24436120",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;DNA, Neoplasm",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Carcinoma, Squamous Cell;Cohort Studies;Cyclin-Dependent Kinase Inhibitor p16;DNA Methylation;DNA, Neoplasm;Female;Gene Expression Regulation, Neoplastic;Genes, p16;Homozygote;Humans;Immunohistochemistry;In Situ Hybridization, Fluorescence;Male;Middle Aged;Sequence Analysis, DNA;Tongue Neoplasms;Treatment Outcome;Young Adult",
        "Doc_meshqualifiers":"metabolism;metabolism;genetics;metabolism",
        "_version_":1605907206238109696},
      {
        "Doc_abstract":"Vascular endothelial growth factor A (VEGFA) is a specific mitogen for vascular endothelial cells that plays a critical role in cancer neoangiogenesis. Here, we report that the nucleolar tumor suppressor p19(ARF) suppresses VEGFA expression, acting at the level of mRNA translation without affecting the transcription of the VEGFA gene. Translational repression of VEGFA mRNA by p19(ARF) does not require p53, a major target of the ARF tumor suppressor pathway, but instead correlates with binding to nucleophosmin/B23. Maintaining VEGFA expression relies on nucleophosmin/B23, and downregulating this protein by RNAi or p19(ARF) leads to translational repression of VEGFA. p19(ARF) inhibits VEGFA-dependent tumor angiogenesis in nude mice. Additionally, p14(ARF) expression and microvessel density are inversely correlated in human colon carcinomas. Taken together, our results define a mechanism by which the ARF tumor suppressor targets the translational repression of specific oncogenes during neoplastic transformation.",
        "Doc_title":"ARF suppresses tumor angiogenesis through translational control of VEGFA mRNA.",
        "Journal":"Cancer research",
        "Do_id":"20501856",
        "Doc_ChemicalList":"Nuclear Proteins;RNA, Messenger;Tumor Suppressor Protein p14ARF;Vascular Endothelial Growth Factor A;nucleophosmin",
        "Doc_meshdescriptors":"Animals;Cell Nucleolus;Cell Transformation, Neoplastic;Colonic Neoplasms;Gene Expression Regulation, Neoplastic;Humans;Mice;NIH 3T3 Cells;Neovascularization, Pathologic;Nuclear Proteins;Protein Biosynthesis;RNA, Messenger;Tumor Suppressor Protein p14ARF;Vascular Endothelial Growth Factor A",
        "Doc_meshqualifiers":"genetics;metabolism;genetics;pathology;blood supply;genetics;metabolism;genetics;metabolism;genetics;metabolism;genetics;metabolism;genetics;metabolism;antagonists & inhibitors;biosynthesis;genetics",
        "_version_":1605893616997236736},
      {
        "Doc_abstract":"To investigate the effect of silencing Bmi-1 expression in reversing cisplatin resistance in human lung cancer cells and explore the possible mechanisms.;Cisplatin-resistant A549/DDP cells with small interference RNA (siRNA)-mediated Bmi-1 expression silencing were examined for cisplatin sensitivity using MTT assay and alterations in cell cycle distribution and apoptosis with flow cytometry, and the changes in cell senescence was assessed using -galactosidase staining. The protein expressions of Bmi-1, P14(ARF), P16(INK4a), P53, P21, Rb and ubi-H2AK119 in the cells were determined with Western blotting.;A549/DDP cells showed significantly higher Bmi-1 expression than A549 cells. After siRNA-mediated Bmi-1 silencing, A549/DDP cells showed significantly enhanced cisplatin sensitivity with an increased IC50 from 40.34.1 mol/L to 18.32.8 mol/L (P<0.01) and increased cell percentage in G0/G1 phase from (48.92.3)% to (78.77.6)% (P<0.01). Silencing Bmi-1 did not cause significant changes in the cell apoptosis rate but induced obvious senescence phenotype in A549/DDP cells with down-regulated expression of ubi-H2AK119 and up-regulated expressions of P14(ARF), P16(INK4a), P53, P21 and Rb.;Silencing Bmi-1 by RNA interference can induce cell senescence and resensitize A549/DDP cells to cisplatin possibly by regulating INK4a/ARF/Rb senescence pathway.",
        "Doc_title":"[Effect of silencing Bmi-1 expression in reversing cisplatin resistance in lung cancer cells and its mechanism].",
        "Journal":"Nan fang yi ke da xue xue bao = Journal of Southern Medical University",
        "Do_id":"25057072",
        "Doc_ChemicalList":"Antineoplastic Agents;BMI1 protein, human;RNA, Small Interfering;Polycomb Repressive Complex 1;Cisplatin",
        "Doc_meshdescriptors":"Antineoplastic Agents;Apoptosis;Cell Cycle;Cell Line, Tumor;Cisplatin;Drug Resistance, Neoplasm;Gene Silencing;Humans;Lung Neoplasms;Polycomb Repressive Complex 1;RNA, Small Interfering",
        "Doc_meshqualifiers":"pharmacology;pharmacology;genetics;genetics",
        "_version_":1605792690666995712},
      {
        "Doc_abstract":"Squamous cell carcinoma of the head and neck region (HNSCC) is the sixth most frequent cancer worldwide. In the USA, 30,000 new cases and 8,000 deaths are reported each year. Differences between normal epithelium and cancer cells from the upper aerodigestive tract arise from alterations in expression of specific genes controlling proliferation and immortalization. The protein products of these genes include growth factor receptors, cell cycle regulators, and tumor suppressors which affect a variety of intracellular signaling pathways. To determine how altered expression of these gene products contribute to HNSCC progression, we examined expression of epidermal growth factor receptor (EGFR), cyclins, p16INK4A, c-myc, proliferating cell nuclear antigen (PCNA), and telomerase in archival pathology specimens by immunohistochemistry. A substantial majority of HNSCC tumors showed loss of p16INK4A expression and dramatic overexpression of EGFR. Overexpression of this receptor correlated with increased cyclin A levels and high mitotic index. EGFR, cyclins A, -B1, -E, and c-myc overexpression was significantly increased in stage III and IV tumors compared to early stage cancers. hTERT was expressed in all tumors and primarily in the basal layer cells of dysplastic epithelial lesions. Suprabasal expression of hTERT was found in a significantly higher number of HNSCC cases than in dysplastic lesions. These results indicate that overexpression of cell cycle regulatory proteins correlates with advanced tumor stage in HNSCC.",
        "Doc_title":"Overexpression of cell cycle regulatory proteins correlates with advanced tumor stage in head and neck squamous cell carcinomas.",
        "Journal":"International journal of oncology",
        "Do_id":"12738995",
        "Doc_ChemicalList":"Cell Cycle Proteins;Proliferating Cell Nuclear Antigen;Receptor, Epidermal Growth Factor;Telomerase",
        "Doc_meshdescriptors":"Carcinoma, Squamous Cell;Cell Cycle Proteins;Cell Division;Head and Neck Neoplasms;Humans;Immunohistochemistry;Neoplasm Staging;Proliferating Cell Nuclear Antigen;Receptor, Epidermal Growth Factor;Telomerase",
        "Doc_meshqualifiers":"genetics;pathology;genetics;genetics;pathology;genetics;genetics;genetics",
        "_version_":1605742116730830848},
      {
        "Doc_abstract":"Primary fibroblasts respond to activated H-RAS(V12) by undergoing premature arrest, which resembles replicative senescence. This irreversible 'fail-safe mechanism' requires p19(ARF), p53 and the Retinoblastoma (Rb) family: upon their disruption, RAS(V12)-expressing cells fail to undergo senescence and continue to proliferate. Similarly, co-expression of oncogenes such as c-MYC or E1A rescues RAS(V12)-induced senescence. To identify novel genes that allow escape from RAS(V12)-induced senescence, we designed an unbiased, retroviral complementary DNA library screen. We report on the identification of DRIL1, the human orthologue of the mouse Bright and Drosophila dead ringer transcriptional regulators. DRIL1 renders primary murine fibroblasts unresponsive to RAS(V12)-induced anti-proliferative signalling by p19(ARF)/p53/p21(CIP1), as well as by p16(INK4a). In this way, DRIL1 not only rescues RAS(V12)-induced senescence but also causes these fibroblasts to become highly oncogenic. Furthermore, DRIL1 immortalizes mouse fibroblasts, in the presence of high levels of p16(INK4a). Immortalization by DRIL1, whose product binds the pRB-controlled transcription factor E2F1 (ref. 8), is correlated with induction of E2F1 activity. Correspondingly, DRIL1 induces the E2F1 target Cyclin E1, overexpression of which is sufficient to trigger escape from senescence. Thus, DRIL1 disrupts cellular protection against RAS(V12)-induced proliferation downstream of the p19(ARF)/p53 pathway.",
        "Doc_title":"A functional screen identifies hDRIL1 as an oncogene that rescues RAS-induced senescence.",
        "Journal":"Nature cell biology",
        "Do_id":"11812999",
        "Doc_ChemicalList":"ARID3A protein, human;Arid3a protein, mouse;Cdkn2a protein, mouse;Cyclin E;Cyclin-Dependent Kinase Inhibitor p16;DNA-Binding Proteins;Trans-Activators;Transcription Factors;Tumor Suppressor Protein p14ARF",
        "Doc_meshdescriptors":"Animals;Cell Aging;Cells, Cultured;Cyclin E;Cyclin-Dependent Kinase Inhibitor p16;DNA-Binding Proteins;Fibroblasts;Genes, ras;Humans;Mice;Mice, Inbred BALB C;Mice, Inbred C57BL;Oncogenes;Signal Transduction;Trans-Activators;Transcription Factors;Tumor Suppressor Protein p14ARF",
        "Doc_meshqualifiers":"physiology;genetics;metabolism;metabolism;genetics;metabolism;cytology;metabolism;genetics;physiology;metabolism",
        "_version_":1605852343211917312},
      {
        "Doc_abstract":"The two gene products of the CDKN2A gene, p16 and p19ARF, have recently been linked to each of two major tumour suppressor pathways in human carcinogenesis, the RB1 pathway and the p53 pathway. p16 inhibits the phosphorylation of the retinoblastoma gene product by cyclin D-dependent kinases, whereas p19ARF targets MDM2, a p53 inhibitory protein, for degradation. A deletion of CDKN2A would therefore disturb both pathways. To explore the p53 pathway genes as a functional unit in diffuse large B cell non-Hodgkin's lymphomas (DLCL), we wanted to see whether there exists mutually exclusiveness of aberrations of CDKN2A, MDM2 and p53, since this has not been analysed previously. We investigated 37 DLCL for aberrations of p15, p16, p19ARF, MDM2, and p53 at the epigenetic, genetic and/or protein levels. Homozygous deletion of CDKN2A was detected in seven (19%) of 37 tumours, and another three cases were hypermethylated at the 5' CpG island of p16. No point mutations were found in CDKN2B or CDKN2A. Immunohistochemical staining of formalin-fixed, paraffin-embedded tissue for p16 confirmed these results, as all tumours with alterations of CDKN2A were p16 immunonegative. We found p53 mutations in eight (22%) cases and MDM2 overexpression in 16 (43%) tumours. Twenty-three (62%) tumours had alterations of one or more p53 pathway components (p53, p19ARF and MDM2). Furthermore, 7/9 (78%) p16-immunonegative tumours showed co-aberration of p53 and/or MDM2. The lack of correlation between these aberrations suggests that DLCL acquire additional growth advantage by inactivating both of these critical regulatory pathways.",
        "Doc_title":"Aberrations of the p53 pathway components p53, MDM2 and CDKN2A appear independent in diffuse large B cell lymphoma.",
        "Journal":"Leukemia",
        "Do_id":"10086736",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;Nuclear Proteins;Proto-Oncogene Proteins;Tumor Suppressor Protein p53;MDM2 protein, human;Proto-Oncogene Proteins c-mdm2",
        "Doc_meshdescriptors":"Cyclin-Dependent Kinase Inhibitor p16;DNA Methylation;Humans;Immunohistochemistry;Lymphoma, B-Cell;Lymphoma, Large B-Cell, Diffuse;Mutation;Nuclear Proteins;Promoter Regions, Genetic;Proto-Oncogene Proteins;Proto-Oncogene Proteins c-mdm2;Tumor Suppressor Protein p53",
        "Doc_meshqualifiers":"genetics;metabolism;genetics;metabolism;genetics;metabolism;genetics;metabolism;genetics;metabolism",
        "_version_":1605929111897767936},
      {
        "Doc_abstract":"Penile verrucous carcinoma is a rare disease and little is known of its aetiology or pathogenesis. In this study we examined cell-cycle proteins expression and correlation with human papillomavirus infection in a series of 15 pure penile verrucous carcinomas from a single centre. Of 148 penile tumours, 15 (10%) were diagnosed as pure verrucous carcinomas. The expression of the cell-cycle-associated proteins p53, p21, RB, p16(INK4A) and Ki67 were examined by immunohistochemistry. Human papillomavirus infection was determined by polymerase chain reaction to identify a wide range of virus types. The expression of p16(INK4A) and Ki67 was significantly lower in verrucous carcinoma than in usual type squamous cell carcinoma, whereas the expression of p53, p21 and RB was not significantly different. p53 showed basal expression in contrast to usual type squamous cell carcinoma. Human papillomavirus infection was present in only 3 out of 13 verrucous carcinomas. Unique low-risk, high-risk and mixed viral infections were observed in each of the three cases. In conclusion, lower levels of p16(INK4A) and Ki67 expressions differentiate penile verrucous carcinoma from usual type squamous cell carcinoma. The low Ki67 index reflects the slow-growing nature of verrucous tumours. The low level of p16(INK4A) expression and human papillomavirus detection suggests that penile verrucous carcinoma pathogenesis is unrelated to human papillomavirus infection and the oncogenes and tumour suppressor genes classically altered by virus infection.",
        "Doc_title":"HPV infection and immunochemical detection of cell-cycle markers in verrucous carcinoma of the penis.",
        "Journal":"Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc",
        "Do_id":"19465901",
        "Doc_ChemicalList":"Biomarkers, Tumor;Cell Cycle Proteins;Cyclin-Dependent Kinase Inhibitor p16;Cyclin-Dependent Kinase Inhibitor p21;Ki-67 Antigen;Retinoblastoma Protein;Tumor Suppressor Protein p53",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Biomarkers, Tumor;Carcinoma, Verrucous;Cell Cycle Proteins;Cyclin-Dependent Kinase Inhibitor p16;Cyclin-Dependent Kinase Inhibitor p21;Humans;Immunohistochemistry;Ki-67 Antigen;Male;Middle Aged;Papillomavirus Infections;Penile Neoplasms;Polymerase Chain Reaction;Retinoblastoma Protein;Retrospective Studies;Tumor Suppressor Protein p53",
        "Doc_meshqualifiers":"analysis;metabolism;pathology;virology;biosynthesis;biosynthesis;biosynthesis;biosynthesis;complications;epidemiology;metabolism;pathology;virology;biosynthesis;biosynthesis",
        "_version_":1605746340727357441},
      {
        "Doc_abstract":"Cell cycle regulators have recently been implicated in oncogenic transformation of cells, including the cyclins active in the G1 phase of the cell cycle and their respective cyclin-dependent kinases (CDK) whose activities are regulated by a set of inhibitors of CDK (CDKI). Since CDKIs can inhibit cell proliferation, they may have a role as tumor suppressor genes. To determine if alterations of CDKI genes may be involved in tumorigenesis of breast cancer, we examined the mutational status of p16(INK4A), p15(INK4B), p18(INK4C), p19(INK4D) CDKI genes in 36 primary breast carcinomas and 9 breast cancer cell lines using polymerase chain reaction-single strand conformational polymorphism (PCR-SSCP), direct DNA sequencing, and Southern blot analysis. Furthermore, amplification of cyclin D1, D2, D3 genes were also examined in these samples. One mutation of p15(INK4B) gene occurred, resulting in change of aspartic acid to asparagine at codon 85. Since aspartic acid at this position is conserved between all four human and murine INK4 proteins, this missense mutation may have functional significance. The sample with a p15(INK4B) point mutation was accompanied by amplification of the cyclin D1 gene. A deletion of the p18(INK4C) gene was found in a primary tumor. Three deletions of the p16(INK4A) gene and two deletions of the p15(INK4B) gene were found in the cell lines. Also, we found amplification of the p15(INK4B) and p16(INK4A) loci in a clinical sample as well as amplification of the p19(INK4D) in another sample, and amplification of the myeloperoxidase (MPO) gene in one cell line and two primary tumors. We suspect that a critical gene for breast cancer is amplified near the MPO gene. These data indicate that CDKI mutations are moderately rare in breast cancer and are often associated with the simultaneous alteration of more than one cell-cycle regulatory gene.",
        "Doc_title":"Molecular analysis of INK4 genes in breast carcinomas.",
        "Journal":"International journal of oncology",
        "Do_id":"21528268",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605843961278103552},
      {
        "Doc_abstract":"Alterations in the p16/cyclinD1/Rb and ARF/Mdm2/p53 pathways are frequent events in the pathogenesis of squamous cell carcinomas. Different mechanisms of p16 regulation have been described for penile carcinomas so far. Therefore, expression of p16 and p53 was immunohistochemically detected with monoclonal antibodies in 52 primary invasive penile squamous cell carcinomas. The carcinomas were analyzed for allelic loss (LOH) in p16(INK4A) and p53, as well as for mutations in the p16(INK4A) and the p53 gene. In addition, we examined the promoter status of p16(INK4A) by methylation-specific PCR. The presence of human papilloma virus (HPV) 6/11, HPV 16 and HPV 18 DNA was analyzed by PCR. Data were compared to clinical data. Concerning p16, 26 (50%) tumors showed positive immunohistochemistry, 32 (62%) tumors showed allelic loss and 22 tumors (42%) showed promoter hypermethylation. All tumors with negative p16 immunohistochemistry showed LOH near the p16(INK4A) locus and/or hypermethylation of the p16(INK4A) promoter. HPV 16 DNA was detected in 17 tumors, ten of them with positive p16 immunostaining. The remaining seven tumors with negative p16 staining showed allelic loss and/or promoter hypermethylation. Evidence of lymph node metastasis was significantly associated with negative p16 immunohistochemistry as well as with combined LOH and promoter hypermethylation (p=0.003 and p=0.018, respectively). Allelic loss around p53 was found in 22 tumors (42%), and seven mutations of the p53 gene could be demonstrated in our tumors. No correlations could be found between any p53 alteration and clinical parameters.",
        "Doc_title":"Alterations in the tumor suppressor gene p16(INK4A) are associated with aggressive behavior of penile carcinomas.",
        "Journal":"Virchows Archiv : an international journal of pathology",
        "Do_id":"21085986",
        "Doc_ChemicalList":"DNA, Viral",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Carcinoma, Squamous Cell;DNA Methylation;DNA, Viral;Genes, p16;Genes, p53;Humans;Immunohistochemistry;Loss of Heterozygosity;Lymphatic Metastasis;Male;Middle Aged;Papillomavirus Infections;Penile Neoplasms;Reverse Transcriptase Polymerase Chain Reaction;Young Adult",
        "Doc_meshqualifiers":"genetics;pathology;virology;analysis;genetics;genetics;pathology;complications;genetics;pathology;virology",
        "_version_":1605742763325784064},
      {
        "Doc_abstract":"In the present study, we analyzed p16, retinoblastoma (Rb), and cyclin D1 abnormalities in head and neck squamous cell carcinoma (HNSCC) tissues and cell lines from Korean patients. We found a 40% loss of heterozygosity at the D9S171 locus (9p21 region) these tissues. All eight of the HNSCC cell lines did not express the p16 protein, and in two of these cell lines (Amc-HN-6 and 8), this was due to a deletion of the p16 gene. Three of the cell lines (Amc-HN-3 to 5) that expressed the p16 mRNA had the same nonsense mutation at codon 50 (CGA-Arg to TGA-Ter). The Amc-HN-1 and Amc-HN-7 cell lines, which did not express the p16 mRNA, had a missense mutation at codon 9 (GCC-Ala to GTC-Val) and a silent mutation at codon 106 (CCC-Pro to CCA), respectively. The Amc-HN-2 cell line (p16 exon-positive/mRNA-negative) had a single base deletion at codon 38 (CGG-Arg to CG), which resulted in a frameshift and a consequent stop signal at codon 44. The Rb protein was detected in all of the eight cell lines, although it was inactive in five of these due to hyperphosphorylation. The inverse relationship between p16 and Rb was 62.5% (5/8). Cyclin D1 was overexpressed in all of the eight cell lines. Our results suggest that the abrogation of p16, the overexpression of cyclin D1, and the consequent inactivation of Rb could be important factors in the carcinogenesis of HNSCCs.",
        "Doc_title":"Abrogation of the p16-retinoblastoma-cyclin D1 pathway in head and neck squamous cell carcinomas.",
        "Journal":"Oncology reports",
        "Do_id":"17549378",
        "Doc_ChemicalList":"Cyclin D;Cyclin-Dependent Kinase Inhibitor p16;Cyclins;Retinoblastoma Protein",
        "Doc_meshdescriptors":"Carcinoma, Squamous Cell;Chromosomes, Human, Pair 9;Cyclin D;Cyclin-Dependent Kinase Inhibitor p16;Cyclins;Gene Deletion;Gene Expression Regulation, Neoplastic;Head and Neck Neoplasms;Humans;Korea;Loss of Heterozygosity;Retinoblastoma Protein;Tumor Cells, Cultured",
        "Doc_meshqualifiers":"genetics;metabolism;genetics;genetics;metabolism;genetics;metabolism;genetics;metabolism;genetics;metabolism",
        "_version_":1605742654375591936},
      {
        "Doc_abstract":"Patients with cancer of unknown primary (CUP) in the head neck region are generally treated with neck dissection followed by radiotherapy at times combined with chemotherapy, a treatment associated with considerable side effects. Some of these tumors may originate as human papillomavirus (HPV)-positive oropharyngeal squamous cell carcinoma (OSCC), with better clinical outcome than head neck squamous cell cancer (HNSCC) in general, and could potentially do well with less treatment. Here, we therefore investigated whether HPV status and p53-expression correlated to clinical outcome in patients with CUP in the head neck region. Fifty metastases were analyzed for presence of HPV DNA, and expression of p16(INK4A) and p53 and the data were correlated to clinical outcome. Patients with HPV DNA-positive (HPVDNA+) metastases had significantly better 5-year overall survival (OS) compared to those with HPVDNA- metastases (80.0% vs. 36.7%, respectively; P = 0.004), with a similar tendency for disease-free survival (DFS). These survival rates showed excellent concordance with those of HPVDNA+ and HPVDNA- OSCC in Sweden during the same time period, strengthening the hypothesis that HPVDNA+ head and neck CUP may originate from HPVDNA+ OSCC. In addition, having absent/intermediary-low as compared to high expression of p53 correlated to a better prognosis with a 69% as compared to 14% 5-year OS, respectively (P < 0.001), and for DFS the tendency was analogous. In conclusion, both HPV status and p53 expression are valuable prognostic factors in patients with CUP in the head and neck region and should be further explored for clinical use.",
        "Doc_title":"Human papillomavirus and p53 expression in cancer of unknown primary in the head and neck region in relation to clinical outcome.",
        "Journal":"Cancer medicine",
        "Do_id":"24510528",
        "Doc_ChemicalList":"DNA, Viral;Neoplasm Proteins;P16 protein, human;TP53 protein, human;Tumor Suppressor Protein p53",
        "Doc_meshdescriptors":"Aged;Carcinoma, Squamous Cell;DNA, Viral;Disease-Free Survival;Female;Head and Neck Neoplasms;Humans;Male;Middle Aged;Neoplasm Proteins;Neoplasms, Unknown Primary;Papillomaviridae;Papillomavirus Infections;Paraffin Embedding;Prognosis;Treatment Outcome;Tumor Suppressor Protein p53",
        "Doc_meshqualifiers":"genetics;metabolism;virology;analysis;genetics;genetics;metabolism;virology;biosynthesis;genetics;genetics;metabolism;virology;genetics;isolation & purification;metabolism;biosynthesis;genetics",
        "_version_":1605809516348178432},
      {
        "Doc_abstract":"The INK4a/ARF locus encodes two cell cycle-regulatory proteins, p16INK4a andp14ARF, which share an exon using different reading frames. p14ARF antagonizes MDM2-dependent p53 degradation. However, no point mutations in p14ARF not altering p16INK4a have been described in primary tumors. We report that p14ARF is epigenetically inactivated in several colorectal cell lines, and its expression is restored by treatment with demethylating agents. In primary colorectal carcinomas, p14ARF promoter hypermethylation was found in 31 of 110 (28%) of the tumors and observed in 13 of 41 (32%) colorectal adenomas but was not present in any normal tissues. p14ARF methylation appears in the context of an adjacent unmethylated p16INK4a promoter in 16 of 31 (52%) of the carcinomas methylated at p14ARF. Although p14ARF hypermethylation was slightly overrepresented in tumors with wild-type p53 compared to tumors harboring p53 mutations [19 of 55 (34%) versus 12 of 55 (22%)], this difference did not reach statistical significance. p14ARF aberrant methylation was not related to the presence of K-ras mutations. Our results demonstrate that p14ARF promoter hypermethylation is frequent in colorectal cancer and occurs independently of the p16INK4a methylation status and only marginally in relation to the p53 mutational status.",
        "Doc_title":"Hypermethylation-associated inactivation of p14(ARF) is independent of p16(INK4a) methylation and p53 mutational status.",
        "Journal":"Cancer research",
        "Do_id":"10646864",
        "Doc_ChemicalList":"Carrier Proteins;Cyclin-Dependent Kinase Inhibitor p16;Proteins;Tumor Suppressor Protein p14ARF",
        "Doc_meshdescriptors":"Carrier Proteins;Colorectal Neoplasms;CpG Islands;Cyclin-Dependent Kinase Inhibitor p16;DNA Methylation;Gene Silencing;Genes, p53;Genes, ras;HL-60 Cells;Humans;Polymorphism, Single-Stranded Conformational;Proteins;Reverse Transcriptase Polymerase Chain Reaction;Tumor Cells, Cultured;Tumor Suppressor Protein p14ARF",
        "Doc_meshqualifiers":"genetics;metabolism;genetics;metabolism;genetics;genetics;genetics;metabolism",
        "_version_":1605853266637225984},
      {
        "Doc_abstract":"Inactivation of the Rb pathway in non-small cell lung carcinoma (NSCLC) occurs mostly through inactivation of the cyclin-dependent kinase inhibitor p16(INK4A) and/or up-regulation of cyclin D1. In order to assess the frequency and the prognostic value of these abnormalities in NSCLC, immunohistochemical analysis of Rb, p16(INK4), and cyclin D1 has been performed on 168 cases of NSCLC including 77 squamous cell carcinomas, 43 adenocarcinomas, and 48 basaloid carcinomas. The reduced survival rate of basaloid carcinoma (stage I-II) compared with other histological types of NSCLC was confirmed (p = 0.008). Loss of protein expression of Rb and p16(INK4A) was observed in 12 per cent and 58 per cent of NSCLC cases respectively and cyclin D1 overexpression in 43 per cent. There was an inverse correlation between Rb and p16 expression ( p < 0.0001) and a direct correlation between Rb and cyclin D1 expression ( p = 0.0007). In univariate analysis, Rb-negative adenocarcinomas at stages I-II had a significantly shorter survival than Rb-positive cases ( p = 0.04) and stages I-II p16-positive cases had a shorter survival than p16-negative cases ( p = 0.02), which was more significant in basaloid carcinoma ( p = 0.003). p16 status retained its influence on survival in multivariate analysis at stage I-II for all cases ( p = 0.01) and for basaloid carcinoma ( p = 0.005). Cyclin D1 overexpression did not influence survival. Combined Rb/p16/cyclin D1 phenotypes in univariate analysis showed a shorter survival for Rb-negative/p16-positive/cyclin D1-negative tumours ( p = 0.002). These results, linked to previous data, indicate that the Rb pathway of G1 arrest is initially disrupted in the vast majority of NSCLCs (83 per cent), but could not confirm an unfavourable role for each individual event (p16(INK4A) loss or cyclin D1 up-regulation) in prognosis.",
        "Doc_title":"Alterations of expression of Rb, p16(INK4A) and cyclin D1 in non-small cell lung carcinoma and their clinical significance.",
        "Journal":"The Journal of pathology",
        "Do_id":"10440744",
        "Doc_ChemicalList":"Biomarkers, Tumor;Cyclin-Dependent Kinase Inhibitor p16;Neoplasm Proteins;Retinoblastoma Protein;Cyclin D1",
        "Doc_meshdescriptors":"Adenocarcinoma;Biomarkers, Tumor;Carcinoma, Non-Small-Cell Lung;Carcinoma, Squamous Cell;Carcinoma, Transitional Cell;Cyclin D1;Cyclin-Dependent Kinase Inhibitor p16;Humans;Immunoenzyme Techniques;Lung Neoplasms;Multivariate Analysis;Neoplasm Proteins;Prognosis;Retinoblastoma Protein;Survival Rate",
        "Doc_meshqualifiers":"metabolism;pathology;metabolism;metabolism;pathology;metabolism;pathology;metabolism;pathology;metabolism;metabolism;metabolism;pathology;metabolism;metabolism",
        "_version_":1605881093095948288},
      {
        "Doc_abstract":"Heat shock protein 90 (Hsp90) is a molecular chaperone that promotes the conformational maturation of numerous client proteins, many of which play critical roles in tumor cell growth and survival. The ansamycin-based Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin (17-AAG) is currently in phase I/II clinical testing. However, 17-AAG is difficult to formulate and displays weak activity against some tumors. A novel dimeric ansamycin, EC5, was evaluated for antitumor activity in eight head and neck squamous cell carcinoma (HNSCC) cell lines. Both 17-AAG and EC5 inhibited tumor cell proliferation effectively, but EC5 was more potent, with IC(50) below 200 nmol/L in most cell lines tested, including several lines that were resistant to 17-AAG. The inability of 17-AAG to kill JHU12 cells was linked to a defect in retinoblastoma signaling and could be rescued by ectopic expression of p16(INK4a). EC5 induced G(1) growth arrest of tumor cells and apoptosis, with the degradation of client proteins including epidermal growth factor receptor, c-Raf-1, Akt, and Cdk4 and inhibition of Akt phosphorylation. In vivo, EC5 dramatically reduced the growth rate of established HNSCC xenografts in nude mice and decreased expression of epidermal growth factor receptor and Akt within the xenografts. These results suggest that this novel ansamycin-based Hsp90 inhibitor affects multiple pathways involved in tumor development and progression and may represent a new strategy for the treatment of HNSCC patients.",
        "Doc_title":"Potent activity of a novel dimeric heat shock protein 90 inhibitor against head and neck squamous cell carcinoma in vitro and in vivo.",
        "Journal":"Clinical cancer research : an official journal of the American Association for Cancer Research",
        "Do_id":"15897590",
        "Doc_ChemicalList":"Benzoquinones;EC5 compound;HSP90 Heat-Shock Proteins;Lactams, Macrocyclic;Rifabutin;tanespimycin;Protein-Serine-Threonine Kinases",
        "Doc_meshdescriptors":"Animals;Apoptosis;Benzoquinones;Carcinoma, Squamous Cell;Cell Cycle;Cell Proliferation;Gene Expression Profiling;HSP90 Heat-Shock Proteins;Head and Neck Neoplasms;Humans;Lactams, Macrocyclic;Mice;Protein-Serine-Threonine Kinases;Rifabutin;Transplantation, Heterologous;Tumor Cells, Cultured",
        "Doc_meshqualifiers":"pathology;drug effects;antagonists & inhibitors;pathology;antagonists & inhibitors;analogs & derivatives;pharmacology",
        "_version_":1605907144495857664},
      {
        "Doc_abstract":"In myxoid/round cell liposarcoma (MLS/RCLS), the presence of a round cell (RC) component has been reported to correlate with a worse prognosis for the patients. However, little is known about the molecular genetic differences between conventional myxoid (MX) components and RC components in this tumour. The aim of this study was to investigate the possible implications of molecular alterations of G1 to S-phase check-point genes, especially in the RC component. We evaluated the immunohistochemical expression of p53, MDM2, p14 and p16 protein and assessed proliferative activities using MIB-1 in 29 RC components and 81 MX components from 90 cases. Mutation of the p53 gene, amplification of the MDM2 gene, homozygous deletion, methylation status and mutation of the p16(INK4a)/p14(ARF) genes were also investigated, using concordant paraffin-embedded and frozen material. The data were analysed together with clinicopathological factors to assess their prognostic implications in MLS/RCLS. Immunohistochemically, the over-expression of p53 protein (p = 0.01366) and the reduced expression of p14 (p < 0.0001) and p16 (p < 0.0001) proteins were significantly more frequently observed in RC components than in MX components. Reduced expression of p14 protein correlated significantly with hypermethylation of the p14(ARF) gene promoter (p = 0.0176) and over-expression of p53 protein (p = 0.00837). By univariate analysis, reduced expression of p14 and p53 missense mutation were found to reduce the rate of survival significantly (p < 0.05). Multivariate analysis, including clinicopathological factors, revealed that tumour site (p = 0.0251), the presence of an RC component (p = 0.0113), high MIB-1 labelling index (p = 0.0005) and p53 missense mutation (p = 0.0036) were adverse prognostic factors. In MLS/RCLS, reduction of p14 protein expression and p53 mutation were related to poor prognosis. Accordingly, the p14(ARF)/p53 pathway may contribute to the presence of an RC component and malignant progression in this tumour.",
        "Doc_title":"Frequent alteration of p16(INK4a)/p14(ARF) and p53 pathways in the round cell component of myxoid/round cell liposarcoma: p53 gene alterations and reduced p14(ARF) expression both correlate with poor prognosis.",
        "Journal":"The Journal of pathology",
        "Do_id":"16177957",
        "Doc_ChemicalList":"Biomarkers, Tumor;Cyclin-Dependent Kinase Inhibitor p16;DNA, Neoplasm;Tumor Suppressor Protein p14ARF",
        "Doc_meshdescriptors":"Adolescent;Adult;Aged;Biomarkers, Tumor;Cyclin-Dependent Kinase Inhibitor p16;DNA Mutational Analysis;DNA, Neoplasm;Female;Genes, p53;Humans;Immunoenzyme Techniques;Liposarcoma, Myxoid;Male;Middle Aged;Polymerase Chain Reaction;Polymorphism, Single-Stranded Conformational;Prognosis;Soft Tissue Neoplasms;Survival Analysis;Tumor Suppressor Protein p14ARF",
        "Doc_meshqualifiers":"genetics;metabolism;genetics;metabolism;genetics;genetics;metabolism;pathology;methods;genetics;metabolism;pathology;genetics;metabolism",
        "_version_":1605752705479868416},
      {
        "Doc_abstract":"A subset of head and neck cancers is associated with the human papillomavirus (HPV). Viral infection is closely correlated with expression of p16(INK4A) in these tumors. We evaluated p16(INK4A) as a prognostic marker of treatment response and survival in a well-defined and prospectively collected cohort of patients treated solely with conventional radiotherapy in the Danish Head and Neck Cancer Group (DAHANCA) 5 trial.;Immunohistochemical expression of p16(INK4A) was analyzed in pretreatment paraffin-embedded tumor blocks from 156 patients treated with conventional primary radiotherapy alone. The influence of p16(INK4A) status on locoregional tumor control, disease-specific survival, and overall survival after radiotherapy was evaluated.;p16(INK4A) positivity was found in 35 tumors (22%). Tumor-positivity for p16(INK4A) was significantly correlated with improved locoregional tumor control (5-year actuarial values 58% v 28%; P = .0005), improved disease-specific survival (72% v 34%; P = .0006), and improved overall survival (62% v 26%; P = .0003). In multivariate analysis, p16(INK4A) remained a strong independent prognostic factor for locoregional failure (hazard ratio [HR], 0.35; 95% CI, 0.19 to 0.64), disease-specific death (HR, 0.36; 95% CI, 0.20 to 0.64), and overall death (HR, 0.44; 95% CI, 0.28 to 0.68).;Expression of p16(INK4A) has a major impact on treatment response and survival in patients with head and neck cancer treated with conventional radiotherapy.",
        "Doc_title":"Effect of HPV-associated p16INK4A expression on response to radiotherapy and survival in squamous cell carcinoma of the head and neck.",
        "Journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
        "Do_id":"19289615",
        "Doc_ChemicalList":"Biomarkers, Tumor;Cyclin-Dependent Kinase Inhibitor p16;Placebos",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Biomarkers, Tumor;Carcinoma, Squamous Cell;Cohort Studies;Cyclin-Dependent Kinase Inhibitor p16;Female;Follow-Up Studies;Head and Neck Neoplasms;Humans;In Situ Hybridization;Male;Middle Aged;Neoplasm Staging;Papillomaviridae;Papillomavirus Infections;Placebos;Prognosis;Prospective Studies;Survival Rate;Treatment Outcome;Young Adult",
        "Doc_meshqualifiers":"metabolism;metabolism;mortality;radiotherapy;virology;metabolism;metabolism;mortality;radiotherapy;virology;isolation & purification;metabolism;mortality;radiotherapy;virology",
        "_version_":1605765998061813760},
      {
        "Doc_abstract":"The INK4a gene encodes two distinct growth inhibitors--the cyclin-dependent kinase inhibitor p16Ink4a, which is a component of the Rb pathway, and the tumor suppressor p19Arf, which has been functionally linked to p53. Here we show that p19Arf potently suppresses oncogenic transformation in primary cells and that this function is abrogated when p53 is neutralized by viral oncoproteins and dominant-negative mutants but not by the p53 antagonist MDM2. This finding, coupled with the observations that p19Arf and MDM2 physically interact and that p19Rrf blocks MDM2-induced p53 degradation and transactivational silencing, suggests that p19Arf functions mechanistically to prevent MDM2's neutralization of p53. Together, our findings ascribe INK4a's potent tumor suppressor activity to the cooperative actions of its two protein products and their relation to the two central growth control pathways, Rb and p53.",
        "Doc_title":"The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53.",
        "Journal":"Cell",
        "Do_id":"9529248",
        "Doc_ChemicalList":"Deoxyuracil Nucleotides;Neoplasm Proteins;Nuclear Proteins;Proteins;Proto-Oncogene Proteins;Retinoblastoma Protein;Tumor Suppressor Protein p14ARF;Tumor Suppressor Protein p53;Biotin;Mdm2 protein, mouse;Proto-Oncogene Proteins c-mdm2",
        "Doc_meshdescriptors":"Animals;Apoptosis;Biotin;Cell Line;DNA Fragmentation;Deoxyuracil Nucleotides;Genes, p16;Lens, Crystalline;Mice;Neoplasm Proteins;Nuclear Proteins;Osteoblasts;Proteins;Proto-Oncogene Proteins;Proto-Oncogene Proteins c-mdm2;Retinoblastoma Protein;Staining and Labeling;Transformation, Genetic;Tumor Suppressor Protein p14ARF;Tumor Suppressor Protein p53",
        "Doc_meshqualifiers":"genetics;chemistry;cytology;physiology;physiology;cytology;genetics;metabolism;chemistry;cytology;physiology;metabolism;metabolism;metabolism;metabolism",
        "_version_":1605796356315676672},
      {
        "Doc_abstract":"Common genetic variants in a 58-kb region of chromosome 9p21, near the CDKN2A/CDKN2B tumor suppressor locus, are strongly associated with coronary artery disease. However, the underlying mechanism of action remains unknown.;We previously reported a congenic mouse model harboring an atherosclerosis susceptibility locus and the region of homology with the human 9p21 locus. Microarray and transcript-specific expression analyses showed markedly decreased Cdkn2a expression, including both p16(INK4a) and p19(ARF), but not Cdkn2b (p15(INK4b)), in macrophages derived from congenic mice compared with controls. Atherosclerosis studies in subcongenic strains revealed genetic complexity and narrowed 1 locus to a small interval including Cdkn2a/b. Bone marrow (BM) transplantation studies implicated myeloid lineage cells as the culprit cell type, rather than resident vascular cells. To directly test the role of BM-derived Cdkn2a transcripts in atherogenesis and inflammatory cell proliferation, we performed a transplantation study using Cdkn2a(-/-) cells in the Ldlr(-/-) mouse model. Cdkn2a-deficient BM recipients exhibited accelerated atherosclerosis, increased Ly6C proinflammatory monocytes, and increased monocyte/macrophage proliferation compared with controls.;These data provide a plausible mechanism for accelerated atherogenesis in susceptible congenic mice, involving decreased expression of Cdkn2a and increased proliferation of monocyte/macrophages, with possible relevance to the 9p21 human locus.",
        "Doc_title":"Cdkn2a is an atherosclerosis modifier locus that regulates monocyte/macrophage proliferation.",
        "Journal":"Arteriosclerosis, thrombosis, and vascular biology",
        "Do_id":"21868699",
        "Doc_ChemicalList":"Cdkn2a protein, mouse;Cyclin-Dependent Kinase Inhibitor p16;Receptors, LDL",
        "Doc_meshdescriptors":"Animals;Atherosclerosis;Bone Marrow Transplantation;Cell Proliferation;Cyclin-Dependent Kinase Inhibitor p16;Disease Models, Animal;Genes, p16;Genetic Predisposition to Disease;Macrophages;Mice;Mice, Congenic;Mice, Knockout;Monocytes;Receptors, LDL",
        "Doc_meshqualifiers":"genetics;metabolism;pathology;genetics;metabolism;genetics;metabolism;pathology;metabolism;pathology;deficiency;genetics",
        "_version_":1605820851070959616},
      {
        "Doc_abstract":"Gene inactivation through DNA hypermethylation plays a pivotal role in carcinogenesis. This study aimed to profile aberrant DNA methylation in different stages of liver disease, namely noncirrhosis, cirrhosis and hepatocellular carcinoma (HCC), and also to clarify the influence of hepatitis B virus (HBV) infection on the aberrant DNA methylation in HCCs. Promoter methylation in p14(ARF), p16(INK4a), O(6)-methylguanine-DNA methyltransferase (MGMT), glutathione S-transferase pi (GSTP1) and E-cadherin (E-Cad) genes of 58 HCCs paired with adjacent nontumorous tissues was assayed by methylation-specific PCR. HBV infection was determined using a hepatitis B virus surface antigen (HBsAg) serological assay. The frequency of p16(INK4a) promoter methylation increased from noncirrhotic, cirrhotic, to HCC tissues (noncirrhotic vs. HCC, p < 0.001), while that of GSTP1 promoter methylation increased in cirrhotic tissues compared to noncirrhotic ones (p = 0.029). The frequency of GSTP1 promoter hypermethylation is significantly higher in HCC than in nontumorous tissues (p = 0.022) from HBsAg-positive patients, but not the HBsAg-negative controls (p = 0.289). While the frequency of E-Cad promoter hypermethylation remained high in both nontumorous tissues and HCCs from HBsAg-positive patients (p = 0.438), it was lower in HCCs than in nontumorous tissues from HBsAg-negative patients (p = 0.002). In contrast, the frequency of p16(INK4a), MGMT and p14(ARF) promoter hypermethylation in HCCs was unrelated to HBsAg status. In conclusion, aberrant DNA methylation may begin at different stages of liver disease in a gene-dependent manner. Moreover, HBV infection may enhance or maintain GSTP1 and E-Cad promoter methylation and thereby affect hepatocarcinogenesis.",
        "Doc_title":"Differential DNA methylation associated with hepatitis B virus infection in hepatocellular carcinoma.",
        "Journal":"International journal of cancer",
        "Do_id":"17534893",
        "Doc_ChemicalList":"Cadherins;Retinoblastoma Protein;Tumor Suppressor Protein p14ARF;Tumor Suppressor Proteins;DNA Modification Methylases;MGMT protein, human;Glutathione S-Transferase pi;DNA Repair Enzymes",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Cadherins;Carcinoma, Hepatocellular;DNA Methylation;DNA Modification Methylases;DNA Repair Enzymes;Female;Gene Expression;Genes, p16;Glutathione S-Transferase pi;Hepatitis B;Humans;Immunohistochemistry;Liver Cirrhosis;Liver Neoplasms;Male;Middle Aged;Polymerase Chain Reaction;Promoter Regions, Genetic;Retinoblastoma Protein;Tumor Suppressor Protein p14ARF;Tumor Suppressor Proteins",
        "Doc_meshqualifiers":"genetics;genetics;virology;genetics;genetics;genetics;genetics;genetics;genetics;virology;genetics;genetics;genetics;genetics",
        "_version_":1605851127152115712},
      {
        "Doc_abstract":"The naked mole rat (Heterocephalus glaber) is a long-lived and tumor-resistant rodent. Tumor resistance in the naked mole rat is mediated by the extracellular matrix component hyaluronan of very high molecular weight (HMW-HA). HMW-HA triggers hypersensitivity of naked mole rat cells to contact inhibition, which is associated with induction of the INK4 (inhibitors of cyclin dependent kinase 4) locus leading to cell-cycle arrest. The INK4a/b locus is among the most frequently mutated in human cancer. This locus encodes three distinct tumor suppressors: p15(INK4b), p16(INK4a), and ARF (alternate reading frame). Although p15(INK4b) has its own ORF, p16(INK4a) and ARF share common second and third exons with alternative reading frames. Here, we show that, in the naked mole rat, the INK4a/b locus encodes an additional product that consists of p15(INK4b) exon 1 joined to p16(INK4a) exons 2 and 3. We have named this isoform pALT(INK4a/b) (for alternative splicing). We show that pALT(INK4a/b) is present in both cultured cells and naked mole rat tissues but is absent in human and mouse cells. Additionally, we demonstrate that pALT(INK4a/b) expression is induced during early contact inhibition and upon a variety of stresses such as UV, gamma irradiation-induced senescence, loss of substrate attachment, and expression of oncogenes. When overexpressed in naked mole rat or human cells, pALT(INK4a/b) has stronger ability to induce cell-cycle arrest than either p15(INK4b) or p16(INK4a). We hypothesize that the presence of the fourth product, pALT(INK4a/b) of the INK4a/b locus in the naked mole rat, contributes to the increased resistance to tumorigenesis of this species. ",
        "Doc_title":"INK4 locus of the tumor-resistant rodent, the naked mole rat, expresses a functional p15/p16 hybrid isoform.",
        "Journal":"Proceedings of the National Academy of Sciences of the United States of America",
        "Do_id":"25550505",
        "Doc_ChemicalList":"CDKN2B protein, human;Cdkn2a protein, mouse;Cyclin-Dependent Kinase Inhibitor p15;Cyclin-Dependent Kinase Inhibitor p16",
        "Doc_meshdescriptors":"Alternative Splicing;Animals;Cell Aging;Cell Cycle Checkpoints;Cell Line;Cell Transformation, Neoplastic;Cyclin-Dependent Kinase Inhibitor p15;Cyclin-Dependent Kinase Inhibitor p16;Genetic Loci;Humans;Mice;Mole Rats;Rats;Species Specificity",
        "Doc_meshqualifiers":"physiology;physiology;physiology;genetics;metabolism;biosynthesis;genetics;biosynthesis;genetics;physiology",
        "_version_":1605825857587249152},
      {
        "Doc_abstract":"The 9p21.3 locus was the first to yield to genome-wide association studies (GWAS) seeking common genetic variants predisposing to increased risk of coronary artery atherosclerotic disease (CAD). The 59 single nucleotide polymorphisms that show highest association with CAD are clustered in a region 100,000 to 150,000 base pairs 5' to the cyclin-dependent kinase inhibitors CDKN2B (coding for p15(ink4b)) and CDKN2A (coding for p16(ink4a) and p14(ARF)). This region also covers the 3' end of a long noncoding RNA transcribed antisense to CDKN2B (CDKN2BAS, aka ANRIL for antisense noncoding RNA at the ink4 locus) whose expression has been linked to chromatin remodeling at the locus. Despite intensive investigation over the past 7years, the functional significance of the 9p21.3 locus remains elusive. Other variants at this locus have been associated with glaucoma, glioma, and type 2 diabetes mellitus, diseases that implicate tissue-resident macrophages. Here, we review the evidence that genetic variants at 9p21.3 disrupt tissue-specific enhancers and propose new insights to guide future studies. ",
        "Doc_title":"Functional genomics of the 9p21.3 locus for atherosclerosis: clarity or confusion?",
        "Journal":"Current cardiology reports",
        "Do_id":"24893939",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Atherosclerosis;Chromosomes, Human, Pair 9;Genome-Wide Association Study;Genomics;Humans;Phenotype;Signal Transduction",
        "Doc_meshqualifiers":"genetics;genetics",
        "_version_":1605742708352090113},
      {
        "Doc_abstract":"The incidence of oropharyngeal squamous cell cancer (OPSCC) in Finland has increased during the past decades. A similar change has been seen in the relative frequency of p16-positive head and neck squamous cell carcinoma (HNSCC). As p16 is a surrogate marker for human papilloma virus (HPV) infection, and as most p16-positive HNSCCs are OPSCC, HPV infection may have had a role in the observed increased incidence of OPSCC.;Numerous studies have shown that HPV is an independent risk factor for OPSCC. We aimed to use p16 as a surrogate marker of HPV infection to study its role as a possible risk factor in OPSCC. Furthermore, the change in the incidence of OPSCC in Finland was studied.;HPV status was determined by p16 immunohistochemistry of 135 HNSCC tumour specimens retrieved from patients treated at the Helsinki University Central Hospital. Incidence data on OPSCC were obtained from the Finnish Cancer Registry.;The incidence of OPSCC in Finland increased from 0.66/100 000 person-years during 1989-1993 to 1.36 during 2004-2008. During the same period a significant increase in the relative frequency of p16 positive HNSCC tumours from 22% during 1990-1999 to 41% during 2000-2007 could be seen at our institution. In all, 85% of the p16-positive specimens were OPSCC.",
        "Doc_title":"Increased incidence of oropharyngeal cancer and p16 expression.",
        "Journal":"Acta oto-laryngologica",
        "Do_id":"21542673",
        "Doc_ChemicalList":"Biomarkers;Neoplasm Proteins;P16 protein, human",
        "Doc_meshdescriptors":"Biomarkers;Biopsy;Carcinoma, Squamous Cell;Cohort Studies;Cross-Sectional Studies;Female;Finland;Gene Expression;Head and Neck Neoplasms;Humans;Incidence;Male;Middle Aged;Neoplasm Proteins;Oropharyngeal Neoplasms;Papillomavirus Infections;Risk Factors",
        "Doc_meshqualifiers":"metabolism;epidemiology;genetics;pathology;genetics;epidemiology;genetics;pathology;genetics;epidemiology;genetics;pathology;epidemiology;genetics;pathology",
        "_version_":1605742744255332352},
      {
        "Doc_abstract":"Head and neck squamous cell carcinoma (HNSCC) is a common, morbid, and frequently lethal malignancy. To uncover its mutational spectrum, we analyzed whole-exome sequencing data from 74 tumor-normal pairs. The majority exhibited a mutational profile consistent with tobacco exposure; human papillomavirus was detectable by sequencing DNA from infected tumors. In addition to identifying previously known HNSCC genes (TP53, CDKN2A, PTEN, PIK3CA, and HRAS), our analysis revealed many genes not previously implicated in this malignancy. At least 30% of cases harbored mutations in genes that regulate squamous differentiation (for example, NOTCH1, IRF6, and TP63), implicating its dysregulation as a major driver of HNSCC carcinogenesis. More generally, the results indicate the ability of large-scale sequencing to reveal fundamental tumorigenic mechanisms.",
        "Doc_title":"The mutational landscape of head and neck squamous cell carcinoma.",
        "Journal":"Science (New York, N.Y.)",
        "Do_id":"21798893",
        "Doc_ChemicalList":"NOTCH1 protein, human;Receptor, Notch1",
        "Doc_meshdescriptors":"Algorithms;Apoptosis;Carcinoma;Carcinoma, Squamous Cell;Cell Differentiation;Exons;Head and Neck Neoplasms;Humans;Mutation;Neoplasms, Squamous Cell;Papillomaviridae;Papillomavirus Infections;Point Mutation;Receptor, Notch1;Sequence Analysis, DNA;Sequence Deletion;Signal Transduction;Smoking;Tobacco",
        "Doc_meshqualifiers":"genetics;metabolism;virology;genetics;metabolism;virology;genetics;metabolism;virology;isolation & purification;virology;genetics;metabolism",
        "_version_":1605757455498739712},
      {
        "Doc_abstract":"Cervical cancer is caused by persistent infections through high risk (HR) types of human HPVs, particularly HPV 16 and 18. HR-HPV types encode two potent oncogenes, referred to as E6 and E7. Both are required to induce and maintain neoplastic growth of cervical cancer cells. Cyclin dependent kinase inhibitor genes as for example p16INK4A were shown to be negative regulated by active pRb. Inactivation of pRb by E7 thus releases the p16 gene from its negative transcriptional control and results in significant overexpression of p16 encoded protein in HPV transformed cells. It has been demonstrated that p16 protein can be detected in cervical preneoplasia all high grade SIL or invasive cancers, whereas no expression was detected in normal, metaplastic or inflammatory cervical lesions. Moreover, low grade cervical lesions induced by low risk HPV infection but histological indistinguishable from low grade lesions induced by HR-HPV-infections could be clearly differentiated by p16INK4A immunohistochemistry, showing negative staining for p16 protein. The objective of this study is to examine the expression of p16 protein in cervical carcinoma in Thailand. Immunohistochemical analysis of p16INK4A was performed on 53 formalin fixed and paraffin embedded samples of various stages of cervical neoplastic lesions. There are squamous cell carcinoma in situ 8 cases, squamous cell carcinoma in situ with glandular involvement 16 cases, microinvasive squamous cell carcinoma 13 cases and invasive squamous cell carcinoma 16 cases. The specimens were taken from cervical biopsy, cervical conization and hysterectomy in the year 2000 at National Cancer Institute. Strong immunoreactivity for the p16 protein was observed in only the nuclei and cytoplasm of all cervical neoplastic cells. This study supported the idea that immunohistochemical overexpression of the p16 protein may be a useful screening test for cervical cancer. In addition, p16 immunohistochemistry is useful for helping in the interpretation of cervical histology samples, facilitating more rapid diagnosis.",
        "Doc_title":"Immunohistochemical overexpression of p16 protein associated with cervical cancer in Thailand.",
        "Journal":"Asian Pacific journal of cancer prevention : APJCP",
        "Do_id":"19256750",
        "Doc_ChemicalList":"Biomarkers, Tumor;Cyclin-Dependent Kinase Inhibitor p16",
        "Doc_meshdescriptors":"Adult;Aged;Biomarkers, Tumor;Biopsy, Needle;Carcinoma, Squamous Cell;Cyclin-Dependent Kinase Inhibitor p16;Female;Humans;Immunohistochemistry;Middle Aged;Neoplasm Invasiveness;Neoplasm Staging;Prognosis;Sampling Studies;Sensitivity and Specificity;Taiwan;Uterine Cervical Neoplasms",
        "Doc_meshqualifiers":"metabolism;epidemiology;metabolism;pathology;metabolism;pathology;epidemiology;epidemiology;metabolism;pathology",
        "_version_":1605799684421451776},
      {
        "Doc_abstract":"The incidence of head and neck squamous cell carcinomas (HNSCC) associated with human papillomavirus (HPV) infection has increased over the past decades in the United States. We aimed at examining the global impact of HPV-associated HNSCC and whether the established key role of mTOR activation in HNSCC is also observed in HPV(+) HNSCC lesions, thereby providing novel treatment options for HPV-associated HNSCC patients.;An international HNSCC tissue microarray (TMA) was used to analyze the expression of p16(INK4A), a surrogate for HPV infection, and Akt-mTOR pathway activation. Results were confirmed in a large collection of HPV(-) and HPV(+) HNSCC cases and in a cervical cancer (CCSCC) TMA. Observations were validated in HNSCC and CCSCC-derived cell lines, which were xenografted into immunodeficient mice for tumorigenesis assays.;Approximately 20% of all HNSCC lesions could be classified as HPV(+), irrespective of their country of origin. mTOR pathway activation was observed in most HPV(+) HNSCC and CCSCC lesions and cell lines. The preclinical efficacy of mTOR inhibition by rapamycin and RAD001 was explored in HPV(+) HNSCC and CCSCC tumor xenografts. Both mTOR inhibitors effectively decreased mTOR activity in vivo and caused a remarkable decrease in tumor burden. These results emphasize the emerging global impact of HPV-related HNSCCs and indicate that the activation of the mTOR pathway is a widespread event in both HPV(-) and HPV-associated HNSCC and CCSCC lesions.;The emerging results may provide a rationale for the clinical evaluation of mTOR inhibitors as a molecular targeted approach for the treatment of HPV-associated malignancies.",
        "Doc_title":"mTOR as a molecular target in HPV-associated oral and cervical squamous carcinomas.",
        "Journal":"Clinical cancer research : an official journal of the American Association for Cancer Research",
        "Do_id":"22409888",
        "Doc_ChemicalList":"DNA, Viral;Neoplasm Proteins;P16 protein, human;MTOR protein, human;TOR Serine-Threonine Kinases;Proto-Oncogene Proteins c-akt;Sirolimus",
        "Doc_meshdescriptors":"Animals;Blotting, Western;Carcinoma, Squamous Cell;Cell Line, Tumor;Cervix Uteri;Cohort Studies;DNA, Viral;Female;Humans;Immunoenzyme Techniques;Mice;Mice, Nude;Mouth Neoplasms;Neoplasm Proteins;Papillomaviridae;Papillomavirus Infections;Polymerase Chain Reaction;Proto-Oncogene Proteins c-akt;Sirolimus;TOR Serine-Threonine Kinases;Tissue Array Analysis;Uterine Cervical Neoplasms;Xenograft Model Antitumor Assays",
        "Doc_meshqualifiers":"drug therapy;metabolism;virology;metabolism;pathology;genetics;drug therapy;metabolism;virology;genetics;drug therapy;metabolism;virology;antagonists & inhibitors;metabolism;therapeutic use;antagonists & inhibitors;metabolism;drug therapy;metabolism;virology",
        "_version_":1605811430762741760},
      {
        "Doc_abstract":"This study examines the tumour-host immune interactions in head and neck squamous cell carcinoma (HNSCC) and their relationship to human papillomavirus (HPV) infectivity and patient survival.;The adaptive and innate immune profile of surgical tumour specimens obtained from HNSCC patients was determined using qRT-PCR and immunohistochemistry. Intratumoural and invading margin leukocyte populations (CD3, CD8, CD16, CD20, CD68, FoxP3 and HLA-DR) were quantified and compared with patient disease-specific survival. Additionally, the expression of 41 immune activation- and suppression-related genes was evaluated in the tumour microenvironment. Tumour cells were also assessed for expression of HLA-A, HLA-G and HLA-DR. HPV infectivity of tumour biopsies was determined using HPV consensus primers (MY09/MY11 and GP5+/GP6+) and confirmed with p16 immunohistochemistry.;HPV",
        "Doc_title":"Immune cell infiltration patterns and survival in head and neck squamous cell carcinoma.",
        "Journal":"Head & neck oncology",
        "Do_id":"24723971",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605800492935413760},
      {
        "Doc_abstract":"Vulvar intraepithelial neoplasia (VIN) is defined histopathologically by distinctive abnormalities of cellular maturation and differentiation. The purpose of this study was to investigate the functional properties of VIN related to expression of p16(INK4a) protein as well as to detection of human papillomavirus (HPV) type 16 by real-time polymerase chain reaction (RT-PCR) analysis.;A total of 49 vulvar biopsy samples were examined by hematoxylin-eosin staining from benign/reactive lesions, condyloma acuminatum, VIN, and invasive squamous cell carcinoma (SCC). JC8 mouse monoclonal antibodies were used that recognize p16(INK4a) epitope at a dilution of 1:25. The reaction pattern for p16(INK4a) was graded in each sample between 0 and 3+. RT-PCR analysis of formalin-fixed paraffin-embedded sections determined positivity for HPV type 16.;p16(INK4a) immunoreactivity was different in VIN 1, VIN 2, VIN 3, and squamous cell carcinoma. Strong expression of p16(INK4a) protein was observed in 92% (22 of 24) of VIN 2 and VIN 3 lesions and 100% (4 of 4) of invasive SCCs. Two (67%) of 3 VIN 2 lesions, 17 (81%) of 21 VIN 3 lesions, and 4 (100%) of 4 SCCs were positive for HPV type 16 by PCR analysis. Two (20%) of 10 VIN 1 lesions were immunoreactive for p16(INK4a), with only 1 lesion positive for HPV type 16. No p16(INK4a) immunoreactivity was observed in any of the benign/reactive and condyloma acuminatum lesions. In addition, none of the benign/reactive or condyloma lesions were positive for HPV type 16 by RT-PCR analysis.;Upregulation of INK4a gene occurs in vulvar carcinogenesis. p16(INK4a) is not a sensitive marker for differentiation of benign vulvar squamous epithelium from condyloma acuminatum or VIN 1 lesions because most VIN 1 lesions are p16(INK4a) negative. Expression of p16(INK4a) may aid in the diagnosis of HPV-related lesions and as such may be of value as a surrogate marker in the diagnosis of vulvar premalignant and malignant lesions.",
        "Doc_title":"Human papillomavirus infection and p16(INK4a) protein expression in vulvar intraepithelial neoplasia and invasive squamous cell carcinoma.",
        "Journal":"Journal of lower genital tract disease",
        "Do_id":"15870532",
        "Doc_ChemicalList":"Biomarkers, Tumor;Cyclin-Dependent Kinase Inhibitor p16;DNA, Viral",
        "Doc_meshdescriptors":"Adult;Biomarkers, Tumor;Carcinoma in Situ;Carcinoma, Squamous Cell;Cyclin-Dependent Kinase Inhibitor p16;DNA, Viral;Female;Humans;Immunohistochemistry;Middle Aged;Neoplasm Invasiveness;Papillomaviridae;Papillomavirus Infections;Polymerase Chain Reaction;Vulva;Vulvar Neoplasms",
        "Doc_meshqualifiers":"analysis;metabolism;pathology;virology;metabolism;pathology;virology;analysis;genetics;genetics;pathology;virology;chemistry;pathology;virology;metabolism;pathology;virology",
        "_version_":1605818660621910016},
      {
        "Doc_abstract":"The multi tumor suppressor genes MTS1 (CDKN2 p16INK4A) and MTS2 (CDKN1, p15INK4B) located at 9p21-22 are inactivated in some human cancers via several mechanisms including deletion and hypermethylation. We have investigated the deletion and methylation status of MTS1 and MTS2 in childhood acute lymphoblastic leukemia (ALL) of both T-cell (17 cases) and B-cell phenotypes (29 cases), and p16INK4A and p15INK4B mRNA expression in 36 of these cases. Biallelic or monoallelic loss of both MTS1 and MTS2 was observed in 12 cases of B-ALL and nine cases of T-ALL. Two cases of T-ALL showed deletion of MTS1 but not MTS2. The 5' CpG region of MTS2 was hypermethylated in 12 cases of precursor B-ALL and eight cases of T-ALL but no hypermethylation was found in the 5' CpG region of MTS1. All cases with homozygous deletion of MTS1 or MTS2 had no or low levels of mRNA expression and similar low levels of expression were found in cases in which MTS2 was present but fully methylated. Thus hypermethylation of MTS2, in contrast to MTS1, is frequent in childhood ALL. Furthermore our data show that although inactivation of MTS1 by deletion is common, inactivation of MTS2 by a combination of deletion and hypermethylation is more frequent in both B-ALL (20/29, 69%) and T-ALL (17/17, 100%). This suggests that both MTS1 and MTS2 are important targets of the 9p21-22 deletion.",
        "Doc_title":"Methylation of the multi tumor suppressor gene-2 (MTS2, CDKN1, p15INK4B) in childhood acute lymphoblastic leukemia.",
        "Journal":"Oncogene",
        "Do_id":"9399648",
        "Doc_ChemicalList":"CDKN2B protein, human;Carrier Proteins;Cell Cycle Proteins;Cyclin-Dependent Kinase Inhibitor p15;Cyclin-Dependent Kinase Inhibitor p16;RNA, Messenger;Tumor Suppressor Proteins",
        "Doc_meshdescriptors":"Carrier Proteins;Cell Cycle Proteins;Child;Cyclin-Dependent Kinase Inhibitor p15;Cyclin-Dependent Kinase Inhibitor p16;Genes, Tumor Suppressor;Humans;In Situ Hybridization, Fluorescence;Methylation;Polymerase Chain Reaction;Precursor Cell Lymphoblastic Leukemia-Lymphoma;RNA, Messenger;Tumor Suppressor Proteins",
        "Doc_meshqualifiers":"genetics;metabolism;genetics;metabolism;analysis",
        "_version_":1605763989159018496},
      {
        "Doc_abstract":"Hypopharyngeal cancer is a subset of head neck squamous cell carcinoma (HNSCC) with particularly poor prognosis. Human papillomavirus (HPV) is a risk factor for some HNSCC, and its presence is of prognostic value for certain subsites. However, its influence on survival in hypopharyngeal cancer has not been thoroughly investigated. Here we examine HPV DNA and p16(INK4a) (p16) overexpression in relation to clinical outcome.;Hypopharyngeal tumour biopsies from 82 patients diagnosed 2008-2013 were examined for presence of HPV DNA by a bead-based multiplex assay and for p16 expression by immunohistochemistry, and the obtained data compared to that acquired previously from 109 patients diagnosed 2000-2007 at the same clinic. A survival analysis was then performed on 142 patients (from both studies) treated with curative intent and a 3-year follow-up time.;Of the tumour biopsies 3/82 (3.7%) were HPV16 DNA and p16 positive, while 12/82 (14.6%) were p16 positive, equivalent to that in the previous study. Overall 3-year survival was significantly more favourable for patients with HPV16 DNA and p16 positive tumours as compared to survival of the other patients (86% vs. 31%, p=0.0185). A similar but not statistically significant trend was found for disease specific survival.;HPV DNA and p16 positive hypopharyngeal cancer was rare and had not increased, but had a better clinical outcome as compared to other HPV-unrelated hypopharyngeal cancer. In addition, p16 overexpression was not a suitable surrogate marker for presence of HPV or for prediction of survival in this type of cancer.",
        "Doc_title":"Human papillomavirus DNA and p16(INK4a) expression in hypopharyngeal cancer and in relation to clinical outcome, in Stockholm, Sweden.",
        "Journal":"Oral oncology",
        "Do_id":"26120094",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;DNA, Viral",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Cyclin-Dependent Kinase Inhibitor p16;DNA, Viral;Female;Human papillomavirus 16;Humans;Hypopharyngeal Neoplasms;Male;Middle Aged;Papillomavirus Infections;Prognosis;Survival Analysis;Sweden",
        "Doc_meshqualifiers":"metabolism;metabolism;metabolism;metabolism;mortality;metabolism;mortality;epidemiology",
        "_version_":1605928311628759040},
      {
        "Doc_abstract":"Accurate morphologic distinction between small cell carcinoma and poorly differentiated squamous cell carcinoma has critical therapeutic significance, but can be limited by crush artifact, tumor necrosis, limited tumor representation, and overlapping morphologic features. We evaluated a panel of antibodies for their efficacy in distinguishing between these neoplasms. Formalin-fixed paraffin-embedded tissue sections of small cell carcinomas and poorly differentiated squamous cell carcinomas underwent immunohistochemical staining with antibodies to thyroid transcription factor-1, p63, high molecular weight keratin, and p16(INK4A). Of 28 small cell carcinomas, 26 (93%) small cell carcinomas showed diffuse moderate or strong staining for thyroid transcription factor-1 with no staining for high molecular weight keratin and p63. In contrast, 27/28 (96%) poorly differentiated squamous cell carcinomas manifested opposite immunoreactivities, with diffuse moderate or strong staining for high molecular weight keratin and p63, and no or minimal staining for thyroid transcription factor-1. In two additional cases originally interpreted as small cell carcinoma, high molecular weight keratin highlighted small numbers of neoplastic large cells, leading to reclassification as combined small cell and non-small cell carcinomas. p16(INK4A) expression varied widely in poorly differentiated squamous cell carcinomas, but was consistently moderate or strong and diffuse in small cell carcinomas, and proved helpful in the two thyroid transcription factor-1-negative small cell carcinomas. This study demonstrates that a panel consisting of antibodies to thyroid transcription factor-1, p63, high molecular weight keratin, and p16(INK4A) is highly effective for distinguishing between small cell carcinoma and poorly differentiated squamous cell carcinoma. This panel also facilitates diagnosis of combined small cell and non-small cell carcinomas.",
        "Doc_title":"Distinction of pulmonary small cell carcinoma from poorly differentiated squamous cell carcinoma: an immunohistochemical approach.",
        "Journal":"Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc",
        "Do_id":"15309021",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;DNA-Binding Proteins;Nuclear Proteins;Phosphoproteins;TP63 protein, human;Trans-Activators;Transcription Factors;Tumor Suppressor Proteins;thyroid nuclear factor 1;Keratins",
        "Doc_meshdescriptors":"Carcinoma, Small Cell;Carcinoma, Squamous Cell;Cell Differentiation;Cyclin-Dependent Kinase Inhibitor p16;DNA-Binding Proteins;Diagnosis, Differential;Genes, Tumor Suppressor;Humans;Immunohistochemistry;Keratins;Lung Neoplasms;Nuclear Proteins;Phosphoproteins;Trans-Activators;Transcription Factors;Tumor Suppressor Proteins",
        "Doc_meshqualifiers":"metabolism;pathology;metabolism;pathology;analysis;analysis;metabolism;pathology;analysis;analysis;analysis;analysis",
        "_version_":1605818567546109952},
      {
        "Doc_abstract":"MicroRNAs (miRs) are non-coding RNA molecules regulating diverse cellular processes essential in carcinogenesis. Little is known regarding miRs in head and neck squamous cell cancer (HNSCC). The aim of the present study was to investigate miRs in relation to the clinico pathological features of site-specific HNSCC.;The study comprised of 51 patients with HNSCC (23 oropharyngeal, 24 laryngeal and 4 hypopharyngeal carcinomas). Total RNA was extracted from tumor tissue and normal squamous epithelium using the miRNeasy FFPE Kit. A quantitative estimation of let-7a, miR-21, miR-200c, miR-34a, miR-375 was performed by a real-time polymerase chain reaction (PCR) method using the TagMan MicroRNA assay. Additionally, p16 expression was detected by immuno histo chemistry.;Significant differences of let-7a, miR-200c, miR-34a levels between oropharyngeal and laryngeal cancers were found (p<0.05). Compared to non-neoplastic tissues, miR-21, miR-200c, miR-34a were up-regulated and miR-375 was down-regulated in tumors of all sites. MiR-34a tumor levels significantly correlated with oropharyngeal origin (p=0.0284) and p16 positivity (p=0.0218).;The microRNA profile seems to play a potential role in the pathobiology of oropharyngeal and laryngeal HNSCC. Up-regulation of miR34a in p16-positive oropharyngeal cancer has not been so far described and additional studies are warranted.",
        "Doc_title":"MicroRNA profile in site-specific head and neck squamous cell cancer.",
        "Journal":"Anticancer research",
        "Do_id":"25862914",
        "Doc_ChemicalList":"Biomarkers, Tumor;MIRN34 microRNA, human;MicroRNAs",
        "Doc_meshdescriptors":"Aged;Aged, 80 and over;Biomarkers, Tumor;Carcinoma, Squamous Cell;Cell Proliferation;Female;Gene Expression Regulation, Neoplastic;Head and Neck Neoplasms;Humans;Laryngeal Neoplasms;Male;MicroRNAs;Middle Aged;Oropharyngeal Neoplasms;Transcriptome",
        "Doc_meshqualifiers":"biosynthesis;genetics;genetics;pathology;genetics;genetics;pathology;genetics;pathology;biosynthesis;genetics;genetics;pathology;genetics",
        "_version_":1605792817758601216},
      {
        "Doc_abstract":"The Epstein-Barr virus (EBV) nuclear proteins EBNA3A, EBNA3B, and EBNA3C interact with the cell DNA binding protein RBPJ and regulate cell and viral genes. Repression of the CDKN2A tumor suppressor gene products p16(INK4A) and p14(ARF) by EBNA3A and EBNA3C is critical for EBV mediated transformation of resting B lymphocytes into immortalized lymphoblastoid cell lines (LCLs). To define the composition of endogenous EBNA3 protein complexes, we generated lymphoblastoid cell lines (LCLs) expressing flag-HA tagged EBNA3A, EBNA3B, or EBNA3C and used tandem affinity purification to isolate each EBNA3 complex. Our results demonstrated that each EBNA3 protein forms a distinct complex with RBPJ. Mass-spectrometry revealed that the EBNA3A and EBNA3B complexes also contained the deubquitylation complex consisting of WDR48, WDR20, and USP46 (or its paralog USP12) and that EBNA3C complexes contained WDR48. Immunoprecipitation confirmed that EBNA3A, EBNA3B, and EBNA3C association with the USP46 complex. Using chromatin immunoprecipitation, we demonstrate that WDR48 and USP46 are recruited to the p14(ARF) promoter in an EBNA3C dependent manner. Mapping studies were consistent with WDR48 being the primary mediator of EBNA3 association with the DUB complex. By ChIP assay, WDR48 was recruited to the p14(ARF) promoter in an EBNA3C dependent manner. Importantly, WDR48 associated with EBNA3A and EBNA3C domains that are critical for LCL growth, suggesting a role for USP46/USP12 in EBV induced growth transformation.",
        "Doc_title":"The EBNA3 family of Epstein-Barr virus nuclear proteins associates with the USP46/USP12 deubiquitination complexes to regulate lymphoblastoid cell line growth.",
        "Journal":"PLoS pathogens",
        "Do_id":"25855980",
        "Doc_ChemicalList":"EBNA-3A antigen;EBNA-3B antigen;EBNA-3C, epstein-barr virus;Epstein-Barr Virus Nuclear Antigens;USP12 protein, human;Endopeptidases;ubiquitin-specific peptidase 46, human;Ubiquitin Thiolesterase",
        "Doc_meshdescriptors":"Blotting, Western;Cell Line;Cell Proliferation;Cell Transformation, Viral;Chromatin Immunoprecipitation;Endopeptidases;Epstein-Barr Virus Nuclear Antigens;Gene Expression Regulation, Viral;Herpesvirus 4, Human;Humans;Immunoprecipitation;Mass Spectrometry;Ubiquitin Thiolesterase",
        "Doc_meshqualifiers":"genetics;genetics;metabolism;metabolism;genetics;genetics;metabolism;genetics;metabolism",
        "_version_":1605804440512626688},
      {
        "Doc_abstract":"Iodine intake is related to thyroid disease. This study investigated the effect of the amount of iodine intake on p14ARF and p16INK4a expression of thyroid papillary carcinoma in rats.;A cohort of 240 SD rats were randomly divided into control group, low iodine, normal iodine, and high iodine groups (n=60 per group). We inoculated 2  10(5) papillary thyroid carcinoma (PTC) cells on the left side of the thyroid gland. After 6 and 12 weeks, serum thyroid hormone level and urine iodine level were measured in addition to morphological observations of tumor tissues. Expression of p14ARF, p16INK4a was detected by immunohistochemical staining.;The expression of p14ARF, p16INK4a, FT3, and FT4 levels in all iodine-treated animals were significantly lower than in the control group, while TSH level was significantly higher (P<0.05). Compared to the normal iodine group, the low and high groups had lower p14ARF and p16INK4a expression, lower FT3 and FT4 levels, higher TSH levels, and heavier tumors (P<0.05). In a further between-group comparison, p14ARF and p16INK4a expression and FT3 and FT4 levels at 12 weeks were lower than at 6 weeks. Expression of p14ARF and p16INK4a were positively correlated with FT3 and FT4, and negatively correlated with TSH and tumor weight.;Low and high iodine diet intake could reduce p14ARF and p16INK4a expressions and promote tumor development.",
        "Doc_title":"Effect of Iodine Intake on p14ARF and p16INK4a Expression in Thyroid Papillary Carcinoma in Rats.",
        "Journal":"Medical science monitor : international medical journal of experimental and clinical research",
        "Do_id":"26248224",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;Thyroid Hormones;Tumor Suppressor Protein p14ARF;Iodine",
        "Doc_meshdescriptors":"Animals;Carcinoma, Papillary;Cyclin-Dependent Kinase Inhibitor p16;Iodine;Male;Rats;Rats, Sprague-Dawley;Thyroid Hormones;Tumor Suppressor Protein p14ARF",
        "Doc_meshqualifiers":"metabolism;metabolism;metabolism;urine;blood;metabolism;metabolism",
        "_version_":1605818705328996354},
      {
        "Doc_abstract":"Many tumors have large homozygous deletions of the CDKN2A locus (encoding p14(ARF) and p16) and of CDKN2B (p15). Our aim was to determine which gene is the major target in bladder cancer. We used quantitative real-time PCR (RTQ-PCR) to determine copy number of p15, of p14(ARF) exon 1beta, and p16 exon 2 in 22 tumor cell lines and 83 bladder tumors, some of which had been assessed previously by duplex PCR. Titration experiments showed that homozygous deletion could be detected in the presence of up to 30% normal DNA. Results for cell lines were compatible with previous cytogenetic analyses. Ten cell lines and 32 tumors (38.5%) had homozygous deletion of at least one target. Thirteen tumors (15.7%) had deletion of all three targets. Two tumors had deletion of p14(ARF) exon 1beta alone and four of p16 exon 2 alone. RTQ-PCR detected more homozygous deletions than duplex PCR. Finally we used a multiplex ligation-dependent probe amplification kit to provide independent confirmation of results. We conclude that with appropriate controls RTQ-PCR is a sensitive and robust method to detect copy number changes in tumors even in the presence of contaminating normal cell DNA.",
        "Doc_title":"Measurement of relative copy number of CDKN2A/ARF and CDKN2B in bladder cancer by real-time quantitative PCR and multiplex ligation-dependent probe amplification.",
        "Journal":"The Journal of molecular diagnostics : JMD",
        "Do_id":"15507675",
        "Doc_ChemicalList":"CDKN2B protein, human;Cell Cycle Proteins;Cyclin-Dependent Kinase Inhibitor p15;DNA Primers;Tumor Suppressor Protein p14ARF;Tumor Suppressor Proteins;DNA",
        "Doc_meshdescriptors":"Cell Cycle Proteins;Cell Line, Tumor;Chromosomes, Human, Pair 9;Cyclin-Dependent Kinase Inhibitor p15;Cytogenetics;DNA;DNA Primers;Exons;Gene Deletion;Genes, p16;Genetic Techniques;Homozygote;Humans;Polymerase Chain Reaction;Reverse Transcriptase Polymerase Chain Reaction;Sensitivity and Specificity;Tumor Suppressor Protein p14ARF;Tumor Suppressor Proteins;Urinary Bladder Neoplasms",
        "Doc_meshqualifiers":"biosynthesis;genetics;metabolism;chemistry;methods;biosynthesis;biosynthesis;genetics;genetics",
        "_version_":1605844762009534464},
      {
        "Doc_abstract":"Head and neck squamous cell carcinoma tumors positive for laboratory biomarkers hrHPV and p16 and negative for EGFR often respond better to nonsurgical organ-preservation therapy than hrHPV-negative, p16-negative, and EGFR overexpressing tumors. CTP has been shown to distinguish which locally advanced head and neck squamous cell carcinomas will respond to induction chemotherapy or chemoradiation. Our purpose was to determine whether a relationship exists between CTP measures and the expression of these laboratory biomarkers, because both appear to separate head and neck squamous cell carcinoma tumors into similar groups.;We conducted an institutional review board-approved, Health Insurance Portability and Accountability Act-compliant retrospective review of head and neck CTP in 25 patients with locally advanced head and neck squamous cell carcinoma who had signed informed consent. Eight women and 17 men, 41-80 years of age, constituted a pretreatment group of 18 patients and a palliative group of 7 patients. Tumor biopsy samples were analyzed for overexpression of hrHPV, p16, and EGFR. The hrHPV, p16, and EGFR status of the tumors was correlated with CTP parameters (MTT, BV, BF, CP) by using the Wilcoxon evaluation and Fischer exact test.;There were significantly lower CP values in pretreatment tumors overexpressing EGFR (P = .04). CP values 17.23 were significantly correlated with EGFR overexpression (P = .015). A trend toward higher CP values was present in hrHPV-positive and p16-overexpressing pretreatment tumors (P = .14).;A significant correlation exists between CTP measures and EGFR overexpression in head and neck squamous cell carcinomas, suggesting an association between certain imaging findings and molecular biomarkers. These results may be related to a tumor cell survival mechanism linking perfusion and biomarker expression.",
        "Doc_title":"Human papillomavirus, p16, and epidermal growth factor receptor biomarkers and CT perfusion values in head and neck squamous cell carcinoma.",
        "Journal":"AJNR. American journal of neuroradiology",
        "Do_id":"23370473",
        "Doc_ChemicalList":"Biomarkers, Tumor;Neoplasm Proteins;P16 protein, human;Receptor, Epidermal Growth Factor",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Alphapapillomavirus;Biomarkers, Tumor;Carcinoma, Squamous Cell;Female;Head and Neck Neoplasms;Humans;Male;Middle Aged;Neoplasm Proteins;Perfusion Imaging;Receptor, Epidermal Growth Factor;Reproducibility of Results;Sensitivity and Specificity;Tomography, X-Ray Computed",
        "Doc_meshqualifiers":"isolation & purification;analysis;diagnosis;metabolism;virology;diagnosis;metabolism;analysis;methods;analysis;methods",
        "_version_":1605742667518443522},
      {
        "Doc_abstract":"Immunohistochemical analysis of Rb, p16(INK4A) and cyclin D1 expression was performed on 78 oral squamous cell carcinoma (SCC), 46 leukoplakia, and 20 normal mucosa. Rb and p16(INK4A) expression were observed in all normal mucosa and most of leukoplakia. Lack of Rb and p16(INK4A) was observed in 56.4 and 67.9% of SCC, respectively. The overexpression of cyclin D1 was not observed in normal mucosa and was observed in 35.9% of SCC. A strong reciprocal relationship between Rb and p16(INK4A) expression was observed in oral SCC, and all these SCC cases have at least one of the alterations in the Rb pathway.",
        "Doc_title":"Alterations of Rb, p16(INK4A) and cyclin D1 in the tumorigenesis of oral squamous cell carcinomas.",
        "Journal":"Cancer letters",
        "Do_id":"11098077",
        "Doc_ChemicalList":"Carrier Proteins;Cyclin-Dependent Kinase Inhibitor p16;Proliferating Cell Nuclear Antigen;Retinoblastoma Protein;Cyclin D1",
        "Doc_meshdescriptors":"Carcinoma, Squamous Cell;Carrier Proteins;Cyclin D1;Cyclin-Dependent Kinase Inhibitor p16;Humans;Immunohistochemistry;Mouth Neoplasms;Proliferating Cell Nuclear Antigen;Retinoblastoma Protein",
        "Doc_meshqualifiers":"metabolism;pathology;analysis;analysis;metabolism;pathology;analysis;analysis",
        "_version_":1605928357039439872},
      {
        "Doc_abstract":"To investigate the presence and persistence of human papillomavirus (HPV) infection in the oral mucosa of patients with head and neck squamous cell carcinoma (HNSCC), and its correlation with prognosis.;HPV infection was characterized in tumors and pre and posttreatment oral scrapings in 51 patients with HNSCC and matched controls using the SPF10 LiPA Extra assay. p16INK4A immunostain and in situ hybridization for high-risk HPV genotypes recognized transcriptionally active infection in tumor samples. The risk of infection was compared in patients and controls. The association of pretreatment HPV status with recurrence and survival and with posttreatment HPV persistence was assessed.;Oral HPV infection risk was significantly higher in patients with HNSCC than in controls (P < .001). Oral HPV infection was associated with infection in the first posttreatment scrapings (P = .015), but did not affect recurrence or prognosis.;Oral HPV infection is frequent in patients with HNSCC and has no prognostic implications, suggesting that posttreatment polymerase chain reaction monitoring on oral cells is not effective to monitor patient recurrence risk.",
        "Doc_title":"Oral HPV infection and persistence in patients with head and neck cancer.",
        "Journal":"Oral surgery, oral medicine, oral pathology and oral radiology",
        "Do_id":"24035114",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;DNA, Viral",
        "Doc_meshdescriptors":"Aged;Carcinoma, Squamous Cell;Case-Control Studies;Cyclin-Dependent Kinase Inhibitor p16;DNA, Viral;Female;Genotype;Head and Neck Neoplasms;Humans;In Situ Hybridization;Logistic Models;Male;Middle Aged;Mouth Mucosa;Papillomaviridae;Papillomavirus Infections;Prognosis;Proportional Hazards Models;Recurrence;Risk",
        "Doc_meshqualifiers":"complications;virology;analysis;analysis;genetics;complications;virology;pathology;virology;genetics;complications;genetics;virology",
        "_version_":1605846412805799936},
      {
        "Doc_abstract":"Single-nucleotide polymorphisms (SNPs) in the 9p21.3 locus have recently been demonstrated to be strongly associated with the risk of developing human atherosclerotic lesions. However, the pathophysiology of this locus is insufficiently studied. Here, the methylation profile of the nearest mapped genes for cyclin-dependent kinase inhibitors CDKN2A (p16(INK4a), p14(ARF)) and CDKN2B (p15(LNK4b)) in the tissues of the carotid artery in patients with atherosclerosis was evaluated for the first time. Aberrant DNA methylation of the analyzed loci was not established in either the atherosclerotic plaques and in the tissues from the macroscopically unchanged previa vascular wall in the same patients.",
        "Doc_title":"[Methylation profile of INK4B-ARF-INK4A locus in atherosclerosis].",
        "Journal":"Genetika",
        "Do_id":"24450202",
        "Doc_ChemicalList":"CDKN2B protein, human;Cyclin-Dependent Kinase Inhibitor p15;Cyclin-Dependent Kinase Inhibitor p16;Tumor Suppressor Protein p14ARF",
        "Doc_meshdescriptors":"Aged;Atherosclerosis;Carotid Arteries;Case-Control Studies;Cyclin-Dependent Kinase Inhibitor p15;Cyclin-Dependent Kinase Inhibitor p16;DNA Methylation;Genetic Loci;Humans;Male;Middle Aged;Tumor Suppressor Protein p14ARF",
        "Doc_meshqualifiers":"genetics;metabolism;metabolism;genetics;metabolism;genetics;metabolism;genetics;metabolism",
        "_version_":1605818683323580416},
      {
        "Doc_abstract":"Replicative senescence is preceded by loss of repeat sequences of DNA from the telomeres that eventually leads to telomere dysfunction, the accumulation of irreparable DNA double strand breaks and a DNA damage response (DDR). However, we have previously reported that whilst telomere dysfunction in human keratinocytes is associated with a permanent cell cycle arrest, the DDR was very weak and transcriptional profiling also revealed several molecules normally associated with keratinocytes terminal differentiation, including S100A7 (psoriasin).;We show here that S100A7 and the closely related S100A15 (koebnerisin) are not induced by repairable or irreparable DSBs, ruling out the hypotheses that these genes are induced either by the low DDR observed or by non-specific cell cycle arrest. We next tested whether S100A7 was induced by the cell cycle effectors ARF (p14(ARF)), CDKN2A (p16(INK4A)) and TP53 (p53) and found that, although all induced a similar level of acute and permanent cell cycle arrest to telomere dysfunction, none induced S100A7 (except p53 over-expression at high levels), showing that cell cycle arrest is not sufficient for its induction. The closely related transcript S100A15 was also upregulated by telomere dysfunction, to a similar extent by p16(INK4A) and p53 and to a lesser extent by p14(ARF).;Our results show that mere cell cycle arrest, the upregulation of senescence-associated cell cycle effectors and DNA damage are not sufficient for the induction of the S100 transcripts; they further suggest that whilst the induction of S100A15 expression is linked to both telomere-dependent and -independent senescence, S100A7 expression is specifically associated with telomere-dependent senescence in normal keratinocytes. As both S100A7 and S100A15 are secreted proteins, they may find utility in the early detection of human keratinocyte telomere dysfunction and senescence.",
        "Doc_title":"The secreted protein S100A7 (psoriasin) is induced by telomere dysfunction in human keratinocytes independently of a DNA damage response and cell cycle regulators.",
        "Journal":"Longevity & healthspan",
        "Do_id":"25621169",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605751619874455552},
      {
        "Doc_abstract":"Carcinoma of the uterine cervix is one of the most common malignancies among women worldwide. Human papillomaviruses (HPV) have been identified as the major etiological factor in cervical carcinogenesis. However, the time lag between HPV infection and the diagnosis of cancer indicates that multiple steps, as well as multiple factors, may be necessary for the development of cervical cancer. The development and progression of cervical carcinoma have been shown to be dependent on various genetic and epigenetic events, especially alterations in the cell cycle checkpoint machinery. In mammalian cells, control of the cell cycle is regulated by the activity of cyclin-dependent kinases (CDKs) and their essential activating coenzymes, the cyclins. Generally, CDKs, cyclins, and CDK inhibitors function within several pathways, including the p16(INK4A)-cyclin D1-CDK4/6-pRb-E2F, p21(WAF1)- p27(KIP1)-cyclinE-CDK2, and p14(ARF)-MDM2-p53 pathways. The results from several studies showed aberrant regulation of several cell cycle proteins, such as cyclin D, cyclin E, p16(INK4A), p21(WAF1), and p27(KIP1), as characteristic features of HPV- infected and HPV E6/E7 oncogene-expressing cervical carcinomas and their precursors. These data suggested further that interactions of viral proteins with host cellular proteins, particularly cell cycle proteins, are involved in the activation or repression of cell cycle progression in cervical carcinogenesis.",
        "Doc_title":"Aberrant cell cycle regulation in cervical carcinoma.",
        "Journal":"Yonsei medical journal",
        "Do_id":"16259056",
        "Doc_ChemicalList":"CDKN1A protein, human;Cyclin E;Cyclin-Dependent Kinase Inhibitor p16;Cyclin-Dependent Kinase Inhibitor p21;E2F Transcription Factors;Retinoblastoma Protein;Tumor Suppressor Protein p14ARF;Tumor Suppressor Protein p53;Cyclin D1;Cyclin-Dependent Kinase Inhibitor p27;MDM2 protein, human;Proto-Oncogene Proteins c-mdm2;Cyclin-Dependent Kinase 2;Cyclin-Dependent Kinase 4",
        "Doc_meshdescriptors":"Cell Cycle;Cyclin D1;Cyclin E;Cyclin-Dependent Kinase 2;Cyclin-Dependent Kinase 4;Cyclin-Dependent Kinase Inhibitor p16;Cyclin-Dependent Kinase Inhibitor p21;Cyclin-Dependent Kinase Inhibitor p27;E2F Transcription Factors;Female;Humans;Proto-Oncogene Proteins c-mdm2;Retinoblastoma Protein;Tumor Suppressor Protein p14ARF;Tumor Suppressor Protein p53;Uterine Cervical Neoplasms",
        "Doc_meshqualifiers":"physiology;physiology;physiology;physiology;physiology;physiology;physiology;physiology;physiology;physiology;physiology;physiology;physiology;pathology",
        "_version_":1605751440412770304},
      {
        "Doc_abstract":"This study is aimed at investigating the significance of gene promoter methylation status and protein expression of p16 INK4A and O6-methylguanine-DNA methyltransferase (MGMT) in the various uterine cervical lesions.;Methylation status by using methylation-specific polymerase chain reaction (MS-PCR) and protein expression by using immunohistochemistry for p16 INK4A and MGMT genes were performed in cervical squamous intraepithelial neoplasms (CIN), invasive squamous cell carcinomas (SCC), adenocarcinomas and non-neoplastic cervices.;None of 20 non-neoplastic cervices showed p16 INK4A and MGMT gene hypermethylation, whereas at least one of these genes was hypermethylated with 50.0% (5/10) of CIN I, 65.0% (13/20) of CIN II-III, 70.2% (33/47) of SCC and 85.0% (17/20) of adenocarcinoma. p16 INK4A protein was totally negative in non-neoplastic cervices, but positive with 90.0% of CIN I, 100% of CIN II-III and adenocarcinoma, and 78.7% of SCC. MGMT protein was expressed in 10% of non-neoplastic cervices, but significantly increased in SCC (42.5%) and adenocarcinoma (70.0%). The protein expression of p16 INK4A and MGMT was not related to their gene promoter methylation status.;The hypermethylation of p16 INK4A and MGMT genes in the uterine cervix may indicate the presence of malignant cells, and p16 INK4A immunostaining is useful in grading CIN and diagnosing invasive SCC and adenocarcinoma.",
        "Doc_title":"The hypermethylation and protein expression of p16 INK4A and DNA repair gene O6-methylguanine-DNA methyltransferase in various uterine cervical lesions.",
        "Journal":"Journal of cancer research and clinical oncology",
        "Do_id":"15785933",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;DNA;O(6)-Methylguanine-DNA Methyltransferase",
        "Doc_meshdescriptors":"Adenocarcinoma;Carcinoma, Squamous Cell;Cervical Intraepithelial Neoplasia;Cervix Uteri;Cyclin-Dependent Kinase Inhibitor p16;DNA;DNA Methylation;DNA Repair;Female;Gene Silencing;Humans;Immunoenzyme Techniques;Neoplasm Invasiveness;O(6)-Methylguanine-DNA Methyltransferase;Polymerase Chain Reaction;Promoter Regions, Genetic;Uterine Cervical Neoplasms",
        "Doc_meshqualifiers":"genetics;metabolism;pathology;genetics;metabolism;pathology;genetics;metabolism;pathology;metabolism;genetics;metabolism;metabolism;genetics;pathology;genetics;metabolism;genetics;metabolism;pathology",
        "_version_":1605837080939724800},
      {
        "Doc_abstract":"The D-type cyclins and their major kinase partners CDK4 and CDK6 regulate G0-G1-S progression by contributing to the phosphorylation and inactivation of the retinoblastoma gene product, pRB. Assembly of active cyclin D-CDK complexes in response to mitogenic signals is negatively regulated by INK4 family members. Here we show that although all four INK4 proteins associate with CDK4 and CDK6 in vitro, only p16(INK4a) can form stable, binary complexes with both CDK4 and CDK6 in proliferating cells. The other INK4 family members form stable complexes with CDK6 but associate only transiently with CDK4. Conversely, CDK4 stably associates with both p21(CIP1) and p27(KIP1) in cyclin-containing complexes, suggesting that CDK4 is in equilibrium between INK4 and p21(CIP1)- or p27(KIP1)-bound states. In agreement with this hypothesis, overexpression of p21(CIP1) in 293 cells, where CDK4 is bound to p16(INK4a), stimulates the formation of ternary cyclin D-CDK4-p21(CIP1) complexes. These data suggest that members of the p21 family of proteins promote the association of D-type cyclins with CDKs by counteracting the effects of INK4 molecules.",
        "Doc_title":"Cyclin D-CDK subunit arrangement is dependent on the availability of competing INK4 and p21 class inhibitors.",
        "Journal":"Molecular and cellular biology",
        "Do_id":"10022865",
        "Doc_ChemicalList":"CDKN1A protein, human;CDKN2B protein, human;CDKN2C protein, human;CDKN2D protein, human;Carrier Proteins;Cdkn1a protein, mouse;Cdkn1b protein, mouse;Cdkn2b protein, mouse;Cdkn2c protein, mouse;Cdkn2d protein, mouse;Cell Cycle Proteins;Cyclin-Dependent Kinase Inhibitor p15;Cyclin-Dependent Kinase Inhibitor p16;Cyclin-Dependent Kinase Inhibitor p18;Cyclin-Dependent Kinase Inhibitor p19;Cyclin-Dependent Kinase Inhibitor p21;Cyclins;Enzyme Inhibitors;Microtubule-Associated Proteins;Proto-Oncogene Proteins;Tumor Suppressor Proteins;Cyclin-Dependent Kinase Inhibitor p27;Protein-Serine-Threonine Kinases;CDK4 protein, human;CDK6 protein, human;Cdk4 protein, mouse;Cdk6 protein, mouse;Cyclin-Dependent Kinase 4;Cyclin-Dependent Kinase 6;Cyclin-Dependent Kinases",
        "Doc_meshdescriptors":"Amino Acid Sequence;Animals;Carrier Proteins;Cell Cycle Proteins;Cell Line, Transformed;Cyclin-Dependent Kinase 4;Cyclin-Dependent Kinase 6;Cyclin-Dependent Kinase Inhibitor p15;Cyclin-Dependent Kinase Inhibitor p16;Cyclin-Dependent Kinase Inhibitor p18;Cyclin-Dependent Kinase Inhibitor p19;Cyclin-Dependent Kinase Inhibitor p21;Cyclin-Dependent Kinase Inhibitor p27;Cyclin-Dependent Kinases;Cyclins;Enzyme Inhibitors;Humans;Mice;Microtubule-Associated Proteins;Molecular Sequence Data;Protein-Serine-Threonine Kinases;Proto-Oncogene Proteins;Tumor Suppressor Proteins",
        "Doc_meshqualifiers":"metabolism;antagonists & inhibitors;metabolism;metabolism;metabolism;metabolism",
        "_version_":1605742064885039106},
      {
        "Doc_abstract":"Expression of the p16INK4A (p16), p15INK4B (p15), and p14ARF genes, located at 9p21, was examined in pediatric neuroblastoma (NB), Ewing's sarcoma (ES), and rhabdomyosarcoma (RMS). p16 expression was absent in 4 of 5 ESs, and 2 of these 4 cases died. p16 expression was reduced or absent in 10 of 12 RMSs, and 4 of these 10 cases died. These results suggested the possibility that p16 expression was associated with the progression of ES and RMS. There has been no previous report on p14ARF in NB. Our investigation might indicate that abnormal expression of the p16 and p14ARF was associated with a poor prognosis in NB, although in some cases of NB normal p16 and abnormal p14ARF expression was seen. These findings suggest an important role of p14ARF gene in the tumorigenesis of NB. The different incidence of expression of the p16, p15, and p14ARF genes in these 3 tumor types may reflect differences of the molecular process through which the 3 tumors develop. Our results suggest that abnormal expression of the p16 and/or p14ARF may be associated with a poor prognosis in these 3 tumors.",
        "Doc_title":"Aberrations of p16INK4A, p14ARF and p15INK4B genes in pediatric solid tumors.",
        "Journal":"International journal of oncology",
        "Do_id":"12963998",
        "Doc_ChemicalList":"CDKN2B protein, human;Cell Cycle Proteins;Cyclin-Dependent Kinase Inhibitor p15;Cyclin-Dependent Kinase Inhibitor p16;Tumor Suppressor Protein p14ARF;Tumor Suppressor Proteins;RNA;DNA",
        "Doc_meshdescriptors":"Blotting, Southern;Blotting, Western;Cell Cycle Proteins;Cell Line, Tumor;Chromosome Aberrations;Cyclin-Dependent Kinase Inhibitor p15;Cyclin-Dependent Kinase Inhibitor p16;DNA;DNA Methylation;Gene Deletion;Humans;Neoplasms;Neuroblastoma;Prognosis;RNA;Reverse Transcriptase Polymerase Chain Reaction;Rhabdomyosarcoma;Sarcoma, Ewing;Tumor Suppressor Protein p14ARF;Tumor Suppressor Proteins",
        "Doc_meshqualifiers":"genetics;genetics;chemistry;metabolism;genetics;mortality;chemistry;genetics;mortality;genetics;mortality;genetics;genetics",
        "_version_":1605839951786672128},
      {
        "Doc_abstract":"The tumor suppressor ARF carries out different functions in different cellular compartments. In the nucleus, ARF interacts physically and functionally with Mdm2 to inhibit cell cycle progression through activation of p53. In the nucleolus, ARF interacts with B23/NPM to inhibit ribosomal biogenesis through control of rRNA processing. Recent studies have expanded ARF's territory into the mitochondria. New data have shown that ARF interacts with the mitochondrial protein p32/C1QBP and that the interaction is critical in order for ARF to localize to the mitochondria and induce apoptosis. Remarkably, the ARF-p32 interaction, and hence ARF's pro-apoptotic function, can be interrupted by human cancer-derived mutations in exon2 of the p14(ARF)-p16(INK4a) gene locus. Here, we discuss the implications of these studies and their potential relevance to human cancer.",
        "Doc_title":"ARF in the mitochondria: the last frontier?",
        "Journal":"Cell cycle (Georgetown, Tex.)",
        "Do_id":"19033735",
        "Doc_ChemicalList":"Mitochondrial Proteins;Tumor Suppressor Protein p14ARF;mitochondrial p32 protein, human",
        "Doc_meshdescriptors":"Cytoplasm;Humans;Mitochondria;Mitochondrial Proteins;Models, Biological;Protein Transport;Tumor Suppressor Protein p14ARF",
        "Doc_meshqualifiers":"metabolism;metabolism;metabolism;metabolism",
        "_version_":1605853502173609984},
      {
        "Doc_abstract":"Inactivation of both the pRb (pRb-cyclin D1/cyclin-dependent kinase 4/6-p16) and p53 (p53-p21(WAF1)-p14(ARF)) pathways is thought to be essential for immortalization in vitro and malignant transformation in vivo. We identified different combinations of pRb and p53 pathway alterations in 12 invasive transitional cell carcinomas (TCCs) and addressed the functional significance of the different combinations observed. Results showed four combinations of alterations including -pRb/-p53 (ie., pRb inactivated in the pRb pathway and p53 inactivated in the p53 pathway; four TCCs), -p16/-p53 (four TCCs), -p16/-p21(WAF1) (one TCC), and -p16/ -p14(ARF) (two TCCs). These groups include two new combinations (ie., -p16/-p53 and -p16/-p21(WAF1)) not reported previously for TCCs. An alteration in the key components of the p53 pathway was not detected in one invasive TCC that had inactivated p16. Note that all four TCCs with inactivated pRb had mutant p53; thus, the combinations of -pRb/ -p21(WAF1) and -pRb/-p14(ARF) were not observed. Only two of eight TCCs with altered p16 had concomitant p14(ARF) loss, demonstrating that simultaneous inactivation of these two 9p21INK4a tumor suppressor genes is not obligatory. To determine the biological phenotypes of TCCs with different combinations of pRb and p53 pathway alterations, their downstream responses to gamma radiation were studied in vitro. As expected, none of eight TCCs with mutant p53 responded to gamma radiation by elevation of p53, p21(WAF1), or mdm2 or by cell cycle arrest. Only two of four TCCs with wild-type p53 and wild-type pRb (the combination of -p16/-p14(ARF)) showed normal downstream responses to gamma radiation and underwent cell cycle arrest. Two TCCs with wild-type pRb and wild-type p53 (the combination of -pl6/-p21(WAF1) and one TCC with -p16) failed to show cell cycle arrest in response to radiation. This was attributed to the absence of p21(WAF1) in one TCC. In summary, these data support a model of invasive bladder cancer pathogenesis in which both the pRb and p53 pathways are usually inactivated and the biology of the tumor is impacted by the mechanism of their inactivations.",
        "Doc_title":"Different combinations of genetic/epigenetic alterations inactivate the p53 and pRb pathways in invasive human bladder cancers.",
        "Journal":"Cancer research",
        "Do_id":"10919661",
        "Doc_ChemicalList":"Carrier Proteins;Cyclin-Dependent Kinase Inhibitor p16;Proteins;Retinoblastoma Protein;Tumor Suppressor Protein p14ARF;Tumor Suppressor Protein p53",
        "Doc_meshdescriptors":"Blotting, Northern;Blotting, Southern;Carcinoma, Transitional Cell;Carrier Proteins;Chromosomes, Human, Pair 9;Cyclin-Dependent Kinase Inhibitor p16;Flow Cytometry;Genes, p53;Humans;Immunohistochemistry;Neoplasm Invasiveness;Phenotype;Proteins;Retinoblastoma Protein;Sequence Analysis, DNA;Tumor Suppressor Protein p14ARF;Tumor Suppressor Protein p53;Urinary Bladder Neoplasms",
        "Doc_meshqualifiers":"genetics;metabolism;metabolism;genetics;metabolism;genetics;genetics;metabolism;genetics;metabolism;metabolism;genetics;metabolism",
        "_version_":1605742736134111233},
      {
        "Doc_abstract":"The incidence of vulvar squamous cell carcinomas located between the clitoris and urethra in young women is rising in distinct geographic regions, but characteristics of the tumors indicating certain carcinogenic mechanisms are unknown. The present study aimed at characterizing these vulvar cancers for their human papillomavirus (HPV), p16(INK4a), and p53 status, revealing potential pathways of carcinogenesis.;Squamous cell vulvar cancers of the anterior fourchette were retrospectively collected from 8 German hospitals, with additional squamous cell cancers located at other sites of the vulva from 2 of the hospitals. All tumors were analyzed for HPV DNA by polymerase chain reaction and for p16(INK4a) and p53 expression by immunohistochemistry.;Potentially HPV-associated tumors (HPV and p16(INK4a) positive, 21.4% [27/126] of the anterior fourchette and 27.7% [13/47] from other locations), p53-overexpressing tumors (35.7% [45/126] and 29.8% [14/47]), and a third group (HPV/p16(INK4a) negative/p53 not overexpressed, 42.9% [54/126] and 42.6% [20/47]) were observed among tumors from the anterior fourchette as well as among vulvar cancers from other locations. Women with vulvar cancers of the anterior fourchette were of young age irrespective of the HPV/p16(INK4a)/p53 status.;Different types of vulvar cancers can be found in squamous cell tumors of the anterior fourchette, similar to the finding in vulvar cancers from other locations and to what has previously been reported for vulvar squamous cell carcinomas in general.",
        "Doc_title":"Characterization of squamous cell cancers of the vulvar anterior fourchette by human papillomavirus, p16INK4a, and p53.",
        "Journal":"Journal of lower genital tract disease",
        "Do_id":"23645067",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;Tumor Suppressor Protein p53",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Cyclin-Dependent Kinase Inhibitor p16;Female;Germany;Humans;Immunohistochemistry;Middle Aged;Neoplasms, Squamous Cell;Papillomaviridae;Polymerase Chain Reaction;Retrospective Studies;Tumor Suppressor Protein p53;Vulvar Neoplasms;Young Adult",
        "Doc_meshqualifiers":"biosynthesis;pathology;virology;classification;genetics;isolation & purification;biosynthesis;pathology;virology",
        "_version_":1605876465366204416},
      {
        "Doc_abstract":"The tumor suppressor proteins p16INK4A and p14ARF, encoded by the INK4A-ARF locus, are key regulators of cellular senescence. The locus is epigenetically silenced by the repressive H3K27me3 mark in normally growing cells, but becomes activated in response to oncogenic stress. Here, we show that expression of the histone H3 Lys 27 (H3K27) demethylase JMJD3 is induced upon activation of the RAS-RAF signaling pathway. JMJD3 is recruited to the INK4A-ARF locus and contributes to the transcriptional activation of p16INK4A in human diploid fibroblasts. Additionally, inhibition of Jmjd3 expression in mouse embryonic fibroblasts results in suppression of p16Ink4a and p19Arf expression and in their immortalization.",
        "Doc_title":"The H3K27me3 demethylase JMJD3 contributes to the activation of the INK4A-ARF locus in response to oncogene- and stress-induced senescence.",
        "Journal":"Genes & development",
        "Do_id":"19451217",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;Jumonji Domain-Containing Histone Demethylases;KDM6B protein, human;Kdm6b protein, mouse;Oxidoreductases, N-Demethylating;BRAF protein, human;Proto-Oncogene Proteins B-raf;raf Kinases;ras Proteins",
        "Doc_meshdescriptors":"Animals;Cell Aging;Cell Line;Cell Proliferation;Cyclin-Dependent Kinase Inhibitor p16;Fibroblasts;Gene Expression Regulation;Genes, p16;Humans;Jumonji Domain-Containing Histone Demethylases;Mice;Neoplasms;Oncogenes;Oxidoreductases, N-Demethylating;Proto-Oncogene Proteins B-raf;Stress, Physiological;raf Kinases;ras Proteins",
        "Doc_meshqualifiers":"physiology;metabolism;cytology;metabolism;physiology;metabolism;physiology;metabolism;metabolism;physiology;metabolism;metabolism",
        "_version_":1605837122158198784},
      {
        "Doc_abstract":"The molecular status of the p16(INK4) tumor-suppressor gene has not been fully elucidated in hepatocellular carcinoma. The aim of this study was to clarify the mechanism that gives rise to inactivation of p16(INK4) in hepatocellular carcinoma.;The status of p16(INK4) was evaluated in 60 hepatocellular carcinomas by immunohistochemical staining, differential polymerase chain reaction, single-strand conformational polymorphism, methylation-specific polymerase chain reaction, and methylation-sensitive single nucleotide primer extension.;Immunohistochemical staining showed that 29 of the 60 tumors exhibited complete loss of p16(INK4) expression. High levels of DNA methylation were detected in 24 of 29 cases of hepatocellular carcinoma with negative p16(INK4) expression, with methylation of 60%-85% of the CpG islands. In contrast, the level of methylation was <25% in tumors with faint p16(INK4) staining, and no methylation was detected in tumors with positive immunostaining. Intragenic alteration of p16(INK4) was detected in 4 cases.;A strong correlation was found between the extent of methylation and the degree of expression of p16(INK4) in tumor tissues, indicating that epigenetic change due to extensive CpG methylation is the main cause of inactivation of p16(INK4) in hepatocellular carcinoma.",
        "Doc_title":"p16(INK4) is inactivated by extensive CpG methylation in human hepatocellular carcinoma.",
        "Journal":"Gastroenterology",
        "Do_id":"9922321",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;DNA Primers;DNA, Neoplasm",
        "Doc_meshdescriptors":"Adult;Aged;Carcinoma, Hepatocellular;CpG Islands;Cyclin-Dependent Kinase Inhibitor p16;DNA Primers;DNA, Neoplasm;Female;Gene Expression Regulation, Neoplastic;Genes, p16;Humans;Immunohistochemistry;Liver Neoplasms;Male;Methylation;Middle Aged;Polymerase Chain Reaction;Polymorphism, Single-Stranded Conformational",
        "Doc_meshqualifiers":"genetics;metabolism;genetics;metabolism;analysis;genetics;metabolism",
        "_version_":1605742664113717248},
      {
        "Doc_abstract":"Cited2 (CBP/p300 interacting transactivator with ED-rich tail 2) is required for embryonic development, coactivation of transcription factor AP-2, and inhibition of hypoxia-inducible factor 1 transactivation. Cited2 is induced by multiple growth factors and cytokines and oncogenically transforms cells. Here, we show that the proliferation of Cited2(-/-) mouse embryonic fibroblasts ceases prematurely. This is associated with a reduction in growth fraction, senescent cellular morphology, and increased expression of the cell proliferation inhibitors p16(INK4a), p19(ARF), and p15(INK4b). Deletion of INK4a/ARF (encoding p16(INK4a) and p19(ARF)) completely rescued the defective proliferation of Cited2(-/-) fibroblasts. However, the deletion of INK4a/ARF did not rescue the embryonic malformations observed in Cited2(-/-) mice, indicating that INK4a/ARF-independent pathways are likely to be involved here. We found that Cited2(-/-) fibroblasts had reduced expression of the polycomb-group genes Bmi1 and Mel18, which function as INK4a/ARF and Hox repressors. Complementation with CITED2-expressing retrovirus enhanced proliferation, induced Bmi1/Mel18 expression, and decreased INK4a/ARF expression. Bmi1- and Mel18-expressing retroviruses enhanced the proliferation of Cited2(-/-) fibroblasts, indicating that they function downstream of Cited2. Our results provide genetic evidence that Cited2 controls the expression of INK4a/ARF and fibroblast proliferation, at least in part via the polycomb-group genes Bmi1 and Mel18.",
        "Doc_title":"Transcriptional coactivator Cited2 induces Bmi1 and Mel18 and controls fibroblast proliferation via Ink4a/ARF.",
        "Journal":"Molecular and cellular biology",
        "Do_id":"14560011",
        "Doc_ChemicalList":"Bmi1 protein, mouse;CITED2 protein, human;Cdkn2a protein, mouse;Cited2 protein, mouse;Cyclin-Dependent Kinase Inhibitor p16;DNA-Binding Proteins;Nuclear Proteins;PCGF2 protein, human;Pcgf6 protein, mouse;Proto-Oncogene Proteins;Repressor Proteins;Trans-Activators;Tumor Suppressor Protein p14ARF;Polycomb Repressive Complex 1",
        "Doc_meshdescriptors":"Animals;Cell Division;Cells, Cultured;Cyclin-Dependent Kinase Inhibitor p16;DNA-Binding Proteins;Embryo, Mammalian;Fibroblasts;Gene Expression Regulation;Mice;Mice, Inbred C57BL;Mice, Knockout;Morphogenesis;Nuclear Proteins;Polycomb Repressive Complex 1;Proto-Oncogene Proteins;Repressor Proteins;Trans-Activators;Tumor Suppressor Protein p14ARF",
        "Doc_meshqualifiers":"physiology;genetics;metabolism;genetics;metabolism;anatomy & histology;pathology;physiology;cytology;physiology;genetics;metabolism;genetics;metabolism;genetics;metabolism;genetics;metabolism",
        "_version_":1605742129798184961},
      {
        "Doc_abstract":"Wip1 over-expression inhibits p53 function and reduces selection for TP53 mutations during cancer progression. To clarify the correlation of Wip1 with TP53/p14(ARF) pathway disruption in astyrocytomas, the expression of Wip1 and TP53/p14(ARF) pathway alterations have been investigated.;Tumor samples of 52 patients of astrocytomas were examined for TP53 mutations, p14(ARF) expression, and Wip1 expression. Direct sequencing of region from exons 5 to 8 of the TP53 gene was performed on the genomic DNA in each sample. The DNA methylation states of the CpG islands of the p14(ARF) gene were determined by MSP. The expression of Wip1 was analyzed by real-time quantitative PCR, Western blot, and immunohistochemical staining.;Disruption of the TP53/p14ARF pathway was detected in 57.7% of samples. Among 22 cases without TP53 and p14ARF alterations, 11 (50%) had Wip1 mRNA over-expression. In tumors with wild-type TP53 and p14ARF, Wip1 mRNA was over-expressed only 1 case out of 30 (3.3%). Higher levels of Wip1 were associated with TP53 mutations but not with lower levels of expression of p14(ARF) or aberrant promoter hypermethylation of the p14(ARF) gene.;Wip1 is selectively over-expressed in astyrocytomas without alterations in TP53 or p14(ARF). Wip1 may inhibit the TP53/p14(ARF) pathway.",
        "Doc_title":"Wip1 over-expression correlated with TP53/p14(ARF)  pathway disruption in human astrocytomas.",
        "Journal":"Journal of surgical oncology",
        "Do_id":"21695702",
        "Doc_ChemicalList":"RNA, Messenger;TP53 protein, human;Tumor Suppressor Protein p14ARF;Tumor Suppressor Protein p53;PPM1D protein, human;Phosphoprotein Phosphatases;Protein Phosphatase 2C",
        "Doc_meshdescriptors":"Adolescent;Adult;Aged;Astrocytoma;Blotting, Western;Child;DNA Methylation;Female;Humans;Immunoenzyme Techniques;Male;Middle Aged;Mutation;Phosphoprotein Phosphatases;Polymerase Chain Reaction;Prognosis;Promoter Regions, Genetic;Protein Phosphatase 2C;RNA, Messenger;Signal Transduction;Tumor Suppressor Protein p14ARF;Tumor Suppressor Protein p53;Young Adult",
        "Doc_meshqualifiers":"genetics;metabolism;pathology;genetics;genetics;metabolism;genetics;genetics;genetics;metabolism;genetics;metabolism",
        "_version_":1605764005447598080},
      {
        "Doc_abstract":"The incidence of human papilloma virus (HPV) induced oropharyngeal squamous cell carcinoma (OPSCC) increases in the western countries. These OPSCC show distinct molecular characteristics and are characterized by an overexpression of p16, considered a surrogate marker for HPV infection. When compared to patients with p16 negative OPSCC, patients with HPV induced p16 positive OPSCC show a significantly better prognosis, which is reported to be caused by increased radiosensitivity. The objective of the present study was to analyze the impact of p16 expression status on the prognosis of OPSCC treated by either radiotherapy (RT) or primary surgery. Results are based upon a tissue microarray (TMA) of 365 head neck squamous cell carcinomas (HNSCC) including 85 OPSCC with clinico-pathological and follow-up data. p16 positivity correlated significantly with oropharyngeal tumor localization (p < 0.001). Patients with p16 positive OPSCC exhibited a significantly better overall survival than those with p16 negative tumors (p = 0.007). In a multivariate analysis, survival benefit of patients with p16 positive OPSCC was independent of clinico-pathological parameters such as cT and cN classification and treatment modality. The improved prognosis of p16 positive OPSCC is found after RT as well as after surgery.",
        "Doc_title":"Is the improved prognosis of p16 positive oropharyngeal squamous cell carcinoma dependent of the treatment modality?",
        "Journal":"International journal of cancer",
        "Do_id":"19697324",
        "Doc_ChemicalList":"Antineoplastic Agents;Cyclin-Dependent Kinase Inhibitor p16",
        "Doc_meshdescriptors":"Antineoplastic Agents;Carcinoma, Squamous Cell;Combined Modality Therapy;Cyclin-Dependent Kinase Inhibitor p16;Humans;Immunohistochemistry;Kaplan-Meier Estimate;Neoplasm Staging;Oropharyngeal Neoplasms;Papillomavirus Infections;Prognosis;Radiotherapy;Tissue Array Analysis",
        "Doc_meshqualifiers":"therapeutic use;pathology;therapy;virology;biosynthesis;pathology;therapy;virology;complications",
        "_version_":1605818786376581121},
      {
        "Doc_abstract":"Human papilloma virus (HPV) infection is a major risk factor for a distinct subset of head and neck squamous cell carcinoma (HNSCC). The current review summarizes the epidemiology of HNSCC and the disease burden, the infectious cycle of HPV, the roles of viral oncoproteins, E6 and E7, and the downstream cellular events that lead to malignant transformation. Current techniques for the clinical diagnosis of HPV-associated HNSCC will also be discussed, that is, the detection of HPV DNA, RNA, and the HPV surrogate marker, p16 in tumor tissues, as well as HPV-specific antibodies in serum. Such methods do not allow for the early detection of HPV-associated HNSCC and most cases are at an advanced stage upon diagnosis. Novel noninvasive approaches using oral fluid, a clinically relevant biological fluid, allow for the detection of HPV and cellular alterations in infected cells, which may aid in the early detection and HPV-typing of HNSCC tumors. Noninvasive diagnostic methods will enable early detection and intervention, leading to a significant reduction in mortality and morbidity associated with HNSCC. ",
        "Doc_title":"Current trends in the etiology and diagnosis of HPV-related head and neck cancers.",
        "Journal":"Cancer medicine",
        "Do_id":"25644715",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;DNA, Viral;Oncogene Proteins;RNA, Viral",
        "Doc_meshdescriptors":"Carcinoma, Squamous Cell;Cell Transformation, Neoplastic;Cell Transformation, Viral;Cyclin-Dependent Kinase Inhibitor p16;DNA, Viral;Female;Head and Neck Neoplasms;Human papillomavirus 16;Human papillomavirus 6;Humans;Immunohistochemistry;Male;Middle Aged;Oncogene Proteins;Papillomavirus Infections;RNA, Viral;Saliva",
        "Doc_meshqualifiers":"diagnosis;virology;metabolism;metabolism;diagnosis;virology;isolation & purification;isolation & purification;metabolism;diagnosis;metabolism;virology",
        "_version_":1605783596449136640},
      {
        "Doc_abstract":"The inhibitor of cyclin-dependent kinase 4, CDKN2 (also known as p16INK4 or MTS-1, multiple tumor suppressor gene 1), has been mapped to 9p21. The gene has been shown to be deleted or mutated in high frequency in human melanoma cell lines and familial melanoma patients, suggesting that it could be a melanoma suppressor gene. How these observations are related to tumorigenicity and metastasis of human melanoma is not clear however. To test the role of CDKN2 in human melanoma metastasis, 14 human melanoma cell lines with different metastatic abilities in nude mice were analysed for possible abnormalities in the CDKN2 gene. Homozygous deletions that resulted in a lack of gene expression were found in six of 14 cell lines tested. SSCP-direct sequencing revealed point mutations in three other cell lines. One cell line displayed CC to TT transitions which constitute a hallmark of ultraviolet-induced DNA damage. Overall, abnormalities in the CDKN2 gene were found in nine of 14 (64%) cell lines tested. Homozygous deletion and lack of gene expression were found in several low tumorigenic and nonmetastatic melanoma lines, whereas other metastatic cells did not exhibit abnormalities in the CDKN2 gene. These data suggest that the absence of normal CDKN2 does not confer growth advantage to melanoma cells in vivo and that the production of metastasis by human melanoma cells can occur in the absence of CDKN2 gene abnormalities.",
        "Doc_title":"Abnormalities in the CDKN2 (p16INK4/MTS-1) gene in human melanoma cells: relevance to tumor growth and metastasis.",
        "Journal":"Oncogene",
        "Do_id":"7478563",
        "Doc_ChemicalList":"Carrier Proteins;Cyclin-Dependent Kinase Inhibitor p16;DNA Primers",
        "Doc_meshdescriptors":"Animals;Base Sequence;Carrier Proteins;Cell Division;Cyclin-Dependent Kinase Inhibitor p16;DNA Damage;DNA Primers;Gene Deletion;Homozygote;Humans;Melanoma;Mice;Mice, Nude;Molecular Sequence Data;Neoplasm Metastasis;Neoplasm Transplantation;Tumor Cells, Cultured",
        "Doc_meshqualifiers":"genetics;genetics;genetics;pathology;genetics",
        "_version_":1605898364809904128},
      {
        "Doc_abstract":"The Ink4a/Arf tumor suppressor locus is widely inactivated in cancer but little is known about the tumor biology of its two products, p16(Ink4a) (p16) and Arf. Both the p16 and Arf promoters are methylated in a significant fraction of human colon carcinomas, implying a functional role. We have demonstrated previously that Ink4a/Arf-null colon tumors display increased growth and vascularity in C57Bl6 mice carrying the Min (multiple intestinal neoplasia) mutation. We present here an analysis in a mixed genetic background of Min colon tumors (N=215) in mice with or without selective deficiencies in p16 or Arf, respectively. Absence of Arf did not significantly alter tumor formation. In contrast, tumors in mice lacking p16 were moderately larger and redder. Histological analysis demonstrated that these tumors contained significantly more pockets of necrosis (p=0.02), a marker of carcinoma in situ; less apoptosis (p=0.02); and higher red blood cell density (p=0.02, 0.006 within vessels). Biochemical analyses demonstrated increased levels of vascular endothelial cell growth factor (VEGF, p<0.01). Exogenous p16 expression in human colon tumor cells in vitro inhibited VEGF production. These results suggest that p16 constrains colon tumor progression, in part through inhibiting angiogenic signaling.",
        "Doc_title":"p16(Ink4a) inhibits histologic progression and angiogenic signaling in min colon tumors.",
        "Journal":"Cancer biology & therapy",
        "Do_id":"16322687",
        "Doc_ChemicalList":"Tumor Suppressor Protein p14ARF",
        "Doc_meshdescriptors":"Animals;Apoptosis;Colonic Neoplasms;Disease Progression;Genes, p16;HT29 Cells;Humans;Mice;Mice, Inbred C57BL;Necrosis;Neovascularization, Pathologic;Signal Transduction;Tumor Suppressor Protein p14ARF",
        "Doc_meshqualifiers":"blood supply;genetics;metabolism;pathology;pathology;genetics;pathology;genetics;physiology",
        "_version_":1605898434241363968},
      {
        "Doc_abstract":"The INK4A/ARF locus on chromosome 9 is a tumor suppressor gene frequently mutated in human cancers. In order to study the effects of p14ARF expression in tumor cells, we constructed a recombinant adenovirus containing p14ARF cDNA (Adp14ARF). Adp14ARF infection of U2OS osteosarcoma cells which has wild type p53 and mutant p14ARF revealed high levels of p14 (ARF) expression within 24h. In addition, Adp14ARF-mediated expressing of p14 (ARF) was associated with increased levels of p53, p21, and mdm2 protein. Growth inhibition assays following Adp14ARF infection demonstrated that the growth of U2OS cells was inhibited relative to infection with control virus. Furthermore, TUNEL analysis as well as PARP cleavage assays demonstrated that Adp14ARF infection was associated with increased apoptosis in U2OS cell line and that it was associated with Adp14ARF induced overexpression of Fas and Fas-L. Addition of Fas-L neutralizing antibody NOK-1 decreased Adp14-mediated cell death, indicating that p14 (ARF) induction of the Fas pathway is associated with increased apoptosis. The finding that Adp14ARF infection did not induce Fas expression in U2OS/E6 and MCF/E6 cells suggests that wild type p53 expression may be necessary for Adp14ARF-mediated induction of Fas. The observation that overexpression of p53 by Adp53 infection in MCF-7 does not induce increased Fas protein levels nor apoptotic cell death suggests that p53 overexpression is required but not sufficient enough for apoptosis. These studies suggest there are other mechanisms other than induction of p53 in ARF-mediated apoptosis and gene therapy using Adp14ARF may be a promising treatment option for human cancers containing wild type p53 and mutant or deleted p14 expression.",
        "Doc_title":"Apoptosis induced by adenovirus-mediated p14ARF expression in U2OS osteosarcoma cells is associated with increased Fas expression.",
        "Journal":"Biochemical and biophysical research communications",
        "Do_id":"15207713",
        "Doc_ChemicalList":"Antigens, CD95;Tumor Suppressor Protein p14ARF",
        "Doc_meshdescriptors":"Adenoviridae;Adenoviridae Infections;Antigens, CD95;Apoptosis;Breast Neoplasms;Cell Cycle;Cell Line, Tumor;Genetic Vectors;Humans;Osteosarcoma;Tumor Suppressor Protein p14ARF",
        "Doc_meshqualifiers":"genetics;growth & development;genetics;metabolism;metabolism;genetics;metabolism;pathology;virology;genetics;genetics;metabolism;pathology;virology;metabolism",
        "_version_":1605896837912330240},
      {
        "Doc_abstract":"Determining the primary site of uterine adenocarcinoma (ADC) may be problematic, especially with small specimens. This is particularly important in light of the increase of endocervical and endometrial adenocarcinoma and the decrease in incidence of squamous cell carcinoma. P16(INK4a) , a member of the INK4 family of cell cycle regulatory proteins, plays a critical role. It functions as a negative regulator of cell cycle progression and differentiation by controlling the activity of the tumor-suppressor protein retinoblastoma (pRb), which regulates the cell cycle. Its expression is variable according to the tumoral histotype and in metastasis. The aim of this study was to investigate P16(INK4a) expression in endocervical, endometrial, and metastatic ADCs of extra-uterine origin. Fifty gynaecological biopsies (cervix or endometrium) comprised the study for P16(INK4a) determination. Cases were classified as (1) diffuse positive (P), in intense nuclear immunostaining and/or cytoplasmic in > 30% of neoplastic cells; (2) focal positive (FP), in intense immunostaining in 10% to 30% in isolated cells or small groups; and (3) negative (N), in absence of immunostaining or weak, sporadic immunostaining in < 10% of neoplastic cells. Included in the study were the following: 6 endocervical ADCs, 11 endometrioid-type endometrial ADCs, 5 endometrial serous papillary ADCs, 7 ovarian ADCs, 4 large intestine ADCs, 1 breast ADC, 12 not-otherwise-specified (NOS) ADCs, and 4 endocervical biopsy without atypia (as control). Diffuse, strong positivity with P16(INK4a) suggests an endocervical rather than an endometrial or metastatic ADC. In fact, a P16(INK4a) positive immunostaining pattern was prevalent in endocervical (83%) and serous papillary ADCs of endometrial or ovarian origin, whereas endometrioid ADCs such as metastatic non-ovarian lesions generally presented only focal or negative immunostaining. 10/12 cases of ADC-NOS were reclassified using P16(INK4a) immunostaining: 2 as endocervical ADCs (2 P), 4 as endometrioid-type endometrial ADCs (2 FP, 2 N), 3 as endometrial serous papillary ADCs (3 FP), and 1 as ovarian serous papillary ADC (1 FP).",
        "Doc_title":"P16(INK4a) protein expression in endocervical, endometrial and metastatic adenocarcinomas of extra-uterine origin: diagnostic and clinical considerations.",
        "Journal":"Cancer biomarkers : section A of Disease markers",
        "Do_id":"24878818",
        "Doc_ChemicalList":"Biomarkers, Tumor;Cyclin-Dependent Kinase Inhibitor p16",
        "Doc_meshdescriptors":"Adenocarcinoma;Biomarkers, Tumor;Biopsy;Cyclin-Dependent Kinase Inhibitor p16;Endometrial Neoplasms;Female;Humans;Ovarian Neoplasms;Uterine Cervical Neoplasms",
        "Doc_meshqualifiers":"metabolism;pathology;analysis;metabolism;analysis;metabolism;metabolism;pathology;metabolism;pathology;metabolism;pathology",
        "_version_":1605748224796131328},
      {
        "Doc_abstract":"Previous studies have shown that the p16(INK4a) tumor suppressor gene is inactivated in up to 98% of human pancreatic cancer specimens and 83% of oral squamous cell carcinomas. Inactivation of the related p15(INK4b) gene has also been identified in a number of tumors and cell lines, however, its role as an independent tumor suppressor remains to be elucidated. Chemically-induced tumors in the Syrian Golden hamster (Mesocricetus auratus) have been shown to be excellent representative models for the comparative development and progression of a number of human malignancies. The purpose of this study was to determine the importance of the p16(INK4a) and p15(INK4b) genes in two experimental hamster models for human pancreatic and oral carcinogenesis. First, hamster p16(INK4a) and p15(INK4b) cDNAs were cloned and sequenced. The hamster p16(INK4a) cDNA open reading frame (ORF) shares 78%, 80%, and 81% identity with the human, mouse, and rat p16(INK4a) sequences, respectively. Similarly, the hamster p15(INK4b) cDNA ORF shares 82% and 89% sequence identity with human and mouse p15(INK4b), respectively. Second, a deletion analysis of hamster p16(INK4a) and p15(INK4b) genes was performed for several tumorigenic and non-tumorigenic hamster cell lines and revealed that both p16(INK4a) and p15(INK4b) were homozygously deleted in a cheek pouch carcinoma cell line (HCPC) and two pancreatic adenocarcinoma cell lines (KL5B, H2T), but not in tissue matched, non-tumorigenic cheek pouch (POT2) or pancreatic (KL5N) cell lines. These data strongly suggest that homozygous deletion of the p16(INK4a) and p15(INK4b) genes plays a prominent role in hamster pancreatic and oral tumorigenesis, as has been well established in correlative studies in comparable human tumors. Furthermore, this study supports the comparative importance of the hamster pancreatic and cheek pouch models of carcinogenesis in subsequent mechanistic-, therapeutic-, and preventive-based studies aimed at providing important translational data applicable to pancreatic adenocarcinoma and oral squamous cell carcinoma in humans.",
        "Doc_title":"Identification and sequencing of the Syrian Golden hamster (Mesocricetus auratus) p16(INK4a) and p15(INK4b) cDNAs and their homozygous gene deletion in cheek pouch and pancreatic tumor cells.",
        "Journal":"Gene",
        "Do_id":"11707341",
        "Doc_ChemicalList":"Cell Cycle Proteins;Cyclin-Dependent Kinase Inhibitor p15;Cyclin-Dependent Kinase Inhibitor p16;DNA, Complementary;Tumor Suppressor Proteins",
        "Doc_meshdescriptors":"Amino Acid Sequence;Animals;Base Sequence;Cell Cycle Proteins;Cloning, Molecular;Cricetinae;Cyclin-Dependent Kinase Inhibitor p15;Cyclin-Dependent Kinase Inhibitor p16;DNA Mutational Analysis;DNA, Complementary;Gene Deletion;Homozygote;Mesocricetus;Molecular Sequence Data;Mouth Neoplasms;Neoplasms, Experimental;Pancreatic Neoplasms;Sequence Alignment;Sequence Analysis, DNA;Sequence Homology, Amino Acid;Sequence Homology, Nucleic Acid;Tumor Cells, Cultured;Tumor Suppressor Proteins",
        "Doc_meshqualifiers":"genetics;genetics;chemistry;genetics;genetics;genetics;pathology;genetics;pathology;genetics;pathology",
        "_version_":1605755671691657216},
      {
        "Doc_abstract":"The genetic alterations observed in head and neck cancer are mainly due to oncogene activation (gain of function mutations) and tumor suppressor gene inactivation (loss of function mutations), leading to deregulation of cell proliferation and death. These genetic alterations include gene amplification and overexpression of oncogenes such as myc, erbB-2, EGFR and cyclinD1 and mutations, deletions and hypermethylation leading to p16 and TP53 tumor suppressor gene inactivation. In addition, loss of heterozygosity in several chromosomal regions is frequently observed, suggesting that other tumor suppressor genes not yet identified could be involved in the tumorigenic process of head and neck cancers. The exact temporal sequence of the genetic alterations during head and neck squamous cell carcinoma (HNSCC) development and progression has not yet been defined and their diagnostic or prognostic significance is controversial. Advances in the understanding of the molecular basis of head and neck cancer should help in the identification of new markers that could be used for the diagnosis, prognosis and treatment of the disease.",
        "Doc_title":"Genetic alterations in head and neck squamous cell carcinomas.",
        "Journal":"Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas",
        "Do_id":"10454750",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Carcinoma, Squamous Cell;Gene Amplification;Gene Expression Regulation, Neoplastic;Genes, Tumor Suppressor;Genes, ras;Head and Neck Neoplasms;Humans;Oncogenes",
        "Doc_meshqualifiers":"genetics;genetics;genetics;genetics;genetics;genetics",
        "_version_":1605909331420643328},
      {
        "Doc_abstract":"The CDKN2A gene locus encodes two different proteins derived from alternative splicing. p16 (exons 1alpha, 2, and 3) acts as a G1 cell cycle regulator, and p14ARF (exons 1beta, 2, and 3) acts to modulate MDM2-mediated degradation of p53. Inactivation of p16 is a common finding in many cancers; however, there is little data on CDKN2A gene abnormalities in oral precancer. In this longitudinal study, we examined changes in the CDKN2A gene locus in sequential epithelial dysplasias and oral carcinomas from 11 patients. Genomic DNA was extracted from laser-microdissected lesional tissue, and exons 1alpha, 1beta, and 2 were analyzed by duplex PCR. Immunohistochemistry was done to identify p16 and p14ARF protein expression. Two adjacent polymorphic microsatellite markers were used for allelotyping. Homozygous deletion of exon 1alpha was identified in 2 of 17 (12%) precancerous lesions. Loss of either exon 1alpha, exon 2, or both was seen in seven of nine (78%) carcinomas. In five of these carcinomas, there was loss of only exon 1alpha. No case showed deletion of exon 1beta. In 5 of 11 patients, microsatellite markers showed differing patterns of allelic imbalance in the precancerous lesions and the subsequent carcinoma, suggesting a complex genetic pattern of progression from dysplasia to carcinoma. We conclude that during oral carcinogenesis homozygous deletion of exon 1alpha of the CDKN2A gene is common but that deletion of exon 2 and 1beta is less frequent. Moreover, our results suggest that the progression from oral precancer to cancer, in some cases, is more complex genetically than predicted by linear models of carcinogenesis.",
        "Doc_title":"Patterns of CDKN2A gene loss in sequential oral epithelial dysplasias and carcinomas.",
        "Journal":"Cancer research",
        "Do_id":"11289098",
        "Doc_ChemicalList":"Actins;Cyclin-Dependent Kinase Inhibitor p16;Proteins;Tumor Suppressor Protein p14ARF",
        "Doc_meshdescriptors":"Actins;Carcinoma in Situ;Carcinoma, Squamous Cell;Cyclin-Dependent Kinase Inhibitor p16;Disease Progression;Epithelial Cells;Female;Gene Amplification;Gene Deletion;Genes, p16;Humans;Immunohistochemistry;Longitudinal Studies;Male;Microsatellite Repeats;Mouth Mucosa;Mouth Neoplasms;Polymerase Chain Reaction;Precancerous Conditions;Proteins;Tumor Suppressor Protein p14ARF",
        "Doc_meshqualifiers":"genetics;genetics;metabolism;pathology;genetics;metabolism;pathology;metabolism;metabolism;pathology;genetics;genetics;metabolism;pathology;genetics;metabolism;pathology;genetics;metabolism;pathology;metabolism",
        "_version_":1605891746585116672},
      {
        "Doc_abstract":"Eukaryotic cell division is regulated by cyclins, cyclin-dependent kinases (CDK), and cyclin-dependent kinase inhibitors (CKI). Genes encoding these proteins are mutated or deleted in many types of cancer. For example, 20%-30% of B-lineage acute lymphoblastic leukemias (ALL) have deletions in the CKI known as INK4a. The contribution of INK4a deletions to the progression of B-lineage ALL is uncertain, partially due to a paucity of data on expression in normal B-cell precursors. We therefore conducted a comparative analysis of normal and leukemic human B-cell development for the expression of cyclins, CDK, and CKI. Specific stages of human B-cell development from normal bone marrow were purified by fluorescence-activated cell sorting. The sorted populations and B-lineage ALL cell lines (BLIN-1, 2, 3, 4) were examined for expression of cyclins, CDK, and CKI by reverse transcriptase polymerase chain reaction (RT-PCR) and Western blotting.RT-PCR analysis showed that cyclin D2, cyclin D3, CDK4, and CDK6 were ubiquitously expressed in normal B-cell development and in the BLIN ALL cell lines. The p19(INK4d) CKI was the most commonly expressed member of the INK4 family, whereas p16(INK4a) was more weakly and variably expressed. Expression of the p57(KIP2) CKI varied as a function of the stage of B-cell development. Analysis of normal B-cell precursors by Western blotting indicated that CDK4, CDK6, p19(INK4d), and p57(KIP2) were expressed, whereas p16(INK4a) was not detected. Cyclin D/CDK expression in normal and leukemic human B-cell precursors is similar to expression of these proteins in human and murine mature B cells. In contrast, the ubiquitous expression of p19(INK4d) has not been previously described in human or murine B-lineage cells. Our results suggest that loss of INK4a may only minimally contribute to tumor cell progression in B-lineage ALL, since expression of INK4d could provide a compensatory function as a cyclin-dependent kinase inhibitor.",
        "Doc_title":"Novel expression of cyclin-dependent kinase inhibitors in human B-cell precursors.",
        "Journal":"Experimental hematology",
        "Do_id":"11301189",
        "Doc_ChemicalList":"Antigens, CD19;Antigens, CD34;CCND2 protein, human;CCND3 protein, human;CDKN2D protein, human;Carrier Proteins;Cell Cycle Proteins;Cyclin D2;Cyclin D3;Cyclin-Dependent Kinase Inhibitor p16;Cyclin-Dependent Kinase Inhibitor p19;Cyclins;Enzyme Inhibitors;Fungal Proteins;KIP2 protein, S cerevisiae;Microtubule-Associated Proteins;Molecular Motor Proteins;Proto-Oncogene Proteins;Saccharomyces cerevisiae Proteins;Protein-Serine-Threonine Kinases;CDK4 protein, human;CDK6 protein, human;Cyclin-Dependent Kinase 4;Cyclin-Dependent Kinase 6;Cyclin-Dependent Kinases",
        "Doc_meshdescriptors":"Antigens, CD19;Antigens, CD34;B-Lymphocytes;Bone Marrow Cells;Carrier Proteins;Cell Cycle Proteins;Cells, Cultured;Cyclin D2;Cyclin D3;Cyclin-Dependent Kinase 4;Cyclin-Dependent Kinase 6;Cyclin-Dependent Kinase Inhibitor p16;Cyclin-Dependent Kinase Inhibitor p19;Cyclin-Dependent Kinases;Cyclins;Embryo, Mammalian;Enzyme Inhibitors;Fungal Proteins;Gene Expression;Hematopoietic Stem Cells;Humans;Microtubule-Associated Proteins;Molecular Motor Proteins;Precursor Cell Lymphoblastic Leukemia-Lymphoma;Protein-Serine-Threonine Kinases;Proto-Oncogene Proteins;Reverse Transcriptase Polymerase Chain Reaction;Saccharomyces cerevisiae Proteins;Tumor Cells, Cultured",
        "Doc_meshqualifiers":"analysis;analysis;metabolism;metabolism;genetics;antagonists & inhibitors;genetics;genetics;genetics;metabolism;genetics;genetics;genetics",
        "_version_":1605755125206351872},
      {
        "Doc_abstract":"To examine the potential of p16(INK4A) as a biomarker for dysplastic squamous and glandular cells of the cervix in tissue sections and ThinPrep smears.;Immunocytochemical analysis of p16(INK4A) expression was performed on 22 normal cervical tissue samples, five cervical glandular intraepithelial neoplasia (cGIN), 38 cervical intraepithelial neoplasia 1 (CIN1), 33 CIN2, 46 CIN3, and 10 invasive cancer cases (eight squamous and two adenocarcinomas). All samples were formalin fixed and paraffin wax embedded, and immunohistochemical analysis was carried out using a mouse monoclonal anti-p16(INK4A) antibody after antigen unmasking. The staining intensity was assessed using a 0 to 3 scoring system. In addition, the expression status of p16(INK4A) was examined in 12 normal ThinPrep smears, one smear exhibiting cGIN, and a total of 20 smears exhibiting mild, moderate, and severe dyskaryosis. Human papillomavirus (HPV) detection was carried out using a modified SYBR green assay system. Fluorogenic polymerase chain reaction (PCR) and solution phase PCR were used for specific HPV typing.;p16(INK4A) immunoreactivity was absent in all normal cervical tissues examined. Dysplastic squamous and glandular cells were positive for p16(INK4A) expression in all cases included in this study, except for one CIN3 case. p16(INK4A) expression was mainly nuclear in CIN1 cases, and both nuclear and cytoplasmic in CIN2, CIN3, cGIN, and invasive cases. All cases positive for HPV expressed the p16(INK4A) protein, although not all cases found positive for p16(INK4A) were HPV positive. In general, the p16(INK4A) staining intensity was lower in cases negative for HPV or those containing a low risk HPV type.;This pattern of overexpression demonstrates the potential use of p16(INK4A) as a diagnostic marker for cervical squamous and also glandular neoplastic lesions. In addition, the technique can be used to identify individual dyskaryotic cells in ThinPrep smears. Thus, p16(INK4A) is a useful marker of cervical dyskaryosis.",
        "Doc_title":"p16INK4A as a marker for cervical dyskaryosis: CIN and cGIN in cervical biopsies and ThinPrep smears.",
        "Journal":"Journal of clinical pathology",
        "Do_id":"12499437",
        "Doc_ChemicalList":"Biomarkers;Biomarkers, Tumor;Cyclin-Dependent Kinase Inhibitor p16;Neoplasm Proteins",
        "Doc_meshdescriptors":"Biomarkers;Biomarkers, Tumor;Biopsy;Blotting, Western;Carcinoma, Squamous Cell;Cervical Intraepithelial Neoplasia;Cyclin-Dependent Kinase Inhibitor p16;Female;Humans;Neoplasm Proteins;Papillomaviridae;Sensitivity and Specificity;Tumor Cells, Cultured;Uterine Cervical Neoplasms;Vaginal Smears",
        "Doc_meshqualifiers":"analysis;analysis;diagnosis;pathology;virology;diagnosis;pathology;virology;analysis;analysis;classification;isolation & purification;diagnosis;pathology;virology",
        "_version_":1605804609063878656},
      {
        "Doc_abstract":"To investigate the relationship between human papillomavirus (HPV) infection and concurrent esophagus and gastric cardia cancer from the same patient (CC) and examine the significance of P16(INK4A) protein expression.;Polymerase chain reaction was used to detect the presence of HPV type16 (HPV16). The expression of P16(INK4A) protein was detected using immunohistochemistry.;Among the CC specimens, HPV16-DNA was found in eight cases of esophageal squamous cell carcinoma (ESCC) and five cases of gastric cardia adenocarcinoma (GCA), respectively (47% vs 29%), and two of both ESCC and GCA. P16(INK4A) was highly expressed in both ESCC and GCA. In the HPV-associated positive CC, higher P16(INK4A) expression was observed in the GCA than in the ESCC (75% vs 25%, P < 0.05).;HPV16 as a correlated risk factor may play an important role in the development of ESCC and GCA. P16(INK4A) may be a screening index in the HPV-associated carcinoma of gastric cardia.",
        "Doc_title":"Human papillomavirus DNA and P16(INK4A) expression in concurrent esophageal and gastric cardia cancers.",
        "Journal":"World journal of gastroenterology",
        "Do_id":"21155014",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;DNA, Viral",
        "Doc_meshdescriptors":"Aged;Cardia;Cyclin-Dependent Kinase Inhibitor p16;DNA, Viral;Esophageal Neoplasms;Female;Human papillomavirus 16;Humans;Male;Middle Aged;Stomach Neoplasms",
        "Doc_meshqualifiers":"pathology;genetics;metabolism;genetics;metabolism;pathology;virology;genetics;metabolism;pathology;virology",
        "_version_":1605791296507609088},
      {
        "Doc_abstract":"Human papillomavirus (HPV) infection is implicated as an aetiological factor in head and neck squamous carcinomas (HNSCC), especially in the tonsils of the oropharyngeal region. This study investigates the frequency of HPV infection, p16 and p53 tumour profile and mutations in epidermal growth factor receptor (EGFR), Kirsten RNA Associated Rat Sarcoma 2 Virus (KRAS) and B-Raf proto-oncogene serine/threonine protein kinase (BRAF) genes in tonsillar and non-tonsillar HNSCCs and correlates with clinical outcome and histopathological parameters in previously unstudied cohort of patients.;A retrospective clinical study was performed utilising the demographic data and pathological specimens from 60 out of 726 head and neck cancer patients. Smoking and alcohol history, tumour staging, treatment and outcomes were recorded. Histopathology and immunochemistry for p16 and p53 was performed and HPV DNA was detected with polymerase chain reaction. Genomic DNA from all cancers were analysed for somatic mutations of EGFR, BRAF and KRAS genes.;20 (33%) of 60 cases were tonsillar squamous carcinomas and 38 (66%) were non-tonsillar. 19 (95%) of the 20 tonsillar cancers and three (8%) of 38 non-tonsillar patients were patients who were HPV 16-positive. Nine (47%) of the 19 HPV 16-positive tonsillar cases were p16 positive. Gene mutations were rare. There was a statistically significant (P < 0.05) improved survival of patients with HPV positive tonsillar tumours, younger age and non-smokers.;Although limited in numbers, this study reinforces the role of HPV infection in HNSCC and its association with a more favourable clinical course in younger non-smokers worldwide. Gene mutation frequencies were low in all cancers tested and routine testing not recommended.",
        "Doc_title":"Human papillomavirus and gene mutations in head and neck squamous carcinomas.",
        "Journal":"ANZ journal of surgery",
        "Do_id":"22507644",
        "Doc_ChemicalList":"DNA, Viral;KRAS protein, human;Proto-Oncogene Proteins;Receptor, Epidermal Growth Factor;BRAF protein, human;Proto-Oncogene Proteins B-raf;Proto-Oncogene Proteins p21(ras);ras Proteins",
        "Doc_meshdescriptors":"Alphapapillomavirus;Carcinoma, Squamous Cell;DNA, Viral;Genes, p16;Genes, p53;Head and Neck Neoplasms;Humans;Mutation;Papillomavirus Infections;Proto-Oncogene Proteins;Proto-Oncogene Proteins B-raf;Proto-Oncogene Proteins p21(ras);Receptor, Epidermal Growth Factor;Retrospective Studies;Western Australia;ras Proteins",
        "Doc_meshqualifiers":"genetics;virology;genetics;virology;complications;genetics;virology;genetics;genetics;genetics;genetics",
        "_version_":1605754558094508032},
      {
        "Doc_abstract":"Evidence suggests that overexpression of p16(INK4a) protein indicates infection and genomic integration of high-risk human papillomavirus (HR HPV) and predicts progression to cervical high-grade squamous intraepithelial lesions (HSILs) and carcinoma. The authors compared the ability of p16(INK4a) and HR HPV detection by Hybrid Capture 2 (HC2) to detect the presence of significant cervical disease. METHODS.: Four hundred ThinPrep specimens (100 each in 4 categories: 100 specimens that were negative for intraepithelial lesions, 100 specimens of atypical squamous cells of undetermined significance [ASC-US], 100 specimens of low-grade squamous intraepithelial lesions [LSILs], and 100 specimens of HSILs) were analyzed. p16(INK4a) protein was immunolocalized using a specific monoclonal antibody, and the detection of HR HPV in all 400 specimens was determined using HC2.;p16(INK4a) was found to be positive in 78% of HSIL specimens, 42% of LSIL specimens, and 36% of ASC-US specimens; whereas HC2 was positive in 92% of HSIL specimens, 81% of LSIL specimens, and 45% of ASC-US specimens. In the HSIL category, the sensitivity, which was calculated using Grade 2 or greater cervical intraepithelial neoplasia as the endpoint, was 78% (50 of 66 specimens) for p16(INK4a) and 91% (60 of 66 specimens) for HC2. For LSIL, the sensitivity was 75% (3 of 4 specimens) for p16(INK4a) and 100% (4 of 4 specimens) for HC2. In the ASC-US category, the sensitivity was 89% (8 of 9 specimens) for p16(INK4a) and 100% (9 of 9 specimens) for HC2. Overall, the sensitivity for HSIL was 92% for HC2 and 78% for p16(INK4a). The specificity for HC2 was 8.3% for HSIL, 16.9% for LSIL, and 48.7% for ASC-US; whereas the specificity for p16(INK4a) was 25% in HSIL, 59.1% in LSIL, and 68.4% in ASC-US. The overall specificity was 25% for HC2 and 56% for p16(INK4a).;Although both p16(INK4a) and HC2 may aid in the clinical management of patients with clinically significant lesions, HC2 was found to have greater sensitivity, and p16(INK4a) greater specificity. The labeling of normal cells and bacteria may preclude the use of p16(INK4a) in automated screening or nonmorphologic assays.",
        "Doc_title":"A comparison of the clinical utility of p16(INK4a) immunolocalization with the presence of human papillomavirus by hybrid capture 2 for the detection of cervical dysplasia/neoplasia.",
        "Journal":"Cancer",
        "Do_id":"17078096",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;DNA, Viral",
        "Doc_meshdescriptors":"Adolescent;Adult;Aged;Carcinoma, Squamous Cell;Cervical Intraepithelial Neoplasia;Cyclin-Dependent Kinase Inhibitor p16;DNA, Viral;Diagnosis, Differential;Female;Humans;Middle Aged;Papillomaviridae;Papillomavirus Infections;Predictive Value of Tests;Uterine Cervical Dysplasia;Uterine Cervical Neoplasms;Vaginal Smears",
        "Doc_meshqualifiers":"metabolism;virology;metabolism;virology;metabolism;genetics;genetics;isolation & purification;metabolism;virology;metabolism;virology;metabolism;virology",
        "_version_":1605842190110556160},
      {
        "Doc_abstract":"The Rb/p16(Ink4a) and p53/p19Arf tumor suppressor pathways have been linked to diverse cancer-relevant processes, including those governing the cellular responses to telomere dysfunction. In this study, we sought to provide direct genetic evidence of a role for the Ink4a/Arf tumor suppressor gene, encoding both p16(Ink4a) and p19(Arf), in modulating the cellular and tissue phenotypes associated with telomere dysfunction by using the mTerc Ink4a/Arf mouse model. In contrast to the rescue associated with p53 deficiency, Ink4a/Arf deficiency did not attenuate the degenerative phenotypes elicited by telomere dysfunction in the late-generation mTerc-/- mice. Furthermore, in contrast to accelerated cancer onset and increased epithelial cancers of late-generation mTerc-/- p53 mutant mice, late-generation mTerc-/- Ink4a/Arf mutant mice experienced a delayed tumor onset and maintained the lymphoma and sarcoma spectrum. Consistent with the negligible role of Ink4a/Arf in the telomere checkpoint response in vivo, late-generation mTerc-/- Ink4a/Arf-/- tissues show activated p53, and derivative tumor cell lines sustain frequent loss of p53 function, whereas all early generation mTerc Ink4a/Arf-/- tumor cell lines remain intact for p53. In addition, the late-generation mTerc-/- Ink4a/Arf-/- tumors showed activation of the alternative lengthening of telomere mechanism, underscoring the need for adaptation to the presence of telomere dysfunction in the absence of p16(Ink4a) and p19(Arf). These observations highlight the importance of genetic context in dictating whether telomere dysfunction promotes or suppresses age-related degenerative conditions as well as the rate of initiation and type of spontaneous cancers.",
        "Doc_title":"Ink4a/Arf tumor suppressor does not modulate the degenerative conditions or tumor spectrum of the telomerase-deficient mouse.",
        "Journal":"Proceedings of the National Academy of Sciences of the United States of America",
        "Do_id":"17360455",
        "Doc_ChemicalList":"Cdkn2a protein, mouse;Cyclin-Dependent Kinase Inhibitor p16;Tumor Suppressor Protein p53;Telomerase",
        "Doc_meshdescriptors":"3T3 Cells;Animals;Cyclin-Dependent Kinase Inhibitor p16;Genes, Tumor Suppressor;Genes, p53;In Situ Hybridization, Fluorescence;Mice;Mice, Transgenic;Neoplasms;Neoplasms, Glandular and Epithelial;Phenotype;Telomerase;Telomere;Time Factors;Tumor Suppressor Protein p53",
        "Doc_meshqualifiers":"genetics;physiology;metabolism;genetics;deficiency;genetics;physiology;metabolism;ultrastructure;metabolism",
        "_version_":1605897710711341056},
      {
        "Doc_abstract":"Despite the importance of the INK4a/ARF locus in tumor suppression, its modulation by histone deacetylase inhibitors (HDACis) remains to be characterized. Here, we have shown that the levels of p16INK4a are decreased in human and murine fibroblasts upon exposure to relatively high concentrations of trichostatin A and sodium butyrate. Interestingly, the levels of p19ARF are strongly upregulated in murine cells even at low concentrations of HDACis. Using ARF-deficient cells, we have demonstrated that p19ARF plays an active role in HDACi-triggered cytostasis and the contribution of p19ARF to this arrest is of higher magnitude than that of the well established HDACi target p21Waf1/Cip. Moreover, chemically induced fibrosarcomas in ARF-null mice are more resistant to the therapeutic effect of HDACis than similar tumors in wild type or p21Waf1/Cip-null mice. Together, our results have established the tumor suppressor ARF as a relevant target for HDACi chemotherapy.",
        "Doc_title":"Regulation of the INK4a/ARF locus by histone deacetylase inhibitors.",
        "Journal":"The Journal of biological chemistry",
        "Do_id":"16251190",
        "Doc_ChemicalList":"Cdkn2a protein, mouse;Cyclin-Dependent Kinase Inhibitor p16;DNA Primers;Enzyme Inhibitors;Heterochromatin;Histone Deacetylase Inhibitors;Histones;Tumor Suppressor Protein p14ARF",
        "Doc_meshdescriptors":"Acetylation;Animals;Base Sequence;Cell Division;Cells, Cultured;Chromatin Immunoprecipitation;Cyclin-Dependent Kinase Inhibitor p16;DNA Primers;Enzyme Inhibitors;Gene Expression Regulation;Heterochromatin;Histone Deacetylase Inhibitors;Histones;Humans;Mice;Transcription, Genetic;Tumor Suppressor Protein p14ARF",
        "Doc_meshqualifiers":"drug effects;genetics;pharmacology;drug effects;metabolism;metabolism;drug effects;genetics",
        "_version_":1605837665023819776},
      {
        "Doc_abstract":"9p21 is a major target in the pathogenesis of human urinary bladder cancer. The locus harbors the CDKN2A/ARF tumor suppressor gene, which encodes two cell cycle regulatory proteins cyclin dependent kinase 2A (p16(INK4a)) and alternate reading frame (p14(ARF)). We have designed a real-time quantitative PCR (QPCR) application to study homozygous deletion (HD) of CDKN2A/ARF in 186 urinary bladder cancer patients.;Real-time QPCR, based on simultaneous amplification of ARF and a reference gene, GAPDH, was developed and evaluated in three melanoma cell lines with HDs at the CDKN2A/ARF locus (IGR-1, SK-MEL-5, and WM-266-4). In addition, loss of heterozygosity was analyzed at the D9S942, D9S1748, and D12S99 markers. Mutation analysis of the CDKN2A/ARF gene was performed using single-strand conformational polymorphism and sequencing. Results from the present investigation were combined with previous p53 analysis of the same urinary bladder neoplasms.;Real-time QPCR analysis showed 26 (14%) HDs, 22 (12%) hemizygous deletions, and 3 (2%) multiple duplications. Loss of heterozygosity was determined in 30 (22%) cases at the D9S942 locus, which is located between E1alpha and E1beta of the CDKN2A/ARF gene. No association was established between occurrence of genetic aberrations at 9p21 and tumor stage or grade, supporting previous suggestions that CDKN2A/ARF inactivation is an early event in bladder carcinogenesis.;We have established a fast and efficient method for detection of HDs. Our data support the notion that inactivation, including HDs, of CDKN2A/ARF is an early event in transitional cell carcinoma. We observed separate and specific targeting of the CDKN2A and ARF genes, respectively, and that simultaneous inactivation of ARF and p53 occurs.",
        "Doc_title":"Detecting homozygous deletions in the CDKN2A(p16(INK4a))/ARF(p14(ARF)) gene in urinary bladder cancer using real-time quantitative PCR.",
        "Journal":"Clinical cancer research : an official journal of the American Association for Cancer Research",
        "Do_id":"12538475",
        "Doc_ChemicalList":"Genetic Markers;RNA, Messenger",
        "Doc_meshdescriptors":"Carcinoma, Transitional Cell;Exons;Gene Deletion;Genes, p16;Genes, p53;Genetic Markers;Homozygote;Humans;Microsatellite Repeats;Models, Genetic;Mutation;Open Reading Frames;Polymorphism, Genetic;Polymorphism, Single-Stranded Conformational;RNA, Messenger;Reverse Transcriptase Polymerase Chain Reaction;Time Factors;Urinary Bladder Neoplasms",
        "Doc_meshqualifiers":"genetics;metabolism;genetics",
        "_version_":1605876309180809216},
      {
        "Doc_abstract":"p18(INK4c) is a member of the INK4 family of proteins that regulate the G(1) to S cell cycle transition by binding to and inhibiting the pRb kinase activity of cyclin-dependent kinases 4 and 6. The p16(INK4a) member of the INK4 protein family is altered in a variety of cancers and structure-function studies of the INK4 proteins reveal that the vast majority of missense tumor-derived p16(INK4a) mutations reduce protein thermodynamic stability. Based on this observation, we used p18(INK4c) as a model to test the proposal that INK4 proteins with increased stability might have enhanced cell cycle inhibitory activity. Structure-based mutagenesis was used to prepare p18(INK4c) mutant proteins with a predicted increase in stability. Using this approach, we report the generation of three mutant p18(INK4C) proteins, F71N, F82Q, and F92N, with increased stability toward thermal denaturation of which the F71N mutant also showed an increased stability to chemical denaturation. The x-ray crystal structures of the F71N, F82Q, and F92N p18INK4C mutant proteins were determined to reveal the structural basis for their increased stability properties. Significantly, the F71N mutant also showed enhanced CDK6 interaction and cell cycle inhibitory activity in vivo, as measured using co-immunoprecipitation and transient transfection assays, respectively. These studies show that a structure-based approach to increase the thermodynamic stability of INK4 proteins can be exploited to prepare more biologically active molecules with potential applications for the development of molecules to treat p16(INK4a)-mediated cancers.",
        "Doc_title":"Structure-based design of p18INK4c proteins with increased thermodynamic stability and cell cycle inhibitory activity.",
        "Journal":"The Journal of biological chemistry",
        "Do_id":"12370184",
        "Doc_ChemicalList":"Cell Cycle Proteins;Cyclin-Dependent Kinase Inhibitor p18;Enzyme Inhibitors;Tumor Suppressor Proteins",
        "Doc_meshdescriptors":"Cell Cycle;Cell Cycle Proteins;Circular Dichroism;Crystallography, X-Ray;Cyclin-Dependent Kinase Inhibitor p18;Enzyme Inhibitors;Models, Molecular;Mutagenesis;Protein Conformation;Thermodynamics;Tumor Suppressor Proteins",
        "Doc_meshqualifiers":"drug effects;chemistry;pharmacology;chemistry;genetics;pharmacology",
        "_version_":1605818577414258689},
      {
        "Doc_abstract":"To review the literature on the role of oncogenic human papillomaviruses (HPVs) in the carcinogenesis of the head and neck mucosa.;Molecular and epidemiological studies concerning the high-risk HPV types and their role in carcinogenesis in the head and neck region were screened.;Different studies revealed that: (i) 15-25% of head and neck squamous cell carcinomas (HNSCCs) are clonally associated with high risk HPV types (type 16); (ii) the oropharynx and particularly the tonsils are the most susceptible sites; (iii) patients with HPV-positive tumours present with more advanced stages of disease, are relatively younger, do not have extravagant tobacco and alcohol intake and seem to have a better survival; (iv) HPV-positive tumours are characterized by poor differentiation grade and a basaloid appearance; and (v) HPV-positive tumours exhibit integrated HPV DNA, wild-type p53, pRb downregulation and overexpression of p16INK4A.;Taken together, these data support the view that HPV-harbouring HNSCC can be considered a discrete tumour entity with, moreover, a favourable prognosis. Screening of patients, especially those with tonsillar cancers, for the presence of HPV may help to further optimize treatment protocols and to provide more accurate prognostic information.",
        "Doc_title":"Role of human papillomavirus in the development of head and neck squamous cell carcinomas.",
        "Journal":"Acta oto-laryngologica",
        "Do_id":"15224887",
        "Doc_ChemicalList":"Oncogene Proteins, Viral",
        "Doc_meshdescriptors":"Alcohol Drinking;Carcinoma, Squamous Cell;Cocarcinogenesis;Humans;Oncogene Proteins, Viral;Otorhinolaryngologic Neoplasms;Papillomaviridae;Papillomavirus Infections;Prognosis;Risk Factors;Smoking;Tonsillar Neoplasms",
        "Doc_meshqualifiers":"adverse effects;diagnosis;genetics;therapy;virology;analysis;diagnosis;genetics;therapy;virology;isolation & purification;complications;adverse effects;virology",
        "_version_":1605783968888651776},
      {
        "Doc_abstract":"The prognostic value of p16(INK4A) in esophageal squamous cell carcinoma (ESCC) has been evaluated for several years although the results remain controversial.;Various databases were systematically searched to identify studies published on the p16(INK4A) survival rate of ESCC patients. The pooled risk ratios and odds ratios with their corresponding 95% CIs were used to estimate the effect sizes.;A total of 16 studies comprising 1314 patients were included. p16(INK4A) overexpression was significantly associated with improved 5-year overall survival, disease-free survival, early tumor TNM stages, better tumor histological grade, no lymph node metastasis and more shallow tumor invasive depth (p < 0.05).;p16(INK4A) expression could be a useful biomarker to predict better prognosis for ESCC patients.",
        "Doc_title":"Prognostic significance of overexpressed p16(INK4A) in esophageal squamous cell carcinoma: a meta-analysis.",
        "Journal":"Biomarkers in medicine",
        "Do_id":"27071776",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605756992004030464},
      {
        "Doc_abstract":"Inactivation of p14ARF and p16INK4A by epigenetic changes in cutaneous and uveal melanoma has been here investigated. Compared with melanocytes, p14ARF mRNA reduction and p16INK4A inactivation were frequently noticed. No association between p14ARF promoter methylation and mRNA levels was found, whereas aberrant p16INK4A methylation was associated with gene silencing (p<0.001). Comparative analysis within melanomas of different Breslow's thicknesses showed that drastic reductions in p14ARF and p16INK4A expression appeared at the level of thin/intermediate and intermediate/thick transitions. The effects of 5-aza-2'-deoxycytidine (5-aza-dC) and suberanilohydroxamic acid (SAHA) on in vivo binding of DNA methyltransferases (DNMTs) and acetyl histone H3/H4 to p14ARF and p16INK4A promoters were tested together with the impact of ectopic expression of p14ARF and p16INK4A on cell proliferation, migration, and invasion. SAHA treatment induced H3 and H4 hyperacetylation at the p14ARF promoter followed by increased p14ARF expression, whereas exposure to 5-aza-dC decreased the recruitment of DNMT1 and DNMT3b at the p16INK4A promoter and reactivated p16INK4A. Studies on promoter-associated di-methyl histone H3 (Lys4) levels ruled out an involvement of this epigenetic trait on p14ARF and p16INK4A expression. The enforced expression of p14ARF or p16INK4A and, even more so, their co-expression, significantly reduced cell proliferation, migration and invasion. Our data pinpoint: i) a frequent impairment of p14ARF and p16INK4A gene expression by epigenetic modifications in melanoma; ii) histone hypoacetylation as the dominant mechanism of p14ARF silencing; and iii) 5' CpG promoter methylation as the major mechanism of p16INK4A gene inactivation. Collectively, our data suggest that selected epi-drugs may be useful in melanoma treatment.",
        "Doc_title":"Epigenetic regulation of p14ARF and p16INK4A expression in cutaneous and uveal melanoma.",
        "Journal":"Biochimica et biophysica acta",
        "Do_id":"25497382",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;Tumor Suppressor Protein p14ARF;decitabine;Histone Deacetylases;Azacitidine",
        "Doc_meshdescriptors":"Adult;Azacitidine;Cell Line, Tumor;Cyclin-Dependent Kinase Inhibitor p16;DNA Methylation;Epigenesis, Genetic;Female;Gene Expression Regulation, Neoplastic;Gene Silencing;Histone Deacetylases;Humans;Melanoma;Promoter Regions, Genetic;Tumor Suppressor Protein p14ARF;Uveal Neoplasms",
        "Doc_meshqualifiers":"administration & dosage;analogs & derivatives;biosynthesis;genetics;drug effects;genetics;drug therapy;genetics;pathology;biosynthesis;drug therapy;genetics;pathology",
        "_version_":1605812899382558720},
      {
        "Doc_abstract":"A tissue field of somatic genetic alterations precedes the histopathological phenotypic changes of carcinoma. Genomic changes could be of potential use in the diagnosis and prognosis of pre-invasive squamous head and neck carcinoma (HNSCC) lesions and as markers for cancer risk assessment. Studies of sequential molecular alterations and genetic progression of pre-invasive HNSCC have not been clearly defined. Studies have shown recurring alterations at chromosome 9p21 (location of the CDKN2A) and TP53 mutations in the early stages of HNSCC. However, gene silencing via hypermethylation is still a relatively new idea in the development of HNSCC and little is known about the contribution of epigenetics to the development of neoplasia, its transformation, progression, and recurrence in HNSCC. This review examines the role of promoter hypermethylation of tumor suppressor genes in the progression continuum from benign papillomas to malignancy in HNSCC.",
        "Doc_title":"Delineating an epigenetic continuum in head and neck cancer.",
        "Journal":"Cancer letters",
        "Do_id":"22388100",
        "Doc_ChemicalList":"Biomarkers, Tumor",
        "Doc_meshdescriptors":"Animals;Biomarkers, Tumor;Carcinoma, Squamous Cell;Cell Transformation, Neoplastic;DNA Methylation;Disease Progression;Epigenesis, Genetic;Gene Expression Regulation, Neoplastic;Genetic Predisposition to Disease;Genetic Testing;Head and Neck Neoplasms;Humans;Papilloma;Phenotype;Predictive Value of Tests;Prognosis",
        "Doc_meshqualifiers":"genetics;diagnosis;genetics;pathology;genetics;diagnosis;genetics;pathology;diagnosis;genetics;pathology",
        "_version_":1605746444012093442},
      {
        "Doc_abstract":"Although the presence of racial differences in vulvar squamous cell carcinomas has been suggested, fully analyzed data concerning such tumors in Japanese women have not been reported. A total of 21 vulvar squamous cell carcinomas of Japanese women who lived in north-east Japan, were studied with respect to histological subtype, HPV, p53 and p16(INK4a). The majority of tumors consisted of keratinizing and non-keratinizing types (16/21, 76%), all of which were negative for HPV. The remaining five tumors of basaloid, warty or verrucous types were positive for HPV. HPV-negative tumors showed a trend of greater accumulation of gene abnormalities, including p53 gene mutation, than HPV-positive ones. p16(INK4a) overexpression was shown to not always be a marker for vulvar squamous cell carcinoma in Japanese women with activated high-risk HPV.",
        "Doc_title":"Characteristics of vulvar squamous cell carcinoma in Japanese women.",
        "Journal":"Pathology international",
        "Do_id":"17539962",
        "Doc_ChemicalList":"Biomarkers, Tumor;Cyclin-Dependent Kinase Inhibitor p16;DNA, Neoplasm;DNA, Viral;Tumor Suppressor Protein p53",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Biomarkers, Tumor;Carcinoma, Squamous Cell;Cyclin-Dependent Kinase Inhibitor p16;DNA, Neoplasm;DNA, Viral;Female;Humans;Immunoenzyme Techniques;Japan;Loss of Heterozygosity;Middle Aged;Papillomaviridae;Papillomavirus Infections;Tumor Suppressor Protein p53;Vulvar Neoplasms",
        "Doc_meshqualifiers":"analysis;chemistry;epidemiology;etiology;pathology;analysis;genetics;analysis;analysis;epidemiology;genetics;isolation & purification;complications;epidemiology;pathology;analysis;genetics;chemistry;epidemiology;etiology;pathology",
        "_version_":1605760757685813248},
      {
        "Doc_abstract":"The human Ink4a/Arf tumor suppressor locus encodes two distinct products: p16(Ink4a) which prevents phosphorylation and inactivation of the retinoblastoma protein and, p14(Arf), a nucleolar protein which activates the function of the tumor suppressor p53 protein in the nucleoplasm in response to oncogenic stimulation through an as yet ill-defined mechanism. Here we show that the level of endogenous p14(Arf) and its balance between the nucleolus and the nucleoplasm in HeLa cells are exquisitely sensitive to changes in cell morphology and to short-lived perturbations in cell cycle and in nucleolar function such as those induced by the cyclin-dependent kinase inhibitor, roscovitine, and the casein kinase II and RNA synthesis inhibitor, DRB. Most remarkably, whereas p14(Arf) predominantly concentrates in the nucleolus of interphase cells and transiently disappears between metaphase and early G1 under normal growth conditions, it massively and reversibly accumulates in the nucleoplasm of postmitotic and S-phase cells upon short-term treatment with roscovitine and, at a lesser extent, DRB. In line with the fact that the nuclear level of p53 reaches a peak between mid-G1 and the G1/S border in p53-expressor cells which lack Arf expression, these results provide a clue that, in p53+/Arf+ cells, Arf proteins might serve both to speed and to amplify p53-mediated responses in conditions and cell cycle periods in which the mechanisms involved in p53 stabilization and activation are not fully operational. They further suggest that human endogenous p14(Arf) might activate p53 pathways in physiologic situations by acting inside the nucleoplasm, especially when normal cell cycle progression and nucleolar function are compromised.",
        "Doc_title":"Human p14(Arf): an exquisite sensor of morphological changes and of short-lived perturbations in cell cycle and in nucleolar function.",
        "Journal":"Oncogene",
        "Do_id":"12360404",
        "Doc_ChemicalList":"Cyclin E;Ki-67 Antigen;Purines;Tumor Suppressor Protein p14ARF;Tumor Suppressor Protein p53;roscovitine;Protein-Serine-Threonine Kinases;CDC2-CDC28 Kinases;CDK2 protein, human;Cyclin-Dependent Kinase 2;Cyclin-Dependent Kinases;DUSP5 protein, human;Dual-Specificity Phosphatases;Protein Tyrosine Phosphatases",
        "Doc_meshdescriptors":"CDC2-CDC28 Kinases;Cell Cycle;Cell Nucleolus;Cyclin E;Cyclin-Dependent Kinase 2;Cyclin-Dependent Kinases;Cytoplasm;Dual-Specificity Phosphatases;HeLa Cells;Humans;Ki-67 Antigen;Mitosis;Protein Tyrosine Phosphatases;Protein-Serine-Threonine Kinases;Purines;Tumor Suppressor Protein p14ARF;Tumor Suppressor Protein p53",
        "Doc_meshqualifiers":"physiology;chemistry;physiology;physiology;physiology;chemistry;analysis;analysis;physiology;pharmacology;analysis;physiology;physiology",
        "_version_":1605902922668834816},
      {
        "Doc_abstract":"Evaluation of hyperchromatic crowded groups in Papanicolaou (Pap) tests from women during menstruation can be a diagnostic pitfall due to similar morphological appearances with significant cervical lesions. We studied the results of p16(INK4a) and ProEx C on cell blocks from Pap tests during menstruation in an attempt to facilitate the differentiation.;Immunohistochemical stains for p16(INK4a) and ProEx C were performed on 25 cell blocks prepared from residual liquid-based cervical material with menstrual contamination.;Strong, diffuse, and full thickness staining pattern for p16(INK4a) and ProEx C was observed in cases of high-grade squamous intraepithelial lesion (HSIL) and small cell carcinoma of the cervix. The low-grade squamous intraepithelial lesion cases and cases negative for intraepithelial lesion or malignancy were negative for ProEx C, with focal staining for p16(INK4a). The benign endometrial cells had either negative or focal patchy staining, which is often associated with tubal metaplasia.;p16(INK4a) and ProEx C are sensitive markers for identifying significant lesions in Pap test specimens with menstrual contamination. Patchy/mosaic staining may be seen in benign endometrial tissue with tubal metaplasia, but strong, diffuse staining likely indicates HSIL or carcinoma. These findings can be helpful in interpreting hyperchromatic crowded groups in menstrual Pap specimens. Further study may be prudent, being aware of the small study group.",
        "Doc_title":"p16(INK4a) and ProEx C immunostains facilitate differential diagnosis of hyperchromatic crowded groups in liquid-based Papanicolaou tests with menstrual contamination.",
        "Journal":"Acta cytologica",
        "Do_id":"22236746",
        "Doc_ChemicalList":"Biomarkers, Tumor;Cell Cycle Proteins;Cyclin-Dependent Kinase Inhibitor p16;Nuclear Proteins;MCM2 protein, human;Minichromosome Maintenance Complex Component 2",
        "Doc_meshdescriptors":"Adult;Artifacts;Biomarkers, Tumor;Cell Cycle Proteins;Cervical Intraepithelial Neoplasia;Cyclin-Dependent Kinase Inhibitor p16;Diagnosis, Differential;Female;Humans;Immunohistochemistry;Menstruation;Middle Aged;Minichromosome Maintenance Complex Component 2;Nuclear Proteins;Papanicolaou Test;Uterine Cervical Dysplasia;Uterine Cervical Neoplasms;Vaginal Smears;Young Adult",
        "Doc_meshqualifiers":"metabolism;metabolism;diagnosis;metabolism;metabolism;methods;blood;metabolism;diagnosis;metabolism;diagnosis;metabolism",
        "_version_":1605763805203136512},
      {
        "Doc_abstract":"BubR1 insufficiency occurs with natural aging and induces progeroid phenotypes in both mice and children with mosaic variegated aneuploidy syndrome. In response to BubR1 insufficiency, skeletal muscle, fat, and lens tissue engage p19(Arf) to attenuate senescence and age-related deterioration. Here, we address how p19(Arf) exerts this caretaker role using BubR1 progeroid mice lacking p53 or its transcriptional target p21. We show that p53 delays functional decline of skeletal muscle and fat in a p21-dependent fashion by inhibiting p16(Ink4a)-mediated senescence of progenitor cells. Strikingly, p53 also attenuates the formation of cataractous lenses, but here its antiaging effect is p21 independent, as we found p21 to promote senescence of lens epithelial cells and cataract formation. Together, these results demonstrate that p53 counteracts tissue destruction in response to BubR1 insufficiency through diverse mechanisms and uncover a causal link between senescence of the progenitor cell compartment and age-related dysfunction.",
        "Doc_title":"p21 both attenuates and drives senescence and aging in BubR1 progeroid mice.",
        "Journal":"Cell reports",
        "Do_id":"23602569",
        "Doc_ChemicalList":"Bub1b protein, mouse;Cell Cycle Proteins;Cyclin-Dependent Kinase Inhibitor p19;Cyclin-Dependent Kinase Inhibitor p21;Tumor Suppressor Protein p53;Bub1 spindle checkpoint protein;Protein-Serine-Threonine Kinases",
        "Doc_meshdescriptors":"Adipose Tissue;Alleles;Animals;Cataract;Cell Aging;Cell Cycle Proteins;Cell Line;Chromosome Disorders;Cyclin-Dependent Kinase Inhibitor p19;Cyclin-Dependent Kinase Inhibitor p21;Genotype;Lens, Crystalline;Longevity;Mice;Mosaicism;Muscle, Skeletal;Protein-Serine-Threonine Kinases;Stem Cells;Tumor Suppressor Protein p53",
        "Doc_meshqualifiers":"metabolism;metabolism;pathology;genetics;metabolism;mortality;genetics;metabolism;genetics;metabolism;metabolism;metabolism;genetics;metabolism;cytology;metabolism;genetics;metabolism",
        "_version_":1605802540419514368},
      {
        "Doc_abstract":"Head and neck squamous cell carcinoma (HNSCC) involves the upper aerodigestive tract and can destroy the structure and function of organs involved in voice, speech, taste, smell and hearing, as well as vital structures necessary for survival. HNSCC has long been a treatment challenge because of the high rate of recurrences and of advanced disease at the time of diagnosis. Molecular identification of tissue biomarkers in diagnostic biopsy specimens may not only identify patients at risk for developing HNSCC but may also select patients that may benefit from more aggressive treatment modalities. Several biomarkers studied to date such as the proteins p53, cyclin D1, p16, Cox-2 enzyme, epidermal growth factor and vascular endothelial growth factor receptors, matrix metalloproteinases and the Fhit marker for genomic instability could be manipulated for the therapeutic benefit of these patients. This review presents the most updated information on molecular biomarkers with the greatest prognostic potential in HNSCC and discusses some factors that contribute to the controversy concerning their prognostic importance.",
        "Doc_title":"Molecular predictors of clinical outcome in patients with head and neck squamous cell carcinoma.",
        "Journal":"International journal of experimental pathology",
        "Do_id":"16309541",
        "Doc_ChemicalList":"Biomarkers, Tumor",
        "Doc_meshdescriptors":"Biomarkers, Tumor;Carcinoma, Squamous Cell;Gene Expression Profiling;Genes, Tumor Suppressor;Head and Neck Neoplasms;Humans;Neoplasm Recurrence, Local;Oligonucleotide Array Sequence Analysis;Prognosis",
        "Doc_meshqualifiers":"genetics;genetics;pathology;genetics;pathology;genetics",
        "_version_":1605902949242896384},
      {
        "Doc_abstract":"The cyclin-dependent kinases 4 and 6 (Cdk4/6) that control the G1 phase of the cell cycle and their inhibitor, the p16INK4a tumour suppressor, have a central role in cell proliferation and in tumorigenesis. The structures of Cdk6 bound to p16INK4a and to the related p19INK4d reveal that the INK4 inhibitors bind next to the ATP-binding site of the catalytic cleft, opposite where the activating cyclin subunit binds. They prevent cyclin binding indirectly by causing structural changes that propagate to the cyclin-binding site. The INK4 inhibitors also distort the kinase catalytic cleft and interfere with ATP binding, which explains how they can inhibit the preassembled Cdk4/6-cyclin D complexes as well. Tumour-derived mutations in INK4a and Cdk4 map to interface contacts, solidifying the role of CDK binding and inhibition in the tumour suppressor activity of p16INK4a.",
        "Doc_title":"Structural basis for inhibition of the cyclin-dependent kinase Cdk6 by the tumour suppressor p16INK4a.",
        "Journal":"Nature",
        "Do_id":"9751050",
        "Doc_ChemicalList":"CDKN2D protein, human;Carrier Proteins;Cell Cycle Proteins;Cyclin D;Cyclin-Dependent Kinase Inhibitor p16;Cyclin-Dependent Kinase Inhibitor p19;Cyclins;Enzyme Inhibitors;Recombinant Proteins;Adenosine Triphosphate;Protein-Serine-Threonine Kinases;CDK6 protein, human;Cyclin-Dependent Kinase 6;Cyclin-Dependent Kinases",
        "Doc_meshdescriptors":"Adenosine Triphosphate;Amino Acid Sequence;Binding Sites;Carrier Proteins;Cell Cycle Proteins;Crystallography, X-Ray;Cyclin D;Cyclin-Dependent Kinase 6;Cyclin-Dependent Kinase Inhibitor p16;Cyclin-Dependent Kinase Inhibitor p19;Cyclin-Dependent Kinases;Cyclins;Enzyme Inhibitors;Escherichia coli;Genes, Tumor Suppressor;Humans;Models, Molecular;Molecular Sequence Data;Protein Binding;Protein Conformation;Protein-Serine-Threonine Kinases;Recombinant Proteins;Structure-Activity Relationship",
        "Doc_meshqualifiers":"metabolism;chemistry;metabolism;chemistry;genetics;metabolism;pharmacology;metabolism;antagonists & inhibitors;chemistry;genetics;metabolism;chemistry;metabolism",
        "_version_":1605812926853152768},
      {
        "Doc_abstract":"Recent evidence suggests that human papillomavirus (HPV)-related head and neck squamous cell carcinoma (HNSCC) is a separate HNSCC subgroup with distinct epidemiology, histopathological characteristics, therapeutic response to chemotherapy and radiation, and clinical outcome. This study aimed to investigate the role of HPV infection in oral squamous cell carcinoma (OSCC) and the correlation between HPV infection, tumor suppressor protein p16 expression, and clinicopathological features in Japanese patients.;In total, 174 OSCC specimens were examined for p16 levels by immunohistochemistry, and p16-positive OSCCs were analyzed for HPV DNA by in situ hybridization (ISH) and HPV genotypes by real-time PCR. The results were evaluated for the association with clinicopathological characteristics of OSCC patients.;Twenty-four OSCC samples were found positive for p16 expression; all of them were well-differentiated tumors. P16 immunoreactivity was significantly associated with the invasion depth and tended to correlate with sex, site in the oral cavity, stromal reaction, TNM stage, and survival. HPV DNA was detected in 13 of 24 (54%) p16-positive OSCC by real-time PCR; HPV 16, 18, and other high-risk genotypes were the most prevalent. However, ISH failed to detect HPV DNA in p16-positive OSCCs.;P16 immunoreactivity and HPV genotyping by real-time PCR may be useful markers of HPV infection in OSCC. However, although HPV-related OSCC showed good outcomes, HPV infection may have a minor role in oral oncogenesis in Japanese patients.",
        "Doc_title":"Detection of human papillomavirus infection in oral squamous cell carcinoma: a cohort study of Japanese patients.",
        "Journal":"Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology",
        "Do_id":"26711722",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605891344807493632},
      {
        "Doc_abstract":"C-terminal binding protein-2 (CtBP2), as a transcriptional co-repressor, has been shown to mediate the repression of p16(INK4A) , a tumor suppressor gene product, in primary human cells. Here we aimed to investigate how the correlation between CtBP2 and p16(INK4A) influenced the development of esophageal squamous cell carcinoma (ESCC). Immunohistochemistry of ESCC tissue sections indicated that the CtBP2 and p16(INK4A) expressions were inversely correlated to each other with a linear regression coefficient of -0.747 (P < 0.05), and Western blot analysis revealed that CtBP2 was higher expressed in tumorous tissues than in adjacent non-tumorous tissues. Either CtBP2 or p16(INK4A) expression was significantly related to histological differentiation (P = 0.016 or 0.001) and to the expression of Ki-67, a proliferating marker (P = 0.006 or 0.02), and patients with higher CtBP2 and lower p16(INK4A) expressions had shorter overall survival. We also observed that CtBP2 modulated the cell proliferation and cell cycle in ECA109 cells, an ESCC cell line, by inhibiting p16(INK4A) . Overexpression or knockdown of CtBP2 in ECA109 cells was found to inhibit or activate the mRNA or protein expression of p16(INK4A) , which in turn altered the cell proliferation and cell cycle in ECA109 cells, as measured by flow cytometry and cell count assay. Additionally, after ECA109 cells silenced for CtBP2 were treated with cisplatin (an anti-ESCC agent), the p16(INK4A) expression was up-regulated, and the cell apoptosis was promoted, thus confirming the repression of p16(INK4A) by CtBP2. Collectively, all results suggested that CtBP2 might contribute to the progression of ESCC through a negative transcriptional regulation of p16(INK4A).",
        "Doc_title":"CtBP2 contributes to malignant development of human esophageal squamous cell carcinoma by regulation of p16INK4A.",
        "Journal":"Journal of cellular biochemistry",
        "Do_id":"23255392",
        "Doc_ChemicalList":"Antineoplastic Agents;Cyclin-Dependent Kinase Inhibitor p16;Nerve Tissue Proteins;Alcohol Oxidoreductases;CTBP2 protein, human;Cisplatin",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Alcohol Oxidoreductases;Antineoplastic Agents;Carcinogenesis;Carcinoma, Squamous Cell;Cell Line, Tumor;Cell Proliferation;Cisplatin;Cyclin-Dependent Kinase Inhibitor p16;Esophageal Neoplasms;Female;Gene Expression;Gene Expression Regulation, Neoplastic;Humans;Kaplan-Meier Estimate;Male;Middle Aged;Nerve Tissue Proteins;Prognosis",
        "Doc_meshqualifiers":"physiology;pharmacology;genetics;metabolism;genetics;metabolism;mortality;pharmacology;genetics;metabolism;genetics;metabolism;mortality;physiology",
        "_version_":1605742701492305921},
      {
        "Doc_abstract":"The cyclin D-Cdk4-6/INK4/Rb/E2F pathway plays a key role in controlling cell growth by integrating multiple mitogenic and antimitogenic stimuli. The members of INK4 family, comprising p16(INK4a), p15(INK4b), p18(INK4c), and p19(INK4d), block the progression of the cell cycle by binding to either Cdk4 or Cdk6 and inhibiting the action of cyclin D. These INK4 proteins share a similar structure dominated by several ankyrin repeats. Although they appear to be structurally redundant and equally potent as inhibitors, the INK4 family members are differentially expressed during mouse development. The striking diversity in the pattern of expression of INK4 genes suggested that this family of cell cycle inhibitors might have cell lineage-specific or tissue-specific functions. The INK4 proteins are commonly lost or inactivated by mutations in diverse types of cancer, and they represent established or candidate tumor suppressors. Apart from their capacity to arrest cells in the G1-phase of the cell cycle they have been shown to participate in an increasing number of cellular processes. Given their emerging roles in fundamental physiological as well as pathological processes, it is interesting to explore the diverse roles for the individual INK4 family members in different functions other than cell cycle regulation. Extensive studies, over the past few years, uncover the involvement of INK4 proteins in senescence, apoptosis, DNA repair, and multistep oncogenesis. We will focus the discussion here on these unexpected issues.",
        "Doc_title":"INK4 proteins, a family of mammalian CDK inhibitors with novel biological functions.",
        "Journal":"IUBMB life",
        "Do_id":"17654117",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor Proteins;Cyclin-Dependent Kinase 4",
        "Doc_meshdescriptors":"Animals;Apoptosis;Cell Aging;Cell Transformation, Neoplastic;Cyclin-Dependent Kinase 4;Cyclin-Dependent Kinase Inhibitor Proteins;DNA Repair;Humans;Multigene Family",
        "Doc_meshqualifiers":"genetics;physiology;genetics;physiology;genetics;metabolism;pathology;antagonists & inhibitors;genetics;genetics;physiology;physiology",
        "_version_":1605851256933318656},
      {
        "Doc_abstract":"Metastatic cutaneous melanoma is highly resistant to cytotoxic drugs, and this contributes to poor prognosis. In vivo studies on the chemosensitivity of metastatic melanoma are rare and hampered by poor response rates to systemic chemotherapeutics. Patients who undergo isolated limb infusion (ILI) with cytotoxic drugs show high response rates and are, therefore, a good cohort for studying chemosensitivity in vivo. We used tumors from patients who underwent ILI to study the role of melanoma tumor-suppressor genes and oncogenes on melanoma chemosensitivity. Prospectively acquired tumors from 30 patients who subsequently underwent ILI with melphalan and actinomycin-D for metastatic melanoma were investigated for mRNA expression levels of p14(ARF), p16(INK4a), and MITFm. The mutation status of B-RAF, N-RAS, and PTEN were also determined. A high percentage of tumors had activating mutations in either B-RAF (15/30) or N-RAS (10/30) and only two tumors carried altered PTEN. High expression of p16(INK4a) and absence of an activating B-RAF mutation independently predicted response to treatment. Further, inducible expression of p16(INK4a) sensitized a melanoma cell line to death induced by melphalan or actinomycin-D. This study shows that high expression of p16(INK4a) or the absence of activated B-RAF correlates with in vivo response of melanoma to cytotoxic drugs.",
        "Doc_title":"p16INK4a expression and absence of activated B-RAF are independent predictors of chemosensitivity in melanoma tumors.",
        "Journal":"Neoplasia (New York, N.Y.)",
        "Do_id":"18953432",
        "Doc_ChemicalList":"Antineoplastic Agents;Cyclin-Dependent Kinase Inhibitor p16;MITF protein, human;Microphthalmia-Associated Transcription Factor;Tumor Suppressor Protein p14ARF;Dactinomycin;BRAF protein, human;Proto-Oncogene Proteins B-raf;PTEN Phosphohydrolase;PTEN protein, human;Melphalan",
        "Doc_meshdescriptors":"Aged;Aged, 80 and over;Antineoplastic Agents;Apoptosis;Cell Cycle;Cyclin-Dependent Kinase Inhibitor p16;Dactinomycin;Female;Gene Expression Regulation, Neoplastic;Genes, p16;Genes, ras;Humans;Male;Melanoma;Melphalan;Microphthalmia-Associated Transcription Factor;Middle Aged;Mutation;PTEN Phosphohydrolase;Polymorphism, Single-Stranded Conformational;Proto-Oncogene Proteins B-raf;Reverse Transcriptase Polymerase Chain Reaction;Statistics, Nonparametric;Tumor Suppressor Protein p14ARF",
        "Doc_meshqualifiers":"therapeutic use;genetics;metabolism;therapeutic use;drug therapy;genetics;therapeutic use;genetics;metabolism;genetics;metabolism;genetics;metabolism;genetics;metabolism",
        "_version_":1605824684274745344},
      {
        "Doc_abstract":"The inactivation of p16 and p14ARF is considered to be an important step in the carcinogenesis of oropharygeal carcinomas. This consideration is supported by the observation of multiple allelic losses in the coding loci of chromosome 9p21 in squamous cell carcinomas and in dysplastic premalignant lesions. The present study hypothesized that comparable alterations already occur in leukoplakia, which are seen as potential predecessors of oral squamous cell carcinomas and that it is possible to differ leukoplakia with from leukoplakia without further malignant transformation. Furthermore we evaluated, whether such leukoplakia show sequence alterations in the genes p16 and p14ARF, which are capable to cause a limitation in gene function. The results show that the LOH pattern in genes p16 and p14ARF occur as well in leuplakia with malignant transformation as in leukoplakia, that do not show clinical alterations. The rate of allelic loss did not differ significantly. Overall, the incidence of allelic loss was lower in leuplakia compared to succeeding squamous-cell carcinomas (p<0,05). The results further illustrated an increase in LOH patterns in dyplastic leukoplakia, without reaching statistical significance. Significant increases in allelic losses were found in heavy smokers, (p < 0,05). PCR analysis of the exons 1-alpha, exon 1-beta and exon 2 in leukoplakia, containing LOH patterns did not show genetic alterations. Thus we concluded, that gene deletion and gene mutation have a minor role in the inactivation process of p16 and p14ARF in oral leukoplakia. Representing an early process in carcinogenesis, gene deletion and mutation occur in leukoplakia with and without malignant transformation. Therefore, taken as a singular parameter they represent an uncertain criteria to assess the potential of malignant transformation. However they could provide information in combination with other genetic factors like chromosomal methylation patterns and histology.",
        "Doc_title":"[Exploration of tumor suppressors p16INK4a and p14ARF in oral leukoplakias].",
        "Journal":"Mund-, Kiefer- und Gesichtschirurgie : MKG",
        "Do_id":"17990010",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;Tumor Suppressor Protein p14ARF",
        "Doc_meshdescriptors":"Carcinoma, Squamous Cell;Cell Transformation, Neoplastic;Chromosome Deletion;Chromosomes, Human, Pair 9;Cyclin-Dependent Kinase Inhibitor p16;DNA Mutational Analysis;Exons;Female;Humans;Leukoplakia, Oral;Loss of Heterozygosity;Male;Microsatellite Repeats;Mouth Neoplasms;Polymerase Chain Reaction;Risk Factors;Sequence Analysis, DNA;Smoking;Tumor Suppressor Protein p14ARF",
        "Doc_meshqualifiers":"genetics;pathology;genetics;pathology;genetics;genetics;genetics;genetics;pathology;genetics;pathology;adverse effects;genetics",
        "_version_":1605746485029240832},
      {
        "Doc_abstract":"Rhabdomyosarcoma (RMS) is the most common soft-tissue sarcoma of childhood. The simultaneous loss of Ink4a/Arf function and disruption of Met signaling in Ink4a/Arf-/- mice transgenic for hepatocyte growth factor/scatter factor (HGF/SF) induces RMS with extremely high penetrance and short latency. To address the roles of MET and CDKN2A (p16INK4A/p14ARF) in human RMS, we performed mutational analyses in 39 samples of RMS by PCR-SSCP. No mutations were detected in exons 14-21 of MET whereas a nonsense mutation at codon 80 of p16(INK4A) was identified in an alveolar RMS cell line. We also quantified the relative expression levels and DNA copy numbers of these genes in seven cell lines and 17 fresh tumors by real-time quantitative PCR. Expression of MET was detected in all samples; however, more than 10-fold difference was found in the samples with higher or lower expression level, despite a normal DNA copy number. The protein expression level was consistent with that of mRNA, and in cell lines with a higher expression level, MET was constitutively activated. Notably, the expression level of MET was significantly higher in patients who died (P = 0.02), in patients with stage IV (P = 0.04), as well as in patients with PAX3-FKHR chimeric transcript (P = 0.04). On the other hand, reduced or absent expression of p16INK4A and/or p14(ARF) showed no significant correlation with the clinicopathological parameters, except for the age at diagnosis. Our data suggest that MET plays a role in the progression of RMS.",
        "Doc_title":"Mutation and expression analyses of the MET and CDKN2A genes in rhabdomyosarcoma with emphasis on MET overexpression.",
        "Journal":"Genes, chromosomes & cancer",
        "Do_id":"17243166",
        "Doc_ChemicalList":"Codon, Nonsense;Cyclin-Dependent Kinase Inhibitor p16;Proto-Oncogene Proteins;Receptors, Growth Factor;MET protein, human;Proto-Oncogene Proteins c-met",
        "Doc_meshdescriptors":"Age of Onset;Cell Line, Tumor;Codon, Nonsense;Cyclin-Dependent Kinase Inhibitor p16;DNA Mutational Analysis;Gene Expression Profiling;Humans;Mutation, Missense;Point Mutation;Proto-Oncogene Proteins;Proto-Oncogene Proteins c-met;Receptors, Growth Factor;Rhabdomyosarcoma",
        "Doc_meshqualifiers":"genetics;biosynthesis;genetics;biosynthesis;genetics;genetics;metabolism",
        "_version_":1605847033477857280},
      {
        "Doc_abstract":"Head and neck squamous cell carcinoma (HNSCC) is notorious for local recurrence and metastatic spread to regional lymph nodes. Distant spread is uncommon, and brain involvement is rare. Over the past decade there has been a rising incidence of HPV-related HNSCC, but it is not known if this escalation has had any impact on trends relating to brain involvement. Cases of metastatic squamous cell carcinoma (SCC) to the brain were identified from a computerized search of the surgical pathology files of The Johns Hopkins Hospital between 1985 and 2012. The medical records were reviewed to document primary site of tumor origin, treatment, and patient outcome. P16 immunohistochemistry and HPV in situ hybridization were performed on those metastases arising from the head and neck. Of the 38 metastatic SCCs, 7 (18 %) originated in the head and neck. HPV-16 was detected in 4 (57 %) of the metastatic HNSCCs. All 4 HPV-positive metastases were from oropharyngeal primaries. The time from treatment of the primary to development of the brain metastasis ranged from 19 to 57 months (mean, 45). Following aggressive treatment (surgery and radiation), two patients died of disease progression (7 and 34 months), and two are alive with recurrent brain metastases (4 and 10 months). Although HPV positivity is regarded as a favorable prognostic indicator, it does not safeguard from spread to the brain. In our experience, just over half of the HNSCCs that metastasized to the brain were HPV-related. The potential for developing a brain metastasis long after curative therapy argues for extended patient follow-up. The development of a brain metastasis is an ominous finding signaling rapid clinical deterioration.",
        "Doc_title":"Metastatic squamous cell carcinoma to the brain: an unrecognized pattern of distant spread in patients with HPV-related head and neck cancer.",
        "Journal":"Journal of neuro-oncology",
        "Do_id":"23408186",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Adult;Aged;Brain Neoplasms;Carcinoma, Squamous Cell;Female;Head and Neck Neoplasms;Human papillomavirus 16;Humans;Immunohistochemistry;In Situ Hybridization;Male;Middle Aged;Papillomavirus Infections",
        "Doc_meshqualifiers":"secondary;secondary;virology;pathology;virology;isolation & purification;complications",
        "_version_":1605759807367675904},
      {
        "Doc_abstract":"Evidence from cytogenetics, multipoint linkage analyses of familial melanoma, and loss of heterozygosity studies of familial and sporadic melanomas support localization of a melanoma susceptibility or tumor suppressor gene at chromosomal region 9p21-23. Recently, the inhibitor of cyclin-dependent kinase 4 (CDK4I; also known as p16INK4, multiple tumor suppressor 1, or CDKN2 gene) has been mapped to 9p21 and shown to be mutated or deleted in a large fraction of cell lines derived from many tumor types, including melanoma, suggesting that this gene could be a melanoma suppressor gene. In order to test for somatic mutations in the CDK4I gene in tumors, DNAs from 30 surgically resected melanomas of both cutaneous and uveal origins were sequenced. No mutations were detected in the coding region of the CDK4I gene, while mutations or deletions were detected in 60% (9 of 15) of the cultured melanoma cell line DNAs. Among presumptive familial cases, nine of which were members of families with one or two other documented melanoma cases, no germline mutations were detected by sequence analysis. A deletion in the second exon of the CDK4I gene was found in one germline allele of a familial melanoma patient from a family with eight affected first degree relatives. These results not only support the suggestion that the CDK4I gene is a familial malignant melanoma gene, they also suggest the presence of another suppressor gene locus within 9p21 which is the target of loss of heterozygosity in sporadic melanomas.",
        "Doc_title":"Rarity of somatic and germline mutations of the cyclin-dependent kinase 4 inhibitor gene, CDK4I, in melanoma.",
        "Journal":"Cancer research",
        "Do_id":"7923152",
        "Doc_ChemicalList":"Proto-Oncogene Proteins;Protein-Serine-Threonine Kinases;CDK4 protein, human;Cyclin-Dependent Kinase 4;Cyclin-Dependent Kinases",
        "Doc_meshdescriptors":"Base Sequence;Chromosomes, Human, Pair 9;Cyclin-Dependent Kinase 4;Cyclin-Dependent Kinases;DNA Mutational Analysis;Exons;Gene Deletion;Genes, Tumor Suppressor;Humans;Melanoma;Molecular Sequence Data;Protein-Serine-Threonine Kinases;Proto-Oncogene Proteins;Skin Neoplasms;Uveal Neoplasms",
        "Doc_meshqualifiers":"genetics;genetics;enzymology;genetics;antagonists & inhibitors;genetics;enzymology;genetics;enzymology;genetics",
        "_version_":1605879627706793984},
      {
        "Doc_abstract":"The p16 gene (CDKN2), a tumor suppressor gene located on chromosome 9p21, has been demonstrated to be mutated or deleted with high frequency in a variety of tumor cell lines, including breast. While previous studies have not demonstrated CDKN2 mutations in primary breast carcinomas, it is possible that gene deletion in neoplastic DNA was marked by the presence of contaminating normal stromal DNA in breast carcinoma specimens.;We investigated the incidence of homozygous deletion of CDKN2 by analyzing 20 microdissected pure populations of primary breast carcinoma cells. Using polymerase chain reaction (PCR) techniques, the entire coding region and intervening introns of CDKN2 were amplified. The PCR products were resolved by agarose gel electrophoresis and single-strand conformation polymorphism (SSCP) analysis.;We detected no deletions or mutations of the p16 gene.;CDKN2 is not deleted with high frequency in primary breast carcinomas, and the p16 gene does not play a role in breast carcinogenesis via this mechanism.",
        "Doc_title":"Absence of p16 gene (CDKN2) deletions in microdissected primary breast carcinoma specimens.",
        "Journal":"Annals of surgical oncology",
        "Do_id":"9259969",
        "Doc_ChemicalList":"Carrier Proteins;Cyclin-Dependent Kinase Inhibitor p16;DNA, Neoplasm",
        "Doc_meshdescriptors":"Breast Neoplasms;Carrier Proteins;Cyclin-Dependent Kinase Inhibitor p16;DNA, Neoplasm;Electrophoresis, Agar Gel;Female;Gene Deletion;Genes, Tumor Suppressor;Humans;Mutation;Polymerase Chain Reaction;Polymorphism, Single-Stranded Conformational",
        "Doc_meshqualifiers":"genetics;pathology;genetics;analysis",
        "_version_":1605844873046392832},
      {
        "Doc_abstract":"Inactivation of the p16 tumor suppressor gene is a common phenomenon in squamous cell carcinoma of the head and neck (SCCHN). Less commonly described is the observation of p16 overexpression in SCCHN. Since overexpression of p16 is a potent predictor of outcome in other cancers, we were interested in determining the level of expression of p16 in our SCCHN specimens as a prerequisite to later prognostic studies. We were also interested in determining the mutational status of p16 in these tumors, in order to determine whether the combination of overexpression and gene alteration may predict a different clinical outcome from overexpression alone. A total of 84 specimens of SCCHN were selected for study. These specimens were obtained from all major sites within the oral cavity, oropharynx, pharynx and larynx. The level of expression of p16 in SCCHN specimens was measured by semi-quantitative RT-PCR. In 35 cases, RNA was also isolated from matched normal tissue obtained from a negative tumor margin. In the other 49 cases, the expression level was compared with the level of expression measured in pooled normal RNA obtained from 10 specimens of normal epithelial tissue. Overexpression of p16 was documented when the level of expression in the tumor specimen was 2-fold or greater above the level of expression found in normal tissue. A total of 46 specimens demonstrated overexpression of p16 (55%). All specimens demonstrating overexpression were then subject to sequence analysis. Thirty specimens (65%) showed p16-specific gene alterations, ranging from intragenic deletions to single point mutations, and 15 of these cases concomitantly affect p14ARF. A single specimen demonstrated a silent point mutation within the p16 reading frame. This mutation produces a stop codon at residue 85 in the context of the p14ARF reading frame, predicting premature termination of p14ARF within a previously determined nucleolar localization signal. This observation suggests that in some cases at least, p14ARF may be a selective target for alteration, independently of p16. Analysis of a normal tissue specimen obtained from a negative tumor margin, and a blood sample obtained approximately five years after surgery indicate that this p14ARF-specific alteration may represent a germline mutation.",
        "Doc_title":"Mutational status of overexpressed p16 in head and neck cancer: evidence for germline mutation of p16/p14ARF.",
        "Journal":"International journal of oncology",
        "Do_id":"12118338",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;DNA Primers;RNA, Messenger;RNA, Neoplasm;Tumor Suppressor Protein p14ARF",
        "Doc_meshdescriptors":"Carcinoma, Squamous Cell;Cyclin-Dependent Kinase Inhibitor p16;DNA Primers;Gene Deletion;Germ-Line Mutation;Head and Neck Neoplasms;Humans;RNA, Messenger;RNA, Neoplasm;Reverse Transcriptase Polymerase Chain Reaction;Tumor Suppressor Protein p14ARF;Up-Regulation",
        "Doc_meshqualifiers":"genetics;genetics;metabolism;chemistry;genetics;metabolism;metabolism;genetics;metabolism",
        "_version_":1605875868279767040},
      {
        "Doc_abstract":"To investigate the expression of p15(INK4b), p16(INK4a) and p21(Waf1/Cip1) in specimens from cases of normal cervical epithelium (NCE), cervical intraepithelial neoplasia (CIN) and squamous cell carcinoma (SCC), and to evaluate whether there is evidence implicating oncogene-induced senescence (OIS) in cervical squamous cell cancer development.;The immunohistochemical expression of p15(INK4b), p16(INK4a) and p21(Waf1/Cip1) were investigated in formalin-fixed paraffin-embedded specimens from 19 NCE, 51 CIN and 21 SCC cases, respectively. Comparisons among different groups for each marker were performed with Chi-square test.;The expression of p15(INK4b), p16(INK4a) and p21(Waf1/Cip1) were significantly higher in both CIN and SCC compared to NCE. Furthermore, the expression of p15(INK4b) and p21(Waf1/Cip1) was significantly higher in CIN  compared to CIN , and these expressions were statistically higher in CIN  compared to CIN , respectively. The p16(INK4a) expression was significantly higher in CIN  compared to CIN .;The results suggested that the senescence programs mediated by p15(INK4b), p16(INK4a) and p21(Waf1/Cip1) were activated during the stage of CIN and SCC, and demonstrated that senescence may play important role in preventing from NCE to SCC.",
        "Doc_title":"Increased expression of oncogene-induced senescence markers during cervical squamous cell cancer development.",
        "Journal":"International journal of clinical and experimental pathology",
        "Do_id":"25674264",
        "Doc_ChemicalList":"Biomarkers, Tumor;CDKN1A protein, human;Cyclin-Dependent Kinase Inhibitor p15;Cyclin-Dependent Kinase Inhibitor p16;Cyclin-Dependent Kinase Inhibitor p21",
        "Doc_meshdescriptors":"Biomarkers, Tumor;Carcinoma, Squamous Cell;Cell Aging;Cell Transformation, Neoplastic;Cervical Intraepithelial Neoplasia;Cyclin-Dependent Kinase Inhibitor p15;Cyclin-Dependent Kinase Inhibitor p16;Cyclin-Dependent Kinase Inhibitor p21;Female;Humans;Immunohistochemistry;Oncogenes;Retrospective Studies;Uterine Cervical Neoplasms",
        "Doc_meshqualifiers":"analysis;pathology;physiology;metabolism;pathology;pathology;biosynthesis;biosynthesis;biosynthesis;pathology",
        "_version_":1605908425215049728},
      {
        "Doc_abstract":"Alterations in the ARF tumor suppressor protein (also known as p14ARF in humans and p19ARF in the mouse) occur frequently in cancer and are associated with susceptibility to melanoma, pancreatic cancer and nervous system tumors. ARF proteins interact with the E2F-1, -2 and -3 transcription activators to inhibit their transcriptional activity and induce their degradation via the 26S proteasome pathway. The impact of ARF on the E2F proteins may provide a mechanism for p53-independent ARF activity on cell cycle progression and tumor susceptibility. In this report we explored the effects of ARF on E2F ubiquitination and degradation in relationship to cell cycle effects and p53 status. We now show that ARF induced the rapid ubiquitination and degradation of E2F-1 only in the presence of functional p53. E2F-1 continued to be ubiquitinated following ARF induction in cycling p53-wild-type, p21-null cells, showing that effects of ARF were not simply a result of p14ARF induced cell-cycle arrest. Importantly, these data establish that the ARF-E2F-1 pathway is an extension of the p53-mdm2-ARF tumor suppressor network and is unlikely to constitute a p53-independent pathway for ARF function.",
        "Doc_title":"p14ARF regulates E2F-1 ubiquitination and degradation via a p53-dependent mechanism.",
        "Journal":"Cell cycle (Georgetown, Tex.)",
        "Do_id":"17630509",
        "Doc_ChemicalList":"E2F1 Transcription Factor;E2F1 protein, human;Tumor Suppressor Protein p14ARF;Tumor Suppressor Protein p53;Ubiquitin",
        "Doc_meshdescriptors":"Animals;Cell Cycle;Cell Line, Tumor;E2F1 Transcription Factor;Genetic Predisposition to Disease;Humans;Mice;Signal Transduction;Tumor Suppressor Protein p14ARF;Tumor Suppressor Protein p53;Ubiquitin;Ubiquitination",
        "Doc_meshqualifiers":"physiology;genetics;metabolism;physiology;genetics;metabolism;genetics;metabolism;metabolism",
        "_version_":1605756252468543488},
      {
        "Doc_abstract":"Tobacco and alcohol use are established risk factors for head and neck squamous cell carcinoma (HNSCC). However, patients with a unique subset of human papilloma virus (HPV)-associated HNSCC have been documented to have a better survival outcome. These tumors occur more frequently in the tonsils and oropharyngeal sites, among younger patients, higher socioeconomic group, and those exposed to more sexual partners and oral sex compared with HPV-negative HNSCC. Although tobacco- and alcohol-related HNSCCs appear to be on the decline, tonsillar and oropharyngeal HPV-associated tumors seem to be on the rise, and their prevalence varies widely in published reports, ranging from 20% to 60%. Human papilloma virus detection methods in tumor tissue vary and include polymerase chain reaction, in situ hybridization (ISH) technique for HPV DNA, and E6/E7 messenger RNA, with p16 immunohistochemistry (IHC) as a surrogate marker. The sensitivity and specificity of the different methods used are likely contributory factors to this wide variation. This study compares the p16 IHC staining patterns in HNSCC and laryngeal papillomas and assesses the concordance of p16 and high-risk HPV-ISH to determine the usefulness of p16 as a first-line marker. Using an objective criterion of diffuse intense confluent staining pattern as definite positive (akin to the 3+ of HER2/neu in breast cancer) and focal scattered staining pattern as equivocal reaction requiring confirmatory HPV assay, p16 IHC expression shows good concordance with high-risk HPV-ISH and can be used as a first-line marker. We propose p16 overexpression as a suitable surrogate and screening marker, with high potential of impacting the standard of care.",
        "Doc_title":"Is p16 immunohistochemistry a more cost-effective method for identification of human papilloma virus-associated head and neck squamous cell carcinoma?",
        "Journal":"Annals of diagnostic pathology",
        "Do_id":"22197546",
        "Doc_ChemicalList":"Biomarkers, Tumor;Cyclin-Dependent Kinase Inhibitor p16",
        "Doc_meshdescriptors":"Biomarkers, Tumor;Carcinoma, Squamous Cell;Cyclin-Dependent Kinase Inhibitor p16;Head and Neck Neoplasms;Humans;Immunohistochemistry;Papillomavirus Infections;Sensitivity and Specificity",
        "Doc_meshqualifiers":"analysis;diagnosis;metabolism;virology;analysis;biosynthesis;diagnosis;metabolism;virology;complications;diagnosis;metabolism",
        "_version_":1605746301636444160},
      {
        "Doc_abstract":"Promoter hypermethylation is one of the major mechanisms in the transcriptional inactivation of certain carcinoma-associated genes. Concurrent methylation analysis of multiple, functionally distinct genes may provide important information on their differential alterations and potential association in head and neck squamous carcinogenesis.;Methylation-specific PCR analysis of the CpG islands of 8 cancer-related genes was performed on 19 cell lines and 32 primary head and neck squamous cell carcinoma (HNSC) specimens with matched histologically normal mucosa and 6 dysplastic lesions. The methylation status and histological features of the specimens were investigated.;In histologically normal squamous mucosa, no to low-level methylation (0-22%) was noted in some specimens at all genes except RARbeta2 (50%). Considerable variation in the incidence of methylation of these genes within and between cell lines and tumor specimens was noted. The highest incidences of methylation in the cell lines and primary tumors were noted in RARbeta2 (53%), MGMT (37%), p16 (33%), and DAP-K (25%); low incidence of methylations were noted in E-cadherin (2%), p73 (2%) RASSF1A (10%), and p14 (20%) genes. The incidences of methylation of each gene were almost similar between the HNSC cell lines and primary cancer specimens, although methylation of RASSF1A was observed in cell line (26%), but not in dysplasia and primary tumor. RARbeta, p16, and MGMT genes showed the highest incidences of methylation in premalignant and invasive carcinomas.;Methylation of p16, RARbeta, and MGMT may constitute early events in HNSC tumorigenesis. The infrequent methylation at certain genes suggests a minimal role for this feature in their functional assessment in HNSC. The variability within and between cell lines and tumor specimens supports a heterogeneous and dynamic state of methylation in genes associated with HNSC tumorigenesis.",
        "Doc_title":"Differential methylation status of tumor-associated genes in head and neck squamous carcinoma: incidence and potential implications.",
        "Journal":"Clinical cancer research : an official journal of the American Association for Cancer Research",
        "Do_id":"15173091",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Carcinoma, Squamous Cell;Cell Differentiation;Cell Line, Tumor;CpG Islands;DNA Methylation;Female;Head and Neck Neoplasms;Humans;Lymphatic Metastasis;Male;Middle Aged;Neoplasm Metastasis;Polymerase Chain Reaction;Promoter Regions, Genetic",
        "Doc_meshqualifiers":"genetics;genetics",
        "_version_":1605891886060404736},
      {
        "Doc_abstract":"Combining information derived from cellular biomarkers as telomerase and genes encoding cyclin dependent kinase inhibitors (p16(INK4a) and p15(INK4b)) is needed to facilitate the stratification of individual patients within the conventional clinicopathologic parameters.;One hundred forty laryngeal squamous cell carcinoma (LSCC) tissue specimens were investigated for telomerase activity and the deletions of p16(INK4a) and p15(INK4b) genes.;Of the 140 tissues assayed, 71% demonstrated high telomerase activity, 68.6% and 80% showed deletions in p16(INK4a) and p15(INK4b) genes, respectively. Significant difference was observed between telomerase activity, p16(INK4a) and p15(INK4b) deletions among each other and with advanced stage, poorly differentiated grades, high proliferation and DNA aneuploidy. The markers and the aforementioned clinicopathological factors were correlated with progression in univariate analysis; and associated with survival in multivariate analysis.;Progression of LSCC is accompanied by a parallel increase in telomerase activity and deletions in cell-cycle regulators (p16(INK4a), p15(INK4b)) which may assist in prognostication and better classification of patients for treatment.",
        "Doc_title":"Prognostic value of cell-cycle regulators and cellular biomarkers in laryngeal squamous cell carcinoma.",
        "Journal":"Clinical biochemistry",
        "Do_id":"18602381",
        "Doc_ChemicalList":"Biomarkers, Tumor;Cyclin-Dependent Kinase Inhibitor p15;Cyclin-Dependent Kinase Inhibitor p16;Telomerase",
        "Doc_meshdescriptors":"Adolescent;Adult;Aged;Aged, 80 and over;Biomarkers, Tumor;Carcinoma, Squamous Cell;Combined Modality Therapy;Cyclin-Dependent Kinase Inhibitor p15;Cyclin-Dependent Kinase Inhibitor p16;Disease Progression;Female;Gene Deletion;Humans;Laryngeal Neoplasms;Male;Middle Aged;Prognosis;Regression Analysis;Risk Factors;Survival Analysis;Telomerase",
        "Doc_meshqualifiers":"analysis;diagnosis;therapy;genetics;genetics;diagnosis;therapy;metabolism",
        "_version_":1605844797309845504},
      {
        "Doc_abstract":"To study the diagnostic value of p16(INK4a) in squamous intraepithelial lesion in gynecologic cytology and its relationship with types of human papillomavirus (HPV).;88 liquid-based gynecologic cytology cases with histologic correlation, including 20 cases of cervicitis, 18 cases of low-grade squamous intraepithelial lesion (LSIL), 34 cases of high-grade squamous intraepithelial lesion (HSIL) and 16 cases of squamous cell carcinoma (SCC), were enrolled into the study. Immunocytochemistry for p16(INK4a) protein and polymerase chain reaction-based HPV DNA testing (for HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66 and 68, as well as HPV types 6, 11, 42, 43 and 44) were performed.;The rate of expression of p16(INK4a) protein was 0, 27.8%, 100% and 100% in the cervicitis group, LSIL group, HSIL group and SCC group, respectively. The expression was significantly higher in the latter 3 groups than that in the cervicitis group (P < 0.01). Besides, the expression was significantly higher in cases associated with high-risk HPV genotypes (96.4%) than in cases associated with low-risk HPV genotypes (7.7%).;p16(INK4a) is a valuable biomarker for detection of HPV-related dysplastic squamous cells, with high sensitivity and specificity.",
        "Doc_title":"[Diagnostic value of p16INK4a in squamous intraepithelial lesion in gynecologic cytology].",
        "Journal":"Zhonghua bing li xue za zhi = Chinese journal of pathology",
        "Do_id":"17980098",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16",
        "Doc_meshdescriptors":"Carcinoma, Squamous Cell;Cervical Intraepithelial Neoplasia;Cyclin-Dependent Kinase Inhibitor p16;Diagnosis, Differential;Female;Genotype;Humans;Immunohistochemistry;Papillomaviridae;Papillomavirus Infections;Polymerase Chain Reaction;Sensitivity and Specificity;Uterine Cervical Dysplasia;Uterine Cervical Neoplasms;Uterine Cervicitis",
        "Doc_meshqualifiers":"diagnosis;metabolism;virology;diagnosis;metabolism;virology;metabolism;genetics;isolation & purification;diagnosis;metabolism;virology;diagnosis;metabolism;virology;diagnosis;metabolism;virology",
        "_version_":1605742674991644674},
      {
        "Doc_abstract":"Squamous cell carcinoma of the head and neck, particularly basaloid squamous cell carcinoma, may be difficult to distinguish from high-grade adenoid cystic carcinoma. Evidence of human papilloma virus (HPV) infection, particularly HPV 16, is frequently found in non-keratinizing oropharyngeal squamous cell carcinoma. Immunoreactivity for p16, a surrogate marker for HPV infection, often parallels the HPV infection status in oropharyngeal squamous cell carcinoma. However, the incidence and correlation between p16 expression and HPV infection in high-grade adenoid cystic carcinoma is unknown. Sixteen cases of high-grade adenoid cystic carcinoma, three cases of dedifferentiated adenoid cystic carcinoma and eight cases of low-/intermediate-grade adenoid cystic carcinoma were identified for inclusion in the study. All cases were tested by immunohistochemistry for p16 expression and in situ hybridization for high- and low-risk HPV. Eight cases (100%) of low-to-intermediate-grade adenoid cystic carcinoma were focally positive for p16, all of which were negative for HPV. In all, 14 of 16 cases (88%) of high-grade adenoid cystic carcinoma and three cases (100%) of dedifferentiated adenoid cystic carcinoma were positive for p16; strong and diffuse staining was noted in three cases (3 of 19, 16%). Two cases (11%) of high-grade adenoid cystic carcinoma, which were also diffusely positive for p16, showed the presence of high-risk HPV. These findings suggest that the presence of HPV infection in high-grade adenoid cystic carcinoma is infrequent, even in the presence of p16 immunostaining. Nevertheless, HPV positivity should not be used to exclude the possibility of high-grade adenoid cystic carcinoma when the differential diagnosis includes squamous cell carcinoma. Moreover, although p16 overexpression is often used as a surrogate marker for HPV in squamous cell carcinoma, it cannot be used in this manner in high-grade adenoid cystic carcinoma.",
        "Doc_title":"Detection of human papilloma virus and p16 expression in high-grade adenoid cystic carcinoma of the head and neck.",
        "Journal":"Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc",
        "Do_id":"22157933",
        "Doc_ChemicalList":"Biomarkers, Tumor;Cyclin-Dependent Kinase Inhibitor p16;DNA, Viral",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Biomarkers, Tumor;Carcinoma, Adenoid Cystic;Cell Differentiation;Cyclin-Dependent Kinase Inhibitor p16;DNA, Viral;Female;Head and Neck Neoplasms;Human papillomavirus 16;Humans;Immunohistochemistry;In Situ Hybridization;Male;Middle Aged;Minnesota;Neoplasm Grading;Papillomavirus Infections;Predictive Value of Tests;Prognosis;Time Factors;Up-Regulation",
        "Doc_meshqualifiers":"analysis;chemistry;mortality;pathology;virology;analysis;isolation & purification;chemistry;mortality;pathology;virology;genetics;isolation & purification;complications;mortality;virology",
        "_version_":1605742102596026368},
      {
        "Doc_abstract":"During malignant transformation in skin, epidermal keratinocytes (KCs) frequently acquire the capacity to by-pass cellular senescence, a response that normally limits their unrestricted proliferation. Despite growing interest in the role for senescence during aging of skin and cutaneous carcinogenesis, little is known regarding regulation of three proteins encoded by the INK4a/ARF locus (p12, p14(ARF), p16) in KCs. In this study, several molecular pathways are explored using cultured KCs and KCs freshly isolated from psoriatic plaques. p16 and p14(ARF) are predominantly expressed spontaneously when foreskin-derived early-passage KCs undergo confluency-induced premature senescence. Induction of p14(ARF) on confluency occurred with low E2F-1 levels. Suspension of KCs in methylcellulose induced p12 expression. Addition of various cytokines (interferon-gamma, tumor necrosis factor-alpha) or a phorbol ester [12-O-tetradecanoylphorbol-13-acetate (TPA)] only induced p16, but not p14(ARF). Confluent KCs up-regulated Ras activity and the downstream signaling involving ERK. Addition of MAPK inhibitor blocked cytokine and TPA-induced p16 expression. Confluency and interferon-gamma induced premature senescence and p16 expression was linked to induction of the transcription factor Egr-1. KCs derived from chronic psoriatic plaques were characterized by enhanced p16, p14(ARF), and p12 expression accompanied by elevated Egr-1 levels. These results demonstrate that multiple and highly divergent stimuli can trigger the senescent checkpoint in human KCs with differential regulation of p16, p14(ARF), and p12. Although abnormal mitogenic signaling by oncogenic Ras is generally cited as being responsible for induction of premature senescence, our findings indicate that a broader perspective is warranted, to include confluency and cytokine-/TPA-induced pathways for KCs.",
        "Doc_title":"Role of INK4a/Arf locus-encoded senescent checkpoints activated in normal and psoriatic keratinocytes.",
        "Journal":"The American journal of pathology",
        "Do_id":"12507899",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;Cytokines;DNA-Binding Proteins;EGR1 protein, human;Early Growth Response Protein 1;Enzyme Inhibitors;Immediate-Early Proteins;Transcription Factors;Tumor Suppressor Protein p14ARF;Methylcellulose;Mitogen-Activated Protein Kinases;ras Proteins;Tetradecanoylphorbol Acetate",
        "Doc_meshdescriptors":"Cell Aging;Cell Division;Cells, Cultured;Cyclin-Dependent Kinase Inhibitor p16;Cytokines;DNA-Binding Proteins;Early Growth Response Protein 1;Enzyme Inhibitors;Gene Expression Regulation;Genes, Reporter;Genes, cdc;Humans;Immediate-Early Proteins;Keratinocytes;Methylcellulose;Mitogen-Activated Protein Kinases;Psoriasis;Reference Values;Signal Transduction;Tetradecanoylphorbol Acetate;Transcription Factors;Transfection;Tumor Suppressor Protein p14ARF;ras Proteins",
        "Doc_meshqualifiers":"physiology;drug effects;genetics;biosynthesis;genetics;pharmacology;biosynthesis;genetics;pharmacology;drug effects;physiology;drug effects;metabolism;pathology;pharmacology;metabolism;genetics;metabolism;pathology;drug effects;physiology;pharmacology;biosynthesis;genetics;biosynthesis;genetics;metabolism",
        "_version_":1605757205401829376},
      {
        "Doc_abstract":"Genetic alterations of p14ARF contribute to dysfunction of p53 pathways by disruption of MDM2-mediated inhibition of p53. P14(ARF) was investigated by focusing on the homozygous deletion (HD) in the INK4a/ARF locus and hypermethylation of the p14(ARF) promoter in renal cell cancer (RCC).;Using 6 RCC cell lines, RT-PCR and Western blotting was performed for p14(ARF). DNA from 34 RCCs was analyzed for HD in the INK4a/ARF locus, promoter hypermethylation and p53 gene mutation.;HD was confirmed in 4 out of 6 cell lines and in 8 out of 34 (23.5%) RCC specimens, which correlated with the presence of metastasis, high tumor grade and had a tendency to more advanced stage (I vs. II-IV). No hypermethylation of the p14(ARF) promoter or p53 mutation was detected among the RCC specimens.;These results indicate that the deletion in the INK4a/ARF locus might contribute to tumor progression in RCC at least partly by functional inactivation of wild-type p53.",
        "Doc_title":"Homozygous deletions of the INK4a/ARF locus in renal cell cancer.",
        "Journal":"Anticancer research",
        "Do_id":"17201148",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;DNA Primers",
        "Doc_meshdescriptors":"Base Sequence;Carcinoma, Renal Cell;Cyclin-Dependent Kinase Inhibitor p16;DNA Methylation;DNA Primers;Gene Deletion;Homozygote;Humans;Kidney Neoplasms;Reverse Transcriptase Polymerase Chain Reaction",
        "Doc_meshqualifiers":"genetics;genetics;genetics",
        "_version_":1605818650430799874},
      {
        "Doc_abstract":"To detect the blood genomic DNA methylation in coke oven workers and find a possible early screening index for occupational lung cancer, 74 coke oven workers as the exposed group and 47 water pump workers as the controls were surveyed, and urine samples and peripheral blood mononuclear cells (PBMCs) were collected. Airborne benzo[a]pyrene (B[a]P) levels in workplace and urinary 1-hydroxypyrene (1-OH-Py) levels were determined by high-performance liquid chromatography. DNA damage of PBMCs and the p14(ARK), p15(INK4b) and p16(INK4a) gene CpG island methylation in the promoter region were detected by comet assay and methylation-specific polymerase chain reaction techniques, respectively. Results show that compared with the controls, concentration of airborne B[a]Ps was elevated in the coke plant, and urinary 1-OH-Py's level and DNA olive tail moment in comet assay were significantly increased in the coke oven workers, and p14(ARK), p15(INK4b) and p16(INK4a) gene methylation rates were also significantly increased. With the working years and urinary 1-OH-Py's level, the rates of p14(ARK) and p16(INK4a) gene methylation were significantly increased while that of p15(INK4b) gene methylation displayed no statistical change. We conclude that PBMCs' p14(ARK) and p16(INK4a) gene methylation may be used for screening and warning lung cancer in coke oven workers. ",
        "Doc_title":"Methylation of CpG island of p14(ARK), p15(INK4b) and p16(INK4a) genes in coke oven workers.",
        "Journal":"Human & experimental toxicology",
        "Do_id":"24837742",
        "Doc_ChemicalList":"Air Pollutants, Occupational;Coke;Cyclin-Dependent Kinase Inhibitor p15;Cyclin-Dependent Kinase Inhibitor p16;Pyrenes;Tumor Suppressor Protein p14ARF;Benzo(a)pyrene;1-hydroxypyrene",
        "Doc_meshdescriptors":"Adult;Air Pollutants, Occupational;Benzo(a)pyrene;Coke;CpG Islands;Cyclin-Dependent Kinase Inhibitor p15;Cyclin-Dependent Kinase Inhibitor p16;DNA Damage;Environmental Monitoring;Humans;Male;Methylation;Occupational Exposure;Pyrenes;Tumor Suppressor Protein p14ARF",
        "Doc_meshqualifiers":"analysis;analysis;genetics;genetics;analysis;urine;genetics",
        "_version_":1605783629166804992},
      {
        "Doc_abstract":"Epidemiologic studies have provided evidence of an alcohol-associated increased risk of upper aerodigestive tract cancers. Recently we reported ethanol-induced proliferation in a squamous cell carcinoma of the head and neck (SCCHN) cell line, but the underlying mechanisms are unknown. In order to further clarify these findings, major G0/G1-regulating proteins were investigated in the present study. Synchronized cells of a SCCHN line (JP-PA) and a human immortalized keratinocyte line (HaCaT)-used as a control-were cultured with or without 10(-3) M ethanol for up to 96 h. At distinct time intervals the expression of cyclin D1 and the inhibitors p16, p18, p19 and p21 were determined by Western blot analyses. In both lines ethanol had no influence on the protein expression of cyclin D1. In contrast, distinct downregulations of p21, p18 and p19 were detectable at the protein level. The p16 protein was not expressed in the SCCHN line and was unchanged in the control line after the addition of ethanol. In these in vitro experiments the marked downregulation of important cell-cycle inhibitors may accelerate progression from the G1 to the S phase of the cell cycle. The relevance of our findings to in vivo conditions remains speculative, but the observed mechanisms of significantly reduced expression of cell-cycle inhibitor proteins may be involved in the carcinogenesis of head and neck malignancies.",
        "Doc_title":"Ethanol decreases negative cell-cycle-regulating proteins in a head and neck squamous cell carcinoma cell line.",
        "Journal":"Acta oto-laryngologica",
        "Do_id":"12030586",
        "Doc_ChemicalList":"CDKN1A protein, human;Cyclin-Dependent Kinase Inhibitor p16;Cyclin-Dependent Kinase Inhibitor p21;Cyclins;Enzyme Inhibitors;Cyclin D1;Ethanol;Cyclin-Dependent Kinases",
        "Doc_meshdescriptors":"Blotting, Western;Carcinoma, Squamous Cell;Cell Cycle;Cell Line;Cyclin D1;Cyclin-Dependent Kinase Inhibitor p16;Cyclin-Dependent Kinase Inhibitor p21;Cyclin-Dependent Kinases;Cyclins;Down-Regulation;Enzyme Inhibitors;Ethanol;Flow Cytometry;Head and Neck Neoplasms;Humans;In Vitro Techniques;Tumor Cells, Cultured",
        "Doc_meshqualifiers":"pathology;metabolism;metabolism;metabolism;metabolism;metabolism;pharmacology;pathology",
        "_version_":1605741979302363136},
      {
        "Doc_abstract":"In the present study, we comprehensively analyzed the prevalence of transcriptionally active human papilloma virus (HPV) in tissue samples of Indian patients with leukoplakia, predominantly hyperplastic lesions and head and neck squamous cell carcinoma (HNSCC). In addition, saliva samples from patients with HNSCC were screened for HPV detection.;P16 overexpression was analyzed by immunohistochemistry. Tissue samples of leukoplakia (n=121) and HNSCC (n=427) and saliva from patients with HNSCC (n=215) were tested for HPV using nested polymerase chain reaction. Positive samples were sequenced for subtyping. The presence of HPV E6/E7 mRNA was confirmed by RNA in situ hybridization.;P16 expression and HPV DNA were not detected in any of the leukoplakia specimens. Of the 427 HNSCC tumors, 9 showed p16 overexpression and 7/427 cases were positive for HPV16 DNA, in saliva or tissue. E6/E7 mRNA positivity was observed in 8 HNSCC samples, primarily from patients with no habit of tobacco consumption. The prevalence of high-risk HPV was restricted to oropharynx and larynx, with very little concordance between p16 overexpression and HPV positivity. All patients with HPV-positive saliva samples had transcriptionally active HPV present in their tumors.;The presence of HPV DNA does not necessarily reflect transcriptionally active virus in tumors; hence, it is important to consider this fact while categorizing HPV-associated tumors.",
        "Doc_title":"Low prevalence of transcriptionally active human papilloma virus in Indian patients with HNSCC and leukoplakia.",
        "Journal":"Oral surgery, oral medicine, oral pathology and oral radiology",
        "Do_id":"27765330",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605756815980625920},
      {
        "Doc_abstract":"In this study, we examined the expression of cyclins, cyclin dependent kinase (CDKs) and CDK inhibitors by immunohistochemical analysis in 20 normal mucosa, 42 epithelial dysplasia (ED), and 117 oral squamous cell carcinoma. Neither Cyclin D1 nor CDK2 were detectable in normal tissue and ED. Their presence, however, was detectable in squamous cell carcinoma (SCCs) (Cyclin D1, 35.9%; CDK2, 66.7%). Cyclin E was detectable in 57.1% of severe ED and 62.8% of SCCs. For the CDK inhibitors, these proteins were detectable in all normal mucosa and most of the mild and moderate ED. For severe ED, expression of these proteins was not observed in some cases (p12(DOC-1), 14.3%; p16(INK4A), 28.6%; p27(KIP1), 7.1%). For SCCs, the expression of p12(DOC-1) was lost in 71.8%, p16(INK4A) in 69.2% and p27(KIP1) in 35.9%. These results suggest that elevated expression of cyclin D1, cyclin E, CDK2 and loss of p12(DOC-1), p16(INK4A) and p27(KIP1) may contribute to the multistep nature of oral carcinogenesis.",
        "Doc_title":"Expression of cell cycle control proteins in normal epithelium, premalignant and malignant lesions of oral cavity.",
        "Journal":"Oral oncology",
        "Do_id":"11978545",
        "Doc_ChemicalList":"Biomarkers, Tumor;CDK2AP1 protein, human;CDKN1B protein, human;Carrier Proteins;Cell Cycle Proteins;Cyclin E;Cyclin-Dependent Kinase Inhibitor p16;Intracellular Signaling Peptides and Proteins;Tumor Suppressor Proteins;Cyclin D1;Cyclin-Dependent Kinase Inhibitor p27;Protein-Serine-Threonine Kinases;CDC2-CDC28 Kinases;CDK2 protein, human;Cyclin-Dependent Kinase 2;Cyclin-Dependent Kinases",
        "Doc_meshdescriptors":"Biomarkers, Tumor;Blotting, Western;CDC2-CDC28 Kinases;Carcinoma, Squamous Cell;Carrier Proteins;Cell Cycle Proteins;Cyclin D1;Cyclin E;Cyclin-Dependent Kinase 2;Cyclin-Dependent Kinase Inhibitor p16;Cyclin-Dependent Kinase Inhibitor p27;Cyclin-Dependent Kinases;Epithelium;Humans;Immunohistochemistry;Intracellular Signaling Peptides and Proteins;Mouth Mucosa;Mouth Neoplasms;Precancerous Conditions;Protein-Serine-Threonine Kinases;Tumor Suppressor Proteins",
        "Doc_meshqualifiers":"analysis;chemistry;analysis;analysis;analysis;analysis;analysis;analysis;chemistry;chemistry;chemistry;chemistry;analysis;analysis",
        "_version_":1605797574853263360},
      {
        "Doc_abstract":"We assessed the frequency of genomic deletion of p16INK4A (CDKN2A) in synovial sarcomas (SSs) and its possible association with immunoexpression of p16 and cyclin D1 and the Ki-67 proliferation index using dual-color fluorescence in situ hybridization (FISH) on tissue microarray sections of 41 histologically and molecularly confirmed SSs. A heterozygous p16INK4A gene deletion was identified in 28 (74%) of 38 cases, with 25 (89%) of them showing abnormal p16 protein expression (20 negative and 5 heterogeneous). Of 25 cases, 19 (76%) exhibiting increased cyclin D1expression also demonstrated heterozygous p16INK4A deletion. No significant association was observed between p16INK4A deletion and Ki-67 proliferation index, tumor grade, or histologic subtype. Our results demonstrate that p16INK4A (CDKN2A) gene deletion is a frequent genetic event in SS.",
        "Doc_title":"p16INK4A (CDKN2A) gene deletion is a frequent genetic event in synovial sarcomas.",
        "Journal":"American journal of clinical pathology",
        "Do_id":"17074682",
        "Doc_ChemicalList":"Biomarkers, Tumor;Cyclin D;Cyclin-Dependent Kinase Inhibitor p16;Cyclins;Ki-67 Antigen",
        "Doc_meshdescriptors":"Biomarkers, Tumor;Cell Nucleus;Cyclin D;Cyclin-Dependent Kinase Inhibitor p16;Cyclins;Gene Deletion;Heterozygote;Humans;Immunohistochemistry;In Situ Hybridization, Fluorescence;Ki-67 Antigen;Sarcoma, Synovial;Soft Tissue Neoplasms;Tissue Array Analysis",
        "Doc_meshqualifiers":"metabolism;metabolism;pathology;genetics;metabolism;metabolism;metabolism;genetics;metabolism;pathology;genetics;metabolism;pathology",
        "_version_":1605752725783445504},
      {
        "Doc_abstract":"The INK4A/ARF locus yields two tumor suppressors, p16INK4A and p14ARF, and is frequently deleted in human tumors. We studied their mRNA expressions in 41 hematopoietic cell lines and in 137 patients with hematological malignancies; we used a quantitative reverse transcription-PCR assay. Normal peripheral bloods, bone marrow and lymph nodes expressed little or undetectable p16INK4A and p14ARF mRNAs, which were readily detected in 12 and 17 of 41 cell lines, respectively. Patients with hematological malignancies frequently lacked p16INK4A expression (60/137) and lost p14ARF expression less frequently (19/137, 13.9%). Almost all patients without p14ARF expression lacked p16INK4A expression, which may correspond to deletions of the INK4A/ARF locus. Undetectable p16INK4A expression with p14ARF expression in 41 patients may correspond to p16INK4A promoter methylation or to normal expression status of the p16INK4A gene. All patients with follicular lymphoma (FL), myeloma or acute myeloid leukemia (AML) expressed p14ARF while nine of 23 patients with diffuse large B cell lymphoma (DLBCL) lost p14ARF expression. Patients with ALL, AML or blast crisis of chronic myelogenous leukemia expressed abundant p16INK4A mRNAs more frequently than patients with other diseases (12/33 vs 6/104, P < 0.01). Patients with FL and high p14ARF expression had a significantly shorter survival time while survival for patients with DLBCL and increased p14ARF expression tended to be longer. These observations indicate that p16INK4A and p14ARF expression is differentially affected among hemato- logical malignancies and that not only inactivation but also increased expression may have clinical significance.",
        "Doc_title":"Expression of p16INK4A and p14ARF in hematological malignancies.",
        "Journal":"Leukemia",
        "Do_id":"10557050",
        "Doc_ChemicalList":"Proteins;RNA, Messenger;Retinoblastoma Protein;Tumor Suppressor Protein p14ARF;Cyclin D1",
        "Doc_meshdescriptors":"Adolescent;Adult;Aged;Aged, 80 and over;Bone Marrow;Cyclin D1;DNA Methylation;Female;Gene Expression;Gene Expression Regulation, Neoplastic;Genes, p16;Hematologic Neoplasms;Humans;Lymph Nodes;Lymphoma, Follicular;Male;Middle Aged;Prognosis;Proteins;RNA, Messenger;Retinoblastoma Protein;Reverse Transcriptase Polymerase Chain Reaction;Tumor Cells, Cultured;Tumor Suppressor Protein p14ARF",
        "Doc_meshqualifiers":"metabolism;genetics;genetics;blood;diagnosis;genetics;mortality;metabolism;blood;diagnosis;genetics;mortality;genetics;analysis;genetics;analysis;genetics",
        "_version_":1605796293749243904},
      {
        "Doc_abstract":"Patients with head and neck squamous cell carcinoma (HNSCC) often come to clinical attention with a neck mass due to metastatic spread to lymph nodes. Treatment is dictated by the subsequent determination of primary tumor site and stage. However, the primary site remains elusive in some patients even after an exhaustive examination. Human papillomavirus type 16 (HPV-16) is an important etiologic agent for HNSCCs that arise within the oropharynx but less so for tumors from nonoropharyngeal sites. Detection of HPV-16 or a surrogate marker may be useful in localizing tumor origin in patients who present with metastatic HNSCC.;We performed in situ hybridization (ISH) for HPV-16 on lymph node metastases from 68 patients with HNSCC. P16 immunohistochemistry was also performed because HPV-16 integration disrupts the retinoblastoma pathway and induces an overexpression of p16.;HPV-16 was detected in 22 of the 68 (32%) cases by ISH. When stratified by site of origin, HPV-16 was detected in 22 of 31 (71%) metastases from the oropharynx, but in none of the 37 (0%) metastases from other sites (P < 0.001; Fisher's exact). P16 expression was associated with the presence of HPV-16 by ISH: 21 of 22 HPV-16 positive tumors exhibited p16 expression, whereas only 4 of the 46 HPV-16-negative tumors were p16 positive (95% versus 9%; P < 0.001; Fisher's exact). P16 expression in the node metastases also correlated with site of tumor origin: 24 of 31 oropharyngeal tumors were p16 positive, whereas only 1 of 37 nonoropharyngeal tumors was p16 positive (77% versus 3%; P < 0.001; Fisher's exact).;For patients with metastatic HNSCC, detection of HPV-16 is a reliable way to establish origin from the oropharynx, either directly by ISH or indirectly by immunohistochemistry for p16 overexpression.",
        "Doc_title":"Detection of human papillomavirus in cervical lymph nodes: a highly effective strategy for localizing site of tumor origin.",
        "Journal":"Clinical cancer research : an official journal of the American Association for Cancer Research",
        "Do_id":"14695150",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Carcinoma, Squamous Cell;Cervix Uteri;Female;Head and Neck Neoplasms;Humans;Immunohistochemistry;In Situ Hybridization;Lymph Nodes;Lymphatic Metastasis;Neoplasm Metastasis;Papillomaviridae",
        "Doc_meshqualifiers":"metabolism;metabolism;virology;metabolism;metabolism;virology;metabolism",
        "_version_":1605825245688627200},
      {
        "Doc_abstract":"Senescent cells, which express p16 (INK4a) , accumulate with aging and contribute to age-related pathology. To understand whether cytotoxic agents promote molecular aging, we measured expression of p16 (INK4a) and other senescence markers in breast cancer patients treated with adjuvant chemotherapy.;Blood and clinical information were prospectively obtained from 33 women with stage I to III breast cancer at four time points: before anthracycline-based chemotherapy, immediately after anthracycline-based chemotherapy, 3 months after anthracycline-based chemotherapy, and 12 months after anthracycline-based chemotherapy. Expression of senescence markers p16 (INK4a) and ARF mRNA was determined using TaqMan quantitative reverse-transcription polymerase chain reaction in CD3(+) T lymphocytes, telomere length was determined by Southern analysis, and senescence-associated cytokines were determined by enzyme-linked immunosorbent assay. Findings were independently assessed in a cross-sectional cohort of 176 breast cancer survivors enrolled a median of 3.4 years after treatment; 39% previously received chemotherapy. All statistical tests were two-sided.;In prospectively analyzed patients, expression of p16 (INK4a) and ARF increased immediately after chemotherapy and remained elevated 12 months after treatment. Median increase in log2 p16 (INK4a) was 0.81 (interquartile range = 0.28-1.62; Wilcoxon signed-rank P < .001), or a 75% absolute increase in expression, equivalent to the increase observed over 14.7 years of chronological aging. ARF expression was comparably increased (P < .001). Increased expression of p16 (INK4a) and ARF was associated with dose-dense therapy and hematological toxicity. Expression of two senescence-associated cytokines (VEGFA and MCP1) was durably increased by adjuvant chemotherapy. Telomere length was not affected by chemotherapy. In a cross-sectional cohort, prior chemotherapy exposure was independently associated with a log2-increase in p16 (INK4a) expression of 0.57 (repeated measures model, P < .001), comparable with 10.4 years of chronological aging.;Adjuvant chemotherapy for breast cancer is gerontogenic, inducing cellular senescence in vivo, thereby accelerating molecular aging of hematopoietic tissues.",
        "Doc_title":"Effect of cytotoxic chemotherapy on markers of molecular age in patients with breast cancer.",
        "Journal":"Journal of the National Cancer Institute",
        "Do_id":"24681605",
        "Doc_ChemicalList":"Anthracyclines;Biomarkers;Cyclin-Dependent Kinase Inhibitor p16;Cytokines;ADP-Ribosylation Factors",
        "Doc_meshdescriptors":"ADP-Ribosylation Factors;Adult;Aged;Animals;Anthracyclines;Antineoplastic Combined Chemotherapy Protocols;Biomarkers;Breast Neoplasms;Cell Aging;Cross-Sectional Studies;Cyclin-Dependent Kinase Inhibitor p16;Cytokines;Female;Humans;Mice;Middle Aged;Neoplasm Staging;Prospective Studies;Reverse Transcriptase Polymerase Chain Reaction;T-Lymphocytes;Telomere",
        "Doc_meshqualifiers":"blood;administration & dosage;adverse effects;administration & dosage;adverse effects;blood;drug therapy;pathology;surgery;drug effects;blood;metabolism;metabolism",
        "_version_":1605747029622915074},
      {
        "Doc_abstract":"To determine the duration of expression of the cell cycle regulators p21 and p16 and the effect of these 2 genes both alone and in combination on the growth of squamous cell carcinoma of the head and neck cell lines in vitro. EXPERIMENTAL METHODS AND DESIGN: Cells were transduced via an adenoviral vector with p21 (Ad5CMV-p21), p16 (Ad5CMV-p16), or both. Western blotting was performed to determine duration of expression of the protein products of the transduced p21 and p16 genes. In vitro growth assays and cell cycle analyses were performed on transduced cells.;Transduced gene products were detected up to day 12 after infection. Western blotting showed high levels of p21 and p16 in transduced cells. Growth suppression was observed in squamous cell carcinoma of the head and neck cell lines transduced with Ad5CMV-p21, Ad5CMV-p16, or both, but the combination of p21 and p16 did not achieve significantly greater growth suppression than that seen in cells transduced with Ad5CMV-p16 alone. Cell cycle analysis demonstrated that the percentage of cells arrested at G1 stage in the cells transduced with Ad5CMV-p16 was similar to that in the cells transduced with both Ad5CMV-p21 and Ad5CMV-p16. No significant in vivo growth suppression was observed in tumor nodules treated with Ad5CMV-p16.;Although p21 and p16 are believed to function as cell cycle regulators of cyclin-dependent kinases, we observed no additive or synergistic effect when using them in combination. The expression of transduced p21 and p16 gene products up to days 9 and 12, respectively, was consistent with the growth suppression and cell cycle arrest observed. This work provides information on the previously uncharacterized duration of p21 and p16 transgene product expression and also lends insight into the interaction of these 2 cell cycle regulators in squamous cell carcinoma of the head and neck.",
        "Doc_title":"In vitro growth suppression by adenoviral transduction of p21 and p16 in squamous cell carcinoma of the head and neck: a research model for combination gene therapy.",
        "Journal":"Archives of otolaryngology--head & neck surgery",
        "Do_id":"9440786",
        "Doc_ChemicalList":"HRAS protein, human;Proto-Oncogene Proteins p21(ras)",
        "Doc_meshdescriptors":"Adenoviruses, Human;Animals;Carcinoma, Squamous Cell;Cell Cycle;Gene Expression Regulation, Neoplastic;Genes, p16;Genetic Therapy;Head and Neck Neoplasms;Humans;Mice;Mice, Nude;Proto-Oncogene Proteins p21(ras);Transduction, Genetic;Tumor Cells, Cultured",
        "Doc_meshqualifiers":"genetics;genetics;pathology;therapy;genetics;genetics;pathology;therapy",
        "_version_":1605827528489959424},
      {
        "Doc_abstract":"The cytotoxicity of 5-aza-2'-deoxycytidine (DAC) has been linked to demethylation of the INK4a/ARF tumor suppressor gene locus in various cell systems, but the causality of this association remains unproven. To test this assumption, we have examined the effects of DAC in two human cancer cell lines of differing INK4a/ARF promoter methylation status: MDA-MB-468 breast cancer cells in which INK4a/ARF is unmethylated and normally expressed, and DLD-1 colorectal cancer cells in which INK4a/ARF is methylated and repressed. In MDA-MB-468 cells, DAC induces cytotoxicity in the absence of any detectable increase of p14 or p16 expression, whereas small interfering RNA knockdown of p16/p14 expression fails to attenuate DAC cytotoxicity. In DLD-1 cells, DAC demethylates INK4a/ARF and restores both p16 and p14 expression at concentrations that fail to cause detectable growth inhibition or apoptosis; moreover, neither ARF nor INK4a transgene expression inhibits DLD-1 cell growth despite normalization of p14 and p16 expression. These data imply that neither of these cell lines depends on up-regulated expression of INK4a/ARF for DAC cytotoxicity. We propose that optimal anticancer use of this drug will await unambiguous identification of those DAC target genes primarily responsible for triggering growth inhibition, followed by clarification as to whether these upstream events are caused by hypomethylation or DNA damage.",
        "Doc_title":"Growth inhibition of human cancer cells by 5-aza-2'-deoxycytidine does not correlate with its effects on INK4a/ARF expression or initial promoter methylation status.",
        "Journal":"Molecular cancer therapeutics",
        "Do_id":"19372550",
        "Doc_ChemicalList":"Antimetabolites, Antineoplastic;Cyclin-Dependent Kinase Inhibitor p16;RNA, Messenger;Tumor Suppressor Protein p14ARF;decitabine;Azacitidine",
        "Doc_meshdescriptors":"Antimetabolites, Antineoplastic;Apoptosis;Azacitidine;Blotting, Western;Breast Neoplasms;Cell Cycle;Cell Proliferation;Colorectal Neoplasms;Cyclin-Dependent Kinase Inhibitor p16;DNA Methylation;Flow Cytometry;Gene Expression Regulation, Neoplastic;Humans;Polymerase Chain Reaction;Promoter Regions, Genetic;RNA, Messenger;Reverse Transcriptase Polymerase Chain Reaction;Tumor Suppressor Protein p14ARF",
        "Doc_meshqualifiers":"pharmacology;drug effects;analogs & derivatives;pharmacology;genetics;pathology;drug effects;drug effects;genetics;pathology;genetics;metabolism;physiology;genetics;genetics;metabolism;genetics;metabolism",
        "_version_":1605755667496304640},
      {
        "Doc_abstract":"The prognostic significance of human papillomavirus (HPV) in the context of head and neck squamous cell carcinoma (HNSCC) of cancer of unknown primary (CUP) origin is unclear.;Patients treated for CUP at the Princess Margaret Cancer Centre between 2001 and 2013 were stratified by p16 status and retrospectively reviewed.;Of the 73 patients included, those with p16-positive tumors (63%) had less advanced nodal status (N1-N2b; 52% vs 89%; p = .035) and less aggressive treatment. Patients with p16-positive tumors had improved 3-year disease-free survival (DFS; 79% vs 56%; p = .012) independent of nodal status and treatment in multivariable analysis (hazard ratio [HR] = 0.27; 95% confidence interval [CI] = 0.08-0.95).;Among patients with CUP, p16-positive status is an independent predictor of DFS but not overall survival (OS).  2016 Wiley Periodicals, Inc. Head Neck, 2016  2016 Wiley Periodicals, Inc. Head Neck 38: 1347-1353, 2016.",
        "Doc_title":"Impact of p16 expression, nodal status, and smoking on oncologic outcomes of patients with head and neck unknown primary squamous cell carcinoma.",
        "Journal":"Head & neck",
        "Do_id":"27002481",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605761223906820096},
      {
        "Doc_abstract":"Historically, head and neck squamous cell carcinoma (HNSCC) has been earmarked a lymphatic malignancy. Recently, this has been called into question. Our study aims to (1) illustrate the robust differences in distant metastases between p16+ and p16- oropharyngeal squamous cell carcinoma (OPSCC) and (2) provide support that p16+ OPSCC has a predilection toward vasculature invasion and hematogenous spread.;Multi-institutional, case series with chart review.;Four academic institutions.;Within a group of 1113 patients with primary OPSCC who received treatment between 1979 and 2013, those who developed distant metastasis (DM) were divided into 2 cohorts based on p16 status. Intergroup and intragroup univariate analysis was performed as well as descriptive analysis of end-organ sites.;Of the 1058 patients included, 89 developed DM. Thirty were p16- and 59 were p16+. Of the p16- patients with DM, only 10% had disseminated disease (distant metastases at 2 sites) compared with 74% of p16+ patients. Distant disease in p16+ patients included brain, abdomen, and a distinct pattern of pulmonary metastases.;Our large, multi-institutional study supports published reports that p16+ OPSCC metastasizes with a unique phenotype that is hematogenous and widely disseminated with atypical end-organ sites. Our data suggest that p16+ OPSCC has a predilection toward active vasculature invasion as evidenced by the results and illustrative radiologic and pathohistologic examples. These findings may have implications for future targeted therapy when treating p16+ OPSCC.",
        "Doc_title":"Robust Differences in p16-Dependent Oropharyngeal Squamous Cell Carcinoma Distant Metastasis: Implications for Targeted Therapy.",
        "Journal":"Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery",
        "Do_id":"25917669",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Carcinoma, Squamous Cell;Female;Human papillomavirus 16;Humans;Immunohistochemistry;Male;Middle Aged;Neoplasm Metastasis;Oropharyngeal Neoplasms;Retrospective Studies",
        "Doc_meshqualifiers":"pathology;virology;isolation & purification;pathology;pathology;virology",
        "_version_":1605880098538389504},
      {
        "Doc_abstract":"Actinic keratosis (AK) and Bowen's disease (squamous cell carcinoma in situ, SCCIS) are pre-invasive stages in the development of squamous cell carcinoma (SCC).;Immunohistochemical study of cyclin D1, cyclin E, p16(INK4a) and p21(Cip1) (/Waf1) in AK (53 cases), SCCIS (16 cases) and SCC (40 cases), in relation to the type of the lesion and SCC prognostic parameters (grade, diameter and thickness).;Diffuse cyclin D1 distribution was more frequent in SCCIS and SCC than in AK (p=0.03) and similar pattern was observed for p16(INK4a) . For cyclin E, central distribution dominated in SCC compared with the AK (p=0.001) and SCCIS (p=0.03). p21(Cip1) (/Waf1) displayed suprabasal distribution more frequently in AK than in SCCIS (p=0.001) and SCC (p=0.0004). Semiquantitative assessment showed more positive cells in AK (p=0.04) and SCCIS (p=0.04) than in SCC for cyclin E. SCC with diameter over 20mm and those thicker than 6mm revealed higher labeling index with p16(INK4a) and p21(Cip1) (/Waf1) , respectively.;Our results suggest different alterations for p16(INK4a) and p21(Cip1) (/Waf1) in AK, SCCIS and SCC. Immunostaining distribution showed closer correlation with the type of the lesion, whereas percentage of positive cells displayed better association with the SCC prognostic parameters.",
        "Doc_title":"Expression of G1/S-cyclins and cyclin-dependent kinase inhibitors in actinic keratosis and squamous cell carcinoma.",
        "Journal":"Journal of cutaneous pathology",
        "Do_id":"26349899",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605755065143918592},
      {
        "Doc_abstract":"The human ARF/INK4a locus encodes two cell cycle inhibitors, p16(INK4a) and p14(ARF), by using separate promoters. A variety of mitogenic stimuli upregulate ARF but a direct modulation at the transcriptional level has been reported only for E2F-1. We show here that the ARF promoter is strongly responsive also to E2F2 and E2F3, thus providing a strong support to their suggested role in the induction of apoptosis. Through the usage of both deletion mutants and/or site-directed mutants, we surprisingly found that none of the four putative E2F consensus sites is strictly necessary for the upregulation of ARF expression, as a minimal deletion mutant, lacking all the putative E2F binding sites, is still transactivated by E2F. Moreover, our data suggest that the ARF promoter is regulated by E2F through both direct binding to the promoter sequences and indirectly, probably by being tethered to the ARF promoter by Sp1-like factors.",
        "Doc_title":"Transcriptional regulation of the human tumor suppressor p14(ARF) by E2F1, E2F2, E2F3, and Sp1-like factors.",
        "Journal":"Biochemical and biophysical research communications",
        "Do_id":"11883935",
        "Doc_ChemicalList":"Cell Cycle Proteins;DNA-Binding Proteins;E2F Transcription Factors;E2F1 Transcription Factor;E2F1 protein, human;E2F2 Transcription Factor;E2F2 protein, human;E2F3 Transcription Factor;E2F3 protein, human;E2f1 protein, mouse;E2f3 protein, mouse;Sp1 Transcription Factor;Transcription Factors;Tumor Suppressor Protein p14ARF",
        "Doc_meshdescriptors":"3T3 Cells;Animals;Apoptosis;Binding Sites;Cell Cycle Proteins;Cell Line;DNA-Binding Proteins;E2F Transcription Factors;E2F1 Transcription Factor;E2F2 Transcription Factor;E2F3 Transcription Factor;HeLa Cells;Humans;Mice;Promoter Regions, Genetic;Sp1 Transcription Factor;Transcription Factors;Transcription, Genetic;Transcriptional Activation;Tumor Suppressor Protein p14ARF",
        "Doc_meshqualifiers":"physiology;physiology;physiology;genetics",
        "_version_":1605807903510364161},
      {
        "Doc_abstract":"The INK4b-ARF-INK4a locus encodes two members of the INK4 family of cyclin-dependent kinase inhibitors, p15(INK4b) and p16(INK4a), and a completely unrelated protein, known as ARF. All three products participate in major tumour suppressor networks that are disabled in human cancer and influence key physiological processes such as replicative senescence, apoptosis and stem-cell self-renewal. Transcription from the locus is therefore kept under strict control. Mounting evidence suggests that although the individual genes can respond independently to positive and negative signals in different contexts, the entire locus might be coordinately suppressed by a cis-acting regulatory domain or by the action of Polycomb group repressor complexes.",
        "Doc_title":"Regulation of the INK4b-ARF-INK4a tumour suppressor locus: all for one or one for all.",
        "Journal":"Nature reviews. Molecular cell biology",
        "Do_id":"16921403",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p15;Cyclin-Dependent Kinase Inhibitor p16;Polycomb-Group Proteins;Repressor Proteins;ADP-Ribosylation Factors",
        "Doc_meshdescriptors":"ADP-Ribosylation Factors;Animals;Apoptosis;Cell Aging;Cyclin-Dependent Kinase Inhibitor p15;Cyclin-Dependent Kinase Inhibitor p16;Gene Expression Regulation;Humans;Polycomb-Group Proteins;Quantitative Trait Loci;Repressor Proteins;Signal Transduction;Stem Cells",
        "Doc_meshqualifiers":"genetics;genetics;genetics;genetics;genetics;genetics;genetics;genetics;genetics;physiology",
        "_version_":1605788966156500992},
      {
        "Doc_abstract":"There are approximately 200,000 new cases of cutaneous squamous cell carcinoma diagnosed each year in the United States, with between 1300 and 2300 deaths per year from metastatic disease. The tumor suppressor p16, encoded by the CDKN2/INK4a locus, has been reported mutated in >or=24% of squamous cell carcinomas. Mutations of the p16 gene have also been found in actinic keratoses, the first identifiable lesion in the continuum from normal skin to squamous cell carcinoma. We hypothesized that there may be an appreciable difference in expression of p16 between normal skin, actinic keratoses, squamous cell carcinoma in situ, and invasive squamous cell carcinoma. Ten actinic keratoses, 10 in situ squamous cell carcinomas, and 10 invasive squamous cell carcinomas were examined using the immunoperoxidase method with antigen retrieval for anti-p16(INK4a) antibody. All 10 actinic keratoses were positive for weak to moderate p16 staining in the lower third to lower half of the epidermis (especially the basal keratinocytes). This staining was significant when compared with the lack of staining seen in normal skin controls. Twenty percent of in situ squamous cell carcinomas had moderate to strong staining in only the lower half to lower two thirds of the epidermis, whereas 70% of the in situ squamous cell carcinomas exhibited full-thickness p16 staining, with no staining in the dermis. Thirty percent of invasive squamous cell carcinomas had full-thickness staining of the in situ component of the lesion, and 100% of invasive squamous cell carcinomas exhibited moderate to strong staining of the invasive component of the lesion. These findings indicate correlation between the increased expression of p16 during the progression of skin from actinic keratosis to in situ squamous cell carcinoma to invasive squamous cell carcinoma. These data may lend further support to the view of the actinic keratosis as a precursor lesion to squamous cell carcinoma.",
        "Doc_title":"Immunohistochemical comparison of p16 expression in actinic keratoses and squamous cell carcinomas of the skin.",
        "Journal":"Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc",
        "Do_id":"12429789",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16",
        "Doc_meshdescriptors":"Carcinoma, Squamous Cell;Cyclin-Dependent Kinase Inhibitor p16;Humans;Immunohistochemistry;Keratosis;Skin;Skin Neoplasms",
        "Doc_meshqualifiers":"metabolism;pathology;biosynthesis;metabolism;pathology;chemistry;pathology;metabolism;pathology",
        "_version_":1605818676941946880},
      {
        "Doc_abstract":"Promoter methylation of colorectal cancer-related genes were examined with respect to phenotype and tumor progression.;We assayed promoter methylation of 11 genes including established CpG island methylator phenotype (CIMP) markers (MLH1, MINT1, MINT2, MINT31, p16 ( INK4a ), p14 ( ARF ), and CACNA1G) and four genes (COX2, DAPK, MGMT, and APC) frequently methylated in colorectal cancer in 285 patients with sporadic colorectal cancer.;CIMP+ tumors were more than two times more frequent among high-frequency microsatellite instability tumors (MSI-H) than in tumors without MSI (P < or = .0001-.002). COX2 and DAPK methylation were significantly associated with CIMP+ and MSI. KRAS showed tendency toward more frequent codon 12-13 mutations identified in tumors with APC and p16 ( INK4a ) methylation than in those with unmethylation (P = .033 and .05, respectively). Additionally, tumors with synchronous adenoma were associated with p16 ( INK4a ) methylation (P = .004). The p16 ( INK4a ) methylation was significantly associated with poor overall and disease-free survival in 131 rectal cancer patients who underwent curative operation, according to multivariate analyses (relative risk [RR] = 0.317 and 0.349; P = .033 and .024, respectively). Specifically, in 175 stage II and III patients receiving adjuvant-based fluoropyrimidine chemotherapy, p16 ( INK4a ) methylation and MINT31 unmethylation showed a significant or tendency toward an association with recurrence and DFS (P = .007-.032).;The study suggests that specific CIMP markers, such as p16 ( INK4a ) and MINT31, should be further verified as potential epigenetic targets for the design of efficient chemotherapy regimens. We also identified a subset of colorectal cancer, possibly comprising APC methylation-KRAS mutation-p16 ( INK4a ) methylation.",
        "Doc_title":"Promoter methylation of specific genes is associated with the phenotype and progression of colorectal adenocarcinomas.",
        "Journal":"Annals of surgical oncology",
        "Do_id":"20077021",
        "Doc_ChemicalList":"Biomarkers, Tumor;KRAS protein, human;Proto-Oncogene Proteins;Proto-Oncogene Proteins p21(ras);ras Proteins",
        "Doc_meshdescriptors":"Adenocarcinoma;Biomarkers, Tumor;Colorectal Neoplasms;CpG Islands;DNA Methylation;Disease Progression;Female;Gene Expression Regulation, Neoplastic;Genes, Tumor Suppressor;Humans;Male;Microsatellite Instability;Middle Aged;Mutation;Phenotype;Prognosis;Promoter Regions, Genetic;Proto-Oncogene Proteins;Proto-Oncogene Proteins p21(ras);ras Proteins",
        "Doc_meshqualifiers":"genetics;pathology;genetics;genetics;pathology;genetics;genetics;genetics;genetics;genetics",
        "_version_":1605799341440630784},
      {
        "Doc_abstract":"The tumor suppressor p16(INK4a) inhibits cyclin-dependent kinases 4 and 6. This activates the retinoblastoma protein (pRB) and, through incompletely understood events, arrests the cell division cycle. To permit biochemical analysis of the arrest, we generated U2-OS osteogenic sarcoma cell clones in which p16 transcription could be induced. In these clones, binding of p16 to cdk4 and cdk6 abrogated binding of cyclin D1, p27(KIP1), and p21(WAF1/CIP1). Concomitantly, the total cellular level of p21 increased severalfold via a posttranscriptional mechanism. Most cyclin E-cdk2 complexes associated with p21 and became inactive, expression of cyclin A was curtailed, and DNA synthesis was strongly inhibited. Induction of p21 alone, in a sibling clone, to the level observed during p16 induction substantially reproduced these effects. Overexpression of either cyclin E or A prevented p16 from mediating arrest. We then extended these studies to HCT 116 colorectal carcinoma cells and a p21-null clone derived by homologous recombination. In the parental cells, p16 expression also augmented total cellular and cdk2-bound p21. Moreover, p16 strongly inhibited DNA synthesis in the parental cells but not in the p21-null derivative. These findings indicate that p21-mediated inhibition of cdk2 contributes to the cell cycle arrest imposed by p16 and is a potential point of cooperation between the p16/pRB and p14(ARF)/p53 tumor suppressor pathways.",
        "Doc_title":"Induction of p21(WAF1/CIP1) and inhibition of Cdk2 mediated by the tumor suppressor p16(INK4a).",
        "Journal":"Molecular and cellular biology",
        "Do_id":"10207115",
        "Doc_ChemicalList":"CDKN1A protein, human;Cell Cycle Proteins;Cyclin-Dependent Kinase Inhibitor p16;Cyclin-Dependent Kinase Inhibitor p21;Cyclins;Microtubule-Associated Proteins;Retinoblastoma Protein;Tumor Suppressor Protein p53;Tumor Suppressor Proteins;Cyclin-Dependent Kinase Inhibitor p27;Protein-Serine-Threonine Kinases;CDC2-CDC28 Kinases;CDK2 protein, human;Cyclin-Dependent Kinase 2;Cyclin-Dependent Kinases",
        "Doc_meshdescriptors":"Apoptosis;CDC2-CDC28 Kinases;Cell Cycle Proteins;Cyclin-Dependent Kinase 2;Cyclin-Dependent Kinase Inhibitor p16;Cyclin-Dependent Kinase Inhibitor p21;Cyclin-Dependent Kinase Inhibitor p27;Cyclin-Dependent Kinases;Cyclins;DNA Replication;Gene Expression Regulation;Humans;Microscopy, Fluorescence;Microtubule-Associated Proteins;Polyribosomes;Protein Binding;Protein-Serine-Threonine Kinases;Retinoblastoma Protein;Signal Transduction;Tumor Cells, Cultured;Tumor Suppressor Protein p53;Tumor Suppressor Proteins",
        "Doc_meshqualifiers":"genetics;metabolism;metabolism;metabolism;metabolism;metabolism;metabolism;metabolism",
        "_version_":1605783987974832128},
      {
        "Doc_abstract":"Squamous cell carcinoma (SCC) accounts for approximately 95% of the malignant tumors of the vaginal vulva and is mostly found in elderly women. The future numbers of patients with vulvar SCC is expected to rise, mainly because of the proportional increase in the average age of the general population. Two different pathways for vulvar SCC have been put forth. The first pathway is triggered by infection with a high-risk-type Human Papillomavirus (HPV). Integration of the HPV DNA into the host genome leads to the development of a typical vulvar intraepithelial neoplasia (VIN), accompanied with overexpression of p14(ARF) and p16(INK4A). This lesion subsequently forms a warty- or basaloid-type SCC. The HPV vaccine is a promising new tool for prevention of this HPV related SCC of the vulva. The second pathway is HPV-independent. Keratinizing SCC develops within a background of lichen sclerosus (LS) through a differentiated VIN. It has a different set of genetic alterations than those in the first pathway, including p53 mutations, allelic imbalances (AI), and microsatellite instability (MSI). Further clinical and basic research is still required to understand and prevent vulvar SCC. Capsule. Two pathway for pathogenesis of squamous cell carcinoma of the value are reviewed.",
        "Doc_title":"Two distinct pathways to development of squamous cell carcinoma of the vulva.",
        "Journal":"Journal of skin cancer",
        "Do_id":"21188235",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605783199268470784},
      {
        "Doc_abstract":"Infection with high-risk human papillomavirus (HPV) is linked to a sub-group of squamous cell oropharyngeal tumors (OPSCC). Our aim was to compare an HPV Polymerase Chain Reaction (PCR) assay and p16(INK4A) expression status by immunohistochemistry (IHC) as a surrogate marker.;This was a retrospective study considering patients affected by squamous cell oropharyngeal tumors. All included samples were processed for IHC for p16(INK4A) and tested by PCR for detection of HPV DNA and HPV genotyping.;A total of 84 patients affected by squamous cell oropharyngeal tumors were included and tested. A significant positive correlation was found between HPV PCR and p16(INK4A) IHC but the agreement was poor (k coefficient of 0.25). In fact, the sensitivity of p16(INK4A) IHC positivity in detecting HPV PCR positivity was low (28.21%, 95% confidence interval=16.54% - 43.78%).;Positivity of p16(INK4A) by IHC had a low sensitivity in detecting HPV DNA and our results suggest the need at least to test p16(INK4A) IHC- negative samples using HPV PCR to increase detection accuracy and provide valuable information for the clinical management of these patients.",
        "Doc_title":"HPV-related Oropharyngeal Squamous Cell Carcinoma: p16INK4A Immunohistochemistry or HPV Genotyping?",
        "Journal":"Anticancer research",
        "Do_id":"26254363",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Carcinoma, Squamous Cell;Cyclin-Dependent Kinase Inhibitor p16;Female;Genotype;Humans;Immunohistochemistry;Male;Middle Aged;Oropharyngeal Neoplasms;Papillomaviridae",
        "Doc_meshqualifiers":"metabolism;pathology;virology;metabolism;metabolism;pathology;virology;genetics",
        "_version_":1605832472287772672},
      {
        "Doc_abstract":"The regulatory pathways necessary for the maintenance of adult hematopoietic stem cells (HSCs) remain poorly defined. By using loss-of-function approaches, we report a selective and cell-autonomous requirement for the p300/CBP-binding transcriptional coactivator Cited2 in adult HSC maintenance. Conditional deletion of Cited2 in the adult mouse results in loss of HSCs causing multilineage bone marrow failure and increased lethality. In contrast, conditional ablation of Cited2 after lineage specification in lymphoid and myeloid lineages has no impact on the maintenance of these lineages. Additional deletion of Ink4a/Arf (encoding p16(Ink4a) and p19(Arf)) or Trp53 (encoding p53, a downstream target of p19(Arf)) in a Cited2-deficient background restores HSC functionality and rescues mice from bone marrow failure. Furthermore, we show that the critical role of Cited2 in primitive hematopoietic cells is conserved in humans. Taken together, our studies provide genetic evidence that Cited2 selectively maintains adult HSC functions, at least in part, via Ink4a/Arf and Trp53.",
        "Doc_title":"Cited2 is an essential regulator of adult hematopoietic stem cells.",
        "Journal":"Cell stem cell",
        "Do_id":"19951693",
        "Doc_ChemicalList":"Cited2 protein, mouse;Cyclin-Dependent Kinase Inhibitor p16;RNA, Small Interfering;Repressor Proteins;Trans-Activators;Tumor Suppressor Protein p53;p300-CBP Transcription Factors;ADP-Ribosylation Factors",
        "Doc_meshdescriptors":"ADP-Ribosylation Factors;Adult Stem Cells;Animals;Cell Differentiation;Cell Lineage;Cyclin-Dependent Kinase Inhibitor p16;Hematopoietic Stem Cells;Mice;Mice, Inbred C57BL;Mice, Knockout;RNA, Small Interfering;Repressor Proteins;Trans-Activators;Transcriptional Activation;Tumor Suppressor Protein p53;p300-CBP Transcription Factors",
        "Doc_meshqualifiers":"genetics;metabolism;immunology;metabolism;pathology;genetics;metabolism;immunology;metabolism;pathology;genetics;genetics;immunology;metabolism;genetics;immunology;metabolism;genetics;genetics;metabolism;genetics;metabolism",
        "_version_":1605791669770256384},
      {
        "Doc_abstract":"Breast cancers frequently progress or relapse during targeted therapy, but the molecular mechanisms that enable escape remain poorly understood. We elucidated genetic determinants underlying tumor escape in a transgenic mouse model of Wnt pathway-driven breast cancer, wherein targeted therapy is simulated by abrogating doxycycline-dependent Wnt1 transgene expression within established tumors. In mice with intact tumor suppressor pathways, tumors typically circumvented doxycycline withdrawal by reactivating Wnt signaling, either via aberrant (doxycycline-independent) Wnt1 transgene expression or via acquired somatic mutations in the gene encoding beta-catenin. Germline introduction of mutant tumor suppressor alleles into the model altered the timing and mode of tumor escape. Relapses occurring in the context of null Ink4a/Arf alleles (disrupting both the p16 Ink4a and p19 Arf tumor suppressors) arose quickly and rarely reactivated the Wnt pathway. In addition, Ink4a/Arf-deficient relapses resembled p53-deficient relapses in that both displayed morphologic and molecular hallmarks of an epithelial-to-mesenchymal transition (EMT). Notably, Ink4a/Arf deficiency promoted relapse in the absence of gross genomic instability. Moreover, Ink4a/Arf-encoded proteins differed in their capacity to suppress oncogene independence. Isolated p19 Arf deficiency mirrored p53 deficiency in that both promoted rapid, EMT-associated mammary tumor escape, whereas isolated p16 Ink4a deficiency failed to accelerate relapse. Thus, p19 Arf/p53 pathway lesions may promote mammary cancer relapse even when inhibition of a targeted oncogenic signaling pathway remains in force.",
        "Doc_title":"Tumor escape in a Wnt1-dependent mouse breast cancer model is enabled by p19Arf/p53 pathway lesions but not p16 Ink4a loss.",
        "Journal":"The Journal of clinical investigation",
        "Do_id":"18060046",
        "Doc_ChemicalList":"Cdkn2a protein, mouse;Cyclin-Dependent Kinase Inhibitor p16;Tumor Suppressor Protein p53;Wnt1 Protein;Wnt1 protein, mouse",
        "Doc_meshdescriptors":"Alleles;Animals;Cyclin-Dependent Kinase Inhibitor p16;Female;Genomic Instability;Mammary Neoplasms, Experimental;Mice;Mice, Transgenic;Mutation;Recurrence;Signal Transduction;Tumor Escape;Tumor Suppressor Protein p53;Wnt1 Protein",
        "Doc_meshqualifiers":"genetics;metabolism;genetics;genetics;metabolism;pathology;genetics;genetics;genetics;metabolism;genetics;metabolism",
        "_version_":1605818791345782784},
      {
        "Doc_abstract":"Oncogenic human papillomavirus (HPV) is a causative agent in a subgroup of head and neck carcinomas, particularly tonsillar squamous cell carcinomas (TSCC). This study was undertaken because controversial data exist on the physical status of HPV-DNA and the use of p16(INK4A) overexpression as surrogate HPV marker, and to examine the impact of HPV and tobacco consumption on the clinical course of TSCC. Tissue sections of 81 TSCC were analyzed by HPV 16-specific fluorescence in situ hybridization (FISH) and p16(INK4A)-specific immunohistochemistry. Results were correlated with clinical and demographic data. HPV 16 integration was detected by FISH as punctate signals in 33 out of 81 (41%) TSCC, 32 of which showed p16(INK4A) accumulation. Only 5 out of 48 HPV-negative tumors showed p16(INK4A) immunostaining (p < 0.0001). The presence of HPV furthermore correlates significantly with low tobacco (p = 0.002) and alcohol intake (p = 0.011), poor differentiation grade (p = 0.019), small tumor size (p = 0.024), presence of a local metastasis (p = 0.001) and a decreased (loco)regional recurrence rate (p = 0.039). Statistical analysis revealed that smoking significantly increases the risk of cancer death from TSCC and that non-smoking patients with HPV-containing TSCC show a remarkably better disease-specific survival rate. HPV 16 is integrated in 41% of TSCC and strongly correlates with p16(INK4A) overexpression, implicating the latter to be a reliable HPV biomarker. Patients with HPV-positive tumors show a favorable prognosis as compared to those with HPV-negative tumors, but tobacco use is the strongest prognostic indicator. These findings indicate that oncogenic processes in the tonsils of non-smokers differ from those occurring in smokers, the former being related to HPV 16 infection.",
        "Doc_title":"Marked differences in survival rate between smokers and nonsmokers with HPV 16-associated tonsillar carcinomas.",
        "Journal":"International journal of cancer",
        "Do_id":"18360824",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;DNA, Viral",
        "Doc_meshdescriptors":"Carcinoma, Squamous Cell;Cyclin-Dependent Kinase Inhibitor p16;DNA, Viral;Female;Humans;Immunohistochemistry;In Situ Hybridization, Fluorescence;Male;Middle Aged;Neoplasm Metastasis;Papillomaviridae;Polymerase Chain Reaction;Prognosis;Smoking;Survival Rate;Tonsillar Neoplasms",
        "Doc_meshqualifiers":"pathology;virology;genetics;genetics;genetics;isolation & purification;adverse effects;pathology;virology",
        "_version_":1605831995405893632},
      {
        "Doc_abstract":"p16(INK4) and RB1 are two potent cell cycle regulators to control the G1/S transition by interacting with CDK4/6, E2F, and D-type cyclins, respectively. Depending on the tumour type, genetic alterations resulting in the functional inactivation have frequently been reported in both genes. By contrast, much less is known regarding the overexpression of these proteins in the tumor cells. In this study, expressions of p16(INK4) RB1, and CDKN2A copy number variances (CNV) in the tumor cells were assessed by immunohistochemistry and fluorescence in situ hybridization (FISH), respectively, in 73 nonsmall cell lung cancer (NSCLC) with known 5-year survivals. The histologic type (P = 0.01), p16(INK4) (P = 0.004), and RB1 (P < 0.001) were predictive of survivals. The CDKN2A CNV (P < 0.05) was also significant when compared to those cases without CNV. Therefore, among the molecular genetic prognostic factors, expressions of RB1 and p16(INK4) in the tumor cells were the most strongly predictive of adverse outcomes in stage I and II nonsquamous NSCLC.",
        "Doc_title":"Altered p16(INK4) and RB1 Expressions Are Associated with Poor Prognosis in Patients with Nonsmall Cell Lung Cancer.",
        "Journal":"Journal of oncology",
        "Do_id":"22619677",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605874905975357440},
      {
        "Doc_abstract":"Sulfatase 2 (SULF2), an extracellular sulfatase that alters sulfation on heparan sulfate proteoglycans, is involved in the tumorigenesis and progression of several carcinomas. SULF2 expression has not been evaluated in squamous cell carcinoma of the head and neck (HNSCC). Here we report results of IHC of SULF2 expression in HNSCC tissue. SULF2 was detected in 57% of tumors (n = 40) with a significant increase in intensity and number of stained cells compared to adjacent cancer-free tissue (p-value < 0.01), increasing with cancer stage when comparing stages 1 and 2 to stages 3 and 4 (p-value 0.01). SULF2 was not detected in epithelial cells of cancer-free controls, and expression was independent of patient demographics, tumor location and etiological factors, smoking and HPV infection by p16 IHC analysis. Sandwich ELISA was performed on serum of HNSCC patients (n = 28) and controls (n = 35), and although SULF2 was detectable, no change was observed in HNSCC. Saliva, collected by mouthwash, from HNSCC patients (n = 8) and controls (n = 8) was also tested by ELISA in a preliminary investigation and an increase in SULF2 was observed in HNSCC (p-value 0.041). Overall, this study shows that SULF2 is increased in HNSCC independent of tissue location (oral cavity, oropharynx, larynx and hypopharynx), patient demographics and etiology. Although no change in SULF2 was detected in HNSCC serum, its detection in saliva makes it worthy of further investigation as a potential HNSCC biomarker.",
        "Doc_title":"Expression of the extracellular sulfatase SULF2 is associated with squamous cell carcinoma of the head and neck.",
        "Journal":"Oncotarget",
        "Do_id":"27223083",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605766464259751936},
      {
        "Doc_abstract":"Human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinomas (OPSCCs) frequently show different clinical and pathological features, which tend to be younger age, better performance status, less tobacco and alcohol consumption, more poorly differentiated histopathology, but usually with better treatment response and prognosis compared with HPV-negative OPSCCs. In tumor tissue, HPV infection is closely correlated with p16(INK4A) expression, which has been suggested to be a surrogate biomarker of HPV infection. However, there is diversity of sensitivity and specificity about p16(INK4A) in surrogate detection of HPV status. Herein, we summarize the current knowledge and note some aspects for consideration concerning p16(INK4A) as a surrogate biomarker for HPV-associated OPSCC. ",
        "Doc_title":"P16INK4A as a surrogate biomarker for human papillomavirus-associated oropharyngeal carcinoma: consideration of some aspects.",
        "Journal":"Cancer science",
        "Do_id":"24344719",
        "Doc_ChemicalList":"Biomarkers, Tumor;Cyclin-Dependent Kinase Inhibitor p16;DNA, Viral",
        "Doc_meshdescriptors":"Alphapapillomavirus;Biomarkers, Tumor;Cyclin-Dependent Kinase Inhibitor p16;DNA, Viral;Humans;Oropharyngeal Neoplasms;Papillomavirus Infections;Prognosis",
        "Doc_meshqualifiers":"pathogenicity;genetics;metabolism;genetics;metabolism;genetics;diagnosis;drug therapy;virology;complications;diagnosis;virology",
        "_version_":1605742791664599041},
      {
        "Doc_abstract":"The INK4 family of proteins negatively regulates cell cycle progression at the G(1)-S transition by inhibiting cyclin-dependent kinases. Two of these cell cycle inhibitors, p16(INK4A) and p15(INK4B), have tumor suppressor activities and are inactivated in human cancer. Interestingly, both INK4 genes express alternative splicing variants. In addition to p16(INK4A), the INK4A locus encodes a splice variant, termed p12--specifically expressed in human pancreas--and ARF, a protein encoded by an alternative reading frame that acts as a tumor suppressor through the p53 pathway. Similarly, the human INK4B locus encodes the p15(INK4B) tumor suppressor and one alternatively spliced form, termed as p10. We show here that p10, which arises from the use of an alternative splice donor site within intron 1, is conserved in the mouse genome and is widely expressed in mouse tissues. Similarly to mouse p15(INK4B), p10 expression is also induced by oncogenic insults and transforming growth factor-beta treatment and acts as a cell cycle inhibitor. Importantly, we show that mouse p10 is able to induce cell cycle arrest in a p53-dependent manner. We also show that mouse p10 is able to inhibit foci formation and anchorage-independent growth in wild-type mouse embryonic fibroblasts, and that these antitransforming properties of mouse p10 are also p53-dependent. These results indicate that the INK4B locus, similarly to INK4A-ARF, harbors two different splicing variants that can be involved in the regulation of both the p53 and retinoblastoma pathways, the two major molecular pathways in tumor suppression.",
        "Doc_title":"Mouse p10, an alternative spliced form of p15INK4b, inhibits cell cycle progression and malignant transformation.",
        "Journal":"Cancer research",
        "Do_id":"15833857",
        "Doc_ChemicalList":"Cdkn2b protein, mouse;Cell Cycle Proteins;Cyclin-Dependent Kinase Inhibitor p15;Protein Isoforms;Retinoblastoma Protein;Transforming Growth Factor beta;Tumor Suppressor Protein p53;Tumor Suppressor Proteins",
        "Doc_meshdescriptors":"Alternative Splicing;Amino Acid Sequence;Animals;Base Sequence;Cell Cycle;Cell Cycle Proteins;Cell Transformation, Neoplastic;Cyclin-Dependent Kinase Inhibitor p15;Genes, ras;Mice;Molecular Sequence Data;NIH 3T3 Cells;Protein Isoforms;Retinoblastoma Protein;Transforming Growth Factor beta;Tumor Suppressor Protein p53;Tumor Suppressor Proteins",
        "Doc_meshqualifiers":"genetics;biosynthesis;genetics;genetics;pathology;genetics;metabolism;genetics;pharmacology;metabolism;biosynthesis;genetics",
        "_version_":1605790898862424064},
      {
        "Doc_abstract":"Aberrant promoter methylation of normally unmethylated CpG-islands offers a promising tool for the development of molecular biomarkers. We investigated bronchial aspirates of patients admitted for suspected lung cancer with regard to the prevalence of aberrant methylation of potential marker genes. Applying quantitative methylation specific PCR (QMSP) we analyzed bronchial aspirates from 75 patients with primary lung cancer and 64 bronchial aspirates of patients diagnosed with benign lung disease for promoter methylation of 3 candidate marker genes (p16(INK4a), RARB2 and SEMA3B). Hypermethylation of p16(INK4a) detected 18/75 (24%) cases with primary lung cancer and was present predominantly in squamous cell carcinomas (14/25; 56%). RARB2 QMSP at an assay threshold greater than 30 was found in 42/75 (56%) patients with lung cancer without relation to histological subtype. Patients with benign lung disease showed methylation of p16(INK4a) and a RARB2 QMSP at an assay threshold greater than 30 in 0/64 (0%) and 8/64 (13%) cases, respectively. Combining the 2 methylation markers, p16(INK4a) and RARB2, yielded a sensitivity of 69% and a specificity of 87% for the diagnosis of pulmonary malignancy. In contrast, SEMA3B displayed frequent promoter methylation (around 90%) both in bronchial aspirates of tumor and nontumor cases and thus was not suited as a biomarker. The results of this study indicate that QMSP analysis of p16(INK4a) and RARB2 may aid the diagnosis of primary lung cancer in bronchial aspirates. In particular, detection of p16(INK4a) methylation by QMSP may serve as a highly specific marker of pulmonary squamous cell carcinoma.",
        "Doc_title":"Aberrant promoter methylation of p16(INK4a), RARB2 and SEMA3B in bronchial aspirates from patients with suspected lung cancer.",
        "Journal":"International journal of cancer",
        "Do_id":"15849750",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;Membrane Glycoproteins;Receptors, Retinoic Acid;SEMA3B protein, human;Semaphorins;retinoic acid receptor beta",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Bronchi;Cell Line, Tumor;Cyclin-Dependent Kinase Inhibitor p16;DNA Methylation;Female;Humans;Lung Neoplasms;Male;Membrane Glycoproteins;Middle Aged;Promoter Regions, Genetic;Receptors, Retinoic Acid;Semaphorins;Sensitivity and Specificity",
        "Doc_meshqualifiers":"metabolism;genetics;genetics;pathology;genetics;genetics",
        "_version_":1605757110481584128},
      {
        "Doc_abstract":"A germline mutation in the 3'-untranslated region of KRAS (rs61764370, KRAS-variant: TG/GG) has previously been associated with altered patient outcome and drug resistance/sensitivity in various cancers. We examined the prognostic and predictive significance of this variant in recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).;We conducted a retrospective study of 103 HNSCCs collected from three completed clinical trials. KRAS-variant genotyping was conducted for these samples and 8 HNSCC cell lines. p16 expression was determined in a subset of 26 oropharynx tumors by immunohistochemistry. Microarray analysis was also utilized to elucidate differentially expressed genes between KRAS-variant and non-variant tumors. Drug sensitivity in cell lines was evaluated to confirm clinical findings.;KRAS-variant status was determined in 95/103 (92%) of the HNSCC tumor samples and the allelic frequency of TG/GG was 32% (30/95). Three of the HNSCC cell lines (3/8) studied had the KRAS-variant. No association between KRAS-variant status and p16 expression was observed in the oropharynx subset (Fisher's exact test, P = 1.0). With respect to patient outcome, patients with the KRAS-variant had poor progression-free survival when treated with cisplatin (log-rank P = 0.002). Conversely, KRAS-variant patients appeared to experience some improvement in disease control when cetuximab was added to their platinum-based regimen (log-rank P = 0.04).;The TG/GG rs61764370 KRAS-variant is a potential predictive biomarker for poor platinum response in R/M HNSCC patients.;NCT00503997, NCT00425750, NCT00003809.",
        "Doc_title":"A 3'-UTR KRAS-variant is associated with cisplatin resistance in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.",
        "Journal":"Annals of oncology : official journal of the European Society for Medical Oncology",
        "Do_id":"25081901",
        "Doc_ChemicalList":"3' Untranslated Regions;Antibodies, Monoclonal, Humanized;Cyclin-Dependent Kinase Inhibitor p16;KRAS protein, human;Proto-Oncogene Proteins;Proto-Oncogene Proteins p21(ras);ras Proteins;Cetuximab;Cisplatin",
        "Doc_meshdescriptors":"3' Untranslated Regions;Adult;Aged;Aged, 80 and over;Antibodies, Monoclonal, Humanized;Carcinoma, Squamous Cell;Cetuximab;Cisplatin;Cyclin-Dependent Kinase Inhibitor p16;Disease-Free Survival;Drug Resistance, Neoplasm;Female;Gene Expression Regulation, Neoplastic;Genotype;Head and Neck Neoplasms;Humans;Male;Middle Aged;Neoplasm Metastasis;Neoplasm Recurrence, Local;Prognosis;Proto-Oncogene Proteins;Proto-Oncogene Proteins p21(ras);ras Proteins",
        "Doc_meshqualifiers":"genetics;drug therapy;genetics;pathology;administration & dosage;adverse effects;biosynthesis;genetics;drug therapy;genetics;pathology;drug therapy;genetics;pathology;biosynthesis;genetics;biosynthesis;genetics",
        "_version_":1605807010402533376},
      {
        "Doc_abstract":"The INK4a/ARF locus encodes two unrelated tumor suppressor proteins, p16INK4a and p14ARF, which participate in the two main cell-cycle control pathways, p16-Rb and p14-p53. Methylation of CpG promoter islands has been described as a mechanism of gene silencing. Exon 1 of the p16INK4a gene and the p14ARF promoter gene reside within CpG islands. Therefore, both can become methylated de novo and silenced. It has recently been proposed that the methylation changes in certain genes could be used as molecular markers for the detection of almost all forms of human cancer. Here, we analyzed concomitantly in each tumor sample and normal tissue the methylation status of p16INK4a and p14ARF by methylation-specific PCR (MSP) in 100 breast, 95 colon and 27 bladder carcinomas. A series of clinicopathological parameter were obtained from the medical records of the patients, p14ARF showed a higher rate of hypermethylation than p16INK4a in all three tumor types. p16INK4a and p14ARF aberrant methylation was significantly correlated with poor prognosis clinicopathological parameters of the three tumor types. We conclude that both p16INKa and p14ARF hypermethylation may be involved in breast, colon and bladder carcinogenesis, with special emphasis on the role of the lesser studied p14ARF gene, and that tumors with aberrant methylation in the two genes were associated with worse prognosis.",
        "Doc_title":"Prevalence of aberrant methylation of p14ARF over p16INK4a in some human primary tumors.",
        "Journal":"Mutation research",
        "Do_id":"14563526",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;Tumor Suppressor Protein p14ARF",
        "Doc_meshdescriptors":"Breast Neoplasms;Carcinoma;Colonic Neoplasms;Cyclin-Dependent Kinase Inhibitor p16;DNA Methylation;Female;Humans;Male;Middle Aged;Neoplasms;Prognosis;Promoter Regions, Genetic;Tumor Suppressor Protein p14ARF;Urinary Bladder Neoplasms",
        "Doc_meshqualifiers":"genetics;genetics;genetics;genetics;genetics;genetics;genetics",
        "_version_":1605800973053198336},
      {
        "Doc_abstract":"Head and neck squamous cell carcinoma of an unknown primary site (HNSCCUP) is a heterogeneous group of tumors that includes the human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma. To investigate the relationship between HNSCCUP and HPV, we reviewed p16 overexpression and HPV DNA in lymph node metastases and examined their correlation with the primary site and clinical features.;Thirty-three patients with HNSCCUP were retrospectively studied. Dissected neck metastases were analyzed for p16 overexpression by immunohistochemistry, and the presence of HPV DNA was investigated by in situ hybridization.;Of the 33 patients, 8 (24%) exhibited p16 overexpression. p16-positive lymph node metastases contained significantly more HPV DNA and were most frequently associated with occult primary lesions in the oropharynx and a favorable prognosis. Patients with a lower alcohol consumption, only level II/III metastasis, and cystic lymph node metastasis tended to have p16 overexpression.;This is the first report on the relationship of HNSCCUP with p16 and HPV DNA status in Asian patients. In total, 24% of the HNSCCUP patients were p16 positive. p16 overexpression in neck metastasis was predictive of both an occult primary lesion in the oropharynx and an association with HPV infection. Alcohol consumption, location, and features of neck metastasis were correlated with p16 expression.",
        "Doc_title":"Clinical features of human papilloma virus-related head and neck squamous cell carcinoma of an unknown primary site.",
        "Journal":"ORL; journal for oto-rhino-laryngology and its related specialties",
        "Do_id":"24993345",
        "Doc_ChemicalList":"Biomarkers, Tumor;DNA, Viral;Neoplasm Proteins;P16 protein, human",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Biomarkers, Tumor;Carcinoma, Squamous Cell;DNA, Viral;Female;Head and Neck Neoplasms;Humans;Immunohistochemistry;In Situ Hybridization;Lymph Nodes;Lymphatic Metastasis;Male;Middle Aged;Neoplasm Proteins;Neoplasms, Unknown Primary;Papillomaviridae;Papillomavirus Infections;Retrospective Studies",
        "Doc_meshqualifiers":"metabolism;pathology;virology;metabolism;metabolism;pathology;virology;metabolism;pathology;metabolism;metabolism;pathology;virology;genetics;pathology",
        "_version_":1605785421686505472},
      {
        "Doc_abstract":"SLUG represses E-cadherin to promote epithelial-mesenchymal transition (EMT) in various cancers. Mechanisms that regulate SLUG/E-cadherin pathway remain poorly understood, especially during tumorigenesis in vivo. Here we report that p19(Arf) (p14(ARF) in human) stabilizes Slug to inhibit E-cadherin in prostate cancer mouse models. Inactivation of p19(Arf) reduces Slug levels, resulting in increased E-cadherin expression and delaying the onset and progression of prostate cancer in Pten/Trp53 double null mice. Mechanistically, p14(ARF) stabilizes SLUG through increased sumoylation at lysine residue 192. Importantly, levels of SLUG and p14(ARF) are positively correlated in human prostate cancer specimens. These data demonstrated that ARF modulates the SLUG/E-cadherin signaling axis for augmenting prostate tumorigenesis in vivo, revealing a novel paradigm where the oncogenic functions of SLUG require ARF to target E-cadherin in prostate cancer. Collectively, our findings further support that ARF has dual tumor suppressive/oncogenic roles in cancers in a context-dependent manner.",
        "Doc_title":"Slug regulates E-cadherin repression via p19Arf in prostate tumorigenesis.",
        "Journal":"Molecular oncology",
        "Do_id":"24910389",
        "Doc_ChemicalList":"Cadherins;Cdkn2a protein, mouse;Cyclin-Dependent Kinase Inhibitor p16;SNAI1 protein, human;SUMO-1 Protein;Snai2 protein, mouse;Snail Family Transcription Factors;Transcription Factors",
        "Doc_meshdescriptors":"Animals;Cadherins;Cyclin-Dependent Kinase Inhibitor p16;Epithelial-Mesenchymal Transition;Gene Expression Regulation, Neoplastic;Gene Knockout Techniques;Humans;Male;Mice;Prostate;Prostatic Neoplasms;SUMO-1 Protein;Snail Family Transcription Factors;Transcription Factors",
        "Doc_meshqualifiers":"genetics;metabolism;genetics;metabolism;metabolism;pathology;genetics;metabolism;pathology;metabolism;metabolism",
        "_version_":1605839265282916352},
      {
        "Doc_abstract":"Cancer of unknown primary of the head and neck is a challenging entity for the oncologist. The role of human papilloma virus/p16 in carcinogenesis and in prognosis is well established in certain HNSCC especially in that of the oropharynx. In the case of occult primary of the head and neck the role of HPV/p16 positivity is not well defined regarding prognosis and localization of the primary. An independent review of PubMed and ScienceDirect database was performed up to May 2014 using combinations of terms such as \"occult primary of the head and neck\", \"CUP of the head and neck\" \"metastatic cervical squamous cell carcinoma of unknown primary\", \"HPV\" and \"HPV and head and neck cancer\". Literature review shows a strong association between HPV/p16 positivity and primary location in the oropharynx in patients with CUP of the head and neck as well as a better clinical outcome. HPV positivity and p16 overexpression could be used as surrogate markers in the search of the primary site of patients with CUP of the head and neck therefore maybe guiding treatment decisions. ",
        "Doc_title":"The role of human papilloma virus and p16 in occult primary of the head and neck: a comprehensive review of the literature.",
        "Journal":"Oral oncology",
        "Do_id":"25467774",
        "Doc_ChemicalList":"Viral Proteins",
        "Doc_meshdescriptors":"Alphapapillomavirus;Carcinoma, Squamous Cell;Head and Neck Neoplasms;Humans;Neoplasms, Unknown Primary;Prognosis;Viral Proteins",
        "Doc_meshqualifiers":"metabolism;pathogenicity;metabolism;pathology;virology;pathology;virology;virology;metabolism",
        "_version_":1605766094512979968},
      {
        "Doc_abstract":"To evaluate the impact of p16INK4a (p16) expression on clinical efficacy of induction low-dose fractionated radiation therapy (LDFRT) with concurrent chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN).;Historical cohort study.;Tertiary medical center.;A total of 66 Patients with locally advanced SCCHN were enrolled in 2 clinical trials using paclitaxel, carboplatin, and concurrent LDFRT induction therapy. Patients were evaluated for response to induction by a multidisciplinary team and then were given definitive treatment. Adequate tissue samples from the pretreatment biopsies of 42 individuals were identified and analyzed for p16 expression. Expression was correlated with clinical outcomes.;Of 42 tumors, 15 (35.7%) were positive for p16. Patients with p16-positive tumors had improved response to induction, but this was not statistically significant (P = .06). Five-year overall survival was 80% in p16-positive patients and 58% in p16-negative patients (P = .025).;p16 Expression affects treatment response in patients treated with induction LDFRT with concurrent chemotherapy. This is similar to results reported for standard induction chemotherapy.",
        "Doc_title":"p16INK4a Status and Response to Induction Low-Dose Fractionated Radiation in Advanced Head and Neck Cancer.",
        "Journal":"The Annals of otology, rhinology, and laryngology",
        "Do_id":"25810339",
        "Doc_ChemicalList":"Antineoplastic Agents;Carboplatin;Paclitaxel",
        "Doc_meshdescriptors":"Adult;Antineoplastic Agents;Biopsy;Carboplatin;Carcinoma, Squamous Cell;Chemoradiotherapy;Cohort Studies;Dose Fractionation;Dose-Response Relationship, Radiation;Female;Gene Expression Profiling;Genes, p16;Head and Neck Neoplasms;Humans;Male;Middle Aged;Neoplasm Staging;Oropharyngeal Neoplasms;Paclitaxel;Papillomavirus Infections;Remission Induction;Survival Analysis;Treatment Outcome",
        "Doc_meshqualifiers":"administration & dosage;administration & dosage;genetics;pathology;therapy;methods;physiology;genetics;pathology;therapy;pathology;therapy;administration & dosage;genetics;pathology;therapy;methods",
        "_version_":1605826675219628032},
      {
        "Doc_abstract":"Tumor suppressor proteins must be exquisitely regulated since they can induce cell death while preventing cancer. For example, the p19(ARF) tumor suppressor (p14(ARF) in humans) appears to stimulate the apoptotic function of the p53 tumor suppressor to prevent lymphomagenesis and carcinogenesis induced by oncogene overexpression. Here we present a genetic approach to defining the role of p19(ARF) in regulating the apoptotic function of p53 in highly proliferating, homeostatic tissues. In contrast to our expectation, p19(ARF) did not activate the apoptotic function of p53 in lymphocytes or epithelial cells. These results demonstrate that the mechanisms that control p53 function during homeostasis differ from those that are critical for tumor suppression. Moreover, the Mdm2/p53/p19(ARF) pathway appears to exist only under very restricted conditions.",
        "Doc_title":"Mdm2 regulates p53 independently of p19(ARF) in homeostatic tissues.",
        "Journal":"Molecular and cellular biology",
        "Do_id":"14673154",
        "Doc_ChemicalList":"Cdkn2a protein, mouse;Cyclin-Dependent Kinase Inhibitor p16;Nuclear Proteins;Proto-Oncogene Proteins;Tumor Suppressor Protein p14ARF;Tumor Suppressor Protein p53;Mdm2 protein, mouse;Proto-Oncogene Proteins c-mdm2",
        "Doc_meshdescriptors":"Animals;Body Weight;Cyclin-Dependent Kinase Inhibitor p16;Epithelium;Homeostasis;Intestine, Small;Mice;Mice, Transgenic;Nuclear Proteins;Proto-Oncogene Proteins;Proto-Oncogene Proteins c-mdm2;Tumor Suppressor Protein p14ARF;Tumor Suppressor Protein p53",
        "Doc_meshqualifiers":"genetics;metabolism;physiology;metabolism;genetics;metabolism;genetics;metabolism;metabolism",
        "_version_":1605746996392493058},
      {
        "Doc_abstract":"The cyclin-dependent kinase (CDK) inhibitors, p18(INK4c) and p16(INK4a), both have the credentials of tumor suppressors in human cancers and mouse models. For p16(INK4a), the underlying rationale is its role in senescence, but the selective force for inactivation of p18(INK4c) in incipient cancer cells is less clear. Here, we show that in human fibroblasts undergoing replicative or oncogene-induced senescence, there is a marked decline in the levels of p18(INK4c) protein and RNA, which mirrors the accumulation of p16(INK4a). Downregulation of INK4c is not dependent on p16(INK4a), and RAS can promote the loss of INK4c without cell-cycle arrest. Downregulation of p18(INK4c) correlates with reduced expression of menin and E2F1 but is unaffected by acute cell-cycle arrest or inactivation of the retinoblastoma protein (pRb). Collectively, our data question the idea that p18(INK4c) acts as a backup for loss of p16(INK4a) and suggest that the apparent activation of p18(INK4c) in some settings represents delayed senescence rather than increased expression. We propose that the contrasting behavior of the two very similar INK4 proteins could reflect their respective roles in senescence versus differentiation.",
        "Doc_title":"Contrasting behavior of the p18INK4c and p16INK4a tumor suppressors in both replicative and oncogene-induced senescence.",
        "Journal":"Cancer research",
        "Do_id":"22080569",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;Cyclin-Dependent Kinase Inhibitor p18",
        "Doc_meshdescriptors":"Base Sequence;Cell Aging;Cyclin-Dependent Kinase Inhibitor p16;Cyclin-Dependent Kinase Inhibitor p18;Down-Regulation;Genes, Tumor Suppressor;Humans;Oncogenes;RNA Interference;Reverse Transcriptase Polymerase Chain Reaction",
        "Doc_meshqualifiers":"physiology;physiology",
        "_version_":1605792425142386688},
      {
        "Doc_abstract":"In colorectal carcinomas, p16(INK4a) inactivation is known to occur by allelic loss and by promoter methylation, but mutations are rare. p16(INK4a) is up-regulated in tumor buds, and the consequent shutdown of proliferation may be a prerequisite for tumor budding. Fifty-seven colorectal carcinomas from a consecutive series were investigated. Using DNA from tissue homogenates, p16(INK4a) promoter methylation was seen in 17 of 57 tumors by methylation-specific polymerase chain reaction, and this could be confirmed using DNA from laser-capture microdissected material in 16 of these cases. A total loss of immunohistochemical p16(INK4a) expression was seen in 6 of 17 tumors with promoter methylation. Quantification of immunohistochemical p16(INK4a) expression for the remaining 11 cases revealed statistically lower frequencies of expression as compared with cases without p16(INK4a) promoter methylation. 9p21 allelic loss was observed in 9 cases, but p16(INK4a) expression in these carcinomas was not reduced. Attempted linear regression of p16(INK4a) expression in tumor buds on the degree of tumor budding, as counted on pan-cytokeratin immunostains, did not show a correlation. p16(INK4a) promoter methylation can completely abrogate p16(INK4a) expression in colorectal carcinomas. In many cases, however, it has an appreciable but only modulatory influence on p16(INK4a) expression. Possibly, methylations are heterozygous, and/or mosaic in colorectal carcinomas and/or methylations are not totally stable but can be lost between carcinoma cell replication cycles. Up-regulation of p16(INK4a) does not seem to be a strict requirement for tumor budding, hence, the absence of a correlation.",
        "Doc_title":"p16(INK4a) promoter methylation and 9p21 allelic loss in colorectal carcinomas: relation with immunohistochemical p16(INK4a) expression and with tumor budding.",
        "Journal":"Human pathology",
        "Do_id":"16647956",
        "Doc_ChemicalList":"Biomarkers, Tumor;Cyclin-Dependent Kinase Inhibitor p16;DNA, Neoplasm",
        "Doc_meshdescriptors":"Adenocarcinoma;Adult;Aged;Aged, 80 and over;Biomarkers, Tumor;Cell Movement;Chromosomes, Human, Pair 9;Colorectal Neoplasms;Cyclin-Dependent Kinase Inhibitor p16;DNA Methylation;DNA, Neoplasm;Female;Humans;Immunohistochemistry;Lasers;Loss of Heterozygosity;Male;Microdissection;Middle Aged",
        "Doc_meshqualifiers":"genetics;metabolism;pathology;genetics;metabolism;genetics;genetics;metabolism;pathology;genetics;metabolism;analysis",
        "_version_":1605809121521565696},
      {
        "Doc_abstract":"Liquid-based cytology (LBC) enables the use of supplementary methods in the diagnosis and prognosis of cervical lesions. The aim of this study was to analyze the correlation between p16-INK4a immunoexpression in ThinPrep cervical cytologic samples and human papillomavirus (HPV) detection by polymerase chain reaction (PCR) from the same sample. LBC-ThinPrep (Cytyc, USA) cervical cytology samples, prepared and stained by Papanicolaou method, were analyzed using modified Bethesda cytologic classification named \"Zagreb 2002\". A second ThinPrep slide, prepared from the same sample, was immunostained for p16INK4a using CINtec p16INK4a Cytology Kit (DakoCytomation, Denmark). Increased expression of the high-risk (HR) HPV E6 and E7 oncogenes results in a highly specific increase in p16 protein expression and overexpression of p16INK4a acts as a potential biomarker for cervical cancer progression from premalignant lesions. Brown nuclear and/or cytoplasmic staining of abnormal cells was considered a positive result. Residual material was used for 13 HR HPV-DNA detection by the PCR based AMPLICOR HPV test (Roche Molecular Systems). A total of 120 ThinPrep Pap tests with the following cytologic diagnoses: 17 within normal limits, 17 atypical squamous cell (ASC) (7 ASC of undetermined significance /ASCUS/ and 10 ASC of high-grade squamous intraepithelial lesions cannot be excluded /ASC-H/), 26 low-grade squamous intraepithelial lesions (LSIL) corresponding cervical intraepithelial neoplasia (CIN) 1, 57 high-grade SIL (HSIL) i.e. 24 CIN II and 33 CIN III and 3 squamous cell carcinoma (SCC) were included in the study. All CIN III (n = 33) and SCC (n = 3) specimens expressed p16INK4a immunoreactivity, whereas the HR HPV test was positive in 97% (32/33) of CIN III and 100% (3/3) of SCC specimens. The p16INK4a biomarker was positive in 87.5% (21/24) of CIN II and 69% (18/26) of CIN I, while the HR HPV was positive in 75% (18/24) of CIN II and 50% (13/26) of CIN I. In ASCUS cytology, p16INK4a and HR HPV showed the same rate of positivity (28.5%; 2/7). Expression of p16INK4a was detected in all cytologic (10/10) ASC-H lesions, in contrast to HR HPV detected in only 20% (2/10) of ASC-H cases. These data suggest the p16INK4a evaluation in ThinPrep cervical samples to be significantly associated with HR HPV testing by PCR in the same sample for the diagnosis of HSIL lesions and cervical carcinomas. A prospective study with longer follow up may clarify the predictive values in the management of LSIL and ASC diagnosis.",
        "Doc_title":"Liquid-based cytology--new possibilities in the diagnosis of cervical lesions.",
        "Journal":"Collegium antropologicum",
        "Do_id":"20432728",
        "Doc_ChemicalList":"Biomarkers, Tumor;Cyclin-Dependent Kinase Inhibitor p16;DNA Probes, HPV",
        "Doc_meshdescriptors":"Biomarkers, Tumor;Biopsy;Carcinoma, Squamous Cell;Cervical Intraepithelial Neoplasia;Cyclin-Dependent Kinase Inhibitor p16;DNA Probes, HPV;Female;Human papillomavirus 16;Human papillomavirus 18;Humans;Immunohistochemistry;Papanicolaou Test;Papillomavirus Infections;Polymerase Chain Reaction;Precancerous Conditions;Predictive Value of Tests;Risk Factors;Uterine Cervical Neoplasms;Vaginal Smears",
        "Doc_meshqualifiers":"metabolism;methods;metabolism;pathology;virology;metabolism;pathology;virology;metabolism;genetics;isolation & purification;genetics;isolation & purification;complications;epidemiology;pathology;metabolism;pathology;virology;metabolism;pathology;virology;methods",
        "_version_":1605824106304897024},
      {
        "Doc_abstract":"We questioned whether the use of p16(INK4a) immunohistochemistry in endocervical curettage (ECC) specimens would improve the detection of high-grade squamous intraepithelial lesions (HSIL) in a high-risk patient population.;Papanicolaou test results were retrieved in 58 consecutive ECC specimens that were previously diagnosed as no histopathologic abnormality in patients with antecedent HSIL or atypical squamous cells, cannot exclude HSIL. An H&E recut and immunohistochemistry for p16(INK4a) were performed on all cases.;HSIL were found in 18 (31%) ECC specimens originally interpreted as negative. Of these 18 cases, three had moderate-sized fragments of ectocervical epithelium with HSIL seen on the recut H&E with concurrent positivity for p16(INK4a). Fourteen cases had rare to occasional clusters of atypical cells with strong immunoreactivity for p16(INK4a). A single case showed a medium-sized fragment of HSIL on the p16(INK4a)-stained section.;The use of recuts and adjunct p16(INK4a) should be considered when evaluating ECC specimens in high-risk patient populations.",
        "Doc_title":"Adjunct p16(INK4a) immunohistochemistry aids the detection of high-grade squamous intraepithelial lesions in endocervical curettage specimens.",
        "Journal":"American journal of clinical pathology",
        "Do_id":"24515761",
        "Doc_ChemicalList":"Biomarkers, Tumor;Cyclin-Dependent Kinase Inhibitor p16",
        "Doc_meshdescriptors":"Adult;Biomarkers, Tumor;Carcinoma, Squamous Cell;Cervical Intraepithelial Neoplasia;Cervix Uteri;Curettage;Cyclin-Dependent Kinase Inhibitor p16;Female;Humans;Immunohistochemistry;Middle Aged;Papanicolaou Test;Uterine Cervical Neoplasms",
        "Doc_meshqualifiers":"metabolism;diagnosis;metabolism;pathology;diagnosis;metabolism;pathology;metabolism;pathology;metabolism;diagnosis;metabolism;pathology",
        "_version_":1605832461475905536},
      {
        "Doc_abstract":"Head and neck squamous cell carcinoma (HNSCC) accounts for a bulk of the oral and laryngeal cancers, the majority (70%) of which are associated with smoking and excessive drinking, major known risk factors for the development of HNSCC. In contrast to reports that suggest an inverse relationship between smoking and global DNA CpG methylation, hypermethylation of promoters of a number of genes was detected in saliva collected from patients with HNSCC. Using a sensitive methylation-specific polymerase chain reaction (MSP) assay to determine specific methylation events in the promoters of RASSF1A, DAPK1, and p16 genes, we demonstrate that we can detect tumor presence with an overall accuracy of 81% in the DNA isolated from saliva of patients with HNSCC (n = 143) when compared with the DNA isolated from the saliva of healthy nonsmoker controls (n = 31). The specificity for this MSP panel was 87% and the sensitivity was 80% (with a Fisher exact test P < .0001). In addition, the test panel performed extremely well in the detection of the early stages of HNSCCs, with a sensitivity of 94% and a specificity of 87%, and a high  concordance value of 0.8, indicating an excellent overall agreement between the presence of HNSCC and a positive MSP panel result. In conclusion, we demonstrate that the promoter methylation of RASSF1A, DAPK1, and p16 MSP panel is useful in detecting hypermethylation events in a noninvasive manner in patients with HNSCC.",
        "Doc_title":"Tumor-suppressor Gene Promoter Hypermethylation in Saliva of Head and Neck Cancer Patients.",
        "Journal":"Translational oncology",
        "Do_id":"23066440",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605897682693390336},
      {
        "Doc_abstract":"The tumor suppressor gene p16, when altered, has been shown to play a role in oncogenesis in many different tumor types including head and neck cancer. The goal of this study was to analyse alterations to p16 in squamous cell carcinoma (SCC) of the head and neck and to correlate these with clinical outcome. RNA was isolated from 26 SCC head and neck tumors and from 24 matched controls. A reverse transcription polymerase chain reaction was utilized to generate p16 cDNA, which was sequenced and analysed for alterations. In the 26 patient group 58% of the tumors had a p16 alteration, which were characterized by: 8 deletions, 1 insertion/deletion, 4 point mutations and 2 with no p16 expression. In 24 matched normal tissue samples there were no p16 alterations. Those patients with p16 alterations appear to have survival rates comparable to those without p16 alterations, although patients with p16 alterations appear to have more recurrences.",
        "Doc_title":"p16 mutation frequency and clinical correlation in head and neck cancer.",
        "Journal":"Acta oto-laryngologica",
        "Do_id":"10320093",
        "Doc_ChemicalList":"DNA, Neoplasm;RNA, Neoplasm",
        "Doc_meshdescriptors":"Carcinoma, Squamous Cell;Case-Control Studies;DNA, Neoplasm;Genes, p16;Head and Neck Neoplasms;Humans;Mutation;Neoplasm Recurrence, Local;RNA, Neoplasm;Reverse Transcriptase Polymerase Chain Reaction",
        "Doc_meshqualifiers":"genetics;mortality;genetics;genetics;genetics;mortality;genetics;genetics",
        "_version_":1605845914216300544},
      {
        "Doc_abstract":"Germline mutations in the cyclin-dependent kinase inhibitor 2a (CDKN2a) gene, which maps to the 9p21 chromosomal region and encodes the cyclin-dependent kinase inhibitor p16INK4a, have been detected in a proportion of familial melanoma kindreds, suggesting that it is the putative 9p21-linked melanoma susceptibility gene. The p19ARF transcript, an alternative spliced form of the CDKN2a gene, has recently been shown to inhibit, like the p16INK4a protein, cell cycle progression, raising the possibility that it might constitute an additional melanoma tumor suppressor gene at the 9p21 locus. To determine the contribution of these candidate genes to familial melanoma genetic predisposition, we screened 10 such kindreds for germline mutations in the p16INK4a and p19ARF genes. Four independent germline missense mutations, mapping in exon 1alpha (Gly23Asp; Arg24Pro) and exon 2 (Asn71Ileu; Pro114Leu) of the CDKN2a gene, were identified. Two previously described polymorphisms were also detected, Ala148Thr in exon 2 and a base change in the 3' untranslated region of exon 3. No disease-associated mutations in exon 1beta of the p19ARF gene were found. Our data support the hypothesis that the CDKN2a is a melanoma susceptibility gene in familial melanoma, whereas the p19ARF gene does not seem to play a significant role.",
        "Doc_title":"CDKN2a/p16INK4a mutations and lack of p19ARF involvement in familial melanoma kindreds.",
        "Journal":"The Journal of investigative dermatology",
        "Do_id":"9856841",
        "Doc_ChemicalList":"Proteins;Tumor Suppressor Protein p14ARF",
        "Doc_meshdescriptors":"Adult;Aged;Family Health;Female;Genes, p16;Genetic Variation;Germ-Line Mutation;Humans;Male;Melanoma;Middle Aged;Pedigree;Point Mutation;Proteins;Tumor Suppressor Protein p14ARF",
        "Doc_meshqualifiers":"genetics;genetics;genetics",
        "_version_":1605800723867500544},
      {
        "Doc_abstract":"Hypoxia is a consistent finding in fast-growing tumors; it contributes to tumor progression and therapeutic responses. We explored the expression of hypoxia-associated biomarkers in head and neck squamous cell carcinoma (HNSCC) to assess their relationship with clinical factors in HNSCC. In total, 90 patients with HNSCC were enrolled. Expression of HIF-1, HSP70, HSP90, VEGF, IGF-1R, and P16 was investigated by immunohistochemistry. Their correlations with clinical factors, including location of primary sites, T stage, N stage, M stage, HPV status, primary treatment success/failure, recurrences, disease-free survival (DFS), and overall survival, were analyzed. HIF-1, HPS70, HPS90, VEGF, and IGF-1R were positive in 33 of 89 (37.1 %), 62 of 87 (71.3 %), 83 of 89 (93.3 %), 41 of 87 (47.1 %), and 50 of 56 (89.3 %) cases, respectively. Expression levels of some of these markers were correlated. High HIF-1 or HSP 70 correlated with poor DFS, and expression of HSP70 correlated with LN metastasis. HPV-related carcinomas showed high HSP 70 and IGF-1R expression. Hypoxia-associated proteins were highly expressed and associated with aggressive clinical features in HNSCC. Expression of HIF-1 or HSP70 can be considered poor prognostic indicator in HNSCC. Our results suggest that hypoxic signaling is activated in HNSCC, especially in HPV-related tumors.",
        "Doc_title":"Expression of hypoxic signaling markers in head and neck squamous cell carcinoma and its clinical significance.",
        "Journal":"European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery",
        "Do_id":"24627073",
        "Doc_ChemicalList":"Biomarkers, Tumor",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Biomarkers, Tumor;Carcinoma, Squamous Cell;Cell Hypoxia;Female;Head and Neck Neoplasms;Humans;Immunohistochemistry;Male;Middle Aged;Prognosis;Retrospective Studies;Signal Transduction",
        "Doc_meshqualifiers":"biosynthesis;metabolism;pathology;metabolism;pathology",
        "_version_":1605824191686246400},
      {
        "Doc_abstract":"Both genetic mutations and UV irradiation (UVR) can predispose individuals to melanoma. Although BRAF(V600E) is the most prevalent oncogene in melanoma, the BRAF(V600E) mutant is not sufficient to induce tumors in vivo. Mutation at the CDKN2A locus is another melanoma-predisposing event that can disrupt the function of both p16(INK4a) and ARF. Numerous studies have focused on the role of p16(INK4a) in melanoma, but the involvement of ARF, a well-known p53 activator, is still controversial. Using a transgenic BRAF(V600E) mouse model previously generated in our laboratory, we report that loss of ARF is able to enhance spontaneous melanoma formation and cause profound sensitivity to neonatal UVB exposure. Mechanistically, BRAF(V600E) and ARF deletion synergize to inhibit nucleotide excision repair by epigenetically repressing XPC and inhibiting the E2F4/DP1 complex. We suggest that the deletion of ARF promotes melanomagenesis not by abrogating p53 activation but by acting in concert with BRAF(V600E) to increase the load of DNA damage caused by UVR.",
        "Doc_title":"Loss of ARF sensitizes transgenic BRAFV600E mice to UV-induced melanoma via suppression of XPC.",
        "Journal":"Cancer research",
        "Do_id":"23650282",
        "Doc_ChemicalList":"Cdkn2a protein, mouse;Cyclin-Dependent Kinase Inhibitor p16;DNA-Binding Proteins;E2F4 Transcription Factor;E2f4 protein, mouse;Tfdp1 protein, mouse;Transcription Factor DP1;Tumor Suppressor Protein p53;Xpc protein, mouse;Braf protein, mouse;Proto-Oncogene Proteins B-raf",
        "Doc_meshdescriptors":"Animals;Cell Line, Tumor;Cells, Cultured;Cyclin-Dependent Kinase Inhibitor p16;DNA Methylation;DNA Repair;DNA-Binding Proteins;E2F4 Transcription Factor;Humans;Melanoma;Melanoma, Experimental;Mice;Mice, Inbred C57BL;Mice, Knockout;Mice, Transgenic;Neoplasms, Radiation-Induced;Promoter Regions, Genetic;Proto-Oncogene Proteins B-raf;Transcription Factor DP1;Tumor Suppressor Protein p53;Ultraviolet Rays",
        "Doc_meshqualifiers":"genetics;antagonists & inhibitors;genetics;genetics;genetics;genetics;genetics;genetics;genetics;genetics",
        "_version_":1605883951486861312},
      {
        "Doc_abstract":"The osteogenic Runt-related (Runx2) transcription factor negatively regulates proliferation and ribosomal gene expression in normal diploid osteoblasts, but is up-regulated in metastatic breast and prostate cancer cells. Thus, Runx2 may function as a tumor suppressor or an oncogene depending on the cellular context. Here we show that Runx2-deficient primary osteoblasts fail to undergo senescence as indicated by the absence of beta-gal activity and p16(INK4a) tumor suppressor expression. Primary Runx2-null osteoblasts have a growth advantage and exhibit loss of p21(WAF1/CIP1) and p19(ARF) expression. Reintroduction of WT Runx2, but not a subnuclear targeting-defective mutant, induces both p21(WAF/CIP1) and p19(ARF) mRNA and protein resulting in cell-cycle inhibition. Accumulation of spontaneous phospho-H2A.X foci, loss of telomere integrity and the Mre11/Rad50/Nbs1 DNA repair complex, and a delayed DNA repair response all indicate that Runx2 deficiency leads to genomic instability. We propose that Runx2 functions as a tumor suppressor in primary diploid osteoblasts and that subnuclear targeting contributes to Runx2-mediated tumor suppression.",
        "Doc_title":"Runx2 deficiency and defective subnuclear targeting bypass senescence to promote immortalization and tumorigenic potential.",
        "Journal":"Proceedings of the National Academy of Sciences of the United States of America",
        "Do_id":"18077419",
        "Doc_ChemicalList":"Cdkn1a protein, mouse;Core Binding Factor Alpha 1 Subunit;Cyclin-Dependent Kinase Inhibitor p21;Runx2 protein, mouse",
        "Doc_meshdescriptors":"Animals;Cell Aging;Cell Nucleus;Cell Proliferation;Cell Transformation, Neoplastic;Cells, Cultured;Core Binding Factor Alpha 1 Subunit;Cyclin-Dependent Kinase Inhibitor p21;Gene Targeting;Genomic Instability;Mice;Mice, Knockout;Osteoblasts",
        "Doc_meshqualifiers":"genetics;genetics;metabolism;genetics;metabolism;pathology;deficiency;genetics;metabolism;physiology;physiology;physiology;metabolism;pathology",
        "_version_":1605902771529187328},
      {
        "Doc_abstract":"RNA interference is a powerful tool for studying gene function, however, the reproducible generation of RNAi transgenic mice remains a significant limitation. By combining optimized fluorescence-coupled miR30-based shRNAs with high efficiency ES cell targeting, we developed a fast, scalable pipeline for the production of shRNA transgenic mice. Using this system, we generated eight tet-regulated shRNA transgenic lines targeting Firefly and Renilla luciferases, Oct4 and tumor suppressors p53, p16(INK4a), p19(ARF) and APC and demonstrate potent gene silencing and GFP-tracked knockdown in a broad range of tissues invivo. Further, using an shRNA targeting APC, we illustrate how this approach can identify predicted phenotypes and also unknown functions for a well-studied gene. In addition, through regulated gene silencing we validate APC/Wnt and p19(ARF) as potential therapeutic targets in Tcell acute lymphoblastic leukemia/lymphoma and lung adenocarcinoma, respectively. This system provides a cost-effective and scalable platform for the production of RNAi transgenic mice targeting any mammalian gene. PAPERCLIP:",
        "Doc_title":"A rapid and scalable system for studying gene function in mice using conditional RNA interference.",
        "Journal":"Cell",
        "Do_id":"21458673",
        "Doc_ChemicalList":"MicroRNAs;RNA, Small Interfering;Wnt Proteins",
        "Doc_meshdescriptors":"Adenocarcinoma;Animals;Embryonic Stem Cells;Gene Knockdown Techniques;Lung Neoplasms;Mice;Mice, Transgenic;MicroRNAs;Precursor T-Cell Lymphoblastic Leukemia-Lymphoma;RNA Interference;RNA Processing, Post-Transcriptional;RNA, Small Interfering;Signal Transduction;Wnt Proteins",
        "Doc_meshqualifiers":"genetics;therapy;metabolism;economics;methods;genetics;therapy;genetics;genetics;therapy;genetics;metabolism",
        "_version_":1605801916220047360},
      {
        "Doc_abstract":"To investigate the clinicopathological significance of p16(INK4A) expression and DNA ploidy status in HPV-negative uterine cervical cancers and their precursors.;HPV-negative cervical lesions, including 20 cases of cervicitis, 20 cases of cervical intraepithelial neoplasm (CIN), 3 cases of cervical glandular intraepithelial neoplasm (CGIN), 38 cases of invasive squamous cell carcinoma (SCCs) and 15 cases of invasive adenocarcinoma were selected and subject to screening for HPV infection by PCR method. The p16(INK4A) protein expression and DNA ploidy status were studied by immunohistochemistry and flow cytometry respectively.;Specific expression of p16(INK4A) was seen in both the nucleus and cytoplasm of the dysplastic and malignant cells of CIN, CGIN, cervical SCC and adenocarcinoma. In contrast, no expression was present in normal and inflammatory squamous or glandular epithelium. DNA aneuploidy was significantly more frequent in invasive SCCs and adenocarcinomas than in CIN (P < 0.01). Aneuploid was also more frequent in the lymph node positive group than lymph node negative group, although no statistic significance was found. Among the 8 cases of p16(INK4A) negative SCCs, two showed DNA aneuploidy.;Immunohistochemical detection for p16(INK4A) can be an early diagnostic marker for HPV-negative cervical SCC and adenocarcinoma. DNA ploidy analysis may further assist the diagnosis of cervical malignancies.",
        "Doc_title":"[Study of p16(INK4A) expression and DNA ploidy in HPV-negative cervical cancers and precursors].",
        "Journal":"Zhonghua bing li xue za zhi = Chinese journal of pathology",
        "Do_id":"17069677",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;DNA, Neoplasm",
        "Doc_meshdescriptors":"Adenocarcinoma;Aneuploidy;Carcinoma, Squamous Cell;Cervical Intraepithelial Neoplasia;Cyclin-Dependent Kinase Inhibitor p16;DNA, Neoplasm;Female;Flow Cytometry;Humans;Immunohistochemistry;Papillomaviridae;Polymerase Chain Reaction;Uterine Cervical Neoplasms;Uterine Cervicitis",
        "Doc_meshqualifiers":"genetics;metabolism;pathology;genetics;metabolism;pathology;genetics;metabolism;pathology;metabolism;genetics;genetics;isolation & purification;genetics;metabolism;pathology;genetics;metabolism;pathology",
        "_version_":1605800453643173888},
      {
        "Doc_abstract":"To explore the significance of survivin, P16(INK4a), COX-2, and Ki-67 expressions for prediction of cervical cancer progression.;A retrospective study was performed in 129 cases including 24 squamous carcinoma of the cervix (SCC), 70 cervical intraepithelial neoplasias (CIN), 15 cervical condyloma acuminatum (CCA), ten chronic cervicitis (CC), and ten normal cervix (NC). Protein expressions were evaluated using immunohistochemistry.;Survivin, P16(INK4a); COX-2, and Ki-67 were highly expressed in SCC and CIN compared with others. Their expression rates were gradually increased in CIN I, CIN II, CIN III, and SCC groups, showing 72.00%, 88.00%, 90.00%, and 95.83% for P16(INK4a), 68.00%, 84.00%, 95.00% and 100.00% for COX-2, 76.00%, 96.00%, 100.00%, and 100.00 for Ki-67, respectively. There were significant correlations between survivin and P16(INK4a), COX-2, Ki-67, as well as P16(INK4a) and Ki-67.;Survivin, P16(INK4a), COX-2 and Ki-67 play critical roles for development and progression of cervical cancer.",
        "Doc_title":"Expressions of survivin, P16(INK4a), COX-2, and Ki-67 in cervical cancer progression reveal the potential clinical application.",
        "Journal":"European journal of gynaecological oncology",
        "Do_id":"25872337",
        "Doc_ChemicalList":"BIRC5 protein, human;Cyclin-Dependent Kinase Inhibitor p16;Inhibitor of Apoptosis Proteins;Ki-67 Antigen;Cyclooxygenase 2",
        "Doc_meshdescriptors":"Adult;Carcinoma, Squamous Cell;Cervical Intraepithelial Neoplasia;Cervix Uteri;Chronic Disease;Condylomata Acuminata;Cyclin-Dependent Kinase Inhibitor p16;Cyclooxygenase 2;Disease Progression;Female;Humans;Inhibitor of Apoptosis Proteins;Ki-67 Antigen;Middle Aged;Predictive Value of Tests;Retrospective Studies;Uterine Cervical Neoplasms;Uterine Cervicitis",
        "Doc_meshqualifiers":"chemistry;chemistry;pathology;chemistry;metabolism;analysis;analysis;analysis;analysis;chemistry;pathology;metabolism",
        "_version_":1605909603383508992},
      {
        "Doc_abstract":"Phenolphthalein was commonly used as a laxative for most of the 20th century. The use of phenolphthalein in laxatives has decreased since 1997 when the United States Food and Drug Administration (FDA) proposed to withdraw its classification as an over-the-counter drug (21 CFR, Part 310). Phenolphthalein has been previously evaluated in 2-year carcinogenicity studies by the National Toxicology Program (1996). The major route of human exposure to phenolphthalein is via ingestion, dermal contact, and inhalation of contaminated air originating from process units manufacturing the compound. In this study, the carcinogenic effects of phenolphthalein were studied in the haploinsufficient p16(Ink4a)/p19(Arf) mouse model as an ongoing goal of the NTP is to seek model systems for toxicology and carcinogenesis studies, especially those that can provide mechanistic information relative to understanding an agent's mode of action. Male and female haploinsufficient p16(Ink4a)/p19(Arf) mice were exposed to phenolphthalein (greater than 97% pure) in feed for 27 weeks. Genetic toxicology studies were conducted in mouse peripheral blood erythrocytes. 27-WEEK STUDY IN MICE: Groups of 15 male and 15 female mice were exposed to 0, 200, 375, 750, 3,000, or 12,000 ppm phenolphthalein (equivalent to average daily doses of approximately 35, 65, 135, 540, and 2,170 mg phenolphthalein/kg body weight to males and 50, 90, 170, 680, 2,770 mg/kg to females) in feed for 27 weeks. Survival of all exposed groups of male and female mice was similar to that of the control groups. Mean body weights of males in the 12,000 ppm group were less than those of the control group after week 11. No differences in feed consumption were noted between exposed and control groups. Atypical hyperplasia of the thymus, a premalignant change of chemically induced thymic lymphoma, occurred in exposed males and females, and the incidence was significantly increased in 12,000 ppm females. Atrophy of the seminiferous tubules in the testis, hyperplasia of the testicular interstitial (Leydig) cells, and epididymal hypospermia occurred in most 3,000 and 12,000 ppm males. Additionally, the left and right testis weights, the left epididymis weights, sperm motility, the numbers of spermatid heads per testis, and sperm heads per cauda and per gram cauda epididymis were generally significantly less in 3,000 and 12,000 ppm males than in the control group. The incidences of nephropathy were significantly increased in 3,000 and 12,000 ppm males; incidences of hypertrophy of renal tubules were significantly increased in males receiving 750 ppm or greater. Hematopoietic cell proliferation of the spleen occurred in all 12,000 ppm males, and the incidences of this lesion were significantly increased in 375, 750, and 12,000 ppm females.;The frequency of micronucleated erythrocytes was assessed at four time points during the 27-week study in male and female haploinsufficient p16(Ink4a)/p19(Arf) mice. Significant concentration-related increases in micronucleated cells were observed at all time points in male and female mice.;Under the conditions of this 27-week feed study, there was no evidence of carcinogenic activity of phenolphthalein in male or female haploinsufficient p16(Ink4a)/p19(Arf) mice exposed to 200, 375, 750, 3,000, or 12,000 ppm. Because this is a new model, there is uncertainty whether the study possessed sufficient sensitivity to detect a carcinogenic effect. Phenolphthalein induced atypical hyperplasia, a preneoplastic lesion of the thymus, in male and female mice, hematopoietic cell proliferation of the spleen in male and female mice, and toxicity to the kidney and reproductive system in male mice.",
        "Doc_title":"The toxicology and carcinogenesis study of phenolphthalein (CAS No. 77-09-8) in genetically modified haploinsufficient p16(Ink4a)/p19(Arf) mice (feed study).",
        "Journal":"National Toxicology Program genetically modified model report",
        "Do_id":"18784766",
        "Doc_ChemicalList":"Cdkn2a protein, mouse;Cyclin-Dependent Kinase Inhibitor p16;Indicators and Reagents;Laxatives;Phenolphthalein",
        "Doc_meshdescriptors":"Animals;Atrophy;Cyclin-Dependent Kinase Inhibitor p16;Female;Hyperplasia;Hypertrophy;Indicators and Reagents;Kidney;Laxatives;Male;Mice;Mice, Transgenic;Phenolphthalein;Spleen;Testis;Thymus Gland",
        "Doc_meshqualifiers":"chemically induced;pathology;genetics;chemically induced;pathology;chemically induced;pathology;toxicity;drug effects;pathology;toxicity;toxicity;cytology;drug effects;drug effects;pathology;drug effects;pathology",
        "_version_":1605747567248801794},
      {
        "Doc_abstract":"p16(INK4a) immunohistochemistry has revealed a high rate of positivity in cervical intraepithelial neoplasia grade 2 (CIN2) and more severe conditions (CIN2+). The Lower Anogenital Squamous Terminology Standardization project proposed p16(INK4a) immunohistochemistry as an ancillary test for CIN. Immunocytochemistry involving dual staining for p16(INK4a) and Ki-67 in the triage of atypical squamous cells of undetermined significance (ASCUS) and low-grade squamous intraepithelial lesions (LSIL) is reported to be useful in the identification of CIN2+. However, it is unclear whether p16(INK4a)/Ki-67 immunocytochemistry is of practical relevance for the triage of ASCUS and LSIL in the Japanese screening system.;From 427 women fulfilling the eligibility criteria, 188 ASCUS and 239 LSIL specimens were analyzed. The accuracy of p16(INK4a)/Ki-67 immunocytochemistry and genotyping of high-risk human papillomaviruses (HPVs) in detecting CIN2+ were compared.;p16(INK4a)/Ki-67 immunocytochemistry was positive in 33.5 % (63/188) of ASCUS, and 36.8 % (88/239) of LSIL specimens. The sensitivity and specificity of p16(INK4a)/Ki-67 immunocytochemistry was 87.3 % (95 % confidence interval 78.0-93.8 %) and 76.4 % (71.6-80.8 %), respectively. The positive and negative predictive values were 45.7 % (37.6-54.0 %) and 96.4 % (93.4-98.3 %), respectively; positive and negative likelihood ratios were 3.71 and 0.17, respectively. Using the McNemar test, p16(INK4a)/Ki-67 immunocytochemistry showed equivalent sensitivity but higher specificity than the HPV genotyping test;Compared with high-risk HPV genotyping, p16(INK4a)/Ki-67 immunocytochemistry was a more accurate triage test for identifying CIN2+ in ASCUS and LSIL specimens.",
        "Doc_title":"Performance of p16INK4a/Ki-67 immunocytochemistry for identifying CIN2+ in atypical squamous cells of undetermined significance and low-grade squamous intraepithelial lesion specimens: a Japanese Gynecologic Oncology Group study.",
        "Journal":"International journal of clinical oncology",
        "Do_id":"24744261",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;Ki-67 Antigen",
        "Doc_meshdescriptors":"Adult;Asian Continental Ancestry Group;Atypical Squamous Cells of the Cervix;Cervical Intraepithelial Neoplasia;Cyclin-Dependent Kinase Inhibitor p16;Female;Genotype;Humans;Immunohistochemistry;Ki-67 Antigen;Middle Aged;Papillomaviridae;Papillomavirus Infections;Sensitivity and Specificity;Squamous Intraepithelial Lesions of the Cervix;Uterine Cervical Neoplasms;Young Adult",
        "Doc_meshqualifiers":"diagnosis;pathology;immunology;methods;immunology;genetics;diagnosis;pathology;diagnosis;pathology;diagnosis;pathology",
        "_version_":1605811096249171968},
      {
        "Doc_abstract":"Adult T-cell leukemia/lymphoma (ATL) is one of the peripheral T-cell malignant neoplasms strongly associated with human T-cell leukemia virus type-I (HTLV-I). Although the viral transactivator protein Tax has been proposed to play a critical role in leukemogeneis, additional cellular events are required for the development of ATL. One of the genetic events of the disease is inactivation of tumor suppressor genes. The CDKN2A locus on chromosome 9p encodes 2 cell cycle regulatory proteins, p14ARF and p16INK4a, which share exon 2 using different reading frames. The p14ARF and p16INK4a genes have been implicated as tumor suppressor genes by their frequent mutation, deletion or promoter hypermethylation in a variety of human tumors. In this report, we describe the expression status of p14ARF and p16INK4a in 9 ATL cell lines (MT1, MT2, OKM3T, F6T, K3T, Oh13T, S1T, Su9T01 and HUT102). By reverse transcription polymerase chain reaction (RT-PCR), expression of p14ARF was not detected in one cell line (OKM3T), while expression of p16INK4a was not detected in 6 cell lines (OKM3T, MT1, MT2, Oh13T, S1T and Su9T01). In the OKM3T cell line, the shared exon 2 of the p14ARF/p16INK4a gene was deleted; however, the p16INK4a gene, was epigenetically inactivated in 5 other cells lines. In primary tumor cells obtained from ATL patients, p14ARF expression was absent in 6 of the 11 samples. We confirmed the methylation of the p16INK4a gene in MT1 and MT2 cells using the methylation-specific PCR (MSP) method. Treatment with 2.0 M of Azacitidine (AZA), a demethylating agent, for 72 h restored p16INK4a transcript expression and induced growth inhibition in MT2 cells. Our results demonstrate that p16INK4a is epigenetically silenced in ATL. AZA offers a potential new therapeutic approach to improve the poor outcomes associated with ATL.",
        "Doc_title":"Azacitidine induces demethylation of p16INK4a and inhibits growth in adult T-cell leukemia/lymphoma.",
        "Journal":"International journal of molecular medicine",
        "Do_id":"21785817",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;Azacitidine",
        "Doc_meshdescriptors":"Azacitidine;Cell Line, Tumor;Cell Proliferation;Cyclin-Dependent Kinase Inhibitor p16;Humans;Leukemia-Lymphoma, Adult T-Cell;Methylation;Polymerase Chain Reaction;Reverse Transcriptase Polymerase Chain Reaction",
        "Doc_meshqualifiers":"pharmacology;drug effects;metabolism;metabolism;drug effects",
        "_version_":1605905250406891520},
      {
        "Doc_abstract":"Squamous cell carcinomas of the anal canal are associated with infection with Human Papilloma Viruses (HPVs). Chemo-radiotherapy (CRT) gives 70% 3-year relapse-free survival. Improved predictive markers and therapeutic options are required.;Tumours from 153 patients treated with radical chemo-radiotherapy (50.4 Gy in 28# with concurrent Mitomycin and 5-Fluorouracil between 2004 and 2009) were retrieved and immunohistochemistry performed for p16(INK4A), p53 and EGFR and correlated with outcome. Primary and relapsed samples were analysed for mutations in KRAS.;137/153 (89.5%) stained moderately or strongly for p16(INK4A). p16(INK4A) correlated strongly with outcome. 37/137 patients demonstrating moderate/strong p16(INK4A) expression relapsed (27.0%), as opposed to 10/16 (62.5%) with absent/weak staining (log rank test p<0.001). p16 and p53 expression were inversely correlated. p16(INK4A) negative tumours were more frequent in men. p16(INK4A) negative patients had significantly worse overall survival (p<0.001). No mutations in KRAS were identified in primary tumours or relapses following treatment.;p16(INK4A) is strongly associated with relapse in SCC of the anus and identifies patients with very poor rates of relapse-free and overall survival. Primary and recurrent anal cancer expresses wild type KRAS, unaffected by treatment, supporting trials targeting EGFR in poor risk/recurrent anal cancer.",
        "Doc_title":"p16INK4A, p53, EGFR expression and KRAS mutation status in squamous cell cancers of the anus: correlation with outcomes following chemo-radiotherapy.",
        "Journal":"Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology",
        "Do_id":"24021343",
        "Doc_ChemicalList":"KRAS protein, human;Neoplasm Proteins;P16 protein, human;Proto-Oncogene Proteins;Tumor Suppressor Protein p53;Receptor, Epidermal Growth Factor;Proto-Oncogene Proteins p21(ras);ras Proteins",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Anus Neoplasms;Carcinoma, Squamous Cell;Chemoradiotherapy;Female;Humans;Immunohistochemistry;Male;Middle Aged;Mutation;Neoplasm Proteins;Proportional Hazards Models;Proto-Oncogene Proteins;Proto-Oncogene Proteins p21(ras);Receptor, Epidermal Growth Factor;Tumor Suppressor Protein p53;ras Proteins",
        "Doc_meshqualifiers":"chemistry;mortality;pathology;therapy;chemistry;mortality;pathology;therapy;analysis;genetics;analysis;analysis;genetics",
        "_version_":1605819591644151808},
      {
        "Doc_abstract":"The importance of detecting human papillomavirus (HPV) in head and neck squamous cell carcinoma (HNSCC) has resulted in a growing expectation for HPV testing of clinical samples. Although testing protocols vary, most pertain to primary tumor biopsies/resections. Testing of fine-needle aspirates and core biopsies (FNACBs) is advantageous, but it is unclear whether technical and biological factors adversely affect the fidelity of HPV detection in these samples.;Data was collected for 85 patients with regionally metastatic HNSCC that had undergone FNACB with HPV analysis as part of clinical care. HPV testing consisted of p16 immunostaining and HPV in situ hybridization (ISH). The FNACBs were compared with the subsequent biopsies/resections for HPV status.;p16 staining was present in 60 cases (71%). p16 positivity was predictive of oropharyngeal origin (p<0.001) and correlated with the presence of HPV by ISH (98% correlation). On comparison of the metastases and primary cancers, the HPV status was concordant in 58 of 59 cases (98%).;For patients with metastatic HNSCC, p16 staining reliably reflects the HPV status of the primary tumor. p16 staining of FNACBs may obviate the need for more invasive sampling of the primary cancer solely for the purpose of HPV testing.",
        "Doc_title":"The Fidelity of p16 Staining as a Surrogate Marker of Human Papillomavirus Status in Fine-Needle Aspirates and Core Biopsies of Neck Node Metastases: Implications for HPV Testing Protocols.",
        "Journal":"Acta cytologica",
        "Do_id":"25765380",
        "Doc_ChemicalList":"Biomarkers, Tumor;Cyclin-Dependent Kinase Inhibitor p16",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Biomarkers, Tumor;Biopsy, Fine-Needle;Carcinoma, Squamous Cell;Cyclin-Dependent Kinase Inhibitor p16;Female;Head and Neck Neoplasms;Humans;Immunohistochemistry;In Situ Hybridization;Lymph Nodes;Lymphatic Metastasis;Male;Middle Aged;Neck;Papillomaviridae;Papillomavirus Infections;Staining and Labeling;Young Adult",
        "Doc_meshqualifiers":"metabolism;diagnosis;pathology;virology;metabolism;diagnosis;pathology;virology;pathology;pathology;pathology;isolation & purification;diagnosis;pathology",
        "_version_":1605891981904445440},
      {
        "Doc_abstract":"The aim of this study is to evaluate the expression of human papilloma virus (HPV) in oral squamous cell carcinoma (OSCC) and to correlate the association of HPV in histological grades of OSCC using p16 (p16INK4a) immunohistochemistry (IHC).;This study consists of 30 histological diagnosed cases of OSCC (10-well-differentiated oral squamous cell carcinoma [WDOSCC], 10-moderately differentiated oral squamous cell carcinoma [MDOSCC] and 10-poorly differentiated oral squamous cell carcinoma [PDOSCC]). The sections were subjected to IHC procedure using p16. Two parameters in immunohistochemical p16 expression were evaluated by 3 observers based on the criteria by Galgano M. Tetal (2010) (a) percentage of p16 positive cases (b) pattern of p16 staining in various grades of OSCC.;Kappa test.;Totally, 30 samples of 0SCC, p16 positivity was noted in 26/30 (86.66%). Of 26 positive cases, p16 staining was positive in 7/10 (70%) of WDOSCC, 9/10 (90%) in MDOSCC and, 10/10 (100%) PDOSCC. Incidentally, we also found single dispersed cell staining in WDOSCC, patchy staining in MDOSCC and more diffuse staining pattern predominant in PDOSCC.;Our study revealed an association between HPV and OSCC. Diffuse staining pattern was noted in PDOSCC, which in turn depicts the increase viral overload, which might have an influence on its aggressive behavior.",
        "Doc_title":"Analysis of human papilloma virus in oral squamous cell carcinoma using p16: An immunohistochemical study.",
        "Journal":"Journal of International Society of Preventive & Community Dentistry",
        "Do_id":"24818098",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605844706637381632},
      {
        "Doc_abstract":"The epigenetic changes in pituitary adenomas were identified by evaluating the methylation status of nine genes (RB1, p14(ARF), p16(INK4a), p73, TIMP-3, MGMT, DAPK, THBS1 and caspase-8) in a series of 35 tumours using methylation-specific PCR analysis plus sequencing. The series included non-functional adenomas (n=23), prolactinomas (n=6), prolactinoma plus thyroid-stimulating hormone adenoma (n=1), growth hormone adenomas (n=4), and adrenocorticotropic adenoma (n=1). All of the tumours had methylation of at least one of these genes and 40% of samples (14 of 35) displayed concurrent methylation of at least three genes. The frequencies of aberrant methylation were: 20% for RB1, 17% for p14(ARF), 34% for p16(INK4a), 29% for p73, 11% for TIMP-3, 23% for MGMT, 6% for DAPK, 43% for THBS1 and 54% for caspase-8. No aberrant methylation was observed in two non-malignant pituitary samples from healthy controls. Although some differences in the frequency of gene methylation between functional and non-functional adenomas were detected, these differences did not reach statistical significance. Our results suggest that promoter methylation is a frequent event in pituitary adenoma tumourigenesis, a process in which inactivation of apoptosis-related genes (DAPK, caspase-8) might play a key role.",
        "Doc_title":"Promoter CpG methylation of multiple genes in pituitary adenomas: frequent involvement of caspase-8.",
        "Journal":"Oncology reports",
        "Do_id":"16391867",
        "Doc_ChemicalList":"CASP8 protein, human;Caspase 8;Caspases",
        "Doc_meshdescriptors":"Adenoma;Adult;Age Factors;Aged;Caspase 8;Caspases;CpG Islands;DNA Methylation;Epigenesis, Genetic;Female;Genes, Neoplasm;Humans;Immunohistochemistry;Male;Middle Aged;Pituitary Neoplasms;Polymerase Chain Reaction;Promoter Regions, Genetic;Sex Factors",
        "Doc_meshqualifiers":"genetics;metabolism;genetics;genetics;genetics;genetics",
        "_version_":1605902145163362304},
      {
        "Doc_abstract":"Although recent studies have suggested that p16(INK4a) may be a useful surrogate biomarker of cervical neoplasia, Ki-67 and human papillomavirus testing have also been shown to be useful in detecting neoplasia. To help delineate the utility of p16(INK4a), biopsy samples (n = 569: negative, 133; reactive, 75; atypical, 39; low grade, 76; moderate, 80; and severe intraepithelial neoplasia, 113; also, squamous cell carcinoma, 46; adenocarcinoma, 7) were analyzed by immunohistochemistry for expression of p16(INK4a) and Ki-67 (n = 432), as well as by in situ hybridization for human papillomavirus Type 16 (n = 219). Testing for high-risk human papillomavirus types by polymerase chain reaction and HybridCapture2 was performed on concurrent cervical swab specimens. Recuts of the original blocks were reexamined (n = 198). Endometrial biopsies (n = 10) were also analyzed for p16(INK4a) expression. Degree of p16(INK4a) and Ki-67 expression correlated with degree of cervical neoplasia (P <.001) and with presence of high-risk human papillomavirus types (P <.001). There was no relationship between p16(INK4a) overexpression and inflammation or hormonal status. Ki-67 expression correlated with inflammation (P = 0.003) and was expressed in more reactive and atypical lesions than p16(INK4a) (P = 0.008). Probes for human papillomavirus 16 stained 54% of cervical neoplastic lesions; the degree of staining correlated significantly with degree of neoplasia (P <.001) and p16(INK4a) staining (P <.001). Interobserver reproducibility was substantial for p16(INK4a) and Ki-67 interpretation (weighted kappa: 0.74 and 0.70, respectively). Expression of p16(INK4a) was observed in all endometrial biopsies. Compared with Ki-67 expression and detection of high-risk human papillomavirus, p16(INK4a) was less likely to be positive in samples from women with negative, reactive, and atypical biopsies. Although expression of p16(INK4a) in endometrial epithelium may be problematic in terms of screening, the potential of p16(INK4a) as a screening test warrants investigation.",
        "Doc_title":"p16(INK4a) expression correlates with degree of cervical neoplasia: a comparison with Ki-67 expression and detection of high-risk HPV types.",
        "Journal":"Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc",
        "Do_id":"12861062",
        "Doc_ChemicalList":"Biomarkers, Tumor;Cyclin-Dependent Kinase Inhibitor p16;DNA, Viral;Ki-67 Antigen",
        "Doc_meshdescriptors":"Adenocarcinoma;Biomarkers, Tumor;Biopsy;Cervical Intraepithelial Neoplasia;Cyclin-Dependent Kinase Inhibitor p16;DNA, Viral;Female;Humans;In Situ Hybridization;Ki-67 Antigen;Observer Variation;Papillomaviridae;Polymerase Chain Reaction;Reproducibility of Results;Uterine Cervical Neoplasms",
        "Doc_meshqualifiers":"metabolism;pathology;virology;metabolism;pathology;virology;metabolism;analysis;metabolism;classification;genetics;isolation & purification;metabolism;pathology;virology",
        "_version_":1605751968423215104},
      {
        "Doc_abstract":"A-type lamins, predominantly lamins A and C, are nuclear intermediate filaments believed to act as scaffolds for assembly of transcription factors. Lamin A/C is necessary for the retinoblastoma protein (pRB) stabilization through unknown mechanism(s). Two oncoproteins, gankyrin and MDM2, are known to promote pRB degradation in other contexts. Consequently, we tested the hypothesis that gankyrin and/or MDM2 are required for enhanced pRB degradation in Lmna-/- fibroblasts. Principal Findings. To determine if gankyrin promotes pRB destabilization in the absence of lamin A/C, we first analyzed its protein levels in Lmna-/- fibroblasts. Both gankyrin mRNA levels and protein levels are increased in these cells, leading us to further investigate its role in pRB degradation. Consistent with prior reports, overexpression of gankyrin in Lmna+/+ cells destabilizes pRB. This decrease is functionally significant, since gankyrin overexpressing cells are resistant to p16(ink4a)-mediated cell cycle arrest. These findings suggest that lamin A-mediated degradation of pRB would be gankyrin-dependent. However, effective RNAi-enforced reduction of gankyrin expression in Lmna-/- cells was insufficient to restore pRB stability. To test the importance of MDM2, we disrupted the MDM2-pRB interaction by transfecting Lmna-/- cells with p14(arf). p14(arf) expression was also insufficient to stabilize pRB or confer cell cycle arrest, suggesting that MDM2 also does not mediate pRB degradation in Lmna-/- cells.;Our findings suggest that pRB degradation in Lmna-/- cells occurs by gankyrin and MDM2-independent mechanisms, leading us to propose the existence of a third proteasome-dependent pathway for pRB degradation. Two findings from this study also increase the likelihood that lamin A/C functions as a tumor suppressor. First, protein levels of the oncoprotein gankyrin are elevated in Lmna-/- fibroblasts. Second, Lmna-/- cells are refractory to p14(arf)-mediated cell cycle arrest, as was previously shown with p16(ink4a). Potential roles of lamin A/C in the suppression of tumorigenesis are discussed.",
        "Doc_title":"Evidence that proteasome-dependent degradation of the retinoblastoma protein in cells lacking A-type lamins occurs independently of gankyrin and MDM2.",
        "Journal":"PloS one",
        "Do_id":"17896003",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;Lamin Type A;Retinoblastoma Protein;Transcription Factors;Tumor Suppressor Protein p14ARF;gankyrin protein, mouse;Proto-Oncogene Proteins c-mdm2",
        "Doc_meshdescriptors":"Animals;Blotting, Western;Cell Cycle;Cell Line;Cell Line, Tumor;Cyclin-Dependent Kinase Inhibitor p16;Flow Cytometry;Fluorescent Antibody Technique, Indirect;Humans;Lamin Type A;Mice;Mutation;NIH 3T3 Cells;Protein Binding;Proto-Oncogene Proteins c-mdm2;RNA Interference;Retinoblastoma Protein;Retroviridae;Reverse Transcriptase Polymerase Chain Reaction;Transcription Factors;Transfection;Tumor Suppressor Protein p14ARF",
        "Doc_meshqualifiers":"drug effects;genetics;genetics;metabolism;genetics;metabolism;genetics;metabolism;genetics;metabolism;genetics;genetics;metabolism;genetics;metabolism",
        "_version_":1605843711860670464},
      {
        "Doc_abstract":"p53 has been extensively studied in external genital carcinoma (EGC), and is frequently inactivated, but little is known about the role of the CDKN2A tumour suppressor gene in the oncogenesis of EGC.;To investigate the role of CDKN2A and p53 in the pathogenesis of EGCs and their precursor lesions vulval intraepithelial neoplasia (VIN3), penile intraepithelial neoplasia and lichen sclerosus (LS).;By means of CDKN2A and p53 mutation screening (single-strand conformational polymorphism analysis and sequencing), methylation analysis of alternative CDKN2A promoters (methylation-specific polymerase chain reaction) and p53 immununochemistry, we analysed eight invasive EGCs (five from vulva and three from penis) and 25 precancerous lesions (two undifferentiated VIN3 and 23 vulval/penile lesions of LS) from 33 patients.;p53 mutations (mainly transversions) and CDKN2A mutations (including one hot spot) were present in 75% and 50% of invasive tumours, respectively, but were absent in all precancerous lesions. Remarkably, all CDKN2A-mutated tumours also harboured a p53 mutation. CDKN2A or p53 mutations were observed more frequently in LS-derived EGCs than in human papillomavirus-derived EGCs (P = 0.053). A positive anti-p53 staining, but without p53 mutations, was also detected in 30% of LS lesions, suggesting a p53 stabilization in response to inflammation and carcinogenic insult. Methylation of p16(INK4a) and p14(ARF) promoters was not a frequent mechanism of CDKN2A inactivation.;Our study shows a high prevalence of co-inactivating mutations of p53 and/or CDKN2A genes in EGC, that seem to occur preferentially in LS-derived tumours and late in oncogenesis.",
        "Doc_title":"Inactivation of the CDKN2A and the p53 tumour suppressor genes in external genital carcinomas and their precursors.",
        "Journal":"The British journal of dermatology",
        "Do_id":"17300232",
        "Doc_ChemicalList":"DNA, Neoplasm;Tumor Suppressor Protein p53",
        "Doc_meshdescriptors":"Aged;Aged, 80 and over;Carcinoma in Situ;Cell Transformation, Neoplastic;DNA Methylation;DNA, Neoplasm;Female;Gene Silencing;Genes, p16;Genes, p53;Humans;Lichen Sclerosus et Atrophicus;Male;Middle Aged;Penile Neoplasms;Polymorphism, Single-Stranded Conformational;Precancerous Conditions;Promoter Regions, Genetic;Tumor Suppressor Protein p53;Vulvar Lichen Sclerosus;Vulvar Neoplasms",
        "Doc_meshqualifiers":"genetics;genetics;genetics;genetics;genetics;genetics;metabolism;genetics;metabolism;genetics;metabolism;genetics;metabolism",
        "_version_":1605804888407670784},
      {
        "Doc_abstract":"For years, head and neck squamous cell carcinomas (HNSCC) have been among the leading cancers worldwide. Despite considerable efforts, the 5-year survival rate for HNSCC has not changed significantly. To improve this situation, it is necessary to understand the fundamental biological processes leading to the disease and its progression. In addition to known genetic changes in HNSCC, molecular cytogenetic investigations have identified chromosomal regions of gains and losses, but many of the responsible candidate genes have yet to be identified. Furthermore, recent results indicate the importance of epigenetic modifications in HNSCC, such as DNA methylation. Several genes, including the tumor suppressor CDKN2A and other candidates such as DAPK1, MGMT, TIMP3, TCF21, and C/EBPalpha, have been found to harbor hypermethylated regulatory sequences that lead to reduced expression or gene silencing. Hypermethylation in such genes could be used not only as biomarkers for the early detection of HNSCC but also to improve prevention strategies and therapy outcomes.",
        "Doc_title":"[Epigenetic aspects in carcinomas of the head and neck].",
        "Journal":"HNO",
        "Do_id":"18483718",
        "Doc_ChemicalList":"Biomarkers, Tumor;Genetic Markers",
        "Doc_meshdescriptors":"Biomarkers, Tumor;Carcinoma, Squamous Cell;DNA Methylation;Epigenesis, Genetic;Genetic Markers;Genetic Predisposition to Disease;Head and Neck Neoplasms;Humans;Models, Genetic",
        "Doc_meshqualifiers":"genetics;genetics;genetics;genetics;genetics;genetics",
        "_version_":1605822088685289472},
      {
        "Doc_abstract":"The INK4a/ARF locus encodes two tumour suppressor proteins, p16INK4a and p14ARF, which act in the two main cell-cycle control pathways, p16-Rb and p14-p53 respectively. The present study examined the mRNA expression of these genes by reverse transcription-polymerase chain reaction (RT-PCR), and the inactivation mechanisms that alter these levels, in 100 primary breast carcinomas. Furthermore, the interdependence of these mechanisms was examined, since it has been reported that p14ARF is altered in most tumours in concordance with p16INK4a. The results show that promoter hypermethylation, tested by methylation-specific PCR (MSP), was the major mechanism of inactivation of these genes and was present in 31 (31%) and 50 (50%) of the tumours that showed decreased p16INK4a and p14ARF expression, respectively. Hemizygous deletion was the second cause of down-regulation. Homozygous deletion was rare and mutation was absent. In most tumours overexpressing p16INK4a or p14ARF, no detectable inactivation mechanisms were observed. Finally, the results indicate that these proteins are often co-altered in primary breast tumours and that p16INK4a and p14ARF had non-independent behaviour, since they were silenced or overexpressed concomitantly with a significant correlation (p < 0.05).",
        "Doc_title":"Concomitant expression of p16INK4a and p14ARF in primary breast cancer and analysis of inactivation mechanisms.",
        "Journal":"The Journal of pathology",
        "Do_id":"12579530",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;Neoplasm Proteins;RNA, Messenger;RNA, Neoplasm;Tumor Suppressor Protein p14ARF",
        "Doc_meshdescriptors":"Breast Neoplasms;Cyclin-Dependent Kinase Inhibitor p16;DNA Methylation;Female;Gene Expression Regulation, Neoplastic;Gene Silencing;Genes, p16;Humans;Loss of Heterozygosity;Neoplasm Proteins;Polymerase Chain Reaction;Promoter Regions, Genetic;RNA, Messenger;RNA, Neoplasm;Reverse Transcriptase Polymerase Chain Reaction;Tumor Suppressor Protein p14ARF",
        "Doc_meshqualifiers":"genetics;metabolism;biosynthesis;genetics;biosynthesis;genetics;methods;genetics;genetics;genetics;biosynthesis;genetics",
        "_version_":1605750453426978816},
      {
        "Doc_abstract":"The aim of this study was to analyse the alterations of the genes in the CDKN2A/CCND1/CDK4/RB1 pathway in the G1-S phase of the cell cycle during development of head and neck squamous cell carcinoma (HNSCC).;The alterations of these genes were analysed in 22 dysplastic lesions, 26 stage-I/II and 33 stage-III/IV HNSCC tumours of Indian patients.;The alterations [mutation, hypermethylation, homozygous deletion and loss of heterozygosity/microsatellite size alteration (LOH/MA)] in the CDKN2A were found to be highest in 57% of the samples, followed by CCND1 amplification and LOH/MA at the RB1 locus in 14% and 8.5% of the samples, respectively. No dominant CDK4 Arg24Cys mutation was seen in our samples. Comparatively high frequency of CDKN2A alterations (except homozygous deletion) was found in dysplastic head and neck lesions and remained almost constant or increased during progression of the tumour, whereas the homozygous deletion of CDKN2A and the alterations in CCND1 and RB1 genes were seen mainly in the later stages of the tumour.;Our study suggested that mutation/hypermethylation/allelic alterations (LOH/MA) of CDKN2A were associated with the development of dysplastic head and neck lesions. All the other alterations might provide some cumulative effect during progression of later stages of the tumour to have selective growth advantages.",
        "Doc_title":"Differential alterations of the genes in the CDKN2A-CCND1-CDK4-RB1 pathway are associated with the development of head and neck squamous cell carcinoma in Indian patients.",
        "Journal":"Journal of cancer research and clinical oncology",
        "Do_id":"14586645",
        "Doc_ChemicalList":"Proto-Oncogene Proteins;Retinoblastoma Protein;Cyclin D1;CDK4 protein, human;Cyclin-Dependent Kinase 4;Cyclin-Dependent Kinases",
        "Doc_meshdescriptors":"Carcinoma, Squamous Cell;Cyclin D1;Cyclin-Dependent Kinase 4;Cyclin-Dependent Kinases;Female;Genes, p16;Head and Neck Neoplasms;Humans;India;Loss of Heterozygosity;Male;Methylation;Mutation;Polymorphism, Genetic;Promoter Regions, Genetic;Proto-Oncogene Proteins;Retinoblastoma Protein",
        "Doc_meshqualifiers":"genetics;genetics;metabolism;genetics;metabolism;genetics;genetics",
        "_version_":1605880096926728192},
      {
        "Doc_abstract":"Four and a half LIM-only protein 2 (FHL2) has been implicated in multiple signaling pathways that regulate cell growth and tissue homeostasis. We reported previously that FHL2 regulates cyclin D1 expression and that immortalized FHL2-null mouse embryo fibroblasts (MEFs) display reduced levels of cyclin D1 and low proliferative activity.;Here we address the contribution of FHL2 in cell transformation by investigating the effects of oncogenic Ras in FHL2-null context. We show that H-RasV12 provokes cell cycle arrest accompanied by accumulation of p53 and p16(INK4a) in immortalized FHL2(-/-) MEFs. These features contrast sharply with Ras transforming activity in wild type cell lines. We further show that establishment of FHL2-null cell lines differs from conventional immortalization scheme by retaining functional p19(ARF)/p53 checkpoint that is required for cell cycle arrest imposed by Ras. However, after serial passages of Ras-expressing FHL2(-/-) cells, dramatic increase in the levels of D-type cyclins and Rb phosphorylation correlates with the onset of cell proliferation and transformation without disrupting the p19(ARF)/p53 pathway. Interestingly, primary FHL2-null cells overexpressing cyclin D1 undergo a classical immortalization process leading to loss of the p19(ARF)/p53 checkpoint and susceptibility to Ras transformation.;Our findings uncover a novel aspect of cellular responses to mitogenic stimulation and illustrate a critical role of FHL2 in the signalling network that implicates Ras, cyclin D1 and p53.",
        "Doc_title":"The LIM-only protein FHL2 mediates ras-induced transformation through cyclin D1 and p53 pathways.",
        "Journal":"PloS one",
        "Do_id":"19018287",
        "Doc_ChemicalList":"Cdkn2a protein, mouse;Cyclin-Dependent Kinase Inhibitor p16;Fhl2 protein, mouse;Homeodomain Proteins;LIM-Homeodomain Proteins;Muscle Proteins;Transcription Factors;Tumor Suppressor Protein p53;Cyclin D1;Lim Kinases;ras Proteins",
        "Doc_meshdescriptors":"Animals;Cell Line;Cell Line, Transformed;Cell Nucleus;Cyclin D1;Cyclin-Dependent Kinase Inhibitor p16;Fibroblasts;Homeodomain Proteins;LIM-Homeodomain Proteins;Lim Kinases;Mice;Models, Biological;Muscle Proteins;Phenotype;Signal Transduction;Transcription Factors;Tumor Suppressor Protein p53;ras Proteins",
        "Doc_meshqualifiers":"metabolism;metabolism;metabolism;metabolism;metabolism;physiology;metabolism;metabolism;physiology;metabolism;physiology;metabolism;metabolism",
        "_version_":1605818752418447361},
      {
        "Doc_abstract":"The link between head and neck squamous cell cancer (HNSCC), especially oropharyngeal cancer, and HPV has become established. HPV16 is the most common genotype in these tumours but HPV6 and HPV11 can also be found in a minority of these cancers, implying that these low-risk HPV types are not entirely benign in the head and neck region. HPV status is also associated with p16 expression and HPV+ tumours are less likely to harbour p53 mutations. HPV DNA is closely associated with poorly differentiated cancers, positive lymph nodes and late-stage disease, which all indicate poor prognosis. Contradictory to this, patients with HPV+ HNSCC seem to have significantly improved response to chemotherapy and radiotherapy as compared with HPV-negative tumours. Interestingly, the risk factors of HNSCC are the same as for HPV, including the number of sexual partners, younger age at first sexual intercourse, practice of oral sex, history of genital warts and younger age.",
        "Doc_title":"The role of human papillomavirus infection in head and neck cancers.",
        "Journal":"Annals of oncology : official journal of the European Society for Medical Oncology",
        "Do_id":"20943622",
        "Doc_ChemicalList":"DNA, Viral;Papillomavirus Vaccines",
        "Doc_meshdescriptors":"Carcinoma;Carcinoma, Squamous Cell;DNA, Viral;Genetic Testing;Head and Neck Neoplasms;Humans;Neoplasms, Squamous Cell;Oropharyngeal Neoplasms;Papillomaviridae;Papillomavirus Infections;Papillomavirus Vaccines;Prognosis",
        "Doc_meshqualifiers":"complications;epidemiology;prevention & control;virology;isolation & purification;complications;epidemiology;prevention & control;virology;complications;epidemiology;prevention & control;virology;complications;epidemiology;virology;isolation & purification;physiology;complications;diagnosis;epidemiology;therapy;therapeutic use",
        "_version_":1605792664384438272},
      {
        "Doc_abstract":"ARF couples with TP53 in a canonical signaling pathway to activate cellular senescence for tumor suppressive function under oncogenic insults. However, the mechanisms on aberrant elevation of ARF in cancers are still poorly understood. We previously showed that ARF (p14ARF in human and p19Arf in mouse) elevation correlates with PTEN loss and stabilizes SLUG to reduce cell adhesion in prostate cancer (PCa). Here we report that ARF is essential for MMP7 expression, E-Cadherin decrease and the anchorage loss to the extracellular matrix (ECM) in PCa in vitro and in vivo. We found that Mmp7 is aberrantly elevated in cytosol and nucleus of malignant prostate tumors of Pten/Trp53 mutant mice. Interestingly, p19Arf deficiency strikingly decreases Mmp7 levels but increases E-Cadherin in Pten/Trp53/p19Arf mice. ARF knockdown markedly reduces MMP7 in human PCa cells. Conversely, tetracycline-inducible expression of ARF increases MMP7 with a decrease of E-Cadherin in PCa cells. Importantly, MMP7 physically binds ARF to show the co-localization in nucleus. Co-expression of MMP7 and ARF promotes cell migration, and MMP7 knockdown decreases wound healing in PCa cells. Furthermore, MMP7 elevation correlates with ARF expression in advanced human PCa. Our findings reveal for the first time that the crosstalk between ARF and MMP7 in nucleus contributes to ECM network in tumor microenvironments in vivo, implicating a novel therapeutic target for advanced PCa treatment.",
        "Doc_title":"MMP7 interacts with ARF in nucleus to potentiate tumor microenvironments for prostate cancer progression in vivo.",
        "Journal":"Oncotarget",
        "Do_id":"27356744",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605812113459118080},
      {
        "Doc_abstract":"Tumor cell lines are commonly used as experimental tools in cancer research, but their relevance for the in vivo situation is debated. In a series of 11 microsatellite stable (MSS) and 9 microsatellite unstable (MSI) colon cancer cell lines and primary colon carcinomas (25 MSS and 28 MSI) with known ploidy stem line and APC, KRAS, and TP53 mutation status, we analyzed the promoter methylation of the following genes: hMLH1, MGMT, p16INK4a (CDKN2A alpha-transcript), p14ARF (CDKN2A beta-transcript), APC, and E-cadherin (CDH1). We compared the DNA methylation profiles of the cell lines with those of the primary tumors. Finally, we examined if the epigenetic changes were associated with known genetic markers and/or clinicopathological variables.;The cell lines and primary tumors generally showed similar overall distribution and frequencies of gene methylation. Among the cell lines, 15%, 50%, 75%, 65%, 20% and 15% showed promoter methylation for hMLH1, MGMT, p16INK4a, p14ARF, APC, and E-cadherin, respectively, whereas 21%, 40%, 32%, 38%, 32%, and 40% of the primary tumors were methylated for the same genes. hMLH1 and p14ARF were significantly more often methylated in MSI than in MSS primary tumors, whereas the remaining four genes showed similar methylation frequencies in the two groups. Methylation of p14ARF, which indirectly inactivates TP53, was seen more frequently in tumors with normal TP53 than in mutated samples, but the difference was not statistically significant. Methylation of p14ARF and p16INK4a was often present in the same primary tumors, but association to diploidy, MSI, right-sided location and female gender was only significant for p14ARF. E-cadherin was methylated in 14/34 tumors with altered APC further stimulating WNT signaling.;The present study shows that colon cancer cell lines are in general relevant in vitro models, comparable with the in vivo situation, as the cell lines display many of the same molecular alterations as do the primary carcinomas. The combined pattern of epigenetic and genetic aberrations in the primary carcinomas reveals associations between them as well as to clinicopathological variables, and may aid in the future molecular assisted classification of clinically distinct stages.",
        "Doc_title":"A CpG island hypermethylation profile of primary colorectal carcinomas and colon cancer cell lines.",
        "Journal":"Molecular cancer",
        "Do_id":"15476557",
        "Doc_ChemicalList":"Adaptor Proteins, Signal Transducing;Cadherins;Carrier Proteins;Cyclin-Dependent Kinase Inhibitor p16;MLH1 protein, human;Neoplasm Proteins;Nuclear Proteins;Tumor Suppressor Protein p14ARF;O(6)-Methylguanine-DNA Methyltransferase;MutL Protein Homolog 1",
        "Doc_meshdescriptors":"Adaptor Proteins, Signal Transducing;Cadherins;Carrier Proteins;Cell Line, Tumor;Colonic Neoplasms;Colorectal Neoplasms;CpG Islands;Cyclin-Dependent Kinase Inhibitor p16;DNA Methylation;Female;Genes, APC;Humans;Male;Microsatellite Repeats;MutL Protein Homolog 1;Neoplasm Proteins;Nuclear Proteins;O(6)-Methylguanine-DNA Methyltransferase;Promoter Regions, Genetic;Sex Factors;Tumor Suppressor Protein p14ARF",
        "Doc_meshqualifiers":"genetics;genetics;pathology;genetics;pathology;genetics;genetics;genetics;genetics;genetics",
        "_version_":1605746353568219137},
      {
        "Doc_abstract":"Latent infection by Epstein-Barr virus (EBV) is highly associated with the endemic form of Burkitt lymphoma (eBL), which typically limits expression of EBV proteins to EBNA-1 (Latency I). Interestingly, a subset of eBLs maintain a variant program of EBV latency - Wp-restricted latency (Wp-R) - that includes expression of the EBNA-3 proteins (3A, 3B and 3C), in addition to EBNA-1. In xenograft assays, Wp-R BL cell lines were notably more tumorigenic than their counterparts that maintain Latency I, suggesting that the additional latency-associated proteins expressed in Wp-R influence cell proliferation and/or survival. Here, we evaluated the contribution of EBNA-3A. Consistent with the enhanced tumorigenic potential of Wp-R BLs, knockdown of EBNA-3A expression resulted in abrupt cell-cycle arrest in G0/G1 that was concomitant with conversion of retinoblastoma protein (Rb) to its hypophosphorylated state, followed by a loss of Rb protein. Comparable results were seen in EBV-immortalized B lymphoblastoid cell lines (LCLs), consistent with the previous observation that EBNA-3A is essential for sustained growth of these cells. In agreement with the known ability of EBNA-3A and EBNA-3C to cooperatively repress p14(ARF) and p16(INK4a) expression, knockdown of EBNA-3A in LCLs resulted in rapid elevation of p14(ARF) and p16I(NK4a). By contrast, p16(INK4a) was not detectably expressed in Wp-R BL and the low-level expression of p14(ARF) was unchanged by EBNA-3A knockdown. Amongst other G1/S regulatory proteins, only p21(WAF1/CIP1), a potent inducer of G1 arrest, was upregulated following knockdown of EBNA-3A in Wp-R BL Sal cells and LCLs, coincident with hypophosphorylation and destabilization of Rb and growth arrest. Furthermore, knockdown of p21(WAF1/CIP1) expression in Wp-R BL correlated with an increase in cellular proliferation. This novel function of EBNA-3A is distinct from the functions previously described that are shared with EBNA-3C, and likely contributes to the proliferation of Wp-R BL cells and LCLs.",
        "Doc_title":"Epstein-Barr virus nuclear antigen 3A promotes cellular proliferation by repression of the cyclin-dependent kinase inhibitor p21WAF1/CIP1.",
        "Journal":"PLoS pathogens",
        "Do_id":"25275486",
        "Doc_ChemicalList":"Antigens, Viral;Cyclin-Dependent Kinase Inhibitor p21;EBV-encoded nuclear antigen 1;Epstein-Barr Virus Nuclear Antigens;lymphocryptovirus nuclear antigen 3A;Cyclin-Dependent Kinases",
        "Doc_meshdescriptors":"Animals;Antigens, Viral;Burkitt Lymphoma;Cell Line;Cell Proliferation;Cyclin-Dependent Kinase Inhibitor p21;Cyclin-Dependent Kinases;Epstein-Barr Virus Nuclear Antigens;Humans;Mice",
        "Doc_meshqualifiers":"metabolism;virology;physiology;metabolism;genetics;metabolism;metabolism",
        "_version_":1605874157276364800},
      {
        "Doc_abstract":"The p16INK4a gene is often disrupted or transcriptionally silenced by CpG island methylation in human cancers. However, in acute myeloid leukaemia (AML) alterations of the INK4a-ARF tumour suppressor locus are rarely found despite the noted variable p16INK4a mRNA and protein levels. The p14ARF, an alternative reading frame protein encoded from the same INK4a-ARF locus, is a potent tumour suppressor functionally linked to p53. There is little known regarding the role of p14ARF in primary human tumours. Therefore, we analysed the expression patterns of these two tumour suppressors in 37 cases of AML. The relative expression of p16INK4a and p14ARF mRNA in AML blasts, measured by a specific p16INK4a/p14ARF multiplex RT-PCR, was significantly shifted towards p14ARF whereas relatively lower levels of p16INK4a were detected. Quantitative RT-PCR revealed significantly higher expression of both transcripts in AML blasts when compared to normal differentiated myeloid cells or CD34+ progenitor cells. Furthermore, a good correlation between p16INK4a protein and mRNA was observed, whereas no correlation was found with p14ARF. Our results suggest: a) increased levels of both p16INK4a and p14ARF may participate in the pathogenesis of AML, b) that high p14ARF mRNA expression might influence p16INK4a transcription and c) that post-transcriptional regulatory mechanisms are important for p14ARF expression.",
        "Doc_title":"Different p16INK4a and p14ARF expression patterns in acute myeloid leukaemia and normal blood leukocytes.",
        "Journal":"Leukemia & lymphoma",
        "Do_id":"11697625",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;RNA, Neoplasm;Tumor Suppressor Protein p14ARF",
        "Doc_meshdescriptors":"Acute Disease;Cyclin-Dependent Kinase Inhibitor p16;Gene Expression Regulation;Humans;Leukemia, Myeloid;Leukocytes;RNA, Neoplasm;Reverse Transcriptase Polymerase Chain Reaction;Stem Cells;Tumor Suppressor Protein p14ARF",
        "Doc_meshqualifiers":"genetics;metabolism;etiology;metabolism;pathology;cytology;metabolism;analysis;cytology;metabolism;genetics;metabolism",
        "_version_":1605837171749552128},
      {
        "Doc_abstract":"The molecular biology underlying the development of highly malignant peripheral nerve sheath tumors (MPNSTs) remains mostly unknown. In the present study, the expression pattern of 10 selected cell cycle components is investigated in a series of 15 MPNSTs from patients with (n = 9) or without (n = 5) neurofibromatosis type 1 (NF1). Thirteen tumors did not express the cyclin-dependent kinase inhibitor, p16(INK4A), an observation that was related to homozygote gene deletions in three tumors, heterozygote deletions in five, and gross gene rearrangements in five. The absence of protein expression in the tumors with one seemingly intact allele was not caused by promoter hypermethylation of p16(INK4A) or p14(ARF). All tumor samples expressed normal sized RB1, cyclin D3, CDK2, CDK4, p21(CIP1), and p27(KlP1) proteins, and only a single tumor showed an aberrant protein band for one of these proteins, p21(CIP1). Cyclin D1 was absent in four tumors; all except one tumor showed expression of TP53 protein, and three of nine MPNSTs had expression of normal-sized MDM2. In conclusion, this study shows that the vast majority of MPNSTs had gross rearrangements of the p16(INK4A) gene, explaining the absence of the encoded protein in the same tumors. The level of expression was equally distributed between the familial (NF1) and sporadic cases, although it should be noted that the 2 cases with p16(INK4A) expression were sporadic. The data imply that the complete absence of p16(INK4A) is sufficient for activation of the cell cycle in most MPNSTs; thus, it is not necessary for tumor proliferation to further stimulate the cycle through alteration of other central components.",
        "Doc_title":"Expression patterns of cell cycle components in sporadic and neurofibromatosis type 1-related malignant peripheral nerve sheath tumors.",
        "Journal":"Journal of neuropathology and experimental neurology",
        "Do_id":"15715087",
        "Doc_ChemicalList":"Cell Cycle Proteins;Cyclin-Dependent Kinase Inhibitor p16;Retinoblastoma Protein;Tumor Suppressor Protein p53",
        "Doc_meshdescriptors":"Adult;Aged;Blotting, Western;Cell Cycle;Cell Cycle Proteins;Cyclin-Dependent Kinase Inhibitor p16;Female;Gene Expression Regulation, Neoplastic;Humans;Male;Middle Aged;Nerve Sheath Neoplasms;Neurofibromatosis 1;Retinoblastoma Protein;Tumor Suppressor Protein p53",
        "Doc_meshqualifiers":"biosynthesis;genetics;biosynthesis;genetics;genetics;metabolism;pathology;genetics;metabolism;pathology;biosynthesis;genetics;biosynthesis;genetics",
        "_version_":1605819488801914880},
      {
        "Doc_abstract":"The bmi-1 gene was first isolated as an oncogene that cooperates with c-myc in the generation of mouse lymphomas. We subsequently identified Bmi-1 as a transcriptional repressor belonging to the mouse Polycomb group. The Polycomb group comprises an important, conserved set of proteins that are required to maintain stable repression of specific target genes, such as homeobox-cluster genes, during development. In mice, the absence of bmi-1 expression results in neurological defects and severe proliferative defects in lymphoid cells, whereas bmi-1 overexpression induces lymphomas. Here we show that bmi-1-deficient primary mouse embryonic fibroblasts are impaired in progression into the S phase of the cell cycle and undergo premature senescence. In these fibroblasts and in bmi-1-deficient lymphocytes, the expression of the tumour suppressors p16 and p19Arf, which are encoded by ink4a, is raised markedly. Conversely, overexpression of bmi-1 allows fibroblast immortalization, downregulates expression of p16 and p19Arf and, in combination with H-ras, leads to neoplastic transformation. Removal of ink4a dramatically reduces the lymphoid and neurological defects seen in bmi-1-deficient mice, indicating that ink4a is a critical in vivo target for Bmi-1. Our results connect transcriptional repression by Polycomb-group proteins with cell-cycle control and senescence.",
        "Doc_title":"The oncogene and Polycomb-group gene bmi-1 regulates cell proliferation and senescence through the ink4a locus.",
        "Journal":"Nature",
        "Do_id":"9923679",
        "Doc_ChemicalList":"BMI1 protein, human;Bmi1 protein, mouse;Cyclin-Dependent Kinase Inhibitor p16;Nuclear Proteins;Proteins;Proto-Oncogene Proteins;Repressor Proteins;Tumor Suppressor Protein p14ARF;Polycomb Repressive Complex 1",
        "Doc_meshdescriptors":"Animals;Cell Aging;Cell Cycle;Cell Division;Cells, Cultured;Cyclin-Dependent Kinase Inhibitor p16;Fibroblasts;Gene Expression Regulation;Genes, Tumor Suppressor;Humans;Mice;Mice, Knockout;Nuclear Proteins;Oncogenes;Polycomb Repressive Complex 1;Proteins;Proto-Oncogene Proteins;Repressor Proteins;Tumor Suppressor Protein p14ARF",
        "Doc_meshqualifiers":"genetics;physiology;physiology;genetics;physiology;genetics;physiology;genetics;physiology;genetics;physiology",
        "_version_":1605789708203327488},
      {
        "Doc_abstract":"Studies in cervical dysplasia have reported overexpression of the tumour suppressors p14 and p16 - and absence of p53 - in high-risk human papilloma virus (HPV)- associated lesions. In skin carcinogenesis, the relation between these tumour suppressors and HPV remain unclear. We evaluated the expression of the tumour suppressors p14, p16 and p53 in pre-malignant and malignant squamous skin tumours, and its relation with risk factors for skin carcinogenesis (HPV, immune status and sun exposure). We performed immunohistochemical stainings for p14, p16 and p53 on paraffin embedded material of 71 pre-malignant squamous skin lesions and 34 squamous cell carcinomas, from 52 renal transplant recipients (RTRs) and 53 immunocompetent individuals. PCR-based assays were used for detection and genotyping of beta-papilloma virus (beta-PV) types and mucosal HPV types. P14 expression was independent of the expression of p16 and p53, irrespective of immune status and skin site. In 49 of 105 specimens (46.6%), one or more beta-PV types were detected. We found no significant association between p14, p16 or p53 protein expression and overall presence of beta-PV, irrespective of immune status. There was a significant association between presence of beta-PV and lesions from sun-exposed skin sites in the RTRs (P = 0.002). We conclude that in skin carcinogenesis, relations between the herein studied tumour suppressors and HPV are different from what one would expect based on findings in cervical neoplasia. P14, p16 and p53 expressions are independent of immune status. Our data indicate that in immunosuppressed patients, beta-PV together with ultraviolet radiation act synergetic in promoting carcinogenesis.",
        "Doc_title":"Expression of p14ARF, p16INK4a and p53 in relation to HPV in (pre-)malignant squamous skin tumours.",
        "Journal":"Journal of cellular and molecular medicine",
        "Do_id":"18681909",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;Tumor Suppressor Protein p14ARF;Tumor Suppressor Protein p53",
        "Doc_meshdescriptors":"Carcinoma, Squamous Cell;Cyclin-Dependent Kinase Inhibitor p16;Humans;Papillomaviridae;Precancerous Conditions;Skin Neoplasms;Tumor Suppressor Protein p14ARF;Tumor Suppressor Protein p53",
        "Doc_meshqualifiers":"metabolism;virology;metabolism;isolation & purification;metabolism;virology;metabolism;virology;metabolism;metabolism",
        "_version_":1605784937487663104},
      {
        "Doc_abstract":"Previous studies have reported <5% incidence of contralateral nodal metastasis in patients with T1-2 tonsillar squamous cell carcinoma. We analyzed the nodal staging of T1-2 tonsillar squamous cell carcinoma stratified for p16 status, a marker of human papillomavirus positivity.;Clinical and radiographic nodal staging and p16 status of 41 T1-2 tonsillar squamous cell carcinoma patients who were treated between January 2002 and June 2009 were retrospectively analyzed. Patients with a history of prior head and neck cancer, synchronous cancers, base of tongue or soft palate invasion, or distant metastases at diagnosis were excluded.;Of the 41 patients, 28 (68.2%) had p16+ tumors and 13 (31.7%) had p16- tumors. Seven patients (17.0%) presented with contralateral cervical nodal disease, all of whom had p16+ tumors. Furthermore, 25.0% of patients with p16+ tumors presented with contralateral cervical nodal disease compared with 0% of patients with p16- tumors.;Patients with p16+ T1-2 tonsillar squamous cell carcinoma present with a higher incidence of contralateral nodal spread than those patients with p16- disease. This may have clinical implications when determining which patients are good candidates for ipsilateral cervical nodal irradiation.",
        "Doc_title":"Clinical nodal staging of T1-2 tonsillar squamous cell carcinoma stratified by p16 status and implications for ipsilateral neck irradiation.",
        "Journal":"Cancer journal (Sudbury, Mass.)",
        "Do_id":"20526108",
        "Doc_ChemicalList":"Biomarkers, Tumor;Neoplasm Proteins;P16 protein, human",
        "Doc_meshdescriptors":"Biomarkers, Tumor;Carcinoma, Squamous Cell;Humans;Lymphatic Metastasis;Neoplasm Proteins;Retrospective Studies;Tonsillar Neoplasms",
        "Doc_meshqualifiers":"metabolism;metabolism;pathology;radiotherapy;radiotherapy;metabolism;metabolism;pathology;radiotherapy",
        "_version_":1605751564079726592},
      {
        "Doc_abstract":"Malignant Mesothelioma (MM) is a very aggressive cancer with low survival rates and often diagnosed at an advanced stage. Several players have been implicated in the development of this cancer, such as asbestos, erionite and the simian virus 40 (SV40). Here, we have reviewed the involvement of erionite, SV40, as well as, the role of several genes (p16(INK4a), p14(ARF), NF2, LATS2, SAV, CTNNB1 and among others), the pathways (RAS, PI3K, Wnt, BCL and Hippo), and their respective roles in the development of MM. ",
        "Doc_title":"The role of key genes and pathways involved in the tumorigenesis of Malignant Mesothelioma.",
        "Journal":"Biochimica et biophysica acta",
        "Do_id":"24491449",
        "Doc_ChemicalList":"erionite;Zeolites;Asbestos;Phosphatidylinositol 3-Kinases",
        "Doc_meshdescriptors":"Asbestos;Carcinogenesis;Cell Transformation, Neoplastic;Humans;Lung Neoplasms;Mesothelioma;Phosphatidylinositol 3-Kinases;Signal Transduction;Simian virus 40;Zeolites",
        "Doc_meshqualifiers":"toxicity;genetics;genetics;pathology;etiology;genetics;pathology;etiology;genetics;pathology;genetics;metabolism;genetics;pathogenicity;toxicity",
        "_version_":1605812814348288000},
      {
        "Doc_abstract":"Indicators of poor oral health, including smoking, have been associated with increased risk of head and neck squamous cell carcinoma, especially oropharyngeal squamous cell carcinoma (OPSCC), yet few studies have examined whether this association is modified by human papillomavirus (HPV) status.;Data from interviews and tumor HPV status from a large population-based case-control study, the Carolina Head and Neck Cancer Study (CHANCE), were used to estimate the association between oral health indicators and smoking among 102 HPV-positive patients and 145 HPV-negative patients with OPSCC and 1396 controls. HPV status was determined by p16INK4a (p16) immunohistochemistry. Unconditional, multinomial logistic regression was used to estimate odds ratios (ORs) for all oral health indictors adjusting for important covariates.;Routine dental examinations were associated with a decreased risk of both HPV-negative OPSCC (OR, 0.52; 95% confidence interval [CI], 0.35-0.76) and HPV-positive OPSCC (OR, 0.55; 95% CI, 0.36-.86). Tooth mobility (a proxy for periodontal disease) increased the risk of HPV-negative disease (OR, 1.70; 95% CI, 1.18-2.43) slightly more than the risk for HPV-positive disease (OR, 1.45; 95% CI, 0.95-2.20). Ten or more pack-years of cigarette smoking were strongly associated with an increased risk of HPV-negative OPSCC (OR, 4.26; 95% CI, 2.85-6.37) and were associated less with an increased risk of HPV-positive OPSCC (OR, 1.62; 95% CI, 1.10-2.38).;Although HPV-positive and HPV-negative HNSCC differ significantly with respect to etiology and tumorigenesis, the current findings suggest a similar pattern of association between poor oral health, frequency of dental examinations, and both HPV-positive and HPV-negative OPSCC. Future research is required to elucidate interactions between poor oral health, tobacco use, and HPV in the development of OPSCC. Cancer 2016.  2016 American Cancer Society.",
        "Doc_title":"Oral health and human papillomavirus-associated head and neck squamous cell carcinoma.",
        "Journal":"Cancer",
        "Do_id":"27571516",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605819868258500608},
      {
        "Doc_abstract":"To evaluate head and neck squamous cell carcinomas (HNSCCs) for differences in protein expression between oral cavity, oropharynx, larynx, and hypopharynx subsites.;Retrospective proteomic analysis using tissue microarray (TMA) and 2-dimensional difference gel electrophoresis (2D-DIGE). For the TMA, automated quantitative protein expression analysis was used to interrogate levels of 4 cell-cycle regulatory proteins chosen for their known roles in cancer (cyclin D1, p53, Rb, and p14). For the 2D-DIGE, lesional and normal adjacent tissues were enriched by laser capture microdissection. Total protein was extracted, analyzed by 2D-DIGE with saturation dye labeling, and evaluated for relative abundance levels of individual protein spots.;Two tertiary-care academic medical centers.;Seventy-one patients with HNSCC for TMA, and 14 patients with HNSCC with frozen tumor and normal tissue for 2D-DIGE.;The automated quantitative analysis of protein expression analysis revealed no difference between subsite for cyclin D1, p53, Rb, or p14 expression. The 2D-DIGE study was based on 28 gels (14 cancer gels and 14 adjacent normal gels), and 732 spots were identified as matching across more than 90% of gels. Significance was evaluated based on false discovery rate (FDR) estimated from permuted data sets. There were no significant differences in protein expression between subsites (FDR greater than or equal to 30% in all instances).;Observed differences in outcomes between HNSCCs from different subsites may not reflect differences in tumor biologic characteristics between subsites. Rather, it is possible that observed clinical heterogeneity among HNSCCs may be based on other factors, such as viral vs chemical carcinogenesis.",
        "Doc_title":"Use of combination proteomic analysis to demonstrate molecular similarity of head and neck squamous cell carcinoma arising from different subsites.",
        "Journal":"Archives of otolaryngology--head & neck surgery",
        "Do_id":"19620592",
        "Doc_ChemicalList":"Membrane Proteins",
        "Doc_meshdescriptors":"Adult;Aged;Carcinoma, Squamous Cell;Electrophoresis, Gel, Two-Dimensional;Female;Head and Neck Neoplasms;Humans;Hypopharyngeal Neoplasms;Laryngeal Neoplasms;Male;Membrane Proteins;Microdissection;Middle Aged;Oropharyngeal Neoplasms;Protein Array Analysis;Proteomics",
        "Doc_meshqualifiers":"genetics;metabolism;therapy;genetics;metabolism;therapy;genetics;metabolism;genetics;metabolism;physiology;methods;genetics;metabolism",
        "_version_":1605800823860756480},
      {
        "Doc_abstract":"Tumor human papillomavirus (HPV) status is an important prognostic factor in locoregionally advanced squamous cell carcinoma of the head and neck (SCCHN). Prognostic value in recurrent and/or metastatic (R/M) disease remains to be confirmed. This retrospective analysis of the EXTREME trial, comparing chemotherapy plus cetuximab with chemotherapy first line in R/M SCCHN, investigated efficacy and prognosis according to tumor p16 and HPV status.;Paired tissue samples were used: p16INK4A expression was assessed by immunohistochemistry, and HPV status determined in extracted DNA samples using oligonucleotide hybridization assays.;Altogether, 416 of 442 patients had tumor samples available for p16 and HPV: 10% of tumors were p16 positive and 5% were HPV positive. Adding cetuximab to chemotherapy improved survival, irrespective of tumor p16 or HPV status. This pattern remained in a combined analysis of p16 and HPV. p16 positivity and HPV positivity were associated with prolonged survival compared with p16 negativity and HPV negativity. Subgroup analysis of patients with oropharyngeal cancer demonstrated a similar pattern to all evaluable patients.;The results from this analysis suggest that p16 and HPV status have prognostic value in R/M SCCHN and survival benefits of chemotherapy plus cetuximab over chemotherapy alone are independent of tumor p16 and HPV status.",
        "Doc_title":"Impact of tumor HPV status on outcome in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck receiving chemotherapy with or without cetuximab: retrospective analysis of the phase III EXTREME trial.",
        "Journal":"Annals of oncology : official journal of the European Society for Medical Oncology",
        "Do_id":"24577117",
        "Doc_ChemicalList":"Antibodies, Monoclonal, Humanized;Cyclin-Dependent Kinase Inhibitor p16;Cetuximab",
        "Doc_meshdescriptors":"Aged;Antibodies, Monoclonal, Humanized;Carcinoma, Squamous Cell;Cetuximab;Cyclin-Dependent Kinase Inhibitor p16;Disease-Free Survival;Female;Head and Neck Neoplasms;Humans;Male;Middle Aged;Neoplasm Metastasis;Neoplasm Recurrence, Local;Papillomaviridae;Prognosis",
        "Doc_meshqualifiers":"administration & dosage;drug therapy;genetics;pathology;virology;genetics;isolation & purification;drug therapy;genetics;pathology;virology;drug therapy;genetics;pathology;virology;genetics;isolation & purification;pathogenicity",
        "_version_":1605742021306220546},
      {
        "Doc_abstract":"Ectopic expression of telomerase blocks both telomeric attrition and senescence, suggesting that telomeric attrition is a mitotic counting mechanism that culminates in replicative senescence. By holding human fibroblast cultures confluent for up to 12 weeks at a time, we confirmed previous observations and showed that telomeric attrition requires cell division and also, that senescence occurs at a constant average telomere length, not at a constant time point. However, on resuming cell division, these long-term confluent (LTC) cultures completed 15-25 fewer mean population doublings (MPDs) than the controls prior to senescence. These lost divisions were mainly accounted for by slow cell turnover of the LTC cultures and by permanent cell cycle exit of 94% of the LTC cells, which resulted in many cell divisions being unmeasured by the MPD method. In the LTC cultures, p27(KIP1) accumulated and pRb became under-phosphorylated and under-expressed. Also, coincident with permanent cell cycle exit and before 1 MPD was completed, the LTC cultures upregulated the cell cycle inhibitors p21(WAF) and p16(INK4A) but not p14(ARF) and developed other markers of senescence. We then tested the relationship between cell cycle re-entry and the cell cycle-inhibitory proteins following subculture of the LTC cultures. In these cultures, the downregulation of p27(KIP1) and the phosphorylation of pRb preceded the complete resumption of normal proliferation rate, which was accompanied by the down-regulation of p16(INK4A). Our results show that most normal human fibroblasts can accumulate p16(INK4A), p21(WAF) and p27(KIP1) and senesce by cell division-independent mechanism(s). Furthermore, this form of senescence likely requires p16(INK4A) and perhaps p27(KIP1).",
        "Doc_title":"Human fibroblast replicative senescence can occur in the absence of extensive cell division and short telomeres.",
        "Journal":"Oncogene",
        "Do_id":"11429701",
        "Doc_ChemicalList":"DNA-Binding Proteins;Recombinant Proteins;telomerase RNA;RNA;Telomerase",
        "Doc_meshdescriptors":"3T3 Cells;Animals;Cell Aging;Cell Division;Cells, Cultured;Coculture Techniques;Colony-Forming Units Assay;DNA-Binding Proteins;Fetus;Fibroblasts;Humans;Mice;RNA;Recombinant Proteins;Retroviridae;Skin;Skin Physiological Phenomena;Telomerase;Telomere;Transfection",
        "Doc_meshqualifiers":"physiology;physiology;cytology;physiology;metabolism;cytology;genetics;metabolism;physiology",
        "_version_":1605823970146254848},
      {
        "Doc_abstract":"The ARF tumor suppressor protein stabilizes p53 by antagonizing its negative regulator, Mdm2 (Hdm2 in humans). Both mouse p19(ARF) and human p14(ARF) bind to the central region of Mdm2 (residues 210 to 304), a segment that does not overlap with its N-terminal p53-binding domain, nuclear import or export signals, or C-terminal RING domain required for Mdm2 E3 ubiquitin ligase activity. The N-terminal 37 amino acids of mouse p19(ARF) are necessary and sufficient for binding to Mdm2, localization of Mdm2 to nucleoli, and p53-dependent cell cycle arrest. Although a nucleolar localization signal (NrLS) maps within a different segment (residues 82 to 101) of the human p14(ARF) protein, binding to Mdm2 and nucleolar import of ARF-Mdm2 complexes are both required for cell cycle arrest induced by either the mouse or human ARF proteins. Because many codons of mouse ARF mRNA are not recognized by the most abundant bacterial tRNAs, we synthesized ARF minigenes containing preferred bacterial codons. Using bacterially produced ARF polypeptides and chemically synthesized peptides conjugated to Sepharose, residues 1 to 14 and 26 to 37 of mouse p19(ARF) were found to interact independently and cooperatively with Mdm2, while residues 15 to 25 were dispensable for binding. Paradoxically, residues 26 to 37 of mouse p19(ARF) are also essential for ARF nucleolar localization in the absence of Mdm2. However, the mobilization of the p19(ARF)-Mdm2 complex into nucleoli also requires a cryptic NrLS within the Mdm2 C-terminal RING domain. The Mdm2 NrLS is unmasked upon ARF binding, and its deletion prevents import of the ARF-Mdm2 complex into nucleoli. Collectively, the results suggest that ARF binding to Mdm2 induces a conformational change that facilitates nucleolar import of the ARF-Mdm2 complex and p53-dependent cell cycle arrest. Hence, the ARF-Mdm2 interaction can be viewed as bidirectional, with each protein being capable of regulating the subnuclear localization of the other.",
        "Doc_title":"Cooperative signals governing ARF-mdm2 interaction and nucleolar localization of the complex.",
        "Journal":"Molecular and cellular biology",
        "Do_id":"10713175",
        "Doc_ChemicalList":"Nuclear Proteins;Peptide Fragments;Proteins;Proto-Oncogene Proteins;Recombinant Proteins;Tumor Suppressor Protein p14ARF;Tumor Suppressor Protein p53;MDM2 protein, human;Mdm2 protein, mouse;Proto-Oncogene Proteins c-mdm2",
        "Doc_meshdescriptors":"3T3 Cells;Amino Acid Sequence;Animals;Cell Cycle;Cell Division;Cell Nucleolus;Fluorescent Antibody Technique;Humans;Mice;Molecular Sequence Data;Mutation;Nuclear Proteins;Peptide Fragments;Protein Binding;Protein Conformation;Proteins;Proto-Oncogene Proteins;Proto-Oncogene Proteins c-mdm2;Recombinant Proteins;Retroviridae;Transfection;Tumor Suppressor Protein p14ARF;Tumor Suppressor Protein p53",
        "Doc_meshqualifiers":"genetics;genetics;metabolism;metabolism;genetics;genetics;metabolism;metabolism;genetics;metabolism",
        "_version_":1605796096633733120},
      {
        "Doc_abstract":"The INK4a/ARF locus encodes two cell cycle-regulatory proteins, p16INK4a and p14ARF. These share an exon using different reading frames, and act through Rb and p53 pathways. Recently, it has been found that silencing of p16INK4a and p14ARF expressions by aberrant methylation of the CpG islands in the promoter regions is an alternative mechanism that inactivates possible tumor suppressor functions in various tumors. To clarify the features of gastric cancers with promoter methylation of p16INK4a and p14ARF, we investigated the methylation status in gastric cancer cell lines and primary gastric cancers using methylation-specific PCR (MSP), and correlated the methylation status with microsatellite instability (MSI), DNA ploidy pattern, p53 immunohistochemistry, and various clinicopathologic factors, paying attention to the correlations with the histologic types. Of 10 cell lines studied, silencing of the expression of p16INK4a and p14ARF due to promoter methylation was detected by MSP and RT-PCR in six (60%) and two (20%) cell lines, respectively. p14ARF silencing was detected only in cell lines derived from gastric cancer of the diffuse type, while p16INK4a silencing was found in cell lines derived from both diffuse and intestinal types. In 59 primary gastric cancers, promoter methylation of p16INK4a and p14ARF was found in 10 (17%) and 14 (24%) of the tumors independently, there being an association with DNA diploidy, but not with p53 immunohistochemistry. p16INK4a methylation was found irrespective of tumor stages and histology. Whereas p14ARF methylation was found more frequently in intestinal type cancers in an early stage and in diffuse type cancers in an advanced stage, MSI tended to be related especially to p14ARF methylation in cancers of the intestinal type. Thus, the significance of p14ARF methylation differed between intestinal and diffuse types, while such a difference was not observed in p16INK4a methylation.",
        "Doc_title":"Promoter methylations of p16INK4a and p14ARF genes in early and advanced gastric cancer. Correlations of the modes of their occurrence with histologic type.",
        "Journal":"Pathology, research and practice",
        "Do_id":"12608655",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;DNA Primers;Tumor Suppressor Protein p14ARF;Tumor Suppressor Protein p53",
        "Doc_meshdescriptors":"CpG Islands;Cyclin-Dependent Kinase Inhibitor p16;DNA Methylation;DNA Primers;Gene Silencing;Humans;Immunohistochemistry;Microsatellite Repeats;Neoplasm Metastasis;Ploidies;Promoter Regions, Genetic;Reverse Transcriptase Polymerase Chain Reaction;Stomach Neoplasms;Tumor Cells, Cultured;Tumor Suppressor Protein p14ARF;Tumor Suppressor Protein p53",
        "Doc_meshqualifiers":"genetics;genetics;metabolism;pathology;genetics;metabolism",
        "_version_":1605901721415974912},
      {
        "Doc_abstract":"Surgical margin status is reported to be a relevant prognostic factor in head and neck squamous cell carcinoma (HNSCC), associated with a high risk of local recurrence. This study examines whether gene-promoter hypermethylation could be detected in HNSCC surgical margins with no histologic evidence of malignancy, and if so, whether it reflects epigenetic events of primary tumors.;Promoter methylation status of MGMT, p16, and DAP-K genes was evaluated by methylation-specific PCR in 20 primary HNSCC tumors. Histopathologically negative surgical margins of hypermethylated tumors were collected, and their methylation status compared with the primary tumor status.;Promoter hypermethylation in at least one of the three tested genes was detected in 65% (13 of 20) of tumors. MGMT was hypermethylated in 50% (10 of 20), DAP-K in 45% (9 of 20), and p16 in 20% (4 of 20) of tumors. Methylation status was analyzed in 35 margins from 11 of 13 patients showing promoter hypermethylation in the tumor tissue. Identical methylation events were seen for at least one gene in primary tumor and surgical margins in 9 of 11 cases (82%). Association was found for gene-specific hypermethylation status in tumors and paired surgical margins, and gene-specific concordance was 63% for MGMT (kappa = 0.24), 90% for DAP-K (kappa = 0.74), and 90% for p16 (kappa = 0.79).;Our results support the hypothesis that detection of gene promoter hypermethylation in HNSCC tumor cells-free surgical margins may be a helpful biomarker to identify molecularly altered fields in areas adjacent to the tumor.",
        "Doc_title":"Association between hypermethylated tumor and paired surgical margins in head and neck squamous cell carcinomas.",
        "Journal":"Clinical cancer research : an official journal of the American Association for Cancer Research",
        "Do_id":"17785562",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Carcinoma, Squamous Cell;DNA Methylation;Female;Head and Neck Neoplasms;Humans;Male;Middle Aged;Prognosis;Promoter Regions, Genetic",
        "Doc_meshqualifiers":"genetics;mortality;surgery;genetics;mortality;surgery",
        "_version_":1605804439459856384},
      {
        "Doc_abstract":"The p16(INK4a) gene methylation has been reported to be a major tumorigenic mechanism.;We evaluated the methylation status of the p16(INK4a) genes in 231 invasive breast cancer and 90 intraductal carcinoma specimens using a methylation-specific polymerase chain reaction and p16 protein expression using immunohistochemistry. The quantity of cell-free methylated p16(INK4a) DNA in the plasma samples of 200 patients with invasive breast cancer was also examined using a fluorescence-based real-time polymerase chain reaction assay.;The frequencies of p16(INK4a) methylation in invasive and intraductal tumors were 52.8% (122/231) and 57.8% (52/90), respectively. The p16 protein was overexpressed in 145 of the 231 invasive carcinomas (62.8%) and 63 of the 90 intraductal carcinomas (70%). High p16 expression in invasive carcinomas correlated significantly with a high histologic grade, a negative estrogen receptor and progesterone receptor status, p53 immunoreactivity and high Ki-67 expression with immunohistochemistry. In addition, the methylation index of p16(INK4a) was significantly higher in the cancer patients than the normal controls (p<0.001).;High p16 immunoreactivity correlated with a loss of differentiation in breast carcinomas and high frequency of p16(INK4a) promoter methylation in both invasive and intraductal carcinomas, suggesting it may be involved in the pathogenesis of breast cancer.",
        "Doc_title":"Methylation and Immunoexpression of p16(INK4a) Tumor Suppressor Gene in Primary Breast Cancer Tissue and Their Quantitative p16(INK4a) Hypermethylation in Plasma by Real-Time PCR.",
        "Journal":"Korean journal of pathology",
        "Do_id":"23323106",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605928374909272064},
      {
        "Doc_abstract":"The cell cycle is composed of a series of steps that can be negatively or positively regulated by various factors. A group of low-molecular-weight proteins have recently been identified that specifically inhibit the function of cyclin-dependent kinases in mammalian cells. Inactivation of the CDKN2A gene (also known as p16INK4A and MTS1) attracted considerable interest after it was mapped to 9p21, a locus for familial melanoma. In an effort to standardize the information regarding human CDKN2A mutations detected in cancers, a database with information of 146 point mutations has been created. Cancer type, origin of cells, specific mutation, amino acid change, literature citation, and other data are provided for each mutation entry. Studies of biochemical and biological functions of both wild-type and mutant proteins are central to our understanding of the role of p16INK4a mutations in tumorigenesis, a summary of these studies is also included in the present update.",
        "Doc_title":"CDKN2A (p16INK4A) somatic and germline mutations.",
        "Journal":"Human mutation",
        "Do_id":"8723678",
        "Doc_ChemicalList":"Carrier Proteins;Cyclin-Dependent Kinase Inhibitor p16",
        "Doc_meshdescriptors":"Carrier Proteins;Cyclin-Dependent Kinase Inhibitor p16;Germ-Line Mutation;Humans;Mutation;Neoplasms",
        "Doc_meshqualifiers":"genetics;genetics",
        "_version_":1605755284946419712},
      {
        "Doc_abstract":"Mucosal squamous cell carcinomas are the most common head and neck malignancies. We hypothesised that over-expression of intracellular signalling proteins and decreased expression of desmoglein molecules would be associated with aggressive tumour behaviour in patients with head and neck squamous cell carcinoma.;Seventy-eight cases of head and neck squamous cell carcinoma were immunohistochemically stained for desmoglein 1, desmoglein 2, desmoglein 3, p53, bcl-2, vimentin, cyclin D1, p16, p21, p27, E-cadherin, and E2F-1 in paraffin-embedded tissue blocks in a microarray.;The disease-specific survival was 56% at 5 years and 49% at 10 years. Expression of the desmoglein isotypes correlated positively with each other except for desmoglein 2 and desmoglein 3, which did not show a significant correlation. Desmoglein 1 and E-cadherin expression also correlated. On univariate analysis, only expression of desmoglein 1 correlated with patient outcome; lack of expression of desmoglein 1 was associated with a significantly worse disease-specific survival (p = 0.035). Hierarchical clustering analysis identified a subgroup of three patients with an immunophenotype distinct from the other tumours, characterised by co-expression of p16, p27, E2F-1 and bcl-2. Further statistical analysis of the prognostic significance of this small subgroup was not possible, but these three patients are alive and well.;Decreased expression of desmoglein 1 is associated with a worse prognosis in head and neck squamous cell carcinoma patients. Examination of an extended panel of immunomarkers revealed a rare subtype of squamous cell carcinoma characterised by the expression of multiple proliferation-associated markers and the anti-apoptotic protein, bcl-2; determination of the prognostic significance of this subgroup will require study of a larger case series.",
        "Doc_title":"Loss of desmoglein 1 expression associated with worse prognosis in head and neck squamous cell carcinoma patients.",
        "Journal":"Pathology",
        "Do_id":"18752129",
        "Doc_ChemicalList":"Biomarkers, Tumor;DSG1 protein, human;Desmoglein 1",
        "Doc_meshdescriptors":"Biomarkers, Tumor;Carcinoma, Squamous Cell;Cluster Analysis;Desmoglein 1;Head and Neck Neoplasms;Humans;Immunohistochemistry;Kaplan-Meier Estimate;Prognosis;Tissue Array Analysis",
        "Doc_meshqualifiers":"analysis;metabolism;mortality;pathology;biosynthesis;metabolism;mortality;pathology",
        "_version_":1605827155628916736},
      {
        "Doc_abstract":"DNA damage induces cell-intrinsic checkpoints, including p53 and retinoblastoma (RB), as well as upstream regulators (exonuclease 1 (EXO1), ataxia telangiectasia mutated (ATM), ATR, p16(INK4a) and p19(ARF)) and downstream targets (p21, PUMA (p53 upregulated modulator of apoptosis) and sestrins). Clearance of damaged cells by cell-intrinsic checkpoints suppresses carcinogenesis but as a downside may impair stem cell and tissue maintenance during ageing. Modulating the activity of DNA damage checkpoints can either accelerate or decelerate tissue ageing and age-related carcinogenesis. The outcome depends on cell-intrinsic and cell-extrinsic mechanisms that regulate the clearance of damaged cells and on the molecular context in ageing tissues, including the level of DNA damage accumulation itself.",
        "Doc_title":"DNA damage checkpoints in stem cells, ageing and cancer.",
        "Journal":"Nature reviews. Molecular cell biology",
        "Do_id":"22914294",
        "Doc_ChemicalList":"Cell Cycle Proteins",
        "Doc_meshdescriptors":"Animals;Cell Aging;Cell Cycle Checkpoints;Cell Cycle Proteins;Cell Transformation, Neoplastic;DNA Damage;Humans;Models, Genetic;Stem Cells;Telomere",
        "Doc_meshqualifiers":"genetics;genetics;genetics;genetics;metabolism;genetics;metabolism",
        "_version_":1605784235390533632},
      {
        "Doc_abstract":"Human colorectal carcinomas display an infiltrative front of invasion where tumor cells undergo an epithelomesenchymal transition associated with low survival. Epithelomesenchymal transition is regulated by a nuclear beta-catenin accumulation, and subsequently, activation of beta-catenin/TCF4 target genes similar to CYCLIN D(1). Unexpectedly, these tumor cells are characterized by low proliferation, which correlates with the expression of the cell cycle inhibitor p16(INK4A). Therefore, we investigated the molecular mechanism of the transcriptional regulation of p16(INK4A) in colorectal cancer and its correlation with survival.;Molecular biological techniques were used for investigating the transcriptional mechanisms of the p16(INK4A) gene regulation. Moreover, p16(INK4A) expression was correlated with the 10-year survival of patients with colorectal carcinomas.;In colorectal carcinomas, expression of the p16(INK4A) gene is regulated by beta-catenin/TCF4 and correlates with low survival rates of patients with tumors displaying an infiltrative front of invasion.;beta-catenin/TCF4 regulates cell cycle promoting (c-MYC, CYCLIN D(1)) and inhibiting genes (p16(INK4A)) at the same time in the mesenchymally differentiated tumor cells at the front of invasion. The function of p16(INK4A) seems to supersede in this context thus leading to low proliferation. Moreover, these tumor cells seem to govern the outcome of colorectal cancer independently of their proliferation.",
        "Doc_title":"p16INK4a is a beta-catenin target gene and indicates low survival in human colorectal tumors.",
        "Journal":"Gastroenterology",
        "Do_id":"18951899",
        "Doc_ChemicalList":"Basic Helix-Loop-Helix Leucine Zipper Transcription Factors;DNA-Binding Proteins;TCF4 protein, human;Transcription Factors;beta Catenin",
        "Doc_meshdescriptors":"Adult;Aged;Basic Helix-Loop-Helix Leucine Zipper Transcription Factors;Cell Line, Tumor;Colorectal Neoplasms;DNA-Binding Proteins;Enhancer Elements, Genetic;Female;Gene Expression Regulation;Genes, p16;Humans;Male;Middle Aged;Neoplasm Invasiveness;Promoter Regions, Genetic;Transcription Factors;beta Catenin",
        "Doc_meshqualifiers":"genetics;mortality;pathology;metabolism;metabolism;physiology",
        "_version_":1605754641275944960},
      {
        "Doc_abstract":"Targeted inactivation of Runx3 in mouse lung induced mucinous and nonmucinous adenomas and markedly shortened latency of adenocarcinoma formation induced by oncogenic K-Ras. RUNX3 was frequently inactivated in K-RAS mutated human lung adenocarcinomas. A functional genetic screen of a fly mutant library and molecular analysis in cultured cell lines revealed that Runx3 forms a complex with BRD2 in a K-Ras-dependent manner in the early phase of the cell cycle; this complex induces expression of p14(ARF)/p19(Arf) and p21(WAF/CIP). When K-Ras was constitutively activated, the Runx3-BRD2 complex was stably maintained and expression of both p14(ARF) and p21(WAF/CIP) was prolonged. These results provide a missing link between oncogenic K-Ras and the p14(ARF)-p53 pathway, and may explain how cells defend against oncogenic K-Ras. ",
        "Doc_title":"Runx3 inactivation is a crucial early event in the development of lung adenocarcinoma.",
        "Journal":"Cancer cell",
        "Do_id":"24229708",
        "Doc_ChemicalList":"CCND1 protein, human;CDKN1A protein, human;Core Binding Factor Alpha 3 Subunit;Cyclin-Dependent Kinase Inhibitor p21;KRAS protein, human;Proto-Oncogene Proteins;Repressor Proteins;Runx3 protein, human;Runx3 protein, mouse;Cyclin D1;BRD2 protein, human;Protein-Serine-Threonine Kinases;HDAC4 protein, human;Histone Deacetylases;ADP-Ribosylation Factors;Kras2 protein, mouse;Proto-Oncogene Proteins p21(ras);ras Proteins",
        "Doc_meshdescriptors":"ADP-Ribosylation Factors;Acetylation;Adenocarcinoma;Alveolar Epithelial Cells;Animals;Carcinogenesis;Cell Differentiation;Cell Line, Tumor;Core Binding Factor Alpha 3 Subunit;Cyclin D1;Cyclin-Dependent Kinase Inhibitor p21;Gene Expression;Gene Knockout Techniques;HEK293 Cells;Histone Deacetylases;Humans;Lung Neoplasms;Mice;Mice, Transgenic;Protein Processing, Post-Translational;Protein-Serine-Threonine Kinases;Proto-Oncogene Proteins;Proto-Oncogene Proteins p21(ras);Repressor Proteins;Respiratory Mucosa;ras Proteins",
        "Doc_meshqualifiers":"metabolism;metabolism;physiology;metabolism;genetics;metabolism;metabolism;metabolism;metabolism;metabolism;metabolism;genetics;metabolism;genetics;metabolism;metabolism;pathology;genetics;metabolism",
        "_version_":1605765874385420288},
      {
        "Doc_abstract":"Squamous cell carcinoma of the urinary bladder is unusual and of unknown etiology. There is a well-established association between human papillomavirus (HPV) infection and the development of cervical and head/neck squamous cell carcinomas. However, the role of HPV in the pathogenesis of squamous cell carcinoma of the urinary bladder is uncertain. The purposes of this study were to investigate the possible role of HPV in the development of squamous cell carcinoma of the urinary bladder and to determine if p16 expression could serve as a surrogate marker for HPV in this malignancy. In all, 42 cases of squamous cell carcinoma of the urinary bladder and 27 cases of urothelial carcinoma with squamous differentiation were investigated. HPV infection was analyzed by both in situ hybridization at the DNA level and immunohistochemistry at the protein level. p16 protein expression was analyzed by immunohistochemistry. HPV DNA and protein were not detected in 42 cases of squamous cell carcinoma (0%, 0/42) or 27 cases of urothelial carcinoma with squamous differentiation (0%, 0/15). p16 expression was detected in 13 cases (31%, 13/42) of squamous cell carcinoma and 9 cases (33%, 9/27) of urothelial carcinoma with squamous differentiation. There was no correlation between p16 expression and the presence of HPV infection in squamous cell carcinoma of the bladder or urothelial carcinoma with squamous differentiation. Our data suggest that HPV does not play a role in the development of squamous cell carcinoma of the urinary bladder or urothelial carcinoma with squamous differentiation. p16 expression should not be used as a surrogate marker for evidence of HVP infection in either squamous cell carcinoma of the urinary bladder or urothelial carcinoma with squamous differentiation as neither HVP DNA nor protein is detectable in these neoplasms.",
        "Doc_title":"p16 expression is not associated with human papillomavirus in urinary bladder squamous cell carcinoma.",
        "Journal":"Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc",
        "Do_id":"22684221",
        "Doc_ChemicalList":"Biomarkers, Tumor;Cyclin-Dependent Kinase Inhibitor p16;DNA, Viral",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Biomarkers, Tumor;Carcinoma, Squamous Cell;Cell Differentiation;Cyclin-Dependent Kinase Inhibitor p16;DNA, Viral;Female;Human Papillomavirus DNA Tests;Humans;Immunohistochemistry;In Situ Hybridization;Male;Middle Aged;Papillomaviridae;Papillomavirus Infections;Predictive Value of Tests;Risk Factors;Urinary Bladder;Urinary Bladder Neoplasms",
        "Doc_meshqualifiers":"analysis;chemistry;pathology;virology;analysis;analysis;genetics;complications;diagnosis;virology;chemistry;pathology;virology;chemistry;pathology;virology",
        "_version_":1605845161658548224},
      {
        "Doc_abstract":"The Cancer Genome Atlas profiled 279 head and neck squamous cell carcinomas (HNSCCs) to provide a comprehensive landscape of somatic genomic alterations. Here we show that human-papillomavirus-associated tumours are dominated by helical domain mutations of the oncogene PIK3CA, novel alterations involving loss of TRAF3, and amplification of the cell cycle gene E2F1. Smoking-related HNSCCs demonstrate near universal loss-of-function TP53 mutations and CDKN2A inactivation with frequent copy number alterations including amplification of 3q26/28 and 11q13/22. A subgroup of oral cavity tumours with favourable clinical outcomes displayed infrequent copy number alterations in conjunction with activating mutations of HRAS or PIK3CA, coupled with inactivating mutations of CASP8, NOTCH1 and TP53. Other distinct subgroups contained loss-of-function alterations of the chromatin modifier NSD1, WNT pathway genes AJUBA and FAT1, and activation of oxidative stress factor NFE2L2, mainly in laryngeal tumours. Therapeutic candidate alterations were identified in most HNSCCs. ",
        "Doc_title":"Comprehensive genomic characterization of head and neck squamous cell carcinomas.",
        "Journal":"Nature",
        "Do_id":"25631445",
        "Doc_ChemicalList":"DNA, Neoplasm;RNA, Neoplasm;Transcription Factors",
        "Doc_meshdescriptors":"Carcinoma, Squamous Cell;DNA Copy Number Variations;DNA, Neoplasm;Female;Gene Expression Regulation, Neoplastic;Genome, Human;Genomics;Head and Neck Neoplasms;Humans;Male;Molecular Targeted Therapy;Mutation;Oncogenes;RNA, Neoplasm;Signal Transduction;Transcription Factors",
        "Doc_meshqualifiers":"genetics;genetics;genetics;genetics;genetics;genetics;genetics;genetics;genetics;genetics;metabolism",
        "_version_":1605763377097867264},
      {
        "Doc_abstract":"The primary goal of this study was to compare the clinical performance of an optimized and rigorously controlled immunocytochemical (ICC) assay for p16(INK4a) to high-risk (HR) human papillomavirus (HPV) detection by polymerase chain reaction (PCR) as diagnostic adjuncts for cytology specimens from colposcopy patients.;: The study included 403 cervical cytology specimens collected within 3 months of colposcopy. The colposcopic impression and cervical biopsy diagnosis served as the standards for correlation with cytological, p16(INK4a), and HPV data. p16(INK4a) was evaluated using an immunoperoxidase-based assay that was linear over 4 logs for the detection of HeLa-spiked positive control cytology specimens, using a threshold for positive test results that was based on receiver operating characteristic curve analysis. HR-HPV was detected by multiplex PCR using genotype-specific primers.;: In all combined diagnostic categories (negative for intraepithelial lesion and malignancy, atypical glandular cells, atypical squamous cells of undetermined significance, atypical squamous cells cannot exclude high-grade squamous intraepithelial lesion, low-grade squamous intraepithelial lesion, and high-grade squamous intraepithelial lesion), the p16(INK4a) ICC and HR-HPV assays, respectively, had sensitivity of 81.7% and 83.3% (P = .81) and specificity of 78.1% and 50.9% (P < .001) for the detection of underlying > or =grade 2 cervical intraepithelial neoplasia (CIN) lesions on biopsy. Furthermore, the positive predictive value of p16(INK4a) ICC was greater than that of HR-HPV for patients with biopsies > or =CIN-2 (41.2% and 24.2%, respectively, P = .001).;: This p16(INK4a) immunocytochemical assay has superior specificity but similar sensitivity to HR-HPV testing to predict underlying high-grade dysplastic lesions in patients who are referred for colposcopy. The determination of the overall performance characteristics of p16(INK4a) immunocytochemistry, as an independent test or in combination with HPV testing in low-risk screening populations, however, will require subsequent large-scale prospective clinical trials.",
        "Doc_title":"p16(INK4a) is superior to high-risk human papillomavirus testing in cervical cytology for the prediction of underlying high-grade dysplasia.",
        "Journal":"Cancer cytopathology",
        "Do_id":"20544710",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;DNA, Viral",
        "Doc_meshdescriptors":"Cervical Intraepithelial Neoplasia;Cyclin-Dependent Kinase Inhibitor p16;DNA, Viral;Female;Humans;Papillomaviridae;Polymerase Chain Reaction;Precancerous Conditions;Risk;Sensitivity and Specificity;Uterine Cervical Dysplasia",
        "Doc_meshqualifiers":"diagnosis;analysis;analysis;isolation & purification;diagnosis;diagnosis;pathology;virology",
        "_version_":1605898115301244928},
      {
        "Doc_abstract":"The cyclin-dependent kinase inhibitor p16INK4a encoded by the INK4A/CDKN2A/MTS1 gene is a frequent target of 9p21 inactivation in human lung cancers. The p14ARF transcript, which is an alternative spliced form of this locus, is also altered or deleted in a proportion of human lung cancers and has been shown to inhibit cell cycle progression as an endogenous cellular regulator of the p53 protein, raising the possibility that it might constitute an additional lung tumor suppressor gene at the 9p21 locus. To test the candidacy of p14ARF as a lung cancer suppressor and assess the role it plays in radiosensitivity, we transfected the wild-type p14ARF gene into four cell lines which had various endogenous gene backgrounds of INK4A-/p53+/RB+ (A549 and H460), INK4A+/p53+/RB- (H446) as well as p14ARF+/p53-/RB+ (Calu-1). We found that transfection of p14ARF is related to an obvious growth inhibition in all wtp53 cell lines, regardless of INK4A/ARF and RB status. Although it has been shown that p53-induced G1 checkpoint in response to DNA damage by ionizing radiation is p14ARF-independent, we found the radiosensitivity of two p14ARF-deficient cell lines was increased after p14ARF gene transfer. The results indicated that cell cycle redistribution after acquiring the exogenous gene might be the main explanation for the enhanced sensitization. An increased radiation-induced apoptotic proportion in one cell line also suggested a fortified p53 function that might be triggered by the restored p14ARF protein.",
        "Doc_title":"The exogenous wild-type p14ARF gene induces growth arrest and promotes radiosensitivity in human lung cancer cell lines.",
        "Journal":"Journal of cancer research and clinical oncology",
        "Do_id":"11414196",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;Proteins;RNA, Messenger;Tumor Suppressor Protein p14ARF",
        "Doc_meshdescriptors":"Cell Cycle;Cell Division;Cell Survival;Cyclin-Dependent Kinase Inhibitor p16;Genes, Tumor Suppressor;Genes, p53;Genetic Therapy;Humans;Lung Neoplasms;Proteins;RNA, Messenger;Radiation Tolerance;Transfection;Tumor Cells, Cultured;Tumor Stem Cell Assay;Tumor Suppressor Protein p14ARF",
        "Doc_meshqualifiers":"radiation effects;radiation effects;genetics;metabolism;pathology;radiotherapy;genetics;physiology;analysis",
        "_version_":1605897325639630848},
      {
        "Doc_abstract":"The product of the p16INK4/CDKN2/MTS1 (p16) controls the transition from the G1 phase to the S-phase in the cell cycle by inhibiting the phosphorylation of the retinoblastoma gene product. A lack of p16 expression has been reported in various cancer cell lines and tumors; however, there have been only a few reports on the prognostic significance of p16 alteration. The authors studied p16 expression in nonsmall cell lung carcinoma (NSCLC) and also examined its correlation with clinicopathologic features and prognosis.;p16 expression was determined by immunohistochemical analysis of 115 paraffin specimens of primary NSCLC that were curatively resected. The immunohistochemical study was performed using the labeled streptavidin-biotin method with anti-p16 rabbit polyclonal antibody.;Thirty-one of 115 NSCLC specimens (27%) showed negative p16 staining. The frequency of negative p16 expression was significantly higher in squamous cell carcinoma (39.5%) than in adenocarcinoma (20.3%) (P = 0.026). There were no statistically significant differences in the p16 status with respect to age, gender, smoking history, histologic differentiation, or stage of the disease. The Kaplan-Meier survival curves demonstrated that patients with negative p16 expression survived for a significantly shorter period of time than those with positive p16 expression (P = 0.043). p16 status was a significant prognostic factor, especially in patients with early stage disease (Stages I-II) (P = 0.039).;A lack of p16INK4 expression in NSCLC was observed more frequently in squamous cell carcinoma than in adenocarcinoma, and also was found to be closely related to prognosis, especially in patients with early stage squamous cell carcinoma.",
        "Doc_title":"Prognostic value of the immunohistochemical detection of p16INK4 expression in nonsmall cell lung carcinoma.",
        "Journal":"Cancer",
        "Do_id":"9241072",
        "Doc_ChemicalList":"Carrier Proteins;Cyclin-Dependent Kinase Inhibitor p16;Neoplasm Proteins",
        "Doc_meshdescriptors":"Adenocarcinoma;Aged;Blotting, Western;Carcinoma, Non-Small-Cell Lung;Carcinoma, Squamous Cell;Carrier Proteins;Cyclin-Dependent Kinase Inhibitor p16;Female;Humans;Immunoenzyme Techniques;Lung Neoplasms;Male;Middle Aged;Neoplasm Proteins;Prognosis;Survival Analysis",
        "Doc_meshqualifiers":"metabolism;metabolism;mortality;pathology;metabolism;metabolism;metabolism;mortality;pathology;metabolism",
        "_version_":1605801434540933120},
      {
        "Doc_abstract":"In addition to cytoreductive surgery, most patients with malignant gliomas also undergo radio- and chemotherapy. An improved understanding of the molecular genetic mechanisms underlying the radio- and chemosensitivity of gliomas may help to identify glioma patients who will benefit from aggressive and, therefore, potentially toxic adjuvant treatment. It may also allow for the development of new therapies aimed at improving the response of these tumors towards chemo- and radiotherapy. The INK4a gene products, p16 and p14ARF, have been suggested as potential regulators of glioma chemo- and radiosensitivity. We have used tetracycline controlled expression of p16 and plasmid-based p14ARF expression to study the chemo- and radiosensitivity of glioma cell lines. Ectopic p16 sensitized U-87MG cells towards treatment with vincristine and possibly also BCNU by approximately 1.5 to 2-fold, and towards ionizing radiation by a factor of 1.5. p14ARF expression was found to render U-87MG cells 2-fold more radioresistant than controls. These findings support a role for p16 and p14ARF as modulators of the radio-and chemosensitivity of gliomas. Further studies of the role of cell cycle regulators in glioma chemo- and radio-sensitivity seem warranted. We would like to point out that such candidate genes which may code for potent growth suppressors (like p16) or even toxic gene products can be successfully investigated using the approach detailed in this manuscript.",
        "Doc_title":"Role of p16 and p14ARF in radio- and chemosensitivity of malignant gliomas.",
        "Journal":"Oncology reports",
        "Do_id":"16786135",
        "Doc_ChemicalList":"Antineoplastic Agents, Alkylating;Antineoplastic Agents, Phytogenic;Cyclin-Dependent Kinase Inhibitor p16;Tumor Suppressor Protein p14ARF;Vincristine;Carmustine",
        "Doc_meshdescriptors":"Antineoplastic Agents, Alkylating;Antineoplastic Agents, Phytogenic;Brain Neoplasms;Carmustine;Cell Line, Tumor;Cyclin-Dependent Kinase Inhibitor p16;Drug Resistance, Neoplasm;Genes, Tumor Suppressor;Glioma;Humans;Radiation Tolerance;Radiation, Ionizing;Tumor Suppressor Protein p14ARF;Vincristine",
        "Doc_meshqualifiers":"pharmacology;pharmacology;drug therapy;genetics;radiotherapy;pharmacology;metabolism;physiology;drug therapy;genetics;radiotherapy;metabolism;physiology;pharmacology",
        "_version_":1605824542330060800},
      {
        "Doc_abstract":"Nodal metastasis is an important prognostic factor in head and neck squamous cell carcinoma. This study aimed to determine the average nodal basin yield per level of neck dissection, and to investigate if age, gender, body mass index, tumour size, depth of tumour invasion and p16 status influence nodal yield.;A retrospective review of 185 patients with head and neck squamous cell carcinoma generated 240 neck dissection specimens.;The respective mean nodal yields for levels I, II, III, IV and V were 5.27, 9.43, 8.49, 7.43 and 9.02 in non-cutaneous squamous cell carcinoma patients, and 4.2, 7.57, 9.65, 4.33 and 12.29 in cutaneous squamous cell carcinoma patients. Multiple regression analysis revealed that p16-positive patients with mucosal squamous cell carcinoma yielded, on average, 2.4 more nodes than their p16-negative peers (p = 0.04, 95 per cent confidence interval = 0.116 to 4.693). This figure was 3.84 (p = 0.008, 95 per cent confidence interval = 1.070 to 6.605) for p16-positive patients with oral cavity squamous cell carcinoma.;In mucosal squamous cell carcinoma, p16-positive status significantly influenced nodal yield, with the impact being more pronounced in oral cavity squamous cell carcinoma patients.",
        "Doc_title":"Do demographics and tumour-related factors affect nodal yield at neck dissection? A retrospective cohort study.",
        "Journal":"The Journal of laryngology and otology",
        "Do_id":"27786150",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605818573952909313},
      {
        "Doc_abstract":"H. pylori infection of the gastric mucosa is associated with increased epithelial cell apoptosis. In vitro, interferon-gamma and TNF-alpha have been shown to increase the sensitivity of cells to apoptosis induced by H. pylori. The p53 tumor suppressor gene is frequently mutated in many cancers, including gastric cancer. Since p53 protein can induce apoptosis, we sought to determine whether or not p53 increases the ability of gastric epithelial cells to undergo apoptosis in response to H. pylori-induced cell injury. Human gastric epithelial cell lines, AGS (p53 wild-type) cells and AGS cells infected with HPV E6 gene (AGS-E6) to inactivate p53 were exposed to H. pylori. The p53, p21, and p14ARF proteins were measured in gastric epithelial cells by immunoelectrophoresis. Gastric epithelial cell apoptosis was measured by DNA end-labeling assay (TUNEL) and subG0 cell fractions using flow cytometry, and by agarose gel electrophoresis of DNA. Exposure to H. pylori increased the levels of p53, p21, and p14ARF proteins two fold in AGS cells. Gastric AGS cells with fragmented DNA increased from 1.1% to 68% in after exposure to H. pylori for 24 hr. However, AGS-E6 cells were relatively resistant to apoptosis induced by H. pylori (only 15% of cells underwent apoptosis). In additional experiments, mouse embryonic fibroblasts (MEFs) were used to further investigate the role of ARF in stabilizing p53 after exposure to H. pylori. Wild-type and p19ARF-/- MEFs were exposed to H. pylori and evaluated for activation of p53, p19ARF, and apoptosis. As with AGS cells, H. pylori stimulated a 2-fold increase in p53 and p19ARF in wild-type MEFs; however, there was no increase in p53 in ARF-null MEFs. H. pylori easily stimulated apoptosis in wild-type MEFs, although, the absence of p19ARF significantly reduced the ability of H. pylori to induce apoptosis in these cells. Activation of ARF by H. pylori is important in stabilizing p53 resulting in increased apoptosis. Thus, inactivation of either ARF or p53 in gastric cells may reduce their ability to undergo apoptosis in response to injury induced by H. pylori.",
        "Doc_title":"p53 and p14 increase sensitivity of gastric cells to H. pylori-induced apoptosis.",
        "Journal":"Digestive diseases and sciences",
        "Do_id":"12870784",
        "Doc_ChemicalList":"Tumor Suppressor Protein p14ARF;Tumor Suppressor Protein p53",
        "Doc_meshdescriptors":"Adenocarcinoma;Apoptosis;Gastric Mucosa;Helicobacter Infections;Helicobacter pylori;Humans;Stomach Neoplasms;Tumor Cells, Cultured;Tumor Suppressor Protein p14ARF;Tumor Suppressor Protein p53",
        "Doc_meshqualifiers":"etiology;physiopathology;physiology;complications;physiopathology;etiology;physiopathology;physiology;physiology",
        "_version_":1605809552462184448},
      {
        "Doc_abstract":"Enlarged neck lymph nodes are very often subject to fine needle aspiration biopsy to detect metastatic disease in patients with suspected or proven squamous cell carcinoma in head and neck region. Cytology specimens of metastatic carcinoma in such patients are routinely evaluated for human papilloma virus (HPV) to identify patients with HPV-related head and neck squamous cell carcinoma. Different types of cytology specimens including smears, cytospins, cell blocks and aspirated material in the rinse can all be used for different types of HPV testing such as immunohistochemistry for p16, HPV-in situ hybridization, and HPV-Polymerase chain reaction. There is currently no consensus regarding the testing of high-risk HPV in cytology specimens. The establishment of standardized HPV testing of cytology specimens is of utmost importance and is eagerly awaited.",
        "Doc_title":"The role of cytology in the era of HPV-related head and neck carcinoma.",
        "Journal":"Seminars in diagnostic pathology",
        "Do_id":"25638437",
        "Doc_ChemicalList":"DNA, Viral",
        "Doc_meshdescriptors":"Biopsy, Fine-Needle;Carcinoma, Squamous Cell;DNA, Viral;Head and Neck Neoplasms;Human Papillomavirus DNA Tests;Humans;Lymph Nodes;Lymphatic Metastasis;Papillomaviridae;Papillomavirus Infections;Predictive Value of Tests;Prognosis",
        "Doc_meshqualifiers":"pathology;virology;genetics;isolation & purification;pathology;virology;pathology;virology;genetics;isolation & purification;pathology;virology",
        "_version_":1605896934187335680},
      {
        "Doc_abstract":"Homozygous deletions of the tumor suppressor gene p16INK4A and deficiency of methylthioadenosine phosphorylase (MTAP), both located on chromosome 9p21, have been independently reported in non-small cell lung cancer (NSCLC). To determine the frequency of co-deletion of these two genes, we investigated 50 samples of primary NSCLC using a quantitative PCR-ELISA. All specimens were fixed in formalin, paraffin embedded and stored until assayed. Histologic subtypes included 25 adenocarcinomas (50%), 21 squamous cell carcinomas (42%) and four large cell carcinomas (8%). Homozygous deletions of MTAP exon 8 could be detected in 19 of 50 NSCLC samples (38%). Adenocarcinoma (11 of 25, 44%) showed a higher deletion frequency than squamous cell carcinoma (six of 21, 29%). In contrast, homozygous p16INK4A deletions were detected in only nine of 50 (18%) samples using specific primers for p16INK4A exon 1alpha. No difference between the histological subtypes and p16INK4A deletion frequency was observed. We further investigated the ten samples with MTAP deletions but intact p16INK4A exon 1alpha with primers specific for p16INK4A exon 3, the exon nearest to MTAP exon 8. Interestingly, none of the ten samples had deletion of the p16INK4A exon 3 coding region. Fine mapping analysis performed in ten samples showed a frequent breakpoint between MTAP exon 4 and exon 5. In addition, p16 protein expression could not be detected in five out of six samples with intact p16 but deleted MTAP locus. These data show a high frequency of homozygous MTAP deletions in NSCLC which is associated with detectable co-deletion of p16INK4A in only half of the cases. This result suggests the existence either of another tumor suppressor gene telomeric of p16INK4A or of deletions involving 3'-untranslated (3'-UTR) regulatory regions of p16INK4A that can interfere with its expression or function.",
        "Doc_title":"Homozygous deletions of methylthioadenosine phosphorylase (MTAP) are more frequent than p16INK4A (CDKN2) homozygous deletions in primary non-small cell lung cancers (NSCLC).",
        "Journal":"Oncogene",
        "Do_id":"9840931",
        "Doc_ChemicalList":"DNA Primers;DNA, Neoplasm;Neoplasm Proteins;Purine-Nucleoside Phosphorylase;5'-methylthioadenosine phosphorylase",
        "Doc_meshdescriptors":"Carcinoma, Non-Small-Cell Lung;Chromosomes, Human, Pair 9;DNA Primers;DNA, Neoplasm;Gene Deletion;Genes, Tumor Suppressor;Genes, p16;Homozygote;Humans;Lung Neoplasms;Male;Neoplasm Proteins;Polymerase Chain Reaction;Pseudogenes;Purine-Nucleoside Phosphorylase",
        "Doc_meshqualifiers":"genetics;genetics;genetics;genetics;genetics;genetics",
        "_version_":1605826609597644800},
      {
        "Doc_abstract":"Congenital unilateral linear porokeratosis (CULP) is a rare disorder of keratinization that shares clinical and molecular similarities with psoriasis. It also has an increased risk for malignant transformation to cutaneous squamous cell carcinoma (SCC). We investigated the expression of psoriasin, human beta-defensin-2, cathelicidin antimicrobial peptide/LL-37, e-cadherin, involucrin, p16(INK4a) , p53, cyclin D1 and microchromosome maintenance protein 7 in healthy skin and in lesions of psoriasis, CULP and SCC from the same patient. p16(INK4a)  was overexpressed in CULP but not in the subsequent SCC. Psoriasin was overexpressed in psoriasis, CULP and SCC compared with healthy skin. Speculatively, p16(INK4a)  and psoriasin could be involved in the pathogenesis of CULP. Moreover, psoriasin may play a role in the malignant transformation of CULP to SCC.",
        "Doc_title":"Altered gene expression in squamous cell carcinoma arising from congenital unilateral linear porokeratosis.",
        "Journal":"Clinical and experimental dermatology",
        "Do_id":"22998543",
        "Doc_ChemicalList":"Biomarkers, Tumor;Neoplasm Proteins;RNA, Messenger",
        "Doc_meshdescriptors":"Adult;Biomarkers, Tumor;Carcinoma, Squamous Cell;Female;Gene Expression;Humans;Neoplasm Proteins;Porokeratosis;Psoriasis;RNA, Messenger;Skin",
        "Doc_meshqualifiers":"metabolism;genetics;metabolism;metabolism;genetics;metabolism;genetics;metabolism;metabolism;metabolism",
        "_version_":1605819905286864896},
      {
        "Doc_abstract":"Tumor-specific molecular alterations in surgical margins have been shown to predict risk of local recurrence. However, assays used for these analyses are time-consuming and therefore cannot be used in the intraoperative setting.;To detect and quantify tumor-specific methylated promoter sequences in surgical margins in a time frame suitable for intraoperative use.;A novel quantitative methylation-specific polymerase chain reaction (QMSP) protocol.;A total of 13 patients with head and neck squamous cell carcinoma (HNSCC) were initially characterized for molecular alterations in their tumor at the time of biopsy. Six primary tumors were found to harbor promoter hypermethylation for p16 and O6-methylguanine-DNA-methyltransferase (MGMT) genes. Rapid QMSP was then used to identify promoter hypermethylation of these genes in the surgical margins. Results were compared with standard intraoperative histologic frozen section analysis and with conventional QMSP.;Using our rapid QMSP assay, we found that 3 patients had methylation-positive margins. Tumor margins from 2 patients were methylated for p16 alone, and margins from 1 patient were methylated for p16 and MGMT simultaneously. Molecular margin analysis was completed in less than 5 hours, a time frame appropriate for selected major HNSCC resections that require combined primary tumor resection, cervical lymphadenectomy, and complex reconstruction. This technique was comparable in sensitivity to conventional QMSP.;Rapid molecular margin analysis using QMSP is feasible and may be performed intraoperatively in selected patients with HNSCC that requires extensive resection.",
        "Doc_title":"Intraoperative molecular margin analysis in head and neck cancer.",
        "Journal":"Archives of otolaryngology--head & neck surgery",
        "Do_id":"14732766",
        "Doc_ChemicalList":"DNA, Neoplasm",
        "Doc_meshdescriptors":"Carcinoma, Squamous Cell;DNA Methylation;DNA, Neoplasm;Genes, p16;Head and Neck Neoplasms;Humans;Intraoperative Period;Polymerase Chain Reaction;Promoter Regions, Genetic;Sensitivity and Specificity",
        "Doc_meshqualifiers":"genetics;surgery;genetics;surgery;methods;genetics",
        "_version_":1605754198517874688},
      {
        "Doc_abstract":"Overexpression of p16 has been demonstrated to be strongly related to the presence of HPV16, 18. Squamous cell carcinoma of the head and neck has been shown to be associated with human papillomavirus (HPV) infection. The main aim of this study was to investigate the relationship between HPV presence and p16 expression in a representative collection of 60 head and neck carcinomas by tissue microarrays. The presence of HPV (HPV6, 11-low risk, HPV16, 18-high risk) was detected by applying in situ hybridisation. P-16 protein expression was detected immunohistochemically. HPV6, 11 positivity was observed in 10 out of 60 carcinomas. HPV16, 18 presence was found in 30 out of 60 tumours. P-16 expression was detected in 35 out of 60 tumours. A statistically significant relationship was demonstrated between HPV16, 18 presence and increased expression of p16. Also the HPV6, 11 presence was significantly correlated with p16 immunoreactivity. Additionally, this study demonstrates that it is possible to analyse p16 expression and HPV presence by tissue microarrays.",
        "Doc_title":"Relation between human papillomavirus positivity and p16 expression in head and neck carcinomas--a tissue microarray study.",
        "Journal":"Anticancer research",
        "Do_id":"17352245",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Alphapapillomavirus;Carcinoma, Squamous Cell;Cyclin-Dependent Kinase Inhibitor p16;Female;Human papillomavirus 11;Human papillomavirus 16;Human papillomavirus 18;Humans;Immunohistochemistry;In Situ Hybridization;Laryngeal Neoplasms;Male;Middle Aged;Mouth Neoplasms;Papillomavirus Infections;Tissue Array Analysis",
        "Doc_meshqualifiers":"isolation & purification;metabolism;virology;biosynthesis;isolation & purification;isolation & purification;isolation & purification;metabolism;virology;metabolism;virology;complications;metabolism;virology",
        "_version_":1605754702566260736},
      {
        "Doc_abstract":"Periocular sebaceous carcinoma is an aggressive neoplasm with significant morbidity and mortality. Its pathogenesis is poorly understood. It is only rarely associated with Muir-Torre syndrome. Previous studies from Asian countries, have suggested that human papillomavirus (HPV) infection plays a role in the pathogenesis and overexpression of p16(INK4a), a surrogate marker of HPV infection, have also been reported. However, data from western countries seem contradictory. In order to clarify and explore the molecular and epigenetic basis of HPV, CDKN2A status and role of microsatellite instability in the development of periocular sebaceous carcinoma, 24 cases of periocular sebaceous carcinoma were analyzed for the expression of p16(INK4a) and mismatch repair proteins (MLH1, MSH2, MSH6 and PMS2) via immunohistochemistry. Nested polymerase chain reaction (PCR) and genechip HPV typing were used to detect HPV infection and decide its genotype when present. PCR amplification using a consensus primer pair was also performed to detect -HPV. The methylation status of CDKN2A promoter region was studied by methylation-specific polymerase chain reaction. HPV-positivity was demonstrated in only one of our cases (HPV 16), while another case showed p16(INK4a) overexpression. All cases showed preserved expression of mismatch repair proteins. CDKN2A promoter hypermethylation was noted in nearly half of our cases (11/24) and was associated with younger patient age (P = .013). Our results showed that periocular sebaceous carcinoma is rarely associated with HPV and microsatellite instability. Higher frequency of CDKN2A promoter hypermethylation in younger patients implies a significant epigenetic role in tumor development in this age group. ",
        "Doc_title":"Hypermethylation of the CDKN2A gene promoter is a frequent epigenetic change in periocular sebaceous carcinoma and is associated with younger patient age.",
        "Journal":"Human pathology",
        "Do_id":"24440092",
        "Doc_ChemicalList":"Biomarkers, Tumor;Cyclin-Dependent Kinase Inhibitor p16",
        "Doc_meshdescriptors":"Age Factors;Aged;Aged, 80 and over;Biomarkers, Tumor;Carcinoma;Carcinoma, Squamous Cell;Cyclin-Dependent Kinase Inhibitor p16;DNA Methylation;Epigenesis, Genetic;Eyelid Neoplasms;Female;Humans;Male;Microsatellite Instability;Middle Aged;Papillomaviridae;Papillomavirus Infections;Promoter Regions, Genetic;Sebaceous Gland Neoplasms;Uterine Cervical Neoplasms",
        "Doc_meshqualifiers":"genetics;metabolism;genetics;metabolism;pathology;virology;genetics;pathology;virology;genetics;metabolism;genetics;metabolism;pathology;virology;genetics;pathology;genetics;metabolism;pathology;virology;genetics;pathology;virology",
        "_version_":1605795759502917632},
      {
        "Doc_abstract":"Germline mutations of the CDKN2A gene are found in melanoma-prone families and individuals with multiple sporadic melanomas. The encoded protein, p16(INK4A), comprises four ankyrin-type repeats, and the mutations, most of which are missense and occur throughout the entire coding region, can disrupt the conformation of these structural motifs as well as the association of p16(INK4a) with its physiological targets, the cyclin-dependent kinases (CDKs) CDK4 and CDK6. Assessing pathogenicity of nonsynonymous mutations is critical to evaluate melanoma risk in carriers. In the current study, we investigate 20 CDKN2A germline mutations whose effects on p16(INK4A) structure and function have not been previously documented (Thr18_Ala19dup, Gly23Asp, Arg24Gln, Gly35Ala, Gly35Val, Ala57Val, Ala60Val, Ala60Arg, Leu65dup, Gly67Arg, Gly67_Asn71del, Glu69Gly, Asp74Tyr, Thr77Pro, Arg80Pro, Pro81Thr, Arg87Trp, Leu97Arg, Arg99Pro, and [Leu113Leu;Pro114Ser]). By considering genetic information, the predicted impact of each variant on the protein structure, its ability to interact with CDK4 and impede cell proliferation in experimental settings, we conclude that 18 of the 20 CDKN2A variants can be classed as loss of function mutations, whereas the results for two remain ambiguous. Discriminating between mutant and neutral variants of p16(INK4A) not only adds to our understanding of the functionally critical residues in the protein but provides information that can be used for melanoma risk prediction.",
        "Doc_title":"Functional, structural, and genetic evaluation of 20 CDKN2A germ line mutations identified in melanoma-prone families or patients.",
        "Journal":"Human mutation",
        "Do_id":"19260062",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;CDK4 protein, human;Cyclin-Dependent Kinase 4",
        "Doc_meshdescriptors":"Cell Line;Cell Proliferation;Cyclin-Dependent Kinase 4;Cyclin-Dependent Kinase Inhibitor p16;Family Health;Genetic Testing;Germ-Line Mutation;Humans;Melanoma;Models, Molecular;Mutation, Missense;Protein Binding;Protein Structure, Tertiary",
        "Doc_meshqualifiers":"metabolism;chemistry;genetics;metabolism;diagnosis;genetics",
        "_version_":1605756022731833344},
      {
        "Doc_abstract":"Hypermethylation of CpG islands within the promoter region is one of the mechanisms by which genes are inactivated and may be one of the reason for silencing of cell cycle control or DNA-mismatch repair genes in myelodysplastic syndrome (MDS). Since the function of cell cycle control genes including the cyclin-dependent kinase inhibitors known as p15(INK4b) and p16(INK4a), as well as p14(ARF) which blocks MDM-2 (an inhibitor of p53), the retinoblastoma (RB1) protein and the mismatch repair gene MGMT is critical for hematopoietic proliferation and differentiation, we performed methylation specific polymerase chain reaction (MSP) in low-density, non-adherent bone marrow cells from 49 patients with MDS. In addition, expression of p15(INK4b) and RB1 was analysed by quantitative real-time PCR. From selected patients, we analyzed the methylation pattern of cell cycle control genes in CD34+ bone marrow cells. Thirty-nine of 49 cases (80%) had at least one of five genes methylated in our MDS samples by analysing low-density non-adherent bone marrow cells. The frequency of p15(INK4b) methylation was 34 of 49 samples (69%). The incidence of methylation of both p14(ARF) and p16(INK4a) was four of 49 (8%). RB1 gene was methylated in seven samples (14%) and each patient had RA. Interestingly, none of these genes were methylated in the purified CD34+ hematopoietic stem cells from the MDS patients. Furthermore, all our RARS patients had a methylated p15(INK4b) promoter correlating with non-detectable expression of this gene in bone marrow cells from those patients. These results indicate that hypermethylation of cell cycle control genes in MDS may occur late during the differentiation of myelodysplastic stem cells.",
        "Doc_title":"Comparative analysis of hypermethylation of cell cycle control and DNA-mismatch repair genes in low-density and CD34+ bone marrow cells from patients with myelodysplastic syndrome.",
        "Journal":"Leukemia research",
        "Do_id":"16682076",
        "Doc_ChemicalList":"Antigens, CD34;Cell Cycle Proteins;Cyclin-Dependent Kinase Inhibitor p15;Retinoblastoma Protein",
        "Doc_meshdescriptors":"Adult;Aged;Antigens, CD34;Bone Marrow Cells;Cell Cycle;Cell Cycle Proteins;Cyclin-Dependent Kinase Inhibitor p15;DNA Methylation;DNA Mismatch Repair;Female;Gene Expression Profiling;Humans;Male;Middle Aged;Myelodysplastic Syndromes;Retinoblastoma Protein;Reverse Transcriptase Polymerase Chain Reaction",
        "Doc_meshqualifiers":"metabolism;metabolism;genetics;genetics;genetics;genetics;metabolism;genetics;methods",
        "_version_":1605893372039397376},
      {
        "Doc_abstract":"Tissue imprinting can generate molecular marker maps of tumor cells at deep surgical margins. The purpose of this study was to evaluate the feasibility of this method for detection of residual head and neck squamous cell carcinoma (HNSCC).;Paired fresh tissue and nitrocellulose membrane imprints of tumor and deep margins were collected from 17 HNSCC resections. DNA was amplified using quantitative methylation-specific polymerase chain reaction (qMSP) for p16, DCC, KIF1A, and EDNRB. Levels of methylation in tumors and deep margins were compared.;DNA from imprints was adequate for qMSP. Hypermethylation of target genes was present in 12 of 17 tumors and in 8 deep margins. Methylation level was better from margin imprints than tissue. During follow-up (median, 13 months), local or regional recurrences occurred in 6 cases of which 5 had molecularly positive margins.;Tissue imprinting is feasible for molecular detection of residual tumor at deep surgical margins and may correlate with locoregional recurrence.",
        "Doc_title":"Tissue imprint for molecular mapping of deep surgical margins in patients with head and neck squamous cell carcinoma.",
        "Journal":"Head & neck",
        "Do_id":"22223471",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Carcinoma, Squamous Cell;DNA Methylation;Early Detection of Cancer;Feasibility Studies;Female;Head and Neck Neoplasms;Humans;Male;Middle Aged;Molecular Diagnostic Techniques;Molecular Imprinting;Neoplasm Recurrence, Local;Neoplasm, Residual;Real-Time Polymerase Chain Reaction",
        "Doc_meshqualifiers":"diagnosis;surgery;methods;diagnosis;surgery;methods;diagnosis;genetics",
        "_version_":1605799847324024832},
      {
        "Doc_abstract":"Both the retinoblastoma and p53 pathways are often genetically altered in human cancers and their complex regulation is in part mediated by the three gene products p16, p14(ARF), and p15 of the INK4 locus on chromosome 9p21. Partial or complete biallelic deletions of the INK4 locus have been recognized in a variety of malignant tumors, including malignant melanoma. We have in the present study measured the frequency of INK4 deletions in a large number of melanoma metastases and determined their association with clinicopathologic variables and survival data.;Quantitative real-time PCR, as well as fluorescence-based fragment analysis, has been used to perform measurements of the relative allelic concentrations of the INK4 genes in 112 human melanoma tumor samples from 86 patients.;Thirty-eight of 86 melanoma patients (44%) had metastases with biallelic losses in INK4. Ten of 20 patients with multiple metastases showed similar deletion patterns in all analyzed tumors. There was no significant association between any of the clinicopathologic variables and loss of INK4. However, loss of INK4 had an adverse effect on median survival from time of diagnosis. Patients with tumors with diploid INK4 had a median survival of 142 months, whereas those with monoallelic or biallelic loss in INK4 had a median survival of only 47 months (P = 0.006).;Our results point to homozygous deletions in the INK4 region as being one of the most common genetic alterations in malignant cutaneous melanoma. INK4 deletions are associated with an adverse prognosis.",
        "Doc_title":"Biallelic deletions in INK4 in cutaneous melanoma are common and associated with decreased survival.",
        "Journal":"Clinical cancer research : an official journal of the American Association for Cancer Research",
        "Do_id":"15837753",
        "Doc_ChemicalList":"CDKN2B protein, human;Cell Cycle Proteins;Cyclin-Dependent Kinase Inhibitor p15;Cyclin-Dependent Kinase Inhibitor p16;DNA, Neoplasm;Tumor Suppressor Protein p14ARF;Tumor Suppressor Proteins",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Alleles;Analysis of Variance;Cell Cycle Proteins;Chi-Square Distribution;Cyclin-Dependent Kinase Inhibitor p15;Cyclin-Dependent Kinase Inhibitor p16;DNA Mutational Analysis;DNA, Neoplasm;Female;Gene Deletion;Genotype;Homozygote;Humans;Loss of Heterozygosity;Male;Melanoma;Middle Aged;Neoplasm Metastasis;Polymerase Chain Reaction;Skin Neoplasms;Survival Analysis;Tumor Suppressor Protein p14ARF;Tumor Suppressor Proteins",
        "Doc_meshqualifiers":"genetics;genetics;chemistry;genetics;genetics;pathology;methods;genetics;pathology;genetics;genetics",
        "_version_":1605808704855212032},
      {
        "Doc_abstract":"Since p14 (ARF) and human papillomavirus (HPV) 16 E6/E7 oncoproteins are important regulators participating in the p53/Rb pathways, genetic variations of p14 (ARF) may modify tumor HPV16 status and survival of HPV16-positive squamous cell carcinoma of the oropharynx (SCCOP) patients. We determined tumor HPV16 status and expression of p14/p53 and genotyped p14 (ARF) -rs3731217 and -rs3088440 polymorphisms in 552 incident SCCOP patients. We found that patients having variant genotypes for each p14 (ARF) polymorphism were approximately two or three times as likely to have HPV16-positive tumors compared with patients with corresponding common homozygous genotype, and such an association was particularly pronounced in patients with variant genotypes of both polymorphisms. After definitive chemoradiotherapy, patients having p14 (ARF) rs3731217 TG/GG variant genotypes had significantly better overall, disease-specific and disease-free survival than those having TT genotype, respectively. Multivariable analysis found that patients with p14 (ARF) -rs3731217 TT genotype had an ~7-, 11- and 3-fold increased risk for death overall, death due to SCCOP and recurrence than those with TG/GG variant genotypes, respectively. Furthermore, such significantly prognostic effect was also found when survival analysis was limited to HPV16-positive patients. Additionally, potentially functional relevance of the two variants was characterized to explore the genotype-phenotype correlation. Our findings indicate p14 (ARF) variants may predict tumor HPV16-positive SCCOP patients and survival. ",
        "Doc_title":"Potentially functional variants of p14ARF are associated with HPV-positive oropharyngeal cancer patients and survival after definitive chemoradiotherapy.",
        "Journal":"Carcinogenesis",
        "Do_id":"24104554",
        "Doc_ChemicalList":"Tumor Suppressor Protein p14ARF",
        "Doc_meshdescriptors":"Carcinoma, Squamous Cell;Chemoradiotherapy;Disease-Free Survival;Female;Homozygote;Human papillomavirus 16;Humans;Male;Middle Aged;Neoplasm Recurrence, Local;Oropharyngeal Neoplasms;Papillomavirus Infections;Polymorphism, Genetic;Prognosis;Texas;Tumor Suppressor Protein p14ARF",
        "Doc_meshqualifiers":"genetics;mortality;therapy;virology;pathogenicity;genetics;genetics;mortality;therapy;virology;complications;genetics;virology;genetics",
        "_version_":1605906556298199040},
      {
        "Doc_abstract":"Both p16(INK4) and p21(Waf1) are tumor suppressors with similar biological functions in the regulation of cellular senescence. Previous reports showed that p16(INK4) could be activated by p21(Waf1) through transcriptional factor Sp1 in HeLa cells. This study was undertaken to determine the effects of p16(INK4) on the expression and functions of p21(Waf1).;Human diploid fibroblast 2BS cells were stably transfected with sense (2BS/p16(INK4)), antisense p16(INK4) (2BS/asp16(INK4)) or empty vector (2BS/neo). Then they were assayed by reverse-transcription polymerase chain reaction (RT-PCR), fluorescence activated cell sorting (FACS) and Western blot.;2BS/p16(INK4) cells exhibited cell cycle arrest in both G1 and G2/M phases. Endogenous p21(Waf1) protein levels increased twofold in the 2BS/p16(INK4) cells, but not decreased in the 2BS/asp16(INK4) cells. p21(Waf1) mRNA levels were not affected in neither 2BS/p16(INK4) nor 2BS/asp16(INK4) cells.;p16(INK4) may play an important role in the regulation of cellular senescence by modulating the p21(Waf1) protein level via the posttranscriptional mechanism.",
        "Doc_title":"Posttranscriptional induction of p21Waf1 mediated by ectopic p16INK4 in human diploid fibroblast.",
        "Journal":"Chinese medical journal",
        "Do_id":"17376312",
        "Doc_ChemicalList":"CDKN1A protein, human;Cyclin-Dependent Kinase Inhibitor p16;Cyclin-Dependent Kinase Inhibitor p21",
        "Doc_meshdescriptors":"Cell Aging;Cell Cycle;Cells, Cultured;Cyclin-Dependent Kinase Inhibitor p16;Cyclin-Dependent Kinase Inhibitor p21;Fibroblasts;Humans;Transcription, Genetic",
        "Doc_meshqualifiers":"physiology;physiology;metabolism",
        "_version_":1605759106461728768},
      {
        "Doc_abstract":"Human papillomavirus (HPV) infection in cervix is the most important reason for cervical cancer, but only 2% cervical HPV infection will develop into cervical cancer. So how to identify patients at risk of progressive cervical lesions from those infected with HPV to avoid over treatment is a big issue in clinic. The aims of this study were to detect the expression of HPV L1 capsid protein and p16(INK4a) in cervical lesions and to investigate the combination expression of HPV L1 capsid protein and p16(INK4a) in cervical lesions and its diagnostic efficiency in clinic. Immunochemical method was used to detect the expression of HPV L1 capsid protein and p16(INK4a) in 169 cases of abnormal cytology. Histopathologic test was performed to identify cervical lesions of all the cases. chi(2) test and spearman's rank correlation were used for statistical analysis. The diagnostic sensitivity, specificity, positive predictive values (PPV), negative predictive values (NPV), accuracy, and the area under the receive operating characteristic (ROC) curve (denoted by A(Z)) were calculated with SPSS 13.0. All the statistical tests were two sided at the 5% level of significance. L1 expression decreased (P < 0.001), but p16(INK4a) expression increased (P < 0.001) with histopathologic diagnosis increasing. The expression rates of HPV L1 capsid protein, p16(INK4a), and L1(-)/p16(+) in cervical intraepithelial neoplasia (CIN)2, CIN3, and squamous-cell carcinoma were statistically different from those in CIN1 (P < 0.001). The expressions of HPV L1 capsid protein, L1(+)/p16(+), L1(+)/p16(-), and L1(-)/p16(-) were negatively correlated with the severity of cervical lesions (P < 0.001), whereas the expressions of p16(INK4a) and L1(-)/p16(+) were positively correlated with the severity of cervical lesions (P < 0.001). The specificity and A(Z) of combining L1 with p16 (INK4a) were statistically higher than L1 or p16 (INK4a) alone (P < 0.05). L1 and p16(INK4a) are useful biomarkers for the early diagnosis of cervical lesions. The combination of L1 and p16(INK4a) has a higher diagnostic accuracy than L1 or p16(INK4a) alone in diagnosis of cervical lesions.",
        "Doc_title":"An analysis on the combination expression of HPV L1 capsid protein and p16INK4a in cervical lesions.",
        "Journal":"Diagnostic cytopathology",
        "Do_id":"19941368",
        "Doc_ChemicalList":"Capsid Proteins;Cyclin-Dependent Kinase Inhibitor p16;HPV L1 protein, Human papillomavirus;Oncogene Proteins, Viral",
        "Doc_meshdescriptors":"Adolescent;Adult;Aged;Capsid Proteins;Cyclin-Dependent Kinase Inhibitor p16;Female;Humans;Middle Aged;Oncogene Proteins, Viral;Staining and Labeling;Uterine Cervical Neoplasms;Young Adult",
        "Doc_meshqualifiers":"metabolism;metabolism;metabolism;diagnosis;metabolism;pathology",
        "_version_":1605907991194763264},
      {
        "Doc_abstract":"Based on the concept that tumor suppressor genes are involved in the pathogenesis of urinary bladder carcinogenesis, we analysed the mRNA expression of the retinoblastoma (Rb) and p16 (CDKN2, INK4A, MTS1) genes as well as of the proto-oncogene cyclin D-dependent kinase 4 (CDK4) in 71 transitional cell carcinomas (TCC) of the urinary bladder in relation to the tumor grades and stages, and with reference to certain lifestyle and occupational risk factors. Using real-time quantitative reverse transcription-polymerase chain reaction, high-stage muscle invasive TCC expressed the Rb, p16 and CDK4 mRNA at lower levels than low-stage superficial cancers, indicating down-regulation to be linked with tumor progression. The drop of the expression in the group of grade 2 TCC when invading the muscle layer compared to grade 2 carcinomas with a superficial pattern of growth is considered to represent a key event in promoting urothelial carcinogenesis in this subset of carcinomas. The protein expression of the Rb gene evaluated by immunohistochemistry proved to be closely related to the tumor grades and stages as well as to the mRNA expression, high-grade and high-stage TCC disclosing a lower rate of positive immunoreactivity than low-grade and low-stage carcinomas. The p16 protein product was expressed at a lower level in grade 3 than in grade 1 TCC, but there was no correlation with the tumor stages or the mRNA expression. TCC with loss of heterozygosity (LOH) at the INK4A region showed a decreased expression of p16 mRNA compared to those without an allelic loss. Tobacco smoke was not identified to substantially modulate the Rb/p16/CDK4 pathways, except for a ten-fold elevated mRNA expression of the p16 gene in TCC of light compared to heavy smokers. Heavy coffee consumption was associated with a reduced expression of CDK4 mRNA. Among occupational exposures, TCC of patients in contact with stone dust, paints and lacquer, plastics, wood and wood preservers and chemical solvents and adhesives displayed altered partly elevated, partly reduced levels of Rb, p16 and CDK4 mRNA compared to non-exposed subjects. Although the underlying molecular-genetic pathways are not yet fully understood, the current results suggest functional reduction of the tumor suppressor genes Rb and p16 to be associated with progression of bladder cancer to a more malignant and aggressive behaviour.",
        "Doc_title":"Altered mRNA expression of the Rb and p16 tumor suppressor genes and of CDK4 in transitional cell carcinomas of the urinary bladder associated with tumor progression.",
        "Journal":"Anticancer research",
        "Do_id":"15161057",
        "Doc_ChemicalList":"Proto-Oncogene Proteins;RNA, Messenger;Retinoblastoma Protein;CDK4 protein, human;Cyclin-Dependent Kinase 4;Cyclin-Dependent Kinases",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Carcinoma, Transitional Cell;Cyclin-Dependent Kinase 4;Cyclin-Dependent Kinases;Disease Progression;Female;Genes, p16;Humans;Immunohistochemistry;Male;Middle Aged;Neoplasm Staging;Occupational Exposure;Proto-Oncogene Proteins;RNA, Messenger;Retinoblastoma Protein;Risk Factors;Smoking;Urinary Bladder Neoplasms",
        "Doc_meshqualifiers":"genetics;metabolism;pathology;biosynthesis;genetics;physiology;biosynthesis;genetics;biosynthesis;genetics;genetics;metabolism;pathology",
        "_version_":1605824603681193984},
      {
        "Doc_abstract":"Although previous studies have shown that p16(INK4a) and Ki-67 are sensitive and specific markers for high-grade lesions (CIN2) on cervical biopsies, limited information is available regarding the performance of a dual-staining approach as a diagnostic adjunct in cervical cytology. We evaluated a dual p16(INK4a)/Ki-67 immunocytochemistry (ICC) assay to determine its sensitivity and specificity versus that of high-risk HPV (HR-HPV) in a US-based pilot cytology study.;ThinPrep specimens from 122 cervical cytology specimens encompassing 23 negative (NILM), 20 ASC-US, 22 LSIL, 17 ASCH, 22 HSIL, and 18AGC cases were processed for multiplexed ICC staining using a CINtec Plus Kit. Dual-positive assay results were defined based on the detection of 1 or more epithelial cells that were stained for both p16INK4a and Ki-67 without regard to cellular morphology. HR-HPV testing was performed by multiplex PCR with capillary electrophoresis genotyping.;Dual staining for p16(INK4a) and Ki-67 was frequently detected in HSIL and AGC but was rarely detected in NILM cases. The HR-HPV assay showed a sensitivity of 76.2% and a specificity of 55.8% for the detection of clinically significant cervical squamous or endometrial lesions. In contrast, the colocalization of p16(INK4a) plus Ki-67 maintained a high sensitivity of 81.8% and improved specificity to 81.8% for biopsy-confirmed CIN2/3, endocervical adenocarcinoma, or endometrial adenocarcinoma.;Dual staining for p16(INK4a)/Ki-67 immunocytochemistry dramatically increased specificity and maintained high-level sensitivity for the diagnosis of CIN2/3 or glandular lesions compared with PCR-based testing for HR-HPV.",
        "Doc_title":"Immunocytochemical colocalization of P16(INK4a) and Ki-67 predicts CIN2/3 and AIS/adenocarcinoma.",
        "Journal":"Cancer cytopathology",
        "Do_id":"22162342",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;Ki-67 Antigen",
        "Doc_meshdescriptors":"Adenocarcinoma;Carcinoma, Squamous Cell;Cervical Intraepithelial Neoplasia;Cyclin-Dependent Kinase Inhibitor p16;Cytodiagnosis;Early Detection of Cancer;Female;Humans;Immunohistochemistry;Ki-67 Antigen;Multiplex Polymerase Chain Reaction;Papillomavirus Infections;Pilot Projects;Sensitivity and Specificity;Uterine Cervical Neoplasms",
        "Doc_meshqualifiers":"diagnosis;diagnosis;diagnosis;analysis;methods;methods;analysis;diagnosis;diagnosis;virology",
        "_version_":1605752510899814400},
      {
        "Doc_abstract":"p16, a member of the INK4a family of cyclin-dependent kinase inhibitors, is known as a negative regulator of cell cycle progression and differentiation. Although p16 has been shown to be a promising biomarker for the detection of cervical intraepithelial neoplasia, few data have been published on vulvar cancer. Using immunohistochemistry, we evaluated the expression of p16 in 80 cases of invasive vulvar squamous cell carcinoma. Results were correlated with clinicopathologic parameters and survival data to determine the prognostic significance of p16 in vulvar cancer. p16 expression was detected in 34 of 80 (43%) cases of invasive vulvar squamous cell carcinoma. The expression was localized to the cytoplasm and the nuclei of the tumor cells. Correlations between p16 expression status and any clinicopathologic variables failed to be of statistical significance. In a univariate analysis, groin lymph node status, tumor stage, and tumor grade were associated with disease-free and overall survival, respectively. Patients positive for p16 expression showed a significantly longer disease-free and overall survival by univariate analysis. p16 expression was not associated with survival in a multivariate Cox-regression model. Our data add on those published in the literature and suggest that p16 may be of prognostic significance in invasive vulvar squamous cell carcinoma.",
        "Doc_title":"p16INK4a expression in invasive vulvar squamous cell carcinoma.",
        "Journal":"Applied immunohistochemistry & molecular morphology : AIMM",
        "Do_id":"17721272",
        "Doc_ChemicalList":"Biomarkers, Tumor;Cyclin-Dependent Kinase Inhibitor p16",
        "Doc_meshdescriptors":"Biomarkers, Tumor;Carcinoma, Squamous Cell;Cyclin-Dependent Kinase Inhibitor p16;Female;Humans;Immunohistochemistry;Middle Aged;Neoplasm Invasiveness;Prognosis;Vulvar Neoplasms",
        "Doc_meshqualifiers":"analysis;diagnosis;pathology;analysis;diagnosis;pathology",
        "_version_":1605844355740860416},
      {
        "Doc_abstract":"The increased knowledge regarding HPV-infections in head and neck squamous cell carcinoma (HNSCC) has unexpectedly contributed to several uncertainties related to i) prevalence diversities depending on tumour site and geographical origin of the patients, ii) proportion of HPV-driven tumours among HPV-DNA-positive cases, and iii) identification of patients with HPV-attributed survival benefit. To investigate this heterogeneity, we analysed 307 HNSCC cases (tonsillar, n=135; non-tonsillar, n=172) from eight health care centers mostly from Northern Germany and determined HPV-DNA/mRNA and p16INK4A-status and combined results with the patient outcome. Overall HPV-DNA prevalence rate was 23.5% (72/307); attributed to: 43.7% (59/135) and 7.6% (13/172) tonsillar and non-tonsillar cases, respectively. Among these, 96.6% tonsillar and 38.5% non-tonsillar SCC were HPV-mRNA-positive. Although the study cohort was composed of patients from regions of rather close proximity, prevalence rates showed diversities of up to 40% in HNSCC subsite analysis with the lowest prevalence for tonsillar SCC in metropolitan areas (22.2%) vs. 50.9% in rural areas. Survival analysis identified p16INK4A alone as strongest predictor, followed by HPV-DNA-status alone or in combination with p16INK4A. This survival benefit was shown for tonsillar and non-tonsillar cases. Smoking significantly correlated with HPV-status, however, it does not influence survival when stratified for HPV. In conclusion, the data emphasize the urge for further data on HPV-infection in HNSCC to, e.g. clarify to what extent survival benefits of p16INK4A-positive patients are truly attributed to HPV-infections. ",
        "Doc_title":"Geographical and anatomical influences on human papillomavirus prevalence diversity in head and neck squamous cell carcinoma in Germany.",
        "Journal":"International journal of oncology",
        "Do_id":"25310104",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Carcinoma, Squamous Cell;Female;Genetic Variation;Geography;Germany;Head and Neck Neoplasms;Humans;Male;Middle Aged;Papillomaviridae;Papillomavirus Infections;Prevalence",
        "Doc_meshqualifiers":"complications;epidemiology;pathology;virology;epidemiology;complications;epidemiology;pathology;virology;genetics;complications;epidemiology",
        "_version_":1605741975637590016},
      {
        "Doc_abstract":"The tumor suppressor Arf (Alternative Reading Frame) protein (p14ARF in human and p19ARF in mouse) is mainly located in the nucleolus consistent with its subcellular localization, the protein has been shown to specifically interact with 5.8S rRNA and with B23/Nucleophosmin and to regulate ribosome biogenesis. Here, we show that the p14ARF protein interacts with chromatin and is recovered by chromatin immunoprecipitation (ChIP) in a fraction that contains a DNA sequence of the rRNA gene promoter. In addition, topoisomerase I (Topo I) that has been shown to interact with p14ARF coprecipitates with p14ARF containing chromatin. These data, in view of the function for Topo I in rRNA transcription, are consistent with a role for the p14ARF-Topo I complex in rRNA transcription and/or maturation.",
        "Doc_title":"Human Arf tumor suppressor specifically interacts with chromatin containing the promoter of rRNA genes.",
        "Journal":"Oncogene",
        "Do_id":"15361825",
        "Doc_ChemicalList":"Chromatin;Tumor Suppressor Protein p14ARF;DNA Topoisomerases, Type I",
        "Doc_meshdescriptors":"Chromatin;DNA Topoisomerases, Type I;Genes, rRNA;Humans;Promoter Regions, Genetic;Tumor Suppressor Protein p14ARF",
        "Doc_meshqualifiers":"metabolism;metabolism;physiology",
        "_version_":1605874866404196352},
      {
        "Doc_abstract":"To study the relationship of suppressor gene p16 and lung cancer for prognosis evaluation.;Immunohistochemical method was used to detect and analyse the expression of P16 protein of CDKN2 suppressor gene of 76 cases in formalin-fixed, paraffin-embedded tissue specimens of human lung cancer.;P16 positive rate was 45%: 52% for 23 of 44 cases of squamous carcinoma and 29% for 7 of 24 cases of adenocarcinoma. Differentiation degree and prognosis of lung cancer were associated significantly with P16 expression. P16 expression was somewhat related to clinical stage.;P16 gene plays a key role in the prognosis of patients with lung cancer.",
        "Doc_title":"[P16 expression in lung cancer and its significance].",
        "Journal":"Zhonghua yi xue za zhi",
        "Do_id":"10923439",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16",
        "Doc_meshdescriptors":"Adenocarcinoma;Carcinoma, Squamous Cell;Cyclin-Dependent Kinase Inhibitor p16;Female;Gene Expression;Genes, p16;Humans;Immunohistochemistry;Lung Neoplasms;Male;Middle Aged;Prognosis",
        "Doc_meshqualifiers":"genetics;metabolism;genetics;metabolism;biosynthesis;genetics;metabolism",
        "_version_":1605840530844942336},
      {
        "Doc_abstract":"Myc is a well known proto-oncogene encoding for a transcription factor whose activity is tightly regulated in the cellular context. Myc was the first oncogene recognized to activate the ARF tumor suppressor gene which suppresses cell proliferation partly through stabilization of the p53 tumor suppressor protein but which also has p53-independent growth-suppressive functions. Recent studies have indicated that mouse p19ARF negatively regulates Myc's transcriptional activity. We here show that the human p14ARF directly associates with Myc and relocates Myc from the nucleoplasm to the nucleolus. We found that p14ARF interacts with the Myc-Max complex and the binding of p14ARF does not interfere with Myc-Max interaction in vitro. Protein interaction assays define the Myc BoxII as a critical domain required for interaction with p14ARF. Moreover, we identify 30 amino acids encompassing Myc BoxII domain required for p14ARF interaction and colocalization in vivo. Finally, we show that p14ARF down regulates Myc activated transcription and that this activity cannot be addressed to an intrinsic p14ARF repressor domain.",
        "Doc_title":"p14ARF directly interacts with Myc through the Myc BoxII domain.",
        "Journal":"Cancer biology & therapy",
        "Do_id":"16410719",
        "Doc_ChemicalList":"Basic Helix-Loop-Helix Leucine Zipper Transcription Factors;MAX protein, human;MYC protein, human;Proto-Oncogene Proteins c-myc;Recombinant Proteins;Tumor Suppressor Protein p14ARF",
        "Doc_meshdescriptors":"Basic Helix-Loop-Helix Leucine Zipper Transcription Factors;Cell Line;Cell Nucleolus;Dimerization;Down-Regulation;Gene Deletion;Humans;Protein Binding;Protein Interaction Mapping;Protein Structure, Tertiary;Proto-Oncogene Proteins c-myc;Recombinant Proteins;Transcription, Genetic;Tumor Suppressor Protein p14ARF",
        "Doc_meshqualifiers":"metabolism;metabolism;chemistry;metabolism;metabolism;chemistry;metabolism",
        "_version_":1605812275613007872},
      {
        "Doc_abstract":"Endothelial progenitor cells (EPCs) contribute to the regeneration of endothelium. Aging-associated senescence results in reduced number and function of EPCs, potentially contributing to increased cardiac risk, reduced angiogenic capacity, and impaired cardiac repair effectiveness. The mechanisms underlying EPC senescence are unknown. Increasing evidence supports the role of microRNAs in regulating cellular senescence.;We aimed to determine whether microRNAs regulated EPC senescence and, if so, what the underlying mechanisms are.;To map the microRNA/gene expression signatures of EPC senescence, we performed microRNA profiling and microarray analysis in lineage-negative bone marrow cells from young and aged wild-type and apolipoprotein E-deficient mice. We identified 2 microRNAs, microRNA-10A* (miR-10A*), and miR-21, and their common target gene Hmga2 as critical regulators for EPC senescence. Overexpression of miR-10A* and miR-21 in young EPCs suppressed Hmga2 expression, caused EPC senescence, as evidenced by senescence-associated -galactosidase upregulation, decreased self-renewal potential, increased p16(Ink4a)/p19(Arf) expression, and resulted in impaired EPC angiogenesis in vitro and in vivo, resembling EPCs derived from aged mice. In contrast, suppression of miR-10A* and miR-21 in aged EPCs increased Hmga2 expression, rejuvenated EPCs, resulting in decreased senescence-associated -galactosidase expression, increased self-renewal potential, decreased p16(Ink4a)/p19(Arf) expression, and improved EPC angiogenesis in vitro and in vivo. Importantly, these phenotypic changes were rescued by miRNA-resistant Hmga2 cDNA overexpression.;miR-10A* and miR-21 regulate EPC senescence via suppressing Hmga2 expression and modulation of microRNAs may represent a potential therapeutic intervention in improving EPC-mediated angiogenesis and vascular repair.",
        "Doc_title":"MicroRNA-10A* and MicroRNA-21 modulate endothelial progenitor cell senescence via suppressing high-mobility group A2.",
        "Journal":"Circulation research",
        "Do_id":"23072816",
        "Doc_ChemicalList":"Apolipoproteins E;Cdkn2a protein, mouse;Cyclin-Dependent Kinase Inhibitor p16;HMGB3 Protein;MIRN10 microRNA, mouse;MIRN21 microRNA, mouse;MicroRNAs;beta-Galactosidase",
        "Doc_meshdescriptors":"Aging;Animals;Apolipoproteins E;Cell Aging;Cell Proliferation;Cells, Cultured;Cyclin-Dependent Kinase Inhibitor p16;Disease Models, Animal;Down-Regulation;Endothelial Cells;Gene Expression Profiling;Genotype;HMGB3 Protein;Hindlimb;Ischemia;Mice;Mice, Inbred C57BL;Mice, Knockout;MicroRNAs;Muscle, Skeletal;Neovascularization, Physiologic;Oligonucleotide Array Sequence Analysis;Phenotype;Stem Cells;Transfection;beta-Galactosidase",
        "Doc_meshqualifiers":"genetics;metabolism;deficiency;genetics;genetics;genetics;metabolism;metabolism;methods;genetics;metabolism;genetics;metabolism;physiopathology;metabolism;blood supply;metabolism;genetics;metabolism",
        "_version_":1605836245355724800},
      {
        "Doc_abstract":"The p16(INK4a) gene is a cell cycle inhibitor and a major tumour suppressor protein, but the regulation and effects on tumour cells' invasion process of p16(INK4a) is poorly known. A role for p16(INK4a) in basal cell carcinoma is suggested by the observation that p16(INK4a) was upregulated at the invasive front of the majority of basal cell carcinomas with infiltrative growth patterns, accompanied by cessation of proliferation. In this paper, we explore whether there is a difference of tumour cells' proliferative activity between the centre and the invasion front tissues of human colorectal cancer and its relationship with the expression and methylation status of p16(INK4a) gene. We obtained the centre and the invasion front tissues of colorectal cancer respectively by the technology of laser mircodissection. The expressions of the proliferating cell nuclear antigen ki67 and p16(INK4a) were assessed by immunohistochemistry, methylation-specific polymerase chain reaction (MS-PCR) and reverse-transcription polymerase chain reaction (RT-PCR) in the different areas. There was a significant difference in the expressions of ki67 between the centre and the invasion front tissues (p < 0.05). The difference did not correlate with age, sex, Dukes stage but did correlate with expression of p16(INK4a) gene (chi(2) = 25.37, p < 0.01). Furthermore, hypermethylation of the promoter was the major mechanism of inactivation of p16(INK4a) in the centre areas. Demethylation of the p16(INK4a) promoter, the elevated expression of p16(INK4a) protein and mRNA level was proved in the invasion front. Our finding suggested that enhanced invasion in tumours was accompanied by ceased proliferation in the invasion fronts of human colorectal cancer. This interesting phenomenon may be due to not only the microenvironment, but also the molecular changes such as p16(INK4a) status.",
        "Doc_title":"Relationship between expression and methylation status of p16INK4a and the proliferative activity of different areas' tumour cells in human colorectal cancer.",
        "Journal":"International journal of clinical practice",
        "Do_id":"17537196",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;Ki-67 Antigen",
        "Doc_meshdescriptors":"Adolescent;Adult;Aged;Colorectal Neoplasms;Cyclin-Dependent Kinase Inhibitor p16;Female;Gene Expression;Genes, p16;Humans;Immunohistochemistry;Ki-67 Antigen;Male;Methylation;Middle Aged;Neoplasm Invasiveness;Neoplasm Staging",
        "Doc_meshqualifiers":"genetics;mortality;pathology;genetics;metabolism;physiology;metabolism",
        "_version_":1605796079236808704},
      {
        "Doc_abstract":"The p16 protein is encoded by the CDKN2 gene, and functions as an inhibitor of cyclin-dependent kinase 4 and 6 (CDK4/6). Phosphorylation of the retinoblastoma protein (pRb) by CDK4/6 represents a vital step in cell cycle progression. Alterations of p16INK4A are frequent events in human malignancies. In non-small cell lung carcinoma (NSCLC) the data concerning the mechanisms of p16INK4A inactivation suggest that point mutations and aberrant methylation of its promoter can only account for a proportion of the cases with abnormal p16 immunoexpression. The role of deletions in this procedure is not yet clarified. In order to gain more insight into the role of deletions in p16INK4A deregulated expression, we investigated the state of the chromosomal region 9p21-22 in a series of 57 NSCLCs, by performing a detailed mapping analysis, using a tight cluster of highly polymorphic microsatellite markers, and correlating the findings with p16 immunostaining. Abnormal p16 expression was observed in 46% of the NSCLCs examined. No relationship was observed between p16 abnormal staining and various clinicopathological parameters. Abnormal p16 protein staining was strongly associated with hemizygous deletions at the IFNA and D9S171 microsatellite loci, which demarcate the region encoding the p16INK4A gene (P = 0.002). These findings suggest that deregulated expression of p16 is involved in the multistage process of NSCL carcinogenesis and that deletions may represent a predominant mechanism of p16INK4A inactivation. A significant percentage also of LOH was noticed at the D9S162 (35%) and D9S126 (38%) loci which lie 6cM and 4cM, respectively, far from the area which encodes p16INK4A, implying that other tumor suppressor genes (TSGs) may reside in this region. Although the overall incidence of LOH at the examined region was high (58%), we did not observe any correlation with smoking habits, histology and lymph node status. Another noteworthy finding was the existence of microsatellite instability (MI) in 11% of the patients. MI provides a marker for replication error phenotype (RER+), a recently defined manifestation of genetic instability observed in a wide range of tumors. In conclusion, alterations (LOH + MI) at the 9p21-22 chromosome region are frequent events in NSCLCs and may affect directly or indirectly the expression of p16.",
        "Doc_title":"Aberrant p16 expression is correlated with hemizygous deletions at the 9p21-22 chromosome region in non-small cell lung carcinomas.",
        "Journal":"Anticancer research",
        "Do_id":"10470133",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;Neoplasm Proteins",
        "Doc_meshdescriptors":"Carcinoma, Non-Small-Cell Lung;Cell Transformation, Neoplastic;Chromosomes, Human, Pair 9;Cyclin-Dependent Kinase Inhibitor p16;Female;Gene Expression Regulation, Neoplastic;Genes, p16;Humans;Loss of Heterozygosity;Lung Neoplasms;Male;Microsatellite Repeats;Neoplasm Proteins;Sequence Deletion",
        "Doc_meshqualifiers":"genetics;metabolism;genetics;genetics;ultrastructure;biosynthesis;physiology;genetics;metabolism;biosynthesis;genetics;physiology",
        "_version_":1605746287116812288},
      {
        "Doc_abstract":"Nearly all human gliomas exhibit alterations in one of three genetic loci governing G1 arrest: INK4a-ARF, CDK4, or RB. To discern the roles of CDK4 amplification and INK4a-ARF loss in gliomagenesis, we compared the behavior of astrocytes lacking a functional INK4a-ARF locus with astrocytes overexpressing CDK4. Either a deficiency of p16(INK4a) and p19(ARF) or an increase in Cdk4 allows cultured astrocytes to grow without senescence. Astrocytes overexpressing CDK4 grow more slowly than INK4a-ARF-deficient astrocytes and convert to a tetraploid state at high efficiency; in contrast, INK4a-ARF-deficient cells remain pseudodiploid, consistent with properties observed in human gliomas with corresponding lesions in these genes.",
        "Doc_title":"Modeling mutations in the G1 arrest pathway in human gliomas: overexpression of CDK4 but not loss of INK4a-ARF induces hyperploidy in cultured mouse astrocytes.",
        "Journal":"Genes & development",
        "Do_id":"9851971",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;Proteins;Proto-Oncogene Proteins;Tumor Suppressor Protein p14ARF;Tumor Suppressor Protein p53;CDK4 protein, human;Cdk4 protein, mouse;Cyclin-Dependent Kinase 4;Cyclin-Dependent Kinases",
        "Doc_meshdescriptors":"Animals;Astrocytes;Cells, Cultured;Cyclin-Dependent Kinase 4;Cyclin-Dependent Kinase Inhibitor p16;Cyclin-Dependent Kinases;G1 Phase;Glioma;Humans;Mice;Mice, Mutant Strains;Mice, Transgenic;Ploidies;Proteins;Proto-Oncogene Proteins;Tumor Suppressor Protein p14ARF;Tumor Suppressor Protein p53",
        "Doc_meshqualifiers":"cytology;biosynthesis;genetics;genetics;metabolism;genetics",
        "_version_":1605765828251222016},
      {
        "Doc_abstract":"There is an exciting complementarity between the spatial resolution provided by molecular imaging of a single, often unspecific, biomarker on one hand and the more detailed biological profile achievable from a diagnostic biopsy using a panel of immunohistochemical (IHC) markers on the other. A number of previous studies have shown a relationship between glucose transport protein expression and 18F-Fludeoxyglucose (FDG) PET uptake. Here, FDG uptake is analyzed in relation to expression of a selected panel of IHC cancer biomarkers in head and neck squamous cell carcinomas (HNSCC).;IHC staining for Bcl-2, -tubulin-1 and 2, p53, EGFR, Ki-67, glutathione-S-transferase- and p16 was performed on formalin-fixed paraffin embedded diagnostic biopsies from 102 HNSCC cases treated at Rigshospitalet during 2005-2009. The proportion of positive cells was used for analyses, except p16, which was scored according to EORTC guidelines. In all cases, maximal FDG standardized uptake value (SUV) metrics were extracted for the primary tumor, TSUVmax. Univariate linear regression and multiple linear regression of TSUVmax versus IHC markers were performed.;In univariate analyses, TSUVmax showed negative associations with Bcl-2 (p = 0.002) and p16 (p = 0.005) indices and positive association with -tubulin-1 index (p = 0.003). On multivariate analysis, TSUVmax remained associated with -tubulin-1 (p = 0.009), Bcl-2 (p = 0.03) and p16 (p = 0.03). All correlations had r-squared < 0.3.;Statistically significant correlations were observed between the expression of IHC biomarkers and maximum FDG uptake in the primary tumor.",
        "Doc_title":"Immunohistochemical biomarkers and FDG uptake on PET/CT in head and neck squamous cell carcinoma.",
        "Journal":"Acta oncologica (Stockholm, Sweden)",
        "Do_id":"26256482",
        "Doc_ChemicalList":"BCL2 protein, human;Biomarkers, Tumor;Ki-67 Antigen;Neoplasm Proteins;P16 protein, human;Proto-Oncogene Proteins c-bcl-2;Radiopharmaceuticals;Tubulin;Tumor Suppressor Protein p53;Fluorodeoxyglucose F18;Glutathione Transferase;EGFR protein, human;Receptor, Epidermal Growth Factor",
        "Doc_meshdescriptors":"Biomarkers, Tumor;Carcinoma, Squamous Cell;Fluorodeoxyglucose F18;Glutathione Transferase;Head and Neck Neoplasms;Humans;Immunohistochemistry;Ki-67 Antigen;Multimodal Imaging;Multivariate Analysis;Neoplasm Proteins;Positron-Emission Tomography;Proto-Oncogene Proteins c-bcl-2;Radiopharmaceuticals;Receptor, Epidermal Growth Factor;Tomography, X-Ray Computed;Tubulin;Tumor Suppressor Protein p53",
        "Doc_meshqualifiers":"metabolism;diagnostic imaging;metabolism;pharmacokinetics;metabolism;diagnostic imaging;metabolism;metabolism;metabolism;metabolism;pharmacokinetics;metabolism;metabolism;metabolism",
        "_version_":1605924193406287872},
      {
        "Doc_abstract":"Gene inactivation by promoter hypermethylation has been demonstrated in the colonic mucosa of colorectal cancer (CRC) patients. However, current data do not prove direct involvement of this epigenetic modification in the early stages of CRC. Promoter methylation profiles of E-cadherin, hMLH1, MGMT, p16(INK4a), p15(INK4b) and p14(ARF); mutations of K-ras, B-raf and TP53 and microsatellite instability (MSI) were examined in normal and cancerous colonic mucosal tissue in 82 CRC patients using methylation-specific PCR assays. Methylation of hMLH1 and MGMT in normal mucosa correlated significantly with MSI and K-ras activation in neighbouring cancerous mucosal tissues. Similarly, poorly differentiated tumours were associated with methylated p16(INK4a) and E-cadherin in neighbouring normal colonic tissues (NCTs). Our results indicate that epigenetic changes in mucosa surrounding colorectal neoplastic lesions may describe a 'field cancerisation' phenomenon that may occur previous to genetic alterations in early stages of carcinogenesis.",
        "Doc_title":"Epigenetic events in normal colonic mucosa surrounding colorectal cancer lesions.",
        "Journal":"European journal of cancer (Oxford, England : 1990)",
        "Do_id":"18938072",
        "Doc_ChemicalList":"Proto-Oncogene Proteins B-raf",
        "Doc_meshdescriptors":"Adenocarcinoma;Adult;Aged;Aged, 80 and over;Cell Transformation, Neoplastic;Colorectal Neoplasms;DNA Methylation;Epigenesis, Genetic;Female;Genes, Neoplasm;Genes, p53;Genes, ras;Humans;Intestinal Mucosa;Lymphatic Metastasis;Male;Microsatellite Repeats;Middle Aged;Mutation;Promoter Regions, Genetic;Proto-Oncogene Proteins B-raf",
        "Doc_meshqualifiers":"genetics;genetics;genetics;genetics;genetics;genetics;genetics;genetics;genetics;genetics;genetics",
        "_version_":1605789108142080000},
      {
        "Doc_abstract":"Cyclin D1 and p16INK4A are molecules with pivotal roles in cell cycle control and the development of diverse human cancers, and overexpression of cyclin D1 and loss of p16INK4A expression are common genetic events in head and neck squamous cell carcinoma. The prognostic significance of these molecular events at different sites within the head and neck, however, remains controversial. Thus, we sought to determine the relationship between cyclin D1 and/or p16INK4A expression and disease outcome in squamous cell carcinoma of the anterior tongue. Immunohistochemical detection of nuclear proteins cyclin D1, p53, and p16INK4A, and the Ki-67 labeling index was undertaken in tissue sections from 148 tongue cancers treated by surgical resection. Nuclear antigen status was analyzed in relation to pathological variables, tumor recurrence, and patient survival. Statistical significance was assessed using chi2 analysis for pathological variables and the Kaplan-Meier method, log rank test, and the Cox proportional hazards model for survival parameters. Overexpression of cyclin D1 occurred in 68% of tumors (100 of 147) and was associated with increased lymph node stage (P = 0.014), increased tumor grade (P = 0.003), and reduced disease-free (P = 0.006) and overall (P = 0.01) survival. Loss of p16INK4A expression was demonstrated in 55% of tumors (78 of 143) and was associated with reduced disease-free (P = 0.007) and overall (P = 0.014) survival. Multivariate analysis confirmed that in addition to pathological stage and regional lymph node status, cyclin D1 overexpression and loss of p16INK4A expression are independent predictors of death from tongue cancer. Loss of p16INK4A in the presence of cyclin D1 overexpression conferred a significantly worse disease-free (P = 0.011) and overall (P = 0.002) survival at 5 years. p53 nuclear accumulation and the Ki-67 labeling index were not prognostic. These data indicate that cyclin D1 overexpression and loss of p16INK4A expression predict early relapse and reduced survival in squamous cell carcinoma of the anterior tongue. Simultaneous assessment of cyclin D1 and p16INK4A protein levels define subgroups of patients at increased risk of relapse and may be of clinical utility in optimizing therapy.",
        "Doc_title":"Cyclin D1 and p16INK4A expression predict reduced survival in carcinoma of the anterior tongue.",
        "Journal":"Clinical cancer research : an official journal of the American Association for Cancer Research",
        "Do_id":"10537346",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;Ki-67 Antigen;Tumor Suppressor Protein p53;Cyclin D1",
        "Doc_meshdescriptors":"Carcinoma, Squamous Cell;Cyclin D1;Cyclin-Dependent Kinase Inhibitor p16;Female;Humans;Ki-67 Antigen;Lymphatic Metastasis;Male;Tongue Neoplasms;Tumor Suppressor Protein p53",
        "Doc_meshqualifiers":"chemistry;mortality;pathology;analysis;analysis;analysis;chemistry;mortality;pathology;analysis",
        "_version_":1605843932036464640},
      {
        "Doc_abstract":"The G1/S checkpoint of the cell cycle is regulated by p16, p53 and RB tumor suppressor genes. Loss of expression of the p16INK4 tumor suppressor protein, the product of the CDKN2 gene, has been associated with a wide variety of human malignancies. Mutations, loss of heterozygosity and deletions of the CDKN2 locus have been reported in sporadic and familial cutaneous malignant melanomas (CMM). To investigate the role of the alterations of p16 expression in melanoma, we evaluated by immunohistochemistry the p16 expression and cell proliferation in 79 primary CMM and 10 benign melanocytic nevi (BMN). Forty-six melanomas (58%) and all BMN were found to be p16 positive; 33 melanomas (42%) were considered p16 negative. The extent of invasion according to Clark was significantly higher in p16-negative tumors than in p16-positive tumors. Cell proliferation as expressed by the proportion of positive cells in Ki-67 immunostaining was found to be significantly higher in p16-negative tumors than in p16-positive tumors, although there was no significant difference in the mitotic index between p16-positive and p16-negative tumors. In p16-positive tumors, the number of Ki-67-positive cells correlated with the mitotic index; in p16-negative tumors, there was no correlation between these parameters. Our data suggest that loss of p16 expression is more common in advanced melanomas, and that G1/S checkpoint regulation is disrupted in p16-negative melanomas. Our results show that loss of p16 expression is a common event in primary melanomas, which further substantiates the role of p16 as a major tumor suppressor.",
        "Doc_title":"Loss of expression of the p16INK4/CDKN2 gene in cutaneous malignant melanoma correlates with tumor cell proliferation and invasive stage.",
        "Journal":"International journal of cancer",
        "Do_id":"9221801",
        "Doc_ChemicalList":"Carrier Proteins;Cyclin-Dependent Kinase Inhibitor p16;Ki-67 Antigen;Neoplasm Proteins",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Carrier Proteins;Cell Division;Cyclin-Dependent Kinase Inhibitor p16;Female;Genes, Tumor Suppressor;Humans;Ki-67 Antigen;Male;Melanoma;Middle Aged;Neoplasm Proteins;Skin Neoplasms",
        "Doc_meshqualifiers":"genetics;metabolism;genetics;metabolism;genetics;metabolism;pathology;genetics;metabolism;genetics;metabolism;pathology",
        "_version_":1605842400643645441},
      {
        "Doc_abstract":"The genetic locus CDKN2A has been linked to familial melanoma, and mutations or deletions in its coding sequence are seen in some cases of sporadic and familial melanomas. The protein encoded by CDKN2A, p16(INK4a), functions as a negative regulator of cell cycle progression and as a tumor suppressor, but the regulatory mechanisms involved in controlling its expression remain poorly defined.;This study tested the hypothesis that UVB irradiation, which transiently inhibits the growth of human melanocytes, is one of the regulators of p16(INK4a) expression.;Cultured human melanocytes were irradiated with UVB over a sublethal dosage range, and p16(INK4a) protein and mRNA levels were quantified at varying times thereafter by quantitative immunostaining and by Western and Northern blotting.;Levels of p16(INK4a) protein in melanocytes increased significantly after sublethal UVB irradiation as compared with nonirradiated cells. Northern analysis indicated that p16(INK4a) messenger RNA coordinately increased in a dose-dependent manner more than 2-fold in irradiated cells at the tested doses.;UVB irradiation transcriptionally activates the expression of p16(INK4a) in cultured human melanocytes. Therefore the growth arrest that occurs with irradiation of melanocytes could be mediated, in part, by upregulation of p16(INK4a). This transient arrest may allow repair of UVB-induced DNA damage before cell division. Conversely, hereditary or acquired defects in CDK4A that give rise to functional insufficiency of p16(INK4a) could permit the premature propagation of melanocytes harboring potentially carcinogenic DNA damage.",
        "Doc_title":"The expression of p16(INK4a), the product of a tumor suppressor gene for melanoma, is upregulated in human melanocytes by UVB irradiation.",
        "Journal":"Journal of the American Academy of Dermatology",
        "Do_id":"10775848",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;RNA, Messenger",
        "Doc_meshdescriptors":"Blotting, Northern;Blotting, Western;Cells, Cultured;Cyclin-Dependent Kinase Inhibitor p16;Dose-Response Relationship, Radiation;Gene Expression Regulation;Genes, p16;Humans;Immunohistochemistry;Melanocytes;Melanoma;RNA, Messenger;Radiation Dosage;Skin Neoplasms;Ultraviolet Rays;Up-Regulation",
        "Doc_meshqualifiers":"metabolism;radiation effects;genetics;metabolism;radiation effects;genetics;analysis;genetics",
        "_version_":1605791922926911488},
      {
        "Doc_abstract":"Natural killer (NK) cell neoplasms, which are derived from mature or precursor NK cells, are rare diseases and are observed predominantly in Asian countries. We analyzed the status of the Rb, p53, p15INK4B, p16INK4A and p14ARF genes in these diseases by Southern blot, polymerase chain reaction-single strand conformational polymorphism (PCR-SSCP) and western blot analysis. We used 31 NK cell neoplasms, including four cell lines derived from NK cell neoplasms, 3 myeloid / NK cell precursor acute leukemias, 4 blastic NK cell lymphoma / leukemias, 4 aggressive NK cell leukemia / lymphomas, 4 nasal NK cell lymphomas, and 12 chronic NK lymphocytosis. We found gene amplification of the p53 gene in one nasal NK cell lymphoma, and point mutations of the p53 gene in one blastic NK cell lymphoma / leukemia and one chronic NK lymphocytosis. In addition, homozygous deletions of p15, p16 and p14 genes in 5 out of 31 samples were detected; 3 were from nasal NK cell lymphoma and 2 from blastic NK cell lymphoma / leukemia. Also hemizygous deletion of the Rb gene in one blastic NK cell lymphoma was detected. Rb proteins were highly expressed in one cell line as well as two myeloid / NK cell precursor acute leukemias. In other cell lines, complete loss and an aberrant migration pattern of Rb protein expression were observed. Comparative genomic hybridization suggested that the homozygous deletions of the p15, p16 and p14 were subtle chromosomal deletions and could not be identified by standard karyotyping in some cases. Although the number of cases we analyzed was not large, alterations identified in the Rb, p53, p16, p15 and p14 genes are of significance and might be associated with tumorigenesis in NK cell neoplasms.",
        "Doc_title":"Molecular analysis of tumor suppressor genes, Rb, p53, p16INK4A, p15INK4B and p14ARF in natural killer cell neoplasms.",
        "Journal":"Japanese journal of cancer research : Gann",
        "Do_id":"11676855",
        "Doc_ChemicalList":"Tumor Suppressor Protein p14ARF",
        "Doc_meshdescriptors":"Blotting, Southern;Blotting, Western;Chromosome Deletion;Chromosome Mapping;DNA Mutational Analysis;Genes, Retinoblastoma;Genes, Tumor Suppressor;Genes, p16;Genes, p53;Humans;Killer Cells, Natural;Lymphoma;Mutation;Polymerase Chain Reaction;Polymorphism, Single-Stranded Conformational;Tumor Cells, Cultured;Tumor Suppressor Protein p14ARF",
        "Doc_meshqualifiers":"metabolism;pathology;genetics;genetics;genetics",
        "_version_":1605783527808303104},
      {
        "Doc_abstract":"Atypical squamous cells 'cannot exclude high-grade squamous epithelial lesion' (ASC-H) cytology represents clear risk and has been a controversial issue in clinical practice. The objective of this study is to investigate the diagnostic performance of p16(INK4A) immunohistochemistry (IHC) among ASC-H Pap smears in predicting high-grade cervical intraepithelial lesions. Decolourisation and staining process with p16(INK4A) is applied to 27 ASC-H diagnosed conventional Pap smears, which were all managed with colposcopy-directed cervical biopsy priorly. Staining characteristics of ASC-H Pap smears were compared with histopathological data and sensitivity-specificity values of p16 triage to detect CIN2 + histopathology were determined. The sensitivity and specificity of positive p16(INK4A) immune staining to detect CIN2 + histopathology were as 87.5% and 68%, respectively. The positive predictive value of p16 triage is found as 53.8% and negative predictive value was as 92.8%. p16(INK4A) IHC seems applicable for conventional Pap smears and may provide an alternative triage option in ASC-H category.",
        "Doc_title":"Diagnostic performance of p16 staining in atypical squamous cells 'cannot exclude high-grade squamous epithelial lesion' in predicting high-grade cervical pathology.",
        "Journal":"Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology",
        "Do_id":"24999727",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16",
        "Doc_meshdescriptors":"Adult;Cervical Intraepithelial Neoplasia;Cervix Uteri;Cyclin-Dependent Kinase Inhibitor p16;Female;Humans;Middle Aged;Papanicolaou Test;Retrospective Studies;Uterine Cervical Neoplasms;Vaginal Smears",
        "Doc_meshqualifiers":"chemistry;pathology;chemistry;pathology;analysis;chemistry;pathology",
        "_version_":1605891767322804224},
      {
        "Doc_abstract":"The role of human papillomavirus (HPV) in bladder carcinogenesis remains controversial. Overexpression of p16(INK4a), a surrogate marker for infection with oncogenic HPV in other tumours, has been described for urothelial carcinoma in situ (UCIS). Our goal was therefore to evaluate whether overexpression of p16(INK4a) is associated with HPV infection and to identify mechanisms of p16(INK4a) upregulation in UCIS.;In 60 tissue specimens from a total of 45 patients (UCIS and controls), we performed p16(INK4a) immunohistochemistry followed by detection and subclassification of HPV DNA. In a subset of samples, we tested for gene amplification of p16(INK4a) applying fluorescence in situ hybridization (FISH). RAS/MAPK signalling and epithelial-mesenchymal transition (EMT) was assessed using immunohistochemistry. Finally, we transfected urothelial carcinoma cells with KRAS and examined the expression of p16(INK4a) as well as markers of EMT.;We found overexpression of p16(INK4a) in 92.6% of UCIS and in all cervical intraepithelial neoplasia (CIN) controls. In contrast, we detected high-risk HPV DNA in 80% of CIN, but none in UCIS. There was no gene amplification of p16(INK4a). High levels of phosphorylated kinases and urokinase plasminogen activator (uPA) and loss of membraneous E-cadherin were detected in UCIS. KRAS transfection of urothelial carcinoma cells led to upregulation of p16(INK4a) and uPA accompanied by loss of E-cadherin that could be inhibited by application of the kinase-inhibitor Sorafenib.;Our results show that overexpression of p16(INK4a) in UCIS is neither associated with HPV infection nor p16(INK4a) gene amplification but is a consequence of enhanced RAS/MAPK signalling that promotes EMT, possibly due to Sorafenib-sensitive paracrine secretion of the EMT activator uPA. These findings might open a novel therapeutic option for localized but aggressive urothelial cancer.",
        "Doc_title":"Overexpression of p16(INK4a) in urothelial carcinoma in situ is a marker for MAPK-mediated epithelial-mesenchymal transition but is not related to human papillomavirus infection.",
        "Journal":"PloS one",
        "Do_id":"23724131",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;Phenylurea Compounds;Niacinamide;sorafenib;Mitogen-Activated Protein Kinases;Urokinase-Type Plasminogen Activator",
        "Doc_meshdescriptors":"Aged;Carcinoma in Situ;Cell Line, Tumor;Cervical Intraepithelial Neoplasia;Cyclin-Dependent Kinase Inhibitor p16;Epithelial-Mesenchymal Transition;Female;Humans;Immunohistochemistry;In Situ Hybridization, Fluorescence;MAP Kinase Signaling System;Male;Mitogen-Activated Protein Kinases;Niacinamide;Papillomaviridae;Papillomavirus Infections;Phenylurea Compounds;Transfection;Urokinase-Type Plasminogen Activator;Urothelium;Uterine Cervical Neoplasms",
        "Doc_meshqualifiers":"enzymology;pathology;virology;enzymology;pathology;virology;metabolism;drug effects;drug effects;metabolism;analogs & derivatives;pharmacology;drug effects;isolation & purification;enzymology;pathology;virology;pharmacology;metabolism;pathology;virology;enzymology;pathology;virology",
        "_version_":1605818578648432640},
      {
        "Doc_abstract":"We analyzed allelic loss at the p53 gene (17p13) and at chromosome region 9p21 in 35 primary head and neck squamous cell carcinomas. Loss of heterozygosity (LOH) at p53 and 9p21 was found in 50 and 75% of informative cases, respectively. LOH at the p53 gene did not increase significantly with tumor stage, but was more frequent in moderately and poorly differentiated tumors than in well-differentiated tumors. LOH plus mutation or homozygous deletion of p53 was limited to advanced stage and poorly differentiated tumors. Allelic loss at 9p21 is frequent in early stage head and neck squamous cell carcinoma and is not significantly associated with LOH at p53. The second exon of the p16/MTS1/CDKN2 gene was found to be homozygously deleted in 1 of 19 cases showing LOH at 9p21, but direct sequencing did not show mutations in the remaining 18 cases. This suggests that p16 plays a limited role in the development of head and neck squamous cell carcinoma.",
        "Doc_title":"Loss of heterozygosity and mutation analysis of the p16 (9p21) and p53 (17p13) genes in squamous cell carcinoma of the head and neck.",
        "Journal":"Clinical cancer research : an official journal of the American Association for Cancer Research",
        "Do_id":"9816078",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Carcinoma, Squamous Cell;Chromosomes, Human, Pair 17;Chromosomes, Human, Pair 9;DNA Mutational Analysis;Genes, p16;Genes, p53;Head and Neck Neoplasms;Humans;Loss of Heterozygosity;Microsatellite Repeats",
        "Doc_meshqualifiers":"genetics;genetics;genetics;genetics;genetics;genetics",
        "_version_":1605906275079553024},
      {
        "Doc_abstract":"p73 was studied in squamous cancers and precursor lesions of the vulva. Over-expression of p73 occurred commonly in both human papillomavirus (HPV)-positive and -negative squamous cell cancers (SCC) and high-grade premalignant lesions. Whereas expression in normal vulval epithelium was detected only in the basal and supra-basal layers, expression in neoplastic epithelium increased with grade of neoplasia, being maximal at both protein and RNA levels in SCC. p73 Delta 2 was the principal over-expressed isoform in the majority of cases of vulval SCC and often the sole form expressed in SCC. Over-expression of p73 was associated with expression of HPV-encoded E7 or with hypermethylation or mutation of p16(INK4a) in HPV-negative cases. There was a close correlation between expression of p73 and p14(ARF) in cancers with loss of p53 function. The frequent over-expression of p73 Delta 2 in neoplastic but not normal vulval epithelium, and its co-ordinate deregulation with other E2F-1 responsive genes suggests a role in the oncogenic process.",
        "Doc_title":"p73 is over-expressed in vulval cancer principally as the Delta 2 isoform.",
        "Journal":"British journal of cancer",
        "Do_id":"11720444",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;DNA-Binding Proteins;Nuclear Proteins;Oncogene Proteins, Viral;Papillomavirus E7 Proteins;Protein Isoforms;RNA, Neoplasm;Tumor Protein p73;Tumor Suppressor Protein p14ARF;Tumor Suppressor Protein p53;Tumor Suppressor Proteins;oncogene protein E7, Human papillomavirus type 16;p73 protein, human",
        "Doc_meshdescriptors":"Cyclin-Dependent Kinase Inhibitor p16;DNA Methylation;DNA-Binding Proteins;Female;Genes, Tumor Suppressor;Humans;Immunohistochemistry;Mutation;Neoplasms, Squamous Cell;Nuclear Proteins;Oncogene Proteins, Viral;Papillomavirus E7 Proteins;Papillomavirus Infections;Protein Isoforms;RNA, Neoplasm;Transcriptional Activation;Tumor Protein p73;Tumor Suppressor Protein p14ARF;Tumor Suppressor Protein p53;Tumor Suppressor Proteins;Tumor Virus Infections;Vulvar Diseases;Vulvar Neoplasms",
        "Doc_meshqualifiers":"genetics;biosynthesis;genetics;immunology;genetics;metabolism;virology;biosynthesis;genetics;immunology;biosynthesis;genetics;genetics;metabolism;virology;biosynthesis;genetics;biosynthesis;metabolism;physiology;genetics;metabolism;virology;genetics;metabolism;genetics;metabolism;virology",
        "_version_":1605789914318766080},
      {
        "Doc_abstract":"High-grade neuroendocrine carcinomas (HGNECs) of the head and neck have the morphological appearance of undifferentiated carcinomas and could be histologically similar to human papillomavirus (HPV)-associated non-keratinizing squamous cell carcinomas of the head and neck. The aim of the study is to characterize histologically, immunohistochemically, and virologically these unusual neoplasms. Nineteen HGNECs of the head and neck (1 oropharyngeal, 5 sinonasal, 7 of the larynx, and 6 of the parotid gland) were reviewed and analyzed with a immunohistochemical panel, with special emphasis on cell cycle proteins. The tumors were tested for HPV by in situ hybridization (GenPoint HPV, Dako) and PCR (SPF10-DEIA-LiPA25). Merkel cell polyomavirus was studied using the antibody CM2B4. Fifteen HGNEC were of small cell and 4 of large cell type. Most of the tumors (14/19, 73.7%), including all the pure small cell carcinomas, showed a strong and diffuse positive staining for p16. Eleven of them (78.5%) had Rb loss and a low or absent cyclin D1 expression. All cases were negative for HPV and polyomavirus. Most patients were smokers, diagnosed at advanced stages of the disease, and had a poor outcome, with a 5-year survival of 18%. In conclusion, HGNECs of the head and neck are infrequently related to HPV infection, but usually show strong, diffuse positive p16 immunostaining due to Rb pathway dysregulation. Awareness of this immunohistochemical pattern of expression may avoid a potential diagnostic pitfall with HPV-associated non-keratinizing squamous cell carcinomas, which have a better prognosis. ",
        "Doc_title":"p16 overexpression in high-grade neuroendocrine carcinomas of the head and neck: potential diagnostic pitfall with HPV-related carcinomas.",
        "Journal":"Virchows Archiv : an international journal of pathology",
        "Do_id":"27392929",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605765345344225280},
      {
        "Doc_abstract":"Tumor-Node-Metastasis classification does not fully predict outcome of treatment and prognosis in patients with squamous cell carcinoma of the head and neck. Different biomarkers have been suggested to yield additional prognostic information, but no single marker has thus far been introduced in the clinic. The objective of the present study was to analyze the copy number of the frequently amplified oncogenes CCND1 and c-MYC in relation to the commonly deleted tumor suppressor gene cyclin-dependent kinase (CDK)N2A (p16) to enhance the clinical significance.;Extracted DNA from diagnostic biopsies of 78 untreated patients were analyzed by real-time PCR with specific primers for c-MYC, CCND1, and CDKN2A. Gene copy number ratios were calculated by dividing the copy number of c-MYC or CCND1 with CDKN2A. Ratios > 2 were defined as enhanced. These data were related to disease-free interval and disease-specific survival.;Enhanced gene ratio of c-MYC:CDKN2A was detected in 35 of 78 (45%) and enhanced ratio of CCND1:CDKN2A in 36 of 78 (46%) of the cases. The c-MYC:CDKN2A and CCND1:CDKN2A ratios correlated with disease-specific survival with respect to death (P = 0.042 and 0.049, respectively; Log-rank test). Furthermore, enhancement of c-MYC:CDKN2A was associated with a shorter disease-free interval as marked by the development of recurrences or metastases (P = 0.014; Log-rank test).;We conclude that CCND1 and/or c-MYC amplification, when combined with CDKN2A deletion, yield additional prognostic information as compared with analysis of single genetic aberrations. These gene ratios, as analyzed by a sensitive method like real-time PCR on diagnostic biopsies, might help clinicians to individualize the treatment of squamous cell carcinoma of the head and neck as they reflect the biological properties of the tumors. This could be used as an adjunct to the Tumor-Node-Metastasis classification system.",
        "Doc_title":"The gene ratios c-MYC:cyclin-dependent kinase (CDK)N2A and CCND1:CDKN2A correlate with poor prognosis in squamous cell carcinoma of the head and neck.",
        "Journal":"Clinical cancer research : an official journal of the American Association for Cancer Research",
        "Do_id":"12738730",
        "Doc_ChemicalList":"Cyclin D1",
        "Doc_meshdescriptors":"Carcinoma, Squamous Cell;Cyclin D1;Female;Gene Amplification;Gene Deletion;Gene Dosage;Genes, myc;Genes, p16;Head and Neck Neoplasms;Humans;Male;Neoplasm Recurrence, Local;Neoplasm Staging;Prognosis;Survival Rate",
        "Doc_meshqualifiers":"genetics;pathology;secondary;genetics;genetics;genetics;pathology;genetics;pathology",
        "_version_":1605823842985443328},
      {
        "Doc_abstract":"The INK4 cyclin dependent kinase inhibitors (CDKI), such as p15(INK4B) and p16(INK4A), block cell cycle progression from G to S phase. This is mediated by inhibition of phosphorylation of proteins, including the retinoblastoma susceptibility protein (Rb), by cyclin dependent kinases. Ectopic over-expression of the p16(INK4A) CDKI can inhibit growth of cell lines depending on Rb status. Cell lines lacking Rb, with few exceptions, are resistant to growth inhibition by p16(INK4A). The effects of ectopic over-expression of p15(INK4B) in cell lines with and without wild type Rb were examined by measuring cell recovery. Proliferation was inhibited in cells lacking Rb as well as in cells with wild type Rb expression. Experiments analyzing the effectiveness of chimeric p15(INK4B)/p16(INK4A) proteins indicated that the Rb independent growth inhibition required N-terminal residues of p15(INK4B). Linker insertion mutation of p15(INK4B) showed that the inhibition was dependent on intact ankyrin structures. Double staining flow cytometry found that the growth inhibition correlated with a decrease in cells in G2/M phases of the cell cycle. These findings are consistent with Rb independent inhibition of the progression from G1 to S caused by overexpression of p15(INK4B).",
        "Doc_title":"Rb independent inhibition of cell growth by p15(INK4B).",
        "Journal":"Biochemical and biophysical research communications",
        "Do_id":"10462509",
        "Doc_ChemicalList":"Carrier Proteins;Cell Cycle Proteins;Cyclin-Dependent Kinase Inhibitor p15;Cyclin-Dependent Kinase Inhibitor p16;Growth Inhibitors;Recombinant Fusion Proteins;Retinoblastoma Protein;Tumor Suppressor Proteins;Cyclin-Dependent Kinases",
        "Doc_meshdescriptors":"Carrier Proteins;Cell Cycle;Cell Cycle Proteins;Cell Transformation, Neoplastic;Cyclin-Dependent Kinase Inhibitor p15;Cyclin-Dependent Kinase Inhibitor p16;Cyclin-Dependent Kinases;Growth Inhibitors;Recombinant Fusion Proteins;Retinoblastoma Protein;Transfection;Tumor Suppressor Proteins",
        "Doc_meshqualifiers":"genetics;metabolism;physiology;genetics;metabolism;antagonists & inhibitors;metabolism;metabolism;deficiency;genetics;metabolism",
        "_version_":1605808602551943168},
      {
        "Doc_abstract":"The p16(INK4) protein has been identified as a potent inhibitor of cyclin-dependent kinase (cdk)4 by blocking cdk4-mediated phosphorylation of the tumor suppressor retinoblastoma (Rb) protein, thus allowing Rb-mediated growth suppression.;Loss of p16(INK4) has been associated with a poor cancer prognosis, but its potential significance in bronchioloalveolar carcinomas (BACs) has not been explored.;We examined immunohistochemical expression of p16(INK4), cdk4, and Rb proteins in 38 BACs and correlated their expression levels with known clinicopathological features of the disease.;All BACs expressed cdk4, while 89 and 82% expressed p16(INK4) and Rb proteins, respectively. None of the clinicopathological factors correlated with p16(INK4), cdk4, or Rb expression separately. A low p16(INK4)/cdk4 ratio was significantly associated with a high disease stage (p = 0.04), and the ratio tended to be lower in mucinous than nonmucinous tumors. BACs with a low p16(INK4)/cdk4 ratio showed significantly higher Rb expression levels (p = 0.02). Univariable survival analyses showed a significantly lower 5-year survival probability in patients with a high stage (p = 0.002) or low p16(INK4)/cdk4 ratio (p = 0.01).;The results suggest a role of the cdk4/p16(INK4) pathway in the prognosis of BACs. Further studies are warranted to clarify whether a low p16(INK4)/cdk4 ratio may identify tumors that are destined to behave unfavorably.",
        "Doc_title":"Role of cdk4, p16INK4, and Rb expression in the prognosis of bronchioloalveolar carcinomas.",
        "Journal":"Respiration; international review of thoracic diseases",
        "Do_id":"15753637",
        "Doc_ChemicalList":"Antibodies, Monoclonal;Biomarkers, Tumor;Cyclin-Dependent Kinase Inhibitor p16;Proto-Oncogene Proteins;Retinoblastoma Protein;CDK4 protein, human;Cyclin-Dependent Kinase 4;Cyclin-Dependent Kinases",
        "Doc_meshdescriptors":"Adenocarcinoma, Bronchiolo-Alveolar;Aged;Antibodies, Monoclonal;Biomarkers, Tumor;Blotting, Western;Cyclin-Dependent Kinase 4;Cyclin-Dependent Kinase Inhibitor p16;Cyclin-Dependent Kinases;Female;Humans;Immunohistochemistry;Lung Neoplasms;Male;Middle Aged;Neoplasm Staging;Prognosis;Proto-Oncogene Proteins;Pulmonary Alveoli;Retinoblastoma Protein",
        "Doc_meshqualifiers":"metabolism;pathology;immunology;biosynthesis;immunology;biosynthesis;immunology;metabolism;pathology;biosynthesis;immunology;metabolism;pathology;biosynthesis;immunology",
        "_version_":1605897909436416000},
      {
        "Doc_abstract":"To investigate the expression of p14(ARF), p53, mdm2 and p21(WAF/CIP1) proteins and their relationship in exocrine pancreatic carcinoma.;Specimens of pancreatic carcinoma, adjacent non-neoplastic pancreatic tissue and pancreatic benign lesions were examined for p14(ARF), p53, mdm2 and p21(WAF/CIP1) protein expression by tissue microarray technique and immunohistochemistry.;The expression of p14(ARF), p53, mdm2 and p21(WAF/CIP1) proteins in pancreatic carcinoma were 35.3% (59/167), 57.5% (96/101), 64.1% (107/167) and 39.5% (66/167) respectively. The expression of p53 proteins was increased in pancreatic carcinoma (P < 0.01), while the expression of p14(ARF) and p21(WAF/CIP1) proteins was reduced (P < 0.05), as compared with that in non-neoplastic pancreatic tissue. p21(WAF/CIP1) protein expression in pancreatic carcinoma significantly correlated with the age of patients and perineural invasion (P < 0.05). p53 protein expression correlated significantly with tumor differentiation, lymph node metastasis and perineural invasion (P < 0.05). Mdm2 protein expression correlated significantly with tumor differentiation (P < 0.05), while p14(ARF) protein expression correlated significantly with the age of patients and metastasis (P < 0.05). There was also statistic correlation between the expression of these four genes (P < 0.05).;Overexpression of p53 and mdm2 and loss of p14(ARF) and p21(WAF/CIP1) expression may contribute to the pathogenesis of pancreatic carcinoma. These proteins play a critical role in cell cycle arrest and apoptosis after DNA damage through p14(ARF)-mdm2-p53-p21(WAF/CIP1) pathway. Detection of p53 and Mdm2 protein overexpression may be useful in evaluation of the aggressiveness of pancreatic carcinoma.",
        "Doc_title":"[Expression of proteins in p53 (p14ARF-mdm2-p53-p21WAF/CIP1) pathway and their significance in exocrine pancreatic carcinoma].",
        "Journal":"Zhonghua bing li xue za zhi = Chinese journal of pathology",
        "Do_id":"15132849",
        "Doc_ChemicalList":"CDKN1A protein, human;Cell Cycle Proteins;Cyclin-Dependent Kinase Inhibitor p21;Nuclear Proteins;Proto-Oncogene Proteins;Tumor Suppressor Protein p14ARF;Tumor Suppressor Protein p53;MDM2 protein, human;Proto-Oncogene Proteins c-mdm2",
        "Doc_meshdescriptors":"Adult;Age Factors;Apoptosis;Cell Cycle;Cell Cycle Proteins;Cyclin-Dependent Kinase Inhibitor p21;Female;Follow-Up Studies;Gene Expression Regulation, Neoplastic;Humans;Lymphatic Metastasis;Male;Middle Aged;Neoplasm Invasiveness;Nuclear Proteins;Pancreatic Neoplasms;Proto-Oncogene Proteins;Proto-Oncogene Proteins c-mdm2;Tumor Suppressor Protein p14ARF;Tumor Suppressor Protein p53",
        "Doc_meshqualifiers":"metabolism;metabolism;metabolism;pathology;metabolism;metabolism;metabolism",
        "_version_":1605875820942852096},
      {
        "Doc_abstract":"The 9p21-23 chromosome region harbors a number of known and putative tumor-suppressor genes (TSGs). The best characterized gene in this area is p16(INK4A) (CDKN2A). Alterations of its product have been observed in various malignancies, including non-small-cell lung carcinomas (NSCLCs). We earlier investigated the mechanisms underlying p16(INK4A) inactivation. In the present study, we examined, in a series of 87 NSCLCs, its relationship with the kinetic parameters [proliferation index (PI) and apoptotic index (Al)] and the ploidy status of the tumors. In addition, we extended our previous LOH analysis of the 9p21-23 region by examining flanking areas of p16(INK4A). Aberrant p16 expression was observed in 41.4% of the carcinomas. A significant association was found with increased PI (p = 0.037), but not with apoptosis. Aneuploid tumors were more frequently correlated with abnormal p16 staining (p = 0. 05). A high frequency of allelic imbalance (Alm) was noticed at the D9S161 (51.3%) and D9S157 (64.5%) loci, which lie approximately 4cM centromeric and 7cM telomeric, respectively, to CDKN2A. Abnormal p16(INK4A) expression was strongly correlated with Alm at D9S161 (p = 0.004). Allelic losses at D9S157 occurred more frequently in early stages (p = 0.018) and were significantly associated with deletions at D9S161 (p = 0.035). We conclude that, in a sub-set of NSCLCs, (i) abnormal p16 expression contributes to tumor growth mainly by increasing the proliferative activity in the initial stages of carcinogenesis; (ii) the association with aneuploidy merely reflects the impact of aberrant p16 on proliferative activity; and (iii) other putative TSGs possibly reside within the 9p21-23 region that possibly co-operate in certain cases with CDKN2A in the development of NSCLCs.",
        "Doc_title":"Expression of p16(INK4A) and alterations of the 9p21-23 chromosome region in non-small-cell lung carcinomas: relationship with tumor growth parameters and ploidy status.",
        "Journal":"International journal of cancer",
        "Do_id":"10754490",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16",
        "Doc_meshdescriptors":"Aged;Alleles;Apoptosis;Carcinoma, Non-Small-Cell Lung;Carcinoma, Squamous Cell;Cell Division;Chromosomes, Human, Pair 9;Cyclin-Dependent Kinase Inhibitor p16;Female;Gene Expression Regulation, Neoplastic;Genes, p16;Humans;Immunoenzyme Techniques;Immunohistochemistry;Loss of Heterozygosity;Lung Neoplasms;Male;Middle Aged;Ploidies;Survival Analysis",
        "Doc_meshqualifiers":"genetics;metabolism;pathology;metabolism;genetics;biosynthesis;genetics;genetics;genetics;metabolism;pathology",
        "_version_":1605742049628258306},
      {
        "Doc_abstract":"The tumor suppressor p14(ARF) and proto-oncogene epidermal growth factor receptor (EGFR) play important roles in the development of laryngeal squamous cell carcinoma (LSCC). This study was aimed to determine whether combining recombinant p14(ARF) with antisense complementary DNA of EGFR could improve the therapeutic effectiveness in LSCC.;After human larynx cancer cells (Hep-2) were infected with recombinant adenoviruses (Ad-p14(ARF) and Ad-antisense EGFR) together or alone in vitro, the proliferation and cell cycle distribution of Hep-2 cells were detected by MTT assay and flow cytometer analysis, respectively. Furthermore, the antitumor effects of recombinant adenoviruses together or alone on Hep-2 xenografts were examined in vivo. The levels of p14(ARF) and EGFR expressed in Hep-2 cells and xenografts were determined by western blot assay.;Ad-p14(ARF) combining with Ad-antisense EGFR markedly inhibited the Hep-2 proliferation compared with alone (P=0.001, P=0.002 respectively). Combination of Ad-p14(ARF) and Ad-antisense EGFR led to the proportion of Hep-2 cells in G0/G1 phases increased by up to 86.9%. The down-expression of EGFR protein and overexpression of p14(ARF) protein were observed in vitro and in vivo, and this effect was preserved when Ad-p14(ARF) was combined with Ad-antisense EGFR. Besides, Ad-p14(ARF) plus Ad-antisense EGFR significantly (P<0.05) increased the antitumor activity against Hep-2 tumor xenografts comparing with Ad-p14(ARF) or Ad-antisense EGFR alone.;Combination Ad-p14(ARF) with Ad-antisense EGFR significantly increased the antitumor responses in LSCC. An effectively potential gene therapy to prevent proliferation of LSCC was provided.",
        "Doc_title":"Improved therapeutic effectiveness by combining recombinant p14(ARF) with antisense complementary DNA of EGFR in laryngeal squamous cell carcinoma.",
        "Journal":"American journal of otolaryngology",
        "Do_id":"26545468",
        "Doc_ChemicalList":"DNA, Antisense;Tumor Suppressor Protein p14ARF;Receptor, Epidermal Growth Factor",
        "Doc_meshdescriptors":"Adenoviridae;Carcinoma, Squamous Cell;Cell Cycle;Cell Line, Tumor;Cell Proliferation;DNA, Antisense;Genetic Therapy;Genetic Vectors;Humans;Laryngeal Neoplasms;Receptor, Epidermal Growth Factor;Transfection;Tumor Suppressor Protein p14ARF",
        "Doc_meshqualifiers":"genetics;pathology;therapy;genetics;pathology;therapy;genetics;genetics",
        "_version_":1605820614318227456},
      {
        "Doc_abstract":"Bladder cancer is potentially curable in the majority of cases; however, the prognosis for patients with advanced disease at presentation remains poor. Current noninvasive tests such as cytology lack sufficient sensitivity to detect low-grade, low-stage tumors. Silencing of tumor suppressor genes, such as p16(INK4a), VHL, and the mismatch repair gene hMLH1, has established promoter hypermethylation as a common mechanism for tumor suppressor inactivation in human cancers. It is also a promising new target for molecular detection in bodily fluids including urine, a readily accessible fluid known to contain bladder cancer cells. Methylation-specific PCR (MSP) can determine the presence or absence of methylation of a gene locus at a sensitivity level of up to 1 methylated allele in 1000 unmethylated alleles, appropriate for identifying cancer cell DNA in a bodily fluid.;We first determined the frequency of hypermethylation of the Rb tumor suppressor gene by bisulfite sequencing and of the p16(INK4a), p14(ARF), APC, and RASSF1A tumor suppressor genes by MSP in 45 bladder cancers. We then designed a panel optimal for diagnostic coverage composed of the APC, RASSF1A, and p14(ARF) tumor suppressor genes. This panel was tested for detection of hypermethylation in matched sediment DNA from urine specimens obtained before surgery from the same 45 bladder cancer patients (2 Tis, 16 Ta, 10 T1, and 17 T2-4) as well as normal and benign control DNAs.;Hypermethylation of at least one of three suppressor genes (APC, RASSF1A, and p14(ARF)) was found in all 45 tumor DNAs (100% diagnostic coverage). We detected gene hypermethylation in the matched urine DNA from 39 of 45 patients (87% sensitivity), including 16 cases that had negative cytology. No hypermethylation of APC, RASSF1A, or p14(ARF) was observed in normal transitional cell DNAs or in urine DNAs from normal healthy individuals and patients with inflammatory urinary disease (cystitis). Furthermore, an unmethylated gene in the tumor DNA was always found to be unmethylated in the matched urine DNA (100% specificity).;Promoter hypermethylation of tumor suppressor genes is common in bladder cancer and was found in all grades and stages of tumors examined. Hypermethylation was detected in the urine DNA from 39 of 45 (87%) patients, including cases of early-stage disease amenable to cure. MSP may enhance early detection of bladder cancer using a noninvasive urine test.",
        "Doc_title":"Detection of bladder cancer in urine by a tumor suppressor gene hypermethylation panel.",
        "Journal":"Clinical cancer research : an official journal of the American Association for Cancer Research",
        "Do_id":"15041703",
        "Doc_ChemicalList":"DNA, Neoplasm;RASSF1 protein, human;Tumor Suppressor Proteins",
        "Doc_meshdescriptors":"Base Pair Mismatch;DNA Methylation;DNA, Neoplasm;Gene Silencing;Genes, APC;Genes, Retinoblastoma;Genes, Tumor Suppressor;Humans;Promoter Regions, Genetic;Tumor Suppressor Proteins;Urinary Bladder Neoplasms",
        "Doc_meshqualifiers":"genetics;urine;genetics;genetics;diagnosis;genetics;urine",
        "_version_":1605897044457684992},
      {
        "Doc_abstract":"The INK4A and INK4B genes map to 9p21, with the INK4A gene encoding two products, p16 and p19ARF. Many neoplasms in which INK4A and INK4B genes are altered show deletions involving both genes. Mice carrying a targeted Ink4a deletion develop tumors at an early age. In the present study we examined the genetic alterations affecting the remaining Ink4a allele and the Ink4b gene in tumors arising in heterozygous Ink4a mice. We identified deletion of the remaining Ink4a allele in 7 of 18 (39%) tumors. We also observed deletion of the exon 1beta in 3 cases, one of them presenting this deletion as a unique alteration. In conclusion, the deletion of the remaining Ink4a allele was the alteration most frequently observed, representing the inactivation of two proteins capable of arresting the cell cycle through different pathways that involve the tumor suppressors pRB and p53.",
        "Doc_title":"Involvement of the Ink4a gene (p16 and p19arf) in murine tumorigenesis.",
        "Journal":"International journal of oncology",
        "Do_id":"10375589",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;DNA, Neoplasm;Proteins;Retinoblastoma Protein;Tumor Suppressor Protein p14ARF",
        "Doc_meshdescriptors":"Animals;Cell Cycle;Cyclin-Dependent Kinase Inhibitor p16;DNA, Neoplasm;Gene Deletion;Gene Targeting;Genes, p16;Genetic Predisposition to Disease;Heterozygote;Mice;Mice, Knockout;Neoplasms, Experimental;Polymerase Chain Reaction;Polymorphism, Single-Stranded Conformational;Proteins;Retinoblastoma Protein;Tumor Suppressor Protein p14ARF",
        "Doc_meshqualifiers":"genetics;deficiency;genetics;physiology;genetics;chemically induced;genetics;pathology;genetics;physiology;physiology",
        "_version_":1605905781531607040},
      {
        "Doc_abstract":"Opioid growth factor (OGF) is an endogenous opioid peptide ([Met(5)]enkephalin) that interacts with the OGF receptor (OGFr) and serves as a tonically active negative growth factor in cell proliferation of normal cells. To clarify the mechanism by which OGF inhibits cell replication in normal cells, we investigated the effect of the OGF-OGFr axis on cell cycle activity in human umbilical vein endothelial cells (HUVECs) and human epidermal keratinocytes (NHEKs). OGF markedly depressed cell proliferation of both cell lines by up to 40% of sterile water controls. Peptide treatment induced cyclin-dependent kinase inhibitor (CKI) p16(INK4a) protein expression and p21(WAF1/CIP1) protein expression in HUVECs and NHEKs, but had no effect on p15, p18, p19, or p27 protein expression in either cell type. Inhibition of either p16(INK4a) or p21(WAF1/CIP1) activation by specific siRNAs blocked OGF inhibitory action. Human dermal fibroblasts and mesenchymal stem cells also showed a similar dependence of OGF action on p16(INK4a) and p21(WAF1/CIP1). Collectively, these results indicate that both p16(INK4a) and p21(WAF1/CIP1) are required for the OGF-OGFr axis to inhibit cell proliferation in normal cells.",
        "Doc_title":"The OGF-OGFr axis utilizes the p16INK4a and p21WAF1/CIP1 pathways to restrict normal cell proliferation.",
        "Journal":"Molecular biology of the cell",
        "Do_id":"18923142",
        "Doc_ChemicalList":"CDKN1A protein, human;Cyclin-Dependent Kinase Inhibitor p16;Cyclin-Dependent Kinase Inhibitor p21;Neurotransmitter Agents;RNA, Small Interfering;Receptors, Opioid;methionine-enkephalin receptor;Enkephalin, Methionine",
        "Doc_meshdescriptors":"Animals;Cell Cycle;Cell Line;Cell Proliferation;Cyclin-Dependent Kinase Inhibitor p16;Cyclin-Dependent Kinase Inhibitor p21;Endothelial Cells;Enkephalin, Methionine;Humans;Keratinocytes;Neurotransmitter Agents;RNA, Small Interfering;Receptors, Opioid;Signal Transduction",
        "Doc_meshqualifiers":"physiology;genetics;metabolism;genetics;metabolism;cytology;physiology;genetics;metabolism;cytology;physiology;metabolism;genetics;metabolism;genetics;metabolism;physiology",
        "_version_":1605763118628077568},
      {
        "Doc_abstract":"Pathogenetically, endometrioid adenocarcinomas of the endometrium are associated with hyperestrogenism and serous papillary carcinomas with alterations of p53. The etiology of primary endometrial squamous cell carcinoma (ESCC), however, is speculative. The purpose of this study was to evaluate the role of p14, p16, p53, cyclin D1, steroid hormone receptors, and human papillomaviruses (HPV) infection in the pathogenesis of primary endometrial squamous cell carcinoma. The expression of p16, p14, p53, cyclin D1, and steroid hormone receptors (estrogen, progesterone, and androgen) was examined immunohistochemically in 8 primary ESCCs. HPV analysis was performed using general primers and HPV typing. The median age of the patients was 62.1 years. Four cases showed positive nuclear and cytoplasmic p16 staining in an insular pattern, and 1 case nuclear positivity for p53 and estrogen receptors, respectively. Four of 8 cases were positive for progesterone receptor analysis and cyclin D1. All cases were negative for p14 and androgen receptor staining. All but one case were negative for HPV analysis. Five patients were alive with and without evidence of disease after a mean follow-up of 6.1 years. The results of this study suggest that alterations of the p16 pathway may play an etiologic role in at least a proportion of the ESCC, but without any association to HPV infection. Factors known to play a pathogenetic role in types 1 and 2 of endometrial carcinomas are not associated with primary ESCC. However, prognostically, ESCCs are more related to type 1 cancers.",
        "Doc_title":"p16, p14, p53, cyclin D1, and steroid hormone receptor expression and human papillomaviruses analysis in primary squamous cell carcinoma of the endometrium.",
        "Journal":"Annals of diagnostic pathology",
        "Do_id":"16844559",
        "Doc_ChemicalList":"Biomarkers, Tumor;Cell Cycle Proteins;Cyclin-Dependent Kinase Inhibitor p16;Receptors, Steroid;Tumor Suppressor Protein p14ARF;Tumor Suppressor Protein p53;Cyclin D1",
        "Doc_meshdescriptors":"Adult;Aged, 80 and over;Biomarkers, Tumor;Carcinoma, Squamous Cell;Cell Cycle Proteins;Cyclin D1;Cyclin-Dependent Kinase Inhibitor p16;Endometrial Neoplasms;Female;Humans;Middle Aged;Papillomaviridae;Papillomavirus Infections;Receptors, Steroid;Tumor Suppressor Protein p14ARF;Tumor Suppressor Protein p53",
        "Doc_meshqualifiers":"metabolism;metabolism;pathology;virology;metabolism;metabolism;metabolism;metabolism;pathology;virology;isolation & purification;complications;metabolism;pathology;metabolism;metabolism;metabolism",
        "_version_":1605763011260186624},
      {
        "Doc_abstract":"Cervical lymph node metastases from unknown primary sites account for approximately 3% to 9% of all head and neck malignant lesions. Squamous cell carcinoma is the most common type of cervical metastatic carcinoma. Our aim was to investigate the possibility of determining the site of primary tumors using an immunohistochemical diagnostic panel in metastatic cervical lymph nodes. Expression profiles of cytokeratins, 5/6; 8/18; 10; 13; 14; and 19, p16, and pRb were evaluated in 101 consecutive patients with cervical nodal metastasis who had undergone neck dissection to treat known head and neck squamous cell carcinoma (primary sites: 16, oral cavity; 38, oropharynx; 26, hypopharynx; 21, larynx). Cytokeratin 10 was more frequently expressed in oral cavity primary tumors, whereas cytokeratin 19 staining was more frequently observed in tumors originated from the pharynx and larynx. The expression of p16 and altered pRb status (0% or >50%) were more frequently observed in oropharynx primary tumors. To select the best subset among the 8 antibodies tested, classification and regression tree analysis was performed. The analysis correctly classified the four primary sites (25.0% of oral cavity, 89.5% of oropharynx, 30.8% of hypopharynx, and 57.1% of larynx) using 5 variables (histologic subtype, p16, cytokeratins 10 and 19, and pRb). The p16 was the single best predictor. The classification tree method using immunostaining profiles of p16, cytokeratins 10 and 19, or pRb may be helpful in the identification of the primary site of metastatic squamous cell carcinoma with occult primary.",
        "Doc_title":"The use of an immunohistochemical diagnostic panel to determine the primary site of cervical lymph node metastases of occult squamous cell carcinoma.",
        "Journal":"Human pathology",
        "Do_id":"19954817",
        "Doc_ChemicalList":"Keratins",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Carcinoma, Squamous Cell;Chi-Square Distribution;Female;Head and Neck Neoplasms;Humans;Immunohistochemistry;Keratins;Lymph Nodes;Lymphatic Metastasis;Male;Middle Aged;Neoplasms, Unknown Primary;Retrospective Studies;Tissue Array Analysis",
        "Doc_meshqualifiers":"metabolism;secondary;metabolism;secondary;metabolism;metabolism;pathology;pathology;metabolism;pathology",
        "_version_":1605746811295760384},
      {
        "Doc_abstract":"Squamous cell carcinomas of the head and neck (HNSCC) are a frequent diagnosis in anatomic pathology practice. Tobacco use and heavy alcohol consumption are known risk factors for HNSCC but in other cases human papillomavirus (HPV) is linked to carcinogenesis. HPV proteins E6 and E7 promote oncogenesis by blocking the action of p53 and pRB, respectively. An absence of p53 mutations in addition to expression of p16 are part of the distinct molecular profile identified in the subset of HNSCCs because of HPV. Various methods are available for HPV detection but polymerase chain reaction and in situ hybridization techniques are commonly used. Both methods are amenable for testing formalin-fixed paraffin-embedded tissue that is a sample type readily available to the pathologist. HPV is detectable in approximately a quarter of all HNSCCs, and is particularly prevalent in the oropharynx in which the positivity rates approach 40%. A vast majority of HPV-related HNSCCs are owing to HPV type 16 with types 18, 31, and 33 accounting for almost all of the remaining cases. HPV-related HNSCCs are associated with better prognosis for both recurrence and survival. This group of tumors has also been shown to respond well to radiation treatment. As the clinical relevance of HPV in HNSCCs continues to emerge, anatomic pathologists are likely to receive increasing requests for testing. Herein, the authors review the biological and clinical aspects of HPV-associated HNSCC and review techniques for HPV detection.",
        "Doc_title":"Human papillomavirus detection in head and neck squamous cell carcinomas.",
        "Journal":"Advances in anatomic pathology",
        "Do_id":"20966645",
        "Doc_ChemicalList":"DNA, Viral",
        "Doc_meshdescriptors":"Carcinoma, Squamous Cell;DNA, Viral;Head and Neck Neoplasms;Humans;In Situ Hybridization;Papillomaviridae;Papillomavirus Infections;Polymerase Chain Reaction",
        "Doc_meshqualifiers":"virology;isolation & purification;virology;isolation & purification;complications",
        "_version_":1605761032193572864},
      {
        "Doc_abstract":"To examine whether p16(ink4a) immunocytochemical (ICC) expression detected intraepithelial disease in liquid-based cytology (LBC) specimens from women with high-grade squamous intraepithelial lesions (HSIL), whose specimen was labeled negative for intraepithelial lesion or malignany (NILM).;Residual LBC specimens from women treated for HSIL (n = 21), whose LBC test was interpreted as NILM including marked benign inflammatory changes (BCC) were used. The control (n = 25) consisted of residual LBC specimens from women with documented HSIL. ICC for p16p(16k4a) was performed on a second ThinPrep (ThinPrep 2000, Cylyl Corporation, Boxborough, Massachusetts, U.S.A.) preparation; the percentage ofpositive cells and intensity of immunostaining were recorded. Standard LBC preparations for p16(ink4a) ICC-positive and ICC-negative control cases were reviewed.;Twenty-four of 25 (96%) of the HSIL control group were ICC p16(ink4a) positive. In the NILM/BCC group, 2 of 21 with adequate LBC residua were ICC p16(ink4a) positive; on review both were reclassified as epithelial abnormality--1 HSIL and 1 atypical squamous cells cannot exclude HSIL. In both, subsequent colposcopic biopsy yielded HSIL.;p16(ink4a) ICC positivity on NILM/BCC LBC residua from patients with HSIL may identify cases that merit cytologic review and possible reclassification. The utility of p16(ink4a) ICC in this situation requires further study.",
        "Doc_title":"Utility of p16(ink4a) immunocytochemistry in liquid-based cytology specimens from women treated for high-grade squamous intraepithelial lesions.",
        "Journal":"Acta cytologica",
        "Do_id":"17718114",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16",
        "Doc_meshdescriptors":"Cervical Intraepithelial Neoplasia;Cyclin-Dependent Kinase Inhibitor p16;Female;Humans;Immunohistochemistry;Neoplasms, Squamous Cell;Uterine Cervical Neoplasms;Vaginal Smears",
        "Doc_meshqualifiers":"metabolism;pathology;metabolism;metabolism;pathology;metabolism;pathology",
        "_version_":1605818787316105216},
      {
        "Doc_abstract":"The INK4a/ARF locus encodes two physically linked tumor suppressor proteins, p16(INK4a) and ARF, which regulate the RB and p53 pathways, respectively. The unusual genomic relationship of the open reading frames of these proteins initially fueled speculation that only one of the two was the true tumor suppressor, and loss of the other merely coincidental in cancer. Recent human and mouse genetic data, however, have firmly established that both proteins possess significant in vivo tumor suppressor activity, although there appear to be species- and cell-type specific differences between the two. For example, ARF plays a clear role in preventing Myc-induced lymphomagenesis in mice, whereas the role for p16(INK4a) is human carcinomas is more firmly established. In this review, I discuss the evolutionary history of the locus, the relative importance of these tumor suppressor genes in human cancer, and recent information suggesting novel biochemical and physiologic functions of these proteins in vivo.",
        "Doc_title":"INK4a/ARF: a multifunctional tumor suppressor locus.",
        "Journal":"Mutation research",
        "Do_id":"15878778",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;Tumor Suppressor Protein p14ARF",
        "Doc_meshdescriptors":"Amino Acid Sequence;Animals;Cyclin-Dependent Kinase Inhibitor p16;Genes, Tumor Suppressor;Genetic Predisposition to Disease;Humans;Molecular Sequence Data;Sequence Homology, Amino Acid;Tumor Suppressor Protein p14ARF",
        "Doc_meshqualifiers":"physiology;physiology",
        "_version_":1605756296783462400},
      {
        "Doc_abstract":"While p14(ARF) suppression of tumorigenesis in a p53-dependent manner is well studied, the mechanism by which p14(ARF) inhibits tumorigenesis independently of p53 remains elusive. A variety of factors have been reported to play a role in this latter process. We report here that p14(ARF) displays different effects on the anchorage-dependent and -independent growth of p53-null/Mdm2 wild type cells. p14(ARF) blocks both the anchorage-dependent and-independent (soft agar) proliferation of 293T and p53(-/-) HCT116, but not p53-null H1299 lung carcinoma cells. While p14(ARF) had no effect on the anchorage-dependent proliferation of p53(-/-) MEFs and Ras12V-transformed p53(-/-) MEFs, it inhibited the growth of Ras12V-transformed p53(-/-) MEFs in soft agar. Furthermore, ectopic expression of p14(ARF) did not lead to degradation of the E2F1 protein and did not result in the reduction of E2F1 activity detected by two E2F1 responsible promoters, Apaf1 and p14(ARF) promoter, in 293T, p53(-/-) HCT116, and H1299 cells. This is consistent with our observations that p14(ARF) did not result in G1 arrest, but induced apoptosis via Bax up-regulation. Taken together, our data demonstrate that the response of p53-null cells to ARF is cell type dependent and involves factors other than Mdm2 and E2F1.",
        "Doc_title":"p14ARF inhibits the growth of p53 deficient cells in a cell-specific manner.",
        "Journal":"Biochimica et biophysica acta",
        "Do_id":"16764954",
        "Doc_ChemicalList":"E2F1 Transcription Factor;E2F1 protein, human;E2f1 protein, mouse;Tumor Suppressor Protein p14ARF;bcl-2-Associated X Protein",
        "Doc_meshdescriptors":"Animals;Apoptosis;Cell Adhesion;Cell Division;Cell Line;Cell Proliferation;E2F1 Transcription Factor;Gene Deletion;Gene Expression;Genes, p53;Humans;Mice;Tumor Suppressor Protein p14ARF;bcl-2-Associated X Protein",
        "Doc_meshqualifiers":"genetics;physiology;metabolism;genetics;physiology;metabolism",
        "_version_":1605742060816564225},
      {
        "Doc_abstract":"Promoter hypermethylation of various tumor-related genes is extremely frequent in gastric carcinoma (GC) associated with Epstein-Barr virus (EBV). To investigate the significance of the promoter methylation in this type of GC, we examined the methylation densities of the promoter regions of p14ARF and p16INK4A in EBV-associated (n=7) and EBV-negative (n=14) GC. Bisulfite sequencing demonstrated a high frequency of concurrent methylation of p14ARF and p16INK4A promoter regions in EBVaGC. Methylation was observed in all 29 CpG sites of p14ARF and all 16 sites of p16INK4A with equally high densities. In EBV-negative GC, the methylation profiles differed between the 2 genes. Promoter methylation was sporadic and variable in p14ARF, and only the last position of CpG in p14ARF was methylated at high frequency. High-density methylation in p16INK4A was observed in a subset of GC, but the first position of CpG was never methylated in EBV-negative GC. These findings suggest the presence of mechanisms of de novo and maintenance methylation specific to EBVaGC that might be associated with EBV infection.",
        "Doc_title":"High-density methylation of p14ARF and p16INK4A in Epstein-Barr virus-associated gastric carcinoma.",
        "Journal":"International journal of cancer",
        "Do_id":"15352040",
        "Doc_ChemicalList":"Tumor Suppressor Protein p14ARF",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Base Sequence;Carcinoma;DNA Methylation;Epstein-Barr Virus Infections;Female;Genes, p16;Humans;Male;Middle Aged;Molecular Sequence Data;Promoter Regions, Genetic;Stomach Neoplasms;Tumor Suppressor Protein p14ARF",
        "Doc_meshqualifiers":"genetics;physiopathology;virology;complications;genetics;physiopathology;virology;metabolism",
        "_version_":1605742735417933826},
      {
        "Doc_abstract":"The molecular mechanisms by which the p14ARF gene is altered in non-small cell lung cancer (NSCLC) are complex and unclear. Using genetic and epigenetic analyses, we examined various molecular alterations including the loss of protein and mRNA expression, and 5'CpG hypermethylation, allelic imbalance, and mutation of the p14ARF gene in a series of 102 NSCLC samples, in parallel with clinicopathological and prognostic analyses. To clarify the biological significance of p14ARF alterations, its relationship with p16INK4a and p53 alterations was also examined.;We found that 34% of NSCLC patients had aberrant P14ARF protein expression, which was more frequent in adenocarcinomas (AD; 44%) than in squamous cell carcinomas (22%; P = 0.024). A high concordance was observed between alterations in protein and mRNA expression and 5'CpG hypermethylation (P </= 0.001). The p14ARF hypermethylation inversely correlated with P53 overexpression (P = 0.001). This mutually exclusive relationship for alteration between p14ARF and p53 was also supported by a worse prognosis of AD patients with positive P14ARF expression (P = 0.01) and of AD patients with P53 overexpression (P = 0.006). Our data also indicated that hemizygous/homozygous deletion and mutation in the p14ARF gene occurred at 26%, 9%, and 0%, respectively, of microdissected NSCLCs.;Our data suggest that p14ARF 5'CpG hypermethylation is the predominant mechanism involved in the aberrant expression of the p14ARF gene. In addition, p14ARF 5'CpG hypermethylation occurs inversely to P53 overexpression.",
        "Doc_title":"5' cytosine-phospho-guanine island methylation is responsible for p14ARF inactivation and inversely correlates with p53 overexpression in resected non-small cell lung cancer.",
        "Journal":"Clinical cancer research : an official journal of the American Association for Cancer Research",
        "Do_id":"15269146",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;RNA, Messenger;Tumor Suppressor Protein p14ARF;Tumor Suppressor Protein p53",
        "Doc_meshdescriptors":"Adult;Aged;Carcinoma, Non-Small-Cell Lung;Chromosomes, Human, Pair 9;CpG Islands;Cyclin-Dependent Kinase Inhibitor p16;DNA Methylation;Female;Gene Deletion;Gene Expression Regulation, Neoplastic;Gene Silencing;Homozygote;Humans;Immunohistochemistry;Loss of Heterozygosity;Lung Neoplasms;Male;Microsatellite Repeats;Middle Aged;Mutation;Prognosis;RNA, Messenger;Survival Analysis;Tumor Suppressor Protein p14ARF;Tumor Suppressor Protein p53",
        "Doc_meshqualifiers":"genetics;metabolism;pathology;genetics;genetics;genetics;metabolism;genetics;metabolism;pathology;genetics;metabolism;genetics;metabolism;genetics;metabolism",
        "_version_":1605746348585385986},
      {
        "Doc_abstract":"The INK4a/ARF locus on chromosome 9p21 encodes two gene products that are involved in cell cycle regulation through inhibition of CDK4-mediated RB phosphorylation (p16INK4a) and binding to MDM2 leading to p53 stabilization (p14ARF). The locus is deleted in up to 25% of oligodendrogliomas and 50% of anaplastic oligodendrogliomas, but little is known on the frequency of gene silencing by DNA methylation. We assessed promoter hypermethylation of p14ARF and p16INK4a using methylation-specific PCR, and homozygous deletion of the p14ARF and p16INK4a genes by differential PCR in 29 oligodendrogliomas (WHO grade II) and 20 anaplastic oligodendrogliomas (WHO grade III). Promoter hypermethylation of the p14ARF gene was detected in 6/29 (21%) oligodendrogliomas and 3/20 (15%) anaplastic oligodendrogliomas. None of the oligodendrogliomas and only 1 out of 20 anaplastic oligodendrogliomas showed hypermethylation of p16INK4a. Homozygous deletion was not detected in any of the WHO grade II oligodendrogliomas but was present in 5/20 (25%) anaplastic oligodendrogliomas and always affected both genes. In one tumor containing distinct areas with and without anaplasia, p14ARF hypermethylation was detected in the WHO grade II area, while homozygous co-deletion of p14ARF and p16INK4a was found in the region with anaplastic features (grade III). These data suggest that aberrant p14ARF expression due to hypermethylation is the earliest INK4a/ARF change in the evolution of oligodendrogliomas, while the presence of p14ARF and p16INK4a deletions indicates progression to anaplastic oligodendroglioma.",
        "Doc_title":"Promoter hypermethylation and homozygous deletion of the p14ARF and p16INK4a genes in oligodendrogliomas.",
        "Journal":"Acta neuropathologica",
        "Do_id":"11307615",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;Proteins;Tumor Suppressor Protein p14ARF",
        "Doc_meshdescriptors":"Adolescent;Adult;Aged;Chromosomes, Human, Pair 9;Cyclin-Dependent Kinase Inhibitor p16;DNA Methylation;DNA Mutational Analysis;Disease Progression;Female;Gene Deletion;Gene Silencing;Homozygote;Humans;Male;Middle Aged;Mutation;Oligodendroglioma;Promoter Regions, Genetic;Proteins;Tumor Suppressor Protein p14ARF",
        "Doc_meshqualifiers":"genetics;genetics;metabolism;physiology;physiology;genetics;pathology;physiopathology;genetics;genetics;metabolism",
        "_version_":1605874888450506752},
      {
        "Doc_abstract":"The Papanicolaou test (Pap) has been responsible for a significant reduction of cervical cancer-related morbimortality. In order to increase its sensitivity and specificity new markers have been studied and incorporated to cytological and histological methods for diagnosis for cervical cancer, such as p16INK4A that has been considered the immunocytochemical marker of choice for detection of HPV related cancers. We considered that p14ARF could be a complementary marker in order to improve the accuracy of cytological diagnosis because its genetic proximity to p16INK4A. We performed a systematic analysis of several putative cervical cancer markers in order to evaluate their performance in the detection of malignancy, in comparison with p16INK4A and p14ARF, using immunocytochemistry (ICC), immunofluorescence (IF) and Western blot analyses. Most markers were non-specific and could not discriminate HPV infected cancer cell lines from other non HPV malignant. In contrast, nuclear co-expression of p16INK4A and p14ARF was observed only in HPV-transformed cancer cell lines. Notably, in C-33A cervical cancer cells (HPV negative), p14ARF was present in the nucleoli, but p16INK4A was conspicuously absent from the nuclei of these cells. We conclude that both markers; p16INK4A and p14ARF are complementary and should be evaluated jointly in order to improve the accuracy of cytological diagnosis of cervical cancer.",
        "Doc_title":"Nuclear co-expression of p14ARF and p16INK4A in uterine cervical cancer-derived cell lines containing HPV.",
        "Journal":"Cancer biomarkers : section A of Disease markers",
        "Do_id":"22072122",
        "Doc_ChemicalList":"Cell Cycle Proteins;Cyclin-Dependent Kinase Inhibitor p16;E2F1 Transcription Factor;E2F1 protein, human;Oncogene Proteins, Viral;Retinoblastoma Protein;Tumor Suppressor Protein p14ARF;Tumor Suppressor Protein p53;Cathepsins;Matrix Metalloproteinases",
        "Doc_meshdescriptors":"Cathepsins;Cell Cycle Proteins;Cell Line, Tumor;Cell Nucleus;Cyclin-Dependent Kinase Inhibitor p16;E2F1 Transcription Factor;Female;Gene Expression Regulation, Neoplastic;HeLa Cells;Humans;Matrix Metalloproteinases;Oncogene Proteins, Viral;Papillomaviridae;Retinoblastoma Protein;Tumor Suppressor Protein p14ARF;Tumor Suppressor Protein p53;Uterine Cervical Neoplasms",
        "Doc_meshqualifiers":"metabolism;metabolism;metabolism;genetics;metabolism;metabolism;metabolism;genetics;metabolism;genetics;metabolism;genetics;metabolism;genetics;metabolism;genetics;metabolism;genetics;metabolism;virology",
        "_version_":1605902901524299776},
      {
        "Doc_abstract":"Flow cytometric analysis of fibroblasts, normal breast epithelial cells and breast or other cancer cell lines identified variation in the abilities of cell lines to undergo cell cycle arrest as a response to hypoxia. Human mammary epithelial cells (HMEC), normal fibroblasts (Hs68 and WI38), HeLa cervical carcinoma and HTB-30 breast carcinoma cells arrest in G(1)/S in response to severe hypoxia. Hep3B hepatocellular carcinoma cells did not exhibit orderly G(1)/S arrest in response to severe hypoxia. We found a general decrease in p16(INK4a) (p16) mRNA levels, with an associated decrease in p16 protein levels in both normal cells and in cancer cells, regardless of their cell cycle response to hypoxia. p27 protein levels did not correlate with the cell line's ability to enter a hypoxic G(1)/S arrest. Furthermore, cell lines that underwent G(1)/S arrest showed decreased expression of hypoxia inducible factor 1 (HIF-1alpha) and at least one member of INK4 or Sdi cell cycle kinase inhibitors families after 12-24 h of hypoxia. Conversely, Hep3B, which did not exhibit orderly hypoxia-associated G(1)/S arrest, also did not show decreased HIF-1alpha, INK4 or Sdi protein levels in hypoxia. Furthermore, Hep3B showed constitutive activating phosphorylation of Akt and inhibitory phosphorylation of GSK3beta, which was the opposite pattern to that exhibited by the cell lines showing the G(1)/S arrest phenotype. Inhibition of GSK3beta by lithium chloride treatment of HeLa cells converted the HIF-1alpha, p16 and p27 loss to levels unchanged by hypoxic exposure. Our results suggest that regulation of the cell cycle during hypoxia in either normal or cancer cells is not simply due to up-regulation of cell cycle kinase inhibitors. Furthermore, decreased protein expression of HIF-1alpha, p16 and p27 was associated with both a hypoxia-induced G(1)/S arrest phenotype and increased GSK3beta activity.",
        "Doc_title":"Cell cycle kinase inhibitor expression and hypoxia-induced cell cycle arrest in human cancer cell lines.",
        "Journal":"Carcinogenesis",
        "Do_id":"15347600",
        "Doc_ChemicalList":"Cell Cycle Proteins;Cyclin-Dependent Kinase Inhibitor p16;HIF1A protein, human;Hypoxia-Inducible Factor 1, alpha Subunit;Proto-Oncogene Proteins;RNA, Messenger;Transcription Factors;Tumor Suppressor Proteins;Cyclin-Dependent Kinase Inhibitor p27;AKT1 protein, human;GSK3B protein, human;Glycogen Synthase Kinase 3 beta;Protein-Serine-Threonine Kinases;Proto-Oncogene Proteins c-akt;Glycogen Synthase Kinase 3",
        "Doc_meshdescriptors":"Apoptosis;Carcinoma, Hepatocellular;Cell Cycle Proteins;Cell Hypoxia;Cyclin-Dependent Kinase Inhibitor p16;Cyclin-Dependent Kinase Inhibitor p27;Enzyme Activation;Fibroblasts;G1 Phase;Glycogen Synthase Kinase 3;Glycogen Synthase Kinase 3 beta;HeLa Cells;Humans;Hypoxia-Inducible Factor 1, alpha Subunit;Liver Neoplasms;Phosphorylation;Protein-Serine-Threonine Kinases;Proto-Oncogene Proteins;Proto-Oncogene Proteins c-akt;RNA, Messenger;S Phase;Transcription Factors;Tumor Cells, Cultured;Tumor Suppressor Proteins",
        "Doc_meshqualifiers":"genetics;metabolism;genetics;metabolism;genetics;metabolism;metabolism;genetics;metabolism;genetics;metabolism;genetics;metabolism;genetics;metabolism;genetics;metabolism;genetics;metabolism;genetics;metabolism",
        "_version_":1605875504853811200},
      {
        "Doc_abstract":"Malignant peripheral nerve sheath tumor (MPNST) can arise sporadically or in association with neurofibromatosis type 1. Deletions at the 9p21 locus have been reported in these tumors. To additionally characterize the status of this chromosomal region, in this study we performed a comprehensive, mostly PCR-based molecular analysis of the three tumor suppressor genes p15(INK4b), p14(ARF) and p16(INK4a) located at the 9p21 locus in 26 cryopreserved MPNSTs.;Fourteen neurofibromatosis type 1-related and 12 sporadic cases were investigated for homozygous deletion coupled with fluorescent in situ hybridization, promoter methylation, and mutational analysis, as well as m-RNA expression.;The results showed that an inactivation of one or more genes occurred in 77% of MPNSTs and was mainly achieved through homozygous deletion (46%), which, in turn, encompassed all of the three tandemly linked genes in 83% of the deleted cases. Promoter methylation was at a less extent involved in gene silencing (18%), and no mutations were found. Loss of function at DNA level strongly correlated with loss of mRNA expression accounting for 80% of the cases. Because of the close relationship between p14(ARF) and TP53 and between p15(INK4b)/p16(INK4a) and Rb, these results support a model of a coinactivation of TP53 and Rb pathways in 75% of MPNSTs, with functional consequences on cell growth control and apoptosis.;The inactivation of the 9p21 locus is a frequent and peculiar hallmark of MPNST genetic profile leading also to an impaired apoptosis that could be taken into account in treatment planning of these tumors.",
        "Doc_title":"p15INK4b, p14ARF, and p16INK4a inactivation in sporadic and neurofibromatosis type 1-related malignant peripheral nerve sheath tumors.",
        "Journal":"Clinical cancer research : an official journal of the American Association for Cancer Research",
        "Do_id":"14519636",
        "Doc_ChemicalList":"CDKN2B protein, human;Cell Cycle Proteins;Cyclin-Dependent Kinase Inhibitor p15;Cyclin-Dependent Kinase Inhibitor p16;DNA Primers;Tumor Suppressor Protein p14ARF;Tumor Suppressor Proteins",
        "Doc_meshdescriptors":"Adult;Aged;Base Sequence;Cell Cycle Proteins;Cyclin-Dependent Kinase Inhibitor p15;Cyclin-Dependent Kinase Inhibitor p16;DNA Primers;Female;Humans;In Situ Hybridization, Fluorescence;Male;Middle Aged;Nerve Sheath Neoplasms;Neurofibromatosis 1;Peripheral Nervous System Neoplasms;Polymerase Chain Reaction;Tumor Suppressor Protein p14ARF;Tumor Suppressor Proteins",
        "Doc_meshqualifiers":"antagonists & inhibitors;genetics;antagonists & inhibitors;genetics;genetics;pathology;genetics;pathology;genetics;pathology;antagonists & inhibitors;genetics;antagonists & inhibitors;genetics",
        "_version_":1605841632299581440},
      {
        "Doc_abstract":"Head and neck squamous cell carcinoma (HNSCC) is an aggressive disease marked by frequent recurrence and metastasis and stagnant survival rates. To enhance molecular knowledge of HNSCC and define a non-coding RNA (ncRNA) landscape of the disease, we profiled the transcriptome-wide dysregulation of long non-coding RNA (lncRNA), microRNA (miRNA), and PIWI-interacting RNA (piRNA) using RNA-sequencing data from 422 HNSCC patients in The Cancer Genome Atlas (TCGA). 307 non-coding transcripts differentially expressed in HNSCC were significantly correlated with patient survival, and associated with mutations in TP53, CDKN2A, CASP8, PRDM9, and FBXW7 and copy number variations in chromosomes 3, 5, 7, and 18. We also observed widespread ncRNA correlation to concurrent TP53 and chromosome 3p loss, a compelling predictor of poor prognosis in HNSCCs. Three selected ncRNAs were additionally associated with tumor stage, HPV status, and other clinical characteristics, and modulation of their expression in vitro reveals differential regulation of genes involved in epithelial-mesenchymal transition and apoptotic response. This comprehensive characterization of the HNSCC non-coding transcriptome introduces new layers of understanding for the disease, and nominates a novel panel of transcripts with potential utility as prognostic markers or therapeutic targets.",
        "Doc_title":"The non-coding landscape of head and neck squamous cell carcinoma.",
        "Journal":"Oncotarget",
        "Do_id":"27323410",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605892253827465216},
      {
        "Doc_abstract":"Penile squamous cell carcinoma (PSCC) is a rare tumor associated with high-risk human papillomavirus (HR-HPV) infection in 30% to 60% of cases. Altered expression of miRNAs has been reported in HPV-related cervical and head and neck cancers, but such data have not been available for PSCC. We analyzed a series of 59 PSCCs and 8 condylomata for presence of HPV infection, for p16(INK4a), Ki-67, and p53 immunohistochemical expression, and for expression of a panel of cellular miRNAs (let-7c, miR-23b, miR-34a, miR-145, miR-146a, miR-196a, and miR-218) involved in HPV-related cancer. HR-HPV DNA (HPV16 in most cases) was detected in 17/59 (29%) PSCCs; all penile condylomata (8/8) were positive for low-risk HPV6 or HPV11. HR-HPV(+) PSCCs overexpressed p16(INK4a) in 88% cases and p53 in 35% of cases, whereas HR-HPV(-) PSCCs were positive for p16(INK4a) and p53 immunostaining in 9% and 44% of cases, respectively. Among the miRNAs investigated, expression of miR-218 was lower in PSCCs with HR-HPV infection and in p53(-) cancers. Hypermethylation of the promoter of the SLIT2 gene, which contains miR-218-1 in its intronic region, was frequently observed in PSCCs, mainly in those with low miR-218 expression. Epigenetic silencing of miR-218 is a common feature in HR-HPV(+) PSCCs and in HR-HPV(-) PSCCs without immunohistochemical detection of p53. ",
        "Doc_title":"Profiling of expression of human papillomavirus-related cancer miRNAs in penile squamous cell carcinomas.",
        "Journal":"The American journal of pathology",
        "Do_id":"25455689",
        "Doc_ChemicalList":"Intercellular Signaling Peptides and Proteins;Membrane Proteins;MicroRNAs;Nerve Tissue Proteins;SLIT3 protein, human;Slit homolog 2 protein",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Carcinoma, Squamous Cell;DNA Methylation;Epigenesis, Genetic;Gene Expression Profiling;Gene Expression Regulation, Neoplastic;Humans;Immunohistochemistry;Intercellular Signaling Peptides and Proteins;Male;Membrane Proteins;MicroRNAs;Middle Aged;Nerve Tissue Proteins;Papillomaviridae;Papillomavirus Infections;Penile Neoplasms",
        "Doc_meshqualifiers":"complications;metabolism;virology;genetics;genetics;metabolism;genetics;complications;complications;metabolism;virology",
        "_version_":1605796739713859584},
      {
        "Doc_abstract":"To explore the the correlations of p16INK4A (p16) and survivin expressions with cervical intraepithelial neoplasia (CIN) and cervical squamous cell carcinoma.;The p16 and survivin expressions were detected in 50 cervical squamous cell carcinoma tissues, 150 various grades of CIN tissues and 30 normal cervical tissues using immunohistochemistry. All data were analyzed applying SPSS 17.0 software.;The p16 and survivin expressions showed the presence of statistical significance in cervical cancer, CINI, CINII, CINIII and normal cervical tissues (P<0.05), and the comparison also revealed statistical significance among groups (all P<0.05); the p16 and survivin expressions were positively correlated with the grade of cervical diseases (both P<0.05). Moreover, p16 protein was associated with CIN grade and lymph node metastases in cervical cancer (all P<0.05); survivin protein was also related with clinical stages, CIN grade and lymph node metastases (all P<0.05); the p16 and survivin expressions were positively correlated with cervical cancer (r=0.854, P<0.001), and associated with poor prognosis of cervical cancer.;Briefly, p16 and survivin expression may be correlated with the clinico-pathological and prognosis of cervical cancer.",
        "Doc_title":"P16INK4A and survivin: Diagnostic and prognostic markers in cervical intraepithelial neoplasia and cervical squamous cell carcinoma.",
        "Journal":"Experimental and molecular pathology",
        "Do_id":"25910412",
        "Doc_ChemicalList":"BIRC5 protein, human;Biomarkers, Tumor;Cyclin-Dependent Kinase Inhibitor p16;Inhibitor of Apoptosis Proteins",
        "Doc_meshdescriptors":"Adult;Aged;Biomarkers, Tumor;Carcinoma, Squamous Cell;Cervical Intraepithelial Neoplasia;Cyclin-Dependent Kinase Inhibitor p16;Female;Follow-Up Studies;Humans;Immunohistochemistry;Inhibitor of Apoptosis Proteins;Middle Aged;Prognosis;Uterine Cervical Neoplasms;Young Adult",
        "Doc_meshqualifiers":"genetics;metabolism;diagnosis;genetics;diagnosis;genetics;genetics;metabolism;genetics;metabolism;diagnosis;genetics",
        "_version_":1605750523697299456},
      {
        "Doc_abstract":"The cyclin-dependent kinase inhibitor p16 gene (P16, MTS1, CDKN2) has been shown to be altered by deletion or point mutation in some human tumours and cancer cell lines, suggesting that it works as a tumour suppressor. We analysed p16 gene mutation and p16 protein expression in 42 primary ovarian carcinomas and in five human ovarian cancer cell lines. Polymerase chain reaction (PCR) amplifications of exons 1 and 2 of the gene showed no deletion or gross rearrangement in the p16 gene. The lack of deletion was further demonstrated by Southern blot analysis. Looking for point mutations, we used single-strand confirmation polymorphism (SSCP) analysis and, in half of the tumours, we sequenced both strands of exons 1 and 2. No mutations were detected. In 11 out of 42 patients (26%), however, we detected no protein expression by Western blot analysis, suggesting that decreased expression of p16 rather than deletion of the gene can occur in a significant percentage of human ovarian cancers. In the same experiment CDK4 protein was found homogeneously expressed in all the tumour specimens and in the five cell lines. The lack of expression of p16 was not due to hypermethylation of the gene assessed by digestion of genomic DNAs with a methylation sensitive enzyme, suggesting that other mechanisms, not yet identified, are involved in the decreased expression of the p16 gene in human ovarian tumours.",
        "Doc_title":"Absence of deletions but frequent loss of expression of p16INK4 in human ovarian tumours.",
        "Journal":"British journal of cancer",
        "Do_id":"9231912",
        "Doc_ChemicalList":"Carrier Proteins;Cyclin-Dependent Kinase Inhibitor p16;DNA Primers;DNA, Neoplasm;Enzyme Inhibitors;Protein Kinase Inhibitors",
        "Doc_meshdescriptors":"Adenocarcinoma;Carcinoma, Endometrioid;Carrier Proteins;Cyclin-Dependent Kinase Inhibitor p16;DNA Primers;DNA, Neoplasm;Enzyme Inhibitors;Female;Gene Deletion;Genes, Tumor Suppressor;Humans;Ovarian Neoplasms;Point Mutation;Polymerase Chain Reaction;Protein Kinase Inhibitors;Tumor Cells, Cultured",
        "Doc_meshqualifiers":"chemistry;genetics;metabolism;chemistry;genetics;metabolism;biosynthesis;genetics;chemistry;analysis;metabolism;genetics;chemistry;genetics;metabolism",
        "_version_":1605824183848140800},
      {
        "Doc_abstract":"Most head and neck squamous cell carcinoma (HNSCC) patients present with late-stage cancers, which are difficult to treat. Therefore, early diagnosis of high-risk premalignant lesions and incipient cancers is important. HNSCC is currently perceived as a single progression mechanism, resulting in immortal invasive cancers. However, we have found that approximately 40% of primary oral SCCs are mortal in culture, and these have a better prognosis. About 60% of oral premalignancies (dysplasias) are also mortal. The mortal and immortal tumors are generated in vivo as judged by p53 mutations and loss of p16(INK4A) expression being found only in the original tumors from which the immortal cultures were derived. To investigate the relationships of dysplasias to SCCs, we did microarray analysis of primary cultures of 4 normal oral mucosa biopsies, 19 dysplasias, and 16 SCCs. Spectral clustering using the singular value decomposition and other bioinformatic techniques showed that development of mortal and immortal SCCs involves distinct transcriptional changes. Both SCC classes share most of the transcriptional changes found in their respective dysplasias but have additional changes. Moreover, high-risk dysplasias that subsequently progress to SCCs more closely resemble SCCs than nonprogressing dysplasias. This indicates for the first time that there are divergent mortal and immortal pathways for oral SCC development via intermediate dysplasias. We believe that this new information may lead to new ways of classifying HNSCC in relation to prognosis.",
        "Doc_title":"Divergent routes to oral cancer.",
        "Journal":"Cancer research",
        "Do_id":"16885335",
        "Doc_ChemicalList":"TP53 protein, human;Tumor Suppressor Protein p53",
        "Doc_meshdescriptors":"Carcinoma, Squamous Cell;Gene Expression Profiling;Humans;Mouth Neoplasms;Oligonucleotide Array Sequence Analysis;Precancerous Conditions;Transcription, Genetic;Tumor Cells, Cultured;Tumor Suppressor Protein p53",
        "Doc_meshqualifiers":"genetics;metabolism;pathology;genetics;metabolism;pathology;genetics;metabolism;pathology;biosynthesis;genetics",
        "_version_":1605911078239207424},
      {
        "Doc_abstract":"The regulation of cell growth is one of the most important effects of type I interferons (IFNs). This response may involve a cytostatic effect or the induction of apoptosis depending on the cell context. Often the growth-inhibitory response of type I IFNs is studied in tumor cell lines carrying mutations of tumor suppressor genes, and therefore, the growth-inhibitory effect can be influenced by inactivation of these important regulators of cell proliferation. In this report, we explored the role of the ARF-p53 pathway in the growth-inhibitory effect of type I IFNs. We found that p53 is only induced in cells that express p14(ARF) (p19(ARF) in mouse cells). Surprisingly, mouse embryonal fibroblasts that are null for p19(ARF) or P53, even after transformation with oncogenic RAS, respond as well as wild type to the growth-inhibitory effect of type I IFNs. Similarly, human ARF(-/-) U2OS and P53(-/-) SAOS-2 cells show a significant decrease in cell proliferation. However, only SAOS-2 or U2OS reconstituted with inducible p14(ARF) undergo apoptosis in response to IFN beta treatment, and this effect was not inhibited by expression of dominant negative p53. These data suggest that (i) at least in specific cell types, the induction of apoptosis by type I IFNs requires an ARF pathway that is p53-independent and (ii) the cytostatic and pro-apoptotic effects of type I IFNs employ different pathways.",
        "Doc_title":"Different requirements for the cytostatic and apoptotic effects of type I interferons. Induction of apoptosis requires ARF but not p53 in osteosarcoma cell lines.",
        "Journal":"The Journal of biological chemistry",
        "Do_id":"15169789",
        "Doc_ChemicalList":"Interferon-alpha;Tubulin;Tumor Suppressor Protein p14ARF;Tumor Suppressor Protein p53;Interferon-beta;Interferons",
        "Doc_meshdescriptors":"Animals;Apoptosis;Cell Division;Cell Line, Tumor;Dose-Response Relationship, Drug;Fibroblasts;Genes, Dominant;Genetic Vectors;Humans;Immunoblotting;Interferon-alpha;Interferon-beta;Interferons;Mice;Mice, Inbred C57BL;Mutation;Osteosarcoma;Precipitin Tests;Time Factors;Transgenes;Tubulin;Tumor Suppressor Protein p14ARF;Tumor Suppressor Protein p53",
        "Doc_meshqualifiers":"metabolism;metabolism;metabolism;metabolism;metabolism;metabolism;metabolism;physiology;metabolism;physiology",
        "_version_":1605742660821188608},
      {
        "Doc_abstract":"Growing evidence has demonstrated that clonogenic cancer stem (initiating) cells are responsible for tumor regrowth and disease relapse. Bmi-1 plays a critical role in the self-renewal of adult stem cells. The Bmi-1 protein is elevated in many types of cancers, and experimental reduction of Bmi-1 protein levels by small interfering RNA (siRNA) causes apoptosis and/or senescence in tumor cells in vitro and increases susceptibility to cytotoxic agents. The Bmi-1 protein has no known enzymatic activity, but serves as the key regulatory component of the PRC1 complex (polycomb repressive complex-1). This complex influences chromatin structure and regulates transcriptional activity of a number of important loci including the Ink4a locus which encodes the tumor suppressor proteins p16(Ink4a) and p14(Arf) . In this prospective study, we will discuss the implication of BMI1 in cancers, the biology of BMI1, and the regulatory control of BMI1 expression. The target validation and the future prospects of targeting BMI1 in cancer therapy are also discussed.",
        "Doc_title":"BMI1 as a novel target for drug discovery in cancer.",
        "Journal":"Journal of cellular biochemistry",
        "Do_id":"21678481",
        "Doc_ChemicalList":"BMI1 protein, human;Nuclear Proteins;Polycomb-Group Proteins;Proto-Oncogene Proteins;Repressor Proteins;Polycomb Repressive Complex 1",
        "Doc_meshdescriptors":"Animals;Humans;Neoplastic Stem Cells;Nuclear Proteins;Polycomb Repressive Complex 1;Polycomb-Group Proteins;Proto-Oncogene Proteins;Repressor Proteins",
        "Doc_meshqualifiers":"metabolism;pathology;genetics;metabolism;genetics;metabolism;genetics;metabolism",
        "_version_":1605811495969488896},
      {
        "Doc_abstract":"The main high-penetrance melanoma susceptibility gene is CDKN2A, encoding p16INK4A and p14ARF. The gene MITF variant p.E318K also predisposes to melanoma and renal cell carcinoma. To date, the prevalence of MITF p.E318K and its clinical and phenotypical implications has not been previously assessed in a single cohort of Spanish patients with melanoma or in p16INK4A mutation carriers.;To evaluate the prevalence of MITF p.E318K in Spanish patients with melanoma and assess the association with clinical and phenotypic features.;A hospital-based, case-control study was conducted at the Melanoma Unit of Hospital Clinic of Barcelona, with MITF p.E318K genotyped in all patients using TaqMan probes. We included 531 patients: 271 patients with multiple primary melanoma (MPM) without mutations affecting p16INK4A (wild-type p16INK4A); 191 probands from melanoma-prone families with a single melanoma diagnosis and without mutations affecting p16INK4A, and 69 probands from different families carrying CDKN2A mutations affecting p16INK4A. A population-based series of 499 age- and sex-matched cancer-free individuals from the Spanish National Bank of DNA were included as controls. Patients were recruited between January 1, 1992, and June 30, 2014; data analysis was conducted from September 1 to November 30, 2014.;The genetic results of the MITF p.E318K variant were correlated with clinical and phenotypic features.;Among the 531 patients, the prevalence of the MITF p.E318K variant was calculated among the different subsets of patients included and was 1.9% (9 of 462) in all melanoma patients with wild-type p16INK4A, 2.6% (7 of 271) in those with MPM, and 2.9% (2 of 69) in the probands of families with p16INK4A mutations. With results reported as odds ratio (95% CI), the MITF p.E318K was associated with an increased melanoma risk (3.3 [1.43-7.43]; P <.01), especially in MPM (4.5 [1.83-11.01]; P <.01) and high nevi count (>200 nevi) (8.4 [2.14-33.19]; P <.01). Two fast-growing melanomas were detected among 2 MITF p.E318K carriers during dermatologic digital follow-up.;In addition to melanoma risk, MITF p.E318K is associated with a high nevi count and could play a role in fast-growing melanomas. Testing for MITF p.E318K should not exclude patients with known mutations in p16INK4A. Strict dermatologic surveillance, periodic self-examination, and renal cell carcinoma surveillance should be encouraged in this context.",
        "Doc_title":"Prevalence of MITF p.E318K in Patients With Melanoma Independent of the Presence of CDKN2A Causative Mutations.",
        "Journal":"JAMA dermatology",
        "Do_id":"26650189",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;MITF protein, human;Microphthalmia-Associated Transcription Factor",
        "Doc_meshdescriptors":"Adult;Aged;Case-Control Studies;Cyclin-Dependent Kinase Inhibitor p16;Female;Follow-Up Studies;Genetic Predisposition to Disease;Genotype;Humans;Male;Melanoma;Microphthalmia-Associated Transcription Factor;Middle Aged;Mutation;Neoplasms, Multiple Primary;Nevus;Phenotype;Prevalence;Risk;Skin Neoplasms;Spain",
        "Doc_meshqualifiers":"genetics;epidemiology;genetics;pathology;genetics;epidemiology;genetics;pathology;epidemiology;genetics;epidemiology;genetics;pathology;epidemiology",
        "_version_":1605751247178039296},
      {
        "Doc_abstract":"Sporadic colorectal cancer (CRC) is characterized by genetic and epigenetic changes such as regional DNA hypermethylation and global DNA hypomethylation. Epidemiological and animal studies suggest that aberrant DNA methylation is associated with low dietary folate intake, which is aggravated by high alcohol intake. The relationship between promoter methylation of genes involved in CRC carcinogenesis and folate and alcohol intake was investigated. Methylation of the APC-1A, p14(ARF), p16(INK4A), hMLH1, O(6)-MGMT, and RASSF1A promoters was studied using methylation-specific PCR in 122 sporadic CRCs, derived from patients with folate and alcohol intake at either the lower or the higher quintiles of the distribution. Overall, promoter hypermethylation frequencies observed were: 39% for APC; 33% for p14(ARF); 31% for p16(INK4A); 29% for hMLH1; 41% for O(6)-MGMT; and 20% for RASSF1A. For each of the tested genes, the prevalence of promoter hypermethylation was higher in CRCs derived from patients with low folate/high alcohol intake (n = 61) when compared with CRCs from patients with high folate/low alcohol intake (n = 61), but the differences were not statistically significant. The number of CRCs with at least one gene methylated was higher (84%) in the low folate intake/high alcohol intake group when compared with the high folate intake/low alcohol intake group (70%; P = 0.085). Despite the size limitations of this study, these data suggest that folate and alcohol intake may be associated with changes in promoter hypermethylation in CRC.",
        "Doc_title":"Effects of dietary folate and alcohol intake on promoter methylation in sporadic colorectal cancer: the Netherlands cohort study on diet and cancer.",
        "Journal":"Cancer research",
        "Do_id":"12810640",
        "Doc_ChemicalList":"DNA, Neoplasm;Iron, Dietary;Ethanol;Folic Acid;Ascorbic Acid",
        "Doc_meshdescriptors":"Aged;Alcohol Drinking;Ascorbic Acid;Cocarcinogenesis;Cohort Studies;Colorectal Neoplasms;DNA Methylation;DNA, Neoplasm;Diet;Dietary Fiber;Dose-Response Relationship, Drug;Energy Intake;Ethanol;Feeding Behavior;Female;Folic Acid;Folic Acid Deficiency;Gene Silencing;Humans;Iron, Dietary;Male;Middle Aged;Netherlands;Pilot Projects;Promoter Regions, Genetic;Risk Factors",
        "Doc_meshqualifiers":"adverse effects;epidemiology;epidemiology;etiology;genetics;drug effects;drug effects;adverse effects;pharmacology;administration & dosage;pharmacology;epidemiology;drug effects;epidemiology;drug effects",
        "_version_":1605753107940114432},
      {
        "Doc_abstract":"Acute myelogenous leukemia is a heterogeneous disease that appears to evade the normal regulatory controls of tumor suppressor genes. Studies in AML have documented mutations in both p53 and Retinoblastoma (Rb) genes, but these mutations are relatively uncommon, especially compared to their mutational frequency in solid tumors. In addition, expression abnormalities have now been documented in several tumor suppressor genes or related genes including MDM2, p73, Rb, p14(ARF), p15(INK4B), and p16(INK4A). We review the current literature regarding tumor suppressor genes in AML and suggest how these genes may be involved in the development of the disease.",
        "Doc_title":"Malignancy: Tumor Suppressor Gene Aberrations in Acute Myelogenous Leukemia.",
        "Journal":"Hematology (Amsterdam, Netherlands)",
        "Do_id":"11399598",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605746988885737473},
      {
        "Doc_abstract":"Human papillomavirus (HPV) infection frequently causes squamous intraepithelial lesions (SIL) of the uterine cervix and consequently gives rise to squamous cell carcinoma. It is therefore important to identify cases that potentially develop higher grades of SIL at an early stage of the disease. In this study, we thus investigated whether immunocytochemistry for p21(WAF1/Cip1) and p16(INK4a) could be applicable in the diagnosis and the prognostic prediction of SIL in combination with genomic analyses of HPV. The genomic analysis of high-risk HPV (hrHPV), which was done by reversed dot blotting and by in situ hybridization, and immunocytochemistry were performed on liquid-based cytological specimens. A cross-sectional study comprising 145 cases of NILM, ASC-US, LSIL, and HSIL indicated that the incidence of the positive cases for p16(INK4a) and p21(WAF1/Cip1) and hrHPV increased with the grade of SIL. A double positive status for p16(INK4a) and p21(WAF1/Cip1) was a significant discriminator between HSIL and LSIL/NILM, even when applied in conjunction with the genomic test for hrHPV (P = 0.006 by logistic regression analysis). However, a prospective study employing 61 NILM/ASC-US cases, revealed that the p16(INK4a) /p21(WAF1/Cip1) immunostaining was not a significant predictor for the progression of SIL, whereas the cytological diagnosis (NILM vs. ASC-US) and the infection status of hrHPV conferred significant effects on the prognosis. Immunostaining of p16(INK4a) and p21(WAF1/Cip1) provides additional information on the cytological diagnosis of SIL. A further analysis using a larger population is warranted to obtain a conclusive result regarding the prognostic significance of p16(INK4a) /p21(WAF1/Cip1) immunocytochemistry in the diagnosis of SIL.",
        "Doc_title":"An evaluation of the diagnostic and prognostic significance of p16(INK4a) /p21(WAF1/Cip1) immunostaining in squamous intraepithelial lesions of the uterine cervix using liquid-based cytology specimens.",
        "Journal":"Diagnostic cytopathology",
        "Do_id":"23754829",
        "Doc_ChemicalList":"Biomarkers, Tumor;CDKN1A protein, human;Cyclin-Dependent Kinase Inhibitor p16;Cyclin-Dependent Kinase Inhibitor p21",
        "Doc_meshdescriptors":"Adult;Biomarkers, Tumor;Carcinoma, Squamous Cell;Cervical Intraepithelial Neoplasia;Cross-Sectional Studies;Cyclin-Dependent Kinase Inhibitor p16;Cyclin-Dependent Kinase Inhibitor p21;Female;Follow-Up Studies;Humans;Immunohistochemistry;Logistic Models;Papillomavirus Infections;Prognosis;Uterine Cervical Neoplasms",
        "Doc_meshqualifiers":"analysis;chemistry;pathology;virology;chemistry;pathology;virology;analysis;analysis;pathology;virology;chemistry;pathology;virology",
        "_version_":1605747007202263040},
      {
        "Doc_abstract":"The INK4a/ARF locus which is frequently inactivated in human tumours encodes two different tumour suppressive proteins, p16(INK4a) and ARF. p16(INK4a) is a major component of the RB pathway. ARF is part of an ARF-mdm2-p53 network that exerts a negative control on hyperproliferative signals emanating from oncogenic stimuli. Among these is the transcription factor E2F1, a final effector of the RB pathway, that induces ARF expression. Recent data suggest that ARF function is not restricted to the p53 pathway. However, ARF target(s) implicated in this p53-independent function remains to be identified. We show that ARF is able to inhibit the proliferation of human cell lines independently of their p53 status. In this context, we demonstrate that ARF interacts physically with E2F1 and inhibits its transcriptional activity. Moreover, we show that mdm2 is required for the modulation of E2F1 activity by ARF. Beside the well-known p53 and mdm2 partners, these results identify E2F1 as a new ARF target. Thus, ARF can be viewed as a dual-acting tumour suppressor protein in both the p53 and RB pathways, further emphasizing its role in tumour surveillance.",
        "Doc_title":"Human ARF binds E2F1 and inhibits its transcriptional activity.",
        "Journal":"Oncogene",
        "Do_id":"11314038",
        "Doc_ChemicalList":"Carrier Proteins;Cell Cycle Proteins;DNA-Binding Proteins;E2F Transcription Factors;E2F1 Transcription Factor;E2F1 protein, human;Nuclear Proteins;Proto-Oncogene Proteins;Retinoblastoma-Binding Protein 1;Transcription Factor DP1;Transcription Factors;Tumor Suppressor Protein p53;Luciferases;Chloramphenicol O-Acetyltransferase;MDM2 protein, human;Proto-Oncogene Proteins c-mdm2;Glutathione Transferase;ADP-Ribosylation Factors",
        "Doc_meshdescriptors":"ADP-Ribosylation Factors;Adenocarcinoma, Bronchiolo-Alveolar;Blotting, Western;Carrier Proteins;Cell Cycle Proteins;Cell Division;Chloramphenicol O-Acetyltransferase;Colony-Forming Units Assay;DNA-Binding Proteins;E2F Transcription Factors;E2F1 Transcription Factor;Exons;Gene Deletion;Glutathione Transferase;Humans;Luciferases;Mutagenesis;Nuclear Proteins;Osteosarcoma;Precipitin Tests;Protein Binding;Proto-Oncogene Proteins;Proto-Oncogene Proteins c-mdm2;Retinoblastoma-Binding Protein 1;Transcription Factor DP1;Transcription Factors;Transcription, Genetic;Transfection;Tumor Suppressor Protein p53",
        "Doc_meshqualifiers":"metabolism;pharmacology;genetics;metabolism;genetics;metabolism;physiology;chemistry;metabolism;metabolism;physiology;genetics;metabolism;metabolism;metabolism;drug effects;analysis;metabolism",
        "_version_":1605761454382776320},
      {
        "Doc_abstract":"To investigate the impact of HPV status in patients with locally advanced head and neck squamous cell carcinoma (HNSCC), who received surgery and cisplatin-based postoperative radiochemotherapy.;For 221 patients with locally advanced squamous cell carcinoma of the hypopharynx, oropharynx or oral cavity treated at the 8 partner sites of the German Cancer Consortium, the impact of HPV DNA, p16 overexpression and p53 expression on outcome were retrospectively analysed. The primary endpoint was loco-regional tumour control; secondary endpoints were distant metastases and overall survival.;In the total patient population, univariate analyses revealed a significant impact of HPV16 DNA positivity, p16 overexpression, p53 positivity and tumour site on loco-regional tumour control. Multivariate analysis stratified for tumour site showed that positive HPV 16 DNA status correlated with loco-regional tumour control in patients with oropharyngeal carcinoma (p=0.02) but not in the oral cavity carcinoma group. Multivariate evaluation of the secondary endpoints in the total population revealed a significant association of HPV16 DNA positivity with overall survival (p<0.01) but not with distant metastases.;HPV16 DNA status appears to be a strong prognosticator of loco-regional tumour control after postoperative cisplatin-based radiochemotherapy of locally advanced oropharyngeal carcinoma and is now being explored in a prospective validation trial.",
        "Doc_title":"HPV16 DNA status is a strong prognosticator of loco-regional control after postoperative radiochemotherapy of locally advanced oropharyngeal carcinoma: results from a multicentre explorative study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG).",
        "Journal":"Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology",
        "Do_id":"25480095",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;DNA",
        "Doc_meshdescriptors":"Carcinoma, Squamous Cell;Chemoradiotherapy;Cyclin-Dependent Kinase Inhibitor p16;DNA;Female;Head and Neck Neoplasms;Humans;Male;Oropharyngeal Neoplasms;Papillomaviridae;Postoperative Period;Prognosis;Prospective Studies;Retrospective Studies;Survival Analysis;Treatment Outcome",
        "Doc_meshqualifiers":"genetics;therapy;virology;methods;genetics;genetics;genetics;therapy;virology;genetics;therapy;virology;genetics",
        "_version_":1605752091528134656},
      {
        "Doc_abstract":"The epidermal growth factor receptor (EGFR) is a validated target in head and neck squamous cell carcinoma (HNSCC). In recurrent and/or metastatic (R/M) HNSCC, resistance to anti-EGFR therapy inevitably occurs. Downstream activation of the PI3K/Akt/mTOR pathway is an established resistance mechanism. Concurrent mTOR blockade may improve efficacy of anti-EGFR therapy.;Erlotinib 150 mg daily and temsirolimus 15 mg weekly were administered to patients with platinum-refractory R/M HNSCC and ECOG performance status 0-2. The primary endpoint was progression-free survival (PFS). Correlative studies determined PIK3CA and HRAS mutation status; p16, EGFR, pS6K, pAkt and PTEN expression; and pre- and post-treatment plasma levels of 20 immunomodulatory cytokines.;Twelve patients enrolled; six withdrew within 6 weeks due to toxicity or death, prompting early closure of the trial. Grade  3 toxicities included fatigue, diarrhea, gastrostomy tube infection, peritonitis, pneumonia, dyspnea, and HN edema. Median PFS was 1.9 months. Median overall survival was 4.0 months. Six/12 tumors were p16(+), 9/11 lacked measurable PTEN expression, and 1/12 harbored a PIK3CA mutation. On exploratory analysis, high baseline plasma VEGF and interferon-gamma levels marginally associated with tumor progression.;The combination of erlotinib and temsirolimus was poorly tolerated. Low prevalence of PTEN expression and 8% incidence of PIK3CA mutations indicate biological relevance of this pathway in R/M disease. Investigation of more tolerable combinations of EGFR and PI3K/Akt/mTOR pathway inhibitors in selected HNSCC patients is warranted.",
        "Doc_title":"A phase II study of temsirolimus and erlotinib in patients with recurrent and/or metastatic, platinum-refractory head and neck squamous cell carcinoma.",
        "Journal":"Oral oncology",
        "Do_id":"23384718",
        "Doc_ChemicalList":"Antineoplastic Agents;Cyclin-Dependent Kinase Inhibitor p16;Cytokines;Protein Kinase Inhibitors;Quinazolines;Tumor Suppressor Proteins;Platinum;temsirolimus;Erlotinib Hydrochloride;Phosphatidylinositol 3-Kinases;MTOR protein, human;TOR Serine-Threonine Kinases;PIK3CA protein, human;Receptor, Epidermal Growth Factor;Oncogene Protein v-akt;Ribosomal Protein S6 Kinases;PTEN Phosphohydrolase;PTEN protein, human;HRAS protein, human;Proto-Oncogene Proteins p21(ras);Sirolimus",
        "Doc_meshdescriptors":"Aged;Aged, 80 and over;Antineoplastic Agents;Antineoplastic Combined Chemotherapy Protocols;Carcinoma, Squamous Cell;Cyclin-Dependent Kinase Inhibitor p16;Cytokines;Drug Resistance, Neoplasm;Erlotinib Hydrochloride;Female;Head and Neck Neoplasms;Humans;Male;Middle Aged;Mutation;Neoplasm Recurrence, Local;Oncogene Protein v-akt;PTEN Phosphohydrolase;Phosphatidylinositol 3-Kinases;Platinum;Protein Kinase Inhibitors;Proto-Oncogene Proteins p21(ras);Quinazolines;Receptor, Epidermal Growth Factor;Ribosomal Protein S6 Kinases;Sirolimus;Survival Rate;TOR Serine-Threonine Kinases;Tumor Suppressor Proteins",
        "Doc_meshqualifiers":"administration & dosage;adverse effects;adverse effects;therapeutic use;drug therapy;secondary;analysis;analysis;drug therapy;genetics;drug therapy;analysis;analysis;analysis;genetics;administration & dosage;analysis;genetics;administration & dosage;adverse effects;antagonists & inhibitors;analysis;administration & dosage;adverse effects;analogs & derivatives;antagonists & inhibitors;analysis",
        "_version_":1605746406888308737},
      {
        "Doc_abstract":"Persistence and eventual integration of high-risk HPV (hrHPV) into the cervical cell is crucial to the progression of cervical neoplasia and it would be beneficial to morphologically identify this transformation in routine surgical pathology practice. Increased p16(INK4a) (p16) expression is a downstream event following HPV E7 binding to pRB. A study was conducted to assess the correlation between hrHPV detection using a commercial in-situ hybridization assay (Ventana INFORM HPV ISH) and p16 immunoexpression (CINtec Histology Kit) in cervical squamous intraepithelial lesions and squamous carcinoma. 27 formalin-fixed, paraffin-embedded cervical low-grade squamous intraepithelial lesions (LSIL), 21 high-grade squamous intraepithelial lesions (HSIL) and 51 squamous carcinoma (SCC) were interrogated. hrHPV was significantly more frequent in HSIL (76.2%) and SCC (88.2%) compared to LSIL(37.0%). p16 expression was similarly more frequent in HSIL (95.2%) and SCC (90.2%) compared to LSIL(3.7%). That the rates of hrHPV when compared with p16 expression were almost equivalent in HSIL and SCC while p16 was expressed in only 1 of the 10 LSIL with hrHPV, are expected considering the likelihood that transformation has occurred in HSIL and SCC but does not occur in majority of LSIL. ",
        "Doc_title":"Correlation of p16INK4a immunoexpression and human papillomavirus (HPV) detected by in-situ hybridization in cervical squamous neoplasia.",
        "Journal":"The Malaysian journal of pathology",
        "Do_id":"27126662",
        "Doc_ChemicalList":"Biomarkers, Tumor;Cyclin-Dependent Kinase Inhibitor p16;DNA, Viral;Reagent Kits, Diagnostic",
        "Doc_meshdescriptors":"Biomarkers, Tumor;Cervical Intraepithelial Neoplasia;Cyclin-Dependent Kinase Inhibitor p16;DNA, Viral;Female;Human Papillomavirus DNA Tests;Humans;Immunohistochemistry;In Situ Hybridization;Neoplasm Grading;Papillomaviridae;Papillomavirus Infections;Predictive Value of Tests;Reagent Kits, Diagnostic;Reproducibility of Results;Squamous Intraepithelial Lesions of the Cervix;Uterine Cervical Neoplasms",
        "Doc_meshqualifiers":"analysis;chemistry;diagnosis;pathology;virology;analysis;genetics;methods;genetics;diagnosis;metabolism;pathology;virology;diagnosis;metabolism;pathology;virology;chemistry;diagnosis;pathology;virology",
        "_version_":1605837406535155713},
      {
        "Doc_abstract":"Cervical cancer screening test performance has been hampered by either lack of sensitivity of Pap cytology or lack of specificity of Human Papillomavirus (HPV) testing. This uncertainty can lead to unnecessary referral and treatment, which is disturbing for patients and increases costs for health care providers. The identification of p16(INK4a) as a marker for neoplastic transformation of cervical squamous epithelial cells by HPVs allows the identification of HPV-transformed cells in histopathology or cytopathology specimens. Diagnostic studies have demonstrated that the use of p16(INK4a) immunohistochemistry substantially improves the reproducibility and diagnostic accuracy of histopathologic diagnoses. p16(INK4a) cytology has substantially higher sensitivity for detection of cervical precancer in comparison to conventional Pap tests. Compared to HPV DNA tests, immunochemical detection of p16(INK4a) -stained cells demonstrates a significantly improved specificity with remarkably good sensitivity. About 15 years after the initial observation that p16(INK4a) is overexpressed in HPV-transformed cells we review the accumulated clinical evidence suggesting that p16(INK4a) can serve as a useful biomarker in the routine diagnostic work up of patients with HPV infections and associated lesions of the female anogenital tract. ",
        "Doc_title":"The clinical impact of using p16(INK4a) immunochemistry in cervical histopathology and cytology: an update of recent developments.",
        "Journal":"International journal of cancer",
        "Do_id":"24740700",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16",
        "Doc_meshdescriptors":"Cyclin-Dependent Kinase Inhibitor p16;Cytodiagnosis;Female;Host-Pathogen Interactions;Humans;Immunohistochemistry;Papillomaviridae;Papillomavirus Infections;Sensitivity and Specificity;Uterine Cervical Neoplasms",
        "Doc_meshqualifiers":"metabolism;methods;methods;physiology;diagnosis;metabolism;virology;diagnosis;metabolism;virology",
        "_version_":1605818597021581314},
      {
        "Doc_abstract":"Since more than 5years, it becomes evident that there is a new group of patients with squamous cell carcinomas of the head and neck area, namely human papillomavirus (HPV)-related (caused) tumors. As clinical statistics indicate, those patients have better prognosis, even despite more advanced stage compared to those with HPV-negative tumors. In fact, as a surrogate of HPV infection for clinical studies, an immunohistochemical expression of p16 protein is used. In the following chapter, the spectrum of squamous cell carcinomas variants with indication of the percentage cases with proved HPV infection will be presented.",
        "Doc_title":"HPV-Related Head and Neck Squamous Cell Carcinomas.",
        "Journal":"Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer",
        "Do_id":"27699531",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605840622425473024},
      {
        "Doc_abstract":"To explore the inhibitory effect of p14ARF on the cell growth of laryngeal carcinoma and the expression on endogenous p53.;p14ARF cDNA was transferred to the cell line Hep-2 of squamous cell carcinoma of the larynx by gene transfer to study the cell cycles and the expression of endogenous wild type p53 using flow cytometry, polymerase chain reaction(PCR) and Western-Blotting.;Expression of p14ARF significantly affected the Hep-2 cell growth. The clone-forming efficiency of the Hep-2 cells transferred with p14ARF was 57%, compared with empty vector pcDNA3. The number of 48 hours after transfer with p14ARF cDNA at both G0/G1 and G2/M was two fold as the control. The expression of endogenous wild type p53 was significantly enhanced.;Expression of p14ARF can up-regulate the expression of endogenous wild type p53 and inhibit the Hep-2 cell growth of human laryngeal squamous cell carcinoma at both G0/G1 and G2/M.",
        "Doc_title":"[Effect of p14ARF gene on cell growth of human laryngeal tumor cells and expression of endogenous p53 protein].",
        "Journal":"Zhonghua er bi yan hou ke za zhi",
        "Do_id":"12761983",
        "Doc_ChemicalList":"Tumor Suppressor Protein p14ARF;Tumor Suppressor Protein p53",
        "Doc_meshdescriptors":"Carcinoma, Squamous Cell;Cell Cycle;Humans;Laryngeal Neoplasms;Transfection;Tumor Cells, Cultured;Tumor Suppressor Protein p14ARF;Tumor Suppressor Protein p53",
        "Doc_meshqualifiers":"genetics;pathology;genetics;pathology;genetics;biosynthesis",
        "_version_":1605746300372910083},
      {
        "Doc_abstract":"The Ink4/Arf locus encodes two tumour-suppressor proteins, p16Ink4a and p19Arf, that govern the antiproliferative functions of the retinoblastoma and p53 proteins, respectively. Here we show that Arf binds to the product of the Mdm2 gene and sequesters it into the nucleolus, thereby preventing negative-feedback regulation of p53 by Mdm2 and leading to the activation of p53 in the nucleoplasm. Arf and Mdm2 co-localize in the nucleolus in response to activation of the oncoprotein Myc and as mouse fibroblasts undergo replicative senescence. These topological interactions of Arf and Mdm2 point towards a new mechanism for p53 activation.",
        "Doc_title":"Nucleolar Arf sequesters Mdm2 and activates p53.",
        "Journal":"Nature cell biology",
        "Do_id":"10559859",
        "Doc_ChemicalList":"Nuclear Proteins;Proto-Oncogene Proteins;Recombinant Proteins;Tumor Suppressor Protein p53;Mdm2 protein, mouse;Proto-Oncogene Proteins c-mdm2;ADP-Ribosylation Factors",
        "Doc_meshdescriptors":"3T3 Cells;ADP-Ribosylation Factors;Animals;Cell Aging;Cell Nucleolus;Feedback;Fibroblasts;Gene Expression Regulation;Genes, myc;Genes, p53;Mice;Nuclear Proteins;Proto-Oncogene Proteins;Proto-Oncogene Proteins c-mdm2;Recombinant Proteins;Transfection;Tumor Suppressor Protein p53",
        "Doc_meshqualifiers":"genetics;metabolism;metabolism;ultrastructure;cytology;physiology;genetics;metabolism;metabolism;metabolism",
        "_version_":1605766148162322432},
      {
        "Doc_abstract":"Homozygous deletions of the cyclin-dependent kinase 4 (CDK4) inhibitor gene CDKN2 (p16, MTS1) have been demonstrated to occur frequently in human cancer cell lines of different origin. However, in most primary tumours the frequencies of CDKN2 deletions are not well defined. We studied primary samples of 100 patients with lymphoid leukaemias [B-lineage acute lymphoblastic leukaemia (ALL), n = 23; T-ALL, n = 7; B-cell chronic lymphocytic (B-CLL) or prolymphocytic (B-PLL) leukaemia, n = 50; T-CLL/T-PLL, n = 20] using fluorescence in situ hybridization (FISH) with eight overlapping cosmid clones covering the region on chromosome band 9p21 containing CDKN2. We did not observe any CDKN2 deletions in the 70 patients with chronic lymphoid leukaemias of B- or T-cell origin. Of the 23 patients with B-lineage ALL, one (4%) exhibited a CDKN2 deletion: in this patient, two clones were detected, one exhibiting a hemizygous and the other a homozygous deletion. On chromosome banding analysis, four patients with B-lineage ALL had a 9p aberration, whereas all CDKN2 copies were retained. In contrast, six of the seven (86%) patients with T-ALL exhibited CDKN2 deletions (homozygous, n = 4; hemizygous, n = 2). We conclude that hemizygous or homozygous deletions of the CDKN2 gene occur at high frequency in T-ALL and at low frequency in B-lineage ALL, supporting the role of this gene as a tumour suppressor, especially in T-ALL. However, from our data there is no evidence that CDKN2 is involved in the pathogenesis of chronic lymphoid leukaemias of B- or T-cell origin.",
        "Doc_title":"CDKN2 gene deletion is not found in chronic lymphoid leukaemias of B- and T-cell origin but is frequent in acute lymphoblastic leukaemia.",
        "Journal":"British journal of haematology",
        "Do_id":"8547131",
        "Doc_ChemicalList":"Carrier Proteins;Cyclin-Dependent Kinase Inhibitor p16;Protein Kinase Inhibitors",
        "Doc_meshdescriptors":"Adolescent;Adult;Aged;Carrier Proteins;Child;Child, Preschool;Cyclin-Dependent Kinase Inhibitor p16;Humans;Infant;Leukemia, B-Cell;Leukemia, T-Cell;Middle Aged;Precursor Cell Lymphoblastic Leukemia-Lymphoma;Protein Kinase Inhibitors",
        "Doc_meshqualifiers":"genetics;genetics;genetics;genetics",
        "_version_":1605896320340459520},
      {
        "Doc_abstract":"Loss-of-function mutations in p16(INK4A) (CDKN2A) occur in approximately 80% of sporadic pancreatic ductal adenocarcinoma (PDAC), contributing to its early progression. Although this loss activates the cell-cycle-dependent kinases CDK4/6, which have been considered as drug targets for many years, p16(INK4A)-deficient PDAC cells are inherently resistant to CDK4/6 inhibitors. This study searched for targeted therapies that might synergize with CDK4/6 inhibition in this setting. We report that the IGF1R/IR inhibitor BMS-754807 cooperated with the CDK4/6 inhibitor PD-0332991 to strongly block proliferation of p16(INK4A)-deficient PDAC cells in vitro and in vivo. Sensitivity to this drug combination correlated with reduced activity of the master cell growth regulator mTORC1. Accordingly, replacing the IGF1R/IR inhibitor with the rapalog inhibitor temsirolimus broadened the sensitivity of PDAC cells to CDK4/6 inhibition. Our results establish targeted therapy combinations with robust cytostatic activity in p16(INK4A)-deficient PDAC cells and possible implications for improving treatment of a broad spectrum of human cancers characterized by p16(INK4A) loss.",
        "Doc_title":"CDK4/6 and IGF1 receptor inhibitors synergize to suppress the growth of p16INK4A-deficient pancreatic cancers.",
        "Journal":"Cancer research",
        "Do_id":"24986516",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;Retinoblastoma Protein;Tumor Suppressor Proteins;tuberous sclerosis complex 2 protein;TOR Serine-Threonine Kinases;Receptor, IGF Type 1;Ribosomal Protein S6 Kinases, 70-kDa;ribosomal protein S6 kinase, 70kD, polypeptide 1;Cyclin-Dependent Kinase 4;Cyclin-Dependent Kinase 6",
        "Doc_meshdescriptors":"Animals;Cell Aging;Cell Line, Tumor;Cell Survival;Cyclin-Dependent Kinase 4;Cyclin-Dependent Kinase 6;Cyclin-Dependent Kinase Inhibitor p16;Disease Models, Animal;Drug Resistance, Neoplasm;Drug Synergism;Female;G1 Phase Cell Cycle Checkpoints;Gene Deletion;Humans;Mice;Pancreatic Neoplasms;Phosphorylation;Receptor, IGF Type 1;Retinoblastoma Protein;Ribosomal Protein S6 Kinases, 70-kDa;TOR Serine-Threonine Kinases;Tumor Suppressor Proteins;Xenograft Model Antitumor Assays",
        "Doc_meshqualifiers":"drug effects;drug effects;antagonists & inhibitors;antagonists & inhibitors;deficiency;genetics;drug effects;genetics;metabolism;pathology;antagonists & inhibitors;metabolism;antagonists & inhibitors;metabolism;antagonists & inhibitors;metabolism",
        "_version_":1605842423901061120},
      {
        "Doc_abstract":"Progressive deregulation of the cell-division cycle is thought to contribute to the establishment and progression of neoplasia. Previously, we have documented the in vivo inactivation of p16INK4A, an inhibitor of G1 cyclin-dependent kinases, in squamous cell carcinomas of the head and neck region. In the present study, we extend these findings by examining the expression and functional activity of cyclin-dependent kinases (CDKs) and their regulatory subunits using a model system of cell lines derived from squamous cell carcinomas. Increased activity of CDK4 and 6 was universal in tumor cells compared with normal keratinocytes, reflecting over-expression of either or both kinases. In contrast to other studies, over-expression of cyclin D1, a regulatory subunit of CDK4 and 6, was not observed. Increased activity of CDK2 was less frequent and was related to over-expression of cyclin A and/or E. All tumor cell lines showed increased expression of proliferating cell nuclear antigen compared to normal keratinocytes. Four SCC cell lines, including one tumor-metastasis pair derived from a single patient, failed to express the p15INK4B transcript. Western blot analysis of cell lysates revealed normal or reduced levels of p27KIP1 in tumor cells compared to normal keratinocytes. However, failure to express wild-type p53 was not reflected by lower levels of p21WAF1. Our data suggest that cell-cycle deregulation is likely to occur by multiple mechanisms during the genesis of head and neck squamous cell carcinomas. Furthermore, p16INK4A is likely to be the primary target for inactivation on chromosome 9p21 in these tumors as p15INK4B loss occurs less frequently.",
        "Doc_title":"Altered expression and activity of G1/S cyclins and cyclin-dependent kinases characterize squamous cell carcinomas of the head and neck.",
        "Journal":"International journal of cancer",
        "Do_id":"9389571",
        "Doc_ChemicalList":"CCNG1 protein, human;Cyclin G;Cyclin G1;Cyclins;Neoplasm Proteins;Proliferating Cell Nuclear Antigen;Cyclin-Dependent Kinases",
        "Doc_meshdescriptors":"Carcinoma, Squamous Cell;Cyclin G;Cyclin G1;Cyclin-Dependent Kinases;Cyclins;Head and Neck Neoplasms;Humans;Neoplasm Proteins;Proliferating Cell Nuclear Antigen;Tumor Cells, Cultured",
        "Doc_meshqualifiers":"metabolism;antagonists & inhibitors;metabolism;metabolism;metabolism;metabolism;metabolism",
        "_version_":1605819899100266496},
      {
        "Doc_abstract":"Several studies have described p16INK4A and prostaglandin E2 (PGE2) co-alterations in various solid tumors, including non-small cell lung cancer (NSCLC). In this study, we examined the correlation between PGE2 receptor 2 (EP2) expression and p16INK4A methylation in NSCLC, and the association with clinicopathological features and prognostic significance. We retrospectively reviewed 88 NSCLC patients who underwent resection from July 1993 to May 1997. The tumors included 43 adenocarcinomas, 39 squamous cell carcinomas, and 6 large cell carcinomas. EP2 expression was determined by immunostaining, and p16INK4A methylation was analyzed by methylation specific PCR. EP2 was overexpressed in 44% of NSCLC patients, 61% of adenocarcinoma cases, 28% of squamous cell carcinoma cases, and 33% of large cell carcinoma cases. EP2 expression positively correlated with lymph node metastasis (P=0.034), especially in patients with squamous cell carcinoma (P<0.009). Methylation of p16INK4A was detected in 34% of NSCLC patients, 23% of adenocarcinoma cases, 44% of squamous cell carcinoma cases, and 50% of large cell carcinoma cases. In patients with squamous cell carcinoma, EP2 overexpression correlated with poor prognosis with a relative risk of 2.4 (confidence interval 2.1-51.8, P<0.003), and positively correlated with p16INK4A methylation (P<0.024). Adenocarcinoma patients with p16INK4A methylation had poor prognosis with a relative risk of 2.4 (confidence interval 1.8-69.7, P<0.009), but this was not correlated with EP2 expression. In conclusion, EP2 overexpression was common in NSCLCs, especially in adenocarcinomas. Synchronous alteration of p16INK4A and EP2 may accelerate progression of squamous cell carcinomas. These two alterations may differentially affect pathogenesis among subtypes of NSCLC.",
        "Doc_title":"Prostaglandin E2 receptor 2 overexpression in squamous cell carcinoma of the lung correlates with p16INK4A methylation and an unfavorable prognosis.",
        "Journal":"International journal of oncology",
        "Do_id":"19212685",
        "Doc_ChemicalList":"PTGER2 protein, human;Receptors, Prostaglandin E;Receptors, Prostaglandin E, EP2 Subtype",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Carcinoma, Squamous Cell;DNA Methylation;Disease Progression;Female;Gene Expression Regulation, Neoplastic;Genes, p16;Humans;Lung Neoplasms;Male;Middle Aged;Neoplasm Staging;Prognosis;Receptors, Prostaglandin E;Receptors, Prostaglandin E, EP2 Subtype;Retrospective Studies;Survival Rate",
        "Doc_meshqualifiers":"genetics;metabolism;pathology;genetics;metabolism;pathology;biosynthesis;genetics;metabolism",
        "_version_":1605810321468948480},
      {
        "Doc_abstract":"A genomic region near the CDKN2A locus, encoding p16(INK4a), has been associated to type 2 diabetes and atherosclerotic vascular disease, conditions in which inflammation plays an important role. Recently, we found that deficiency of p16(INK4a) results in decreased inflammatory signaling in murine macrophages and that p16(INK4a) influences the phenotype of human adipose tissue macrophages. Therefore, we investigated the influence of immune cell p16(INK4a) on glucose tolerance and atherosclerosis in mice.;Bone marrow p16(INK4a)-deficiency in C57Bl6 mice did not influence high fat diet-induced obesity nor plasma glucose and lipid levels. Glucose tolerance tests showed no alterations in high fat diet-induced glucose intolerance. While bone marrow p16(INK4a)-deficiency did not affect the gene expression profile of adipose tissue, hepatic expression of the alternative markers Chi3l3, Mgl2 and IL10 was increased and the induction of pro-inflammatory Nos2 was restrained on the high fat diet. Bone marrow p16(INK4a)-deficiency in low density lipoprotein receptor-deficient mice did not affect western diet-induced atherosclerotic plaque size or morphology. In line, plasma lipid levels remained unaffected and p16(INK4a)-deficient macrophages displayed equal cholesterol uptake and efflux compared to wild type macrophages.;Bone marrow p16(INK4a)-deficiency does not affect plasma lipids, obesity, glucose tolerance or atherosclerosis in mice.",
        "Doc_title":"Bone marrow p16INK4a-deficiency does not modulate obesity, glucose homeostasis or atherosclerosis development.",
        "Journal":"PloS one",
        "Do_id":"22403661",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;Receptors, LDL;Glucose",
        "Doc_meshdescriptors":"Animals;Atherosclerosis;Bone Marrow;Cyclin-Dependent Kinase Inhibitor p16;Diet, High-Fat;Glucose;Glucose Intolerance;Homeostasis;Humans;Hyperlipidemias;Male;Mice;Mice, Inbred C57BL;Obesity;Receptors, LDL",
        "Doc_meshqualifiers":"metabolism;pathology;metabolism;deficiency;adverse effects;metabolism;chemically induced;metabolism;metabolism;pathology;chemically induced;metabolism;deficiency",
        "_version_":1605881398536699904},
      {
        "Doc_abstract":"Human papillomavirus (HPV) is a risk and prognostic factor for oropharyngeal cancer (OPC). Determining whether the incidence of HPV-associated OPC is rising informs health policy.;HPV status was ascribed using p16 immunohistochemistry in 683/1474 OPC patients identified from the Princess Margaret Hospital's Cancer Registry (from 2000 to 2010). Missing p16 data was estimated using multiple (n=100) imputation (MI) and validated using an independent OPC cohort (n=214). Non-OPC head and neck squamous cell carcinoma (HNSCC) (n=3262) were also used for time-trend comparison. Regression was used to compare HNSCC subsets and time-trends. The c-index was used to measure the predictive ability of MI.;The incidence of OPC rose from 23.3% of all HNSCC in 2000 to 31.2% in 2010 (p=0.002). In the subset of OPC tested for p16, there was no change in p16 positivity over time (p=0.9). However, p16 testing became more frequent over time (p<0.0001), but was nonetheless biased, favouring never-smokers [OR 1.87 (95% CI 1.29-2.70)] and tumors of the tonsil [OR 2.30 (1.52-3.47)] or base-of-tongue [OR 1.72 (1.10-2.70)]. These same factors were also associated with p16-positivity [ORs 3.22 (1.27-8.16), 7.26 (3.50-15.1), 5.83 (2.70-12.7), respectively]. Following MI and normalization, the proportion of OPC that was p16-associated rose from 39.8% in 2000 to 65.0% in 2010, p=0.002, fully explaining the rise in OPC in our patient population.;The rise in HNSCC referrals seen from 2000 to 2010 at our institution was driven primarily by p16-associated OPC. MI was necessary to derive reliable conclusions when cases with missing data are considerable.",
        "Doc_title":"The changing incidence of human papillomavirus-associated oropharyngeal cancer using multiple imputation from 2000 to 2010 at a Comprehensive Cancer Centre.",
        "Journal":"Cancer epidemiology",
        "Do_id":"24184275",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16",
        "Doc_meshdescriptors":"Adolescent;Adult;Aged;Canada;Carcinoma, Squamous Cell;Cohort Studies;Cyclin-Dependent Kinase Inhibitor p16;Female;Follow-Up Studies;Head and Neck Neoplasms;Humans;Immunoenzyme Techniques;Incidence;Male;Middle Aged;Neoplasm Staging;Oropharyngeal Neoplasms;Papillomaviridae;Papillomavirus Infections;Prognosis;Time Factors;Young Adult",
        "Doc_meshqualifiers":"epidemiology;diagnosis;epidemiology;virology;metabolism;diagnosis;epidemiology;virology;diagnosis;epidemiology;virology;pathogenicity;epidemiology;virology",
        "_version_":1605742774442786819},
      {
        "Doc_abstract":"The UVB component of the solar spectrum induces DNA lesions that, in the absence of error-free DNA repair, may give rise during DNA replication to mutations in caretaker and gatekeeper genes. The DNA repair genes are the best candidates for caretaker genes as exemplified by the human hereditary xeroderma pigmentosum (XP) syndrome. Cultured XP cells are hypermutable after UVB irradiation. This increased mutation frequency is also found in gatekeeper genes, which govern signalling pathways implicated in the control of cellular proliferation, differentiation and survival of human epidermal keratinocytes. We describe and discuss the role of mutated gatekeeper genes in five specific signalling pathways which have been implicated in skin carcinogenesis. The pathways we focus on in this review are: (i) P16(INK4A)-CDK4/6-RB; (ii) P14(ARF)-HDM2-P53; (iii) Sonic hedgehog (SHH)/GLI; (iv) WNT/beta-catenin; and (v) Bone Morphogenetic Protein (BMP)/SMAD. 70-80% of XP skin cancers exhibit one or several mutations in the P53, PTCH-1, SMO or CDKN2A genes, the type and frequency of mutated genes being different between squamous cell (SCCs) and basal cell carcinomas (BCCs). In XP cancers, the typically UVB-induced CC to TT tandem transitions represent approximately 60% of total mutations compared to 10-15% in skin tumours from DNA repair-proficient patients. Acquired activation of the pathways described herein can alter proliferation and differentiation of keratinocytes, allowing a damaged cell to replicate and give rise to mutated daughter cells, then eventually to the development of the carcinogenic process following clonal selection.",
        "Doc_title":"UVB-induced mutations in human key gatekeeper genes governing signalling pathways and consequences for skin tumourigenesis.",
        "Journal":"Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology",
        "Do_id":"14521217",
        "Doc_ChemicalList":"Hedgehog Proteins;SHH protein, human;Trans-Activators;Tumor Suppressor Proteins",
        "Doc_meshdescriptors":"Cocarcinogenesis;DNA Repair;Genes, Tumor Suppressor;Hedgehog Proteins;Humans;Keratinocytes;Mutation;Neoplasms, Radiation-Induced;Signal Transduction;Skin Neoplasms;Trans-Activators;Tumor Suppressor Proteins;Ultraviolet Rays",
        "Doc_meshqualifiers":"physiology;radiation effects;cytology;metabolism;radiation effects;etiology;genetics;genetics;radiation effects;etiology;genetics;metabolism;radiation effects;metabolism;radiation effects;adverse effects",
        "_version_":1605758356056702976},
      {
        "Doc_abstract":"The p16 gene (MTS1 or CDK4I) encoding an inhibitor of cyclin-dependent kinase 4 (cdk4), has been reported to be deleted in various tumor cell lines, including lines derived from leukemic cells. The reported frequency of p16 gene loss is much higher in established cell lines than in primary tumor specimens. We investigated the status of the p16 gene in pediatric leukemias using 12 established cell lines of differing phenotypes and their corresponding primary leukemic cells. Six of 12 cell lines, including acute lymphoblastic leukemia (ALL) lines of T-cell (three of four), of precursor-B cell (two of four) and of mixed phenotype (one of four), showed homozygous deletion of the p16 gene using PCR and Southern blotting. Comparison of the cell lines with their corresponding primary leukemic cells clearly showed that in all 12 paired samples there were identical findings with respect to the presence or absence of the p16 gene, demonstrating that loss of the gene was a feature of the primary leukemic cells. This is the first study to show this correlation using a panel of paired samples, indicating that p16 gene deletions were not an artifact of in vitro cell culture. Furthermore, the survival of ALL patients with p16 gene deletions was significantly inferior to those without deletions, suggesting that this genetic alteration may be a clinical prognostic factor.",
        "Doc_title":"Deletions of the p16 gene in pediatric leukemia and corresponding cell lines.",
        "Journal":"Oncogene",
        "Do_id":"8668350",
        "Doc_ChemicalList":"Carrier Proteins;Cyclin-Dependent Kinase Inhibitor p16",
        "Doc_meshdescriptors":"Blotting, Southern;Carrier Proteins;Child;Child, Preschool;Cyclin-Dependent Kinase Inhibitor p16;Gene Deletion;Homozygote;Humans;Infant;Infant, Newborn;Leukemia, T-Cell;Precursor B-Cell Lymphoblastic Leukemia-Lymphoma;Precursor Cell Lymphoblastic Leukemia-Lymphoma;Translocation, Genetic;Tumor Cells, Cultured",
        "Doc_meshqualifiers":"genetics;genetics;genetics;genetics",
        "_version_":1605928647288422400},
      {
        "Doc_abstract":"The implication of human papilloma virus (HPV) in head and neck squamous cell carcinoma (HNSCC) is well established, especially in oropharyngeal SCC. HIV patients have a higher risk of persistent HPV infection. We investigated the role of HPV in HNSCC carcinogenesis in HIV population.;Retrospective monocentric study.;We studied HIV patients who presented with HNSCC between 1994 and 2014. For each patient, tumor characteristics, HIV disease, and survival information were collected. Tumor HPV testing was performed using p16 immunohistochemistry (IHC), in-situ hybridization and PCR. We assessed the percentage of HPV in this population of HIV patients with HNSCC and compared HIV disease characteristics based on HPV status.;Forty-seven patients were included: 11 women/36 men, the median age was 50 years. Tumor HPV testing was performed in 40 patients. Tumors were located in oropharynx (32%), oral cavity (32%), larynx (21%), and hypopharynx (11%). At the time of diagnosis, median CD4 level was 385cells/l, 31% of the patients were stage (Centers for Disease Control, stage C). The percentage of HPV linked to HNSCC for all locations in HIV patients was 30% (n=12). HPV16 accounted for 50% of all HPV genotypes. HPV positive status was associated with a CD4 nadir of less than 200 (P=0.026), but not with CD4 level at time of diagnosis (P=0.414). HPV-negative tumors tend to be associated with poorer 5-year overall survival (hazard ratio=2.9, P=0.0711).;HPV plays a critical role in HNSCC development in HIV population. HIV immunodeficiency may increase HPV persistence and progression of HNSCC.",
        "Doc_title":"Human papilloma virus prevalence in HIV patients with head and neck squamous cell carcinoma.",
        "Journal":"AIDS (London, England)",
        "Do_id":"26807970",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605906411137531904},
      {
        "Doc_abstract":"The p14(ARF) tumor suppressor triggers cell death or cell cycle arrest upon oncogenic stress. In MCF-7 breast carcinoma cells, expression of the tumor suppressor gene p14(ARF) fails to trigger apoptosis but induces an arrest in the G1 and, to a lesser extent, in the G2 phase in the cell division cycle. Here, inhibition of cell cycle arrest resulted in apoptosis induction in caspase-3 proficient MCF-7 cells upon expression of p14(ARF) . This occurred in the absence of S-phase progression or mitotic entry. In contrast, syngeneic, caspase-3-deficient MCF-7 cells remained entirely resistant to p14(ARF) -induced apoptosis. Thus, cell cycle checkpoint abrogation overcomes resistance to p14(ARF) -induced cell death and promotes cell death via a caspase-3-dependent pathway. Cell death coincided with dissipation of the mitochondrial membrane potential, release of cytochrome c, and was inhibitable by pan-caspase inhibitors and the caspase-3/7 inhibitor zDEVD-fmk. Of note, mitochondrial events of apoptosis execution depended entirely on caspase-3 proficiency indicating that caspase-3 either acts \"up-stream\" of the mitochondria in a \"non-canonical\" pathway or mediates a mitochondrial feedback loop to amplify the apoptotic caspase signal in p14(ARF) -induced stress signaling. ",
        "Doc_title":"p14ARF induces apoptosis via an entirely caspase-3-dependent mitochondrial amplification loop.",
        "Journal":"International journal of cancer",
        "Do_id":"23686572",
        "Doc_ChemicalList":"Tumor Suppressor Protein p14ARF;Caspase 3",
        "Doc_meshdescriptors":"Apoptosis;Breast Neoplasms;Caspase 3;Cell Cycle Checkpoints;Female;Gene Expression Regulation, Neoplastic;Humans;MCF-7 Cells;Mitochondria;Signal Transduction;Tumor Suppressor Protein p14ARF",
        "Doc_meshqualifiers":"genetics;metabolism;genetics;genetics;metabolism;genetics;metabolism",
        "_version_":1605742017746305024},
      {
        "Doc_abstract":"Exposure of primary cells to mitogenic stimuli or oncogenes often causes them to undergo premature senescence. This is most likely a protective function that prevents uncontrolled proliferation. Pak4 is a target for the Rho GTPase Cdc42. Pak4 is overexpressed in human tumor cell lines, and it is the only member of the Pak family that is highly transforming in immortalized fibroblasts. Here we show that in primary fibroblasts, activated Pak4 inhibits cell proliferation and promotes premature senescence. Furthermore, Pak4 expression levels are upregulated in response to stimuli that promote senescence. Pak4-induced arrest appears to be mediated by a pathway that requires the ERK mitogen-activated protein kinase, as well as the cell cycle inhibitors p16(INK4) and p19(ARF). These new results describing a role for Pak4 in senescence are important for understanding why this protein is associated with cancer and how it promotes transformation in immortalized cells.",
        "Doc_title":"Pak4 induces premature senescence via a pathway requiring p16INK4/p19ARF and mitogen-activated protein kinase signaling.",
        "Journal":"Molecular and cellular biology",
        "Do_id":"16227603",
        "Doc_ChemicalList":"Cdkn2a protein, mouse;Cyclin-Dependent Kinase Inhibitor p16;Tumor Suppressor Protein p14ARF;Pak4 protein, mouse;Protein-Serine-Threonine Kinases;p21-Activated Kinases;Extracellular Signal-Regulated MAP Kinases",
        "Doc_meshdescriptors":"Animals;Cell Aging;Cell Proliferation;Cell Transformation, Neoplastic;Cells, Cultured;Cyclin-Dependent Kinase Inhibitor p16;Extracellular Signal-Regulated MAP Kinases;Fibroblasts;Humans;MAP Kinase Signaling System;Mice;Protein-Serine-Threonine Kinases;Tumor Suppressor Protein p14ARF;Up-Regulation;p21-Activated Kinases",
        "Doc_meshqualifiers":"physiology;genetics;metabolism;metabolism;physiology;physiology;genetics;physiology;genetics;metabolism",
        "_version_":1605818718413127682},
      {
        "Doc_abstract":"Human papillomaviruses (HPV) may play an important role as one of the possible etiologies of oral squamous cell carcinoma (OSCC). The present study aimed to investigate the association between HPV and OSCC in young Japanese patients by examining the presence of HPV DNA and surrogate markers in OSCC tissues.;Forty young patients with OSCC whose surgical specimens were available were analyzed and compared with 40 patients randomly recruited from a pool of patients aged >40 years. HPV DNA was detected using the polymerase chain reaction-based AMPLICOR() HPV test, and surrogate markers of HPV infection were analyzed using immunohistochemical techniques to detect p16(INK4a) and p53.;Only two (5%) young patients and one (2.5%) older patient were positive for HPV DNA. p16(INK4a) overexpression was identified in six (15%) young patients. p53 staining levels were not high in tissues of most young patients (27 patients, 67.5%). HPV DNA status did not significantly correlate with p16(INK4a) expression levels. Profiles of increased levels of p16(INK4a) expression with diminished levels of p53 staining were not associated with the presence of HPV DNA. The combined p53 with p16(INK4a) profiles were significantly correlated with alcohol consumption in younger patients (p=0.006).;RESULTS of the present study indicate that HPV is less likely to cause OSCC in young Japanese patients, and the p16(INK4a) expression level is not an appropriate surrogate marker for HPV infection in OSCC.",
        "Doc_title":"Lack of association between high-risk human papillomaviruses and oral squamous cell carcinoma in young Japanese patients.",
        "Journal":"Asian Pacific journal of cancer prevention : APJCP",
        "Do_id":"24935359",
        "Doc_ChemicalList":"Biomarkers, Tumor;Cyclin-Dependent Kinase Inhibitor p16;DNA, Viral",
        "Doc_meshdescriptors":"Adult;Age Factors;Alcohol Drinking;Biomarkers, Tumor;Carcinoma, Squamous Cell;Cyclin-Dependent Kinase Inhibitor p16;DNA, Viral;Female;Human Papillomavirus DNA Tests;Humans;Japan;Male;Mouth Neoplasms;Papillomaviridae;Papillomavirus Infections",
        "Doc_meshqualifiers":"blood;virology;biosynthesis;genetics;blood;virology;etiology",
        "_version_":1605808750022623232},
      {
        "Doc_abstract":"The role of p16(INK4A) as a marker of HR-HPV and in the diagnosis of CIN has been well established, but its predictive value in the clearance of the virus after CIN treatment and its use as a prognostic marker of cervical cancer has not been studied. A series of 302 archival samples, including 150 squamous cell carcinomas (SCCs) and 152 CIN lesions, were subjected to immunohistochemical staining for p16(INK4A) and HPV testing using PCR with three primer sets (MY09/11, GP5/GP6, SPF). Follow-up data were available of 88 SCC patients, and 67 of the CIN lesions had been followed-up with serial PCR after conization. HR-HPV types were closely associated with CIN (OR 19.12; 95%CI 2.31-157.81) and SCC (OR 27.25; 95%CI 3.28-226.09). There was a significant linear relationship between the lesion grade and intensity of p16(INK4A) staining (p = 0.0001). The expression of p16(INK4A) was also closely related to HR-HPV (p = 0.0001). p16(INK4A) staining was a 100% specific indicator of CIN, with 100% PPV, and showed 83.5% sensitivity and 80.1% PPV in detecting HR-HPV. However, p16(INK4A) staining did not predict clearance/persistence of HR-HPV after treatment of CIN. Similarly, despite a slightly more favorable survival in women with strong/intense p16(INK4A) staining in univariate analysis, p16(INK4A) expression was not an independent prognostic predictor in multivariate survival (Cox) analysis. After adjustment for p16(INK4A) staining, HR-HPV, histological grade, International Federation of Gynecology and Obstetrics (FIGO) stage, and age, only the last two were significant prognostic predictors (p = 0.0001 and p = 0.003, respectively). The present data confirm the role of p16(INK4A) as a highly specific marker of CIN and HR-HPV type, but expression of this protein does not seem to be of any prognostic value in cervical cancer or in predicting the clearance of HR-HPV after treatment of CIN. We speculate that different subgroups of cervical cancer are characterized by aberrant p16(INK4A)/cyclin D/Rb pathways that are due to different mechanisms that can be mutually exclusive.",
        "Doc_title":"p16(INK4A) expression is related to grade of cin and high-risk human papillomavirus but does not predict virus clearance after conization or disease outcome.",
        "Journal":"International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists",
        "Do_id":"15381905",
        "Doc_ChemicalList":"Biomarkers, Tumor;Cyclin-Dependent Kinase Inhibitor p16",
        "Doc_meshdescriptors":"Adolescent;Adult;Biomarkers, Tumor;Cervical Intraepithelial Neoplasia;Conization;Cyclin-Dependent Kinase Inhibitor p16;Female;Humans;Immunohistochemistry;Middle Aged;Papillomaviridae;Papillomavirus Infections;Polymerase Chain Reaction;Prognosis;Sensitivity and Specificity;Survival Analysis;Uterine Cervical Neoplasms",
        "Doc_meshqualifiers":"analysis;pathology;surgery;virology;biosynthesis;isolation & purification;complications;pathology;pathology;surgery;virology",
        "_version_":1605907366033752064},
      {
        "Doc_abstract":"Human adipose tissue macrophages (ATMs) display an alternatively activated (M2) phenotype, but are still able to produce excessive inflammatory mediators. However, the processes driving this particular ATM phenotype are not understood. Genome-wide association studies associated the CDKN2A locus, encoding the tumour suppressor p16(INK4A), with the development of type 2 diabetes. In the present study, p16(INK4A) levels in human ATMs and the role of p16(INK4A) in acquiring the ATM phenotype were assessed.;Gene expression of p16                            (                               INK4A                            ) in ATMs was analysed and compared with that in monocyte-derived macrophages (MDMs) from obese patients or with macrophages from human atherosclerotic plaques (AMs). Additionally, p16(INK4A) levels were studied during macrophage differentiation and polarisation of monocytes isolated from healthy donors. The role of p16(INK4A) in MDMs from healthy donors was investigated by small interfering (si)RNA-mediated silencing or adenovirus-mediated overproduction of p16(INK4A).;Compared with MDMs and AMs, ATMs from obese patients expressed lower levels of p16                            (                               INK4A                            ). In vitro, IL-4-induced M2 polarisation resulted in lower p16(INK4A) protein levels after differentiation of monocytes from healthy donors in macrophages. Silencing of p16(INK4A) in MDMs mediated by siRNA increased the expression of M2 marker genes and enhanced the response to lipopolysaccharide (LPS), to give a phenotype resembling that of ATM. By contrast, adenovirus-mediated overproduction of p16(INK4A) in MDMs diminished M2 marker gene expression and the response to LPS. Western blot analysis revealed that p16(INK4A) overproduction inhibits LPS- and palmitate-induced Toll-like receptor 4 (TLR4)-nuclear factor of  light polypeptide gene enhancer in B cells (NF-B) signalling.;These results show that p16(INK4A) inhibits the acquisition of the ATM phenotype. The age-related increase in p16(INK4A) level may thus influence normal ATM function and contribute to type 2 diabetes risk.",
        "Doc_title":"Downregulation of the tumour suppressor p16INK4A contributes to the polarisation of human macrophages toward an adipose tissue macrophage (ATM)-like phenotype.",
        "Journal":"Diabetologia",
        "Do_id":"21968977",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;NF-kappa B;RNA, Small Interfering;TLR4 protein, human;Toll-Like Receptor 4",
        "Doc_meshdescriptors":"Adipose Tissue;Cell Polarity;Cyclin-Dependent Kinase Inhibitor p16;Diabetes Mellitus, Type 2;Down-Regulation;Female;Gene Silencing;Humans;Macrophages;Male;NF-kappa B;Obesity;Plaque, Atherosclerotic;RNA, Small Interfering;Toll-Like Receptor 4",
        "Doc_meshqualifiers":"metabolism;biosynthesis;genetics;metabolism;metabolism;metabolism;metabolism;metabolism;metabolism;metabolism",
        "_version_":1605747086266990593},
      {
        "Doc_abstract":"Determine human papillomavirus (HPV) incidence in unknown primary squamous cell carcinomas (SCCa) of the head and neck and assess if HPV status influenced survival.;Historical cohort study.;Tertiary care center.;Patients with unknown primary SCCa despite a complete workup who underwent neck dissection or excisional biopsy and postoperative comprehensive  chemoradiotherapy between 2002 and 2009.;HPV fluorescence in situ hybridization (FISH) and p16(INK4a) immunohistochemistry (p16 IHC) were performed. Results were compared with survival, age, race, gender, tobacco use, alcohol use, and nodal stage.;Twenty-five patients met the inclusion criteria, of whom 88% were >10 pack year tobacco users. Twenty-eight percent were HPV-positive defined by both p16+ and FISH+. Five-year overall survival was 66.7% in HPV-positive and 48.5% in HPV-negative patients (P = .35). Similarly, 5-year disease-free survival rates were 66.7% in HPV-positive and 48.5% in HPV-negative patients (P = .54). All 3 HPV-positive nonsmokers were survivors, but this was not significant because of the small sample size (P > .05). No other characteristics were associated with survival (P > .05).;Twenty-eight percent of metastatic lymph nodes from occult primary tumors were HPV positive. There was no survival difference associated with HPV status. Most of the HPV-positive patients in this study were tobacco users who had similar survival to HPV-negative patients, so caution should be used in interpreting HPV status in these patients.",
        "Doc_title":"Human papillomavirus in metastatic lymph nodes from unknown primary head and neck squamous cell carcinoma.",
        "Journal":"Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery",
        "Do_id":"21493313",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16",
        "Doc_meshdescriptors":"Aged;Aged, 80 and over;Biopsy;Carcinoma, Squamous Cell;Combined Modality Therapy;Cyclin-Dependent Kinase Inhibitor p16;Disease-Free Survival;Female;Follow-Up Studies;Human papillomavirus 16;Humans;Immunoenzyme Techniques;In Situ Hybridization, Fluorescence;Kaplan-Meier Estimate;Lymph Nodes;Lymphatic Metastasis;Male;Middle Aged;Neoplasm Staging;Neoplasms, Unknown Primary;Otorhinolaryngologic Neoplasms;Papillomavirus Infections;Smoking",
        "Doc_meshqualifiers":"mortality;pathology;secondary;therapy;virology;analysis;pathology;mortality;pathology;therapy;virology;mortality;pathology;secondary;therapy;virology;pathology;surgery;virology;adverse effects;pathology",
        "_version_":1605818710985015297},
      {
        "Doc_abstract":"The INK4 family members p16(INK4a) and p15(INK4b) negatively regulate cell cycle progression by inhibition of cyclin-dependent kinase (CDK) 4/6. Loss of p16(INK4a) functional activity is frequently observed in tumor cells, and is thought to be one of the primary causes of carcinogenesis. In contrast, despite the biochemical similarity to p16(INK4a), the frequency of defects in p15(INK4b) was found to be lower than in p16(INK4a), suggesting that p15(INK4b)-inductive agents may be useful for tumor suppression. Here we report the discovery of a novel pyrido-pyrimidine derivative, JTP-70902, which exhibits p15(INK4b)-inducing activity in p16(INK4a)-inactivated human colon cancer HT-29 cells. JTP-70902 also induced another CDK-inhibitor, p27(KIP1), and downregulated the expression of c-Myc and cyclin D1, resulting in G(1) cell cycle arrest. MEK1/2 was identified by compound-immobilized affinity chromatography as the molecular target of JTP-70902, and this was further confirmed by the inhibitory activity of JTP-70902 against MEK1/2 in kinase assays. JTP-70902 suppressed the growth of most colorectal and some other cancer cell lines in vitro, and showed antitumor activity in an HT-29 xenograft model. However, JTP-70902 did not inhibit the growth of COLO320 DM cells; in these, constitutive extracellular signal-regulated kinase phosphorylation was not detected, and neither p15(INK4b) nor p27(KIP1) induction was observed. Moreover, p15(INK4b)-deficient mouse embryonic fibroblasts were found to be more resistant to the growth-inhibitory effect of JTP-70902 than wild-type mouse embryonic fibroblasts. These findings suggest that JTP-70902 restores CDK inhibitor-mediated cell cycle control by inhibiting MEK1/2 and exerts a potent antitumor effect.",
        "Doc_title":"Identification of JTP-70902, a p15(INK4b)-inductive compound, as a novel MEK1/2 inhibitor.",
        "Journal":"Cancer science",
        "Do_id":"17784872",
        "Doc_ChemicalList":"Antineoplastic Agents;Cyclin-Dependent Kinase Inhibitor p15;Protein Kinase Inhibitors;MAP2K2 protein, human;MAP Kinase Kinase 1;MAP Kinase Kinase 2;MAP2K1 protein, human",
        "Doc_meshdescriptors":"Animals;Antineoplastic Agents;Cell Cycle;Cell Division;Cell Line;Cell Line, Tumor;Colonic Neoplasms;Colorectal Neoplasms;Cyclin-Dependent Kinase Inhibitor p15;Humans;MAP Kinase Kinase 1;MAP Kinase Kinase 2;Mice;Mice, Nude;Protein Kinase Inhibitors;Transplantation, Heterologous",
        "Doc_meshqualifiers":"pharmacology;drug effects;drug effects;biosynthesis;antagonists & inhibitors;antagonists & inhibitors;pharmacology",
        "_version_":1605792483059433472},
      {
        "Doc_abstract":"Multiple genetic alterations occur in melanoma, a lethal skin malignancy of increasing incidence. These include mutations that activate Ras and two of its effector cascades, Raf and phosphoinositide 3-kinase (PI3K). Induction of Ras and Raf can be caused by active N-Ras and B-Raf mutants as well as by gene amplification. Activation of PI3K pathway components occurs by PTEN loss and by AKT3 amplification. Melanomas also commonly show impairment of the p16(INK4A)-CDK4-Rb and ARF-HDM2-p53 tumor suppressor pathways. CDKN2A mutations can produce p16(INK4A) and ARF protein loss. Rb bypass can also occur through activating CDK4 mutations as well as by CDK4 amplification. In addition to ARF deletion, p53 pathway disruption can result from dominant negative TP53 mutations. TERT amplification also occurs in melanoma. The extent to which these mutations can induce human melanocytic neoplasia is unknown. Here we characterize pathways sufficient to generate human melanocytic neoplasia and show that genetically altered human tissue facilitates functional analysis of mutations observed in human tumors.",
        "Doc_title":"Use of human tissue to assess the oncogenic activity of melanoma-associated mutations.",
        "Journal":"Nature genetics",
        "Do_id":"15951821",
        "Doc_ChemicalList":"DNA-Binding Proteins;Proto-Oncogene Proteins;Tumor Suppressor Protein p53;Tumor Suppressor Proteins;CDK4 protein, human;Cdk4 protein, mouse;Cyclin-Dependent Kinase 4;Cyclin-Dependent Kinases;TERT protein, human;Telomerase;Tert protein, mouse;Phosphoric Monoester Hydrolases;PTEN Phosphohydrolase;PTEN protein, human",
        "Doc_meshdescriptors":"Animals;Cells, Cultured;Cyclin-Dependent Kinase 4;Cyclin-Dependent Kinases;DNA-Binding Proteins;Gene Expression Profiling;Gene Expression Regulation, Neoplastic;Genes, ras;Humans;Melanocytes;Melanoma;Mice;Mice, SCID;Mutation;Neoplasm Invasiveness;PTEN Phosphohydrolase;Phosphoric Monoester Hydrolases;Proto-Oncogene Proteins;Skin;Skin Neoplasms;Telomerase;Transplants;Tumor Suppressor Protein p53;Tumor Suppressor Proteins",
        "Doc_meshqualifiers":"biosynthesis;genetics;genetics;metabolism;genetics;metabolism;pathology;biosynthesis;genetics;biosynthesis;genetics;metabolism;pathology;genetics;metabolism;pathology;biosynthesis;genetics;biosynthesis;genetics;biosynthesis;genetics",
        "_version_":1605750527443861504},
      {
        "Doc_abstract":"CDKN2A promoter hypermethylation has been widely related to many cancers. In astrocytomas, although CDKN2A (p16(INK4A) protein) is often inactivated, there are still some controversial issues regarding the mechanism by which this alteration occurs. Thus, we analyzed a series of astrocytomas to assess the association between CDKN2A expression and methylation of grade I-IV tumors (WHO) and clinicopathological parameters. DNA extracted from formalin-fixed paraffin-embedded material of 93 astrocytic tumors was available for CDKN2A promoter methylation analysis and p16(INK4A) expression by methylation-specific PCR and immunohistochemistry, respectively. A strong negative correlation between nuclear and cytoplasmic immunostaining and CDKN2A promoter methylation was found. Additionally, a significant negative correlation between CDKN2A promoter methylation and age was observed; also, female patients had statistically more CDKN2A methylated promoters (p=0.036) than men. In conclusion, CDKN2A inactivation by promoter methylation is a frequent event in astrocytomas and it is related to the age and sex of patients. ",
        "Doc_title":"CDKN2A promoter hypermethylation in astrocytomas is associated with age and sex.",
        "Journal":"International journal of surgery (London, England)",
        "Do_id":"23721661",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16",
        "Doc_meshdescriptors":"Adolescent;Adult;Aged;Aged, 80 and over;Astrocytoma;Brain Neoplasms;Chi-Square Distribution;Child;Child, Preschool;Cyclin-Dependent Kinase Inhibitor p16;DNA Methylation;Female;Humans;Male;Middle Aged;Promoter Regions, Genetic;Statistics, Nonparametric",
        "Doc_meshqualifiers":"chemistry;genetics;metabolism;chemistry;genetics;metabolism;chemistry;genetics;metabolism",
        "_version_":1605799983427092480},
      {
        "Doc_abstract":"To investigate the relationship between tumor suppressor genes p14(ARF) and p53 expression and the biological behavior of pancreatic carcinoma.;Modified Envision method of immunohistochemistry was used on 42 specimens of pancreatic adenocarcinoma and 10 normal specimens of normal pancreas resected during operation to examine the expression of the gene p14(ARF). and ABC immunohistochemical technique was used to examine the expression of p53.;The positive rates of p14(ARF) in of normal pancreatic tissues and pancreatic carcinoma were 90% and 35.7% respectively (P < 0.01). The positive rates of p53 in tissues of normal pancreatic and pancreatic carcinoma were 0 and 42.5% (P < 0.05) respectively. Significant correlation was detected between the expression of p14(AR) and p53 and the diameter of tumor, the rate of lymph node metastasis, pathological grade, and clinic stage in pancreatic carcinoma. No correlation was found between the expression of p14(ARF) and p53 and the tumor infiltration in pancreatic carcinoma.;The tumor suppressor gene p14(ARF) and p53 are closely related to the occurrence and development of pancreatic carcinoma. It is possible to treat pancreatic carcinoma by gene intervention.",
        "Doc_title":"[The relationship between tumor suppressor genes p14ARF and p53 expression and biological behavior of pancreatic carcinoma].",
        "Journal":"Zhonghua yi xue za zhi",
        "Do_id":"12895341",
        "Doc_ChemicalList":"Tumor Suppressor Protein p14ARF;Tumor Suppressor Protein p53",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Female;Humans;Immunohistochemistry;Male;Middle Aged;Pancreatic Neoplasms;Tumor Suppressor Protein p14ARF;Tumor Suppressor Protein p53",
        "Doc_meshqualifiers":"genetics;pathology;analysis;genetics;analysis",
        "_version_":1605742732963217410},
      {
        "Doc_abstract":"Human papillomavirus type 16 (HPV16) plays a role in the development of a subgroup of head and neck squamous cell carcinomas (HNSCC). However, uncertainty exists about the true impact of HPV in this tumor type as conflicting reports have been published with prevalence rates from 0 to 100%. We aimed to find a detection algorithm of a biologically and thus clinically meaningful infection, applicable for high-throughput screening of frozen and formalin-fixed paraffin embedded (FFPE) specimens. By considering detection of HPV E6 oncogene expression in frozen biopsies as gold standard for a meaningful HPV infection, the value of several assays was evaluated on FFPE tumor specimens and sera of 48 HNSCC patients. The following assays were evaluated on FFPE tissue samples: HPV DNA general primer (GP)5+/6+ PCR, viral load analysis, HPV16 DNA FISH detection, HPV16 E6 mRNA RT-PCR, p16 immunostaining, and on corresponding serum samples detection of antibodies against the HPV16 proteins L1, E6 and E7. Comparing single assays on FFPE tissue samples detection of E6 expression by RT-PCR was superior, but application remains at present limited to HPV16 detection. Most suitable algorithm with 100% sensitivity and specificity appeared p16 immunostaining followed by GP5+/6+ PCR on the p16-positive cases. We show that clinically meaningful viral HPV infections can be more reliably measured in FFPE HNSCC samples in a standard and high throughput manner, paving the way for prognostic and experimental vaccination studies, regarding not only HNSCC, but possibly also cancer types with HPV involvement in subgroups such as penile and anal cancer.",
        "Doc_title":"A novel algorithm for reliable detection of human papillomavirus in paraffin embedded head and neck cancer specimen.",
        "Journal":"International journal of cancer",
        "Do_id":"17680565",
        "Doc_ChemicalList":"DNA, Viral",
        "Doc_meshdescriptors":"Adult;Aged;Algorithms;Biopsy;Carcinoma, Squamous Cell;DNA, Viral;Female;Head and Neck Neoplasms;Human papillomavirus 16;Humans;Immunohistochemistry;In Situ Hybridization, Fluorescence;Male;Middle Aged;Papillomavirus Infections;Paraffin Embedding;Polymerase Chain Reaction;Reverse Transcriptase Polymerase Chain Reaction;Sensitivity and Specificity;Tumor Virus Infections;Viral Load",
        "Doc_meshqualifiers":"methods;virology;isolation & purification;virology;isolation & purification;diagnosis;epidemiology;diagnosis;epidemiology",
        "_version_":1605827458005729280},
      {
        "Doc_abstract":"Genetic data indicate that abrogation of Notch-Rbpj or Wnt--catenin pathways results in the loss of the intestinal stem cells (ISCs). However, whether the effect of Notch is direct or due to the aberrant differentiation of the transit-amplifying cells into post-mitotic goblet cells is unknown. To address this issue, we have generated composite tamoxifen-inducible intestine-specific genetic mouse models and analyzed the expression of intestinal differentiation markers. Importantly, we found that activation of -catenin partially rescues the differentiation phenotype of Rbpj deletion mutants, but not the loss of the ISC compartment. Moreover, we identified Bmi1, which is expressed in the ISC and progenitor compartments, as a gene that is co-regulated by Notch and -catenin. Loss of Bmi1 resulted in reduced proliferation in the ISC compartment accompanied by p16(INK4a) and p19(ARF) (splice variants of Cdkn2a) accumulation, and increased differentiation to the post-mitotic goblet cell lineage that partially mimics Notch loss-of-function defects. Finally, we provide evidence that Bmi1 contributes to ISC self-renewal. ",
        "Doc_title":"Bmi1 regulates murine intestinal stem cell proliferation and self-renewal downstream of Notch.",
        "Journal":"Development (Cambridge, England)",
        "Do_id":"25480918",
        "Doc_ChemicalList":"Bmi1 protein, mouse;Cyclin-Dependent Kinase Inhibitor p16;Cyclin-Dependent Kinase Inhibitor p19;Immunoglobulin J Recombination Signal Sequence-Binding Protein;Proto-Oncogene Proteins;Rbpj protein, mouse;Receptors, Notch;Wnt Proteins;beta Catenin;Polycomb Repressive Complex 1",
        "Doc_meshdescriptors":"Animals;Cell Compartmentation;Cell Proliferation;Cyclin-Dependent Kinase Inhibitor p16;Cyclin-Dependent Kinase Inhibitor p19;DNA Repair;Homeostasis;Immunoglobulin J Recombination Signal Sequence-Binding Protein;Intestines;Mice, Inbred C57BL;Mice, Knockout;Phenotype;Polycomb Repressive Complex 1;Proto-Oncogene Proteins;Receptors, Notch;Signal Transduction;Transcriptional Activation;Wnt Proteins;beta Catenin",
        "Doc_meshqualifiers":"genetics;metabolism;genetics;metabolism;deficiency;metabolism;abnormalities;pathology;deficiency;genetics;metabolism;deficiency;genetics;metabolism;deficiency;metabolism;genetics;metabolism;metabolism",
        "_version_":1605822474781458432},
      {
        "Doc_abstract":"In this study we explored the mutation types of p16(CDKN2A) exon 1 and the corresponding frequencies in experimental rat tongue carcinogenesis. Twenty barrier Sprague-Dawley (SD) rats were divided into the control (n = 5) and experimental group (n = 15), to which 4-nitroquinoline-1-oxide (4-NQO) in drinking water was administered. Two samples of normal, three samples of moderate/severe dysplasia and four samples of invasive squamous cell carcinoma lesions were selected following strict histopathological examination in double-blind manner. The PCR products of p16(CDKN2A) exon 1 amplified from these tissues were sequenced. Point mutations of p16(CDKN2A) exon 1 were found in all of the precancerous and cancerous lesions. Half of the mutations were detected on guanine (G). Twenty mutations, including a missense mutation of the start codon resulting in alternative reading frame of p16(CDKN2A) exon 1, were also identified. These preliminary results suggested that mutation of p16(CDKN2A) exon 1 might be an early molecular event of rat tongue carcinogenesis induced by 4NQO and G was the mutation hotspot.",
        "Doc_title":"Frequent mutation of p16(CDKN2A) exon 1 during rat tongue carcinogenesis induced by 4-nitroquinoline-1-oxide.",
        "Journal":"Molecular carcinogenesis",
        "Do_id":"17091472",
        "Doc_ChemicalList":"Carcinogens;4-Nitroquinoline-1-oxide;DNA",
        "Doc_meshdescriptors":"4-Nitroquinoline-1-oxide;Animals;Base Sequence;Carcinogens;Cell Transformation, Neoplastic;DNA;Exons;Genes, p16;Male;Molecular Sequence Data;Mutation;Polymerase Chain Reaction;Rats;Rats, Sprague-Dawley;Tongue Neoplasms",
        "Doc_meshqualifiers":"toxicity;toxicity;genetics;chemically induced;genetics",
        "_version_":1605765734542082048},
      {
        "Doc_abstract":"Diffuse large B-cell lymphoma (DLBCL) represents the most frequent type of aggressive lymphoma. Deletions of the CDKN2A locus, encoding the proteins CDKN2A (P16), P14ARF, and of the CDKN2B locus, encoding the protein CDKN2B (P15), affect one-third of DLBCL patients. Although other mechanisms that decrease gene expression have been reported, such as promoter methylation, the prognostic value of these mechanisms is still unclear. We studied the deletion and methylation status of these genes in 171 patients and correlated the genomic results with their mRNA expression level and clinical outcome. CDKN2A, P14ARF, and CDKN2B deletions were significantly correlated with decreased mRNA expression (P<0.0001, P<0.0001, and P=0.0148, respectively). P14ARF was methylated in only two patients (1.3%), whereas CDKN2A and CDKN2B were methylated in 36.7 and 31.4% of patients, respectively. Methylation levels greater than 25% were associated with decreased expression of CDKN2A (P=0.0169). CDKN2A and CDKN2B inactivation by deletion or methylation was observed in 42.7 and 37.4% of cases, respectively. Including P14ARF deletions, we identified an inactivating mechanism for at least one of these genes in 47% of patients. Although gene inactivation was not correlated with the international prognostic index, P14ARF and CDKN2B inactivation was significantly associated with shorter survival (P=0.0048 and P=0.0413, respectively), whereas CDKN2A was not (P=0.085). Low mRNA expression levels of these genes were correlated with the ABC phenotype. Furthermore, our results show that an inactivating methylation was more frequent in the GCB phenotype.",
        "Doc_title":"Several mechanisms lead to the inactivation of the CDKN2A (P16), P14ARF, or CDKN2B (P15) genes in the GCB and ABC molecular DLBCL subtypes.",
        "Journal":"Genes, chromosomes & cancer",
        "Do_id":"22619049",
        "Doc_ChemicalList":"CDKN2B protein, human;Cyclin-Dependent Kinase Inhibitor p15;Cyclin-Dependent Kinase Inhibitor p16;RNA, Messenger;Tumor Suppressor Protein p14ARF",
        "Doc_meshdescriptors":"Adolescent;Adult;Aged;Aged, 80 and over;CpG Islands;Cyclin-Dependent Kinase Inhibitor p15;Cyclin-Dependent Kinase Inhibitor p16;DNA Methylation;Female;Gene Dosage;Gene Silencing;Humans;Lymphoma, Large B-Cell, Diffuse;Male;Middle Aged;Prognosis;Promoter Regions, Genetic;RNA, Messenger;Real-Time Polymerase Chain Reaction;Reverse Transcriptase Polymerase Chain Reaction;Sequence Deletion;Survival Rate;Tumor Suppressor Protein p14ARF;Young Adult",
        "Doc_meshqualifiers":"genetics;genetics;genetics;classification;genetics;mortality;genetics;genetics;genetics",
        "_version_":1605804253211787264},
      {
        "Doc_abstract":"The recombinant adenovirus vector carrying p14ARF gene was constructed for using in the interference therapy in signal transduction of laryngeal squamous cell carcinoma.;The total cDNA fragment of p14ARF was cloned into the shuttle plasmid pAdTrack-CMV, with the resultant plasmid and the backbone plasmid pAdEasy-1, the homologous recombination took place in the E.Coli BJ5183 and the recombinant adenoviral plasmid was generated. The adenoviruses were packaged and amplified in the 293 cells. Then the viral titer was checked by GFP.;The recombinant adenovirus vector carrying p14ARF was constructed successfully. The viral titer was 2.3 x 10(9).;The recombinant adenovirus vector could introduce p14ARF gene into the laryngeal squamous cell carcinoma line or tumor tissue effectively, which would provide experimental basis for the mechanisms and further study of the interference therapy in signal transduction of laryngeal squamous cell carcinoma.",
        "Doc_title":"[Construction of recombinant adenovirus vector carrying cell cycle controlling gene-p14ARF].",
        "Journal":"Hua xi kou qiang yi xue za zhi = Huaxi kouqiang yixue zazhi = West China journal of stomatology",
        "Do_id":"16845966",
        "Doc_ChemicalList":"Tumor Suppressor Protein p14ARF",
        "Doc_meshdescriptors":"Adenoviridae;Cell Cycle;Genetic Vectors;Humans;Plasmids;Recombination, Genetic;Tumor Suppressor Protein p14ARF",
        "Doc_meshqualifiers":"None",
        "_version_":1605750234234748928},
      {
        "Doc_abstract":"As with other solid tumor types, head and neck squamous cell carcinoma (HNSCC) has been identified as an epigenetic, as well as genetic, disease. Consequently, promoter hypermethylation, being the most important aberrant epigenetic characteristic, has been intensively investigated for its biomarker potential in this cancer type. As many of these evaluations are obscured by a heterogeneity of treatments, the current study aimed to evaluate the incidence and prognostic value of the promoter hypermethylation of TIMP3, CDH1, DAPK, RASSF1A, p16INK4A and MGMT in HNSCC treated solely by radiotherapy. In 46 patients with advanced HNSCC treated with a hybrid accelerated fractionation radiotherapy schedule, DNA extracted from pretreatment paraffin-embedded tumor biopsies was used to determine the methylation status of the genes of interest by methylation-specific PCR (MSP). The detected epigenetic silencing was related with outcome in terms of locoregional control (LRC), and overall (OS), disease-free (DFS) and disease-specific survival (DSS). Tumor biopsies revealed the epigenetic silencing of MGMT in 42.5% (17 of 40) of patients and of TIMP3 in 40.5% (17 of 42) of cases. For the remaining investigated genes, a lower methylation percentage was detected: 13.2% (5 of 38) for CDH1, 11.4% (4 of 44) for DAPK, 4.8% (2 of 42) for p16INK4A and 2.4% (1 of 41) for RASSF1A. The promoter hypermethylation of TIMP3 and CDH1 was significantly related with better LRC (p=0.009 and p=0.02, respectively), OS (p=0.005 and p=0.002, respectively), DFS (p=0.02 and p=0.004, respectively) and DSS (p=0.12 and p=0.007, respectively). In conclusion, in this representative group of 46 patients with advanced HNSCC treated by radiotherapy only, the epigenetic silencing of TIMP3 and CDH1 predicted a better outcome.",
        "Doc_title":"Promoter methylation of TIMP3 and CDH1 predicts better outcome in head and neck squamous cell carcinoma treated by radiotherapy only.",
        "Journal":"Oncology reports",
        "Do_id":"19148529",
        "Doc_ChemicalList":"Apoptosis Regulatory Proteins;Biomarkers, Tumor;CDH1 protein, human;Cadherins;RASSF1 protein, human;TIMP3 protein, human;Tissue Inhibitor of Metalloproteinase-3;Tumor Suppressor Proteins;DNA Modification Methylases;MGMT protein, human;Death-Associated Protein Kinases;Calcium-Calmodulin-Dependent Protein Kinases;DNA Repair Enzymes",
        "Doc_meshdescriptors":"Adult;Aged;Apoptosis Regulatory Proteins;Biomarkers, Tumor;Cadherins;Calcium-Calmodulin-Dependent Protein Kinases;Carcinoma, Squamous Cell;DNA Methylation;DNA Modification Methylases;DNA Repair Enzymes;Death-Associated Protein Kinases;Disease-Free Survival;Female;Gene Silencing;Genes, p16;Head and Neck Neoplasms;Humans;Kaplan-Meier Estimate;Male;Middle Aged;Polymerase Chain Reaction;Prognosis;Promoter Regions, Genetic;Tissue Inhibitor of Metalloproteinase-3;Treatment Outcome;Tumor Suppressor Proteins",
        "Doc_meshqualifiers":"genetics;genetics;genetics;genetics;genetics;pathology;radiotherapy;genetics;genetics;genetics;genetics;pathology;radiotherapy;genetics;genetics;genetics",
        "_version_":1605746282650927104},
      {
        "Doc_abstract":"Penile squamous cell carcinoma (PSCC) is a tumor with a high metastatic potential. In PSCC the attributable fraction to human papillomavirus (HPV) is not well established.;We sought to provide novel data about the prevalence of HPV in a large series of penile intraepithelial neoplasia (PeIN) and invasive PSCC, correlating the results with the histologic subtype, p16(INK4a) immunostaining, and prognosis.;A total of 82 PSCC were included in the study, 69 invasive and 13 PeIN. HPV detection was performed by polymerase chain reaction with SPF-10 broad-spectrum primers followed by DNA enzyme immunoassay and genotyping with a reverse hybridization line probe assay. P16(INK4a) immunohistochemical expression on tissue microarrays was also analyzed.;HPV DNA was identified in 31 of 77 (40.2%) PSCC (22 of 67 invasive and 9 of 10 PeIN). In 25 of 31 (80.6%) cases HPV-16 was identified. HPV detection was significantly associated with some histologic subtypes: most basaloid and warty tumors were high-risk HPV (hrHPV) positive, whereas only 15% of usual PSCC were hr-HPV positive. All hrHPV-positive PSCC had an adjacent undifferentiated PeIN. Strong p16(INK4a) immunostaining correlated with hrHPV infection. Most undifferentiated PeIN showed p16(INK4a) immunohistochemical overexpression. Both hrHPV-positive and p16(INK4a)-positive tumors showed a better overall survival without reaching statistical significance.;This was a retrospective study.;Our results suggest that most hrHPV-positive PSCC develop from undifferentiated hrHPV-positive PeIN. P16(INK4a) immunostaining may be useful in identifying both etiologically related hrHPV-positive tumors and those with better outcome. The routine use of p16(INK4a) staining should be incorporated in histologic evaluation of PSCC.",
        "Doc_title":"Identification and genotyping of human papillomavirus in a Spanish cohort of penile squamous cell carcinomas: correlation with pathologic subtypes, p16(INK4a) expression, and prognosis.",
        "Journal":"Journal of the American Academy of Dermatology",
        "Do_id":"22863066",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Carcinoma in Situ;Carcinoma, Squamous Cell;Cyclin-Dependent Kinase Inhibitor p16;Genotype;Humans;Kaplan-Meier Estimate;Male;Middle Aged;Papillomaviridae;Papillomavirus Infections;Penile Neoplasms;Prevalence;Prognosis;Retrospective Studies;Spain",
        "Doc_meshqualifiers":"metabolism;pathology;virology;metabolism;pathology;virology;metabolism;genetics;isolation & purification;epidemiology;metabolism;pathology;virology;epidemiology",
        "_version_":1605783593302360064},
      {
        "Doc_abstract":"The development of oral and head and neck squamous cell carcinomas occurs in relation with multiple events including mainly: loss of cycle cell control, evasion from apoptosis, telomerase reactivation. Complex interactions between a set of molecules, cell cycle proteins, tumour suppressor genes, oncogenes and the telomerase, occur in the multiple step process of carcinogenesis. The 2 main ways of control of the cell cycle rely on 2 tumour suppressor genes: the P53 gene and the retinoblastoma gene or RB gene. One of the regulation pathways or the 2 regulation pathways are disabled during the development of oral and head and neck squamous cell carcinomas. Most of the time, the inactivation of the P53 pathway results from a loss of function of the p53 protein, secondary to mutation and/or deletion of the P53 gene; It may also result of the amplification of the MDM2 gene and of the inactivation of the arf protein. The RB pathway leads to cell proliferation by loss of the p16 protein, by amplification of the cyclin D1 gene and less frequently by mutation of the RB gene or loss of the retinoblastoma protein. In India and South-East Asia, the activation of RAS and MYC oncogenes appears to be related with the presence of specific carcinogens in snuff and tobacco. By blocking apoptosis, the Bcl2 protein seems to increase the resistance of tumours to radiotherapy and chemotherapy.",
        "Doc_title":"[Genic alterations in oral and head and neck squamous cell carcinomas: analysis of international literature].",
        "Journal":"Pathologie-biologie",
        "Do_id":"12781800",
        "Doc_ChemicalList":"Microfilament Proteins;Muscle Proteins;Nuclear Proteins;Proto-Oncogene Proteins;Retinoblastoma Protein;Tagln protein, mouse;MDM2 protein, human;Proto-Oncogene Proteins c-mdm2;Telomerase",
        "Doc_meshdescriptors":"Carcinoma, Squamous Cell;Gene Deletion;Genes, bcl-1;Genes, bcl-2;Genes, myc;Genes, p53;Genes, ras;Head and Neck Neoplasms;Humans;Microfilament Proteins;Mouth Neoplasms;Muscle Proteins;Mutation;Nuclear Proteins;Proto-Oncogene Proteins;Proto-Oncogene Proteins c-mdm2;Retinoblastoma Protein;Telomerase",
        "Doc_meshqualifiers":"genetics;genetics;genetics;genetics;genetics;genetics;genetics;genetics;genetics;genetics;genetics",
        "_version_":1605820166366560256},
      {
        "Doc_abstract":"Hyperexpression of p16(INK4a) protein is an early marker of cervical cancer. Hyperexpression of INK4a gene encoding this protein at the level of mRNA and p16(INK4a) was detected in tumor cells of some patients with bladder cancer associated with human papilloma virus-16. However, in contrast to cervical cancer, this phenomenon in urothelial carcinomas does not correlate with expression of human papilloma virus-16 oncogenes E6 and E7.",
        "Doc_title":"Cellular expression of INK4a gene in cells of bladder cancer associated with human papilloma virus-16.",
        "Journal":"Bulletin of experimental biology and medicine",
        "Do_id":"21113501",
        "Doc_ChemicalList":"Biomarkers, Tumor;Cyclin-Dependent Kinase Inhibitor p16;DNA Primers;E6 protein, Human papillomavirus type 16;Oncogene Proteins, Viral;Papillomavirus E7 Proteins;Repressor Proteins;oncogene protein E7, Human papillomavirus type 16",
        "Doc_meshdescriptors":"Biomarkers, Tumor;Cyclin-Dependent Kinase Inhibitor p16;DNA Primers;Human papillomavirus 16;Humans;Immunohistochemistry;Oncogene Proteins, Viral;Papillomavirus E7 Proteins;Repressor Proteins;Reverse Transcriptase Polymerase Chain Reaction;Urinary Bladder Neoplasms",
        "Doc_meshqualifiers":"metabolism;metabolism;genetics;metabolism;metabolism;metabolism;diagnosis;metabolism;virology",
        "_version_":1605746315954749440},
      {
        "Doc_abstract":"Histiocytic sarcoma (HS) is a rare malignant proliferation of histiocytes of uncertain molecular pathogenesis. Here, genetic analysis of coincident loss of Pten and Ink4a/Arf tumor suppressors in the mouse revealed a neoplastic phenotype dominated by a premalignant expansion of biphenotypic myelolymphoid cells followed by the development of HS. Pten protein loss occurred only in the histiocytic portion of tumors, suggesting a stepwise genetic inactivation in the generation of HS. Similarly, human HS showed genetic or epigenetic inactivation of PTEN, p16(INK4A), and p14(ARF), supporting the relevance of this genetically engineered mouse model of HS. These genetic and translational observations establish a cooperative role of Pten and Ink4a/Arf in the development of HS and provide mechanistic insights into the pathogenesis of human HS.",
        "Doc_title":"The PTEN and INK4A/ARF tumor suppressors maintain myelolymphoid homeostasis and cooperate to constrain histiocytic sarcoma development in humans.",
        "Journal":"Cancer cell",
        "Do_id":"16697958",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;Tumor Suppressor Protein p14ARF;Proto-Oncogene Proteins c-akt;Extracellular Signal-Regulated MAP Kinases;PTEN Phosphohydrolase",
        "Doc_meshdescriptors":"Animals;Cyclin-Dependent Kinase Inhibitor p16;Enzyme Activation;Extracellular Signal-Regulated MAP Kinases;Histiocytic Disorders, Malignant;Homeostasis;Humans;Immunophenotyping;Lymphocytes;Methylation;Mice;Mutation;Myeloid Cells;PTEN Phosphohydrolase;Proto-Oncogene Proteins c-akt;Sarcoma;Tumor Suppressor Protein p14ARF",
        "Doc_meshqualifiers":"metabolism;metabolism;immunology;pathology;immunology;genetics;immunology;deficiency;metabolism;metabolism;immunology;pathology;deficiency;metabolism",
        "_version_":1605755304633434112},
      {
        "Doc_abstract":"Cytology has been proposed as a potential screening tool in the evaluation of squamous anorectal disease in view of the morphologic similarities between anal and cervical squamous lesions. Previous studies have demonstrated that p16 overexpression correlates with the degree of dysplasia in the uterine cervix with promising results. Due to potential diagnostic pitfalls in anal cytology, p16 overexpression in these specimens was studied.;Patients with anorectal cytology who underwent follow-up biopsy within 1 year were selected. Forty-three anorectal cytologic specimens from 29 patients were selected. One slide of each case was destained. Avidin-biotin immunocytochemical studies with the monoclonal antibody CINtec p16(INK4a) were performed. The results of the p16 immunostaining were correlated with the histologic findings.;Twenty-eight of the 43 cases demonstrated the presence of squamous cells immunoreactive for p16 in cytology specimens. The p16-positive cells were identified in cases of low-grade squamous intraepithelial lesion (LSIL) (n = 3 cases), high-grade squamous intraepithelial lesion (HSIL) (n = 22 cases), and invasive squamous carcinoma (n = 1 case), and in 2 cases with negative follow-up biopsies. No cell immunoreactive for p16 was found in 15 cases (5 benign cases and 10 cases with either LSIL or HSIL). The sensitivity and specificity of p16 immunoreactivity in the detection of anal intraepithelial neoplasia or carcinoma were 72% and 71%, respectively. The positive and negative predictive values were 93% and 33%, respectively.;The presence of p16 immunoreactivity is a good predictor of dysplasia in anal specimens. However, the sensitivity and specificity of this marker are not high.",
        "Doc_title":"Immunoreactivity of p16 in anal cytology specimens: histologic correlation.",
        "Journal":"Cancer",
        "Do_id":"16404747",
        "Doc_ChemicalList":"Biomarkers, Tumor;Cyclin-Dependent Kinase Inhibitor p16",
        "Doc_meshdescriptors":"Adult;Aged;Anus Neoplasms;Biomarkers, Tumor;Carcinoma in Situ;Cyclin-Dependent Kinase Inhibitor p16;Female;Humans;Immunohistochemistry;Male;Middle Aged;Neoplasms, Squamous Cell;Sensitivity and Specificity",
        "Doc_meshqualifiers":"metabolism;pathology;analysis;metabolism;pathology;metabolism;pathology",
        "_version_":1605766050172895232},
      {
        "Doc_abstract":"This study was aimed at investigating the involvement of the SUV39H1 histone methyltransferase on the epigenetic change of euchromatic promoter in colorectal cancer. We retrospectively analyzed the mRNA levels of SUV39H1 and the promoter methylation of the p14(ARF), p16(INK4a) and HLTF genes as well as the mRNA levels of DNA methyltransferase 1 (DNMT1) in fresh frozen tissues from 219 colorectal cancer patients. The mRNA levels of the SUV39H1 and DNMT1 were assessed via quantitative real-time PCR and the methylation profiles of the CpG islands were determined using methylation-specific PCR. The mRNA levels of SUV39H1 and DNMT1 were elevated in 25% and 42% of 219 colorectal cancers, respectively. The hypermethylation of the p14(ARF), p16(INK4a) and HLTF genes occurred in 36%, 51% and 34% of the patients. The elevated mRNA levels of SUV39H1 were not associated with the hypermethylation of the 3 genes. However, the mRNA levels of DNMT1 were significantly different between patients with elevated mRNA levels of SUV39H1 and those without (1.62 +/- 0.84, 0.91 +/- 0.81, respectively; p = 0.007). Patients with elevated mRNA levels of SUV39H1 showed a higher prevalence of DNMT1 elevation than those without (61 vs. 35%, p = 0.0008). Patients with an elevated mRNA level of SUV39H1 had a 2.71 (95% CI = 1.09-4.48, p = 0.002) times greater risk of an elevated mRNA level of DNMT1, after controlling for age and gender. In conclusion, the present study suggests that SUV39H1 is significantly associated with DNMT1, but not with euchromatic promoter methylation in colorectal cancer.",
        "Doc_title":"Association of the SUV39H1 histone methyltransferase with the DNA methyltransferase 1 at mRNA expression level in primary colorectal cancer.",
        "Journal":"International journal of cancer",
        "Do_id":"17657744",
        "Doc_ChemicalList":"RNA, Messenger;Repressor Proteins;SUV39H1 protein, human;Methyltransferases;Protein Methyltransferases;histone methyltransferase;DNA (Cytosine-5-)-Methyltransferase;DNA (cytosine-5-)-methyltransferase 1;Histone-Lysine N-Methyltransferase",
        "Doc_meshdescriptors":"Colorectal Neoplasms;DNA (Cytosine-5-)-Methyltransferase;DNA Methylation;Female;Gene Expression Regulation, Enzymologic;Gene Expression Regulation, Neoplastic;Histone-Lysine N-Methyltransferase;Humans;Male;Methyltransferases;Middle Aged;Protein Methyltransferases;RNA, Messenger;Repressor Proteins",
        "Doc_meshqualifiers":"enzymology;genetics;pathology;genetics;metabolism;genetics;metabolism;genetics;metabolism;genetics;genetics;metabolism",
        "_version_":1605840044930629632},
      {
        "Doc_abstract":"The analysis of p53, p21(WAF1/CIP1), p16(INK4A) and Ki-67 expression in serous ovarian carcinomas of different grade.;In total, 43 ovarian adenocarcinomas and 8 non-altered ovarian epithelial tissues were immunohistochemically investigated for expression of Ki-67, p53, p21(WAF1/CIP1) and p16(INK4A).;It has been shown that expression of Ki-67, p53, p21(WAF1/CIP1) and p16(INK4A) in non-altered ovarian epithelial tissue is absent. Serous ovarian carcinomas are characterized by high proliferative activity (PI Ki-67 = 30.0 +/- 0.3%), p53 and p16(INK4A) overexpression (LI is 40.3 +/- 0.3% and 31.1 +/- 0.6% respectively) and low expression of p21(WAF1/CIP1) (LI = 6.8 +/- 0.3%). The association between expression of these markers and ovarian tumor grade was defined: the maximal level of Ki-67, p53 and p16/(INK4A) and minimal of p21(WAF1/CIP1) expression were observed in G3 tumors. So, low p21(WAF1/CIP1) expression (LI < 7.0%) combined with p16(INK4A) overexpression is considered to be the factor for a poor prognosis in serous ovarian cancer.;The present study has indicated that biomolecular markers of cell proliferation along with traditional clinical and morphologic characteristics can be used for differential diagnostics of ovarian tumors.",
        "Doc_title":"Expression of p53, p21WAF1/CIP1, p16INK4A and Ki-67 proteins in serous ovarian tumors.",
        "Journal":"Experimental oncology",
        "Do_id":"17431389",
        "Doc_ChemicalList":"Biomarkers, Tumor;Cyclin-Dependent Kinase Inhibitor p16;Cyclin-Dependent Kinase Inhibitor p21;Ki-67 Antigen;Tumor Suppressor Protein p53",
        "Doc_meshdescriptors":"Adenocarcinoma;Adult;Aged;Biomarkers, Tumor;Cyclin-Dependent Kinase Inhibitor p16;Cyclin-Dependent Kinase Inhibitor p21;Cystadenocarcinoma, Serous;Female;Gene Expression Regulation, Neoplastic;Humans;Ki-67 Antigen;Middle Aged;Ovarian Neoplasms;Prognosis;Tumor Suppressor Protein p53",
        "Doc_meshqualifiers":"metabolism;metabolism;metabolism;metabolism;pathology;metabolism;metabolism;pathology;metabolism",
        "_version_":1605742790410502145},
      {
        "Doc_abstract":"Salivary rinses have been recently proposed as a valuable resource for the development of epigenetic biomarkers for detection and monitoring of head and neck squamous cell carcinoma (HNSCC). Both salivary rinses collected with and without an exfoliating brush from patients with HNSCC are used in detection of promoter hypermethylation, yet their correlation of promoter hypermethylation has not been evaluated. This study was to evaluate the concordance of promoter hypermethylation between salivary rinses collected with and without an exfoliating brush from patients with HNSCC. METHODOLGY: 57 paired salivary rinses collected with or without an exfoliating brush from identical HNSCC patients were evaluated for promoter hypermethylation status using Quantitative Methylation-Specific PCR. Target tumor suppressor gene promoter regions were selected based on our previous studies describing a panel for HNSCC screening and surveillance, including P16, CCNA1, DCC, TIMP3, MGMT, DAPK and MINT31.;In salivary rinses collected with and without brush, frequent methylation was detected in P16 (8.8% vs. 5.2%), CCNA1 (26.3% vs. 22.8%), DCC (33.3% vs. 29.8%), TIMP3 (31.6% vs. 36.8%), MGMT (29.8% vs. 38.6%), DAPK (14.0% vs. 19.2%), and MINT31 (10.5% vs. 8.8%). Spearman's rank correlation coefficient showed a positive correlation between salivary rinses collected with and without brush for P16 ( = 0.79), CCNA1 ( = 0.61), DCC ( = 0.58), TIMP3 ( = 0.10), MGMT ( = 0.70), DAPK ( = 0.51) and MINT31 ( = 0.72) (P<0.01). The percent agreement of promoter methylation between salivary rinses with brush and without brush were 96.5% for P16, 82.5% for CCNA1, 78.9% for DCC, 59.7% for TIMP3, 84.2% for MGMT, 84.2% for DAPK, and 94.7% for MINT31.;Our study demonstrated strong correlations of gene promoter hypermethylation between salivary rinses collected with and without an exfoliating brush. Salivary rinse collection without using an exfoliating brush may offer a cost effective, rapid, non-invasive, and reliable means for development of epigenetic salivary rinse biomarkers.",
        "Doc_title":"Comparison of promoter hypermethylation pattern in salivary rinses collected with and without an exfoliating brush from patients with HNSCC.",
        "Journal":"PloS one",
        "Do_id":"22438973",
        "Doc_ChemicalList":"Apoptosis Regulatory Proteins;CCNA1 protein, human;Cyclin A1;DNA, Neoplasm;Tissue Inhibitor of Metalloproteinase-3;Tumor Suppressor Proteins;DNA Modification Methylases;MGMT protein, human;Death-Associated Protein Kinases;Calcium-Calmodulin-Dependent Protein Kinases;DNA Repair Enzymes",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Apoptosis Regulatory Proteins;Calcium-Calmodulin-Dependent Protein Kinases;Carcinoma, Squamous Cell;Cyclin A1;DNA Methylation;DNA Modification Methylases;DNA Repair Enzymes;DNA, Neoplasm;Death-Associated Protein Kinases;Epigenesis, Genetic;Female;Genes, DCC;Genes, p16;Head and Neck Neoplasms;Humans;Male;Middle Aged;Promoter Regions, Genetic;Saliva;Tissue Inhibitor of Metalloproteinase-3;Tumor Suppressor Proteins",
        "Doc_meshqualifiers":"genetics;genetics;genetics;genetics;genetics;genetics;genetics;isolation & purification;genetics;chemistry;cytology;genetics;genetics",
        "_version_":1605798179860643840},
      {
        "Doc_abstract":"One copy of the galanin receptor 1 (GALR1) locus on 18q is often deleted and expression is absent in some head and neck squamous cell carcinoma (HNSCC) cell lines. To determine if loss of heterozygosity and hypermethylation might silence the GALR1 gene, promoter methylation status and gene expression were assessed in a large panel of HNSCC cell lines and tumors.;Promoter methylation of GALR1 in 72 cell lines and 100 primary tumor samples was analyzed using methylation-specific PCR. GALR1 expression and methylation status were analyzed further by real-time PCR and bisulfite sequencing analysis.;The GALR1 promoter was fully or partially methylated in 38 of 72 (52.7%) HNSCC cell lines but not in the majority 18 of 20 (90.0%) of nonmalignant lines. GALR1 methylation was also found in 38 of 100 (38%) primary tumor specimens. Methylation correlated with decreased GALR1 expression. In tumors, methylation was significantly correlated with increased tumor size (P = 0.0036), lymph node status (P = 0.0414), tumor stage (P = 0.0037), cyclin D1 expression (P = 0.0420), and p16 methylation (P = 0.0494) and survival (P = 0.045). Bisulfite sequencing of 36 CpG sites upstream of the transcription start site revealed that CpG methylation within transcription factor binding sites correlated with complete suppression of GALR1 mRNA. Treatment with trichostatin A and 5-azacytidine restored GALR1 expression. In UM-SCC-23 cells that have total silencing of GALR1, exogenous GALR1 expression and stimulation with galanin suppressed cell proliferation.;Frequent promoter hypermethylation, gene silencing, association with prognosis, and growth suppression after reexpression support the hypothesis that GALR1 is a tumor suppressor gene in HNSCC.",
        "Doc_title":"Epigenetic inactivation of galanin receptor 1 in head and neck cancer.",
        "Journal":"Clinical cancer research : an official journal of the American Association for Cancer Research",
        "Do_id":"19047085",
        "Doc_ChemicalList":"Biomarkers, Tumor;Receptor, Galanin, Type 1",
        "Doc_meshdescriptors":"Aged;Biomarkers, Tumor;Blotting, Western;DNA Methylation;Epigenesis, Genetic;Female;Gene Expression;Genes, Tumor Suppressor;Head and Neck Neoplasms;Humans;Immunohistochemistry;Loss of Heterozygosity;Male;Promoter Regions, Genetic;Receptor, Galanin, Type 1;Reverse Transcriptase Polymerase Chain Reaction;Transfection",
        "Doc_meshqualifiers":"genetics;genetics;genetics",
        "_version_":1605783437694730240},
      {
        "Doc_abstract":"A phase II clinical trial evaluating the feasibility and outcome of treating locally advanced head and neck squamous cell carcinoma (HNSCC) with accelerated radiotherapy, the hypoxic modifier nimorazole and weekly cisplatin.;A total of 227 patients with stage III or IV HNSCC of the larynx, oropharynx, hypopharynx, or oral cavity where included between January 2007 and December 2010. The prescribed radiotherapy (RT) dose was 66-68 Gy in 2 Gy fractions, 6 F/W. The hypoxic radiosensitiser nimorazole was given orally at a dose of 1200 mg/m(2) before each fraction. Concomitant cisplatin (40 mg/m(2)) i.v. was given once a week for a maximum of six cycles. Outcome data were evaluated in terms of loco-regional tumour control (LRC), event-free survival (EFS) and overall survival (OS). Morbidity data were evaluated based on the DAHANCA routine registration. Human papillomavirus (HPV)-status was estimated by immunohistochemical staining of p16.;Included were 178 (78%) men and 49 (22%) women with a median age of 57 years. All except five patients received RT as prescribed. At least five series of cisplatin was given to 164 (72%) of the patients, and 149 patients (66%) received the full dose of nimorazole. The five-year actuarial LRC, EFS and OS rates were 80%, 67% and 72%, respectively. The LRC rates according to site were: oropharynx: 88%, larynx: 77%, hypopharynx 72% and oral cavity 49%, respectively. HPV/p16 staining was obtained in 141 of the 150 oropharyngeal cancers. Of these, 112 (79%) were p16 pos and 29 (21%) were p16 neg. LRC for the p16 neg oropharyngeal cancers was poorer than for the p16 pos (74% vs. 91%; p = 0.02). Tube feeding during treatment was necessary for 146 (64%) patients. At 12 months this number was reduced to 6%.;The treatment was tolerable in this cohort of locally advanced HNSCC patients. Acute and late toxicity was comparable to similar studies of chemoradiotherapy, and the outcome superior to the data reported in the literature. This strongly indicates that RT of advanced head and neck cancer must include as well hypoxic modification, accelerated fractionation as chemoradiotherapy to yield optimal outcome.",
        "Doc_title":"Locally advanced head and neck cancer treated with accelerated radiotherapy, the hypoxic modifier nimorazole and weekly cisplatin. Results from the DAHANCA 18 phase II study.",
        "Journal":"Acta oncologica (Stockholm, Sweden)",
        "Do_id":"25629651",
        "Doc_ChemicalList":"Nimorazole;Cisplatin",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Antineoplastic Combined Chemotherapy Protocols;Carcinoma, Squamous Cell;Chemoradiotherapy;Cisplatin;Disease-Free Survival;Female;Head and Neck Neoplasms;Humans;Male;Middle Aged;Nimorazole",
        "Doc_meshqualifiers":"administration & dosage;therapeutic use;drug therapy;mortality;radiotherapy;adverse effects;methods;administration & dosage;adverse effects;drug therapy;mortality;radiotherapy;administration & dosage;adverse effects",
        "_version_":1605792049061167104},
      {
        "Doc_abstract":"The present study aimed to explore the etiological role of human papillomavirus (HPV) in tonsillar squamous cell carcinoma (TSCC).;HPV status, including viral load and E6 variants, and the expression of P53, p16(INK4A), and FANCD2, in tissues of TSCC (n=24) and tonsillitis (n=31) were investigated.;The frequency of high-risk HPV (HPV-16) in TSCCs (42%) was higher than that of tonsillitis (16%). HPV-16 genome was partially or fully integrated in all HPV-16-positive TSCCs. However, the viral genome was partially integrated in three out of five HPV-16-positive tonsillitis cases (p=0.037). HPV-16-positive TSCCs showed a higher frequency of p16(INK4A) expression than HPV-16-negative TSCCs and tonsillitis (p=0.011). Regardless of HPV status, TSCCs had a lower expression of FANCD2 than tonsillitis (p=0.008).;The present study supports the etiological role of HPV-16 in the development of TSCC, and p16(INK4A) overexpression can be applied as a surrogate marker for the detection of high-risk-HPV in TSCC.",
        "Doc_title":"Molecular Pathogenesis of Human Papillomavirus Type 16 in Tonsillar Squamous Cell Carcinoma.",
        "Journal":"Anticancer research",
        "Do_id":"26637879",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Aged;Carcinoma, Squamous Cell;Human papillomavirus 16;Humans;Middle Aged;Tonsillar Neoplasms",
        "Doc_meshqualifiers":"pathology;virology;genetics;pathology;virology",
        "_version_":1605751298846621696},
      {
        "Doc_abstract":"Overexpression of p16(INK4a) independent of the presence of E6-E7 oncoproteins of high-risk papillomaviruses has been identified in bladder carcinoma in situ lesions with or without concurrent papillary or invasive high-grade (HG) urothelial carcinoma. As p16(INK4a) and Ki-67 co-expression clearly indicates deregulation of the cell cycle, the aim of this study was to investigate the frequency of p16(INK4a) /Ki-67 dual labelling in urinary cytology samples.;Immunolabelling was performed in demounted, destained Papanicolaou slides after ThinPrep() processing. A total of 84 urinary cytology samples (18 negative, 10 low grade, 19 atypical urothelial cells and 37 high grade) were analysed for p16(INK4a) /Ki-67 co-expression. We assessed underlying urothelial malignancy with cystoscopy, histopathology and follow-up data in every case.;Compared with raw histopathological results, p16 (INK4a) /Ki-67 dual labelling was observed in 48 out of 55 (87.3%) HG lesions and in 11 out of 29 (37.9%) negative, papillary urothelial neoplasia of low malignant potential or low-grade carcinomas (P=0.05). All cases with high-grade/malignant cytology were dual labelled. Sixteen out of 17 (94.1%) carcinoma in situ cases and eight out of 14 (57.1%) cases with atypical urothelial cells matching with HG lesions were dual labelled. Extended follow-up allowed three cases of progression to be diagnosed in dual-labelled cases with negative/low-grade cytology results after a 9- to 11-months delay.;The data show that p16(INK4a) /Ki-67 co-expression allows most HG cancer cells to be detected initially and in the follow-up period. Additional studies are needed in order to determine whether dual labelling can be used as a triage tool for atypical urothelial cells in the urine.",
        "Doc_title":"p16(INK4a) /Ki-67 dual labelling as a marker for the presence of high-grade cancer cells or disease progression in urinary cytopathology.",
        "Journal":"Cytopathology : official journal of the British Society for Clinical Cytology",
        "Do_id":"23003335",
        "Doc_ChemicalList":"Biomarkers, Tumor;Cyclin-Dependent Kinase Inhibitor p16;Ki-67 Antigen",
        "Doc_meshdescriptors":"Aged;Biomarkers, Tumor;Cyclin-Dependent Kinase Inhibitor p16;Cytodiagnosis;Female;Gene Expression Regulation, Neoplastic;Humans;Ki-67 Antigen;Male;Middle Aged;Neoplasm Staging;Papillomaviridae;Pregnancy;Urinary Bladder Neoplasms",
        "Doc_meshqualifiers":"urine;biosynthesis;urine;biosynthesis;urine;isolation & purification;diagnosis;pathology;urine;virology",
        "_version_":1605742727930052608},
      {
        "Doc_abstract":"The human papillomavirus (HPV) is an important cause of some head and neck squamous cell carcinomas (HNSCCs), but its role in cancer of the lateral tongue is debatable. Suspicion of HPV causation is heightened when these lateral tongue carcinomas arise in patients that are young and/or have never smoked. The purpose of this study was to determine the incidence of transcriptionally active high risk HPV in these tumors, with a particular emphasis on non-smoking patients who are often presumed to have HPV-positive tumors.;We evaluated 78 HNSCCs of the lateral tongue for the presence of HPV using p16 immunohistochemistry and an RNA in situ hybridization assay targeting HPV E6/E7 mRNA. The study population was enriched for patients without traditional risk factors such as smoking and drinking.;P16 overexpression was detected in 9 (11.5%) of 78 cases, but HPV E6/E7 mRNA transcripts were detected in only 1 (1.3%) case (positive predictive value of p16 staining for the presence of transcriptionally active HPV=0.12). HPV mRNA transcripts were not detected in any patient under 40 (n=11), or in patients who had never smoked (n=44), had quit smoking (n=15), and/or were only light consumers of alcohol (n=57).;HPV is not detected in the vast majority of lateral tongue carcinomas. In light of the observation that HPV plays little if any role in the development of these cancers, routine HPV testing is unwarranted , even for patients without traditional risk factors. P16 staining is not a reliable marker for the presence of transcriptionally active HPV at this particular anatomic site.",
        "Doc_title":"Human papillomavirus (HPV) status of non-tobacco related squamous cell carcinomas of the lateral tongue.",
        "Journal":"Oral oncology",
        "Do_id":"24485566",
        "Doc_ChemicalList":"RNA, Messenger",
        "Doc_meshdescriptors":"Adult;Carcinoma, Squamous Cell;Female;Humans;Male;Papillomaviridae;RNA, Messenger;Tongue Neoplasms",
        "Doc_meshqualifiers":"virology;genetics;isolation & purification;genetics;virology",
        "_version_":1605746828258574338},
      {
        "Doc_abstract":"Phosphorylation of the product of the retinoblastoma susceptibility gene (Rb) physiologically inactivates its growth-suppressive properties. Rb phosphorylation is mediated by cyclin-dependent kinases (CDKs), whose activity is enhanced by cyclins and inhibited by CDK inhibitors. p16(INK4A) is a member of a family of inhibitors specific for CDK4 and CDK6. p16(INK4A) is deleted and inactivated in a wide variety of human malignancies, including familial melanomas and pancreatic carcinoma syndromes, indicating that it is an authentic human tumor suppressor. Although one mechanism for its tumor suppression may be prevention of Rb phosphorylation, thereby causing G1 arrest, many normal cell types express p16(INK4A), and are still able to traverse the cell cycle. In a search for other mechanisms, we have found that p16(INK4A) is required for p53-independent G1 arrest in response to DNA-damaging agents, including topoisomerase I and II inhibitors. Thus, like other tumor suppressors, p16(INK4A) plays an essential role in a DNA-damage checkpoint that leads to cell cycle arrest.",
        "Doc_title":"The physiology of p16(INK4A)-mediated G1 proliferative arrest.",
        "Journal":"Cell biochemistry and biophysics",
        "Do_id":"11325039",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;Tumor Suppressor Protein p53",
        "Doc_meshdescriptors":"Animals;Cell Cycle;Cyclin-Dependent Kinase Inhibitor p16;DNA Damage;G1 Phase;Genes, p16;Humans;Neoplasms;Tumor Suppressor Protein p53",
        "Doc_meshqualifiers":"physiology;genetics;physiology;genetics;metabolism",
        "_version_":1605879566978514944},
      {
        "Doc_abstract":"Human papillomavirus (HPV) types 16 and 18 are associated with cervical carcinogenesis. This is possibly achieved through an interaction between HPV oncogenic proteins and some cell cycle regulatory genes. However, the exact pathogenetic mechanisms are not well defined yet.;We investigated 110 subjects (43 invasive squamous cell carcinoma (ISCC), 38 CIN III, 11 CIN II, 18 CIN I) confirmed to be positive for HPV16 and/or 18 as well as 20 normal cervical tissue (NCT) samples for abnormal expression of cyclin D1, cyclin E, CDK4, cyclin inhibitors (p21 (waf), p27, p16 (INK4A)) and Ki-67 using immunohistochemistry and differential PCR techniques.;There was a significant increase in the expression of Ki-67, cyclin E, CDK4, p16 (INK4A) (p=0.003, 0.001, 0.001) and a significant decrease in p27 (Kip1) from NCT to ISCC (p=0.003). There was a significant correlation between altered expression of p27 (KIP1) and p16(INK4A) (p<0.001), cyclin D1 and CDK4 (p=0.001), cyclin E and p27 (Kip1) (p=0.011) in all studied groups. In ISCC, there was significant relationship between standard clinicopathological prognostic factors and high Ki-67 index , increased cyclin D1 and cyclin E, reduced p27 (Kip1) and p21 (waf).;1) Aberrations involving p27 (KIP1), cyclin E, CDK4 and p16 (INK4A) are considered early events in HPV 16 and 18-associated cervical carcinogenesis (CINI & II), whereas cyclin D1 aberrations are late events (CINIII & ISCC) 2) Immunohistochemical tests for p16 (INK4A) and cyclin E could help in early diagnosis of cervical carcinoma 3) Only FIGO stage, cyclin D1, p27 (Kip1) and Ki-67 are independent prognostic factors that might help in predicting outcome of cervical cancer patients.",
        "Doc_title":"The role of cyclins and cyclins inhibitors in the multistep process of HPV-associated cervical carcinoma.",
        "Journal":"Journal of the Egyptian National Cancer Institute",
        "Do_id":"18301453",
        "Doc_ChemicalList":"Cyclin E;Cyclin-Dependent Kinase Inhibitor Proteins;Cyclins;Ki-67 Antigen;Cyclin-Dependent Kinase Inhibitor p27;CDC2 Protein Kinase;CDK4 protein, human;Cyclin-Dependent Kinase 4;Cyclin-Dependent Kinases",
        "Doc_meshdescriptors":"CDC2 Protein Kinase;Carcinoma, Squamous Cell;Cervical Intraepithelial Neoplasia;Cyclin E;Cyclin-Dependent Kinase 4;Cyclin-Dependent Kinase Inhibitor Proteins;Cyclin-Dependent Kinase Inhibitor p27;Cyclin-Dependent Kinases;Cyclins;Female;Gene Expression Regulation, Neoplastic;Genes, bcl-1;Genes, p16;Human papillomavirus 16;Human papillomavirus 18;Humans;Ki-67 Antigen;Papillomavirus Infections;Tumor Cells, Cultured;Uterine Cervical Neoplasms",
        "Doc_meshqualifiers":"genetics;metabolism;diagnosis;enzymology;genetics;pathology;diagnosis;enzymology;genetics;pathology;genetics;metabolism;genetics;metabolism;genetics;metabolism;physiology;genetics;metabolism;genetics;metabolism;physiology;genetics;metabolism;physiology;genetics;metabolism;complications;enzymology;genetics;diagnosis;enzymology;genetics;pathology",
        "_version_":1605774769974673408},
      {
        "Doc_abstract":"Stable silencing of the INK4b-ARF-INK4a tumor suppressor locus occurs in a variety of human cancers, including malignant rhabdoid tumors (MRTs). MRTs are extremely aggressive cancers caused by the loss of the hSNF5 subunit of the SWI/SNF chromatin-remodeling complex. We found previously that, in MRT cells, hSNF5 is required for p16(INK4a) induction, mitotic checkpoint activation, and cellular senescence. Here, we investigated how the balance between Polycomb group (PcG) silencing and SWI/SNF activation affects epigenetic control of the INK4b-ARF-INK4a locus in MRT cells. hSNF5 reexpression in MRT cells caused SWI/SNF recruitment and activation of p15(INK4b) and p16(INK4a), but not of p14(ARF). Gene activation by hSNF5 is strictly dependent on the SWI/SNF motor subunit BRG1. SWI/SNF mediates eviction of the PRC1 and PRC2 PcG silencers and extensive chromatin reprogramming. Concomitant with PcG complex removal, the mixed lineage leukemia 1 (MLL1) protein is recruited and active histone marks supplant repressive ones. Strikingly, loss of PcG complexes is accompanied by DNA methyltransferase DNMT3B dissociation and reduced DNA methylation. Thus, various chromatin states can be modulated by SWI/SNF action. Collectively, these findings emphasize the close interconnectivity and dynamics of diverse chromatin modifications in cancer and gene control.",
        "Doc_title":"SWI/SNF mediates polycomb eviction and epigenetic reprogramming of the INK4b-ARF-INK4a locus.",
        "Journal":"Molecular and cellular biology",
        "Do_id":"18332116",
        "Doc_ChemicalList":"CDKN2B protein, human;Chromosomal Proteins, Non-Histone;Cyclin-Dependent Kinase Inhibitor p15;Cyclin-Dependent Kinase Inhibitor p16;DNA Primers;DNA, Neoplasm;DNA-Binding Proteins;Nuclear Proteins;Polycomb-Group Proteins;Repressor Proteins;SMARCB1 Protein;SMARCB1 protein, human;Transcription Factors;SMARCA4 protein, human;DNA Helicases",
        "Doc_meshdescriptors":"Base Sequence;Cell Line, Tumor;Chromosomal Proteins, Non-Histone;Cyclin-Dependent Kinase Inhibitor p15;Cyclin-Dependent Kinase Inhibitor p16;DNA Helicases;DNA Methylation;DNA Primers;DNA, Neoplasm;DNA-Binding Proteins;Epigenesis, Genetic;Gene Silencing;Humans;Nuclear Proteins;Polycomb-Group Proteins;Promoter Regions, Genetic;Repressor Proteins;Rhabdoid Tumor;SMARCB1 Protein;Transcription Factors",
        "Doc_meshqualifiers":"genetics;metabolism;genetics;metabolism;genetics;metabolism;genetics;metabolism;genetics;chemistry;genetics;genetics;metabolism;genetics;metabolism;genetics;metabolism;genetics;metabolism;genetics;metabolism",
        "_version_":1605892804164190208},
      {
        "Doc_abstract":"Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer worldwide. To explore the genetic origins of this cancer, we used whole-exome sequencing and gene copy number analyses to study 32 primary tumors. Tumors from patients with a history of tobacco use had more mutations than did tumors from patients who did not use tobacco, and tumors that were negative for human papillomavirus (HPV) had more mutations than did HPV-positive tumors. Six of the genes that were mutated in multiple tumors were assessed in up to 88 additional HNSCCs. In addition to previously described mutations in TP53, CDKN2A, PIK3CA, and HRAS, we identified mutations in FBXW7 and NOTCH1. Nearly 40% of the 28 mutations identified in NOTCH1 were predicted to truncate the gene product, suggesting that NOTCH1 may function as a tumor suppressor gene rather than an oncogene in this tumor type.",
        "Doc_title":"Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1.",
        "Journal":"Science (New York, N.Y.)",
        "Do_id":"21798897",
        "Doc_ChemicalList":"Cell Cycle Proteins;Codon, Nonsense;F-Box Proteins;NOTCH1 protein, human;Receptor, Notch1;Ubiquitin-Protein Ligases;FBXW7 protein, human",
        "Doc_meshdescriptors":"Carcinoma;Carcinoma, Squamous Cell;Cell Cycle Proteins;Codon, Nonsense;Exons;F-Box Proteins;Gene Dosage;Genes, Tumor Suppressor;Genes, p53;Head and Neck Neoplasms;Humans;INDEL Mutation;Mutation;Mutation, Missense;Neoplasms, Squamous Cell;Oligonucleotide Array Sequence Analysis;Oncogenes;Papillomaviridae;Papillomavirus Infections;Receptor, Notch1;Sequence Analysis, DNA;Smoking;Tobacco;Ubiquitin-Protein Ligases",
        "Doc_meshqualifiers":"drug therapy;genetics;virology;genetics;genetics;drug therapy;genetics;virology;drug therapy;genetics;virology;isolation & purification;virology;chemistry;genetics;genetics",
        "_version_":1605759818912497664},
      {
        "Doc_abstract":"Traditional Chinese medicine is recently emerged as anti-cancer therapy or adjuvant with reduced side-effects and improved quality of life. In the present study, an active ingredient, 1,6,7-trihydroxyxanthone (THA), derived from Goodyera oblongifolia was found to strongly suppress cell growth and induce apoptosis in liver cancer cells. MicroRNAs are a group of small non-coding RNAs that regulate gene expression at post-transcriptional levels. Our results demonstrated that miR-218 was up-regulated and oncogene Bmi-1 was down-regulated by THA treatment. Further investigation showed that THA-induced-miR-218 up-regulation could lead to activation of tumor suppressor P16(Ink4a) and P14(ARF), the main down-stream targets of Bmi-1. In conclusion, THA might be a potential anti-cancer drug candidate, at least in part, through the activation of miR-218 and suppression of Bmi-1 expression. ",
        "Doc_title":"MiR-218-targeting-Bmi-1 mediates the suppressive effect of 1,6,7-trihydroxyxanthone on liver cancer cells.",
        "Journal":"Apoptosis : an international journal on programmed cell death",
        "Do_id":"25416134",
        "Doc_ChemicalList":"1,6,7-trihydroxyxanthone;Antineoplastic Agents;BMI1 protein, human;MIRN218 microRNA, human;MicroRNAs;Plant Extracts;Xanthones;Polycomb Repressive Complex 1",
        "Doc_meshdescriptors":"Antineoplastic Agents;Apoptosis;Cell Line, Tumor;Cell Proliferation;Humans;Liver Neoplasms;MicroRNAs;Orchidaceae;Plant Extracts;Polycomb Repressive Complex 1;Xanthones",
        "Doc_meshqualifiers":"pharmacology;drug effects;drug effects;metabolism;pathology;therapy;genetics;metabolism;chemistry;pharmacology;metabolism;chemistry;pharmacology",
        "_version_":1605830747554316288},
      {
        "Doc_abstract":"In human cutaneous malignant melanoma, a predominance of activated mutations in the N-ras gene has been documented. To obtain a mouse model most closely mimicking the human disease, a transgenic mouse line was generated by targeting expression of dominant-active human N-ras (N-RasQ61K) to the melanocyte lineage by tyrosinase regulatory sequences (Tyr::N-RasQ61K). Transgenic mice show hyperpigmented skin and develop cutaneous metastasizing melanoma. Consistent with the tumor suppressor function of the INK4a locus that encodes p16INK4A and p19(ARF), >90% of Tyr::N-RasQ61K INK4a-/- transgenic mice develop melanoma at 6 months. Primary melanoma tumors are melanotic, multifocal, microinvade the epidermis or epithelium of hair follicles, and disseminate as metastases to lymph nodes, lung, and liver. Primary melanoma can be transplanted s.c. in nude mice, and if injected i.v. into NOD/SCID mice colonize the lung. In addition, primary melanomas and metastases contain cells expressing the stem cell marker nestin suggesting a hierarchical structure of the tumors comprised of primitive nestin-expressing precursors and differentiated cells. In conclusion, a novel mouse model with melanotic and metastasizing melanoma was obtained by recapitulating genetic lesions frequently found in human melanoma.",
        "Doc_title":"Metastasizing melanoma formation caused by expression of activated N-RasQ61K on an INK4a-deficient background.",
        "Journal":"Cancer research",
        "Do_id":"15899789",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;Monophenol Monooxygenase;ras Proteins",
        "Doc_meshdescriptors":"Animals;Cyclin-Dependent Kinase Inhibitor p16;Female;Gene Expression Regulation, Neoplastic;Genes, ras;Liver Neoplasms, Experimental;Lung Neoplasms;Lymph Nodes;Lymphatic Metastasis;Male;Melanoma, Experimental;Mice;Mice, Inbred BALB C;Mice, Inbred C57BL;Mice, Inbred DBA;Mice, SCID;Mice, Transgenic;Monophenol Monooxygenase;Promoter Regions, Genetic;ras Proteins",
        "Doc_meshqualifiers":"deficiency;genetics;genetics;metabolism;secondary;genetics;metabolism;secondary;pathology;genetics;metabolism;pathology;secondary;biosynthesis;genetics;biosynthesis;genetics",
        "_version_":1605875824833069056},
      {
        "Doc_abstract":"To determine the prognostic influence of p16(INK4a) immunohistochemistry on the survival of resectable oropharyngeal carcinomas (OPSCC).;Retrospective pathologic evaluation of a prospective single-arm cohort study at a tertiary referral center.;There were 48 patients with resectable OPSCC who consented for transoral robotic surgery (TORS) and banked tissue specimen for assessment. TORS was with or without adjuvant radiation or chemoradiation. Main outcome measures were p16(INK4a) status, human papillomavirus status, local-regional disease control, and overall, disease-specific, and disease-free survival.;p16(INK4a) and HPV positivity were identified in 73% and 74% of patients respectively. With a median follow-up of 38.8 months (2.5-63.3 months), only one local-regional relapse has occurred in both the p16(INK4a)-positive and p16(INK4a) -negative cohorts. No disease-specific, disease-free, and overall survival differences were observed between p16(INK4a) -positive and p16(INK4a)-negative patients (P = .446, P = .277, P = .643, respectively).;p16(INK4a) was not prognostic in resectable OPSCC when treated with an initial TORS approach.",
        "Doc_title":"Transoral robotic surgery and adjuvant therapy for oropharyngeal carcinomas and the influence of p16 INK4a on treatment outcomes.",
        "Journal":"The Laryngoscope",
        "Do_id":"22588642",
        "Doc_ChemicalList":"Biomarkers, Tumor;Cyclin-Dependent Kinase Inhibitor p16",
        "Doc_meshdescriptors":"Biomarkers, Tumor;Carcinoma, Squamous Cell;Cyclin-Dependent Kinase Inhibitor p16;Disease-Free Survival;Head and Neck Neoplasms;Humans;Immunohistochemistry;Oropharyngeal Neoplasms;Papillomavirus Infections;Prognosis;Radiotherapy, Adjuvant;Retrospective Studies;Robotics;Treatment Outcome",
        "Doc_meshqualifiers":"metabolism;metabolism;mortality;pathology;surgery;virology;metabolism;metabolism;mortality;pathology;surgery;virology;metabolism;mortality;pathology;surgery;virology;metabolism;methods",
        "_version_":1605899253386838016},
      {
        "Doc_abstract":"The p16IN4/CDKN2/MTS1 gene encodes two structurally different proteins: a cyclin-dependent kinase inhibitor called p16INK4a, which regulates retinoblastoma protein-dependent G1 arrest, and a cell cycle inhibitor designated p19ARF, which arrests cell growth in G1-S and also in G2-M. Whereas inactivation of p16INK4a has been described as a frequent event in lung cancer, the current function of p19ARF is still poorly understood. We have examined the expression of the human p19ARF (hp19ARF) protein in a large series of lung cancers using immunohistochemistry and showed that the protein was more frequently lost in high-grade neuroendocrine (NE) lung tumors (large cell NE carcinoma and small cell lung carcinoma; 51 of 78, 65%) than it was in non-small cell lung cancer (25 of 101, 25%). No deleterious mutation was found in exons 1beta and 2 of hp19ARF in those NE tumors with negative immunoreactivity, and a beta transcript was detected in the majority of them. Concomitant absence of hp19ARF and retinoblastoma proteins was frequently detected in high-grade NE lung tumors, whereas no relationship could be found between the status of hp19ARF and p53 proteins in those tumors. These results are consistent with an alternative growth suppressor function for hp19ARF in NE lung cancer that is distinct from that of p16INK4a. Moreover, the frequent uncoupling between the beta transcript and the hp19ARF protein suggests a novel mechanism of inactivation at the translational level.",
        "Doc_title":"The human p19ARF protein encoded by the beta transcript of the p16INK4a gene is frequently lost in small cell lung cancer.",
        "Journal":"Cancer research",
        "Do_id":"9731504",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;Nuclear Proteins;Proteins;Proto-Oncogene Proteins;RNA, Messenger;Retinoblastoma Protein;Tumor Suppressor Protein p14ARF;Tumor Suppressor Protein p53;MDM2 protein, human;Proto-Oncogene Proteins c-mdm2",
        "Doc_meshdescriptors":"Carcinoma, Small Cell;Chromosome Mapping;Cyclin-Dependent Kinase Inhibitor p16;Exons;Humans;Immunohistochemistry;Lung;Lung Neoplasms;Nuclear Proteins;Polymorphism, Single-Stranded Conformational;Proteins;Proto-Oncogene Proteins;Proto-Oncogene Proteins c-mdm2;RNA, Messenger;Retinoblastoma Protein;Tumor Suppressor Protein p14ARF;Tumor Suppressor Protein p53",
        "Doc_meshqualifiers":"chemistry;analysis;genetics;chemistry;chemistry;analysis;genetics;physiology;analysis;analysis;analysis",
        "_version_":1605818764239044611},
      {
        "Doc_abstract":"Cancer is one of the most common and severe problems in clinical medicine, and nervous system tumors represent about 2% of the types of cancer. The central role of the nervous system in the maintenance of vital activities and the functional consequences of the loss of neurons can explain how severe brain cancers are. The cell cycle is a highly complex process, with a wide number of regulatory proteins involved, and such proteins can suffer alterations that transform normal cells into malignant ones. The INK4 family members (CDK inhibitors) are the cell cycle regulators that block the progression of the cycle through the R point, causing an arrest in G1 stage. The p14ARF (alternative reading frame) gene is a tumor suppressor that inhibits p53 degradation during the progression of the cell cycle. The PTEN gene is related to the induction of growth suppression through cell cycle arrest, to apoptosis and to the inhibition of cell adhesion and migration. The purpose of the present study was to assess the mutational state of the genes p14ARF, p15INK4b, p16INK4a, and PTEN in 64 human nervous system tumor samples. Homozygous deletions were found in exon 2 of the p15INK4b gene and exon 3 of the p16INK4a gene in two schwannomas. Three samples showed a guanine deletion (63 codon) which led to a loss of heterozygosity in the p15 gene, and no alterations could be seen in the PTEN gene. Although the group of patients was heterogeneous, our results are in accordance with other different studies that indicate that homozygous deletion and loss of heterozygosity in the INK4 family members are frequently observed in nervous system tumors.",
        "Doc_title":"Mutational analysis of genes p14ARF, p15INK4b, p16INK4a, and PTEN in human nervous system tumors.",
        "Journal":"Genetics and molecular research : GMR",
        "Do_id":"18551412",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p15;Cyclin-Dependent Kinase Inhibitor p16;Tumor Suppressor Protein p14ARF;PTEN Phosphohydrolase;PTEN protein, human",
        "Doc_meshdescriptors":"Cyclin-Dependent Kinase Inhibitor p15;Cyclin-Dependent Kinase Inhibitor p16;DNA Mutational Analysis;Gene Deletion;Homozygote;Humans;Loss of Heterozygosity;Nervous System Neoplasms;PTEN Phosphohydrolase;Polymerase Chain Reaction;Tumor Suppressor Protein p14ARF",
        "Doc_meshqualifiers":"genetics;genetics;methods;genetics;pathology;genetics;genetics",
        "_version_":1605755976004141056},
      {
        "Doc_abstract":"Nasopharyngeal carcinoma (NPC) is the most tightly Epstein-Barr virus (EBV)-associated tumour. The EBV oncoprotein latent membrane protein 1 (LMP1) is frequently expressed in NPC tumours and may play a role in the genesis of the disease. NPC tumours often exhibit loss of expression (by deletion or methylation) of the INK4a locus, which encodes the tumour suppressor genes p16INK4a and p14ARF. To investigate the contribution of LMP1 and INK4a loss to tumourigenesis, skin chemical carcinogenesis was conducted using PyLMP1 and INK4a null mice. Surprisingly, INK4a null mice developed significantly fewer papillomas than wild-type mice, nevertheless, the papillomas that did develop grew faster and converted more rapidly to carcinoma than controls. This indicates that while loss of the INK4a locus plays an important role in the later stages of tumourigenesis, initially its loss inhibits papilloma formation. Conversely, LMP1 promoted papilloma formation but paradoxically inhibited papilloma growth. Using cross-breeds, it was found that LMP1 cooperates with loss of the INK4a locus during epithelial tumourigenesis. The expression of LMP1 overcame the inhibition of papilloma formation observed in INK4a null mice, whilst the loss of the INK4a locus counteracted the inhibition of papilloma growth rate found in PyLMP1 mice. This suggests that LMP1 mediates the inhibition of papilloma growth via one or both of the INK4a locus products. Intriguingly, mice heterozygous for INK4a loss showed lesion growth rates intermediate between wild-type and null, demonstrative of haploinsufficiency. We propose that LMP1 acts at the early stages in carcinogenesis to promote the development of benign tumours and that early reduction of INK4a locus expression allows these lesions to expand in size. In addition, loss of the INK4a locus accelerates the development of a more aggressive lesion. Conversely, complete loss of the INK4a locus in an otherwise normal cell might inhibit lesion formation.",
        "Doc_title":"The latent membrane protein 1 of Epstein-Barr virus and loss of the INK4a locus: paradoxes resolve to cooperation in carcinogenesis in vivo.",
        "Journal":"Carcinogenesis",
        "Do_id":"12807717",
        "Doc_ChemicalList":"Carcinogens;Cyclin-Dependent Kinase Inhibitor p16;DNA Primers;EBV-associated membrane antigen, Epstein-Barr virus;Viral Matrix Proteins;9,10-Dimethyl-1,2-benzanthracene;DNA",
        "Doc_meshdescriptors":"9,10-Dimethyl-1,2-benzanthracene;Animals;Blotting, Western;Carcinogens;Cell Differentiation;Cell Division;Cell Transformation, Neoplastic;Cyclin-Dependent Kinase Inhibitor p16;DNA;DNA Primers;Disease Progression;Disease Susceptibility;Epidermis;Epithelial Cells;Epstein-Barr Virus Infections;Herpesvirus 4, Human;Humans;Mice;Mice, Knockout;Mice, Transgenic;Nasopharyngeal Neoplasms;Papilloma;Polymerase Chain Reaction;Skin Neoplasms;Viral Matrix Proteins",
        "Doc_meshqualifiers":"toxicity;toxicity;drug effects;drug effects;deficiency;genetics;metabolism;metabolism;chemistry;cytology;drug effects;virology;cytology;drug effects;virology;virology;genetics;metabolism;chemistry;chemically induced;etiology;virology;chemically induced;etiology;virology;physiology",
        "_version_":1605902557270507520},
      {
        "Doc_abstract":"A standardized assay to determine the HPV status of head and neck squamous cell carcinoma (HNSCC) specimens has not yet been established, particularly for cytologic samples. The goal of this study was to determine whether the hybrid capture-2 (HC-2) assay, already widely used for the detection of high risk HPV in cervical brushings, is applicable to cytologic specimens obtained from patients with suspected HNSCCs.;Fine needle aspirates (FNA) of cervical lymph nodes were pre-operatively obtained from patients with suspected HNSCCs and evaluated for the presence of HPV using the HC-2 assay. HPV analysis was performed on the corresponding resected tissue specimens using p16 immunohistochemistry (IHC) and HR-HPV in situ hybridization (ISH). A cost analysis was performed using the Center for Medicare & Medicaid Services.;HPV status of the cervical lymph node metastases was correctly classified using the HC-2 assay in 84% (21/25) of cases. Accuracy was improved to 100% when cytologic evaluation confirmed the presence of cancer cells in the test samples. The estimated cost savings to CMS using the HC-2 assay ranged from $113.74 to $364.63 per patient.;HC-2 is a reliable method for determining the HPV status of HNSCCs. Its application to HNSCCs may reduce costs by helping to localize the primary site during the diagnostic work-up as well as decrease the interval time of determining the HPV status which would be relevant for providing prognostic information to the patient as well as determining eligibility for clinical trials targeting this unique patient population.",
        "Doc_title":"Human papillomavirus status of head and neck cancer as determined in cytologic specimens using the hybrid-capture 2 assay.",
        "Journal":"Oral oncology",
        "Do_id":"24630260",
        "Doc_ChemicalList":"DNA, Viral",
        "Doc_meshdescriptors":"Alphapapillomavirus;Biopsy, Fine-Needle;DNA, Viral;Head and Neck Neoplasms;Humans;In Situ Hybridization;Lymph Nodes",
        "Doc_meshqualifiers":"genetics;isolation & purification;genetics;pathology;virology;virology",
        "_version_":1605783223443390464},
      {
        "Doc_abstract":"To study the relationship between hepatitis B virus X (HBx) protein and DNA methylation of p16(INK4a) and the role of HBx in the  carcinogenesis of hepatocellular carcinoma.;Eukaryonic expression vectors pcDNA3.1B-HBx and pcDNA3.1B were transduced into Chang  liver cells by using Lipofectamine 2000 to establish the Chang-HBx liver cell line (HBx expression) and Chang-vector liver cell line (non-HBx  expression). RT-PCR and Western blot were used to test the expression of p16(INK4a) in the two cell lines. The level of p16(INK4a) promoter methylation  was tested by methylation specific PCR (MSP). The proliferation curves were drew by CCK-8, and S-phase in cell cycle and apoptosis were observed by  flow cytometry.;Hypermethylation of p16 can be mediated by HBx, which decreases the expression of mRNA and protein of p16. Chang-HBx  cells grow faster. Chang-HBx cells have much higher S-phase population (28.96% vs. 21.53%, P<0.001; 28.96% vs. 21.5%, P<0.001) and lower apoptosis  rate (2.71% vs. 3.69%, P<0.001; 2.71% vs. 3.36%, P<0.001) than Chang-vector cells and Chang cells respectively.;p16(INK4a) expression  was repressed by HBx protein via DNA methylation of p16(INK4a), which can induce the malignant transformation tendency of Chang cells.",
        "Doc_title":"[Hepatitis B virus X protein induces malignant transformation tendency of Chang liver cells involving p16(INK4a) hypermethylation].",
        "Journal":"Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences",
        "Do_id":"23247461",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;Trans-Activators;hepatitis B virus X protein",
        "Doc_meshdescriptors":"Carcinoma, Hepatocellular;Cell Line;Cell Transformation, Neoplastic;Cyclin-Dependent Kinase Inhibitor p16;DNA Methylation;Hepatitis B, Chronic;Hepatocytes;Humans;Trans-Activators;Transfection",
        "Doc_meshqualifiers":"genetics;pathology;virology;genetics;genetics;metabolism;genetics;pathology;virology;cytology;genetics",
        "_version_":1605822742258515968},
      {
        "Doc_abstract":"The expression of p16(INK4a) has been reported to induce cell-cycle arrest and cellular senescence. The p16(INK4a) expression has never been examined in human mast cells and mastocytosis. We immunohistologically examined the expression of p16(INK4a) and tryptase in 5 normal human skin and 4 mastocytosis. In normal mast cells, only 5.9  3.4 (mean  standard deviation) % of tryptase-positive mast cells coexpressed p16(INK4a). However, significantly higher percentage (86.0  14.1%) of tryptase-positive tumor cells was immunoreactive to p16(INK4a) in all of 4 mastocytosis. The p16(INK4a) overexpression may induce the senescence of neoplastic mast cells to undergo spontaneous regression of mastocytosis.",
        "Doc_title":"Overexpression of p16(INK4a) in Mastocytosis (Urticarial Pigmentosa).",
        "Journal":"Fukuoka igaku zasshi = Hukuoka acta medica",
        "Do_id":"27333655",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;Tryptases",
        "Doc_meshdescriptors":"Cell Aging;Cell Cycle Checkpoints;Cell Transformation, Neoplastic;Cyclin-Dependent Kinase Inhibitor p16;Gene Expression;Humans;Mast Cells;Mastocytosis, Cutaneous;Neoplasm Regression, Spontaneous;Skin;Tryptases;Urticaria Pigmentosa",
        "Doc_meshqualifiers":"genetics;genetics;genetics;metabolism;genetics;metabolism;physiology;pathology;genetics;pathology;genetics;pathology;metabolism;pathology;genetics;metabolism;genetics;pathology",
        "_version_":1605876964174856192},
      {
        "Doc_abstract":"A subgroup of head and neck squamous cell carcinomas (HNSCCs) contains high-risk human papillomavirus-type 16 (HPV16). The viral E6 and E7 oncoproteins inactivate the p53 and pRb proteins, respectively. We examined the causative effect of HPV16 E6 and E7 expression on the immortalization of normal oral keratinocytes (OKCs) and compared the resulting phenotype with alternative ways of p53- and pRb-pathway abrogation frequently found in HNSCCs without HPV. Primary OKCs were conditionally immortalized with temperature-sensitive SV40 large T-antigen and human telomerase, allowing these cells to return to their senescent primary state after temperature shift. HPV16 E6 and E7 were introduced to overcome senescence, determined with population doubling (PD) as read-out. For comparison, we downregulated p53 and p16 by short hairpin RNA genes and expressed mutant p53R(175)H and cyclinD1. Expression of HPV16 E6 caused an extended life span similar to expression of mutant p53R(175)H or p53 knockdown. Expression of mutant p53R(175)H seemed to cause additional activation of the hypoxia and WNT signaling pathways. HPV16 E7 expression had no direct effect on lifespan, similar to p16 knockdown or cyclinD1 expression. In combination with HPV16 E6 or other functional inactivations of p53, abrogation of the pRb-pathway by either HPV16 E7 or other manipulations caused an immortal phenotype. Our data show the causative role of HPV16 E6/E7 in early squamous carcinogenesis. Activity of each gene could be mimicked by other genetic events frequently found in HNSCC without HPV. This data provides the experimental proof of causal association of HPV in HNSCC carcinogenesis and further support the crucial role of the p53- and pRb-pathways.",
        "Doc_title":"Immortalization of oral keratinocytes by functional inactivation of the p53 and pRb pathways.",
        "Journal":"International journal of cancer",
        "Do_id":"20499310",
        "Doc_ChemicalList":"E6 protein, Human papillomavirus type 16;Oncogene Proteins, Viral;Repressor Proteins;Retinoblastoma Protein;Tumor Suppressor Protein p53;Cyclin D1;Calcium",
        "Doc_meshdescriptors":"Calcium;Cell Line, Tumor;Cyclin D1;Gene Expression Profiling;Gene Expression Regulation;Genetic Vectors;Head and Neck Neoplasms;Humans;Keratinocytes;Oncogene Proteins, Viral;Papillomaviridae;Phenotype;Repressor Proteins;Retinoblastoma Protein;Signal Transduction;Tumor Suppressor Protein p53",
        "Doc_meshqualifiers":"metabolism;biosynthesis;metabolism;cytology;metabolism;metabolism;metabolism;metabolism;metabolism;metabolism",
        "_version_":1605751091385860096},
      {
        "Doc_abstract":"Oncogenic stimuli trigger the DNA damage response (DDR) and induction of the alternative reading frame (ARF) tumor suppressor, both of which can activate the p53 pathway and provide intrinsic barriers to tumor progression. However, the respective timeframes and signal thresholds for ARF induction and DDR activation during tumorigenesis remain elusive. Here, these issues were addressed by analyses of mouse models of urinary bladder, colon, pancreatic and skin premalignant and malignant lesions. Consistently, ARF expression occurred at a later stage of tumor progression than activation of the DDR or p16(INK4A), a tumor-suppressor gene overlapping with ARF. Analogous results were obtained in several human clinical settings, including early and progressive lesions of the urinary bladder, head and neck, skin and pancreas. Mechanistic analyses of epithelial and fibroblast cell models exposed to various oncogenes showed that the delayed upregulation of ARF reflected a requirement for a higher, transcriptionally based threshold of oncogenic stress, elicited by at least two oncogenic 'hits', compared with lower activation threshold for DDR. We propose that relative to DDR activation, ARF provides a complementary and delayed barrier to tumor development, responding to more robust stimuli of escalating oncogenic overload. ",
        "Doc_title":"The DNA damage checkpoint precedes activation of ARF in response to escalating oncogenic stress during tumorigenesis.",
        "Journal":"Cell death and differentiation",
        "Do_id":"23852374",
        "Doc_ChemicalList":"DNA-Binding Proteins;Tumor Suppressor Protein p14ARF",
        "Doc_meshdescriptors":"Amino Acid Sequence;Animals;Carcinogenesis;DNA Damage;DNA-Binding Proteins;Disease Models, Animal;Gene Expression;Heterografts;Humans;Immunohistochemistry;Mice;Molecular Sequence Data;Neoplasms;Oncogenes;Transfection;Tumor Suppressor Protein p14ARF",
        "Doc_meshqualifiers":"genetics;genetics;metabolism;genetics;metabolism;pathology;genetics;metabolism",
        "_version_":1605749739720015872},
      {
        "Doc_abstract":"Although numerous somatic mutations that contribute to the pathogenesis of childhood acute lymphoblastic leukemia (ALL) have been identified, no specific cytogenetic or molecular abnormalities are known to be consistently associated with relapse. The p16(INK4A) (p16), which encodes for both p16(INK4A) and p19(ARF) proteins, and p15(INK4B) (p15) genes are inactivated by homozygous deletion and/or p15 promoter hypermethylation in a significant proportion of cases of childhood ALL at the time of initial diagnosis. To determine whether alterations in these genes play a role in disease progression, we analyzed a panel of 18 matched specimen pairs collected from children with ALL at the time of initial diagnosis and first bone marrow relapse for homozygous p16 and/or p15 deletions or p15 promoter hypermethylation. Four sample pairs contained homozygous p16 and p15 deletions at both diagnosis and relapse. Among the 14 pairs that were p16/p15 germline at diagnosis, three ALLs developed homozygous deletions of both p16 and p15, and two developed homozygous p16 deletions and retained p15 germline status at relapse. In two patients, p15 promoter hypermethylation developed in the interval between initial diagnosis and relapse. In total, homozygous p16 deletions were present in nine of 18 cases, homozygous p15 deletions in seven of 18 cases, and p15 promoter hypermethylation in two of eight cases at relapse. These findings indicate that loss of function of proteins encoded by p16 and/or p15 plays an important role in the biology of relapsed childhood ALL, and is associated with disease progression in a subset of cases.",
        "Doc_title":"Acquisition of p16(INK4A) and p15(INK4B) gene abnormalities between initial diagnosis and relapse in children with acute lymphoblastic leukemia.",
        "Journal":"Blood",
        "Do_id":"10090949",
        "Doc_ChemicalList":"CDKN2B protein, human;Carrier Proteins;Cell Cycle Proteins;Cyclin-Dependent Kinase Inhibitor p15;Cyclin-Dependent Kinase Inhibitor p16;Tumor Suppressor Proteins",
        "Doc_meshdescriptors":"Carrier Proteins;Cell Cycle Proteins;Child;Child, Preschool;Cyclin-Dependent Kinase Inhibitor p15;Cyclin-Dependent Kinase Inhibitor p16;DNA Methylation;Disease Progression;Female;Gene Expression Regulation, Leukemic;Genes, Tumor Suppressor;Genes, p16;Humans;Infant;Karyotyping;Loss of Heterozygosity;Male;Mutagenesis;Precursor Cell Lymphoblastic Leukemia-Lymphoma;Promoter Regions, Genetic;Recurrence;Sequence Deletion;Tumor Suppressor Proteins",
        "Doc_meshqualifiers":"genetics;physiology;deficiency;physiology;diagnosis;genetics;therapy",
        "_version_":1605831490212462592},
      {
        "Doc_abstract":"The tumor suppressor genes p53 and p16(INK4a), both of which act in tumor surveillance, are homozygously deleted in the human leukemia cell line K562. This study was performed to assess whether co-transfection of the p16(INK4a) and p53 genes could inhibit K562 cell proliferation.;p16(INK4a) and p53 genes were co-transfected into K562 cells with liposome, and the expression of the transfected genes was detected by Western-immunoblotting and immunocytochemistry. The effect of the p16(INK4a) and p53 transfected cell culture was quantified by trypan blue staining, and the number of recovered viable cells was assessed every day after transfection. Cells were analyzed for expression of annexin V in order to detect apoptosis. Differentiation of transfected K562 cells was measured by the benzidine oxidation test, and the cell cycle was analyzed by flow cytometry.;After co-transfection, there were 23% and 28% p53 and p16(INK4a) positive cells respectively. Co-transfection with p16(INK4a) and p53 genes significantly inhibited cell proliferation when compared to transfection with either p16(INK4a) or p53 gene. The percentage of cells expressing the apoptosis-related cell surface antigen annexin V was significantly higher in p53 and p16(INK4a) transfected cells than in p53 or p16(INK4a) transfected cells (6.24+/-0.37% vs 4.88+/- 0.17%, p<0.05 and vs 2.78+/-0.26%, p<0.05, respectively). p16(INK4a) and p53 co-transfection significantly increased the number of cells in G1 phase and decreased that in S phase.;Expression of wild-type p16(INK4a) and p53 genes in K562 cells results in reduced proliferation and apoptosis. Introduction of exogenous p16(INK4a) and p53 genes into K562 cells might contribute to the clinical treatment of leukemia.",
        "Doc_title":"Co-transfection of p16(INK4a) and p53 genes into the K562 cell line inhibits cell proliferation.",
        "Journal":"Haematologica",
        "Do_id":"11836163",
        "Doc_ChemicalList":"Annexin A5;Cyclin-Dependent Kinase Inhibitor p16;Hemoglobins;Liposomes;Recombinant Fusion Proteins;Tumor Suppressor Protein p53",
        "Doc_meshdescriptors":"Annexin A5;Apoptosis;Cell Differentiation;Cell Division;Cyclin-Dependent Kinase Inhibitor p16;G1 Phase;Genes, p16;Genes, p53;Genetic Therapy;Hemoglobins;Humans;K562 Cells;Liposomes;Recombinant Fusion Proteins;S Phase;Transfection;Tumor Suppressor Protein p53",
        "Doc_meshqualifiers":"analysis;physiology;physiology;physiology;physiology;biosynthesis;cytology;metabolism;physiology;physiology",
        "_version_":1605852454695469056},
      {
        "Doc_abstract":"Aberrant expression of key cell cycle regulatory genes is essential for the immortalization and transformation of cells in vitro. We examined 20 mouse lung epithelial cell lines (2 nontumorigenic, 5 nonmetastatic, and 13 metastatic) for mutations or alterations in the expression of key components of the Rb pathway (pRb and p16INK4a) and the p53 pathway (p53 and p19ARF). Seven cell lines had a mutation in exons 5 to 8 of p53. p19ARF was inactivated in the remaining 13 cell lines, primarily by homozygous deletion. Rb expression was present and unaltered in all cell lines, with both phosphorylated and unphosphorylated protein forms detectable. p16INK4a transcripts were undetectable in all cell lines tested except LM1. Loss of p16INK4a expression was a result of homozygous deletion in 11 out of 20 lung cell lines and promoter-exon 1 hypermethylation in 6 out of the remaining 8 cell lines. Other related components that were examined in this study included p21WAF1 and cyclin D1. Compared to normal lung tissue, p21WAF1 expression levels were reduced or undetectable in all cell lines, which did not correlate with loss of p53 function, but did correlate with inactivation of either p53 or p19ARF. Although cyclin D1 expression was variable between cell lines, transcript levels were decreased by at least 50% in the nontumorigenic lines C10 and E10 compared to the tumorigenic cell lines. These results demonstrate mutually exclusive relationships between p53 and p19ARF and between Rb and p16INK4a, but perhaps not between cyclin D1 and p16INK4a, and further describe the nature of involvement of both pathways in mouse lung tumorigenesis.",
        "Doc_title":"Inactivation of both Rb and p53 pathways in mouse lung epithelial cell lines.",
        "Journal":"Experimental lung research",
        "Do_id":"11293330",
        "Doc_ChemicalList":"Cdkn1a protein, mouse;Cyclin-Dependent Kinase Inhibitor p16;Cyclin-Dependent Kinase Inhibitor p21;Cyclins;DNA Primers;Proteins;RNA, Messenger;RNA, Neoplasm;Tumor Suppressor Protein p14ARF;Cyclin D1",
        "Doc_meshdescriptors":"Animals;Base Sequence;Cell Line;Cell Transformation, Neoplastic;Cyclin D1;Cyclin-Dependent Kinase Inhibitor p16;Cyclin-Dependent Kinase Inhibitor p21;Cyclins;DNA Primers;Epithelial Cells;Gene Expression;Genes, Retinoblastoma;Genes, p53;Lung;Lung Neoplasms;Mice;Mutation;Proteins;RNA, Messenger;RNA, Neoplasm;Tumor Cells, Cultured;Tumor Suppressor Protein p14ARF",
        "Doc_meshqualifiers":"genetics;genetics;genetics;genetics;genetics;metabolism;metabolism;genetics;genetics;genetics;metabolism;genetics;metabolism",
        "_version_":1605831834518683648},
      {
        "Doc_abstract":"The genetic differences between human papilloma virus (HPV)-positive and -negative head and neck squamous cell carcinomas (HNSCC) remain largely unknown. To identify differential biology and novel therapeutic targets for both entities, we determined mutations and copy-number aberrations in a large cohort of locoregionally advanced HNSCC.;We performed massively parallel sequencing of 617 cancer-associated genes in 120 matched tumor/normal samples (42.5% HPV-positive). Mutations and copy-number aberrations were determined and results validated with a secondary method.;The overall mutational burden in HPV-negative and HPV-positive HNSCC was similar with an average of 15.2 versus 14.4 somatic exonic mutations in the targeted cancer-associated genes. HPV-negative tumors showed a mutational spectrum concordant with published lung squamous cell carcinoma analyses with enrichment for mutations in TP53, CDKN2A, MLL2, CUL3, NSD1, PIK3CA, and NOTCH genes. HPV-positive tumors showed unique mutations in DDX3X, FGFR2/3 and aberrations in PIK3CA, KRAS, MLL2/3, and NOTCH1 were enriched in HPV-positive tumors. Currently targetable genomic alterations were identified in FGFR1, DDR2, EGFR, FGFR2/3, EPHA2, and PIK3CA. EGFR, CCND1, and FGFR1 amplifications occurred in HPV-negative tumors, whereas 17.6% of HPV-positive tumors harbored mutations in fibroblast growth factor receptor genes (FGFR2/3), including six recurrent FGFR3 S249C mutations. HPV-positive tumors showed a 5.8% incidence of KRAS mutations, and DNA-repair gene aberrations, including 7.8% BRCA1/2 mutations, were identified.;The mutational makeup of HPV-positive and HPV-negative HNSCC differs significantly, including targetable genes. HNSCC harbors multiple therapeutically important genetic aberrations, including frequent aberrations in the FGFR and PI3K pathway genes. See related commentary by Krigsfeld and Chung, p. 495.",
        "Doc_title":"Integrative and comparative genomic analysis of HPV-positive and HPV-negative head and neck squamous cell carcinomas.",
        "Journal":"Clinical cancer research : an official journal of the American Association for Cancer Research",
        "Do_id":"25056374",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Adult;Aged;Carcinoma, Squamous Cell;Cohort Studies;DNA Copy Number Variations;Female;Gene Expression Profiling;Genomics;Head and Neck Neoplasms;Human papillomavirus 16;Human papillomavirus 18;Humans;Male;Middle Aged;Mutation;Neoplasm Staging;Papillomaviridae;Papillomavirus Infections;Prognosis;Protein Interaction Maps;Risk Factors;Signal Transduction;Tumor Virus Infections",
        "Doc_meshqualifiers":"etiology;metabolism;mortality;pathology;etiology;metabolism;mortality;pathology;complications;complications",
        "_version_":1605843881252880384},
      {
        "Doc_abstract":"Cell-cycle inhibitors of the Cip/Kip and INK4 families are involved in cellular senescence and tumor suppression. Some of these proteins, p21(Cip1), p16(INK4a) and p15(INK4b), are coexpressed in response to antiproliferative signals such as cellular senescence resulting in cell-cycle arrest. To understand the roles of these inhibitors and their synergistic effect, we have characterized the growth properties and senescent behavior of primary cells deficient in p21(Cip1) and expressing an endogenous Cdk4(R24C) (cyclin-dependent kinase) mutant (Cdk4(R24C) knock-in cells) insensitive to INK4 proteins. Inactivation of both p21(Cip1) and INK4 pathways strongly cooperate in suppressing cellular senescence in vitro. These double mutant cells behavior as immortal cultures and display high sensitivity to cellular transformation by oncogenes. Moreover, mice double mutant in the INK4 and p21(Cip1) pathways (Cdk4(R24C); p21(Cip1)-null mice) display an increased incidence of specific sarcomas, suggesting a significant cooperation between these two families of cell-cycle inhibitors in senescence responses and tumor suppression in vivo.",
        "Doc_title":"Genetic cooperation between p21Cip1 and INK4 inhibitors in cellular senescence and tumor suppression.",
        "Journal":"Oncogene",
        "Do_id":"17599058",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor Proteins;Cyclin-Dependent Kinase Inhibitor p15;Cyclin-Dependent Kinase Inhibitor p16;Cyclin-Dependent Kinase Inhibitor p21;Cyclin-Dependent Kinase 4",
        "Doc_meshdescriptors":"Animals;Cell Aging;Cyclin-Dependent Kinase 4;Cyclin-Dependent Kinase Inhibitor Proteins;Cyclin-Dependent Kinase Inhibitor p15;Cyclin-Dependent Kinase Inhibitor p16;Cyclin-Dependent Kinase Inhibitor p21;Mice;Mice, Mutant Strains;Sarcoma",
        "Doc_meshqualifiers":"genetics;genetics;genetics;physiology;genetics;physiology;genetics;physiology;genetics;physiology;genetics;metabolism;pathology",
        "_version_":1605875362960506880},
      {
        "Doc_abstract":"We aimed to determine the role of HPV in the pathogenesis and outcome of oropharyngeal squamous cell carcinoma (OSCC) in lifelong nonsmoking and nondrinking patients. A case-case analysis was performed to compare the presence of HPV-DNA in tumor cells of 16 nonsmoking and nondrinking with 16 matched smoking and drinking patients (matching criteria: age at incidence, gender, tumor sublocation, tumor stage). HPV was detected using 2 PCR tests, FISH analysis, and p16(INK4A) immunostaining. Nonsmoking and nondrinking patients had more HPV-positive tumors than smoking and drinking patients (n = 12; 75% versus n = 2; 13%; P < 0.001). All HPV-positive tumors showed p16(INK4A) overexpression, and 1 HPV-negative tumor had p16(INK4A) overexpression, (P < 0.001). Overall survival and disease-specific survival were higher for HPV-positive compared to HPV-negative cases (P = 0.027, P = 0.039, resp.). In conclusion, HPV is strongly associated with OSCC of nonsmoking and nondrinking patients. Specific diagnostic and therapeutic actions should be considered for these patients to achieve a better prognosis.",
        "Doc_title":"Human Papillomavirus and Oropharyngeal Squamous Cell Carcinoma: A Case-Control Study regarding Tobacco and Alcohol Consumption.",
        "Journal":"Pathology research international",
        "Do_id":"21789265",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605794977949941760},
      {
        "Doc_abstract":"A comprehensive analysis of 53 penile carcinomas was performed to determine which mechanisms might be involved in the disruption of the p16(INK4A)/cyclin D/Rb pathway. To that end, human papillomavirus (HPV) presence, p16(INK4A) expression and promoter methylation, and expression of the BMI-1 polycomb gene product were studied. Sixteen (30%) of the carcinomas were found to harbour high-risk HPV DNA, 15 of which contained HPV 16. HPV 16 E6/E7 oncogene transcripts were detected in 13 (87%) of the carcinomas that contained HPV 16. Strong immunostaining for p16(INK4A) was significantly more frequent in carcinomas that contained high-risk HPV DNA (p < 0.001) and amongst those with HPV 16 DNA, it was more frequent in lesions in which E6/E7 transcripts were detectable (p = 0.029). This supports an active role for HPV E7 in interfering with the p16(INK4A)/cyclin D/Rb pathway. Methylation of the p16(INK4A) promoter or overexpression of the BMI-1 polycomb gene product may provide alternative modes of interference with this pathway. These phenomena were mutually exclusive and found in the absence of HPV in 15% and 10% of the penile carcinomas, respectively. These data indicate that there are at least three plausible mechanisms by which the p16(INK4A)/cyclin D/Rb pathway can become disrupted during penile carcinogenesis.",
        "Doc_title":"Evidence for at least three alternative mechanisms targeting the p16INK4A/cyclin D/Rb pathway in penile carcinoma, one of which is mediated by high-risk human papillomavirus.",
        "Journal":"The Journal of pathology",
        "Do_id":"12950023",
        "Doc_ChemicalList":"BMI1 protein, human;Cyclin-Dependent Kinase Inhibitor p16;DNA, Viral;Neoplasm Proteins;Nuclear Proteins;Proto-Oncogene Proteins;RNA, Viral;Repressor Proteins;Polycomb Repressive Complex 1",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Cell Transformation, Neoplastic;Cyclin-Dependent Kinase Inhibitor p16;DNA Methylation;DNA, Viral;Genes, p16;Humans;Male;Middle Aged;Neoplasm Proteins;Nuclear Proteins;Papillomaviridae;Papillomavirus Infections;Penile Neoplasms;Polycomb Repressive Complex 1;Polymerase Chain Reaction;Promoter Regions, Genetic;Proto-Oncogene Proteins;RNA, Viral;Repressor Proteins;Tumor Virus Infections",
        "Doc_meshqualifiers":"metabolism;metabolism;analysis;metabolism;metabolism;isolation & purification;complications;metabolism;virology;methods;metabolism;analysis;complications",
        "_version_":1605788853181874176},
      {
        "Doc_abstract":"The p14(ARF) tumor suppressor is frequently targeted for inactivation in many human cancers and in individuals predisposed to cutaneous melanoma. The functions of p14(ARF) are closely linked with its subcellular distribution. Nucleolar p14(ARF) dampens ribosome biosynthesis and nucleoplasmic forms of p14(ARF) activate the p53 pathway and induce cell cycle arrest. p14(ARF) can also be recruited to mitochondria where it interacts with many mitochondrial proteins, including Bcl-x(L) and p32 to induce cell death. It has been suggested that the movement of p14(ARF) to mitochondria requires its interaction with p32, but we now show that the ARF-p32 interaction is not necessary for the accumulation of p14(ARF) in mitochondria. Instead, highly hydrophobic domains within the amino-terminal half of p14(ARF) act as mitochondrial import sequences. We suggest that once this hydrophobic pocket is exposed, possibly in a stimulus-dependent manner, it accelerates the mitochondrial import of p14(ARF). This allows the interaction of p14(ARF) with mitochondrial proteins, including p32 and enables p53-independent cell death.",
        "Doc_title":"Amino terminal hydrophobic import signals target the p14(ARF) tumor suppressor to the mitochondria.",
        "Journal":"Cell cycle (Georgetown, Tex.)",
        "Do_id":"20107316",
        "Doc_ChemicalList":"Mitochondrial Proteins;Tumor Suppressor Protein p14ARF;Tumor Suppressor Protein p53;bcl-X Protein;mitochondrial p32 protein, human",
        "Doc_meshdescriptors":"Amino Acid Sequence;Animals;Apoptosis;Cell Line, Tumor;Humans;Hydrophobic and Hydrophilic Interactions;Mice;Mitochondria;Mitochondrial Proteins;Molecular Sequence Data;Protein Structure, Tertiary;Sequence Alignment;Signal Transduction;Tumor Suppressor Protein p14ARF;Tumor Suppressor Protein p53;bcl-X Protein",
        "Doc_meshqualifiers":"metabolism;metabolism;metabolism;metabolism;metabolism",
        "_version_":1605742683425341441},
      {
        "Doc_abstract":"Lymphomagenesis in Emu-Myc mice is opposed by the Arf tumor suppressor, whose inactivation compromises p53 function and accelerates disease. Finding nascent Emu-Myc-induced tumors in which p19Arf causes cell-cycle arrest or apoptosis is problematic, since such cells will be eliminated until Arf or p53 function is lost. Knock-in mice expressing a green fluorescent protein (GFP) in lieu of Arf coding sequences allow analysis of Arfpromoter regulation uncoupled from p19Arf action. Prior to frank lymphoma development, unexpectedly low levels of Emu-Myc-induced p19Arf or GFP were expressed. However, as lymphomas arose in Arf+/GFP heterozygotes, additional oncogenic events synergized with Emu-Myc to further induce the functionally null Arf-Gfp allele. Concomitant up-regulation of p19Arf was not observed; instead, the wild-type allele was inactivated. We infer that very low levels of Arf are tumor suppressive, and that further induction provides the selective pressure for the emergence of tumors that have inactivated the gene.",
        "Doc_title":"Regulation of the Arf tumor suppressor in Emicro-Myc transgenic mice: longitudinal study of Myc-induced lymphomagenesis.",
        "Journal":"Blood",
        "Do_id":"16968893",
        "Doc_ChemicalList":"Cdkn2a protein, mouse;Cyclin-Dependent Kinase Inhibitor p16;Proto-Oncogene Proteins c-myc;Tumor Suppressor Protein p53",
        "Doc_meshdescriptors":"Animals;Cyclin-Dependent Kinase Inhibitor p16;Disease Progression;Gene Expression Regulation, Neoplastic;Genes, Reporter;Genes, Tumor Suppressor;Lymphoma;Mice;Mice, Transgenic;Proto-Oncogene Proteins c-myc;Tumor Suppressor Protein p53",
        "Doc_meshqualifiers":"genetics;metabolism;genetics;metabolism;genetics;metabolism;metabolism",
        "_version_":1605742665862742016},
      {
        "Doc_abstract":"The MTS1 gene on chromosome 9p21 encodes the p16 inhibitor of cyclinD/Cdk-4 complexes, and is deleted or mutated in a variety of tumour types. We found allelic deletions of 9p21-p22 in 85% of pancreatic adenocarcinomas. Analysis of MTS1 in pancreatic carcinomas (27 xenografts and 10 cell lines) showed homozygous deletions in 15 (41%) and sequence changes in 14 (38%). These included eight point mutations (four nonsense, two missense and two splice site mutations) and six deletions/insertions, all accompanied by loss of the wild-type allele. Sequencing of MTS1 from primary tumours confirmed the mutations. Coexistent inactivations of both MTS1 and p53 was common and suggests that abnormal regulation of cyclin-dependent kinases may play an important role in the biology of pancreatic carcinoma.",
        "Doc_title":"Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma.",
        "Journal":"Nature genetics",
        "Do_id":"7726912",
        "Doc_ChemicalList":"Carrier Proteins;Cyclin-Dependent Kinase Inhibitor p16",
        "Doc_meshdescriptors":"Adenocarcinoma;Base Sequence;Carrier Proteins;Chromosome Deletion;Chromosomes, Human, Pair 9;Cyclin-Dependent Kinase Inhibitor p16;Gene Deletion;Genes, p53;Humans;Molecular Sequence Data;Mutation;Pancreatic Neoplasms;Tumor Cells, Cultured",
        "Doc_meshqualifiers":"genetics;genetics;genetics",
        "_version_":1605910432491503616},
      {
        "Doc_abstract":"Up-regulation of p16INK4A is associated with high-risk human papillomavirus (HPV) in preinvasive and invasive cervical neoplasia. However, its expression in vulvar carcinomas, which have a diverse pathogenesis, has not been extensively studied. One hundred seventy-seven vulvar intraepithelial neoplasms (VIN), squamous cell carcinomas (SCC), and benign squamous epithelia were analyzed for p16 expression. RNA/RNA in situ hybridization was used to detect HPV 16 E6/E7 transcripts in 112. Ninety-five percent of VIN 3 and basaloid or warty SCCs (76/80) and 4% of keratinizing SCC (2/48) were moderately to strongly immunopositive for p16, which localized to nucleus and cytoplasm; 52/58 analyzed (90%) contained HPV 16 transcripts. The positive predictive value (PPV) of moderate to strong diffuse p16 immunostaining and HPV positivity for the diagnosis of VIN 3 and of basaloid or warty SCC was 97% and 95%, respectively. Conversely, 94% of keratinizing SCC contained heterogeneous staining, and when present, it was strictly cytoplasmic and frequently localized to the cells at the epithelial-stromal interface. Benign squamous epithelia were p16 negative, with the exception of lichen sclerosus, which contained focal and heterogeneously p16 positive in 42%. As in the cervix, intense diffuse p16 expression supports an HPV-related neoplastic process in vulvar neoplasia, irrespective of the level of differentiation. Up-regulation of p16 at the epithelial-stromal interface in HPV negative keratinizing SCCs is consistent with an HPV-independent response to alterations associated with invasion. These disparate patterns of p16 expression underscore 2 different mechanisms for p16 expression in HPV-related and HPV-unrelated vulvar carcinomas.",
        "Doc_title":"p16INK4A expression as biomarker for HPV 16-related vulvar neoplasias.",
        "Journal":"Human pathology",
        "Do_id":"15619206",
        "Doc_ChemicalList":"Biomarkers, Tumor;Cyclin-Dependent Kinase Inhibitor p16;DNA, Viral;RNA, Messenger",
        "Doc_meshdescriptors":"Adult;Aged;Biomarkers, Tumor;Carcinoma in Situ;Carcinoma, Squamous Cell;Cyclin-Dependent Kinase Inhibitor p16;DNA, Viral;Female;Humans;In Situ Hybridization;Middle Aged;Papillomaviridae;Papillomavirus Infections;RNA, Messenger;Up-Regulation;Vulvar Neoplasms",
        "Doc_meshqualifiers":"metabolism;metabolism;pathology;virology;metabolism;pathology;virology;genetics;metabolism;isolation & purification;classification;genetics;pathogenicity;complications;metabolism;pathology;metabolism;metabolism;pathology;virology",
        "_version_":1605783361715961856},
      {
        "Doc_abstract":"To investigate the expression of p16(INK4a) in cervical carcinoma and its relation to the transition of carcinoma in situ to invasive carcinoma, and its role in recurrence of cervical lesions as well, a series of 90 patients with cervical carcinoma (49 with in situ lesion and 41 with invasive lesion) were selected from July 2001 and September 2002. Groups with in situ and invasive lesions were paired for a series of risk variables for cervical cancer and followed up for 60 months. The follow-up visits occurred every 6 months in the first three years and annually up to the fifth year. It was observed that 87.9% of the patients with invasive lesion showed overexpression of p16(INK4a), in comparison with 37.6% of those with in situ lesion (X(2): 13.68; 2 df; p=0.0002; OR: 12.08), demonstrating overexpression of p16(INK4a) as a risk of invasion of the basal layer by dysplastic cells. We also observed an association between overexpression of p16(INK4a) and staging of cancer (X(2): 18.38; 6 df; p=0.0003). A prospective analysis, when controlled for interaction with cervical lesion groups (by Cox regression), demonstrated a risk of recurrence of 4.83 times attributed to overexpression of p16(INK4a), albeit not statistically significant (p=0.14).",
        "Doc_title":"Transition of cervical carcinoma in situ to invasive cancer: role of p16 INK4a expression in progression and in recurrence.",
        "Journal":"Experimental and molecular pathology",
        "Do_id":"19100258",
        "Doc_ChemicalList":"Biomarkers, Tumor;Cyclin-Dependent Kinase Inhibitor p16;Neoplasm Proteins;Tumor Suppressor Protein p53",
        "Doc_meshdescriptors":"Adult;Biomarkers, Tumor;Cyclin-Dependent Kinase Inhibitor p16;Disease Progression;Female;Humans;Neoplasm Proteins;Neoplasm Recurrence, Local;Neoplasm Staging;Prospective Studies;Survival Analysis;Tumor Suppressor Protein p53;Uterine Cervical Neoplasms",
        "Doc_meshqualifiers":"genetics;metabolism;genetics;metabolism;genetics;metabolism;genetics;metabolism;metabolism;pathology",
        "_version_":1605842387863601152},
      {
        "Doc_abstract":"The INK4b-ARF-INK4a locus in the chromosome 9p21 region is known to play an important role in the development of atherosclerosis. The INK4/ARF transcript p16(INK4a) inhibits the activity of the cyclin-dependent kinases CDK4/CDK6 and arrests cell-cycle progression. CDK inhibitors also regulate G1/S phase progression in vascular smooth muscle cells(VSMCs) and may modulate the early stages of atherosclerosis. Therefore, we aimed to study the expression of the INK4/ARF locus genes CDKN2A and CDKN2BAS in order to examine the p16(INK4a) protein expression and the level of cell proliferation in carotid plaques and saphenous tissue samples.;A total of 50 patients(33 symptomatic subjects and 17 asymptomatic subjects) with carotid atherosclerosis CA) were studied. The CDKN2A and CDKN2BAS gene expression levels were determined using quantitative real-time polymerase chain reaction(qRT-PCR). All tissue sections were also analyzed for the p16(INK4a) and proliferating cell nuclear antigen(PCNA) protein expression using immunohistochemistry(IHC).;The CDKN2A gene expression was significantly higher in the carotid plaques than in the saphenous tissues(p=0.009), whereas no such differences were observed in the CDKN2BAS transcripts(p=0.157). The carotid plaque CDKN2A mRNA levels were higher in the symptomatic patients than in the asymptomatic patients(p=0.050); this finding was also associated with the severity of internal carotid artery(ICA) stenosis(p=0.034). The p16(INK4a) immune() cell counts in the carotid plaques were higher in the symptomatic patients than in the asymptomatic patients (p=0.056), as was the cell proliferation index(p=0.001).;An increased CDKN2A gene expression in carotid plaques may increase the severity of ICA stenosis, thus raising the risk of atherosclerosis and contributing to the development of symptoms. In addition, the p16(INK4a) expression is associated with carotid atherosclerosis in various patient subgroups.",
        "Doc_title":"The severity of internal carotid artery stenosis is associated with the cyclin-dependent kinase inhibitor 2A gene expression.",
        "Journal":"Journal of atherosclerosis and thrombosis",
        "Do_id":"24599170",
        "Doc_ChemicalList":"ANRIL long non-coding RNA, human;Biomarkers;Cyclin-Dependent Kinase Inhibitor p16;Proliferating Cell Nuclear Antigen;RNA, Long Noncoding;RNA, Messenger",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Biomarkers;Carotid Stenosis;Case-Control Studies;Cyclin-Dependent Kinase Inhibitor p16;Female;Follow-Up Studies;Humans;Immunoenzyme Techniques;Male;Middle Aged;Prognosis;Proliferating Cell Nuclear Antigen;RNA, Long Noncoding;RNA, Messenger;Real-Time Polymerase Chain Reaction;Reverse Transcriptase Polymerase Chain Reaction;Severity of Illness Index",
        "Doc_meshqualifiers":"analysis;genetics;metabolism;pathology;genetics;metabolism;genetics;metabolism;genetics;metabolism;genetics",
        "_version_":1605873846244605952},
      {
        "Doc_abstract":"Pactamycin, although putatively touted as a potent antitumor agent, has never been used as an anticancer drug due to its high cytotoxicity. In this study, we characterized the effects of two novel biosynthetically engineered analogs of pactamycin, de-6MSA-7-demethyl-7-deoxypactamycin (TM-025) and 7-demethyl-7-deoxypactamycin (TM-026), in head and neck squamous cell carcinoma (HNSCC) cell lines SCC25 and SCC104. Both TM-025 and TM-026 exert growth inhibitory effects on HNSCC cells by inhibiting cell proliferation. Interestingly, unlike their parent compound pactamycin, the analogs do not inhibit synthesis of nascent protein in a cell-based assay. Furthermore, they do not induce apoptosis or autophagy in a dose- or a time-dependent manner, but induce mild senescence in the tested cell lines. Cell cycle analysis demonstrated that both analogs significantly induce cell cycle arrest of the HNSCC cells at S-phase resulting in reduced accumulation of G2/M-phase cells. The pactamycin analogs induce expression of cell cycle regulatory proteins including master regulator p53, its downstream target p21Cip1/WAF1, p27kip21, p19, cyclin E, total and phospho Cdc2 (Tyr15) and Cdc25C. Besides, the analogs mildly reduce cyclin D1 expression without affecting expression of cyclin B, Cdk2 and Cdk4. Specific inhibition of p53 by pifithrin- reduces the percentage of cells accumulated in S-phase, suggesting contribution of p53 to S-phase increase. Altogether, our results demonstrate that Pactamycin analogs TM-025 and TM-026 induce senescence and inhibit proliferation of HNSCC cells via accumulation in S-phase through possible contribution of p53. The two PCT analogs can be widely used as research tools for cell cycle inhibition studies in proliferating cancer cells with specific mechanisms of action. ",
        "Doc_title":"Novel Pactamycin Analogs Induce p53 Dependent Cell-Cycle Arrest at S-Phase in Human Head and Neck Squamous Cell Carcinoma (HNSCC) Cells.",
        "Journal":"PloS one",
        "Do_id":"25938491",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p21;Hydrocarbons, Fluorinated;TM-025;TM-026;Tumor Suppressor Protein p53;Pactamycin",
        "Doc_meshdescriptors":"Apoptosis;Autophagy;Carcinoma, Squamous Cell;Cell Aging;Cell Cycle Checkpoints;Cell Line, Tumor;Cell Proliferation;Cell Survival;Cyclin-Dependent Kinase Inhibitor p21;Dose-Response Relationship, Drug;Gene Silencing;Head and Neck Neoplasms;Humans;Hydrocarbons, Fluorinated;Models, Biological;Pactamycin;Protein Biosynthesis;S Phase;Tumor Suppressor Protein p53;Up-Regulation",
        "Doc_meshqualifiers":"drug effects;drug effects;pathology;drug effects;drug effects;drug effects;drug effects;metabolism;drug effects;pathology;pharmacology;analogs & derivatives;pharmacology;drug effects;drug effects;metabolism;drug effects",
        "_version_":1605795022469332992},
      {
        "Doc_abstract":"The survival of patients with hepatocellular carcinoma (HCC) has been improved with various diagnostic tools and treatment modalities. Consequently, spinal metastases from HCC are diagnosed more frequently. We investigated the clinical biomarkers of HCC patients presenting with spinal metastasis. Between January 2001 and December 2007, we recruited 30 consecutive HCC patients presenting with spinal metastasis. Their tissue samples were collected and analyzed by immunohistochemistry in a tissue microarray. A total of 16 proteins were assessed in the tissue microarray; we found that expression of p16(INK4) correlated with the survival time (log-rank test, P = 0.05), and loss of p16(INK4) was significantly associated with osteopontin overexpression (Fisher exact test: P = 0.045, logistic regression: P = 0.024, OR = 0.184, 95% CI 0.035-0.963). Patients with osteopontin (-) and with p16(INK4) (+) lived longer than patients with osteopontin (+) and with p16(INK4) (-). We found that p16(INK4) and osteopontin might be the biomarkers of patients with spinal metastasis from HCC, a more large-scaled randomized study might be required to confirm the result and study the mechanism.",
        "Doc_title":"Loss of p16INK4, alone and with overexpression of osteopontin, correlates with survival of patients with spinal metastasis from hepatocellular carcinoma.",
        "Journal":"Medical oncology (Northwood, London, England)",
        "Do_id":"19813107",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;Neoplasm Proteins;Osteopontin",
        "Doc_meshdescriptors":"Adult;Aged;Carcinoma, Hepatocellular;Cyclin-Dependent Kinase Inhibitor p16;Female;Follow-Up Studies;Gene Expression Regulation, Neoplastic;Genes, p16;Humans;Kaplan-Meier Estimate;Liver Neoplasms;Male;Middle Aged;Neoplasm Proteins;Oligonucleotide Array Sequence Analysis;Osteopontin;Paralysis;Spinal Cord Compression;Spinal Neoplasms;Time Factors",
        "Doc_meshqualifiers":"genetics;metabolism;mortality;secondary;analysis;deficiency;genetics;mortality;pathology;analysis;biosynthesis;genetics;analysis;biosynthesis;genetics;etiology;etiology;complications;genetics;metabolism;mortality;secondary",
        "_version_":1605904155637972992},
      {
        "Doc_abstract":"Barrett's esophagus (BE) is the only known precursor to esophageal adenocarcinoma, a cancer of which the incidence has been increasing at an alarming rate in Western countries. p16(INK4a) lesions occur frequently in esophageal adenocarcinomas but their role in neoplastic progression is not well understood. We detected 9p21 loss of heterozygosity, p16 CpG island methylation, and p16 mutations in biopsies from 57%, 61%, and 15%, respectively, of 107 patients with BE. In contrast, no mutations were found in p14(ARF) or p15, and methylation was found in only 4% and 13%, respectively. >85% of Barrett's segments had clones with one (p16+/-) or two (p16-/-) p16 lesions. Both p16+/- and p16-/- clones underwent extensive expansion involving up to 17 cm of esophageal mucosa. The prevalence of established biomarkers in BE, such as 17p (p53) loss of heterozygosity, aneuploidy, and/or increased 4N (tetraploid) populations, increased from 0% to 20% to 44% in patients whose biopsies were p16+/+, p16+/-, and p16-/-, respectively (P < 0.001). Barrett's segment lengths also increased with change in p16 status with a median of 1.5, 6.0, and 8.0 cm for patients with p16+/+, p16+/-, and p16-/- biopsies, respectively (P < 0.001). We conclude that most Barrett's metaplasia contains genetic and/or epigenetic p16 lesions and has the ability to undergo clonal expansion, creating a field in which other abnormalities can arise that can lead to esophageal adenocarcinoma.",
        "Doc_title":"p16(INK4a) lesions are common, early abnormalities that undergo clonal expansion in Barrett's metaplastic epithelium.",
        "Journal":"Cancer research",
        "Do_id":"11719461",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Aneuploidy;Barrett Esophagus;Biopsy;Chromosomes, Human, Pair 9;Clone Cells;CpG Islands;Cyclin-Dependent Kinase Inhibitor p16;DNA Methylation;Epithelial Cells;Esophageal Neoplasms;Humans;Loss of Heterozygosity;Metaphase;Middle Aged;Mutation;Precancerous Conditions",
        "Doc_meshqualifiers":"genetics;pathology;genetics;pathology;genetics;pathology;genetics;genetics;pathology",
        "_version_":1605892474157400064},
      {
        "Doc_abstract":"p16(INK4a) (p16) and p53 are tumor suppressor genes that are inactivated during carcinogenesis in many tumors. Here we show that p16 gene activity inversely modulates p53 status and function in primary human mammary epithelial cells. Reduced levels of p16 protein stabilize p53 protein through inhibition of proteolytic degradation, and this increase in p53 protein levels enhances the cellular response to radiation, represses proliferation, and transcriptionally activates downstream targets. Stabilization of p53 is mediated through the retinoblastoma/E2F/p14(ARF)/murine double minute-2 pathway. However, we have observed that p16 does not modulate p53 in fibroblasts, indicating a possible cell type-specific regulation of this pathway.",
        "Doc_title":"p16INK4a modulates p53 in primary human mammary epithelial cells.",
        "Journal":"Cancer research",
        "Do_id":"17079452",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;Retinoblastoma Protein;Tumor Suppressor Protein p53",
        "Doc_meshdescriptors":"Breast;Breast Neoplasms;Cell Proliferation;Cells, Cultured;Cyclin-Dependent Kinase Inhibitor p16;Epithelial Cells;Female;Genes, p16;Humans;Retinoblastoma Protein;Signal Transduction;Tumor Suppressor Protein p53",
        "Doc_meshqualifiers":"cytology;etiology;analysis;physiology;cytology;physiology;analysis;physiology",
        "_version_":1605879703304929280},
      {
        "Doc_abstract":"The p16(ink4a) tumor suppressor protein plays a critical role in cell cycle control, tumorogenesis and senescence. The best known activity for p16(ink4a) is the inhibition of the activity of CDK4 and CDK6 kinases, both playing a key role in cell cycle progression. With the aim to study new p16(ink4a) functions we used affinity chromatography and MS techniques to identify new p16(ink4a)-interacting proteins. We generated p16(ink4a) columns by coupling the protein to activated Sepharose 4B. The proteins from MOLT-4 cell line that bind to p16(ink4a) affinity columns were resolved by SDS-PAGE and identified by MS using a MALDI-TOF. Thirty-one p16(ink4a) -interacting proteins were identified and grouped in functional clusters. The identification of two of them, proliferating cell nuclear antigen (PCNA) and minichromosome maintenance protein 6 (MCM6), was confirmed by Western blotting and their in vivo interactions with p16(ink4a) were demonstrated by immunoprecipitation and immunofluorescence studies. Results also revealed that p16(ink4a) interacts directly with the DNA polymerase delta accessory protein PCNA and thereby inhibits the polymerase activity.",
        "Doc_title":"Proteomic analysis of p16ink4a-binding proteins.",
        "Journal":"Proteomics",
        "Do_id":"17955473",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;Proliferating Cell Nuclear Antigen;DNA Polymerase III",
        "Doc_meshdescriptors":"Animals;Blotting, Western;Cell Line, Tumor;Chromatography, Affinity;Cyclin-Dependent Kinase Inhibitor p16;DNA Polymerase III;Electrophoresis, Polyacrylamide Gel;Enzyme Activation;Fluorescent Antibody Technique;HeLa Cells;Humans;Immunoprecipitation;Mice;Proliferating Cell Nuclear Antigen;Proteomics;Sensitivity and Specificity;Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization;Tumor Cells, Cultured",
        "Doc_meshqualifiers":"methods;chemistry;metabolism;pharmacology;antagonists & inhibitors;drug effects;methods;metabolism;pharmacology;methods",
        "_version_":1605791506448252928},
      {
        "Doc_abstract":"Rat embryo fibroblasts (REFs) are inefficiently transformed by RAS-oncogenes. Induction of p16INK4A expression by RAS has been suggested to contribute to this resistance. Glucocorticoid hormones, (DEX), enhance REF transformation by RAS and facilitates the isolation of transformed and immortal cell lines. We show that DEX induced cell proliferation is paralleled by a decrease in Cdkn2a gene transcripts, suggesting a mechanism for hormone promotion. The mechanisms of progression into hormone independent cell lines were examined. Twenty-two of 30 clones which reached a population size of approximately 10(6) cells could be established as cell lines. All lines studied showed homozygous deletions of the Cdkn2 loci (Cdkn2a and Cdkn2b) on RNO5. LOH was found for all RNO5 genetic markers examined in 7 of 19 cell lines, suggesting non-disjunction events. In the remaining 12 cell lines, both copies of Cdkn2 appeared to be lost by deletions/rearrangements, some of which could by demonstrated by karyotype analysis. We conclude that (i) clonal expansion of RAS-transfected REF by DEX is paralleled by down-regulation of Cdkn2a expression; (ii) homozygous deletion of Cdkn2 were estimated to occur at a frequency of 2 x 10(-8)/cell/generation or higher, and (iii) deletion/rearrangements and nondisjunction appear to be the main mechanisms leading to deletion of Cdkn2.",
        "Doc_title":"Analysis of mechanisms and frequency of CDKN2A/B gene loss during progression of RAS-transformed rat embryo fibroblast clones.",
        "Journal":"Somatic cell and molecular genetics",
        "Do_id":"10763411",
        "Doc_ChemicalList":"CDKN2B protein, human;Carrier Proteins;Cdkn2b protein, rat;Cell Cycle Proteins;Cyclin-Dependent Kinase Inhibitor p15;Cyclin-Dependent Kinase Inhibitor p16;Tumor Suppressor Proteins",
        "Doc_meshdescriptors":"Animals;Carrier Proteins;Cell Cycle Proteins;Cell Line, Transformed;Cell Transformation, Neoplastic;Clone Cells;Cyclin-Dependent Kinase Inhibitor p15;Cyclin-Dependent Kinase Inhibitor p16;Down-Regulation;Embryo, Mammalian;Fibroblasts;Gene Deletion;Genes, ras;Homozygote;Humans;Karyotyping;Loss of Heterozygosity;Rats;Rats, Inbred BN;Rats, Inbred Lew;Tumor Suppressor Proteins",
        "Doc_meshqualifiers":"genetics;metabolism;genetics;genetics;genetics;metabolism;pathology;genetics;genetics",
        "_version_":1605852483156967424},
      {
        "Doc_abstract":"Human papilloma virus (HPV) is postulated as a risk factor in the etiology of some specific mucosal pathologies in the head and neck regions. Despite the frequent use of p16(INK4a) as a surrogate marker for HPV-infection, there is still controversy with respect to its reliability. This study has been undertaken to assess the potential role of p16(INK 4a) and Ki-67 expression in HPV-related lesions. The study was conducted on 71 specimens of oral, tonsillar and laryngeal lesions which comprised 25 dysplasia and 46 papilloma specimens. Specimens were immunohistochemically stained for p16(INK4A) and Ki-67 proteins. HPV DNA was determined by one step multiplex polymerase chain reaction. HPV DNA was detected in 33.8% of all lesions. Tonsil and larynx lesions showed significant differences with oral lesions for HPV positivity (p < 0.001). p16(INK 4a) over-expression was seen in 56.5% of papilloma and 60% of dysplasia specimens. HPV status showed a positive correlation with p16(INK 4a) expression in tonsillar dysplasias (p < 0.001). p16(INK 4a) expression may have a value as a marker in high risk HPV induced dysplasias, but not in low risk infected lesions. The proliferation index is not related to HPV-induced lesions and may be evaluated as an independent marker in head and neck premalignant lesions.",
        "Doc_title":"P16(INK 4a) and Ki-67 expression in human papilloma virus-related head and neck mucosal lesions.",
        "Journal":"Investigacion clinica",
        "Do_id":"25920185",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;Ki-67 Antigen",
        "Doc_meshdescriptors":"Adolescent;Adult;Aged;Aged, 80 and over;Child;Cyclin-Dependent Kinase Inhibitor p16;Female;Head and Neck Neoplasms;Humans;Ki-67 Antigen;Male;Middle Aged;Papillomaviridae;Young Adult",
        "Doc_meshqualifiers":"biosynthesis;pathology;virology;biosynthesis;metabolism",
        "_version_":1605877255273185280},
      {
        "Doc_abstract":"We immunochemically studied p16(INK4a) expression in 116 urine cytologic samples and compared results with 190 histologic samples. The cytologic samples were classified into 4 groups: 1, mild cellular atypia; 2, moderate cellular atypia; 3, severe cellular atypia; and 4, malignancy. Overexpression of p16(INK4a) was detected in none of 32 cases in group 1, 8 (16%) of 50 cases in group 2, 5 (42%) of 12 cases in group 3, and 11 (50%) of 22 cases in group 4. In addition, by histologic analysis, p16(INK4a) overexpression was not detected in nonneoplastic urothelium, except for a few cases of reactive atypia, but it was detected in about 50% of urothelial carcinomas. In particular, a high incidence (16/20 [80%]) of p16(INK4a) overexpression in high-grade carcinomas was noted in cytologic samples. Immunocytologic analysis of p16(INK4a) expression in cytologic samples is a useful ancillary tool for detection of urothelial carcinoma with infiltrating potential.",
        "Doc_title":"p16(INK4a) expression analysis as an ancillary tool for cytologic diagnosis of urothelial carcinoma.",
        "Journal":"American journal of clinical pathology",
        "Do_id":"19846821",
        "Doc_ChemicalList":"Biomarkers, Tumor;Cyclin-Dependent Kinase Inhibitor p16",
        "Doc_meshdescriptors":"Aged;Biomarkers, Tumor;Carcinoma, Transitional Cell;Cyclin-Dependent Kinase Inhibitor p16;Cytological Techniques;Female;Gene Expression;Gene Expression Profiling;Humans;Immunohistochemistry;Male;Urinary Bladder Neoplasms",
        "Doc_meshqualifiers":"analysis;metabolism;pathology;biosynthesis;metabolism;pathology",
        "_version_":1605766704354295808},
      {
        "Doc_abstract":"The p14(ARF) protein directly inhibits the MDM-2 oncoprotein, which mediates degradation of the p53 protein. It has been shown that p14(ARF) expression is frequently down-regulated by p14(ARF) gene hypermethylation in colorectal cancer. To determine whether p14(ARF) inactivation was involved in ulcerative colitis (UC)-associated carcinogenesis, the frequency and timing of p14(ARF) methylation was investigated in four different histological stages of UC-associated carcinogenesis. Methylation-specific PCR and bisulfite sequencing were used to determine the prevalence of p14(ARF) gene methylation. p14(ARF) methylation was observed in 19 of 38 (50%) adenocarcinomas, 4 of 12 (33%) dysplasias, and 3 of the 5 (60%) nonneoplastic UC mucosae. In contrast, 3 of 40 (3.7%) normal tissues showed p14(ARF) methylation (chi(2) test: P = 0.0003). Bisulfite sequencing was used to analyze 28 CpGs of p14(ARF) gene in 20 samples. The number of methylated CpGs ranged from 0 to 4, 0 to 20, and 0 to 28 in the normal, dysplastic, and carcinomatous samples, respectively (Kruskall-Wallis test: P = 0.0005). Densely methylated alleles were detected only in carcinomas by bisulfite sequencing. In conclusion, our data suggest that methylation of p14(ARF) is a relatively common early event in UC-associated carcinogenesis. p14(ARF) offers potential as a biomarker for the early detection of cancer or dysplasia in UC. Finally, analyses of p14(ARF) methylation in other organs should explore not only frank cancers but other premalignant lesions.",
        "Doc_title":"Hypermethylation of the p14(ARF) gene in ulcerative colitis-associated colorectal carcinogenesis.",
        "Journal":"Cancer research",
        "Do_id":"11861396",
        "Doc_ChemicalList":"Sulfites;Tumor Suppressor Protein p14ARF",
        "Doc_meshdescriptors":"Base Sequence;Colitis, Ulcerative;Colorectal Neoplasms;DNA Methylation;Humans;Intestinal Mucosa;Molecular Sequence Data;Polymerase Chain Reaction;Sequence Analysis, DNA;Sulfites;Tumor Suppressor Protein p14ARF",
        "Doc_meshqualifiers":"complications;genetics;metabolism;etiology;genetics;metabolism;metabolism;pathology;methods;genetics",
        "_version_":1605818680954847233},
      {
        "Doc_abstract":"Surgery, radiation, or hormone deprivation alone does not adequately affect local control of clinical or pathologic stage T3 prostate cancer. Lack of local cancer control ultimately leads to a higher incidence of morbidity, distant metastasis, and decreased survival, with patients having disease-specific mortality exceeding 75%. Other novel therapies against this devastating and common disease are needed for the achievement of long-term local cancer control. For this purpose, therapeutic interventions should target prostate-cancer cells at the molecular and cellular level in ways not possible by current modalities of cancer treatment. Any strategy that can modify the biologic behavior of these cells may potentially have the most significant clinical impact. As prostate cancer represents an accumulation of genetic mutations that causes a prostate cell to lose the ability to control its growth, one new approach against prostate cancer may be gene therapy. Identification of key missing or mutated tumor-suppressor genes that, when replaced, may inhibit or destroy prostate-cancer cells may have the best chance of clinical success. One such gene appears to be tumor-suppressor gene p16 (also known as MTS1, INK4A, and CDKN2). Tumor-suppressor gene p16 is an important negative cell-cycle regulator whose functional loss may significantly contribute to malignant transformation and progression. Alterations in the p16 gene and its protein expression often occur in prostate cancer. An adenoviral vector containing wild-type p16 (Adp16) had a high transduction efficiency in prostate-cancer cells both in vitro and in vivo. Moreover, prostate tumors injected with Adp16 expressed p16 and the adenoviral vector expressed the transgene for up to 14 days. Wild-type p16 inhibited prostate-cancer proliferation in vitro and markedly suppressed tumors in vivo. Pathologic evaluation of the Adp16-treated tumors showed dose-dependent necrosis and fibrosis. Although the mechanism of p16 inhibition in cancer remains to be elucidated, senescence and apoptosis may both be important; however, the data suggest that p16-induced growth inhibition can function independently of the retinoblastoma gene product.",
        "Doc_title":"Adenovirus p16 gene therapy for prostate cancer.",
        "Journal":"World journal of urology",
        "Do_id":"10854145",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16",
        "Doc_meshdescriptors":"Adenoviridae;Animals;Apoptosis;Cell Aging;Cell Division;Cyclin-Dependent Kinase Inhibitor p16;Fibrosis;Gene Expression Regulation, Viral;Genetic Therapy;Genetic Vectors;Humans;In Vitro Techniques;Male;Mice;Mice, Nude;Necrosis;Neoplasm Transplantation;Prostatic Neoplasms;Survival Analysis;Transplantation, Heterologous;Tumor Cells, Cultured",
        "Doc_meshqualifiers":"genetics;genetics;genetics;genetics;genetics;methods;mortality;pathology;therapy;cytology",
        "_version_":1605896803103801344},
      {
        "Doc_abstract":"CDKN2A locus on chromosome 9p21 encodes two tumour suppressor proteins pl6INK4A, which is a regulator of the retinoblastoma (RB) protein, and p14ARF, which is involved in the ARF-Mdm2-p53 pathway. The aim of this study was to determine if CDKN2A gene products are implicated in differentiated thyroid carcinogenesis and progression. We used real-time quantitative RT-PCR and immunohistochemistry to assess both transcripts and proteins levels in 60 tumours specimens. Overexpression of p14ARF and pl6INK4A was observed in follicular adenomas, follicular carcinomas and papillary carcinomas, while downregulation was found in oncocytic adenomas compared to nontumoral paired thyroid tissues. These deregulations were statistically significant for pl6INK4a (P=0.006) in follicular adenomas and close to statistical significance for p14ARF in follicular adenomas (P=0.06) and in papillary carcinomas (P=0.05). In all histological types, except papillary carcinomas, we observed a statistically significant relationship between p14ARF and E2F1 (r=0.64 to 1, P<0.05). Our data are consistent with involvement of CDKN2A transcript upregulation in thyroid follicular tumorigenesis as an early event. However, these deregulations do not appear to be correlated to the clinical outcome and they could not be used as potential prognostic markers.",
        "Doc_title":"The status of CDKN2A alpha (p16INK4A) and beta (p14ARF) transcripts in thyroid tumour progression.",
        "Journal":"British journal of cancer",
        "Do_id":"17117177",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;RNA, Messenger;Tumor Suppressor Protein p14ARF",
        "Doc_meshdescriptors":"Adenocarcinoma, Follicular;Adult;Aged;Aged, 80 and over;Carcinoma, Papillary;Cell Differentiation;Cyclin-Dependent Kinase Inhibitor p16;Disease Progression;Humans;Immunoenzyme Techniques;Middle Aged;RNA, Messenger;Reverse Transcriptase Polymerase Chain Reaction;Thyroid Gland;Thyroid Neoplasms;Transcription, Genetic;Tumor Suppressor Protein p14ARF",
        "Doc_meshqualifiers":"genetics;metabolism;pathology;genetics;metabolism;pathology;genetics;metabolism;genetics;metabolism;metabolism;pathology;genetics;metabolism;pathology;physiology;genetics;metabolism",
        "_version_":1605898723124051968},
      {
        "Doc_abstract":"The INK4a/ARF tumor suppressor locus, a key executor of cellular senescence, is regulated by members of the Polycomb group (PcG) of transcriptional repressors. Here we show that signaling from oncogenic RAS overrides PcG-mediated repression of INK4a by activating the H3K27 demethylase JMJD3 and down-regulating the methyltransferase EZH2. In human fibroblasts, JMJD3 activates INK4a, but not ARF, and causes p16(INK4a)-dependent arrest. In mouse embryo fibroblasts, Jmjd3 activates both Ink4a and Arf and elicits a p53-dependent arrest, echoing the effects of RAS in this system. Our findings directly implicate JMJD3 in the regulation of INK4a/ARF during oncogene-induced senescence and suggest that JMJD3 has the capacity to act as a tumor suppressor.",
        "Doc_title":"Histone demethylase JMJD3 contributes to epigenetic control of INK4a/ARF by oncogenic RAS.",
        "Journal":"Genes & development",
        "Do_id":"19451218",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;Jumonji Domain-Containing Histone Demethylases;KDM6B protein, human;Kdm6b protein, mouse;Oxidoreductases, N-Demethylating;ras Proteins",
        "Doc_meshdescriptors":"Animals;Cell Aging;Cyclin-Dependent Kinase Inhibitor p16;Epigenesis, Genetic;Fibroblasts;Gene Expression Regulation;Humans;Jumonji Domain-Containing Histone Demethylases;Mice;Oxidoreductases, N-Demethylating;Signal Transduction;ras Proteins",
        "Doc_meshqualifiers":"metabolism;genetics;cytology;metabolism;metabolism;metabolism",
        "_version_":1605755551915966464},
      {
        "Doc_abstract":"The p16 gene (MTS1, CDKN2, p16INK4A, CDKI) encoding an inhibitor of cyclin-dependent kinase 4 (cdk4) has been found to be deleted in various types of tumors, including leukemia, and is thought to code for a tumor suppressor gene. Our preliminary findings on eight pediatric patients with acute lymphoblastic leukemia (ALL) suggested that the survival of patients carrying a homozygous p16 gene deletion was significantly inferior to that of those without a deletion. The present study on 48 patients tested the hypothesis that the clinical outcome for pediatric ALL patients is correlated with the presence or absence of the p16 gene. Overall, nine of 48 children (18.3%) carried a homozygous p16 deletion. Such deletions were significantly more common (P = .003) among T-ALL patients (five of eight, 62.5%) than among precursor-B-ALL patients (four of 40, 10.0%). Of nine patients exhibiting p16 deletions, eight (88.9%) were classified as high-risk patients by the recognized prognostic factors of age, white blood cell count, and T-cell phenotype. The 4-year event-free survival in the study population as a whole was 72.7%. Without adjustment for other risk factors (univariate model), the presence of a homozygous p16 deletion was associated with a markedly increased probability of both relapse (P = .0003) and death (P = .002). These findings raise the question of whether the p16 deletion itself confers an increased risk of relapse after adjusting for the known risk factors. In this analysis, the estimated risk multiplier factor for relapse in patients carrying the p16 deletion was 14.0 (P = .0004) and for the risk of death 15.6 (P = .0008). We therefore conclude that the presence of a homozygous p16 deletion may well be an important risk factor for both relapse and death in childhood ALL, and that its prognostic effect is not a consequence of confounding by other factors already known to influence outcome in this disease.",
        "Doc_title":"Homozygous deletion of the p16/MTS1 gene in pediatric acute lymphoblastic leukemia is associated with unfavorable clinical outcome.",
        "Journal":"Blood",
        "Do_id":"9166859",
        "Doc_ChemicalList":"Carrier Proteins;Cyclin-Dependent Kinase Inhibitor p16",
        "Doc_meshdescriptors":"Adolescent;Carrier Proteins;Child;Child, Preschool;Cyclin-Dependent Kinase Inhibitor p16;Gene Deletion;Genes, Tumor Suppressor;Homozygote;Humans;Infant;Infant, Newborn;Precursor Cell Lymphoblastic Leukemia-Lymphoma;Prognosis",
        "Doc_meshqualifiers":"genetics;genetics;physiopathology",
        "_version_":1605746352024715265},
      {
        "Doc_abstract":"INK4 (p15, p16, p18 and p19) and CIP/KIP (p21, p27 and p57) are two families of cyclin-dependent kinase inhibitors (CKI) targeting CDK4/6 and CDK2, respectively.;To study the role of methylation in the inactivation of CKI in chronic lymphocytic leukaemia (CLL).;Methylation-specific polymerase chain reaction was carried out on DNA obtained from the bone marrow of 56 newly diagnosed patients with CLL.;Similar demographic features and clinical outcome were observed in our patients when compared with Caucasian patients, including an indolent clinical course (10-year overall survival 51%) and advanced Rai stage (p = 0.006), and a high-risk karyotype such as trisomy 12 and complex aberrations (p = 0.03). In the INK4 family, methylation in p15 and p16 occurred in 20 (35.7%) and 8 (14.3%) patients, respectively. In all, 5 (8.9%) CLL samples harboured concurrent methylation of both p15 and p16. Apart from an association of p16 methylation with higher presenting leucocyte count (64.5 x 10(9)/l in methylated p16 and 16.0 x 10(9)/l in unmethylated p16 patients; p = 0.016), there was no association between p15 and p16 methylation and age, sex and Rai stage. No difference was observed in the overall survival for patients with and without p15 and p16 methylation. By contrast, p18 and Rb were unmethylated in all samples. In the CIP/KIP family, apart from infrequent methylation of p57 in 4 (7.1%) patients, methylation of p21 and p27 was uniformly absent.;p15 and, less frequently, p16 of the INK4 family of CKI, instead of the CIP or KIP family, were targeted by methylation in CLL. p16 methylation was associated with a higher lymphocyte count at presentation. This is the first comprehensive study of the epigenetic dysregulation of the INK4 and CIP/KIP families of CKI in Chinese patients with CLL.",
        "Doc_title":"Methylation of INK4 and CIP/KIP families of cyclin-dependent kinase inhibitor in chronic lymphocytic leukaemia in Chinese patients.",
        "Journal":"Journal of clinical pathology",
        "Do_id":"16565223",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor Proteins;Cyclin-Dependent Kinase Inhibitor p15;Cyclin-Dependent Kinase Inhibitor p16;DNA, Neoplasm;Neoplasm Proteins",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Base Sequence;Cyclin-Dependent Kinase Inhibitor Proteins;Cyclin-Dependent Kinase Inhibitor p15;Cyclin-Dependent Kinase Inhibitor p16;DNA Methylation;DNA, Neoplasm;Epigenesis, Genetic;Female;Humans;Karyotyping;Leukemia, Lymphocytic, Chronic, B-Cell;Lymphocyte Count;Male;Middle Aged;Molecular Sequence Data;Neoplasm Proteins;Polymerase Chain Reaction;Prognosis;Survival Analysis",
        "Doc_meshqualifiers":"genetics;genetics;genetics;genetics;genetics;genetics;methods",
        "_version_":1605784359937245184},
      {
        "Doc_abstract":"Human papillomavirus (HPV) has been implicated as an etiologic agent for the development of squamous cell carcinoma of the anorectal region. It has been shown that the HPV E6 and E7 oncoproteins are able to inactivate the tumor suppressor functions of p53 and Rb. In cervical and head and neck cancers, HPV infection is also associated with an overexpression of p16, a cyclin-dependent kinase inhibitor. The expression of these cell cycle regulators in squamous cell carcinomas of the anorectal region has not been well studied. In the current study, 29 cases of squamous cell carcinoma of the anorectal region were immunohistochemically examined for the expression of p16, Rb, and p53 proteins. Tumor cell DNA was also extracted from paraffin blocks and subjected to broad-spectrum HPV DNA testing and typing. The results show that the tumor cells exhibited a strong and diffuse nuclear stain (with some cytoplasmic positivity) for p16 in all 29 cases (100%). The adjacent nonneoplastic squamous epithelium or colonic mucosa, in contrast, was completely negative. Loss of Rb nuclear staining in tumor cells was observed in 20 cases (69%). The p53 protein was essentially undetectable, with only 6 cases containing <10% positive cells. HPV DNA was detected in every case (100%), with 25 cases (86%) harboring Type 16. In addition, almost identical results were obtained in 12 HPV-positive squamous cell carcinomas of the upper aerodigestive tract. This was in marked contrast to those of HPV-negative tumors, where positive p16 staining and loss of Rb expression were seen in only 2/21 (10%) and 1/21 (5%) cases, respectively. These observations indicate that overexpression of p16 and loss of Rb nuclear staining are commonly associated with high-risk HPV infection, which may serve as useful surrogate biomarkers for identifying squamous cell carcinomas harboring HPV DNA.",
        "Doc_title":"Expression of p16, Rb, and p53 proteins in squamous cell carcinomas of the anorectal region harboring human papillomavirus DNA.",
        "Journal":"Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc",
        "Do_id":"12861066",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;DNA, Neoplasm;DNA, Viral;Retinoblastoma Protein;Tumor Suppressor Protein p53",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Anus Neoplasms;Carcinoma, Squamous Cell;Cyclin-Dependent Kinase Inhibitor p16;DNA, Neoplasm;DNA, Viral;Female;Humans;Immunoenzyme Techniques;Male;Middle Aged;Neoplasm Staging;Papillomaviridae;Papillomavirus Infections;Retinoblastoma Protein;Tumor Suppressor Protein p53",
        "Doc_meshqualifiers":"metabolism;pathology;virology;metabolism;pathology;virology;metabolism;analysis;analysis;classification;genetics;isolation & purification;complications;metabolism;pathology;metabolism;metabolism",
        "_version_":1605837613466386432},
      {
        "Doc_abstract":"Oropharyngeal squamous cell carcinomas (OPSCCs) associated with human papillomavirus (HPV) represent a distinct clinical and pathologic entity. The majority of HPV-related OPSCCs have a characteristic nonkeratinizing morphology. This study sought to determine the strength of the association between nonkeratinizing histology and HPV status compared with other squamous cell carcinoma variants in 4 years of routine clinical practice on a high-volume head and neck service. Primary and/or nodal metastatic tumors in all cases of OPSCC from 2010 to 2013 were typed by 1 of 3 head and neck pathologists as keratinizing, nonkeratinizing, nonkeratinizing with maturation, or another defined variant. All were assessed for p16 by immunohistochemistry with a 70% nuclear and cytoplasmic positivity cutoff as part of routine clinical practice. In addition, 70 consecutive cases from 1 year were \"audited\" for high-risk HPV mRNA by reverse transcription polymerase chain reaction and in situ hybridization. Of the 435 cases, the majority (90%) consisted of 1 of the 3 main types described and the rest (10%) of uncommon variants. Nonkeratinizing morphology had 99.1% and 100.0% positive predictive value for p16 and high-risk HPV mRNA positivity, respectively. Nonkeratinizing with maturation, keratinizing, and other specific squamous cell carcinoma variants were p16 positive in 91.8%, 22.8%, and 79.5%, respectively. All 47 nonkeratinizing OPSCCs tested for HPV mRNA were positive. In summary, strictly defined nonkeratinizing OPSCC (which constitutes 55% of all tumors) essentially implies positivity for both p16 and transcriptionally active high-risk HPV. ",
        "Doc_title":"Histologic Typing in Oropharyngeal Squamous Cell Carcinoma: A 4-Year Prospective Practice Study With p16 and High-Risk HPV mRNA Testing Correlation.",
        "Journal":"The American journal of surgical pathology",
        "Do_id":"27035614",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605840483382198272},
      {
        "Doc_abstract":"Surgery remains the only curative treatment option for cholangiocarcinoma (CC). Currently, both early identification of CC in affected individuals at high risk and accurate diagnosis of unexplained biliary strictures are problematic. However, growing insights into biochemical and molecular mechanisms underlying biliary carcinogenesis have suggested serum and bile markers for the diagnosis of CC. These tools include tumor antigens or products (e.g., carbohydrate antigen [CA] 19-9), cytokines (e.g., interleukin-6), metabolic products (e.g., lactate), proteases (e.g., trypsinogen-2), regulatory peptides (e.g., pancreatic polypeptide), and (epi-)genetic lesions (e.g., K- ras and p53 mutations, p16 (INK4a) or p14 (ARF) promoter hypermethylation). In this article we discuss these new potential tumor markers for the diagnosis of CC.",
        "Doc_title":"Serum and bile markers for cholangiocarcinoma.",
        "Journal":"Seminars in liver disease",
        "Do_id":"15192787",
        "Doc_ChemicalList":"Antigens, Neoplasm;Biomarkers, Tumor;Cytokines;Genetic Markers",
        "Doc_meshdescriptors":"Antigens, Neoplasm;Bile Duct Neoplasms;Bile Ducts, Intrahepatic;Biomarkers, Tumor;Cholangiocarcinoma;Cytokines;Genetic Markers;Humans",
        "Doc_meshqualifiers":"analysis;diagnosis;analysis;diagnosis;analysis",
        "_version_":1605750679611113472},
      {
        "Doc_abstract":"Inactivation of relevant tumor-suppressor genes by allelic or homozygous deletion is a characteristic event in tumor cells. Here, the prognostic value of allelic deletions on 5p13-12 at the putative del-27 tumor-suppressor locus and in the APC tumor-suppressor gene on 5q21, as well as homozygous deletions of the MTS1 (p16INK4, CDKN 2) tumor-suppressor gene on 9p21 was assessed in 87 bladder cancers using microdissection and PCR-based assays. Tumor-specific LOH was detected in 10 of 38 (26%, del-27), and 15 of 30 (50%, APC) informative specimens. Homozygous deletion of the MTS1 gene was detected in 33% of 84 tumors investigated. These deletion frequencies implicate the 3 tumor-suppressor regions in the genesis of transitional-cell carcinoma. In contrast to deletions of the APC or MTS1 genes, LOH at the del-27 locus correlated with tumor progression. This suggests that loss of the putative tumor-suppressor gene DEL-27 is involved in an aggressive behavior of the tumor cells and appears to be a prognostic marker for the clinical outcome of patients with transitional-cell carcinoma.",
        "Doc_title":"Deletion analysis at the DEL-27, APC and MTS1 loci in bladder cancer: LOH at the DEL-27 locus on 5p13-12 is a prognostic marker of tumor progression.",
        "Journal":"International journal of cancer",
        "Do_id":"9221807",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Carcinoma, Transitional Cell;Disease Progression;Gene Deletion;Genes, APC;Genes, Tumor Suppressor;Humans;Polymerase Chain Reaction;Urinary Bladder Neoplasms",
        "Doc_meshqualifiers":"genetics;genetics;genetics;genetics",
        "_version_":1605742124738805760},
      {
        "Doc_abstract":"To examine the prognostic significance of c-Met expression in relation to p16 and epidermal growth factor receptor (EGFR) in patients with locally advanced head and neck squamous cell carcinoma (HNSCC) treated with definitive concurrent chemoradiation.;Archival tissue from 107 HNSCC patients treated with chemoradiation was retrieved, and a tissue microarray was assembled. Immunohistochemical staining of c-Met, p16, and EGFR was performed. c-Met expression was correlated with p16, EGFR, clinical characteristics, and clinical endpoints including locoregional control (LRC), distant metastasis (DM), disease-free survival (DFS), and overall survival (OS).;Fifty-one percent of patients were positive for p16, and 53% were positive for EGFR. Both p16-negative (P.001) and EGFR-positive (P=.019) status predicted for worse DFS. Ninety-three percent of patients stained positive for c-Met. Patients were divided into low (0, 1, or 2+ intensity) or high (3+ intensity) c-Met expression. On univariate analysis, high c-Met expression predicted for worse LRC (hazard ratio [HR] 2.27; 95% CI, 1.08-4.77; P=.031), DM (HR 4.41; 95% CI, 1.56-12.45; P=.005), DFS (HR 3.00; 95% CI, 1.68-5.38; P<.001), and OS (HR 4.35; 95% CI, 2.13-8.88; P<.001). On multivariate analysis, after adjustment for site, T stage, smoking history, and EGFR status, only high c-Met expression (P=.011) and negative p16 status (P=.003) predicted for worse DFS. High c-Met expression was predictive of worse DFS in both EGFR-positive (P=.032) and -negative (P=.008) patients. In the p16-negative patients, those with high c-Met expression had worse DFS (P=.036) than did those with low c-Met expression. c-Met expression was not associated with any outcome in the p16-positive patients.;c-Met is expressed in the majority of locally advanced HNSCC cases, and high c-Met expression predicts for worse clinical outcomes. High c-Met expression predicted for worse DFS in p16-negative patients but not in p16-positive patients. c-Met predicted for worse outcome regardless of EGFR status.",
        "Doc_title":"c-Met expression is a marker of poor prognosis in patients with locally advanced head and neck squamous cell carcinoma treated with chemoradiation.",
        "Journal":"International journal of radiation oncology, biology, physics",
        "Do_id":"24521684",
        "Doc_ChemicalList":"Biomarkers, Tumor;Neoplasm Proteins;P16 protein, human;Proto-Oncogene Proteins c-met;Receptor, Epidermal Growth Factor",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Analysis of Variance;Antineoplastic Combined Chemotherapy Protocols;Biomarkers, Tumor;Carcinoma, Squamous Cell;Chemoradiotherapy;Disease-Free Survival;Female;Head and Neck Neoplasms;Humans;Male;Middle Aged;Neoplasm Proteins;Neoplasm Staging;Prognosis;Proto-Oncogene Proteins c-met;Receptor, Epidermal Growth Factor;Tissue Array Analysis",
        "Doc_meshqualifiers":"therapeutic use;metabolism;metabolism;mortality;pathology;therapy;metabolism;mortality;pathology;therapy;metabolism;metabolism;metabolism;methods",
        "_version_":1605826415084699648},
      {
        "Doc_abstract":"To study and compare the effectiveness of p16(INK4a) staining and specific human papillomavirus (HPV) subtypes as a prognostic marker in cervical intraepithelial neoplasia grade 1 (CIN1; low-grade squamous intraepithelial lesions).;Sixty-four cervical samples diagnosed as CIN1 and stained with p16(INK4a), with HPV status assessed by polymerase chain reaction-direct sequencing.;Of the 34 p16(INK4a)-negative biopsy specimens, 26 regressed, seven persisted, and one progressed. Of the 20 p16(INK4a) diffusely positive biopsy specimens, seven regressed, eight persisted, and five progressed. Ten biopsy specimens stained positive only in the lower one-third of the sample, of which seven regressed and three persisted. p16(INK4a) diffusely positive CIN1 lesions were associated with only high-risk HPV subtypes, with the exception of one HPV-negative biopsy specimen. Three different high-risk HPV subtypes and one low-risk HPV subtype (HPV66) were identified in the six CIN1 lesions that progressed.;There is a significant relationship between p16(INK4a) immunostaining and follow-up (P = .002). p16(INK4a)-negative specimens or positivity in the lower one-third of CIN1 lesions seldom progress to a CIN2-3 lesion.",
        "Doc_title":"Assessment of correlation between p16INK4a staining, specific subtype of human papillomavirus, and progression of LSIL/CIN1 lesions: first comparative study.",
        "Journal":"American journal of clinical pathology",
        "Do_id":"24926093",
        "Doc_ChemicalList":"Biomarkers, Tumor;Cyclin-Dependent Kinase Inhibitor p16",
        "Doc_meshdescriptors":"Adult;Biomarkers, Tumor;Carcinoma, Squamous Cell;Cervical Intraepithelial Neoplasia;Cyclin-Dependent Kinase Inhibitor p16;Disease Progression;Female;Humans;Middle Aged;Papillomaviridae;Papillomavirus Infections;Prognosis;Uterine Cervical Neoplasms",
        "Doc_meshqualifiers":"metabolism;pathology;virology;metabolism;pathology;virology;metabolism;isolation & purification;diagnosis;metabolism;pathology;metabolism;pathology;virology",
        "_version_":1605845790749622272},
      {
        "Doc_abstract":"Dysfunctional telomeres limit cellular proliferative capacity by activating the p53-p21- and p16(INK4a)-Rb-dependent DNA damage responses (DDRs). The p16(INK4a) tumor suppressor accumulates in aging tissues, is a biomarker for cellular senescence, and limits stem cell function in vivo. While the activation of a p53-dependent DDR by dysfunctional telomeres has been well documented in human cells and mouse models, the role for p16(INK4a) in response to telomere dysfunction remains unclear. Here, we generated protection of telomeres 1b p16-/- mice (Pot1b/;p16-/-) to address the function of p16(INK4a) in the setting of telomere dysfunction in vivo. We found that deletion of p16(INK4a) accelerated organ impairment and observed functional defects in highly proliferative organs, including the hematopoietic system, small intestine, and testes. Pot1b/;p16-/- hematopoietic cells exhibited increased telomere loss, increased chromosomal fusions, and telomere replication defects. p16(INK4a) deletion enhanced the activation of the ATR-dependent DDR in Pot1b/ hematopoietic cells, leading to p53 stabilization, increased p21-dependent cell cycle arrest, and elevated p53-dependent apoptosis. In contrast to p16(INK4a), deletion of p21 did not activate ATR, rescued proliferative defects in Pot1b/ hematopoietic cells, and significantly increased organismal lifespan. Our results provide experimental evidence that p16(INK4a) exerts protective functions in proliferative cells bearing dysfunctional telomeres.",
        "Doc_title":"p16(INK4a) protects against dysfunctional telomere-induced ATR-dependent DNA damage responses.",
        "Journal":"The Journal of clinical investigation",
        "Do_id":"24091330",
        "Doc_ChemicalList":"Cdkn2a protein, mouse;Cyclin-Dependent Kinase Inhibitor p16;Cyclin-Dependent Kinase Inhibitor p21;DNA-Binding Proteins;POT1b protein, mouse;Tumor Suppressor Protein p53;Atr protein, mouse;Ataxia Telangiectasia Mutated Proteins",
        "Doc_meshdescriptors":"Aging;Animals;Apoptosis;Ataxia Telangiectasia Mutated Proteins;Bone Marrow Transplantation;Cell Proliferation;Cells, Cultured;Cyclin-Dependent Kinase Inhibitor p16;Cyclin-Dependent Kinase Inhibitor p21;DNA Damage;DNA Repair;DNA-Binding Proteins;Female;Hematopoiesis;Hematopoietic Stem Cells;Intestine, Small;Male;Mice;Mice, SCID;Mice, Transgenic;Protein Stability;Sequence Deletion;Spleen;Telomere;Telomere Homeostasis;Tumor Suppressor Protein p53",
        "Doc_meshqualifiers":"metabolism;physiology;metabolism;genetics;metabolism;physiology;pathology;pathology;physiology;metabolism",
        "_version_":1605802176890798080},
      {
        "Doc_abstract":"Nuclear beta-catenin is required for changes in morphology from glandular to morular phenotypes of endometrial carcinoma (Em Ca) cells, with activation of p14(ARF)/p53/p21(Waf1) and alteration of p16(INK4A)/pRb pathways. Having demonstrated previously that the homeodomain transcription factor Cdx2 increases markedly during intestinal epithelial cell differentiation, we have examined its effects in beta-catenin signaling during transdifferentiation of Em Ca cells. In clinical cases, Cdx2 immunoreactivity, along with increased mRNA signals, was found to overlap with nuclear accumulation of beta-catenin and p21(Waf1) in morules, demonstrating an inverse correlation with cell proliferation. In cell lines, over-expression of active form beta-catenin resulted in a significant increase in endogenous Cdx2 expression at both mRNA and protein levels. Furthermore, the Cdx2 promoter was activated by T-cell factor 4 (TCF4) -independent activated beta-catenin, as well as Cdx2 itself, through the region from -39 to +9 bp relative to transcription start site. Cells over-expressing exogenous Cdx2 showed high levels of p21(Waf1) expression due to stabilization of the mRNA status, resulting in significant decrease in the proliferation rate, in contrast to the lack of apparent changes in morphology. Moreover, transfected Cdx2 could inhibit beta-catenin/TCF4-mediated transcriptional activation of target genes, including p14(ARF) and cyclin D1, probably through indirect mechanisms. These data suggest that over-expression of Cdx2 mediated by nuclear beta-catenin and Cdx2 itself can cause an inhibition of Em Ca cell proliferation through up-regulation of p21(Waf1) expression, modulating beta-catenin/TCF4-mediated transcription. We therefore conclude that an association between Cdx2 and beta-catenin signaling may participate in induction of transdifferentiation of Em Ca cells.",
        "Doc_title":"A functional role of Cdx2 in beta-catenin signaling during transdifferentiation in endometrial carcinomas.",
        "Journal":"Carcinogenesis",
        "Do_id":"17468517",
        "Doc_ChemicalList":"CDX2 Transcription Factor;CDX2 protein, human;DNA, Complementary;Homeodomain Proteins;RNA, Messenger;RNA, Neoplasm;beta Catenin",
        "Doc_meshdescriptors":"CDX2 Transcription Factor;Cell Differentiation;Cell Transdifferentiation;DNA, Complementary;Endometrial Neoplasms;Female;Homeodomain Proteins;Humans;Immunohistochemistry;In Situ Hybridization;Plasmids;Polymerase Chain Reaction;RNA, Messenger;RNA, Neoplasm;Signal Transduction;beta Catenin",
        "Doc_meshqualifiers":"genetics;pathology;physiopathology;surgery;physiology;genetics;genetics;physiology",
        "_version_":1605822394310590464},
      {
        "Doc_abstract":"The ARF protein product of the ink4a/arf locus is induced by a variety of oncogenic signals. ARF facilitates growth arrest through the p53 pathway by hindering the down-regulation of p53 activity mediated by MDM2, through the formation of a protein complex with MDM2. Here we have explored the possibility that human p14(ARF) activity is integrated with growth regulating pathways other than p53, and report our results that p14(ARF) can control the activity of the E2F transcription factor. p14(ARF) regulates E2F activity in different cell-types, including p53(-/-)/mdm(-/-) MEFs, thus excluding that the effects of p14(ARF) are indirectly caused through MDM2 modulation. p14(ARF) down-regulates E2F-dependent transcription, and in cells undergoing E2F-dependent apoptosis prompts cell cycle arrest. p14(ARF) possesses multiple binding domains for E2F-1, one of which resides within the N-terminal region and coincides with the regulation of E2F activity. A mutational analysis of p14(ARF) indicates that the E2F-1 and MDM2 binding domains can be distinguished. These results highlight the potential interplay between p14(ARF) and E2F, and establish p14(ARF) as a pleiotrophic regulator of cell growth that acts by targetting at least two key pathways in the control of proliferation, namely E2F and p53.",
        "Doc_title":"p14(ARF) regulates E2F activity.",
        "Journal":"Oncogene",
        "Do_id":"12082609",
        "Doc_ChemicalList":"Cell Cycle Proteins;DNA-Binding Proteins;E2F Transcription Factors;E2F1 Transcription Factor;E2F1 protein, human;E2f1 protein, mouse;Nuclear Proteins;Proto-Oncogene Proteins;Recombinant Fusion Proteins;Transcription Factors;Tumor Suppressor Protein p14ARF;Tumor Suppressor Protein p53;MDM2 protein, human;Mdm2 protein, mouse;Proto-Oncogene Proteins c-mdm2",
        "Doc_meshdescriptors":"Animals;Apoptosis;Binding Sites;Bone Neoplasms;Cell Cycle;Cell Cycle Proteins;Cell Division;DNA-Binding Proteins;E2F Transcription Factors;E2F1 Transcription Factor;Fibroblasts;Gene Expression Regulation;Humans;Mice;Models, Biological;Nuclear Proteins;Osteosarcoma;Protein Interaction Mapping;Protein Structure, Tertiary;Proto-Oncogene Proteins;Proto-Oncogene Proteins c-mdm2;Recombinant Fusion Proteins;Signal Transduction;Transcription Factors;Transcription, Genetic;Tumor Cells, Cultured;Tumor Suppressor Protein p14ARF;Tumor Suppressor Protein p53",
        "Doc_meshqualifiers":"physiology;pathology;physiology;physiology;cytology;physiology;pathology;deficiency;physiology;physiology;chemistry;physiology;physiology;pathology;chemistry;genetics;physiology;deficiency;physiology",
        "_version_":1605873631861145600},
      {
        "Doc_abstract":"To assess the role of p16( INK4A), bcl-2, and p53 in cervical cancer screening, we conducted a retrospective trial of prospectively collected data. Sixty two women with abnormal Pap smears were subjected to colposcopy and biopsies from any abnormal lesion. Human papillomavirus (HPV)-DNA typing, histology, and immunochemistry for p16(INK4A), bcl-2, and p53 were performed for these women. Histologic diagnosis was that of low grade squamous intraepithelial lesion (LSIL), high grade squamous intraepithelial lesion (HSIL), or cancer in all cases. Human papillomavirus strains were identified in 56 patients (90.3%). All HSIL and invasive cancer cases were HPV positive. p16(INK4A) immunostaining yielded 100% sensitivity, 76% specificity, 61% positive predictive value, and 100% negative predictive value in cancer patients. The corresponding performance indicators for HSIL patients were 75%, 62%, 32%, and 91%. bcl-2 and p53 expression did not correlate with worsening grades of cervical disease. We conclude that p16(INK4A) seems to be a sensitive biomarker of high grade cervical intraepithelial neoplasia and cancer.",
        "Doc_title":"p16 INK4A is a strong biomarker for cervical intraepithelial neoplasia and invasive cervical carcinoma: a reappraisal.",
        "Journal":"Reproductive sciences (Thousand Oaks, Calif.)",
        "Do_id":"19372590",
        "Doc_ChemicalList":"Biomarkers, Tumor;Cyclin-Dependent Kinase Inhibitor p16",
        "Doc_meshdescriptors":"Adult;Aged;Biomarkers, Tumor;Cervical Intraepithelial Neoplasia;Cyclin-Dependent Kinase Inhibitor p16;Female;Humans;Middle Aged;Neoplasm Invasiveness;Prospective Studies;Retrospective Studies;Uterine Cervical Neoplasms",
        "Doc_meshqualifiers":"analysis;chemistry;diagnosis;analysis;chemistry;diagnosis",
        "_version_":1605746992650125314},
      {
        "Doc_abstract":"p53 is known to play a central role in sensing and signaling for the growth arrest and apoptosis in cells with DNA damage. Mutation of p53 is a frequent event in esophageal squamous cell carcinoma (ESCC). p16 protein binds to cyclin dependent kinase 4 (CDK4) inhibiting the ability of CDK4 to interact with cyclin D1, and stimulates the passage through the G1 phase of cell cycle. We observed the expression patterns and frequencies of p53, p16, and cyclin D1 in esophageal dysplasia and in esophageal squamous cell carcinomas.;In 15 patients of ESCC, 5 patients of esophageal dysplasia and 5 volunteers with normal esophagus, tissue specimens were taken from esophageal lesions during the operation or endoscopic examination. We used specific monoclonal antibodies for p53 protein, p16(INK4 ) protein and cyclin D1. Immunoreactivity was scored.;Mean age of all groups was 66 years old (range 47-93) and men to women ratio was 19:1. p53 mutation was observed in 87% (13/15) of ESCC, in 80% (4/5) of esophageal dysplasia, in 0% (0/5) of normal mucosa (p=0.001). p16 expression was seen in 40% (2/5) of esophageal dysplasia, 27% (4/15) of ESCC and 100% (5/5) of normal mucosa (p=0.016). Cyclin D1 expression was not significantly different among 20% (1/5) of esophageal dysplasia, 53% (8/15) of ESCC and 20% (1/5) of normal mucosa. Either the expression of p53 mutation or the loss of p16 occurred in 80% (4/5) of esophageal dysplasia and in 93% (14/15) of ESCC.;The expression of p53 mutation and the loss of p16 might play a central role in the pathogenesis of esophageal squamous cell carcinoma (ESCC), and contribute to the development of precancerous lesion such as dysplasia. In addition, there is a possibility that the mutations of p53 and p16 silencing would be the early events in ESCC development.",
        "Doc_title":"[The expression of p53, p16, cyclin D1 in esophageal squamous cell carcinoma and esophageal dysplasia].",
        "Journal":"The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi",
        "Do_id":"17060721",
        "Doc_ChemicalList":"Antibodies, Monoclonal;Biomarkers, Tumor;Cyclin-Dependent Kinase Inhibitor p16;Tumor Suppressor Protein p53;Cyclin D1",
        "Doc_meshdescriptors":"Aged;Aged, 80 and over;Antibodies, Monoclonal;Biomarkers, Tumor;Carcinoma, Squamous Cell;Cyclin D1;Cyclin-Dependent Kinase Inhibitor p16;Esophageal Neoplasms;Esophagus;Female;G1 Phase;Humans;Immunohistochemistry;Male;Middle Aged;Tumor Suppressor Protein p53",
        "Doc_meshqualifiers":"metabolism;metabolism;pathology;immunology;metabolism;immunology;metabolism;metabolism;pathology;abnormalities;metabolism;pathology;immunology;metabolism",
        "_version_":1605818565302157312},
      {
        "Doc_abstract":"Aberrant promoter methylation of specific genes and infection with human papillomavirus 16 (HPV16) are known risk factors for the development of Head and Neck Squamous Cell Carcinoma (HNSCC). Little knowledge exists on the interaction of HPV16 infection and promoter methylation in HNSCC. The promoter methylation status of 12 genes (TIMP3, CDH1, CDKN2A, DAPK1, transcription factor 21 (TCF21), CD44, MLH1, MGMT, RASSF1, cyclin A1 (CCNA1), LARS2, and CEBPA) was evaluated by methylation-specific polymerase chain reaction in 55 primary HNSCC and 31 controls. The results were correlated with HPV16 status and clinicopathological characteristics. CCNA1 and p53 protein expression were additionally determined by immunohistochemistry and compared with p53 mutation status. Methylation of DAPK1 (P = 0.043), CCNA1 (P = 0.016) and TCF21 (P = 0.0005) was significantly more present in HNSCC than in controls. The genes TIMP3 (P = 0.018) and CCNA1 (P = 0.015) showed higher methylation frequency in HPV16 positive HNSCC compared to HPV16 negative tumors. CCNA1 methylation did not correlate with CCNA1 protein expression and p53 mutation, respectively. Methylation of TCF21 was associated with higher age (P = 0.044) and nicotine abuse (P = 0.035). Methylation of CCNA1 was significantly more present in females (P = 0.003). Methylation of TCF21 and CCNA1 are important risk factors for HNSCC development. CCNA1 methylation may play a crucial role in HPV16-induced carcinogenesis of HNSCC independently of p53.",
        "Doc_title":"Promoter methylation of cyclin A1 is associated with human papillomavirus 16 induced head and neck squamous cell carcinoma independently of p53 mutation.",
        "Journal":"Molecular carcinogenesis",
        "Do_id":"21563216",
        "Doc_ChemicalList":"Cyclin A1;DNA Primers",
        "Doc_meshdescriptors":"Aged;Base Sequence;Carcinoma, Squamous Cell;Cyclin A1;DNA Methylation;DNA Primers;Female;Genes, p53;Head and Neck Neoplasms;Human papillomavirus 16;Humans;Immunohistochemistry;In Situ Hybridization;Male;Middle Aged;Mutation;Polymerase Chain Reaction;Promoter Regions, Genetic",
        "Doc_meshqualifiers":"genetics;virology;genetics;genetics;virology;pathogenicity",
        "_version_":1605799387964899328},
      {
        "Doc_abstract":"Hematopoietic stem cells (HSCs) are sustained in a specific microenvironment known as the stem cell niche. Mammalian HSCs are kept quiescent in the endosteal niche, a hypoxic zone of the bone marrow (BM). In this study, we show that normal HSCs maintain intracellular hypoxia and stabilize hypoxia-inducible factor-1alpha (HIF-1alpha) protein. In HIF-1alpha-deficient mice, the HSCs lost their cell cycle quiescence and HSC numbers decreased during various stress settings including bone marrow transplantation, myelosuppression, or aging, in a p16(Ink4a)/p19(Arf)-dependent manner. Overstabilization of HIF-1alpha by biallelic loss of an E3 ubiquitin ligase for HIF-1alpha (VHL) induced cell cycle quiescence in HSCs and their progenitors but resulted in an impairment in transplantation capacity. In contrast, monoallelic loss of VHL induced cell cycle quiescence and improved BM engraftment during bone marrow transplantation. These data indicate that HSCs maintain cell cycle quiescence through the precise regulation of HIF-1alpha levels.",
        "Doc_title":"Regulation of the HIF-1alpha level is essential for hematopoietic stem cells.",
        "Journal":"Cell stem cell",
        "Do_id":"20804974",
        "Doc_ChemicalList":"Hypoxia-Inducible Factor 1, alpha Subunit",
        "Doc_meshdescriptors":"Animals;Bone Marrow;Bone Marrow Transplantation;Cell Count;Cell Cycle;Hematopoietic Stem Cells;Homeostasis;Hypoxia;Hypoxia-Inducible Factor 1, alpha Subunit;Mice;Mice, Knockout;Stem Cell Niche",
        "Doc_meshqualifiers":"cytology;metabolism;physiology;metabolism;cytology;metabolism",
        "_version_":1605747035027275776},
      {
        "Doc_abstract":"ANRIL is a long noncoding RNA transcribed from the INK4 locus that encodes three tumor suppressor genes, p15, p16, and ARF. Previous studies demonstrated that ANRIL represses p15 and p16, which positively regulate the pRB pathway, leading to repression of cellular senescence of human normal fibroblasts. However, the role of ANRIL in cancer cell proliferation is less well understood. Here we report that ANRIL is involved in the proliferation of colorectal cancer HCT116 cells in two- and three-dimensional culture. Silencing ANRIL by both transfection with small interfering RNA and retrovirally produced small hairpin RNA reduced HCT116 cell proliferation in both two- and three-dimensional culture. HCT116 cells depleted for ANRIL were arrested in the S phase of cell cycle. Notably, silencing ANRIL did not result in the activation of expression of the INK4 locus. These results suggest that ANRIL positively regulates the proliferation of HCT116 cells in two- and three-dimensional culture in a p15/p16-pRB pathway-independent manner. ",
        "Doc_title":"ANRIL regulates the proliferation of human colorectal cancer cells in both two- and three-dimensional culture.",
        "Journal":"Molecular and cellular biochemistry",
        "Do_id":"26708220",
        "Doc_ChemicalList":"ANRIL long non-coding RNA, human;RNA, Long Noncoding",
        "Doc_meshdescriptors":"Cell Line, Tumor;Cell Proliferation;Colorectal Neoplasms;Gene Silencing;Humans;RNA, Long Noncoding",
        "Doc_meshqualifiers":"physiology;pathology;genetics;physiology",
        "_version_":1605841384966717440},
      {
        "Doc_abstract":"As a cyclin-dependent kinase inhibitor, p16(INK4a) plays a key role in cell cycle progression and cellular differentiation, and its expression is frequently altered in human cancers through epigenetically mediated transcriptional silencing. In this report, we demonstrate that p300 was able to induce cell cycle arrest, and this process was reversed by p16(INK4a) silencing by RNA interference in HeLa cells. We also show that p300 was involved in activation of p16(INK4a) expression in 293T cells. Specifically, p300 cooperated with Sp1 to stimulate both p16(INK4a) promoter activity and mRNA expression. Co-immunoprecipitation and mammalian two-hybrid assays revealed that p300 and Sp1 formed a complex through interaction between the Q domain of p300 and the N-terminal domain of Sp1. The chromatin immunoprecipitation assays verified that p300 was recruited to p16(INK4a) promoter, and the histone acetyltransferase domain of p300 participated in p16(INK4a) activation through inducing hyperacetylation of histone H4 at p16(INK4a) gene. These data suggest that p300 plays a critical role in transcriptional regulation of p16(INK4a) and in cell cycle arrest.",
        "Doc_title":"P300 plays a role in p16(INK4a) expression and cell cycle arrest.",
        "Journal":"Oncogene",
        "Do_id":"17906698",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;Histones;RNA, Messenger;Sp1 Transcription Factor;E1A-Associated p300 Protein;EP300 protein, human;Histone Acetyltransferases",
        "Doc_meshdescriptors":"Acetylation;Blotting, Western;Chromatin Immunoprecipitation;Colony-Forming Units Assay;Cyclin-Dependent Kinase Inhibitor p16;E1A-Associated p300 Protein;Flow Cytometry;G1 Phase;Gene Expression Regulation, Neoplastic;Gene Silencing;HeLa Cells;Histone Acetyltransferases;Histones;Humans;Immunoprecipitation;Kidney;Mutation;Promoter Regions, Genetic;RNA, Messenger;Reverse Transcriptase Polymerase Chain Reaction;S Phase;Sp1 Transcription Factor;Transcription, Genetic;Transcriptional Activation;Two-Hybrid System Techniques",
        "Doc_meshqualifiers":"antagonists & inhibitors;metabolism;physiology;physiology;metabolism;metabolism;metabolism;genetics;genetics;metabolism;physiology;metabolism",
        "_version_":1605804660361265152},
      {
        "Doc_abstract":"Deletion of the INK4a/ARF locus at 9p21 is detected with high frequency in human melanoma. Within a short genomic distance, this locus encodes several proteins with established tumor-suppressor roles in a broad spectrum of cancer types. Several lines of evidence support the view that p16INK4a and p19ARF exert the tumor-suppressor activities of this locus, although their relative importance in specific cancer types such as melanoma has been less rigorously documented on the genetic level. Here, we exploit a well-defined mouse model of RAS-induced melanomas to examine the impact of germline p16INK4a or p19ARF nullizygosity on melanoma formation. We demonstrate that loss of either Ink4a/Arf product can cooperate with RAS activation to produce clinically indistinguishable melanomas. In line with the common phenotypic end point, we further show that RAS+ p16INK4a-/- melanomas sustain somatic inactivation of p19ARF-p53 and, correspondingly, that RAS+ p19ARF-/- melanomas experience high-frequency loss of p16INK4a. These genetic studies provide definitive proof that p16INK4a and p19ARF cooperate to suppress the development of melanoma in vivo.",
        "Doc_title":"Both products of the mouse Ink4a/Arf locus suppress melanoma formation in vivo.",
        "Journal":"Oncogene",
        "Do_id":"12902988",
        "Doc_ChemicalList":"Cdkn2a protein, mouse;Cyclin-Dependent Kinase Inhibitor p16;Tumor Suppressor Protein p14ARF",
        "Doc_meshdescriptors":"Animals;Cell Transformation, Neoplastic;Cyclin-Dependent Kinase Inhibitor p16;Melanoma;Mice;Tumor Suppressor Protein p14ARF",
        "Doc_meshqualifiers":"metabolism;metabolism;metabolism;metabolism",
        "_version_":1605818597324619778},
      {
        "Doc_abstract":"The cell cycle inhibitor p16(INK4A) (also known as cyclin-dependent kinase inhibitor 2A) is expressed in vivo in many tissues with age. The exposure of certain chronic stresses can trigger p16(INK4A) expression and a senescence-like phenotype. We studied whether p16(INK4A) expression is induced in glomerular disease (GD). We performed p16(INK4A) immunostaining on 35 biopsies with GD, 12 tubulointerstitial nephritis (TIN), and 19 normal live donor kidneys at transplantation. Based on values for 42 normal kidneys, we calculated expected nuclear p16(INK4A) expression for age and compared the observed values in diseased kidneys to those expected for age. In GD, p16(INK4A) expression was strikingly increased in glomerular and interstitial cell nuclei compared to normals and TIN, and could not be attributed to age (P<0.05). By multivariate analyses, GD was independently associated with increased nuclear p16(INK4a) expression in glomeruli (P<0.001) and interstitium (P=0.01). The p16(INK4A) expression in glomerular and interstitial cell nuclei, and tubular cytoplasm was higher in kidneys with proteinuria and with atrophy/fibrosis (P<0.05). Older age was associated with increased nuclear p16(INK4a) expression in tubules (P=0.01), and interstitial inflammation was associated with increased nuclear p16(INK4a) expression in interstitial cells (P=0.001). The p16(INK4a) staining in tubular cytoplasm was increased in both GD and TIN compared to normals (P<0.001), and was not related to age (P>0.05). Thus, kidneys with GD display increased expression of senescence marker p16(INK4A) in glomerular and interstitial cell nuclei compared to kidneys with normal aging or TIN. The findings suggest a role for somatic cell senescence mechanisms in progression of GD.",
        "Doc_title":"Accelerated expression of senescence associated cell cycle inhibitor p16INK4A in kidneys with glomerular disease.",
        "Journal":"Kidney international",
        "Do_id":"17183247",
        "Doc_ChemicalList":"Biomarkers;Cyclin-Dependent Kinase Inhibitor p16",
        "Doc_meshdescriptors":"Adult;Age Factors;Aged;Aged, 80 and over;Aging;Biomarkers;Cell Cycle;Cell Nucleus;Cyclin-Dependent Kinase Inhibitor p16;Cytoplasm;Female;Glomerulonephritis;Humans;Immunohistochemistry;Kidney Glomerulus;Male;Middle Aged;Nephritis, Interstitial;Proteinuria",
        "Doc_meshqualifiers":"metabolism;analysis;chemistry;analysis;metabolism;chemistry;metabolism;pathology;chemistry;metabolism;pathology;metabolism;pathology;metabolism",
        "_version_":1605909303627087872},
      {
        "Doc_abstract":"The immortalization process is a fundamental step in the development of most (if not all) human cancers, including the aggressive endothelial cell (EC)-derived malignancy angiosarcoma. Inactivation of the tumor suppressor p16(INK4a) and the development of multiple chromosomal abnormalities are features of angiosarcoma that are recapitulated during telomerase-mediated immortalization of human ECs in vitro. The present study used a panel of telomerase-immortalized bone marrow EC (BMEC) lines to define the consequences of inactivation of p16(INK4a) on EC function and to identify molecular changes associated with repression of p16(INK4a). In a comparison of two immortalized BMEC mass cultures and six clones, the cell lines that repressed p16(INK4a) showed a higher rate of proliferation and an impaired ability to undergo morphogenic differentiation and form vessel-like structures in vitro. Proteomic comparison of a p16(INK4a)-negative and a p16(INK4a)-positive BMEC mass culture at early- and late-passage time points following transduction with telomerase reverse transcriptase (hTERT) revealed altered expression of cytoskeletal proteins, including vimentin and -tropomyosin (Tm), in the immortal cells. Immunoblot analyses of a panel of 11 immortal clones showed that cells that lacked p16(INK4a) expression tended to accumulate more dramatic changes in these cytoskeletal proteins than cells that retained p16(INK4a) expression. This corresponded with aberrant cytoskeletal architectures among p16(INK4a)-negative clones, which featured thicker actin stress fibers and less fluid membrane ruffles than p16(INK4a)-positive cells. A direct link between p16(INK4a) repression and defective EC function was confirmed by analysis of normal cells transfected with small interfering RNA (siRNA) targeting p16(INK4a). siRNA-mediated repression of p16(INK4a) significantly impaired random motility and vessel formation in vitro. This report is the first to demonstrate that ECs that repress the expression of p16(INK4a) are prone to defects in motility, morphogenesis and cytoskeletal organization. These defects are likely to reflect alterations that occur during the development of EC-derived malignancies.",
        "Doc_title":"Endothelial cell dysfunction and cytoskeletal changes associated with repression of p16(INK4a) during immortalization.",
        "Journal":"Oncogene",
        "Do_id":"22310292",
        "Doc_ChemicalList":"Actins;Cyclin-Dependent Kinase Inhibitor p16;Cytoskeletal Proteins;Tropomyosin;Vimentin;TERT protein, human;Telomerase",
        "Doc_meshdescriptors":"Actins;Bone Marrow Cells;Cell Differentiation;Cell Line;Cell Movement;Cell Proliferation;Cyclin-Dependent Kinase Inhibitor p16;Cytoskeletal Proteins;Cytoskeleton;Endothelial Cells;Humans;Proteomics;Telomerase;Tropomyosin;Vimentin",
        "Doc_meshqualifiers":"genetics;metabolism;metabolism;physiology;genetics;physiology;genetics;genetics;metabolism;genetics;metabolism;metabolism;physiology;cytology;metabolism;physiology;methods;genetics;metabolism;genetics;metabolism;genetics;metabolism",
        "_version_":1605765863757053952},
      {
        "Doc_abstract":"-Testing for high-risk human papillomavirus (HR-HPV) in head and neck squamous cell carcinomas (HNSCCs) is important for both prognostication and clinical management. Several testing platforms are available for HR-HPV; however, effective alternative automated approaches are needed.;-To assess the performance of the automated Roche cobas 4800 HPV real-time polymerase chain reaction-based system on formalin-fixed, paraffin-embedded HNSCC specimens and compare results with standard methods of in situ hybridization (ISH) and p16 immunohistochemistry.;-Formalin-fixed, paraffin-embedded samples of HNSCC were collected from archival specimens in the Department of Pathology, Massachusetts General Hospital (Boston), and prepared using the automated system by deparaffinization and dehydration followed by tissue lysis. Samples were integrated into routine cervical cytology testing runs by cobas. Corresponding formalin-fixed, paraffin-embedded samples were evaluated for HR-HPV by ISH and p16 by immunohistochemistry. Discrepant cases were adjudicated by polymerase chain reaction.;-Sixty-two HNSCC samples were analyzed using the automated cobas system, ISH, and immunohistochemistry. Fifty-two percent (n = 32 of 62) of formalin-fixed, paraffin-embedded tumors were positive for HR-HPV by cobas. Eighty-eight percent (n = 28 of 32) of cases were the HPV 16 subtype and 12% (n = 4 of 32) were other HR-HPV subtypes. Corresponding testing with ISH was concordant in 92% (n = 57 of 62) of cases. Compared with the adjudication polymerase chain reaction standard, there were 3 false-positive cases by cobas.;-Concordance in HNSCC HR-HPV status between cobas and ISH was more than 90%. The cobas demonstrated a sensitivity of 100% and a specificity of 91% for detection of HR-HPV. Advantages favoring cobas include its automation, cost efficiency, objective results, and ease of performance.",
        "Doc_title":"Automated Extraction of Formalin-Fixed, Paraffin-Embedded Tissue for High-Risk Human Papillomavirus Testing of Head and Neck Squamous Cell Carcinomas Using the Roche Cobas 4800 System.",
        "Journal":"Archives of pathology & laboratory medicine",
        "Do_id":"27031775",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605818731764645888},
      {
        "Doc_abstract":"Basal cell carcinoma (BCC) develops predominantly in sun-exposed skin in fair-skinned individuals prone to sunburn. BCC typically occurs in adults. High exposure to ultraviolet (UV) radiation increases rate of developing BCC, a slowly growing tumor that occurs in hair-growing squamous epithelium and rarely metastasizes. In genetic studies, BCC patients have cell-cycle abnormalities of different parts of the signaling pathway. Retinoblastoma regulatory pathway is important in cell cycle arrest. In this pathway, p16INK4a, an inhibitor of Rb pathway, binds to CDK4 and CDK6 competitively with cyclin D1 to prevent phosphorylation of tumor suppressor pRB gene. Alteration of this pathway contributes to development of human cancers and also is effective in skin cancers. In this study, we analyzed mRNA expression using in situ RT-PCR and the role of immunohistochemical expression of p16INK4a in BCC.;Expression of p16 in ten samples of Iranian paraffin-embedded skin BCC were studied using in situ RT-PCR and immunohistochemistry on p16INK4a gene.;Nuclear and cytoplasmic staining intensity of samples within tumor cells and normal skin tissue illustrates different mRNA and protein expression of p16 gene. mRNA of p16 gene and the expressed protein induce cell cycle proliferation and involve both tumor tissue as well as normal skin tissue. However, in this study it was found that there is significant protein and mRNA expression in BCC cells when compared to normal skin tissue (p<0.05).;p16 gene is involved in the pathogenesis of human skin BCC in view of increased p16 mRNA and expressed protein within tumor cells.",
        "Doc_title":"p16 gene expression in basal cell carcinoma.",
        "Journal":"Archives of medical research",
        "Do_id":"18760195",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16",
        "Doc_meshdescriptors":"Carcinoma, Basal Cell;Cyclin-Dependent Kinase Inhibitor p16;Gene Expression Regulation, Neoplastic;Genes, p16;Humans;Reverse Transcriptase Polymerase Chain Reaction;Skin Neoplasms",
        "Doc_meshqualifiers":"genetics;metabolism;pathology;metabolism;genetics;metabolism;pathology",
        "_version_":1605747562300571648},
      {
        "Doc_abstract":"Cellular senescence, an irreversible growth arrest, is considered to play as safeguard against malignant progression, though such a mechanism is speculative in human carcinogenesis. In gallbladder carcinoma, cholecystolithiasis and pancreaticobiliary maljunction (PBM) are major risk factors. Here, by using 113 surgically resected gallbladders and cultures of human gallbladder epithelial cells (HGECs) and gallbladder carcinoma cell line (TGBC2TKB), we examined carcinogenesis with respect to cellular senescence. Among 15 cases of PBM in which carcinoma was found in 4 cases, nonneoplastic gallbladder mucosa showed diffuse papillary hyperplasia (PHP). PHP was not found in gallbladders with cholecystolithiasis. Interestingly, PHP exhibited senescent features such as expression of p16(INK4A) and low cell proliferative activity. In contrast, EZH2, a polycomb group protein, was overexpressed in intraepithelial neoplasm and carcinoma in gallbladders with cholecystolithiasis. In PBM, EZH2 was expressed only in carcinoma foci but not in PHP. Cultured HGECs treated with lysolecithin, the level of which is elevated in gallbladder bile of PBM, showed increased expression of p16(INK4A) and senescence-associated beta-galactosidase. Conversely, enforced overexpression of EZH2 in senescent HGECs reduced p16(INK4A) expression. A knockdown of EZH2 in cultured TGBC2TKB cells increased p16(INK4a) expression. In conclusion, PHP in PBM may act as a barrier to malignant transformation for decades. EZH2 may be responsible for the escape from cellular senescence followed by malignant transformation in the gallbladder of PBM.",
        "Doc_title":"Papillary hyperplasia of the gallbladder in pancreaticobiliary maljunction represents a senescence-related lesion induced by lysolecithin.",
        "Journal":"Laboratory investigation; a journal of technical methods and pathology",
        "Do_id":"19564843",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;DNA-Binding Proteins;Lysophosphatidylcholines;Transcription Factors;EZH2 protein, human;Enhancer of Zeste Homolog 2 Protein;Polycomb Repressive Complex 2",
        "Doc_meshdescriptors":"Adolescent;Adult;Aged;Aged, 80 and over;Aging;Carcinoma in Situ;Cell Line, Tumor;Cell Proliferation;Cell Transformation, Neoplastic;Cholecystolithiasis;Common Bile Duct;Common Bile Duct Diseases;Cyclin-Dependent Kinase Inhibitor p16;DNA-Binding Proteins;Enhancer of Zeste Homolog 2 Protein;Epithelial Cells;Female;Gallbladder;Gallbladder Neoplasms;Gene Silencing;Humans;Hyperplasia;Lysophosphatidylcholines;Male;Middle Aged;Pancreatic Diseases;Pancreatic Ducts;Polycomb Repressive Complex 2;Transcription Factors;Young Adult",
        "Doc_meshqualifiers":"metabolism;pathology;metabolism;pathology;metabolism;pathology;complications;pathology;abnormalities;complications;metabolism;pathology;metabolism;metabolism;drug effects;pathology;metabolism;pathology;complications;metabolism;pathology;metabolism;pharmacology;complications;metabolism;pathology;abnormalities;metabolism",
        "_version_":1605747095319347200},
      {
        "Doc_abstract":"Alteration of the p16/pRb pathway may cooperate with telomerase activation during cellular immortalization and tumour progression. We studied p16 expression status by immunohistochemistry and telomerase activity using the TRAP assay in 21 premalignant lesions of the head and neck epithelium as well as 27 squamous-cell carcinomas. We also examined expression of other components of the pathway (cyclin D1 and pRb) as well as presence of human papillomavirus genomes which can target these molecules. 4 of 9 mild dysplastic lesions (44%), 8 of 12 moderate/severe dysplastic lesions (67%), and 25 of 27 squamous-cell carcinomas (92%) demonstrated high telomerase activity (P = 0.009). There was a parallel increase with severity of lesions for the trend in proportions of cases demonstrating p16 inactivation or cyclin D1 overexpression (P = 0.02 and P = 0.01, respectively). For Ki67, a marker of cell proliferation, this trend was not significant (P = 0.08). Human papillomavirus infection was only found in 4 cases among the 48 samples tested (8.3%). In conclusion, progression of disease is accompanied by a parallel and continuous increase in telomerase activity and alterations in cell cycle regulators (p16, cyclin D1), as proposed by in vitro models.",
        "Doc_title":"Telomerase activation cooperates with inactivation of p16 in early head and neck tumorigenesis.",
        "Journal":"British journal of cancer",
        "Do_id":"11207046",
        "Doc_ChemicalList":"DNA, Neoplasm;Telomerase",
        "Doc_meshdescriptors":"Adult;Aged;Carcinoma, Squamous Cell;Cell Cycle;Cell Transformation, Neoplastic;DNA, Neoplasm;Disease Progression;Enzyme-Linked Immunosorbent Assay;Female;Gene Expression Regulation, Neoplastic;Genes, p16;Head and Neck Neoplasms;Humans;Immunohistochemistry;Male;Middle Aged;Papillomaviridae;Polymerase Chain Reaction;Severity of Illness Index;Telomerase",
        "Doc_meshqualifiers":"enzymology;genetics;genetics;genetics;enzymology;genetics;genetics;genetics;metabolism",
        "_version_":1605818710810951681},
      {
        "Doc_abstract":"ONYX-015 has been reported to kill selectively tumor cells lacking functional p53. Genetic alterations of INK4a/ARF locus, which is a predominant event in malignant pleural mesothelioma, may result in loss of p14(ARF) and subsequent disruption of p53 pathway in cancer cells. In the present study, ONYX-015 was able to kill three mesothelioma cell lines (H28, H513, and 211H) with wild-type p53 but lacking p14(ARF). In contrast, MS-1 mesothelioma cells, which expressed both p53 and p14(ARF), were resistant to ONYX-015. Introducing p14(ARF) gene into the H28 cell, a mesothelioma cell without p14(ARF) expression, significantly increased the resistance of this cell line to the cytolytic effect of ONYX-015. Our results suggest that human mesotheliomas with wild-type p53 yet lacking p14(ARF) are potential candidates for ONYX-015 therapy.",
        "Doc_title":"p14(ARF) modulates the cytolytic effect of ONYX-015 in mesothelioma cells with wild-type p53.",
        "Journal":"Cancer research",
        "Do_id":"11507034",
        "Doc_ChemicalList":"Adenovirus E1B Proteins;CDKN1A protein, human;Cyclin-Dependent Kinase Inhibitor p21;Cyclins;Proteins;Tumor Suppressor Protein p14ARF;Tumor Suppressor Protein p53",
        "Doc_meshdescriptors":"Adenovirus E1B Proteins;Adenoviruses, Human;Cyclin-Dependent Kinase Inhibitor p21;Cyclins;Cytopathogenic Effect, Viral;Genes, p53;Genetic Therapy;Genetic Vectors;Humans;Mesothelioma;Pleural Neoplasms;Protein Biosynthesis;Proteins;Tumor Cells, Cultured;Tumor Suppressor Protein p14ARF;Tumor Suppressor Protein p53",
        "Doc_meshqualifiers":"genetics;genetics;physiology;biosynthesis;genetics;genetics;methods;genetics;genetics;metabolism;therapy;virology;genetics;metabolism;therapy;virology;genetics;physiology;biosynthesis;physiology",
        "_version_":1605928887827562496},
      {
        "Doc_abstract":"We studied the methylation status of the CpG promoter regions of the p16 and p14 genes, mutations of four exons of the CDKN2A gene, and expressions of their corresponding proteins. Thirty-two frozen osteosarcoma tissues were used for methylation-specific polymerase chain reaction and sequence analysis. Immunohistochemical staining for p16 and p14 proteins was done. The histologic and clinical data were analyzed to find their prognostic implications. The promoter of p16 gene was methylated in 16%, and p14 in 47%. Poor survival was related to methylation of p14. The methylation of p14 correlated with down-regulation of its protein expression. The methylation of p14 showed the highest hazard ratio by multivariate survival analysis. Our data suggest methylation of the CDKN2A gene is the main mechanism of its protein repression. For the p14 gene, methylation of the promoter region was related to repression of p14 protein and poor prognosis.;Prognostic study, Level II (retrospective study). See the Guidelines for Authors for a complete description of levels of evidence.",
        "Doc_title":"Aberrant methylation of p14ARF gene correlates with poor survival in osteosarcoma.",
        "Journal":"Clinical orthopaedics and related research",
        "Do_id":"16394764",
        "Doc_ChemicalList":"Tumor Suppressor Protein p14ARF",
        "Doc_meshdescriptors":"Adolescent;Adult;Bone Neoplasms;Child;Child, Preschool;DNA Methylation;Exons;Female;Gene Expression;Genes, p16;Humans;Immunoenzyme Techniques;Male;Middle Aged;Mutation;Osteosarcoma;Polymerase Chain Reaction;Prognosis;Promoter Regions, Genetic;Retrospective Studies;Survival Analysis;Tumor Suppressor Protein p14ARF",
        "Doc_meshqualifiers":"genetics;genetics;genetics",
        "_version_":1605818566194495488},
      {
        "Doc_abstract":"Cervical cancer caused by the human papillomavirus (HPV) is endemic in East Africa. Recent, dramatic, increases in the incidence of oropharyngeal cancer in the United States and Europe are linked to the same high risk HPV genotypes responsible for cervical cancer. Currently, there is extremely limited data regarding the role of HPV in head and neck cancers in Africa. Evidence of HPV as an etiologic agent in head and neck cancers in Africa would have important prevention and treatment implications.;A retrospective single institution review of oral tongue and oropharyngeal squamous cell carcinomas diagnosed between 2005 and 2013 was performed. Individual case data for 51 patients with biopsy proven squamous cell carcinoma (SCC) from the oropharynx (n=22) and oral tongue (n=29) were identified. Formalin fixed, paraffin embedded biopsy samples were obtained and evaluated for p16 by immunohistochemistry and HPV genotype 16 specific oncogenes, E6 and E7, by PCR.;All of the positive controls, but none of the oropharyngeal samples stained positively for p16. Two of the oral tongue samples stained positive for p16. None of the oropharyngeal or oral tongue cases demonstrated PCR products for HPV-16 E6 or E7.;Though Mozambique has extremely high levels of HPV positive cervical cancer this study demonstrates an absence of HPV positive oropharyngeal or oral tongue squamous cell carcinoma within biopsy samples from a single referral hospital in Maputo, the capital of Mozambique.",
        "Doc_title":"Investigation of the presence of HPV related oropharyngeal and oral tongue squamous cell carcinoma in Mozambique.",
        "Journal":"Cancer epidemiology",
        "Do_id":"26590333",
        "Doc_ChemicalList":"DNA, Viral",
        "Doc_meshdescriptors":"Adult;Biopsy;Carcinoma, Squamous Cell;DNA, Viral;Female;Humans;Immunohistochemistry;Male;Middle Aged;Mozambique;Oropharyngeal Neoplasms;Papillomaviridae;Papillomavirus Infections;Polymerase Chain Reaction;Retrospective Studies;Tongue Neoplasms",
        "Doc_meshqualifiers":"pathology;virology;analysis;genetics;epidemiology;pathology;virology;genetics;complications;epidemiology;virology;pathology;virology",
        "_version_":1605876215194845184},
      {
        "Doc_abstract":"The cell cycle inhibitor p16(INK4A) is frequently inactivated in acute lymphoblastic T-cell leukemia (T-ALL). We analyzed mechanisms and consequences of p16(INK4A) reconstitution in T-ALL cells lacking this tumor suppressor. CCRF-CEM cells with tetracycline-regulated p16(INK4A) expression underwent stable G1-phase cell cycle arrest for 72 h followed by massive apoptosis. p16(INK4A) expression caused pRB hypophosphorylation and repression of certain E2F target genes. Interestingly, cyclin E and c-Myc were not affected, suggesting pRB/E2F-independent expression of these E2F targets. Cyclin E/CDK2, however, was inactive due to stabilization and redistribution of p27(Kip1) from CDK4/CDK6 to CDK2. Analyses of c-Myc target genes suggested that c-Myc was transcriptionally inactive, which correlated with hypophosphorylation of the c-Myc inhibitor p107. Thus, p16(INK4A), although unable to repress the expression of deregulated cyclin E and c-Myc, functionally inactivated these potential oncogenes. p16(INK4A)-arrested cells showed morphologic changes, induction of T-cell-specific surface markers and repression of telomerase activity, suggesting differentiation. Moreover, p16(INK4A) reconstitution was associated with increased cellular volume, normal protein synthesis rates and elevated ATP levels. Taken together, p16(INK4A) reconstitution in p16(INK4A)-deficient T-ALL cells induced cell cycle arrest in the presence of cyclin E and c-Myc expression, uncoupled growth from cell cycle progression and caused a sequential process of growth, differentiation and apoptosis.",
        "Doc_title":"G1 arrest by p16INK4A uncouples growth from cell cycle progression in leukemia cells with deregulated cyclin E and c-Myc expression.",
        "Journal":"Leukemia",
        "Do_id":"15800668",
        "Doc_ChemicalList":"Biomarkers, Tumor;Cyclin E;Cyclin-Dependent Kinase Inhibitor p16;Nuclear Proteins;RBL1 protein, human;Retinoblastoma-Like Protein p107;Telomerase",
        "Doc_meshdescriptors":"Apoptosis;Biomarkers, Tumor;Cell Differentiation;Cell Division;Child;Cyclin E;Cyclin-Dependent Kinase Inhibitor p16;G1 Phase;Gene Expression Regulation, Leukemic;Genes, myc;Humans;Nuclear Proteins;Phosphorylation;Precursor Cell Lymphoblastic Leukemia-Lymphoma;Retinoblastoma-Like Protein p107;T-Lymphocytes;Telomerase;Transcriptional Activation",
        "Doc_meshqualifiers":"physiology;physiology;physiology;genetics;genetics;metabolism;physiology;physiology;genetics;metabolism;metabolism;pathology;physiopathology;pathology;physiology;metabolism;physiology",
        "_version_":1605811146462330880},
      {
        "Doc_abstract":"Human papillomavirus (HPV) positive tonsillar squamous cell carcinoma (TSCC) is associated with a favorable clinical outcome. However, the HPV detected in a given tumor may be causal (driver HPV) or an incidental bystander (passenger HPV). There is a need to discriminate these forms of HPV in TSCCs to understand their impact on HPV as a biomarker for use in TSCC patient management. This study has compared the polymerase chain reaction (PCR), chromogenic in situ hybridization (CISH), and p16(INK4a) immunohistochemistry in the assessment of HPV status in TSCC. Archival specimens of TSCC from thirty patients were investigated. HPV was detected by PCR in 25/30 (83.3%) tumors; HPV16 (70.0%) and HPV52 (6.7%) were the most common types. HPV was corroborated by CISH in 22/25 (88.0%) specimens; integrated HPV was implicated by the presence of punctate signals in each of these cases. p16(INK4a) staining was found in 20/22 (90.9%) HPV PCR positive samples; two PCR/CISH HPV positive cases were p16(INK4a) negative and two HPV negative samples were p16(INK4a) positive. These data suggest that a minority of HPV positive TSCCs are positive for passenger HPV and that two or more assays may be required for diagnosing driver HPV status. Further studies are required to exam whether oropharyngeal tumors positive for passenger HPV have a less favorable prognosis than tumors that are driver HPV positive. The clinical significance of TSCCs that test HPV negative/p16(INK4a) positive, PCR and CISH HPV positive/p16 (INK4a) negative, or PCR HPV positive/p16 (INK4a) and CISH negative, also requires further investigation.",
        "Doc_title":"Discrimination of 'driver' and 'passenger' HPV in tonsillar carcinomas by the polymerase chain reaction, chromogenic in situ hybridization, and p16(INK4a) immunohistochemistry.",
        "Journal":"Head and neck pathology",
        "Do_id":"21786153",
        "Doc_ChemicalList":"Biomarkers, Tumor;Cyclin-Dependent Kinase Inhibitor p16;DNA, Viral",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Biomarkers, Tumor;Carcinoma, Squamous Cell;Cyclin-Dependent Kinase Inhibitor p16;DNA, Viral;Female;Genotype;Humans;Immunohistochemistry;In Situ Hybridization;Male;Middle Aged;Papillomaviridae;Polymerase Chain Reaction;Prognosis;Retrospective Studies;Tonsillar Neoplasms",
        "Doc_meshqualifiers":"metabolism;diagnosis;metabolism;virology;metabolism;genetics;metabolism;classification;genetics;diagnosis;metabolism;virology",
        "_version_":1605831034703708160},
      {
        "Doc_abstract":"The Arf tumor suppressor inhibits cell cycle progression through both p53-dependent and p53-independent mechanisms, including interference with rRNA processing. Using tandem-affinity-tagged p19(Arf), we purified Arf-associated proteins from mouse NIH 3T3 fibroblasts undergoing cell cycle arrest. Tagged p19(Arf) associated with nucleolar and ribosomal proteins, including nucleophosmin/B23 (NPM), a protein thought to foster the maturation of preribosomal particles. NPM is an abundant protein, only a minor fraction of which binds to p19(Arf); however, a significant proportion of p19(Arf) associates with NPM. The interaction between p19(Arf) and NPM requires amino acid sequences at the Arf amino terminus, which are also required for Mdm2 binding, as well as the central acidic domain of NPM and an adjacent segment that regulates NPM oligomerization. The interaction between p19(Arf) and NPM occurs in primary mouse embryonic fibroblasts, including those lacking both Mdm2 and p53. In an NIH 3T3 derivative cell line (MT-Arf) engineered to conditionally express an Arf transgene, induced p19(Arf) associates with NPM and colocalizes with it in high-molecular-weight complexes (2 to 5 MDa). An NPM mutant lacking its carboxyl-terminal nucleic acid-binding domain oligomerizes with endogenous NPM, inhibits p19(Arf) from entering into 2- to 5-MDa particles, and overrides the ability of p19(Arf) to retard rRNA processing.",
        "Doc_title":"Physical and functional interactions of the Arf tumor suppressor protein with nucleophosmin/B23.",
        "Journal":"Molecular and cellular biology",
        "Do_id":"14729947",
        "Doc_ChemicalList":"Cdkn2a protein, mouse;Cyclin-Dependent Kinase Inhibitor p16;Nuclear Proteins;RNA, Ribosomal;Tumor Suppressor Protein p14ARF;nucleophosmin",
        "Doc_meshdescriptors":"Animals;Cyclin-Dependent Kinase Inhibitor p16;Genes, Reporter;Mice;Mutation;NIH 3T3 Cells;Nuclear Proteins;Protein Binding;RNA, Ribosomal;Ribosomes;Transfection;Tumor Suppressor Protein p14ARF",
        "Doc_meshqualifiers":"genetics;metabolism;metabolism;metabolism;metabolism",
        "_version_":1605911152582197248},
      {
        "Doc_abstract":"Basal cell carcinoma of the skin is the most common neoplasia in humans. Previous studies have shown the existence of allelic imbalance (loss of heterozygosity and microsatellite instability) in BCC on several human chromosomes. Chromosome region 9p21-p22 harbors the CDKN2a/p16INK4a, p19ARF, and p15INK4b tumor suppressor genes. To determine the contribution of these genes to the development of basal cell carcinomas we looked for evidence of allelic imbalance in 67 sporadic basal cell carcinoma specimens from Greek patients and screened 28 of them presenting loss of heterozygosity at 9p21-p22 for germline mutations in p16INK4a and p19ARF genes. Chromosome regions 17q21 and 17p13 were also screened for allelic imbalance in all the 67 basal cell carcinoma specimens. Overall, 69% (46 of 67) of the specimens displayed loss of heterozygosity in at least one microsatellite marker, whereas only six of the 67 (9%) exhibited microsatellite instability. For the 9p21-p22 locus the overall frequency of loss of heterozygosity reached 55% (37 of 67) and is the highest reported. The overall frequency of loss of heterozygosity for the 17q21 locus is 34% (22 of 64) and for the 17p13 locus is 11% (seven of 65). Two of the 28 loss of heterozygosity positive cases were heterozygous for a previously described polymorphism, Ala148Thr, in exon 2 of the CDKN2a gene. This is the first demonstration of polymorphism in the CDKN2a gene in human basal cell carcinomas. No sequence variation in exon 1beta of the p19ARF gene was found. Our results provide evidence of a significantly high occurrence of loss of heterozygosity for the 9p21-p22 locus; however, lack of p16INK4a/p19ARF mutation suggests that these genes seem not to be implicated by mutational inactivation in the development of basal cell carcinoma. Other(s), yet unidentified, tumor suppressor gene(s) located in this locus may be related to this specific type of skin cancer.",
        "Doc_title":"High frequency of loss of heterozygosity on chromosome region 9p21-p22 but lack of p16INK4a/p19ARF mutations in greek patients with basal cell carcinoma of the skin.",
        "Journal":"The Journal of investigative dermatology",
        "Do_id":"10998150",
        "Doc_ChemicalList":"Carrier Proteins;Cyclin-Dependent Kinase Inhibitor p16",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Carcinoma, Basal Cell;Carrier Proteins;Chromosomes, Human, Pair 9;Cyclin-Dependent Kinase Inhibitor p16;Female;Genes, Tumor Suppressor;Greece;Humans;Loss of Heterozygosity;Male;Middle Aged;Mutation;Polymorphism, Genetic;Skin Neoplasms",
        "Doc_meshqualifiers":"epidemiology;genetics;genetics;genetics;epidemiology;epidemiology;genetics",
        "_version_":1605880269395460096},
      {
        "Doc_abstract":"Transitional cell tumors of the ovary include benign, borderline (atypically proliferating), and malignant Brenner tumors (BT), as well as transitional cell carcinoma (TCC). Some TCCs could conceivably be examples of malignant BT where the benign component has been overgrown. Our objectives were: (A) compare the immunophenotypes of BT and TCC and (B) examine a large cohort of ovarian carcinomas for cases with the immunophenotype of BT and transitional features but lacking a benign BT component. Seven BTs (3 benign, 3 borderline/atypically proliferating, 1 malignant) and 7 TCCs were stained for WT1, ER, p53, and p16(INK4a). The BTs were negative for WT1, p53 overexpression, ER (except for weak positivity in 1), and negative or weakly positive for p16(INK4a). In contrast, the TCCs stained as follows: 4/6 positive for WT1, 5/7 positive for ER, 2/7 strongly positive for p16(INK4a), and 6/7 showed abnormal p53, an immunophenotype resembling that of high-grade serous carcinoma. A database of 500 cases of ovarian carcinoma was searched and 116 showed an immunoprofile characteristic of BT: WT1 negative, ER negative, p16(INK4a) or weak positive, p53 negative (77 clear cell carcinoma, 14 endometrioid carcinoma, 12 mucinous carcinoma, 8 high-grade serous carcinoma). None of these tumors showed transitional features on review, indicating that if examples of malignant BT where there has been overgrowth of benign BT components exist, they are rare. Our results suggest that BT and TCC are unrelated, and should not be combined for classification purposes.",
        "Doc_title":"Transitional cell carcinoma of the ovary is related to high-grade serous carcinoma and is distinct from malignant brenner tumor.",
        "Journal":"International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists",
        "Do_id":"23018212",
        "Doc_ChemicalList":"Keratin-20;Neoplasm Proteins;P16 protein, human;Receptors, Estrogen;Tumor Suppressor Protein p53",
        "Doc_meshdescriptors":"Brenner Tumor;Carcinoma, Transitional Cell;Cystadenocarcinoma, Serous;Female;Humans;Immunohistochemistry;Immunophenotyping;Keratin-20;Neoplasm Proteins;Ovarian Neoplasms;Receptors, Estrogen;Tumor Suppressor Protein p53",
        "Doc_meshqualifiers":"chemistry;pathology;chemistry;pathology;chemistry;pathology;analysis;analysis;chemistry;pathology;analysis;analysis",
        "_version_":1605762620014460928},
      {
        "Doc_abstract":"Human papillomavirus 16 (HPV-16) has been implicated as a causative agent in a subset of head and neck squamous cell carcinomas (HNSCC). This study was undertaken to discern the distribution and timing of HPV viral integration during tumorigenesis of the upper respiratory tract.;A tissue array was assembled from a consecutive group of 176 patients with HNSCCs. The array was evaluated by HPV-16 in situ hybridization and p16 immunohistochemistry. Patients with HPV-positive tonsillar cancers who had undergone bilateral tonsillectomies were selected for more complete mapping of viral integration.;HPV-16 was detected in 38 of the 176 (22%) cases by in situ hybridization. When stratified by site of origin, HPV-16 was detected in 37 of 45 cancers arising from the oropharynx but in only 1 of 131 tumors arising from nonoropharyngeal sites (82% versus 0.8%, P < 0.00001). P16 expression was associated with the presence of HPV-16: 31 of 38 HPV-positive tumors exhibited p16 expression, whereas only 9 of the 138 HPV-negative tumors were p16-positive (82% versus 6%, P < 0.00001). In the bilateral tonsil sections, hybridization signals were strictly limited to the invasive cancers and associated dysplasias. P16 staining was widely distributed throughout the nonneoplastic crypt epithelium of individuals with and without tonsillar cancer.;HPV-16 is strongly associated with carcinomas arising from the oropharynx, and integration is tightly coupled to the neoplastic process. Viral integration does not occur as a field alteration throughout normal tonsillar epithelium. P16 expression localizes to HPV-positive cancers, and is intrinsic to the specialized epithelium of the tonsillar crypts. For risk assessment, early cancer detection and disease surveillance, evidence of HPV-16 integration may represent a meaningful finding, whereas high p16 expression, by itself, may not.",
        "Doc_title":"Tissue distribution of human papillomavirus 16 DNA integration in patients with tonsillar carcinoma.",
        "Journal":"Clinical cancer research : an official journal of the American Association for Cancer Research",
        "Do_id":"16115905",
        "Doc_ChemicalList":"DNA, Viral",
        "Doc_meshdescriptors":"Carcinoma, Squamous Cell;DNA, Viral;Humans;Immunohistochemistry;In Situ Hybridization;Palatine Tonsil;Papillomaviridae;Papillomavirus Infections;Tonsillar Neoplasms",
        "Doc_meshqualifiers":"pathology;virology;genetics;pathology;virology;genetics;metabolism;pathology;virology;pathology;virology",
        "_version_":1605903898897285120},
      {
        "Doc_abstract":"The inactivation of the tumor suppressor gene p16 plays an important role in the development of malignant tumors. p16 loss can result from point mutations, loss of heterozygosity (LOH) or methylation of the promoter region. A total of 67 samples of tumor tissue from squamous cell carcinoma of the oral cavity, the pharynx and the larynx were analyzed for an inactivation of p16. The results of the molecular-biological investigations were correlated with the known clinical prognostic parameters after a follow-up period of approximately 3 years. Methylation of the promoter region and LOH were the main mechanisms of p16 inactivation. Point mutations presented as rare events. An inactivation of p16 did not have any statistical influence on tumor prognosis. Patients with a p16 gene inactivated by promoter methylation appeared to have a slightly lower tendency for local and regional recurrences. The inactivation of the tumor suppressor gene p16 plays a role in the carcinogenesis of head and neck cancer.",
        "Doc_title":"The prognostic relevance of p16 inactivation in head and neck cancer.",
        "Journal":"ORL; journal for oto-rhino-laryngology and its related specialties",
        "Do_id":"17085950",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Carcinoma, Squamous Cell;DNA Methylation;Gene Silencing;Genes, p16;Humans;Loss of Heterozygosity;Otorhinolaryngologic Neoplasms;Point Mutation;Prognosis;Promoter Regions, Genetic;Survival Rate",
        "Doc_meshqualifiers":"genetics;mortality;genetics;mortality",
        "_version_":1605754666384097280},
      {
        "Doc_abstract":"Cervical cancer develops from precancerous high-grade cervical intraepithelial neoplasia (CIN) harboring a transforming infection with high-risk human papillomavirus, which is characterized by p16(INK4a) overexpression. Once such a lesion has developed, progression toward an invasive squamous cell carcinoma (SCC) may take one or more decades, underlining the heterogeneity of these lesions in terms of duration of existence and progression risk. We performed array-based comparative genomic hybridization (array CGH) on 46 p16(INK4a) immunopositive CIN2/3 lesions to determine whether this heterogeneity is reflected in their chromosomal profiles. Chromosomal profiles of CIN2/3 lesions were related to those of invasive cervical SCC and promoter methylation of CADM1, a tumor suppressor gene known to be functionally involved in the tumorigenic phenotype of cervical cancer cells. Frequent alterations found in CIN2/3 lesions included gains located at chromosome 1, 3, 7, and 20 and losses located at 4, 11, 16, 17, and 19. Unsupervised hierarchical clustering identified two subsets of CIN2/3 lesions, chromosomal profiles of one of which closely resembled invasive SCCs. Gains of 1, 3q, and 20 were characteristic for CIN2/3 lesions with chromosomal signatures resembling carcinomas. In addition, dense promoter methylation of the CADM1 gene was significantly more frequent in these CIN2/3 lesions (P = 0.004). No chromosomal alterations were detected in six CIN1 lesions, five of which were completely p16(INK4a) immunonegative. These findings suggest that biomarkers associated with gains at chromosomes 1, 3q, and 20 are potential hallmarks of advanced p16(INK4a)-positive CIN2/3 lesions with a high short-term risk of progression.",
        "Doc_title":"Chromosomal signatures of a subset of high-grade premalignant cervical lesions closely resemble invasive carcinomas.",
        "Journal":"Cancer research",
        "Do_id":"19147580",
        "Doc_ChemicalList":"CADM1 protein, human;Cell Adhesion Molecules;Cyclin-Dependent Kinase Inhibitor p16;Immunoglobulins;Membrane Proteins;Tumor Suppressor Proteins",
        "Doc_meshdescriptors":"Adult;Cell Adhesion Molecules;Cervical Intraepithelial Neoplasia;Chromosome Aberrations;Comparative Genomic Hybridization;Cyclin-Dependent Kinase Inhibitor p16;DNA Methylation;Female;Humans;Immunoglobulins;Membrane Proteins;Neoplasm Invasiveness;Papillomaviridae;Papillomavirus Infections;Promoter Regions, Genetic;Tumor Suppressor Proteins;Uterine Cervical Neoplasms",
        "Doc_meshqualifiers":"genetics;pathology;virology;biosynthesis;genetics;genetics;genetics;pathology;genetics;genetics;pathology;virology",
        "_version_":1605806174535417856},
      {
        "Doc_abstract":"To determine biomarkers of recurrence and survival in patients with spindle cell variant squamous cell carcinoma (SpSCC) of the head and neck.;Retrospective case control study.;Tertiary academic center.;Thirty-two SpSCC patients (mean age, 68.8) between 1987 and 2009 were identified and reviewed. A tissue microarray (TMA) was constructed from tumor specimens. Tumor biomarkers under study included p16, epidermal growth factor receptor (EGFR), p53, EZH2, cyclin D1, CD104, HGFa, p21, and cMET. An additional TMA was constructed from patients with non-SpSCC oral cavity squamous cell carcinoma for comparative purposes. The main outcomes were overall survival (OS), disease-specific survival (DSS), and recurrence-free survival (RFS).;In the SpSCC cohort, tumors positive for cMet had worse OS (P < .001). Patients positive for cMet (P = .007), cyclin D1 (P = .019), and p16 (P = .004) had worse DSS. Recurrence-free survival was also worse in patients with tumors positive for cMet (P = .037), cyclin D1 (P = .012), and p16 (P < .001). Compared with the oral cavity cohort, there was a significantly larger proportion of patients in the SpSCC group with tumors staining positive for cMet and a lower proportion of tumors positive for cyclin D1.;cMet, cyclin D1, and p16 are predictive tumor biomarkers for risk of recurrence and worse DSS in patients with SpSCC.",
        "Doc_title":"Tumor Biomarkers in Spindle Cell Variant Squamous Cell Carcinoma of the Head and Neck.",
        "Journal":"Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery",
        "Do_id":"26980915",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605825975561486336},
      {
        "Doc_abstract":"The aim of this study was to assess the prognostic value of p16(INK4a) as a marker of post-conization relapse in patients treated for cervical intraepithelial neoplasia grade 3 (CIN 3). A retrospective study of 76 women with CIN 3 diagnoses, treated at the Hospital of Santa Casa de Misericrdia of So Paulo (Brazil) between January 2003 and September 2004, was performed. The study samples were obtained from cervical conization procedures, where paraffin blocks containing areas with the greatest amount of neoplastic tissue were selected. Immunohistochemical techniques were used on individual paraffin blocks for each case to detect p16(INK4a) protein expression. The p16(INK4a) cell counts were performed in 10 different high-amplification fields (400x) by light microscopy and total cell count expressed as number of cells per mm(2) . Patients involved in this study were followed up at the colposcopy outpatient unit for at least 48 months after cervical conization. The correlation of p16(INK4a) values with post-conization evolution in the patients (disease relapse or disease free) was determined. A significantly higher count of cells expressing p16(INK4a) was found in those patients with disease relapse during follow-up (p < 0.001). The variables age, number of gestations, and births correlated positively with number of cells expressing p16(INK4a) cells (p < 0.001; p = 0.001; 0.009, respectively). No correlation was found for the variables menopause, hormonal contraception, or smoking (p = 0.369, 0.425 and 0.853, respectively). p16(INK4a) can be considered a biomarker of cervical intraepithelial neoplasia grade 3 cases presenting high risk of relapse or evolution to invasive carcinoma.",
        "Doc_title":"Prognostic value of p16(INK4a) as a marker of clinical evolution in patients with cervical intraepithelial neoplasia grade 3 (CIN 3) treated by cervical conization.",
        "Journal":"APMIS : acta pathologica, microbiologica, et immunologica Scandinavica",
        "Do_id":"23763281",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;Genetic Markers",
        "Doc_meshdescriptors":"Adolescent;Adult;Aged;Cervical Intraepithelial Neoplasia;Cervix Uteri;Conization;Cyclin-Dependent Kinase Inhibitor p16;Female;Follow-Up Studies;Genetic Markers;Humans;Immunohistochemistry;Linear Models;Middle Aged;Neoplasm Recurrence, Local;Prognosis;Retrospective Studies;Uterine Cervical Neoplasms;Young Adult",
        "Doc_meshqualifiers":"diagnosis;pathology;surgery;pathology;surgery;methods;genetics;metabolism;diagnosis;pathology;surgery;diagnosis;pathology;surgery",
        "_version_":1605799520625491968},
      {
        "Doc_abstract":"Approximately 90% of melanomas retain wild-type p53, a characteristic that may help shape the development of novel treatment strategies. Here, we employed an adenoviral vector where transgene expression is controlled by p53 to deliver the p19 alternate reading frame (Arf) and interferon- (IFN) complementary DNAs in the B16 mouse model of melanoma. In vitro, cell death was enhanced by combined gene transfer (63.8215.30% sub-G0 cells); yet introduction of a single gene resulted in significantly fewer hypoploid cells (37.737.3% or 36.9611.58%, p19Arf or IFN, respectively, P<0.05). Annexin V staining and caspase-3 cleavage indicate a cell death mechanism consistent with apoptosis. Using reverse transcriptase quantitative PCR, we show that key transcriptional targets of p53 were upregulated in the presence of p19Arf, although treatment with IFN did not alter expression of the genes studied. In situ gene therapy revealed significant inhibition of subcutaneous tumors by IFN (57125mm3) or the combination of p19Arf and IFN (489124mm3) as compared with the LacZ control (187533mm3, P<0.001), whereas p19Arf yielded an intermediate result (1053169mm3, P<0.01 vs control). However, only the combination was associated with increased cell death and prolonged survival (P<0.01). As shown here, the combined transfer of p19Arf and IFN using p53-responsive vectors enhanced cell death both in vitro and in vivo.",
        "Doc_title":"Combined p19Arf and interferon-beta gene transfer enhances cell death of B16 melanoma in vitro and in vivo.",
        "Journal":"Cancer gene therapy",
        "Do_id":"23618951",
        "Doc_ChemicalList":"Cdkn2a protein, mouse;Cyclin-Dependent Kinase Inhibitor p16;Interferon-beta",
        "Doc_meshdescriptors":"Animals;Apoptosis;Cell Death;Cell Line, Tumor;Cyclin-Dependent Kinase Inhibitor p16;Disease Models, Animal;Female;Interferon-beta;Melanoma, Experimental;Mice;Mice, Inbred C57BL;Transduction, Genetic",
        "Doc_meshqualifiers":"genetics;genetics;biosynthesis;genetics;metabolism;biosynthesis;genetics;metabolism;genetics;pathology;therapy",
        "_version_":1605846461027713024},
      {
        "Doc_abstract":"Head and neck squamous cell carcinoma (HNSCC) remains a challenging cancer to treat with overall 5-year survival on the order of 50-60%. Therefore, predictive biomarkers for this disease would be valuable to provide more effective and individualized therapeutic approaches for these patients. While prognostic biomarkers such as p16 expression correlate with outcome; to date, no predictive biomarkers have been clinically validated for HNSCC. We generated xenografts in immunocompromised mice from six established HNSCC cell lines and evaluated response to cisplatin, cetuximab, and radiation. Tissue microarrays were constructed from pre- and posttreatment tumor samples derived from each xenograft experiment. Quantitative immunohistochemistry was performed using a semiautomated imaging and analysis platform to determine the relative expression of five potential predictive biomarkers: epidermal growth factor receptor (EGFR), phospho-EGFR, phospho-Akt, phospho-ERK, and excision repair cross-complementation group 1 (ERCC1). Biomarker levels were compared between xenografts that were sensitive versus resistant to a specific therapy utilizing a two-sample t-test with equal standard deviations. Indeed the xenografts displayed heterogeneous responses to each treatment, and we linked a number of baseline biomarker levels to response. This included low ERCC1 being associated with cisplatin sensitivity, low phospho-Akt correlated with cetuximab sensitivity, and high total EGFR was related to radiation resistance. Overall, we developed a systematic approach to identifying predictive biomarkers and demonstrated several connections between biomarker levels and treatment response. Despite these promising initial results, this work requires additional preclinical validation, likely involving the use of patient-derived xenografts, prior to moving into the clinical realm for confirmation among patients with HNSCC. ",
        "Doc_title":"Xenograft assessment of predictive biomarkers for standard head and neck cancer therapies.",
        "Journal":"Cancer medicine",
        "Do_id":"25619980",
        "Doc_ChemicalList":"Antineoplastic Agents;Biomarkers;DNA-Binding Proteins;Receptor, Epidermal Growth Factor;Proto-Oncogene Proteins c-akt;Extracellular Signal-Regulated MAP Kinases;ERCC1 protein, human;Endonucleases;Cetuximab;Cisplatin",
        "Doc_meshdescriptors":"Animals;Antineoplastic Agents;Biomarkers;Cell Line, Tumor;Cetuximab;Cisplatin;DNA-Binding Proteins;Disease Models, Animal;Endonucleases;Extracellular Signal-Regulated MAP Kinases;Female;Head and Neck Neoplasms;Humans;Immunohistochemistry;Mice;Prognosis;Proto-Oncogene Proteins c-akt;Radiotherapy;Receptor, Epidermal Growth Factor;Signal Transduction;Xenograft Model Antitumor Assays",
        "Doc_meshqualifiers":"administration & dosage;pharmacology;administration & dosage;pharmacology;administration & dosage;pharmacology;metabolism;metabolism;metabolism;metabolism;mortality;pathology;therapy;virology;metabolism;metabolism;drug effects;radiation effects",
        "_version_":1605929301162590208},
      {
        "Doc_abstract":"Hypermethylation of tumor suppressor gene promoters has been found in head and neck squamous carcinoma (HNSCC) and other solid tumors. We evaluated these alterations in pretreatment salivary rinses from HNSCC patients by using real-time quantitative methylation-specific PCR (Q-MSP).;Pretreatment saliva DNA samples from HNSCC patients were evaluated for patterns of hypermethylation by using Q-MSP. Target tumor suppressor gene promoter regions were selected based on a previous study describing a screening panel for HNSCC in a high-risk population subjects. The selected genes were: DAPK, DCC, MINT-31, TIMP-3, p16, MGMT, CCNA1.;We analyzed the panel in a cohort of 61 HNSCC patients. Thirty-three of the analyzed patients (54.1%) showed methylation of at least one of the selected genes in the saliva DNA. Pretreatment methylated saliva DNA was not significantly associated with tumor site (P = 0.209) nor clinical stage (P = 0.299). However, local disease control and overall survival were significantly lower in patients presenting hypermethylation in saliva rinses (P = 0.010 and P = 0.015, respectively). Multivariate analysis confirmed that this hypermethylation pattern remained as an independent prognostic factor for local recurrence (HR = 12.2; 95% CI = 1.8-80.6; P = 0.010) and overall survival (HR = 2.8; 95% CI = 1.2-6.5; P = 0.016).;We were able to confirm an elevated rate of promoter hypermethylation in HNSCC saliva of patients by using a panel of gene promoters previously described as methylated specifically in HNSCC. Detection of hypermethylation in pretreatment saliva DNA seems to be predictive of local recurrence and overall survival. This finding has potential to influence treatment and surveillance of HNSCC patients.",
        "Doc_title":"Detection of promoter hypermethylation in salivary rinses as a biomarker for head and neck squamous cell carcinoma surveillance.",
        "Journal":"Clinical cancer research : an official journal of the American Association for Cancer Research",
        "Do_id":"21628494",
        "Doc_ChemicalList":"Biomarkers, Tumor",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Biomarkers, Tumor;Carcinoma, Squamous Cell;DNA Methylation;Female;Head and Neck Neoplasms;Humans;Male;Middle Aged;Prognosis;Promoter Regions, Genetic;Saliva",
        "Doc_meshqualifiers":"genetics;metabolism;diagnosis;mortality;pathology;genetics;diagnosis;mortality;pathology;metabolism",
        "_version_":1605819501914357760},
      {
        "Doc_abstract":"The p14(ARF), p15(INK4B), and p16(INK4A) genes are important negative cell-cycle regulators often inactivated by deletions, mutations, or hypermethylation in malignancy. Hypermethylation of the three genes was studied in 81 patients with therapy-related myelodysplasia (t-MDS) or acute myeloid leukemia (t-AML) by methylation-specific PCR, and p15 methylation additionally by bisulfite genomic sequencing. In all, 55 patients disclosed p15 methylation, five patients showed p16 methylation, whereas p14 methylation was not observed. Methylation of p15 was closely associated with deletion or loss of chromosome arm 7q (P=0.0006). In t-MDS, the p15 methylation frequency and the p15 methylation density both increased significantly by stage (P=0.004 and 0.0002), and p15 methylation frequency increased with an increasing percentage of myeloblasts in the bone marrow (P=0.006). In a two-variable Cox model including the percentage of myeloblasts, p15 methylation was an independent prognostic factor (P=0.005). Methylation of p15 was less common in t-AML of subtype M5 than in other FAB subtypes (P=0.03). Methylation of p15 was unrelated to type of previous therapy, to latent period from start of therapy, to platelet count, and to p53 mutations. Inactivation of p15 and deletion of genes on chromosome arm 7q possibly cooperate in leukemogenesis.",
        "Doc_title":"Methylation of p15INK4B is common, is associated with deletion of genes on chromosome arm 7q and predicts a poor prognosis in therapy-related myelodysplasia and acute myeloid leukemia.",
        "Journal":"Leukemia",
        "Do_id":"12970781",
        "Doc_ChemicalList":"CDKN2B protein, human;Cell Cycle Proteins;Cyclin-Dependent Kinase Inhibitor p15;Cyclin-Dependent Kinase Inhibitor p16;DNA, Neoplasm;Enzyme Inhibitors;Tumor Suppressor Protein p14ARF;Tumor Suppressor Proteins",
        "Doc_meshdescriptors":"Acute Disease;Cell Cycle Proteins;Chromosome Aberrations;Chromosomes, Human, Pair 7;Cyclin-Dependent Kinase Inhibitor p15;Cyclin-Dependent Kinase Inhibitor p16;DNA Methylation;DNA, Neoplasm;Enzyme Inhibitors;Female;Gene Deletion;Gene Silencing;Genes, Tumor Suppressor;Hodgkin Disease;Humans;Leukemia, Myeloid;Male;Middle Aged;Myelodysplastic Syndromes;Neoplasm Recurrence, Local;Neoplasms, Second Primary;Polymerase Chain Reaction;Prognosis;Promoter Regions, Genetic;Remission Induction;Tumor Suppressor Protein p14ARF;Tumor Suppressor Proteins",
        "Doc_meshqualifiers":"genetics;genetics;genetics;genetics;genetics;pathology;therapy;genetics;genetics;genetics;genetics;genetics;genetics",
        "_version_":1605755884880789504},
      {
        "Doc_abstract":"p53-p21-cyclin-dependent kinase and p16(INK4a)-cyclin-dependent kinase pathways have parallel functions in preventing tumorigenesis. In cancer patients, tumor suppressor p53 is frequently inactivated through mutations, whereas p16(INK4a) is silenced through promoter methylation. However, the interaction between these two pathways is less well understood. Here, we report that p53 controls p16(INK4a) expression in a unique way. p53 deficiency led to up-regulation of p16(INK4a) in primary mouse embryonic fibroblasts, osteoblasts, and various mouse organs, and an increase in the p16(INK4a) promoter activity, without affecting the half-life of p16(INK4a). Reconstitution of p53, but not mutant p53, restored the proper expression of p16(INK4a). These results indicate that p53 is necessary in repressing p16(INK4a) expression. However, up-regulation of p53 in response to genotoxic stress or nutlin-3 treatment did not down-regulate p16(INK4a). p53 did not repress the p16(INK4a) promoter activity either. These findings suggest that p53 has a necessary but not sufficient role in repressing p16(INK4a) expression. p16(INK4a) elevation in p53(-/-) cells is, at least partially, mediated by Ets1, a known positive regulator of p16(INK4a), as p53 deficiency up-regulated Ets1 through protein stabilization and knockdown of Ets1 down-regulated p16(INK4a) expression in p53(-/-) mouse embryonic fibroblasts. These studies uncover a compensatory mechanism for the loss of p53 and provide a basis for targeting both p53 and p16(INK4a) in cancer therapy.",
        "Doc_title":"p53 Deficiency leads to compensatory up-regulation of p16INK4a.",
        "Journal":"Molecular cancer research : MCR",
        "Do_id":"19240179",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;Proto-Oncogene Protein c-ets-1;RNA, Messenger;Tumor Suppressor Protein p53",
        "Doc_meshdescriptors":"Animals;Blotting, Western;Cyclin-Dependent Kinase Inhibitor p16;Fibroblasts;Mice;Proto-Oncogene Protein c-ets-1;RNA, Messenger;Signal Transduction;Transcription, Genetic;Transfection;Tumor Suppressor Protein p53;Up-Regulation",
        "Doc_meshqualifiers":"biosynthesis;deficiency;genetics;metabolism;metabolism;physiology;biosynthesis;genetics;biosynthesis;genetics;deficiency;genetics;metabolism",
        "_version_":1605911396138090496},
      {
        "Doc_abstract":"Oropharyngeal squamous cell carcinomas (OPSCC) that are associated with human papilloma virus (HPV) infection carry a more favorable prognosis than those that are HPV-negative. However, it remains unclear which biomarker(s) can reliably determine which OPSCC specimens are truly driven by HPV infection. In this study, we analyzed 199 fresh-frozen OPSCC specimens for HPV DNA, viral load, RNA expression patterns typical for cervical carcinomas (CxCaRNA(+)), and the HPV-targeted tumor suppressor protein p16(INK4a) as markers for HPV infection. In this set of specimens, there was a 49% prevalence of DNA for the cancer-associated HPV type 16 (HPV(+)). However, there was only a 16% prevalence of high viral load and only a 20% prevalence of CxCaRNA(+), a marker of HPV16 carcinogenic activity. Among the CxCaRNA(+) tumors, 78% of the specimens exhibited overexpression of p16(INK4a), which also occurred in 14% of the HPV-negative tumors. Using a multivariate survival analysis with HPV negativity as the reference group, CxCaRNA(+) as a single marker conferred the lowest risk of death [HR = 0.28, 95% confidence interval (CI), 0.13-0.61] from oropharyngeal cancer, closely followed by high viral load (HR = 0.32, 95% CI, 0.14-0.73). In contrast, a weaker inverse association was found for OPSCC that were HPV(+) and p16(INK4a) high (HR = 0.55, 95% CI, 0.29-1.08). In summary, our findings argued that viral load or RNA pattern analysis is better suited than p16(INK4a) expression to identify HPV16-driven tumors in OPSCC patient populations.",
        "Doc_title":"Viral RNA patterns and high viral load reliably define oropharynx carcinomas with active HPV16 involvement.",
        "Journal":"Cancer research",
        "Do_id":"22991302",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;DNA, Viral;RNA, Viral",
        "Doc_meshdescriptors":"Carcinoma, Squamous Cell;Cyclin-Dependent Kinase Inhibitor p16;DNA, Viral;Female;Host-Pathogen Interactions;Human papillomavirus 16;Humans;Immunohistochemistry;Male;Middle Aged;Multivariate Analysis;Oropharyngeal Neoplasms;Papillomavirus Infections;RNA, Viral;Real-Time Polymerase Chain Reaction;Survival Analysis;Tissue Array Analysis;Viral Load",
        "Doc_meshqualifiers":"metabolism;virology;analysis;genetics;metabolism;genetics;physiology;metabolism;virology;metabolism;virology;genetics;metabolism",
        "_version_":1605764141476216832},
      {
        "Doc_abstract":"The aim of present study is to investigate the immunohistochemical expression of tumor suppressor gene p16(INK4a) and proliferative marker Ki-67 in dysplastic vulvar lesions and nondysplastic ones.;30 female patients (mean age = 49.5 +/- 4.5) - Ca in situ (n = 2), VIN (n = 10), lichen sclerorosus (n = 8), squamous cell hyperplasia (n = 1), mixed vulvar dystrophy (n = 5), papilloma (n = 1), condyllomata accuminata (n = 3) are separated into two groups (first group of non-dysplastic- and second group of dysplastic lesions). The immunohistochemical method with monoclonal antibody for identification of p16(INK4a) and Ki-67 was applied.;P16(INK4a) is expressed in 1 patient (5.56%) in first group and in 8 patients (66.67%) in second group (chi2 = 84.93; p < 0.001). Ki-67 is positive in 4 patients (22.22%) in first group and in 12 of cases (100%) in second group (chi2 = 41.3; p < 0.001).;There is a significant statistical difference between immunohistochemical expression of p16(INK4a) and Ki-67 in HPV-associated dysplastic and non-dysplastic vulvar lesions.",
        "Doc_title":"[The expression of p16(INK4a) and Ki-67 in atrophic-hyperplastic and dysdysplastic lesions of the vulva].",
        "Journal":"Akusherstvo i ginekologiia",
        "Do_id":"20198771",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;Ki-67 Antigen",
        "Doc_meshdescriptors":"Cyclin-Dependent Kinase Inhibitor p16;Female;Humans;Hyperplasia;Immunohistochemistry;Ki-67 Antigen;Middle Aged;Neoplasms, Squamous Cell;Papilloma;Vulva;Vulvar Neoplasms",
        "Doc_meshqualifiers":"analysis;immunology;pathology;analysis;immunology;pathology;pathology;pathology;pathology",
        "_version_":1605742042534641666},
      {
        "Doc_abstract":"The incidence of head and neck squamous cell carcinoma (HNSCC) is quite high in North Eastern India. Apart from the traditional risk factors like tobacco and alcohol consumption, human papilloma virus (HPV) is now considered an established causative agent. These HPV related tumour have a clinico-pathological profile that is quite divergent from conventional non-HPV related tumours. Association of HPV in oral cancers has not been explored in north-east India.;Thirty-one patients with oral cavity squamous cell carcinoma (OSCC) on treatment from October 2010 to January 2013 were included in the study. Patients who received neo-adjuvant chemotherapy were excluded. HPV 16/18 DNA was evaluated using Chromogenic in-situ Hybridization (CISH). Presence of nuclear signals was taken as positive HPV expression. p16 was evaluated using immunohistochemistry and was considered positive if  80% of the tumour cells showed strong and diffuse nuclear/cytoplasmic immunostaining. The results were analysed using Fisher exact test and confidence interval was calculated where required.;The study group age ranged from 30 to 80 years (median age- 54.2 years). The most common site was gum, with well differentiated squamous cell carcinoma being the most common histology. HPV 16/18 DNA was positive in 29% (95% CI: 13.03% - 44.97%) cases and had a clear tendency towards statistical significance with non-smoker cases (p=0.05), lymph node metastasis (p=0.05) and a significant correlation with p16 overexpression (p=0.04). There was no significant correlation with other clinico-pathological parameters.;HPV 16/18 is associated with OSCC, commonly seen among non-smokers and may be related to nodal metastasis. So, HPV may be used as a prognostic factor in OSCC and p16 may be considered as a surrogate marker for HPV.",
        "Doc_title":"Analysis of Human Papilloma Virus 16/18 DNA and its Correlation with p16 Expression in Oral Cavity Squamous Cell Carcinoma in North-Eastern India: A Chromogenic in-situ Hybridization Based Study.",
        "Journal":"Journal of clinical and diagnostic research : JCDR",
        "Do_id":"26435951",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605896645527994368},
      {
        "Doc_abstract":"Weakening the Spindle Assembly Checkpoint by reduced expression of its components induces chromosome instability and aneuploidy that are hallmarks of cancer cells. The tumor suppressor p14(ARF) is overexpressed in response to oncogenic stimuli to stabilize p53 halting cell progression. Previously, we found that lack or reduced expression of p14(ARF) is involved in the maintenance of aneuploid cells in primary human cells, suggesting that it could be part of a pathway controlling their proliferation. To investigate this aspect further, p14(ARF) was ectopically expressed in HCT116 cells after depletion of the Spindle Assembly Checkpoint MAD2 protein that was used as a trigger for aneuploidy. p14(ARF) Re-expression reduced the number of aneuploid cells in MAD2 post-transcriptionally silenced cells. Also aberrant mitoses, frequently displayed in MAD2-depleted cells, were decreased when p14(ARF) was expressed at the same time. In addition, p14(ARF) ectopic expression in MAD2-depleted cells induced apoptosis associated with increased p53 protein levels. Conversely, p14(ARF) ectopic expression did not induce apoptosis in HCT116 p53KO cells. Collectively, our results suggest that the tumor suppressor p14(ARF) may have an important role in counteracting proliferation of aneuploid cells by activating p53-dependent apoptosis.",
        "Doc_title":"p14(ARF) Prevents Proliferation of Aneuploid Cells by Inducing p53-Dependent Apoptosis.",
        "Journal":"Journal of cellular physiology",
        "Do_id":"25752701",
        "Doc_ChemicalList":"MAD2L1 protein, human;Mad2 Proteins;TP53 protein, human;Tumor Suppressor Protein p14ARF;Tumor Suppressor Protein p53",
        "Doc_meshdescriptors":"Aneuploidy;Apoptosis;Cell Proliferation;Gene Knockout Techniques;HCT116 Cells;Humans;M Phase Cell Cycle Checkpoints;Mad2 Proteins;Mitosis;RNA Interference;Tumor Suppressor Protein p14ARF;Tumor Suppressor Protein p53",
        "Doc_meshqualifiers":"genetics;physiology;genetics;physiology;genetics;physiology;genetics;physiology;genetics;physiology;genetics;physiology;deficiency;genetics;physiology",
        "_version_":1605762617078448129},
      {
        "Doc_abstract":"Hematopoiesis is regulated by proliferation, differentiation, and death. p16(INK4a) has been reported to regulate apoptosis and differentiation of diverse cells, as well as arresting the cell cycle at G1 phase. The aim of this study is to explore the properties of p16 in apoptosis and differentiation of erythroid cells.;We transfected the INK4a gene to K562 cells, which defect the INK4a gene, and compared the effect of enforced expression of p16(INK4a) with that of various additives, topoisomerase I inhibitor (SN 38), interferon-alpha, phosphatidyl-inositol-3 kinase inhibitor (LY294002), and serum deprivation, which arrest cell cycle at different phases. We also investigated the role of p16(INK4a) in normal day-6 human erythroid colony-forming cells by transfecting the INK4a gene.;p16(INK4a) induced cell cycle arrest at the G0/G1 phase, and promoted erythroid differentiation in viable K562 cells, but induced apoptosis in K562 cells with incomplete differentiation. The apoptosis induced by p16 was accompanied with downregulation of bcl-x and nuclear NF-kappaB. These findings were not observed in K562 cells treated with various additives. p16(INK4a) decreased the cell viability and promoted apoptosis in day-9 ECFC.;We propose that p16(INK4a) plays a role in maintaining homeostasis during erythroid differentiation, and that the mechanisms for this effect are not confined to those inducing cell cycle arrest.",
        "Doc_title":"p16(INK4a) induces differentiation and apoptosis in erythroid lineage cells.",
        "Journal":"Experimental hematology",
        "Do_id":"12763133",
        "Doc_ChemicalList":"BCL2L1 protein, human;Cyclin-Dependent Kinase Inhibitor p16;Microfilament Proteins;Muscle Proteins;NF-kappa B;Oligonucleotides, Antisense;Proto-Oncogene Proteins c-bcl-2;Tagln protein, mouse;bcl-X Protein",
        "Doc_meshdescriptors":"Apoptosis;Cell Division;Cyclin-Dependent Kinase Inhibitor p16;Erythropoiesis;Homeostasis;Humans;K562 Cells;Microfilament Proteins;Muscle Proteins;NF-kappa B;Oligonucleotides, Antisense;Proto-Oncogene Proteins c-bcl-2;Transfection;bcl-X Protein",
        "Doc_meshqualifiers":"physiology;analysis;analysis;pharmacology;analysis",
        "_version_":1605746442289283073},
      {
        "Doc_abstract":"Senescence of somatic cells in vitro can occur through the gradual erosion of the chromosomal telomeres following multiple rounds of cell division, or more acutely following cellular stresses connected with oncogene activation, tumour suppressor loss, ageing and migration. These various forms of senescence are associated with the activation of DNA damage checkpoints, the over-expression of p16(INK4A) and the secretion of cytokines, all of which are detected in pre-malignant lesions but muted upon malignant conversion. The various senescence signals are integrated by p16(INK4A) and p53 to produce the permanent cell cycle arrest associated with senescence. Both pRB/p16(INK4A) and p53 are dysfunctional in many cancers, including the most common type of oral cancer, squamous cell carcinoma (OSCC) and other evidence is accumulating in support of the idea that senescence acts as a barrier to tumour development and/or progression. However, senescence of the non-epithelial component of developing human tumours has been shown to enhance growth and invasion of the pre-malignant epithelial component and so senescence may well enhance cancer as well as suppress it depending on the context.",
        "Doc_title":"Senescence as a modulator of oral squamous cell carcinoma development.",
        "Journal":"Oral oncology",
        "Do_id":"21050803",
        "Doc_ChemicalList":"Tumor Suppressor Protein p53",
        "Doc_meshdescriptors":"Carcinoma, Squamous Cell;Cell Aging;Cell Line, Tumor;Female;Genes, p16;Humans;Male;Mouth Neoplasms;Tumor Suppressor Protein p53",
        "Doc_meshqualifiers":"genetics;pathology;genetics;physiology;physiology;genetics;pathology;genetics;physiology",
        "_version_":1605795444803239936},
      {
        "Doc_abstract":"Thirty-four to fifty-six percent of malignant gliomas harbor homozygous co-deletions of the INK4a(p16-p14ARF) and INK4b(p15) tumor suppressor genes. Recently, an alternatively spliced form of p15 has been cloned and termed p10 based on the presumed molecular weight of the protein. In this study, we have investigated the role of p10 expression in human glioblastomas. Both, wild-type p15 and p10 were detected in three of nine glioblastoma cell lines. Sixteen of twenty-nine (55%) glioblastoma tumor samples contained INK4b transcripts, but only nine (31%) tumors expressed p15 protein. Three p15 protein-negative tumors expressed only p10 mRNA. Preferential expression of p10 was not due to splice site mutations. Strong suppression of tumorigenicity was seen in four glioblastoma cell lines after transfection with p15 but not with p10. Loss of p15 protein expression was almost always accompanied by loss of p16 expression. p1 6/p15-negative tumors commonly lacked p14ARF expression. These results suggest that differential splicing of the INK4b gene may result in the expression of p10 at the expense of p15, which would lead to loss of p15-mediated growth suppression. This novel mechanism of loss of p15 might complement alterations of the INK4a tumor suppressor gene in some glioblastomas, resulting in combined loss of p16, p15 and p14ARF.",
        "Doc_title":"Alternative splicing of the p15 cdk inhibitor in glioblastoma multiforme.",
        "Journal":"Acta neuropathologica",
        "Do_id":"11563632",
        "Doc_ChemicalList":"CDKN2B protein, human;Cell Cycle Proteins;Cyclin-Dependent Kinase Inhibitor p15;Cyclin-Dependent Kinase Inhibitor p16;RNA, Messenger;Tumor Suppressor Protein p14ARF;Tumor Suppressor Proteins",
        "Doc_meshdescriptors":"Alternative Splicing;Brain Neoplasms;Cell Cycle Proteins;Cyclin-Dependent Kinase Inhibitor p15;Cyclin-Dependent Kinase Inhibitor p16;Gene Expression Regulation, Neoplastic;Glioblastoma;Humans;RNA, Messenger;Reverse Transcriptase Polymerase Chain Reaction;Tumor Cells, Cultured;Tumor Suppressor Protein p14ARF;Tumor Suppressor Proteins",
        "Doc_meshqualifiers":"genetics;genetics;metabolism;physiopathology;genetics;genetics;physiology;genetics;metabolism;physiopathology;metabolism;genetics",
        "_version_":1605929279306072064},
      {
        "Doc_abstract":"p19(ARF) is a potent tumor suppressor. By inactivating Mdm2, p19(ARF) upregulates p53 activities to induce cell cycle arrest and sensitize cells to apoptosis in the presence of collateral signals. It has also been demonstrated that cell cycle arrest is induced by overexpressed p19(ARF) in p53-deficient mouse embryonic fibroblasts, only in the absence of the Mdm2 gene. Here, we show that apoptosis can be induced without additional apoptosis signals by expression of p19(ARF) using an adenovirus-mediated expression system in p53-intact cell lines as well as p53-deficient cell lines. Also, in primary mouse embryonic fibroblasts (MEFs) lacking p53/ARF, p53-independent apoptosis is induced irrespective of Mdm2 status by expression of p19(ARF). In agreement, p19(ARF)-mediated apoptosis in U2OS cells, but not in Saos2 cells, was attenuated by coexpression of Mdm2. We thus conclude that there is a p53-independent pathway for p19(ARF)-induced apoptosis that is insensitive to inhibition by Mdm2.",
        "Doc_title":"p53-independent apoptosis is induced by the p19ARF tumor suppressor.",
        "Journal":"Biochemical and biophysical research communications",
        "Do_id":"12099684",
        "Doc_ChemicalList":"Cdkn2a protein, mouse;Cyclin-Dependent Kinase Inhibitor p16;Nuclear Proteins;Proto-Oncogene Proteins;Tumor Suppressor Protein p14ARF;Tumor Suppressor Protein p53;MDM2 protein, human;Proto-Oncogene Proteins c-mdm2",
        "Doc_meshdescriptors":"Adenoviridae;Apoptosis;Cell Cycle;Cell Death;Cell Line;Cell Separation;Cyclin-Dependent Kinase Inhibitor p16;Fibroblasts;Flow Cytometry;Humans;Immunoblotting;Immunohistochemistry;In Situ Nick-End Labeling;Lac Operon;Nuclear Proteins;Plasmids;Precipitin Tests;Proto-Oncogene Proteins;Proto-Oncogene Proteins c-mdm2;Signal Transduction;Time Factors;Transfection;Tumor Suppressor Protein p14ARF;Tumor Suppressor Protein p53;Up-Regulation",
        "Doc_meshqualifiers":"genetics;metabolism;metabolism;metabolism;metabolism;metabolism",
        "_version_":1605791788781535232},
      {
        "Doc_abstract":"On integration into the host cervical keratinocyte genome, human papillomavirus (HPV) E7 protein binds pRB,releasing E2F from normally incompetent pRB-E2F complexes and allowing propagation of G1-S transition by the E2F. p16(INK4a), a tumour suppressor protein, increases in reflex response to counter this. 29 histologically re-confirmed low-grade squamous intraepithelial lesions (LSIL), 27 high-grade squamous intraepithelial lesions (HSIL) and 30 invasive cervical squamous carcinoma (SCC) were immunohistochemically stained for p16(INK4a) expression using the CINtec Histology Kit (REF 9511, mtm laboratories AG, Heidelberg, Germany) to re-affirm the notion that integration of HPV occurs predominantly in SCC and possibly HSIL and less in LSIL and normal squamous epithelium (NSqE). Implicit was also the attempt to understand the role of E2F, as indicated by p16(INK4a), in evolution of SCC from HSIL. No ethnic predilection was noted for LSIL, HSIL or SCC. Patients with SCC were significantly older by about 14-years compared with HSIL (p < 0.05) while there was no significant age difference between HSIL and LSIL. p16(INK4a) expression was significantly increased (p < 0.05) in both HSIL (88.9%) and SCC (83.3%) compared with LSIL (3.4%) and NSqE (0%); the NSqE being normal squamous epithelium noted in 17 of the LSIL, 19 HSIL and 5 SCC. From these findings there is suggestion that fundamental upstream events viz HPV integration, E7 upregulation followed by E2F activation occurs at point of transformation to HSIL and continues unrelentingly for another one to two decades before hitherto unclear factors convert a non-invasive lesion into an overtly invasive malignant counterpart. Interestingly, the occurrence of HSIL and LSIL in almost the same age group could mean that alteration from episomal to integrated form of HPV may not incur a prolonged incubation period, unlike from HSIL to SCC.",
        "Doc_title":"Implications of continued upregulation of p16(INK4a) through the evolution from high-grade squamous intraepithelial lesion to invasive squamous carcinoma of the cervix.",
        "Journal":"The Malaysian journal of pathology",
        "Do_id":"22299207",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16",
        "Doc_meshdescriptors":"Adolescent;Adult;Aged;Aged, 80 and over;Carcinoma, Squamous Cell;Cell Transformation, Viral;Cervical Intraepithelial Neoplasia;Cyclin-Dependent Kinase Inhibitor p16;Disease Progression;Female;Humans;Immunohistochemistry;Middle Aged;Neoplasm Grading;Papillomavirus Infections;Uterine Cervical Neoplasms;Young Adult",
        "Doc_meshqualifiers":"metabolism;pathology;virology;physiology;metabolism;pathology;virology;biosynthesis;complications;metabolism;pathology;virology",
        "_version_":1605903339905613824},
      {
        "Doc_abstract":"Progression of cutaneous squamous neoplasms from actinic keratosis (AK) to Bowen's disease (BD; squamous cell carcinoma in situ) has important implications for clinical management and treatment, thus requiring accurate diagnosis. p16INK4a is a cell cycle regulatory tumour suppressor protein that negatively regulates D-type cyclins in the G1 cell cycle phase via intimate interplay with the retinoblastoma gene. Expression of a paraffin-reactive p16INK4a marker has recently been shown to increase in cervical squamous neoplasms as lesions progress from low-grade dysplasia to squamous cell carcinoma in situ. p16INK4a expression in the progression of squamous cutaneous neoplasia, however, has not been evaluated.;To evaluate p16INK4a expression in the progression of squamous cutaneous neoplasia.;Biopsies of 203 squamous cutaneous neoplasms with unequivocal features of AK (n = 87) and BD (n = 116) as well as a benign squamous control group (verruca vulgaris: n = 10; seborrhoeic keratosis: n = 11; scar tissue: n = 8) obtained between January and December 2001 at Henry Ford Hospital (Detroit, MI, U.S.A.) were immunostained for p16INK4a (Dako; clone E6H4; dilution 1 : 50) using large core (1.5 mm) tissue microarray analysis. Nuclear/cytoplasmic immunoreactivity in > 10% of neoplastic cells was considered positive.;Of 203 cases, 166 (81.8%) were interpretable (AK 59; BD 107). Mean patient age was 71.0 years (range 33-93); 57% were male. Sites of involvement were: head and extremities 75.9%, trunk/buttocks 21.7%, genital region 2.4%. p16INK4a immunostaining was positive in 90 of 107 (84.1%) BD cases, four of 59 (6.8%) AK cases and none of 29 benign squamous controls. The sensitivity and specificity of p16INK4a for a diagnosis of BD (vs. benign squamous controls/AK) was 84.1% and 95.5%, respectively (P < 0.0001, Fisher's exact test, two-sided).;p16INK4a is a sensitive and specific marker for distinguishing BD from AK/benign squamous cutaneous lesions and may be helpful as an adjunct to histomorphology in the diagnosis and appropriate clinical management of these lesions.",
        "Doc_title":"p16INK4a expression in actinic keratosis and Bowen's disease.",
        "Journal":"The British journal of dermatology",
        "Do_id":"14632806",
        "Doc_ChemicalList":"Biomarkers, Tumor;Cyclin-Dependent Kinase Inhibitor p16",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Biomarkers, Tumor;Bowen's Disease;Cyclin-Dependent Kinase Inhibitor p16;Disease Progression;Female;Humans;Keratosis;Male;Middle Aged;Precancerous Conditions;Sensitivity and Specificity;Skin Neoplasms",
        "Doc_meshqualifiers":"metabolism;diagnosis;metabolism;pathology;metabolism;diagnosis;metabolism;pathology;diagnosis;metabolism;pathology;diagnosis;metabolism;pathology",
        "_version_":1605909652844838912},
      {
        "Doc_abstract":"Pancreatic cancer is characterized by oncogenic activation of K-Ras and inactivation of the cell cycle inhibitor p16(INK4a) . We previously demonstrated that reintroduction of p16(INK4a) reversed anoikis resistance and clonogenicity of human pancreatic cancer cells, properties commonly attributed to the transforming potential of oncogenic K-Ras. Therefore, we aimed to determine the role of Ras after p16(INK4a) re-expression. Here, we show that restitution of p16(INK4a) in pancreatic cancer cell lines elicits a profound suppression of K-Ras activity. A more detailed analysis in p16(INK4a) reconstituted Capan-1 cells indicated selective reduction of both K-Ras activity and protein stability. Re-expression of K-Ras in p16(INK4a) restituted Capan-1 cells reversed the anoikis-sensitive phenotype and increased colony formation, indicating that K-Ras suppression was required for p16(INK4a) -mediated reversion of the transformed phenotype. Inducible expression of p16(INK4a) in DanG cells confirmed inhibition of K-Ras activity as well as an increase in anoikis susceptibility. Thus, our results delineate a novel functional interaction with defined biological consequences for the two most frequent alterations observed in pancreatic cancer.",
        "Doc_title":"Tumor suppressor p16INK4a controls oncogenic K-Ras function in human pancreatic cancer cells.",
        "Journal":"Cancer science",
        "Do_id":"22049925",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;Oncogene Protein p21(ras)",
        "Doc_meshdescriptors":"Anoikis;Cell Cycle;Cell Cycle Checkpoints;Cell Line, Tumor;Cell Transformation, Neoplastic;Colonic Neoplasms;Cyclin-Dependent Kinase Inhibitor p16;Genes, Tumor Suppressor;Humans;Oncogene Protein p21(ras);Pancreatic Neoplasms",
        "Doc_meshqualifiers":"genetics;genetics;metabolism;biosynthesis;metabolism;biosynthesis;metabolism;genetics;metabolism;pathology",
        "_version_":1605893069921583104},
      {
        "Doc_abstract":"Although inhibition of p16(INK4a) expression is critical to preserve the proliferative capacity of stem cells, the molecular mechanisms responsible for silencing p16(INK4a) expression remain poorly characterized. Here, we show that the histone acetyltransferase (HAT) monocytic leukemia zinc finger protein (MOZ) controls the proliferation of both hematopoietic and neural stem cells by modulating the transcriptional repression of p16(INK4a) . In the absence of the HAT activity of MOZ, expression of p16(INK4a) is upregulated in progenitor and stem cells, inducing an early entrance into replicative senescence. Genetic deletion of p16(INK4a) reverses the proliferative defect in both Moz(HAT) (-) (/) (-) hematopoietic and neural progenitors. Our results suggest a critical requirement for MOZ HAT activity to silence p16(INK4a) expression and to protect stem cells from early entrance into replicative senescence.",
        "Doc_title":"MOZ-mediated repression of p16(INK) (4) (a) is critical for the self-renewal of neural and hematopoietic stem cells.",
        "Journal":"Stem cells (Dayton, Ohio)",
        "Do_id":"24307508",
        "Doc_ChemicalList":"Antigens, CD34;Cyclin-Dependent Kinase Inhibitor p16;Histone Acetyltransferases;MOZ protein, mouse;Proto-Oncogene Proteins c-kit",
        "Doc_meshdescriptors":"Animals;Antigens, CD34;Cell Aging;Cell Cycle;Cell Proliferation;Cell Separation;Cyclin-Dependent Kinase Inhibitor p16;Embryo, Mammalian;Fibroblasts;Gene Deletion;Gene Silencing;Hematopoietic Stem Cells;Histone Acetyltransferases;Mice;Models, Biological;Neural Stem Cells;Promoter Regions, Genetic;Protein Binding;Proto-Oncogene Proteins c-kit;Telencephalon;Up-Regulation",
        "Doc_meshqualifiers":"metabolism;metabolism;cytology;metabolism;cytology;metabolism;metabolism;cytology;metabolism;genetics;genetics;metabolism;cytology;genetics",
        "_version_":1605765319566032896},
      {
        "Doc_abstract":"While considerable progress has been made in the understanding of the genetic changes involved in the pathogenesis of several human neoplasms, there is limited information about the genetic changes involved in the development of gallbladder carcinoma. Several studies indicate that TP53 (17p13) and p16(Ink4)/CDKN2 (9p21-22) gene loci abnormalities are frequent and early events in the pathogenesis of this neoplasm, in some cases preceding the onset of histological changes of invasion. Preliminary data also suggest that deletions at other chromosomal regions (8p21 and DCC at 18q21 loci) may play an important role in the development of gallbladder carcinoma; however, they need to be further analyzed. K-ras gene mutations appear to be an infrequent event in this neoplasm, except in gallbladder carcinomas associated with congenital abnormalities of the biliary tract. Genetic studies confirm that the sequence dysplasia-carcinoma in situ (CIS) is the usual route for the development of gallbladder carcinoma, and our recent data strongly suggest that adenomas are not precursors of this neoplasm.",
        "Doc_title":"Genetic abnormalities involved in the pathogenesis of gallbladder carcinoma.",
        "Journal":"Journal of hepato-biliary-pancreatic surgery",
        "Do_id":"10526058",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Adenocarcinoma;Female;Gallbladder Neoplasms;Gene Expression;Genes, p53;Genes, ras;Genetic Predisposition to Disease;Humans;Male;Mutation;Sensitivity and Specificity",
        "Doc_meshqualifiers":"genetics;pathology;genetics;pathology;genetics;genetics",
        "_version_":1605899197491445760},
      {
        "Doc_abstract":"Ultraviolet radiation induces DNA damage and is the major risk factor for the development of non-melanoma skin cancer (NMSC). Different mutation rates of p53, p16(INK4a) and Ha-ras in cutaneous squamous cell carcinoma (SCC) and the earlier stage actinic keratosis (AK) have been reported.;To assess the presence of missense mutations in hotspot exons of p53, p16(INK4a) and Ha-ras in low-graded AK.;Cryo-biopsies of 75 sun-exposed AK lesions and 75 sun-shielded areas of normal skin from 75 AK patients were analysed to identify mutations in p53 (exons 7 and 8), p16(INK4a) (exon 2) and Ha-ras (exon 1) using polymerase chain reaction (PCR) followed by direct sequencing. As a representative subset of the specimens, ten mutation-negative AK were also micro-dissected in order to exclude the possibility that additional mutations were undetected.;Eight missense and one nonsense point mutations were found in the 75 AK lesions examined (12%), of which seven (9%) were tumour-specific (i.e. present in AK lesions only) and two (3%) were p16(INK4a) mutations (i.e. also detected in normal skin). Three of the tumour-specific mutations (42%) were cytosine (C) to thymine (T) transitions at pyrimidine-rich sequences. Tumour-specific mutations were identified in 1% of p16(INK4a) (exon 2), 1% of Ha-ras (exon 1) and at a higher rate of 7% in p53 (exons 7 and 8), including one nonsense mutation.;The evaluation of a large number of AK specimens in this study have found a low gene mutation rate in low-graded AK lesions. p53 mutations rather than p16(INK4a) and/or Ha-ras mutations may be an early event in the development of AK to cutaneous SCC.",
        "Doc_title":"Low prevalence of p53, p16(INK4a) and Ha-ras tumour-specific mutations in low-graded actinic keratosis.",
        "Journal":"The British journal of dermatology",
        "Do_id":"17488404",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16",
        "Doc_meshdescriptors":"Aged;Aged, 80 and over;Carcinoma, Squamous Cell;Cyclin-Dependent Kinase Inhibitor p16;Female;Genes, p53;Genes, ras;Humans;Keratosis;Male;Middle Aged;Point Mutation;Polymerase Chain Reaction;Skin Neoplasms",
        "Doc_meshqualifiers":"genetics;genetics;genetics;genetics;genetics;genetics;genetics",
        "_version_":1605909705143615488},
      {
        "Doc_abstract":"The p16(INK4a)-Rb tumour suppressor pathway is required for the initiation and maintenance of cellular senescence, a state of permanent growth arrest that acts as a natural barrier against cancer progression. Senescence can be overcome if the pathway is not fully engaged, and this may occur when p16(INK4a) is inactivated. p16(INK4a) is frequently altered in human cancer and germline mutations affecting p16(INK4a) have been linked to melanoma susceptibility. To characterize the functions of melanoma-associated p16(INK4a) mutations, in terms of promoting proliferative arrest and initiating senescence, we utilized an inducible expression system in a melanoma cell model. We show that wild-type p16(INK4a) promotes rapid cell cycle arrest that leads to a senescence programme characterized by the appearance of chromatin foci, activation of acidic beta-galactosidase activity, p53 independence and Rb dependence. Accumulation of wild-type p16(INK4a) also promoted cell enlargement and extensive vacuolization independent of Rb status. In contrast, the highly penetrant p16(INK4a) variants, R24P and A36P failed to arrest cell proliferation and did not initiate senescence. We also show that overexpression of CDK4, or its homologue CDK6, but not the downstream kinase, CDK2, inhibited the ability of wild-type p16(INK4a) to promote cell cycle arrest and senescence. Our data provide the first evidence that p16(INK4a) can initiate a CDK4/6-dependent autonomous senescence programme that is disabled by inherited melanoma-associated mutations.",
        "Doc_title":"p16INK4a-induced senescence is disabled by melanoma-associated mutations.",
        "Journal":"Aging cell",
        "Do_id":"18843795",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;CDK4 protein, human;CDK6 protein, human;Cyclin-Dependent Kinase 4;Cyclin-Dependent Kinase 6",
        "Doc_meshdescriptors":"Cell Aging;Cell Line;Cell Line, Tumor;Clone Cells;Cyclin-Dependent Kinase 4;Cyclin-Dependent Kinase 6;Cyclin-Dependent Kinase Inhibitor p16;Humans;Melanoma;Mutation",
        "Doc_meshqualifiers":"genetics;physiology;antagonists & inhibitors;genetics;physiology;antagonists & inhibitors;genetics;physiology;physiology;enzymology;genetics;pathology",
        "_version_":1605765173298069504},
      {
        "Doc_abstract":"Amelanotic melanoma (AM) is a rare subtype of melanoma with little or no clinically visible pigment; it is more difficult to diagnose than pigmented melanoma (PM), and has a worse prognosis. In the attempt to find a genetic explanation for the distinction between AM and PM, we conducted a case-case study, matching AM and PM patients, and testing them for germline mutations in high- (p16INK4A, p14ARF, CDK4) and low-penetrance (MC1R) melanoma susceptibility genes. Similar CDKN2A mutations were found in both sets of melanomas. A p14ARF splice germline mutation was detected for the first time in an Italian family with AM. This rare mutation, which has been described only once previously, may be involved in predisposition to the amelanotic phenotype in combination with germline MC1R variants and coordinate somatic expression of pigmentation genes and their regulators.",
        "Doc_title":"CDKN2A and MC1R analysis in amelanotic and pigmented melanoma.",
        "Journal":"Melanoma research",
        "Do_id":"19339902",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;Receptor, Melanocortin, Type 1;Tumor Suppressor Protein p14ARF",
        "Doc_meshdescriptors":"Alternative Splicing;Cyclin-Dependent Kinase Inhibitor p16;Female;Genetic Predisposition to Disease;Humans;Italy;Male;Melanoma, Amelanotic;Mutation;Pedigree;Penetrance;Pigmentation;Receptor, Melanocortin, Type 1;Skin Neoplasms;Tumor Suppressor Protein p14ARF",
        "Doc_meshqualifiers":"genetics;epidemiology;epidemiology;genetics;pathology;genetics;genetics;genetics;epidemiology;genetics;pathology;genetics",
        "_version_":1605760995879288832},
      {
        "Doc_abstract":"Focal adhesion kinase (FAK) and p53 have been associated with metastatic activity and a poor prognosis in oral squamous cell carcinoma (OSCC). Recently, a feedback mechanism in which FAK regulates p53 has been proposed. The present study aims to determine the role of p53 in FAK regulation in these tumors. FAK and p53 expression was examined by immunohistochemistry in normal oral mucosa and in 67 oral squamous cell carcinomas. p16(INK4a) was also studied in view of its association with human papillomavirus infection. The association between FAK and p53 was subsequently analyzed. FAK expression in OSCCs was heterogeneous: 22 (33%) cases showed weak expression, 16 (24%) showed moderate expression, and 22 (33%) cases showed high expression. Regarding p53, 31 of 67 (46%) available tumor specimens showed negative staining, and 36 of 67 (54%) showed positive nuclear staining for p53. FAK expression was inversely correlated with p53 expression (Fisher's exact test, p=0.005). There was no association between p16(INK4a) and p53 or FAK expression. In conclusion, our results support the hypothesis that FAK activity might be involved in the down-regulation of p53 expression in OSCC.",
        "Doc_title":"In oral squamous cell carcinoma, high FAK expression is correlated with low P53 expression.",
        "Journal":"Virchows Archiv : an international journal of pathology",
        "Do_id":"22790665",
        "Doc_ChemicalList":"Biomarkers, Tumor;Cyclin-Dependent Kinase Inhibitor p16;TP53 protein, human;Tumor Suppressor Protein p53;Focal Adhesion Kinase 1;PTK2 protein, human",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Biomarkers, Tumor;Carcinoma, Squamous Cell;Cyclin-Dependent Kinase Inhibitor p16;Down-Regulation;Female;Focal Adhesion Kinase 1;Humans;Immunohistochemistry;Male;Middle Aged;Mouth Neoplasms;Neoplasm Grading;Neoplasm Staging;Tumor Suppressor Protein p53;Young Adult",
        "Doc_meshqualifiers":"analysis;metabolism;pathology;analysis;biosynthesis;analysis;biosynthesis;metabolism;pathology;analysis;biosynthesis",
        "_version_":1605825746881740800},
      {
        "Doc_abstract":"The p14(ARF) protein encoded by the INK4a/ARF locus promotes degradation of the MDM2 protein and thus prevents the MDM2-mediated inhibition of p53. Homozygous deletion of the INK4a/ARF locus is common in human mesothelioma and may result in the loss of p14(ARF) and the inactivation of p53. We designed this study to evaluate the biologic and potential therapeutic roles of p14(ARF) expression in mesothelioma cells.;We constructed Adp14, an adenoviral vector carrying human p14(ARF) complementary DNA, and used it to transfect human mesothelioma cell lines H28, H513, H2052, and MSTO-211H. Overexpression of p14(ARF) led to increased amounts of p53 and the p21(WAF) proteins and dephosphorylation of the retinoblastoma protein. The growth rate of mesothelioma cells was inhibited markedly by infection with Adp14 compared with mock infection or infection with a control adenovirus vector, AdCtrl. Overexpression of p14(ARF) induced G(1)-phase cell cycle arrest and apoptotic cell death. Cytotoxicity assays showed that Adp14 had a statistically significantly (P =.002) greater effect on colon cancer (HCT116) cell lines containing two copies of the wild-type p53 gene than on p53-null cells, suggesting that functional p53 is a critical determinant of p14(ARF)-mediated cytotoxicity.;The transfection of p14(ARF) into mesothelioma cells led to the overexpression of p14(ARF), which resulted in G(1)-phase arrest and apoptotic cell death. These results suggest that this gene therapy-based approach may be of use in the treatment of mesothelioma.",
        "Doc_title":"Adenovirus-mediated p14(ARF) gene transfer in human mesothelioma cells.",
        "Journal":"Journal of the National Cancer Institute",
        "Do_id":"10772681",
        "Doc_ChemicalList":"CDKN1A protein, human;Cyclin-Dependent Kinase Inhibitor p21;Cyclins;Proteins;Tumor Suppressor Protein p14ARF;Tumor Suppressor Protein p53",
        "Doc_meshdescriptors":"Adenoviridae;Apoptosis;Cell Cycle;Cell Division;Cyclin-Dependent Kinase Inhibitor p21;Cyclins;Gene Transfer Techniques;Genetic Vectors;Humans;Mesothelioma;Proteins;Tumor Cells, Cultured;Tumor Suppressor Protein p14ARF;Tumor Suppressor Protein p53",
        "Doc_meshqualifiers":"genetics;metabolism;genetics;metabolism;genetics;metabolism",
        "_version_":1605880262565036032},
      {
        "Doc_abstract":"The aim of the present study was to identify HPV-attributable SCC of the oral cavity (OSCC) in a cohort of patients from southern Germany.;A sensitive PCR-enzyme immunoassay (EIA) was followed by a more specific in situ hybridization (ISH) to detect high risk human papillomavirus (HPV). An immunohistochemical dual-staining for p16(INK4a) and the proliferation marker Ki-67 was used to assess whether co-expression of p16(INK4a)/Ki-67 is a better surrogate marker for HPV in OSCC than p16(INK4a) alone, based on the hypothesis that combined p16(INK4a) and Ki-67 expression might specifically discriminate oncogene-induced p16(INK4a) expression from cell-cycle arrest-inducing senescence-associated p16(INK4a) expression.;HPV-DNA by PCR-EIA could be detected in 25.1% (69/275) of the tumors, but ISH was negative in all of them. Diffuse p16(INK4a) overexpression was detected in 11 HPV PCR-positive tumors, but also in 6 HPV PCR-negative tumors. p16(INK4a)-expressing cells in diffusely positive tumors co-expressed Ki-67, irrespective of the HPV status. Neither the sole HPV status nor combined HPV/p16(INK4a) status nor the sole p16(INK4a) status was significantly associated with disease free or overall survival, however a trend towards better overall survival of patients whose tumor expressed p16(INK4a) in a focal pattern (=p16(INK4a)-positive/Ki-67-negative cells) compared to no p16(INK4a) expression (p=0.09) was observed.;Viral DNA can be detected in some tumors by a sensitive PCR, but absence of ISH signals indicates that the HPV-attributable fraction is smaller than estimated from PCR positivity. p16(INK4a)/Ki-67 co-expression is detectable in a fraction of OSCC irrespective of the HPV status.",
        "Doc_title":"Lack of evidence of human papillomavirus-induced squamous cell carcinomas of the oral cavity in southern Germany.",
        "Journal":"Oral oncology",
        "Do_id":"23608471",
        "Doc_ChemicalList":"Biomarkers, Tumor",
        "Doc_meshdescriptors":"Adult;Biomarkers, Tumor;Carcinoma, Squamous Cell;Female;Genotype;Germany;Humans;Male;Middle Aged;Mouth Neoplasms;Papillomaviridae;Prognosis",
        "Doc_meshqualifiers":"analysis;epidemiology;virology;epidemiology;epidemiology;virology;isolation & purification",
        "_version_":1605746465339080704},
      {
        "Doc_abstract":"In contrast to the initial notion that the biological activity of p14(ARF) strictly depends on a functional mdm-2/p53 signaling axis, we recently demonstrated that p14(ARF) mediates apoptosis in a p53/Bax-independent manner. Here, we show that p14(ARF) induces breakdown of the mitochondrial membrane potential and cytochrome c release before triggering caspase-9- and caspase-3/7-like activities in p53/Bax-deficient DU145 prostate cancer cells expressing wild-type Bak. Re-expression of Bax in these cells failed to further enhance p14(ARF)-induced apoptosis, suggesting that p14(ARF)-induced apoptosis primarily depends on Bak but not Bax in these cells. To further define the role of Bak and Bax in p14(ARF)-induced mitochondrial apoptosis, we employed short interference RNA for the knockdown of bak in isogeneic, p53 wild-type HCT116 colon cancer cells either proficient or deficient for Bax. There, combined loss of Bax and Bak attenuated p14(ARF)-induced apoptosis whereas single loss of Bax or Bak was only marginally effective, as in the case of DU145. Notably, HCT116 cells deficient for Bax and Bak failed to release cytochrome c and showed attenuated activation of caspase-9 (LEHDase) and caspase-3/caspase-7 (DEVDase) upon p14(ARF) expression. These data indicate that p14(ARF) triggers apoptosis via a Bax/Bak-dependent pathway in p53-proficient HCT116, whereas Bax is dispensable in p53-deficient DU145 cells. Nevertheless, a substantial proportion of p14(ARF)-induced cell death proceeds in a Bax/Bak-independent manner. This is also the case for inhibition of clonogenic growth that occurs, at least in part, through an entirely Bax/Bak-independent mechanism.",
        "Doc_title":"Bak functionally complements for loss of Bax during p14ARF-induced mitochondrial apoptosis in human cancer cells.",
        "Journal":"Oncogene",
        "Do_id":"16847458",
        "Doc_ChemicalList":"Apoptosis Inducing Factor;Tumor Suppressor Protein p14ARF;bcl-2 Homologous Antagonist-Killer Protein;bcl-2-Associated X Protein;Caspase 3;Caspase 7;Caspase 9;Caspases",
        "Doc_meshdescriptors":"Apoptosis;Apoptosis Inducing Factor;Caspase 3;Caspase 7;Caspase 9;Caspases;Cell Survival;Genes, p53;HCT116 Cells;Humans;Mitochondria;Models, Biological;Tumor Cells, Cultured;Tumor Suppressor Protein p14ARF;bcl-2 Homologous Antagonist-Killer Protein;bcl-2-Associated X Protein",
        "Doc_meshqualifiers":"physiology;metabolism;metabolism;metabolism;metabolism;metabolism;physiology;genetics;metabolism;physiology;metabolism;physiology;genetics",
        "_version_":1605810181375000576},
      {
        "Doc_abstract":"There have been reports showing a protective role of nonsteroidal anti-inflammatory drugs (NSAIDs) against gastrointestinal cancers. CpG island hyper methylation (CIHM) of tumor suppressor genes is a major event in carcinogenesis. We investigated the CIHM status of non-cancerous gastric mucosa in chronic NSAID users and non-users and assessed the effect of NSAIDs on CIHM. Gastric mucosa samples were obtained from 51 chronic NSAID users and 180 non-users. CIHM of p14(ARF), p16(INK4a), death-associated protein kinase (DAP-kinase), and E-cadherin (CDH1) genes were determined by methylation-specific PCR. CIHM high was defined as two or more CpG islands methylated. CIHM of p14, p16, CDH1, and CIHM high were lower in chronic NSAID users than in non-users (p14: non-users vs users = 32.2%vs 9.8%, P = 0.003; p16: non-users vs users = 35.0%vs 15.7%, P = 0.02; CDH1: non-users vs users = 36.1%vs 9.8%, P = 0.0009; CIHM high: non-users vs users = 44.4%vs 17.6%, P = 0.0009). NSAID use was also associated with decreased number of CIHM by anova (R = -0.32, P < 0.0001). Multivariate logistic regression analysis with adjustment for sex, age, Helicobacter pylori infection, and NSAID use revealed that NSAID use was inversely correlated with all four CIHM and CIHM high as an independent factor (p14: odds ratio [OR] = 0.17, 95% confidence interval [CI] = 0.06-0.48; p16: OR = 0.32, 95% CI = 0.14-0.75; DAP-kinase: OR = 0.45, 95% CI = 0.22-0.92; CDH1: OR = 0.18, 95% CI = 0.06-0.48; CIHM high: OR = 0.21, 95% CI = 0.09-0.49). No association was found between CIHM status and the duration or dose of NSAIDs. Chronic NSAID use suppresses CIHM in human gastric mucosa. NSAIDs may have a suppressive role against methylation-related gastric carcinogenesis.",
        "Doc_title":"Chronic nonsteroidal anti-inflammatory drug (NSAID) use suppresses multiple CpG islands hyper methylation (CIHM) of tumor suppressor genes in the human gastric mucosa.",
        "Journal":"Cancer science",
        "Do_id":"19432886",
        "Doc_ChemicalList":"Anti-Inflammatory Agents, Non-Steroidal",
        "Doc_meshdescriptors":"Anti-Inflammatory Agents, Non-Steroidal;CpG Islands;DNA Methylation;Female;Gastric Mucosa;Gastrointestinal Neoplasms;Genes, Tumor Suppressor;Humans;Male;Middle Aged",
        "Doc_meshqualifiers":"administration & dosage;pharmacology;drug effects;drug effects;drug therapy;genetics;drug effects",
        "_version_":1605751493461278720},
      {
        "Doc_abstract":"Polycomb group proteins are epigenetic transcriptional repressors that function through recognition and modification of histone methylation and chromatin structure. As a member of PcG proteins, enhancer of zeste homolog 2 (EZH2) targets cell cycle regulatory proteins which govern cell cycle progression and cellular senescence. In previous work, we reported that EZH2 depletion functionally induced cellular senescence in human gastric cancer cells with mutant p53. However, whether EZH2 expression contributes to the change of key cell cycle regulators and the mechanism involved are still unclear. To address this issue, we investigated the effects of EZH2 depletion on alteration of histone methylation pattern. In gastric cancer cells, INK4/ARF locus was activated to certain extent in consequence of a decrease of H3K27me3 along it caused by EZH2 silence, which contributed substantially to an increase in the expression of p15(INK4b), p14(ARF) and p16(INK4a) and resulted in cellular senescence ultimately. Furthermore, MKN28 cells, which did not express p16(INK4a) and p21(cip), could be induced to senescence via p15(INK4b) activation and suppression of p15(INK4b) reversed senescence progression induced by EZH2 downregulated. These data unravel a crucial role of EZH2 in the regulation of INK4/ARF expression and senescence procedure in gastric cancer cells, and show that the cellular senescence could just depend on the activation of p15(INK4b)/Rb pathway, suggesting the cell-type and species specificity involved in the mechanisms of senescence inducement. ",
        "Doc_title":"Enhancer of zeste homolog 2 depletion induces cellular senescence via histone demethylation along the INK4/ARF locus.",
        "Journal":"The international journal of biochemistry & cell biology",
        "Do_id":"26004298",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p15;Cyclin-Dependent Kinase Inhibitor p16;Histones;Tumor Suppressor Protein p14ARF;EZH2 protein, human;Enhancer of Zeste Homolog 2 Protein;Polycomb Repressive Complex 2",
        "Doc_meshdescriptors":"Cell Aging;Cell Cycle;Cell Line, Tumor;Cell Proliferation;Cyclin-Dependent Kinase Inhibitor p15;Cyclin-Dependent Kinase Inhibitor p16;Enhancer of Zeste Homolog 2 Protein;Histones;Humans;Methylation;Polycomb Repressive Complex 2;Stomach Neoplasms;Tumor Suppressor Protein p14ARF",
        "Doc_meshqualifiers":"physiology;physiology;physiology;genetics;metabolism;genetics;metabolism;metabolism;deficiency;genetics;metabolism;genetics;metabolism;pathology;genetics;metabolism",
        "_version_":1605812063904464896},
      {
        "Doc_abstract":": Inherited mutations in the CDKN2A tumor suppressor gene, which encodes the p16(INK4a) protein, and in the cyclin-dependent kinase 4 (CDK4) gene confer susceptibility to cutaneous malignant melanoma. We analyzed families with two or more cases of melanoma for germline mutations in CDKN2A and CDK4 to elucidate the contribution of these gene defects to familial malignant melanoma and to the occurrence of other cancer types.;: The entire CDKN2A coding region and exon 2 of the CDK4 gene of an affected member of each of 52 families from southern Sweden with at least two cases of melanoma in first- or second-degree relatives were screened for mutations by use of polymerase chain reaction-single-strand conformation polymorphism analysis. Statistical tests were two-sided.;: CDKN2A mutations were found in 10 (19%) of the 52 families. Nine families carried an identical alteration consisting of the insertion of arginine at position 113 of p16(INK4a), and one carried a missense mutation, in which the valine at position 115 was replaced with a glycine. The 113insArg mutant p16(INK4a) was unable to bind cdk4 and cdk6 in an in vitro binding assay. Six of the 113insArg families had at least one member with multiple primary melanomas; the 113insArg families also had a high frequency of other malignancies-in particular, breast cancer (a total of eight cases compared with the expected 2.1; P =.0014) and pancreatic cancer (a total of six cases compared with the expected 0.16; P<.0001). Families with breast cancer also had a propensity for multiple melanomas in females, suggesting that a sex-dependent factor may modify the phenotypic expression of CDKN2A alterations.;: Our findings confirm that the majority of CDKN2A-associated melanoma families in Sweden are due to a single founder mutation. They also show that families with the CDKN2A 113insArg mutation have an increased risk not only of multiple melanomas and pancreatic carcinoma but also of breast cancer.",
        "Doc_title":"High frequency of multiple melanomas and breast and pancreas carcinomas in CDKN2A mutation-positive melanoma families.",
        "Journal":"Journal of the National Cancer Institute",
        "Do_id":"10922411",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Amino Acid Sequence;Breast Neoplasms;Female;Genes, p16;Humans;Male;Melanoma;Molecular Sequence Data;Mutation;Neoplasms, Multiple Primary;Pancreatic Neoplasms;Pedigree;Polymerase Chain Reaction;Polymorphism, Single-Stranded Conformational;Promoter Regions, Genetic;Risk;Sex Factors;Skin Neoplasms;Sweden",
        "Doc_meshqualifiers":"genetics;genetics;genetics;genetics;methods;genetics;genetics",
        "_version_":1605840236892389376},
      {
        "Doc_abstract":"The presence of cancer stem cells, in both hematopoietic and solid malignancies, has been recently linked to their pathogenesis. We aimed to identify the characteristics and stem-like properties of sphere-colony forming cells in rat osteosarcoma and malignant fibrous histiocytoma cell lines. The results showed that both cell lines possessed an ability to form spherical, clonally expanding colonies in anchorage-independent, serum-starved conditions in N2/1% methylcellulose medium. The sphere cells showed stem-like properties with the ability to self-renew, and expressed the stem cell-related STAT3 and Bmi1 genes. Interestingly, spheres from both sarcomas remarkably decreased the expression of INK4a/ARF locus genes, p16(INK4a) and p19(ARF), which could be related to the resistance against cell senescence and apoptosis. Spheres showed strong tumorigenicity with metastatic potential in vivo via the inoculation into syngeneic rats, suggesting the presence of these populations might contribute to the tumor development such as metastasis via the resistance to apoptotic stimuli.",
        "Doc_title":"Reduced expression of INK4a/ARF genes in stem-like sphere cells from rat sarcomas.",
        "Journal":"Biochemical and biophysical research communications",
        "Do_id":"17761140",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;DNA Primers;STAT3 Transcription Factor;Tumor Suppressor Protein p14ARF;p19(ARF) protein, rat",
        "Doc_meshdescriptors":"Animals;Cell Line, Tumor;Cyclin-Dependent Kinase Inhibitor p16;DNA Primers;Gene Expression Regulation, Neoplastic;Histiocytoma, Malignant Fibrous;Microscopy, Phase-Contrast;Neoplasm Metastasis;Osteosarcoma;Phenotype;Rats;STAT3 Transcription Factor;Sarcoma;Stem Cells;Tumor Suppressor Protein p14ARF",
        "Doc_meshqualifiers":"chemistry;metabolism;chemistry;metabolism;metabolism;pathology;metabolism;metabolism;cytology;metabolism;metabolism",
        "_version_":1605782974927732736},
      {
        "Doc_abstract":"To evaluate the prognostic relevance of key cell cycle regulatory proteins p53, p16(INK4a), pRb and Cyclin D1 expression, the presence of high risk HPVs and their association with clinicopathological parameters and the clinical follow up in ovarian cancer patients.;53 cases of primary ovarian serous carcinomas were immunohistochemically examined for the expression of p53, p16(INK4a), pRb and Cyclin D1 proteins. Tumor DNA was extracted from paraffin blocks and subjected to HPV 16 and 18 testing. The association between HPV 16 and 18 E6 oncoprotein and cell cycle proteins expression in ovarian carcinomas also was evaluated by immunohistochemistry.;We demonstrated that a majority of moderately and poorly differentiated ovarian carcinomas are characterized by strong expression of p53 and p16(INK4a) proteins. In contrast, strong staining with cyclin D1 antibody was observed in well differentiated tumors. The correlation between strong p53, pRb, Cyclin D1 and clinical stages of disease was also observed. We show that patients with high positivity for p53, p16(INK4a) and Cyclin D1 had a poor prognosis and reduced overall survival. The presence of HPV 16/18 DNA was detected in 17% of ovarian carcinomas. The tumor tissues that reacted positively to HPV E6 antibody in focal and diffuse manners had also significantly low p53 expression profile.;These findings suggest that p53, p16(INK4a) and Cyclin D1 expression and HPV infection may represent a promising tool toward the identification of ovarian cancer patients with poorer prognosis and shorter survival who might therefore need a more aggressive therapy and HPV screening.",
        "Doc_title":"Analysis of p53, p16(INK4a), pRb and Cyclin D1 expression and human papillomavirus in primary ovarian serous carcinomas.",
        "Journal":"Experimental oncology",
        "Do_id":"21956468",
        "Doc_ChemicalList":"Antibodies, Monoclonal;Biomarkers, Tumor;Cell Cycle Proteins;Cyclin-Dependent Kinase Inhibitor p16;DNA-Binding Proteins;E6 protein, Human papillomavirus type 16;E6 protein, Human papillomavirus type 18;Oncogene Proteins, Viral;Repressor Proteins;Retinoblastoma Protein;Tumor Suppressor Protein p53;Cyclin D1",
        "Doc_meshdescriptors":"Adolescent;Adult;Aged;Alphapapillomavirus;Antibodies, Monoclonal;Biomarkers, Tumor;Cell Cycle;Cell Cycle Proteins;Cyclin D1;Cyclin-Dependent Kinase Inhibitor p16;DNA-Binding Proteins;Female;Human papillomavirus 16;Human papillomavirus 18;Humans;Immunohistochemistry;Middle Aged;Oncogene Proteins, Viral;Ovarian Neoplasms;Papillomavirus Infections;Prognosis;Repressor Proteins;Retinoblastoma Protein;Tumor Suppressor Protein p53",
        "Doc_meshqualifiers":"isolation & purification;analysis;analysis;analysis;genetics;immunology;analysis;genetics;analysis;isolation & purification;isolation & purification;analysis;metabolism;pathology;virology;complications;virology;analysis;analysis;genetics;analysis;genetics",
        "_version_":1605747006439948288},
      {
        "Doc_abstract":"Previously we reported that TGF-1-induced growth suppression was associated with a decrease in mutant p53 levels in B-cell lymphoma cells. The goal of the present study was to understand the mechanism involved in TGF-1-mediated down-regulation of mutant p53. In RL and CA46, two B-cell lymphoma cell lines, TGF-1 treatment caused down-regulation of E2F-1 transcription factor resulting in the down-regulation of both p14(ARF) and mutant p53, leading to growth arrest. Experimental overexpression of E2F-1 increased p14(ARF) level and blocked TGF-1-induced down-regulation of p14(ARF). Overexpression of p14(ARF) blocked the down-regulation of mutant p53 and prevented growth arrest. p14(ARF) also attenuated TGF-1-induced p21(Cip1/WAF1) induction, which was reversible by p53 siRNA, indicating the involvement of mutant p53 in controlling the TGF-1-induced expression of p21(Cip1/WAF1). The interaction observed between phospho-Smad2 and mutant p53 in the nucleus could be the mechanism responsible for blocking the growth-suppressive effects of TGF-1. In RL cells, p14(ARF) is present in a trimer consisting of mutant p53-Mdm2-p14(ARF) and in a dimer consisting of Mdm2-p14(ARF). Because it is known that Mdm2 can degrade p53, it is possible that, in its trimeric form, p14(ARF) is able to stabilize mutant p53 by inhibiting Mdm2. In its dimeric form, p14(ARF) may be sequestering Mdm2, limiting its ability to degrade p53. Collectively, these data demonstrate a unique mechanism in which the inhibition of TGF-1-mediated growth suppression by mutant p53 can be reversed by the down-regulation of its stabilizing protein p14(ARF). This work suggests that the high levels of p14(ARF) often found in tumor cells could be a potential therapeutic target.",
        "Doc_title":"Transforming growth factor 1 (TGF-1) suppresses growth of B-cell lymphoma cells by p14(ARF)-dependent regulation of mutant p53.",
        "Journal":"The Journal of biological chemistry",
        "Do_id":"22621932",
        "Doc_ChemicalList":"Antineoplastic Agents;CDKN1A protein, human;Cyclin-Dependent Kinase Inhibitor p21;RNA, Messenger;RNA, Small Interfering;SMAD2 protein, human;Smad2 Protein;TP53 protein, human;Transforming Growth Factor beta1;Tumor Suppressor Protein p14ARF;Tumor Suppressor Protein p53",
        "Doc_meshdescriptors":"Antineoplastic Agents;Cell Division;Cyclin-Dependent Kinase Inhibitor p21;Down-Regulation;Drug Design;Gene Expression Regulation, Neoplastic;Humans;Lymphoma, B-Cell;Promoter Regions, Genetic;RNA, Messenger;RNA, Small Interfering;Smad2 Protein;Transforming Growth Factor beta1;Tumor Cells, Cultured;Tumor Suppressor Protein p14ARF;Tumor Suppressor Protein p53",
        "Doc_meshqualifiers":"pharmacology;drug effects;physiology;genetics;drug effects;physiology;drug effects;physiology;drug therapy;genetics;pathology;physiology;metabolism;genetics;metabolism;pharmacology;genetics;metabolism;genetics;metabolism",
        "_version_":1605746978446114817},
      {
        "Doc_abstract":"CD8 T cells used in adoptive immunotherapy may be manipulated to optimize their effector functions, tissue-migratory properties and long-term replicative potential. We reported that antigen-stimulated CD8 T cells transduced to express an active form of the transcription factor signal transducer and activator of transcription 5 (STAT5CA) maintained these properties upon adoptive transfer. We now report on the requirements of STAT5CA-expressing CD8 T cells for cell survival and proliferation invivo. We show that STAT5CA expression allows for greater expansion of T cells invivo, while preserving dependency on T-cell-receptor-mediated tonic stimulation for their invivo maintenance and return to a quiescent stage. STAT5CA expression promotes the formation of a large pool of effector memory T cells that respond upon re-exposure to antigen and present an increased sensitivity to c receptor cytokine engagement for STAT5 phosphorylation. In addition, STAT5CA expression prolongs the survival of what would otherwise be short-lived terminally differentiated KLRG1-positive effector cells with up-regulated expression of the senescence-associated p16(INK) (4A) transcripts. However, development of a KLRG1-positive CD8 T cell population was independent of either p16(INK) (4A) or p19(ARF) expression (as shown using T cells from CDKN2A(-/-) mice) but was associated with expression of transcripts encoding p15(INK) (4B) , another protein involved in senescence induction. We conclude that T-cell-receptor- and cytokine-dependent regulation of effector T cell homeostasis, as well as mechanisms leading to senescent features of a population of CD8 T cells are maintained in STAT5CA-expressing CD8 T cells, even for cells that are genetically deficient in expression of the tumour suppressors p16(INK) (4A) and p19(ARF) . ",
        "Doc_title":"Control of CD8 T cell proliferation and terminal differentiation by active STAT5 and CDKN2A/CDKN2B.",
        "Journal":"Immunology",
        "Do_id":"25882552",
        "Doc_ChemicalList":"Cdkn2a protein, mouse;Cdkn2b protein, mouse;Cyclin-Dependent Kinase Inhibitor p15;Cyclin-Dependent Kinase Inhibitor p16;Klrg1 protein, mouse;Receptors, Antigen, T-Cell;Receptors, Immunologic;STAT5 Transcription Factor",
        "Doc_meshdescriptors":"Animals;CD8-Positive T-Lymphocytes;Cell Aging;Cell Differentiation;Cell Proliferation;Cyclin-Dependent Kinase Inhibitor p15;Cyclin-Dependent Kinase Inhibitor p16;Gene Expression Regulation;Mice;Mice, Knockout;Receptors, Antigen, T-Cell;Receptors, Immunologic;STAT5 Transcription Factor",
        "Doc_meshqualifiers":"immunology;genetics;immunology;genetics;immunology;genetics;immunology;genetics;immunology;immunology;genetics;immunology;genetics;immunology;genetics;immunology",
        "_version_":1605800721074094080},
      {
        "Doc_abstract":"It is known that the cyclin-dependent kinase inhibitor (CDKI) gene p21(Cip1) suppresses rheumatoid inflammation by down-modulating type I interleukin-1 receptor (IL-1RI) expression and inhibiting JNK activity. The purpose of this study was to determine whether CDK activity directly modulates the production of inflammatory molecules in patients with rheumatoid arthritis (RA).;Genes for the CDKIs p16(INK4a) and p18(INK4c), a constitutively active form of retinoblastoma (RB) gene product, cyclin D1, and CDK-4, were transferred into RA synovial fibroblasts (RASFs). RASFs were also treated with a synthetic CDK-4/6 inhibitor (CDK4I). Levels of matrix metalloproteinase 3 (MMP-3), monocyte chemoattractant protein 1 (MCP-1), and IL-1RI expression were determined by Northern blotting, real-time polymerase chain reaction analysis, and enzyme-linked immunosorbent assay. CDKIs were immunoprecipitated to reveal their association with JNK.;Transfer of the p16(INK4a) and p18(INK4c) genes and CDK4I suppressed the production of MMP-3 and MCP-1. Unlike p21(Cip1), neither CDKI gene inhibited IL-1RI or JNK. The expression of MMP-3 was up-regulated when CDK-4 activity was augmented. This regulation functioned at the messenger RNA (mRNA) level in MMP-3, but not in MCP-1. Transfer of active RB suppressed the production of MMP-3 and MCP-1 without changing their mRNA levels.;CDK-4/6 modulated the production of MMP-3 and MCP-1. MMP-3 production was regulated primarily at the mRNA level in an RB-independent manner, whereas MCP-1 production was controlled posttranscriptionally by RB. These results show that cell cycle proteins are associated with control of mediators of inflammation through multiple pathways.",
        "Doc_title":"Direct modulation of rheumatoid inflammatory mediator expression in retinoblastoma protein-dependent and -independent pathways by cyclin-dependent kinase 4/6.",
        "Journal":"Arthritis and rheumatism",
        "Do_id":"16802342",
        "Doc_ChemicalList":"CCL2 protein, human;Chemokine CCL2;Cyclin-Dependent Kinase Inhibitor p16;Cyclin-Dependent Kinase Inhibitor p18;Cyclin-Dependent Kinase Inhibitor p21;RNA, Messenger;Receptors, Interleukin-1;Receptors, Interleukin-1 Type I;Retinoblastoma Protein;Cyclin D1;Cyclin-Dependent Kinase 4;Cyclin-Dependent Kinase 6;MAP Kinase Kinase 4;Matrix Metalloproteinase 3",
        "Doc_meshdescriptors":"Arthritis, Rheumatoid;Cell Proliferation;Cells, Cultured;Chemokine CCL2;Cyclin D1;Cyclin-Dependent Kinase 4;Cyclin-Dependent Kinase 6;Cyclin-Dependent Kinase Inhibitor p16;Cyclin-Dependent Kinase Inhibitor p18;Cyclin-Dependent Kinase Inhibitor p21;Fibroblasts;Gene Expression Regulation;Humans;MAP Kinase Kinase 4;Matrix Metalloproteinase 3;RNA, Messenger;Receptors, Interleukin-1;Receptors, Interleukin-1 Type I;Retinoblastoma Protein;Synovial Membrane",
        "Doc_meshqualifiers":"genetics;pathology;physiopathology;genetics;metabolism;genetics;metabolism;antagonists & inhibitors;genetics;metabolism;antagonists & inhibitors;genetics;metabolism;genetics;physiology;genetics;physiology;genetics;physiology;drug effects;metabolism;pathology;drug effects;physiology;genetics;metabolism;genetics;metabolism;genetics;metabolism;genetics;metabolism;genetics;physiology;drug effects;metabolism;pathology",
        "_version_":1605875869733093376},
      {
        "Doc_abstract":"Prostate cancer (PCa) is the most prevalent cancer in men. Hyperactive STAT3 is thought to be oncogenic in PCa. However, targeting of the IL-6/STAT3 axis in PCa patients has failed to provide therapeutic benefit. Here we show that genetic inactivation of Stat3 or IL-6 signalling in a Pten-deficient PCa mouse model accelerates cancer progression leading to metastasis. Mechanistically, we identify p19(ARF) as a direct Stat3 target. Loss of Stat3 signalling disrupts the ARF-Mdm2-p53 tumour suppressor axis bypassing senescence. Strikingly, we also identify STAT3 and CDKN2A mutations in primary human PCa. STAT3 and CDKN2A deletions co-occurred with high frequency in PCa metastases. In accordance, loss of STAT3 and p14(ARF) expression in patient tumours correlates with increased risk of disease recurrence and metastatic PCa. Thus, STAT3 and ARF may be prognostic markers to stratify high from low risk PCa patients. Our findings challenge the current discussion on therapeutic benefit or risk of IL-6/STAT3 inhibition. ",
        "Doc_title":"STAT3 regulated ARF expression suppresses prostate cancer metastasis.",
        "Journal":"Nature communications",
        "Do_id":"26198641",
        "Doc_ChemicalList":"Cdkn2a protein, mouse;Cyclin-Dependent Kinase Inhibitor p16;Interleukin-6;STAT3 Transcription Factor;Stat3 protein, mouse;Tumor Suppressor Protein p53;interleukin-6, mouse;Mdm2 protein, mouse;Proto-Oncogene Proteins c-mdm2;PTEN Phosphohydrolase;Pten protein, mouse",
        "Doc_meshdescriptors":"Animals;Cell Line;Cyclin-Dependent Kinase Inhibitor p16;Disease Progression;Genes, p16;Humans;Interleukin-6;Male;Mice;Mice, Transgenic;Neoplasms, Experimental;PTEN Phosphohydrolase;Prostatic Neoplasms;Proto-Oncogene Proteins c-mdm2;STAT3 Transcription Factor;Tumor Suppressor Protein p53",
        "Doc_meshqualifiers":"metabolism;genetics;metabolism;genetics;metabolism;metabolism;genetics;metabolism;metabolism",
        "_version_":1605795613579935744},
      {
        "Doc_abstract":"A wide panel of murine induced T-cell lymphomas have been analysed for p16INK4a or p15INK4b alterations. Only one gamma-radiation-induced lymphoma showed p16INK4a homozygous deletion and no other intragenic mutations were found in these INK4 genes. However, de novo methylation of the 5' CpG islands of the murine p15INK4b and p16INK4a genes was found to be highly frequent. While p16INK4a hypermethylation was found in 36% of the neutron-radiation-induced lymphomas and 15% of the gamma-radiation-induced lymphomas, de novo methylation of p15INK4b occurs in 88% and 42% of these tumors respectively, correlating with deficient expression of the corresponding mRNA and allelic losses in the p15INK4b and p16INK4a chromosome location. These data represent, to our knowledge, the first report on the significant involvement of hypermethylation of these INK4 genes in murine primary tumors. Moreover, they show the importance of allelic losses and CpG island methylation of p15INK4b gene inactivation and support a tumor suppressor role for p15INK4b in T-cell lymphomas independent of p16INK4a.",
        "Doc_title":"Inactivation of the cyclin-dependent kinase inhibitor p15INK4b by deletion and de novo methylation with independence of p16INK4a alterations in murine primary T-cell lymphomas.",
        "Journal":"Oncogene",
        "Do_id":"9178896",
        "Doc_ChemicalList":"Carrier Proteins;Cdkn2b protein, mouse;Cell Cycle Proteins;Cyclin-Dependent Kinase Inhibitor p15;Cyclin-Dependent Kinase Inhibitor p16;Tumor Suppressor Proteins",
        "Doc_meshdescriptors":"Animals;Carrier Proteins;Cell Cycle Proteins;CpG Islands;Cyclin-Dependent Kinase Inhibitor p15;Cyclin-Dependent Kinase Inhibitor p16;DNA Methylation;Gene Deletion;Gene Expression Regulation, Neoplastic;Lymphoma, T-Cell;Mice;Mice, Inbred Strains;Molecular Sequence Data;Polymorphism, Single-Stranded Conformational;Tumor Suppressor Proteins",
        "Doc_meshqualifiers":"antagonists & inhibitors;genetics;genetics;genetics;genetics",
        "_version_":1605748030998315008},
      {
        "Doc_abstract":"Paraffin sections from 190 epithelial ovarian tumours, including 159 malignant and 31 benign epithelial tumours, were analysed immunohistochemically for expression of cyclin-dependent kinase inhibitor 2 (CDKN2A) gene product p16INK4A (p16). Most benign tumours showed no p16 expression in the tumour cells, whereas only 11% of malignant cancers were p16 negative. A high proportion of p16-positive tumour cells was associated with advanced stage and grade, and with poor prognosis in cancer patients. For FIGO stage I tumours, a high proportion of p16-positive tumour cells was associated with poorer survival, suggesting that accumulation of p16 is an early event of ovarian tumorigenesis. In contrast to tumour cells, high expression of p16 in the surrounding stromal cells was not associated with the stage and grade, but was associated with longer survival. When all parameters were combined in a multivariate analysis, high p16 expression in stromal cells was not an independent predictor for survival, indicating that low p16 expression in stromal cells is associated with other markers of tumour progression. High expression of p16 in the stromal cells of tumours from long-term survivors suggests that tumour growth is limited to some extent by factors associated with p16 expression in the matrix.",
        "Doc_title":"Increased expression of cyclin-dependent kinase inhibitor 2 (CDKN2A) gene product P16INK4A in ovarian cancer is associated with progression and unfavourable prognosis.",
        "Journal":"International journal of cancer",
        "Do_id":"9036870",
        "Doc_ChemicalList":"Biomarkers, Tumor;Carrier Proteins;Cyclin-Dependent Kinase Inhibitor p16",
        "Doc_meshdescriptors":"Biomarkers, Tumor;Blotting, Western;Carrier Proteins;Cyclin-Dependent Kinase Inhibitor p16;Disease Progression;Female;Genes, Tumor Suppressor;HeLa Cells;Humans;Immunohistochemistry;Ovarian Neoplasms;Prognosis;Survival Rate;Time Factors",
        "Doc_meshqualifiers":"analysis;analysis;biosynthesis;genetics;mortality;pathology;surgery",
        "_version_":1605754512461529088},
      {
        "Doc_abstract":"P19(INK4d) is a tumor suppressing protein and belongs to a family of cyclin D-dependent kinase inhibitors of CDK4 and CDK6, which play a key role in human cell cycle control. P19 comprises ten alpha-helices arranged sequentially in five ankyrin repeats forming an elongated structure. This rather simple topology, combined with its physiological function, makes p19 an interesting model protein for folding studies. Urea-induced unfolding transitions monitored by far-UV CD and phenylalanine fluorescence coincide and suggest a two-state mechanism for equilibrium unfolding. Unfolding of p19 followed by 2D (1)H-(15)N HSQC spectra revealed a third species at moderate urea concentrations with a maximum population of about 30 % near 3.2 M urea. It shows poor chemical shift dispersion, but cross-peaks emerge for some residues that are distinct from the native or unfolded state. This equilibrium intermediate either arises only at high protein concentrations (as in the NMR experiment) or has similar optical properties to the unfolded state. Stopped-flow far-UV CD experiments at various urea concentrations revealed that alpha-helical structure is formed in three phases, of which only the fastest phase (10 s(-1)) depends upon the urea concentration. The kinetic of the slowest phase (0.017 s(-1)) can be resolved by 1D real-time NMR and accelerated by cyclophilin. It is limited in rate by prolyl isomerization, and native-like ordered structure cannot form prior to this isomerization. The two fast phases lead to 83 % native protein within the dead time of the NMR experiment. In contrast to p16(INK4a), which exhibits only a marginal stability and high unfolding rates, p19 shows the expected stability for a protein of this size with a clear kinetic barrier between the unfolded and folded state. Therefore, p19 might complement the function of less stable INK4 inhibitors in cell cycle control under unfavorable conditions.",
        "Doc_title":"Protein folding and stability of human CDK inhibitor p19(INK4d).",
        "Journal":"Journal of molecular biology",
        "Do_id":"11786024",
        "Doc_ChemicalList":"CDKN2D protein, human;Cell Cycle Proteins;Cyclin-Dependent Kinase Inhibitor p16;Cyclin-Dependent Kinase Inhibitor p19;Phenylalanine;Urea;Cyclin-Dependent Kinases",
        "Doc_meshdescriptors":"Cell Cycle Proteins;Circular Dichroism;Cyclin-Dependent Kinase Inhibitor p16;Cyclin-Dependent Kinase Inhibitor p19;Cyclin-Dependent Kinases;Fluorescence;Humans;Kinetics;Magnetic Resonance Spectroscopy;Models, Molecular;Phenylalanine;Protein Denaturation;Protein Folding;Protein Renaturation;Protein Structure, Secondary;Protein Structure, Tertiary;Thermodynamics;Urea",
        "Doc_meshqualifiers":"chemistry;metabolism;antagonists & inhibitors;metabolism;drug effects;drug effects;drug effects;pharmacology",
        "_version_":1605791222614458368},
      {
        "Doc_abstract":"Gap juctions are transmembrane communication channels known to be involved in the control of cell proliferation by mediating the exchange of ions and small molecules between cells. Gap junctions are composed of connexon hemichannels made up of 6 connexin proteins, which abnormal expression and functions have been linked to tumor progression and poorer prognosis. Here, we studied the prognostic impact of the most prevalent connexin isotype, connexin 43 (Cx43) in head and neck squamous cell carcinomas (HNSCC). Tissue microarrays made from tumor samples of 90 HNSCC patients were immunostained for Cx43 and cell cycle regulation-related biomarkers including p53, Ki67, p16, aurora A, geminin, and p21 proteins. Scoring and histopathologic evaluation were performed in digital slides. A 4-tier scoring distinguishing the percentage of positively stained tumor cells was used including score 1: <5%, score 2: 6% to 20%, score 3: 21% to 60%, and score 4: >60%. For statistics, Kaplan-Meier curves with log-rank tests, Cox-regression, and Pearson /Fisher exact tests were used.A significant positive correlation was found between Cx43 expression and disease-specific survival of patients (P=0.004). The rate of p21 protein-positive tumor cells also proved to be a significant positive prognostic marker (P=0.014). Cx43 levels also showed a significant positive correlation with p53 expression (P=0.036). However, there was no statistical association between Cx43 levels and the rest of the markers tested neither with T, N, or M stage.In conclusion, our data suggest that reduced Cx43 expression and low p21 protein levels may have a significant negative impact on HNSCC prognosis. ",
        "Doc_title":"The Potential Prognostic Value of Connexin 43 Expression in Head and Neck Squamous Cell Carcinomas.",
        "Journal":"Applied immunohistochemistry & molecular morphology : AIMM",
        "Do_id":"26447893",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605831918193999872},
      {
        "Doc_abstract":"High-risk human papillomaviruses are the causative agents of cervical cancer and are also believed to be aetiologically involved in a subset of squamous cell carcinomas of the head and neck region, especially the tonsil. Cervical cancers arise through disruption of the pathways of p53 and the product of the retinoblastoma gene by the human papillomavirus oncoproteins E6 and E7. It is generally assumed that the same pathways are involved in human papillomavirus-induced carcinogenesis at other mucosal surfaces. However, the patterns of expression of cell cycle proteins targeted by human papillomavirus E6 and E7 in cancers from different anatomic sites have been inconsistent, due to either biologic or technological factors. In this study, 73 human papillomavirus, 16-positive cervical squamous cell carcinomas (35 from Australian and 38 from Chinese women) were analysed for the expression of p53, pRb, p16(INK4A), p21(CIP1/WAF1), p27(KIP1) and cyclin D1 by semiquantitative immunohistochemistry. Cervical cancers from Chinese women were found to be significantly more likely to overexpress p53, pRb, p21 and p27 than their Australian counterparts. These findings were compared with those from 31 human papillomavirus 16-positive tonsillar squamous cell carcinomas, all of Australian origin, tested using the same methodology. Comparisons of the tonsillar and combined cervical data showed that tonsillar cancers were significantly more likely to be p53-positive, whereas cervical cancers were significantly more likely to overexpress pRb, p16 and p27. When the tonsillar data were compared with cervical data from Australian women, the associations for p53 and pRb remained. These findings represent new evidence that the molecular pathways to human papillomavirus-induced mucosal cancer may be influenced by anatomic location and ethnicity.",
        "Doc_title":"The site of infection and ethnicity of the patient influence the biological pathways to HPV-induced mucosal cancer.",
        "Journal":"Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc",
        "Do_id":"15143339",
        "Doc_ChemicalList":"CDKN1A protein, human;Cell Cycle Proteins;Cyclin-Dependent Kinase Inhibitor p16;Cyclin-Dependent Kinase Inhibitor p21;Retinoblastoma Protein;Tumor Suppressor Protein p53;Tumor Suppressor Proteins;Cyclin D1;Cyclin-Dependent Kinase Inhibitor p27",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Australia;Carcinoma, Squamous Cell;Cell Cycle Proteins;China;Cyclin D1;Cyclin-Dependent Kinase Inhibitor p16;Cyclin-Dependent Kinase Inhibitor p21;Cyclin-Dependent Kinase Inhibitor p27;Female;Humans;Immunohistochemistry;Middle Aged;Neoplasm Staging;Papillomaviridae;Papillomavirus Infections;Retinoblastoma Protein;Tonsillar Neoplasms;Tumor Suppressor Protein p53;Tumor Suppressor Proteins;Uterine Cervical Neoplasms",
        "Doc_meshqualifiers":"ethnology;etiology;metabolism;pathology;analysis;analysis;analysis;complications;analysis;ethnology;etiology;metabolism;pathology;analysis;analysis;ethnology;etiology;metabolism;pathology",
        "_version_":1605746976611106817},
      {
        "Doc_abstract":"The purpose of the study is to test the hypothesis that expression of cell cycle regulatory proteins p16(INK4a) and pRb is significantly associated with prognosis in ovarian carcinomas. We performed immunohistochemical analysis of p16(INK4a) and pRb expression and correlated with survival in a series of 300 patients with FIGO stage IIb-IV ovarian carcinoma which were enrolled in a randomized prospective trial evaluating two different platinum and paxlitaxel chemotherapy combinations after radical surgery. p16(INK4a) negative tumours (17/300; 6%) had a significantly worse prognosis (univariate analysis, P<0.001; multivariate analysis: odds ratio 2.41, P=0.009). Among p16(INK4a)-positive tumours (283 out of 300; 94%), survival was better for patients with intermediate expression as compared to low or high expression levels (P=0.001). High expression levels of pRb were associated with an incremental deterioration of prognosis (univariate analysis, P=0.004; multivariate analysis: odds ratio 2.98, P=0.002). This observation held also true in the subgroup of optimally debulked patients (n=82), in whom the most important established prognostic factor, postoperative residual tumour cannot be applied. In conclusion p16(INK4a) and pRb are independent prognostic factors in advanced-stage ovarian carcinomas after radical surgery and postoperative chemotherapy. High pRb expression is a significant prognosticator in optimally debulked patients and may hold potential for subgroup stratification in postoperative treatment.",
        "Doc_title":"Independent prognostic significance of cell cycle regulator proteins p16(INK4a) and pRb in advanced-stage ovarian carcinoma including optimally debulked patients: a translational research subprotocol of a randomised study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group.",
        "Journal":"British journal of cancer",
        "Do_id":"17242700",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;Retinoblastoma Protein",
        "Doc_meshdescriptors":"Combined Modality Therapy;Cyclin-Dependent Kinase Inhibitor p16;Female;Humans;Ovarian Neoplasms;Prognosis;Prospective Studies;Retinoblastoma Protein;Survival Rate",
        "Doc_meshqualifiers":"physiology;drug therapy;metabolism;pathology;surgery;physiology",
        "_version_":1605758828333236224},
      {
        "Doc_abstract":"Aberrant promoter methylation is an important mechanism for gene silencing. Inflammation-related reactive oxygens contribute to this CpG island methylation. The nuclear factor-erythroid 2-related factor 2 gene (Nrf2) is known to regulate the expression of detoxifying and antioxidant genes. We investigated the relationship between promoter polymorphisms of Nrf2 gene and the CpG island methylation in non-cancerous gastric mucosa. The study was performed in 85 subjects (46 without gastric malignancies, non-GC group, and 39 with gastric cancer, GC group). The promoter methylation status of p14(ARF), p16(INK4a) and p21(Waf1) genes was determined by methylation-specific-polymerase chain reaction. The Nrf2 gene genotypes were determined by the PCR-SSCP method. In the 85 subjects, CpG island methylation was found in 25.9% for p14, 15.3% for p16, none for p21. The frequency of the methylated genes was significantly higher in GC group than non-GC group (OR, 2.67; 95% CI, 1.10-6.49; p=0.029). In particular, the frequency of p16 gene methylation was much higher in GC group (p=0.0023). The Nrf2 -686/-684 G/G haplotype was positively associated and A/G haplotype was inversely associated with the development of CpG island methylation, especially p14 gene methylation (OR, 3.28; 95% CI, 1.26-8.59; p=0.015, and OR, 0.38; 95% CI, 0.15-0.96; p=0.040, respectively). In Helicobacter pylori (H. pylori) infected subjects, the number of -686/-684 G/G allele was positively correlated and that of A/G allele was inversely correlated to the methylation status, especially p14 methylation, by the adjusted analysis (OR, 2.90; 95% CI, 1.14-7.36; p=0.026, and OR, 0.33; 95% CI, 0.13-0.88; p=0.027, respectively). Our results suggested that the promoter polymorphisms of Nrf2 gene may affect the methylation status of tumor-related genes, especially the p14 gene, under the influence of H. pylori-induced gastric inflammation.",
        "Doc_title":"The influence of promoter polymorphism of nuclear factor-erythroid 2-related factor 2 gene on the aberrant DNA methylation in gastric epithelium.",
        "Journal":"Oncology reports",
        "Do_id":"18097597",
        "Doc_ChemicalList":"NF-E2 Transcription Factor;Tumor Suppressor Protein p14ARF",
        "Doc_meshdescriptors":"Aged;CpG Islands;DNA Methylation;Female;Gastric Mucosa;Gastritis;Helicobacter Infections;Humans;Male;Middle Aged;NF-E2 Transcription Factor;Polymerase Chain Reaction;Polymorphism, Single-Stranded Conformational;Promoter Regions, Genetic;Stomach Neoplasms;Tumor Suppressor Protein p14ARF",
        "Doc_meshqualifiers":"physiology;genetics;microbiology;complications;genetics;genetics;genetics;genetics",
        "_version_":1605892849239326720},
      {
        "Doc_abstract":"Different histopathology and prognosis characterise the human papillomavirus (HPV)-related oropharyngeal tumours, but squamous cell carcinomas (SCC) of other localisations have not been exhaustively studied. Tissues from 120 patients with a head and neck SCC were studied for the expression of p16 and p53, and the Brandwein-Gensler (BG) histological risk assessment model. p16 positivity and p53 normal expression were significantly correlated with non-smoking, an earlier T stage and a non-keratinising morphology. The BG risk score was not associated with p16 or p53 expression; p16 expression was associated with a lymphocytic T-cytotoxic response. BG risk score was significantly correlated with overall survival and progression-free survival, while neither p16 nor p53 expression were associated with prognosis. p16 and p53 expression are associated with the histological subtype and the T stage even in non-oropharyngeal-restricted tumours. The BG risk score is not correlated with p16 or p53 and retains its power in non-site-specific SCCs. ",
        "Doc_title":"p16 and p53 expression status in head and neck squamous cell carcinoma: a correlation with histological, histoprognostic and clinical parameters.",
        "Journal":"Pathology",
        "Do_id":"27113547",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605752139996463104},
      {
        "Doc_abstract":"We generated A21-13 cells expressing p14(ARF) in the presence of doxycycline in order to examine the stability of p14(ARF) protein. The effects of proteasome inhibitor MG132 on p14(ARF) protein stabilization were detectable using our experimental procedure. Introduction of mutant p53 did not affect MG132-mediated p14(ARF) protein stabilization. We found that phorbol ester TPA (12-o-tetradecanoyl-phorbol 13-acetate) stabilized p14(ARF) protein and that p53 status had no effect on TPA-mediated stabilization. TPA-mediated stabilization was abolished by staurosporine but not by lovastatin or U0126. We further investigated which isoforms of PKC were involved in TPA-mediated p14(ARF) stabilization using short-interference RNA. Knockdown of PKCalpha, but not PKCdelta, attenuated TPA-mediated p14(ARF) stabilization. These findings suggest that PKCalpha is involved in TPA-mediated stabilization of p14(ARF) protein, and this effect of TPA was not affected by the Ras/MAPK pathway or p53 status. Our results are indicative of a novel role of PKC in p14(ARF) protein stability.",
        "Doc_title":"PKCalpha is involved in phorbol ester TPA-mediated stabilization of p14ARF.",
        "Journal":"Biochemical and biophysical research communications",
        "Do_id":"15823586",
        "Doc_ChemicalList":"Butadienes;Leupeptins;Nitriles;Proteasome Inhibitors;RNA, Small Interfering;Tumor Suppressor Protein p14ARF;U 0126;Lovastatin;PRKCA protein, human;Protein Kinase C;Protein Kinase C beta;Protein Kinase C-alpha;MAP Kinase Kinase Kinases;HRAS protein, human;Proto-Oncogene Proteins p21(ras);Staurosporine;Doxycycline;Tetradecanoylphorbol Acetate;benzyloxycarbonylleucyl-leucyl-leucine aldehyde",
        "Doc_meshdescriptors":"Butadienes;Cell Line, Tumor;Doxycycline;Genes, p53;Humans;Leupeptins;Lovastatin;MAP Kinase Kinase Kinases;MAP Kinase Signaling System;Nitriles;Proteasome Inhibitors;Protein Kinase C;Protein Kinase C beta;Protein Kinase C-alpha;Proto-Oncogene Proteins p21(ras);RNA, Small Interfering;Staurosporine;Tetradecanoylphorbol Acetate;Tumor Suppressor Protein p14ARF",
        "Doc_meshqualifiers":"pharmacology;pharmacology;physiology;pharmacology;pharmacology;antagonists & inhibitors;physiology;pharmacology;antagonists & inhibitors;genetics;physiology;antagonists & inhibitors;metabolism;pharmacology;pharmacology;metabolism",
        "_version_":1605790439036682240},
      {
        "Doc_abstract":"Previous authors have suggested that tumor suppressor expression promotes aging while preventing cancer, but direct experimental support for this cancer-aging hypothesis has been elusive. Here, by using somatic, tissue-specific inactivation of the p16(INK4a) tumor suppressor in murine T- or B-lymphoid progenitors, we report that ablation of p16(INK4a) can either rescue aging or promote cancer in a lineage-specific manner. Deletion of p16(INK4a) in the T lineage ameliorated several aging phenotypes, including thymic involution, decreased production of naive T cells, reduction in homeostatic T-cell proliferation, and attenuation of antigen-specific immune responses. Increased T-cell neoplasia was not observed with somatic p16(INK4a) inactivation in T cells. In contrast, B lineage-specific ablation of p16(INK4a) was associated with a markedly increased incidence of systemic, high-grade B-cell neoplasms, which limited studies of the effects of somatic p16(INK4a) ablation on B-cell aging. Together, these data show that expression of p16(INK4a) can promote aging and prevent cancer in related lymphoid progeny of a common stem cell.",
        "Doc_title":"Expression of p16(INK4a) prevents cancer and promotes aging in lymphocytes.",
        "Journal":"Blood",
        "Do_id":"21245485",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;Lymphocyte Specific Protein Tyrosine Kinase p56(lck);Cre recombinase;Integrases",
        "Doc_meshdescriptors":"Animals;Cell Aging;Cell Lineage;Cell Proliferation;Cell Transformation, Neoplastic;Cyclin-Dependent Kinase Inhibitor p16;Gene Deletion;Gene Expression;Integrases;Lymphocyte Specific Protein Tyrosine Kinase p56(lck);Lymphocytes;Lymphoid Progenitor Cells;Mice;Mice, Inbred C57BL;Mice, Transgenic;Neoplasms;Organ Specificity",
        "Doc_meshqualifiers":"genetics;physiology;genetics;immunology;genetics;genetics;metabolism;physiology;physiology;genetics;physiology;genetics;metabolism;pathology;physiology;immunology;metabolism;physiology;genetics;metabolism;pathology;prevention & control;genetics",
        "_version_":1605792142207221760},
      {
        "Doc_abstract":"Standard treatment for patients with poor-risk, resected head and neck squamous cell carcinoma (HNSCC) is adjuvant radiation therapy combined with high-dose cisplatin. Many patients are treated with weekly cisplatin; it is not known whether weekly and high-dose cisplatin are equivalent. This study compares the outcomes of patients with locally-advanced HPV-negative HNSCC and HPV/p16-positive oropharynx HNSCC treated with adjuvant chemoradiation therapy with either high-dose or weekly cisplatin.;Retrospective review of patients with Stage III/IV HNSCC who had surgery followed by adjuvant chemoradiation therapy at Mayo Clinic, Rochester. HPV and/or p16 status was available for all oropharynx patients.;104 Patients (51 high-dose, 53 weekly) were analyzed. The 3-year overall survival was 84% and 75% for patients who received high dose and weekly cisplatin, respectively (p=0.30). The 3-year recurrence free survival was 71% and 74% in the high dose and weekly cisplatin group, respectively (p=0.95). Patients with HPV/p16-positive oropharynx cancer who received adjuvant chemoradiation therapy with high-dose and weekly cisplatin had three-year overall survival rates of 91% and 86% (p=0.56), and 3-year recurrence free survival of 84% and 82% (p=0.93). Extracapsular extension did not affect prognosis in either group.;No significant survival difference was seen between patients with locally advanced HNSCC treated with adjuvant chemoradiation therapy with high-dose or weekly cisplatin, although there was a trend for improved survival with high-dose cisplatin. Weekly cisplatin in the adjuvant setting may be a better treatment for patients with HPV-positive oropharynx cancer to preserve survival and minimize toxicity.",
        "Doc_title":"Adjuvant chemoradiation therapy with high-dose versus weekly cisplatin for resected, locally-advanced HPV/p16-positive and negative head and neck squamous cell carcinoma.",
        "Journal":"Oral oncology",
        "Do_id":"24467937",
        "Doc_ChemicalList":"Antineoplastic Agents;Cisplatin",
        "Doc_meshdescriptors":"Antineoplastic Agents;Cisplatin;Dose-Response Relationship, Drug;Female;Head and Neck Neoplasms;Humans;Male;Papillomaviridae",
        "Doc_meshqualifiers":"therapeutic use;therapeutic use;drug therapy;radiotherapy;surgery;virology;isolation & purification",
        "_version_":1605741985803534337},
      {
        "Doc_abstract":"Age-associated cellular senescence is thought to promote vascular dysfunction. p16(INK4a) is a cell cycle inhibitor that promotes senescence and is upregulated during normal aging. In this study, we examine the contribution of p16(INK4a) overexpression to venous thrombosis.;Mice overexpressing p16(INK4a) were studied with 4 different vascular injury models: (1) ferric chloride (FeCl(3)) and (2) Rose Bengal to induce saphenous vein thrombus formation; (3) FeCl(3) and vascular ligation to examine thrombus resolution; and (4) lipopolysaccharide administration to initiate inflammation-induced vascular dysfunction. p16(INK4a) transgenic mice had accelerated occlusion times (13.1  0.4 minutes) compared with normal controls (19.7  1.1 minutes) in the FeCl(3) model and 12.7  2.0 and 18.6  1.9 minutes, respectively in the Rose Bengal model. Moreover, overexpression of p16(INK4a) delayed thrombus resolution compared with normal controls. In response to lipopolysaccharide treatment, the p16(INK4a) transgenic mice showed enhanced thrombin generation in plasma-based calibrated automated thrombography assays. Finally, bone marrow transplantation studies suggested increased p16(INK4a) expression in hematopoietic cells contributes to thrombosis, demonstrating a role for p16(INK4a) expression in venous thrombosis.;Venous thrombosis is augmented by overexpression of the cellular senescence protein p16(INK4a).",
        "Doc_title":"Overexpression of the cell cycle inhibitor p16INK4a promotes a prothrombotic phenotype following vascular injury in mice.",
        "Journal":"Arteriosclerosis, thrombosis, and vascular biology",
        "Do_id":"21233453",
        "Doc_ChemicalList":"Cdkn2a protein, mouse;Chlorides;Cyclin-Dependent Kinase Inhibitor p16;Ferric Compounds;Lipopolysaccharides;Plasminogen Activator Inhibitor 1;Rose Bengal;ferric chloride",
        "Doc_meshdescriptors":"Animals;Blood Coagulation;Blood Coagulation Tests;Bone Marrow Transplantation;Chlorides;Cyclin-Dependent Kinase Inhibitor p16;Disease Models, Animal;Ferric Compounds;Genotype;Hematopoietic Stem Cell Transplantation;Hematopoietic Stem Cells;Ligation;Lipopolysaccharides;Mice;Mice, Inbred C57BL;Mice, Transgenic;Phenotype;Plasminogen Activator Inhibitor 1;Rose Bengal;Time Factors;Up-Regulation;Vascular System Injuries;Venous Thrombosis",
        "Doc_meshqualifiers":"genetics;genetics;metabolism;metabolism;blood;blood;etiology;genetics;blood;etiology;genetics",
        "_version_":1605755619579527168},
      {
        "Doc_abstract":"Atypical squamous cell cannot exclude high-grade squamous intraepithelial lesion (ASC-H) and low-grade intraepithelial lesion cannot exclude high-grade squamous intraepithelial lesion (LSIL-H) are ambiguous diagnostic entities for the prediction of high-grade cervical lesion. Objective and reproducible tests for predicting high-grade cervical lesions are needed to reduce unnecessary colposcopic referrals or follow-ups.;We aimed to identify an adequate set of adjunctive markers to predict cervical intraepithelial neoplasia grade 2+ (CIN2+) in residual liquid-based cytology specimens (LBCS).;We conducted p16 (INK4a)/Ki-67 and L1 capsid protein immunostaining and human papillomavirus (HPV) DNA typing on 56 LBCS diagnosed with ASC-H or LSIL-H, all of which were subjected to histologic confirmation or follow-up cytologic examination.;Positivity for p16 (INK4a)/Ki-67 was associated with a histology of CIN2+ (P=0.047) and CIN3+ (P=0.002). Negativity for L1 capsid protein was associated with CIN2+ confirmed at follow-up (P=0.02).Positivity for high-risk HPV (HR-HPV) was associated with CIN2+ confirmed at follow-up (P=0.036) and a histology of CIN2+ (P=0.037). The sensitivity, specificity, positive predictive value, and negative predictive value for predicting follow-up CIN2+ were 76.2%, 51.4%, 48.5%, and 78.3%, respectively, for p16 (INK4a)/Ki-67 immunostaining; 95.2%, 34.3%, 46.5%, and 92.3%, respectively, for L1 capsid protein; and 66.7%, 67.7%, 54.5%, and 77.8%, respectively, for HR-HPV. The classification and regression tree analysis showed that the combined results of p16 (INK4a)/Ki-67 andL1 capsid protein immunostaining and the HR-HPV test, conducted sequentially, correctly classified 81.8% of samples (27/33)in the prediction of a histology of CIN2 + in ASC-H or LSIL-H. For determination of the histology of cervical intraepithelial neoplasia grade 3+ (CIN3+)in ASC-H or LSIL-H, we found that the combined results of p16 (INK4a)/Ki-67 and L1 capsid protein immunostaining correctly classified 78.8% (26/33) of samples.;p16(INK4a)/Ki-67 and L1 capsid protein immunostaining and HR-HPV testing of residual LBCS diagnosed with ASC-H or LSIL-H are useful objective biomarkers for predicting CIN2+. Immunostaining for p16(INK4a)/Ki-67 and L1 capsid protein are sufficient to predict CIN3+.",
        "Doc_title":"Immunostaining of p16(INK4a)/Ki-67 and L1 capsid protein on liquid-based cytology specimens obtained from ASC-H and LSIL-H cases.",
        "Journal":"International journal of medical sciences",
        "Do_id":"24151431",
        "Doc_ChemicalList":"Biomarkers, Tumor;Capsid Proteins;Cyclin-Dependent Kinase Inhibitor p16;Ki-67 Antigen",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Biomarkers, Tumor;Capsid Proteins;Cervical Intraepithelial Neoplasia;Cyclin-Dependent Kinase Inhibitor p16;Cytodiagnosis;Female;Human papillomavirus 16;Humans;Ki-67 Antigen;Middle Aged;Neoplasm Staging;Pregnancy;Vaginal Smears",
        "Doc_meshqualifiers":"genetics;isolation & purification;genetics;isolation & purification;diagnosis;pathology;virology;genetics;isolation & purification;methods;genetics;isolation & purification;genetics;isolation & purification",
        "_version_":1605742754800861185},
      {
        "Doc_abstract":"The elucidation of the molecular mechanisms underlying the effects of traditional Chinese medicines in clinical practice is a key step toward their worldwide application, and this topic is currently a subject of intense research interest. Rg1, a component of ginsenoside, has recently been shown to perform several pharmacological functions; however, the underlying mechanisms of these effects remain unclear. In the present study, we investigated whether Rg1 has an anti-senescence effect on hematopoietic stem cells (HSCs) and the possible molecular mechanisms driving any effects. The results showed that Rg1 could effectively delay tert-butyl hydroperoxide (t-BHP)-induced senescence and inhibit gene expression in the p16(INK4a)-Rb and p19(Arf)-p53-p21(Cip/Waf1) signaling pathways in HSCs. Our study suggested that these two signaling pathways might be potential targets for elucidating the molecular mechanisms of the Rg1 anti-senescence effect. ",
        "Doc_title":"Gene expression of the p16(INK4a)-Rb and p19(Arf)-p53-p21(Cip/Waf1) signaling pathways in the regulation of hematopoietic stem cell aging by ginsenoside Rg1.",
        "Journal":"Genetics and molecular research : GMR",
        "Do_id":"25501220",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;Cyclin-Dependent Kinase Inhibitor p19;Cyclin-Dependent Kinase Inhibitor p21;Ginsenosides;RNA, Messenger;Retinoblastoma Protein;Tumor Suppressor Protein p53;tert-Butylhydroperoxide;beta-Galactosidase;ginsenoside Rg1",
        "Doc_meshdescriptors":"Animals;Cell Aging;Cyclin-Dependent Kinase Inhibitor p16;Cyclin-Dependent Kinase Inhibitor p19;Cyclin-Dependent Kinase Inhibitor p21;Gene Expression Regulation;Ginsenosides;Hematopoietic Stem Cells;Mice, Inbred C57BL;RNA, Messenger;Retinoblastoma Protein;Signal Transduction;Tumor Suppressor Protein p53;beta-Galactosidase;tert-Butylhydroperoxide",
        "Doc_meshqualifiers":"drug effects;genetics;genetics;metabolism;genetics;metabolism;genetics;metabolism;drug effects;chemistry;pharmacology;cytology;drug effects;metabolism;genetics;metabolism;genetics;metabolism;drug effects;genetics;genetics;metabolism;metabolism;pharmacology",
        "_version_":1605800248251252736},
      {
        "Doc_abstract":"The Polycomb group gene Bmi1 is essential for the proliferation of neural and hematopoietic stem cells. Much remains to be learned about the pathways involved in the severe hematopoietic phenotype observed in Bmi1 homozygous mutant mice except for the fact that loss of p53 or concomitant loss of p16(Ink4a) and p19(Arf) functions achieves only a partial rescue. Here we report the identification of E4F1, an inhibitor of cellular proliferation, as a novel BMI1-interacting partner in hematopoietic cells. We provide evidence that Bmi1 and E4f1 genetically interact in the hematopoietic compartment to regulate cellular proliferation. Most importantly, we demonstrate that reduction of E4f1 levels through RNA interference mediated knockdown is sufficient to rescue the clonogenic and repopulating ability of Bmi1(-/-) hematopoietic cells up to 3 mo post-transplantation. Using cell lines and MEF, we also demonstrate that INK4A/ARF and p53 are not essential for functional interaction between Bmi1 and E4f1. Together, these findings identify E4F1 as a key modulator of BMI1 activity in primitive hematopoietic cells.",
        "Doc_title":"E4F1: a novel candidate factor for mediating BMI1 function in primitive hematopoietic cells.",
        "Journal":"Genes & development",
        "Do_id":"16882984",
        "Doc_ChemicalList":"Bmi1 protein, mouse;Cyclin-Dependent Kinase Inhibitor p16;DNA-Binding Proteins;E4f1 protein, mouse;Nuclear Proteins;Proto-Oncogene Proteins;Repressor Proteins;Transcription Factors;Tumor Suppressor Protein p14ARF;Tumor Suppressor Protein p53;Polycomb Repressive Complex 1",
        "Doc_meshdescriptors":"Animals;Apoptosis;Cell Cycle;Cell Proliferation;Colony-Forming Units Assay;Cyclin-Dependent Kinase Inhibitor p16;DNA-Binding Proteins;Hematopoietic Stem Cells;Humans;Immunoprecipitation;Liver;Mice;Mice, Knockout;Nuclear Proteins;Polycomb Repressive Complex 1;Proto-Oncogene Proteins;Repressor Proteins;Saccharomyces cerevisiae;Transcription Factors;Tumor Suppressor Protein p14ARF;Tumor Suppressor Protein p53;Two-Hybrid System Techniques",
        "Doc_meshqualifiers":"genetics;metabolism;genetics;metabolism;metabolism;metabolism;genetics;physiology;genetics;physiology;genetics;physiology;genetics;metabolism;genetics;metabolism;genetics;metabolism",
        "_version_":1605843656513683456},
      {
        "Doc_abstract":"The relationships between the expression of ID2, EBV-LMP1 and P16(INK4A) in Chinese classical Hodgkin lymphoma are unknown and need exploring.;Samples of classical Hodgkin lymphoma from 60 Chinese patients were analyzed for the expression of ID2, EBV-LMP1 and p16(INK4A) proteins by immunohistochemistry.;ID2 protein was expressed in 83.3% of this group of classical Hodgkin lymphoma, staining strongly in both cytoplasm and nucleus of the Hodgkin and Reed-Sternberg (HRS) cells. EBV-LMP1 and P16(INK4A) were overexpressed in 85.0% and 71.7% of Hodgkin lymphoma, respectively. EBV-LMP1 was noted in the cytoplasm, membrane and nucleus of HRS cells; P16(INK4A) was in the nucleus and cytoplasm. Microscopically, ID2, EBV-LMP1 and P16(INK4A) staining distinguished the HRS cells from the complex background of lymphocytes. ID2 was positively correlated with EBV-LMP1(P < 0.01), but P16(INK4A) was inversely related to EBV-LMP1 (P < 0.05).;It is suggested that ID2, EBV-LMP1 and P16(INK4A) could play an important role in the evolution of classical Hodgkin lymphoma, and be considered as potential adjunct markers to identify HRS cells in diagnosis.",
        "Doc_title":"Aberrant expression of ID2 protein and its correlation with EBV-LMP1 and P16(INK4A) in classical Hodgkin lymphoma in China.",
        "Journal":"BMC cancer",
        "Do_id":"19099554",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;EBV-associated membrane antigen, Epstein-Barr virus;ID2 protein, human;Inhibitor of Differentiation Protein 2;Viral Matrix Proteins",
        "Doc_meshdescriptors":"Cell Membrane;Cell Nucleus;China;Cyclin-Dependent Kinase Inhibitor p16;Cytoplasm;Female;Hodgkin Disease;Humans;Immunohistochemistry;Inhibitor of Differentiation Protein 2;Lymphocytes;Male;Reed-Sternberg Cells;Viral Matrix Proteins",
        "Doc_meshqualifiers":"metabolism;metabolism;metabolism;metabolism;metabolism;pathology;metabolism;metabolism;metabolism;pathology;metabolism",
        "_version_":1605818688505643008},
      {
        "Doc_abstract":"To validate a panel of methylation-based salivary rinse biomarkers (P16, CCNA1, DCC, TIMP3, MGMT, DAPK, and MINT31) previously shown to be independently associated with poor overall survival and local recurrence in a larger, separate cohort of patients with head and neck squamous cell carcinoma (HNSCC).;One hundred ninety-seven patients were included. All pretreatment saliva DNA samples were evaluated for the methylation status of the gene promoters by quantitative methylation-specific PCR. The main outcome measures were overall survival, local recurrence-free survival, and disease-free survival.;In univariate analyses, the detection of hypermethylation of CCNA1, MGMT, and MINT31 was significantly associated with poor overall survival; the detection of hypermethylation of TIMP3 was significantly associated with local recurrence-free survival; and the detection of hypermethylation of MINT31 was significantly associated with poor disease-free survival. In multivariate analyses, detection of hypermethylation at any single marker was not predictive of overall survival in patients with HNSCC; detection of hypermethylation of TIMP3 in salivary rinse had an independent, significant association with local recurrence-free survival (HR = 2.51; 95% CI: 1.10-5.68); and none of the studied markers was significantly associated with disease-free survival.;The detection of promoter hypermethylation of the seven genes in salivary rinse as an independent prognostic indicator of overall survival in patients with HNSCC was not validated. Detection of promoter hypermethylation of TIMP3 in pretreatment salivary rinse is independently associated with local recurrence-free survival in patients with HNSCC and may be a valuable salivary rinse biomarker for HNSCC recurrence.",
        "Doc_title":"Detection of TIMP3 promoter hypermethylation in salivary rinse as an independent predictor of local recurrence-free survival in head and neck cancer.",
        "Journal":"Clinical cancer research : an official journal of the American Association for Cancer Research",
        "Do_id":"22228635",
        "Doc_ChemicalList":"Apoptosis Regulatory Proteins;CCNA1 protein, human;Cyclin A1;Cyclin-Dependent Kinase Inhibitor p16;Tissue Inhibitor of Metalloproteinase-3;Tumor Suppressor Proteins;DNA Modification Methylases;MGMT protein, human;Death-Associated Protein Kinases;Calcium-Calmodulin-Dependent Protein Kinases;DNA Repair Enzymes",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Apoptosis Regulatory Proteins;Calcium-Calmodulin-Dependent Protein Kinases;Carcinoma, Squamous Cell;Cyclin A1;Cyclin-Dependent Kinase Inhibitor p16;DNA Methylation;DNA Modification Methylases;DNA Repair Enzymes;Death-Associated Protein Kinases;Disease-Free Survival;Female;Genes, DCC;Head and Neck Neoplasms;Humans;Male;Middle Aged;Prognosis;Promoter Regions, Genetic;Saliva;Survival Analysis;Tissue Inhibitor of Metalloproteinase-3;Tumor Suppressor Proteins",
        "Doc_meshqualifiers":"genetics;genetics;genetics;mortality;genetics;genetics;genetics;genetics;genetics;mortality;metabolism;genetics;genetics",
        "_version_":1605826238569512960},
      {
        "Doc_abstract":"The adenovirus E1A oncogene activates p53 through a signaling pathway involving the retinoblastoma protein and the tumor suppressor p19(ARF). The ability of E1A to induce p53 and its transcriptional targets is severely compromised in ARF-null cells, which remain resistant to apoptosis following serum depletion or adriamycin treatment. Reintroduction of p19(ARF) restores p53 accumulation and resensitizes ARF-null cells to apoptotic signals. Therefore, p19(ARF) functions as part of a p53-dependent failsafe mechanism to counter uncontrolled proliferation. Synergistic effects between the p19(ARF) and DNA damage pathways in inducing p53 may contribute to E1A's ability to enhance radio- and chemosensitivity.",
        "Doc_title":"E1A signaling to p53 involves the p19(ARF) tumor suppressor.",
        "Journal":"Genes & development",
        "Do_id":"9694807",
        "Doc_ChemicalList":"Adenovirus E1A Proteins;Proteins;Tumor Suppressor Protein p14ARF",
        "Doc_meshdescriptors":"Adenovirus E1A Proteins;Animals;Apoptosis;Cell Division;Cells, Cultured;DNA Damage;Gene Expression Regulation;Genes, Tumor Suppressor;Genes, Viral;Genes, p53;Mice;Mice, Knockout;Proteins;Signal Transduction;Tumor Suppressor Protein p14ARF",
        "Doc_meshqualifiers":"genetics;genetics;genetics;genetics",
        "_version_":1605794914227978240},
      {
        "Doc_abstract":"Human papillomavirus (HPV) infection is emerging as a major prognostic and predictive marker in head and neck squamous cell carcinoma (HNSCC). Researches are focused on the development of HPV detection assays specially designed for HNSCC. The HPV diagnosis in these tumours is relevant toprognosis even in an already-developed tumour, whereas in the cervix, where the HPV is the cause of almost all tumours, this information has less clinical relevance. The better outcome of HPV-associated HNSCC raises the question about the best methodologies to distinguish between HPV and non-HPV-associated SCC. However, no consensus has been reached on the optimal way to identify HPV-associated SCC and ancillary studies have utilised many different methodologies, including HPV polymerase chain reaction testing, HPV in situ hybridization analysis, immunohistochemical staining for p16, and newer techniques that are currently under investigation. The objective of this review is to explain and give examples of various techniques of HPV detection highlighting how they might be used clinically. Although currently insufficiently specific due to the possibility of HPV infection originating at other sites, methodologies utilising serum and plasma to measure HPV infection will also be described, mostly for their potential future development and use. Finally, DNA/RNA microarray platforms will be briefly summarized for their capacity to identify the profile of molecular changes in any particular HPV+/HPV- cancer. In this way, it is expected to be possible to correlate the appropriate transcriptome-based diagnosis to the patients' specific cancer risk.",
        "Doc_title":"HPV detection methods in head and neck cancer.",
        "Journal":"Head and neck pathology",
        "Do_id":"22782225",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Blotting, Southern;Carcinoma, Squamous Cell;Head and Neck Neoplasms;Humans;Immunohistochemistry;In Situ Hybridization;Oligonucleotide Array Sequence Analysis;Papillomaviridae;Papillomavirus Infections;Real-Time Polymerase Chain Reaction",
        "Doc_meshqualifiers":"diagnosis;virology;diagnosis;virology;isolation & purification;complications;diagnosis",
        "_version_":1605741970411487234},
      {
        "Doc_abstract":"Two genes, p16 (also known as CDKN2, INK4A, or MTS1) and p15 (also described as INK4B or MTS2), are found in tandem at chromosome 9p21. These genes are designated as candidate tumor suppressor genes because they encode proteins that function as negative cell cycle regulators. (The encoded polypeptides inactivate specific cyclin-protein kinase complexes that are required for progression through the cell cycle.) Molecular genetic studies have revealed that deletion of the p16 and p15 genes occurs frequently in cancer cell lines and in certain malignant neoplasms.;We evaluated the frequency of p16 and p15 gene alterations in a well-characterized cohort of human transitional cell bladder cancers, and we explored potential associations between alterations in these genes and tumor stage and/or grade.;Tumor tissue and normal tissue from 110 patients with transitional cell carcinoma of the urinary bladder were examined. The status of the p16 and p15 genes in these tissues was determined by Southern blotting and hybridization with gene-specific probes, by coupled polymerase chain reaction and single-strand conformation polymorphism analysis (PCR-SSCP), and by sequencing DNA fragments produced during PCR. Associations between alterations in the genes and tumor stage and/or grade were evaluated using the two-tailed Fisher's exact test.;Homozygous deletion (both alleles lost) of the p16 and the p15 genes was observed in 11 and nine bladder tumors, respectively. Eight of the 11 tumors exhibiting complete loss of the p16 gene also displayed homozygous deletion of the p15 gene. Exclusive loss of either gene was detected in only three tumors. Hemizygous deletion (one allele lost, also referred to as loss of heterozygosity [LOH] of the p16 and/or p15 genes was observed in eight tumors. Rearrangement of the two genes was indicated in three additional tumors. No point mutations were identified in either gene. The overall frequency of alteration in this cohort of bladder tumors was approximately 18% for each gene (in 20 [18.3%, 95% confidence interval (CI) = 11.1%-25.6%] of 109 informative tumors for the p16 gene and in 18 [18%, 95% CI = 10.5%-25.5%] of 100 informative tumors for the p15 gene). A statistically significant association between p16 gene alteration and bladder tumors of low stage (P < .01) and grade (P < .01) was observed; a significant association between p15 gene alteration and tumors of low stage (P < .01) was also detected.;Alteration of the p16 and p15 genes, especially coincident homozygous deletion, appears to be a common event in bladder cancer.",
        "Doc_title":"Deletion of the p16 and p15 genes in human bladder tumors.",
        "Journal":"Journal of the National Cancer Institute",
        "Do_id":"7563186",
        "Doc_ChemicalList":"Cyclin-Dependent Kinases",
        "Doc_meshdescriptors":"Aged;Base Sequence;Blotting, Southern;Carcinoma, Transitional Cell;Chromosomes, Human, Pair 9;Cyclin-Dependent Kinases;Female;Gene Deletion;Gene Rearrangement;Genes, Tumor Suppressor;Heterozygote;Homozygote;Humans;Male;Middle Aged;Molecular Sequence Data;Polymerase Chain Reaction;Urinary Bladder Neoplasms",
        "Doc_meshqualifiers":"genetics;pathology;genetics;genetics;methods;genetics;pathology",
        "_version_":1605902211409248256},
      {
        "Doc_abstract":"Expression of p16 has been proposed as a marker for malignant transformation. This study aimed to evaluate p16 expression in oral squamous cell carcinoma (OSCC) and premalignant lesions including oral leukoplakia (OL) with and without dysplasia.;Expression of p16 was investigated in 56 samples including OSCC, OL with and without dysplasia, and normal oral mucosa. Expression of p16 was identified by immunohistochemistry, using the CINtecTM p16INK4a Histology Kit. Both nuclear and/or cytoplasmic staining of the keratinocytes were considered to be positive and the percentage of positive cells was calculated.;Expression of p16 was detected in 3/16 (18.75%) cases of OSCC, in 4/15 (26.7%) cases of OL without dysplasia, and in none of OL with dysplasia and normal mucosa. No significant differences in p16 expression prevalence were found among OSCC, OL with and without dysplasia and normal mucosa. The percentages of positive cells in OSCC and OL without dysplasia were 0.89 and 0.17, respectively. No significant difference in the percentage of positive keratinocytes was found.;As a marker, p16 is not reliable for oral mucosal dysplasia and malignant transformation.",
        "Doc_title":"Expression of p16 in oral cancer and premalignant lesions.",
        "Journal":"Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology",
        "Do_id":"19192055",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;Tumor Suppressor Protein p14ARF",
        "Doc_meshdescriptors":"Adult;Aged;Carcinoma, Squamous Cell;Cell Nucleus;Cyclin-Dependent Kinase Inhibitor p16;Cytoplasm;Epithelial Cells;Female;Genes, p16;Humans;Keratinocytes;Leukoplakia, Oral;Male;Middle Aged;Mouth Mucosa;Mouth Neoplasms;Precancerous Conditions;Tumor Suppressor Protein p14ARF",
        "Doc_meshqualifiers":"pathology;pathology;analysis;pathology;pathology;pathology;pathology;pathology;pathology;pathology;analysis",
        "_version_":1605808258958753792},
      {
        "Doc_abstract":"To investigate the effect of cell cycle inhibitor p14ARF on replicative senescence of human diploid cell, recombinant p19ARF eukaryotic expression vector was constructed and p19ARF gene was transfected into human diploid fibroblasts (WI-38 cells) by liposome-mediated transfection for overexpression. Then, the effects of p19ARF on replicative senescence of WI-38 cells were observed. The results revealed that, compared with control cells, the WI-38 cells in which p19ARF gene was introduced showed significant up-regulation of p53 and p21 expression level, decrease of cell generation by 10-12 generations, decline of cell growth rate with cell cycle being arrested at G1 phase, increase of positive rate of senescent marker SA-beta-gal staining, and decrease of mitochondrial membrane potential. The morphology of the transfected fibroblasts presented the characteristics changes similar to senescent cells. These results indicated that high expression of p19ARF may promote the senescent process of human diploid cells.",
        "Doc_title":"Effect of cell cycle inhibitor p19ARF on senescence of human diploid cell.",
        "Journal":"Science in China. Series C, Life sciences",
        "Do_id":"17447021",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;PAK1 protein, human;Protein-Serine-Threonine Kinases;p21-Activated Kinases",
        "Doc_meshdescriptors":"Cell Aging;Cell Division;Cell Line;Cyclin-Dependent Kinase Inhibitor p16;Diploidy;Flow Cytometry;Genes, p53;Genetic Vectors;Humans;Protein-Serine-Threonine Kinases;Transfection;p21-Activated Kinases",
        "Doc_meshqualifiers":"drug effects;drug effects;pharmacology;genetics",
        "_version_":1605907024736944128},
      {
        "Doc_abstract":"There is increasing evidence for a role of somatic cellular senescence in physiological aging but also in injury and disease. Cell cycle inhibitor p16(INK4a) is the key mediator for stress and aberrant signaling induced senescence. Here we report that elevated blood pressure markedly induced p16(INK4a) expression in rat kidneys and hearts, as well as in human kidneys. In kidneys from deoxycorticosterone acetate-salt-treated rats, p16(INK4a) induction was found in tubular, glomerular, interstitial, and vascular cells and correlated with the typical histopathologic features of hypertensive target organ damage. p16(INK4a) expression also correlated with phospho-p38, a positive upstream regulator of p16(INK4a) expression. In left ventricles, increased p16(INK4a) expression was found in myocardium and cardiac arteries. Antihypertensive medication consistent of hydrochlorothiazide, hydralazine, and reserpine ameliorated the histopathologic changes and attenuated p16(INK4a) expression in kidneys of deoxycorticosterone acetate-salt-treated rats. Nonantihypertensive administration of spironolactone also reduced kidney damage and p16(INK4a) expression. p16(INK4a) induction was further observed in kidneys from hypertensive transgenic rats heterozygous for the mouse Ren-2 gene and was prevented by the angiotensin II type 1 receptor blocker losartan. In human kidney biopsies showing hypertensive nephrosclerosis, increased p16(INK4a) expression was found compared with age-matched normotensive control subjects. Thus, hypertension induces cellular senescence via p16(INK4a), possibly through p38, thereby contributing to hypertensive target organ damage. This detrimental effect can be overcome by different therapeutic drug strategies.",
        "Doc_title":"Hypertension induces somatic cellular senescence in rats and humans by induction of cell cycle inhibitor p16INK4a.",
        "Journal":"Hypertension (Dallas, Tex. : 1979)",
        "Do_id":"18504326",
        "Doc_ChemicalList":"Angiotensin II Type 1 Receptor Blockers;Antihypertensive Agents;Cyclin-Dependent Kinase Inhibitor p16;Mineralocorticoid Receptor Antagonists;RNA, Messenger;Ren2 protein, mouse;Hydrochlorothiazide;Hydralazine;Spironolactone;Desoxycorticosterone;Reserpine;p38 Mitogen-Activated Protein Kinases;Renin;Losartan",
        "Doc_meshdescriptors":"Angiotensin II Type 1 Receptor Blockers;Animals;Animals, Genetically Modified;Antihypertensive Agents;Blood Pressure;Cell Aging;Cyclin-Dependent Kinase Inhibitor p16;Desoxycorticosterone;Heart Ventricles;Humans;Hydralazine;Hydrochlorothiazide;Hypertension, Renal;Kidney;Losartan;Mice;Mineralocorticoid Receptor Antagonists;Nephrosclerosis;RNA, Messenger;Rats;Renin;Reserpine;Spironolactone;p38 Mitogen-Activated Protein Kinases",
        "Doc_meshqualifiers":"pharmacology;therapeutic use;pharmacology;therapeutic use;drug effects;drug effects;genetics;metabolism;pharmacology;metabolism;pathology;pharmacology;therapeutic use;pharmacology;therapeutic use;drug therapy;metabolism;pathology;drug effects;metabolism;pathology;pharmacology;therapeutic use;pharmacology;drug therapy;metabolism;pathology;metabolism;genetics;pharmacology;therapeutic use;pharmacology;therapeutic use;metabolism",
        "_version_":1605758623255887872},
      {
        "Doc_abstract":"Hepatic haemangiosarcoma is a deadly malignancy whose aetiology remains poorly understood. Inactivation of the CDKN2A locus, which houses the ARF and p16(INK4a) tumour suppressor genes, is a common event in haemangiosarcoma patients, but the precise role of ARF in vascular tumourigenesis is unknown. To determine the extent to which ARF suppresses vascular neoplasia, we examined the incidence of hepatic vascular lesions in Arf-deficient mice exposed to the carcinogen urethane [intraperitoneal (i.p.), 1 mg/g]. Loss of Arf resulted in elevated morbidity and increased the incidence of both haemangiomas and incipient haemangiosarcomas. Suppression of vascular lesion development by ARF was heavily dependent on both Arf gene-dosage and the genetic strain of the mouse. Trp53-deficient mice also developed hepatic vascular lesions after exposure to urethane, suggesting that ARF signals through a p53-dependent pathway to inhibit the development of hepatic haemangiosarcoma. Our findings provide strong evidence that inactivation of Arf is a causative event in vascular neoplasia and suggest that the ARF pathway may be a novel molecular target for therapeutic intervention in haemangiosarcoma patients.",
        "Doc_title":"ARF suppresses hepatic vascular neoplasia in a carcinogen-exposed murine model.",
        "Journal":"The Journal of pathology",
        "Do_id":"22430984",
        "Doc_ChemicalList":"Carcinogens;Cdkn2a protein, mouse;Cyclin-Dependent Kinase Inhibitor p16;Tumor Suppressor Protein p53;Urethane",
        "Doc_meshdescriptors":"Animals;Carcinogens;Cell Transformation, Neoplastic;Cyclin-Dependent Kinase Inhibitor p16;Gene Dosage;Genetic Predisposition to Disease;Hemangiosarcoma;Liver Neoplasms;Mice;Mice, Inbred C57BL;Mice, Knockout;Phenotype;Signal Transduction;Time Factors;Tumor Suppressor Protein p53;Urethane",
        "Doc_meshqualifiers":"chemically induced;genetics;metabolism;pathology;deficiency;genetics;metabolism;chemically induced;genetics;metabolism;pathology;prevention & control;chemically induced;genetics;metabolism;pathology;prevention & control;deficiency;genetics",
        "_version_":1605892299335663616},
      {
        "Doc_abstract":"Murine double minute 2 (MDM2) oncoprotein and p14(ARF) tumor suppressor play pivotal roles in regulating p53 and function in the MAPK pathway, which is mutated frequently in differentiated thyroid carcinoma (DTC). We hypothesized that functional polymorphisms in the promoters of MDM2 and p14(ARF) contribute to the interindividual difference in predisposition to DTC.;MDM2-rs2279744, MDM2-rs937283, p14(ARF)-rs3731217, and p14(ARF)-rs3088440 were genotyped in 303 patients with DTC and 511 cancer-free healthy controls. Multivariate logistic regression analysis was performed to calculate odds ratios (ORs) and 95% confidence intervals (CIs).;MDM2-rs2279744 and p14(ARF)-rs3731217 were associated with a significantly increased risk of DTC (MDM2-rs2279744: TT versus TG/GG; OR, 1.5; 95% CI, 1.1-2.0; p14(ARF)-rs3731217: TG/GG versus TT; OR, 1.7; 95% CI, 1.2-2.3). No association was found for MDM2-rs937283 or p14(ARF)-rs3088440. Individuals carrying 3-4 risk genotypes of MDM2 and p14(ARF) had 2.2 times (95% CI, 1.4-3.5) the risk for DTC of individuals carrying 0-1 risk genotypes (P trend = .021). The combined effect of MDM2 and p14(ARF) on risk of DTC was confined to young subjects ( 45 years), nonsmokers, nondrinkers, and subjects with a first-degree family history of cancer. These associations were quite similar in strength when cases were restricted to those with papillary thyroid cancer.;Our results suggest that polymorphisms of MDM2 and p14(ARF) contribute to the interindividual difference in susceptibility to DTC, either alone or more likely jointly. The observed associations warrant further confirmation in independent studies.",
        "Doc_title":"Significance of MDM2 and P14 ARF polymorphisms in susceptibility to differentiated thyroid carcinoma.",
        "Journal":"Surgery",
        "Do_id":"23218882",
        "Doc_ChemicalList":"Genetic Markers;Tumor Suppressor Protein p14ARF;MDM2 protein, human;Proto-Oncogene Proteins c-mdm2",
        "Doc_meshdescriptors":"Adenocarcinoma, Follicular;Adenoma, Oxyphilic;Adolescent;Adult;Aged;Aged, 80 and over;Carcinoma;Case-Control Studies;Female;Genetic Association Studies;Genetic Markers;Genetic Predisposition to Disease;Genotyping Techniques;Humans;Logistic Models;Male;Middle Aged;Multivariate Analysis;Polymorphism, Single Nucleotide;Proto-Oncogene Proteins c-mdm2;Thyroid Neoplasms;Tumor Suppressor Protein p14ARF;Young Adult",
        "Doc_meshqualifiers":"genetics;genetics;genetics;genetics;genetics",
        "_version_":1605751282040045568},
      {
        "Doc_abstract":"Chromosome 9p21 gene copy number in Ewing's sarcoma family of tumour (ESFT) cell lines and primary ESFT has been evaluated using Multiplex Ligation-dependent probe amplification, and the clinical significance of CDKN2A loss and p16/p14(ARF) expression investigated. Homozygous deletion of CDKN2A was identified in 4/9 (44%) of ESFT cell lines and 4/42 (10%) primary ESFT; loss of one copy of CDKN2A was identified in a further 2/9 (22%) cell lines and 2/42 (5%) tumours. CDKN2B was co-deleted in three (33%) cell lines and two (5%) tumours. Co-deletion of the MTAP gene was observed in 1/9 (11%) cell lines and 3/42 (7%) tumours. No correlation was observed between CDKN2A deletion and clinical parameters. However, co-expression of high levels of p16/p14(ARF) mRNA predicted a poor event-free survival (P=0.046, log-rank test). High levels of p16/p14(ARF) mRNA did not correlate with high expression of p16 protein. Furthermore, p16 protein expression did not predict event-free or overall survival. Methylation is not a common mechanism of p16 gene silencing in ESFT. These studies demonstrate that loss (homozygous deletion or single copy) of CDKN2A was not prognostically significant in primary ESFT. However, high levels of p16/p14(ARF) mRNA expression were predictive of a poor event-free survival and should be investigated further.",
        "Doc_title":"Chromosome 9p21 gene copy number and prognostic significance of p16 in ESFT.",
        "Journal":"British journal of cancer",
        "Do_id":"17533400",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;DNA, Neoplasm;RNA, Neoplasm",
        "Doc_meshdescriptors":"Bone Neoplasms;Cell Line, Tumor;Chromosome Mapping;Chromosomes, Human, Pair 9;Cyclin-Dependent Kinase Inhibitor p16;DNA, Neoplasm;Gene Deletion;Genes, p16;Humans;Prognosis;RNA, Neoplasm;Reverse Transcriptase Polymerase Chain Reaction;Sarcoma, Ewing;Survival Analysis",
        "Doc_meshqualifiers":"genetics;mortality;pathology;deficiency;genetics;genetics;isolation & purification;genetics;isolation & purification;genetics;mortality;pathology",
        "_version_":1605785471448776704},
      {
        "Doc_abstract":"ZBTB7A (Pokemon) is a member of the POK family of transcriptional repressors. Its main function is the suppression of the p14ARF tumour suppressor gene. Although ZBTB7A expression has been found to be increased in various types of lymphoma, there are no reports dealing with its expression in solid tumours. Given that p14(ARF) inhibits MDM2, the main negative regulator of p53, we hypothesized that overexpression of ZBTB7A could lead indirectly to p53 inactivation. To this end, we examined the status of ZBTB7A and its relationship with tumour kinetics (proliferation and apoptosis) and nodal members of the p53 network in a panel of 83 non-small cell lung carcinomas (NSCLCs). We observed, in the majority of the samples, prominent expression of ZBTB7A in the cancerous areas compared to negligible presence in the adjacent normal tissue elements. Gene amplification (two- to five-fold) was found in 27.7% of the cases, denoting its significance as a mechanism driving ZBTB7A overproduction in NSCLCs. In the remaining non-amplified group of carcinomas, analysis of the mRNA and protein expression patterns suggested that deregulation at the transcriptional and post-translational level accounts for ZBTB7A overexpression. Proliferation was associated with ZBTB7A expression (p = 0.033) but not apoptosis. The association with proliferation was reflected in the positive correlation between ZBTB7A expression and tumour size (p = 0.018). The overexpression of ZBTB7A in both p53 mutant and p53 wild-type cases, implies either a synergistic effect or that ZBTB7A exerts its oncogenic properties independently of the p14(ARF)-MDM2-p53 axis. The concomitant expression of ZBTB7A with p14(ARF) (p = 0.039), instead of the anticipated inverse relation, supports the latter notion. In conclusion, regardless of the pathway followed, the distinct expression of ZBTB7A in cancerous areas and the association with proliferation and tumour size pinpoints a role for this novel cell cycle regulator in the pathogenesis of lung cancer.",
        "Doc_title":"Gene amplification is a relatively frequent event leading to ZBTB7A (Pokemon) overexpression in non-small cell lung cancer.",
        "Journal":"The Journal of pathology",
        "Do_id":"17907153",
        "Doc_ChemicalList":"Biomarkers, Tumor;DNA-Binding Proteins;E2F1 Transcription Factor;E2F1 protein, human;Transcription Factors;Tumor Suppressor Protein p14ARF;ZBTB7A protein, human",
        "Doc_meshdescriptors":"Aged;Biomarkers, Tumor;Carcinoma, Non-Small-Cell Lung;Case-Control Studies;Cell Proliferation;DNA-Binding Proteins;E2F1 Transcription Factor;Female;Gene Amplification;Gene Expression Regulation, Neoplastic;Humans;Immunohistochemistry;Lung Neoplasms;Male;Middle Aged;Reverse Transcriptase Polymerase Chain Reaction;Statistics, Nonparametric;Transcription Factors;Tumor Suppressor Protein p14ARF",
        "Doc_meshqualifiers":"analysis;genetics;metabolism;pathology;analysis;genetics;analysis;genetics;metabolism;pathology;analysis;genetics",
        "_version_":1605810842483294208},
      {
        "Doc_abstract":"Cell cycle aberration was immunohistochemically examined in relation to preneoplastic liver cell foci expressing glutathione S-transferase placental form (GST-P) at early stages of tumor-promotion in rats with thioacetamide (TAA), a hepatocarcinogen facilitating liver cell regeneration. Immunoexpression of p16(Ink4a) following exposure to other hepatocarcinogens/promoters and its DNA methylation status were also analyzed during early and late tumor-promotion stages. GST-P(+) liver cell foci increased cell proliferation and decreased apoptosis when compared with surrounding liver cells. In concordance with GST-P(+) foci, checkpoint proteins at G(1)/S (p21(Cip1), p27(Kip1) and p16(Ink4a)) and G(2)/M (phospho-checkpoint kinase 1, Cdc25c and phospho-Wee1) were either up- or downregulated. Cellular distribution within GST-P(+) foci was either increased or decreased with proteins related to G(2)-M phase or DNA damage (topoisomerase II, phospho-histone H2AX, phospho-histone H3 and Cdc2). In particular, p16(Ink4a) typically downregulated in GST-P(+) foci and regenerative nodules at early tumor-promotion stage with hepatocarcinogens facilitating liver cell regeneration and in neoplastic lesions at late tumor-promotion stage with hepatocarcinogens/promoters irrespective of regenerating potential. Hypermethylation at exon 2 of Cdkn2a was detected at both early- and late-stages. Thus, diverse disruptive expression of G(1)/S and G(2)/M proteins, which allows for clonal selection of GST-P(+) foci, results in the acquisition of multiple aberrant phenotypes to disrupt checkpoint function. Moreover, increased DNA-damage responses within GST-P(+) foci may be the signature of genetic alterations. Intraexonic hypermethylation may be responsible for p16(Ink4a)-downregulation, which facilitates cell cycle progression in early preneoplastic lesions produced by repeated cell regeneration and late-stage neoplastic lesions irrespective of the carcinogenic mechanism.",
        "Doc_title":"Disruptive cell cycle regulation involving epigenetic downregulation of Cdkn2a (p16(Ink4a)) in early-stage liver tumor-promotion facilitating liver cell regeneration in rats.",
        "Journal":"Toxicology",
        "Do_id":"22659510",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;Thioacetamide;RNA;Glutathione S-Transferase pi;Gstp1 protein, rat",
        "Doc_meshdescriptors":"Animals;Cell Cycle;Cyclin-Dependent Kinase Inhibitor p16;Down-Regulation;Epigenesis, Genetic;Gene Expression Profiling;Glutathione S-Transferase pi;Immunohistochemistry;Liver Neoplasms;Liver Regeneration;Male;Neoplasm Staging;RNA;Rats;Rats, Inbred F344;Real-Time Polymerase Chain Reaction;Thioacetamide",
        "Doc_meshqualifiers":"physiology;genetics;metabolism;metabolism;metabolism;pathology;physiology;chemistry;genetics;toxicity",
        "_version_":1605811922144329728},
      {
        "Doc_abstract":"p16INK4a (MTS1) is an important negative regulator of mammalian cell proliferation, acting via inhibition of CDK4/cyclin D-dependent phosphorylation of pRb to prevent progression through the G1 phase of the cell cycle. Loss of p16 activity by either gene deletion, mutation or transcriptional inactivation has now been found in a wide range of human cancers of both epithelial and mesenchymal origin, at a frequency rivalling that of p53 mutation. As a first step towards investigating its possible role as a tumour suppressor gene in thyroid tumorigenesis, we have carried out a Southern blot analysis of the p16 gene locus in a series of cell lines derived from differentiated human thyroid cancers. Homozygous deletion of the entire p16 coding sequence was observed in two of three follicular and two of four papillary cancer cell lines, but not in normal tissue or normal cells immortalised by SV40 T antigen. Given the co-existence of p16 abnormalities in primary tumours and cell lines observed in other tumour types, this high frequency of deletion suggests that p16 is a key tumour suppressor gene in the genesis of differentiated thyroid cancer.",
        "Doc_title":"High frequency deletion of the tumour suppressor gene P16INK4a (MTS1) in human thyroid cancer cell lines.",
        "Journal":"Molecular and cellular endocrinology",
        "Do_id":"8822272",
        "Doc_ChemicalList":"Carrier Proteins;Cyclin-Dependent Kinase Inhibitor p16;DNA Probes;DNA, Neoplasm;Proto-Oncogene Proteins;CDK4 protein, human;Cyclin-Dependent Kinase 4;Cyclin-Dependent Kinases",
        "Doc_meshdescriptors":"Adenocarcinoma, Follicular;Carcinoma, Papillary;Carrier Proteins;Cell Differentiation;Cyclin-Dependent Kinase 4;Cyclin-Dependent Kinase Inhibitor p16;Cyclin-Dependent Kinases;DNA Probes;DNA, Neoplasm;Gene Deletion;Genes, Tumor Suppressor;Homozygote;Humans;Proto-Oncogene Proteins;Thyroid Neoplasms;Tumor Cells, Cultured",
        "Doc_meshqualifiers":"genetics;pathology;genetics;pathology;genetics;genetics;antagonists & inhibitors;genetics;genetics;pathology",
        "_version_":1605882737179230208},
      {
        "Doc_abstract":"Malignant transformation of epidermal cyst is rare, with most cases arising in the head and neck. Here, we report a case of squamous cell carcinoma arising from a longstanding epidermal cyst in the right vulva of a 65-year-old woman. The patient presented with a sudden increase in size of the cyst over 6 weeks to the size of a golf ball. Excisional biopsy and histology indicated moderately differentiated squamous cell carcinoma within an epidermal cyst (FIGO stage IB). Strong p16 immunopositivity was also demonstrated and the potential significance of this is discussed. Limited right hemivulvectomy and right groin node dissection were performed.",
        "Doc_title":"Squamous cell carcinoma arising from a vulval epidermal cyst.",
        "Journal":"The journal of obstetrics and gynaecology research",
        "Do_id":"27785896",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605799936438304768},
      {
        "Doc_abstract":"Increasing experimental evidence suggests that ubiquitin-specific protease 22 (USP22) could exhibit a critical function in pathological processes, including oncogenesis and cell cycle progression. The aim of this study was to investigate the role of USP22 and the association with its potential targets in colorectal cancer (CRC).;We evaluated the implication of USP22 and the candidate targets, such as B-cell-specific murine leukemia virus integration site-1 (BMI-1), cellular homolog of avian myelocytomatosis virus oncogene (c-Myc), cyclin D2, inhibitor of cyclin-dependent kinase (CDK) 4 (p16INK4a), and an alternate reading frame product of the CDKN2A locus (p14ARF), in matched samples comprising carcinoma and adjacent non-cancerous mucosa from 82 patients with CRC using quantitative reverse transcription-polymerase chain reaction and immunostaining analyses.;The USP22 mRNA expression in the CRC tissues was significantly higher than those in the non-cancerous mucosa tissues (P < 0.0001). Increased mRNA expression of USP22 was associated with advanced American Joint Committee on Cancer stage (P = 0.033) and high likelihood of therapy failure after radical resection (P < 0.0001). The Cox regression analysis revealed that the USP22 mRNA expression level was a significant factor for predicting prognosis (P < 0.0001). The statistical correlation analysis in mRNA levels showed that USP22 was strongly correlated with BMI-1 (r = 0.790, P < 0.0001), c-Myc (r = 0.528, P < 0.0001), and cyclin D2 (r = 0.657, P < 0.0001), but not p16INK4a (r = 0.103, P = 0.358) or p14ARF (r = -0.039, P = 0.731).;Our results indicate that activation of USP22 correlates with CRC progression and therapy failure. Additionally, the oncogenic role of USP22 in the progression of CRC can be mechanistically linked with BMI-1, c-Myc, and cyclin D2, but not with p16INK4a and p14ARF.",
        "Doc_title":"Increased expression of ubiquitin-specific protease 22 can promote cancer progression and predict therapy failure in human colorectal cancer.",
        "Journal":"Journal of gastroenterology and hepatology",
        "Do_id":"21039844",
        "Doc_ChemicalList":"BMI1 protein, human;Nuclear Proteins;Proto-Oncogene Proteins;RNA, Messenger;Repressor Proteins;Polycomb Repressive Complex 1;Thiolester Hydrolases;Usp22 protein, human;Endopeptidases;Ubiquitin-Specific Proteases",
        "Doc_meshdescriptors":"Carcinoma;Colorectal Neoplasms;Disease Progression;Disease-Free Survival;Endopeptidases;Female;Gene Expression;Genes, myc;Humans;Kaplan-Meier Estimate;Male;Nuclear Proteins;Polycomb Repressive Complex 1;Prognosis;Proportional Hazards Models;Proto-Oncogene Proteins;RNA, Messenger;Repressor Proteins;Reverse Transcriptase Polymerase Chain Reaction;Signal Transduction;Thiolester Hydrolases;Treatment Failure;Ubiquitin-Specific Proteases;Up-Regulation",
        "Doc_meshqualifiers":"enzymology;genetics;surgery;enzymology;genetics;surgery;genetics;metabolism;genetics;genetics;genetics;metabolism;genetics;genetics;genetics;metabolism",
        "_version_":1605759883256266752},
      {
        "Doc_abstract":"To explore the relationship between p16 gene expression and oncogenesis , and development of human lung cancer.;Immunohistochemistry was employed to detect the expression of p16 protein in 114 paraffin-embedded primary lung cancer tissues. Loss of p16 INK4 gene exon 2 (E2) was analyzed using PCR technique in 62 cancer samples with p16 protein-negative stain and 14 paracancerous lung tissues.;The positive rates of p16 protein expression in squamous cell carcinoma , adenocarcinoma and small cell lung cancer (SCLC) were 43. 3 % , 48. 2 % and 27. 0 % respectively , and no significant difference was found among them ( P > 0. 05) . The expression level of p16 protein was closely correlated with histological grade and lymph node metastasis of lung cancer. The deletion of p16 E2 was 45. 2 % in NSCLC and closely related to lymph node metastasis and histological grade ( P < 0. 05) . No deletion was observed in 37 cases of SCLC and 14 paracancerous lung tissues.;Alteration of p16 gene and protein is closely related to the histological grade and lymph node metastasis of NSCLC. It may play an important role in the oncogenesis , development and lymph node metastasis of NSCLC.",
        "Doc_title":"[The clinicopathologic significance of the p16 gene expression in primary lung cancer.].",
        "Journal":"Zhongguo fei ai za zhi = Chinese journal of lung cancer",
        "Do_id":"20937211",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605846439229915136},
      {
        "Doc_abstract":"The correlation between p16 upregulation and high-risk HPV infection is well known in head and neck squamous cell cancer. However, no information is available on rare carcinomas of the minor salivary glands. We analyzed 38 samples of minor salivary gland malignancies. p16 expression was determined by immunohistochemistry, HPV DNA by using in situ hybridization to detect low (type 6 and 11) and high (type 16 and 18) risk HPV types. In 71% of samples p16 expression was found. Low-risk HPV DNA could not be detected in any of the samples, whereas high-risk HPV DNA was found in two samples of mucoepidermoid carcinoma, which also showed the highest immunoreactivity with p16. HPV infection does not seem to be a common event in minor salivary gland carcinoma. Upregulation of p16 is present in the majority of cases but only diffuse staining correlates with HPV 16 and 18 infections.",
        "Doc_title":"HPV infection and p16 expression in carcinomas of the minor salivary glands.",
        "Journal":"European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery",
        "Do_id":"22207527",
        "Doc_ChemicalList":"Biomarkers, Tumor;Cyclin-Dependent Kinase Inhibitor p16",
        "Doc_meshdescriptors":"Adenocarcinoma;Alphapapillomavirus;Biomarkers, Tumor;Carcinoma, Mucoepidermoid;Cyclin-Dependent Kinase Inhibitor p16;Gene Expression Regulation, Neoplastic;Genes, p16;Human papillomavirus 16;Human papillomavirus 18;Humans;In Situ Hybridization;Papillomavirus Infections;Salivary Gland Neoplasms;Salivary Glands, Minor;Up-Regulation",
        "Doc_meshqualifiers":"metabolism;isolation & purification;analysis;metabolism;metabolism;isolation & purification;isolation & purification;epidemiology;epidemiology;genetics",
        "_version_":1605758281195716608},
      {
        "Doc_abstract":"Bmi1, the main component of the Polycomb repressive complex 1, plays a key role in self-renewal of stem cells as well as in proliferation of progenitor cells and senescence, at least in part through inhibition of the Cdkn2a locus. Bmi1 is highly expressed in the developing cerebellum, where it contributes to Shh-mediated expansion of granule cell precursors. Overexpression of Bmi1 has been described in medulloblastoma, highly aggressive brain neoplasms of childhood, which are thought to originate from deregulated proliferation of granule cell precursors. Here, we dissected the molecular mechanisms mediating the role of Bmi1 in granule cell development by means of transcriptome analysis in loss of function mouse models in vitro and in vivo. We demonstrate that lack of Bmi1 causes significant shift in gene expression levels in Shh stimulated cerebellar granule progenitors. Our results revealed differences in the expression of a number of genes involved in TGF-beta signal transduction pathway, ECM remodeling and cell adhesion, and particularly, in cell cycle control, not only the well known cell cycle inhibitors p16(Ink4a), p19(Arf) but also Cdkn1a (p21(Waf1/Cip1)). Finally, we demonstrate that Bmi1 directly regulates p21(Waf1/Cip1) expression through direct binding to its promoter and may therefore represent a key mechanism mediating the role of Shh in postnatal cerebellar neurogenesis.",
        "Doc_title":"Bmi1 directly represses p21Waf1/Cip1 in Shh-induced proliferation of cerebellar granule cell progenitors.",
        "Journal":"Molecular and cellular neurosciences",
        "Do_id":"20600931",
        "Doc_ChemicalList":"Bmi1 protein, mouse;Cdkn1a protein, mouse;Cyclin-Dependent Kinase Inhibitor p16;Cyclin-Dependent Kinase Inhibitor p21;Hedgehog Proteins;Nuclear Proteins;Proto-Oncogene Proteins;Repressor Proteins;Shh protein, mouse;Transforming Growth Factor beta;Polycomb Repressive Complex 1",
        "Doc_meshdescriptors":"Animals;Cell Culture Techniques;Cell Proliferation;Cerebellum;Cyclin-Dependent Kinase Inhibitor p16;Cyclin-Dependent Kinase Inhibitor p21;Hedgehog Proteins;Mice;Neural Stem Cells;Neurogenesis;Nuclear Proteins;Polycomb Repressive Complex 1;Proto-Oncogene Proteins;Repressor Proteins;Transforming Growth Factor beta",
        "Doc_meshqualifiers":"cytology;metabolism;metabolism;metabolism;physiology;metabolism;metabolism;metabolism;metabolism",
        "_version_":1605785037448413184},
      {
        "Doc_abstract":"Germ-line mutations in the CDKN2A tumor-suppressor gene (also known as p16, p16INK4a, and MTS1) have been linked to the development of melanoma in some families with inherited melanoma. Whether mutations in CDKN2A confer a predisposition to sporadic (nonfamilial) melanoma is not known. In some patients with sporadic melanoma, one or more additional primary lesions develop, suggesting that some of these patients have an underlying genetic susceptibility to the cancer. We hypothesized that this predisposition might be due to germ-line CDKN2A mutations.;We used the polymerase chain reaction, single-strand conformation polymorphism analysis, and direct DNA sequencing to identify germ-line mutations in the CDKN2A gene in patients with multiple primary melanomas who did not have family histories of the disease. A quantitative yeast two-hybrid assay was used to evaluate the functional importance of the CDKN2A variants.;Of 33 patients with multiple primary melanomas, 5 (15 percent; 95 percent confidence interval, 4 percent to 27 percent) had germ-line CDKN2A mutations. These included a 24-bp insertion at the 5' end of the coding sequence, three missense mutations (Arg24Pro, Met53Ile, and Ser56Ile), and a 2-bp deletion at position 307 to 308 (resulting in a truncated CDKN2A protein). In three families, CDKN2A mutations identical to those in the probands were found in other family members. In two families with mutations, we uncovered previously unknown evidence of family histories of melanoma.;Some patients with multiple primary melanomas but without family histories of the disease have germ-line mutations of the CDKN2A gene. The presence of multiple primary melanomas may signal a genetic susceptibility to melanoma not only in the index patient but also in family members, who may benefit from melanoma-surveillance programs.",
        "Doc_title":"CDKN2A mutations in multiple primary melanomas.",
        "Journal":"The New England journal of medicine",
        "Do_id":"9516223",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Adult;Aged;DNA Mutational Analysis;Female;Genes, p16;Genetic Predisposition to Disease;Germ-Line Mutation;Humans;Male;Melanoma;Middle Aged;Neoplasms, Multiple Primary;Pedigree;Skin Neoplasms",
        "Doc_meshqualifiers":"methods;genetics;genetics;genetics;genetics",
        "_version_":1605760045207781376},
      {
        "Doc_abstract":"Oral squamous cell carcinoma (OSCC) is the most prevalent malignancy among males in India. While tobacco and alcohol are main aetiological factors, human papilloma virus (HPV) presence has surprisingly increased in head and neck Squamous Cell Carcinoma (HNSCC) in the past two decade but its frequency in OSCCS is still uncertain. We aim to explore the frequency of HPV and its major genotypes in North Indian patients and their association with clinicopathological and histopathological features and p16 expression pattern.;The study group comprised 250 histologically proven cases of OSCC. HPV was detected by real time PCR in tumor biopsy specimens and confirmed by conventional PCR with PGMY09/ PGMY11 primers. Genotyping for high-risk types 16/ 18 was conducted by type specific PCR. p16 expression was assessed by immunohistochemsitry.;HPV presence was confirmed in 23/250 (9.2%) OSCC cases, of which 30.4% had HPV 16 infection, 17.4%were positive for HPV 18 and 26.1% had co-infections. HPV presence was significantly associated with male gender (p=0.02) and habit of pan masala chewing (p=0.01). HPV positive cases also had a history of tobacco consumption in 91.3% cases. p16 over expression was observed in 39.1% of HPV positive cases but this was not significantly different from negative cases (p=0.54).;The frequency of HPV in OSCC is low in North-India and majority of cases are associated with a tobacco habit. It appears that tobacco shows a confounding effect in HPV positive cases and use of p16 protein as a reliable marker to assess the potential etiological role of HPV in OSCC in our population is not suggested.",
        "Doc_title":"Do Human Papilloma Viruses Play Any Role in Oral Squamous Cell Carcinoma in North Indians?",
        "Journal":"Asian Pacific journal of cancer prevention : APJCP",
        "Do_id":"26514493",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16",
        "Doc_meshdescriptors":"Adult;Areca;Carcinoma, Squamous Cell;Coinfection;Cyclin-Dependent Kinase Inhibitor p16;Female;Genotype;Human Papillomavirus DNA Tests;Human papillomavirus 16;Human papillomavirus 18;Humans;India;Male;Middle Aged;Mouth Neoplasms;Papillomavirus Infections;Risk Factors;Sex Factors;Survival Rate;Tobacco Use",
        "Doc_meshqualifiers":"chemistry;epidemiology;virology;virology;analysis;genetics;isolation & purification;genetics;isolation & purification;epidemiology;chemistry;epidemiology;virology;complications;epidemiology;adverse effects",
        "_version_":1605746468748001280},
      {
        "Doc_abstract":"The modes of proliferation and differentiation of neural stem cells (NSCs) are coordinately controlled during development, but the underlying mechanisms remain largely unknown. In this study, we show that the protooncoprotein Myc and the tumor suppressor p19(ARF) regulate both NSC self-renewal and their neuronal and glial fate in a developmental stage-dependent manner. Early-stage NSCs have low p19(ARF) expression and retain a high self-renewal and neurogenic capacity, whereas late-stage NSCs with higher p19(ARF) expression possess a lower self-renewal capacity and predominantly generate glia. Overexpression of Myc or inactivation of p19(ARF) reverts the properties of late-stage NSCs to those of early-stage cells. Conversely, inactivation of Myc or forced p19(ARF) expression attenuates self-renewal and induces precocious gliogenesis through modulation of the responsiveness to gliogenic signals. These actions of p19(ARF) in NSCs are mainly mediated by p53. We propose that opposing actions of Myc and the p19(ARF)-p53 pathway have important functions in coordinated developmental control of self-renewal and cell fate choices in NSCs.",
        "Doc_title":"Coordinated control of self-renewal and differentiation of neural stem cells by Myc and the p19ARF-p53 pathway.",
        "Journal":"The Journal of cell biology",
        "Do_id":"19114593",
        "Doc_ChemicalList":"Cdkn2a protein, mouse;Cyclin-Dependent Kinase Inhibitor p16;Proto-Oncogene Proteins c-myc;Tumor Suppressor Protein p53",
        "Doc_meshdescriptors":"Animals;Cell Differentiation;Cells, Cultured;Cyclin-Dependent Kinase Inhibitor p16;Female;Mice;Mice, Inbred Strains;Neurogenesis;Neurons;Pregnancy;Proto-Oncogene Proteins c-myc;Rats;Rats, Sprague-Dawley;Signal Transduction;Stem Cells;Tumor Suppressor Protein p53",
        "Doc_meshqualifiers":"genetics;metabolism;cytology;metabolism;genetics;metabolism;cytology;metabolism;genetics;metabolism",
        "_version_":1605832331024662528},
      {
        "Doc_abstract":"Id1, a member of Id family of helix-loop-helix transcriptional regulatory proteins, is implicated in cellular senescence by repressing p16(INK4a) expression, but the mechanisms and cellular effects in human diploid fibroblasts remain unknown. Here we analyzed the patterns of p16(INK4a) and Id1 expression during the lifespan of 2BS cells and presented the inverse correlation between these two proteins. Immunoprecipitation assays demonstrated the presence of endogenous interaction of Id1 and E47 proteins that was strong in young 2BS cells and weakened during replicative senescence and, thereby, influenced the transcription activation of p16(INK4a) by E47. Furthermore, we found that E47 protein could bind to the E-box-containing region in p16(INK4a) promoter in senescent cells by chromatin immunoprecipitation analyses, suggesting that E47 is indeed ultimately involved in the regulation of p16(INK4a) transcription in vivo. Silencing Id1 expression in young cells by RNA interference induced an increased p16(INK4a) level and premature cellular senescence, whereas silencing E47 expression inhibited the expression of p16(INK4a) and delayed the onset of senescent phenotype. The present study demonstrated not only the capacity of Id1 to regulate p16(INK4a) gene expression by E47, but also the phenotypic consequence of the regulation on cellular senescence, moreover, raised the possibility of Id1-specific gene silencing for human cancer therapy.",
        "Doc_title":"Regulation of cellular senescence and p16(INK4a) expression by Id1 and E47 proteins in human diploid fibroblast.",
        "Journal":"The Journal of biological chemistry",
        "Do_id":"15138269",
        "Doc_ChemicalList":"DNA Primers;DNA-Binding Proteins;ID1 protein, human;Inhibitor of Differentiation Protein 1;RNA, Small Interfering;Repressor Proteins;TCF Transcription Factors;TCF7L1 protein, human;Transcription Factor 7-Like 1 Protein;Transcription Factors;beta-Galactosidase",
        "Doc_meshdescriptors":"Base Sequence;Cell Aging;Cell Division;Cell Line;DNA Primers;DNA-Binding Proteins;Fibroblasts;Gene Expression Regulation;Genes, p16;Helix-Loop-Helix Motifs;Humans;Inhibitor of Differentiation Protein 1;RNA Interference;RNA, Small Interfering;Repressor Proteins;TCF Transcription Factors;Transcription Factor 7-Like 1 Protein;Transcription Factors;Transfection;beta-Galactosidase",
        "Doc_meshqualifiers":"genetics;physiology;genetics;genetics;metabolism;cytology;metabolism;genetics;genetics;metabolism;genetics;metabolism;metabolism",
        "_version_":1605761785739083777},
      {
        "Doc_abstract":"INK4 proteins are members of a family of cyclin-dependent kinase (CDK) inhibitors that function in G(1) to block the activity of CDKs 4 and 6. While they share clear structural similarities, numerous studies have shown that INK4 proteins differ in their expression patterns during development and in the adult, and have differing roles in tumor suppression. A recent study from our laboratory showed that expression of the gene encoding p19(INK4D) is induced by the hormonal form of vitamin D(3) and by retinoids, both of which signal through related nuclear receptor transcription factors. Although vitamin D(3) and retinoids have distinct developmental and physiological functions, both regulate the cell cycle and have been shown to have chemopreventive effects in a range of studies. Induction of p19(INK4D) expression contributed to cell cycle arrest by both ligands. However, knockdown of p19(INK4D) rendered cells sensitive to autophagic cell death, a remarkable phenotype given the hyperproliferative responses to loss of other INK4 proteins. We discuss the relevance of our studies and recent findings of others to the cell death observed in p19(INK4D)-deficient animals and to a possible role for p19(INK4D) induction in chemoprevention.",
        "Doc_title":"p19INK4D and cell death.",
        "Journal":"Cell cycle (Georgetown, Tex.)",
        "Do_id":"16582618",
        "Doc_ChemicalList":"Cell Cycle Proteins;Cyclin-Dependent Kinase Inhibitor p19;Retinoids;Cholecalciferol",
        "Doc_meshdescriptors":"Animals;Cell Cycle Proteins;Cell Death;Cell Transformation, Neoplastic;Chemoprevention;Cholecalciferol;Cyclin-Dependent Kinase Inhibitor p19;Genes, Tumor Suppressor;Genes, cdc;Humans;Retinoids",
        "Doc_meshqualifiers":"genetics;metabolism;genetics;genetics;metabolism;metabolism;genetics;physiology;physiology;metabolism",
        "_version_":1605812218924892160},
      {
        "Doc_abstract":"The p16/MTS1/CDKN2 gene and the cyclin D1/PRAD-1 gene cooperatively regulate cyclin-dependent kinase 4-mediated phosphorylation of pRB in the cell cycle of normal cells. p16/CDKN2 gene and cyclin D1/PRAD-1 gene alterations have been detected in squamous cell carcinoma cell lines and in several primary squamous cell carcinomas of the esophagus. We immunohistochemically assessed p16 and cyclin D1 expression in 111 squamous cell carcinomas of the esophagus after evaluation of the antibodies against p16 and cyclin D1 protein using four squamous cell carcinoma cell lines. Loss of p16 expression was detected in 56 of 111 cases (50%). The mean number of metastatic lymph nodes without p16 expression was significantly higher than the number of nodes with p16 expression (P = 0.04). The postoperative survival rate for patients without p16 expression was significantly lower than that of patients with p16 expression (P = 0.04). Cyclin D1 overexpression was found in 28 of the 111 cases (25%) and correlated with distant organ metastasis after curative surgery (P = 0.05). The survival rate of patients with cyclin D1 overexpression was significantly lower than that of patients without cyclin D1 overexpression (P = 0.01). A positive correlation between the loss of p16 expression and cyclin D1 overexpression was observed (P = 0. 03). The loss of p16 expression and overexpression of cyclin D1 may be useful prognostic indicators in patients with squamous cell carcinomas of the esophagus. It may be possible to select more suitable treatment for patients with squamous cell carcinomas of the esophagus by evaluating the status of p16 and cyclin D1 expression.",
        "Doc_title":"Altered p16/MTS1/CDKN2 and cyclin D1/PRAD-1 gene expression is associated with the prognosis of squamous cell carcinoma of the esophagus.",
        "Journal":"Clinical cancer research : an official journal of the American Association for Cancer Research",
        "Do_id":"9815619",
        "Doc_ChemicalList":"Antibodies, Monoclonal;Cyclin-Dependent Kinase Inhibitor p16;Cyclin D1",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Antibodies, Monoclonal;Carcinoma, Squamous Cell;Cyclin D1;Cyclin-Dependent Kinase Inhibitor p16;Esophageal Neoplasms;Female;Gene Expression Regulation, Neoplastic;Genes, p16;Humans;Male;Middle Aged;Prognosis;Survival Analysis;Time Factors;Tumor Cells, Cultured",
        "Doc_meshqualifiers":"genetics;mortality;pathology;surgery;analysis;genetics;analysis;biosynthesis;genetics;mortality;pathology;surgery",
        "_version_":1605874350754365440},
      {
        "Doc_abstract":"The aim of our study was to identify the frequency of expression of p16(INK4a) (CDKN2A) and HPV (human papilloma virus) in different grades of conjunctival intraepithelial neoplasia (CIN).Twelve specimens including CIN I (2), II (3), III (5), and CIN with beginning invasion (2), as well as 15 control specimens, were stained with antibodies against p16(INK4a) and MIB1. The presence of HPV was examined by PCR.p16 as well as MIB1 were significantly elevated in CIN compared to control specimens (p<0.01) without correlation with the differentiation grade. Only two cases with CIN grade 3 contained HPV 16.As few control specimens also showed increased p16(INK4a) expression, p16(INK4a) seems not to be a very reliable marker for the exact determination of CIN. It could serve as an additional diagnostic tool besides the morphological characterization. Our study suggested that p16(INK4a) elevation is not associated with HPV infection.",
        "Doc_title":"Expression of p16 in conjunctival intraepithelial neoplasia does not correlate with HPV-infection.",
        "Journal":"The open ophthalmology journal",
        "Do_id":"19516893",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605759118435418112},
      {
        "Doc_abstract":"The stabilization and subcellular localization of the p19(Arf) tumor suppressor protein and the SUMO-2/3 deconjugating protease Senp3 each depend upon their binding to the abundant nucleolar protein nucleophosmin (Npm/B23). Senp3 and p19(Arf) antagonize each other's functions in regulating the SUMOylation of target proteins including Npm itself. The p19(Arf) protein triggers the sequential phosphorylation, polyubiquitination and rapid proteasomal degradation of Senp3, and this ability of p19(Arf) to accelerate Senp3 turnover also depends on the presence of Npm. In turn, endogenous p19(Arf) and Senp3 are both destabilized in viable Npm-null mouse embryo fibroblasts (that also lack p53), and reintroduction of the human NPM protein into these cells reverses this phenotype. NPM mutants that retain their acidic and oligomerization domains can re-stabilize both p19(Arf) and Senp3 in this setting, but the nucleolar localization of NPM is not strictly required for these effects. Knockdown of Senp3 with shRNAs mimics the antiproliferative functions of p19(Arf) in cells that lack p53 alone or in triple knock-out cells that lack the Arf, Mdm2 and p53 genes. These findings reinforce the hypothesis that the p53-independent tumor suppressive functions of p19(Arf) may be mediated by its ability to antagonize Senp3, thereby inducing cell cycle arrest by abnormally elevating the cellular levels of SUMOylated proteins.",
        "Doc_title":"Arf-induced turnover of the nucleolar nucleophosmin-associated SUMO-2/3 protease Senp3.",
        "Journal":"Cell cycle (Georgetown, Tex.)",
        "Do_id":"18948745",
        "Doc_ChemicalList":"Cdkn2a protein, mouse;Cyclin-Dependent Kinase Inhibitor p16;Nuclear Proteins;SUMO2 protein, mouse;Small Ubiquitin-Related Modifier Proteins;Sumo3 protein, mouse;Ubiquitins;nucleophosmin;Polyubiquitin;Senp3 protein, mouse;Peptide Hydrolases;Proteasome Endopeptidase Complex",
        "Doc_meshdescriptors":"Animals;Cell Nucleolus;Cell Proliferation;Cyclin-Dependent Kinase Inhibitor p16;Down-Regulation;Humans;Mice;NIH 3T3 Cells;Nuclear Proteins;Peptide Hydrolases;Phosphorylation;Polyubiquitin;Proteasome Endopeptidase Complex;Protein Binding;Protein Stability;Protein Structure, Tertiary;Small Ubiquitin-Related Modifier Proteins;Ubiquitins",
        "Doc_meshqualifiers":"metabolism;metabolism;chemistry;metabolism;metabolism;metabolism;metabolism;metabolism;metabolism",
        "_version_":1605908089688555520},
      {
        "Doc_abstract":"There are no good genomic markers of survival in patients with advanced colorectal cancer. The CpG island methylator phenotype (CIMP) marks a distinctive pathway in colorectal cancer. We sought to determine the prognostic significance of CIMP in advanced colorectal cancer patients treated with 5-fluorouracil (5-FU) in an Eastern Cooperative Oncology Group clinical trial.;We studied 188 patients enrolled on protocol E2290, a five-arm trial comparing 5-FU, 5-FU in combination with N-phosphonoacetyl-l-aspartic acid, oral leucovorin, i.v. leucovorin, or IFNalpha-2a in patients with advanced colorectal cancer. Methylation of MINT1, MINT31, hMLH1, p14ARF, and p16INK4a in DNA extracted from formalin-fixed paraffin-embedded specimens was evaluated by combined bisulfite restriction analysis, and methylation of MINT2 was studied by methylation-specific PCR.;Methylation frequencies were 21% for MINT1, 23% for MINT2, 24% for MINT31, 4% for hMLH1, 11% for p14ARF, and 17% for p16INK4a. Methylation of MINT1, MINT31, p14ARF, and p16INK4a were correlated, as expected. There was no association between methylation and clinicopathologic factors or response to therapy. Methylation of MINT1, MINT31, p14ARF, or p16INK4a was associated individually with shortened overall survival. Hazard ratios were 1.51 (P = 0.05) for MINT1, 1.70 (P = 0.006) for MINT31, 2.22 (P = 0.001) for p14ARF, and 1.51 (P = 0.05) for p16INK4a. Concurrent methylation of two or more genes of the CIMP-associated subset (MINT1, MINT31, p14ARF and p16INK4a) defined a group of cases with markedly reduced overall survival and hazard ratio was 3.22 (P < 0.0001 in multivariate analyses).;CIMP is associated with poor survival in advanced colorectal cancer patients.",
        "Doc_title":"Association between DNA methylation and shortened survival in patients with advanced colorectal cancer treated with 5-fluorouracil based chemotherapy.",
        "Journal":"Clinical cancer research : an official journal of the American Association for Cancer Research",
        "Do_id":"17947473",
        "Doc_ChemicalList":"Antineoplastic Agents;Sulfites;hydrogen sulfite;Leucovorin;Fluorouracil",
        "Doc_meshdescriptors":"Aged;Antineoplastic Agents;Colorectal Neoplasms;CpG Islands;DNA Methylation;Female;Fluorouracil;Humans;Leucovorin;Male;Middle Aged;Phenotype;Polymerase Chain Reaction;Sulfites;Treatment Outcome",
        "Doc_meshqualifiers":"pharmacology;genetics;mortality;therapy;pharmacology;pharmacology;pharmacology",
        "_version_":1605742700231917568},
      {
        "Doc_abstract":"The INK4a/ARF locus encodes two distinct tumor suppressors, p16INK4a and p14ARF. Although the contribution of p16INK4a to human tumorigenesis through point mutation, deletion, and hypermethylation has been widely documented, little is known about specific p14ARF lesions and their consequences. Recent data indicate that p14ARF suffers inactivation by promoter hypermethylation in colorectal cancer cells. Because it is known that p14ARF prevents MDM2 nucleocytoplasmic shuttling and thus stabilizes p53 by attenuating MDM2-mediated degradation, we studied the relationship of p14ARF epigenetic silencing to the expression and localization of MDM2 and p53. Cancer cell lines with an unmethylated p14ARF promoter showed strong nuclear expression of MDM2, whereas in a colorectal cell line with p14ARF hypermethylation-associated inactivation, MDM2 protein was also seen in the cytosol. Treatment with the demethylating agent 5-aza-2'-deoxycytidine was able to reinternalize MDM2 to the nucleus, and p53 expression was restored. No apparent changes in retinoblastoma localization were observed. We also studied the profile of p14ARF promoter hypermethylation in an extensive collection of 559 human primary tumors of different cell types, observing that in colorectal, gastric, renal, esophageal, and endometrial neoplasms and gliomas, aberrant methylation of p14ARF was a relatively common epigenetic event. MDM2 expression patterns revealed that lack of p14ARF promoter hypermethylation was associated with tumors showing exclusive nuclear MDM2 staining, whereas MDM2 cytosolic staining was frequently observed in neoplasms with aberrant p14ARF methylation. Taken together, these data support that epigenetic silencing of p14ARF by promoter hypermethylation is a key mechanism in the disturbance of the MDM2 nuclear localization in human cancer.",
        "Doc_title":"p14ARF silencing by promoter hypermethylation mediates abnormal intracellular localization of MDM2.",
        "Journal":"Cancer research",
        "Do_id":"11306450",
        "Doc_ChemicalList":"Nuclear Proteins;Proteins;Proto-Oncogene Proteins;Tumor Suppressor Protein p14ARF;MDM2 protein, human;Proto-Oncogene Proteins c-mdm2",
        "Doc_meshdescriptors":"DNA Methylation;Gene Expression Regulation, Neoplastic;Gene Silencing;Humans;Nuclear Proteins;Promoter Regions, Genetic;Protein Biosynthesis;Proteins;Proto-Oncogene Proteins;Proto-Oncogene Proteins c-mdm2;Tumor Cells, Cultured;Tumor Suppressor Protein p14ARF",
        "Doc_meshqualifiers":"genetics;physiology;metabolism",
        "_version_":1605907621301190656},
      {
        "Doc_abstract":"The p53 tumor suppressor is a stress sensor, driving cell cycle arrest or apoptosis in response to DNA damage or oncogenic signals. p53 activation by oncogenic signals relies on the p19(Arf) tumor suppressor, while p53 activation downstream of acute DNA damage is reported to be p19(Arf)-independent. Accordingly, p19(Arf)-deficient mouse embryo fibroblasts (MEFs) arrest in response to acute DNA damage. However, p19(Arf) is required for replicative senescence, a condition associated with an activated DNA damage response, as p19(Arf)-/- MEFs do not senesce after serial passage. A possible explanation for these seemingly disparate roles for p19(Arf) is that acute and chronic DNA damage responses are mechanistically distinct. Replicative senescence may result from chronic, low-dose DNA damage responses in which p19(Arf) has a specific role. We therefore examined the role of p19(Arf) in cellular responses to chronic, low-dose DNA-damaging agent treatment by maintaining MEFs in low oxygen and administering 0.5Gy -irradiation daily or 150M hydroxyurea, a replication stress inducer. In contrast to their response to acute DNA damage, p19(Arf)-/- MEFs exposed to chronic DNA damage do not senesce, revealing a selective role for p19(Arf) in senescence upon low-level, chronic DNA damage. We show further that p53 pathway activation in p19(Arf)-/- MEFs exposed to chronic DNA damage is attenuated relative to wild-type MEFs, suggesting a role for p19(Arf) in fine-tuning p53 activity. However, combined Nutlin3a and chronic DNA-damaging agent treatment is insufficient to promote senescence in p19(Arf)-/- MEFs, suggesting that the role of p19(Arf) in the chronic DNA damage response may be partially p53-independent. These data suggest the importance of p19(Arf) for the cellular response to the low-level DNA damage incurred in culture or upon oncogene expression, providing new insight into how p19(Arf) serves as a tumor suppressor. Moreover, our study helps reconcile reports suggesting crucial roles for both p19(Arf) and DNA damage-signaling pathways in tumor suppression. ",
        "Doc_title":"p19(Arf) is required for the cellular response to chronic DNA damage.",
        "Journal":"Oncogene",
        "Do_id":"26725325",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605741993283026945},
      {
        "Doc_abstract":"Recently, it has been shown that the homozygous deletion of the cyclin-dependent kinase-4 inhibitor (CDK4I;p16) gene, which is mapped to chromosome 9p21, is frequently observed in a wide spectrum of human cancers, including leukemias. Therefore, the CDK4I gene is thought to be a putative tumor-suppressor gene. We report here that both alleles of the CDK4I gene were completely or partially deleted in human leukemia cells derived from both patients and established cell lines. Thirty-seven hematopoietic cell lines and samples from 72 patients with leukemias were examined for homozygous loss of the CDK4I gene locus by Southern blot analysis. We found that a part or the whole of the CDK4I gene was homozygously deleted in 14 of the 37 (38%) cell lines and 4 of 72 (6%) samples from leukemia patients, including 45 with acute myelocytic leukemia, 14 with acute lymphocytic leukemia (ALL), and 13 with chronic myelocytic leukemia in blastic crisis. In the cell lines, the homozygous deletion of the CDK4I gene was detected in a variety of cell lineages, whereas all 4 cases showing the homozygous deletion were confined to ALL. It should be noted that 2 of them had no cytogenetic abnormalities of chromosome 9. Our results suggest that loss of the CDK4I function may contribute to immortalization of human leukemia cells and play a causative role at least in development of human lymphocytic leukemias.",
        "Doc_title":"Homozygous loss of the cyclin-dependent kinase 4-inhibitor (p16) gene in human leukemias.",
        "Journal":"Blood",
        "Do_id":"7919362",
        "Doc_ChemicalList":"Carrier Proteins;Cyclin-Dependent Kinase Inhibitor p16;Proto-Oncogene Proteins;Protein-Serine-Threonine Kinases;CDK4 protein, human;Cyclin-Dependent Kinase 4;Cyclin-Dependent Kinases",
        "Doc_meshdescriptors":"Adult;Alleles;Base Sequence;Blotting, Southern;Carrier Proteins;Child, Preschool;Chromosomes, Human, Pair 9;Cyclin-Dependent Kinase 4;Cyclin-Dependent Kinase Inhibitor p16;Cyclin-Dependent Kinases;Female;Gene Deletion;Homozygote;Humans;Leukemia;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Leukemia, Myeloid, Acute;Male;Middle Aged;Molecular Sequence Data;Precursor Cell Lymphoblastic Leukemia-Lymphoma;Protein-Serine-Threonine Kinases;Proto-Oncogene Proteins;Tumor Cells, Cultured",
        "Doc_meshqualifiers":"genetics;genetics;genetics;genetics;genetics;antagonists & inhibitors",
        "_version_":1605893613837877248},
      {
        "Doc_abstract":"The p14(ARF) protein, the product of an alternate reading frame of the INK4A/ARF locus on human chromosome 9p21, disrupts the ability of MDM2 to target p53 for proteosomal degradation and causes an increase in steady-state p53 levels, leading to a G(1) and G(2) arrest of cells in the cell cycle. Although much is known about the function of p14(ARF) in the p53 pathway, not as much is known about its function in human tumor growth and chemosensitivity independently of up-regulation of p53 protein levels. To learn more about its effect on cellular proliferation and chemoresistance independent of p53 up-regulation, human HT-1080 fibrosarcoma cells null for p14(ARF) and harboring a defective p53 pathway were stably transfected with p14(ARF) cDNA under the tight control of a doxycycline-inducible promoter. Induction of p14(ARF) caused a decrease in cell proliferation rate and colony formation and a marked decrease in the level of dihydrofolate reductase (DHFR) protein. The effect of p14(ARF) on DHFR protein levels was specific, because thymidylate kinase and thymidylate synthase protein levels were not decreased nor were p53 or p21WAF1 protein levels increased. The decrease in DHFR protein was abolished when the cells were treated with the proteasome inhibitor MG132, demonstrating that p14(ARF) augments proteasomal degradation of the protein. Surprisingly, induction of p14(ARF) increased resistance to the folate antagonists methotrexate, trimetrexate, and raltitrexed. Depletion of thymidine in the medium reversed this resistance, indicating that p14(ARF) induction increases the reliance of these cells on thymidine salvage.",
        "Doc_title":"p14ARF expression increases dihydrofolate reductase degradation and paradoxically results in resistance to folate antagonists in cells with nonfunctional p53.",
        "Journal":"Cancer research",
        "Do_id":"15205349",
        "Doc_ChemicalList":"Folic Acid Antagonists;Quinazolines;Thiophenes;Tumor Suppressor Protein p14ARF;Tumor Suppressor Protein p53;Tetrahydrofolate Dehydrogenase;Thymidylate Synthase;raltitrexed;Trimetrexate;Thymidine;Methotrexate",
        "Doc_meshdescriptors":"Cell Division;Cell Line, Tumor;Drug Resistance, Neoplasm;Enzyme Stability;Fibrosarcoma;Folic Acid Antagonists;Humans;Methotrexate;Neoplastic Stem Cells;Quinazolines;Tetrahydrofolate Dehydrogenase;Thiophenes;Thymidine;Thymidylate Synthase;Trimetrexate;Tumor Suppressor Protein p14ARF;Tumor Suppressor Protein p53",
        "Doc_meshqualifiers":"physiology;drug therapy;enzymology;pathology;pharmacology;pharmacology;drug effects;metabolism;pharmacology;metabolism;pharmacology;metabolism;antagonists & inhibitors;metabolism;pharmacology;biosynthesis;genetics;physiology",
        "_version_":1605904015073214464},
      {
        "Doc_abstract":"p16(INK4a) is active in cell senescence, ageing and tumor suppression. Deletion of the small p16(INK4a)/ARF/p15(INK4b) region occurs in many cancers. We screened 25 common polymorphisms across the region and three related genes for associations with physical functioning in older people. In an initial sample of 938 (aged 65-80 years) from the EPIC study (Norfolk, UK), the rs2811712 SNP minor allele (located between the shared p16(INK4a)/ARF locus and p15(INK4b)) was associated with reduced physical impairment. This association remained after testing an additional 1319 EPIC-Norfolk samples (p-value=0.013, total n=2257), and on independent replication in the InCHIANTI study (n=709, p=0.015), and at one-sided significance in Iowa-EPESE (n=419, p=0.079). Overall (n=3372), the prevalence of severely limited physical function was 15.0% in common homozygotes and 7.0% in rare homozygotes (per minor allele odds ratio=1.48, 95% CI: 1.17-1.88, p=0.001, adjusted for age, sex and study). This estimate was similar excluding screening set 1 (OR=1.45, 95% CI: 1.09-1.92, p=0.010, n=2434). These findings require further replication, but provide the first direct evidence that the p16(INK4a)/ARF/p15(INK4b) genetic region and the senescence machinery are active in physical ageing in heterogeneous human populations. The mechanism involved may be via greater cellular restorative activity and reduced stem cell senescence.",
        "Doc_title":"A common variant of the p16(INK4a) genetic region is associated with physical function in older people.",
        "Journal":"Mechanisms of ageing and development",
        "Do_id":"17459456",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p15;Cyclin-Dependent Kinase Inhibitor p16",
        "Doc_meshdescriptors":"Aged;Aged, 80 and over;Aging;Cyclin-Dependent Kinase Inhibitor p15;Cyclin-Dependent Kinase Inhibitor p16;Female;Humans;Male;Motor Activity;Polymorphism, Single Nucleotide",
        "Doc_meshqualifiers":"genetics;genetics;genetics;genetics",
        "_version_":1605800253030662144},
      {
        "Doc_abstract":"Inactivation of the ARF-p53 tumor suppressor pathway leads to immortalization of murine fibroblasts. The role of this pathway in immortalization of human epithelial cells is not clear. We analyzed the functionality of the p14(ARF)-p53 pathway in human mammary epithelial cells (MEC) immortalized by human papillomavirus 16 (HPV16) E6, the p53 degradation-defective E6 mutant Y54D, or hTERT. E6-MEC or E6Y54D-MEC maintains high-level expression of p14(ARF). Late-passage hTERT-immortalized MEC express p53 but down-regulate p14(ARF). Enforced expression of p14(ARF) induces p53-dependent senescence in hTERT-MEC, while both E6-MEC and E6Y54D-MEC are resistant. We show that E6Y54D inhibits p14(ARF)-induced activation of p53 without inactivation of the p53-dependent DNA damage response. Hence, p53 degradation and inhibition of p14(ARF) signaling to p53 are independent functions of HPV16 E6. Our observations imply that long-term proliferation of MEC requires inactivation of the p14(ARF)-p53 pathway.",
        "Doc_title":"Immortalization of human mammary epithelial cells is associated with inactivation of the p14ARF-p53 pathway.",
        "Journal":"Molecular and cellular biology",
        "Do_id":"14966292",
        "Doc_ChemicalList":"CDKN1A protein, human;Cyclin-Dependent Kinase Inhibitor p16;Cyclin-Dependent Kinase Inhibitor p21;Cyclins;DNA-Binding Proteins;E6 protein, Human papillomavirus type 16;Enzyme Inhibitors;Oncogene Proteins, Viral;Repressor Proteins;Tumor Suppressor Protein p14ARF;Tumor Suppressor Protein p53;Telomerase",
        "Doc_meshdescriptors":"Cell Aging;Cell Transformation, Neoplastic;Cells, Cultured;Cyclin-Dependent Kinase Inhibitor p16;Cyclin-Dependent Kinase Inhibitor p21;Cyclins;DNA Damage;DNA-Binding Proteins;Enzyme Inhibitors;Epithelial Cells;Gene Expression Regulation;Humans;Mammary Glands, Human;Oncogene Proteins, Viral;Repressor Proteins;Signal Transduction;Telomerase;Tumor Suppressor Protein p14ARF;Tumor Suppressor Protein p53",
        "Doc_meshqualifiers":"genetics;metabolism;genetics;metabolism;metabolism;cytology;metabolism;anatomy & histology;genetics;metabolism;physiology;genetics;metabolism;genetics;metabolism;genetics;metabolism",
        "_version_":1605806498150088704},
      {
        "Doc_abstract":"The p16INK4a was isolated as a gene which binds and inhibits the cyclin-dependent kinase 4. Other laboratories reported that the isolated gene frequently homozygously deleted within chromosome 9p21 was the p16INK4a. The p16INK4a gene was thought be a hot gene like the p53 gene at the time. Nevertheless, the gene was thought to be a false tumor suppressor gene due to the low incidence the alterations of the gene in various surgical tumor samples. Since then, there have been a lot of reports supporting that p16INK4a is a really tumor suppressor gene including the reports on the high incidence of p16INK4a alterations in some kinds of tumors, on the higher incidence of p16INK4a alterations in the metastatic tumors than that of the primary tumors, on the G1 arrest of p16INK4a lack cells transfected with p16INK4a cDNA, and on the inactivation of p16INK4a gene by hypermethylation. Therefore, the p16INK4a gene has become the tumor suppressor gene, lately. Moreover, the INK4 family including p15INK4b, p18INK4c, and p19INK4d was isolated. These reports taken together, p16INK4a and INK4 family might play important roles in the genesis and development of cancer.",
        "Doc_title":"[Molecullar structure and function of the p16/INK4a/CDKN2/MTS1 and the INK4 family, and their association with carcinogenesis].",
        "Journal":"Nihon rinsho. Japanese journal of clinical medicine",
        "Do_id":"8920670",
        "Doc_ChemicalList":"Cyclins;Cyclin-Dependent Kinases",
        "Doc_meshdescriptors":"Amino Acid Sequence;Animals;Chromosomes, Human, Pair 9;Cyclin-Dependent Kinases;Cyclins;G1 Phase;Gene Deletion;Genes, Tumor Suppressor;Humans;Molecular Sequence Data;Neoplasms",
        "Doc_meshqualifiers":"genetics;genetics;physiology;etiology",
        "_version_":1605818619711717376},
      {
        "Doc_abstract":"Human papillomavirus (HPV) infection has been implicated in the development of high-grade squamous dysplasia and carcinoma of the oral cavity in the absence of other known risk factors such as smoking. HPV-induced oral dysplasia or carcinoma may be a unique tumor entity in terms of biologic behavior and treatment decisions. In detecting such cases, most reported studies have used techniques that are less sensitive than DNA amplification. Recent reports have suggested that overexpression of the p16INK4 protein is a surrogate marker of HPV-induced high-grade dysplasia or carcinoma. However, the correlation between expression of p16INK4 and the presence of HPV DNA as determined by polymerase chain reaction (PCR) amplification has not been previously reported. The purpose of this research was to determine if immunohistochemistry for p16 would serve as a marker of HPV-associated high-grade oral squamous dysplasia.;Archival formalin-fixed, paraffin-embedded tissue sections from 41 cases of high-grade oral squamous dysplasia were randomly selected. Expression of p16INK4 protein was assessed by immunohistochemical analysis (16P04 Neomarkers, Fremont, CA). Strong and diffuse nuclear staining restricted to the dysplastic region in the epithelium was scored as positive for protein expression, whereas focal or weak nuclear or cytoplasmic staining was scored as negative. The presence of HPV was determined by microdissection, DNA extraction, and PCR DNA amplification using elongated primers that align with corresponding sequences of the L1 region of 23 mucosotropic HPV genotypes. The HPV type was determined by direct sequencing of the PCR product. Normal squamous epithelium was used as an internal negative control, and cases of severe cervical high-grade squamous dysplasia were used as a positive control for immunohistochemical staining and PCR.;The results of immunohistochemical analysis for overexpression of p16INK4 were positive in 6 of the 41 tissue sections. The results of PCR DNA amplification were also positive for these 6 sections. HPV-16 was identified in 5 of the positive cases; in the other case, the viral strain could not be determined.;Immunohistochemical detection of p16INK4 is a technically simple and potentially reliable assay for diagnosing cases of HPV-induced oral high-grade squamous dysplasia. Detecting such lesions may influence future therapeutic decisions.",
        "Doc_title":"Overexpression of p16INK4 is a reliable marker of human papillomavirus-induced oral high-grade squamous dysplasia.",
        "Journal":"Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics",
        "Do_id":"16831676",
        "Doc_ChemicalList":"Biomarkers, Tumor;Cyclin-Dependent Kinase Inhibitor p16;DNA Probes, HPV;DNA, Viral",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Biomarkers, Tumor;Carcinoma, Squamous Cell;Cyclin-Dependent Kinase Inhibitor p16;DNA Probes, HPV;DNA, Viral;Female;Human papillomavirus 16;Humans;Immunohistochemistry;Male;Middle Aged;Mouth Neoplasms;Papillomavirus Infections;Precancerous Conditions",
        "Doc_meshqualifiers":"enzymology;etiology;virology;biosynthesis;analysis;pathogenicity;enzymology;etiology;virology;complications;enzymology;etiology;virology",
        "_version_":1605827394155839488},
      {
        "Doc_abstract":"Some features of kidney transplants with dysfunction overlap the lesions of aging, such as tubular atrophy and interstitial fibrosis (TA/IF) without major glomerular abnormalities. Somatic cell limitations could contribute to deterioration in aging and disease states. Since expression of p16(INK4a), a cell cycle inhibitor associated with somatic cell senescence in vitro, is induced in aged kidney, we studied whether kidneys with dysfunction and TA/IF manifested increased p16(INK4a) expression. We performed p16(INK4a) immunostaining on transplanted kidneys and native kidneys with chronic renal diseases. At implantation, transplants manifested little TA/IF, and nuclear p16(INK4a) immunostaining was consistent with age. However, transplants biopsied for abnormal function displaying TA/IF showed strong nuclear and cytoplasmic p16(INK4a) staining, beyond the amount predicted for age. Both atrophic and non-atrophic nephrons displayed increased p16(INK4a), suggesting that it was not simply a feature of atrophy. Epithelial p16(INK4a) staining was not increased in transplants with good function, but was increased in diseased native kidneys. The finding of increased p16(INK4a) expression in renal transplants and diseased kidneys with TA/IF and impaired function supports the concept that some cell senescence changes that accompany aging are also induced by injury and disease stresses. Thus, aging, injury and disease may share common pathways involving somatic cell senescence.",
        "Doc_title":"Increased expression of senescence-associated cell cycle inhibitor p16INK4a in deteriorating renal transplants and diseased native kidney.",
        "Journal":"American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons",
        "Do_id":"15888044",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16",
        "Doc_meshdescriptors":"Adult;Aged;Aging;Chronic Disease;Cyclin-Dependent Kinase Inhibitor p16;Female;Gene Expression Regulation;Graft Rejection;Humans;Kidney Diseases;Kidney Transplantation;Male;Middle Aged;Transplantation, Homologous",
        "Doc_meshqualifiers":"genetics;metabolism;genetics;metabolism;genetics;metabolism;etiology;genetics;metabolism",
        "_version_":1605874162869469184},
      {
        "Doc_abstract":"The aim of this study was to examine biomolecular profiles in a cohort of young adults with squamous cell cancers (SCCs) of the oral tongue.;We identified all patients aged 18 to 39 years diagnosed with SCC of the oral tongue at our institution. Immunohistochemical (IHC) staining was performed for p16(INK4a) , epidermal growth factor receptor (EGFR), phosphorylated-EGFR (pEGFR), p53, and ERCC1. Human papillomavirus (HPV) testing was performed using in situ hybridization (ISH) and polymerase chain reaction (PCR). Biomarker expression and HPV status were correlated with outcomes.;We identified 25 patients with sufficient tumor samples. Median age at diagnosis was 30 years (range, 20-39 years). p16(INK4a) overexpression was observed in 11 of 25 patients, whereas HPV-16 positivity was observed in none of the tumor samples by ISH and 2 of the tumor samples by PCR. p16(INK4a) positivity was correlated with improved relapse-free survival (hazard ratio [HR] = 0.23, p = .01) and overall survival (HR = 0.28, p = .05). Neither EGFR, pEGFR, p53, nor excision repair cross-complementing rodent repair deficiency, complementation group 1 (ERCC1) expression correlated with outcome on univariate analysis.;p16(INK4a) overexpression was common and was a marker of favorable prognosis. p16(INK4a) overexpression was not a reliable predictor of HPV positivity in our cohort.",
        "Doc_title":"Association of p16(INK4a)  overexpression with improved outcomes in young patients with squamous cell cancers of the oral tongue.",
        "Journal":"Head & neck",
        "Do_id":"21990227",
        "Doc_ChemicalList":"Biomarkers, Tumor;DNA, Viral",
        "Doc_meshdescriptors":"Adolescent;Adult;Analysis of Variance;Biomarkers, Tumor;Biopsy, Needle;Carcinoma, Squamous Cell;Cohort Studies;DNA, Viral;Disease-Free Survival;Female;Gene Expression Regulation, Neoplastic;Genes, p16;Humans;Immunohistochemistry;Male;Neoplasm Recurrence, Local;Neoplasm Staging;Papillomaviridae;Papillomavirus Infections;Polymerase Chain Reaction;Prognosis;Proportional Hazards Models;Retrospective Studies;Risk Assessment;Serologic Tests;Statistics, Nonparametric;Survival Analysis;Tongue Neoplasms;Young Adult",
        "Doc_meshqualifiers":"analysis;genetics;mortality;pathology;therapy;analysis;genetics;mortality;pathology;genetics;isolation & purification;complications;diagnosis;methods;genetics;mortality;pathology;therapy",
        "_version_":1605794709146435584},
      {
        "Doc_abstract":"HBP1 is a sequence-specific DNA-binding transcription factor with many important biological roles. It activates or represses the expression of some specific genes during cell growth and differentiation. Previous studies have exhibited that HBP1 binds to p16(INK4A) promoter and activates p16(INK4A) expression. We found that trichostatin A (TSA), an inhibitor of HDAC (histone deacetylase), induces p16(INK4A) expression in an HBP1-dependent manner. This result was drawn from a transactivation experiment by measuring relative luciferase activities of p16(INK4A) promoter with HBP1-binding site in comparison with that of the wild-type p16(INK4A) promoter by transient cotransfection with HBP1 into HEK293T cells and 2BS cells. HBP1 acetylation after TSA treatment was confirmed by immunoprecipitation assay. Our data showed that HBP1 interacted with histone acetyltransferase p300 and CREB-binding protein (CBP) and also recruited p300/CBP to p16(INK4A) promoter. HBP1 was acetylated by p300/CBP in two regions: repression domain (K297/305/307) and P domain (K171/419). Acetylation of Repression domain was not required for HBP1 transactivation on p16(INK4A). However, luciferase assay and western blotting results indicate that acetylation of P domain, especially K419 acetylation is essential for HBP1 transactivation on p16(INK4A). As assayed by SA-beta-gal staining, the acetylation of HBP1 at K419 enhanced HBP1-induced premature senescence in 2BS cells. In addition, HDAC4 repressed HBP1-induced premature senescence through permanently deacetylating HBP1. We conclude that our data suggest that HBP1 acetylation at K419 plays an important role in HBP1-induced p16(INK4A) expression.",
        "Doc_title":"The acetylation of transcription factor HBP1 by p300/CBP enhances p16INK4A expression.",
        "Journal":"Nucleic acids research",
        "Do_id":"21967847",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;HBP1 protein, human;High Mobility Group Proteins;Histone Deacetylase Inhibitors;Hydroxamic Acids;Repressor Proteins;trichostatin A;DNA;CREB-Binding Protein;p300-CBP Transcription Factors;p300-CBP-associated factor;HDAC4 protein, human;Histone Deacetylases;Lysine",
        "Doc_meshdescriptors":"Acetylation;CREB-Binding Protein;Cell Aging;Cell Line;Cyclin-Dependent Kinase Inhibitor p16;DNA;High Mobility Group Proteins;Histone Deacetylase Inhibitors;Histone Deacetylases;Humans;Hydroxamic Acids;Lysine;Promoter Regions, Genetic;Protein Structure, Tertiary;Repressor Proteins;Transcriptional Activation;p300-CBP Transcription Factors",
        "Doc_meshqualifiers":"metabolism;genetics;metabolism;chemistry;metabolism;pharmacology;metabolism;pharmacology;metabolism;chemistry;metabolism;metabolism",
        "_version_":1605832346037125120},
      {
        "Doc_abstract":"Human astrocytomas frequently have allelic losses of chromosome 9p, suggesting the presence of a 9p astrocytoma tumor suppressor gene. The MTS1 (or CDKN2) gene on chromosome 9p encodes a cell-cycle regulator and is deleted in approximately 80% of astrocytoma cell lines. To determine whether MTS1 is the tumor suppressor gene involved in human astrocytoma formation in vivo, we have analyzed chromosome 9p allelic loss and the MTS1 gene in 30 primary astrocytomas. Deletion mapping demonstrated 15 cases with allelic loss of chromosome 9p, with all losses either flanking or involving the MTS1 gene. Direct analysis of the MTS1 gene, however, revealed only a single missense mutation in a high-grade tumor that had lost the second allele. The low frequency of MTS1 mutations in primary astrocytomas with allelic 9p loss suggests that MTS1 may be more important for in vitro than in vivo astrocytoma growth, and that another 9p tumor suppressor gene may be involved in astrocytoma formation in vivo. Analysis of the MTS1 gene also demonstrated two intragenic polymorphisms, one in exon 2 and one in the 3' untranslated region, that can be used to assay allelic loss directly at MTS1.",
        "Doc_title":"MTS1/CDKN2 gene mutations are rare in primary human astrocytomas with allelic loss of chromosome 9p.",
        "Journal":"Human molecular genetics",
        "Do_id":"7849711",
        "Doc_ChemicalList":"Carrier Proteins;Cyclin-Dependent Kinase Inhibitor p16;DNA Primers;Genetic Markers",
        "Doc_meshdescriptors":"Alleles;Astrocytoma;Base Sequence;Carrier Proteins;Chromosome Deletion;Chromosome Mapping;Chromosomes, Human, Pair 9;Cyclin-Dependent Kinase Inhibitor p16;DNA Primers;Exons;Genes, Tumor Suppressor;Genetic Markers;Humans;Molecular Sequence Data;Polymerase Chain Reaction;Polymorphism, Genetic;Polymorphism, Restriction Fragment Length;Reference Values",
        "Doc_meshqualifiers":"genetics;genetics",
        "_version_":1605741949109665794},
      {
        "Doc_abstract":"The p16INK4A tumor suppressor gene is frequently inactivated in non-small cell lung carcinoma (NSCLC) and is less frequently inactivated in small cell lung carcinoma (SCLC) by mutation, deletion or DNA methylation. There are several reports that the reintroduction of the p16INK4A gene into p16(-) NSCLC cells results in significant growth suppression. However, there have been no reports of reintroduction of the p16INK4A gene into SCLC cells. To assess the biological significance of p16INK4A inactivation in the development of SCLC, full-length p16INK4A cDNA was introduced into an SCLC cell line, Ms-13, in which the p16INK4A protein was not detected. SCLC cells stably transfected with the p16INK4A expression vector formed only 2-16% of the number of neomycin-resistant colonies formed by cells transfected with a control vector, and no expression of exogenous p16INK4A protein was detected in any of 16 expanded clones. Transient transfection of the p16INK4A gene into SCLC cells resulted in exogeneous p16INK4A protein expression and dephosphorylation of endogenous retinoblastoma (RB) protein. These results suggest that the restoration of the p16INK4A function suppresses the growth of SCLC cells by dephosphorylation of the RB protein. Therefore, inactivation of p16INK4A may play an important role in the enhancement of growth of p16INK4A(-) RB(+) SCLC tumors in vivo.",
        "Doc_title":"Activation of RB tumor suppressor protein and growth suppression of small cell lung carcinoma cells by reintroduction of p16INK4A gene.",
        "Journal":"International journal of oncology",
        "Do_id":"10339660",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;Growth Inhibitors;Retinoblastoma Protein",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Carcinoma, Small Cell;Cyclin-Dependent Kinase Inhibitor p16;Female;Gene Expression Regulation, Neoplastic;Genes, p16;Genetic Therapy;Growth Inhibitors;Humans;Lung Neoplasms;Male;Middle Aged;Phosphorylation;Retinoblastoma Protein;Transfection;Tumor Cells, Cultured",
        "Doc_meshqualifiers":"genetics;metabolism;pathology;prevention & control;biosynthesis;genetics;physiology;genetics;genetics;metabolism;pathology;prevention & control;biosynthesis;genetics;metabolism;physiology",
        "_version_":1605880801381056512},
      {
        "Doc_abstract":"p16(INK4a) immunoprofiles of non-precancerous and dysplastic squamous cervical lesions were defined and applied to the reclassification of atypical immature squamous metaplasia (AIM). The immunoexpression of cytokeratin 17 (CK 17) in AIM was also evaluated. Totally, 295 cervical cone biopsies representing squamous metaplasia, reactive changes, koilocytosis, flat condyloma, CIN I, CIN II, CIN III and AIM were subjected to p16(INK4a) immunohistochemistry. AIM cases were analyzed using CK 17 antibody. Typical p16(INK4a) immunoprofiles for the metaplastic, LSIL/HPV and HSIL phenotypes were recorded and used for the categorization of AIM into particular phenotype groups. Results were correlated with CK 17 immunoexpression. All CIN II and CIN III lesions, all but one case of CIN I and all flat condylomas overexpressed p16(INK4a). Other non-precancerous lesions, including koilocytosis, were predominantly negative. Contrary to the sporadic and focal immunostaining, diffuse positivity was associated with the dysplastic features of the lesion. CIN II and CIN III were characterized by a diffuse, strong/weak, full-thickness staining, whereas CIN I showed a heterogeneous diffuse/focal, weak/strong, lower half positivity. One third of AIM lesions may be reclassified as HSIL, one third as LSIL/HPV and one third shows metaplastic phenotype. All AIM cases with metaplastic and LSIL/HPV phenotypes expressed CK 17 diffusely, whereas focal positivity slightly prevailed in AIM with HSIL phenotype. We conclude that p16(INK4a) immunohistochemistry is a supporting method for the differential diagnosis of cervical lesions, which may be especially useful for the reclassification of AIM. The efficacy of CK 17 immunohistochemistry seems to be controversial for these purposes. ",
        "Doc_title":"p16(INK4a) immunoprofiles of squamous lesions of the uterine cervix-implications for the reclassification of atypical immature squamous metaplasia.",
        "Journal":"Pathology oncology research : POR",
        "Do_id":"23686439",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16",
        "Doc_meshdescriptors":"Cyclin-Dependent Kinase Inhibitor p16;Female;Humans;Keratin-17;Metaplasia;Uterine Cervical Dysplasia;Uterine Cervical Neoplasms",
        "Doc_meshqualifiers":"metabolism;metabolism;metabolism;metabolism;pathology;metabolism;pathology",
        "_version_":1605792030334648320},
      {
        "Doc_abstract":"The reported prevalence for presence of human papillomavirus (HPV) genome in lung cancer varies across the world, and limited data are available for North America. P16 immunostaining is used as a surrogate marker for the presence of HPV in cervical and head and neck cancers. In non-small cell lung carcinoma (NSCLC), the association between P16 protein overexpression and HPV remains unclear. We investigated the presence of HPV genome by in situ hybridization (ISH) and polymerase chain reaction (PCR) and P16 or Rb protein expression by immunohistochemistry (IHC) in 336 surgically resected primary NSCLC: 204 adenocarcinoma (AdC) and 132 squamous cell carcinoma (SqCC). HPV genome was detected in 5 (1.5%) of 336 tumors studied by both ISH and PCR; all of them were typed as HPV16 and found in SqCC (3.8%). Despite being solitary tumors and clinically considered as primary lung cancers, all 5 patients had past history of HPV associated squamous cell carcinomas of other organ sites, thus highly suggestive of being metastases. P16 immunostaining was found in 137 (40.8%) tumors, with 109 (32.4%) showing high level expression. All HPV positive (+) cases showed P16 high expression. P16 and Rb protein expressions were inversely correlated (P<0.001), suggesting that the high P16 expression is largely driven by non-HPV loss of Rb protein expression. We conclude that HPV is not or rarely associated with NSCLC in Canadian and most likely North American patients, and P16 immunostaining is not a surrogate marker for its presence.",
        "Doc_title":"Human papilloma virus genome is rare in North American non-small cell lung carcinoma patients.",
        "Journal":"Lung cancer (Amsterdam, Netherlands)",
        "Do_id":"23254264",
        "Doc_ChemicalList":"DNA, Viral;Neoplasm Proteins;P16 protein, human",
        "Doc_meshdescriptors":"Aged;Aged, 80 and over;Carcinoma, Non-Small-Cell Lung;DNA, Viral;Female;Genome, Viral;Head and Neck Neoplasms;Humans;Lung Neoplasms;Male;Middle Aged;Neoplasm Proteins;North America;Papillomaviridae;Papillomavirus Infections;Prevalence;Uterine Cervical Neoplasms",
        "Doc_meshqualifiers":"virology;analysis;genetics;epidemiology;virology;virology;genetics;genetics;isolation & purification;epidemiology;virology;epidemiology;virology",
        "_version_":1605830304139837440},
      {
        "Doc_abstract":"Cyclin-dependent kinase-4 inhibitor genes (INK4) regulate the cell cycle and are candidate tumor-suppressor genes. To determine if alterations in the coding regions of the p18 and p19 genes, which are novel members of the INK4 family and if they correlate with the development of human cancer, 100 human cancer cell lines were analyzed. Two other INK4 gene family members, p15INK4b/MTS2 and p16INK4/MTS1 genes were also analyzed. Homozygous deletions of the p15INK4b/MTS2 gene were detected in 29 cancer cell lines. Thirty-five homozygous deletions and 7 intragenic mutations of the pl6INK4/MTS1 gene were also detected in these cell lines. Neither homozygous deletions nor intragenic mutations of the p18 and p19 genes were found except in an ovarian cancer cell line, SKOV3, harboring a single base pair deletion in exon 1 of p19. In p16INK4/MTS1 expression analysis, 5 cell lines with both authentic and alternative spliced p16INK4/MTS1 mRNA had no detectable p16INK4/MTS1 protein. These results suggest the hypotheses that either post-translational modification or enhanced degradation may be responsible for the lack of detection of the p16INK4/MTS1 protein. Using Western blot analysis, subsets of 26 human cancer cell lines were examined for p18 expression and 39 cell lines for p19 expression. All of these cell lines expressed the p18 or p19 protein, with the exception of SKOV3, which did not express p19. Therefore, the INK4 gene family may be divided into 2 groups. One group includes p15INK4b/MTS2 and p16INK4/MTS1, in which genetic and epigenetic alterations might contribute to the development of human cancers. The other group includes p18 and p19, in which somatic mutations are uncommon in many types of human cancer, and their role in human carcinogenesis and cancer progression is uncertain.",
        "Doc_title":"Molecular analysis of the cyclin-dependent kinase inhibitor genes p15INK4b/MTS2, p16INK4/MTS1, p18 and p19 in human cancer cell lines.",
        "Journal":"International journal of cancer",
        "Do_id":"8938142",
        "Doc_ChemicalList":"CDKN2D protein, human;Carrier Proteins;Cell Cycle Proteins;Cyclin-Dependent Kinase Inhibitor p16;Cyclin-Dependent Kinase Inhibitor p19;Enzyme Inhibitors;Cyclin-Dependent Kinases",
        "Doc_meshdescriptors":"Carrier Proteins;Cell Cycle Proteins;Cyclin-Dependent Kinase Inhibitor p16;Cyclin-Dependent Kinase Inhibitor p19;Cyclin-Dependent Kinases;Enzyme Inhibitors;Gene Expression Regulation, Neoplastic;Humans;Tumor Cells, Cultured",
        "Doc_meshqualifiers":"genetics;antagonists & inhibitors",
        "_version_":1605844742020530176},
      {
        "Doc_abstract":"Pancreatic cancer is one of the most lethal of all the common gastrointestinal malignancies. Although surgery offers the best chance for survival, it is not appropriate for all cases. The only adjuvant treatment to show promise is chemotherapy. Hence new treatments are urgently sought. We previously reported that adenoviral (Ad)-mediated delivery of p53 (Adp53) and p16(INK4A) (Adp16) significantly inhibited the growth of pancreatic cancer cell lines and established subcutaneous pancreatic tumours in nude mice (Ghaneh P, et al. Adenovirus mediated transfer of p53 and p16INK4A results in pancreatic cancer regression in vitro and in vivo. Gene Ther 2001; 8: 199-208). In this study we examine whether combining Ad-mediated delivery of p53 or p16(INK4A) with clinically relevant chemotherapeutic drugs has therapeutic potential for pancreatic cancer.;Four pancreatic adenocarcinoma cell lines were evaluated for their sensitivity to 5-fluorouracil (5-FU) and gemcitabine and two of these, Suit-2 and Panc-1, were chosen for combination experiments because they showed moderate and poor sensitivity, respectively, to 5-FU and gemcitabine. We found no evidence for enhanced cytotoxicity when either cell line was transduced with Adp53 before or after incubation with chemotherapeutic drugs. In contrast, incubation of Panc-1 cells with either 5-FU or gemcitabine followed by Ad-mediated overexpression of p16(INK4A) resulted in a substantial reduction in cell viability under conditions where the drugs alone had minimal cytotoxicity. Incubation of Suit-2 cells with 5-FU followed by Ad-mediated overexpression of p16(INK4A) also resulted in a significant reduction in cell viability. This, however, was observed only with higher concentrations of 5-FU and viral vector. Cell cycle analysis of Panc-1 cells showed that the combination of cytotoxic drugs and Adp16 resulted in an increase in the sub-G1 population suggesting an increase in apoptosis. Dual labelling of these cells with annexin V and propidium iodide (PI) confirmed that the combination of 5-FU and Adp16 resulted in a significant increase in early apoptotic cells (annexin V positive and PI negative) compared with controls. Moreover, overexpression of p16(INK4A) was associated with a reduction in pRb levels in these cells-high levels of pRb have been proposed to contribute to chemoresistance in pancreatic cancer cells.;We have shown that the currently used chemotherapeutic drugs for pancreatic adenocarcinoma combined with restoration of p16(INK4A) expression hold promise for the adjuvant treatment of this disease. Importantly, the combination facilitated the use of chemotherapeutic drugs at lower concentrations than would otherwise be effective.",
        "Doc_title":"5-Fluorouracil or gemcitabine combined with adenoviral-mediated reintroduction of p16INK4A greatly enhanced cytotoxicity in Panc-1 pancreatic adenocarcinoma cells.",
        "Journal":"The journal of gene medicine",
        "Do_id":"15133762",
        "Doc_ChemicalList":"Antimetabolites, Antineoplastic;Cyclin-Dependent Kinase Inhibitor p16;Retinoblastoma Protein;Tumor Suppressor Protein p53;Deoxycytidine;gemcitabine;Fluorouracil",
        "Doc_meshdescriptors":"Adenocarcinoma;Adenoviridae;Antimetabolites, Antineoplastic;Apoptosis;Cell Line, Tumor;Cell Proliferation;Cyclin-Dependent Kinase Inhibitor p16;Deoxycytidine;Fluorouracil;Gene Transfer Techniques;Genetic Vectors;Humans;Pancreatic Neoplasms;Retinoblastoma Protein;Tumor Suppressor Protein p53",
        "Doc_meshqualifiers":"genetics;pharmacology;drug effects;drug effects;biosynthesis;genetics;analogs & derivatives;pharmacology;pharmacology;biosynthesis;biosynthesis",
        "_version_":1605752580657381376},
      {
        "Doc_abstract":"We evaluated the clinical significance of p16 and Ki-67 expressions in esophageal squamous cell carcinomas. Operative specimens obtained from 64 patients with esophageal squamous cell carcinomas were investigated by staining with antibodies against p16 and Ki-67. The possible correlations among p16 and Ki-67 expression, clinicopathologic factors and prognosis were studied. The expression of p16 was observed in 68.9%, and it related to histologic classification, lymphatic invasion and clinicopathological stage. Survival rate was significantly better in the patients with p16 positive tumors than in those with p16 negative tumors. Ki-67 positive index (Ki-67-PI) related to only histologic classification. It is suggested that immunohistochemical assessment on the p16 expressions would be useful to select more suitable treatment of squamous cell carcinoma of the esophagus.",
        "Doc_title":"[Immunohistochemical study of p16MTS1/INK4a and Ki-67 expression in esophageal squamous cell carcinomas].",
        "Journal":"Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology",
        "Do_id":"10047686",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;Ki-67 Antigen",
        "Doc_meshdescriptors":"Aged;Carcinoma, Squamous Cell;Cyclin-Dependent Kinase Inhibitor p16;Esophageal Neoplasms;Female;Humans;Immunohistochemistry;Ki-67 Antigen;Lymphatic Metastasis;Male;Middle Aged",
        "Doc_meshqualifiers":"metabolism;secondary;genetics;metabolism;metabolism;pathology;metabolism",
        "_version_":1605899273179758592},
      {
        "Doc_abstract":"Salivary gland tumors (SGT) are a heterogeneous group of lesions. There is conflicting data concerning the molecular events involving the tumour suppressor retinoblastoma protein (pRb) pathway in these tumors. Few studies examined the alterations in components of the Rb pathway by immunohistochemical (IHC) methods in benign and malignant SGTs. Furthermore, recent evidence implicates human papillomavirus (HPV) in mucoepidermoid carcinoma (MEC) carcinogenesis. The purpose of our study is to examine p16(INK4A) and cyclin D1 expression in a variety of benign and malignant salivary gland tumors, and to investigate p16(INK4A) expression as a surrogate marker for HPV infection in MEC. Our series includes 30 malignant tumors [14 MEC, 6 acinic cell carcinomas (ACC), 5 polymorphous low grade adenocarcinomas (PLGA), 5 (AdCC)] and 14 benign tumors (4 benign cysts, 5 Warthin tumors and 5 pleomorphic adenomas (PA). All cases were tested by IHC for p16(INK4A) and cyclin D1. Testing for HPV wide spectrum (HPV-WS) was performed by in situ hybridization in all MEC cases. Staining intensity was recorded semi quantitatively (on a scale from 0 to 4+). Fisher's exact test and Pearson X2 test with a p < 0.05 were used. Cyclin D1 and p16(INK4A) are expressed similarly in malignant and benign tumors (p = 0.146 and p = 0.543, respectively). None of the MEC cases showed nuclear reactivity for HPV-WS. Statistical analysis showed positive correlation between cyclin D1 and p16(INK4A) expression. Our findings suggest that p16(INK4A) overexpression is likely secondary to cyclin D1 gene upregulation or amplification. Further molecular studies are warranted.",
        "Doc_title":"Differential expression of p16(INK4A) and cyclin D1 in benign and malignant salivary gland tumors: a study of 44 Cases.",
        "Journal":"Head and neck pathology",
        "Do_id":"23315417",
        "Doc_ChemicalList":"Biomarkers, Tumor;Cyclin-Dependent Kinase Inhibitor p16;Cyclin D1",
        "Doc_meshdescriptors":"Adolescent;Adult;Aged;Biomarkers, Tumor;Cyclin D1;Cyclin-Dependent Kinase Inhibitor p16;Female;Humans;Immunohistochemistry;Male;Middle Aged;Salivary Gland Neoplasms;Young Adult",
        "Doc_meshqualifiers":"analysis;analysis;biosynthesis;analysis;biosynthesis;metabolism;pathology",
        "_version_":1605762320251748352},
      {
        "Doc_abstract":"The p16(INK4a) cell cycle regulator is one of the best ageing biomarkers because it is suppressed in early embryogenesis and progressively induced during ageing. p16(INK4a) plays a crucial role in key cell fate decisions which contribute to ageing, such as cellular senescence and stem cell dynamics. Detailed examination of the pathways regulating p16(INK4a) expression has revealed an overlap with those regulating early development. We present the hypothesis that ageing might be primarily driven by gradual functional decay of developmental pathways. To support this, we summarise the role of p16(INK4a) in ageing and our current knowledge on p16(INK4a) regulation. The developmental decay hypothesis implies that the much-evidenced damage associated with all aspects of ageing might be secondary to such decay. ",
        "Doc_title":"Ageing as developmental decay: insights from p16(INK4a.).",
        "Journal":"Trends in molecular medicine",
        "Do_id":"25277993",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;Genetic Markers",
        "Doc_meshdescriptors":"Aging;Animals;Cell Aging;Cyclin-Dependent Kinase Inhibitor p16;Epigenetic Repression;Gene Expression Regulation, Developmental;Genetic Loci;Genetic Markers;Humans;Models, Animal",
        "Doc_meshqualifiers":"physiology;physiology;genetics;physiology",
        "_version_":1605792737408319488},
      {
        "Doc_abstract":"The p53 tumor suppressor gene plays an important role in preventing tumor development. The p53 protein interacts with other p53 signal pathway members to control cell proliferation. In this study, expression of the p53, Human homolog of murine Double Minute 2 (HDM2), p14Alternating Reading Frame (ARF), Zinc Finger and BTB domain containing 7A (ZBTB7A), and B-Cell Lymphoma 6 (BCL6) genes was quantitatively investigated by real-time polymerase chain reaction (PCR) in the peripheral blood of patients with chronic lymphocytic leukemia (CLL) and healthy controls. Plasma fibronectin levels were determined by enzyme-linked immunosorbent assay. Expression of the p53, p14, and HDM2 genes were significantly higher in the patients. However, ZBTB7A and BCL6 gene expression was not detectable in both groups. A positive correlation between p14ARF and HDM2 expression and a negative correlation between p53 and p14ARF expression was observed. Expression of the p14ARF and HDM2 genes were inversely correlated in the control group. Neither HDM2 nor p14ARF gene expression was correlated with p53 expression. The p53 gene was also analyzed for the presence of mutations. A splice-site mutation was found in a single patient. Our findings indicate that expression of the p53, p14ARF, and HDM2 genes are associated with CLL. Elucidation of the mutual interactions at the protein level warrants further studies.",
        "Doc_title":"Analysis of p53 tumor suppressor pathway genes in chronic lymphocytic leukemia.",
        "Journal":"DNA and cell biology",
        "Do_id":"22047081",
        "Doc_ChemicalList":"Fibronectins;TP53 protein, human;Tumor Suppressor Protein p14ARF;Tumor Suppressor Protein p53;DNA;MDM2 protein, human;Proto-Oncogene Proteins c-mdm2",
        "Doc_meshdescriptors":"Case-Control Studies;DNA;Female;Fibronectins;Genotype;Humans;Leukemia, Lymphocytic, Chronic, B-Cell;Middle Aged;Neoplasm Staging;Polymerase Chain Reaction;Polymorphism, Genetic;Prognosis;Proto-Oncogene Proteins c-mdm2;Risk Factors;Tumor Suppressor Protein p14ARF;Tumor Suppressor Protein p53",
        "Doc_meshqualifiers":"genetics;blood;genetics;genetics;genetics;genetics;genetics",
        "_version_":1605796791193698304},
      {
        "Doc_abstract":"Inactivation of the retinoblastoma (Rb) protein caused by gene mutation, association with oncoproteins from small DNA viruses, mutational inactivation of p16(Ink4a), or overexpression of cyclin D is a common feature of many human cancer cells and is causally associated with the aberrant proliferation control of cancer cells; whereas normal cells maintain an integrated cell cycle machinery and are subject to cell cycle checkpoint control by cyclin-dependent kinase (CDK) inhibitors (CKIs). To determine whether this difference can be translated into a therapeutic advantage to protect normal cells from adverse cytotoxicity caused by chemotherapy, we established cell model systems for ecdysone-inducible expression of p16(Ink4a), p21(Waf1), and p27(Kip1) in one CKI-responsive cell line (A431 human vulvar epidermoid carcinoma cells with functional Rb) and one CKI-unresponsive cell line (SiHa human cervical cancer cells with nonfunctional Rb). Expression of p16(Ink4a), p21(Waf1), or p27(Kip1) in both SiHa and A431 cells strongly inhibited CDK2 activity, indicating functional expression of the CDK inhibitors in both cell lines. However, only in A431 cells did expression of p16(Ink4a), p21(Waf1), or p27(Kip1) cause Rb dephosphorylation, arrest cell cycle traversal, and potently inhibit cell proliferation. Induction of p16(Ink4a), p21(Waf1), or p27(Kip1) in SiHa cells failed to cause Rb dephosphorylation or to arrest cell cycle traversal, and such induction only minimally inhibited cell proliferation. We then compared the chemosensitivity of clones derived from these two cell lines when the CKIs were and were not induced. Induction of p16(Ink4a), p21(Waf1), or p27(Kip1) conferred strong resistance to paclitaxel- or cisplatin-mediated cytotoxicity on the CKI-responsive A431 cells but not on the CKI-unresponsive SiHa cells. Our results support a novel chemotherapy strategy for treating patients with Rb pathway-impaired cancers by concurrent administration of chemotherapy with CKIs as chemoprotective agents for normal cells.",
        "Doc_title":"Protection against chemotherapy-induced cytotoxicity by cyclin-dependent kinase inhibitors (CKI) in CKI-responsive cells compared with CKI-unresponsive cells.",
        "Journal":"Oncogene",
        "Do_id":"11593424",
        "Doc_ChemicalList":"CDKN1A protein, human;Cell Cycle Proteins;Coloring Agents;Cyclin-Dependent Kinase Inhibitor p16;Cyclin-Dependent Kinase Inhibitor p21;Cyclins;DNA, Complementary;Enzyme Inhibitors;Retinoblastoma Protein;Tetrazolium Salts;Thiazoles;Tumor Suppressor Proteins;Cyclin-Dependent Kinase Inhibitor p27;Ecdysone;thiazolyl blue;Paclitaxel;Cisplatin",
        "Doc_meshdescriptors":"Cell Cycle Proteins;Cell Division;Cisplatin;Coloring Agents;Cyclin-Dependent Kinase Inhibitor p16;Cyclin-Dependent Kinase Inhibitor p21;Cyclin-Dependent Kinase Inhibitor p27;Cyclins;DNA Mutational Analysis;DNA, Complementary;Dose-Response Relationship, Drug;Ecdysone;Enzyme Inhibitors;Flow Cytometry;Humans;Immunoblotting;Mutation;Paclitaxel;Phosphorylation;Promoter Regions, Genetic;Retinoblastoma Protein;Tetrazolium Salts;Thiazoles;Tumor Cells, Cultured;Tumor Suppressor Proteins",
        "Doc_meshqualifiers":"metabolism;pharmacology;pharmacology;metabolism;metabolism;metabolism;genetics;pharmacology;pharmacology;metabolism;pharmacology;pharmacology",
        "_version_":1605893399957733376},
      {
        "Doc_abstract":"In the thymus, T cell development proceeds by successive steps of differentiation, expansion, and selection. Control of thymocyte proliferation is critical to insure the full function of the immune system and to prevent T cells from transformation. Deletion of the cell cycle inhibitor p16(INK4a) is frequently observed in human T cell neoplasias and, in mice, gene targeted inactivation of the Ink4a locus enhances thymocyte expansion and predisposes mutant animal to tumorigenesis. Here, we investigate the mechanism by which p16(Ink4a) controls thymocyte development by analyzing transgenic mice expressing the human p16(INK4a) into the T cell lineage. We show that forced expression of p16(INK4a) in thymocytes blocked T cell differentiation at the early CD4-CD8-CD3-CD25+ stage without significantly affecting the development of gammadelta T cells. Pre-TCR function was mimicked by the induction of CD3 signaling in thymocytes of recombinase activating gene (RAG)-2-deficient mice (RAG-2(-/-)). Upon anti-CD3epsilon treatment in vivo, p16(INK4a)-expressing RAG-2(-/-) thymocytes were not rescued from apoptosis, nor could they differentiate. Our data demonstrate that expression of p16(INK4a) prevents the pre-TCR-mediated expansion and/or survival of differentiating thymocytes.",
        "Doc_title":"Transgenic expression of the p16(INK4a) cyclin-dependent kinase inhibitor leads to enhanced apoptosis and differentiation arrest of CD4-CD8- immature thymocytes.",
        "Journal":"Journal of immunology (Baltimore, Md. : 1950)",
        "Do_id":"11859122",
        "Doc_ChemicalList":"Antibodies;Antigens, CD3;CD3 antigen, zeta chain;Cyclin-Dependent Kinase Inhibitor p16;DNA-Binding Proteins;Nuclear Proteins;RAG2 protein, human;Rag2 protein, mouse;Receptors, Antigen, T-Cell, gamma-delta;V(D)J recombination activating protein 2;RNA",
        "Doc_meshdescriptors":"Animals;Antibodies;Antigens, CD3;Apoptosis;CD4-Positive T-Lymphocytes;CD8-Positive T-Lymphocytes;Cell Differentiation;Cells, Cultured;Cyclin-Dependent Kinase Inhibitor p16;DNA-Binding Proteins;HeLa Cells;Humans;Lymphocyte Activation;Mice;Mice, Knockout;Mice, Transgenic;Nuclear Proteins;RNA;Receptors, Antigen, T-Cell, gamma-delta;Signal Transduction;T-Lymphocytes;Thymus Gland",
        "Doc_meshqualifiers":"immunology;immunology;immunology;immunology;genetics;metabolism;physiology;genetics;analysis;analysis;immunology;immunology",
        "_version_":1605840059317092352},
      {
        "Doc_abstract":"To investigate immunoexpression of P14ARF protein in non-small cell lung cancer (NSCLC) and to evaluate the prognostic significance.;Thirty-nine tumor specimens were immunohistochemically examined with FL-132 antibody against P14ARF protein.;P14 nuclei immunoexpression was found in 25 tumor specimens (64.1%). The patients in stage I and II had a much higher P14 expression rate than the patients in stage III and IV [78.0%(18/23) vs 43.8%(7/16) P =0.043]. The P14 expression rate in patients with and without metastasis was 78.3%(18/23) and 43.8%(7/16) respectively (P=0.043). The mean survival time of patients without P14-immunopositive staining was significantly shorter than that of patients with P14-immunopositive staining (17 months vs 45 months, P=0.023 5).;Patients with the expression of P14ARF protein have a better prognosis. Detection of P14ARF protein in lung cancer tissues may be helpful to predict the prognosis of NSCLC.",
        "Doc_title":"[Immunohistochemical analysis of P14ARF protein expression in non-small cell lung cancer: its prognostic significance].",
        "Journal":"Zhongguo fei ai za zhi = Chinese journal of lung cancer",
        "Do_id":"21272483",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605842677184593920},
      {
        "Doc_abstract":"We recently reported that the vast majority (>90%) of low-grade diffuse gliomas (diffuse astrocytoma, oligoastrocytoma and oligodendroglioma) carry at least one of the following genetic alterations: IDH1/2 mutation, TP53 mutation or 1p/19q loss. Only 7% of cases were triple-negative (ie, lacking any of these alterations). In the present study, array comparative genomic hybridization (CGH) in 15 triple-negative WHO grade II gliomas (eight diffuse astrocytomas and seven oligodendrogliomas) showed loss at 9p21 (p14(ARF) , p15(INK4b) , p16(INK4a)  loci) and 13q14-13q32 (containing the RB1 locus) in three and two cases, respectively. Further analyses in 31 triple-negative cases as well as a total of 160 non-triple-negative cases revealed that alterations in the RB1 pathway (homozygous deletion and promoter methylation of the p15(INK4b) , p16(INK4a)  and RB1 genes) were significantly more frequent in triple-negative (26%) than in non-triple-negative cases (11%; P=0.0371). Multivariate analysis after adjustment for age, histology and treatment showed that RB1 pathway alterations were significantly associated with unfavorable outcome for patients with low-grade diffuse glioma [hazard ratio, 3.024 (1.279-6.631); P=0.0057]. These results suggest that a fraction of low-grade diffuse gliomas lacking common genetic alterations may develop through a distinct genetic pathway, which may include loss of cell-cycle control regulated by the RB1 pathway.",
        "Doc_title":"Alterations in the RB1 pathway in low-grade diffuse gliomas lacking common genetic alterations.",
        "Journal":"Brain pathology (Zurich, Switzerland)",
        "Do_id":"21470325",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p15;Retinoblastoma Protein",
        "Doc_meshdescriptors":"Adult;Aged;Brain Neoplasms;Child;Child, Preschool;Comparative Genomic Hybridization;Cyclin-Dependent Kinase Inhibitor p15;DNA Methylation;Female;Genes, p16;Glioma;Humans;Kaplan-Meier Estimate;Male;Middle Aged;Polymerase Chain Reaction;Promoter Regions, Genetic;Retinoblastoma Protein;Signal Transduction;Young Adult",
        "Doc_meshqualifiers":"genetics;metabolism;mortality;genetics;genetics;genetics;metabolism;mortality;genetics;genetics;metabolism;genetics",
        "_version_":1605820125962829824},
      {
        "Doc_abstract":"Glucocorticoids inhibit proliferation of many cell types, but the relationship between the glucocorticoid receptor (GR) and the proteins regulating cell cycle progression is not fully understood. We previously found that during fibrosarcoma (FS) progression, GR displays only modest transcriptional activity in the preneoplastic stages, whereas it is highly active in FS cells. Now, we report that glucocorticoids reduce proliferation throughout FS development. The cyclin-dependent kinase inhibitor p16(INK4a) is frequently absent in many cancers, including FSs. We observed that p16(INK4a) protein expression is lost at the tumor stage of FS progression. Treatment with the demethylating agent 5-aza-2'-deoxycytidine restores p16(INK4a) expression and reverts the phenotype of FS cells to low GR transcriptional activity, similar to that of the p16(INK4a)-expressing preneoplastic stages. Importantly, exogenous p16(INK4a) introduced by cotransfection is sufficient to reduce GR activity in FS cells, without affecting GR activity in p16-positive aggressive fibromatosis cells. Furthermore, GR transcriptional activity is elevated in mouse embryo fibroblasts derived from INK4a(-/-) mice compared with those derived from WT mice, implying that the difference in p16(INK4a) expression is sufficient to modulate GR activity. These results suggest a relationship between steroid hormone receptor activity and cell cycle inhibition, whereby absence of p16(INK4a) protein leads to higher GR transactivation activity and reduced cell sensitivity to dexamethasone. This observation might have important implications for current cancer therapies.",
        "Doc_title":"Loss of p16INK4a results in increased glucocorticoid receptor activity during fibrosarcoma development.",
        "Journal":"Proceedings of the National Academy of Sciences of the United States of America",
        "Do_id":"12624188",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;DNA, Neoplasm;Receptors, Glucocorticoid;Dexamethasone",
        "Doc_meshdescriptors":"Animals;Base Sequence;Cell Division;Cyclin-Dependent Kinase Inhibitor p16;DNA Methylation;DNA, Neoplasm;Dexamethasone;Fibrosarcoma;Genes, p16;Mice;Precancerous Conditions;Receptors, Glucocorticoid;Transcriptional Activation;Tumor Cells, Cultured",
        "Doc_meshqualifiers":"drug effects;deficiency;genetics;metabolism;chemistry;genetics;pharmacology;etiology;genetics;metabolism;etiology;genetics;metabolism;genetics;metabolism",
        "_version_":1605742643741982721},
      {
        "Doc_abstract":"There is controversy as to whether esophageal squamous dysplasia is a pre-cancerous lesion or a non-cancerous lesion. In this study, we conducted an immunohistochemical investigation of cyclin D1, retinoblastoma (Rb), p16INK4 and p27KIP1 expression in 36 squamous dysplasias and 34 early squamous cell carcinomas of the esophagus. The frequency of cyclin D1 overexpression was similar in dysplasias and early cancers (30% vs. 35%). Loss of p16INK4 and p27KIP1 expression was less frequent in dysplasias than in early cancers (p=0.005 and 0.001, respectively). Loss of Rb protein expression was not detected in dysplasia and rarely observed in early cancer (7%). The proliferation cell nuclear antigen index increased from moderate dysplasia to mucosal invasive carcinoma and was correlated significantly with the expression of cyclin D1, p16INK4 and p27KIP1 (p=0.0001, 0.003, and 0.007, respectively). Thus, this study found that cyclin D1 overexpression starts early in dysplasia and could be a useful marker for its malignant potentiality while reduction of p16INK4 and p27KIP1 occurs during the transformation from dysplasia to cancer. These findings suggest that esophageal dysplasia should be treated as a precancerous lesion.",
        "Doc_title":"Cyclin D1 overexpression in esophageal dysplasia: a possible biomarker for carcinogenesis of esophageal squamous cell carcinoma.",
        "Journal":"International journal of oncology",
        "Do_id":"10639568",
        "Doc_ChemicalList":"Biomarkers, Tumor;Proliferating Cell Nuclear Antigen;Cyclin D1",
        "Doc_meshdescriptors":"Biomarkers, Tumor;Carcinoma in Situ;Carcinoma, Squamous Cell;Cyclin D1;Esophageal Neoplasms;Humans;Proliferating Cell Nuclear Antigen",
        "Doc_meshqualifiers":"metabolism;metabolism;pathology;metabolism;pathology;metabolism;metabolism;pathology;metabolism",
        "_version_":1605795041722236928},
      {
        "Doc_abstract":"Nucleophosmin (NPM), a ubiquitously and abundantly expressed protein, occurs in the nucleolus, shuttling between the nucleoplasm and cytoplasm. The NPM gene is mutated in almost 30% of human acute myeloid leukemia cells. NPM interacts with p53 and p19(Arf), directs localization of p19(Arf) in the nucleolus and protects the latter from degradation. Hepatocyte odd protein shuttling (HOPS) is also a ubiquitously expressed protein that moves between the nucleus and cytoplasm. Within the nucleus of resting cells, HOPS overexpression causes cell cycle arrest in G0/G1. HOPS knockdown causes centrosome hyperamplification leading to multinucleated cells and the formation of micronuclei. We demonstrate a direct interaction of HOPS with NPM and p19(Arf), resulting in a functionally active trimeric complex. NPM appeared to regulate HOPS half-life, which, in turn, stabilized p19(Arf) and controlled its localization in the nucleolus. These findings suggest that HOPS acts as a functional bridge in the interaction between NPM and p19(Arf), providing new mechanistic insight into how NPM and p19(Arf) will oppose tumor cell proliferation. ",
        "Doc_title":"Hepatocyte odd protein shuttling (HOPS) is a bridging protein in the nucleophosmin-p19 Arf network.",
        "Journal":"Oncogene",
        "Do_id":"22890319",
        "Doc_ChemicalList":"Carrier Proteins;Cdkn2a protein, mouse;Cyclin-Dependent Kinase Inhibitor p16;HOPS protein, mouse;Nuclear Proteins;nucleophosmin",
        "Doc_meshdescriptors":"Animals;Carrier Proteins;Cell Cycle;Cell Line;Cyclin-Dependent Kinase Inhibitor p16;Gene Knockout Techniques;Humans;Mice;Nuclear Proteins;Protein Multimerization;Protein Stability;Protein Structure, Quaternary;Protein Transport",
        "Doc_meshqualifiers":"chemistry;genetics;metabolism;chemistry;metabolism;chemistry;deficiency;genetics;metabolism",
        "_version_":1605766456093442048},
      {
        "Doc_abstract":"PI6INK4A (P16) protein expression was analyzed immunohistochemically in archival material derived from 12 cases of follicular thyroid carcinoma, 57 cases of follicular adenoma and 17 cases of nodular goiter. Among follicular carcinomas, 11 out of 12 examined cases (91.7%) were positive for P161NK4A protein. Among follicular adenomas the percentage of immunopositivity was 76.5% (45/57) and among nodular goiter cases it was 19.3% (13/17). Overexpression of P16INK4A protein was found in 66.7% (8/12) of follicular carcinomas and in 19.3% (11/57) of follicular adenomas; the values of this parameter were statistically significantly higher in the follicular carcinoma group (p < 0.005). No P16INK4A protein overexpression was noted in nodular goiter cells. High immunohistochemically-detected expression of P16INK4A protein in follicular thyroid carcinoma cells suggests that the altered expression pattern of P16INK4A protein may disturb the regulatory mechanisms of thyreocyte cell cycle and plays a significant role in the formation of benign neoplasms and their malignant counterparts derived from follicular thyroid cell.",
        "Doc_title":"Analysis of P161NK4A protein expression in follicular thyroid tumors.",
        "Journal":"Polish journal of pathology : official journal of the Polish Society of Pathologists",
        "Do_id":"15757201",
        "Doc_ChemicalList":"Biomarkers, Tumor;Cyclin-Dependent Kinase Inhibitor p16",
        "Doc_meshdescriptors":"Adenocarcinoma, Follicular;Adenoma;Biomarkers, Tumor;Cyclin-Dependent Kinase Inhibitor p16;Goiter, Nodular;Humans;Immunohistochemistry;Retrospective Studies;Thyroid Neoplasms",
        "Doc_meshqualifiers":"metabolism;pathology;metabolism;pathology;analysis;biosynthesis;metabolism;pathology;metabolism;pathology",
        "_version_":1605756837460705280},
      {
        "Doc_abstract":"The progression potential of preinvasive epithelial lesions is usually evaluated by assessing the degree of histologic dysplasia. We examined p16, retinoblastoma protein (pRb), and proliferating cell nuclear antigen (PCNA) immunophenotypes in 57 cases of previously untreated squamous cell carcinoma (SCC) of the upper digestive tract and in the neighboring normal and dysplastic epithelia. Tissue samples were examined for homozygous deletion of exon 2 of the p16 gene using polymerase chain reaction (PCR) analysis. The PCNA index increased with increasing grade of dysplasia. The pRb protein was expressed in 89% of the samples of SCCs and in the neighboring dysplasias and carcinoma in situ (CIS). In cases with a lack of pRb expression, corresponding preinvasive lesions were also negative. Lack of p16 expression was found in 82% of SCCs. The prevalence of p16 expression decreased with increasing grade of dysplasia. Molecular analysis of the p16 gene showed homozygous deletion in 37% of SCCs, 33% of CIS, and 15% of the samples of normal epithelia. Our data indicate that inactivation of p16 may play an important role in early head and neck carcinogenesis, whereas the mutation of Rb may be an infrequent event. The p16 immunophenotype might be a biomarker for an increased risk of progression in squamous dysplasia.",
        "Doc_title":"p16 alterations and retinoblastoma protein expression in squamous cell carcinoma and neighboring dysplasia from the upper aerodigestive tract.",
        "Journal":"Virchows Archiv : an international journal of pathology",
        "Do_id":"11355167",
        "Doc_ChemicalList":"Biomarkers, Tumor;Cyclin-Dependent Kinase Inhibitor p16;DNA Primers;DNA, Neoplasm;Proliferating Cell Nuclear Antigen;Retinoblastoma Protein",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Biomarkers, Tumor;Carcinoma, Squamous Cell;Cyclin-Dependent Kinase Inhibitor p16;DNA Primers;DNA, Neoplasm;Female;Fluorescent Antibody Technique, Indirect;Head and Neck Neoplasms;Humans;Male;Middle Aged;Polymerase Chain Reaction;Precancerous Conditions;Proliferating Cell Nuclear Antigen;Retinoblastoma Protein",
        "Doc_meshqualifiers":"metabolism;genetics;metabolism;pathology;genetics;metabolism;chemistry;analysis;genetics;metabolism;pathology;metabolism;pathology;metabolism;metabolism",
        "_version_":1605883766231793664},
      {
        "Doc_abstract":"Age-related declines in hematopoietic stem cell (HSC) function may contribute to anemia, poor response to vaccination, and tumorigenesis. Here, we show that mammalian target of rapamycin (mTOR) activity is increased in HSCs from old mice compared to those from young mice. mTOR activation through conditional deletion of Tsc1 in the HSCs of young mice mimicked the phenotype of HSCs from aged mice in various ways. These included increased abundance of the messenger RNA encoding the CDK inhibitors p16(Ink4a), p19(Arf), and p21(Cip1); a relative decrease in lymphopoiesis; and impaired capacity to reconstitute the hematopoietic system. In old mice, rapamycin increased life span, restored the self-renewal and hematopoiesis of HSCs, and enabled effective vaccination against a lethal challenge with influenza virus. Together, our data implicate mTOR signaling in HSC aging and show the potential of mTOR inhibitors for restoring hematopoiesis in the elderly.",
        "Doc_title":"mTOR regulation and therapeutic rejuvenation of aging hematopoietic stem cells.",
        "Journal":"Science signaling",
        "Do_id":"19934433",
        "Doc_ChemicalList":"Cdkn1a protein, mouse;Cdkn2a protein, mouse;Cyclin-Dependent Kinase Inhibitor p16;Cyclin-Dependent Kinase Inhibitor p21;Protein Kinases;TOR Serine-Threonine Kinases;mTOR protein, mouse;Sirolimus",
        "Doc_meshdescriptors":"Aging;Animals;Cyclin-Dependent Kinase Inhibitor p16;Cyclin-Dependent Kinase Inhibitor p21;Hematopoiesis;Hematopoietic Stem Cells;Male;Mice;Mice, Inbred C57BL;Orthomyxoviridae;Protein Kinases;Signal Transduction;Sirolimus;TOR Serine-Threonine Kinases;Time Factors",
        "Doc_meshqualifiers":"metabolism;metabolism;cytology;metabolism;metabolism;metabolism;pharmacology",
        "_version_":1605907213441826816},
      {
        "Doc_abstract":"Mesothelioma is inherently chemo-resistant with only 50% of patients responding to the standard of care treatments, and consequently it has a very grim prognosis. The aim of this study was to establish a panel of chemo-resistant mesothelioma models with clinically relevant levels of resistance as tools for investigating chemo-resistance and identifying new treatments for mesothelioma. Chemo-resistant cell lines were established in vitro and characterized in vivo using syngeneic Fischer rats. Tumors derived from all chemo-resistant cell lines were immunohistochemically classified as mesothelioma. Homozygous deletion of p16(INK4A)/p14(ARF) and increased expression of several ATP-binding cassette transporters were demonstrated, consistent with findings in human mesothelioma. Further, the acquisition of chemo-resistance in vitro resulted in changes to tumor morphology and overall survival. In conclusion, these models display many features corresponding with the human disease, and provide the first series of matched parental and chemo-resistant models for in vitro and in vivo mesothelioma studies. ",
        "Doc_title":"Establishing a panel of chemo-resistant mesothelioma models for investigating chemo-resistance and identifying new treatments for mesothelioma.",
        "Journal":"Scientific reports",
        "Do_id":"25141917",
        "Doc_ChemicalList":"Antineoplastic Agents;Cyclin-Dependent Kinase Inhibitor p16;Cytokines;Glutathione",
        "Doc_meshdescriptors":"ATP-Binding Cassette Transporters;Animals;Antineoplastic Agents;Cell Line, Tumor;Cell Survival;Cyclin-Dependent Kinase Inhibitor p16;Cytokines;Disease Models, Animal;Drug Resistance, Neoplasm;Female;Gene Expression;Gene Expression Profiling;Glutathione;Inhibitory Concentration 50;Lymphocyte Count;Mesothelioma;Multigene Family;Phenotype;Rats",
        "Doc_meshqualifiers":"genetics;pharmacology;therapeutic use;drug effects;genetics;blood;metabolism;genetics;metabolism;drug therapy;genetics;immunology;metabolism;mortality;pathology",
        "_version_":1605791361012858880},
      {
        "Doc_abstract":"The p19(Arf)-p53 tumor suppressor pathway plays a critical role in cell-cycle checkpoint control and apoptosis, whereas Rho family small GTPases are key regulators of actin structure and cell motility. By using primary mouse embryonic fibroblasts that lack Arf, p53, or both, we studied the involvement of the p19(Arf)-p53 pathway in the regulation of cell motility and its relationship with Rho GTPases. Deletion of Arf and/or p53 led to actin cytoskeleton reorganization and a significant increase in cell motility. The endogenous phosphoinositide (PI) 3- kinase and Rac1 activities were elevated in Arf(-/-) and p53(-/-) cells, and these activities are required for p19(Arf)- and p53-regulated migration. Reintroduction of the wild type Arf or p53 genes into Arf(-/-) or p53(-/-) cells reversed the PI 3-kinase and Rho GTPase activities as well as the migration phenotype. These results suggest a functional relationship between an established tumor suppressor pathway and a signaling module that controls actin structure and cell motility and show that p19(Arf) and p53 negatively regulate cell migration by suppression of PI 3-kinase and Rac1 activities.",
        "Doc_title":"p19Arf-p53 tumor suppressor pathway regulates cell motility by suppression of phosphoinositide 3-kinase and Rac1 GTPase activities.",
        "Journal":"The Journal of biological chemistry",
        "Do_id":"12578823",
        "Doc_ChemicalList":"Cdkn2a protein, mouse;Culture Media, Serum-Free;Cyclin-Dependent Kinase Inhibitor p16;Enzyme Inhibitors;Luminescent Proteins;Recombinant Fusion Proteins;Tumor Suppressor Protein p14ARF;Tumor Suppressor Protein p53;Green Fluorescent Proteins;Phosphatidylinositol 3-Kinases;rac1 GTP-Binding Protein",
        "Doc_meshdescriptors":"Animals;Blotting, Western;Cell Movement;Cells, Cultured;Culture Media, Serum-Free;Cyclin-Dependent Kinase Inhibitor p16;Enzyme Inhibitors;Fibroblasts;Gene Deletion;Green Fluorescent Proteins;Luminescent Proteins;Mice;Phenotype;Phosphatidylinositol 3-Kinases;Recombinant Fusion Proteins;Tumor Suppressor Protein p14ARF;Tumor Suppressor Protein p53;rac1 GTP-Binding Protein",
        "Doc_meshqualifiers":"pharmacology;pharmacology;cytology;metabolism;antagonists & inhibitors;metabolism;metabolism;genetics;physiology;genetics;metabolism;physiology;antagonists & inhibitors;metabolism",
        "_version_":1605801573364006912},
      {
        "Doc_abstract":"Understanding the interaction of Arf and Hdm2 has recently become a central issue in cancer biology. In response to hyperproliferative signals, p14(Arf) stabilizes p53 by binding to Hdm2 and inhibits the ubiquitination and subsequent proteosome-dependent degradation of p53. The medical importance of the Arf-Hdm2-p53 regulatory system is highlighted by the finding that either p53 or p14(Arf) are lost or modified in virtually all human cancers. Isolated Arf and Hdm2 domains are dynamically disordered in solution, yet they retain the ability to interact in vitro and in cellular assays. Upon binding, domains of both Arf and Hdm2 undergo a dramatic transition from disordered conformations to extended structures comprised of beta-strands. The presence of domains from both proteins are necessary and sufficient for the formation of the highly stable extended beta structures. We have mapped sites within Arf and Hdm2 that interact at a resolution of five amino acid residues using surface plasmon resonance. Surface plasmon resonance and circular dichroism spectropolarimetry confirm the presence of multiple interaction domains within each protein. Both p14(Arf) (human) and p19(Arf) (mouse) interact with Hdm2 through two short motifs present in their N termini. The Arf interacting region of Hdm2 is also composed of two short sequences located in the central acidic domain, between residues 235-264 and 270-289. The binding-induced structural transition is also induced by short peptides, 15 amino acids in length, that contain the binding motifs. Micro-injection and live cell imaging of proteins tagged with fluorescent labels was used to confirm the in vivo function of the interaction domains. Arf and Hdm2 thus appear to interact through a novel mechanism that exerts control over the cell division cycle. The novel molecular mechanism of interaction and the limited size of the protein domains involved provide opportunities for the development of anticancer therapeutics.",
        "Doc_title":"Defining the molecular basis of Arf and Hdm2 interactions.",
        "Journal":"Journal of molecular biology",
        "Do_id":"11718560",
        "Doc_ChemicalList":"Cdkn2a protein, mouse;Cyclin-Dependent Kinase Inhibitor p16;Nuclear Proteins;Peptide Fragments;Proto-Oncogene Proteins;Tumor Suppressor Protein p14ARF;Tumor Suppressor Protein p53;MDM2 protein, human;Mdm2 protein, mouse;Proto-Oncogene Proteins c-mdm2",
        "Doc_meshdescriptors":"3T3 Cells;Amino Acid Motifs;Amino Acid Sequence;Animals;Binding Sites;Cell Nucleolus;Circular Dichroism;Cyclin-Dependent Kinase Inhibitor p16;Gene Deletion;Humans;Magnetic Resonance Spectroscopy;Mice;Molecular Sequence Data;Nuclear Proteins;Peptide Fragments;Protein Binding;Protein Interaction Mapping;Protein Structure, Secondary;Protein Structure, Tertiary;Proto-Oncogene Proteins;Proto-Oncogene Proteins c-mdm2;Sequence Alignment;Surface Plasmon Resonance;Tumor Suppressor Protein p14ARF;Tumor Suppressor Protein p53",
        "Doc_meshqualifiers":"chemistry;metabolism;chemistry;metabolism;chemistry;metabolism;chemistry;genetics;metabolism;metabolism",
        "_version_":1605806280357707776},
      {
        "Doc_abstract":"The purpose of the study was to evaluate the presence of alteration of the tumor suppressor gene p16 and to correlate these changes with the clinical status of the patients in oral squamous cell carcinoma. Forty-eight oral squamous cell carcinomas were included in the analyses. Deletion analysis was performed by the polymerase chain reaction (PCR). Mutation analysis was restricted to exon 1 and exon 2 of the p16 gene, previously shown to have a high incidence of mutations. The sequences containing exon 1 and exon 2 were amplified by PCR and screened with a single-strand conformation polymorphism (SSCP) technique. Samples showing band shifts in SSCP were sequenced by PCR direct sequencing. Western blots were used to detect the protein expression of the p16 gene, and the results were evaluated with regard to their biological relevance in correlation with clinicopathological factors. Seven (14.6%) deletions were found; 5 (10.4%) mutations were discovered and located in different codons; 26 (54%) specimens had no p16 protein expression; in 11 specimens with p16 deletion or mutation, p16 protein could not be detected. One mutation was non-sense. The p16 gene alterations showed no relationship with location and clinical stage of cancer; however, a close relationship between p16 alterations and cancer metastasis to neck lymph node was found. The alteration rate gradually elevated from well to poorly differentiated grades. We perceive two results. First, the alterations of the p16 gene are common in oral squamous cell carcinoma. Second, the alterations of the p16 gene may attribute to the metastatic behavior or histological grade of cancer cells.",
        "Doc_title":"The correlation between alteration of p16 gene and clinical status in oral squamous cell carcinoma.",
        "Journal":"Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology",
        "Do_id":"11555154",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16",
        "Doc_meshdescriptors":"Adult;Aged;Blotting, Western;Carcinoma, Squamous Cell;Chi-Square Distribution;Cyclin-Dependent Kinase Inhibitor p16;DNA Mutational Analysis;Female;Gene Deletion;Genes, p16;Humans;Lymph Nodes;Lymphatic Metastasis;Male;Middle Aged;Mouth Neoplasms;Mutation, Missense;Neck;Polymorphism, Single-Stranded Conformational",
        "Doc_meshqualifiers":"genetics;metabolism;pathology;biosynthesis;genetics;metabolism;pathology",
        "_version_":1605825177464078336},
      {
        "Doc_abstract":"The INK4a/ARF locus, which is frequently inactivated in human tumors, encodes two distinct tumor suppressive proteins, ARF and p16INK4a. ARF stabilizes and activates p53 by negating the effects of mdm2 on p53. Furthermore, its function is not restricted to the p53 pathway and it also inhibits cell proliferation in cells lacking p53. Expression of ARF is up-regulated in response to a number of oncogenic stimuli including E2F1. We show here that while oncogenic Ras does not significantly affect p1(4AR)F expression in normal human cells it activates p1(4AR)F in cells containing deregulated E2F. Moreover, oncogenic Ras and E2F1 synergize in activating p1(4AR)F expression. Activation of p1(4AR)F promoter by E2F1 persists in the absence of the consensus E2F-binding sites in this promoter, indicating that this activation also occurs through non- canonical binding sites. The activation by oncogenic Ras requires both E2F and Sp-1 activity, demonstrating the complex regulation of p14(ARF) in response to oncogenic stimuli.",
        "Doc_title":"E2F and Ras synergize in transcriptionally activating p14ARF expression.",
        "Journal":"Cell cycle (Georgetown, Tex.)",
        "Do_id":"12695664",
        "Doc_ChemicalList":"Cell Cycle Proteins;DNA-Binding Proteins;E2F Transcription Factors;E2F1 Transcription Factor;E2F1 protein, human;E2f1 protein, mouse;Sp1 Transcription Factor;Transcription Factors;Tumor Suppressor Protein p14ARF",
        "Doc_meshdescriptors":"Animals;Cell Cycle Proteins;Cell Line;DNA-Binding Proteins;E2F Transcription Factors;E2F1 Transcription Factor;Genes, ras;Genetic Vectors;Humans;Mice;Promoter Regions, Genetic;Sp1 Transcription Factor;Transcription Factors;Transcriptional Activation;Tumor Suppressor Protein p14ARF;Up-Regulation",
        "Doc_meshqualifiers":"physiology;metabolism;genetics;metabolism",
        "_version_":1605827405054738432},
      {
        "Doc_abstract":"Melanomagenesis is a complex phenomenon in which environmental, genetic and host factors play a role. Sun burns in early childhood are a known risk factor in melanoma development. Alteration of prosurvival genes such as Ras and Akt and loss of function of the p16(INK4a)-CDK4/6-pRb and p14(ARF)-HDM2-p53 pathways are strongly associated with human melanoma. We have demonstrated that normally occurring skin hypoxia represents a previously unappreciated host promoting factor in melanomagenesis. Melanocytes that express oncogenes such as Akt, and are therefore genetically unstable, show a transform phenotype only in a mild hypoxic environment that resembles the hypoxic status of the skin. Hypoxia, therefore, is not just a prerogative of advanced neoplasia; physiologic tissue hypoxia, through the activity of HIF1alpha, can function as a promoting factor in tumorigenesis.",
        "Doc_title":"Skin hypoxia: a promoting environmental factor in melanomagenesis.",
        "Journal":"Cell cycle (Georgetown, Tex.)",
        "Do_id":"16760649",
        "Doc_ChemicalList":"Proto-Oncogene Proteins c-akt",
        "Doc_meshdescriptors":"Animals;Cell Proliferation;Cell Transformation, Neoplastic;Humans;Hypoxia;Melanoma;Proto-Oncogene Proteins c-akt;Skin",
        "Doc_meshqualifiers":"metabolism;pathology;metabolism;pathology;metabolism;pathology;metabolism;metabolism;pathology",
        "_version_":1605898186262577152},
      {
        "Doc_abstract":"Previous studies demonstrated the etiological role of human papilloma virus (HPV) in cervical carcinogenesis. Assessing the distribution of HPV may elucidate these observations.;In total, we examined 3839 specimens, of which 187 abnormally classified cervical smears were immunostained using the p16(INK4A) assay. DNA was extracted from 182 specimens, and polymerase chain reaction (PCR) was performed. Participants' socio-demographics, sexual and reproductive history, HIV status, contraceptive use, and Pap smear history were recorded.;Subject ages, number of sexual partners, and age at first sexual encounter ranged from 15 to 49 years, from 1 to 37 partners, and from 13 to 34 years, respectively. P16 immunoreactivity was detected in 60.4% of cases. The distribution of epithelial lesions and P16 overexpression (bracketed) was: 28 (5) atypical squamous cells of undetermined significance (ASC-US), 96 (50) lower grade squamous intraepithelial lesion (LSIL), 9 (7) atypical squamous cells-cannot exclude HSIL (ASC-H), and 54 (51) higher grade squamous intraepithelial lesion (HSIL). Ninety-four percent of HSIL expressed P16. Fifty-two percent of LSIL expressed P16. P16 expression declined from 61% (25-34 year age group) to 5% (45-49 year age group) for different age groups. HPV-DNA by PCR was detected in 94.5% of P16-positive samples. Type-specific PCR (HPV 16 and 18) was found in 12.2% and 14.5% of abnormal lesions, respectively. Younger age at first sexual encounter and HIV infection predominated in HPV type(s) 16 and/or 18 positive subjects.;This study reinforced the value of the p16(INK4A) surrogate marker in identifying women with progressive cervical disease.",
        "Doc_title":"Prevalence of human papilloma virus in cytological abnormalities: Association of risk factors and cytomorphological findings.",
        "Journal":"CytoJournal",
        "Do_id":"22993533",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605851690128375808},
      {
        "Doc_abstract":"CDK5 regulatory subunit associated protein 3 (CDK5RAP3) is a novel activator of PAK4 and processes important pro-metastatic function in hepatocarcinogenesis. However, it remains unclear if there are other mechanisms by which CDK5RAP3 promotes HCC metastasis. Here, we showed that in CDK5RAP3 stable knockdown SMMC-7721 HCC cells, p14(ARF) tumor suppressor was upregulated at protein and mRNA levels, and ectopic expression of CDK5RAP3 was found to repress the transcription of p14(ARF). Using chromatin immunoprecipitation assay, we demonstrated that CDK5RAP3 bound to p14(ARF) promoter in vivo. Furthermore, knockdown of p14(ARF) in CDK5RAP3 stable knockdown HCC cells reversed the suppression of HCC cell invasiveness mediated by knockdown of CDK5RAP3. Taken together, our findings provide the new evidence that overexpression of CDK5RAP3 promotes HCC metastasis via downregulation of p14(ARF).",
        "Doc_title":"CDK5RAP3 is a novel repressor of p14ARF in hepatocellular carcinoma cells.",
        "Journal":"PloS one",
        "Do_id":"22860085",
        "Doc_ChemicalList":"CDK5RAP3 protein, human;Intracellular Signaling Peptides and Proteins;Nerve Tissue Proteins;Tumor Suppressor Protein p14ARF",
        "Doc_meshdescriptors":"Carcinoma, Hepatocellular;Cell Line, Tumor;Chromatin Immunoprecipitation;Gene Knockdown Techniques;Humans;Intracellular Signaling Peptides and Proteins;Liver Neoplasms;Microscopy, Confocal;Nerve Tissue Proteins;Promoter Regions, Genetic;Reverse Transcriptase Polymerase Chain Reaction;Tumor Suppressor Protein p14ARF",
        "Doc_meshqualifiers":"metabolism;pathology;physiology;metabolism;pathology;physiology;genetics;physiology",
        "_version_":1605742676226867200},
      {
        "Doc_abstract":"Roughly 40% of germinal mutations in melanoma families (MF) affect p16(INK4a) and p14(ARF). We investigated the association between INK4/ARF alterations and the occurrence of pancreatic cancer in MF and in sporadic pancreatic cancer (SPC) patients.;Forty-nine MF, 66 SPC cases and 54 controls were enrolled. The INK4/ARF locus was screened.;As compared with the general population, the risk of pancreatic cancer (PC) was increased 9.4-fold [95% confidence interval (CI) 2.7-33.4] and 2.2-fold (95% CI 0.8-5.7) in G101W-positive and -negative MF, respectively, while mean ages at onset were 61 and 77 years, respectively. A 1.7 (95% CI 1.06-2.79) increased risk of cancer at any site was observed among first-degree relatives of SPC cases as compared with controls. The G101W founder mutation was detected in 4% of SPC cases but the rate increased to 13% when tumor clustering in either branch of families was taken into account. One G101W-positive PC patient with a melanoma in a first-degree relative harbored a germline deletion of the second allele, including exon 1B.;The presence of a deletion including exon 1B in two PC patients points to the involvement of p14(ARF) in the development of PC and may suggest that the increased risk of PC in MF is caused by impairment of both loci.",
        "Doc_title":"INK4/ARF germline alterations in pancreatic cancer patients.",
        "Journal":"Annals of oncology : official journal of the European Society for Medical Oncology",
        "Do_id":"14679123",
        "Doc_ChemicalList":"Tumor Suppressor Protein p14ARF",
        "Doc_meshdescriptors":"Adenocarcinoma;Adolescent;Adult;Aged;Aged, 80 and over;DNA Mutational Analysis;Female;Genes, p16;Genetic Predisposition to Disease;Germ-Line Mutation;Heterozygote;Humans;Incidence;Male;Melanoma;Middle Aged;Molecular Sequence Data;Pancreatic Neoplasms;Pedigree;Polymerase Chain Reaction;Tumor Suppressor Protein p14ARF",
        "Doc_meshqualifiers":"epidemiology;genetics;epidemiology;genetics;physiopathology;epidemiology;genetics;genetics",
        "_version_":1605757743958851584},
      {
        "Doc_abstract":"To test the usefulness of p16(INK4a) immunostaining for improving the diagnostic accuracy of cervical punch biopsies referred to a routine laboratory setting during the investigation of women with abnormal Papanicolaou smears.;A total of 188 consecutive and unselected colposcopically directed cervical biopsies and a single contemporaneous cervical polyp were accessioned prospectively over a 3-month period, step-serially sectioned and examined by H&E and immunostained for p16(INK4a). The clinical context, results of concurrent Papanicolaou smears/ThinPrep slides and Digene hybrid capture tests for high-risk human papillomavirus (HPV) subtypes, as well as follow-up cervical smears/ThinPrep, biopsies and loop excisions of transformation zones or cone biopsies were all correlated with the morphological and immunohistochemical findings.;Seventy-seven biopsies (40.7%) displayed a high-grade squamous intraepithelial lesion (HGSIL; cervical intraepithelial neoplasia [CIN] 2-3), 27 (14.3%) showed a low grade squamous intraepithelial lesion (HPV +/- CIN1) and 85 (45%) showed a range of non-dysplastic (inflammatory or reactive) changes. Diffuse strong parabasal immunostaining for p16(INK4a), suggestive of integrated high-risk HPV DNA into the host genome, was observed in 81 biopsies (42.9%, including the cervical polyp) and correlated (>90%) with HGSIL in the H&E sections. Only one case revealed irreconcilable discordance between the histological features and this strong parabasal immunostaining pattern. Focal and weaker midzonal or superficial p16(INK4a) immunostaining, suggestive of episomal HPV infection, was noted in 19 biopsies (10%) and these biopsies exhibited a range of histological changes but predominantly low grade squamous intraepithelial lesion (LGSIL). No staining of the squamous epithelium was seen in 89 biopsies (47.1%). Again, only one case revealed irreconcilable discordance between the histological features and this negative immunostaining pattern. On review of all cases where discordant results were noted between the H&E appearances and expected p16(INK4a) immunostaining, we found 26 cases (13.7%) in which this discordance prompted justifiable modification of the original diagnosis.;Thus, within a routine diagnostic laboratory, p16(INK4a) immunostaining appears to be a very useful adjunctive test in the examination of colposcopically directed cervical biopsies, in the diagnostic cascade of women investigated for abnormal Papanicolaou smears. It is possible, as further data accumulate concerning the importance of integration of high-risk HPV DNA into the host cell genome and the reliability with which this can be identified by p16(INK4a) immunostaining, that this will become the diagnostic 'lesion of interest', replacing the subjective histological grading of cervical dysplasia, in the management of such patients; i.e., the discriminatory watershed between continued surveillance and active intervention.",
        "Doc_title":"p16(INK4a) as a complementary marker of high-grade intraepithelial lesions of the uterine cervix. I: Experience with squamous lesions in 189 consecutive cervical biopsies.",
        "Journal":"Pathology",
        "Do_id":"16028838",
        "Doc_ChemicalList":"Biomarkers, Tumor;Cyclin-Dependent Kinase Inhibitor p16;DNA, Viral",
        "Doc_meshdescriptors":"Biomarkers, Tumor;Biopsy;Carcinoma, Squamous Cell;Cervical Intraepithelial Neoplasia;Cyclin-Dependent Kinase Inhibitor p16;DNA, Viral;Female;Humans;Immunohistochemistry;Papillomaviridae;Papillomavirus Infections;Precancerous Conditions;Uterine Cervical Neoplasms",
        "Doc_meshqualifiers":"metabolism;metabolism;pathology;virology;metabolism;pathology;virology;metabolism;genetics;genetics;isolation & purification;metabolism;pathology;metabolism;pathology;virology;metabolism;pathology;virology",
        "_version_":1605762259257131008},
      {
        "Doc_abstract":"Determining high-risk human papillomavirus (HR-HPV) status of head and neck squamous cell carcinoma (HNSCC) defines a tumor subset with important clinical implications. Cytologic sampling often provides the sentinel or sole diagnostic specimen. The authors assessed the performance characteristics for the Roche cobas 4800 HPV real-time polymerase chain reaction (PCR)-based system (cobas) on cytologic specimens of HNSCC compared with standard methods of in situ hybridization (ISH) for HR-HPV and immunohistochemistry (IHC) for p16 on formalin-fixed, paraffin-embedded (FFPE) tissue.;Samples of HNSCC were collected by fine-needle aspiration and from surgical biopsies or resections, fixed, and processed with the cobas system. Available corresponding FFPE samples were synchronously evaluated for HR-HPV using ISH and IHC. Discrepant cases underwent additional PCR studies for adjudication.;Thirty-six samples from 33 patients were analyzed. Forty-two percent (n = 15) of tumors were positive for HR-HPV according to cobas. Corresponding histology with ISH (n = 30) was concordant in 91% of samples. Compared with the adjudication PCR standard, there were 3 false-positive cases according to cobas. Ninety-two percent (n = 12) of cases were the HPV16 subtype. The overall sensitivity for the cobas system was 100%, and the specificity was 86%.;Concordance in HNSCC HR-HPV status between cobas and ISH/IHC was > 90%, and cobas demonstrated a sensitivity of 100% and a specificity of 86%, broadening options for HR-HPV testing of fine-needle aspiration samples. Advantages for this system include subtyping of HR-HPV and the ability to discern HR-HPV status earlier in a patient's treatment course.",
        "Doc_title":"Performance of the Roche cobas 4800 high-risk human papillomavirus test in cytologic preparations of squamous cell carcinoma of the head and neck.",
        "Journal":"Cancer cytopathology",
        "Do_id":"24259368",
        "Doc_ChemicalList":"DNA, Viral",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Biopsy, Fine-Needle;Carcinoma, Squamous Cell;Cytological Techniques;DNA, Viral;Female;Head and Neck Neoplasms;Humans;Male;Middle Aged;Papillomaviridae;Papillomavirus Infections;Polymerase Chain Reaction;Retrospective Studies;Risk Assessment;Sensitivity and Specificity",
        "Doc_meshqualifiers":"diagnosis;pathology;virology;analysis;genetics;diagnosis;pathology;virology;genetics;diagnosis;epidemiology;methods",
        "_version_":1605873621951053824},
      {
        "Doc_abstract":"Epigenetic silencing of functionally important genes is important in the development of malignancies and is a source of potential markers for molecular detection. Primary central nervous system lymphoma (PCNSL) is an increasingly common tumor that has not been extensively examined for changes in promoter region methylation. We examined 14 tumor suppressor genes in 25 cases of PCNSL using methylation-specific PCR. Methylation was observed in DAPK (84%), TSP1 (68%), CRBP1 (67%), p16(INK) (4a) (64%), p14(ARF) (59%), MGMT (52%), RARbeta2 (50%), TIMP3 (44%), TIMP2 (42%), p15(INK) (4b) (40%), p73 (28%), hMLH1 (12%), RB1 (8%) and GSTP1 (8%). Promoter methylation of p14(ARF), p16(INK) (4a) and MGMT was correlated with loss of expression by immunohistochemical staining. The methylation of many of these genes in PCNSL is similar to that reported in other high-grade B-cell lymphomas. All 25 cases of PCNSL had methylation of at least 2 genes. Methylation of DAPK, p16(INK) (4a) or MGMT was found in 96% of the tumors, suggesting simple marker strategies to detect circulating methylated DNA in serum that might facilitate early tumor detection. Our study provides insight into the epigenetic alterations in PCNSL and provides potential biomarkers of disease.",
        "Doc_title":"Epigenetic silencing of multiple genes in primary CNS lymphoma.",
        "Journal":"International journal of cancer",
        "Do_id":"16858686",
        "Doc_ChemicalList":"DNA, Neoplasm",
        "Doc_meshdescriptors":"Adult;Aged;Central Nervous System Neoplasms;DNA Methylation;DNA, Neoplasm;Epigenesis, Genetic;Female;Gene Expression Regulation, Neoplastic;Gene Silencing;Genes, Tumor Suppressor;Humans;Immunohistochemistry;Lymphoma;Male;Middle Aged;Promoter Regions, Genetic",
        "Doc_meshqualifiers":"chemistry;genetics;pathology;metabolism;chemistry;genetics;pathology",
        "_version_":1605800517776179200},
      {
        "Doc_abstract":"Cdk4 and Cdk6 are related protein kinases that bind d-type cyclins and regulate cell-cycle progression. Cdk4/6 inhibitors are currently being used in advanced clinical trials and show great promise against many types of tumors. Cdk4 and Cdk6 are inhibited by INK4 proteins, which exert tumor-suppressing functions. To test the significance of this inhibitory mechanism, we generated knock-in mice that express a Cdk6 mutant (Cdk6 R31C) insensitive to INK4-mediated inhibition. Cdk6(R/R) mice display altered development of the hematopoietic system without enhanced tumor susceptibility, either in the presence or absence of p53. Unexpectedly, Cdk6 R31C impairs the potential of hematopoietic progenitors to repopulate upon adoptive transfer or after 5-fluorouracil-induced damage. The defects are overcome by eliminating sensitivity of cells to INK4 inhibitors by introducing the INK4-insensitive Cdk4 R24C allele, and INK4-resistant mice are more susceptible to hematopoietic and endocrine tumors. In BCR-ABL-transformed hematopoietic cells, Cdk6 R31C causes increased binding of p16(INK4a) to wild-type Cdk4, whereas cells harboring Cdk4 R24C and Cdk6 R31C are fully insensitive to INK4 inhibitors, resulting in accelerated disease onset. Our observations reveal that Cdk4 and Cdk6 cooperate in hematopoietic tumor development and suggest a role for Cdk6 in sequestering INK4 proteins away from Cdk4. ",
        "Doc_title":"Cdk4 and Cdk6 cooperate in counteracting the INK4 family of inhibitors during murine leukemogenesis.",
        "Journal":"Blood",
        "Do_id":"25157181",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor Proteins;Mutant Proteins;Fusion Proteins, bcr-abl;Cyclin-Dependent Kinase 4;Cyclin-Dependent Kinase 6",
        "Doc_meshdescriptors":"Alleles;Animals;Carcinogenesis;Cell Death;Cell Line, Transformed;Cell Proliferation;Cyclin-Dependent Kinase 4;Cyclin-Dependent Kinase 6;Cyclin-Dependent Kinase Inhibitor Proteins;Fusion Proteins, bcr-abl;Gene Ontology;Hematopoiesis;Hematopoietic Stem Cells;Mice;Mutant Proteins",
        "Doc_meshqualifiers":"metabolism;pathology;metabolism;genetics;metabolism;metabolism;metabolism;metabolism;metabolism",
        "_version_":1605791524137730048},
      {
        "Doc_abstract":"p16INK4a gene mapped at chromosome 9p21 region encodes a tumor suppressor protein p16 which is frequently inactivated in human cancers, including skin melanoma. In order to clarify the importance of p16 alterations in melanoma, we examined the deletions of p16INK4a and expression of p16 protein in eight unselected primary and metastatic melanoma cell lines from human skin melanomas. Normal skin melanocytes were used as controls. Deletions of entire exons in the p16INK4a gene were detected by PCR technique and expression of the p16 protein was examined by Western blotting and immunocytochemistry. Results showed that the fragments from exons 2A, 2C and 3 in p16INK4a gene were totally deleted in the metastatic melanoma cell line, FM28.7 and the fragment from exon 3 was deleted in the metastatic melanoma cell line, FM55M2. P16 protein was strongly expressed in two of the primary melanomas cell lines (FM55P and RaH3). The p16 protein was weakly expressed in one of the metastatic melanoma cell lines (FM55M1) and negative in the other metastasis (FM55M2) as compared to their matched primary melanoma cells (FM55P). The p16 protein was strongly expressed in normal skin melanocytes. Immunocytochemistry showed that p16 protein was mainly localized in the nuclei of the melanoma cells and normal melanocytes, if it was expressed. Deletions of p16INK4a gene was uncommon and loss of p16 protein expression was common event in melanoma, especially in the later stages of melanoma.",
        "Doc_title":"Deletion in p16INK4a and loss of p16 expression in human skin primary and metastatic melanoma cells.",
        "Journal":"International journal of oncology",
        "Do_id":"14719109",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;DNA Primers",
        "Doc_meshdescriptors":"Blotting, Western;Cell Line, Tumor;Cells, Cultured;Cyclin-Dependent Kinase Inhibitor p16;DNA Primers;Exons;Gene Deletion;Genes, p16;Humans;Immunohistochemistry;Melanocytes;Melanoma;Models, Biological;Neoplasm Metastasis;Polymerase Chain Reaction;Skin",
        "Doc_meshqualifiers":"biosynthesis;genetics;pharmacology;metabolism;genetics;pathology;metabolism",
        "_version_":1605929345825636352},
      {
        "Doc_abstract":"Non-small-cell lung carcinoma (NSCLC) is among the deadliest of human cancers. The CDKN2A locus, which houses the INK4a and ARF tumor suppressor genes, is frequently altered in NSCLC. However, the specific role of ARF in pulmonary tumorigenesis remains unclear. KRAS and other oncogenes induce the expression of ARF, thus stabilizing p53 activity and arresting cell proliferation. To address the role of ARF in Kras-driven NSCLC, we compared the susceptibility of NIH/Ola strain wild-type and Arf-knockout mice to urethane-induced lung carcinogenesis. Lung tumor size, malignancy and associated morbidity were significantly increased in Arf(-/-) compared with Arf(+/+) animals at 25 weeks after induction. Pulmonary tumors from Arf-knockout mice exhibited increased cell proliferation and DNA damage compared with wild-type mice. A subgroup of tumors in Arf(-/-) animals presented as dedifferentiated and metastatic, with many characteristics of pulmonary sarcomatoid carcinoma, a neoplasm previously undocumented in mouse models. Our finding of a role for ARF in NSCLC is consistent with the observation that benign adenomas from Arf(+/+) mice robustly expressed ARF, while ARF expression was markedly reduced in malignant adenocarcinomas. ARF expression also frequently colocalized with the expression of p21(CIP1), a transcriptional target of p53, arguing that ARF induces the p53 checkpoint to arrest cell proliferation in vivo. Taken together, these findings demonstrate that induction of ARF is an early response in lung tumorigenesis that mounts a strong barrier against tumor growth and malignant progression. ",
        "Doc_title":"ARF inhibits the growth and malignant progression of non-small-cell lung carcinoma.",
        "Journal":"Oncogene",
        "Do_id":"23752194",
        "Doc_ChemicalList":"Cdkn2a protein, mouse;Cyclin-Dependent Kinase Inhibitor p16;Tumor Suppressor Protein p53",
        "Doc_meshdescriptors":"Animals;Carcinoma, Non-Small-Cell Lung;Cell Proliferation;Cyclin-Dependent Kinase Inhibitor p16;DNA Damage;Disease Progression;Genes, ras;Lung Neoplasms;Mice;Mice, Knockout;Mutation;Neoplasm Invasiveness;Neoplasm Metastasis;Tumor Suppressor Protein p53",
        "Doc_meshqualifiers":"pathology;genetics;physiology;physiology;pathology;metabolism",
        "_version_":1605819614713872384},
      {
        "Doc_abstract":"Currently, there are discrepancies in the interpretation between cervical liquid-based cytology (LBC) and histologic diagnoses. The aim of our study was to evaluate the utility of p16(INK4a) (p16) and IMP3 staining of LBC specimens to increase the concordance rate. A total of 98 cell blocks with biopsy results, including 37 low-grade squamous intraepithelial lesions (LSIL), 36 high-grade squamous intraepithelial lesions (HSIL), and 25 squamous cell carcinomas (SCC), were selected for the immunocytochemical analysis of p16 and IMP3. The LBC diagnoses corresponded with histological diagnoses for 59.5% (22/37), 63.9% (23/36), and 88.0% (22/25) of LSIL, HSIL, and SCC lesions, respectively. We found a high frequency of p16 positivity in HSIL (72.2%) and SCC (100%), but not LSIL (29.7%). IMP3 was frequently expressed in SCC (84.0%), but rarely in LSIL (8.1%) and HSIL (25.0%). Cervical intraepithelial neoplasia 1 (CIN1) was negative for both p16 and IMP3, CIN2/3 tended to be positive for p16 and negative for IMP3, and SCC was positive for both p16 and IMP3. The combination of p16 and IMP3 immunostaining had a higher sensitivity and specificity for detecting CIN1 and CIN2/3 than cytology. For detecting SCC, p16/IMP3 had a higher sensitivity than cytology, but a lower specificity. IMP3 is a useful diagnostic immunomarker that can be used to identify SCC and the combination of p16/IMP3 expression was found to improve the discrepant results between cytologic and histologic diagnoses. ",
        "Doc_title":"Combined detection of p16(INK4a) and IMP3 increase the concordance rate between cervical cytologic and histologic diagnosis.",
        "Journal":"International journal of clinical and experimental pathology",
        "Do_id":"23923073",
        "Doc_ChemicalList":"Biomarkers, Tumor;Cyclin-Dependent Kinase Inhibitor p16;IMP3 protein, human;RNA-Binding Proteins",
        "Doc_meshdescriptors":"Biomarkers, Tumor;Carcinoma, Squamous Cell;Cervical Intraepithelial Neoplasia;Cyclin-Dependent Kinase Inhibitor p16;Cytodiagnosis;Female;Humans;Immunohistochemistry;Papanicolaou Test;RNA-Binding Proteins;Retrospective Studies;Sensitivity and Specificity;Uterine Cervical Neoplasms;Vaginal Smears",
        "Doc_meshqualifiers":"analysis;diagnosis;metabolism;diagnosis;metabolism;analysis;biosynthesis;methods;analysis;biosynthesis;diagnosis;metabolism",
        "_version_":1605874831672213504},
      {
        "Doc_abstract":"Two distinct types of vulvar squamous cell carcinomas and their precursors, vulvar intraepithelial neoplasias (VIN), which differ in terms of clinical presentation and behavior, have been delineated. Human papillomavirus (HPV)-associated carcinomas are of basaloid or warty type, whereas tumors unrelated to HPV are usually keratinizing and differentiated. Thus, the major stratifying factor for vulvar carcinomas and VIN is their etiopathogenetic relationship with HPV. However, because of technical difficulties in confidently detecting HPV in tissues, this diagnosis is usually based on purely morphologic criteria, even though some overlap exists between these histologic types. Recently, the tumor suppressor protein p16 has been shown to be specifically overexpressed in HPV-related carcinomas and premalignant lesions of the uterine cervix, oral cavity, and anus, but the presence of p16 vulvar squamous lesions has not been examined. We have evaluated the immunohistochemical expression of p16 in a series of formalin-fixed, paraffin-embedded vulvar carcinomas and their putative precursors. p16 was strongly positive in all cases of basaloid/condylomatous VIN3 (30/30) and basaloid (7/7) and warty (3/3) carcinomas. In contrast, p16 was almost consistently negative in normal skin, squamous cell hyperplasia (0/20), lichen sclerosus (0/19), differentiated (simplex) VIN3 (0/11), verrucous carcinoma (0/2), and keratinizing squamous cell carcinoma (3/33, 9%). One of the keratinizing squamous cell carcinomas positive for p16 occurred in a 25-year-old woman and the other two were associated with small foci of basaloid VIN3 adjacent to the tumor, suggesting a probable relationship with HPV. p16 was positive in 6 of 10 of basal cell carcinomas. In conclusion, p16 immunostaining is a good discriminator between HPV-associated and HPV-unrelated vulvar carcinomas and VIN, although it cannot differentiate basaloid squamous and basal cell carcinoma.",
        "Doc_title":"Immunohistochemical staining for p16 and p53 in premalignant and malignant epithelial lesions of the vulva.",
        "Journal":"International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists",
        "Do_id":"15213596",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;Tumor Suppressor Protein p53",
        "Doc_meshdescriptors":"Adolescent;Adult;Aged;Aged, 80 and over;Carcinoma in Situ;Carcinoma, Squamous Cell;Cyclin-Dependent Kinase Inhibitor p16;Female;Humans;Immunohistochemistry;Middle Aged;Papillomaviridae;Papillomavirus Infections;Precancerous Conditions;Retrospective Studies;Tumor Suppressor Protein p53;Tumor Virus Infections;Vulvar Neoplasms",
        "Doc_meshqualifiers":"metabolism;virology;metabolism;virology;metabolism;growth & development;metabolism;metabolism;virology;metabolism;metabolism;metabolism;virology",
        "_version_":1605775011854942208},
      {
        "Doc_abstract":"The tumour suppressor ARF (alternative reading frame) is one of the most important oncogenic stress sensors. ARF provides an 'oncogenic checkpoint' function through both p53-dependent and p53-independent mechanisms. In the present study, we demonstrate a novel p53-independent interaction between p14(ARF) and the adenovirus oncoprotein E1A. p14(ARF) inhibits E1A transcriptional function and promotes ubiquitination-dependent degradation of E1A. p14(ARF) overexpression relocalizes E1A into the nucleolus and inhibits E1A-induced cellular DNA replication independent of p53. Knockdown of endogenous p14(ARF) increases E1A transactivation. In addition, E1A can competitively inhibit ARF-Mdm2 (murine double minute 2) complex formation. These results identify a novel binding partner of p14(ARF) and reveal a mutually inhibitory interaction between p14(ARF) and E1A. We speculate that the ARF-E1A interaction may represent an additional host defence mechanism to limit viral replication. Alternatively, the interaction may allow adenovirus to sense the functional state of p53 in host cells, and fine-tune its own replication activity to prevent the triggering of a detrimental host response.",
        "Doc_title":"p14(ARF) inhibits the functions of adenovirus E1A oncoprotein.",
        "Journal":"The Biochemical journal",
        "Do_id":"21133853",
        "Doc_ChemicalList":"Adenovirus E1A Proteins;Tumor Suppressor Protein p14ARF;Tumor Suppressor Protein p53;Proto-Oncogene Proteins c-mdm2",
        "Doc_meshdescriptors":"Adenovirus E1A Proteins;Binding Sites;Cell Line;DNA Replication;Gene Silencing;HeLa Cells;Humans;Proto-Oncogene Proteins c-mdm2;Tumor Suppressor Protein p14ARF;Tumor Suppressor Protein p53;Virus Replication",
        "Doc_meshqualifiers":"antagonists & inhibitors;metabolism;antagonists & inhibitors;genetics;metabolism;genetics;metabolism;genetics;metabolism;physiology",
        "_version_":1605818700773982210},
      {
        "Doc_abstract":"To determine the correlation between p16 gene CpG methylation sites in the promoter region and HPV16 infection in cervical squamous cell carcinoma in Xinjiang Uyghur women.;MALDI-TOF MS was used quantitatively to analyze p16 gene promotor methylation status of CpG islands in 20 cervix squamous cell carcinomas and 20 corresponding non-cancerous tissues in Uyghur women. HPV16 infection was detected by polymerase chain reaction (PCR) in both groups.;Among the 16 CpG sites in the p16 gene promoter region, CpG1-2 and CpG 6 sites were different between the 2 groups, and the levels of CpG1-2 and CpG6 methylation sites in the cervical squamous cell carcinoma were higher than those in the control group. The presence of HPV16 infection was significantly different between the cervix squamous cell carcinoma tissue and non-cancerous tissues (P<0.05). There was no significant correlation between p16 gene CpG methylation sites and HPV16 infection of cervical squamous cell carcinoma in Uyghur women.;P16 gene CpG 1-2, CpG 6 hypermethylation and HPV16, which are independent of one another, play an important role in cervical squamous cell carcinogenesis in Uyghur women.",
        "Doc_title":"[p16 gene CpG methylation in cervical squamous cell carcinoma and HPV16 infection in Uyghur women].",
        "Journal":"Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences",
        "Do_id":"23406849",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Carcinoma, Squamous Cell;China;CpG Islands;DNA Methylation;Female;Genes, p16;Human papillomavirus 16;Humans;Papillomavirus Infections;Promoter Regions, Genetic;Uterine Cervical Neoplasms",
        "Doc_meshqualifiers":"genetics;virology;ethnology;complications;genetics;virology",
        "_version_":1605742717941317634},
      {
        "Doc_abstract":"Hepatocytes undergo marked changes in proliferation during normal liver development. In order to elucidate the mechanism for these changes, we examined the ontogeny of expression for the known cyclin-dependent kinase inhibitors (CKIs), p15(Ink4b), p16(Ink4a), p18(Ink4c), p19(Ink4d), p21(Cip1), p27(Kip1) and p57(Kip2). All except p16(Ink4a) were expressed at some time between late gestation and adulthood. The mRNA and protein expression patterns for p15(Ink4b) and p57(Kip2) were consistent with a role for these CKIs in the regulation of hepatocyte proliferation. Specifically, p57(Kip2) may contribute to hepatocyte growth arrest that occurs in term fetuses, while p15(Ink4b) may contribute to the maintenance of adult hepatocytes in a quiescent state. These results assign a possible role to two CKIs not previously identified as involved in hepatocyte cell cycle control.",
        "Doc_title":"A potential role for p15(Ink4b) and p57(Kip2) in liver development.",
        "Journal":"FEBS letters",
        "Do_id":"11042273",
        "Doc_ChemicalList":"Carrier Proteins;Cdkn1a protein, rat;Cdkn1b protein, rat;Cdkn2b protein, rat;Cdkn2c protein, rat;Cell Cycle Proteins;Cyclin-Dependent Kinase Inhibitor p15;Cyclin-Dependent Kinase Inhibitor p16;Cyclin-Dependent Kinase Inhibitor p18;Cyclin-Dependent Kinase Inhibitor p19;Cyclin-Dependent Kinase Inhibitor p21;Cyclin-Dependent Kinase Inhibitor p57;Cyclins;Enzyme Inhibitors;Microtubule-Associated Proteins;Nuclear Proteins;Tumor Suppressor Proteins;Cyclin-Dependent Kinase Inhibitor p27;RNA;Cyclin-Dependent Kinases",
        "Doc_meshdescriptors":"Animals;Blotting, Western;Carrier Proteins;Cell Cycle Proteins;Cyclin-Dependent Kinase Inhibitor p15;Cyclin-Dependent Kinase Inhibitor p16;Cyclin-Dependent Kinase Inhibitor p18;Cyclin-Dependent Kinase Inhibitor p19;Cyclin-Dependent Kinase Inhibitor p21;Cyclin-Dependent Kinase Inhibitor p27;Cyclin-Dependent Kinase Inhibitor p57;Cyclin-Dependent Kinases;Cyclins;Enzyme Inhibitors;Female;Gene Expression Regulation, Developmental;Hepatocytes;Immunohistochemistry;Liver;Male;Microtubule-Associated Proteins;Nuclear Proteins;RNA;Rats;Rats, Sprague-Dawley;Tumor Suppressor Proteins",
        "Doc_meshqualifiers":"analysis;genetics;physiology;antagonists & inhibitors;genetics;analysis;chemistry;cytology;metabolism;chemistry;embryology;metabolism;genetics;analysis;genetics;physiology;genetics;metabolism",
        "_version_":1605891748004888576},
      {
        "Doc_abstract":"This study aimed to link expression patterns of AQP1, AQP5, Bcl-2 and p16 to clinicopathological characteristics of oro-hypopharyngeal squamous cell carcinomas.;Immunohistochemical expression of AQP1, AQP5, Bcl-2 and p16 was investigated in 107 consecutive oro-hypopharyngeal squamous cell carcinoma cases. Molecular interrelationship and correlations with clinicopathological parameters and survival were computed.;AQP1 was expressed exclusively by a subgroup of basaloid-like squamous cell carcinomas. AQP5 was detected in 25.2 per cent of the samples, showing significant association with the absence of p16 and Bcl-2 (p = 0.018; p = 0.010). In multivariate analysis, overexpression of p16 was significantly correlated with favourable overall survival (p = 0.014).;AQP5 defined a subset of patients with Bcl-2-negative and p16-negative tumours with a poor clinical outcome. AQP1 was found to be a marker of a subgroup of aggressive basaloid-like squamous cell carcinomas. These findings suggest that AQP1 and AQP5 are interesting candidates for further studies on risk group classification and personalised treatment of oro-hypopharyngeal squamous cell carcinomas.",
        "Doc_title":"AQP1, AQP5, Bcl-2 and p16 in pharyngeal squamous cell carcinoma.",
        "Journal":"The Journal of laryngology and otology",
        "Do_id":"26074259",
        "Doc_ChemicalList":"AQP1 protein, human;AQP5 protein, human;Aquaporin 5;Biomarkers, Tumor;DNA, Neoplasm;Neoplasm Proteins;P16 protein, human;Proto-Oncogene Proteins c-bcl-2;Aquaporin 1",
        "Doc_meshdescriptors":"Aquaporin 1;Aquaporin 5;Biomarkers, Tumor;Carcinoma, Squamous Cell;DNA, Neoplasm;Female;Gene Expression Regulation, Neoplastic;Genotype;Humans;Hypopharyngeal Neoplasms;Male;Middle Aged;Neoplasm Proteins;Prognosis;Proto-Oncogene Proteins c-bcl-2",
        "Doc_meshqualifiers":"biosynthesis;genetics;biosynthesis;genetics;metabolism;genetics;metabolism;pathology;genetics;genetics;metabolism;pathology;biosynthesis;genetics;biosynthesis;genetics",
        "_version_":1605746429393895425},
      {
        "Doc_abstract":"We have previously reported that a set of oral squamous cell carcinoma lines express specifically elevated cdk6 activity. One of the cell lines, SCC4, contains a cdk6 amplification and expresses functional p16ink4a, the other cell lines express undetectable levels of p16ink4a, despite a lack of coding-region mutations. Two of the cell lines, SCC15 and SCC40 have a hypermethylated p16ink4A promoter and a third cell line, SCC9, has a mutation in the p16ink4a promoter. Using the demethylation agent 5-aza-2'-deoxycytidine, we showed that the p16ink4a protein was re-expressed after a 5-day treatment with this chemical. One cell line, SCC15 expressed high levels of p16ink4a. In this line, cdk6 activity was decreased after 5-aza-2'deoxycytidine treatment, and the hypophosphorylated, growth suppressive form of the retinoblastoma tumor suppressor protein pRB was detected. Expression of p16ink4a persisted, even after the drug was removed and the cells expressed senescence-associated beta-galactosidase activity. Ectopic expression of p16ink4a with a recombinant retrovirus in this cell line also induced a similar senescence-like phenotype. Hence, it was possible to restore a functional pRB pathway in an oral squamous cell carcinoma line by inducing re-expression of endogenous p16ink4a in response to treatment with a demethylating agent.",
        "Doc_title":"Re-expression of endogenous p16ink4a in oral squamous cell carcinoma lines by 5-aza-2'-deoxycytidine treatment induces a senescence-like state.",
        "Journal":"Oncogene",
        "Do_id":"10030668",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;Proto-Oncogene Proteins;Recombinant Proteins;Retinoblastoma Protein;decitabine;DNA Modification Methylases;Protein-Serine-Threonine Kinases;CDK4 protein, human;CDK6 protein, human;Cyclin-Dependent Kinase 4;Cyclin-Dependent Kinase 6;Cyclin-Dependent Kinases;beta-Galactosidase;Azacitidine",
        "Doc_meshdescriptors":"Azacitidine;Carcinoma, Squamous Cell;Cell Aging;Cyclin-Dependent Kinase 4;Cyclin-Dependent Kinase 6;Cyclin-Dependent Kinase Inhibitor p16;Cyclin-Dependent Kinases;DNA Methylation;DNA Modification Methylases;Gene Expression Regulation, Neoplastic;Gene Transfer Techniques;Humans;Mouth Neoplasms;Mutation;Phosphorylation;Promoter Regions, Genetic;Protein-Serine-Threonine Kinases;Proto-Oncogene Proteins;Recombinant Proteins;Retinoblastoma Protein;Retroviridae;Tumor Cells, Cultured;beta-Galactosidase",
        "Doc_meshqualifiers":"analogs & derivatives;pharmacology;drug therapy;genetics;drug effects;drug effects;genetics;metabolism;antagonists & inhibitors;drug therapy;genetics;metabolism;genetics;metabolism;drug effects;metabolism;genetics;genetics;metabolism",
        "_version_":1605782989380255744},
      {
        "Doc_abstract":"Pancreatic cancer has a poor prognosis, mainly due to lack of effective therapies. This study demonstrated the ability of dietary agent, indole-3-carbinol (I3C), to lower the LD(50) of gemcitabine (Gemzar) in decreasing growth of both male (MiaPaca2) and female (SU86.86) pancreatic cancer cells. Female pancreatic cancer cells were more resistant to gemcitabine alone. Additionally, RT-PCR analysis of MiaPaca2 cells treated with 1, 10 or 100 M of I3C showed that I3C reactivated the tumor suppressor gene p16INK4a in pancreatic cancer cells. Methylated-specific PCR analysis indicated that I3C demethylated the promoter region of p16 INK4a, which was methylated in the untreated cancer cells. p16INK4a inactivation through promoter hypermethylation is considered an early event in pancreatic carcinogenesis. A positive control using 5-azacytidine also reactivated p16INK4a. This study demonstrated the potential of I3C, a possible non-toxic hypomethylating agent, combined with the anticancer agent, gemcitabine, to be a powerful strategy for treating pancreatic cancer.",
        "Doc_title":"Gender differences in gemcitabine (Gemzar) efficacy in cancer cells: effect of indole-3-carbinol.",
        "Journal":"Anticancer research",
        "Do_id":"21187469",
        "Doc_ChemicalList":"Enzyme Inhibitors;Indoles;Deoxycytidine;gemcitabine;indole-3-carbinol;DNA Modification Methylases",
        "Doc_meshdescriptors":"Antineoplastic Combined Chemotherapy Protocols;Cell Line, Tumor;DNA Modification Methylases;Deoxycytidine;Drug Synergism;Enzyme Inhibitors;Female;Gene Expression Regulation, Neoplastic;Genes, p16;Humans;Indoles;Male;Pancreatic Neoplasms;Reverse Transcriptase Polymerase Chain Reaction;Sex Factors",
        "Doc_meshqualifiers":"pharmacology;antagonists & inhibitors;metabolism;administration & dosage;analogs & derivatives;pharmacology;administration & dosage;pharmacology;drug effects;drug effects;administration & dosage;pharmacology;drug therapy;enzymology;genetics",
        "_version_":1605880349971185664},
      {
        "Doc_abstract":"An increasing subset of patients with head and neck squamous cell carcinoma (HNSCCA) is positive for high-risk human papillomavirus (HR-HPV). Patients tend to be younger, have a minimal or absent tobacco and ethanol abuse history, increased number of lifetime sexual partners (particularly oral-genital sex), and squamous cell carcinomas (SCCAs) arising in the oropharynx. The most common HR-HPV associated with HNSCCA is HPV-16. HR-HPV positivity is associated with decreased expression of the p53 and Rb genes, overexpression of p16, decreased expression of EGFR, and a different genetic expression pattern compared with patients with HR-HPV-negative SCCAs, leading to the conclusion that this is a distinct clinical entity. Patients who have HR-HPV-positive HNSCCAs have an improved prognosis, particularly those with oropharyngeal SCCAs, leading some to speculate that the intensity of treatment might be decreased. At present, whether this can be done safely remains unclear.",
        "Doc_title":"Human papillomavirus and head and neck cancer.",
        "Journal":"American journal of clinical oncology",
        "Do_id":"19652580",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Carcinoma, Squamous Cell;Head and Neck Neoplasms;Human papillomavirus 16;Humans;Papillomaviridae;Papillomavirus Infections;Prognosis;Risk Factors",
        "Doc_meshqualifiers":"virology;virology;genetics;metabolism;genetics;metabolism;complications",
        "_version_":1605750059807277056},
      {
        "Doc_abstract":"Arf is a key mammalian tumor suppressor gene known to be activated in response to aberrant mitogenic signals leading to both p53-dependent and -independent effects. We recently uncovered a new and somewhat unexpected function for mouse Arf as a regulator of mural cell accumulation within an ocular vascular bed destined to regress in the postnatal period. We found that the Arf gene product, p19(Arf), blocks mural cell proliferation driven by Platelet-derived growth factor receptor beta (Pdgfrbeta) in the developing vitreous. In vivo studies and analyses of cultured cells indicate that p19(Arf) dampens the expression of Pdgfrbeta. In cultured mouse embryo fibroblasts, p19(Arf) accomplishes this independently of two established effectors - Mdm2 and p53. Our findings indicating that p19(Arf) responds to specific developmental cues to disrupt Pdgfrbeta signaling in the developing eye extend existing paradigms for Arf tumor suppressor gene biology.",
        "Doc_title":"The Arf tumor suppressor regulates platelet-derived growth factor receptor beta signaling: a new view through the eyes of Arf(-/-) mice.",
        "Journal":"Cell cycle (Georgetown, Tex.)",
        "Do_id":"16205116",
        "Doc_ChemicalList":"Cdkn2a protein, mouse;Cyclin-Dependent Kinase Inhibitor p16;Tumor Suppressor Protein p14ARF;Receptor, Platelet-Derived Growth Factor beta",
        "Doc_meshdescriptors":"Animals;Cyclin-Dependent Kinase Inhibitor p16;Eye;Genotype;Humans;Mice;Mice, Knockout;Receptor, Platelet-Derived Growth Factor beta;Signal Transduction;Tumor Suppressor Protein p14ARF",
        "Doc_meshqualifiers":"embryology;metabolism;metabolism;deficiency;genetics;metabolism",
        "_version_":1605903126185902080},
      {
        "Doc_abstract":"Replicative senescence is defined for human diploid fibroblasts in culture as a cell growth arrest appearing beyond 50 +/- 10 population doublings and associated with telomeres' shortening. This phenomenon shows an increased expression of growth cell inhibitors: p21Waf1 described as an universal CDK inhibitor and p16INK4a as a specific inhibitor for both G1 phase kinases CDK4 and CDK6. The cell proliferation inhibitor p14ARF, product of INK4a/ARF locus is involved in replicative senescence too. Overexpression or homozygotic deletion of these inhibitors demonstrated their role in senescence induction. These proteins are involved in two different metabolic pathways, the first including p53, represented by E2F, ARF, MDM2, p53, p21Waf1, and the second concerning pRb and p16INK4a. These two pathways present numerous interactions and the polymerase (PARP) in relation with p53 and activated by telomere shortening might represent via p21Waf1 a link between this shortening and cell cycle control. An another metabolic pathway involving PTEN and p27KIP1 is discussed in senescent-like phenotype induction, but its activity in replicative senescent is uncertain.",
        "Doc_title":"[Cyclin dependent kinase inhibitors and replicative senescence].",
        "Journal":"Pathologie-biologie",
        "Do_id":"11776695",
        "Doc_ChemicalList":"CDKN1A protein, human;Cyclin-Dependent Kinase Inhibitor p16;Cyclin-Dependent Kinase Inhibitor p21;Cyclins;Retinoblastoma Protein;Tumor Suppressor Protein p14ARF;Tumor Suppressor Protein p53;Cyclin-Dependent Kinases",
        "Doc_meshdescriptors":"Cell Aging;Cell Division;Cyclin-Dependent Kinase Inhibitor p16;Cyclin-Dependent Kinase Inhibitor p21;Cyclin-Dependent Kinases;Cyclins;Fibroblasts;Humans;Retinoblastoma Protein;Tumor Suppressor Protein p14ARF;Tumor Suppressor Protein p53",
        "Doc_meshqualifiers":"genetics;genetics;physiology;antagonists & inhibitors;genetics;physiology;physiology;physiology;physiology",
        "_version_":1605903395329146880},
      {
        "Doc_abstract":"To explore the correlation between homozygous deletions and mutation of p16 gene and the carcinogenesis and progression of squamous cell carcinoma of buccal mucosa.;Thirty buccal cancers, 10 leukoplakias and 8 buccal mucosas were involved. DNA was extracted from the tissues. PCR was used to analyses homozygous deletion of p16 gene. PCR-SSCP-DNA sequencing was performed to detect the point mutation of p16 gene. Immunohistochemical techniques were used to detect the expression of P16 protein.;Gene deletions and point mutations were not found in leukoplakia and normal buccal mucosa. Gene deletions were found in 7 samples out of 30 cases of squamous cell carcinoma of buccal mucosa (23.3%), while point mutations were found in 5 samples out of 30 cases of squamous cell carcinoma of buccal mucosa (16.7%). Sequencing analysis showed that 5 cases point mutations were missense mutations, occurred on exon 2. Three cases occurred in the same point, codon 99 (GAT --> AAT). The result of immunohistochemical stains showed that 11 out of 12 cases gene inactivation did not expressed P16 protein.;Homozygous deletion and point mutation of p16 were the main pattern of gene inactivation in squamous cell carcinoma of buccal mucosa. There was a closely correlation between p16 gene inactivation and the carcinogenesis of squamous cell carcinoma of buccal mucosa.",
        "Doc_title":"[Study of p16INK4/CDKN2 gene homozygous deletions and point mutation in squamous cell carcinoma of buccal mucosa].",
        "Journal":"Hua xi kou qiang yi xue za zhi = Huaxi kouqiang yixue zazhi = West China journal of stomatology",
        "Do_id":"16999361",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16",
        "Doc_meshdescriptors":"Carcinoma, Squamous Cell;Cyclin-Dependent Kinase Inhibitor p16;Gene Deletion;Genes, p16;Humans;Mouth Mucosa;Mutation;Point Mutation",
        "Doc_meshqualifiers":"None",
        "_version_":1605841565104734208},
      {
        "Doc_abstract":"Hypermethylation of the O6-MGMT, p14ARF, p16INK4a, RASSF1A and APC1A genes are unfavourable prognostic markers in colorectal cancer (CRC). We hypothesized that they could be related to prognosis also in cervical cancer. Methylation was studied in DNA extracts from surgical specimens of cancer tissue by novel pyrosequencing methods. In 109 patients (90 squamous cell carcinomas, 19 adenocarcinomas), we found that hypermethylation of the APC1A gene promoter occurred in 8.3% of patients, and of p16INK4a in 1.8%. APC1A hypermethylation was significantly related to more advanced FIGO stage of the tumor (P=0.013), larger tumor diameter (P=0.049) and distant recurrence-free survival (P=0.0007), but not with locoregional recurrence rate, age, HPV status, DNA ploidy, tumor grade or malignancy grading score. We conclude that methylation of the APC1A promoter in cervical cancer, as diagnosed by pyrosequencing, is significantly related to major biological characteristics of the tumor, and may be a new predictor of poor prognosis in cervical cancer.",
        "Doc_title":"Hypermethylation of promoter regions of the APC1A and p16INK4a genes in relation to prognosis and tumor characteristics in cervical cancer patients.",
        "Journal":"International journal of oncology",
        "Do_id":"21674126",
        "Doc_ChemicalList":"Adaptor Proteins, Signal Transducing;Cyclin-Dependent Kinase Inhibitor p16;Tumor Suppressor Proteins;DNA Modification Methylases;MGMT protein, human;DNA Repair Enzymes",
        "Doc_meshdescriptors":"Adaptor Proteins, Signal Transducing;Cyclin-Dependent Kinase Inhibitor p16;DNA Methylation;DNA Modification Methylases;DNA Repair Enzymes;Disease-Free Survival;Epigenomics;Female;Humans;Prognosis;Promoter Regions, Genetic;Tumor Suppressor Proteins;Uterine Cervical Neoplasms",
        "Doc_meshqualifiers":"genetics;metabolism;genetics;metabolism;genetics;metabolism;genetics;metabolism;genetics;metabolism;genetics;metabolism;pathology",
        "_version_":1605753322121199616},
      {
        "Doc_abstract":"We have identified parameters which define a causal role of HPV16 in head and neck cancer. Twenty-eight tumours which were typed positive for HPV16 DNA, were comprehensively analysed for expression of the viral oncogenes E6 and E7, the status of the p53 gene, and the protein status of pRb and p16(INK4a). In a subset of cases, we have searched for integrated viral DNA, and have determined the genomic status of the E6 gene. Expression of E6/E7 was found in 12 tumours most of which were derived from the oropharynx, whereas p53 mutations were present in 13 tumours from various sites. The tumours either carried p53 mutations but did not express E6/E7, or they did express E6/E7 but were p53-wild-type. Coexistence of E6/E7 expression with a mutated p53 was found in only one case. Strikingly, in most p53-mutated tumours without E6/E7 expression, we found the E6 gene to be disrupted. E6/E7 expression was associated with reduced pRb and overexpressed p16(INK4a). Viral-cellular fusion transcripts were found in two cases. Our data demonstrate that HPV16 DNA-positivity in head and neck cancers is not indicative of a causal role. A causal role of HPV16 in head and neck cancer is defined by: E6/E7 expression, viral integration with an intact E6 gene, and perturbation of pRb cell cycle control. Mostly, the p53 gene is wild-type.",
        "Doc_title":"Involvement of intact HPV16 E6/E7 gene expression in head and neck cancers with unaltered p53 status and perturbed pRb cell cycle control.",
        "Journal":"Oncogene",
        "Do_id":"11896579",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;DNA, Neoplasm;E6 protein, Human papillomavirus type 16;Oncogene Proteins, Fusion;Oncogene Proteins, Viral;Papillomavirus E7 Proteins;RNA, Viral;Repressor Proteins;Retinoblastoma Protein;oncogene protein E7, Human papillomavirus type 16",
        "Doc_meshdescriptors":"Base Sequence;Cell Cycle;Cyclin-Dependent Kinase Inhibitor p16;DNA Mutational Analysis;DNA, Neoplasm;Genes, p53;Head and Neck Neoplasms;Humans;Immunohistochemistry;Molecular Sequence Data;Mutation;Oncogene Proteins, Fusion;Oncogene Proteins, Viral;Papillomaviridae;Papillomavirus E7 Proteins;RNA, Viral;Repressor Proteins;Retinoblastoma Protein;Transcription, Genetic",
        "Doc_meshqualifiers":"immunology;metabolism;analysis;genetics;metabolism;virology;genetics;biosynthesis;genetics;isolation & purification;biosynthesis;immunology;metabolism",
        "_version_":1605741996085870592},
      {
        "Doc_abstract":"P14/p19ARF (ARF) plays a major role in the activation of p53 by oncogenic signals. The biochemical basis of this has not been fully elucidated. We report here that forced expression of p14ARF enhances phosphorylation of p53 serine 15 (p53S15) in NIH3T3, IMR90 and MCF7 cells. Ectopic expression of the oncogenes c-myc, E2F1 and E1A, all of which activate p53 at least partially via ARF, lead to p53S15 phosphorylation in IMR90 cells. In addition, ectopic expression of p53 also results in p53S15 phosphorylation, suggesting that this is a common event in the ARF-p53 tumor suppression system. Furthermore, p53-, p14ARF-, c-myc- and E2F1-, but not E1A-, induced p53S15 phosphorylation was substantially reduced in AT fibroblasts (GM05823). Downregulation of ATM in MCF7 cells using RNA interference (RNAi) technology significantly attenuated p14ARF- and p53-induced phosphorylation of p53S15. Ectopically expressed ARF in NIH3T3 cells induced ATM nuclear foci and activated ATM kinase. Functionally, ectopic expression of p14ARF and c-myc inhibited the proliferation of IMR90 but not ATM null GM05823 cells, and p14ARF-induced inhibition of MCF7 cell proliferation was significantly attenuated by downregulation of ATM by RNAi. Taken together, these data show a functional role for ATM in ARF-mediated tumor suppression.",
        "Doc_title":"ATM activity contributes to the tumor-suppressing functions of p14ARF.",
        "Journal":"Oncogene",
        "Do_id":"15258567",
        "Doc_ChemicalList":"Cell Cycle Proteins;DNA-Binding Proteins;RNA, Antisense;RNA, Small Interfering;Recombinant Proteins;Tumor Suppressor Protein p14ARF;Tumor Suppressor Protein p53;Tumor Suppressor Proteins;ATM protein, human;Ataxia Telangiectasia Mutated Proteins;Atm protein, mouse;Protein-Serine-Threonine Kinases",
        "Doc_meshdescriptors":"3T3 Cells;Animals;Ataxia Telangiectasia;Ataxia Telangiectasia Mutated Proteins;Base Sequence;Cell Cycle Proteins;Cell Division;Cell Line, Tumor;DNA-Binding Proteins;Genes, myc;Humans;Mice;Molecular Sequence Data;Phosphorylation;Protein-Serine-Threonine Kinases;RNA, Antisense;RNA, Small Interfering;Recombinant Proteins;Reverse Transcriptase Polymerase Chain Reaction;Transfection;Tumor Suppressor Protein p14ARF;Tumor Suppressor Protein p53;Tumor Suppressor Proteins",
        "Doc_meshqualifiers":"genetics;metabolism;genetics;genetics;metabolism;genetics;metabolism;genetics;physiology;metabolism",
        "_version_":1605796771875782656},
      {
        "Doc_abstract":"Although it is well established that the processes of cellular proliferation and apoptosis are linked, the role of cell cycle regulators in T cell responses in vivo is not well understood. In recent years, tumor suppressor molecule p19(ARF) has emerged as a key cell cycle regulator important in cellular apoptosis against strong mitogenic stimuli. In this study, we compared the antigen-specific T cell responses between wild type (+/+) and p19(ARF)-deficient (p19-/-) mice following an acute infection with lymphocytic choriomeningitis virus (LCMV). p19-/- mice mounted a potent CD8 T cell response and the magnitude of expansion of LCMV-specific CD8 T cells was comparable to that of +/+ mice. Further, the clonal downsizing of the expanded virus-specific CD8 T cells and establishment of long-term T cell memory were minimally affected by p19(ARF) deficiency. Therefore, p19(ARF) function is not essential to regulate T cell responses following an acute viral infection.",
        "Doc_title":"Role of cell cycle regulator p19ARF in regulating T cell responses.",
        "Journal":"Cellular immunology",
        "Do_id":"12576030",
        "Doc_ChemicalList":"Cdkn2a protein, mouse;Cyclin-Dependent Kinase Inhibitor p16;Tumor Suppressor Protein p14ARF",
        "Doc_meshdescriptors":"Acute Disease;Animals;Apoptosis;CD8-Positive T-Lymphocytes;Cyclin-Dependent Kinase Inhibitor p16;Disease Models, Animal;Immunity, Cellular;Immunologic Memory;Lymphocytic Choriomeningitis;Lymphocytic choriomeningitis virus;Male;Mice;Mice, Knockout;Time Factors;Tumor Suppressor Protein p14ARF",
        "Doc_meshqualifiers":"immunology;immunology;immunology;deficiency;genetics;physiology",
        "_version_":1605879457300611072},
      {
        "Doc_abstract":"Transformation by Abelson murine leukemia virus (Ab-MLV) is a multistep process in which growth-stimulatory signals from the v-Abl oncoprotein and growth-suppressive signals from the p19(Arf)-p53 tumor suppressor pathway oppose each other and influence the outcome of infection. The process involves a proliferative phase during which highly viable primary transformants expand, followed by a period of marked apoptosis (called \"crisis\") that is dependent on the presence of p19(Arf) and p53; rare cells that survive this phase emerge as fully transformed and malignant. To understand the way in which v-Abl expression affects p19(Arf) expression, we examined changes in expression of Arf during all stages of Ab-MLV transformation process. As is consistent with the ability of v-Abl to stimulate Myc, a transcription factor known to induce p19(Arf), Myc and Arf are induced soon after infection and p19(Arf) is expressed. At these early time points, the infected cells remain highly viable. The onset of crisis is marked by an increase in p19(Arf) expression and a change in localization of the protein from the nucleoplasm to the nucleolus. These data together suggest that the localization and expression levels of p19(Arf) modulate the effects of the protein during oncogenesis and reveal that the p19(Arf)-mediated response is subject to multiple layers of regulation that influence its function during Ab-MLV-mediated transformation.",
        "Doc_title":"Changes in p19Arf localization accompany apoptotic crisis during pre-B-cell transformation by Abelson murine leukemia virus.",
        "Journal":"Journal of virology",
        "Do_id":"18579612",
        "Doc_ChemicalList":"Cdkn2a protein, mouse;Cyclin-Dependent Kinase Inhibitor p16;Fluorescent Dyes;Indoles;Green Fluorescent Proteins;DAPI",
        "Doc_meshdescriptors":"Abelson murine leukemia virus;Animals;Apoptosis;B-Lymphocytes;Cell Line, Transformed;Cell Transformation, Viral;Crosses, Genetic;Cyclin-Dependent Kinase Inhibitor p16;Flow Cytometry;Fluorescent Dyes;Green Fluorescent Proteins;Heterozygote;Indoles;Mice;Mice, Inbred BALB C;Mice, Inbred C57BL;Mice, Knockout;NIH 3T3 Cells",
        "Doc_meshqualifiers":"genetics;pathology;virology;genetics;metabolism;metabolism;metabolism;metabolism",
        "_version_":1605830427948351488},
      {
        "Doc_abstract":"The p19(ARF) tumor suppressor antagonizes Mdm2 to induce p53-dependent cell cycle arrest. Individual TKO (triple knock out) mice nullizygous for ARF, p53, and Mdm2 develop multiple tumors at a frequency greater than those observed in animals lacking both p53 and Mdm2 or p53 alone, demonstrating that p19(ARF) can act independently of the Mdm2-p53 axis in tumor surveillance. Reintroduction of ARF into TKO mouse embryo fibroblasts (MEFs), but not into those lacking both p53 and ARF, arrested the cell division cycle in the G1 phase. Inhibition of the retinoblastoma protein had no effect on the ability of ARF to arrest TKO MEFs. Thus, in the absence of Mdm2, p19(ARF) interacts with other targets to inhibit cell proliferation.",
        "Doc_title":"p53-independent functions of the p19(ARF) tumor suppressor.",
        "Journal":"Genes & development",
        "Do_id":"10995391",
        "Doc_ChemicalList":"Nuclear Proteins;Proteins;Proto-Oncogene Proteins;Tumor Suppressor Protein p14ARF;Tumor Suppressor Protein p53;Mdm2 protein, mouse;Proto-Oncogene Proteins c-mdm2",
        "Doc_meshdescriptors":"Animals;Cells, Cultured;Fluorescent Antibody Technique;Genes, Tumor Suppressor;Immunoblotting;Mice;Mice, Inbred C57BL;Mice, Knockout;Neoplasms;Nuclear Proteins;Polymerase Chain Reaction;Proteins;Proto-Oncogene Proteins;Proto-Oncogene Proteins c-mdm2;Tumor Suppressor Protein p14ARF;Tumor Suppressor Protein p53",
        "Doc_meshqualifiers":"genetics;pathology;genetics;metabolism;genetics;physiology;genetics;physiology",
        "_version_":1605895621285249024},
      {
        "Doc_abstract":"Lymphoid specific helicase (Lsh) belongs to the family of SNF2/helicases. Disruption of Lsh leads to developmental growth retardation and premature aging in mice. However, the specific effect of Lsh on human cellular senescence remains unknown. Herein, we report that Lsh overexpression delays cell senescence by silencing p16(INK4a) in human fibroblasts. The patterns of p16(INK4a) and Lsh expression during cell senescence present the inverse correlation. We also find that Lsh requires histone deacetylase (HDAC) activity to repress p16(INK4a) and treatment with trichostatin A (TSA) is sufficient to block the repressor effect of Lsh. Moreover, overexpression of Lsh is correlated with deacetylation of histone H3 at the p16 promoter, and TSA treatment in Lsh-expressing cells reverses the acetylation status of histones. Additionally, we demonstrate an interaction between Lsh, histone deacetylase 1 (HDAC1) and HDAC2 in vivo. Furthermore, we demonstrate that Lsh interacts in vivo with the p16 promoter and recruits HDAC1. Our data suggest that Lsh represses endogenous p16(INK4a) expression by recruiting HDAC to establish a repressive chromatin structure at the p16(INK4a) promoter, which in turn delays cell senescence.",
        "Doc_title":"Senescence delay and repression of p16INK4a by Lsh via recruitment of histone deacetylases in human diploid fibroblasts.",
        "Journal":"Nucleic acids research",
        "Do_id":"19561196",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;Heterochromatin;Repressor Proteins;DNA (Cytosine-5-)-Methyltransferase;beta-Galactosidase;HDAC1 protein, human;Hdac2 protein, mouse;Histone Deacetylase 1;Histone Deacetylase 2;Histone Deacetylases;DNA Helicases;HELLS protein, human",
        "Doc_meshdescriptors":"Cell Aging;Cell Line;Cell Proliferation;Cyclin-Dependent Kinase Inhibitor p16;DNA (Cytosine-5-)-Methyltransferase;DNA Helicases;Diploidy;Fibroblasts;G1 Phase;Gene Silencing;Heterochromatin;Histone Deacetylase 1;Histone Deacetylase 2;Histone Deacetylases;Humans;Promoter Regions, Genetic;Repressor Proteins;beta-Galactosidase",
        "Doc_meshqualifiers":"genetics;genetics;metabolism;metabolism;antagonists & inhibitors;genetics;metabolism;cytology;enzymology;metabolism;chemistry;metabolism;metabolism;metabolism",
        "_version_":1605902817638219776},
      {
        "Doc_abstract":"To study the promoter methylation pattern of p16 and hMLH1 genes in esophageal squamous cell carcinoma and reflux esophagitis, and to correlate the results with clinical and pathologic findings.;Twelve cases of normal esophagus, 13 cases of esophageal squamous cell carcinoma, 43 cases of reflux esophagitis with basal cell hyperplasia and 21 cases of reflux esophagitis with dysplasia, as confirmed by endoscopic and pathologic examination, were enrolled into the study. Genomic DNA was extracted. The promoter methylation status of p16 was measured by methylation-specific polymerase chain reaction. The promoter methylation status of hMLH1 was measured by sodium bisulfite-restriction enzyme digestion. Immunohistochemical study for p16 and hMLH1 proteins was also carried out.;The rates of p16 methylation in normal esophageal epithelium, basal cell hyperplasia, dysplasia and esophageal squamous cell carcinoma were 0/12, 14.0% (6/43), 38.1% (8/21) and 6/13, respectively. The p16 methylation correlated with the progress of esophageal lesions. On the other hand, the hMLH1 methylation was not observed in the normal esophageal epithelium and reflux esophagitis. One case of esophageal squamous cell carcinoma showed the presence of hMLH1 methylation. The hMLH1 promoter hypermethylation did not correlate with the clinical and pathologic features.;The p16 methylation may be one of the earliest events in the pathogenesis of esophageal squamous cell carcinoma and is also observed in reflux esophagitis. Reflux esophagitis may be related to the development of esophageal squamous cell carcinoma in Chinese population. In contrast, hMLH1 methylation may not be directly involved in the tumorigenesis of esophageal squamous cell carcinoma.",
        "Doc_title":"[Methylation of p16 and hMLH1 genes in esophageal squamous cell carcinoma and reflux esophagitis].",
        "Journal":"Zhonghua bing li xue za zhi = Chinese journal of pathology",
        "Do_id":"22169643",
        "Doc_ChemicalList":"Adaptor Proteins, Signal Transducing;Cyclin-Dependent Kinase Inhibitor p16;MLH1 protein, human;Nuclear Proteins;MutL Protein Homolog 1",
        "Doc_meshdescriptors":"Adaptor Proteins, Signal Transducing;Adult;Aged;Aged, 80 and over;Carcinoma, Squamous Cell;Cyclin-Dependent Kinase Inhibitor p16;DNA Methylation;Esophageal Neoplasms;Esophagitis, Peptic;Esophagus;Female;Genes, p16;Humans;Hyperplasia;Male;Middle Aged;MutL Protein Homolog 1;Nuclear Proteins;Precancerous Conditions;Promoter Regions, Genetic",
        "Doc_meshqualifiers":"genetics;genetics;pathology;genetics;genetics;pathology;genetics;pathology;pathology;genetics;genetics;pathology;genetics",
        "_version_":1605802444077400064},
      {
        "Doc_abstract":"To investigate the effect of up-regulated expression of tumor suppressor gene p14(ARF) on apoptosis of chronic myeloid leukemia (CML) cells and its interaction with imatinib.;Tumor suppressor gene p14(ARF) was transduced into K562 (K562-p14(ARF)) and 4 blast crisis primary CML cells (CML-BC 1-4) using vesicular stomatitis virus glycoprotein (VSV-G) pseudotyped lentiviral vector with cells transduced by empty vector as control. Fluorescence microscopy and flow cytometry were applied to measure transduction efficiency, and Western blotting assay was used to detect p14(ARF) protein of K562 cells. WST-8 method was used to determine cell growth inhibition rate of K562 cells transduced by the target gene under different concentrations of imatinib (0, 0.015, 0.062, 0.125, 0.25, 0.5, 1.0, 2.0 mol/L). Cell apoptosis and leukemic cellular colony-forming ability were detected by Annexin V-FITC/PI dyeing using flow cytometry (FCM) and semi-solid culture method respectively.;Fluorescence microscopy and FCM showed that transduction efficiency (GFP positive cells) of K562-p14(ARF), K562-VSV and CML-BC1 cells were close to 100%, and CML-BC 2-4 cells were 80% to 90% on average. Results of Western blotting showed that the levels of ARF protein expression of K562 cells transduced by p14(ARF) were significantly higher than of untransduced cells; the apoptosis rate of K562-p14(ARF) was 20%; the mean apoptosis rate of 4 primary leukemic cells transduced by the p14(ARF) [(71.122.4)%] was significantly higher than of control group [(12.46.2)%] (P<0.05). Imatinib significantly inhibited the proliferation of K562-p14(ARF) cells in a dose-dependent manner. The mean leukemic cellular colony-forming unit of 4 primary leukemic cells transduced by the p14(ARF) (41.513.2) was significantly lower than of the control group (88.57.9) (P<0.05).;Increased p14(ARF) gene expression could induce apoptosis of CML cells; Moreover, it could enhance inhibitory effect on cell proliferation when combined with imatinib.",
        "Doc_title":"[Effect of up-regulated expression of tumor suppressor gene p14(ARF) on apoptosis of chronic myeloid leukemia cells].",
        "Journal":"Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi",
        "Do_id":"23827110",
        "Doc_ChemicalList":"Tumor Suppressor Protein p14ARF",
        "Doc_meshdescriptors":"Apoptosis;Gene Expression Regulation, Leukemic;Genetic Vectors;Humans;K562 Cells;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Tumor Suppressor Protein p14ARF;Up-Regulation",
        "Doc_meshqualifiers":"metabolism;pathology;metabolism",
        "_version_":1605762807735779328},
      {
        "Doc_abstract":"We have established that the Arf tumor suppressor gene regulates mural cell biology in the hyaloid vascular system (HVS) of the developing eye. In the absence of Arf, perivascular cells accumulate within the HVS and prevent its involution. We now demonstrate that mural cell accumulation evident at embryonic day (E) 13.5 in Arf(-/-) mice was driven by excess proliferation at E12.5, when Arf expression was detectable in vitreous pericyte-like cells. Their expression of Arf overlapped with Pdgf receptor beta (Pdgfrbeta), which is essential for pericyte accumulation in the mouse. In cultured cells, p19Arf decreased Pdgfrbeta and blocked Pdgf-B-driven proliferation independently of Mdm2 and p53. The presence of a normal Arf allele correlated with decreased Pdgfrbeta in the embryonic vitreous. Pdgfrbeta was required for vitreous cell accumulation in the absence of Arf. Our findings demonstrate a novel, p53- and Mdm2-independent function for p19Arf. Instead of solely sensing excessive mitogenic stimuli, developmental cues induce Arf to block Pdgfrbeta-dependent signals and prevent the accumulation of perivascular cells selectively in a vascular bed destined to regress.",
        "Doc_title":"Arf-dependent regulation of Pdgf signaling in perivascular cells in the developing mouse eye.",
        "Journal":"The EMBO journal",
        "Do_id":"16037818",
        "Doc_ChemicalList":"Cdkn2a protein, mouse;Cyclin-Dependent Kinase Inhibitor p16;Nuclear Proteins;Proto-Oncogene Proteins;Proto-Oncogene Proteins c-sis;Tumor Suppressor Protein p14ARF;Tumor Suppressor Protein p53;Mdm2 protein, mouse;Proto-Oncogene Proteins c-mdm2;Receptor, Platelet-Derived Growth Factor beta",
        "Doc_meshdescriptors":"Animals;Cell Proliferation;Cyclin-Dependent Kinase Inhibitor p16;Eye;Mice;Mice, Knockout;Nuclear Proteins;Proto-Oncogene Proteins;Proto-Oncogene Proteins c-mdm2;Proto-Oncogene Proteins c-sis;Receptor, Platelet-Derived Growth Factor beta;Signal Transduction;Tumor Suppressor Protein p14ARF;Tumor Suppressor Protein p53",
        "Doc_meshqualifiers":"cytology;embryology;metabolism;metabolism;metabolism;antagonists & inhibitors;physiology;physiology;deficiency;genetics;metabolism;metabolism",
        "_version_":1605896007302774784},
      {
        "Doc_abstract":"Spontaneous regression of cervical intraepithelial neoplasia grade 2 (CIN2) lesions has been recognized since 1955, but predictors of this are poorly understood. Among the predictive markers studied, p16(INK4a) has been suggested to be of some value in monitoring the diagnosis of CIN2. In this clinical trial, 90 Brazilian women, diagnosed to CIN2 and high-risk human papillomavirus infection, were randomized into two groups of equal size: 45 women whose lesions were excised and 45 women subjected to prospective follow-up at 3-month intervals at least for 1 year (mean 6.8 months). p16(INK4a) expression was analyzed in paraffin-embedded sections using immunohistochemical staining. Among the 45 women in the follow-up group, 42% experienced spontaneous regression, 11% showed persistence, 22% progressed to CIN3, and 20% had partial regression to CIN1 or ASCUS (atypical squamous cell undetermined signifiance). p16(INK4a) expression was detected in 68.9% of the patients. In univariate survival (Cox) analysis, no significant difference in regression was obtained between p16(INK4a)-negative and -positive CIN2 lesions (adjusted HR = 1.1; 95% CI 0.6-2.0). In conclusion, p16(INK4a) expression could be useful in the diagnosis of CIN2. However, it failed to predict the outcome of CIN2. Because of its high spontaneous regression rate, follow-up could be considered as a management option of CIN2 in young and compliant women.",
        "Doc_title":"p16(INK4a) Expression does not predict the outcome of cervical intraepithelial neoplasia grade 2.",
        "Journal":"International journal of gynecological cancer : official journal of the International Gynecological Cancer Society",
        "Do_id":"17367324",
        "Doc_ChemicalList":"Biomarkers, Tumor;Cyclin-Dependent Kinase Inhibitor p16",
        "Doc_meshdescriptors":"Adolescent;Adult;Biomarkers, Tumor;Cervical Intraepithelial Neoplasia;Cyclin-Dependent Kinase Inhibitor p16;Female;Humans;Immunohistochemistry;Middle Aged;Neoplasm Regression, Spontaneous;Neoplasm Staging;Prognosis;Uterine Cervical Neoplasms",
        "Doc_meshqualifiers":"analysis;diagnosis;pathology;analysis;diagnosis;pathology",
        "_version_":1605761944063574016},
      {
        "Doc_abstract":"Colorectal cancer (CRC) is a complex and heterogeneous disease in which genomic instability and DNA promoter methylation play important roles. The aim of this study was to investigate the relationship between chromosomal instability (CIN), microsatellite instability (MSI) and promoter methylation of CRC-associated genes. Therefore, 71 CRCs were analysed for CIN and MSI by comparative genomic hybridization and the mononucleotide marker BAT-26, respectively. Promoter methylation of the tumour suppressor and DNA repair genes hMLH1, O(6)-MGMT, APC, p14(ARF), p16(INK4A), RASSF1A, GATA-4, GATA-5 and CHFR was analysed using methylation-specific polymerase chain reaction. These integrative analyses showed that in CIN+ CRCs, promoter methylation of GATA-4 and p16(INK4A) was inversely related to chromosomal loss at 15q11-q21 and gain at 20q13, respectively (P values: 3.8 x 10(-2) and 4.5 x 10(-2), respectively). Interestingly, promoter methylation of RASSF1A, GATA-4, GATA-5 and CHFR, as well as a high methylation index (MI), was positively related to chromosomal gain at 8q23-qter (P values: 1.5 x 10(-2), 3.8 x 10(-2), 3.9 x 10(-2), 4.9 x 10(-2) and 8.2 x 10(-3), respectively). MSI was associated with BRAF mutation, promoter methylation of hMLH1, APC and p16(INK4A) and a high MI (total number of methylated genes) (P values: 2.4 x 10(-2), 2.5 x 10(-3), 1.8 x 10(-2), 4.6 x 10(-2) and 1.0 x 10(-2), respectively). Therefore, we conclude that promoter methylation of pivotal tumour suppressor and DNA repair genes is associated with specific patterns of chromosomal changes in CRC, which are different from methylation patterns in MSI tumours.",
        "Doc_title":"Integrated analysis of chromosomal, microsatellite and epigenetic instability in colorectal cancer identifies specific associations between promoter methylation of pivotal tumour suppressor and DNA repair genes and specific chromosomal alterations.",
        "Journal":"Carcinogenesis",
        "Do_id":"18048385",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Chromosomes;Colorectal Neoplasms;DNA Methylation;DNA Repair;Female;Gene Expression Regulation, Neoplastic;Genes, Tumor Suppressor;Genetic Predisposition to Disease;Humans;Male;Middle Aged;Promoter Regions, Genetic",
        "Doc_meshqualifiers":"ultrastructure;genetics;pathology",
        "_version_":1605798970738606080},
      {
        "Doc_abstract":"p16(ink4a) is known to be a major inhibitor of cyclin-dependent kinases of G1-phase. Its accumulation is associated with replicative senescence. We analyzed to what extent the number of cell doublings may participate to p16(ink4a) expression in normal and malignant lymphocytes. p16(ink4a) expression, not found in normal quiescent B or T-lymphocytes, was observed after stimulation of B-lymphocytes (72 h) and T-lymphocytes (2 weeks) before the occurrence of replicative senescence markers such as senescence-associated-beta-galactosidase activity. Afterwards, in lymphocyte long-term cultures, the increase in p16(ink4a) followed the expression of features of cell ageing. In acute lymphoblastic leukemia, the analysis of the individual differences between peripheral blood and blood compartments (34 cases) showed a decrease in cell proliferation (p<0.005), in telomerase activity (p<0.0005), and in hTERT expression (p<0.04), associated with an increase of p16(ink4a) (p<0.035) in blood leukemic cells. These results support the hypothesis that (i) an increase in p16(ink4a) expression in normal lymphocytes is linked, in part, to the number of cell doublings before the occurrence of replicative senescence and (ii) this process is maintained in leukemic cell populations of numerous patients.",
        "Doc_title":"Does p16ink4a expression increase with the number of cell doublings in normal and malignant lymphocytes?",
        "Journal":"Leukemia research",
        "Do_id":"17475325",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;TERT protein, human;Telomerase",
        "Doc_meshdescriptors":"Adolescent;Cell Aging;Cell Division;Cell Proliferation;Child;Child, Preschool;Cyclin-Dependent Kinase Inhibitor p16;Female;Gene Expression Regulation;Humans;Infant;Lymphocytes;Male;Middle Aged;Precursor Cell Lymphoblastic Leukemia-Lymphoma;Telomerase",
        "Doc_meshqualifiers":"genetics;physiology;cytology;pathology;genetics;metabolism",
        "_version_":1605884609404338176},
      {
        "Doc_abstract":"Morphologically normal foci of epithelial cells exhibiting p16 inactivation have been found in several tissues and may be precursors to cancer. Our previous work demonstrates that cells lacking p16(INK4A) activity exhibit phenotypes associated with malignancy (Romanov et al. 2001). The acquisition of genomic instability occurs through the activation of telomeric and centrosomal dysfunction. Additionally, the activation of stress pathways such as COX-2 provides these cells with the mutagenic potential to survive adverse environments as well as the ability to migrate, evade apoptosis and immune surveillance, and summon sustaining vasculature. Examination of archived tissue from women with DCIS (ductal carcinoma in situ) reveals epithelial cells that overexpress markers of premalignant stress activation pathways and mirror the distinctive expression patterns of these markers observed in vitro. These epithelial cells are found within the premalignant lesion as well as in the field of morphologically normal tissue that surrounds the lesion. Here, we show that p16(INK4A)-silenced vHMEC cells exhibit a gene expression profile which is distinct, reproducible, and extends beyond the changes mediated by p16(INK4A) inactivation. The present work suggests that cells lacking p16(INK4A) activity exhibit critical activities which allow cells to evade differentiation processes that would be expected to terminate proliferation. All of these properties are critical to malignancy. These events may be useful biomarkers to detect the earliest events in breast cancer.",
        "Doc_title":"Genetic and epigenetic changes in mammary epithelial cells identify a subpopulation of cells involved in early carcinogenesis.",
        "Journal":"Cold Spring Harbor symposia on quantitative biology",
        "Do_id":"16869768",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Breast;Breast Neoplasms;Carcinoma, Intraductal, Noninfiltrating;Centrosome;DNA Methylation;Epigenesis, Genetic;Epithelial Cells;Female;Fibroblasts;Gene Expression Profiling;Gene Silencing;Genes, p16;Genomic Instability;Humans;In Vitro Techniques;Models, Biological;Promoter Regions, Genetic;Telomere",
        "Doc_meshqualifiers":"metabolism;pathology;etiology;genetics;pathology;etiology;genetics;pathology;metabolism;classification;metabolism;pathology;metabolism;pathology;genetics",
        "_version_":1605882626713845760},
      {
        "Doc_abstract":"The polycomb group gene Bmi1 is required for maintenance of adult stem cells in many organs. Inactivation of Bmi1 leads to impaired stem cell self-renewal due to deregulated gene expression. One critical target of BMI1 is Ink4a/Arf, which encodes the cell-cycle inhibitors p16(Ink4a) and p19(Arf). However, deletion of Ink4a/Arf only partially rescues Bmi1-null phenotypes, indicating that other important targets of BMI1 exist. Here, using the continuously growing mouse incisor as a model system, we report that Bmi1 is expressed by incisor stem cells and that deletion of Bmi1 resulted in fewer stem cells, perturbed gene expression and defective enamel production. Transcriptional profiling revealed that Hox expression is normally repressed by BMI1 in the adult, and functional assays demonstrated that BMI1-mediated repression of Hox genes preserves the undifferentiated state of stem cells. As Hox gene upregulation has also been reported in other systems when Bmi1 is inactivated, our findings point to a general mechanism whereby BMI1-mediated repression of Hox genes is required for the maintenance of adult stem cells and for prevention of inappropriate differentiation.",
        "Doc_title":"BMI1 represses Ink4a/Arf and Hox genes to regulate stem cells in the rodent incisor.",
        "Journal":"Nature cell biology",
        "Do_id":"23728424",
        "Doc_ChemicalList":"Bmi1 protein, mouse;Cyclin-Dependent Kinase Inhibitor p16;Proto-Oncogene Proteins;Polycomb Repressive Complex 1;ADP-Ribosylation Factors",
        "Doc_meshdescriptors":"ADP-Ribosylation Factors;Animals;Cell Differentiation;Cells, Cultured;Cyclin-Dependent Kinase Inhibitor p16;Dental Enamel;Genes, Homeobox;Incisor;Mice;Mice, Knockout;Polycomb Repressive Complex 1;Proto-Oncogene Proteins;Stem Cells",
        "Doc_meshqualifiers":"physiology;physiology;cytology;metabolism;physiology;cytology;metabolism;physiology;physiology;cytology;metabolism",
        "_version_":1605875180171689984},
      {
        "Doc_abstract":"The transcription factor YY1 has been implicated to play a role in cell growth control. In this report, we demonstrate that YY1 was able to suppress NCI-H460 cell senescence through regulating the expression of p16(INK4a), a cyclin-dependent kinase inhibitor. We also show that YY1 participated in the repression of p16(INK4a) expression in 293T cells through an epigenetic mechanism involving histone acetylation modification. Specifically, HDAC3 and HDAC4 inhibited the p16(INK4a) promoter activity. The chromatin immunoprecipitation (ChIP) assays verified that HDAC3 and HDAC4 were recruited to p16(INK4a) promoter by YY1. Moreover, co-immunoprecipitation assays revealed that these three protein factors formed a complex. Furthermore, knockdown of these factors induced cell enlargement and flattened morphology and significantly increased the SA-beta-gal activity, a biochemical marker of cell senescence. Overall, data from this study suggest that YY1, HDAC3 and HDAC4 restrained cell senescence by repressing p16(INK4a) expression through an epigenetic modification of histones.",
        "Doc_title":"YY1 restrained cell senescence through repressing the transcription of p16.",
        "Journal":"Biochimica et biophysica acta",
        "Do_id":"18558095",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;YY1 Transcription Factor;Histone Deacetylases",
        "Doc_meshdescriptors":"Acetylation;Cell Aging;Cyclin-Dependent Kinase Inhibitor p16;Gene Expression Regulation;Histone Deacetylases;Humans;Promoter Regions, Genetic;Protein Binding;RNA Interference;Transcription, Genetic;YY1 Transcription Factor",
        "Doc_meshqualifiers":"physiology;genetics;metabolism;genetics;metabolism;genetics;genetics;genetics;metabolism",
        "_version_":1605851180261441536},
      {
        "Doc_abstract":"The p19ARF gene product responds to oncogenic stresses by interfering with the inhibitory effects of Mdm2 on p53, thus enhancing p53 activity and its antiproliferative functions. The absence of p19ARF in the mouse leads to early tumor susceptibility, presumably in part due to decreased p53 activity. To examine the tumorigenic cooperativity of p19ARF, Mdm2, and p53 in vivo, p19ARF-deficient mice were crossed first to p53-deficient mice and then to Mdm2 transgenic mice. The progeny were monitored for tumors. Cooperativity between p19ARF and p53 deficiencies in accelerating tumor formation was observed for most genotypes except p53-/- p19ARF-/- mice. p53-/- p19ARF-/- mice had a tumor incidence similar to p53-/- mice. In this context, tumor suppression by ARF appears to be primarily p53 dependent. The majority of the p19ARF+/- tumors deleted the wildtype p19ARF allele, in agreement with the previous studies, suggesting that p19ARF is a classic 'two hit' tumor suppressor. In a p53+/- background, however, all p19ARF+/- tumors retained a wildtype ARF allele and most also retained wildtype p53. In the second cross between p19ARF-deficient and Mdm2 transgenic mice, cooperativity in tumor incidence between Mdm2 overexpression and ARF deficiency was observed, consistent with the role of p19ARF in negatively regulating Mdm2 activity. These experiments further demonstrate in vivo the inter-relationships of the p19ARF-Mdm2-p53 signaling axis in tumor suppression.",
        "Doc_title":"Cooperativity of p19ARF, Mdm2, and p53 in murine tumorigenesis.",
        "Journal":"Oncogene",
        "Do_id":"14586409",
        "Doc_ChemicalList":"Cdkn2a protein, mouse;Cyclin-Dependent Kinase Inhibitor p16;Nuclear Proteins;Proto-Oncogene Proteins;Tumor Suppressor Protein p14ARF;Tumor Suppressor Protein p53;Mdm2 protein, mouse;Proto-Oncogene Proteins c-mdm2",
        "Doc_meshdescriptors":"Alleles;Animals;Cyclin-Dependent Kinase Inhibitor p16;Genotype;Mice;Mice, Inbred C57BL;Mice, Transgenic;Neoplasms, Experimental;Nuclear Proteins;Proto-Oncogene Proteins;Proto-Oncogene Proteins c-mdm2;Tumor Suppressor Protein p14ARF;Tumor Suppressor Protein p53",
        "Doc_meshqualifiers":"etiology;genetics;physiology;genetics;physiology;physiology",
        "_version_":1605840288706723840},
      {
        "Doc_abstract":"Aberrant promoter hypermethylation of several known or putative tumor suppressor genes occurs frequently during the pathogenesis of prostate cancers and is a promising marker for cancer detection. We sought to develop a test for prostate cancer based on a quantitative methylation-specific polymerase chain reaction (QMSP) of multiple genes in urine sediment DNA.;We tested urine sediment DNA for aberrant methylation of nine gene promoters (p16INK4a, p14(ARF), MGMT, GSTP1, RARbeta2, CDH1 [E-cadherin], TIMP3, Rassf1A, and APC) from 52 patients with prostate cancer and 21 matched primary tumors by quantitative fluorogenic real-time polymerase chain reaction. We also analyzed urine sediments from 91 age-matched individuals without any history of genitourinary malignancy as controls.;Promoter hypermethylation of at least one of the genes studied was detected in urine samples from all 52 prostate cancer patients. Urine samples from the 91 controls without evidence of genitourinary cancer revealed no methylation of the p16, ARF, MGMT, and GSTP1 gene promoters, whereas methylation of RARbeta2, TIMP3, CDH1, Rassf1A, and APC was detected at low levels.;Overall, methylation found in urine samples matched the methylation status in the primary tumor. A combination of only four genes (p16, ARF, MGMT, and GSTP1) would theoretically allow us to detect 87% of prostate cancers with 100% specificity. Our data support further development of the noninvasive QMSP assay in urine DNA for early detection and surveillance of prostate cancer.",
        "Doc_title":"Quantitative methylation-specific polymerase chain reaction gene patterns in urine sediment distinguish prostate cancer patients from control subjects.",
        "Journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
        "Do_id":"16170165",
        "Doc_ChemicalList":"Biomarkers, Tumor;DNA, Neoplasm;Neoplasm Proteins",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Biomarkers, Tumor;Case-Control Studies;DNA Methylation;DNA, Neoplasm;Gene Expression Regulation, Neoplastic;Genes, Tumor Suppressor;Humans;Logistic Models;Male;Middle Aged;Neoplasm Proteins;Polymerase Chain Reaction;Probability;Promoter Regions, Genetic;Prostatic Neoplasms;Reference Values;Sensitivity and Specificity;Urinalysis",
        "Doc_meshqualifiers":"urine;genetics;urine;physiology;urine;methods;genetics;surgery;urine",
        "_version_":1605818653127737344},
      {
        "Doc_abstract":"A combination of cetuximab and sorafenib in patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) were assessed for potential benefit.;In a randomized phase II study, R/M HNSCC patients were treated with cetuximab 400mg/m(2) IV on day 1 followed by 250mg/m(2) IV weekly (Arm A), or cetuximab at the same dose/schedule plus sorafenib 400mg PO twice-a-day (Arm B). Each cycle was 21days. Tumor p16 and HPV status, and plasma immunomodulatory cytokine levels were assessed.;Of 55 patients enrolled (Arm A-27, Arm B-28), 52 patients received assigned treatments and 43 were evaluable for response. Overall response rate was 8% for both arms. Median overall survival (OS) and progression-free survival (PFS) were 9.0 and 3.0months in Arm A, and 5.7 and 3.2months in Arm B, respectively. Forty-four patients had tumors available for p16 staining (35-negative, 9-positive). Three of nine p16-positive tumors were also HPV positive. The p16-negative patients had significantly better PFS compared to the p16-positive patients (3.7 vs. 1.6months; p-value: 0.03), regardless of study arms. Twenty-four plasma samples were tested for 12 cytokine levels and patients with higher TGF1 levels had inferior PFS compared to lower levels (1.9 vs. 4.7months; adjusted p-value: 0.015), regardless of study arms.;A subset of R/M patients with p16-negative tumors or lower plasma TGF1 levels had longer PFS given the cetuximab-based therapy. However, both arms showed only modest response and sorafenib given with cetuximab did not demonstrate clinical benefit.",
        "Doc_title":"A randomized phase II efficacy and correlative studies of cetuximab with or without sorafenib in recurrent and/or metastatic head and neck squamous cell carcinoma.",
        "Journal":"Oral oncology",
        "Do_id":"25593015",
        "Doc_ChemicalList":"Antineoplastic Agents;Phenylurea Compounds;Niacinamide;sorafenib;Cetuximab",
        "Doc_meshdescriptors":"Adult;Aged;Antineoplastic Agents;Carcinoma, Squamous Cell;Cetuximab;Female;Head and Neck Neoplasms;Humans;Male;Middle Aged;Neoplasm Metastasis;Niacinamide;Phenylurea Compounds;Recurrence",
        "Doc_meshqualifiers":"therapeutic use;drug therapy;pathology;therapeutic use;drug therapy;pathology;analogs & derivatives;therapeutic use;therapeutic use",
        "_version_":1605830381279379456},
      {
        "Doc_abstract":"Overall survival of head and neck squamous cell cancer (HNSCC) patients has not improved despite advances in our understanding of the biology and molecular features of this disease. In particular, patients with advanced HNSCC have the poorest prognosis. To understand more about the contribution of cell cycle alterations to HNSCC development and their possible value in predicting prognosis and response to chemotherapy, we evaluated the levels of proteins involved in cell cycle control in patients diagnosed with advanced HNSCC.;A tissue microarray was made with 122 HNSCC specimens obtained from biopsy material. Protein expression was evaluated by immunohistochemistry and correlated with clinical and pathological characteristics.;Multiple alterations at various checkpoints of cell cycle progression were observed. Loss of P16 protein was less common in oropharyngeal tumors than at other HNSCC locations (P = 0.02). Evaluation of the simultaneous expression of different proteins highlighted direct correlations (P < 0.05) such as that of the cyclin-dependent kinases with their cyclin-partners, and the Ki-67 protein with cyclin-dependent kinases 1, cyclin A (CA) and cyclin B1. Median overall survival and time-to-progression were longer in patients with CA-expressing tumors (not reached versus 34.4 months, P = 0.02) and (47.3 versus 14.6 months, P = 0.006), respectively. Moreover, expression of CA in tumors predicted a better response to chemotherapy. Positive expression of cyclin E in tumors was also associated with an increased median time-to-progression (14.6 versus 25.8 months, P = 0.04). Finally, patients with cyclin D1-expressing tumors had shorter median overall survival (29.6 months versus not reached, P = 0.05) and shorter median time-to-progression (21.5 months versus not reached, P = 0.06). However, in a multivariate analysis a CA-negative-expressing tumor was the only independent poor prognostic factor in the entire cohort of HNSCC patients [odds ratio, 2.3; 95% confidence interval (CI) = 1.2-4.5; P = 0.01].;Our results provide detailed information on the molecular profile of cell cycle components in HNSCCs and identify CA-negative-expressing tumors as an independent marker of tumor progression and poor response to chemotherapy in patients diagnosed with advanced HNSCC.",
        "Doc_title":"Cyclin A as a predictive factor for chemotherapy response in advanced head and neck cancer.",
        "Journal":"Clinical cancer research : an official journal of the American Association for Cancer Research",
        "Do_id":"15623629",
        "Doc_ChemicalList":"Cell Cycle Proteins;Cyclin A;Cisplatin;Fluorouracil",
        "Doc_meshdescriptors":"Adult;Aged;Antineoplastic Combined Chemotherapy Protocols;Carcinoma, Squamous Cell;Cell Cycle;Cell Cycle Proteins;Cisplatin;Cyclin A;Disease Progression;Female;Fluorouracil;Head and Neck Neoplasms;Humans;Immunoenzyme Techniques;Male;Middle Aged;Oropharyngeal Neoplasms;Prognosis;Survival Rate;Time Factors",
        "Doc_meshqualifiers":"therapeutic use;drug therapy;metabolism;pathology;metabolism;administration & dosage;metabolism;administration & dosage;drug therapy;metabolism;pathology;drug therapy;metabolism;pathology",
        "_version_":1605805157976637440},
      {
        "Doc_abstract":"The aim of the present study was to explore the relationship between methylation status of the p16(INK4A) promoter and some HBV-related factors, and the role of these factors in p16(INK4A) hypermethylation and hepatocellular carcinoma (HCC) progression. Twenty-three cases of surgically resected HBV-associated HCC and 25 fine-needle aspiration biopsy cases of chronic hepatitis B (CHB) were studied. The methylation status of the p16(INK4A) promoter was determined by methylation-specific polymerase chain reaction (PCR). Two-step immunohistochemical staining showed the expression of viral antigens in situ. Tissue HBV-DNA levels were determined by fluorescence quantitative real-time PCR. PCR and the direct sequencing method were used for mutation analysis. In peritumoral tissues (P = 0.025) and CHB samples (P = 0.029), the expression of hepatitis B virus X protein (HBx) was higher in methylated groups of p16(INK4A) promoter than in unmethylated groups. Other HBV factors including hepatitis B surface antigen and hepatitis B core antigen, tissue HBV-DNA levels and HBV x gene mutations had no relation to the methylation status of p16(INK4A) promoter. The data indicate that p16(INK4A) promoter hypermethylation correlated closely with higher HBx expression in the precancerous lesions, suggesting that HBx may play an important role in the early stage of HBV-associated hepatocarcinogenesis via induction of hypermethylation of p16(INK4A) promoter.",
        "Doc_title":"Association of p16INK4A hypermethylation with hepatitis B virus X protein expression in the early stage of HBV-associated hepatocarcinogenesis.",
        "Journal":"Pathology international",
        "Do_id":"17539963",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;DNA, Neoplasm;Nuclear Proteins;RSF1 protein, human;Trans-Activators",
        "Doc_meshdescriptors":"Adult;Aged;Carcinoma, Hepatocellular;Cyclin-Dependent Kinase Inhibitor p16;DNA Methylation;DNA Mutational Analysis;DNA, Neoplasm;Female;Gene Expression;Gene Silencing;Hepatitis B, Chronic;Humans;Liver Neoplasms;Male;Middle Aged;Nuclear Proteins;Precancerous Conditions;Trans-Activators",
        "Doc_meshqualifiers":"genetics;pathology;virology;genetics;analysis;genetics;pathology;virology;genetics;pathology;virology;genetics;metabolism;genetics;metabolism;pathology;genetics;metabolism",
        "_version_":1605747542891429890},
      {
        "Doc_abstract":"D-type cyclins, in association with the cyclin-dependent kinases Cdk4 or Cdk6, promote progression through the G1 phase of the cell cycle by phosphorylating the retinoblastoma protein (RB). The activities of Cdk4 and Cdk6 are constrained by inhibitors such as p16, the product of the CDKN2 gene on human chromosome 9p21 (refs 12-14). The frequent deletion or mutation of CDKN2 in tumour cells suggests that p16 acts as a tumour suppressor. We show that wild-type p16 arrests normal diploid cells in late G1, whereas a tumour-associated mutant of p16 does not. Significantly, the ability of p16 to induce cell-cycle arrest is lost in cells lacking functional RB, including primary fibroblasts from Rb-/- mouse embryos. Thus, loss of p16, overexpression of D-cyclins and loss of RB have similar effects on G1 progression, and may represent a common pathway to tumorigenesis.",
        "Doc_title":"Retinoblastoma-protein-dependent cell-cycle inhibition by the tumour suppressor p16.",
        "Journal":"Nature",
        "Do_id":"7777060",
        "Doc_ChemicalList":"Carrier Proteins;Cyclin-Dependent Kinase Inhibitor p16;Cyclins;Oncogene Proteins;Proto-Oncogene Proteins;Recombinant Proteins;Retinoblastoma Protein;Cyclin D1;Protein-Serine-Threonine Kinases;CDK4 protein, human;CDK6 protein, human;Cdk4 protein, mouse;Cdk6 protein, mouse;Cyclin-Dependent Kinase 4;Cyclin-Dependent Kinase 6;Cyclin-Dependent Kinases",
        "Doc_meshdescriptors":"Animals;Carrier Proteins;Cell Cycle;Cells, Cultured;Cloning, Molecular;Cyclin D1;Cyclin-Dependent Kinase 4;Cyclin-Dependent Kinase 6;Cyclin-Dependent Kinase Inhibitor p16;Cyclin-Dependent Kinases;Cyclins;Escherichia coli;G1 Phase;Genes, Tumor Suppressor;Humans;Mice;Mice, Inbred BALB C;Microinjections;Mutation;Oncogene Proteins;Protein-Serine-Threonine Kinases;Proto-Oncogene Proteins;Recombinant Proteins;Retinoblastoma Protein;Tumor Cells, Cultured",
        "Doc_meshqualifiers":"genetics;physiology;physiology;physiology;physiology;physiology;antagonists & inhibitors;metabolism;physiology",
        "_version_":1605879796505509888},
      {
        "Doc_abstract":"The molecular mechanisms of oncogenesis in mesothelioma involve the loss of negative regulators of cell growth including p16(INK4a). Absence of expression of the p16(INK4a) gene product is exhibited in virtually all mesothelioma tumors and cell lines examined to date. Loss of p16(INK4a) expression has also been frequently observed in more common neoplasms such as lung cancer as well. In a wide variety of these malignancies, including lung cancer, p16(INK4a) expression is known to be inactivated by hypermethylation of the first exon. In a survey of ten mesothelioma cell lines, one cell line (NCI-H2596) was identified as possessing loss of p16(INK4a) gene product following gene methylation. This methylation in these mesothelioma cells could be reversed, resulting in re-expression of p16(INK4a) protein, following the treatment of the cells with cytidine analogs, which are known inhibitors of DNA methylation. In previous clinical trials in mesothelioma, the cytidine analog dihydro-5-azacytidine (DHAC) has been found to induce clinical responses in approximately 17% of patients with mesothelioma treated with this drug, including prolonged complete responses. In addition, we identified evidence for methylation of p16(INK4a) in three of 11 resected mesothelioma tumor samples. When both cell lines and tumors are combined, inactivation of p16(INK4a) gene product expression following DNA hypermethylation was found in four of 21 samples (19%). We are further exploring the clinical significance of inhibition of methylation in mesothelioma by cytidine analogs. This may provide a potential treatment target in some mesothelioma tumors by inhibition of methylation.",
        "Doc_title":"Inactivation of p16INK4a expression in malignant mesothelioma by methylation.",
        "Journal":"Lung cancer (Amsterdam, Netherlands)",
        "Do_id":"12399123",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16",
        "Doc_meshdescriptors":"Cell Cycle;Cyclin-Dependent Kinase Inhibitor p16;DNA Methylation;Gene Expression Regulation, Neoplastic;Humans;Mesothelioma;Polymerase Chain Reaction;Tumor Cells, Cultured",
        "Doc_meshqualifiers":"biosynthesis;genetics;physiopathology",
        "_version_":1605755500397330432},
      {
        "Doc_abstract":"The molecular status of the p14(ARF) gene has not been fully elucidated in hepatocellular carcinoma (HCC). This study was performed to determine genetic and epigenetic alterations in the p14(ARF) tumor suppressor gene and their effect on HCC progression.;The status of p14 was evaluated in 117 HCC tumoral nodules and 110 corresponding non-tumor tissues by loss of heterozygosity at the 9p21-22 region, homozygous deletions, single strand conformation polymorphism-polymerase chain reaction mutational analysis and methylation-specific polymerase chain reaction.;The most frequent inactivation mechanism was hypermethylation of the promoter region, which was found in 41.9% of tumor samples and in 19.1% of non-tumor samples. Loss of heterozygosity at the 9p21 region was detected in 27.3% and 10% of tumor and non-tumor tissues, respectively. Homozygous deletions and mutations were less common events in hepatocarcinogenesis. We found 5.9% of the tumor cases with exon 2 homozygous deletions and 3.4% of the cases with mutations. We described a silent mutation in codon 42 of exon 1beta for the first time. No association was found between inactivation of p14(ARF) and clinicopathological characteristics or prognosis.;We can conclude that p14(ARF) is frequently and early altered in HCC, being the main cause of inactivation promoter hypermethylation. Our results suggest that the p14(ARF) gene plays an important role in the pathogenesis of hepatocellular carcinoma.",
        "Doc_title":"P14ARF gene alterations in human hepatocellular carcinoma.",
        "Journal":"European journal of gastroenterology & hepatology",
        "Do_id":"15095848",
        "Doc_ChemicalList":"Tumor Suppressor Protein p14ARF",
        "Doc_meshdescriptors":"Carcinoma, Hepatocellular;Chromosomes, Human, Pair 9;Female;Gene Deletion;Humans;Liver Neoplasms;Loss of Heterozygosity;Male;Middle Aged;Mutation;Polymorphism, Single-Stranded Conformational;Promoter Regions, Genetic;Survival Analysis;Tumor Suppressor Protein p14ARF",
        "Doc_meshqualifiers":"genetics;pathology;genetics;genetics;pathology;genetics;genetics;genetics;genetics",
        "_version_":1605753189759451136},
      {
        "Doc_abstract":"The majority of malignant mesothelioma possesses the wild-type p53 gene with a homologous deletion of the INK4A/ARF locus containing the p14(ARF) and the p16(INK4A) genes. We examined whether forced expression of p53 inhibited growth of mesothelioma cells and produced anti-tumor effects by a combination of cisplatin (CDDP) or pemetrexed (PEM), the first-line drugs for mesothelioma treatments. Transduction of mesothelioma cells with adenoviruses bearing the p53 gene (Ad-p53) induced phosphorylation of p53, upregulated Mdm2 and p21 expression levels and decreased phosphorylation of pRb. The transduction generated cleavage of caspase-8 and -3, but not caspase-9. Cell cycle analysis showed increased G0/G1- or G2/M-phase populations and subsequently sub-G1 fractions, depending on cell types and Ad-p53 doses. Transduction with Ad-p53 suppressed viability of mesothelioma cells and augmented the growth inhibition by CDDP or PEM mostly in a synergistic manner. Intrapleural injection of Ad-p53 and systemic administration of CDDP produced anti-tumor effects in an orthotopic animal model. These data collectively suggest that Ad-p53 is a possible agent for mesothelioma in combination with the first-line chemotherapeutics.",
        "Doc_title":"Upregulated p53 expression activates apoptotic pathways in wild-type p53-bearing mesothelioma and enhances cytotoxicity of cisplatin and pemetrexed.",
        "Journal":"Cancer gene therapy",
        "Do_id":"22223137",
        "Doc_ChemicalList":"Glutamates;TP53 protein, human;Tumor Suppressor Protein p53;Pemetrexed;Guanine;Caspases;Cisplatin",
        "Doc_meshdescriptors":"Adenoviridae;Animals;Antineoplastic Combined Chemotherapy Protocols;Apoptosis;Caspases;Cell Cycle;Cisplatin;Enzyme Activation;Female;Genes, p53;Glutamates;Guanine;Humans;Mesothelioma;Mice;Mice, Inbred BALB C;Mice, Nude;Pemetrexed;Phosphorylation;Tumor Suppressor Protein p53;Up-Regulation;Xenograft Model Antitumor Assays",
        "Doc_meshqualifiers":"genetics;pharmacology;drug effects;physiology;metabolism;drug effects;physiology;administration & dosage;administration & dosage;administration & dosage;analogs & derivatives;drug therapy;genetics;metabolism;pathology;biosynthesis;genetics;metabolism",
        "_version_":1605763734867804160},
      {
        "Doc_abstract":"ARF mRNA encodes two distinct proteins, the nucleolar p19(ARF), and a shorter mitochondrial isoform, named smARF. Inappropriate proliferative signals generated by proto-oncogenes, such as c-Myc and E2F1, can elevate both p19(ARF) and smARF proteins. The two ARF isoforms differ not only in their localization but also in their functions. Nucleolar p19(ARF) inhibits cell growth mainly by activating p53 or by inhibiting ribosomal biogenesis. In contrast, mitochondrial smARF can induce dissipation of the mitochondrial membrane potential and autophagy in a p53 independent manner. Recently, it was proposed by Abida et al., that similar to smARF, the nucleolar p19(ARF) can also induce p53 independent autophagy, but in contrast to smARF it does so from within the nucleolus. Our current work shown here indicates, however, that if the ectopic expression of p19(ARF) is restricted to the nucleolus it cannot induce autophagic vesicle formation. Only upon extreme overexpression, when p19(ARF) is localized to extra nuclear compartments, can it trigger p53-independent autophagic vesicle formation. Thus, our experiments indicate that the nucleolar p19(ARF) is incapable of inducing autophagy from within the nucleolus.",
        "Doc_title":"Nucleolar p19ARF, unlike mitochondrial smARF, is incapable of inducing p53-independent autophagy.",
        "Journal":"Autophagy",
        "Do_id":"18719357",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;Mitochondrial Proteins;Protein Isoforms;Tumor Suppressor Protein p53",
        "Doc_meshdescriptors":"Autophagy;Cell Line;Cell Nucleolus;Cyclin-Dependent Kinase Inhibitor p16;Humans;Mitochondrial Proteins;Protein Isoforms;Tumor Suppressor Protein p53",
        "Doc_meshqualifiers":"metabolism;genetics;metabolism;genetics;metabolism;genetics;metabolism;genetics;metabolism",
        "_version_":1605810164666990592},
      {
        "Doc_abstract":"p16(INK4a) expression in dysplastic cervical lesions is related to high-risk human papillomavirus (HR-HPV) infection. The immunohistochemical expression of this protein in these lesions allows an increase in diagnostic reproducibility in biopsies and the introduction of prognostic factors in low-grade lesions. Here, we studied the immunohistochemical expression of p16 in 86 dysplastic cervical lesions, 54 cervical intraepithelial neoplasms-grade 1 (CIN-I), 23 CIN-II, and 9 CIN-III. In addition, we performed HPV detection and genotyping. We detected HR-HPV in 19/54 CIN-I, 21/23 CIN-II and 9/9 CIN-III cases. p16(INK4a) immunoreactivity was observed in 7/19 CIN-I HR-HPV-positive, 17/21 CIN-II HR-HPV-positive and all CIN-III cases. Immunoreactivity for p16(INK4a) was found in 7/54 CIN-I and in 17/23 CIN-II cases. In the follow-up, we detected 3 p16-positive high-grade squamous epithelial lesions (CIN-II and CIN-III) in the CIN-I/p16-negative group and 5 p16-positive high-grade squamous epithelial lesions cases in the CIN-II/p16-negative group. We conclude that p16 negativity in CIN-I and CIN-II biopsies does not always imply regression of the lesion and that the diagnosis of CIN-II should not be based solely on p16 results. ",
        "Doc_title":"Human papillomavirus detection and p16INK4a expression in cervical lesions: a comparative study.",
        "Journal":"Human pathology",
        "Do_id":"24656093",
        "Doc_ChemicalList":"Biomarkers, Tumor;Cyclin-Dependent Kinase Inhibitor p16",
        "Doc_meshdescriptors":"Adult;Biomarkers, Tumor;Cervical Intraepithelial Neoplasia;Cyclin-Dependent Kinase Inhibitor p16;Female;Humans;Immunohistochemistry;Middle Aged;Papillomaviridae;Papillomavirus Infections;Reverse Transcriptase Polymerase Chain Reaction;Uterine Cervical Neoplasms;Young Adult",
        "Doc_meshqualifiers":"analysis;metabolism;virology;analysis;genetics;isolation & purification;diagnosis;metabolism;virology",
        "_version_":1605832522116104192},
      {
        "Doc_abstract":"As only a minority of low-grade dysplastic lesions of the cervix uteri will eventually progress to carcinoma, predicting the behavior of these lesions could be of high value in clinical practice. The aim of the study was to evaluate p16 ink4a and L1 as immunohistochemical markers of the biologic potentiality of low-grade dysplasia of the uterine cervix. The study included 38 conization specimens with coexisting cervical intraepithelial neoplasia grade 1 (CIN1) and 3 (CIN3) (group A) and 28 punch biopsies from women with CIN1 and proven spontaneous regression in the follow-up (group B). In group A, all CIN3 were p16 ink4a positive (p16+) and L1 negative (L1-). The CIN1 of this group were p16+L1- and p16+L1+ in 68.42% and 31.57%, respectively. No other expression pattern was found in this group. In group B, the p16+L1-, p16+L1+, p16-L1+, and p16-L1- patterns were found in 3.57%, 25%, 14.29%, and 57.14%, respectively. Overall, 96.29% p16+L1- CIN1 were found in group A, whereas all the p16-L1+ and p16-L1- CIN1 were found in group B. A significant difference between staining pattern distributions of group A and B was observed (P<0.0001). The results of the study show that p16 ink4a and L1 immunohistochemistry can be helpful for estimating the biologic potentiality of low-grade squamous cervical lesions. Particularly in cases in which the grade of the lesion is morphologically difficult to assess, the p16/L1 expression pattern could be useful for planning the clinical management of these women.",
        "Doc_title":"p16 ink4a and HPV L1 immunohistochemistry is helpful for estimating the behavior of low-grade dysplastic lesions of the cervix uteri.",
        "Journal":"The American journal of surgical pathology",
        "Do_id":"18769337",
        "Doc_ChemicalList":"Biomarkers, Tumor;Capsid Proteins;Cyclin-Dependent Kinase Inhibitor p16;HPV L1 protein, Human papillomavirus;Oncogene Proteins, Viral",
        "Doc_meshdescriptors":"Adult;Biomarkers, Tumor;Capsid Proteins;Carcinoma, Squamous Cell;Cervical Intraepithelial Neoplasia;Cyclin-Dependent Kinase Inhibitor p16;Disease Progression;Female;Humans;Immunohistochemistry;Oncogene Proteins, Viral;Papillomavirus Infections;Prognosis;Uterine Cervical Dysplasia;Uterine Cervical Neoplasms",
        "Doc_meshqualifiers":"analysis;biosynthesis;metabolism;pathology;virology;metabolism;pathology;virology;biosynthesis;biosynthesis;complications;metabolism;pathology;metabolism;pathology;virology;metabolism;pathology;virology",
        "_version_":1605762917192433664},
      {
        "Doc_abstract":"Evaluation of human papillomavirus (HPV) status in oropharyngeal squamous cell carcinoma (OPSCC) has become increasingly important for prognostication and clinical trial enrollment. This assessment is confounded in OPSCCs that are p16 positive by immunohistochemistry (IHC) but HPV negative by DNA in situ hybridization (DISH). This study evaluates whether E6/E7 mRNA in situ hybridization (RISH) can detect transcriptionally active HPV in these problematic cases.;Eighty-two head and neck squamous cell carcinoma cases that had previously undergone p16 IHC and HPV DISH were evaluated with two RISH platforms and a second-generation DISH probe. The study included 21 p16+/DISH+ concordant cases, 19 p16-/DISH- concordant cases, and 42 p16+/DISH- discordant cases.;RISH identified E6/E7 mRNA in 37 (88%) p16+/DISH- cases, 21 (100%) p16+/DISH+ cases, and 0 (0%) p16-/DISH- cases. RISH signals were clearly visible at low to medium magnification in 97% of positive cases, facilitating almost-perfect inter-observer reproducibility. The performance of the manual and automated RISH platforms were equivalent (kappa=0.915). Only 29% of carcinomas that demonstrated E6/E7 mRNA transcriptional activity were positive using the 2nd generation DISH probe.;HPV RISH is a highly sensitive and specific platform that can clarify the HPV status of those perplexing OPSCCs that are p16 positive by IHC but HPV negative by DISH. Moreover, it is easy to interpret, readily adaptable to the clinical laboratory, and provides direct evidence of HPV transcriptional activity. E6/E7 RISH should be considered as a first-line platform for determination of HPV status in OPSCCs.",
        "Doc_title":"RNA in-situ hybridization is a practical and effective method for determining HPV status of oropharyngeal squamous cell carcinoma including discordant cases that are p16 positive by immunohistochemistry but HPV negative by DNA in-situ hybridization.",
        "Journal":"Oral oncology",
        "Do_id":"27016012",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605841338682572800},
      {
        "Doc_abstract":"Cyclin D-dependent kinases act as mitogen-responsive, rate-limiting controllers of G1 phase progression in mammalian cells. Two novel members of the mouse INK4 gene family, p19 and p18, that specifically inhibit the kinase activities of CDK4 and CDK6, but do not affect those of cyclin E-CDK2, cyclin A-CDK2, or cyclin B-CDC2, were isolated. Like the previously described human INK4 polypeptides, p16INK4a/MTS1 and p15INK4b/MTS2, mouse p19 and p18 are primarily composed of tandemly repeated ankyrin motifs, each ca. 32 amino acids in length, p19 and p18 bind directly to CDK4 and CDK6, whether untethered or in complexes with D cyclins, and can inhibit the activity of cyclin D-bound cyclin-dependent kinases (CDKs). Although neither protein interacts with D cyclins or displaces them from preassembled cyclin D-CDK complexes in vitro, both form complexes with CDKs at the expense of cyclins in vivo, suggesting that they may also interfere with cyclin-CDK assembly. In proliferating macrophages, p19 mRNA and protein are periodically expressed with a nadir in G1 phase and maximal synthesis during S phase, consistent with the possibility that INK4 proteins limit the activities of CDKs once cells exit G1 phase. However, introduction of a vector encoding p19 into mouse NIH 3T3 cells leads to constitutive p19 synthesis, inhibits cyclin D1-CDK4 activity in vivo, and induces G1 phase arrest.",
        "Doc_title":"Novel INK4 proteins, p19 and p18, are specific inhibitors of the cyclin D-dependent kinases CDK4 and CDK6.",
        "Journal":"Molecular and cellular biology",
        "Do_id":"7739547",
        "Doc_ChemicalList":"CDKN2B protein, human;Carrier Proteins;Cdkn2b protein, mouse;Cell Cycle Proteins;Cyclin-Dependent Kinase Inhibitor p15;Cyclin-Dependent Kinase Inhibitor p16;DNA Primers;Proto-Oncogene Proteins;Tumor Suppressor Proteins;Protein-Serine-Threonine Kinases;CDK4 protein, human;CDK6 protein, human;Cdk4 protein, mouse;Cdk6 protein, mouse;Cyclin-Dependent Kinase 4;Cyclin-Dependent Kinase 6;Cyclin-Dependent Kinases",
        "Doc_meshdescriptors":"Amino Acid Sequence;Animals;Base Sequence;Carrier Proteins;Cell Cycle;Cell Cycle Proteins;Cyclin-Dependent Kinase 4;Cyclin-Dependent Kinase 6;Cyclin-Dependent Kinase Inhibitor p15;Cyclin-Dependent Kinase Inhibitor p16;Cyclin-Dependent Kinases;DNA Primers;Humans;Macrophages;Mice;Molecular Sequence Data;Protein-Serine-Threonine Kinases;Proto-Oncogene Proteins;Sequence Homology, Amino Acid;Tissue Distribution;Tumor Suppressor Proteins",
        "Doc_meshqualifiers":"genetics;metabolism;pharmacology;genetics;cytology;metabolism;antagonists & inhibitors;metabolism",
        "_version_":1605845311339626496},
      {
        "Doc_abstract":"The tumor suppressor ARF plays an important role as an inhibitor of the Mdm2-mediated degradation of p53. Here we demonstrate that human ARF (p14ARF) can form homo-oligomers. The stability of the oligomers is favored by oxidizing agents in a reversible fashion and involves all three cysteine residues in p14ARF. Furthermore, the effect of p14ARF in clonogenic assays is moderately but reproducibly increased by the mutation of its cysteine residues. We also observed that altering the amino terminus of p14ARF resulted in the appearance of remarkably stable oligomers. This indicates that the amino terminus of p14ARF interferes with the ability of the protein to form multimeric complexes. These observations suggest that p14ARF activity may be linked to its oligomerization status and sensitive to the redox status of the cell.",
        "Doc_title":"Oligomerization of the human ARF tumor suppressor and its response to oxidative stress.",
        "Journal":"The Journal of biological chemistry",
        "Do_id":"12582152",
        "Doc_ChemicalList":"Macromolecular Substances;Nuclear Proteins;Oxidants;Proto-Oncogene Proteins;Recombinant Proteins;Tumor Suppressor Protein p14ARF;Hydrogen Peroxide;MDM2 protein, human;Mdm2 protein, mouse;Proto-Oncogene Proteins c-mdm2;Cysteine",
        "Doc_meshdescriptors":"Amino Acid Sequence;Animals;Cell Line;Cysteine;Dimerization;Drug Stability;Gene Deletion;Gene Expression;Humans;Hydrogen Peroxide;Immunosorbent Techniques;Macromolecular Substances;Mice;Molecular Sequence Data;Molecular Weight;Mutagenesis, Site-Directed;Nuclear Proteins;Opossums;Oxidants;Oxidation-Reduction;Oxidative Stress;Proto-Oncogene Proteins;Proto-Oncogene Proteins c-mdm2;Recombinant Proteins;Transfection;Tumor Suppressor Protein p14ARF",
        "Doc_meshqualifiers":"chemistry;genetics;pharmacology;pharmacology;metabolism;chemistry;chemistry;genetics;metabolism",
        "_version_":1605884298436542464},
      {
        "Doc_abstract":"CD4+CD56+ haematodermic neoplasms (HDN) constitute a rare disease characterized by aggressive clinical behaviour and a poor prognosis. Tumour cells from HDN are leukaemic counterparts of plasmacytoid dendritic cells (pDCs). Despite increased knowledge of the ontogenetic origin of these tumours, the genetic causes and oncogenic signalling events involved in malignant transformation are still unknown. To delineate novel candidate regions and disease-related genes, we studied nine typical CD4+CD56+ HDN cases using genome-wide high-resolution array comparative genomic hybridization (CGH). Genomic imbalances, which were predominantly losses, were frequently detected. Gross genomic losses or gains involving an entire chromosome were observed in eight cases. The most frequent imbalances were deletions of chromosome 9, chromosome 13 and partial losses affecting 17p or 12p. Combinations of deletions of tumour suppressor genes (TSG), namely RB1, CDKN1B (p27), CDKN2A, (p16(ink4a), p14(arf)) or TP53 (p53), were observed in all cases. These results indicate that deletion events altering G1/S regulation are crucial for HDN oncogenesis. Furthermore, in addition to frequent sporadic gene losses, in one case we observed a 8q24 interstitial deletion that brought MYC closer to miR-30b/miR-30d, which may be related to their deregulation. Taken together, these results indicate that in addition to frequent G1/S checkpoint alterations, various genetic events could contribute to the chemoresistance of the tumour.",
        "Doc_title":"Recurrent genomic aberrations combined with deletions of various tumour suppressor genes may deregulate the G1/S transition in CD4+CD56+ haematodermic neoplasms and contribute to the aggressiveness of the disease.",
        "Journal":"Leukemia",
        "Do_id":"19158833",
        "Doc_ChemicalList":"Antigens, CD4;Antigens, CD56",
        "Doc_meshdescriptors":"Adult;Aged;Antigens, CD4;Antigens, CD56;Chromosome Aberrations;Chromosomes, Human, Pair 12;Chromosomes, Human, Pair 13;Chromosomes, Human, Pair 17;Chromosomes, Human, Pair 9;Comparative Genomic Hybridization;Female;G1 Phase;Gene Deletion;Genes, Tumor Suppressor;Hematologic Neoplasms;Humans;Male;Middle Aged;S Phase",
        "Doc_meshqualifiers":"genetics;genetics;pathology;genetics",
        "_version_":1605906074137788416},
      {
        "Doc_abstract":"Previous reports concerning the prevalence of human papillomavirus (HPV) in oral squamous cell carcinoma (OSCC) have observed varied results. The aim of this study was to evaluate the prevalence of HPV in oral premalignant lesions (OPL) and OSCC. For accurate HPV detection in oral lesions, comparative analysis was performed on cervical lesions as positive controls.;Fifty-seven cases with OPL and 50 with OSCC were selected. Twenty-nine control cases were selected from cervical lesions. The HPV infection rate was analysed by consensus polymerase chain reaction (PCR) using the My09/My11 and Gp5+/Gp6+ primers, and genotyping detection was employed using a PCR-based micro-array. Immunohistochemical staining for p16(INK4a) was performed.;Twenty-eight (96.6%) cases of cervical lesions were positive for HPV by consensus PCR and 24 cases (82.8%) were positive by genotyping. The total HPV-positive rate in cervical lesions was 96.6%. HPV-DNA was detected in nine cases (15.8%) of OPL and six cases (12.0%) of OSCC by consensus PCR. Six cases (10.5%) of OPL and three cases (6.0%) of OSCC were positive by genotyping. The total HPV-positive rate in oral lesions was 22.4% (26.3% of OPL and 18.0% of OSCC). In cervical lesions, immunohistochemistry of p16(INK4a) identified 27 cases (93.1%) as positive. Fifteen cases (26.3%) of OPL and eight cases (16.0%) of OSCC were positive for p16(INK4a).;The HPV infection and p16(INK4a)-positive rates in oral lesions are lower than previously reported. This suggests that HPV may not play a major role in oral lesions although its involvement cannot completely be ruled out.",
        "Doc_title":"The prevalence of human papillomavirus in oral premalignant lesions and squamous cell carcinoma in comparison to cervical lesions used as a positive control.",
        "Journal":"International journal of clinical oncology",
        "Do_id":"21528380",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;DNA, Viral",
        "Doc_meshdescriptors":"Adolescent;Adult;Aged;Aged, 80 and over;Carcinoma, Squamous Cell;Child;Cyclin-Dependent Kinase Inhibitor p16;DNA, Viral;Female;Humans;Male;Middle Aged;Mouth Neoplasms;Neoplasm Staging;Papillomaviridae;Papillomavirus Infections;Precancerous Conditions;Uterine Cervical Neoplasms",
        "Doc_meshqualifiers":"pathology;virology;analysis;analysis;pathology;virology;isolation & purification;pathogenicity;pathology;virology;virology;pathology;virology",
        "_version_":1605883738443481088},
      {
        "Doc_abstract":"To explore the mechanisms underlying spontaneous transformation of mesenchymal stem cells (MSCs), changes in senescence-associated molecules, particularly the epigenetic modification of the p16(INK4a) gene, including histone H3 lysine 27/9 methylation (H3K27/9me) and DNA methylation, were investigated in cultured adult rat bone marrow MSCs at different stages during the transformation process. It was shown that the MSCs underwent replicative senescence after 24 to 25 population doublings, characterized by positive staining for senescence-associated -galactosidase, increased expression of p16(INK4a) and p21, and downregulated phosphorylation of Rb. The upregulation of p16(INK4a) was associated with decreased expression of enhancer of the zeste homolog 2 (Ezh2), and reduced levels of H3K27me and DNA methylation in the p16(INK4a) gene. At week 4 of senescence, reproliferating cells emerged among the senescent MSCs. These senescence-escaped MSCs lost their senescence-related markers (including p16(INK4a)) and became highly proliferative. In addition to H3K27me, another H3 modification pattern, H3K9me, appeared in the p16(INK4a) gene, accompanied by an enhanced DNA methylation. With continued culture, the senescence-escaped MSCs did not show any sign of growth arrest and gained the capacity for anchorage-independent growth. These immortalized (transformed) MSCs showed further enhanced DNA methylation of the p16(INK4a) gene by increased H3K9me. Ezh2 knockdown with shRNA eliminated H3K27me-mediated DNA methylation of the p16(INK4a) gene in presenescent MSCs, but had no effect on H3K9me-enhanced DNA hypermethylation in the cells after senescence escape. These findings identify an Ezh2- and H3K27me-independent, but H3K9me-enhanced, DNA hypermethylation of the p16(INK4a) gene, which might be an epigenetic signature for MSC spontaneous transformation.",
        "Doc_title":"H3K9me-enhanced DNA hypermethylation of the p16INK4a gene: an epigenetic signature for spontaneous transformation of rat mesenchymal stem cells.",
        "Journal":"Stem cells and development",
        "Do_id":"22873822",
        "Doc_ChemicalList":"Biomarkers;Culture Media;Cyclin-Dependent Kinase Inhibitor p16;Histones;RNA, Small Interfering;EZH2 protein, rat;Enhancer of Zeste Homolog 2 Protein;Polycomb Repressive Complex 2;Lysine",
        "Doc_meshdescriptors":"Animals;Biomarkers;Bone Marrow;Cell Aging;Cell Differentiation;Cell Lineage;Cell Proliferation;Cell Transformation, Neoplastic;Cells, Cultured;Culture Media;Cyclin-Dependent Kinase Inhibitor p16;DNA Methylation;Enhancer of Zeste Homolog 2 Protein;Epigenesis, Genetic;Gene Knockdown Techniques;Histones;Lysine;Male;Mesenchymal Stromal Cells;Phosphorylation;Polycomb Repressive Complex 2;RNA, Small Interfering;Rats;Rats, Sprague-Dawley",
        "Doc_meshqualifiers":"metabolism;metabolism;genetics;metabolism;metabolism;genetics;metabolism;genetics;metabolism;metabolism;cytology;metabolism;genetics;metabolism;genetics;metabolism",
        "_version_":1605746288317431810},
      {
        "Doc_abstract":"The gene encoding the cell-cycle regulatory protein p16, CDKN2, is localized on chromosome band 9p21. CDKN2 is frequently deleted or mutated in a variety of tumor cell lines, including pancreatic cancer cell lines and xenografts, as well as in some primary tumors. We examined 32 primary pancreatic adenocarcinomas for CDKN2 mutations and for loss of heterozygosity of 9p21 sequences to assess the role of CDKN2 in pancreatic carcinogenesis. Single-strand conformation variant analysis (SSCV) and direct sequencing of the variants revealed somatic CDKN2 mutations in 11 of 32 tumors (five frame-shift mutations, five nonsense mutations, and one missense mutation). One tumor appeared to be characterized by homozygous deletion of CDKN2. These results suggest that CDKN2 plays an important role during tumorigenesis or tumor progression in a significant proportion of pancreatic adenocarcinomas.",
        "Doc_title":"Frequent mutations of CDKN2 in primary pancreatic adenocarcinomas.",
        "Journal":"Genes, chromosomes & cancer",
        "Do_id":"8589035",
        "Doc_ChemicalList":"Carrier Proteins;Codon;Cyclin-Dependent Kinase Inhibitor p16;DNA, Neoplasm",
        "Doc_meshdescriptors":"Adenocarcinoma;Carrier Proteins;Codon;Cyclin-Dependent Kinase Inhibitor p16;DNA Mutational Analysis;DNA, Neoplasm;Frameshift Mutation;Genes, Tumor Suppressor;Humans;Mutation;Pancreatic Neoplasms;Point Mutation;Sequence Deletion",
        "Doc_meshqualifiers":"genetics;genetics;genetics;genetics;genetics",
        "_version_":1605818604048089088},
      {
        "Doc_abstract":"Uterine myxoid leiomyosarcoma (MLMS) is a rare tumor that requires modified diagnostic criteria compared with conventional leiomyosarcoma. We analyzed the clinicopathological and immunohistochemical features of 10 MLMS cases from a single institution. 9/10 MLMS showed an invasive border and 2/10 had vascular invasion. Seven cases exhibited low-grade nuclear features, low mitotic counts (median: 2/10HPFs) and no tumor cell necrosis. They were all at FIGO stage I. Two recurred at the vaginal vault at 38 and 61 months, respectively. In contrast, 3 MLMS with high-grade nuclei had a high mitotic rate (median: 12/10HPF) and tumor cell necrosis (2/3). They were at an advanced FIGO stage (IIIA-IVB). One had lung metastases at 6 months and another died at 34 months. HMGA2 immunostaining was diffusely expressed in all MLMS. Overexpression of p16 and IMP3 was present in 5 and 3 cases, respectively. We conclude that an invasive tumor border and p16 and/or IMP3 overexpression are helpful features in the diagnosis of MLMS. HMGA2 is a highly sensitive and useful marker for MLMS. MLMS might have two possible subtypes: high grade, clinically aggressive MLMS, and low grade, relatively indolent tumors.",
        "Doc_title":"Myxoid leiomyosarcoma of the uterus: a clinicopathological and immunohistochemical study of 10 cases.",
        "Journal":"Human pathology",
        "Do_id":"27717885",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605810412364759040},
      {
        "Doc_abstract":"The hepatitis B virusprotein (HBx) has been implicated as a potential trigger of the epigenetic deregulation of some genes, but the underlying mechanism remains unknown. The aim of this study is to identify underlying mechanisms involved in HBx-mediated epigenetic modification in the process of HBx induced p16(INK4A) promoter hypermethylation. Liver cell lines were stably transfected with HBx-expressing vector. The methylation status of p16(INK4A) was examined by methyl-specific polymerase chain reaction (MSP) and bisulfite sequencing. Reverse transcription and real-time polymerase chain reaction (real-time RT-PCR), Western blot and immunohistochemistry were used to analyze the expression of HBx, HBx-mediated DNA methylation abnormalities and p16(INK4A). Some cases of HCC and corresponding noncancerous liver tissues were studied. HBx up-regulates DNMT1 and DNMT3A expression in both mRNA level and protein level, and HBx represses p16(INK4A) expression through inducing hypermethylation of p16(INK4A) promoter. Moreover, HBx induces hypermethylation of p16(INK4A) promoter through DNMT1 and DNMT3A. Regulation of DNMT1 and DNMT3A by HBx promoted hypermethylation of p16(INK4A) promoter region. HBx-DNMTs-p16(INK4A) promoter hypermethylation may suggest a mechanism for tumorigenesis during hepatocarcinogenesis.",
        "Doc_title":"Hepatitis B virus X protein promotes hypermethylation of p16(INK4A) promoter through upregulation of DNA methyltransferases in hepatocarcinogenesis.",
        "Journal":"Experimental and molecular pathology",
        "Do_id":"20620135",
        "Doc_ChemicalList":"Trans-Activators;hepatitis B virus X protein;DNA (Cytosine-5-)-Methyltransferase;DNA (cytosine-5-)-methyltransferase 1;DNA methyltransferase 3A",
        "Doc_meshdescriptors":"Adult;Aged;Blotting, Western;Carcinoma, Hepatocellular;Cell Line, Tumor;DNA (Cytosine-5-)-Methyltransferase;DNA Methylation;Female;Gene Expression Regulation, Neoplastic;Genes, p16;Humans;Immunohistochemistry;Liver Neoplasms;Male;Middle Aged;Promoter Regions, Genetic;Reverse Transcriptase Polymerase Chain Reaction;Trans-Activators;Transfection;Up-Regulation",
        "Doc_meshqualifiers":"enzymology;genetics;virology;biosynthesis;genetics;enzymology;genetics;virology;genetics;metabolism",
        "_version_":1605751308228231168},
      {
        "Doc_abstract":"The p16/pocket-protein pathway sets a balance between tumor suppression and capacity for tissue regeneration. Understanding the upstream signaling pathway that turns on the expression of p16 is required both for knowing the tumorigenic stresses from which this pathway provides protection and for appreciating the selective pressure that leads to the loss of this pathway in most human tumors. We report that COOH-terminal binding protein (CtBP), a physiologically regulated transcriptional corepressor that dimerizes to hold together repressive complexes, regulates p16 expression in primary human fibroblasts and keratinocytes. Interfering with CtBP-mediated repression increased p16 expression and accelerated senescence. CtBP had little influence on the expression of the alternate product of the CDKN2A tumor-suppressor gene, p14(ARF). Loss of CtBP-mediated repression diminished the Polycomb-based epigenetic histone mark that is reported to favor silencing of p16 via DNA methylation. Enhancing CtBP-mediated repression by growing cells in low oxygen increased the association of CtBP with the p16 promoter, as assessed by chromatin immunoprecipitation, and reduced p16 expression. Stresses and stimuli that reduce CtBP-mediated repression are associated with increased p16 expression; therefore, CtBP may provide a common final target for regulating the balance among tumor suppression, regenerative capacity, and senescence.",
        "Doc_title":"COOH-terminal binding protein regulates expression of the p16INK4A tumor suppressor and senescence in primary human cells.",
        "Journal":"Cancer research",
        "Do_id":"18676825",
        "Doc_ChemicalList":"RNA, Messenger",
        "Doc_meshdescriptors":"Cell Aging;Cells, Cultured;Chromatin Immunoprecipitation;Fibroblasts;Gene Expression Regulation;Genes, p16;Humans;Keratinocytes;Polymerase Chain Reaction;Protein Binding;RNA, Messenger",
        "Doc_meshqualifiers":"genetics;metabolism;metabolism;genetics",
        "_version_":1605850972153708544},
      {
        "Doc_abstract":"Human keratinocytes grown in co-culture with fibroblast feeder cells have an extended in vitro lifespan and delayed accumulation of the tumor suppressor protein p16(INK4a) when compared to the same cells grown on tissue culture plastic alone. Previous studies have indicated that human keratinocytes can be immortalized by telomerase activity alone when grown in co-culture with feeder cells, suggesting that loss of the p16(INK4a)/Rb pathway is not required for immortalization. Using two independent human keratinocyte cell strains, we found that exogenous telomerase expression and co-culture with feeder cells results in efficient extension of lifespan without an apparent crisis. However, when these cells were transferred from the co-culture environment to plastic alone they experienced only a brief period of slowed growth before continuing to proliferate indefinitely. Examination of immortal cell lines demonstrated p16(INK4a) promoter methylation had occurred in both the absence and presence of feeder cells. Reintroduction of p16(INK4a) into immortal cell lines resulted in rapid growth arrest. Our results suggest that p16(INK4a)/Rb-induced telomere-independent senescence, although delayed in the presence of feeders, still provides a proliferation barrier to human keratinocytes in this culture system and that extended culture of telomerase-transduced keratinocytes on feeders can lead to the methylation of p16(INK4a).",
        "Doc_title":"Methylation of the p16(INK4a) promoter region in telomerase immortalized human keratinocytes co-cultured with feeder cells.",
        "Journal":"Oncogene",
        "Do_id":"16767161",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;DNA Primers;Telomerase",
        "Doc_meshdescriptors":"Base Sequence;Cell Line, Transformed;Coculture Techniques;Cyclin-Dependent Kinase Inhibitor p16;DNA Methylation;DNA Primers;Humans;Immunohistochemistry;Keratinocytes;Promoter Regions, Genetic;Reverse Transcriptase Polymerase Chain Reaction;Telomerase",
        "Doc_meshqualifiers":"genetics;enzymology;genetics",
        "_version_":1605852237448347648},
      {
        "Doc_abstract":"Using alternative reading frames, the human ARF-INK4a locus encodes two unrelated proteins that both function in tumor suppression. p16(INK4a) maintains the retinoblastoma protein in its growth-suppressive state through inhibition of cyclin D-dependent kinase activity, whereas ARF binds with MDM2 and stabilizes p53. The majority of the activity of ARF to date is ascribed to its ability to activate p53, resulting in a G(1) cell cycle arrest or apoptosis. We show here that ARF colocalizes with DNA replication protein A (RPA32) and that overexpression of ARF reduces the rate of DNA synthesis resulting in accumulation of an S-phase cell population. Impediment of DNA synthesis by ARF can occur and becomes more evident in the absence of p53. Hence, the biological consequence of ARF induction varies dependent on cellular p53 status, inducing predominantly a G(1) arrest or apoptosis in p53-positive cells or causing S-phase retardation when p53 function is comprised.",
        "Doc_title":"Human tumor suppressor ARF impedes S-phase progression independent of p53.",
        "Journal":"Cancer research",
        "Do_id":"11861400",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;DNA, Neoplasm;DNA-Binding Proteins;RPA1 protein, human;Replication Protein A;Tumor Suppressor Protein p53;Tumor Suppressor Proteins",
        "Doc_meshdescriptors":"Bone Neoplasms;Cell Division;Cyclin-Dependent Kinase Inhibitor p16;DNA, Neoplasm;DNA-Binding Proteins;Humans;Osteosarcoma;Replication Protein A;S Phase;Tumor Cells, Cultured;Tumor Suppressor Protein p53;Tumor Suppressor Proteins",
        "Doc_meshqualifiers":"genetics;metabolism;pathology;physiology;genetics;physiology;biosynthesis;metabolism;genetics;metabolism;pathology;physiology;biosynthesis;genetics;physiology;biosynthesis;genetics;physiology",
        "_version_":1605818574378631168},
      {
        "Doc_abstract":"Cellular senescence is an irreversible cell cycle arrest triggered by the activation of oncogenes or mitogenic signaling as well as the enforced expression of tumor suppressors such as p53, p16(INK4A) and promyelocytic leukemia protein (PML) in normal cells. E2F-binding protein 1 (E2FBP1), a transcription regulator for E2F, induces PML reduction and suppresses the formation of PML-nuclear bodies, whereas the down-regulation of E2FBP1 provokes the PML-dependent premature senescence in human normal fibroblasts. Here we report that the depletion of E2FBP1 induces the accumulation of PML through the Ras-dependent activation of MAP kinase signaling. The cellular levels of p16(INK4A) and p53 are elevated during premature senescence induced by depletion of E2FBP1, and the depletion of p16(INK4A), but not p53 rescued senescent cells from growth arrest. Therefore, the premature senescence induced by E2FBP1 depletion is achieved through the p16(INK4A)-Rb pathway. Similar to human normal fibroblasts, the growth inhibition induced by E2FBP1 depletion is also observed in human tumor cells with intact p16(INK4A) and Rb. These results suggest that E2FBP1 functions as a critical antagonist to the p16(INK4A)-Rb tumor suppressor machinery by regulating PML stability.",
        "Doc_title":"E2FBP1 antagonizes the p16(INK4A)-Rb tumor suppressor machinery for growth suppression and cellular senescence by regulating promyelocytic leukemia protein stability.",
        "Journal":"International journal of oral science",
        "Do_id":"22010578",
        "Doc_ChemicalList":"ARID3A protein, human;Cyclin-Dependent Kinase Inhibitor p16;DNA-Binding Proteins;Nuclear Proteins;Promyelocytic Leukemia Protein;Protein Isoforms;Retinoblastoma Protein;Transcription Factors;Tumor Suppressor Protein p53;Tumor Suppressor Proteins;PML protein, human;ras Proteins",
        "Doc_meshdescriptors":"Cell Aging;Cell Line, Tumor;Cells, Cultured;Cyclin-Dependent Kinase Inhibitor p16;DNA-Binding Proteins;Down-Regulation;Fibroblasts;Gene Expression Regulation;Humans;Intranuclear Inclusion Bodies;MAP Kinase Signaling System;Nuclear Proteins;Promyelocytic Leukemia Protein;Protein Isoforms;Protein Stability;RNA Interference;Retinoblastoma Protein;Transcription Factors;Transfection;Tumor Suppressor Protein p53;Tumor Suppressor Proteins;Ubiquitination;ras Proteins",
        "Doc_meshqualifiers":"genetics;physiology;antagonists & inhibitors;genetics;physiology;deficiency;genetics;physiology;metabolism;genetics;metabolism;physiology;antagonists & inhibitors;genetics;physiology;deficiency;genetics;metabolism;physiology;physiology;genetics;metabolism;physiology;metabolism",
        "_version_":1605757069899595776},
      {
        "Doc_abstract":"Cancers often exhibit aberrant methylation of gene promoter regions associated with loss of tumor suppressor and/or DNA repair gene function. Such methylation constitutes an excellent marker for the molecular detection of micro-metastases and the diagnosis of tumor recurrences. We have developed a multiplex methylation-specific PCR (MSP) procedure for rapid and simultaneous assessment of the methylation of 5 loci: the tumor suppressor genes p16INK4a, death-associated protein kinase (DAPK) and p14ARF, and the DNA repair genes hMLH1 and O6-methylguanine-DNA-methyltransferase (MGMT). This multiplex test uses one single PCR reaction and only one electrophoretic run. In 98 samples of colorectal cancer studied, methylation of MGMT, DAPK, p16, hMLH1 and p14 was present in 31, 20, 17, 16 and 14% of tumors, respectively. In 58% of the tumors at least one methylated gene was found. This multiplex MSP constitutes a simple and inexpensive method for screening of molecular signatures in colorectal cancer and can be used profitably before employing more expensive and complex techniques such as microarray testing.",
        "Doc_title":"Development and application of a multiplex PCR procedure for the detection of DNA methylation in colorectal cancer.",
        "Journal":"Oncology reports",
        "Do_id":"15643519",
        "Doc_ChemicalList":"Adaptor Proteins, Signal Transducing;Apoptosis Regulatory Proteins;Carrier Proteins;MLH1 protein, human;Neoplasm Proteins;Nuclear Proteins;Death-Associated Protein Kinases;Calcium-Calmodulin-Dependent Protein Kinases;MutL Protein Homolog 1",
        "Doc_meshdescriptors":"Adaptor Proteins, Signal Transducing;Apoptosis Regulatory Proteins;Calcium-Calmodulin-Dependent Protein Kinases;Carrier Proteins;Colorectal Neoplasms;DNA Methylation;Death-Associated Protein Kinases;Genes, p16;Humans;MutL Protein Homolog 1;Neoplasm Proteins;Nuclear Proteins;Polymerase Chain Reaction;Sensitivity and Specificity",
        "Doc_meshqualifiers":"genetics;diagnosis;genetics;genetics;methods",
        "_version_":1605746486786654210},
      {
        "Doc_abstract":"The inhibitor of cyclin-dependent kinase 4-p16INK4 alpha and its alterative reading frame (ARF)-INK4/ARF gene locates at CDKN2A locus of human chromosome 9p21. This locus encodes two overlapped genes: ARF gene and p16INK4 alpha. The amino acid sequences of two genes are completely different because they are encoded by alternative reading frames. ARF participates in the regulation of mdm2-p53 pathway by mdm2. Recent studies showed that ARF gene may play a role in tumorigenesis; the ARF gene promoter hypermethylation may be the principal mechanism in the inactivation of this gene. Here is a review of ARF-mdm2-p53 interacting pathway.",
        "Doc_title":"[Interactive pathway of ARF-mdm2-p53].",
        "Journal":"Ai zheng = Aizheng = Chinese journal of cancer",
        "Do_id":"12654198",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;Nuclear Proteins;Proto-Oncogene Proteins;Tumor Suppressor Protein p53;MDM2 protein, human;Proto-Oncogene Proteins c-mdm2",
        "Doc_meshdescriptors":"Alternative Splicing;Chromosome Mapping;Chromosomes, Human, Pair 9;Cyclin-Dependent Kinase Inhibitor p16;Humans;Neoplasms;Nuclear Proteins;Proto-Oncogene Proteins;Proto-Oncogene Proteins c-mdm2;Tumor Suppressor Protein p53",
        "Doc_meshqualifiers":"metabolism;genetics;metabolism;metabolism;metabolism",
        "_version_":1605825070754693120},
      {
        "Doc_abstract":"The aim of our study was to evaluate the expression of p16INK4A and Ki-67 in cervical intraepithelial neoplasia (CIN) and to correlate the high-risk human papillomavirus (HPV) infection with these two biomarkers.;Sixty patients were included in our study. All of the patient underwent colposcopy-guided biopsy to asses the grade of CIN. For the immunohistochemistry exam we used p161NK4A and Ki-67 antibody and their expression was semiquantitatively classified in 4 classes: 0, 1, 2 and 3. HPV genotyping was used to detect high-risk HPV.;7 of our cases were benign (11.66%); 18 cases presented CIN1 (30%), 14 cases CIN2 (23.33%), 16 cases CIN3 (26.66%) and 5 cases invasive squamous cell carcinoma (8.33%). We observed that the expression of p16INK4A and Ki-67 were positively associated with CIN grade, p161NK4A expressions increased significantly with high-risk HPV infection. We observed a positive correlation between the expression of the p16INK4A and Ki-67.;In our study, the expression of p16 and Ki-67 were positively related to the CIN grade. p16INK4A expressions of high-risk HPV specimens significantly increased more than Ki-67. Therefore, in the diagnosis of CIN and high-risk HPV infection, p16INK4A can be a useful biomarker.",
        "Doc_title":"[Evaluation of p16INK4a and Ki-67 proteins expression in cervical intraepithelial neoplasia and their correlation with HPV-HR infection].",
        "Journal":"Revista medico-chirurgicala a Societatii de Medici si Naturalisti din Iasi",
        "Do_id":"21243810",
        "Doc_ChemicalList":"Biomarkers, Tumor;Cyclin-Dependent Kinase Inhibitor p16;Ki-67 Antigen",
        "Doc_meshdescriptors":"Adult;Aged;Alphapapillomavirus;Biomarkers, Tumor;Carcinoma, Squamous Cell;Cervical Intraepithelial Neoplasia;Cohort Studies;Cyclin-Dependent Kinase Inhibitor p16;Female;Gene Expression Regulation, Neoplastic;Humans;Immunohistochemistry;Ki-67 Antigen;Middle Aged;Neoplasm Staging;Papillomavirus Infections;Predictive Value of Tests;Retrospective Studies;Sensitivity and Specificity;Uterine Cervical Neoplasms",
        "Doc_meshqualifiers":"isolation & purification;metabolism;metabolism;virology;metabolism;virology;metabolism;metabolism;complications;metabolism;metabolism;virology",
        "_version_":1605747051320049665},
      {
        "Doc_abstract":"We examined the genomic status of the CDKN2 gene including de novo methylation of 5' CpG islands in primary and metastatic tumor samples from 31 patients with esophageal squamous cell carcinoma. One somatic frame shift mutation (1 of 31; 3.2%) was identified by PCR-single strand conformational polymorphism analysis and DNA sequencing. Homozygous deletion and de novo methylation of the gene were confirmed in 5 (16%) and 6 (19%) of 31 patients, respectively. Homozygous deletion and de novo methylation were significantly associated with silencing of gene expression (P < 0.01). Aberrations of the CDKN2 gene were detected in tumors with lymph node metastasis and muscular invasion (12 of 22; 54%) and in none of stage I tumors (0 of 9.0%; P < 0.05). These results suggest that homozygous deletion and de novo methylation are predominant mechanisms of inactivation of the CDKN2 gene and may be associated with metastatic and invasive phenotypes of esophageal squamous cell carcinoma.",
        "Doc_title":"Inactivation of the CDKN2 gene by homozygous deletion and de novo methylation is associated with advanced stage esophageal squamous cell carcinoma.",
        "Journal":"Cancer research",
        "Do_id":"8752149",
        "Doc_ChemicalList":"Carrier Proteins;Cyclin-Dependent Kinase Inhibitor p16;DNA, Neoplasm",
        "Doc_meshdescriptors":"Base Sequence;Carcinoma, Squamous Cell;Carrier Proteins;Cyclin-Dependent Kinase Inhibitor p16;DNA, Neoplasm;Esophageal Neoplasms;Gene Deletion;Gene Expression Regulation, Neoplastic;Homozygote;Humans;Lymphatic Metastasis;Methylation;Molecular Sequence Data;Neoplasm Metastasis;Neoplasm Staging;Polymerase Chain Reaction;Polymorphism, Single-Stranded Conformational",
        "Doc_meshqualifiers":"genetics;metabolism;genetics;genetics;metabolism;genetics;metabolism",
        "_version_":1605766841965215744},
      {
        "Doc_abstract":"There is a lack of consensus regarding the causes of the differences in the higher incidence of and the mortality from head and neck squamous cell carcinoma (HNSCC) in African Americans (AA) versus Caucasian Americans (CA). We examined a comprehensive array of risk factors influencing health and disease in an access-to-care, racially diverse, primary HNSCC cohort.;Cross-sectional study.;Primary care academic health care system.;The cohort of 673 patients comprised 391 CA and 282 AA (42%). Risk variables included demographic, histopathology, and clinical/epidemiologic factors. Tumor DNA was interrogated for loss and gain of 113 genes with known involvement in HNSCC/cancer. Logistic regression for univariate analysis was followed by multivariate modeling with determination of model predictability (c-index).;Of the 39 univariate differences between AA and CA, multivariate modeling (c-index = 0.81) retained 7 differences (P < .05). AA were less likely to be married and more likely to have tumor lymphocytic response, undergo radiation treatment, and smoke. Insurance type was a significant predictor of race. AA were more likely to have Medicaid, Medicare, and other HMO types. AA tumors were more likely to have loss of CDKN2A and gain of SCYA3 versus CA.;Multivariate modeling indicated significant differences between AA and CA HNSCC for histopathology, treatment, smoking, marital status, type of insurance, and tumor gene copy number alterations. Our data reiterate that for HNSCC, as in the case of other complex diseases, tumor genetics or biology is only one of many potential contributors to differences among racial groups.",
        "Doc_title":"Disparate molecular, histopathology, and clinical factors in head and neck squamous cell carcinoma racial groups.",
        "Journal":"Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery",
        "Do_id":"22412179",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"African Americans;Aged;Carcinoma, Squamous Cell;Cross-Sectional Studies;European Continental Ancestry Group;Female;Head and Neck Neoplasms;Humans;Male;Middle Aged",
        "Doc_meshqualifiers":"genetics;pathology;genetics;pathology",
        "_version_":1605750762732781568},
      {
        "Doc_abstract":"The INK4A gene maps to the 9p21 region and was initially described [M. Serrano et al., Nature (Lond.), 366: 704-707, 1993; A. Kamb et al., Science (Washington DC), 264: 436-440, 1994] as encoding a 148-amino-acid protein termed p16. The p16 protein associates exclusively with Cdk4 and Cdk6, inhibiting their complexation with D-type cyclins and the consequent phosphorylation of pRb. This contributes to cell cycle arrest. The purpose of the present study was to evaluate patterns of p16 expression in a well-characterized cohort of prostatic adenocarcinomas while exploring potential associations between alterations of p16 and clinicopathological variables. Normal and malignant tissues from 88 patients with prostate carcinoma were examined. In situ hybridization and immunohistochemistry assays were used to determine the status of the INK4A exon 1alpha transcripts and levels of p16 protein, respectively. Associations between altered patterns of expression and clinicopathological variables, including pretreatment prostate-specific antigen (PSA) level, Gleason grade, pathological stage, and hormonal status, were evaluated using the Mantel-Haenszel chi2 test. Biochemical (PSA) relapse after surgery was evaluated using the Kaplan-Meier method and the log-rank test. Levels of p16 expression and INK4A exon 1alpha transcripts in normal prostate and benign hyperplastic tissues were undetectable. However, p16 nuclear overexpression was observed in 38 (43%) prostate carcinomas, whereas the remaining 50 (57%) cases showed undetectable p16 levels. Overexpression of p16 protein was found to correlate with increased INK4A exon 1alpha transcripts. Moreover, p16 overexpression was associated with a higher pretreatment PSA level (P = 0.018), the use of neoadjuvant androgen ablation (P = 0.001), and a sooner time to PSA relapse after radical prostatectomy (P = 0.002). These data suggest that p16 overexpression is associated with tumor recurrence and a poor clinical course in patients with prostate cancer.",
        "Doc_title":"Overexpression of the cyclin-dependent kinase inhibitor p16 is associated with tumor recurrence in human prostate cancer.",
        "Journal":"Clinical cancer research : an official journal of the American Association for Cancer Research",
        "Do_id":"10353729",
        "Doc_ChemicalList":"Androgen Antagonists;Antineoplastic Agents, Hormonal;Biomarkers, Tumor;Cyclin-Dependent Kinase Inhibitor p16;Neoplasm Proteins;RNA, Messenger;RNA, Neoplasm;Prostate-Specific Antigen",
        "Doc_meshdescriptors":"Adenocarcinoma;Aged;Androgen Antagonists;Antineoplastic Agents, Hormonal;Biomarkers, Tumor;Cell Nucleus;Chemotherapy, Adjuvant;Cohort Studies;Combined Modality Therapy;Cyclin-Dependent Kinase Inhibitor p16;Disease-Free Survival;Exons;Gene Expression Regulation, Neoplastic;Genes, p16;Humans;In Situ Hybridization;Life Tables;Male;Middle Aged;Neoplasm Proteins;Neoplasm Recurrence, Local;Prognosis;Prostate;Prostate-Specific Antigen;Prostatectomy;Prostatic Hyperplasia;Prostatic Neoplasms;RNA, Messenger;RNA, Neoplasm;Retrospective Studies;Transcription, Genetic;Treatment Failure",
        "Doc_meshqualifiers":"genetics;pathology;therapy;therapeutic use;therapeutic use;blood;chemistry;biosynthesis;genetics;biosynthesis;genetics;genetics;chemistry;blood;genetics;genetics;pathology;therapy;biosynthesis;biosynthesis",
        "_version_":1605819371409637376},
      {
        "Doc_abstract":"Head and neck squamous cell carcinoma (HNSCC) is an aggressive epithelial malignancy. It is the most common neoplasm appearing in the upper aerodigestive tract and the sixth most common cancer worldwide. The five-year survival rate remains poor despite advances in surgery, radiation and chemotherapy. Furthermore, the incidence of human papillomavirus (HPV)-associated oropharyngeal cancer is rising. Thus, innovative therapy approaches are imperative in order to improve the situation. Everolimus, an inhibitor of the mammalian target of rapamycin (mTOR) and sorafenib and sunitinib, multityrosine kinase inhibitors, have been notably effective in the therapy of different tumor entities. The modest side-effects and oral application of the drugs might improve patient compliance. Expression levels of mTOR and Amphiregulin (AREG) in p16-positive and -negative SCC (squamous cell carcinoma) and the effect of everolimus, sorafenib or sunitinib on the expression levels of these target proteins were assessed. As far as we are aware of, this is one of the first in vitro studies to evaluate the effect of these small-molecule drugs with regard to the p16 status of SCC cells.;p16-negative HNSCC 11A and 14C cells and p16-positive CERV196 cells were exposed to different concentrations of everolimus, sorafenib and sunitinib for 2-8 days. Expression levels of mTOR and AREG were determined by enzyme-linked immunosorbent assay (ELISA) and compared against a chemonave control.;AREG and mTOR were expressed in all tested cell lines. CERV196 displayed a remarkable increase of mTOR expression compared to p16-negative HNSCC. On the contrary, AREG levels were reduced by 50% in CERV196. Everolimus, sorafenib and sunitinib significantly reduced mTOR expression. Everolimus significantly decreased AREG expression independently of the HPV status. Sunitinib and sorafenib increased AREG expression in HNSCC 11A and 14C but not in CERV196.;The applied drugs showed remarkable suppression of mTOR expression, which might delay tumor progression. Interestingly, sorafenib and sunitinib increased AREG in HNSCC 11A and 14C, which could be a possible evasive mechanism following incubation with these drugs. On the contrary, p16-positive CERV196 showed increased susceptibility to sorafenib and sunitinib concerning suppression of AREG expression. Further studies are required to evaluate the HPV-dependent differences of therapy response and the possible consequences for treatment options.",
        "Doc_title":"Targeting mTOR and AREG with everolimus, sunitinib and sorafenib in HPV-positive and -negative SCC.",
        "Journal":"Anticancer research",
        "Do_id":"25862847",
        "Doc_ChemicalList":"AREG protein, human;Amphiregulin;EGF Family of Proteins;Indoles;Phenylurea Compounds;Pyrroles;Niacinamide;Everolimus;sorafenib;MTOR protein, human;TOR Serine-Threonine Kinases;sunitinib;Sirolimus",
        "Doc_meshdescriptors":"Amphiregulin;Carcinoma, Squamous Cell;EGF Family of Proteins;Everolimus;Gene Expression Regulation, Neoplastic;Head and Neck Neoplasms;Human papillomavirus 16;Humans;Indoles;Molecular Targeted Therapy;Niacinamide;Papillomaviridae;Phenylurea Compounds;Pyrroles;Sirolimus;TOR Serine-Threonine Kinases",
        "Doc_meshqualifiers":"drug therapy;genetics;pathology;virology;biosynthesis;genetics;drug therapy;genetics;pathology;virology;genetics;pathogenicity;administration & dosage;administration & dosage;analogs & derivatives;drug effects;administration & dosage;administration & dosage;administration & dosage;analogs & derivatives;biosynthesis;genetics",
        "_version_":1605896969233891328},
      {
        "Doc_abstract":"The tumor suppressor gene, CDKN2A (p16), encodes a cyclin-dependent kinase inhibitor and functions as a negative regulator in the retinoblastoma pathway that blocks cell cycle progression from the G1 phase. The gene has been found to be deleted, truncated, mutated, or silenced by promoter methylation in a wide range of tumor types. Where melanoma CDKN2A mutations have been characterized, C --> T and CC --> TT transitions were found, indicating a direct role for ultraviolet radiation (UVR)-induced pyrimidine dimers in the formation of some tumors. The South American opossum, Monodelphis domestica, has been shown by our group and others to be susceptible to the induction of melanoma on chronic exposure to UVR alone. The CDKN2A gene and its exon 1beta alternate transcript p19ARF were cloned and sequenced from M. domestica to investigate the role of these genes in the development of UVR-induced melanoma and non-melanoma tumors. Both genes were first amplified by polymerase chain reaction (PCR) using cDNA from an opossum corneal-tumor cell-line library and degenerate primers based on human, mouse, and rat CDKN2A gene sequences. To verify these as normal sequences, both genes were then RT-PCR amplified from cultured normal opossum melanocyte mRNA. When comparing the tumor and melanocyte sequences, we found a UVR signature point mutation, a C --> T transition, within exon 2 in the corneal tumor cell line. The same mutation at this site in other tumors has been shown to alter the CDKN2A protein's ability to bind CDK4 kinase, which may lead to uncontrolled cell cycling. A comparison of the amino acid sequence of opossum CDKN2A showed identities relative to human, mouse, and rat between 57% and 63%, and when conserved amino acid substitutions are considered (similarity), the range is 63% to 67%. The amino acid identity and similarity for p19ARF ranged from 39% to 49%.",
        "Doc_title":"Cloning and characterization of the CDKN2A and p19ARF genes from Monodelphis domestica.",
        "Journal":"DNA and cell biology",
        "Do_id":"9839807",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;DNA, Complementary;Proteins;Tumor Suppressor Protein p14ARF",
        "Doc_meshdescriptors":"Amino Acid Sequence;Animals;Base Sequence;Cloning, Molecular;Cyclin-Dependent Kinase Inhibitor p16;DNA, Complementary;Humans;Melanoma;Mice;Molecular Sequence Data;Mutation;Neoplasms, Radiation-Induced;Opossums;Phylogeny;Proteins;Rats;Sequence Alignment;Tumor Cells, Cultured;Tumor Suppressor Protein p14ARF;Ultraviolet Rays",
        "Doc_meshqualifiers":"genetics;etiology;genetics;genetics;classification;genetics;genetics",
        "_version_":1605754462273536000},
      {
        "Doc_abstract":"Rhabdomyosarcoma is the most common soft tissue sarcoma of childhood and adolescence. Despite advances in therapy, patients with a histologic variant of rhabdomyosarcoma known as alveolar rhabdomyosarcoma (ARMS) have a 5-year survival of <30%. ARMS is characterized by a chromosomal translocation generating the PAX3-FKHR fusion gene. However, ectopic expression of PAX3-FKHR often induces inhibition of cell proliferation, or cell death, when expressed in nonmuscle cells. This prompted us to explore the effect of expressing PAX3-FKHR in more relevant cells, specifically primary human skeletal muscle cells because these cells can be converted to a tumorigenic state that mimics rhabdomyosarcoma. PAX3-FKHR expression promoted both fetal and postnatal primary human skeletal muscle cell precursors to bypass the senescence growth arrest checkpoint. This bypass was accompanied by epigenetic DNA methylation of the p16(INK4A) promoter and correspondingly a loss of expression of this tumor suppressor. Knockdown of p16(INK4A) cooperated with PAX3-FKHR to drive proliferation past senescence, whereas reintroduction of wild-type p16(INK4A) in post-senescent cells caused growth arrest. Thus, PAX3-FKHR acts in concert with loss of p16(INK4A) to promote inappropriate proliferation of skeletal muscle cells. This association between PAX3-FKHR expression and p16(INK4A) loss was seen in human ARMS tumor tissue, as both human rhabdomyosarcoma cell lines and tissue microarrays showed a trend toward down-regulation of p16(INK4A) protein in alveolar subsets. We surmise that the generation of the PAX3-FKHR fusion protein may require loss of p16(INK4A) to promote malignant proliferation of skeletal muscle cells as an early step in ARMS tumorigenesis.",
        "Doc_title":"The PAX3-FKHR fusion gene of rhabdomyosarcoma cooperates with loss of p16INK4A to promote bypass of cellular senescence.",
        "Journal":"Cancer research",
        "Do_id":"17638879",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;FOXO1 protein, human;Forkhead Box Protein O1;Forkhead Transcription Factors;PAX3 Transcription Factor;PAX3 protein, human;Paired Box Transcription Factors;Recombinant Fusion Proteins",
        "Doc_meshdescriptors":"Cell Aging;Cell Line, Tumor;Cell Proliferation;Cyclin-Dependent Kinase Inhibitor p16;DNA Methylation;Forkhead Box Protein O1;Forkhead Transcription Factors;Gene Expression Regulation, Neoplastic;Humans;Lung Neoplasms;Muscle, Skeletal;Oligonucleotide Array Sequence Analysis;PAX3 Transcription Factor;Paired Box Transcription Factors;Promoter Regions, Genetic;Recombinant Fusion Proteins;Rhabdomyosarcoma",
        "Doc_meshqualifiers":"metabolism;physiology;metabolism;cytology;physiology;metabolism",
        "_version_":1605799518743298048},
      {
        "Doc_abstract":"Comprehensive genomic analyses of common nervous system cancers provide new insights into their pathogenesis, diagnosis, and treatment. Although analogous studies of rare nervous system tumors are needed, there are major barriers to performing such studies. Cross-species comparative oncogenomics, identifying driver mutations in mouse cancer models and validating them in human tumors, is a promising alternative. Although still in its infancy, this approach is being applied to malignant peripheral nerve sheath tumors (MPNSTs), rare Schwann cell-derived malignancies that occur sporadically, after radiotherapy, and in neurofibromatosis type 1. Studies of human neurofibromatosis type 1-associated tumors suggest that NF1 tumor suppressor loss in Schwann cells triggers cell-autonomous and intercellular changes, resulting in development of benign neurofibromas; subsequent neurofibroma-MPNST progression is caused by aberrant growth factor signaling and mutations affecting the p16(INK4A)-cyclin D1-CDK4-Rb and p19(ARF)-Mdm2-p53 cell cycle pathways. Mice with Nf1, Trp53, and/or Cdkn2a mutations that overexpress the Schwann cell mitogen neuregulin-1 or overexpress the epidermal growth factor receptor validate observations in human tumors and, to various degrees, model human tumorigenesis. Genomic analyses of MPNSTs arising in neuregulin-1 and epidermal growth factor receptor-overexpressing mice and forward genetic screens with Sleeping Beauty transposons implicate additional signaling cascades in MPNST pathogenesis. These studies confirm the utility of mouse models for MPNST driver gene discovery and provide new insights into the complexity of MPNST pathogenesis. ",
        "Doc_title":"The Challenge of Cancer Genomics in Rare Nervous System Neoplasms: Malignant Peripheral Nerve Sheath Tumors as a Paradigm for Cross-Species Comparative Oncogenomics.",
        "Journal":"The American journal of pathology",
        "Do_id":"26740486",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Animals;Cell Cycle;Cell Transformation, Neoplastic;Disease Models, Animal;Genomics;Humans;Mice;Mutation;Nervous System Neoplasms;Neurilemmoma;Neurofibroma;Neurofibromatosis 1;Schwann Cells;Signal Transduction",
        "Doc_meshqualifiers":"genetics;pathology;genetics;pathology;genetics;pathology;genetics;pathology;pathology;genetics",
        "_version_":1605883291095793664},
      {
        "Doc_abstract":"To determine the incidence and clinical significance of TP53 and CDKN2a somatic mutations in never smokers with oral tongue squamous cell carcinoma (OTSCC).;Case series.;Fifty-one paraffin-embedded tumors from never smokers with OTSCC were obtained. p53 and p16 expression was determined by immunohistochemical (IHC) staining. Tumor DNA was amplified by polymerase chain reaction, and direct sequencing and mutation analysis was performed. Statistical relationships among p53 and p16 IHC findings, TP53 and CDKN2a mutation status, and clinicopathologic characteristics were determined. Univariate and multivariate Cox models for survival were performed.;Sixteen tumors (31.4%) showed strong expression of p53 by IHC. There was no correlation between p53 status and clinicopathologic variables or survival outcomes. TP53 mutations were seen in 10 tumors (19.6%). Patients with TP53 mutations had higher tumor-node-metastasis (TNM) stage (P=0.049), worse tumor differentiation (P=0.025), earlier recurrence (P=0.024), and more often died from their disease (P=0.043) than those without mutations. Five tumors (9.8%) showed p16 positivity by IHC. There was no correlation between p16 status and clinicopathologic variables or survival. CDKN2a mutations were seen in four tumors (7.8%). Patients with CDKN2a mutations had earlier recurrence (P=0.019) and more often died from their disease (P=0.010) than those without mutations. Kaplan-Meier curves show worse disease-free survival (P=0.0162, P=0.0025) and overall survival (P=0.0095, P=0.0001) for TP53 and CDKN2a mutations, respectively. Multivariate analysis demonstrated that TP53 and CDKN2a mutations were independent predictors of disease-free survival (P=0.038 and P=0.039, respectively).;TP53 and CDKN2a mutations in never-smoker OTSCC are associated with worse clinicopathologic characteristics and poorer survival outcomes.;N/A.",
        "Doc_title":"TP53 and CDKN2a mutations in never-smoker oral tongue squamous cell carcinoma.",
        "Journal":"The Laryngoscope",
        "Do_id":"24431303",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;DNA, Neoplasm;TP53 protein, human;Tumor Suppressor Protein p53",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Carcinoma, Squamous Cell;Cyclin-Dependent Kinase Inhibitor p16;DNA, Neoplasm;Disease-Free Survival;Female;Follow-Up Studies;Humans;Male;Middle Aged;Mutation;Neoplasm Staging;Polymerase Chain Reaction;Prognosis;Retrospective Studies;Smoking;Tongue Neoplasms;Tumor Suppressor Protein p53;Young Adult",
        "Doc_meshqualifiers":"genetics;metabolism;pathology;genetics;metabolism;genetics;genetics;metabolism;pathology;genetics;metabolism",
        "_version_":1605799894130360320},
      {
        "Doc_abstract":"FOXO (Forkhead box O) transcription factors are involved in cell-cycle arrest or apoptosis induction by transcripting cell-cycle inhibitor p27(KIP1) or apoptosis-related genes, respectively. Akt/protein kinase B promotes cell proliferation and suppresses apoptosis, in part, by phosphorylating FOXOs. Phosphorylated FOXOs could not exhibit transcriptional activity because of their nuclear export. Here we show that p15(INK4b) and p19(INK4d) transcription is associated with FOXO-mediated G1 cell-cycle arrest. Inhibition of Akt signaling by PI3K inhibitors, a PDK1 inhibitor, or dominant-negative Akt transfection increased expression of p15(INK4b) and p19(INK4d) but not p16(INK4a) and p18(INK4c). Ectopic expression of wild type or active FOXO but not inactive form also increased p15(INK4b) and p19(INK4d) levels. FOXOs bound to promoter regions and induced transcription of these genes. No increase in the G1-arrested cell population, mediated by PI3K inhibitor LY294002, was observed in INK4b-/- or INK4d-/- murine embryonic fibroblasts. In summary, FOXOs are involved in G1 arrest caused by Akt inactivation via p15(INK4b) and p19(INK4d) transcription.",
        "Doc_title":"FOXO transcription factor-dependent p15(INK4b) and p19(INK4d) expression.",
        "Journal":"Oncogene",
        "Do_id":"17873901",
        "Doc_ChemicalList":"CDKN2B protein, human;CDKN2D protein, human;Chromones;Cyclin-Dependent Kinase Inhibitor p15;Cyclin-Dependent Kinase Inhibitor p19;Enzyme Inhibitors;Forkhead Transcription Factors;Morpholines;2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one;Phosphatidylinositol 3-Kinases;Proto-Oncogene Proteins c-akt",
        "Doc_meshdescriptors":"Animals;Cell Line;Chromones;Cyclin-Dependent Kinase Inhibitor p15;Cyclin-Dependent Kinase Inhibitor p19;Enzyme Inhibitors;Forkhead Transcription Factors;G1 Phase;Gene Expression Regulation;Humans;Mice;Mice, Knockout;Morpholines;Phosphatidylinositol 3-Kinases;Proto-Oncogene Proteins c-akt;Up-Regulation",
        "Doc_meshqualifiers":"pharmacology;biosynthesis;genetics;biosynthesis;genetics;pharmacology;physiology;drug effects;physiology;drug effects;physiology;pharmacology;antagonists & inhibitors;antagonists & inhibitors;drug effects;physiology",
        "_version_":1605879846297141248},
      {
        "Doc_abstract":"Esophageal squamous cell carcinoma (ESCC) is a cancer of variable outcomes with limited effective treatments resulting in poor overall survival (OS). Epigenetic alterations contributing to this deadly cancer type that can be used as novel therapeutic or diagnostic targets are still poorly understood.;We explored genome-wide DNA methylation data from The Cancer Genome Atlas project and identified a panel of tumor-related genes hypermethylated in ESCC. The methylation statuses of RASSF1, RARB, CDKN2A (p16INK4a, p14ARF), APC, and RUNX3 genes and long interspersed nucleotide element-1 (LINE-1) were validated in a large cohort (n = 140) of clinically well-annotated ESCC specimens and esophageal normal mucosa (n = 28) using a quantitative methylation-specific polymerase chain reaction.;Hypermethylation of RARB, p16INK4a, RASSF1, APC, RUNX3, and p14ARF were observed in 55%, 24%, 20%, 19%, 14%, and 8% of specimens, respectively. Hypermethylation of APC was significantly associated with tumor depth (p = 0.02) and American Joint Committee on Cancer stage (p = 0.03). Global DNA methylation level, assessed by LINE-1, was significantly lower in ESCC than in normal mucosa (p < 0.0001), and lower in greater than or equal to T2 (n = 69) than T1 tumors (n = 45; p = 0.03). There was a significant inverse correlation between LINE-1 and RARB methylation (p = 0.008). Importantly, hypermethylation of RASSF1 and APC genes was significantly associated with overall survival (OS; p = 0.006 and p = 0.007, respectively). In addition, patients with tumors containing a higher number of methylated genes (greater than two genes) presented worse OS (p = 0.003).;This study demonstrates that epigenetic alterations of a panel of tumor-related genes and the noncoding region LINE-1 can be used as prognostic indicators and help in clinical management of ESCC patients.",
        "Doc_title":"Genome-wide hypomethylation and specific tumor-related gene hypermethylation are associated with esophageal squamous cell carcinoma outcome.",
        "Journal":"Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer",
        "Do_id":"25514805",
        "Doc_ChemicalList":"Biomarkers, Tumor;DNA",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Biomarkers, Tumor;Carcinoma, Squamous Cell;Case-Control Studies;Cohort Studies;DNA;DNA Methylation;Esophageal Neoplasms;Esophagus;Female;Follow-Up Studies;Genes, Tumor Suppressor;Genome, Human;Humans;Long Interspersed Nucleotide Elements;Male;Middle Aged;Neoplasm Staging;Prognosis;Promoter Regions, Genetic;Real-Time Polymerase Chain Reaction;Survival Rate",
        "Doc_meshqualifiers":"genetics;genetics;mortality;pathology;analysis;genetics;genetics;mortality;pathology;metabolism;genetics",
        "_version_":1605741938317721602},
      {
        "Doc_abstract":"Despite multimodal treatment, sinonasal malignancies have an unfavorable prognosis. The purpose of this study was to elucidate if these tumors harbor amplifications of the fibroblast growth factor receptor 1 (FGFR1) gene, which has recently been identified as a potential therapeutic target in squamous cell lung cancer.;One hundred twelve primary tumors (including squamous cell carcinoma [SCC], carcinoma associated with an inverted papilloma, sinonasal undifferentiated carcinoma [SNUC], adenocarcinoma, adenoid cystic carcinoma [ACC], esthesioneuroblastoma, and 9 corresponding lymph node metastases) were assessed by fluorescence in situ hybridization (FISH) for FGFR1 copy number status. Human papillomavirus (HPV) status was assessed by p16 immunohistochemical as a surrogate marker.;FGFR1 amplification was found in subsets of sinonasal SCCs (20%), carcinomas associated with an inverted papilloma (33%), and SNUCs (5%). In all cases, metastatic tumor samples shared the same FGFR1 amplification status as the corresponding primary tumor tissue. None of the FGFR1-amplified tumors expressed p16.;FGFR1 amplification represents a potential molecular target in a subset of patients with sinonasal cancer.  2014 Wiley Periodicals, Inc. Head Neck 36: 1253-1257, 2014.",
        "Doc_title":"Fibroblast growth factor receptor-1 as a potential therapeutic target in sinonasal cancer.",
        "Journal":"Head & neck",
        "Do_id":"23913758",
        "Doc_ChemicalList":"Receptor, Fibroblast Growth Factor, Type 1",
        "Doc_meshdescriptors":"Adenocarcinoma;Aged;Carcinoma, Squamous Cell;Cohort Studies;Esthesioneuroblastoma, Olfactory;Female;Gene Amplification;Humans;Male;Middle Aged;Papilloma, Inverted;Paranasal Sinus Neoplasms;Receptor, Fibroblast Growth Factor, Type 1",
        "Doc_meshqualifiers":"genetics;pathology;therapy;genetics;pathology;therapy;genetics;pathology;therapy;genetics;genetics;pathology;therapy;genetics;pathology;therapy;genetics",
        "_version_":1605804721264656384},
      {
        "Doc_abstract":"Transition from G1 to S phase of the cell cycle is mediated by interactions between the Retinoblastoma gene product (pRb), p16, and cyclin D1. To determine the expression of these proteins in the sinonasal mucosa immunohistochemistry was carried out on archived tissue sections from 46 patients (37 men, 9 women, age range 17 to 82 years, median 55 years). Nuclear immunostaining for these proteins was assessed and the expression rates (percentages of immunoreactive nuclei) in normal respiratory epithelium, inverted sinonasal papillomas, cylindrical (oncocytic) sinonasal papillomas, and squamous cell carcinomas were compared. Normal respiratory epithelium showed significantly higher pRb expression in surface cells compared to basal cells (p < 0.05). In contrast, abundant pRb expression in surface and basal cells was detected in columnar differentiation in sinonasal papillomas and adjacent mucosa. Cuboidal and squamous metaplasia in inverted papillomas showed significantly reduced pRb expression in surface cells compared to columnar epithelium in inverted papillomas (p < 0.05, respectively). Expression of p16 was detected in all epithelial cell layers of normal respiratory epithelium, sinonasal papillomas, and adjacent mucosa. Cuboidal and squamous metaplasia in inverted papillomas showed increased p16 expression in surface cells compared to columnar epithelium in inverted papillomas (p < 0.05 between squamous metaplasia and columnar epithelium). Sinonasal squamous cell carcinomas showed the coexpression of pRb and p16. Expression rates of cyclin D1 higher than 10% were detected only in invasive carcinomas but not in carcinoma in situ, sinonasal papillomas or respiratory epithelium. Conclusively, pRb expression accompanies terminal differentiation in columnar surface cells. Expression of pRb in proliferating basal cells is present in sinonasal papillomas and adjacent mucosa but not in normal respiratory epithelium. Cuboidal and squamous metaplasia in inverted papillomas involves downregulation of pRb expression along with increased p16 expression in surface cells. Sinonasal squamous cell carcinomas coexpress pRb and p16. Overexpression of cyclin D1 in sinonasal lesions is confined to invasive squamous cell carcinomas.",
        "Doc_title":"Expression of retinoblastoma gene product in respiratory epithelium and sinonasal neoplasms: relationship with p16 and cyclin D1 expression.",
        "Journal":"Histology and histopathology",
        "Do_id":"12507294",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;Retinoblastoma Protein;Cyclin D1",
        "Doc_meshdescriptors":"Carcinoma, Squamous Cell;Cyclin D1;Cyclin-Dependent Kinase Inhibitor p16;Humans;Papilloma;Respiratory Mucosa;Retinoblastoma Protein",
        "Doc_meshqualifiers":"metabolism;biosynthesis;genetics;biosynthesis;genetics;metabolism;metabolism;biosynthesis;genetics",
        "_version_":1605751378019352576},
      {
        "Doc_abstract":"Alteration of VSMC (vascular smooth-muscle cell) physiology is associated with the development of atherosclerosis and restenosis. We hypothesize that aging up-regulates the expression of p16 INK4a in VSMCs, which may increase the susceptibility of blood vessels to vascular occlusive diseases. Aortic VSMCs were obtained from young and aged mice. Cells from aged mice grew more slowly than those from their younger counterparts. Progression of cell cycle in response to serum stimulation was significantly inhibited in those cells with aging, as determined by FACS after propidium iodide staining. A significant up-regulation of p16 INK4a (2.5-fold, P=0.0012) was found in VSMC from aged animals using gene arrays. The up-regulation of this gene was further confirmed by quantitative RT-PCR (reverse transcription-PCR) and Western-blot experiments. Immunostaining for p16 INK4a confirmed that aortas from aged mice contained more p16 INK4a+ SMA (smooth-muscle cell actin)+ cells than aortas from young animals (26.79+/-2.45 versus 7.06+/-1.44, P=0.00027, n=4). In conclusion, we have shown that aging up-regulates the expression of p16 INK4a in VSMC in both cultures and arteries. The increase in p16 INK4a in the vasculature with aging may modify VSMC's response to post-injury stress and therefore accelerate the development of age-related cardiovascular diseases.",
        "Doc_title":"Aging increases p16 INK4a expression in vascular smooth-muscle cells.",
        "Journal":"Bioscience reports",
        "Do_id":"19196247",
        "Doc_ChemicalList":"Actins;Blood Proteins;Cdkn2a protein, mouse;Cyclin-Dependent Kinase Inhibitor p16;RNA, Messenger",
        "Doc_meshdescriptors":"Actins;Aging;Animals;Aorta;Atherosclerosis;Blood Proteins;Cell Cycle;Cell Proliferation;Cells, Cultured;Coronary Restenosis;Cyclin-Dependent Kinase Inhibitor p16;Male;Mice;Mice, Inbred C57BL;Muscle, Smooth, Vascular;Oligonucleotide Array Sequence Analysis;RNA, Messenger;Reverse Transcriptase Polymerase Chain Reaction;Up-Regulation",
        "Doc_meshqualifiers":"metabolism;metabolism;metabolism;physiopathology;metabolism;physiopathology;pharmacology;drug effects;physiology;drug effects;metabolism;physiopathology;genetics;metabolism;cytology;metabolism;metabolism;genetics",
        "_version_":1605899367640727552},
      {
        "Doc_abstract":"Murine double minute clone 2 (MDM2), p14 alternate reading frame (p14arf), and nucleophosmin (NPM) regulate p53 activity. A total of 200 biopsies, including normal bronchial, pre-invasive and invasive tissues, were examined for changes in NPM, p14arf, MDM2 and p53 expression patterns by immunohistochemistry and immunofluorescence with confocal microscopy. NPM and p14arf displayed a diffuse nuclear staining in most normal bronchial tissue. The fraction of biopsies displaying an increased MDM2 staining or a nucleolar relocalisation of NPM increased at mild and moderate dysplasia, respectively. Two different modifications occurred in p14arf expression, i.e. its loss or its nucleolar relocalisation, both increasing at severe dysplasia and both being associated with high MDM2 expression. In addition, the nucleolar relocalisation of p14arf was associated with that of NPM. Immunofluorescence staining indicated that NPM and p14arf either co-localised in the nucleoplasm or in the nucleoli, before and as a result of severe dysplasia, respectively. MDM2 was not detected in the nucleoli. Thus, changes occur in murine double minute clone 2, p14 alternate reading frame and nucleophosmin level of expression and/or cellular distribution during early steps of lung carcinogenesis. Their relative localisation as determined by immunofluorescence, supports the hypothesis that p14 alternate reading frame nucleolar relocalisation impairs p14 alternate reading frame-murine double minute clone 2 complex formation and that nucleophosmin might sequester p14 alternate reading frame. The demonstration of this hypothesis requires further functional studies.",
        "Doc_title":"The role of NPM, p14arf and MDM2 in precursors of bronchial squamous cell carcinoma.",
        "Journal":"The European respiratory journal",
        "Do_id":"18480108",
        "Doc_ChemicalList":"Nuclear Proteins;Tumor Suppressor Protein p14ARF;nucleophosmin;MDM2 protein, human;Proto-Oncogene Proteins c-mdm2",
        "Doc_meshdescriptors":"Bronchial Neoplasms;Carcinoma, Squamous Cell;Case-Control Studies;Cell Nucleolus;Humans;Nuclear Proteins;Proto-Oncogene Proteins c-mdm2;Tumor Suppressor Protein p14ARF",
        "Doc_meshqualifiers":"metabolism;pathology;metabolism;pathology;metabolism;metabolism;metabolism;metabolism",
        "_version_":1605784350986600448},
      {
        "Doc_abstract":"The INK4a-ARF locus plays a central role in the development of pancreatic tumors as evidenced by the fact that up to 98% of pancreatic tumor specimens harbored genetic alterations at the INK4a-ARF locus. Interestingly, in addition to the well-known P16(INK4A) (P16) and P14ARF tumor suppressors, the INK4a-ARF locus in pancreas encodes another protein, P12, whose structure, function, and contributions to pancreatic carcinogenesis remain to be elucidated. In the current study, we demonstrated that over-expression of p12 in human pancreatic cancer cells led to cell arrest at the G1 phase and such cell cycle arrest was related to down-regulation of a number of oncogenes, such as c-Jun, Fos, and SEI1. Furthermore, unlike P16, P12 did not retain any cyclin-dependent kinase 4 (CDK4)-inhibitory activity. Instead, P12 exhibited a transactivating activity not found in P16. We also examined the genetic status of p12 in a cohort of 40 pancreatic tumor specimens and found that p12 alteration was prevalent in pancreatic tumors with an incidence of 70% (28/40). These results support that P12 is a tumor suppressive protein distinct from P16, and its genetic inactivation is associated with pancreatic carcinogenesis. ",
        "Doc_title":"Evidence that P12, a specific variant of P16(INK4A), plays a suppressive role in human pancreatic carcinogenesis.",
        "Journal":"Biochemical and biophysical research communications",
        "Do_id":"23727582",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;Nuclear Proteins;Proto-Oncogene Proteins c-fos;Proto-Oncogene Proteins c-jun;SERTAD1 protein, human;Trans-Activators;Tumor Suppressor Proteins;p12(INK4a) protein, human",
        "Doc_meshdescriptors":"Alternative Splicing;Amino Acid Sequence;Cell Line, Tumor;Cell Transformation, Neoplastic;Cohort Studies;Cyclin-Dependent Kinase Inhibitor p16;G1 Phase Cell Cycle Checkpoints;Gene Expression Regulation, Neoplastic;Humans;Molecular Sequence Data;Mutation;Nuclear Proteins;Pancreas;Pancreatic Neoplasms;Proto-Oncogene Proteins c-fos;Proto-Oncogene Proteins c-jun;Reverse Transcriptase Polymerase Chain Reaction;Trans-Activators;Transcriptional Activation;Tumor Suppressor Proteins",
        "Doc_meshqualifiers":"genetics;metabolism;pathology;genetics;metabolism;genetics;genetics;metabolism;metabolism;pathology;genetics;metabolism;pathology;genetics;metabolism;genetics;metabolism;genetics;metabolism;genetics;metabolism",
        "_version_":1605840115836387328},
      {
        "Doc_abstract":"The development of human cancers is frequently associated with the silencing of the two major tumor suppressor pathways represented by retinoblastoma protein and p53. As the incidence of p53 mutations is significantly lower in Hodgkin's lymphoma than in other neoplasias, we investigated whether the malfunction of other proteins in this pathway could be responsible for its inactivation. Because the existence of nucleolar complexes between p14(ARF) and Hdm2 has been described as having a critical effect on p53 function by inhibiting its degradation, we analyzed the expression and subcellular localization of these proteins in 52 cases and in Hodgkin's cell lines. Two of four cell lines revealed loss of p14(ARF) expression secondary to gene promoter methylation, this being mutually exclusive with p53 mutations (1 of 4), illustrating the existence of selective pressure to inactivate the p53 pathway. The majority of Hodgkin's samples showed a strong nucleolar expression of p14(ARF) that was not associated with Hdm2. They also showed the existence of Hdm2/p53 complexes, and the absence of complexes containing either p14(ARF)/Hdm2 or p14(ARF)/p53. The different localization of Hdm2 (nucleoplasm) and p14(ARF) (nucleoli) observed in Hodgkin's tumors and cell lines is associated with the presence of short alternatively spliced transcripts of Hdm2 lacking the ARF-binding region and the nuclear export signal. The absence of these p14(ARF)/Hdm2 nucleolar complexes could be sufficient to inactivate the pathway and may explain the low frequency of p53 mutations in this tumor.",
        "Doc_title":"Nucleolar p14(ARF) overexpression in Reed-Sternberg cells in Hodgkin's lymphoma: absence of p14(ARF)/Hdm2 complexes is associated with expression of alternatively spliced Hdm2 transcripts.",
        "Journal":"The American journal of pathology",
        "Do_id":"11839577",
        "Doc_ChemicalList":"Neoplasm Proteins;Nuclear Proteins;Proto-Oncogene Proteins;Tumor Suppressor Protein p14ARF;Tumor Suppressor Protein p53;MDM2 protein, human;Proto-Oncogene Proteins c-mdm2",
        "Doc_meshdescriptors":"Alternative Splicing;Animals;Cell Nucleolus;DNA Methylation;Hodgkin Disease;Humans;Immunohistochemistry;Lymphoid Tissue;Neoplasm Proteins;Nuclear Proteins;Promoter Regions, Genetic;Proto-Oncogene Proteins;Proto-Oncogene Proteins c-mdm2;Reed-Sternberg Cells;Tumor Cells, Cultured;Tumor Suppressor Protein p14ARF;Tumor Suppressor Protein p53",
        "Doc_meshqualifiers":"metabolism;genetics;metabolism;cytology;metabolism;genetics;metabolism;genetics;metabolism;genetics;genetics;metabolism;cytology;metabolism;genetics;metabolism;metabolism",
        "_version_":1605746441630777345},
      {
        "Doc_abstract":"Recent work has shown that expression of the p16(INK4a) tumor suppressor increases with chronological age. Expression is accelerated by gerontogenic behaviors such as tobacco use and physical inactivity, and is also influenced by allelic genotype of a polymorphic single nucleotide polymorphism (SNP) rs10757278 that is physically linked with the p16(INK4a) ORF. To understand the relationship between p16(INK4a) expression, chronologic age, subject characteristics and host genetics, we sought to develop a mathematical model that links p16(INK4a) expression with aging. Using an annotated dataset of 170 healthy adults for whom p16(INK4a) expression and subject genotypes were known, we developed two alternative stochastic models that relate p16(INK4a) expression to age, smoking, exercise and rs10757278 genotype. Levels of p16(INK4a) increased exponentially and then saturated at later chronologic ages. The model, which best fit the data, suggests saturation occurs because of p16(INK4a)-dependent attrition of subjects at older chronologic ages, presumably due to death or chronic illness. An important feature of our model is that factors that contribute to death in a non p16(INK4a)-dependent manner do not affect our analysis. Interestingly, tobacco-related increases in p16(INK4a) expression are predicted to arise from a decrease in the rate of p16(INK4a)-dependent death. This analysis is most consistent with the model that p16(INK4a) expression monotonically increases with age, and higher expression is associated with increased subject attrition.",
        "Doc_title":"A quantitative model for age-dependent expression of the p16INK4a tumor suppressor.",
        "Journal":"Proceedings of the National Academy of Sciences of the United States of America",
        "Do_id":"19805338",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;Tumor Suppressor Proteins",
        "Doc_meshdescriptors":"Aging;Cyclin-Dependent Kinase Inhibitor p16;Genotype;Models, Theoretical;Polymorphism, Single Nucleotide;Tumor Suppressor Proteins",
        "Doc_meshqualifiers":"genetics;metabolism;genetics;metabolism",
        "_version_":1605796136125202432},
      {
        "Doc_abstract":"To investigate the CpG methylation locus and frequency pattern on p16 INK4a gene promoter in epidermis of p16 INK4a methylated patients with psoriasis vulgaris.;The DNA specimens were obtained from epidermal lesion of 50 plaque psoriatic patients. Methylation specific PCR and DNA sequencing were used to detect the frequency and locus of methylation in p16 INK4a gene promoter region.;Approximately 50% CpG was methylated in p16 INK4a methylated patients, methylation was found in specifical locus of p16 INK4a gene promoter.;The distinct methylation pattern is showed on the p16 INK4a gene promoter region in patients with psoriasis.",
        "Doc_title":"[The methylation locus and frequency pattern on p16 INK4a gene promoter CpG in epidermis of patients with psoriasis].",
        "Journal":"Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics",
        "Do_id":"18067081",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;Tumor Suppressor Protein p14ARF",
        "Doc_meshdescriptors":"Adolescent;Adult;Aged;Base Sequence;CpG Islands;Cyclin-Dependent Kinase Inhibitor p16;DNA Methylation;Epidermis;Female;Humans;Male;Middle Aged;Molecular Sequence Data;Polymerase Chain Reaction;Promoter Regions, Genetic;Psoriasis;Sequence Alignment;Tumor Suppressor Protein p14ARF;Young Adult",
        "Doc_meshqualifiers":"genetics;genetics;metabolism;genetics;metabolism;genetics;genetics;genetics",
        "_version_":1605840775268007936},
      {
        "Doc_abstract":"Cellular senescence is a program in normal cells triggered in response to various types of stress that cells experience when they are explanted into culture. In this study, functional analyses on the role of the class II polycomb complex in cellular senescence were performed using mouse embryo fibroblasts (MEFs) with a genetically deleted member of the complex, Mel18. Mel18-null MEFs undergo typical premature senescence accompanied by the up-regulation of ARF/p53/p16(INK4a) and decrease of Ring1b/Bmi1. Our results demonstrated that ARF or p53 deletion cancels the senescence in Mel18-null MEFs, and the fact that p16(INK4a) is up-regulated in double-null MEFs suggests that the ARF/p53 pathway plays a central role in stress-induced senescence. The in vivo binding of Ring1b and E2F3b to the ARF promoter decreased progressively in senescence, and Mel18 inactivation accelerated the exfoliation of Ring1b/E2F3b from the promoter sequence, indicating the cooperation of polycombs/E2F3b on ARF expression and cellular senescence. Taken together, it seems that class II polycomb proteins and E2F3b dually control cellular senescence via the ARF/p53 pathway.",
        "Doc_title":"Polycomb complexes regulate cellular senescence by repression of ARF in cooperation with E2F3.",
        "Journal":"Genes to cells : devoted to molecular & cellular mechanisms",
        "Do_id":"18076574",
        "Doc_ChemicalList":"E2F3 Transcription Factor;E2f3 protein, mouse;Polycomb-Group Proteins;Repressor Proteins;Tumor Suppressor Protein p14ARF;Tumor Suppressor Protein p53",
        "Doc_meshdescriptors":"Animals;Cell Aging;E2F3 Transcription Factor;Embryo, Mammalian;Fibroblasts;Gene Expression Regulation;Mice;Polycomb-Group Proteins;Repressor Proteins;Tumor Suppressor Protein p14ARF;Tumor Suppressor Protein p53",
        "Doc_meshqualifiers":"physiology;metabolism;anatomy & histology;pathology;physiology;cytology;physiology;physiology;metabolism;metabolism",
        "_version_":1605742773416230914},
      {
        "Doc_abstract":"Fragile histidine triad (FHIT) gene plays an important role in the pathogenesis of lung cancer. However, the clinicopathological significance of CpG island hypermethylation of FHIT gene in non-small cell lung cancer (NSCLC) remains to be elucidated. We studied FHIT methylation in 254 NSCLCs in order to further understand the clinicopathological and prognostic significance of FHIT methylation in NSCLC. Methylation status of the FHIT gene was examined using Methylation-Specific PCR. All statistical analyses were two-sided, with a 5% type I error rate. Hypermethylation of the FHIT gene occurred more frequently in squamous cell carcinoma than adenocarcinoma. For 93 adenocarcinomas there was no statistically significant association between FHIT methylation and age, gender, smoking history, pathologic stage and p16 methylation. However, FHIT methylation in 125 squamous cell carcinomas was associated with exposure to tobacco smoke and p16 methylation, but not with age, gender and pathologic stage. Hypermethylation of FHIT in squamous cell carcinomas occurred more frequently in current smokers (45%) than in never-smokers (13%). FHIT methylation was significantly associated with p16 methylation in current- and ex-smokers (P = 0.02 and P = 0.01, respectively) with squamous cell carcinoma and in patients with pathologic stage I squamous cell carcinoma (P = 0.001). Patients with p16 methylation were 3.74 times [95% confidence interval (CI) = 1.62 - 7.95; P = 0.001] more likely to have FHIT methylation in squamous cell carcinoma. FHIT methylation in squamous cell carcinoma occurred at a 4.62 times (95% CI = 1.26 - 34.97; P = 0.02) higher prevalence in current smokers than in never-smokers. No prognostic effect of FHIT methylation was observed in stage I and stage II NSCLCs. In conclusion, hypermethylation of the FHIT gene did not have a prognostic significance in early stage NSCLCs. The FHIT methylation is associated with the p16 methylation and smoking in squamous cell carcinoma, suggesting that FHIT may cooperate with p16 for the development of squamous cell carcinoma of lung in individuals exposed to tobacco smoke.",
        "Doc_title":"Aberrant methylation of the FHIT gene in chronic smokers with early stage squamous cell carcinoma of the lung.",
        "Journal":"Carcinogenesis",
        "Do_id":"15231689",
        "Doc_ChemicalList":"Dinucleoside Phosphates;Neoplasm Proteins;fragile histidine triad protein;cytidylyl-3'-5'-guanosine;Acid Anhydride Hydrolases",
        "Doc_meshdescriptors":"Acid Anhydride Hydrolases;Aged;Carcinoma, Non-Small-Cell Lung;Carcinoma, Squamous Cell;DNA Methylation;Dinucleoside Phosphates;Female;Genes, p16;Humans;Lung Neoplasms;Male;Middle Aged;Neoplasm Proteins;Neoplasm Staging;Polymerase Chain Reaction;Smoking;Survival Analysis",
        "Doc_meshqualifiers":"genetics;genetics;genetics;mortality;pathology;genetics;genetics;mortality;pathology;genetics;adverse effects",
        "_version_":1605910028837978112},
      {
        "Doc_abstract":"The tumor suppressor p16(INK4A), a phosphoprotein that exists in human cells under both phosphorylated and nonphosphorylated forms, plays crucial roles during the cellular response to UV light. However, it is still unclear how this protein is activated in response to this carcinogenic agent. We have shown here that UVC upregulates p16(INK4A) and the phosphorylated form of the protein at the 4 serine sites; Ser-7, Ser-8, Ser-140, and Ser-152. This accumulation of p16(INK4A) occurred through increasing the stability of both forms of the protein. Importantly, phospho-p16(INK4A) showed much higher stability, and UV treatment strongly increased its level in absence of de novo protein synthesis. Furthermore, we have shown that the UV-dependent upregulation of both forms of p16(INK4A) is under the control of the protein kinase Atr, which suppresses their UVC-dependent proteasomal degradation. Interestingly, although this degradation is ubiquitin-related for p16(INK4A) through the Skp2 ubiquitin ligase protein, it is ubiquitin-independent for the phosphorylated form. In addition, we present clear evidence that Skp2 is upregulated in ATR-deficient cells, leading to the downregulation of the p27(Kip1) protein in response to UVC light. Moreover, we have shown a preferential association of endogeneous phospho-p16(INK4A) with Cdk4. This association increased following UV-treatment mainly for p16(INK4A) phosphorylated at Ser-140 and Ser-152. Besides, we have shown that Atr regulates UV-related p16/Cdk4-dependent and -independent phosphorylation of pRB and G1 cell cycle delay. Together, these results indicate that p16(INK4A) and p27(Kip1) are key targets in the Atr-dependent signaling pathway in response to UV damage.",
        "Doc_title":"The atr protein kinase controls UV-dependent upregulation of p16INK4A through inhibition of Skp2-related polyubiquitination/degradation.",
        "Journal":"Molecular cancer research : MCR",
        "Do_id":"21270107",
        "Doc_ChemicalList":"Cell Cycle Proteins;Cyclin-Dependent Kinase Inhibitor p16;Retinoblastoma Protein;S-Phase Kinase-Associated Proteins;Tumor Suppressor Protein p53;Cyclin-Dependent Kinase Inhibitor p27;ATR protein, human;Ataxia Telangiectasia Mutated Proteins;Protein-Serine-Threonine Kinases;Cyclin-Dependent Kinase 4",
        "Doc_meshdescriptors":"Ataxia Telangiectasia Mutated Proteins;Cell Cycle;Cell Cycle Proteins;Cell Line;Cyclin-Dependent Kinase 4;Cyclin-Dependent Kinase Inhibitor p16;Cyclin-Dependent Kinase Inhibitor p27;Fibroblasts;Humans;Phosphorylation;Protein-Serine-Threonine Kinases;Retinoblastoma Protein;S-Phase Kinase-Associated Proteins;Tumor Suppressor Protein p53;Ubiquitination;Ultraviolet Rays;Up-Regulation",
        "Doc_meshqualifiers":"genetics;genetics;metabolism;genetics;metabolism;genetics;metabolism;genetics;metabolism;enzymology;metabolism;genetics;genetics;metabolism;genetics;metabolism;genetics;metabolism;genetics;metabolism;genetics;adverse effects;genetics",
        "_version_":1605758564644683776},
      {
        "Doc_abstract":"p16(INK4a), a tumor suppressor gene that inhibits cyclin-dependent kinase 4 and cyclin-dependent kinase 6, is also implicated in the mechanisms underlying replicative senescence, because its RNA and protein accumulate as cells approach their finite number of population doublings in tissue culture. To further explore the involvement of p16(INK4a) in replicative senescence, we constructed a retroviral vector containing antisense p16(INK4a), pDOR-ASp16, and introduced it into early passages of human diploid fibroblasts. The introduction of this construct significantly suppressed the expression of wild-type p16(INK4a). It also imposed a finite increase in proliferative life span and significant delay of several other cell senescent features, such as cell flattening, cell cycle arrest, and senescence-associated beta-galactosidase positivity. Moreover, telomere shortening and decline in DNA repair capacity, which normally accompany cell senescence, are also postponed by the ASp16 transfection. The life span of fibroblasts was significantly extended, but the onset of replicative senescence could not be totally prevented. Telomerase could not be activated even though telomere shortening was slowed. These observations suggest that the telomere pathway of senescence cannot be bypassed by ASp16 expression. These data not only strongly support a role for p16(INK4a) in replicative senescence but also raise the possibility of using the antisense p16(INK4a) therapeutically.",
        "Doc_title":"Senescence delay of human diploid fibroblast induced by anti-sense p16INK4a expression.",
        "Journal":"The Journal of biological chemistry",
        "Do_id":"11606567",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;DNA Primers;Oligonucleotides, Antisense;beta-Galactosidase",
        "Doc_meshdescriptors":"Base Sequence;Cell Aging;Cells, Cultured;Cyclin-Dependent Kinase Inhibitor p16;DNA Primers;DNA Repair;Diploidy;Fibroblasts;Gene Expression Regulation;Genetic Vectors;Humans;Oligonucleotides, Antisense;Retroviridae;beta-Galactosidase",
        "Doc_meshqualifiers":"genetics;genetics;cytology;genetics;genetics;genetics;genetics",
        "_version_":1605811730315739136},
      {
        "Doc_abstract":"In cancer, gene silencing via hypermethylation is as common as genetic mutations in p53. Understanding the relationship between mutant p53 and hypermethylation of other tumor suppressor genes is essential when elucidate mechanisms of tumor development. In this study, two isogenic human B lymphoblast cell lines with different p53 status include TK6 containing wild-type p53 and WTK1 with mutant p53 were used and contrasted. Lower levels of p16(ink4A) protein were detected in WTK1 cells than in TK6 cells, which were accompanied by increased DNA (cytosine-5)-methyltransferase 1 (DNMT1) gene expression as well as hypermethylation of the p16 ( ink4A ) promoter. siRNA experiments to transiently knock down wild-type p53 in TK6 cells resulted in increase of DNMT1 expression as well as decrease of p16(ink4A) protein. Conversely, siRNA knockdown of mutant p53 in WTK1 cells did not alter either DNMT1 or p16(ink4A) protein levels. Furthermore, loss of suppression function of mutant p53 to DNMT1 in WTK1 was caused by the attenuation of its binding ability to the DNMT1 promoter. In summary, we provide evidences to elucidate the relationship between mutant p53 and DNMT1. Our results indicate that mutant p53 loses its ability to suppress DNMT1 expression, and thus enhances methylation levels of the p16 ( ink4A ) promoter and subsequently down-regulates p16(ink4A )protein.",
        "Doc_title":"DNA (cytosine-5)-methyltransferase 1 as a mediator of mutant p53-determined p16(ink4A) down-regulation.",
        "Journal":"Journal of biomedical science",
        "Do_id":"18038118",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;RNA, Small Interfering;Tumor Suppressor Protein p53;DNA (Cytosine-5-)-Methyltransferase;DNA (cytosine-5-)-methyltransferase 1",
        "Doc_meshdescriptors":"B-Lymphocytes;Cell Line, Tumor;Cyclin-Dependent Kinase Inhibitor p16;DNA (Cytosine-5-)-Methyltransferase;DNA Methylation;Down-Regulation;Humans;Mutation;Neoplasms;Promoter Regions, Genetic;RNA, Small Interfering;Tumor Suppressor Protein p53",
        "Doc_meshqualifiers":"metabolism;genetics;metabolism;genetics;metabolism;genetics;metabolism;genetics;genetics;antagonists & inhibitors;genetics;metabolism",
        "_version_":1605910503185448960},
      {
        "Doc_abstract":"The objective of this study was to evaluate the usefulness of p16(INK4a) staining to classify cervical intraepithelial neoplasia grade 1 according to its progression/regression risk.;Patients with a histologic diagnosis of cervical intraepithelial neoplasia grade 1 were prospectively recruited (n = 138). Simultaneous detection of high-risk human papillomaviruses and p16(INK4a) evaluation were performed. Follow-up was conducted every 6 months by cytology and colposcopy and annually by high-risk human papillomavirus testing, for at least 12 months (mean, 29.0). Progression was defined as a histologic diagnosis of cervical intraepithelial neoplasia grades 2-3, regression as a negative cytology and high-risk human papillomaviruses, and persistence as a cytologic result of low-grade squamous intraepithelial lesions and/or a positive test for high-risk human papillomaviruses.;Progression was observed in 14 women (10.1%), 66 (47.6%) regressed, and 58 (42.0%) had a persistent disease. p16(INK4a) was positive in 77 (55.8%) initial biopsy specimens. Progression to cervical intraepithelial neoplasia grades 2-3 was identified in 14 of 77 (18.2%) women with positive and none of 61 (0.00%) women with negative p16(INK4a) immunostaining (P < .001).;p16(INK4a) negative cervical intraepithelial neoplasia grade 1 lesions rarely progress and may benefit from a less intensive follow-up.",
        "Doc_title":"Value of p16(INK4a) as a marker of progression/regression in cervical intraepithelial neoplasia grade 1.",
        "Journal":"American journal of obstetrics and gynecology",
        "Do_id":"19683687",
        "Doc_ChemicalList":"Biomarkers;Cyclin-Dependent Kinase Inhibitor p16",
        "Doc_meshdescriptors":"Adult;Aged;Biomarkers;Cervical Intraepithelial Neoplasia;Cyclin-Dependent Kinase Inhibitor p16;Disease Progression;Female;Humans;Middle Aged;Prospective Studies;Remission Induction;Uterine Cervical Neoplasms;Young Adult",
        "Doc_meshqualifiers":"chemistry;pathology;surgery;analysis;chemistry;pathology;surgery",
        "_version_":1605763664309125120},
      {
        "Doc_abstract":"Two distinct products are specified by the CDKN2A locus, the p16INK4a cyclin dependent kinase inhibitor and a protein termed ARF. ARF has been shown to bind to the Mdm2-p53 complex, resulting in stabilisation of both proteins, and a feedback loop exists through which ARF levels are negatively regulated by p53. Significantly, ARF expression is positively regulated by members of the E2F family of transcription factors. This provides a link between the Rb and p53 pathways and a mechanism whereby inactivation of Rb and release of E2F will lead to the stabilisation and functional activation of p53. The alternative exon encoding the functional amino terminal portion of ARF presumably represents an independent gene that has become co-localized with p16INK4a in order to exploit a common regulatory mechanism or purpose.",
        "Doc_title":"Alternative product of the p16/CKDN2A locus connects the Rb and p53 tumor suppressors.",
        "Journal":"Progress in cell cycle research",
        "Do_id":"10740816",
        "Doc_ChemicalList":"Carrier Proteins;Cyclin-Dependent Kinase Inhibitor p16;Proteins;Retinoblastoma Protein;Tumor Suppressor Protein p14ARF;Tumor Suppressor Protein p53;Cyclin-Dependent Kinases",
        "Doc_meshdescriptors":"Alternative Splicing;Animals;Carrier Proteins;Cell Cycle;Cyclin-Dependent Kinase Inhibitor p16;Cyclin-Dependent Kinases;Evolution, Molecular;Genes, Tumor Suppressor;Humans;Mammals;Oncogenes;Proteins;Retinoblastoma Protein;Signal Transduction;Tumor Suppressor Protein p14ARF;Tumor Suppressor Protein p53",
        "Doc_meshqualifiers":"genetics;antagonists & inhibitors;genetics;genetics;physiology;genetics;physiology",
        "_version_":1605902418378227712},
      {
        "Doc_abstract":"Recent reports have shown that upon expression of appropriate oncogenes, both stem cells and more differentiated progenitor populations can serve as leukemia-initiating cells. These studies suggest that oncogenic mutations subvert normal development and induce reacquisition of stem-like features. However, no study has described how specific mutations influence the ability of differentiating cell subsets to serve as leukemia-initiating cells and if varying such cellular origins confers a functional difference. We have examined the role of the tumor suppressor gene p19(ARF) in a murine model of acute lymphoblastic leukemia and found that loss of p19(ARF) changes the spectrum of cells capable of tumor initiation. With intact p19(ARF), only hematopoietic stem cells (HSCs) can be directly transformed by BCR/ABL expression. In a p19(ARF)-null genetic background expression of the BCR/ABL fusion protein renders functionally defined HSCs, common lymphoid progenitors (CLP), and precursor B-lymphocytes competent to generate leukemia stem cells. Furthermore, we show that leukemias arising from p19(ARF)-null HSC versus pro-B cells differ biologically, including relative response to drug insult. Our observations elucidate a unique mechanism by which heterogeneity arises in tumor populations harboring identical genetic lesions and show that activity of p19(ARF) profoundly influences the nature of tumor-initiating cells during BCR/ABL-mediated leukemogenesis.",
        "Doc_title":"The biologic properties of leukemias arising from BCR/ABL-mediated transformation vary as a function of developmental origin and activity of the p19ARF gene.",
        "Journal":"Blood",
        "Do_id":"18755985",
        "Doc_ChemicalList":"Cdkn2a protein, mouse;Cyclin-Dependent Kinase Inhibitor p16;Fusion Proteins, bcr-abl",
        "Doc_meshdescriptors":"Animals;Cell Transformation, Neoplastic;Cyclin-Dependent Kinase Inhibitor p16;Disease Models, Animal;Fusion Proteins, bcr-abl;Lymphoid Progenitor Cells;Mice;Mice, Transgenic;Precursor Cell Lymphoblastic Leukemia-Lymphoma",
        "Doc_meshqualifiers":"genetics;metabolism;pathology;genetics;metabolism;genetics;metabolism;metabolism;pathology;genetics;metabolism;pathology",
        "_version_":1605820248452235264},
      {
        "Doc_abstract":"Here we demonstrate a novel p53-independent interaction between the nucleolar tumor suppressors, p14 Arf and Werners helicase (WRN). Binding of p14 Arf to WRN is multivalent and resembles the binding of p14 Arf to Mdm2. Residues 2-14 and 82-101 of p14 Arf and residues in the central region and C terminus of WRN have particular importance for binding. p14 Arf promotes small ubiquitin-like modifier (SUMO) modification of WRN in a synergistic manner with the SUMO-conjugating enzyme, UBCH9. p14 Arf causes redistribution of WRN within the nucleus, and this effect is reversed by expression of a SUMO-specific protease, thus implicating the SUMO conjugation pathway in WRN re-localization. We establish that the ability to promote SUMO conjugation is a general property of the p14 Arf tumor suppressor.",
        "Doc_title":"p14 Arf promotes small ubiquitin-like modifier conjugation of Werners helicase.",
        "Journal":"The Journal of biological chemistry",
        "Do_id":"15355988",
        "Doc_ChemicalList":"Peptide Fragments;SUMO-1 Protein;Tumor Suppressor Protein p14ARF;Exodeoxyribonucleases;DNA Helicases;RecQ Helicases;WRN protein, human;Werner Syndrome Helicase",
        "Doc_meshdescriptors":"DNA Helicases;Exodeoxyribonucleases;Humans;Mutation;Peptide Fragments;Protein Interaction Mapping;RecQ Helicases;SUMO-1 Protein;Sequence Deletion;Tumor Suppressor Protein p14ARF;Werner Syndrome Helicase",
        "Doc_meshqualifiers":"metabolism;metabolism;metabolism;genetics;metabolism",
        "_version_":1605836184388370432},
      {
        "Doc_abstract":"Penile cutaneous horn is a clinical term that describes protruding hyperkeratosis, usually conical in shape, located on penile glans. Penile localization of this lesion, predominantly located on sun-exposed areas, is very rare. The association with malignancy on the penis makes proper identification of these lesions essential. We present a 45-year-old man with a cutaneous horn, 25 mm in size, located on the basis of penile glans. The patient had a history of phimosis, pseudoepitheliomatous balanoposthitis, surgical excision of penile verrucous squamous cell carcinoma (SCC) and postoperative radiotherapy of carcinoma in situ on the same localization, ten years before. Complete surgical removal of the horn with separate excision of the margins and base was done. Pathologic examination revealed squamous hyperplasia with suspicion of carcinoma in situ. Additional negative p16(INK4a) immunohistochemical analysis confirmed benign proliferative lesion. DNA polymerase chain reaction for human papilloma virus infection was negative. These findings suggested sparing surgical procedure in our patient, without indication for partial penile amputation, but with mandatory follow-up. Our case confirmed the association of pseudoepitheliomatous balanoposthitis with verrucous SCC, as well as the possible influence of radiotherapy on the development of penile cutaneous horn. Additionally, we showed the important role p16(INK4a) immunohistochemical analysis in the differential diagnosis of alterations adjacent to invasive SCC of the penis.",
        "Doc_title":"Penile cutaneous horn ten years after treatment of verrucous squamous cell carcinoma on penile glans: case report.",
        "Journal":"Acta dermatovenerologica Croatica : ADC",
        "Do_id":"22507472",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Carcinoma, Verrucous;Diagnosis, Differential;Humans;Immunohistochemistry;Male;Middle Aged;Neoplasm Recurrence, Local;Penile Neoplasms;Skin Diseases;Skin Neoplasms",
        "Doc_meshqualifiers":"pathology;pathology;diagnosis;surgery;pathology",
        "_version_":1605741948939796480},
      {
        "Doc_abstract":"Little or no data exist concerning the inactivation of tumor suppressor genes in intraductal lesions surrounding invasive ductal pancreatic carcinomas. Using a novel improved primer extension and preamplification polymerase chain reaction, we analyzed microdissected paraffin-embedded specimens of pancreatic carcinoma (n = 29) and their corresponding pancreatic intraductal lesions (PIL, n = 331) for loss of heterozygosity (LOH) of p16(INK4), DPC4, and p53 by microsatellite analysis and for p53 protein by immunohistochemistry. LOH at the p16(INK4) locus (9p21) was found in nine of 22 informative tumors (41%), in 15 of 25 tumors (60%) at the DPC4 locus (18q21.1), and in 22 of 27 tumors (81%) at the p53 locus (17p13). Homozygous deletions of p16(INK4) and DPC4 were found in eight of 22 (36%) and four of 25 tumors (16%), respectively. Furthermore, 24 of 29 tumors (83%) revealed considerable intratumoral genetic heterogeneity. In 165 of 277 PILs (60%) having suitable DNA for microsatellite analysis, alterations in at least one tumor suppressor gene were found. In individual PILs, up to three alterations were detected, and p53 LOH occurred even in morphologically normal-appearing ductal epithelium near the tumor. Although deletions of all three tumor suppressor genes were found in PILs without nuclear atypia, there was a tendency toward earlier LOH of p16(INK4) compared to DPC4 and p53 in these lesions. LOH in tumors accompanied positive p53 immunohistochemistry in 81% but only in 38% in PILs.",
        "Doc_title":"Molecular analysis of microdissected tumors and preneoplastic intraductal lesions in pancreatic carcinoma.",
        "Journal":"The American journal of pathology",
        "Do_id":"10880379",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;DNA-Binding Proteins;SMAD4 protein, human;Smad4 Protein;Trans-Activators;Tumor Suppressor Protein p53",
        "Doc_meshdescriptors":"Carcinoma, Intraductal, Noninfiltrating;Cyclin-Dependent Kinase Inhibitor p16;DNA-Binding Proteins;Humans;Immunohistochemistry;Loss of Heterozygosity;Microsatellite Repeats;Neoplasm Staging;Pancreas;Pancreatic Neoplasms;Precancerous Conditions;Smad4 Protein;Trans-Activators;Tumor Suppressor Protein p53",
        "Doc_meshqualifiers":"genetics;metabolism;pathology;genetics;genetics;chemistry;metabolism;pathology;genetics;metabolism;pathology;genetics;metabolism;pathology;genetics;analysis;genetics",
        "_version_":1605758616198971392},
      {
        "Doc_abstract":"Human papillomavirus (HPV), p16 expression, and TP53 mutations are known prognostic factors in head and neck squamous cell carcinoma, but their role in squamous cell carcinoma of the anal canal (SCCAC) is less well established. The objective of this study was to determine the prognostic significance of tumour HPV status, p16 and p53 expression, and mutations in TP53 in patients with SCCAC receiving (chemo)radiotherapy.;Human papillomavirus DNA was determined using an INNO-LiPA-based assay in tumour tissue of 107 patients with locally advanced SCCAC. Patients were treated with radiotherapy, with or without concurrent chemotherapy consisting of a fluoropyrimidine and mitomycin C. Expression of p16 and p53 was determined using immunohistochemistry. Exons 2-11 of TP53 in tumour tissue were sequenced.;DNA of high-risk HPV types was detected in 93 out of 107 tumours (87%), all of which overexpressed p16 (HPV+/p16+). Of 14 HPV-negative (HPV-) tumours (13%), 10 (9%) were p16-negative (HPV-/p16-) and 4 (4%) overexpressed p16 (HPV-/p16+). Patients with HPV-/p16- disease had inferior 3-year locoregional control (LRC) (15%) compared with patients with HPV+/p16+ tumours (82%, P<0.001) and HPV-/p16+ tumours (75%, P=0.078). Similarly, 3-year overall survival (OS) was 35% (HPV-/p16-) vs 87% (HPV+/p16+, P<0.001) and 75% (HPV-/p16+, P=0.219). Disruptive mutations in TP53 were found in 80% of HPV-/p16- tumours vs 6% of HPV+/p16+ tumours (P<0.001). In multivariate analysis, HPV-/p16- status was an independent predictor of inferior LRC and OS.;HPV- tumours are frequently TP53 mutated. HPV-/p16- status is a strong predictor for reduced LRC and OS, and alternative treatment strategies for patients with HPV-/p16- disease need to be explored.",
        "Doc_title":"HPV-negative squamous cell carcinoma of the anal canal is unresponsive to standard treatment and frequently carries disruptive mutations in TP53.",
        "Journal":"British journal of cancer",
        "Do_id":"25871546",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;TP53 protein, human;Tumor Suppressor Protein p53",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Alphapapillomavirus;Anus Neoplasms;Carcinoma, Squamous Cell;Cyclin-Dependent Kinase Inhibitor p16;Drug Therapy;Female;Humans;Male;Middle Aged;Mutation;Papillomavirus Infections;Radiotherapy;Treatment Outcome;Tumor Suppressor Protein p53",
        "Doc_meshqualifiers":"classification;isolation & purification;genetics;therapy;virology;genetics;therapy;virology;metabolism;genetics;virology;genetics",
        "_version_":1605742153775972354},
      {
        "Doc_abstract":"To investigate the methylation of p16(INK4a) and RB gene, and the expression of p16(INK4a) in meningiomas.;Methylation-specific polymerase chain reaction (MSP) was used to detect the methylation of p16(INK4a) and RB in 50 cases of meningiomas, and immunostaining was performed to analyze the protein expression of p16(INK4a) in 25 of those cases.;No methylation was found in the benign meningiomas, whereas methylation of p16(INK4a)or RB occurred in 6(37.5%) cases of grade II tumors and 4(28.6%) cases of grade III tumors, and among these cases, an atypical meningioma showed methylation of both genes. Thirteen cases showed p16(INK4a) positive expression, but none of them was methylated.;The methylation of p16(INK4a) or RB is related with the tumorigenesis and progression of atypical and anaplastic meningiomas, and a probable mechanism is that methylation causes the loss of expression and leads to dysfuncation of the p16(INK4a)/cyclin D1/CDK4/RB pathway.",
        "Doc_title":"[Methylation and expression analysis of p16(INK4a) and RB genes in meningiomas].",
        "Journal":"Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics",
        "Do_id":"15192837",
        "Doc_ChemicalList":"Proto-Oncogene Proteins;Cyclin D1;CDK4 protein, human;Cyclin-Dependent Kinase 4;Cyclin-Dependent Kinases",
        "Doc_meshdescriptors":"Adolescent;Adult;Aged;Aged, 80 and over;Cyclin D1;Cyclin-Dependent Kinase 4;Cyclin-Dependent Kinases;DNA Methylation;Female;Genes, Retinoblastoma;Genes, p16;Humans;Male;Meningeal Neoplasms;Meningioma;Middle Aged;Proto-Oncogene Proteins",
        "Doc_meshqualifiers":"genetics;genetics;genetics;genetics",
        "_version_":1605763855523250176},
      {
        "Doc_abstract":"The role of cell cycle inhibitors in tumorigenesis has been proven in various neoplasms; however, their roles in thymic tumors are still unclear. We examined the expression of cell cycle inhibitors such as those of the Cip/Kip family (p21, p27, and p57) and the INK-4/ARF family (p16 and p14) in thymoma and thymic carcinoma.;Samples from 41 thymoma and 14 thymic carcinoma patients, and 34 normal thymic tissue samples were prepared for the study. Immunohistochemical analysis using antibodies to p21, p27, p57, p16, and p14 was carried out, and the positivity for these inhibitors in each group was estimated in terms of their subcellular location and percentage of cells showing positive staining.;Nuclear p27 showed a stepwise decrease (p < 0.0001), and the cytoplasmic p27 showed a stepwise increase (p < 0.0001) in expression level with the increase in malignancy. p16 in both the nucleus and cytoplasm showed a stepwise increase (p < 0.0001) in expression level with the increase in malignancy. However, as for p21, p57, and p14, there was almost no nuclear or cytoplasmic expression in each group.;Our findings suggest that low nuclear and high cytoplasmic p27 expression levels, and high nuclear and cytoplasmic p16 expression levels may correlate with the increase in thymic malignancy.",
        "Doc_title":"Cyclin-dependent kinase inhibitors, p16 and p27, demonstrate different expression patterns in thymoma and thymic carcinoma.",
        "Journal":"General thoracic and cardiovascular surgery",
        "Do_id":"24938902",
        "Doc_ChemicalList":"Biomarkers, Tumor;Cyclin-Dependent Kinase Inhibitor Proteins;Cyclin-Dependent Kinase Inhibitor p21;Neoplasm Proteins;Cyclin-Dependent Kinase Inhibitor p27",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Biomarkers, Tumor;Cyclin-Dependent Kinase Inhibitor Proteins;Cyclin-Dependent Kinase Inhibitor p21;Cyclin-Dependent Kinase Inhibitor p27;Female;Humans;Male;Middle Aged;Neoplasm Proteins;Neoplasm Staging;Thymoma;Thymus Neoplasms",
        "Doc_meshqualifiers":"metabolism;metabolism;metabolism;metabolism;metabolism;metabolism;pathology;metabolism;pathology",
        "_version_":1605796731706933248},
      {
        "Doc_abstract":"Exposure to total body irradiation (TBI) induces not only acute hematopoietic radiation syndrome but also long-term or residual bone marrow (BM) injury. This residual BM injury is mainly attributed to permanent damage to hematopoietic stem cells (HSCs), including impaired self-renewal, decreased long-term repopulating capacity, and myeloid skewing. These HSC defects were associated with significant increases in production of reactive oxygen species (ROS), expression of p16(Ink4a) (p16) and Arf mRNA, and senescence-associated -galacotosidase (SA--gal) activity, but not with telomere shortening or increased apoptosis, suggesting that TBI induces residual BM injury via induction of HSC premature senescence. This suggestion is supported by the finding that SA--gal(+) HSC-enriched LSK cells showed more pronounced defects in clonogenic activity in vitro and long-term engraftment after transplantation than SA--gal(-) LSK cells isolated from irradiated mice. However, genetic deletion of p16 and/or Arf had no effect on TBI-induced residual BM suppression and HSC senescence, because HSCs from irradiated p16 and/or Arf knockout (KO) mice exhibited changes similar to those seen in HSCs from wild-type mice after exposure to TBI. These findings provide important new insights into the mechanism by which TBI causes long-term BM suppression (eg, via induction of premature senescence of HSCs in a p16-Arf-independent manner). ",
        "Doc_title":"Total body irradiation causes long-term mouse BM injury via induction of HSC premature senescence in an Ink4a- and Arf-independent manner.",
        "Journal":"Blood",
        "Do_id":"24622326",
        "Doc_ChemicalList":"Cdkn2a protein, mouse;Cyclin-Dependent Kinase Inhibitor p16",
        "Doc_meshdescriptors":"Animals;Bone Marrow;Cell Aging;Cells, Cultured;Cyclin-Dependent Kinase Inhibitor p16;Gene Knockout Techniques;Hematopoietic Stem Cells;Mice;Mice, Inbred C57BL;Telomere;Whole-Body Irradiation",
        "Doc_meshqualifiers":"metabolism;pathology;radiation effects;genetics;metabolism;metabolism;pathology;radiation effects;metabolism;pathology;radiation effects",
        "_version_":1605755749359681536},
      {
        "Doc_abstract":"MCS-5A, an analog of sangivamycin, selectively inhibits the cyclin-dependent kinases CDK1 and 4 in HL-60 cells in vitro (IC(50): 9.6 and 8.8 1V, respectively), while weakly inhibiting other housekeeping protein kinases. MCS-5A effectively induces HL-60 cell cycle arrest at the G(1) and G(2)/M phases through direct inhibition of CDK1 and 4 activity. In addition, elevated expression of p16(INK4a) and a reduction in the level of hyperphosphorylated pRb showed that 3 1V MCS-5A also induces p16(INK4a)-mediated cell cycle arrest at the G(1) phase. Furthermore, apoptotic induction in MCS-5A-treated HL-60 cells is associated with the release of cytochrome c from mitochondria, which, in turn, results in the activation of procaspase-8, -9 and -3, and the cleavage of poly(ADP-ribose) polymerase (PARP). In addition, the involvement of p16(INK4a) in this apoptotic induction was demonstrated using A549 cells with a homozygous deletion of p16(INK4a). Based on these results, we conclude that MCS-5A is a candidate therapeutic agent for the treatment of human promyelocytic leukemia via the up-regulation of p16(INK4a).",
        "Doc_title":"Cell cycle arrest and cytochrome c-mediated apoptotic induction by MCS-5A is associated with up-regulation of p16(INK4a) in HL-60 cells.",
        "Journal":"Bioorganic & medicinal chemistry letters",
        "Do_id":"20627562",
        "Doc_ChemicalList":"4-amino-6-bromo-7-(xylofuranosyl)pyrrolo(2,3-d)pyrimidine-5-carboxamide;Cyclin-Dependent Kinase Inhibitor p16;Nucleosides;Cytochromes c;Poly(ADP-ribose) Polymerases;Caspases",
        "Doc_meshdescriptors":"Apoptosis;Caspases;Cell Cycle;Cyclin-Dependent Kinase Inhibitor p16;Cytochromes c;Dose-Response Relationship, Drug;Flow Cytometry;HL-60 Cells;Humans;Mitochondria;Molecular Structure;Nucleosides;Poly(ADP-ribose) Polymerases;Stereoisomerism;Structure-Activity Relationship;Up-Regulation",
        "Doc_meshqualifiers":"drug effects;metabolism;drug effects;antagonists & inhibitors;biosynthesis;metabolism;metabolism;drug effects;metabolism;chemistry;pharmacology;metabolism;drug effects",
        "_version_":1605799442432131072},
      {
        "Doc_abstract":"Accumulation of senescent cells contributes to the reduced regenerative capacity in aged tissues. By evaluating the molecular pathways of senescence in relation to proliferative potential of primary keratinocyte cultures from young and old healthy donors, and from young patients with inherited defects leading to premature aging, we demonstrated that p16(INK4a) is a reliable marker of both physiological and premature epidermal aging. Analysis of the expression and activity of p16(INK4a) regulators showed that stem cell depletion, reduced proliferation, and p16(INK4a) upregulation in keratinocytes derived from the chronologically and prematurely aged epidermis strongly correlate with Bmi-1 downregulation. In highly proliferative tissues, replicative and premature senescence participate in determining senescent cell accumulation. Our findings demonstrated that Bmi-1 is downregulated in human keratinocytes during both in vitro processes, in parallel with p16(INK4a) upregulation and accomplishment of clonal conversion. When premature senescence was induced by specific exogenous stimuli, concomitant Ets-1 upregulation was also observed. Moreover, Bmi-1 inhibited Ets-1-mediated p16(INK4a) upregulation. Finally, Bmi-1 overexpression reduced p16(INK4a) promoter activity and decreased protein expression in aged and diseased keratinocytes, inducing a delay of clonal conversion and an increase of cell clonogenic ability. Altogether these findings underline a key role of Bmi-1 downregulation in enforcing aging in primary human keratinocytes.",
        "Doc_title":"Bmi-1 reduction plays a key role in physiological and premature aging of primary human keratinocytes.",
        "Journal":"The Journal of investigative dermatology",
        "Do_id":"19907431",
        "Doc_ChemicalList":"BMI1 protein, human;Culture Media, Serum-Free;Cyclin-Dependent Kinase Inhibitor p16;ETS1 protein, human;ID1 protein, human;Inhibitor of Differentiation Protein 1;Nuclear Proteins;Proto-Oncogene Protein c-ets-1;Proto-Oncogene Proteins;Repressor Proteins;Polycomb Repressive Complex 1",
        "Doc_meshdescriptors":"Adolescent;Adult;Aged;Aged, 80 and over;Aging, Premature;Cell Aging;Cells, Cultured;Child;Child, Preschool;Coculture Techniques;Culture Media, Serum-Free;Cyclin-Dependent Kinase Inhibitor p16;Down-Regulation;Epidermis;Gene Expression;Humans;Inhibitor of Differentiation Protein 1;Keratinocytes;Middle Aged;Nuclear Proteins;Oxidative Stress;Polycomb Repressive Complex 1;Proto-Oncogene Protein c-ets-1;Proto-Oncogene Proteins;Repressor Proteins;Stromal Cells;Up-Regulation;Young Adult",
        "Doc_meshqualifiers":"pathology;physiopathology;physiology;pharmacology;genetics;metabolism;physiology;cytology;physiology;physiology;metabolism;cytology;physiology;genetics;metabolism;physiology;metabolism;genetics;metabolism;genetics;metabolism;cytology;physiology;physiology",
        "_version_":1605818587395653633},
      {
        "Doc_abstract":"B23 (nucleophosmin/NPM) is a multifunctional protein that recently has been directly implicated in the p53 network by its documented interaction with the p14(ARF)/p19(Arf) tumor suppressor, a major upstream activator of p53. Here we provide an overview of the functional interactions of B23 and ARF. We also integrate the current models into a unified picture, showing that B23 is essential for stabilizing and maintaining a basal level of ARF in the nucleolus, whereas increasing levels of ARF after oncogenic stress promotes B23 degradation and interferes with B23 nucleocytoplasmic shuttling. In this way, ARF can be regarded as a parasitic peptide on the B23 molecule, because ARF uses this chaperone for its own survival but also antagonizes normal activities of B23. Finally, the functional significance of the ARF-B23 interaction for tumor development and the prospects for novel cancer therapies are evaluated.",
        "Doc_title":"B23 and ARF: friends or foes?",
        "Journal":"Cell biochemistry and biophysics",
        "Do_id":"16943625",
        "Doc_ChemicalList":"Nuclear Proteins;Tumor Suppressor Protein p14ARF;Tumor Suppressor Protein p53;nucleophosmin;Proto-Oncogene Proteins c-mdm2",
        "Doc_meshdescriptors":"Animals;Cell Nucleolus;Humans;Mutation;Neoplasms;Nuclear Proteins;Protein Binding;Proto-Oncogene Proteins c-mdm2;Translocation, Genetic;Tumor Suppressor Protein p14ARF;Tumor Suppressor Protein p53",
        "Doc_meshqualifiers":"metabolism;genetics;metabolism;biosynthesis;genetics;physiology;metabolism;biosynthesis;genetics;physiology;metabolism",
        "_version_":1605845124093313024},
      {
        "Doc_abstract":"Using a highly infiltrative tumor type as basal cell carcinoma as the model system, we have examined the relation between invasive behavior and proliferation. Our results studying alterations in G(1)-S cell cycle regulatory proteins and proliferation in infiltrative cells were surprising and clearly indicated that invasion in tumors with an intact p16(INK4a)-cyclin D-retinoblastoma protein (Rb) pathway was equivalent to ceased proliferation. Using immunohistochemistry and Western blotting of microdissected parts of basal cell carcinomas, we showed that p16(INK4a) was up-regulated at the invasive front of the majority of basal cell carcinomas with infiltrative growth patterns, followed by ceased proliferation, as well as decreased phosphorylation of Rb. Besides supporting the fact that basal cell carcinomas have an intact Rb pathway, our results clearly indicate that invasive tumor cells change phenotype from a proliferative state to an invasive phenotype. Thus, invasion is not necessarily analogous with proliferation, implicating a paradigm shift in the understanding of two central processes in malignant behavior.",
        "Doc_title":"Invade or proliferate? Two contrasting events in malignant behavior governed by p16(INK4a) and an intact Rb pathway illustrated by a model system of basal cell carcinoma.",
        "Journal":"Cancer research",
        "Do_id":"12702553",
        "Doc_ChemicalList":"Cyclin D;Cyclin-Dependent Kinase Inhibitor p16;Cyclins;Retinoblastoma Protein",
        "Doc_meshdescriptors":"Blotting, Western;Carcinoma, Basal Cell;Cell Division;Cyclin D;Cyclin-Dependent Kinase Inhibitor p16;Cyclins;Humans;Immunohistochemistry;Neoplasm Invasiveness;Retinoblastoma Protein;Skin Neoplasms;Up-Regulation",
        "Doc_meshqualifiers":"metabolism;pathology;physiology;biosynthesis;metabolism;physiology;metabolism;physiology;metabolism;physiology;metabolism;pathology",
        "_version_":1605746485838741504},
      {
        "Doc_abstract":"Collaborator of ARF (CARF) was first cloned as an ARF partner in yeast two-hybrid screens. It enhances ARF-dependent and -independent p53 functions, which are central to the control of cell growth and tumor suppression in human cells. CARF interacts with ARF, p53, and MDM2 proteins, and in turn gets regulated by MDM2-mediated degradation, suggesting a self-regulatory loop. CARF is upregulated during replicative, oncogenic, and stress-induced senescence. Overexpression of CARF induced premature senescence in normal human fibroblasts that was mediated by upregulation of p53-p21(CIP1/WAF1) and p16(INK4a)- pRB pathways. Knockdown of CARF resulted in mitotic arrest leading to excessive chromosomal condensation, aneuploidy, and apoptosis, suggesting that CARF is essential for cell survival. Most recently, we have found that CARF causes bidirectional regulation of p53 and pRB pathways, either arresting or promoting growth, and thus, it could be a potential threshold link between aging and cancer.",
        "Doc_title":"Molecular bridging of aging and cancer: A CARF link.",
        "Journal":"Annals of the New York Academy of Sciences",
        "Do_id":"20536841",
        "Doc_ChemicalList":"Tumor Suppressor Protein p53;MDM2 protein, human;Proto-Oncogene Proteins c-mdm2",
        "Doc_meshdescriptors":"Aging;Apoptosis;Cell Cycle;Fibroblasts;Genes, p53;Humans;Neoplasms;Nervous System Neoplasms;Proto-Oncogene Proteins c-mdm2;Tumor Suppressor Protein p53",
        "Doc_meshqualifiers":"genetics;genetics;genetics;metabolism;genetics;genetics;genetics;metabolism;genetics;metabolism;physiology",
        "_version_":1605818706799099904},
      {
        "Doc_abstract":"Tumors of the anal canal are mostly epithelial in origin. The transition of gland-forming rectal mucosa via specialized urothelium-like cells at the dentate line to anal non-keratinized and finally perianal keratinized squamous epithelium implies a broad spectrum of tumor types, with most cancers exhibiting a mixture of different histological features. Moreover, secondary neoplasias extending into or metastasizing to the anal region need to be considered. Based on epithelial metaplasia at the transformation zone, poorly differentiated squamous anal carcinomas may show co-expression of both the squamous (CK5/6) and glandular type keratins (CK7). Since HPV infection of high-risk types (often 16 and 18) is etiologically associated with anal cancer, p16(INK4a) is highly sensitive and specific in the detection of high-grade anal squamous intraepithelial neoplasias (ASIN) and corresponding invasive squamous carcinomas. Diagnosis of secondary malignancies, including pagetoid extension into the anogenital region, requires the application of specific immunohistochemical marker panels.",
        "Doc_title":"[Anal cancer: diagnostic and differential diagnostic issues].",
        "Journal":"Der Pathologe",
        "Do_id":"21681470",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Adenocarcinoma;Anal Canal;Anus Neoplasms;Carcinoma in Situ;Carcinoma, Squamous Cell;Cell Transformation, Neoplastic;Diagnosis, Differential;Human papillomavirus 16;Human papillomavirus 18;Humans;Papillomavirus Infections",
        "Doc_meshqualifiers":"pathology;pathology;pathology;surgery;pathology;pathology;pathology;pathology",
        "_version_":1605756562774687744},
      {
        "Doc_abstract":"Oesophageal squamous cell carcinoma (OSCC) often arises from preceding dysplastic lesions in the oesophageal epithelium. However, the molecular changes occurring in premalignant lesions are not well understood. An epigenetic change is an example of OSCC that may occur within the epithelium.;To investigate the methylation status of multiple promoters in cancer-derived DNA, as well as in the background epithelium of OSCC, including dysplastic lesions and non-neoplastic mucosa. The normal epithelium from patients without cancer was also examined. The findings were correlated with the mutational status of p53.;56 patients with advanced OSCC, 21 patients with intraepithelial neoplasia (IEN), 56 patients with a background of non-neoplastic epithelium, adjacent to the OSCC, and 42 normal control epithelia from healthy volunteers were studied. The promoter methylation status of SFRP1, SFRP2, DCC, APC, p16(INK4a), p14(ARF), MINT1, MINT2, MINT31, CACNA1G, COX2, DAPK, hMLH1 and MGMT was examined by methylation-specific single polymerase chain reaction or combined bisulphite restriction analysis. The mutation of p53 by direct sequencing was assessed.;DNA methylation was observed in OSCC and in its background epithelium. The frequency of CpG island methylation increased from a baseline level in the background non-neoplastic epithelium, through IEN, to advanced OSCC. However, mutations in p53 were almost exclusively observed in IEN and OSCC. More extensive DNA methylation was seen in the neoplastic lesions (OSCC or IEN) having a p53 mutation than in those with wild-type p53.;DNA methylation is present at low levels in the non-neoplastic oesophageal epithelium and appears to contribute to the progression of the dysplasia-carcinoma sequence in OSCC carcinogenesis.",
        "Doc_title":"Oesophageal squamous cell carcinoma may develop within a background of accumulating DNA methylation in normal and dysplastic mucosa.",
        "Journal":"Gut",
        "Do_id":"16785283",
        "Doc_ChemicalList":"DNA, Neoplasm;Tumor Suppressor Protein p53",
        "Doc_meshdescriptors":"Adult;Carcinoma in Situ;Carcinoma, Squamous Cell;CpG Islands;DNA Methylation;DNA, Neoplasm;Disease Progression;Epithelium;Esophageal Neoplasms;Female;Humans;Male;Mucous Membrane;Mutation;Promoter Regions, Genetic;Tumor Suppressor Protein p53",
        "Doc_meshqualifiers":"genetics;metabolism;pathology;genetics;metabolism;pathology;genetics;genetics;metabolism;metabolism;genetics;metabolism;pathology;metabolism;genetics;genetics",
        "_version_":1605747071142330368},
      {
        "Doc_abstract":"Paraffin sections (n = 168, 27 benign, 16 low malignant potential [LMP] and 125 malignant tumours) from epithelial ovarian tumours were evaluated immunohistochemically for expression of retinoblastoma gene product (pRB) and p53 protein, and the relationship among pRB, p53 and cyclin-dependent kinase inhibitor 2 (CDKN2) gene product p16INK4A (p16) was analysed, following our previous study of p16. Forty-one percent of the benign, 50% of the LMP and most (71%) of the malignant tumours showed high pRB expression. High expression of pRB (>50% pRB-positive cells) significantly correlated with non-mucinous histological subtypes. Reduced pRB expression, substage and residual disease were significant predictors for poor prognosis in stage I patients. All the benign and most of the LMP (81%) tumours were in either the p53-negative or low p53-positive category, but nearly half of the malignant tumours had high p53 expression. High p53 accumulation was found in non-mucinous, high grade and late stage tumours. For well-differentiated carcinomas, high p53 expression was a predictor of poor prognosis. However, even though high p53 expression was not associated with histological subtype, stage or the presence of residual disease, high p53 expression was not an independent predictor when all clinical parameters were combined. For all ovarian cancers, a close correlation was found between high p53 and high p16 expression. The relationship between the expression of pRB and p16 depended on tumour stage. In stage I tumours, high pRB was associated with low p16 reactivity. On the other hand, most advanced tumours showed both high pRB and high p16 reactivity.",
        "Doc_title":"Reduced expression of retinoblastoma gene product (pRB) and high expression of p53 are associated with poor prognosis in ovarian cancer.",
        "Journal":"International journal of cancer",
        "Do_id":"9291430",
        "Doc_ChemicalList":"Carrier Proteins;Cyclin-Dependent Kinase Inhibitor p16;Retinoblastoma Protein;Tumor Suppressor Protein p53",
        "Doc_meshdescriptors":"Carrier Proteins;Cyclin-Dependent Kinase Inhibitor p16;Female;Genes, Tumor Suppressor;Humans;Immunohistochemistry;Life Tables;Neoplasm Invasiveness;Neoplasm Staging;Ovarian Neoplasms;Predictive Value of Tests;Prognosis;Regression Analysis;Retinoblastoma Protein;Survival Rate;Time Factors;Tumor Suppressor Protein p53",
        "Doc_meshqualifiers":"analysis;biosynthesis;mortality;pathology;surgery;analysis;biosynthesis;analysis;biosynthesis",
        "_version_":1605882642615500800},
      {
        "Doc_abstract":"To reveal the role of Phosphatidylinositol 3-kinases (PI3Ks) in regulating human diploid fibroblast (2BS cell) senescence as well as the possible mechanisms involved.;Using a PI3Ks specific inhibitor, LY294002, cell cycle, apoptosis, proliferation, senescence association beta-galactosidase staining as well as senescence association CKIs, p16(INK4) and p21(Cip1) protein expressions were all measured in the low passages of 2BS cells.;Both 25 micro mol/L and 50 micro mol/L concentrations of LY294002 could cause a significant decrease in cells entering into S phase, and this cell cycle of G(1) phase arrest was dose-dependent. Meanwhile, LY294002 contributed to apoptosis, caused 2BS cell growth arrest, and activated senescence association beta-galactosidase (P < 0.05). In addition, LY294002 could induce time-course expressions of p16(INK4) and p21(Cip1) in 2BS cell lines.;PI3Ks inhibitor LY294002 could induce senescence-like changes in 2BS cell lines. Two senescence associated CKIs, p16(INK4) and p21(Cip1), might be involved in this senescence phenotype proceeding in 2BS cell lines.",
        "Doc_title":"Phosphatidylinositol 3-kinase inhibitor, LY294002, induced senescence-like changes in human diploid fibroblasts.",
        "Journal":"Chinese medical journal",
        "Do_id":"12877804",
        "Doc_ChemicalList":"CDKN1A protein, human;Chromones;Cyclin-Dependent Kinase Inhibitor p16;Cyclin-Dependent Kinase Inhibitor p21;Cyclins;Enzyme Inhibitors;Morpholines;2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one;Phosphatidylinositol 3-Kinases",
        "Doc_meshdescriptors":"Cell Aging;Cells, Cultured;Chromones;Cyclin-Dependent Kinase Inhibitor p16;Cyclin-Dependent Kinase Inhibitor p21;Cyclins;Dose-Response Relationship, Drug;Enzyme Inhibitors;Fibroblasts;G1 Phase;Humans;Morpholines;Phosphatidylinositol 3-Kinases",
        "Doc_meshqualifiers":"drug effects;pharmacology;analysis;analysis;pharmacology;drug effects;physiology;drug effects;pharmacology;antagonists & inhibitors",
        "_version_":1605925229750648832},
      {
        "Doc_abstract":"Cyclin D1, p16, and Rb are key genes that play critical roles in the control of G1/S cell cycle progression and cellular homeostasis. To assess the differential expression of these genes in the biologic evaluation of head and neck squamous carcinoma (HNSC), we analyzed their protein expression in 11 cell lines and 46 primary tumors by Western blotting and correlated the results with clinicopathologic factors. In all cell lines, reciprocal expression between p16 and cyclin-D1 and Rb proteins was noted; p16 protein was detected in one (9%) cell line that lacked Rb and cyclin D1 and was absent in 10 of the cell lines (91%) that expressed both cyclin D1 and Rb proteins. Similar, albeit less striking, results were obtained in primary tumors: 30 tumors (65%) lacked p16 expression, and 33 tumors (72%) and 38 tumors (83%) expressed Rb and cyclin D1 proteins, respectively. p16 and Rb proteins were inversely expressed in 72% of tumors and in all cell lines. Except for gender and age, no significant correlation between protein expression and the clinicopathologic factors was found. Our results indicate that (1) loss of the p16 protein may constitute an early event in the development of these HNSC, (2) the reciprocal expression of p16 and Rb suggests a tight regulatory interaction between these genes in HNSC tumorigenesis, and (3) alteration in at least one of these genes might be required for HNSC development and progression.",
        "Doc_title":"Differential expression of key cell cycle genes (p16/cyclin D1/pRb) in head and neck squamous carcinomas.",
        "Journal":"Laboratory investigation; a journal of technical methods and pathology",
        "Do_id":"10092061",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;Retinoblastoma Protein;Cyclin D1",
        "Doc_meshdescriptors":"Carcinoma, Squamous Cell;Cell Cycle;Cyclin D1;Cyclin-Dependent Kinase Inhibitor p16;Female;Gene Expression;Head and Neck Neoplasms;Humans;Male;Middle Aged;Retinoblastoma Protein;Tumor Cells, Cultured",
        "Doc_meshqualifiers":"genetics;metabolism;physiology;genetics;metabolism;genetics;metabolism;physiology;genetics;metabolism;genetics;metabolism",
        "_version_":1605794655379652608},
      {
        "Doc_abstract":"Recent studies suggest that p16 overexpression determined by immunohistochemistry would be a specific marker for neoplastic and dysplastic squamous cells associated with high-risk HPV. The purpose of this study was to assess the correlation between cyto-histological findings, p16 expression and HPV subtype. A total of 99 biopsies were selected, 4 endocervical curettages and 95 uterine cervix biopsies, as well as 30 cervicovaginal smears from other 30 patients. The samples were divided according to the morphological diagnosis. Paraffin-embedded sections and cervicovaginal smears were immunostained using the CINtec p16INK4a Cytology Kit (DAKO). HPV was analyzed by PCR in 25 of the 99 biopsies with low-grade squamous intraepithelial lesion. Among those patients with neither HPV nor dysplasia, 1 of 35 (2.9%) biopsies and 1 of 11 (9%) smears were positive for p16. Sixteen of 25 (64%) biopsies and 6 of 10 (60%) smears of the low-grade lesion cases, and 38 of 39 (97.4%) biopsies and 8 of 9 (89%) smears of the high-grade lesion and squamous carcinoma were positive for p16. All cases of HPV-6/11 were negative or focally positive for p16. Most cases of HPV-18 or other subtypes were diffusely positive. Our results indicate that p16 expression is highly correlated with cyto-histological diagnosis, and is associated with diffuse staining and high-risk HPV. This technique provides greater objectivity in doubtful cases, and helps select patients at risk of disease progression at an acceptable cost when used in large populations.",
        "Doc_title":"[Immunohistochemistry of p16INK4a in biopsies and cervicovaginal smears, and its correlation with HPV detected by PCR].",
        "Journal":"Medicina",
        "Do_id":"19147423",
        "Doc_ChemicalList":"Biomarkers, Tumor;Cyclin-Dependent Kinase Inhibitor p16",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Biomarkers, Tumor;Biopsy;Carcinoma, Squamous Cell;Cervical Intraepithelial Neoplasia;Cyclin-Dependent Kinase Inhibitor p16;Female;Humans;Immunohistochemistry;Middle Aged;Papillomaviridae;Papillomavirus Infections;Polymerase Chain Reaction",
        "Doc_meshqualifiers":"analysis;metabolism;pathology;virology;pathology;virology;analysis;genetics;metabolism;pathology",
        "_version_":1605846986609655808},
      {
        "Doc_abstract":"To investigate the expression of human telomerase reverse transcripase (hTERT), cyclin D1 mRNA, p16(INK4), p21(WAF1) mRNA and p27(KIP1) protein in human ameloblastoma (ABs).;The expression of hTERT, cyclin D1, p16(INK4), p21(WAF1) mRNA and p27(KIP1) protein in 54 cases of human ABs were detected by in situ hybridization or immunohistochemistry.;The positive cases of hTERT mRNA, cyclin D1 mRNA was 51, 23, respectively. The positive cases of p16(INK4), p21(WAF1) mRNA and p27(KIP1) protein was 17, 12, 9. Comparing with recurred and transformed malignantly, the expression of hTERT mRNA, cyclin D1 mRNA increased, and the expression of p16(INK4), p21(WAF1) mRNA and p27(KIP1) protein decreased or lost. The expression of hTERT mRNA and pl6(INK4), p21(WAF1) mRNA and p27(KIP1) protein in ABs had middle to high negative relation (r(k) = -0.587, r(k) = -0.652, r(k) = -0.783, P < 0.001).;The hTERT mRNA expression in ABs is related to the reguation of pl6(INK4), p21(WAF1) mRNA and p27(KIP1) protein.",
        "Doc_title":"[Expression of cyclin D1 and its inhibitors and hTERT in ameloblastoma].",
        "Journal":"Hua xi kou qiang yi xue za zhi = Huaxi kouqiang yixue zazhi = West China journal of stomatology",
        "Do_id":"17334067",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p21;Cyclins;RNA, Messenger;Cyclin D1;Cyclin-Dependent Kinase Inhibitor p27;Telomerase",
        "Doc_meshdescriptors":"Ameloblastoma;Cyclin D1;Cyclin-Dependent Kinase Inhibitor p21;Cyclin-Dependent Kinase Inhibitor p27;Cyclins;Humans;Immunohistochemistry;RNA, Messenger;Telomerase",
        "Doc_meshqualifiers":"None",
        "_version_":1605826022637305856},
      {
        "Doc_abstract":"DNA methylation is the most important epigenetic change involved in the control of gene expression in human cells. Methylation of the p16(INK4a) gene occurs early in the development of cervical cancer. Low-grade squamous intraepithelial lesions (LSILs) are prevalent, and their behavior is variable.;To identify the HPV DNA type, detect the methylation status of the p16(INK4A) gene, and analyze their association with the cytological evolution of LSIL over a period of two years.;We conducted a cohort study with 40 participants. Cervical scrapings were collected for cytological and molecular analysis. HPV DNA detection and typing were performed by means of polymerase chain reaction (PCR) and restriction fragment length polymorphism (RFLP). Methylation-specific PCR was performed to detect methylation.;HPV DNA was detected in 87% of the cases, and type 16 was the most frequent type. Methylation was detected in 11% of the cases and did not exhibit a significant correlation with the HPV type. Unfavorable cytological evolution exhibited a significant association with the presence of methylation.;HPV 16 was the most frequently detected type of HPV in LSIL. Methylation of the p16(INK4A) gene was infrequent and occurred independent of the presence of HPV DNA. Methylation of the p16(INK4a) gene exhibited a significant correlation with persistence/progression of LSIL.",
        "Doc_title":"HPV DNA genotyping and methylation of gene p16 INK4A in cervical LSIL.",
        "Journal":"Experimental and molecular pathology",
        "Do_id":"25579180",
        "Doc_ChemicalList":"Biomarkers, Tumor;Cyclin-Dependent Kinase Inhibitor p16;DNA, Viral",
        "Doc_meshdescriptors":"Adult;Biomarkers, Tumor;Cervical Intraepithelial Neoplasia;Cohort Studies;Cyclin-Dependent Kinase Inhibitor p16;DNA Methylation;DNA, Viral;Female;Human papillomavirus 16;Humans;Middle Aged;Papillomavirus Infections;Squamous Intraepithelial Lesions of the Cervix;Young Adult",
        "Doc_meshqualifiers":"genetics;virology;genetics;genetics;genetics;genetics;diagnosis;genetics;virology",
        "_version_":1605746996172292097},
      {
        "Doc_abstract":"Protein p 16INK4a is an inhibitor of cyclin-dependent kinases Cdk4/6. It is encoded by the genome INK4a tumors unassociated with human papillomavirus (HPV) frequently inactivates; at the same type p16INK4a is commonly absent in the cells. In cancer of the cervix uteri (CCU) induced by HPV, INK4a hyperexpresses at the level of m-RNA and protein. Therefore p16INK4a is recommended for early diagnosis of CCU. Attention to p16INK4a additionally increases as there is increasing evidence for the implication of HPV in the etiology of some other cancers. The review considers the mechanisms of hyperexpression of p16INK4a in HPV-induced cancers. There is new evidence for the diagnostic value of a positive test for p16INK4a. Moot points of interpreting the results of immunohisto-/cytochemical detection of p16INK4a are discussed.",
        "Doc_title":"[Cell protein p16INK4a hyperexpression in epithelial malignancies induced by human papillomaviruses].",
        "Journal":"Arkhiv patologii",
        "Do_id":"19137788",
        "Doc_ChemicalList":"Biomarkers, Tumor;Cyclin-Dependent Kinase Inhibitor p16",
        "Doc_meshdescriptors":"Biomarkers, Tumor;Carcinoma;Cyclin-Dependent Kinase Inhibitor p16;Diagnosis, Differential;False Negative Reactions;Female;Humans;Papillomavirus Infections;Sensitivity and Specificity;Uterine Cervical Dysplasia;Uterine Cervical Neoplasms;Vaginal Smears",
        "Doc_meshqualifiers":"biosynthesis;diagnosis;metabolism;virology;biosynthesis;complications;diagnosis;metabolism;virology;diagnosis;metabolism;virology",
        "_version_":1605843910330941440},
      {
        "Doc_abstract":"Recent studies indicated that p16 and p14 inactivation owing to promoter methylation was important for colorectal tumorigenesis. In this study, we examined the methylation status of these genes in 86 primary colorectal cancers using methylation-specific PCR (MSP) and correlated the results with the clinicopathological features of the patients. Aberrant promoter methylation of p16 and p14 genes was detected in 43 of 86 (50%) and 25 of 86 (29%) colorectal cancers, respectively. Next, we examined the correlation of methylation status with the clinicopathological features. We found a significant difference in maximal tumor size (P=0.022) when patients with both p16 and p14 methylation were compared to other patients. On the other hand, there was no significant difference in other factors, such as the extent of tumor and Dukes stage. These results suggested that colorectal cancer with both p16 and p14 methylation has the same invasiveness at a smaller size compared to that of the cancer with neither p16 nor p14 methylation. Inactivation of both p16 and p14 genes may result in a malignant change in colorectal cancer cells, leading to advanced cancers with a smaller size than those with p16 or p14 activity.",
        "Doc_title":"Colorectal cancers with both p16 and p14 methylation show invasive characteristics.",
        "Journal":"Japanese journal of cancer research : Gann",
        "Do_id":"12716465",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;Helminth Proteins;Muscle Proteins;Sulfites;calponin homolog protein, Schistosoma japonicum",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Colorectal Neoplasms;Cyclin-Dependent Kinase Inhibitor p16;DNA Methylation;Female;Helminth Proteins;Humans;Immunohistochemistry;Lymphatic Metastasis;Male;Middle Aged;Muscle Proteins;Neoplasm Invasiveness;Polymerase Chain Reaction;Promoter Regions, Genetic;Sulfites;Tumor Cells, Cultured",
        "Doc_meshqualifiers":"genetics;metabolism;biosynthesis;genetics;biosynthesis;genetics;biosynthesis;genetics;pharmacology",
        "_version_":1605903581136814080},
      {
        "Doc_abstract":"Routine pathological examination cannot distinctively predict the clinical course of meningiomas because even histologically benign tumors may recur after gross total resection. Numerous efforts have been made for the evaluation of different immunohistochemical assays in meningioma prognosis. We investigated the prognostic significance of p16INK4a, p14ARF, p18INK4c, p21CIP1, p27KIP1 and p73 expression by immunohistochemical analysis of 271 meningiomas. All tumors were additionally stained for the proliferation markers Ki-67 and DNA topoisomerase II alpha (TopoIIalpha). Significant differences between the number of p16INK4a-, p18INK4c- and p21CIP1-positive cases were noted among the 3 grades of meningiomas. p16INK4a- and p21CIP-positive tumors were found to prevail among benign meningiomas, whereas p18INK4c immunostaining was closely associated to anaplastic meningiomas. The number of p16INK4a- and p21CIP-positive cases was significantly lower in the cohort of recurrent meningiomas. In contrast, p18INK4c-positive cases were clustered among recurrent meningiomas regardless of tumor grade. Immunoreactivity of p14ARF, p27KIP1 and p73 did not show any differences between meningiomas of various histology and clinical outcomes. Multivariate analysis revealed that only tumor grade and TopoIIalpha index are independent criteria for predicting meningioma recurrence. Thus, the immunohistochemical assessment of p16INK4a, p14ARF, p18INK4c, p21CIP1, p27KIP1 and p73 expression in meningiomas does not appear to provide prognostically useful information. Further studies are needed to identify more reliable prognostic markers and to address in more detail the role of cell cycle aberrations in these tumors.",
        "Doc_title":"Immunohistochemical analysis of p16INK4a, p14ARF, p18INK4c, p21CIP1, p27KIP1 and p73 expression in 271 meningiomas correlation with tumor grade and clinical outcome.",
        "Journal":"International journal of cancer",
        "Do_id":"12640680",
        "Doc_ChemicalList":"Antigens, Neoplasm;Biomarkers, Tumor;CDKN1A protein, human;CDKN2C protein, human;Cell Cycle Proteins;Cyclin-Dependent Kinase Inhibitor p16;Cyclin-Dependent Kinase Inhibitor p18;Cyclin-Dependent Kinase Inhibitor p21;Cyclins;DNA-Binding Proteins;Enzyme Inhibitors;Ki-67 Antigen;Neoplasm Proteins;Nuclear Proteins;Tumor Protein p73;Tumor Suppressor Protein p14ARF;Tumor Suppressor Proteins;p73 protein, human;Cyclin-Dependent Kinase Inhibitor p27;DNA Topoisomerases, Type II;DNA topoisomerase II alpha",
        "Doc_meshdescriptors":"Adult;Antigens, Neoplasm;Biomarkers, Tumor;Cell Cycle Proteins;Cyclin-Dependent Kinase Inhibitor p16;Cyclin-Dependent Kinase Inhibitor p18;Cyclin-Dependent Kinase Inhibitor p21;Cyclin-Dependent Kinase Inhibitor p27;Cyclins;DNA Topoisomerases, Type II;DNA-Binding Proteins;Enzyme Inhibitors;Female;Follow-Up Studies;Genes, Tumor Suppressor;Humans;Immunoenzyme Techniques;Ki-67 Antigen;Male;Meningeal Neoplasms;Meningioma;Middle Aged;Neoplasm Proteins;Nuclear Proteins;Prognosis;Tumor Protein p73;Tumor Suppressor Protein p14ARF;Tumor Suppressor Proteins",
        "Doc_meshqualifiers":"analysis;analysis;analysis;analysis;analysis;analysis;analysis;analysis;chemistry;pathology;chemistry;pathology;analysis;analysis;analysis;analysis",
        "_version_":1605783456698073088},
      {
        "Doc_abstract":"Somatic stem cells are ultimately responsible for mediating appropriate organ homeostasis and have therefore been proposed to represent a cellular origin of the ageing process-a state often characterized by inappropriate homeostasis. Specifically, it has been suggested that ageing stem cells might succumb to replicative senescence by a mechanism involving the cyclin-dependent kinase inhibitor p16(INK4A). Here, we tested multiple functional and molecular parameters indicative of p16(INK4A) activity in primary aged murine hematopoietic stem cells (HSCs). We found no evidence that replicative senescence accompanies stem cell ageing in vivo, and in line with p16(INK4A) being a critical determinant of such processes, most aged HSCs (>99%) failed to express p16(INK4A) at the mRNA level. Moreover, whereas loss of epigenetically guided repression of the INK4A/ARF locus accompanied replicative senescent murine embryonic fibroblasts, such repression was maintained in aged stem cells. Taken together, these studies indicate that increased senescence as mediated by the p16(INK4A) tumor suppressor has only a minor function as an intrinsic regulator of steady-state HSC ageing in vivo.",
        "Doc_title":"Hematopoietic stem cell ageing is uncoupled from p16 INK4A-mediated senescence.",
        "Journal":"Oncogene",
        "Do_id":"19398954",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;Histones;DNA",
        "Doc_meshdescriptors":"Animals;Cell Aging;Cell Line;Cell Proliferation;Cyclin-Dependent Kinase Inhibitor p16;DNA;Epigenesis, Genetic;Hematopoietic Stem Cells;Histones;Methylation;Mice;Promoter Regions, Genetic;Up-Regulation",
        "Doc_meshqualifiers":"genetics;metabolism;genetics;metabolism;cytology;metabolism;metabolism",
        "_version_":1605824583366082560},
      {
        "Doc_abstract":"The Arf tumor suppressor protein inhibits cell proliferation through both p53-dependent and -independent mechanisms. Two rat monoclonal antibodies raised against a peptide corresponding to amino acids 54-75 of the mouse p19(Arf) protein reacted with the native protein expressed in mammalian cells. Neither antibody detected human or golden hamster Arf proteins. The two antibodies, both of IgG2b isotype, are directed to adjacent epitopes contained within residues 54-62 and 62-75, respectively, of the mouse p19(Arf) protein, and both were highly efficient in detecting p19(Arf) by immunoprecipitation, immunoblotting, and immunofluorescence. One antibody proved useful for immunohistochemical staining of p19(Arf) in fixed sections of mouse testes, revealing low levels of protein expression within the nucleoli of spermatogonia. This indicates that these antibodies should be useful in detecting the endogenous p(19Arf) protein at specific stages of mouse development and during early stages of tumorigenesis.",
        "Doc_title":"Monoclonal antibodies to the mouse p19(Arf) tumor suppressor protein.",
        "Journal":"Hybridoma and hybridomics",
        "Do_id":"15672607",
        "Doc_ChemicalList":"Antibodies, Monoclonal;Cdkn2a protein, mouse;Cyclin-Dependent Kinase Inhibitor p16;Epitopes;Tumor Suppressor Protein p14ARF",
        "Doc_meshdescriptors":"Animals;Antibodies, Monoclonal;Cyclin-Dependent Kinase Inhibitor p16;Epitope Mapping;Epitopes;Fluorescent Antibody Technique;Immunohistochemistry;Mice;NIH 3T3 Cells;Rats;Species Specificity;Tumor Suppressor Protein p14ARF",
        "Doc_meshqualifiers":"immunology;immunology;analysis;immunology",
        "_version_":1605844553614491648},
      {
        "Doc_abstract":"Methylation of the p16 (INK4a) tumor suppressor gene is observed frequently in multiple myeloma and various forms of lymphoma and mediates silencing of p16 gene expression. In this investigation, we have determined the effect of the DNA demethylating drug decitabine (DAC; 5-aza-2'-deoxycytidine) on the growth, cell cycle kinetics, RB phosphorylation, and expression of p16 (INK4a) and p21(WAF1) in EBV- human myeloma and EBV+ lymphoblastic cell lines possessing silenced, methylated p16 (INK4a) genes to: (1). evaluate its potential as a therapeutic agent and (2). investigate its mechanism of action. Demethylation of the p16 (INK4a) gene and expression of the p16 (INK4a) protein were observed using higher doses (10(-6)-10(-7)M) of drug while growth inhibition at lower doses (IC(50)=2 x 10(-8)-4 x 10(-8)M) was associated with RB dephosphorylation and increased expression of p21 (WAF1), but not with induction of p16 (INK4a), or apoptosis. Kinetic experiments demonstrated that RB dephosphorylation and the increase of p21 (WAF1) preceded the induction of p16 (INK4a). The drug induced cell cycle arrest at the G1 and G2/M phases. Antisense experiments demonstrated that the G1 arrest was mediated by transcriptional induction of p21(WAF1). In addition to these observed effects on cell cycle regulatory proteins, decitabine also increased phosphorylation of p38 MAP kinase. The G2/M arrest was inhibited by the p38 MAP kinase inhibitor SB203580, indicating that activation of p38 MAP kinase pathway was required for G2/M arrest. Thus, decitabine inhibited growth by inducing cell cycle arrest at the G1 phase mediated by p21(WAF1) and the G2/M phase through activation of the p38 MAP kinase pathway.",
        "Doc_title":"Decitabine induces cell cycle arrest at the G1 phase via p21(WAF1) and the G2/M phase via the p38 MAP kinase pathway.",
        "Journal":"Leukemia research",
        "Do_id":"12859993",
        "Doc_ChemicalList":"Antimetabolites, Antineoplastic;Carrier Proteins;Cyclin-Dependent Kinase Inhibitor p21;Cyclins;decitabine;p38 Mitogen-Activated Protein Kinases;Azacitidine",
        "Doc_meshdescriptors":"Antimetabolites, Antineoplastic;Azacitidine;Carrier Proteins;Cell Cycle;Cell Division;Cyclin-Dependent Kinase Inhibitor p21;Cyclins;DNA Methylation;Dose-Response Relationship, Drug;G1 Phase;Kinetics;Leukemia, Lymphoid;Mitosis;Multiple Myeloma;Phosphorylation;Tumor Cells, Cultured;p38 Mitogen-Activated Protein Kinases",
        "Doc_meshqualifiers":"pharmacology;therapeutic use;analogs & derivatives;pharmacology;therapeutic use;metabolism;drug effects;drug effects;metabolism;drug therapy;metabolism;drug therapy;metabolism",
        "_version_":1605850709907996672},
      {
        "Doc_abstract":"Although several studies have evaluated the role of p16(INK4a) as a diagnostic marker of cervical intraepithelial neoplasia (CIN) and its association with disease progression, studies regarding the role of p16(INK4a) in human immunodeficiency virus (HIV)-infected patients remain scarce. The present study was designed to determine the potential utility of p16(INK4a) as a diagnostic marker for CIN and invasive cervical cancer in HIV-positive and negative cervical specimens. An immunohistochemical analysis of p16(INK4a) was performed in 326 cervical tissue microarray specimens. Performance indicators were calculated and compared using receiving operating characteristics curve (ROC)/area under the curve. In HIV-1-negative women, the percentage of cells that was positive for p16(INK4a) expression was significantly correlated with the severity of CIN (p < 0.0001). A ROC curve with a cut-off value of 55.28% resulted in a sensitivity of 89%, a specificity of 81%, a positive predictive value of 91% and a negative predictive value of 78%. HIV-seropositive women exhibited decreased expression of p16(INK4a) in CIN2-3 specimens compared with HIV-negative specimens (p = 0.031). The ROC data underscore the potential utility of p16(INK4a) under defined conditions as a diagnostic marker for CIN 2-3 staging and invasive cervical cancer. HIV-1 infection, however, is associated with relatively reduced p16(INK4a) expression in CIN 2-3.",
        "Doc_title":"An evaluation of p16(INK4a) expression in cervical intraepithelial neoplasia specimens, including women with HIV-1.",
        "Journal":"Memorias do Instituto Oswaldo Cruz",
        "Do_id":"22850945",
        "Doc_ChemicalList":"Biomarkers, Tumor;Cyclin-Dependent Kinase Inhibitor p16",
        "Doc_meshdescriptors":"Adult;Biomarkers, Tumor;Case-Control Studies;Cervical Intraepithelial Neoplasia;Cyclin-Dependent Kinase Inhibitor p16;Female;HIV Infections;HIV-1;Humans;Immunohistochemistry;Middle Aged;Polymerase Chain Reaction;Predictive Value of Tests;ROC Curve;Sensitivity and Specificity;Uterine Cervical Neoplasms",
        "Doc_meshqualifiers":"metabolism;complications;diagnosis;metabolism;metabolism;complications;complications;diagnosis;metabolism",
        "_version_":1605924106265427968},
      {
        "Doc_abstract":"The high frequency of homozygous p16 deletions in squamous cell carcinoma of the esophagus and the relative lack of this event in adenocarcinoma demonstrates obvious differences in the pathogenesis of these two entities. Especially the high frequency of homozygous p16 deletions in squamous cell carcinoma supports the hypothesis of tumorinitiation and promotion by exogenous carcinogens for this tumor type.",
        "Doc_title":"[Expression of p16 and p16 beta in squamous epithelial carcinomas and adenocarcinomas of the esophagus: differences in regulation dependent on kind of tumor and histology].",
        "Journal":"Langenbecks Archiv fur Chirurgie. Supplement. Kongressband. Deutsche Gesellschaft fur Chirurgie. Kongress",
        "Do_id":"14518304",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16",
        "Doc_meshdescriptors":"Adenocarcinoma;Carcinoma, Squamous Cell;Cell Transformation, Neoplastic;Chromosome Deletion;Cyclin-Dependent Kinase Inhibitor p16;Esophageal Neoplasms;Esophagus;Gene Expression Regulation, Neoplastic;Homozygote;Humans;Reverse Transcriptase Polymerase Chain Reaction",
        "Doc_meshqualifiers":"genetics;pathology;genetics;pathology;genetics;pathology;genetics;genetics;pathology;pathology;physiology",
        "_version_":1605844640433438720},
      {
        "Doc_abstract":"Cyclin-dependent kinase 4 (CDK4) is a key molecule in the regulation of cell cycle progression at the G1-S phase restriction point. Its activity is specifically regulated by p16 (also known as p16/CDKN2A, p16(INK4a), and MTS1), a tumor suppressor frequently altered in human cancers. A specific mutation in CDK4 codon 24 (Arginine to Cysteine) prevents p16 binding and thus inhibition by p16. This mutated CDK4 acts as a dominant oncogene and has been found in both sporadic and familial melanoma. To study the effects of other mutations in CDK4, we generated a panel of 18 CDK4 mutants using Charged-to-Alanine scanning mutagenesis, and investigated the p16-binding capacity of these mutants to identify novel sites involved in p16 binding. The mutant CDK4 proteins were generated by direct coupled transcription-translation in vitro and tested for binding to p16 using a p16-GST fusion protein. Several mutants demonstrated loss of p16 binding. In addition to the previously identified codon 24 mutants, alterations in and around codon 22, 25, 97, and 281 all showed loss of p16 binding capacity. These results indicate that several noncontiguous amino acid sequences on CDK4 are required for binding to p16, which suggests the existence of multiple sites of interaction with p16. Since p16-binding deficient CDK4 has oncogenic potential, these mutations may be present in melanomas or other human neoplasms.",
        "Doc_title":"Several noncontiguous domains of CDK4 are involved in binding to the P16 tumor suppressor protein.",
        "Journal":"Biochemical and biophysical research communications",
        "Do_id":"9712735",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;Proto-Oncogene Proteins;Recombinant Fusion Proteins;Tyrosine;Arginine;Glutathione Transferase;CDK4 protein, human;Cyclin-Dependent Kinase 4;Cyclin-Dependent Kinases;Cysteine",
        "Doc_meshdescriptors":"Arginine;Cyclin-Dependent Kinase 4;Cyclin-Dependent Kinase Inhibitor p16;Cyclin-Dependent Kinases;Cysteine;Glutathione Transferase;Humans;Melanoma;Mutagenesis, Site-Directed;Mutation;Proto-Oncogene Proteins;Recombinant Fusion Proteins;Structure-Activity Relationship;Tyrosine",
        "Doc_meshqualifiers":"genetics;genetics;metabolism;chemistry;genetics;metabolism;genetics;genetics;genetics;genetics",
        "_version_":1605761114741669888},
      {
        "Doc_abstract":"Products of cyclin-dependent kinase inhibitor p16(INK4A)and mitotic arrest defective protein 2 (MAD2) genesare key regulator proteins at the G1 restriction point and mitotic checkpoint of the cell cycle. The objective of this study was to investigate the role of promoter methylation of p16(INK4A) and MAD2 genes in gastric marginal-zone B-cell lymphoma (MZBCL).;Gastric biopsies from 40 patients were analyzed by methylation-specific polymerase chain reaction, and the methylation status was compared with the results of BCL10 expression and t(11;18)(q21;q21) translocation.;p16(INK4A) was methylated in 30 of 40 MZBCLs (75%). The lymphomas with p16(INK4A) methylation tended to be negative for t(11;18)(q21;q21) (p = 0.011). MAD2 gene was methylated in 23 of 38 MZBCLs (61%). Lymphomas with MAD2 gene methylation more frequently expressed BCL10 (p = 0.037). These methylation profiles suggest that p16(INK4A) and MAD2 gene may play a role in the pathogenesis of MZBCL via different pathways; MAD2 gene is Helicobacter pylori independent with a close association with BCL10 while p16(INK4A) is H. pylori dependent with an inverse correlation with the t(11;18)(q21;q21) translocation.",
        "Doc_title":"Methylation of p16INK4A and mitotic arrest defective protein 2 (MAD2) genes in gastric marginal-zone B-cell lymphomas.",
        "Journal":"Acta haematologica",
        "Do_id":"19174606",
        "Doc_ChemicalList":"Calcium-Binding Proteins;Cell Cycle Proteins;MAD2L1 protein, human;Mad2 Proteins;Repressor Proteins",
        "Doc_meshdescriptors":"Adult;Aged;Calcium-Binding Proteins;Cell Cycle Proteins;DNA Methylation;Female;Genes, p16;Humans;Lymphoma, B-Cell, Marginal Zone;Mad2 Proteins;Male;Middle Aged;Repressor Proteins",
        "Doc_meshqualifiers":"genetics;genetics;genetics;pathology;genetics",
        "_version_":1605802056842477568},
      {
        "Doc_abstract":"The inactivation mechanisms and functional role of p16INK4a in three Asian esophageal squamous cell carcinoma (ESCC) cell lines were investigated by polymerase chain reaction (PCR) amplification, DNA sequencing, methylation-specific PCR analysis, reverse transcription-PCR, Western blotting, and colony formation assays. The p16INK4a was inactivated by promoter hypermethylation in all three cell lines, a homozygous deletion of exons 2 and 3, and a frameshift deletion on exon 1, leading to transcriptional silencing or the production of mutant p16INK4a protein. Two ESCC cell lines transfected with wild type p16INK4a show significantly reduced cell growth properties. The results of the present studies support the suppressive role of p16INK4a in ESCC development.",
        "Doc_title":"Inactivation mechanisms and growth suppressive effects of p16INK4a in Asian esophageal squamous carcinoma cell lines.",
        "Journal":"Cancer letters",
        "Do_id":"15142680",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Blotting, Western;Carcinoma, Squamous Cell;Cell Line, Tumor;DNA Methylation;Esophageal Neoplasms;Genes, p16;Humans;Loss of Heterozygosity;Polymerase Chain Reaction",
        "Doc_meshqualifiers":"genetics;prevention & control;genetics;prevention & control;physiology",
        "_version_":1605928413748527104},
      {
        "Doc_abstract":"Aberrant methylation of tumor suppressor gene promoters has been extensively investigated in cervical cancer. Transcriptional silencing, as a main consequence of hypermethylation of CpG islands, is the predominant mechanism of p16(INK4a) and E-cadherin gene inactivation in malignant epithelial tumors. This study was conducted to evaluate the promoter methylation status of p16(INK4a) and E-cadherin genes in 22 specimens of cervical carcinomas, four cervical cancer cell lines (HeLa, SiHa, Caski, C33A), and 20 human papillomavirus negative specimens, obtained from normal cervical swabs, using the methylation-specific PCR approach. Hypermethylation of the 5' CpG island of the p16(INK4a) and E-cadherin genes were found in 13 (59.1%) and 10 (45.5%) of 22 cervical cancer samples, respectively. Furthermore, our findings did not show any correlation between promoter methylation of p16(INK4a) and E-cadherin genes and clinicopathological parameters, including HPV infection, phenotypic distribution, and stage of the disease. However, hypermethylation of E-cadherin gene promoter appears to be age related in cervical cancer, whereas the frequency of aberrant methylation of p16(INK4a) gene promoter is unchanged according to the age of patients. Thus, caution must be made to use these markers in the diagnosis of cervical cancer. However, dietary or pharmaceutical agents that can inhibit these epigenetic events may prevent or delay the development of cervical cancer.",
        "Doc_title":"Status of p16(INK4a) and E-cadherin gene promoter methylation in Moroccan patients with cervical carcinoma.",
        "Journal":"Oncology research",
        "Do_id":"20112504",
        "Doc_ChemicalList":"Cadherins;Cyclin-Dependent Kinase Inhibitor p16;DNA, Neoplasm;DNA, Viral",
        "Doc_meshdescriptors":"Cadherins;Carcinoma, Squamous Cell;CpG Islands;Cyclin-Dependent Kinase Inhibitor p16;DNA Methylation;DNA, Neoplasm;DNA, Viral;Female;Gene Expression Regulation, Neoplastic;Humans;Middle Aged;Neoplasm Invasiveness;Papillomaviridae;Papillomavirus Infections;Polymerase Chain Reaction;Promoter Regions, Genetic;Tumor Cells, Cultured;Uterine Cervical Neoplasms",
        "Doc_meshqualifiers":"genetics;genetics;pathology;virology;genetics;genetics;genetics;genetics;genetics;pathology;virology;genetics;genetics;pathology;virology",
        "_version_":1605824657818124288},
      {
        "Doc_abstract":"p14ARF is a protein product of the alternative reading frame of the human INK4a locus. It functions as a tumor suppressor protein. p14ARF suppresses growth through p53-dependent and p53-independent pathways.;p14ARF protein localizes primarily to the nucleoli. Here we show that in transfected cells p14ARF also appears in Hsp70 positive extranucleolar inclusions. The formation of p14ARF inclusions induces the parallel re-localization p53 and HDM2 to these sites that are also targeted by PML bodies and proteasomes.;Our data show that co-localization between p53, HDM2 and p14ARF occurs at extranucleolar sites. Accumulation of PML and proteasomes at these sites suggest that the components of the nuclear inclusions are targeted for proteasome-mediated degradation.",
        "Doc_title":"p14ARF induces the relocation of HDM2 and p53 to extranucleolar sites that are targeted by PML bodies and proteasomes.",
        "Journal":"Molecular cancer",
        "Do_id":"12685933",
        "Doc_ChemicalList":"HSP70 Heat-Shock Proteins;Multienzyme Complexes;Neoplasm Proteins;Nuclear Proteins;Pml protein, mouse;Promyelocytic Leukemia Protein;Proto-Oncogene Proteins;Transcription Factors;Tumor Suppressor Protein p14ARF;Tumor Suppressor Protein p53;Tumor Suppressor Proteins;PML protein, human;MDM2 protein, human;Mdm2 protein, mouse;Proto-Oncogene Proteins c-mdm2;Cysteine Endopeptidases;Proteasome Endopeptidase Complex",
        "Doc_meshdescriptors":"Animals;Cell Line;Cell Nucleolus;Cell Nucleus Structures;Cysteine Endopeptidases;HSP70 Heat-Shock Proteins;Humans;Mice;Microscopy, Fluorescence;Multienzyme Complexes;Neoplasm Proteins;Nuclear Proteins;Promyelocytic Leukemia Protein;Proteasome Endopeptidase Complex;Proto-Oncogene Proteins;Proto-Oncogene Proteins c-mdm2;Transcription Factors;Transfection;Tumor Suppressor Protein p14ARF;Tumor Suppressor Protein p53;Tumor Suppressor Proteins",
        "Doc_meshqualifiers":"chemistry;chemistry;metabolism;metabolism;analysis;metabolism;metabolism;analysis;analysis;metabolism;analysis;metabolism;analysis;analysis;genetics;physiology;analysis;metabolism",
        "_version_":1605819620592189440},
      {
        "Doc_abstract":"Telomerase activity (TA) and the expression of p16(INK4), telomerase reverse-transcriptase catalytic subunit (TERT) and proliferating cell nuclear antigen (PCNA) were analysed in lymph nodes from clinically normal dogs and from dogs with lymphoma. Telomere lengths were measured in 12 histologically normal lymph nodes. These data were related to the overall survival time of the lymphoma patients given chemotherapy, in an effort to identify prognostic significance of the measured variables. There was no significant difference between TA of normal lymph nodes (n = 16) and lymphoma lymph nodes (n = 6). PCNA expression was significantly higher in lymphoma (n = 30) than in normal lymph nodes (n = 10), but TERT expression was not. Expression of p16(INK4) was not significantly different between normal and lymphoma lymph nodes. TA and p16(INK4) expression were inversely correlated within the normal lymph nodes studied. Telomere lengths in normal lymph nodes were consistent with previous studies. No variables examined had any correlation with survival of the lymphoma patients given chemotherapy. The role of p16(INK4) in the regulation of TA warrants further investigation.",
        "Doc_title":"Telomerase activity and related properties of normal canine lymph node and canine lymphoma.",
        "Journal":"Veterinary and comparative oncology",
        "Do_id":"19379313",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605804655597584384},
      {
        "Doc_abstract":"Rb protein in its hypophosphorylated form acts as a cell cycle regulator for G1 arrest. Both cyclin D1 overexpression and P16(INK4) loss of protein produce persistent hyperphosphorylation of Rb with resultant evasion of cell cycle arrest. To better establish the mechanisms of loss of Rb function in neuroendocrine lung tumors, we performed an immunohistochemical analysis of the P16(INK4)/cyclin D1/Rb pathway in the spectrum of neuroendocrine tumors, including 34 typical carcinoids (TCs), 25 atypical carcinoids (ACs), 42 large cell neuroendocrine carcinomas (LCNECs), and 79 small cell lung carcinomas (SCLCs). Absence of Rb expression was not observed in TCs but was seen in 21% of ACs, 68% of LCNECs, and 87% of SCLCs. P16 was expressed in 91% of TCs, 77% of ACs, 78% of LCNECs, and 93% of SCLCs. Cyclin D1 was overexpressed in 6% of TCs, 20% of ACs, 9.5% of LCNECs, and 1.3% of SCLCs. There was an inverse relationship between Rb and P16 in high-grade tumors (P < 0.001) and a direct relationship between cyclin D1 and Rb (P < 0.001) in all tumors, demonstrating that P16 and cyclin D1 act exclusively on the Rb pathway for cell cycle regulation. Overall, the Rb pathway (Rb/P16(INK4)/cyclin D1) was altered more frequently in ACs than in TCs (P = 0.001) and more frequently in LCNECs than in ACs (P = 0.001). Although Rb-negative tumors had shorter survival in the overall group (P < 0.001) as a result of lack of Rb in most SCLCs, cyclin D1 overexpression and P16 loss did not influence survival in any individual category. We conclude that Rb pathway of G1 arrest is consistently compromised in high-grade neuroendocrine lung tumors (92%), primarily through loss of Rb protein, and is intact in low-grade TCs. In ACs an intermediate level of alterations (59%) is seen, consistent with their less-aggressive behavior compared with high-grade tumors. The specific profile of the Rb pathway parameters might provide specific therapeutic targets in neuroendocrine lung tumors.",
        "Doc_title":"The P16/cyclin D1/Rb pathway in neuroendocrine tumors of the lung.",
        "Journal":"Human pathology",
        "Do_id":"12612881",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;Retinoblastoma Protein;Cyclin D1",
        "Doc_meshdescriptors":"Adult;Cyclin D1;Cyclin-Dependent Kinase Inhibitor p16;Female;G1 Phase;Humans;Immunohistochemistry;Lung Neoplasms;Male;Middle Aged;Neuroendocrine Tumors;Prognosis;Retinoblastoma Protein;Survival Rate",
        "Doc_meshqualifiers":"analysis;analysis;chemistry;mortality;pathology;chemistry;mortality;pathology;analysis",
        "_version_":1605742738770231296},
      {
        "Doc_abstract":"p16INK4a is a inhibitory protein of Cyclin-dependent kinase 4(Cdk4).p16 negatively regulates the cell cycle progression from G1 to S phase. Functional p16 is absent from many human cancers, as well as from many established lines of tumor cells. However, it is not clear whether expression of p16 in p16-deficient tumor cells can suppress their anchorage-independent growth. Therefore, we introduced a cDNA for p16INK4a into the human glioblastoma cell line T98G, which lacks a gene for p16INK4a. We isolated several clones that stably expressed various amounts of p16 protein. The doubling time of the various clones was generally prolonged. Clones with high-level expression of p16 protein had characteristics of restricted growth, such as contact inhibition, while the parental T98G cells had no such characteristics. Furthermore, the efficiency of colony formation in soft agar was dramatically decreased in the case of cells that expressed exogenous p16. Our observations suggest that the expression of p16 protein restricts the unbounded growth and the anchorage-independent growth of tumor cells.",
        "Doc_title":"Expression of p16INK4a suppresses the unbounded and anchorage-independent growth of a glioblastoma cell line that lacks p16INK4a.",
        "Journal":"Biochemical and biophysical research communications",
        "Do_id":"9070885",
        "Doc_ChemicalList":"Carrier Proteins;Cyclin-Dependent Kinase Inhibitor p16;Proto-Oncogene Proteins;CDK4 protein, human;Cyclin-Dependent Kinase 4;Cyclin-Dependent Kinases",
        "Doc_meshdescriptors":"Carrier Proteins;Cell Adhesion;Cell Division;Cyclin-Dependent Kinase 4;Cyclin-Dependent Kinase Inhibitor p16;Cyclin-Dependent Kinases;Gene Expression Regulation, Neoplastic;Genetic Complementation Test;Glioblastoma;HeLa Cells;Humans;Proto-Oncogene Proteins;Transfection;Tumor Cells, Cultured",
        "Doc_meshqualifiers":"metabolism;metabolism;pathology",
        "_version_":1605791319617175552},
      {
        "Doc_abstract":"The aim of this study is to target the interference therapy of signal transduction which is a novel therapeutic strategy in laryngeal squamous cell carcinoma (LSCC). We successfully constructed recombinant adenoviruses Ad-p14ARF, and Ad-antisense EGFR using AdEasy-1 vector System. Clonogenic cell assay, western blotting assay, 3'(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay, flow cytometer (FCM) assay, and immunocytochemical technique were designed to examine the inhibition of proliferation, protein expression of p14ARF and EGFR and induction of differentiation, respectively. Furthermore the synergistic effect of Ad-p14ARF and Ad-antisense EGFR on Hep-2 cell was examined. We successfully used AdEasy-1 vector system to construct recombinant adenoviruses Ad-p14ARF and Ad-antisense EGFR. The activity of proliferation of Hep-2 cells was inhibited markedly by infecting Ad-p14ARF or Ad-antisense EGFR by comparing Ad-sense EGFR (P=0.005) with vector control (Ad-Ctrl) (P=0.005) and with PBS (P=0.003). This effect, combining Ad-antisense-EGFR with Ad-p14ARF became more noticeable than alone (P=0.01, P=0.02, respectively). P14 ARF protein overexpression, EGFR protein down expression, and inhibition of proliferation were observed in Hep-2 cells infected by either Ad-p14ARF or Ad-antisense EGFR. FCM revealed that the proportion of apoptosis cells transfected by Ad-p14ARF and Ad-antisense EGFR increased more obviously than the control. The proportion of (Hep-2 cells in) G0/G1 phases was increased by up to 78.5, 77.7, and 86.9% in Ad-antisense EGFR, Ad-p14ARF, and Ad-antisense EGFR+Ad-p14ARF, respectively. Our findings demonstrated that not only EGFR but p14ARF also plays a major role on the genesis and in modulating the cell growth and differentiation of human laryngocarcinoma. They efficaciously blocked the signal transduction of human laryngocarcinoma cell, and may therefore, be an effective potential target of gene therapy to prevent human laryngocarcinoma cell proliferation.",
        "Doc_title":"Signal transduction-related gene transfer leads to inhibition of proliferation and induction of differentiation in laryngeal squamous cell carcinoma in vitro.",
        "Journal":"European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery",
        "Do_id":"17628821",
        "Doc_ChemicalList":"Tumor Suppressor Protein p14ARF;Receptor, Epidermal Growth Factor",
        "Doc_meshdescriptors":"Adenoviridae;Carcinoma, Squamous Cell;Cell Culture Techniques;Cell Line, Tumor;Cell Proliferation;Gene Transfer Techniques;Genetic Vectors;Humans;Laryngeal Neoplasms;Receptor, Epidermal Growth Factor;Signal Transduction;Tumor Suppressor Protein p14ARF",
        "Doc_meshqualifiers":"pathology;therapy;pathology;therapy;genetics;genetics;genetics",
        "_version_":1605746991937093633},
      {
        "Doc_abstract":"Primarily, E2F factors such as E2F1, -2, and -3 stimulate cell-cycle progression, while ARF tumor suppressor mediates growth suppression. The ARF gene can be induced by oncogenic signal through activating E2F-dependent transcription. In turn, ARF may target E2F for its degradation via a p53-dependent mechanism. However, it remains unclear how the cell keeps the balance between the functional opposites of E2F and ARF. In this study, we demonstrate that p14ARF interacts with E2F1-3 factors to directly repress their transcriptional activities through forming p14ARF-E2F/partner-DNA super complexes, regardless of E2F protein degradation. The inhibition of E2F transcriptional activities by p14ARF in this manner occurs commonly in a variety of cell types, including p53-deficient and p53-wild type cells. Thus, E2F-mediated activation of the ARF gene and ARF-mediated functional inhibition of E2F compose a feedback loop, by which the two opposites act in concert to regulate cell proliferation and apoptosis, depending on the cellular context and the environment.",
        "Doc_title":"p14ARF interacts with E2F factors to form p14ARF-E2F/partner-DNA complexes repressing E2F-dependent transcription.",
        "Journal":"Journal of cellular biochemistry",
        "Do_id":"20082327",
        "Doc_ChemicalList":"E2F Transcription Factors;Tumor Suppressor Protein p14ARF;Tumor Suppressor Protein p53;DNA",
        "Doc_meshdescriptors":"Apoptosis;Cell Cycle;Cell Line, Tumor;Cell Proliferation;DNA;E2F Transcription Factors;Feedback, Physiological;Humans;Transcription, Genetic;Tumor Suppressor Protein p14ARF;Tumor Suppressor Protein p53",
        "Doc_meshqualifiers":"metabolism;antagonists & inhibitors;genetics;metabolism;metabolism",
        "_version_":1605802116369088512},
      {
        "Doc_abstract":"Epidemiological and mechanistic evidence on the causative role of human papillomaviruses (HPV) in esophageal squamous cell carcinoma (ESCC) is unclear. We retrieved alcohol- and formalin-fixed paraffin-embedded ESCC tissues from 133 patients seropositive for antibodies against HPV early proteins, from high-incidence ESCC regions: South Africa, China and Iran. With rigorous care to prevent nucleic acid contamination, we analyzed these tissues for the presence of 51 mucosotropic human alpha-papillomaviruses by two sensitive, broad-spectrum genotyping methods, and for the markers of HPV-transformed phenotype: (i) HPV16/18 viral loads by quantitative real-time PCR, (ii) type-specific viral mRNA by E6*I/E6 full-length RT-PCR assays and (iii) expression of cellular protein p16(INK4a). Of 118 analyzable ESCC tissues, 10 (8%) were positive for DNA of HPV types: 16 (4 tumors); 33, 35, 45 (1 tumor each); 11 (2 tumors) and 16, 70 double infection (1 tumor). Inconsistent HPV DNA+ findings by two genotyping methods and negativity in qPCR indicated very low viral loads. A single HPV16 DNA+ tumor additionally harbored HPV16 E6*I mRNA but was p16(INK4a) negative (HPV16 E1 seropositive patient). Another HPV16 DNA+ tumor from an HPV16 E6 seropositive patient showed p16(INK4a) upregulation but no HPV16 mRNA. In the tumor tissues of these serologically preselected ESCC patients, we did not find consistent presence of HPV DNA, HPV mRNA or p16(INK4a) upregulation. These results were supported by a meta-analysis of 14 other similar studies regarding HPV-transformation of ESCC. Our study does not support the etiological role of the 51 analyzed mucosotropic HPV types in the ESCC carcinogenesis.",
        "Doc_title":"Mucosal alpha-papillomaviruses are not associated with esophageal squamous cell carcinomas: Lack of mechanistic evidence from South Africa, China and Iran and from a world-wide meta-analysis.",
        "Journal":"International journal of cancer",
        "Do_id":"26529033",
        "Doc_ChemicalList":"E6 protein, Human papillomavirus type 16;Oncogene Proteins, Viral;Repressor Proteins",
        "Doc_meshdescriptors":"Aged;Carcinogenesis;Carcinoma, Squamous Cell;China;Esophageal Neoplasms;Female;Genotype;Human papillomavirus 16;Human papillomavirus 18;Humans;Iran;Male;Middle Aged;Oncogene Proteins, Viral;Repressor Proteins;South Africa",
        "Doc_meshqualifiers":"genetics;epidemiology;genetics;virology;epidemiology;genetics;virology;genetics;pathogenicity;genetics;pathogenicity;genetics;genetics",
        "_version_":1605818649394806784},
      {
        "Doc_abstract":"In the present study, we investigated the role of p16(INK4a) in the inhibition of DNA synthesis stimulated by hepatocyte growth factor (HGF) or epidermal growth factor (EGF) using RNA interference in primary cultured rat hepatocytes. The transfection of small interfering RNAs targeting p16(INK4a) reduced the corresponding mRNA and protein expression by more than approximately 90% and 50%, respectively, at 24 h after transfection. In the cells transfected with p16(INK4a) small interfering RNA, control, HGF, and EGF-stimulated DNA synthesis as assessed by (3)H-thymidine incorporation increased by approximately 1.5-fold, 1.6-fold, and 1.7-fold, respectively, compared with that in the control small interfering RNA-transfected cells. These findings indicate that p16(INK4a) plays a significant role in the inhibition of DNA synthesis. ",
        "Doc_title":"Role of p16(INK4a) in the inhibition of DNA synthesis stimulated by HGF or EGF in primary cultured rat hepatocytes.",
        "Journal":"Biomedical research (Tokyo, Japan)",
        "Do_id":"24190239",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;RNA, Messenger;Epidermal Growth Factor;Hepatocyte Growth Factor",
        "Doc_meshdescriptors":"Animals;Cyclin-Dependent Kinase Inhibitor p16;DNA Replication;Epidermal Growth Factor;Gene Expression Regulation;Hepatocyte Growth Factor;Hepatocytes;RNA Interference;RNA, Messenger;Rats",
        "Doc_meshqualifiers":"genetics;metabolism;drug effects;pharmacology;drug effects;pharmacology;drug effects;metabolism;genetics;metabolism",
        "_version_":1605812824968265728},
      {
        "Doc_abstract":"We examined racial disparities among 102 oropharyngeal carcinoma (OPC) patients (30 African Americans and 72 whites) comparing rates of transcriptionally active human papillomavirus (HPV)16/18 and p16(INK4a) overexpression, with times to disease progression and disease-specific survival (DSS). Expression of HPV16/18 transcripts was assessed by reverse transcription and polymerase chain reaction using type-specific E6/E7 primers; p16(INK4a) was evaluated by immunohistochemistry. African Americans were significantly more likely to present with high T stage disease and receive nonsurgical treatment. HPV16/18 was present in 63% of patients; no racial differences were observed. Silenced p16(INK4a) in OPC was significantly more common in African Americans (15/24) than in whites (20/69) (P = .004) and in HPV16+ African Americans (6/24) than in HPV+ whites (2/42) (P = .023). Kaplan-Meier analysis for DSS revealed a protective effect for p16(INK4a) overexpression (P = .0028; hazard ratio [HR], 0.23), HPV16+ (P = .036; HR, 0.38), and whites (P = .0039; HR, 0.27). Shorter DSS was associated with primary definitive chemoradiation (P = .019; HR, 3.49) and T3/T4 disease (P = .0001; HR, 7.75). A protective effect with respect to disease progression was observed for HPV16+ (P = .007; HR, 0.27), whites (P = .0006; HR, 0.197), and p16(INK4a) overexpression (P = .0001; HR, 0.116). African Americans with OPC experience poorer outcomes likely due to p16(INK4a) silencing, higher T stage, and nonsurgical treatment but not lower rates of transcriptionally active HPV16/18. ",
        "Doc_title":"African Americans with oropharyngeal carcinoma have significantly poorer outcomes despite similar rates of human papillomavirus-mediated carcinogenesis.",
        "Journal":"Human pathology",
        "Do_id":"24355195",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16",
        "Doc_meshdescriptors":"Adult;African Americans;Aged;Carcinogenesis;Cyclin-Dependent Kinase Inhibitor p16;Female;Gene Silencing;Human papillomavirus 16;Human papillomavirus 18;Humans;Kaplan-Meier Estimate;Male;Middle Aged;Oropharyngeal Neoplasms;Papillomaviridae;Papillomavirus Infections",
        "Doc_meshqualifiers":"biosynthesis;genetics;genetics;ethnology;genetics;mortality;therapy;metabolism;complications",
        "_version_":1605905070781628416},
      {
        "Doc_abstract":"Deletions of chromosomal region 9p21 are among the most common genetic alterations observed during the clonal evolution of high grade malignant gliomas. Structural and functional evidence has suggested that homozygous deletion involving CDKN2A (the genetic locus encoding the cyclin-dependent kinase inhibitor p16(NK4a)) is a mechanism of inactivation of this gene and that it can be a growth suppressor in human gliomas. However, the presence of other potential suppressor genes in the 9p21 region and the relatively large sizes of the deletions has made it difficult to be certain that the CDKN2A gene is their actual target. Here, we tested this hypothesis by determining the growth suppressive effects, cell cycle inhibitions, and the activities of seven naturally occurring glioma-derived CDKN2A alleles carrying point mutations and found that two of them were functionally compromised. To resolve discrepancies among the different existing functional assays, we developed an assay for p16(INK4a) function that allowed us to demonstrate that the expression of wild-type CDKN2A, but not alleles with inactivating mutations, prevents pRB phosphorylation in vivo in human glioma cells. These data suggest that CDKN2A is a critical target for mutational inactivation in human malignant gliomas.",
        "Doc_title":"Point mutations can inactivate in vitro and in vivo activities of p16(INK4a)/CDKN2A in human glioma.",
        "Journal":"Oncogene",
        "Do_id":"9053859",
        "Doc_ChemicalList":"Carrier Proteins;Cyclin-Dependent Kinase Inhibitor p16;Enzyme Inhibitors;Protein Kinase Inhibitors;Recombinant Proteins;Retinoblastoma Protein",
        "Doc_meshdescriptors":"Alleles;Carrier Proteins;Cell Cycle;Chromosome Deletion;Chromosomes, Human, Pair 9;Cyclin-Dependent Kinase Inhibitor p16;Enzyme Inhibitors;Genes, Tumor Suppressor;Glioma;Humans;Phosphorylation;Protein Biosynthesis;Protein Kinase Inhibitors;Recombinant Proteins;Retinoblastoma Protein;Transcription, Genetic;Transfection",
        "Doc_meshqualifiers":"genetics;metabolism;metabolism;enzymology;genetics;pathology;biosynthesis;metabolism;metabolism",
        "_version_":1605796909753040896},
      {
        "Doc_abstract":"p16(INK4a) is a multiple tumor suppressor, playing an important role in proliferation and tumorigenesis. To screen the p16(INK4a)-associated proteins, we performed a yeast two-hybrid assay and identified a novel protein isochorismatase domain containing 2 (ISOC2). ISOC2 conserves in different species, and encodes 205 and 210 amino acids in human and mouse, respectively. The expression of ISOC2 in mouse is universal but predominantly in uterus, stomach, and urinary tract system. Interaction between ISOC2 and p16(INK4a) was verified using in vitro pull-down assays and in vivo co-immunoprecipitation. Confocal microscopy studies using green and cyan fluorescent fusion proteins determined that ISOC2 co-localizes with p16(INK4a). Over-expressed ISOC2 is able to inhibit p16(INK4a) in dose-dependent manner. Our data indicated that ISOC2 is a novel functional protein, which is able to bind and co-localize with a tumor suppressor gene p16(INK4a). Over-expressed ISOC2 inhibits the expression of p16(INK4a), suggesting that this novel gene may play a role during the tumor development by interacting with p16(INK4a).",
        "Doc_title":"Identification and characterization of a novel protein ISOC2 that interacts with p16INK4a.",
        "Journal":"Biochemical and biophysical research communications",
        "Do_id":"17658461",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;Hydrolases;ISOC2 protein, human;isochorismatase",
        "Doc_meshdescriptors":"Amino Acid Sequence;Animals;Cell Line;Cyclin-Dependent Kinase Inhibitor p16;Gene Expression;Humans;Hydrolases;Mice;Microscopy, Confocal;Molecular Sequence Data;Protein Binding;Protein Transport;Reproducibility of Results;Subcellular Fractions;Two-Hybrid System Techniques",
        "Doc_meshqualifiers":"metabolism;chemistry;metabolism;metabolism",
        "_version_":1605850551038246912},
      {
        "Doc_abstract":"We examined the genomic status of the p16INK4A (inhibitor of cyclin-dependent kinase 4 A) and cyclin-dependent kinase 4 (CDK4) genes in 62 human hepatocellular carcinomas (HCCs), 5 cholangiocellular carcinomas and 6 cell lines derived from human liver cancers. Although no samples showed the homozygous deletion of the p16INK4A gene, we detected intragenic mutations of the p16INK4A gene in 3 HCCs and one HCC cell line, which led to an amino-acid substitution or a frameshift. In 2 HCC samples with mis-sense mutations of the p16INK4A gene, loss of heterozygosity on 9p22 was also detected, suggesting that the loss of function of p16 was induced during hepatocarcinogenesis. On the other hand, amplification or rearrangement of the CDK4 gene was not detected in any samples examined in this study. These results indicated that the mutations or deletions of the p16INK4A gene are not frequent, but may play a role in a sub-set of human HCC.",
        "Doc_title":"Infrequent alterations of the p16INK4A gene in liver cancer.",
        "Journal":"International journal of cancer",
        "Do_id":"8760583",
        "Doc_ChemicalList":"Carrier Proteins;Cyclin-Dependent Kinase Inhibitor p16;Proto-Oncogene Proteins;CDK4 protein, human;Cyclin-Dependent Kinase 4;Cyclin-Dependent Kinases",
        "Doc_meshdescriptors":"Base Sequence;Carcinoma, Hepatocellular;Carrier Proteins;Cyclin-Dependent Kinase 4;Cyclin-Dependent Kinase Inhibitor p16;Cyclin-Dependent Kinases;Exons;Gene Deletion;Homozygote;Humans;Liver Neoplasms;Molecular Sequence Data;Mutation;Polymerase Chain Reaction;Proto-Oncogene Proteins;Tumor Cells, Cultured",
        "Doc_meshqualifiers":"genetics;genetics;genetics;genetics",
        "_version_":1605840899526361088},
      {
        "Doc_abstract":"p19ARF encoded by the INK4a tumor suppressor gene locus functions upstream of p53 to induce cell cycle arrest. p19ARF can interact with MDM2 and p53 in cells ectopically overexpressing these three components, but the biochemical cascades from p19ARF to cell cycle arrest has not been fully elucidated. In this study, we generated stably transfected NIH3T3 cells that express exogenous p19ARF under the control of a heavy metal-inducible metalothionine promoter. Cells arrested in G1 by ectopically expressed p19ARF contained considerably reduced G1 cyclin dependent kinase (cdk2 and cdk4) activities. The expression of cyclin A (a regulatory subunit of cdk2) markedly decreased, while cyclin D1, the major cdk4 partner in fibroblasts, expressed at a slightly higher level and formed complexes with cdk2 and cdk6 in addition to cdk4. Induction of p19ARF activated p53 by increasing its stability, and allowed the expression of p21Cip1, which bound to all of the cyclin D1-cdk complexes (cyclin D1-cdk2, -cdk4, and -cdk6) thereby inhibiting their kinase activities. p19ARF formed complexes with several cellular proteins including mouse MDM2. The majority of MDM2 was found in the complex with p19ARF, while no p53 was detected in association with p19ARF. Thus, we propose that p19ARF neutralizes MDM2 by sequestration from p53, which results in activation of p53, inhibition of G1 cyclin-cdk activities, and G1 arrest.",
        "Doc_title":"p19ARF prevents G1 cyclin-dependent kinase activation by interacting with MDM2 and activating p53 in mouse fibroblasts.",
        "Journal":"Oncogene",
        "Do_id":"10348346",
        "Doc_ChemicalList":"Neoplasm Proteins;Nuclear Proteins;Proteins;Proto-Oncogene Proteins;Tumor Suppressor Protein p14ARF;Tumor Suppressor Protein p53;Mdm2 protein, mouse;Proto-Oncogene Proteins c-mdm2;CDC2 Protein Kinase",
        "Doc_meshdescriptors":"3T3 Cells;Animals;CDC2 Protein Kinase;Enzyme Activation;Fibroblasts;G1 Phase;Mice;Neoplasm Proteins;Nuclear Proteins;Proteins;Proto-Oncogene Proteins;Proto-Oncogene Proteins c-mdm2;Tumor Suppressor Protein p14ARF;Tumor Suppressor Protein p53",
        "Doc_meshqualifiers":"metabolism;enzymology;metabolism;physiology;metabolism;physiology;metabolism;metabolism",
        "_version_":1605742100835467264},
      {
        "Doc_abstract":"The retinoblastoma protein (pRb), p16(INK4A), D-type cyclins, and their partners cyclin-dependent kinase (CDK) 4 and 6 constitute a G(1) regulatory pathway commonly targeted in tumorigenesis. Several malignancies show a reciprocal correlation between genetic alterations of single members of the pRb pathway. Therefore, we determined the frequency of Rb deletions and cyclin D1 alterations by fluorescence in situ hybridization as well as 5' CpG island hypermethylation of the p16(INK4A)gene using methylation-specific polymerase chain reaction in bone marrow mononuclear cells from 82 individuals with plasma cell disorders. Alterations in at least one of the components of the pathway were found in 75%. Cyclin D1 translocations or amplifications were detected in 14/82 (17.1%), Rb deletions at 13q14 in 23/82 (28%) of the cases, including three (3.6%) homozygous deletions. p16(INK4A) was hypermethylated in 33/57 (57.9%) of the samples. Further analysis revealed a highly significant correlation between cyclin D1 alterations and extramedullar or leukemic myeloma manifestations (P = 0.014; Fisher's test). Whereas Rb deletions seemed to occur alternatively to cyclin D1 alterations, no reciprocal correlation was found between p16(INK4A) hypermethylations and cyclin D1 or Rb locus aberrations. Cyclin D1 locus alterations and Rb deletions were associated with a significantly worse prognosis whereas p16(INK4A) hypermethylation had no impact on survival. We conclude that cyclin D1 and Rb aberrations seem to occur as alternative events in plasma cell malignancies and contribute to clinical course and prognosis. In contrast, although p16(INK4A) hypermethylation is frequent, inactivation of p16(INK4A) seems not to be involved in the pathogenesis of plasma cell disorders.",
        "Doc_title":"Alterations of the cyclin D1/pRb/p16(INK4A) pathway in multiple myeloma.",
        "Journal":"Leukemia",
        "Do_id":"12200702",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;Immunoglobulins;Retinoblastoma Protein;Cyclin D1",
        "Doc_meshdescriptors":"Chromosome Aberrations;Chromosome Mapping;Chromosomes, Human, Pair 11;Chromosomes, Human, Pair 13;Chromosomes, Human, Pair 14;Cyclin D1;Cyclin-Dependent Kinase Inhibitor p16;Female;Gene Deletion;Humans;Immunoglobulins;Leukemia, Plasma Cell;Male;Middle Aged;Multiple Myeloma;Neoplasm Staging;Retinoblastoma Protein;Survival Rate;Translocation, Genetic",
        "Doc_meshqualifiers":"genetics;genetics;genetics;genetics;metabolism;genetics;metabolism;genetics;metabolism;pathology;genetics;metabolism;pathology;genetics;metabolism",
        "_version_":1605822528396197888},
      {
        "Doc_abstract":"Tumor suppressor genes encode critical cell cycle regulatory proteins that are frequently mutated or deleted in cancer and, therefore, are important candidates for cancer treatment based on gene replacement strategies.;We evaluated and compared the relative potential therapeutic efficacy of p14ARF and p16INK4A expressed in adenoviral vectors (Adp14ARF and Adp16INK4A, respectively) in three human mesothelioma cell lines.;The cytotoxic effects of expressed p16INK4A were significantly greater than that of p14ARF in both H28 and H2052 cells. Cell cycle G1 arrest occurred earlier with Adp16INK4A treatment than Adp14ARF (24 hours vs. 48 hours, respectively). Although both Adp14ARF and Adp16INK4A inhibited cell proliferation significantly and were potentiated by chemotherapy, Adp16INK4A appeared more potent.;Our results suggest that adenoviral gene-based therapy, especially using Adp16INK4A-based strategy, may be effective in the treatment of human mesothelioma.",
        "Doc_title":"A comparison analysis of anti-tumor efficacy of adenoviral gene replacement therapy (p14ARF and p16INK4A) in human mesothelioma cells.",
        "Journal":"Anticancer research",
        "Do_id":"12680192",
        "Doc_ChemicalList":"Antineoplastic Agents;Cyclin-Dependent Kinase Inhibitor p16;Tumor Suppressor Protein p14ARF;Tumor Suppressor Protein p53;Paclitaxel;Cisplatin",
        "Doc_meshdescriptors":"Adenoviridae;Antineoplastic Agents;Cell Cycle;Cisplatin;Combined Modality Therapy;Cyclin-Dependent Kinase Inhibitor p16;Genetic Therapy;Genetic Vectors;Humans;Mesothelioma;Paclitaxel;Tumor Cells, Cultured;Tumor Suppressor Protein p14ARF;Tumor Suppressor Protein p53",
        "Doc_meshqualifiers":"genetics;pharmacology;genetics;pharmacology;biosynthesis;genetics;methods;genetics;drug therapy;genetics;metabolism;therapy;pharmacology;biosynthesis;genetics;physiology",
        "_version_":1605841284457562112},
      {
        "Doc_abstract":"To study the action, characteristics and expression of high methylation of p15(INK4B) and p16(INK4A) genes in multiple myeloma (MM), the sensitive methylation specific PCR method was employed to detect the hypermethylation of p15(INK4B) and p16(INK4A) in 24 patients with MM. Results showed that the methylation incidence of p15(INK4B) and p16(INK4A) genes were 70.8% (17/24) and 58.3% (14/24) in the MM patients, with the products of 148 bp and 150 bp fragments, respectively. The methylation of p15(INK4B) and p16(INK4A) genes were simultaneously happened in MM patients of plasmocytoma type with two cases at II phase and two cases at III phase. The simultaneous non-methylation of p15(INK4B) and p16(INK4A) genes were founded in five cases of MM patients, all of the tumor cells were of small plasmocyte type with mature differention. Conclusion suggested that there were high incidence of methylation of p15(INK4B) and p16(INK4A) genes in patients with MM. Hypermethylation can be detected in the early stage of disease, which was associated with its progress. It indicated a bad prognosis when methylation happended simultaneously in the two genes. Methylation of p15(INK4B) and p16(INK4A) genes may be related to the pathogeny of MM.",
        "Doc_title":"[Detection of High Methylation of p15(INK4B) and p16(INK4A) Genes in Multiple Myeloma]",
        "Journal":"Zhongguo shi yan xue ye xue za zhi",
        "Do_id":"12578664",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605765452624035840},
      {
        "Doc_abstract":"Rising prevalence rates of high-risk human papillomaviruses (hrHPV) infection in oropharyngeal carcinoma (up to 80 %) have been reported in North America and Scandinavia. We have analysed 424 German and 163 Brazilian head and neck squamous cell carcinomas (HNSCC) from the oral cavity (OSCC), oropharynx (OPSCC) and hypopharynx (HPSCC) using p16 immunohistochemistry, HPV DNA PCR and sequencing, hrHPV DNA in situ hybridisation (ISH) and hrHPV E6/E7 RNA ISH. In the German series, 52/424 cases (12.3 %) were p16-positive/hrHPV-positive (OSCC 3.8 % [10/265], OPSCC 34.4 % [42/122], HPSCC 0 % [0/37]). In addition, there were 9 cases that were p16-positive/hrHPV-negative (5 OPSCC and 4 OSCC). In the Brazilian series, the overall hrHPV DNA prevalence by PCR was 11.0 % ([18/163]; OSCC 6 % [5/83], OPSCC 15.5 % [11/71], HPSCC 22.2 % [2/9]). Ten of these cases were hrHPV-positive/p16-positive. The remaining 8 hrHPV-positive/p16-negative cases were also negative in both ISH assays. Furthermore, 5 p16-positive/hrHPV-negative cases (2 OPSCC and 3 OSCC) were identified. In both series, HPV16 was by far the most common HPV type detected. We confirm that regardless of geographical origin, the highest hrHPV prevalence in HNSCC is observed in oropharyngeal carcinomas. The proportion of HPV-associated OPSCC was substantially higher in the German cohort than in the Brazilian series (34.4 vs. 15.5 %), and in both groups, the prevalence of hrHPV in OPSCC was much lower than in recent reports from North America and Scandinavia. We suggest, therefore, that it may be possible to define areas with high (e.g. USA, Canada, Scandinavia), intermediate (e.g. Germany) and low (e.g. Brazil) prevalences of HPV infection in OPSCC.",
        "Doc_title":"Prevalence of HPV infection in head and neck carcinomas shows geographical variability: a comparative study from Brazil and Germany.",
        "Journal":"Virchows Archiv : an international journal of pathology",
        "Do_id":"25820374",
        "Doc_ChemicalList":"Biomarkers, Tumor;Cyclin-Dependent Kinase Inhibitor p16;DNA, Viral",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Biomarkers, Tumor;Brazil;Carcinoma, Squamous Cell;Cyclin-Dependent Kinase Inhibitor p16;DNA, Viral;Female;Germany;Head and Neck Neoplasms;Humans;Immunohistochemistry;In Situ Hybridization;Male;Middle Aged;Papillomavirus Infections;Polymerase Chain Reaction;Prevalence;Tissue Array Analysis;Young Adult",
        "Doc_meshqualifiers":"analysis;epidemiology;epidemiology;virology;analysis;analysis;epidemiology;epidemiology;virology;complications;epidemiology",
        "_version_":1605841972421984256},
      {
        "Doc_abstract":"Genome-wide association studies (GWAS) have linked common single nucleotide polymorphisms (SNPs) on chromosome 9p21 near the INK4/ARF (CDKN2A/B) tumor suppressor locus with risk of atherosclerotic diseases and type 2 diabetes mellitus. To explore the mechanism of this association, we investigated whether expression of proximate transcripts (p16(INK4a), p15(INK4b), ARF, ANRIL and MTAP) correlate with genotype of representative 9p21 SNPs.;We analyzed expression of 9p21 transcripts in purified peripheral blood T-cells (PBTL) from 170 healthy donors. Samples were genotyped for six selected disease-related SNPs spanning the INK4/ARF locus. Correlations among these variables were determined by univariate and multivariate analysis. Significantly reduced expression of all INK4/ARF transcripts (p15(INK4b), p16(INK4a), ARF and ANRIL) was found in PBTL of individuals harboring a common SNP (rs10757278) associated with increased risk of coronary artery disease, stroke and aortic aneurysm. Expression of MTAP was not influenced by rs10757278 genotype. No association of any these transcripts was noted with five other tested 9p21 SNPs.;Genotypes of rs10757278 linked to increased risk of atherosclerotic diseases are also associated with decreased expression in PBTL of the INK4/ARF locus, which encodes three related anti-proliferative transcripts of known importance in tumor suppression and aging.",
        "Doc_title":"INK4/ARF transcript expression is associated with chromosome 9p21 variants linked to atherosclerosis.",
        "Journal":"PloS one",
        "Do_id":"19343170",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor Proteins;RNA, Messenger",
        "Doc_meshdescriptors":"Atherosclerosis;Chromosomes, Human, Pair 9;Cyclin-Dependent Kinase Inhibitor Proteins;Genome-Wide Association Study;Genotype;Humans;Polymorphism, Single Nucleotide;RNA, Messenger",
        "Doc_meshqualifiers":"genetics;genetics;genetics",
        "_version_":1605822136064147456},
      {
        "Doc_abstract":"Inhibition of cyclin dependent kinases (cdk) by proteins of two families of cdk inhibitors (CKIs) represents one of the key modes of cell-cycle control. Although not fully understood at present, the functions of the individual members of the Cip/Kip and INK4 families of CKIs have been implicated in fundamental biological processes as diverse as cellular proliferation, responses to genotoxic stress, regulation of cellular differentiation, and senescence. In addition, the seven currently known CKIs qualify as either established or candidate tumor suppressors whose loss or inactivation contribute to molecular pathogenesis of a wide range of tumor types. In this study, we report the isolation and characterization of a panel of 10 mouse monoclonal antibodies (MAbs) that specifically recognize p21WAF1/CIP1 (p21) or the individual members of the INK4 family of CKIs: p15INK4b (p15), p16INK4a (p16), p18INK4c (p18), or p19INK4d (p19). These antibodies are proving to be invaluable molecular probes for analyses of protein abundance, subcellular localization, interacting cellular proteins, and ultimately the function(s) of these cell cycle regulators. Epitopes targeted by the antibodies were mapped by peptide enzyme-linked immunoadsorbent assay (ELISA), and performance of the MAbs assessed in a range of immunochemical techniques. Individual MAbs of our series recognize distinct pools of the respective CKIs, a feature reflected by their differential applicability in immunoblotting, immunoprecipitation, and immunostaining including immunohistochemistry on archival paraffin-embedded tissue sections. Together, these antibodies represent useful reagents to study CKIs in cells and tissues, a set of tools that should help elucidate the physiological roles played by the individual CKIs, and better understand the molecular mechanisms of loss or inactivation of these (candidate) tumor suppressors in human malignancies.",
        "Doc_title":"Monoclonal antibody probes for p21WAF1/CIP1 and the INK4 family of cyclin-dependent kinase inhibitors.",
        "Journal":"Hybridoma",
        "Do_id":"10768842",
        "Doc_ChemicalList":"Antibodies, Monoclonal;CDKN1A protein, human;Cdkn1a protein, mouse;Cyclin-Dependent Kinase Inhibitor p21;Cyclins;Enzyme Inhibitors;Molecular Probes;Cyclin-Dependent Kinases",
        "Doc_meshdescriptors":"Animals;Antibodies, Monoclonal;Breast Neoplasms;Colonic Neoplasms;Cyclin-Dependent Kinase Inhibitor p21;Cyclin-Dependent Kinases;Cyclins;Enzyme Inhibitors;Humans;Mice;Molecular Probes;Multigene Family;Organ Specificity;Tumor Cells, Cultured",
        "Doc_meshqualifiers":"biosynthesis;chemistry;metabolism;chemistry;enzymology;chemistry;enzymology;analysis;antagonists & inhibitors;metabolism;immunology;immunology;biosynthesis;chemistry;metabolism;immunology;immunology",
        "_version_":1605904318937956352},
      {
        "Doc_abstract":"The genes encoding the AML1 (RUNX1) or CBFbeta subunits of core binding factor (CBF) are commonly altered by translocation or mutation in human leukemias. Because CBF oncoproteins slow G(1), we sought to determine whether mutations that accelerate G(1) potentiate their ability to induce transformation. Wild-type or p16(INK4a)p19(ARF) (-/-) marrow cells transduced with CBFbeta-smooth muscle myosin heavy chain (SMMHC) were transplanted into wild-type, syngeneic recipients. CBFbeta-SMMHC significantly increased the development of acute leukemias from marrow lacking the overlapping p16p19 genes, based on analysis of Kaplan-Meier event-time distributions. Wild-type marrow was also transduced with vectors expressing either E7 alone or both E7 and CBFbeta-SMMHC. Combining oncogenes again increased leukemia formation. Exposing mice transplanted with CBFbeta-SMMHC-transduced cells to a mutagen, ethylnitrosourea, markedly accelerated leukemogenesis compared to expressing CBFbeta-SMMHC with loss of p16p19, indicating the need for multiple \"hits\" for transformation. The INV/p16p19 and INV/E7 leukemias were lymphoid and were clonal and retransplantable. Overall, these findings indicate that CBF mutations cooperate with genetic alterations that accelerate G(1) to induce acute leukemia.",
        "Doc_title":"Acceleration of G(1) cooperates with core binding factor beta-smooth muscle myosin heavy chain to induce acute leukemia in mice.",
        "Journal":"Cancer research",
        "Do_id":"11956074",
        "Doc_ChemicalList":"Cdkn2a protein, mouse;Cyclin-Dependent Kinase Inhibitor p16;DNA-Binding Proteins;Oncogene Proteins, Viral;Papillomavirus E7 Proteins;Transcription Factor AP-2;Transcription Factors;Tumor Suppressor Protein p14ARF;oncogene protein E7, Human papillomavirus type 16;Smooth Muscle Myosins;Myosin Heavy Chains",
        "Doc_meshdescriptors":"Acute Disease;Animals;Cyclin-Dependent Kinase Inhibitor p16;DNA-Binding Proteins;G1 Phase;Leukemia, Experimental;Mice;Mice, Inbred C57BL;Myosin Heavy Chains;Oncogene Proteins, Viral;Papillomavirus E7 Proteins;Retroviridae;Smooth Muscle Myosins;Transcription Factor AP-2;Transcription Factors;Transduction, Genetic;Tumor Suppressor Protein p14ARF",
        "Doc_meshqualifiers":"genetics;physiology;genetics;physiology;physiology;genetics;pathology;genetics;physiology;genetics;physiology;genetics;genetics;physiology;genetics;physiology;genetics;physiology",
        "_version_":1605794598752354304},
      {
        "Doc_abstract":"Colorectal cancer (CRC) has traditionally been classified into two groups: microsatellite stable/low-level instability (MSS/MSI-L) and high-level MSI (MSI-H) groups on the basis of multiple molecular and clinicopathologic criteria. Using methylated in tumor (MINT) markers 1, 2, 12, and 31, we stratified 77 primary CRCs into three groups: MINT++ (>2), MINT+ (1-2), and MINT- (0 markers methylated). The MSS/MSI-L/MINT++ group was indistinguishable from the MSI-H/MINT++ group with respect to methylation of p16(INK4a), p14(ARF), and RIZ1, and multiple morphological features. The only significant difference between MSI-H and non-MSI-H MINT++ cancers was the higher frequency of K-ras mutation (P < 0.004) and lower frequency of hMLH1 methylation (P < 0.001) in the latter. These data demonstrate that the separation of CRC into two nonoverlapping groups (MSI-H versus MSS/MSI-L) is a misleading oversimplification.",
        "Doc_title":"Morphological and molecular heterogeneity within nonmicrosatellite instability-high colorectal cancer.",
        "Journal":"Cancer research",
        "Do_id":"12414620",
        "Doc_ChemicalList":"Adaptor Proteins, Signal Transducing;Carrier Proteins;Cyclin-Dependent Kinase Inhibitor p16;DNA-Binding Proteins;MLH1 protein, human;Mlh1 protein, mouse;Neoplasm Proteins;Nuclear Proteins;Transcription Factors;Tumor Suppressor Protein p14ARF;Histone-Lysine N-Methyltransferase;PRDM2 protein, human;O(6)-Methylguanine-DNA Methyltransferase;MutL Protein Homolog 1",
        "Doc_meshdescriptors":"Adaptor Proteins, Signal Transducing;Carrier Proteins;Colorectal Neoplasms;Cyclin-Dependent Kinase Inhibitor p16;DNA Methylation;DNA-Binding Proteins;Histone-Lysine N-Methyltransferase;Humans;Microsatellite Repeats;MutL Protein Homolog 1;Neoplasm Proteins;Nuclear Proteins;O(6)-Methylguanine-DNA Methyltransferase;Prospective Studies;Transcription Factors;Tumor Suppressor Protein p14ARF",
        "Doc_meshqualifiers":"classification;genetics;pathology;genetics;genetics;genetics;genetics;genetics;genetics",
        "_version_":1605907380454817792},
      {
        "Doc_abstract":"Inactivation of the tumor-suppressor gene p16 (MTS1/ CDKN2/INK4a) has been described in various human malignancies. Although p16 deletion has been found in various ovarian tumor cell lines, p16 inactivation by homozygous deletion or mutation has been reported only sporadically in primary ovarian carcinomas. In a comprehensive study, we analyzed p16 protein expression by immuno-histochemistry (IHC) on paraffin sections of 94 primary ovarian carcinomas of different histological subtype. Loss of expression was detected in 19 primary tumors (20%), mainly mucinous and endometrioid carcinomas. To reveal the cause of suppressed expression, we performed (i) analysis of homozygous deletions by comparative PCR after micro-dissection, (ii) mutation analysis by single-strand conformation polymorphism analysis and subsequent direct sequencing and (iii) methylation-specific PCR to determine the methylation status of 5'-CpG islands. Loss of or weak p16 expression was caused by hyper-methylation (12/19 IHC-negative cases), somatic mutation (10 tumors) or homozygous deletion (1 case). Aberrant p 16 results by one of these methods were detected in 71-79% of endometrioid and mucinous, but in only 10% of serous-papillary, carcinomas. Our data suggest that p16 inactivation is a typical feature of certain subtypes of ovarian carcinoma.",
        "Doc_title":"p16/MTS1 inactivation in ovarian carcinomas: high frequency of reduced protein expression associated with hyper-methylation or mutation in endometrioid and mucinous tumors.",
        "Journal":"International journal of cancer",
        "Do_id":"9495360",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;DNA, Neoplasm",
        "Doc_meshdescriptors":"Adenocarcinoma, Mucinous;Aged;Carcinoma;Carcinoma, Endometrioid;Cyclin-Dependent Kinase Inhibitor p16;Cystadenocarcinoma, Papillary;DNA Methylation;DNA, Neoplasm;Female;Gene Expression Regulation, Neoplastic;Humans;Middle Aged;Ovarian Neoplasms;Point Mutation;Polymorphism, Single-Stranded Conformational",
        "Doc_meshqualifiers":"genetics;genetics;genetics;genetics;genetics;genetics;genetics",
        "_version_":1605841047378722816},
      {
        "Doc_abstract":"Gastrointestinal stromal tumors feature a wide spectrum of biologic behavior, ranging from benign to extremely malignant. To determine the role of p16(INK4a) alteration in progression of gastrointestinal stromal tumors of the stomach, we have investigated protein expression and gene methylation in correlation with clinicopathologic factors and survival. In addition to immunohistochemical analysis of p16(INK4a) in a series of 95 cases, real-time quantitative methylation specific polymerase chain reaction for p16(INK4a) and immunostaining for cyclin D1, cyclin E, pRb, DP-1, E2F-1, and Ki-67 were also evaluated in randomly selected samples. The p16(INK4a) labeling indices ranged from 0% to 74% (median, 21%), demonstrating a significant inverse correlation with size (P = .046). On univariate (P = .003) and multivariate (P = .067) analyses, loss of p16(INK4a) expression increased the likelihood of a poor tumor-related survival. In addition, size (P = .036) and the mitotic index (P = .005) had independent prognostic influence. The p16(INK4a) methylation index, which ranged from 0% to 100% (median, 17%), was significantly higher in larger tumors (P < .001) and in high-risk category lesions (P= .001) and inversely correlated with protein expression. Hierarchical cluster analysis based on expression of p16(INK4a) network members identified 2 clusters in 27 randomly selected tumor samples, containing 11 and 16 tumors each. Former cluster samples demonstrated higher risk category (P = .022), higher p16(INK4a) methylation (P < .001), and more reduced pRb expression (P < .018). In addition, p16(INK4a) network members clustered into 2 groups: (1) showing down-regulated p16(INK4a) protein and up-regulating of both cyclin D1 and DP-1 and (2) down-regulated pRb and up-regulated E2F-1. We conclude that p16(INK4a) alteration has an important role in progression of gastrointestinal stromal tumors of the stomach. Furthermore, the study provides a possible link between regulation of p16(INK4a) network members and gastrointestinal stromal tumors.",
        "Doc_title":"Role for p16(INK4a) in progression of gastrointestinal stromal tumors of the stomach: alteration of p16(INK4a) network members.",
        "Journal":"Human pathology",
        "Do_id":"21496871",
        "Doc_ChemicalList":"Cyclin D;Cyclin E;Cyclin-Dependent Kinase Inhibitor p16;E2F1 Transcription Factor;Retinoblastoma Protein;TFDP1 protein, human;Transcription Factor DP1",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Analysis of Variance;Cluster Analysis;Cyclin D;Cyclin E;Cyclin-Dependent Kinase Inhibitor p16;E2F1 Transcription Factor;Female;Gastrointestinal Stromal Tumors;Humans;Immunohistochemistry;Kaplan-Meier Estimate;Male;Methylation;Middle Aged;Prognosis;Retinoblastoma Protein;Retrospective Studies;Risk Assessment;Stomach Neoplasms;Transcription Factor DP1;Young Adult",
        "Doc_meshqualifiers":"metabolism;metabolism;metabolism;metabolism;diagnosis;metabolism;pathology;metabolism;diagnosis;metabolism;pathology;metabolism",
        "_version_":1605906542375206912},
      {
        "Doc_abstract":"To clarify the roles of the p53-MDM2-p14(ARF) cell cycle regulation system in oncogenesis and cytodifferentiation of odontogenic tumors, p53 gene status and expression of p53, MDM2, and p14(ARF) proteins was analyzed in ameloblastomas as well as tooth germs.;Paraffin sections of 16 tooth germs and 46 benign and 5 malignant ameloblastomas were examined immunohistochemically for the expression of p53, MDM2, and p14(ARF) proteins. Frozen tissue samples of 10 benign ameloblastomas and 1 malignant (metastasizing) ameloblastoma were analyzed by direct DNA sequencing to detect p53 gene alteration.;Immunohistochemical reactivity for p53 was detected in 2 of 13 tooth germs, 13 of 29 ameloblastomas, and 5 of 5 malignant ameloblastomas, and the expression ratio of p53 in tooth germs was significantly lower than those in benign and malignant ameloblastomas. Direct DNA sequencing showed no alteration of p53 gene exons 5-8 in any sample of 10 benign ameloblastomas and 1 metastasizing ameloblastoma. Expression of MDM2 and p14(ARF) was detected in all samples of normal and neoplastic odontogenic epithelium, and the expression ratios in tooth germs tended to be lower than those in benign and malignant ameloblastomas. In ameloblastomas, expression of p53, MDM2, and p14(ARF) was significantly higher in plexiform cases than in follicular cases. Markedly decreased reactivity for p53, MDM2, and p14(ARF) was detected in keratinizing and granular cells in ameloblastoma subtypes. Basal cell ameloblastoma showed slightly higher reactivity for p53, MDM2, and p14(ARF) as compared with other subtypes.;Elevated expression of p53, MDM2, and p14(ARF) in benign and malignant ameloblastomas suggests that alteration of the p53-MDM2-p14(ARF) cascade is involved in oncogenesis and/of malignant transformation of odontogenic epithelium. p53 gene status implied that p53 mutation might play a minor role in neoplastic changes of odontogenic epithelium. Immunoreactivity for p53, MDM2, and p14(ARF) in ameloblastoma variants suggests that these factors might be associated with tissue structuring and cytodifferentiation of ameloblastomas.",
        "Doc_title":"p53 gene status and expression of p53, MDM2, and p14 proteins in ameloblastomas.",
        "Journal":"Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology",
        "Do_id":"15078490",
        "Doc_ChemicalList":"DNA, Neoplasm;Nuclear Proteins;Proto-Oncogene Proteins;Tumor Suppressor Protein p14ARF;Tumor Suppressor Protein p53;MDM2 protein, human;Proto-Oncogene Proteins c-mdm2",
        "Doc_meshdescriptors":"Ameloblastoma;DNA Mutational Analysis;DNA, Neoplasm;Genes, p53;Humans;Immunohistochemistry;Jaw Neoplasms;Nuclear Proteins;Proto-Oncogene Proteins;Proto-Oncogene Proteins c-mdm2;Tooth Germ;Tumor Suppressor Protein p14ARF;Tumor Suppressor Protein p53",
        "Doc_meshqualifiers":"genetics;metabolism;analysis;genetics;genetics;metabolism;biosynthesis;metabolism;biosynthesis;biosynthesis",
        "_version_":1605832014848589824},
      {
        "Doc_abstract":"Malignant mesothelioma (MM) is a tumor with poor prognosis associated with asbestos exposure. While it remains to be clarified how asbestos fibers confer genetic/epigenetic alterations and induce cellular transformation in normal mesothelial cells, the understanding of key molecular mechanisms of MM cell development, proliferation, and invasion has progressed. MM shows frequent genetic inactivation of tumor suppressor genes of p16(INK4a)/p14(ARF) and neurofibromatosis type 2 (NF2) which encodes Merlin, and epigenetic inactivation of RASSF1A. However, no frequent mutations of well-known oncogenes such as K-RAS and PIK3CA have been identified. Activation of multiple receptor tyrosine kinases including the epidermal growth factor receptor (EGFR) family and MET, and subsequent deregulations of mitogen-activated protein kinase (MAPK) and phosphatidylinositol-3-kinase (PI3K)-AKT signaling cascades are frequently observed in most MM cells. The tumor suppressive function of Merlin in MM cells is also being investigated by dissecting its possible downstream signaling cascade called the Hippo pathway. Further comprehensive delineation of dysregulated signaling cascades in MM cells will lead to identification of key addiction pathways for cell survival and proliferation of MM cells, which strongly promote establishment of a new molecular target therapy for MM.",
        "Doc_title":"Genomic abnormalities and signal transduction dysregulation in malignant mesothelioma cells.",
        "Journal":"Cancer science",
        "Do_id":"19793348",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;Tumor Suppressor Protein p14ARF;Asbestos;Phosphatidylinositol 3-Kinases;Proto-Oncogene Proteins c-akt",
        "Doc_meshdescriptors":"Asbestos;Cyclin-Dependent Kinase Inhibitor p16;Genetic Predisposition to Disease;Genome-Wide Association Study;Humans;MAP Kinase Signaling System;Mesothelioma;Mutation;Neurofibromatosis 2;Phosphatidylinositol 3-Kinases;Proto-Oncogene Proteins c-akt;Signal Transduction;Tumor Suppressor Protein p14ARF",
        "Doc_meshqualifiers":"toxicity;genetics;genetics;metabolism;therapy;genetics;physiology;physiology;physiology;genetics",
        "_version_":1605790243182608384},
      {
        "Doc_abstract":"Abnormalities in tumor suppressors p14, p16 and p53 are reported in several human cancers. In ovarian epithelial carcinogenesis, p16 and p53 show higher immunohistochemical staining frequencies in malignant tumors and are associated with poor prognoses. p14 was only analyzed in carcinomas, with conflicting results. There are no reports on its expression in benign and borderline tumors. This study aims to determine p14, p16 and p53 expression frequencies in ovarian benign, borderline and malignant tumors and their associations with clinical parameters.;A cross-sectional study utilizing immunohistochemistry was performed on paraffin-embedded ovarian epithelial tumor samples. Clinical data were collected from medical records. Fisher's exact test and the Bonferroni correction were performed for frequency associations. Survival comparisons utilized Kaplan-Meier and log rank testing. Associations were considered significant when p<0.05.;p14 absent expression was associated with malignant tumors (60% positive) (p=0.000), while 93% and 94% of benign and borderline tumors, respectively, were positive. p16 was positive in 94.6% of carcinomas, 75% of borderline and 45.7% of benign tumors (p=0.000). p53 negative staining was associated with benign tumors (2.9% positive) (p=0.016) but no difference was observed between borderline (16.7%) and malignant tumors (29.7%) (p=0.560). No associations were found between expression rates, disease-free survival times or clinical variables. Carcinoma subtypes showed no difference in expression.;This is the first description of p14 expression in benign and borderline tumors. It remains stable in benign and borderline tumors, while carcinomas show a significant absence of staining. This may indicate that p14 abnormalities occur later in carcinogenesis. p16 and p53 frequencies increase from benign to borderline and malignant tumors, similarly to previous reports, possibly reflecting the accumulation of inactive mutant protein. The small sample size may have prevented statistically significant survival analyses and clinical correlations. Future studies should investigate genetic abnormalities in p14 coding sequences and include all types of ovarian epithelial tumors. Bigger sample sizes may be needed for significant associations.",
        "Doc_title":"p14 expression differences in ovarian benign, borderline and malignant epithelial tumors.",
        "Journal":"Journal of ovarian research",
        "Do_id":"27770808",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605748609227161600},
      {
        "Doc_abstract":"9p21 chromosomal region contains p15INK4b and p16INK4a genes which regulate G1 phase of the cell cycle by inhibition of cyclin-cyclin dependent kinases. The p19ARF protein is translated from an alternative transcript of the p16INK4a gene and regulates G1 and G2 phase of the cell cycle by degradation of the MDM2 protein. p16INK4a and p15INK4b gene homozygous deletions occur mostly in acute lymphoblastic leukemia, ATL secondary to HTLV1 infection, and some lymphoma. Point mutations of p16INK4a or p15INK4b gene seem to be extremely rare, however selective methylations of the p15INK4b or p16INK4a promoters are frequently found in myelodysplastic syndromes and acute leukemias, or lymphomas and myelomas respectively. These data demonstrate that inactivation of gene of the 9p21 region is currently the main molecular event found in hematological malignancies.",
        "Doc_title":"Cylin/CDK inhibitors of the 9p21 chromosomal region and hematological malignancies ",
        "Journal":"Bulletin du cancer",
        "Do_id":"9770602",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605742640786046976},
      {
        "Doc_abstract":"9p21 chromosomal region contains p15INK4b and p16INK4a genes which regulate G1 phase of the cell cycle by inhibition of cyclin-cyclin dependent kinases. The p19ARF protein is translated from an alternative transcript of the p16INK4a gene and regulates G1 and G2 phase of the cell cycle by degradation of the MDM2 protein. p16INK4a and p15INK4b gene homozygous deletions occur mostly in acute lymphoblastic leukemia, ATL secondary to HTLV1 infection, and some lymphoma. Point mutations of p16INK4a or p15INK4b gene seem to be extremely rare, however selective methylations of the p15INK4b or p16INK4a promoters are frequently found in myelodysplastic syndromes and acute leukemias, or lymphomas and myelomas respectively. These data demonstrate that inactivation of gene of the 9p21 region is currently the main molecular event found in hematological malignancies.",
        "Doc_title":"[Inhibitors of cyclins/CDK of the 9p21 chromosomal region and malignant hemopathies].",
        "Journal":"Bulletin du cancer",
        "Do_id":"9817058",
        "Doc_ChemicalList":"CDKN2B protein, human;Cell Cycle Proteins;Cyclin-Dependent Kinase Inhibitor p15;Cyclin-Dependent Kinase Inhibitor p16;Neoplasm Proteins;Transcription Factors;Tumor Suppressor Proteins;Cyclin-Dependent Kinases",
        "Doc_meshdescriptors":"Cell Cycle Proteins;Chromosomes, Human, Pair 9;Cyclin-Dependent Kinase Inhibitor p15;Cyclin-Dependent Kinase Inhibitor p16;Cyclin-Dependent Kinases;Hematologic Neoplasms;Humans;Leukemia, Myeloid, Acute;Myelodysplastic Syndromes;Neoplasm Proteins;Precursor Cell Lymphoblastic Leukemia-Lymphoma;Transcription Factors;Tumor Suppressor Proteins",
        "Doc_meshqualifiers":"genetics;genetics;genetics;genetics;genetics;genetics;genetics;genetics;genetics",
        "_version_":1605742052559028226},
      {
        "Doc_abstract":"The G1/S-phase controlling mechanism known as the RB pathway is commonly deregulated in human malignancies. Here, the abundance and localization of key components of the retinoblastoma (RB) pathway were determined in exophytic and flat colorectal adenomas.;Samples of normal colonic mucosa (n = 41) and flat (n = 45) and exophytic (n = 26) adenomas were examined immunohistochemically using antibodies to cyclins D1, D2, D3, cyclin-dependent kinase (CDK) 4, retinoblastoma protein (pRB), and the CDK inhibitors p16INK4a, p18INK4c, and p19INK4d.;In normal colonic epithelium, cyclin D2 was undetectable; expression of cyclin D1, CDK4, and pRB correlated with proliferation; and p16, p18, p19, and cyclin D3 were most abundant in quiescent, differentiated cells. Adenomas showed elevated expression of cyclin D1 and pRB, frequent induction of cyclin D2, and absence of p16. No obvious abnormalities were found for p18, p19, or cyclin D3. Overexpressed cyclin D2 was more common among exophytic and pRB among flat adenomas, respectively. Elevated cyclin D1, D2, and CDK4 correlated with enhanced dysplasia.;Aberrant expression of cyclins D1, D2, CDK4, p16, and pRB occur in significant subsets of exophytic and flat adenomas, particularly among cases with high-grade dysplasia. Such defects of the RB pathway may perturb cell-cycle control and thereby contribute an early step in colorectal tumorigenesis.",
        "Doc_title":"Aberrant expression of G1-phase cell cycle regulators in flat and exophytic adenomas of the human colon.",
        "Journal":"Gastroenterology",
        "Do_id":"11375949",
        "Doc_ChemicalList":"CCND2 protein, human;CCND3 protein, human;Cyclin D2;Cyclin D3;Cyclin-Dependent Kinase Inhibitor p16;Cyclins;Proto-Oncogene Proteins;Retinoblastoma Protein;Cyclin D1;CDK4 protein, human;Cyclin-Dependent Kinase 4;Cyclin-Dependent Kinases",
        "Doc_meshdescriptors":"Adenoma;Adult;Aged;Aged, 80 and over;Colonic Neoplasms;Cyclin D1;Cyclin D2;Cyclin D3;Cyclin-Dependent Kinase 4;Cyclin-Dependent Kinase Inhibitor p16;Cyclin-Dependent Kinases;Cyclins;Female;G1 Phase;Humans;Male;Middle Aged;Proto-Oncogene Proteins;Retinoblastoma Protein",
        "Doc_meshqualifiers":"metabolism;pathology;metabolism;pathology;analysis;analysis;analysis;analysis;analysis",
        "_version_":1605752757277425664},
      {
        "Doc_abstract":"We report a non-invasive mixed mucin-producing and squamous differentiated tumor of the uterine cervix. This tumor was composed of two cell types: mucin-producing cells and non-mucin-producing cells. These cells were intimately mixed with each other, and showed intraepithelial spreading. The mucin-producing cells showed signet-ring or columnar shapes, and were localized to the lower-to-upper epithelial layer. The non-mucin-producing cells had eosinophilic cytoplasms with a monotonous appearance through the epithelium. Mitosis was sometimes observed in both cell types. Immunohistochemically, both cell types were positive for p16(INK4A) . The non-mucin-producing cells were positive for p63 and 34E12, suggesting squamous differentiation. Although most mucin-producing cells were p63(-) , a few of them were p63(+)  and many 34E12 immunoreactive cells were found in the mucin-producing cells. This tumor was adenosquamous carcinoma in situ.",
        "Doc_title":"Mixed mucin-producing and squamous differentiated tumor of the uterine cervix: a report of a case as adenosquamous carcinoma in situ.",
        "Journal":"The journal of obstetrics and gynaecology research",
        "Do_id":"23294292",
        "Doc_ChemicalList":"Mucins",
        "Doc_meshdescriptors":"Adult;Carcinoma in Situ;Carcinoma, Adenosquamous;Cervix Uteri;Female;Humans;Mucins;Uterine Cervical Neoplasms",
        "Doc_meshqualifiers":"metabolism;pathology;metabolism;pathology;metabolism;pathology;metabolism;metabolism;pathology",
        "_version_":1605845087960432640},
      {
        "Doc_abstract":"Hypermethylation of CpG islands in gene promoters is associated with silencing of various tumour suppressor genes. Recent studies of colorectal and gastric carcinomas have defined a CpG island methylator phenotype (CIMP), which involves the targeting of multiple genes by promoter hypermethylation. In this study, methylation-specific polymerase chain reaction (PCR) was performed to study methylation of CpG islands in the promoters of the p16(INK4a), cadherin 1 (CDH1), and retinoic acid receptor-beta (RAR-beta) genes in 45 gastric carcinomas and to investigate whether CDH1 and RAR-beta promoter hypermethylation is associated with CIMP-positive gastric carcinoma. CpG island hypermethylation of the p16(INK4a), CDH1, and RAR-beta promoters was detected in 12 (27%), 26 (58%), and 24 (53%) of the 45 gastric carcinomas, respectively. Hypermethylation of the p16(INK4a) promoter was more common in intestinal type than in diffuse type gastric carcinomas (p = 0.0023; Fisher's exact test) and was inversely associated with p53 mutations (p = 0.0225; Fisher's exact test). However, CDH1 and RAR-beta promoter hypermethylation was observed more frequently in diffuse-scattered type gastric carcinoma than in other types (intestinal and diffuse-adherent types) (p = 0.0175 and p = 0.0335, respectively; Fisher's exact test) and was not associated with p53 mutation status. Moreover, hypermethylation of the CDH1 and RAR-beta promoters occurred concordantly (p < 0.0001; Fisher's exact test). These results suggest that at least two types of promoter methylation status are involved in the development of the intestinal (p16(INK4a) promoter hypermethylation) and diffuse-scattered types (CDH1 and RAR-beta promoter hypermethylation) of gastric carcinoma.",
        "Doc_title":"Distinct promoter hypermethylation of p16INK4a, CDH1, and RAR-beta in intestinal, diffuse-adherent, and diffuse-scattered type gastric carcinomas.",
        "Journal":"The Journal of pathology",
        "Do_id":"12210063",
        "Doc_ChemicalList":"CDH1 protein, human;Cadherins;DNA, Neoplasm;Neoplasm Proteins;Receptors, Retinoic Acid;retinoic acid receptor beta",
        "Doc_meshdescriptors":"Cadherins;CpG Islands;DNA Methylation;DNA, Neoplasm;Genes, p16;Genes, p53;Humans;Mutation;Neoplasm Proteins;Polymerase Chain Reaction;Promoter Regions, Genetic;Receptors, Retinoic Acid;Stomach Neoplasms",
        "Doc_meshqualifiers":"genetics;genetics;genetics;methods;genetics;genetics;pathology",
        "_version_":1605821083184791552},
      {
        "Doc_abstract":"Human T lymphocytes can be numerically expanded in vitro only to a limited extent. The cyclin-dependent kinase inhibitor p16(INK4a) is essential in the control of cellular proliferation, and its expression, in epithelial cells, is associated with irreversible growth arrest. Using long-term cultured CD8+ T lymphocytes, we have investigated the role of the p16/pRb pathway in the regulation of T cell proliferation and senescence. In this study, we describe at least two mechanisms that cause replicative growth arrest in cultured lymphocytes. The first one depends on the expression of p16(INK4a) and is directly responsible for the exit of a significant proportion of CD8+ T cells from the proliferative population. This induced p16 expression pattern is observed during each round of mitogen stimulation and is not related to activation-induced cell death. Importantly, knocking down p16(INK4a) expression allows increased proliferation of T cells. The second one is a phenomenon that resembles human fibroblast senescence, but is independent of p16(INK4a) and of telomere attrition. Interestingly, virtually all pRb proteins in the senescent population are found in the active form. Our data indicate that newly synthesized p16(INK4a) limits the proliferation of T lymphocytes that respond to mitogen, but is not required for the loss of mitogen responsiveness called senescence.",
        "Doc_title":"Mechanisms that limit the in vitro proliferative potential of human CD8+ T lymphocytes.",
        "Journal":"Journal of immunology (Baltimore, Md. : 1950)",
        "Do_id":"15749865",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;Mitogens;RNA, Small Interfering;Retinoblastoma Protein",
        "Doc_meshdescriptors":"Base Sequence;CD8-Positive T-Lymphocytes;Cell Aging;Cell Cycle;Cell Division;Cells, Cultured;Cyclin-Dependent Kinase Inhibitor p16;Genes, p16;Humans;In Vitro Techniques;Lymphocyte Activation;Mitogens;RNA, Small Interfering;Retinoblastoma Protein;Telomere",
        "Doc_meshqualifiers":"cytology;drug effects;immunology;metabolism;genetics;metabolism;pharmacology;genetics;metabolism;genetics",
        "_version_":1605846723795615744},
      {
        "Doc_abstract":"The aim of this study was to examine p16(INK4a) protein expression in ThinPrep (Cytyc Corporation, Marlborough, Mass) cervical specimens by using the CINtec p16(INK4a) Cytology Kit (Dako, Glostrup, Denmark). The ability of this assay to accurately identify underlying high-grade lesions was assessed by using follow-up biopsies and comparing these results with Hybrid Capture 2 (Digene, Gaithersburg, Md) high-risk HPV (hc(2)) results.;Three hundred ninety-eight residual ThinPrep samples were collected, and histological follow-up data were retrieved for abnormal cytology specimens. After preparation of a Papanicolaou-stained slide, a second slide was processed in preparation for p16(INK4a) immunostaining. High-risk human papillomavirus testing (hc(2)) was also performed.;Of the 163 cytologically abnormal samples, 6-month biopsy follow-up data were available for 45% of the specimens. At initial blinded evaluation, 21 of the 26 cases with cervical intraepithelial neoplasia (CIN) II/III follow-up were positive for p16(INK4a), yielding an overall diagnostic sensitivity of 81%; 29 of the 47 cases diagnosed as CIN I or less were p16(INK4a) negative, yielding a diagnostic specificity of 62%. In comparison, the hc(2) test results indicated a diagnostic sensitivity of 100% with a diagnostic specificity of 15%. After review of selected cases with CIN II/III follow-up, 25 of 26 slides were deemed to be positive for p16(INK4a), increasing the diagnostic sensitivity to 96%.;The CINtec p16(INK4a) Cytology Kit, in combination with ThinPrep cervical samples, allowed clear evaluation of p16(INK4a) protein overexpression. Diagnostic specificity of the CINtec p16(INK4a) assay was significantly improved relative to hc(2). To increase p16(INK4a) immunostaining in abnormal cells, a modified kit version with improved staining performance has been developed and is currently being evaluated.",
        "Doc_title":"Evaluation of p16INK4a expression in ThinPrep cervical specimens with the CINtec p16INK4a assay: correlation with biopsy follow-up results.",
        "Journal":"Cancer",
        "Do_id":"17334990",
        "Doc_ChemicalList":"Biomarkers, Tumor;Cyclin-Dependent Kinase Inhibitor p16",
        "Doc_meshdescriptors":"Biomarkers, Tumor;Biopsy;Cervical Intraepithelial Neoplasia;Cyclin-Dependent Kinase Inhibitor p16;Cytological Techniques;Female;Humans;Immunohistochemistry;Papanicolaou Test;Sensitivity and Specificity;Uterine Cervical Neoplasms;Vaginal Smears",
        "Doc_meshqualifiers":"analysis;diagnosis;metabolism;biosynthesis;diagnosis;metabolism",
        "_version_":1605893058053799936},
      {
        "Doc_abstract":"p53 acts as a potent tumor suppressor largely through its ability to induce cell death by apoptosis. Diverse cellular stress conditions, e.g., DNA damage, hypoxia, and oncogene activation, trigger p53-dependent apoptosis. ARF is a 14-kDa protein encoded by an alternative reading frame within the human INK4a locus that also encodes the p16 protein. ARF induces p53 in response to oncogene activation by preventing its degradation. This ensures the elimination of emerging tumor cells by p53-dependent apoptosis. p53 promotes apoptosis through multiple mechanisms, including transactivation of specific target genes, down-regulation of a distinct set of genes, and transcription-independent mechanisms. This may explain the frequent inactivation of ARF/p53 rather than downstream effectors during tumor development.",
        "Doc_title":"p53-induced apoptosis as a safeguard against cancer.",
        "Journal":"Biochemical and biophysical research communications",
        "Do_id":"10548481",
        "Doc_ChemicalList":"Tumor Suppressor Protein p53;ADP-Ribosylation Factors",
        "Doc_meshdescriptors":"ADP-Ribosylation Factors;Alternative Splicing;Apoptosis;DNA Damage;Genes, p53;Humans;Neoplasms;Oncogenes;Reading Frames;Tumor Suppressor Protein p53",
        "Doc_meshqualifiers":"genetics;metabolism;genetics;prevention & control;therapy;metabolism",
        "_version_":1605791800215207936},
      {
        "Doc_abstract":"To examine the association of cell cycle regulatory gene inactivation with human cell immortalization, we determined the expression status of INK4a, Rb, and WAF1/ CIP1, in eleven in vitro immortalized human cell lines, including fibroblasts and keratinocytes. Two human papillomavirus type 16 E6 expressing cell lines with telomerase activity, including a fibroblast cell line and a keratinocyte cell line, expressed no detectable p16(INK4a). These cell lines had a hyperphosphorylated pRb and reduced expression of p21(WAF1/CIP1). All of seven fibroblast cell lines immortalized either spontaneously or by (60)Co, X-rays, 4-nitroquinoline 1-oxide or aflatoxin B(1), maintaining their telomeres by the ALT (alternative lengthening of telomeres) pathway, displayed loss of expression of p16(INK4a) and hyperphosphorylation of pRb. Levels of p21(WAF1/CIP1) expression varied among the cell lines. Two fibroblast cell lines that became immortalized following infection with a retrovirus vector encoding human telomerase catalytic subunit (hTERT) cDNA were also accompanied by inactivation of p16(INK4a) and pRb pathways. Acquisition of telomerase activity alone was not sufficient for immortalization of these cell lines. Taken together, all the cell lines including fibroblasts and keratinocytes, with either telomerase activity or the ALT pathway for telomere maintenance showed loss of expression of p16(INK4a) and hyperphosphorylation of pRb. These demonstrate the association of inactivation of both p16(INK4a) and pRb with immortalization of human cells including fibroblasts and epithelial cells and telomerase-positive cells and ALT-positive cells.",
        "Doc_title":"Association of p16(INK4a) and pRb inactivation with immortalization of human cells.",
        "Journal":"Carcinogenesis",
        "Do_id":"12507935",
        "Doc_ChemicalList":"CDKN1A protein, human;Carcinogens;Cobalt Radioisotopes;Cyclin-Dependent Kinase Inhibitor p16;Cyclin-Dependent Kinase Inhibitor p21;Cyclins;DNA, Complementary;DNA-Binding Proteins;E6 protein, Human papillomavirus type 16;Oncogene Proteins, Viral;RNA, Messenger;Repressor Proteins;Retinoblastoma Protein;4-Nitroquinoline-1-oxide;Aflatoxin B1;Telomerase",
        "Doc_meshdescriptors":"4-Nitroquinoline-1-oxide;Aflatoxin B1;Carcinogens;Cell Cycle;Cell Line;Cell Transformation, Neoplastic;Cobalt Radioisotopes;Cyclin-Dependent Kinase Inhibitor p16;Cyclin-Dependent Kinase Inhibitor p21;Cyclins;DNA, Complementary;DNA-Binding Proteins;Fibroblasts;Humans;Keratinocytes;Oncogene Proteins, Viral;Phosphorylation;RNA, Messenger;Repressor Proteins;Retinoblastoma Protein;Reverse Transcriptase Polymerase Chain Reaction;Telomerase;Telomere;Time Factors;Tumor Cells, Cultured;X-Rays",
        "Doc_meshqualifiers":"metabolism;metabolism;metabolism;metabolism;metabolism;metabolism;metabolism;metabolism;metabolism",
        "_version_":1605898453202763776},
      {
        "Doc_abstract":"Arf encodes an important tumor suppressor, p19(Arf), which also plays a critical role to control hyperplasia in the primary vitreous during mouse eye development. In the absence of Arf, mice are born blind and display a phenotype closely mimicking severe forms of the human eye disease, persistent hyperplastic primary vitreous (PHPV). In this report, we characterize p19(Arf) expression in perivascular cells that normally populate the primary vitreous and express the Arf promoter. Using a new exvivo model, we show that these cells respond to exogenous Tgf, despite being isolated at a time when Tgf has already turned on the Arf promoter. Treatment of the cells with PDGF-B ligand doubles the population of cells in S-phase and ectopic expression of Arf blunts that effect. We show this effect is mediated through Pdgfr as expression of Arf represses expression of Pdgfr mRNA and protein to approximately 60%. p53 is not required for Arf-dependent blockade of PDGF-B driven proliferation and repression of Pdgfr protein as ectopic expression of Arf is still able to inhibit the 2-fold increase in the S-phase fraction of cells upon treatment with PDGF-B. Finally, induction of mature miR-34a, a microRNA previously identified to be regulated by p19(Arf) does not depend on p53 while the expression of the primary transcript does require p53. These data corroborate that, as invivo, p19(Arf) functions to inhibit PDGF-B driven proliferation exvivo. ",
        "Doc_title":"p19(Arf) limits primary vitreous cell proliferation driven by PDGF-B.",
        "Journal":"Experimental eye research",
        "Do_id":"26778750",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605818717909811203},
      {
        "Doc_abstract":"Combined disruption of the ARF gene and the p53 gene causes mouse predisposition to tumors of a wider variety and at a higher frequency than disruption of the p53 gene, indicating that the ARF gene has p53-independent anti-tumor function in addition to p53-dependent function. Coincidentally with this notion, ectopic expression of the p19(ARF) induces apoptosis for wild-type mouse embryo fibroblasts which have been immortalized by introduction of the SV40 virus genome (SV40-MEFs). The protein expression levels of p53, p21(Cip1), and Bax were not upregulated by ectopic expression of p19(ARF) in SV40-MEFs, indicating that expression of p19(ARF) induced apoptosis through p53-independent pathways in this system. Ectopic expression of p19(ARF) induced prominent apoptosis even in SV40-Bak-/-MEFs. In contrast, expression of p19(ARF) induced only a very low grade of apoptosis in Bax-/- or Bax-/-/Bak-/-SV40-MEFs. Remarkable attenuation of p19(ARF)-induced apoptosis by disruption of the Bax gene thus leads to the conclusion that Bax plays a major role in p53-independent apoptosis induced by p19(ARF).",
        "Doc_title":"p19ARF-induced p53-independent apoptosis largely occurs through BAX.",
        "Journal":"Biochemical and biophysical research communications",
        "Do_id":"14652011",
        "Doc_ChemicalList":"BAK1 protein, human;BAX protein, human;Bak1 protein, mouse;Bax protein, mouse;Cdkn2a protein, mouse;Cyclin-Dependent Kinase Inhibitor p16;Membrane Proteins;Proto-Oncogene Proteins;Proto-Oncogene Proteins c-bcl-2;Tumor Suppressor Protein p14ARF;Tumor Suppressor Protein p53;bcl-2 Homologous Antagonist-Killer Protein;bcl-2-Associated X Protein;Staurosporine",
        "Doc_meshdescriptors":"Animals;Apoptosis;Cell Cycle;Cells, Cultured;Cyclin-Dependent Kinase Inhibitor p16;Dose-Response Relationship, Drug;Fibroblasts;Humans;Kidney;Membrane Proteins;Mice;Proto-Oncogene Proteins;Proto-Oncogene Proteins c-bcl-2;Staurosporine;Tumor Suppressor Protein p14ARF;Tumor Suppressor Protein p53;bcl-2 Homologous Antagonist-Killer Protein;bcl-2-Associated X Protein",
        "Doc_meshqualifiers":"drug effects;physiology;physiology;cytology;drug effects;metabolism;embryology;metabolism;metabolism;metabolism;pharmacology;metabolism;metabolism",
        "_version_":1605741977087770627},
      {
        "Doc_abstract":"Homozygous and heterozygous deletions involving chromosome 9p21 have been reported in a variety of primary human tumors in vivo, and point mutations have been reported in melanoma cell lines in vitro within a probable tumor suppressor gene, MTS1, located at chromosome 9p21. We describe six sequence alterations occurring among twenty-four primary esophageal squamous carcinomas and nineteen primary esophageal adenocarcinomas analyzed by DNA sequencing of MTS1 exon 2. Nucleotide substitutions were observed in five squamous cell carcinomas and in one adenocarcinoma. Two occurred in the germline, while four were somatic alterations. All six nucleotide changes resulted in marked alterations in amino acid sequence. Four were nonsense mutations leading to premature termination codons; nucleotide substitutions identical to two of these stop codons were previously reported in other tumor types. Loss of heterozygosity occurred in all five informative (constitutionally heterozygous) cases in which a sequence alteration was present. Esophageal cancer is one primary human tumor in which MTS1 constitutes an apparent target of heterozygous or homozygous deletions occurring at chromosome 9p21.",
        "Doc_title":"The MTS1 gene is frequently mutated in primary human esophageal tumors.",
        "Journal":"Oncogene",
        "Do_id":"7970734",
        "Doc_ChemicalList":"Carrier Proteins;Cyclin-Dependent Kinase Inhibitor p16;DNA Primers",
        "Doc_meshdescriptors":"Base Sequence;Carcinoma, Squamous Cell;Carrier Proteins;Cyclin-Dependent Kinase Inhibitor p16;DNA Primers;Esophageal Neoplasms;Genes, Tumor Suppressor;Humans;Molecular Sequence Data;Point Mutation",
        "Doc_meshqualifiers":"genetics;genetics;genetics",
        "_version_":1605758461904158720},
      {
        "Doc_abstract":"Loss of heterozygosity (LOH) studies indicate that allelic loss associated with the development of head and neck of squamous cell carcinoma occurs most frequently at 9p21-22. However, the target of chromosome 9p21-22 loss has been the source of significant debate. A putative tumor suppressor gene, p16, has been identified at the 9p21 location, but genetic alterations of p16 located in this region are unusual. To refine the hot spots of LOH on chromosome 9p13-23 will be helpful to find other putative tumor suppressor genes in laryngeal squamous cell carcinoma.;The sections of paraffin-embedded tumor tissues were microdissected to enrich for neoplastic cells. LOH on 9p13-23 was analyzed in a set of 42 paired blood and tumor samples using polymerase chain reaction (PCR) with 13 highly polymorphic microsatellite markers.;Of the 42 total tumors, 41(97.6%) showed LOH in at least one of the microsatellite markers tested at the chromosome 9p13-23 region. The most frequently deleted marker was D9S162 with in 17 of 19 (89.5%) informative samples. The marker D9S171, which is located in 9p21, had LOH detected in 12 of 15 informative cases (80.0%). LOH at the D9S1748 marker (closest to the p16 gene locus) was detected in 18 of 36 informative cases (50.0%). Fine deletion mapping also revealed two minimal regions of LOH encompassing markers D9S161-D9S171 at 9p21 and IFNA-D9S162 at 9p22-23.;These findings imply the high frequency of LOH at 9p13-23 in laryngeal squamous cell carcinoma and the presence of at least two as yet unidentified tumor suppressor genes in 9p13-23 region. Those putative tumor suppressor genes may become inactivated during the progression of the laryngeal squamous cell carcinoma.",
        "Doc_title":"[Loss of heterozygosity on chromosome 9p13-23 in microdissected laryngeal squamous cell carcinoma by microsatellite analysis].",
        "Journal":"Zhonghua er bi yan hou ke za zhi",
        "Do_id":"12761947",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Carcinoma, Squamous Cell;Chromosomes, Human, Pair 9;Female;Genes, Tumor Suppressor;Genes, p16;Humans;Laryngeal Neoplasms;Loss of Heterozygosity;Male;Microsatellite Repeats;Middle Aged",
        "Doc_meshqualifiers":"genetics;genetics;genetics",
        "_version_":1605874518973218816},
      {
        "Doc_abstract":"Many patients with human papillomavirus (HPV)-related head and neck squamous cell carcinoma present initially with cervical nodal metastasis. Fine needle aspiration (FNA) of the nodal disease might be the only diagnostic material available for p16 immunohistochemistry (IHC) and HPV testing. The current study aims to evaluate p16 IHC in FNA and establish guidelines for its interpretation. The percentage and intensity of p16 IHC staining were examined in 60 matched FNA and surgical cases. Cytomorphologic features were included in the analysis. p16 IHC staining was correlated with the results seen in the surgical specimens and with HPV in situ hybridization (ISH). Analysis of different thresholds demonstrated that the threshold of 10% p16 tumor cell positivity had the best overall concordance rate with surgical p16 IHC ( = 0.650) and with FNA HPV-ISH ( = 0.714). Applying the recommended p16 positivity threshold for surgical specimens (70%) on FNA materials resulted in low sensitivity (39%) and low negative predictive value (26%). In comparison with p16 IHC in surgical specimens, 6/46 FNA cases (13%) were falsely negative for p16. All 6 cases were associated with necrotic background, two (33%) lacked large tumor clusters, and one (17%) had low cellularity. The recommended threshold for p16 IHC on surgical specimens should not be used in cytology materials. The cutoff value for p16 immunostain in FNA specimens showing best results in our series is 10%. When p16 IHC is negative in FNA specimens, a repeat stain on a surgical specimen is recommended to avoid a false-negative diagnosis. ",
        "Doc_title":"The utility of p16 immunostaining in fine needle aspiration in p16-positive head and neck squamous cell carcinoma.",
        "Journal":"Human pathology",
        "Do_id":"27105759",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605762779575222272},
      {
        "Doc_abstract":"Although human papillomavirus (HPV)-related oropharyngeal carcinomas (HPV-OPCs) are generally regarded as \"poorly differentiated,\" they actually maintain a close resemblance to the lymphoepithelium of the tonsillar crypts from which they arise: they are basaloid, exhibit minimal keratinization, and are often permeated by lymphocytes. In rare cases, the presence of cilia in a primary HPV-OPC and their persistence in lymph node metastasis can confound the distinction between a benign and malignant process. Three cases of ciliated HPV-OPCs were identified from the archives of The Johns Hopkins Head and Neck Pathology consultation service. HPV status was determined using p16 immunohistochemistry and high-risk HPV in situ hybridization. All 3 patients presented with a cystic lymph node metastasis without a known primary carcinoma. One metastasis was originally diagnosed as a branchial cleft cyst only to regionally recur 7 years later. In 2 cases, a primary HPV-OPC was found in the tonsil. The carcinomas exhibited both nonkeratinizing squamous epithelium and cystic/microcystic spaces lined by ciliated columnar cells. Both the squamous and ciliated cells were HPV positive. This report draws attention to a novel variant of HPV-related head and neck cancer that exhibits ciliated columnar cells. This variant challenges prevailing notions that: (1) HPV-OPCs are uniformly poorly differentiated cancers; (2) cilia are an infallible feature of benignancy; and (3) presence of cilia is a reliable criterion for establishing branchial cleft origin when dealing with cystic lesions of the lateral neck. ",
        "Doc_title":"Ciliated HPV-related Carcinoma: A Well-differentiated Form of Head and Neck Carcinoma That Can Be Mistaken for a Benign Cyst.",
        "Journal":"The American journal of surgical pathology",
        "Do_id":"26457358",
        "Doc_ChemicalList":"Biomarkers, Tumor;Cyclin-Dependent Kinase Inhibitor p16;DNA, Viral;RNA, Viral",
        "Doc_meshdescriptors":"Aged;Biomarkers, Tumor;Biopsy;Carcinoma;Cell Differentiation;Cilia;Cyclin-Dependent Kinase Inhibitor p16;Cysts;DNA, Viral;Diagnosis, Differential;Diagnostic Errors;Female;Human Papillomavirus DNA Tests;Humans;Immunohistochemistry;In Situ Hybridization;Lymphatic Metastasis;Male;Middle Aged;Oropharyngeal Neoplasms;Papillomaviridae;Papillomavirus Infections;Predictive Value of Tests;RNA, Viral",
        "Doc_meshqualifiers":"analysis;chemistry;secondary;therapy;virology;pathology;analysis;pathology;genetics;chemistry;pathology;therapy;virology;genetics;pathology;therapy;virology;genetics",
        "_version_":1605818583254827009},
      {
        "Doc_abstract":"The objective of this study is to evaluate the promoter methylation status of the p14ARF in esophageal squamous cell carcinoma (ESCC). Cell lines were treated with the demethylation agent 5-aza-2'-deoxycytidine, and p14ARF messenger RNA (mRNA) expression was detected by reverse transcription-polymerase chain reaction. We analyzed the methylation status of p14ARF promoter by methylation-specific polymerase chain reaction in 50 ESCC and their noncarcinoma tissues. Then demethylation caused by 5-aza-2'-deoxycytidine increased the p14ARF mRNA expression level in esophagus cancer cell lines. p14ARF methylation was found in 48% (24 of 50) of ESCC patients but only in 18% (9 of 50) corresponding noncarcinoma tissues (P = 0.001). There was a statistically significant correlation between the presence of methylation and tumor metastasis (P < 0.001). The p14ARF mRNA was lower in ESCC tissues than nontumor tissues (mean  standard deviation, 0.47  0.32 vs. 1.40  0.58; P = 0.002). Meanwhile, a signification association was found between the methylation status of p14ARF promoter and p14ARF mRNA expression in tissues (P < 0.05). The aberrant promoter methylation of p14ARF is a common phenomenon in ESCC, which may be an important mechanism of downregulating p14ARF mRNA expression. ",
        "Doc_title":"p14ARF repression induced by promoter methylation associated with metastasis in esophageal squamous cell carcinoma.",
        "Journal":"Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus",
        "Do_id":"22973996",
        "Doc_ChemicalList":"RNA, Messenger;Tumor Suppressor Protein p14ARF",
        "Doc_meshdescriptors":"Base Sequence;Carcinoma, Squamous Cell;Cell Line, Tumor;DNA Methylation;Esophageal Neoplasms;Female;Gene Expression Regulation, Neoplastic;Genes, p16;Humans;Male;Molecular Sequence Data;Promoter Regions, Genetic;RNA, Messenger;Reverse Transcriptase Polymerase Chain Reaction;Tumor Suppressor Protein p14ARF",
        "Doc_meshqualifiers":"genetics;genetics;genetics;metabolism;genetics;metabolism",
        "_version_":1605875055091253248},
      {
        "Doc_abstract":"Senescence, the state of permanent cell cycle arrest, has been associated with endothelial cell dysfunction and atherosclerosis. The cyclin dependent kinase inhibitors p21(CIP1/WAF1) and p16(INK4a) govern the G(1)/S cell cycle checkpoint and are essential for determining whether a cell enters into an arrested state. The homeodomain transcription factor MEOX2 is an important regulator of vascular cell proliferation and is a direct transcriptional activator of both p21(CIP1/WAF1) and p16(INK4a). MEOX1 and MEOX2 have been shown to be partially functionally redundant during development, suggesting that they regulate similar target genes in vivo. We compared the ability of MEOX1 and MEOX2 to activate p21(CIP1/WAF1) and p16(INK4a) expression and induce endothelial cell cycle arrest. Our results demonstrate for the first time that MEOX1 regulates the MEOX2 target genes p21(CIP1/WAF1) and p16(INK4a). In addition, increased expression of either of the MEOX homeodomain transcription factors leads to cell cycle arrest and endothelial cell senescence. Furthermore, we show that the mechanism of transcriptional activation of these cyclin dependent kinase inhibitor genes by MEOX1 and MEOX2 is distinct. MEOX1 and MEOX2 activate p16(INK4a) in a DNA binding dependent manner, whereas they induce p21(CIP1/WAF1) in a DNA binding independent manner.",
        "Doc_title":"Mechanisms of MEOX1 and MEOX2 regulation of the cyclin dependent kinase inhibitors p21 and p16 in vascular endothelial cells.",
        "Journal":"PloS one",
        "Do_id":"22206000",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;Cyclin-Dependent Kinase Inhibitor p21;Homeodomain Proteins;MEOX2 protein, human;Meox1 protein, mouse;Sp1 Transcription Factor;DNA",
        "Doc_meshdescriptors":"Animals;Base Sequence;Binding Sites;Cell Aging;Cell Proliferation;Cyclin-Dependent Kinase Inhibitor p16;Cyclin-Dependent Kinase Inhibitor p21;DNA;Endothelial Cells;HEK293 Cells;Homeodomain Proteins;Human Umbilical Vein Endothelial Cells;Humans;Intracellular Space;Mice;Promoter Regions, Genetic;Protein Transport;Sp1 Transcription Factor;Transcription, Genetic;Transcriptional Activation",
        "Doc_meshqualifiers":"genetics;metabolism;genetics;metabolism;metabolism;cytology;metabolism;metabolism;cytology;metabolism;metabolism;genetics;metabolism",
        "_version_":1605831463081607168},
      {
        "Doc_abstract":"Cyclin-dependent kinase inhibitors (CDKIs) can be classified into two groups based on the structure of the proteins. One group includes the p21 (CIP1, WAF1, CAP20), p27 (Kip1), and p57 (Kip2) CDKIs, which contain a homologous amino-terminal cyclin-dependent kinase (cdk) inhibitory domain. The p16 (INK4A), p15 (INK4B), and p18 (INK4C) CDKIs, which have an ankyrin repeat motifs, belong to the other group. The p16 and p15 CDKI genes are very frequently altered in a variety of cancers including hematopoietic malignancies. The p19 (INK4D) gene is a newly cloned CDKI which belongs to the latter group. To determine if p19 genetic alterations play a role in hematopoietic malignancies, we examined DNA from 45 childhood newly diagnosed acute lymphocytic leukemias (ALLs), 30 acute myeloblastic leukemias (AMLs), 10 chronic myelocytic leukemias (CMLs), 45 adult T cell leukemias (ATLs), 70 non-Hodgkin's lymphomas (NHLs), and 20 multiple myelomas (MM) as well as 14 ALL, 20 AML, two ATL, and five lymphoma cell lines. Using Southern blot analysis, one homozygous deletion of the p19 gene was detected in a human immunodeficiency virus (HIV)-related Burkitt-like lymphoma sample. No point mutations in any of the samples were found by polymerase chain reaction-single strand conformation polymorphism (PCR-SSCP) analysis. Our investigation suggests that alterations of p19 do not play an important role in the development of most hematopoietic malignancies.",
        "Doc_title":"Alterations of the cyclin-dependent kinase inhibitor p19 (INK4D) is rare in hematopoietic malignancies.",
        "Journal":"Leukemia",
        "Do_id":"8946928",
        "Doc_ChemicalList":"CDKN2D protein, human;Carrier Proteins;Cell Cycle Proteins;Cyclin-Dependent Kinase Inhibitor p16;Cyclin-Dependent Kinase Inhibitor p19;DNA, Neoplasm",
        "Doc_meshdescriptors":"Base Sequence;Blotting, Southern;Carrier Proteins;Cell Cycle Proteins;Cyclin-Dependent Kinase Inhibitor p16;Cyclin-Dependent Kinase Inhibitor p19;DNA, Neoplasm;Hematologic Neoplasms;Humans;Molecular Sequence Data;Point Mutation;Polymerase Chain Reaction;Polymorphism, Single-Stranded Conformational;Tumor Cells, Cultured",
        "Doc_meshqualifiers":"genetics;analysis;genetics;genetics",
        "_version_":1605908450183741440},
      {
        "Doc_abstract":"The p16(INK4A) protein (p16) is a cyclin-dependent kinase inhibitor that arrests the cell cycle in the G1 phase.;To explore the potential of p16 as a predictive marker for lymph node (LN) metastasis and prognosis in cervical carcinomas.;145 patients diagnosed with FIGO stage I to IV cervical carcinoma were studied; 95 underwent LN dissection. The expression of p16 protein was studied by immunohistochemistry using tissue microarrays.;Overexpression of p16 was seen in 108 of 145 (74.5%) invasive carcinomas. There was a significant correlation between p16 expression and LN metastasis (p=0.007). Patients with p16 overexpression had poorer survival than patients with p16 underexpression (59.3% vs 83.8% 5-year survival rate, log-rank p=0.015). In univariate analysis, p16 expression was a significant predictor of survival (RR 2.76, p=0.02).;Results suggest that p16 expression is an important predictive factor of LN metastasis in cervical cancer patients. Moreover, p16 overexpression is associated with a poor prognosis. Therefore, immunohistochemical evaluation of p16 expression is of potential value for treatment planning in cervical carcinomas.",
        "Doc_title":"P16INK4A overexpression predicts lymph node metastasis in cervical carcinomas.",
        "Journal":"Journal of clinical pathology",
        "Do_id":"22011452",
        "Doc_ChemicalList":"Biomarkers, Tumor;Cyclin-Dependent Kinase Inhibitor p16",
        "Doc_meshdescriptors":"Adenocarcinoma;Adult;Aged;Aged, 80 and over;Biomarkers, Tumor;Carcinoma;Carcinoma, Adenosquamous;Carcinoma, Squamous Cell;Cyclin-Dependent Kinase Inhibitor p16;Female;Humans;Lymph Node Excision;Lymph Nodes;Lymphatic Metastasis;Middle Aged;Neoplasm Staging;Pelvis;Prognosis;Survival Analysis;Tissue Array Analysis;Uterine Cervical Neoplasms",
        "Doc_meshqualifiers":"metabolism;mortality;pathology;surgery;metabolism;metabolism;mortality;pathology;surgery;metabolism;mortality;pathology;surgery;metabolism;mortality;pathology;surgery;metabolism;metabolism;pathology;surgery;metabolism;mortality;pathology;surgery",
        "_version_":1605851464794636288},
      {
        "Doc_abstract":"Expression of the tumor suppressor p16(INK4a) after stable transfection can restore the susceptibility of epithelial tumor cells to anoikis. This property is linked to increases in the expression and cell-surface presence of the fibronectin receptor. Considering its glycan chains as pivotal signals, we assumed an effect of p16(INK4a) on glycosylation. To test this hypothesis for human Capan-1 pancreatic carcinoma cells, we combined microarray for selected glycosyltransferase genes with 2D chromatographic glycan profiling and plant lectin binding. Major differences between p16-positive and control cells were detected. They concerned expression of beta1,4-galactosyltransferases (down-regulation of beta1,4-galactosyltransferases-I/V and up-regulation of beta1,4-galactosyltransferase-IV) as well as decreased alpha2,3-sialylation of O-glycans and alpha2,6-sialylation of N-glycans. The changes are compatible with increased beta(1)-integrin maturation, subunit assembly and binding activity of the alpha(5)beta(1)-integrin. Of further functional relevance in line with our hypothesis, we revealed differential reactivity towards endogenous lectins, especially galectin-1. As a result of reduced sialylation, the cells' capacity to bind galectin-1 was enhanced. In parallel, the level of transcription of the galectin-1 gene increased conspicuously in p16(INK4a)-positive cells, and even figured prominently in a microarray on 1996 tumor-associated genes and in proteomic analysis. The cells therefore gain optimal responsiveness. The correlation between genetically modulated galectin-1 levels and anoikis rates in engineered transfectants inferred functional significance. To connect these findings to the fibronectin receptor, galectin-1 was shown to be co-immunoprecipitated. We conclude that p16(INK4a) orchestrates distinct aspects of glycosylation that are relevant for integrin maturation and reactivity to an endogenous effector as well as the effector's expression. This mechanism establishes a new aspect of p16(INK4a) functionality.",
        "Doc_title":"Tumor suppressor p16INK4a--modulator of glycomic profile and galectin-1 expression to increase susceptibility to carbohydrate-dependent induction of anoikis in pancreatic carcinoma cells.",
        "Journal":"The FEBS journal",
        "Do_id":"17535296",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;Galectin 1;Lectins;RNA, Messenger",
        "Doc_meshdescriptors":"Anoikis;Cell Membrane;Chromatography;Cyclin-Dependent Kinase Inhibitor p16;Galectin 1;Gene Expression Profiling;Gene Expression Regulation, Neoplastic;Genetic Predisposition to Disease;Glycosylation;Humans;Lectins;Oligonucleotide Array Sequence Analysis;Pancreatic Neoplasms;Proteomics;RNA, Messenger",
        "Doc_meshqualifiers":"metabolism;physiology;biosynthesis;chemistry;genetics;metabolism;metabolism",
        "_version_":1605820802435907584},
      {
        "Doc_abstract":"Immune cell infiltrates are important determinants of colorectal cancer (CRC) outcome. Their presence may be driven by tumour or host-specific factors. From previous studies in mice, senescence, a state of cell cycle arrest, may moderate tumour progression through upregulation of antitumour immune responses. The relationships between senescence and immune infiltrates have not previously been studied in humans. We explore whether a marker of senescence (p16(ink4a)) in combination with low level expression of a proliferation marker (ki-67) relate to T cell infiltrates in CRC, and whether p16(ink4a), Ki-67 and immune infiltrates have similar prognostic value.;Immunostaining of p16(inka) and Ki-67 was performed within a CRC tissue microarray. Nuclear p16(inka) and Ki-67 were categorised as high/low. T-cell markers, CD3, CD45RO, CD8 and FOXP3 were scored separately as high/low grade in three areas of the tumour: the invasive margin (IM), tumour stroma and cancer cell nests (CCNs). results: Two hundred and thirty stage I-III cancers were studied. High nuclear p16(ink4a) was expressed in 63% and high proliferation (Ki-67 >15%) in 61%. p16(ink4a) expression was associated with reduced CD45RO+ cells at the IM (P<0.05) and within the stroma (P<0.05) and reduced CD8+ cells at the IM (P<0.01). A low Ki-67 proliferative index was associated with reduced density of CD3+ cells in CCNs (P<0.01), reduced CD45RO+ cells at the IM (P<0.05) and within the CCNs (P<0.001), reduced FOXP3+ cells at the IM (P<0.001), within the stroma (P=0.001) and within CCNs (P<0.001) and reduced CD8+ cells at the IM (P<0.05) and within the CCNs (P<0.05). Tumours with both a low proliferative index and expression of p16(ink4a) demonstrated similar consistent relationships with reduced densities of T-cell infiltrates. On multivariate analysis, TNM stage (P<0.001), low CD3 cells at the IM (P=0.014), low CD8 cells at the IM (P=0.037), low proliferation (Ki-67; P=0.013) and low senescence (p16(ink4a); P=0.002) were independently associated with poorer cancer survival.;Senescence, proliferation and immune cell infiltrates are independent prognostic factors in CRC. Although related to survival, p16(ink4a)-associated senescence is not associated with an upregulation of antitumour T-cell responses.",
        "Doc_title":"The in situ local immune response, tumour senescence and proliferation in colorectal cancer.",
        "Journal":"British journal of cancer",
        "Do_id":"24022192",
        "Doc_ChemicalList":"Ki-67 Antigen;Neoplasm Proteins;P16 protein, human",
        "Doc_meshdescriptors":"Aged;Cell Aging;Cell Growth Processes;Colorectal Neoplasms;Female;Humans;Immunohistochemistry;Ki-67 Antigen;Lymphocytes, Tumor-Infiltrating;Male;Middle Aged;Neoplasm Proteins;Neoplasm Staging;Paraffin Embedding;T-Lymphocytes;Tissue Array Analysis",
        "Doc_meshqualifiers":"immunology;immunology;immunology;pathology;biosynthesis;immunology;immunology;biosynthesis;immunology;immunology",
        "_version_":1605784072695578624},
      {
        "Doc_abstract":"The INK4a/ARF locus, which encodes the two distinct proteins p16(INK4a) and p14(ARF), is frequently altered in various hematological malignancies as well as in other types of cancers in humans. In this study, we surveyed tumors that had spontaneously developed in Ink4a/Arf-deficient mice with an inbred FVB/NJ genetic background. We found that an Ink4a/Arf-deficiency exerted more severe effects on the induction of hematopoietic malignancies in mice with an inbred FVB/NJ genetic background than in mice with a mixed genetic background. We also provided the evidence that this prevalence of hematopoietic malignancies in Ink4a/Arf-deficient mice is associated with the upregulated expressions of Stat5 and its transcriptional target, Bcl-x(L), both of which are involved in the regulation of hematopoiesis. These results suggest a possible implication of the Ink4a/Arf locus in the control of hematopoietic pathways by negatively regulating the Stat5-signalling pathways.",
        "Doc_title":"Hematopoietic malignancies associated with increased Stat5 and Bcl-x(L) expressions in Ink4a/Arf-deficient mice.",
        "Journal":"Mechanisms of ageing and development",
        "Do_id":"15888328",
        "Doc_ChemicalList":"Bcl2l1 protein, mouse;Cyclin-Dependent Kinase Inhibitor p16;DNA-Binding Proteins;Milk Proteins;Proto-Oncogene Proteins c-bcl-2;STAT5 Transcription Factor;Trans-Activators;Tumor Suppressor Protein p14ARF;bcl-X Protein",
        "Doc_meshdescriptors":"Animals;Cyclin-Dependent Kinase Inhibitor p16;DNA-Binding Proteins;Gene Expression Regulation, Neoplastic;Hematologic Neoplasms;Hematopoiesis;Mice;Mice, Knockout;Milk Proteins;Proto-Oncogene Proteins c-bcl-2;STAT5 Transcription Factor;Signal Transduction;Trans-Activators;Tumor Suppressor Protein p14ARF;bcl-X Protein",
        "Doc_meshqualifiers":"deficiency;biosynthesis;genetics;genetics;metabolism;biosynthesis;biosynthesis;genetics;biosynthesis;deficiency",
        "_version_":1605891630958641152},
      {
        "Doc_abstract":"Cell cycle regulatory proteins are important candidates for therapeutic tumour suppressors. Adenovirus vectors were constructed to overexpress cyclin kinase inhibitors p16INK4A, p18INK4C, p19INK4D, p21(WAF1/CIP1) and p27KIP1 under the control of the murine cytomegalovirus immediate early gene promoter. These vectors directed the efficient expression of each of the cyclin kinase inhibitors and induced growth arrest, inhibited DNA synthesis, and prevented phosphorylation of the retinoblastoma protein (pRb) in cell lines expressing functional pRb. In pRb-deficient cells, expression of the cyclin kinase inhibitors was not effective in inhibiting DNA replication or growth arrest. Interestingly, three of the cyclin kinase inhibitors, p16, p18 and p27 were found to induce apoptotic death in transduced HeLa and A549 cells. When the vectors were tested for their ability to inhibit tumorigenicity in a polyomavirus middle T antigen model of murine breast carcinoma, expression of the cyclin kinase inhibitors resulted in a delay in tumour formation that varied from several weeks for the p19 expressing vector to greater than 25 weeks for the p27 expressing vector. When tumours were injected directly with the adenovirus vectors expressing the cyclin kinase inhibitors, only treatment with the vector expressing p16 resulted in a delay in tumour growth.",
        "Doc_title":"Comparison of the effectiveness of adenovirus vectors expressing cyclin kinase inhibitors p16INK4A, p18INK4C, p19INK4D, p21(WAF1/CIP1) and p27KIP1 in inducing cell cycle arrest, apoptosis and inhibition of tumorigenicity.",
        "Journal":"Oncogene",
        "Do_id":"10208428",
        "Doc_ChemicalList":"CDKN1A protein, human;CDKN2C protein, human;CDKN2D protein, human;Carrier Proteins;Cell Cycle Proteins;Cyclin-Dependent Kinase Inhibitor p16;Cyclin-Dependent Kinase Inhibitor p18;Cyclin-Dependent Kinase Inhibitor p19;Cyclin-Dependent Kinase Inhibitor p21;Cyclins;Enzyme Inhibitors;Microtubule-Associated Proteins;Retinoblastoma Protein;Tumor Suppressor Proteins;Cyclin-Dependent Kinase Inhibitor p27;Cyclin-Dependent Kinases",
        "Doc_meshdescriptors":"Adenocarcinoma;Adenoviruses, Human;Animals;Apoptosis;Blotting, Western;Carcinogenicity Tests;Carrier Proteins;Cell Cycle;Cell Cycle Proteins;Cell Division;Cell Line, Transformed;Cyclin-Dependent Kinase Inhibitor p16;Cyclin-Dependent Kinase Inhibitor p18;Cyclin-Dependent Kinase Inhibitor p19;Cyclin-Dependent Kinase Inhibitor p21;Cyclin-Dependent Kinase Inhibitor p27;Cyclin-Dependent Kinases;Cyclins;Enzyme Inhibitors;Genetic Vectors;HeLa Cells;Humans;Mammary Neoplasms, Experimental;Microtubule-Associated Proteins;Phosphorylation;Retinoblastoma Protein;Transgenes;Tumor Suppressor Proteins",
        "Doc_meshqualifiers":"biosynthesis;genetics;biosynthesis;genetics;antagonists & inhibitors;biosynthesis;genetics;biosynthesis;genetics;metabolism",
        "_version_":1605820464330964992},
      {
        "Doc_abstract":"p16(INK4a) is frequently altered in human cancer, often through epigenetically mediated transcriptional silencing. However, little is known about the transcriptional regulation of this gene. To learn more about such control, we initiated studies of proteins that bind to the promoter in cancer cells that do, and do not, express the gene. We identify RNA helicase A (RHA) as a protein that binds much better to the p16(INK4a) promoter in the expressing cells. RHA has not previously been characterized to manifest sequence-specific DNA interaction but does so to the sequence 5' CGG ACC GCG TGC GC 3' in the p16(INK4a) promoter. The Drosophila homologue to RHA, maleless (Mle), functions in the fly for 2-fold activation of male X-chromosome genes. In our experimental setting, RHA induces a similar modest up-regulation of the p16(INK4a) promoter that is dependent upon its sequence-specific interaction. Mle colocalizes with hyperacetylated H4Ac16 on the X-chromosome and some autosomal loci. The decreased binding of RHA to p16(INK4a) in our cells, where the gene is transcriptionally inactive, is associated with decreased amounts of RHA that immunoprecipitate with acetylated lysine antibodies. Finally, we show RHA to be a cellular substrate for caspase-3, which decreases its sequence-specific binding to p16(INK4a) by cleavage of the N terminus. Thus, we have identified a new protein interaction with the p16(INK4a) promoter that involves an important protein for transcriptional modulation. This interaction is decreased in cancer cells, where this gene is aberrantly transcriptionally silent.",
        "Doc_title":"Sequence-specific DNA binding activity of RNA helicase A to the p16INK4a promoter.",
        "Journal":"The Journal of biological chemistry",
        "Do_id":"11038348",
        "Doc_ChemicalList":"Autoantigens;Cyclin-Dependent Kinase Inhibitor p16;DNA-Binding Proteins;Neoplasm Proteins;Recombinant Proteins;DHX9 protein, human;DEAD-box RNA Helicases;RNA Helicases",
        "Doc_meshdescriptors":"Animals;Autoantigens;Base Sequence;Binding Sites;Carcinoma, Small Cell;Carcinoma, Squamous Cell;Cell Nucleus;Cyclin-Dependent Kinase Inhibitor p16;DEAD-box RNA Helicases;DNA-Binding Proteins;Drosophila;Gene Expression Regulation;Genes, Tumor Suppressor;Humans;Lung Neoplasms;Male;Neoplasm Proteins;Promoter Regions, Genetic;Protein Biosynthesis;RNA Helicases;Rabbits;Recombinant Proteins;Reticulocytes;Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization;Transcription, Genetic;Transfection;Tumor Cells, Cultured;X Chromosome",
        "Doc_meshqualifiers":"genetics;metabolism;metabolism;genetics;metabolism;genetics;genetics;metabolism;metabolism;metabolism",
        "_version_":1605820331426054144},
      {
        "Doc_abstract":"Expression of the tumor suppressor p16(INK4a) increases during aging and replicative senescence.;Here, we report that the microRNA miR-24 suppresses p16 expression in human diploid fibroblasts and cervical carcinoma cells. Increased p16 expression with replicative senescence was associated with decreased levels of miR-24, a microRNA that was predicted to associate with the p16 mRNA coding and 3'-untranslated regions. Ectopic miR-24 overexpression reduced p16 protein but not p16 mRNA levels. Conversely, introduction of antisense (AS)-miR-24 blocked miR-24 expression and markedly enhanced p16 protein levels, p16 translation, and the production of EGFP-p16 reporter bearing the miR-24 target recognition sites.;Together, our results suggest that miR-24 represses the initiation and elongation phases of p16 translation.",
        "Doc_title":"p16(INK4a) translation suppressed by miR-24.",
        "Journal":"PloS one",
        "Do_id":"18365017",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;DNA Primers;MicroRNAs",
        "Doc_meshdescriptors":"Base Sequence;Cyclin-Dependent Kinase Inhibitor p16;DNA Primers;HeLa Cells;Humans;MicroRNAs;Mutagenesis, Site-Directed;Protein Biosynthesis",
        "Doc_meshqualifiers":"genetics;physiology",
        "_version_":1605813051517304832},
      {
        "Doc_abstract":"The G1 cell cycle checkpoint regulates entry into S phase for normal cells. Components of the G1 checkpoint, including retinoblastoma (Rb) protein, cyclin D1 and p16INK4a, are commonly altered in human malignancies, abrogating cell cycle control. Using immunohistochemistry, we examined 79 invasive transitional cell carcinomas of the urinary bladder treated by cystectomy, for loss of Rb or p16INK4a protein and for cyclin D1 overexpression. As p53 is also involved in cell cycle control, its expression was studied as well. Rb protein loss occurred in 23/79 cases (29%); it was inversely correlated with loss of p16INK4a, which occurred in 15/79 cases (19%). One biphenotypic case, with Rb+p16- and Rb-p16+ areas, was identified as well. Cyclin D1 was overexpressed in 21/79 carcinomas (27%), all of which retained Rb protein. Fifty of 79 tumours (63%) showed aberrant accumulation of p53 protein; p53 staining did not correlate with Rb, p16INK4a, or cyclin D1 status. Overall, 70% of bladder carcinomas showed abnormalities in one or more of the intrinsic proteins of the G1 checkpoint (Rb, p16INK4a and cyclin D1). Only 15% of all bladder carcinomas (12/79) showed a normal phenotype for all four proteins. In a multivariate survival analysis, cyclin D1 overexpression was linked to less aggressive disease and relatively favourable outcome. In our series, Rb, p16INK4a and p53 status did not reach statistical significance as prognostic factors. In conclusion, G1 restriction point defects can be identified in the majority of bladder carcinomas. Our findings support the hypothesis that cyclin D1 and p16INK4a can cooperate to dysregulate the cell cycle, but that loss of Rb protein abolishes the G1 checkpoint completely, removing any selective advantage for cells that alter additional cell cycle proteins.",
        "Doc_title":"G1 checkpoint protein and p53 abnormalities occur in most invasive transitional cell carcinomas of the urinary bladder.",
        "Journal":"British journal of cancer",
        "Do_id":"10376969",
        "Doc_ChemicalList":"CCNG1 protein, human;Cyclin G;Cyclin G1;Cyclins;Tumor Suppressor Protein p53",
        "Doc_meshdescriptors":"Aged;Carcinoma, Transitional Cell;Cell Cycle;Cyclin G;Cyclin G1;Cyclins;Female;G1 Phase;Humans;Male;Middle Aged;Neoplasm Invasiveness;Prognosis;Survival Analysis;Tumor Suppressor Protein p53;Urinary Bladder Neoplasms",
        "Doc_meshqualifiers":"pathology;physiopathology;biosynthesis;pharmacology;biosynthesis;pharmacology;pathology;physiopathology",
        "_version_":1605892532807401472},
      {
        "Doc_abstract":"Lung cancer is the most lethal carcinoma worldwide. Mutations of p53, inactivation of p16(INK4a), and overexpression of cyclins E, A and B are independently associated with poor prognoses of patients, while the prognostic value of cyclin D1 or RB expression is inconclusive. Cyclin D binding myb-like protein 1 (Dmp1) encodes a DNA binding protein that receives signals from oncogenic Ras and functions as a tumor suppressor by activating the Arf-p53 [corrected] pathway. Dmp1 has been shown to be haplo-insufficient for tumor suppression in mouse models including K-ras-mediated lung carcinogenesis. The human DMP1 gene is located on chromosome 7q21, and our recent results revealed that the hDMP1 gene is deleted, but not mutated or silenced, in approximately 40 % of human non-small-cell lung carcinomas. These cases typically retained wild-type ARF and p53 and expressed very low levels of the hDMP1 protein. Thus, hDMP1 loss could be a novel diagnostic marker for non-small-cell lung carcinomas.",
        "Doc_title":"Role of DMP1 and its future in lung cancer diagnostics.",
        "Journal":"Expert review of molecular diagnostics",
        "Do_id":"18598225",
        "Doc_ChemicalList":"Biomarkers, Tumor;Cyclin-Dependent Kinase Inhibitor p16;Cyclins;DMTF1 protein, human;Dmtf1 protein, mouse;TP53 protein, human;Transcription Factors;Tumor Suppressor Protein p53;Proto-Oncogene Proteins p21(ras)",
        "Doc_meshdescriptors":"Animals;Biomarkers, Tumor;Carcinoma, Non-Small-Cell Lung;Chromosomes, Human, Pair 7;Cyclin-Dependent Kinase Inhibitor p16;Cyclins;Disease Models, Animal;Gene Deletion;Gene Expression Regulation, Neoplastic;Humans;Lung Neoplasms;Mice;Prognosis;Proto-Oncogene Proteins p21(ras);Transcription Factors;Tumor Suppressor Protein p53",
        "Doc_meshqualifiers":"biosynthesis;genetics;diagnosis;genetics;metabolism;genetics;metabolism;genetics;metabolism;genetics;metabolism;genetics;diagnosis;genetics;metabolism;genetics;metabolism;biosynthesis;genetics;biosynthesis;genetics;metabolism",
        "_version_":1605822669843857408},
      {
        "Doc_abstract":"Reactive oxygen species (ROS) can cause severe damage to DNA, proteins and lipids in normal cells, contributing to carcinogenesis and various pathological conditions. While cellular senescence arrests the early phase of cell cycle without any detectable telomere loss or dysfunction. ROS is reported to contribute to induction of cellular senescence, as evidence by its premature onset upon treatment with antioxidants or inhibitors of cellular oxidant scavengers. Although cellular senescence is known to be implicated in tumor suppression, it remains unknown whether ROS initially contributed to be cellular senescence in normal human epidermal keratinocytes (NHEK) and their malignant counterparts. To clarify whether ROS induce cellular senescence in NHEKs, we examined the effect of hydrogen peroxide (H2O2) on the expression of cellular senescence-associated molecules in NHEKs, compared to in squamous carcinoma cells (SCCs). Hydrogen peroxide increased the number of cells positive in senescence associated--galactosidase (SA--Gal) activity in NHEKs, but not SCCs. The expression of cyclin-dependent kinase (CDK) inhibitors, especially p16(INK4a) was upregulated in NHEKs treated with H2O2. Interestingly, H2O2 suppressed the methylation of p16(INK4a), promoter region in NHEKs, but not in SCCs. Hydrogen peroxide also suppressed the expression of phosphorylated Rb and CDK4, resulting in arrest in G0/G1 phase in NHEKs, but not SCCs. Our results indicate that the ROS-induced cellular senescence in NHEKs was caused by the upregulation p16(INK4a) through demethylation in its promoter region, which is not detected in SCCs, suggesting that ROS-induced cellular senescence contributes to tumor suppression of NHEKs. ",
        "Doc_title":"Reactive oxygen species promotes cellular senescence in normal human epidermal keratinocytes through epigenetic regulation of p16(INK4a.).",
        "Journal":"Biochemical and biophysical research communications",
        "Do_id":"25181340",
        "Doc_ChemicalList":"Biomarkers;Cyclin-Dependent Kinase Inhibitor p16;Reactive Oxygen Species;Retinoblastoma Protein;Hydrogen Peroxide;CDK4 protein, human;Cyclin-Dependent Kinase 4;beta-Galactosidase",
        "Doc_meshdescriptors":"Biomarkers;Cell Aging;Cell Line, Tumor;Cyclin-Dependent Kinase 4;Cyclin-Dependent Kinase Inhibitor p16;DNA Methylation;Epidermis;Epigenesis, Genetic;G1 Phase Cell Cycle Checkpoints;Humans;Hydrogen Peroxide;Keratinocytes;Organ Specificity;Promoter Regions, Genetic;Reactive Oxygen Species;Retinoblastoma Protein;Signal Transduction;beta-Galactosidase",
        "Doc_meshqualifiers":"metabolism;genetics;metabolism;genetics;metabolism;cytology;drug effects;metabolism;genetics;pharmacology;cytology;drug effects;metabolism;agonists;metabolism;genetics;metabolism;genetics;metabolism",
        "_version_":1605822687265947648},
      {
        "Doc_abstract":"p16(INK4A) is strongly expressed in tissues diagnosed as cervical intraepithelial neoplasia (CIN) and cancer in women infected with human papillomavirus (HPV), but few prospective studies have evaluated p16(INK4A) as a marker for the risk of low-grade CIN (CIN1) progression. We investigated the prevalence of p16(INK4A) immunostaining by CIN grade and whether overexpression of p16(INK4A) in CIN1 predicts future risk for high-grade CIN in Chinese women. 6,557 Chinese women aged 30-49 years were screened from 2003 to 2005 using cytology and carcinogenic HPV test. Colposcopy was performed on women with any abnormal result. p16(INK4A) Immunostaining was performed on biopsies from all women with CIN1, as well as randomly selected women with normal or CIN grade 2 and worse (CIN2+) biopsies. Women with CIN1 were followed up without treatment. Colposcopy was performed on all untreated women at a 2-year interval. The prevalence of p16(INK4A) staining was 2.7%, 42.7%, 75.5%, 79.6% and 100% among women with normal, CIN1, 2, 3 and cancer biopsies, respectively (p < 0.001). HPV positivity was strongly associated with p16(INK4A) staining [odds ratios (OR) = 12.8; 95% confidence intervals (CI): 5.2-31.6]. p16(INK4A) staining of CIN1 biopsies at baseline was associated with an increased risk of finding high-grade CIN over 2 years of follow-up (OR = 1.43; 95% CI: 0.52-3.91). The two-year cumulative incidence of CIN2+ for p16(INK4A) positive women was higher at 10.71% than for p16(INK4A) negative women at 1.30% (crude RR = 8.25, 95% CI: 1.02-66.62). p16(INK4A) overexpression is strongly associated with grade of CIN and risk of progression to high-grade CIN in women with low-grade lesions. ",
        "Doc_title":"p16INK4A immunohistochemical staining and predictive value for progression of cervical intraepithelial neoplasia grade 1: a prospective study in China.",
        "Journal":"International journal of cancer",
        "Do_id":"24105727",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16",
        "Doc_meshdescriptors":"Adult;Biopsy;Cervical Intraepithelial Neoplasia;China;Colposcopy;Cyclin-Dependent Kinase Inhibitor p16;Disease Progression;Female;Humans;Papillomaviridae;Papillomavirus Infections;Prospective Studies;Uterine Cervical Neoplasms",
        "Doc_meshqualifiers":"methods;genetics;metabolism;pathology;virology;methods;genetics;metabolism;isolation & purification;diagnosis;metabolism;pathology;virology;genetics;metabolism;pathology;virology",
        "_version_":1605883939594960896},
      {
        "Doc_abstract":"We sought to determine whether early-stage laryngopharyngeal squamous cell carcinomas (SCC) can be detected through molecular analysis of exfoliated cells collected with the use of a pharyngoesophageal brush (PEB).;Thirty-three patients with a single, untreated, early-stage (T1 or T2) SCC of the supraglottic larynx or pharynx underwent collection of cells with a PEB, followed by endoscopic biopsy of the tumor. PEB specimens were also collected from five healthy subjects. PEB samples and tumor tissue were examined for hypermethylation of p16INK4a (CDKN2) gene promoter CpG islands (assayed by methylation-specific PCR) and UT5085 tetranucleotide microsatellite instability (assayed by GeneScan analysis). PEB samples were also subjected to cytologic analysis.;Eight of 33 (24%) tumors exhibited a bandshift at UT5085, and 14 of 33 (42%) exhibited hypermethylation at the p16 promoter. Overall, 17 of 33 (52%) patients had at least one of the two markers in their tumor. Cytologic analysis of PEB samples revealed tumor in 4 of 33 (12%) patients; cytologic findings were normal in all five control subjects. Molecular analysis of PEB samples revealed tumor DNA in 13 of 17 (76%) patients with at least one of the two molecular markers in their tumor. Eight of 14 (57%) patients with p16 hypermethylation in their tumor and 8 of 8 (100%) patients with UT5085 microsatellite instability in their tumor had similar findings in the PEB samples. None of the PEB samples from the control subjects or patients with neither molecular marker in their tumor displayed abnormality.;Molecular analysis of PEB samples holds promise for the early detection of early-stage laryngopharyngeal SCCs. New molecular markers need to be identified to increase the sensitivity of molecular screening.",
        "Doc_title":"Molecular detection of early-stage laryngopharyngeal squamous cell carcinomas.",
        "Journal":"Clinical cancer research : an official journal of the American Association for Cancer Research",
        "Do_id":"15814632",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16",
        "Doc_meshdescriptors":"Carcinoma, Squamous Cell;Cell Line, Tumor;CpG Islands;Cyclin-Dependent Kinase Inhibitor p16;DNA Methylation;Humans;Hypopharyngeal Neoplasms;Laryngeal Neoplasms;Microsatellite Repeats;Neoplasm Staging;Pharyngeal Neoplasms;Promoter Regions, Genetic;Prospective Studies",
        "Doc_meshqualifiers":"genetics;pathology;genetics;genetics;genetics;pathology;genetics;pathology;genetics;methods;genetics;pathology;genetics",
        "_version_":1605746981996593152},
      {
        "Doc_abstract":"We aimed to determine the effects of the inhibition of enhancer of zeste homolog 2 (EZH2) gene expression on the cisplatin resistance of the human ovarian cancer cell line, SKOV3/DDP, and to identify the underlying mechanisms. SKOV3/DDP cells were stably transfected with pSUPER-EZH2 (EZH2 RNA interference plasmid) or pcDNA3.1-EZH2 (EZH2 gene overexpression plasmid) using the lipofection method. Real-time fluorescence quantitative reverse transcription polymerase chain reaction and western blotting confirmed that EZH2 expression was downregulated in pSUPER-EZH2-transfected cells. Flow cytometry revealed that EZH2 inhibition did not induce apoptosis, but significantly inhibited autophagy. In addition, it significantly increased the expression of the cellular senescence-signaling proteins p14(ARF), p16(INK4a), p53, pRb, and p21, and significantly decreased the expression of cyclin-dependent kinase (CDK)1, CDK2, and H3K27me3. Cellular senescence was characterized by a significant increase in the G0/G1 ratio and the restoration of sensitivity to cisplatin in the drug-resistant cells. These findings suggest that interfering with EZH2 expression can inhibit SKOV3/DDP cell autophagy and reverse resistance to cisplatin. The underlying mechanisms could be associated with the regulation of the cellular senescence-signaling pathway. ",
        "Doc_title":"Interfering EZH2 Expression Reverses the Cisplatin Resistance in Human Ovarian Cancer by Inhibiting Autophagy.",
        "Journal":"Cancer biotherapy & radiopharmaceuticals",
        "Do_id":"27610467",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605881438169726976},
      {
        "Doc_abstract":"The tumor suppressor p14ARF is widely deregulated in many types of cancers and is believed to function as a failsafe mechanism, inhibiting proliferation and inducing apoptosis as cellular response to a high oncogene load. We have found that a 22-amino-acid-long peptide derived from the N-terminal part of p14ARF, denoted ARF(1-22), which has previously been shown to mimic the function of p14ARF, has cell-penetrating properties. This peptide is internalized to the same extent as the cell-penetrating peptide (CPP) TP10 and dose-dependently decreases proliferation in MCF-7 and MDA MB 231 cells. Uptake of the ARF(1-22) peptide is associated with low membrane disturbance, measured by deoxyglucose and lactate dehydrogenase (LDH) leakage, as compared to its scrambled peptide. Also, flow cytometric analysis of annexin V/propidium iodide (PI) binding and Hoechst staining of nuclei suggest that ARF(1-22) induces apoptosis, whereas scrambled or inverted peptide sequences have no effect. The ARF(1-22) peptide mainly translocates cells through endocytosis, and is found intact inside cells for at least 3 hours. To our knowledge, this is the first time a CPP having pro-apoptopic activity has been designed from a protein.",
        "Doc_title":"Characterization of a novel cytotoxic cell-penetrating peptide derived from p14ARF protein.",
        "Journal":"Molecular therapy : the journal of the American Society of Gene Therapy",
        "Do_id":"17984975",
        "Doc_ChemicalList":"Cytotoxins;Peptide Nucleic Acids;Peptides;Tumor Suppressor Protein p14ARF",
        "Doc_meshdescriptors":"Amino Acid Sequence;Apoptosis;Cell Line, Tumor;Cell Membrane Permeability;Cell Proliferation;Cytotoxins;HeLa Cells;Humans;Molecular Mimicry;Molecular Sequence Data;Peptide Nucleic Acids;Peptides;Tumor Suppressor Protein p14ARF",
        "Doc_meshqualifiers":"genetics;genetics;chemical synthesis;genetics;physiology;genetics;chemical synthesis;genetics;physiology;chemical synthesis;genetics;physiology;chemistry;genetics;metabolism",
        "_version_":1605875073586036736},
      {
        "Doc_abstract":"We investigated the prognostic value of p16(INK4a) immunocytochemistry (ICC) analysis in 126 cases of newly diagnosed childhood acute lymphoblastic leukemia (ALL). The incidence of negative p16(INK4a) ICC was 38.1% and was more frequent in T-lineage ALL. Overall survival (OS) and event-free survival (EFS) were significantly higher in patients with positive p16(INK4a) ICC than in patients with negative ICC (6 years OS, 90% versus 63%, P =.0014; 6 years EFS, 77.8% versus 55%, P =.0033). The p16(INK4a) ICC remained a significant prognostic factor within the subgroup of B-precursor ALL. Multivariate analysis showed that negative p16(INK4a) ICC was an independent prognostic factor for OS (relative risk [RR], 3.38; P =.02) and EFS (RR, 2.49; P =.018). Sequential study showed that p16(INK4a) expression remained stable during first relapse in most patients. These findings indicate that p16(INK4a) ICC is an independent factor of outcome in childhood ALL.",
        "Doc_title":"p16(INK4a) immunocytochemical analysis is an independent prognostic factor in childhood acute lymphoblastic leukemia.",
        "Journal":"Blood",
        "Do_id":"11895806",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16",
        "Doc_meshdescriptors":"Adolescent;Child;Child, Preschool;Cyclin-Dependent Kinase Inhibitor p16;Female;Humans;Immunohistochemistry;Immunophenotyping;Infant;Karyotyping;Male;Multivariate Analysis;Precursor Cell Lymphoblastic Leukemia-Lymphoma;Predictive Value of Tests;Prognosis;Survival Rate;Time Factors",
        "Doc_meshqualifiers":"analysis;mortality;pathology",
        "_version_":1605836846785363968},
      {
        "Doc_abstract":"Survivin is an essential component of the chromosomal passenger complex and a member of the inhibitor of apoptosis family. It is expressed at high levels in a large variety of malignancies, where it has been implicated in drug resistance. It was also shown previously that survivin is up-regulated during telomerase-mediated immortalization, which occurs at a relatively early stage during carcinogenesis. This study shows that up-regulation of survivin during immortalization of human myofibroblasts is an indirect consequence of the repression of p16(INK4a). Survivin and p16(INK4a) were functionally linked by assays that showed that either the up-regulation of survivin or repression of p16(INK4a) rendered telomerase-transduced MRC-5 myofibroblasts resistant to oxidative stress. Conversely, siRNA-mediated down-regulation of survivin activated caspases and enhanced the sensitivity of immortal MRC-5 cells to oxidative stress. The E2F1 transcription factor, which is negatively regulated by the pRB/p16(INK4a) tumor suppressor pathway, was implicated in the up-regulation of survivin. Using the ChIP assay, it was shown that E2F1 directly interacted with the survivin gene (BIRC5) promoter in cells that spontaneously silenced p16(INK4a) during telomerase-mediated immortalization. E2F1 binding to the BIRC5 was also enhanced in telomerase-transduced cells subjected to shRNA-mediated repression of p16(INK4a). Together, these data show that repression of p16(INK4a) contributes to the up-regulation of survivin and thereby provides a survival advantage to cells exposed to oxidative stress during immortalization. The up-regulation of survivin during immortalization likely contributes to the vulnerability of immortal cells to transformation by oncogenes that alter intracellular redox state.",
        "Doc_title":"Up-regulation of survivin during immortalization of human myofibroblasts is linked to repression of tumor suppressor p16(INK4a) protein and confers resistance to oxidative stress.",
        "Journal":"The Journal of biological chemistry",
        "Do_id":"23449974",
        "Doc_ChemicalList":"BIRC5 protein, human;Cyclin-Dependent Kinase Inhibitor p16;Inhibitor of Apoptosis Proteins;Telomerase",
        "Doc_meshdescriptors":"Cell Line, Transformed;Cell Transformation, Neoplastic;Cyclin-Dependent Kinase Inhibitor p16;Humans;Inhibitor of Apoptosis Proteins;Myofibroblasts;Oxidation-Reduction;Oxidative Stress;Response Elements;Telomerase;Up-Regulation",
        "Doc_meshqualifiers":"genetics;metabolism;pathology;biosynthesis;genetics;biosynthesis;genetics;metabolism;pathology;genetics;metabolism",
        "_version_":1605892124209840128},
      {
        "Doc_abstract":"Homozygous and hemizygous deletions of 9p21 are the earliest and most common genetic alteration in bladder cancer. The identification of two cell cycle regulators, CDKN2 and CDKN2B, that map to the common region of deletion has prompted the hypothesis that they are critical tumor suppressor genes in this malignancy. However, controversy as to whether these genes are the only or even the most important target in bladder cancer oncogenesis remains. To more clearly determine the effect of these 9p21 alterations, we mapped the homozygous deletions and performed a detailed mutational and expression analysis for CDKN2, CDKN2B and a closely linked gene, methylthioadenoside phosphorylase (MTAP), in 16 established bladder cancer cell lines. Nine of the 16 lines exhibit large (30 to > 2000 kb) homozygous deletions on 9p21. All deletions include at least one exon of CDKN2, eight of nine include CDKN2B, and six of nine include MTAP. MTAP function correlates with the genomic deletions. SSCP and sequence analysis does not reveal any inactivating point mutations of CDKN2 or of CDKN2B in any of the cell lines without homozygous deletions, and all express the CDKN2 and the CDKN2B mRNA as well as the encoded p16 protein. The p16 protein levels vary widely and are correlated with absent pRb expression. We conclude that the 9p21 deletions in bladder cancer usually inactivate the CDKN2. CDKN2B, and MTAP genes but that CDKN2 is the most common target. Other mechanisms for inactivating this gene in bladder cancer appear to be uncommon.",
        "Doc_title":"The 9p21 region in bladder cancer cell lines: large homozygous deletion inactivate the CDKN2, CDKN2B and MTAP genes.",
        "Journal":"Urological research",
        "Do_id":"8873383",
        "Doc_ChemicalList":"CDKN2B protein, human;Carrier Proteins;Cell Cycle Proteins;Cyclin-Dependent Kinase Inhibitor p15;Cyclin-Dependent Kinase Inhibitor p16;Enzyme Inhibitors;Tumor Suppressor Proteins;Purine-Nucleoside Phosphorylase;5'-methylthioadenosine phosphorylase",
        "Doc_meshdescriptors":"Carrier Proteins;Cell Cycle Proteins;Chromosome Mapping;Chromosomes, Human, Pair 9;Cyclin-Dependent Kinase Inhibitor p15;Cyclin-Dependent Kinase Inhibitor p16;Enzyme Inhibitors;Gene Deletion;Gene Expression Regulation;Homozygote;Humans;Purine-Nucleoside Phosphorylase;Tumor Cells, Cultured;Tumor Suppressor Proteins;Urinary Bladder Neoplasms",
        "Doc_meshqualifiers":"genetics;genetics;genetics;pathology",
        "_version_":1605841449175220224},
      {
        "Doc_abstract":"Multiple tumor suppressor gene 1 (MTS1) has been found mutated or deleted in a variety of human cancers. Our purpose was to identify and characterize MTS1 gene mutations in primary oral squamous cell carcinomas (SCCs) in each of the three exons of the MTS1 gene. Seventeen archival samples of oral SCC were evaluated for the presence of MTS1 mutations using single strand conformation polymorphism (SSCP) and DNA sequencing. Three of 17 tumors exhibited MTS1 gene mutations: one tumor exhibited a mutation in exon 2 and two tumors exhibited mutations at the splice site junction of intron 2 and exon 3. Three tumors also exhibited a common base change in the 3' untranslated region of exon 3, which is interpreted as a likely polymorphic variant. An examination of the three tumors exhibiting MTS1 point mutations revealed no unique characteristics relative to p53 immunohistochemical activity, mitotic frequency, or degree of histologic differentiation. This study indicates that MTS1 gene mutations may be involved in at least a minor proportion of oral SCCs.",
        "Doc_title":"MTS1 gene mutations in archival oral squamous cell carcinomas.",
        "Journal":"Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology",
        "Do_id":"8986966",
        "Doc_ChemicalList":"Fixatives;Formaldehyde",
        "Doc_meshdescriptors":"Adolescent;Adult;Aged;Aged, 80 and over;Carcinoma, Squamous Cell;Exons;Female;Fixatives;Formaldehyde;Gene Deletion;Genes, Tumor Suppressor;Genes, p53;Humans;Introns;Male;Middle Aged;Mitosis;Mouth Neoplasms;Mutation;Paraffin Embedding;Point Mutation;Polymorphism, Genetic;Polymorphism, Single-Stranded Conformational;Sequence Analysis, DNA",
        "Doc_meshqualifiers":"genetics;genetics;genetics;genetics;genetics;genetics;genetics;genetics;genetics;genetics",
        "_version_":1605742022649446400},
      {
        "Doc_abstract":"Controversy remains over whether the cancer stem cell (CSC) theory applies to all tumors. To determine whether cells within a highly aggressive solid tumor are stochastically or hierarchically organized, we combined a reporter system where the nucleostemin (NS) promoter drives GFP expression (termed NS-GFP) with a mouse brain tumor model induced by retroviral Ras expression on a p16(Ink4a)/p19(Arf)-deficient background. The NS-GFP system allowed us to monitor the differentiation process of normal neural stem/precursor cells by analyzing GFP fluorescence intensity. In tumor-bearing mice, despite the very high frequency of tumorigenic cells, we successfully identified the NS-GFP(+) cells as tumor-initiating cells (T-ICs). The clonal studies conclusively established that phenotypical heterogeneity can exist among the cells comprising a genetically homogeneous tumor, suggesting that this aggressive brain tumor follows the CSC model. Detailed analyses of the NS-GFP(+) brain tumor cells revealed that T-ICs showed activation of the receptor tyrosine kinase c-Met, which functions in tumor invasiveness. Thus, the NS-GFP system provides a powerful tool to elucidate stem cell biology in normal and malignant tissues.",
        "Doc_title":"Identification of tumor-initiating cells in a highly aggressive brain tumor using promoter activity of nucleostemin.",
        "Journal":"Proceedings of the National Academy of Sciences of the United States of America",
        "Do_id":"19805150",
        "Doc_ChemicalList":"AC133 Antigen;Antigens, CD;Carrier Proteins;Cdkn2a protein, mouse;Cyclin-Dependent Kinase Inhibitor p16;Glycoproteins;Nuclear Proteins;Peptides;nucleostemin protein, mouse;Green Fluorescent Proteins;Proto-Oncogene Proteins c-met",
        "Doc_meshdescriptors":"AC133 Antigen;Animals;Animals, Newborn;Antigens, CD;Brain Neoplasms;Carrier Proteins;Cell Differentiation;Clone Cells;Cyclin-Dependent Kinase Inhibitor p16;Flow Cytometry;Glycoproteins;Green Fluorescent Proteins;Immunohistochemistry;Mice;Mice, Inbred C57BL;Mice, Knockout;Mice, Transgenic;Microscopy, Confocal;Neoplastic Stem Cells;Neurons;Nuclear Proteins;Peptides;Promoter Regions, Genetic;Proto-Oncogene Proteins c-met",
        "Doc_meshqualifiers":"metabolism;genetics;metabolism;pathology;genetics;metabolism;pathology;genetics;metabolism;metabolism;genetics;metabolism;metabolism;pathology;metabolism;pathology;genetics;metabolism;genetics;metabolism",
        "_version_":1605806838984474624},
      {
        "Doc_abstract":"A high percentage of tumor cells bear mutations in the Rb tumor suppressor gene. They have high levels of the cdk inhibitor p16(ink4a) and no cyclin D/cdk4-6 complexes. Although p16 is known not to arrest the proliferation of Rb-negative cells, it is not known whether its presence affects how their cycle progresses, how E2F-dependent transcription is modulated, and whether and how Rb-related proteins are inactivated. We have assessed the relevance of p16(ink4a) for cell cycle progression of these cells. Using SaOS2 osteosarcoma cells as a model, we find that downregulation of p16(ink4a) by RNAi and reconstitution of active cyclin D/cdk4 complexes does not affect progression of the cycle of these cells or expression of E2F-dependent genes. Rb-negative tumor cells can functionally inactivate Rb-related proteins in G(1)/S transition independently of their p16(ink4a) status. Furthermore, Rb-negative tumor cells do not arrest when cdk1, cdk2 or cdk3 are inhibited by RNAi, independently of their p16(ink4a) status, and combined inhibition of these cdks is also not enough to arrest their cell cycle. However, cell cycle progression of Rb-negative tumor cells is sensitive to complete cdk inhibition, as it is arrested by the chemical cdk inhibitor roscovitine and the biological cdk inhibitor p27. These results suggest that, despite their lack of cyclin D-containing complexes, Rb-negative tumor cells, like normal untransformed cells, take advantage of the high degree of redundancy of cdks for their cell cycle progression.",
        "Doc_title":"CDK redundancy guarantees cell cycle progression in Rb-negative tumor cells independently of their p16 status.",
        "Journal":"Cell cycle (Georgetown, Tex.)",
        "Do_id":"18604173",
        "Doc_ChemicalList":"Antineoplastic Agents;Cyclin-Dependent Kinase Inhibitor p16;Protein Kinase Inhibitors;Purines;Retinoblastoma Protein;roscovitine;Cyclin-Dependent Kinases",
        "Doc_meshdescriptors":"Antineoplastic Agents;Cell Cycle;Cell Line, Tumor;Cyclin-Dependent Kinase Inhibitor p16;Cyclin-Dependent Kinases;Down-Regulation;Humans;Osteosarcoma;Protein Kinase Inhibitors;Purines;RNA Interference;Retinoblastoma Protein",
        "Doc_meshqualifiers":"pharmacology;genetics;metabolism;metabolism;enzymology;metabolism;physiopathology;pharmacology;pharmacology;metabolism",
        "_version_":1605750643439435776},
      {
        "Doc_abstract":"To study correlation links between expression level of proteins p53, p21(WAF1/CIP), p16(INK4) and proliferative potential in human endometrial adenocarcinoma (EC).;The immunohistochemical analysis of expression level of Ki-67, p53, p21(WAF1/CIP) and p16(INK4) was carried out on surgically resected endometrial cancer samples (n = 74). Scrapes of normal endometrium from 10 patients with polyps of cervical canal of the uterus served as the control.;The data showed that endometrial malignant tumors possess high proliferative activity (proliferation index was 37.3 +/- 0.2%), overexpression of p53 (labeling index (LI) = 46.1 +/- 0.5%) and high expression of p21(WAF1/CIP) (LI = 11.2 +/- 0.4%) and p16(INK4) (LI = 12.0 +/- 0.2%). In low differentiated endometrial adenocarcinomas the highest level of Ki-67, p53 and p21(WAF1/CIP) expression and lowest content of p16(INK4) protein were observed.;The indicated markers may be used along with traditional morphological and clinical characteristics for diagnosis of endometrial neoplasia.",
        "Doc_title":"Expression of the cell cycle regulators p53, p21(WAF1/CIP1) and p16(INK4a) in human endometrial adenocarcinoma.",
        "Journal":"Experimental oncology",
        "Do_id":"16837908",
        "Doc_ChemicalList":"CDKN1A protein, human;Cyclin-Dependent Kinase Inhibitor p16;Cyclin-Dependent Kinase Inhibitor p21;Tumor Suppressor Protein p53",
        "Doc_meshdescriptors":"Adenocarcinoma;Adult;Aged;Cell Proliferation;Cyclin-Dependent Kinase Inhibitor p16;Cyclin-Dependent Kinase Inhibitor p21;Endometrial Neoplasms;Female;Humans;Middle Aged;Prognosis;Tumor Suppressor Protein p53",
        "Doc_meshqualifiers":"diagnosis;pathology;analysis;analysis;diagnosis;pathology;analysis",
        "_version_":1605798341685280768},
      {
        "Doc_abstract":"Cervical cancer is a common and an important public health problem for adult women in developing countries. In contrast, cervical cancer incidence is low in Saudi Arabia. High-risk types of human papilloma viruses (HPV16 and HPV18) are the most significant risk factors for cervical cancer. HPV16/18-E6 oncoprotein is associated with HPV etiology, viral persistence and epithelial transformation. Cell cycle protein p16 INK4a (p16) plays an important role in the pathophysiology of cervical carcinomas. The aims of this study were to investigate the expression of HPV16/18-E6 and p16 in uterine cervical carcinomas in Qassim Region--Saudi Arabia, and to relate the results to the established clinicopathological prognostic parameters (age of the patient, educational level, birth control methods, number of pregnancy, smoking status, degree of histological differentiation, clinical stage, and lymph node metastasis) The study included 40 specimens of uterine cervical squamous cell carcinomas diagnosed and confirmed by biopsy. Histopathological classification of cervical tumors cases was performed according to the International Federation of Gynecology and Obstetrics (FIGO). Immunohistochemical analysis for HPV16/18-E6 and p16 were carried out on formalin-fixed paraffin-embedded sections of cervical tissues using avidin-biotin peroxidase method. There was a significant statistical correlation between HPV16/18-E6 expression in cervical carcinoma and nationality, smoking status and size of the tumor. HPV16/18-E6 oncoprotein expression in normal lymphocytes and endothelial cells in the tumor tissues and the adjacent normal cervical tissues suggest the possibility that HPV infection might spread to other organs through blood circulation. P16 expression has been correlated with high grade, stage of cervical SCC and HPV16/18-E6 expression. The current study supports the critical function of p16 and HPV16/18-E6 as specific markers for cervical carcinoma. However the potential for usage of p16 and HPV16/18-E6 as prognostic markers will require detailed follow data for a larger group of patients.",
        "Doc_title":"Human papilloma virus early proteins E6 (HPV16/18-E6) and the cell cycle marker P16 (INK4a) are useful prognostic markers in uterine cervical carcinomas in Qassim Region--Saudi Arabia.",
        "Journal":"Pathology oncology research : POR",
        "Do_id":"24925218",
        "Doc_ChemicalList":"Biomarkers, Tumor;Cyclin-Dependent Kinase Inhibitor p16;DNA-Binding Proteins;E6 protein, Human papillomavirus type 16;E6 protein, Human papillomavirus type 18;Neoplasm Proteins;Oncogene Proteins, Viral;Repressor Proteins",
        "Doc_meshdescriptors":"Adult;Aged;Biomarkers, Tumor;Carcinoma, Squamous Cell;Cell Cycle;Cyclin-Dependent Kinase Inhibitor p16;DNA-Binding Proteins;Female;Human papillomavirus 16;Human papillomavirus 18;Humans;Middle Aged;Neoplasm Proteins;Oncogene Proteins, Viral;Papillomavirus Infections;Prognosis;Repressor Proteins;Retrospective Studies;Saudi Arabia;Uterine Cervical Neoplasms",
        "Doc_meshqualifiers":"metabolism;genetics;pathology;virology;genetics;genetics;genetics;metabolism;metabolism;metabolism;genetics;metabolism;pathology;virology;genetics;genetics;pathology;virology",
        "_version_":1605929087387303936},
      {
        "Doc_abstract":"Primary brain tumors are unique tumors due to their different pathobiological behavior, while they rarely metastasize outside the central nervous system. Regarding the oncogenesis of primary brain tumors, it was shown that changes in functions of p16 and mouse double minute 2 homolog (MDM2) are related to tumor pathogenesis by enhancing cell proliferation and malign development. The present study aims to evaluate the possible associations between cyclin-dependent kinase 2 (CDKN2) p16 540 C>G and 580 C>T, MDM2 single nucleotide polymorphism 309 (SNP309) T>G polymorphisms and primary brain tumor.;Using polymerase chain reaction-restriction fragment length polymorphism technique, we determined SNPs in 67 patients with primary brain tumors and 71 healthy volunteers without malignancy.;The frequency of CC genotype for CDKN2 p16 540 C>G was significantly two-fold higher (p<0.001) and possessing a C allele conferred a ~7-fold increased risk (p=0.005) of primary brain tumor. We also found that the CC genotype produced a higher ~4-fold risk of glioma (p=0.001) and the G allele had a possibly protective role against meningioma (~4.8-fold reduced risk, p=0.001). We found no significant associations for CDKN2 p16 580 C>T and MDM2 SNP309 T>G variants between cases and controls. CGT haplotype was significantly less frequent in patients with primary brain tumors and glioma cases (p=0.009 and p=0.028, respectively) than controls. CGG haplotype was significantly less frequent in patients with meningioma versus the control group (p=0.023).;These findings show that CDKN2 p16 540 C>G, CDKN2 p16 580 C>T and MDM2 SNP309 T>G variants and their haplotypes may be risk factors for the development of primary brain tumors, especially of glioma.",
        "Doc_title":"Distribution and Effects of CDKN2 p16 540 C>G and 580 C>T, and MDM2 SNP309 T>G Polymorphisms in Patients with Primary Brain Tumors.",
        "Journal":"Anticancer research",
        "Do_id":"26124340",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;MDM2 protein, human;Proto-Oncogene Proteins c-mdm2",
        "Doc_meshdescriptors":"Alleles;Brain Neoplasms;Case-Control Studies;Cyclin-Dependent Kinase Inhibitor p16;Female;Genetic Predisposition to Disease;Glioma;Haplotypes;Humans;Male;Meningioma;Middle Aged;Polymorphism, Single Nucleotide;Proto-Oncogene Proteins c-mdm2;Risk",
        "Doc_meshqualifiers":"genetics;genetics;genetics;genetics;genetics;genetics;genetics;genetics",
        "_version_":1605837718156214272},
      {
        "Doc_abstract":"Oncogenic human papillomaviruses (HPV) are associated with nearly all cervical cancers and are increasingly important in the etiology of oropharyngeal tumors. HPV-associated head and neck squamous cell carcinomas (HNSCC) have distinct risk profiles and appreciate a prognostic advantage compared to HPV-negative HNSCC. Promoter hypermethylation is widely recognized as a mechanism in the progression of HNSCC, but the extent to which this mechanism is consistent between HPV(+) and HPV(-) tumors is unknown. To investigate the epigenetic regulation of gene expression in HPV-induced and carcinogen-induced cancers, we examined genome-wide DNA methylation and gene expression in HPV(+) and HPV(-) SCC cell lines. We used two platforms: the Illumina Infinium Methylation BeadArray and tiling arrays, and confirmed illustrative examples with pyrosequencing and quantitative PCR. These analyses indicate that HPV(+) cell lines have higher DNA methylation in genic and LINE-1 regions than HPV(-) cell lines. Differentially methylated loci between HPV(+) and HPV(-) cell lines significantly correlated with HPV-typed HNSCC primary tumor DNA methylation levels. Novel findings include higher promoter methylation of polycomb repressive complex 2 target genes in HPV(+) cells compared to HPV(-) cells and increased expression of DNMT3A in HPV(+) cells. Additionally, CDKN2A and KRT8 were identified as interaction hubs among genes with higher methylation and lower expression in HPV(-) cells. Conversely, RUNX2, IRS-1and CCNA1 were major hubs with higher methylation and lower expression in HPV(+) cells. Distinct HPV(+) and HPV(-) epigenetic profiles should provide clues to novel targets for development of individualized therapeutic strategies.",
        "Doc_title":"Genome-wide methylation and expression differences in HPV(+) and HPV(-) squamous cell carcinoma cell lines are consistent with divergent mechanisms of carcinogenesis.",
        "Journal":"Epigenetics",
        "Do_id":"21613826",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Adult;Carcinoma, Squamous Cell;DNA Methylation;Female;Gene Expression Regulation;Genome-Wide Association Study;Humans;Male;Middle Aged;Papillomaviridae;Promoter Regions, Genetic;Tumor Cells, Cultured",
        "Doc_meshqualifiers":"genetics;metabolism",
        "_version_":1605809709210664960},
      {
        "Doc_abstract":"Tumor suppressor protein p19(ARF) (Arf; p14(ARF) in humans) functions in both p53-dependent and -independent modes to counteract hyper-proliferative signals caused by proto-oncogene activation, but its p53-independent activities remain poorly understood. Using the tandem affinity purification-tag technique, we purified Arf-containing protein complexes and identified p68 DEAD-box protein (DDX5) as a novel interacting protein of Arf. In this study, we found that DDX5 interacts with c-Myc, and harbors essential roles for c-Myc-mediated transcription and its transforming activity. Furthermore, when c-Myc was forcibly expressed, the expression level of DDX5 protein was drastically increased through the acceleration of protein synthesis of DDX5, suggesting the presence of an oncogenic positive feedback loop including c-Myc and DDX5. Strikingly, Arf blocked the physical interaction between DDX5 and c-Myc, and drove away DDX5 from the promoter of c-Myc target genes. These observations most likely indicate the mechanism by which Arf causes p53-independent tumor-suppressive activity.",
        "Doc_title":"Arf tumor suppressor disrupts the oncogenic positive feedback loop including c-Myc and DDX5.",
        "Journal":"Oncogene",
        "Do_id":"24469041",
        "Doc_ChemicalList":"Cdkn2a protein, mouse;Cyclin-Dependent Kinase Inhibitor p16;Proto-Oncogene Proteins c-myc;Ddx5 protein, mouse;DEAD-box RNA Helicases",
        "Doc_meshdescriptors":"Animals;Cell Line;Cell Line, Tumor;Cells, Cultured;Cyclin-Dependent Kinase Inhibitor p16;DEAD-box RNA Helicases;Embryo, Mammalian;Feedback, Physiological;Fibroblasts;HEK293 Cells;HeLa Cells;Humans;Immunoblotting;MCF-7 Cells;Mice;Mice, 129 Strain;Mice, Inbred C57BL;Mice, Knockout;Mice, Nude;NIH 3T3 Cells;Protein Binding;Proto-Oncogene Proteins c-myc;RNA Interference",
        "Doc_meshqualifiers":"genetics;metabolism;genetics;metabolism;cytology;metabolism;genetics;metabolism",
        "_version_":1605876274424709120},
      {
        "Doc_abstract":"To evaluate the role of p16INK4a immunoexpression and human papillomavirus (HPV) DNA test for the detection of dyskaryotic cells in high-risk women.;This work was a retrospective diagnostic study conducted in the University Hospital of Thessaloniki from January to December 2008. The subjects were women with current or previous HPV infection and current or previous cervical intraepithelial lesion (with or without treatment) or clinical warts. All liquid-based cytological samples were tested for P16INKa and HPV DNA test. The accuracy parameters used for the outcome included sensitivity, specificity, and positive predictive value.;A total of 226 women were included; the mean age was 29 years. Expression of p16INK4a was detected in the cytological samples of 13% of the negative cases, 44% of the cases of atypical squamous cells of undetermined significance, 46% of the cases of low-grade squamous intraepithelial lesion, and 78% of the cases of high-grade squamous intraepithelial lesion. A total of 91 women tested positive for high-risk HPV infection, and 54 of those had p16INK4a-positive staining reaction cells. The concordance between the 2 tests, HPV DNA and p16, was 59% regarding infection-positive cases. Diffuse strong parabasal p16INK4a immunostaining (nuclear score >2) was observed in 17 cases of the abnormal cytological findings (atypical squamous cells of undetermined significance, 2 cases; low-grade squamous intraepithelial lesion, 8 cases; high-grade squamous intraepithelial lesion, 7 cases). Colposcopy-directed biopsies were used as the criterion standard for the detection of cervical intraepithelial neoplasia in 91 women. The sensitivity of p16INK4a was 95% and the specificity was 92%, whereas the sensitivity of high-risk HPV was 100% and the specificity was 78%. The positive predictive value of p16INK4a was 71%, whereas that of HPV DNA was 44%.;The findings suggest that p16INK4a immunostaining can improve the accuracy of cytological examination and HPV DNA test and may be particularly useful in the triage of low-grade lesions.",
        "Doc_title":"The evaluation of p16INK4a immunoexpression/immunostaining and human papillomavirus DNA test in cervical liquid-based cytological samples.",
        "Journal":"International journal of gynecological cancer : official journal of the International Gynecological Cancer Society",
        "Do_id":"21330832",
        "Doc_ChemicalList":"Biomarkers, Tumor;Cyclin-Dependent Kinase Inhibitor p16;DNA, Viral",
        "Doc_meshdescriptors":"Adult;Biomarkers, Tumor;Cervical Intraepithelial Neoplasia;Cyclin-Dependent Kinase Inhibitor p16;Cytodiagnosis;DNA, Viral;Female;Humans;Immunohistochemistry;Middle Aged;Papillomaviridae;Papillomavirus Infections;Predictive Value of Tests;Retrospective Studies;Sensitivity and Specificity;Uterine Cervical Dysplasia;Uterine Cervical Neoplasms",
        "Doc_meshqualifiers":"analysis;chemistry;diagnosis;virology;analysis;methods;analysis;genetics;diagnosis;metabolism;chemistry;diagnosis;virology;chemistry;diagnosis;virology",
        "_version_":1605891841128923136},
      {
        "Doc_abstract":"BMI-1 (B-cell-specific Moloney murine leukemia virus integration site 1), a novel oncogene, has attracted much attention in recent years for its involvement in the initiation of a variety of tumors. Recent evidence showed that BMI-1 was highly expressed in neoplastic skin lesions. However, whether dysregulated BMI-1 expression is causal for the transformation of skin cells remains unknown. In this study, we stably expressed BMI-1 in a human keratinocyte cell line, HaCaT. The expression of wild-type BMI-1 induced the malignant transformation of HaCaT cells in vitro. More importantly, we found that expression of BMI-1 promoted formation of squamous cell carcinomas in vivo. Furthermore, we showed that BMI-1 expression led to the downregulation of tumor suppressors, such as p16INK4a and p14ARF, cell adhesion molecules, such as E-Cadherin, and differentiation related factor, such as KRT6. Therefore, our findings demonstrated that dysregulated BMI-1 could indeed lead to keratinocytes transformation and tumorigenesis, potentially through promoting cell cycle progression and increasing cell mobility.",
        "Doc_title":"Oncoprotein BMI-1 induces the malignant transformation of HaCaT cells.",
        "Journal":"Journal of cellular biochemistry",
        "Do_id":"19021148",
        "Doc_ChemicalList":"BMI1 protein, human;Cell Adhesion Molecules;Nuclear Proteins;Oncogene Proteins;Proto-Oncogene Proteins;Repressor Proteins;Polycomb Repressive Complex 1",
        "Doc_meshdescriptors":"Animals;Cell Adhesion Molecules;Cell Cycle;Cell Proliferation;Cell Transformation, Neoplastic;Cells, Cultured;Humans;Keratinocytes;Mice;Mice, SCID;Nuclear Proteins;Oncogene Proteins;Polycomb Repressive Complex 1;Proto-Oncogene Proteins;Repressor Proteins;Skin Neoplasms",
        "Doc_meshqualifiers":"metabolism;genetics;metabolism;pathology;cytology;metabolism;pathology;genetics;metabolism;genetics;metabolism;genetics;metabolism;genetics;metabolism;genetics;metabolism;pathology",
        "_version_":1605801653758328832},
      {
        "Doc_abstract":"Inactivation of p16(INK4a) in the Rb pathway is among the most common somatic alterations observed in nonsmall cell lung cancers (NSCLCs). While epigenetic inactivation of the p16(INK4a) gene promoter has been shown to be associated with increased tobacco carcinogen exposure, little investigation of any similar association of homozygous deletion or mutation of p16(INK4a) and tobacco use has been completed. In 177 consecutive NSCLCs, we examined the determinants of p16(INK4a) homozygous deletion and mutation, including the pattern of tobacco smoking and asbestos exposure. We observed that p16(INK4a) homozygous deletion occurred at a higher frequency in never smokers as compared to former and current smokers (p = 0.01). This observation suggested that tumors from these patients might be more prone to DNA deletion events; consistent with this, epigenetic silencing of the DNA double-strand break repair genes FancF and BRCA1 was also associated with homozygous deletion of p16(INK4a)(p = 0.002 and p = 0.06, respectively). Finally, mutation of p16(INK4a) was rare and only occurred in patients who were smokers. Hence, the character of somatic alteration in the Rb pathway (deletion, mutation or methylation silencing) in NSCLC is associated with the pattern of tobacco exposure, suggesting that susceptibility to lung cancer is, at least in part, mediated by the biological mechanism that selects for the character of the induced somatic lesion.",
        "Doc_title":"Homozygous deletion of p16INK4a and tobacco carcinogen exposure in nonsmall cell lung cancer.",
        "Journal":"International journal of cancer",
        "Do_id":"16184554",
        "Doc_ChemicalList":"BRCA1 Protein;Carcinogens;Cyclin-Dependent Kinase Inhibitor p16;Asbestos",
        "Doc_meshdescriptors":"Adenocarcinoma;Aged;Analysis of Variance;Asbestos;BRCA1 Protein;Carcinogens;Carcinoma, Non-Small-Cell Lung;Carcinoma, Squamous Cell;Cyclin-Dependent Kinase Inhibitor p16;DNA Methylation;DNA Mutational Analysis;Female;Gene Deletion;Homozygote;Humans;Immunohistochemistry;Lung Neoplasms;Male;Mutation;Neoplasm Staging;Occupational Exposure;Smoking",
        "Doc_meshqualifiers":"genetics;metabolism;pathology;genetics;genetics;metabolism;pathology;genetics;metabolism;pathology;analysis;genetics;genetics;metabolism;pathology",
        "_version_":1605796938359242752},
      {
        "Doc_abstract":"Recently, we read the article \"P16(INK4a) overexpression and survival in osteosarcoma patients: a meta analysis\" by Jie Bu and his colleagues, published in the recent issue of International Journal Of Experimental Pathology. This research performed a meta-analysis to uncover the role of P16(INK4a) expression in overall survival rate in patients with osteosarcoma. The investigators concluded as follows: (i) the pateints with overexpression of P16(INK4a) had a longer overall survival rate than that with loss expression of P16(INK4a); (ii) P16(INK4a) was an effective biomarker of prognosis in patients with osteosarcoma.The findings are valubale and encouraging. However, some flaws and imperfections rooted in this work.",
        "Doc_title":"Comments on Bu et al. \"P16(INKa) overexpression and survival in osteosarcoma patients: a meta analysis\".",
        "Journal":"International journal of clinical and experimental pathology",
        "Do_id":"26261680",
        "Doc_ChemicalList":"Biomarkers, Tumor;Cyclin-Dependent Kinase Inhibitor p16",
        "Doc_meshdescriptors":"Biomarkers, Tumor;Bone Neoplasms;Cyclin-Dependent Kinase Inhibitor p16;Humans;Osteosarcoma",
        "Doc_meshqualifiers":"analysis;chemistry;analysis;chemistry",
        "_version_":1605882758395068416},
      {
        "Doc_abstract":"Very little is known about the genetics of fibrosarcoma (FS) of bone. We applied array comparative genomic hybridization (CGH) to identify genes and genomic regions with potential role in the pathogenesis of this tumor. Seventeen patients with FS of bone were included in the study. Array CGH analysis was carried out in 13 fresh frozen tissue specimens from 11 of these patients (nine primary tumors and four local recurrences). DNA was extracted and hybridizations were performed on Agilent 244K CGH oligoarrays. The data were analyzed using Agilent DNA Analytics Software. The number of changes per patient ranged from 0 to 132 (average = 43). Losses were most commonly detected at 6q, 8p, 9p, 10, 13q, and 20p. CDKN2A was homozygously deleted in 7/11 patients. Hypermethylation of both p16(INK4a) and p14(ARF) was found in 1/14 patients. An internal deletion of STARD13 was found in a region with common losses at 13q13.1. The most frequent gains were seen at 1q, 4q, 5p, 8q, 12p, 15q, 16q, 17q, 20q, 22q, and Xp. Single recurrent high level amplification was detected at 4q12, including KIT, PDGFRA, and KDR. No activating mutations were found in any of them. Immunohistochemistry revealed expression of PDGFRA and/or PDGFRB in 12/17 samples. Moreover, small regions of gains pinpointed genes of particular interest, such as IGF1R at 15q26.3 and CHD1L at 1q21.1. In conclusion, our analysis provided novel findings that can be exploited when searching for markers for diagnosis and prognosis, and targets of therapy in this tumor type.",
        "Doc_title":"Frequent deletion of CDKN2A and recurrent coamplification of KIT, PDGFRA, and KDR in fibrosarcoma of bone--an array comparative genomic hybridization study.",
        "Journal":"Genes, chromosomes & cancer",
        "Do_id":"19862822",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;DNA, Neoplasm;Proto-Oncogene Proteins c-kit;Receptor, Platelet-Derived Growth Factor alpha;Vascular Endothelial Growth Factor Receptor-2",
        "Doc_meshdescriptors":"Adult;Aged;Bone Neoplasms;Chromosome Mapping;Chromosomes, Human, Pair 13;Chromosomes, Human, X;Comparative Genomic Hybridization;Cyclin-Dependent Kinase Inhibitor p16;DNA, Neoplasm;Female;Fibrosarcoma;Gene Amplification;Gene Deletion;Humans;Male;Middle Aged;Proto-Oncogene Proteins c-kit;Receptor, Platelet-Derived Growth Factor alpha;Vascular Endothelial Growth Factor Receptor-2",
        "Doc_meshqualifiers":"genetics;pathology;genetics;genetics;isolation & purification;genetics;pathology;genetics;genetics;genetics",
        "_version_":1605852614058049536},
      {
        "Doc_abstract":"The putative role of TP53 and p16(INK4A) tumor suppressor genes and Ras oncogenes in the development and progression of salivary gland neoplasias was studied in 28 cases of pleomorphic adenomas (PA), 4 cases of cystic adenocarcinomas, and 1 case of carcinoma ex-PA. Genetic and epigenetic alterations in the above genes were analyzed by Polymerase Chain Reaction/Single Strand Conformational Polymorphism (PCR/SSCP) and sequencing and by Methylation Specific-PCR (MS-PCR). Mutations in TP53 were found in 14% (4/28) of PAs and in 60% (3/5) of carcinomas. Mutations in H-Ras and K-Ras were identified in 4% (1/28) and 7% (2/28) of PAs, respectively. Only 20% (1/5) of carcinomas screened displayed mutations in K-Ras. p16(INK4A) promoter hypermethylation was found in 14% (4/28) of PAs and 100% (5/5) carcinomas. All genetic and epigenetic alterations were detected exclusively in the epithelial and transitional tumor components, and were absent in the mesenchymal parts. Our analysis suggests that TP53 mutations and p16(INK4A) promoter methylation, but not alterations in the H-Ras and K-Ras genes, might be involved in the malignant progression of PA into carcinoma.",
        "Doc_title":"TP53 and p16INK4A, but not H-KI-Ras, are involved in tumorigenesis and progression of pleomorphic adenomas.",
        "Journal":"Journal of cellular physiology",
        "Do_id":"16447252",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;Tumor Suppressor Protein p53;Proto-Oncogene Proteins p21(ras)",
        "Doc_meshdescriptors":"Adenoma;Base Sequence;Cell Transformation, Neoplastic;Cyclin-Dependent Kinase Inhibitor p16;Disease Progression;Epigenesis, Genetic;Genotype;Humans;Methylation;Mutation;Proto-Oncogene Proteins p21(ras);Tumor Suppressor Protein p53",
        "Doc_meshqualifiers":"genetics;metabolism;pathology;genetics;metabolism;pathology;genetics;metabolism;genetics;genetics;genetics;genetics",
        "_version_":1605801060109123584},
      {
        "Doc_abstract":"In cervical intraepithelial neoplasia (CIN), p16(INK4a) immunohistochemistry has been reported to be a useful diagnostic biomarker. However, limited information is available about the association between the p16(INK4a) immunohistochemistry and the outcomes of CIN. Here, we report p16(INK4a) immunohistochemistry as an effective biomarker to predict the outcomes of CIN.;p16(INK4a) immunohistochemistry was performed in patients with CIN from January 2000 to August 2009. Among these patients, we have performed a retrospective analysis of the medical records to evaluate the outcome of CIN 1-2 and performed statistical analysis to determine the correlation between p16(INK4a) expression and the outcomes. We also performed HPV genotyping and analyzed the relation between the infecting human papillomavirus (HPV) genotype and the outcomes.;A total of 244 patients, including 82 with CIN 1, 60 with CIN 2, and 102 with CIN 3, were examined. The rate of p16(INK4a) overexpression increased with increasing CIN grade, 20.7% for CIN 1, 80.0% for CIN 2, and 89.2% for CIN 3, with significant differences between CIN 1 and CIN 2-3 group. In the 131 CIN 1-2 patients, the progression rate was significantly higher for the patients showing p16(INK4a) overexpression than for those not showing p16(INK4a) overexpression (p=0.005); the regression rate was also found to be significantly lower for the patients showing p16(INK4a) overexpression (p=0.003). High-risk HPV genotypes were detected in 73 patients (73.7%). Both progression and regression rates were not significantly different between the high-risk HPV-positive and HPV-negative groups (p=0.401 and p=0.381, respectively).;p16(INK4a) overexpression was correlated with the outcome of CIN 1-2, and p16(INK4a) is considered to be a superior biomarker for predicting the outcome of CIN 1-2 compared with HPV genotyping.",
        "Doc_title":"p16(INK4a) immunohistochemistry is a promising biomarker to predict the outcome of low grade cervical intraepithelial neoplasia: comparison study with HPV genotyping.",
        "Journal":"Journal of gynecologic oncology",
        "Do_id":"23875070",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605897097316401152},
      {
        "Doc_abstract":"Silencing of p16(INK4a) by methylation of the CpG islands in the promoter region has been found to be an alternative mechanism of inactivation in several tumors. However, in gastric carcinoma, the relationship between methylation status and the transcriptional silencing of the p16 gene remains to be clarified. In this study, we investigated whether methylation of a few specific CpG sites in the promoter region could significantly down-regulate p16 activity in the tumorigenesis of gastric carcinoma. By Southern analysis and bisulfite-modified genomic sequencing of 9 gastric-carcinoma cell lines, we found that the 5 cell lines (55.5%) not expressing p16 mRNA had methylated CpG sites at the promoter region of p16. In addition, we analyzed the p16-protein expression of 28 primary gastric carcinomas and their normal counterparts by immunohistochemical staining (IHC) on paraffin sections. Loss of p16 expression was detected in 6 cases (22%). In 5 out of these 6 (83%), the actual p16 gene was inactivated by de novo methylation of the promoter sites. Taken together, these results suggest a strong correlation between de novo methylation of a few specific CpG sites and transcriptional silencing of the p16 gene in gastric carcinoma.",
        "Doc_title":"Methylation of specific CpG sites in the promoter region could significantly down-regulate p16(INK4a) expression in gastric adenocarcinoma.",
        "Journal":"International journal of cancer",
        "Do_id":"10861481",
        "Doc_ChemicalList":"Antimetabolites, Antineoplastic;Carrier Proteins;Cyclin-Dependent Kinase Inhibitor p16;Mutagens;RNA, Messenger;Sulfites;decitabine;Azacitidine;sodium bisulfite",
        "Doc_meshdescriptors":"Adenocarcinoma;Adult;Aged;Antimetabolites, Antineoplastic;Azacitidine;Blotting, Northern;Blotting, Southern;Carrier Proteins;CpG Islands;Cyclin-Dependent Kinase Inhibitor p16;DNA Methylation;Down-Regulation;Female;Humans;Immunohistochemistry;Male;Middle Aged;Models, Genetic;Mutagens;Promoter Regions, Genetic;RNA, Messenger;Reverse Transcriptase Polymerase Chain Reaction;Sequence Analysis, DNA;Stomach Neoplasms;Sulfites;Tumor Cells, Cultured",
        "Doc_meshqualifiers":"genetics;pharmacology;analogs & derivatives;pharmacology;biosynthesis;genetics;genetics;pharmacology;metabolism;genetics;pharmacology",
        "_version_":1605902907948924928},
      {
        "Doc_abstract":"Small-cell carcinoma (SCC) of the cervix is an uncommon member of the neuroendocrine group of cervical carcinomas that is frequently intermixed with a non-SCC component in the form of an adenocarcinoma (ADC) or squamous carcinoma.;Colposcopy revealed a cervical mass in a 41-year-old woman and a Pap smear the presence of some tumor cells from SCC, which was confirmed by subsequent biopsy. The patient received 3 cycles of chemotherapy and then underwent major surgery. The cervical samples showed areas of endocervical ADC adjacent to and intermixed with the SCC. Reviewing the Pap smear, a previously missed malignancy was recognized. On subsequent molecular investigation to assess clonality by microsatellite analysis, the presence of HR-HPV DNA18 on real-time polymerase chain reaction, p16(INK4a) fluorescence in situ hybridization status and the corresponding immunohistochemical expression supported the hypothesis that the two components of the tumor shared the same cell origin.;SCC of the cervix is a rare but distinct HR-HPV-18-related cervical carcinoma often intermixed with a clonally related non-small cell component consisting of an ADC or squamous carcinoma. The presence of SCC tumor cells in a cervical smear should prompt a search for malignant glandular or squamous tumor cells.",
        "Doc_title":"Neuroendocrine small cell carcinoma of the cervix associated with endocervical adenocarcinoma: a case report.",
        "Journal":"Acta cytologica",
        "Do_id":"17718130",
        "Doc_ChemicalList":"Antigens, CD56;Chromogranin A;Cyclin-Dependent Kinase Inhibitor p16;Synaptophysin",
        "Doc_meshdescriptors":"Adult;Antigens, CD56;Biopsy;Carcinoma, Small Cell;Cervix Uteri;Chromogranin A;Chromosomes, Human, Pair 17;Chromosomes, Human, Pair 18;Cyclin-Dependent Kinase Inhibitor p16;Female;Humans;In Situ Hybridization, Fluorescence;Microsatellite Repeats;Neuroendocrine Tumors;Papanicolaou Test;Synaptophysin;Uterine Cervical Neoplasms;Vaginal Smears",
        "Doc_meshqualifiers":"metabolism;pathology;pathology;metabolism;genetics;genetics;metabolism;genetics;pathology;metabolism;pathology",
        "_version_":1605822651765358592},
      {
        "Doc_abstract":"Cellular proliferation under stressful conditions may result in permanent genetic and epigenetic changes. Using primary mouse embryonic fibroblasts, we have completed a screening test to identify gene expression changes triggered when cells proliferate under stress. In this manner, we have discovered a novel phenomenon that consists of the rapid and coordinated silencing of genes subject to imprinting, including Cdkn1c, Igf2, H19, Ndn1, Grb10, and Meg3. This generalized silencing of imprinted genes is independent of the stress-responsive tumor suppressors p53, p19(Arf), and p16(Ink4a), and it is also independent of the oxidative culture conditions and the stress response known as \"mouse embryonic fibroblast senescence\". In the case of Cdkn1c and H19, their silencing is associated with unscheduled de novo methylation of the normally expressed allele at their corresponding CpG island promoters, thus resulting in biallelic methylation. Finally, we provide evidence for frequent de novo methylation of Cdkn1c in a variety of murine cancer types. Altogether, our data support the concept that silencing of imprinted genes, including methylation of Cdkn1c, constitutes an epigenetic signature of cellular stress and tumorigenesis.",
        "Doc_title":"Inactivation of imprinted genes induced by cellular stress and tumorigenesis.",
        "Journal":"Cancer research",
        "Do_id":"15665276",
        "Doc_ChemicalList":"DNA Primers;Methylcholanthrene",
        "Doc_meshdescriptors":"Animals;Base Sequence;Cell Transformation, Neoplastic;Cells, Cultured;DNA Primers;Embryo, Mammalian;Fibroblasts;Fibrosarcoma;Genomic Imprinting;Male;Methylcholanthrene;Mice;Mice, Inbred C57BL;Mice, Knockout;Nucleic Acid Hybridization;Polymerase Chain Reaction;Y Chromosome",
        "Doc_meshqualifiers":"physiology;chemically induced;genetics;genetics;genetics",
        "_version_":1605880353134739456},
      {
        "Doc_abstract":"Human papillomaviruses (HPV) are oncogenic DNA viruses implicated in squamous cell carcinomas of several anatomic sites, as well as endocervical adenocarcinomas. Identification of HPV is an actionable finding in some carcinomas, potentially influencing tumor classification, prognosis, and management. We incorporated capture probes for oncogenic HPV strains 16 and 18 into a broader next-generation sequencing (NGS) panel designed to identify actionable mutations in solid malignancies. A total of 21 head and neck, genitourinary, and gynecologic squamous cell carcinomas and endocervical adenocarcinomas were sequenced as part of the UNCSeq project. Using p16 immunohistochemical results as the gold standard, we set a cutoff for proportion of aligned HPV reads that maximized performance of our NGS assay (92% sensitive, 100% specific for HPV). These results suggest that sequencing of oncogenic pathogens can be incorporated into targeted NGS panels, extending the clinical utility of genomic assays. ",
        "Doc_title":"Identification of Human Papillomavirus Infection in Cancer Tissue by Targeted Next-generation Sequencing.",
        "Journal":"Applied immunohistochemistry & molecular morphology : AIMM",
        "Do_id":"26371432",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605823729728749568},
      {
        "Doc_abstract":"The mechanisms of adrenocortical tumorigenesis are still unknown. Evidence that the majority of adrenocortical tumors are monoclonal in origin suggests that a progressive accumulation of genetic aberrations, due to activation of protooncogenes and/or inactivation of tumor suppressor genes, leads to abnormal cell proliferation through a multistep process. Inactivation of the p16 tumor suppressor gene (p16INK4A), which encodes the cell cycle protein p16, was investigated in a series of 14 adrenocortical tumors. Using 11 polymorphic microsatellite markers spanning the short arm of chromosome 9, we demonstrated that three of seven adrenocortical carcinomas and one of seven adrenocortical adenomas had loss of heterozygosity (LOH) within chromosome 9p21, the region containing p16NK4A. Immunohistochemistry showed the absence of p16 nuclear staining in all adrenocortical tumors with LOH within 9p21, and positive staining in all remaining tumors without LOH. In conclusion, LOH within 9p21 associated with lack of p16 expression occurs in a considerable proportion of adrenocortical malignant tumors, but is rare in adenomas. Inactivation of p16INK4A may contribute to the deregulation of cell proliferation in this neoplastic disease.",
        "Doc_title":"Inactivation of the p16 tumor suppressor gene in adrenocortical tumors.",
        "Journal":"The Journal of clinical endocrinology and metabolism",
        "Do_id":"10443678",
        "Doc_ChemicalList":"CDKN2B protein, human;Carrier Proteins;Cell Cycle Proteins;Cyclin-Dependent Kinase Inhibitor p15;Cyclin-Dependent Kinase Inhibitor p16;Tumor Suppressor Proteins",
        "Doc_meshdescriptors":"Adrenal Cortex Neoplasms;Adult;Aged;Carrier Proteins;Cell Cycle Proteins;Chromosomes, Human, Pair 9;Cyclin-Dependent Kinase Inhibitor p15;Cyclin-Dependent Kinase Inhibitor p16;Female;Genes, p16;Humans;Immunohistochemistry;Loss of Heterozygosity;Male;Middle Aged;Tumor Suppressor Proteins",
        "Doc_meshqualifiers":"genetics;genetics",
        "_version_":1605824245141602304},
      {
        "Doc_abstract":"Inhibition of cyclin dependent kinases (CDK) by cyclin dependent kinase inhibitors (CDKI) blocks cell cycle progression and inhibits cellular proliferation. The archetypical member of the INK4 CDKI family, p16INK4A (also called CDKN2), is a tumor suppressor frequently deleted or mutated in certain neoplasms and many cell lines. Because p19INK4D has strong structural and functional similarity to p16INK4A, we have assessed its role as a tumor suppressor. This was accomplished by screening the p19INK4D coding region for mutations, deletions and rearrangements in sarcomas and non-small cell lung cancers. Alterations of the p19INK4D gene were found in samples from five of 67 (7%) patients with osteosarcomas and none were found in other types of sarcomas or in lung cancers. Five osteosarcoma samples had Southern blot patterns consistent with gene rearrangement. These samples included a primary and recurrent osteosarcoma from the same patient; both with the same rearrangement. Four samples had SSCP patterns consistent with sequence alterations, sequencing determined that three were due to silent base changes and apparently polymorphisms. Sequencing the fourth shifted band revealed a one base insertion causing a frameshift beginning with codon 27. In summary, these studies found alterations affecting the p19INK4D gene in a small but significant number of osteosarcomas. Presumably, abnormalities of this gene contribute to the development of cancer of bone cells.",
        "Doc_title":"The p19INK4D cyclin dependent kinase inhibitor gene is altered in osteosarcoma.",
        "Journal":"Oncogene",
        "Do_id":"9244358",
        "Doc_ChemicalList":"CDKN2D protein, human;Carrier Proteins;Cell Cycle Proteins;Cyclin-Dependent Kinase Inhibitor p16;Cyclin-Dependent Kinase Inhibitor p19;Enzyme Inhibitors;DNA;Cyclin-Dependent Kinases",
        "Doc_meshdescriptors":"Carrier Proteins;Cell Cycle Proteins;Cyclin-Dependent Kinase Inhibitor p16;Cyclin-Dependent Kinase Inhibitor p19;Cyclin-Dependent Kinases;DNA;Enzyme Inhibitors;Gene Rearrangement;Genes, Tumor Suppressor;Humans;Osteosarcoma",
        "Doc_meshqualifiers":"genetics;antagonists & inhibitors;chemistry;genetics",
        "_version_":1605741983321554945},
      {
        "Doc_abstract":"Telomere shortening in primary human fibroblasts results in replicative senescence, which can be overcome by telomerase (hTERT) overexpression. However, because immortalization is one of the hallmarks of malignant transformation, careful analysis of hTERT-immortalized cells is of crucial importance for understanding both processes. To this end, we infected WI-38 fibroblasts with a retrovirus carrying the hTERT cDNA and analyzed their proliferative behavior during 600 days [ approximately 500 population doublings (PDLs)] of continuous culture. Growth of three independent mass cultures was uniform for approximately 150 PDLs after telomerase infection, followed by a progressive acceleration of growth in two of three cultures. Expression of p16(INK4A) was significantly elevated in the immortalized cells but gradually disappeared during the accelerated growth phase. This alteration correlated with loss of the contact inhibition response and conferred the cells with sensitivity to H-Ras-induced transformation. In contrast, the p53- and pRb-mediated checkpoints such as the DNA damage response, chromosomal stability and entry into quiescence remained intact, irrespective of INK4A locus expression. Importantly, detailed examination of one of the WI-38/hTERT cultures during the accelerated growth phase revealed overexpression of the c-myc and Bmi-1 oncogenes, as well as loss of p14(ARF) expression. Collectively, our results indicate that although hTERT-immortalized cells behave similarly to primary cells during the first 150 PDLs, long-term growth in culture may favor the appearance of clones carrying potentially malignant alterations.",
        "Doc_title":"Prolonged culture of telomerase-immortalized human fibroblasts leads to a premalignant phenotype.",
        "Journal":"Cancer research",
        "Do_id":"14612508",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;DNA-Binding Proteins;Retinoblastoma Protein;Tumor Suppressor Protein p14ARF;Telomerase",
        "Doc_meshdescriptors":"Cell Division;Cell Transformation, Neoplastic;Contact Inhibition;Cyclin-Dependent Kinase Inhibitor p16;DNA-Binding Proteins;Fibroblasts;Gene Silencing;Genes, p53;Genes, ras;Humans;Precancerous Conditions;Retinoblastoma Protein;Retroviridae;Telomerase;Time Factors;Transduction, Genetic;Tumor Suppressor Protein p14ARF",
        "Doc_meshqualifiers":"physiology;metabolism;pathology;biosynthesis;genetics;cytology;enzymology;physiology;physiology;enzymology;pathology;genetics;enzymology;genetics;biosynthesis;genetics;metabolism;biosynthesis;genetics",
        "_version_":1605831017192488960},
      {
        "Doc_abstract":"Individuals with inherited cancer syndromes are at significant risk of developing both benign and malignant tumours as a result of a germline mutation in a specific tumour suppressor gene. Tumours of familial origin are a rare event in the head and neck but despite this, they deserve a growing interest. Familial paragangliomas are most of the time limited to the paraganglionar system, but also may be part of different syndromic associations. Since early detection of paragangliomas reduces the incidence of morbidity and mortality, genotypic analysis in the search of SDHB, SDHC and SDHD mutations in families of affected patients plays a front-line diagnostic role, leading to more efficient patient management. Multiple endocrine neoplasias type 1 are characterized by the simultaneous occurrence of at least two of the three main related endocrine tumours: parathyroid, enteropancreatic and anterior pituitary. These tumours arise from inactivating germline mutations in the MEN-1 gene. No clear correlation of MEN-1 genotype with genotype has emerged to date, and MEN-1 mutation testing in tumours is not used clinically because it have not implications for tumour staging. Multiple endocrine neoplasia type 2 is due to a germline mutation in the RET proto-oncogene. Hallmarks of MEN-2A (the commonest phenotypic variant) include medullary thyroid carcinoma, pheochromocytoma, and hyperparathyroidism. The most central clinical difference with MEN-1 is that the associated cancer can be prevented or cured by early thyroidectomy in mutation carriers. Individuals with neurofibomatosis type 1 present early in life with pigmentary abnormalities, skinfold freckling and iris hamartomas, as result of NF1 gene mutation. Neurofibromatosis 2 is caused by inactivating mutations of the NF2 gene, and is characterized by the development of nervous system tumours (mainly bilateral vestibular schwannomas), ocular abnormalities, and skin tumours. The molecular genetic basis of nasopharyngeal carcinomas remains unknown, but there is evidence for the linkage of these tumours to chromosome 3p. Finally, the high rate of p16 mutations in squamous cell carcinomas and the association of p16 with familial melanoma propose p16 as an ideal candidate gene predisposing to familial squamous cell carcinomas. The elucidation of the cellular processes affected by dysfunction in familial tumours of the head and neck may serve to identify potential targets for future therapeutic interventions.",
        "Doc_title":"Tumours of familial origin in the head and neck.",
        "Journal":"Oral oncology",
        "Do_id":"16857415",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Carcinoma, Squamous Cell;Head and Neck Neoplasms;Humans;Multiple Endocrine Neoplasia;Nasopharyngeal Neoplasms;Neoplastic Syndromes, Hereditary;Neurofibromatoses;Paraganglioma",
        "Doc_meshqualifiers":"genetics;genetics;genetics;genetics;genetics;genetics;genetics",
        "_version_":1605756203858657280},
      {
        "Doc_abstract":"We have screened for CDKN2A germline mutations in 49 Jewish families with two or more cases of melanoma. The Val59Gly mutation, one of the three different alterations identified among these families, was also detected independently in two kindreds from France and one from Spain. The impact of the Val59Gly substitution on the function of the cyclin-dependent kinase inhibitor p16(INK4a), a product of the CDKN2A gene, was assessed by protein-protein interaction and cell proliferation assays and related to potential structural alterations predicted by molecular modeling. Seven microsatellite markers in the vicinity of the CDKN2A gene were used to determine whether the mutation in these families is identical by descent, or represents a mutational hotspot in the CDKN2A gene. Our results show that the Val59Gly substitution impairs p16(INK4a) function, and this dysfunction is consistent with structural predictions. All melanoma-affected individuals tested in the families under study harbor this mutation. Interestingly, the Israeli pedigree includes an affected individual who is homozygous for the Val59Gly mutation. A common haplotype of microsatellite markers has been demonstrated for mutation carriers in all four pedigrees. The Israeli pedigree and one of the French melanoma families are of Moroccan and Tunisian Jewish descent, respectively, and the other families originate from regions of France and Spain close to the Pyrenees. We conclude that the Val59Gly mutation is a major contributor to melanoma risk in the families under study and that it may derive from a single ancestral founder of Mediterranean (possibly Jewish) origin.",
        "Doc_title":"A single Mediterranean, possibly Jewish, origin for the Val59Gly CDKN2A mutation in four melanoma-prone families.",
        "Journal":"European journal of human genetics : EJHG",
        "Do_id":"12700603",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16",
        "Doc_meshdescriptors":"Chromosome Mapping;Chromosomes, Human, Pair 9;Cyclin-Dependent Kinase Inhibitor p16;Genes, p16;Genetic Predisposition to Disease;Humans;Jews;Mediterranean Region;Melanoma;Microsatellite Repeats;Pedigree;Polymorphism, Single-Stranded Conformational;Protein Conformation",
        "Doc_meshqualifiers":"genetics;chemistry;genetics;genetics",
        "_version_":1605742022810927105},
      {
        "Doc_abstract":"To test the hypothesis that cell cycle regulatory gene abnormalities are determinants of clinical outcome in adult acute lymphoblastic leukemia (ALL), we screened lymphoblasts from patients on a Southwest Oncology Group protocol for abnormalities of the genes, retinoblastoma (Rb), p53, p15(INK4B), and p16(INK4A). Aberrant expression occurred in 33 (85%) patients in the following frequencies: Rb, 51%; p16(INK4A), 41%; p53, 26%. Thirteen patients (33%) had abnormalities in 2 or more genes. Outcomes were compared in patients with 0 to 1 abnormality versus patients with multiple abnormalities. The 2 groups did not differ in a large number of clinical and laboratory characteristics. The CR rates for patients with 0 to 1 and multiple abnormalities were similar (69% and 54%, respectively). Patients with 0 to 1 abnormality had a median survival time of 25 months (n = 26; 95% CI, 13-46 months) versus 8 months (n = 13; 95% CI, 4-12 months) for those with multiple abnormalities (P <.01). Stem cells (CD34+lin-) were isolated from adult ALL bone marrows and tested for p16(INK4A) expression by immunocytochemistry. In 3 of 5 patients lymphoblasts and sorted stem cells lacked p16(INK4A) expression. In 2 other patients only 50% of sorted stem cells expressed p16(INK4A). By contrast, p16 expression was present in the CD34+ lin- compartment in 95% (median) of 9 patients whose lymphoblasts expressed p16(INK4A). Therefore, cell cycle regulatory gene abnormalities are frequently present in adult ALL lymphoblasts, and they may be important determinants of disease outcome. The presence of these abnormalities in the stem compartment suggests that they contribute to leukemogenesis. Eradication of the stem cell subset harboring these abnormalities may be important to achieve cure.",
        "Doc_title":"Cell cycle regulatory gene abnormalities are important determinants of leukemogenesis and disease biology in adult acute lymphoblastic leukemia.",
        "Journal":"Blood",
        "Do_id":"10733508",
        "Doc_ChemicalList":"CDKN2B protein, human;Carrier Proteins;Cell Cycle Proteins;Cyclin-Dependent Kinase Inhibitor p15;Cyclin-Dependent Kinase Inhibitor p16;Tumor Suppressor Proteins",
        "Doc_meshdescriptors":"Adolescent;Adult;Aged;Bone Marrow;Carrier Proteins;Cell Cycle;Cell Cycle Proteins;Cell Separation;Cyclin-Dependent Kinase Inhibitor p15;Cyclin-Dependent Kinase Inhibitor p16;Female;Flow Cytometry;Genes, Retinoblastoma;Genes, p53;Humans;Male;Middle Aged;Mutation;Precursor Cell Lymphoblastic Leukemia-Lymphoma;Remission Induction;Survival Rate;Tumor Suppressor Proteins",
        "Doc_meshqualifiers":"chemistry;genetics;genetics;genetics;genetics;genetics;mortality;pathology",
        "_version_":1605836375624515584},
      {
        "Doc_abstract":"p19(Ink4d) is a member of the INK4 family of cyclin-dependent kinase inhibitors, which are important negative regulators of the G1-phase cyclin-dependent kinases CDK4 and CDK6. On a mixed C57BL/6 x 129P2/OlaHsd background, mice deficient for p19(Ink4d) exhibited defects in male reproductive function including testicular atrophy, alteration in serum follicle stimulating hormone, qualitative increase in germ cell apoptosis, and delayed kinetics of meiotic prophase markers (Zindy et al., 2001. Mol Cell Biol 21:3244-3255; Zindy et al., 2000. Mol Cell Biol 20:372-378). In this study, a quantitative assessment of these aspects of reproductive capacity demonstrated relatively mild deficits in p19(Ink4d-/-) males compared to controls. These effects did not dramatically worsen in older males although some seminiferous tubule defects were observed. Following marker-assisted backcrossing into the C57BL/6 background, p19(Ink4d-/-) males did not display defects in testis weights, sperm numbers, serum FSH, germ cell apoptosis, or kinetics of selected meiotic prophase markers. These studies indicate that a reduction in Ink4 family function by the loss of p19(Ink4d) is sufficient to induce mild reproductive defects in male mice with a mixed genetic background, but not in the C57BL/6 genetic background.",
        "Doc_title":"Mice lacking cyclin-dependent kinase inhibitor p19Ink4d show strain-specific effects on male reproduction.",
        "Journal":"Molecular reproduction and development",
        "Do_id":"17393423",
        "Doc_ChemicalList":"Biomarkers;Cdkn2d protein, mouse;Cyclin-Dependent Kinase Inhibitor p19;Testosterone;Follicle Stimulating Hormone;Cyclin-Dependent Kinase 4;Cyclin-Dependent Kinase 6",
        "Doc_meshdescriptors":"Animals;Apoptosis;Biomarkers;Cyclin-Dependent Kinase 4;Cyclin-Dependent Kinase 6;Cyclin-Dependent Kinase Inhibitor p19;Female;Fertility;Follicle Stimulating Hormone;Germ Cells;Litter Size;Male;Meiosis;Mice;Mice, Inbred Strains;Mice, Knockout;Organ Size;Reproduction;Species Specificity;Testis;Testosterone",
        "Doc_meshqualifiers":"metabolism;metabolism;metabolism;genetics;metabolism;physiology;blood;physiology;anatomy & histology;metabolism;pathology;blood",
        "_version_":1605830937646465024},
      {
        "Doc_abstract":"To investigate the effects of histone acetylation on the expression of p21(WAF1) and p16(INK4A) genes in two human colon cancer cell lines.;Two colon cancer cell lines (SW1116 and Colo-320) were treated with the DNA methyltransferase (DNMT) inhibitor, 5-aza-2'-deoxycytidine (5-aza-dC) and/or the histone deacetylase (HDAC) inhibitor, trichostatin A (TSA) or sodium butyrate (NaBu). The cell cycle distribution was studied by flow cytometry (FCM). The expression of p21(WAF1) and p16(INK4A) genes mRNA was detected by real-time RT-PCR. The level of acetylated histones in chromatin associated with the p21(WAF1) and p16(INK4A) genes was examined by chromatin immunoprecipitation (ChIP) assay.;TSA or NaBu blocked cells mainly in the G(1) phase, whereas 5-aza-dC treatment failed to affect cell cycle distribution. Expression of p16(INK4A) was detected slightly and p21(WAF1) was not expression in SW1116 and Colo-320 cells before treatment. In SW1116 and Colo-320 cells, the expression of p16(INK4A) gene was markedly increased after treatment of 5-aza-dC, although 5-aza-dC treatment did not activate the expression of p21(WAF1) gene. Treatment of TSA and NaBu resulted in the significant over-expression of p21(WAF1) in these two cell lines and induced an accumulation of acetylate histones H3 and H4 in chromatin associated with p21(WAF1) gene.;In these two human colon cancer cell lines, HDAC inhibitors stimulate the p21(WAF1) gene expression by selectively increasing the degree of acetylation of the gene-associated histones, and induce a G(1) cell cycle arrest. The expression of the p16(INK4A) gene is regulated by DNA methylation.",
        "Doc_title":"[Regulation of histone acetylation on the expression of cell cycle-associated genes in human colon cancer cell lines].",
        "Journal":"Zhonghua yi xue za zhi",
        "Do_id":"15059516",
        "Doc_ChemicalList":"Butyrates;CDKN1A protein, human;Cyclin-Dependent Kinase Inhibitor p16;Cyclin-Dependent Kinase Inhibitor p21;Cyclins;Enzyme Inhibitors;Histone Deacetylase Inhibitors;Histones;Hydroxamic Acids;RNA, Messenger;trichostatin A;Histone Deacetylases",
        "Doc_meshdescriptors":"Acetylation;Butyrates;Cell Cycle;Cell Line, Tumor;Colonic Neoplasms;Cyclin-Dependent Kinase Inhibitor p16;Cyclin-Dependent Kinase Inhibitor p21;Cyclins;Enzyme Inhibitors;Flow Cytometry;Gene Expression Regulation, Neoplastic;Histone Deacetylase Inhibitors;Histone Deacetylases;Histones;Humans;Hydroxamic Acids;RNA, Messenger;Reverse Transcriptase Polymerase Chain Reaction",
        "Doc_meshqualifiers":"pharmacology;genetics;physiology;genetics;metabolism;pathology;genetics;genetics;pharmacology;metabolism;metabolism;pharmacology;genetics;metabolism",
        "_version_":1605808524459245568},
      {
        "Doc_abstract":"Actinic keratosis (AK) is an incipient form of cutaneous squamous cell carcinoma (SCC). We determined if the pattern of expression of keratin-14 (K14) is a factor for tumor progression in AK and SCC.;Eighteen sections from the tissues of 16 patients were stained with anti-K14 antibody and p16(INK4a). Among the 16 patients, 4 were diagnosed with both SCC and AK at the same site, but AK developed first and SCC developed subsequently. Thus, SCC may have evolved from AK. The other 12 patients were only diagnosed with AK.;In all of the AK and SCC tissues, basement membranes showed positive staining for K14. However, strong reactivities were shown in the spinous and granular layers and focuses of dermal invasion in the SCC tissues developed from AK. Two and 3 of the 12 AK cases had moderately positive reactions for K14 in the spinous and granular layers, respectively. Also, all SCC tissues except one had moderate-to-strong reactions in the basal, spinous, and granular layers for p16(INK4a). Two of the 12 AK cases had weak-to-moderate positive reactions in the basal, spinous, and horny layers for p16(INK4a).;The results of our study advance our understanding of the pathogenesis of SCC developing from AK. The results also indicate a differential role in the control of K14 in normal epithelia, AK, and SCC. K14 expression in the spinous and granular layers may be a prognostic factor for tumor progression of AK.",
        "Doc_title":"The keratin-14 expression in actinic keratosis and squamous cell carcinoma: is this a prognostic factor for tumor progression?",
        "Journal":"Cancer research and treatment : official journal of Korean Cancer Association",
        "Do_id":"20622965",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605746832594436096},
      {
        "Doc_abstract":"The CDKN2 gene encodes p16, a protein controlling the cell cycle. CDKN2 is deleted in a relevant number of tumor cell lines, but results of the studies in primary tumors are contradictory. We have investigated by using quantitative polymerase chain reaction and single-strand conformation polymorphism analysis the structure of exon 2 of CDKN2 in 32 malignant gliomas. In 11 tumors the amount of amplified material was 21% of that of controls and in 8 tumors it was 42.3%, suggesting the presence of homozygous and hemizygous deletions of the CDKN2 gene, respectively. However, no abnormality could be detected by single-strand conformation polymorphism analysis. The data confirm in primary gliomas that homozygous deletions are a mechanism of CDKN2 inactivation and suggest that another gene in the vicinity could be targeted by mutations.",
        "Doc_title":"Mutation rate of the CDKN2 gene in malignant gliomas.",
        "Journal":"Cancer research",
        "Do_id":"7987825",
        "Doc_ChemicalList":"Carrier Proteins;Cyclin-Dependent Kinase Inhibitor p16",
        "Doc_meshdescriptors":"Base Sequence;Carrier Proteins;Cyclin-Dependent Kinase Inhibitor p16;Exons;Glioma;Humans;Molecular Sequence Data;Mutation;Polymerase Chain Reaction",
        "Doc_meshqualifiers":"genetics;genetics;genetics;genetics",
        "_version_":1605852564022099968},
      {
        "Doc_abstract":"Loss of CDKN2A/p16(INK4A) in hematopoietic stem cells is associated with enhanced self-renewal capacity and might facilitate progression of damaged stem cells into pre-cancerous cells that give rise to leukemia. This is also reflected by the frequent loss of the INK4A locus in acute lymphoblastic T-cell leukemia. T-cell acute lymphoblastic leukemia cells designed to conditionally express p16(INK4A) arrest in the G(0)/G(1) phase of the cell cycle and show increased sensitivity to glucocorticoid- and tumor necrosis factor receptor superfamily 6-induced apoptosis. To investigate the underlying molecular mechanism for increased death sensitivity, we interfered with specific steps of apoptosis signaling by expression of anti-apoptotic proteins. We found that alterations in cell death susceptibility resulted from changes in the composition of pro- and anti-apoptotic BCL2 proteins, i.e. repression of MCL1, BCL2, and PMAIP1/Noxa and the induction of pro-apoptotic BBC3/Puma. Interference with Puma induction by short hairpin RNA technology or retroviral expression of MCL1 or BCL2 significantly reduced both glucocorticoid- and FAS-induced cell death in p16(INK4A)-reconstituted leukemia cells. These results suggest that Puma, in concert with MCL1 and BCL2 repression, critically mediates p16(INK4A)-induced death sensitization and that in human T-cell leukemia the deletion of p16(INK4A) confers apoptosis resistance by shifting the balance of pro- and anti-apoptotic BCL2 proteins toward apoptosis protection.",
        "Doc_title":"p16INK4A sensitizes human leukemia cells to FAS- and glucocorticoid-induced apoptosis via induction of BBC3/Puma and repression of MCL1 and BCL2.",
        "Journal":"The Journal of biological chemistry",
        "Do_id":"19737931",
        "Doc_ChemicalList":"Apoptosis Regulatory Proteins;BBC3 protein, human;Cyclin-Dependent Kinase Inhibitor p16;Fas Ligand Protein;Glucocorticoids;Myeloid Cell Leukemia Sequence 1 Protein;Proto-Oncogene Proteins;Proto-Oncogene Proteins c-bcl-2",
        "Doc_meshdescriptors":"Apoptosis;Apoptosis Regulatory Proteins;Cell Line, Tumor;Cyclin-Dependent Kinase Inhibitor p16;Down-Regulation;Fas Ligand Protein;Gene Expression Regulation, Leukemic;Glucocorticoids;Humans;Leukemia;Myeloid Cell Leukemia Sequence 1 Protein;Proto-Oncogene Proteins;Proto-Oncogene Proteins c-bcl-2",
        "Doc_meshqualifiers":"genetics;metabolism;genetics;metabolism;metabolism;metabolism;genetics;metabolism;physiopathology;genetics;metabolism;genetics;metabolism",
        "_version_":1605765346433695744},
      {
        "Doc_abstract":"(1) To investigate the promoter methylation status of gene p16(INK4a) and gene RB in breast carcinoma and the adjacent non-neoplastic hyperplastic epithelial tissue. (2) To study the correlation of p16(INK4a) gene expression at protein level with the abnormal gene methylation, the clinical manifestation and the pathological parameters.;Methylation status of promoters of p16(INK4a) gene and RB gene was detected by using methylation specific PCR in 46 cases of breast cancer, 22 cases of the adjacent non-neoplastic hyperplastic epithelium tissue and 7 cases of normal breast tissue. In addition, the p16(INK4a) gene protein expression level was also detected using immunohistochemical technique(SP method) in 46 cases of breast cancer and 22 cases of the adjacent hyperplastic epithelial tissue.;The methylation rate of p16(INK4a) gene was 23.9% (11/46) in breast cancer, 18.2% (4/22) in the adjacent non-neoplastic hyperplastic epithelial tissue and 1/7 in normal breast tissue, respectively. The methylation rate of RB gene was relatively low, which was 10.8% (5/46), 9.1% (2/22) and 0(0/7) in the above 3 groups, respectively. Methylation rate of p16(INK4a) gene and RB gene was not significantly different among the breast cancer, the adjacent non-neoplastic hyperplastic tissue and the normal tissues (P > 0.05). However, the methylation status of p16(INK4a) gene was closely correlated with its protein expression level and the negative ER expression result of the breast cancer (P < 0.05), but not correlated with the size of the cancer, differentiation status, lymph node metastasis, and age. The methylation status of RB gene was correlated with lymph node metastasis, but not with the size, the differentiation status, ER expression of the breast cancer and the age of the patients.;The abnormal methylation of p16(INK4a) gene may not play a significant role in the early stage of breast cancinogenesis, but may play a role of in the progression of the cancer. RB gene methylation may also be a indicator in choice to identify the progression and prognosis of breast cancer.",
        "Doc_title":"[Methylation and expression of gene p16INK4a and RB in breast carcinoma].",
        "Journal":"Zhonghua bing li xue za zhi = Chinese journal of pathology",
        "Do_id":"21055153",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;Receptors, Estrogen;Retinoblastoma Protein",
        "Doc_meshdescriptors":"Adult;Aged;Breast Neoplasms;Carcinoma, Ductal, Breast;Carcinoma, Intraductal, Noninfiltrating;Cyclin-Dependent Kinase Inhibitor p16;DNA Methylation;Female;Gene Expression Regulation, Neoplastic;Genes, p16;Humans;Lymphatic Metastasis;Middle Aged;Receptors, Estrogen;Retinoblastoma Protein",
        "Doc_meshqualifiers":"genetics;metabolism;pathology;genetics;metabolism;pathology;genetics;metabolism;pathology;genetics;metabolism;metabolism;genetics;metabolism",
        "_version_":1605764804034691072},
      {
        "Doc_abstract":"Gene amplification is a relatively rare event in hematologic malignancies. The ABL gene on chromosome band 9q34 is a proto-oncogene and is the well-known translocation partner of the BCR gene on 22q11 giving rise to t(9;22)(q34;q11), which is the hallmark of chronic myeloid leukemia and is the most common chromosomal abnormality in adult acute lymphoblastic leukemia (ALL). Amplification of ABL is an exceedingly rare event, with only less than 5 cases reported in the literature. The p16(INK4a) (or CDKN2A) gene on 9p21 is a tumor suppressor gene, and deletion thereof is recently recognized as one of the most common genetic abnormalities in ALL. The authors herein describe an 8-year-old male patient with precursor T-cell ALL harboring both ABL gene amplification and p16(INK4a) gene deletion. Fluorescence in situ hybridization (FISH) analysis using BCR/ABL probes revealed five or more ABL signals, indicating amplification in 51.5% of interphase nuclei. FISH using p16(INK4a) gene probes showed heterozygous p16(INK4a) deletion in 71.0%. On conventional cytogenetic analysis, however, only 10 metaphases were available, which showed the normal karyotype, 46,XY[10], serving no evidence for the findings on FISH. This is the first report of an ALL case with ABL amplification, and the authors speculate that both ABL proto-oncogene amplification and the p16(INK4a) tumor suppressor gene deletion have been implicated in leukemogenesis in the present case, although whether the ABL amplification truly contributes to the leukemogenesis or merely an epiphenomenon representing underlying genomic instability remains to be determined.",
        "Doc_title":"ABL oncogene amplification with p16(INK4a) gene deletion in precursor T-cell acute lymphoblastic leukemia/lymphoma: report of the first case.",
        "Journal":"American journal of hematology",
        "Do_id":"15282669",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Child;Chromosomes, Human, Pair 9;Gene Amplification;Gene Deletion;Genes, abl;Genes, p16;Humans;In Situ Hybridization, Fluorescence;Karyotyping;Male;Precursor T-Cell Lymphoblastic Leukemia-Lymphoma",
        "Doc_meshqualifiers":"genetics;ultrastructure;genetics",
        "_version_":1605882713863094272},
      {
        "Doc_abstract":"Vulvar Intraepithelial Neoplasia (VIN) is the precursor lesion of Vulvar Squamous Cell Carcinoma (VSCC), and the differentiated type (dVIN) is more frequently observed in relation to VSCC. In contrast to usual-type VIN (uVIN), which is related to infection by human papillomavirus (HPV), a germline mutation in the p53 gene is thought to be associated with ~90% of dVIN cases. To date, no infectious agent has been identified in association with dVIN, and studies investigating this possibility have been hindered by the difficulty in accurately diagnosing dVIN from small biopsies. Here, we used immunostaining for p16ink4a), a biomarker for HPV infection, to study 14 uVIN high-grade VIN and 14 dVIN cases, and to select 10 dVIN cases to broadly screen for all kn(own viruses using a pan-viral microarray platform (ViroChip). All of the uVIN tissue samples, including 8 warty and 6 basaloid cases, showed positivity with the p16(ink4a) immunostain. The staining pattern was full-thickness for all except two cases in which positive staining was localized in the lower 1/3 of the epidermis. In contrast, immunostaining for p16(ink4a) was negative in all dVIN cases. ViroChip analysis of 10 pure dVIN samples confirmed the absence of human papillomavirus subtypes or any other virus with the exception of a single sample that showed a weak microarray signature to a porcine herpesvirus. Follow-up PCR testing of the sample was negative for herpesvirus, and in-depth metagenomic next-generation sequencing revealed only sequences corresponding to non-pathogenic viral flora and bacterial contamination. In this study, we demonstrated lack of a virus association in 10 dVIN cases. Alternative pathways for carcinogenesis such as the p53 mutation should be considered for investigation of potential treatment options in dVIN.",
        "Doc_title":"No viral association found in a set of differentiated vulvar intraepithelial neoplasia cases by human papillomavirus and pan-viral microarray testing.",
        "Journal":"PloS one",
        "Do_id":"25894343",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16",
        "Doc_meshdescriptors":"Aged;Carcinoma in Situ;Cyclin-Dependent Kinase Inhibitor p16;Female;High-Throughput Nucleotide Sequencing;Humans;Middle Aged;Oligonucleotide Array Sequence Analysis;Papillomaviridae;Vulvar Neoplasms",
        "Doc_meshqualifiers":"metabolism;pathology;virology;metabolism;genetics;isolation & purification;physiology;metabolism;pathology;virology",
        "_version_":1605819622395740160},
      {
        "Doc_abstract":"Even though p16(INK4a) (p16) immunocytochemistry has proven a useful accessory tool verifying the identification of atypical squamous cells of undetermined significance (ASC-US) categorized smears, the procedure still has limitations. To date few studies examining the usefulness of p16 immunocytochemistry in atypical squamous cells which cannot exclude HSIL (ASC-H), compared with ASC-US in liquid-based cervical smears. Therefore, we examined the correlation of p16 immunocytochemical staining with follow-up biopsy results on ASC-H categorized smears and compared the data with those classified as ASC-US on 105 liquid-based cytology samples. We found no statistical significance in the p16 expression of ASC-US smears and the presence of squamous intraepithelial lesions (SIL) in follow-up biopsies (p = 0.546). However, p16 expression did significantly correlate with the presence of SIL (p = 0.002) in ASC-H smears. There was a statistically significant relationship between p16 expression and presence of high grade squamous intraepithelial lesions (HSIL) or more on the follow-up biopsies in both ASC-US (p = 0.012) and ASC-H (p < 0.001) categorized smears. In ASC-US categorized smears, there was no statistical significance between p16 expression and the HR-HPV viral load (p = 0.091). But there was a statistical significance between p16 expression and the HR-HPV viral load (p < 0.001) in ASC-H categorized smears. Our results indicate that p16 immunostaining is a much better useful marker for HR-HPV infection and detection of SIL in ASC-H categorized smears compared to those defined as ASC-US.",
        "Doc_title":"The use of p16(INK4A) immunocytochemistry in \"Atypical squamous cells which cannot exclude HSIL\" compared with \"Atypical squamous cells of undetermined significance\" in liquid-based cervical smears.",
        "Journal":"Diagnostic cytopathology",
        "Do_id":"19760769",
        "Doc_ChemicalList":"Biomarkers, Tumor;Cyclin-Dependent Kinase Inhibitor p16;DNA, Viral",
        "Doc_meshdescriptors":"Biomarkers, Tumor;Carcinoma, Squamous Cell;Cervical Intraepithelial Neoplasia;Cyclin-Dependent Kinase Inhibitor p16;DNA, Viral;Diagnosis, Differential;Female;Humans;Immunohistochemistry;Papillomaviridae;Papillomavirus Infections;Tumor Virus Infections;Uterine Cervical Neoplasms;Vaginal Smears;Viral Load",
        "Doc_meshqualifiers":"metabolism;metabolism;pathology;virology;metabolism;pathology;virology;metabolism;analysis;genetics;genetics;isolation & purification;complications;metabolism;pathology;complications;metabolism;pathology;metabolism;pathology;virology;methods;standards",
        "_version_":1605774506445504512},
      {
        "Doc_abstract":"p16INK4A is a G1-specific cell cycle inhibitor which maps to human chromosome 9p21, a region frequently mutated or deleted in cancer cell lines and primary tumors. In glioblastomas the frequency of homozygous deletions is 40-70% making it one of the most common mutations in this tumor type. We have analysed the significance of the loss of this gene in gliomas by introducing the cDNA for p16INK4A into the human glioma cell line U-1242 MG which has a deleted CDKN2 locus. We used the tetracycline repressible vector system and obtained two stably transfected clones that expressed p16INK4A upon induction. p16INK4A expression caused a G1 arrest and enlargement of the cells similar to that of senescent cells. When staining for Senescence-Associated beta-galactosidase activity, described to be specific for senescent cells, we could show that the enlarged cells specifically gave a positive staining reaction. This senescence phenotype was dependent on the continuous expression of p16INK4A since it was reversed upon reintroduction of tetracycline suppression. Thus, the induced expression of p16INK4A in these glioma cells reverted their immortal phenotype and caused an immediate cellular senescence.",
        "Doc_title":"Induction of senescence in human malignant glioma cells by p16INK4A.",
        "Journal":"Oncogene",
        "Do_id":"9247304",
        "Doc_ChemicalList":"Carrier Proteins;Cyclin-Dependent Kinase Inhibitor p16;Proto-Oncogene Proteins;Retinoblastoma Protein;Vimentin;CDK4 protein, human;Cyclin-Dependent Kinase 4;Cyclin-Dependent Kinases;beta-Galactosidase;Tetracycline",
        "Doc_meshdescriptors":"Apoptosis;Carrier Proteins;Cell Aging;Cell Division;Cyclin-Dependent Kinase 4;Cyclin-Dependent Kinase Inhibitor p16;Cyclin-Dependent Kinases;G1 Phase;Gene Deletion;Gene Expression Regulation, Neoplastic;Genetic Vectors;Glioma;Homozygote;Humans;Phenotype;Proto-Oncogene Proteins;Retinoblastoma Protein;Tetracycline;Vimentin;beta-Galactosidase",
        "Doc_meshqualifiers":"genetics;genetics;metabolism;genetics;genetics;genetics;metabolism;genetics;drug therapy;genetics;genetics;metabolism;pharmacology;metabolism;genetics;metabolism",
        "_version_":1605852824734793728},
      {
        "Doc_abstract":"Central to many cancers is the aberrant expression of genes that regulate the cell cycle including the cyclin-dependent kinase inhibitors known as p15INK4b and p16INK4a, p14ARF and the retinoblastoma (RB) protein. We performed a detailed analysis of the methylation status of these genes by methylation specific polymerase chain reaction (MSP) in tumor cells of 35 adult T-cell leukemia/lymphoma (ATL) patients. We found in nine of 35 cases (26%) at least one gene methylated. The frequency of p15INK4b methylation was 7 of 35 (20%). The incidence of methylation of p14ARF and p16INK4a was two of 35 (6%) and one of 35 (3%), respectively. The RB gene was not found to be methylated in any of the ATL samples. The data indicate that inactivation of these cell cycle regulatory genes by hypermethylation is important in the development of ATL.",
        "Doc_title":"Methylation analysis of cell cycle control genes in adult T-cell leukemia/lymphoma.",
        "Journal":"Leukemia & lymphoma",
        "Do_id":"11697628",
        "Doc_ChemicalList":"CDKN2B protein, human;Cell Cycle Proteins;Cyclin-Dependent Kinase Inhibitor p15;Cyclin-Dependent Kinase Inhibitor p16;Tumor Suppressor Protein p14ARF;Tumor Suppressor Proteins",
        "Doc_meshdescriptors":"Cell Cycle Proteins;Cyclin-Dependent Kinase Inhibitor p15;Cyclin-Dependent Kinase Inhibitor p16;DNA Methylation;Genes, cdc;Humans;Leukemia-Lymphoma, Adult T-Cell;Retinoblastoma;Tumor Suppressor Protein p14ARF;Tumor Suppressor Proteins",
        "Doc_meshqualifiers":"genetics;genetics;etiology;genetics;pathology;genetics;genetics",
        "_version_":1605746457457983489},
      {
        "Doc_abstract":"To determine the role of human papillomavirus (HPV) in the pathogenesis of primary squamous cell carcinoma of the vagina (SCCVa), and to evaluate its clinicopathological significance.;All cases of SCCVa diagnosed over a 15-year period from two hospitals in Barcelona, Spain (n=32) were retrieved. Patients with a history of carcinoma of the cervix diagnosed <5 years before were excluded. HPV was detected and typed by polymerase chain reaction (PCR) using SPF10 primers. Immunohistochemistry was performed for p16 and p53. HPV was detected in 25 cases (78.1%). HPV16 was the most prevalent type. Patients with HPV-positive tumours were associated frequently with a history of carcinoma or intraepithelial neoplasia of the cervix or vulva diagnosed more than 5 years before (56% versus 0%; P=0.01). HPV-positive tumours were more frequently of non-keratinizing, basaloid or warty type than HPV-negative neoplasms (84% versus 14.3%; P<0.001), and showed diffuse positive immunoreactivity for p16(INK4a) (96%, versus 14.3%; P<0.001). The sensitivity and specificity of p16 to identify HPV-positive tumours were 96% and 85.7%, respectively.;A high number of SCCVs are related to HPV infection and may be identified by immunohistochemistry for p16. HPV-positive tumours tend to affect women with history of cervical neoplasia.",
        "Doc_title":"Primary squamous cell carcinoma of the vagina: human papillomavirus detection, p16(INK4A) overexpression and clinicopathological correlations.",
        "Journal":"Histopathology",
        "Do_id":"21166704",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Carcinoma, Squamous Cell;Cyclin-Dependent Kinase Inhibitor p16;Female;Humans;Immunohistochemistry;Middle Aged;Papillomaviridae;Papillomavirus Infections;Polymerase Chain Reaction;Sensitivity and Specificity;Vaginal Neoplasms",
        "Doc_meshqualifiers":"metabolism;pathology;virology;metabolism;genetics;metabolism;pathology;virology;metabolism;pathology;virology",
        "_version_":1605836355803283456},
      {
        "Doc_abstract":"Inactivation of the p16(INK4a) tumor suppressor protein is critical for the development of human cancers, including human melanoma. However, the molecular basis of the protein's inhibitory effect on cancer development is not clear. Here we investigated a possible mechanism for p16(INK4a) inhibition of neoplastic transformation and UV-induced skin cancer. We show that p16(INK4a) suppresses the activity of c-Jun N-terminal kinases (JNKs) and that it binds to the glycine-rich loop of the N-terminal domain of JNK3. Although p16(INK4a) does not affect the phosphorylation of JNKs, its interaction with JNK inhibits c-Jun phosphorylation induced by UV exposure. This, in turn, interferes with cell transformation promoted by the H-Ras-JNK-c-Jun-AP-1 signaling axis.",
        "Doc_title":"The tumor suppressor p16(INK4a) prevents cell transformation through inhibition of c-Jun phosphorylation and AP-1 activity.",
        "Journal":"Nature structural & molecular biology",
        "Do_id":"16007099",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;Transcription Factor AP-1;Glutathione Transferase;Mitogen-Activated Protein Kinase 10",
        "Doc_meshdescriptors":"Animals;Cell Line, Tumor;Cell Transformation, Neoplastic;Cyclin-Dependent Kinase Inhibitor p16;Fluorescent Antibody Technique;Genetic Vectors;Glutathione Transferase;Humans;Immunoblotting;Melanoma;Mice;Mitogen-Activated Protein Kinase 10;Models, Molecular;Phosphorylation;Protein Binding;Signal Transduction;Skin Neoplasms;Transcription Factor AP-1;Two-Hybrid System Techniques",
        "Doc_meshqualifiers":"metabolism;metabolism;metabolism;metabolism;physiology;metabolism;metabolism",
        "_version_":1605825687742054400},
      {
        "Doc_abstract":"Cushing's disease (CD) is usually caused by ACTH-secreting pituitary microadenomas, while silent corticotroph adenomas (SCA) are macroadenomas without Cushingoid features. However, the molecular mechanism(s) underlying their different tumor growth remains unknown. The aim of the current study was to evaluate and compare the gene expression profile of cell cycle regulators and cell growth-related transcription factors in CD, SCA, and non-functioning adenomas (NFA).;Tumor tissue specimens resected from 43 pituitary tumors were studied: CD (n=10), SCA (n=11), and NFA (n=22). The absolute transcript numbers of the following genes were quantified with real-time quantitative PCR assays: CDKN2A (or p16(INK4a)), cyclin family (A1, B1, D1, and E1), E2F1, RB1, BUB1, BUBR1, ETS1, and ETS2. Protein expressions of p16 and cyclin D1 were semi-quantitatively evaluated by immunohistochemical study.;CDKN2A gene expression was about fourfold greater in CD than in SCA and NFA. The gene expressions of cyclins D1, E1, and B1, but not of A1, in CD were significantly suppressed than those in NFA. Cyclin D1 gene expression positively correlated with cyclins B1 and E1. The gene expressions of E2F1, RB1, BUB1, BUBR1, ETS1, and ETS2 did not differ between each group. Positive immunostaining for p16 and negative immunostaining for cyclin D1 were more frequent in CD than in NFA; there were positive correlations between mRNA and protein expressions of p16 and cyclin D1. Thus, it is suggested that upregulated CDKN2A with the concomitant downregulated cyclin gene family is partly involved in the small size of ACTH-secreting adenoma.",
        "Doc_title":"Upregulation of CDKN2A and suppression of cyclin D1 gene expressions in ACTH-secreting pituitary adenomas.",
        "Journal":"European journal of endocrinology",
        "Do_id":"20616110",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;Cyclin D1",
        "Doc_meshdescriptors":"ACTH-Secreting Pituitary Adenoma;Cyclin D1;Cyclin-Dependent Kinase Inhibitor p16;Female;Gene Expression Regulation, Neoplastic;Humans;Immunohistochemistry;Male;Middle Aged;Pituitary ACTH Hypersecretion;Reverse Transcriptase Polymerase Chain Reaction",
        "Doc_meshqualifiers":"genetics;metabolism;genetics;metabolism;genetics;metabolism;genetics;physiology;genetics;metabolism",
        "_version_":1605818696555560961},
      {
        "Doc_abstract":"The relationships between the expression of cyclin B1, EBV-LMP1, P53 and P16(INK4A) in Chinese classical Hodgkin lymphoma are unknown and need exploring. Samples of classical Hodgkin lymphoma from 60 Chinese patients were analyzed for the expression of cyclin B1, EBV-LMP1, P53 and P16(INK4A) proteins by immunohistochemistry. Cyclin B1 protein was overexpressed in 90.0% (54/60) of this group of classical Hodgkin lymphoma, staining mainly and strongly in cytoplasm but also sparsely and weakly in nucleus of the Hodgkin and Reed-Sternberg (HRS) cells. EBV-LMP1, P53 and P16(INK4A) were overexpressed in 85.0%, 96.7% and 71.7% of Hodgkin lymphoma, respectively. EBV-LMP1, P53 and P16(INK4A) were was noted in the nucleus of HRS cells. Microscopically, cyclin B1 and P53 staining distinguished the HRS cells from the complex background of lymphocytes. Cyclin B1 was positively correlated with EBV-LMP1(P < 0.001) and P53(P < 0.001), but was inversely related to P16(INK4A) (P < 0.05). It is suggested that overexpression of cyclin B1 could play an important role in the evolution of classical Hodgkin lymphoma, and cyclin B1 may be considered as a potential adjunct marker to identify HRS cells in diagnosis and be served as Hodgkin lymphoma-associated antigen in the near future.",
        "Doc_title":"Aberrant cytoplasmic expression of cyclin B1 protein and its correlation with EBV-LMP1, P53 and P16(INK4A) in classical Hodgkin lymphoma in China.",
        "Journal":"Pathology oncology research : POR",
        "Do_id":"21174181",
        "Doc_ChemicalList":"Biomarkers, Tumor;CCNB1 protein, human;Cyclin B1;Cyclin-Dependent Kinase Inhibitor p16;EBV-associated membrane antigen, Epstein-Barr virus;TP53 protein, human;Tumor Suppressor Protein p53;Viral Matrix Proteins",
        "Doc_meshdescriptors":"Biomarkers, Tumor;China;Cyclin B1;Cyclin-Dependent Kinase Inhibitor p16;Cytoplasm;Female;Hodgkin Disease;Humans;Immunohistochemistry;Male;Tumor Suppressor Protein p53;Viral Matrix Proteins",
        "Doc_meshqualifiers":"analysis;biosynthesis;biosynthesis;metabolism;metabolism;virology;biosynthesis;biosynthesis",
        "_version_":1605795959173808128},
      {
        "Doc_abstract":"The interpretation of cervical biopsy specimens guides management of women with suspected cervical cancer precursors. However, morphologic evaluation is subjective and has low interobserver agreement. Addition of p16(INK4a) immunohistochemistry may improve interpretation.;We performed a systematic review and meta-analysis of published data on interobserver agreement of p16(INK4a) positivity using p16(INK4a) immunohistochemistry and of cervical intraepithelial neoplasia grade 2 (CIN2+) and CIN grade 3 (CIN3+) classification using H&E morphology in conjunction with p16(INK4a) in comparison with H&E morphology alone.;The literature search revealed five eligible articles. The results show strong agreement of pathologists' interpretation of cervical biopsy specimens as p16(INK4a) positive or negative (pooled  = 0.90; 95% confidence interval [CI], 0.88-0.92) and significantly higher agreement for a CIN2+ diagnosis with H&E morphology in conjunction with p16(INK4a) ( = 0.73; 95% CI, 0.67-0.79) compared with H&E morphology alone ( = 0.41; 95% CI, 0.17-0.65). Also, a slightly higher agreement for CIN3+ can be observed ( = 0.66; 95% CI, 0.39-0.94 for H&E morphology in conjunction with p16(INK4a) and  = 0.61; 95% CI, 0.44-0.78 for H&E morphology alone), but this difference was not statistically significant.;The published literature indicates improved interobserver agreement of the diagnosis of CIN2+ with the conjunctive use of H&E morphology with p16(INK4a) immunohistochemistry compared with H&E morphology alone.",
        "Doc_title":"p16INK4a immunohistochemistry in cervical biopsy specimens: A systematic review and meta-analysis of the interobserver agreement.",
        "Journal":"American journal of clinical pathology",
        "Do_id":"25389329",
        "Doc_ChemicalList":"Biomarkers, Tumor;Cyclin-Dependent Kinase Inhibitor p16",
        "Doc_meshdescriptors":"Biomarkers, Tumor;Cervical Intraepithelial Neoplasia;Cyclin-Dependent Kinase Inhibitor p16;Female;Humans;Immunohistochemistry;Observer Variation;Uterine Cervical Neoplasms",
        "Doc_meshqualifiers":"analysis;diagnosis;epidemiology;analysis;diagnosis;epidemiology",
        "_version_":1605839334693404672},
      {
        "Doc_abstract":"The ARF tumour suppressor protein (p14(ARF) in human and p19(ARF) in mouse) is a major mediator of the activation of p53 in response to oncogenic stress. Little is known about the signalling pathways connecting oncogenic stimuli to the activation of ARF. Regulation of ARF occurs primarily at the transcriptional level and several modulators of ARF transcription have been identified. Notably, ectopic expression of E2F1 upregulates ARF transcriptionally, and both E2F1 and ARF have been implicated in apoptosis and cell-cycle arrest. We have used primary mouse fibroblasts deficient for E2F1, E2F2, or both to determine the possible role of these E2F proteins as upstream regulators of ARF in response to oncogenic stimuli and other stresses. In particular, we have studied the effects of oncogenic Ras and the viral oncoprotein E1A on ARF levels, neoplastic transformation, and sensitization to apoptosis. We have also examined the behaviour of the E2F-deficient MEFs with respect to immortalization and sensitivity to DNA damage. None of the ARF-mediated responses that we have analysed is significantly affected in E2F1(-/-), E2F2(-/-) or E2F1/2(-/-) MEFs, and ARF is upregulated normally in all cases. Taken together, our results indicate that the activation of ARF in response to oncogenic stress can occur by E2F1- and E2F2-independent mechanisms. This challenges previous suggestions implicating E2F factors as key mediators in the activation of ARF by oncogenic stress.",
        "Doc_title":"Activation of ARF by oncogenic stress in mouse fibroblasts is independent of E2F1 and E2F2.",
        "Journal":"Oncogene",
        "Do_id":"12082524",
        "Doc_ChemicalList":"Adenovirus E1A Proteins;Cdkn2a protein, mouse;Cell Cycle Proteins;Cyclin-Dependent Kinase Inhibitor p16;DNA-Binding Proteins;E2F Transcription Factors;E2F1 Transcription Factor;E2F2 Transcription Factor;E2f1 protein, mouse;Transcription Factors;Tumor Suppressor Protein p14ARF;Oncogene Protein p21(ras)",
        "Doc_meshdescriptors":"Adenovirus E1A Proteins;Animals;Apoptosis;Cell Aging;Cell Cycle Proteins;Cell Transformation, Neoplastic;Cell Transformation, Viral;Cells, Cultured;Cyclin-Dependent Kinase Inhibitor p16;DNA Damage;DNA-Binding Proteins;E2F Transcription Factors;E2F1 Transcription Factor;E2F2 Transcription Factor;Fibroblasts;Gamma Rays;Genes, ras;Genetic Vectors;Genotype;Mice;Mice, Knockout;Mitosis;Oncogene Protein p21(ras);Transcription Factors;Tumor Suppressor Protein p14ARF",
        "Doc_meshqualifiers":"physiology;genetics;genetics;genetics;cytology;metabolism;cytology;metabolism;radiation effects;genetics;physiology;deficiency;physiology;metabolism",
        "_version_":1605797901816037376},
      {
        "Doc_abstract":"Glioblastomas (GBM) are highly radioresistant and lethal brain tumors. Ionizing radiation (IR)-induced DNA double-strand breaks (DSBs) are a risk factor for the development of GBM. In this study, we systematically examined the contribution of IR-induced DSBs to GBM development using transgenic mouse models harboring brain-targeted deletions of key tumor suppressors frequently lost in GBM, namely Ink4a, Ink4b, Arf and/or PTEN. Using low linear energy transfer (LET) X-rays to generate simple breaks or high LET HZE particles (Fe ions) to generate complex breaks, we found that DSBs induce high-grade gliomas in these mice which, otherwise, do not develop gliomas spontaneously. Loss of Ink4a and Arf was sufficient to trigger IR-induced glioma development but additional loss of Ink4b significantly increased tumor incidence. We analyzed IR-induced tumors for copy number alterations to identify oncogenic changes that were generated and selected for as a consequence of stochastic DSB events. We found Met amplification to be the most significant oncogenic event in these radiation-induced gliomas. Importantly, Met activation resulted in the expression of Sox2, a GBM cancer stem cell marker, and was obligatory for tumor formation. In sum, these results indicate that radiation-induced DSBs cooperate with loss of Ink4 and Arf tumor suppressors to generate high-grade gliomas that are commonly driven by Met amplification and activation. ",
        "Doc_title":"DNA double-strand breaks cooperate with loss of Ink4 and Arf tumor suppressors to generate glioblastomas with frequent Met amplification.",
        "Journal":"Oncogene",
        "Do_id":"24632607",
        "Doc_ChemicalList":"Cdkn2a protein, mouse;Cyclin-Dependent Kinase Inhibitor p15;Cyclin-Dependent Kinase Inhibitor p16;Proto-Oncogene Proteins c-met",
        "Doc_meshdescriptors":"Animals;Brain Neoplasms;Cyclin-Dependent Kinase Inhibitor p15;Cyclin-Dependent Kinase Inhibitor p16;DNA Breaks, Double-Stranded;Gene Amplification;Gene Deletion;Glioblastoma;Mice;Mice, Inbred C57BL;Mice, Knockout;Mice, Nude;Proto-Oncogene Proteins c-met;Radiation, Ionizing",
        "Doc_meshqualifiers":"genetics;genetics;genetics;radiation effects;genetics;genetics",
        "_version_":1605746378166763521},
      {
        "Doc_abstract":"Trop2, an oncogenic cell surface protein under investigation as a therapeutic target, is commonly overexpressed in several epithelial tumor types yet its function in tumor biology remains relatively unexplored. To investigate the role of Trop2 in epithelial carcinogenesis, we generated Trop2(-/-) mice, which are viable and possess a normal lifespan. Contrary to expectations, Trop2 loss fails to suppress keratinocyte transformation. Instead, ras-transformed Trop2(-/-) keratinocytes preferentially pass through an epithelial to mesenchymal transition (EMT) and form tumors with spindle cell histology. Furthermore, Trop2 loss renders Arf-null mice susceptible to the formation of biphasic sarcomatoid carcinomas containing both squamous and spindle cell components upon carcinogen exposure in an otherwise skin cancer-resistant strain (C57BL/6). Immortalized keratinocytes derived from Trop2(-/-)Arf(-/-) mice exhibit enhanced proliferative and migratory capacity as well as increased activation of mitogen-activated protein kinase and Src prior to transformation. The clinical relevance of these findings was supported by studying the molecular epidemiology of Trop2 in primary head and neck squamous cell carcinomas. This analysis revealed that Trop2 mRNA levels are decreased in a subset of tumors with features of EMT, and total loss of Trop2 protein expression is observed in the spindle cell component of sarcomatoid carcinomas. Therefore, while previous studies have emphasized the potential importance of Trop2 gain of function, these results uncover a role for Trop2 loss in tumorigenesis and the mesenchymal transdifferentiation observed in a subset of squamous cell carcinomas.",
        "Doc_title":"Loss of Trop2 promotes carcinogenesis and features of epithelial to mesenchymal transition in squamous cell carcinoma.",
        "Journal":"Molecular cancer research : MCR",
        "Do_id":"21970857",
        "Doc_ChemicalList":"12-O-tetradecanoylphorbol-1,3-acetate;Antigens, Neoplasm;Cell Adhesion Molecules;TROP2 protein, mouse;9,10-Dimethyl-1,2-benzanthracene;Tetradecanoylphorbol Acetate",
        "Doc_meshdescriptors":"9,10-Dimethyl-1,2-benzanthracene;Animals;Antigens, Neoplasm;Carcinoma, Squamous Cell;Cell Adhesion Molecules;Cell Dedifferentiation;Cell Line, Tumor;Cell Transformation, Neoplastic;Epithelial-Mesenchymal Transition;Female;Gene Expression Regulation, Neoplastic;Keratinocytes;Male;Mice;Mice, Inbred C57BL;Mice, Knockout;Skin Neoplasms;Tetradecanoylphorbol Acetate",
        "Doc_meshqualifiers":"chemistry;genetics;metabolism;genetics;metabolism;genetics;metabolism;genetics;metabolism;genetics;cytology;metabolism;chemically induced;metabolism;pathology;analogs & derivatives;chemistry",
        "_version_":1605883857279647744},
      {
        "Doc_abstract":"Aberrant p16((INK4a)) promoter methylation is common in colorectal cancer (CRC), but its clinicopathological significance remains controversial. The present study was therefore conducted to analyze p16((INK4a)) methylation and its relationship to clinicopathological features, mRNA levels and immunoreactivity in a series of lesions.;p16((INK4a)) methylation was assessed for normal mucosa (n = 30) and CRC samples (n = 212) by methylation-specific real-time quantitative PCR, and p16((INK4a)) expression by immunostaining in formalin-fixed paraffin-embedded specimens. In addition, fresh DNA (n = 61) was analyzed for relationships to p16((INK4a)) mRNA by reverse-transcription PCR.;The p16((INK4a)) methylation index of normal mucosa samples ranged from 0 to 2% (mean, 0.23%; median, 0.02%), while the values for tumor samples varied widely from 0 to 100% (mean, 25.7%; median, 7.1%), the difference being statistically significant (P < 0.001). Of 151 paraffin-embedded CRC tissue samples, 51 (34%), 54 (36%), and 46 (30%) were classified as low, intermediate, and high for aberrant methylation of p16((INK4a)). High p16((INK4a)) methylation was significantly associated with large tumor size (P = 0.025). Patients with higher methylation further showed more frequent recurrence as compared with the low-methylation group, and shortened cancer-related survival (Hazard ratio [HR], 3.379; P < 0.001) and recurrence-free survival (HR, 3.962; P < 0.001 on multivariate analysis). A significant inverse relationship was apparent between the p16((INK4a)) methylation and immunoreactivity (P = 0.017). A similar tendency was also observed for the methylation status and the mRNA level (P = 0.195).;We conclude that p16((INK4a)) methylation results in transcriptional silencing and defines a group of CRCs with a poor prognosis.",
        "Doc_title":"Aberrant p16((INK4a)) methylation is a frequent event in colorectal cancers: prognostic value and relation to mRNA expression and immunoreactivity.",
        "Journal":"Journal of cancer research and clinical oncology",
        "Do_id":"19779933",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Chemotherapy, Adjuvant;Colorectal Neoplasms;Cyclin-Dependent Kinase Inhibitor p16;DNA Methylation;Disease-Free Survival;Female;Humans;Immunohistochemistry;Male;Middle Aged;Multivariate Analysis;Neoplasm Staging;Odds Ratio;Polymerase Chain Reaction;Predictive Value of Tests;Prognosis;Promoter Regions, Genetic;Reverse Transcriptase Polymerase Chain Reaction",
        "Doc_meshqualifiers":"genetics;pathology;therapy;genetics;methods",
        "_version_":1605877065293234176},
      {
        "Doc_abstract":"Although malignant astrocytomas are a leading cause of cancer-related death in children, rational therapeutic strategies are lacking. We previously identified activating mutations of v-raf murine sarcoma viral oncogene homolog B1 (BRAF) (BRAF(T1799A) encoding BRAF(V600E)) in association with homozygous cyclin-dependent kinase inhibitor 2A (CDKN2A, encoding p14ARF and p16Ink4a) deletions in pediatric infiltrative astrocytomas. Here we report that BRAF(V600E) expression in neural progenitors (NPs) is insufficient for tumorigenesis and increases NP cellular differentiation as well as apoptosis. In contrast, astrocytomas are readily generated from NPs with additional Ink4a-Arf deletion. The BRAF(V600E) inhibitor PLX4720 significantly increased survival of mice after intracranial transplant of genetically relevant murine or human astrocytoma cells. Moreover, combination therapy using PLX4720 plus the Cyclin-dependent kinase (CDK) 4/6-specific inhibitor PD0332991 further extended survival relative to either monotherapy. Our findings indicate a rational therapeutic strategy for treating a subset of pediatric astrocytomas with BRAF(V600E) mutation and CDKN2A deficiency.",
        "Doc_title":"Cooperative interactions of BRAFV600E kinase and CDKN2A locus deficiency in pediatric malignant astrocytoma as a basis for rational therapy.",
        "Journal":"Proceedings of the National Academy of Sciences of the United States of America",
        "Do_id":"22586120",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;Indoles;PLX 4720;Piperazines;Pyridines;Sulfonamides;Braf protein, mouse;Proto-Oncogene Proteins B-raf;Extracellular Signal-Regulated MAP Kinases;palbociclib",
        "Doc_meshdescriptors":"Animals;Apoptosis;Astrocytoma;Blotting, Western;Cell Differentiation;Cell Line, Tumor;Cell Proliferation;Cells, Cultured;Child;Cyclin-Dependent Kinase Inhibitor p16;Extracellular Signal-Regulated MAP Kinases;Female;Humans;Immunohistochemistry;Indoles;Mice;Mice, Inbred BALB C;Mice, Knockout;Mice, Nude;Mice, SCID;Neural Stem Cells;Phosphorylation;Piperazines;Proto-Oncogene Proteins B-raf;Pyridines;Sulfonamides;Xenograft Model Antitumor Assays",
        "Doc_meshqualifiers":"drug effects;drug therapy;genetics;pathology;drug effects;drug effects;antagonists & inhibitors;genetics;metabolism;metabolism;pharmacology;cytology;drug effects;metabolism;drug effects;pharmacology;antagonists & inhibitors;genetics;metabolism;pharmacology;pharmacology",
        "_version_":1605837550186921984},
      {
        "Doc_abstract":"Oral papillary squamous cell carcinoma (OPSCC) is a histologic variant of SCC with a growth pattern suggesting human papillomavirus (HPV) infection. The aim of this study was to investigate the presence of HPV genotypes in OPSCC.;All cases with a histologic diagnosis of OPSCC from 1993 through 2008 were retrieved and confirmed. Immunohistochemical evaluation for the surrogate marker p16(INK4A) and HPV polymerase chain reaction were performed in tissue and DNA derived from formalin-fixed paraffin-embedded tissue.;Forty-four patients with confirmed OPSCC (mean age, 71.96 yr; female-to-male ratio, 1.75:1) comprised the study population. The most common site of involvement was the gingiva followed by the palate and buccal mucosa. Forty cases exhibited an invasive component, 1 was noninvasive, and in 3 cases invasion could not be confirmed owing to suboptimal thickness of the biopsy. Paraffin tissue blocks were available in 41 cases. Twenty-three cases (56.1%) exhibited positive p16(INK4A) staining, which was primarily weak to moderate with a generally focal pattern. Polymerase chain reaction assays were negative for HPV DNA in all cases.;In this study, there was a clinical predilection of OPSCC in older women, with most cases occurring in the masticatory mucosa. Weak to moderate and focal p16(INK4A) staining was appreciated in contrast to reported staining properties in genital and oropharyngeal PSCC. Failure of the polymerase chain reaction assay to exhibit transcriptionally active HPV genotypes suggests that HPV is not associated with OPSCC tumorigenesis.",
        "Doc_title":"Comparison between p16 INK4A immunohistochemistry and human papillomavirus polymerase chain reaction assay in oral papillary squamous cell carcinoma.",
        "Journal":"Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons",
        "Do_id":"23706276",
        "Doc_ChemicalList":"Biomarkers, Tumor;Cyclin-Dependent Kinase Inhibitor p16;DNA, Viral",
        "Doc_meshdescriptors":"Aged;Alphapapillomavirus;Biomarkers, Tumor;Carcinoma, Squamous Cell;Cyclin-Dependent Kinase Inhibitor p16;DNA, Viral;Female;Genotype;Gingival Neoplasms;Humans;Immunohistochemistry;Male;Mandibular Neoplasms;Maxillary Neoplasms;Mouth Neoplasms;Palatal Neoplasms;Papillomavirus Infections;Polymerase Chain Reaction",
        "Doc_meshqualifiers":"genetics;isolation & purification;analysis;virology;analysis;analysis;virology;virology;virology;virology;virology;diagnosis",
        "_version_":1605874230148202496},
      {
        "Doc_abstract":"To study the expressions of Cyclin D1 and p16 proteins in hypopharyngeal squamous cell carcinoma and their clinical significance.;Immunohistochemical technology (P-V) was applied to detect the expression of Cyclin D1 and p16 in 36 cases of hypopharyngeal squamous cell carcinoma and 10 cases of normal epithelium.;(1) The expression of cyclin D1 in the tumorous cell was significantly higher than that in normal epithelium (P < 0.05). The expression of p16 in the tumorous cell was significantly lower than that in normal epithelium (P < 0.05); (2) The positive rate of Cyclin D1 was significantly correlated with clinical stage and cervical lymph node metastases (P < 0.05). The positive rate of p16 was correlated with cervical lymph node metastases (P < 0.05). The positive rates of Cyclin D1 and p16 were not correlated with the gender, age, tumor size, primary lesion and cell differentiation (P > 0.05); (3) There was correlation between the expression of Cyclin D1 and the expression of p16 (r(s) = -0.420, P < 0.05).;The over-expression of Cyclin D1 and the under-expression of p16 may play a significant role in the occurrence incidence and development of hypopharyngeal squamous cell carcinoma, and may be important indicators for cervical lymph node metastases.",
        "Doc_title":"[Expressions of cyclin D1 and p16 in hypopharyngeal squamous cell carcinoma and their clinical significance].",
        "Journal":"Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of clinical otorhinolaryngology, head, and neck surgery",
        "Do_id":"17634024",
        "Doc_ChemicalList":"CCND1 protein, human;Cyclin-Dependent Kinase Inhibitor p16;Cyclin D1",
        "Doc_meshdescriptors":"Adult;Aged;Carcinoma, Squamous Cell;Case-Control Studies;Cyclin D1;Cyclin-Dependent Kinase Inhibitor p16;Female;Humans;Hypopharyngeal Neoplasms;Lymphatic Metastasis;Male;Middle Aged;Prognosis",
        "Doc_meshqualifiers":"metabolism;pathology;metabolism;metabolism;metabolism;pathology",
        "_version_":1605910808088281088},
      {
        "Doc_abstract":"Cellular senescence has been proposed to be an in vitro and in vivo block that cells must overcome in order to immortalize and become tumorigenic. To characterize these pathways, we focused on changes in the cyclin-dependent kinase inhibitors and their binding partners that underlie the cell cycle arrest at senescence. As a model, we utilized normal human prostate epithelial cell (HPEC) and human uroepithelial cell (HUC) cultures. After 30-40 population doublings cells became growth-arrested in G0/1 with a threefold decrease in Cdk2-associated activity, a point defined as pre-senescence. Temporally following this growth arrest, the cells develop a senescence morphology and express senescence-associated beta-galactosidase (SA-beta-gal). Levels of p16(INK4a) and p57(KIP2) rise in HUCs during progressive passages, whereas only p16 increases in HPEC cultures. The induced expression of p57, similar to p16, produces a senescent-like phenotype. pRB, cyclin D, p19(INK4d) and p27(KIP1) decrease in both cell types. We find that p53, p21(CIP1) and p15(INK4b) are transiently elevated in HPECs and HUCs at the pre-senescent growth arrest, then return to low proliferating levels at terminal senescence. Analysis of p53, p21(CIP1), p15(INK4b), p16(INK4a), and p57(KIP2) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells. These results indicate: (i) the existence of a subset of growth inhibiting genes elevated at the onset of the senescence, (ii) a distinct class of genes involved in the maintenance of senescence, and (iii) the frequent inactivation of these pathways during immortalization.",
        "Doc_title":"Role of cyclin-dependent kinase inhibitors in the growth arrest at senescence in human prostate epithelial and uroepithelial cells.",
        "Journal":"Oncogene",
        "Do_id":"11781834",
        "Doc_ChemicalList":"CDKN1C protein, human;Cell Cycle Proteins;Cyclin-Dependent Kinase Inhibitor p57;Nuclear Proteins;Protein-Serine-Threonine Kinases;CDC2-CDC28 Kinases;CDK2 protein, human;Cyclin-Dependent Kinase 2;Cyclin-Dependent Kinases;beta-Galactosidase",
        "Doc_meshdescriptors":"Adult;Blotting, Western;CDC2-CDC28 Kinases;Cell Aging;Cell Cycle;Cell Cycle Proteins;Cell Division;Cell Line, Transformed;Cell Transformation, Viral;Cells, Cultured;Cyclin-Dependent Kinase 2;Cyclin-Dependent Kinase Inhibitor p57;Cyclin-Dependent Kinases;Epithelial Cells;Humans;Male;Middle Aged;Nuclear Proteins;Prostate;Prostatic Neoplasms;Protein-Serine-Threonine Kinases;Transfection;Tumor Cells, Cultured;Urinary Tract;beta-Galactosidase",
        "Doc_meshqualifiers":"physiology;antagonists & inhibitors;cytology;enzymology;metabolism;genetics;physiology;cytology;enzymology;metabolism;etiology;metabolism;pathology;antagonists & inhibitors;cytology;enzymology;metabolism;metabolism",
        "_version_":1605880639234506752},
      {
        "Doc_abstract":"We recently reported an interaction between the p14(ARF) protein and human topoisomerase I (Topo I) resulting in the stimulation of the relaxation activity of Topo I. Our data showed that the complex between the two proteins was located within the nucleolus. In the present work, we have investigated the regions of p14(ARF) involved in this interaction by using targeted point mutagenesis and deletion mutants. A region encompassing exon 2-encoded sequence was required for physical binding of p14(ARF) to Topo I as well as for stimulatory activity of the enzyme. Exon 1 beta-encoded segment was not implicated in the interaction. Moreover, among p14(ARF) point mutants selected for their high conservation among different mammalian species, mutant p14(ARF) (RR87, 88AA) did not stimulate Topo I in spite of its association with the enzyme, suggesting its direct implication in the functional activity of ARF. In contrast, one mutant, p14(ARF) (R71A), was more efficient than wild-type protein to activate Topo I, suggesting that this residue is a key element to modulate Topo I activity. Finally, only ARF-Topo I complexes containing p14(ARF) exon 2 segment were found to be localized in the nucleolus, suggesting that this subnuclear location is linked to the biological function of the ARF-Topo I complex.",
        "Doc_title":"Delineation of the domains required for physical and functional interaction of p14ARF with human topoisomerase I.",
        "Journal":"Oncogene",
        "Do_id":"12673200",
        "Doc_ChemicalList":"Tumor Suppressor Protein p14ARF;DNA Topoisomerases, Type I",
        "Doc_meshdescriptors":"Amino Acid Sequence;Amino Acid Substitution;Animals;Bone Neoplasms;Cell Nucleolus;Cells, Cultured;DNA Topoisomerases, Type I;Enzyme Activation;Genes, p16;Humans;Molecular Sequence Data;Mutation, Missense;Osteosarcoma;Point Mutation;Protein Binding;Protein Interaction Mapping;Protein Structure, Tertiary;Sequence Alignment;Sequence Deletion;Sequence Homology, Amino Acid;Species Specificity;Spodoptera;Structure-Activity Relationship;Transfection;Tumor Cells, Cultured;Tumor Suppressor Protein p14ARF",
        "Doc_meshqualifiers":"pathology;metabolism;chemistry;metabolism;pathology;cytology;chemistry;metabolism",
        "_version_":1605741969524391936},
      {
        "Doc_abstract":"CUDC-101 is a small molecule that simultaneously inhibits the epidermal growth factor receptor (EGFR), human growth factor receptor 2 (HER2), and histone deacetylase (HDAC) with preclinical activity in head and neck squamous cell cancer (HNSCC). The primary objective of this investigation is to determine the maximum tolerated dose (MTD) of CUDC-101 with cisplatin-radiotherapy in the treatment of HNSCC.;CUDC-101 monotherapy was administered intravenously three times weekly (Monday, Wednesday, Friday) for a one-week run-in, then continued with concurrent cisplatin (100 mg/m(2) every 3 weeks) and external beam radiation (70 Gy to gross disease) over 7 weeks.;Twelve patients with intermediate or high-risk HNSCC enrolled. Eleven were p16INKa (p16)-negative. The MTD of CUDC-101-based combination therapy was established at 275 mg/m(2)/dose. Five patients discontinued CUDC-101 due to an adverse event (AE); only one was considered a dose-limiting toxicity (DLT), at the MTD. Pharmacokinetic evaluation suggested low accumulation with this dosing regimen. HDAC inhibition was demonstrated by pharmacodynamic analyses in peripheral blood mononuclear cells (PBMC), tumor biopsies, and paired skin biopsies. Paired tumor biopsies demonstrated a trend of EGFR inhibition. At 1.5 years of median follow-up, there has been one recurrence and two patient deaths (neither attributed to CUDC-101). The remaining nine patients are free of progression.;CUDC-101, cisplatin, and radiation were feasible in intermediate-/high-risk patients with HNSCC, with no unexpected patterns of AE. Although the MTD was identified, a high rate of DLT-independent discontinuation of CUDC-101 suggests a need for alternate schedules or routes of administration.",
        "Doc_title":"A Phase I Study of CUDC-101, a Multitarget Inhibitor of HDACs, EGFR, and HER2, in Combination with Chemoradiation in Patients with Head and Neck Squamous Cell Carcinoma.",
        "Journal":"Clinical cancer research : an official journal of the American Association for Cancer Research",
        "Do_id":"25573383",
        "Doc_ChemicalList":"7-(4-(3-ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide;Antineoplastic Agents;Hydroxamic Acids;Quinazolines;Receptor, Epidermal Growth Factor;Receptor, ErbB-2;Histone Deacetylases;Cisplatin",
        "Doc_meshdescriptors":"Aged;Antineoplastic Agents;Carcinoma, Squamous Cell;Chemoradiotherapy;Cisplatin;Female;Head and Neck Neoplasms;Histone Deacetylases;Humans;Hydroxamic Acids;Male;Maximum Tolerated Dose;Middle Aged;Quinazolines;Radiotherapy;Receptor, Epidermal Growth Factor;Receptor, ErbB-2",
        "Doc_meshqualifiers":"therapeutic use;therapy;methods;administration & dosage;therapy;drug effects;administration & dosage;adverse effects;administration & dosage;adverse effects;methods;antagonists & inhibitors;antagonists & inhibitors",
        "_version_":1605762343235485696},
      {
        "Doc_abstract":"To evaluate the impact of loss of heterozygosity (LOH) at chromosome 9p21 and P16(INK4A)(CDKN2A) expression on the prognosis of gastrointestinal stromal tumor (GIST).;A total of 51 cases with GISTs were characterized by immunohistochemistry and evaluated for LOH at 9p21 by microsatellite analysis in 4 markers(D9S1751, D9S1846, D9S942 and D9S1748). Associations of LOH at 9p21 and P16(INK4A) expression encoded by CDKN2A with clinicopathological parameters and prognosis in GISTs were analyzed.;The frequency of 9p21 LOH was 37.0% (10/27) at D9S1751, 37.5%(12/32) at D9S1846, 42.1%(16/38) at D9S942 and 24.2%(8/33) at D9S1748. The overall frequency of LOH at 9p21 was 63.3%(31/49). In 21 samples of 51 GISTs(41.2%), P16 expression was not detected. Loss of P16 expression was 60%(12/20) in high risk group and 23.5%(4/17) in very low and low risk groups(P<0.05). The 5-year overall survival rate of p16-negative patients was 70.8%, while in P16-positive patients it was 92.0%(P<0.05).;LOH at 9p21 is a frequent event in GIST. Loss of CDKN2A gene at 9p21 may contribute to the progression and malignant transformation of GIST. P16 expression in GIST is associated with prognosis.",
        "Doc_title":"[Study of loss of heterozygosity at 9p21 and P16 expression in gastrointestinal stromal tumors].",
        "Journal":"Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery",
        "Do_id":"20972908",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Chromosomes, Human, Pair 9;Cyclin-Dependent Kinase Inhibitor p16;Female;Gastrointestinal Stromal Tumors;Genes, p16;Humans;Loss of Heterozygosity;Male;Microsatellite Repeats;Middle Aged",
        "Doc_meshqualifiers":"genetics;metabolism;genetics;metabolism;pathology",
        "_version_":1605905468351315968},
      {
        "Doc_abstract":"Numerical alterations of chromosome 9, the status of promoter methylation and protein expression of the CDKN2A gene (aliases include p16 and p16(INK4a)), the possible association with gain of chromosome X, and the interrelation of these findings with clinic and pathological characteristics were investigated in gastric adenocarcinomas. Fluorescence in situ hybridization analysis with centromeric DNA probes, immunohistochemical staining, and methylation-specific polymerase chain reaction assays were performed in 15 gastric adenocarcinomas samples from individuals from northern Brazil. Aneuploidies of chromosomes X and 9 were found in all samples, both intestinal and diffuse type. Monosomy of chromosome 9 and gain of a copy of chromosome X (in both sexes) were observed in 100% of cases. Hypermethylation frequency and protein expression of CDKN2A were also found in all cases analyzed. No association of genetic and epigenetic alterations with histological type, tumor aggressiveness, and invasion was found (P > 0.05), which may be attributable to small sample size. There was a high level of association between absence of p16 protein expression levels, CDKN2A gene promote hypermethylation, and chromosome 9 aneuploidy (100% of cases). Thus, in the present samples, the apparent mechanisms behind p16 silencing include loss of chromosome 9 and promoter region hypermethylation.",
        "Doc_title":"Interrelationships among chromosome aneuploidy, promoter hypermethylation, and protein expression of the CDKN2A gene in individuals from northern Brazil with gastric adenocarcinoma.",
        "Journal":"Cancer genetics and cytogenetics",
        "Do_id":"17981214",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16",
        "Doc_meshdescriptors":"Adenocarcinoma;Adult;Aged;Aneuploidy;Chromosomes, Human, Pair 9;Chromosomes, Human, X;Cyclin-Dependent Kinase Inhibitor p16;DNA Methylation;Female;Genes, p16;Humans;In Situ Hybridization, Fluorescence;Male;Middle Aged;Polymerase Chain Reaction;Promoter Regions, Genetic;Stomach Neoplasms",
        "Doc_meshqualifiers":"genetics;metabolism;pathology;genetics;metabolism;genetics;metabolism;pathology",
        "_version_":1605799472576593920},
      {
        "Doc_abstract":"Mutated ras genes are frequently found in human cancer. However, it has been shown that oncogenic ras inhibits growth of primary cells, through pathways involving p53 and the cell cycle inhibitors p16INK4a and p19ARF. We have analysed the effect of the ectopic expression of the three mammalian ras genes on the proliferation of K562 leukemia cells, which are deficient for p53, p16INK4a, p15INK4b and p19ARF genes. We have found that high expression levels of both wild-type and oncogenic H-, K- and N-ras inhibit the clonogenic growth of K562 cells. Induction of H-rasV12 expression in K562 transfectants retards growth and this effect is accompanied with an increase of p21WAF1 mRNA and protein levels. Furthermore, p21WAF1 promoter is activated potently by oncogenic ras and less pronounced by wild-type ras. This induction is p53-independent since a p21WAF1 promoter devoid of the p53 responsive elements is still activated by Ras. Finally, inhibition of p21WAF1 expression by an antisense construct partially overcomes the growth inhibitory action of oncogenic H-ras. Altogether, these results indicate that the antiproliferative effect of ras in myeloid leukemia cells is associated to the induction of p21WAF1 expression and suggest the existence of p19ARF and p16INK4a-independent pathways for ras-mediated growth inhibition.",
        "Doc_title":"H-, K- and N-Ras inhibit myeloid leukemia cell proliferation by a p21WAF1-dependent mechanism.",
        "Journal":"Oncogene",
        "Do_id":"10698496",
        "Doc_ChemicalList":"CDKN1A protein, human;Cdkn1a protein, mouse;Cyclin-Dependent Kinase Inhibitor p16;Cyclin-Dependent Kinase Inhibitor p21;Cyclins;Oligonucleotides, Antisense;Proteins;Recombinant Fusion Proteins;Tumor Suppressor Protein p14ARF;Tumor Suppressor Protein p53;HRAS protein, human;Proto-Oncogene Proteins p21(ras)",
        "Doc_meshdescriptors":"Acute Disease;Animals;Cell Differentiation;Cell Division;Cyclin-Dependent Kinase Inhibitor p16;Cyclin-Dependent Kinase Inhibitor p21;Cyclins;Gene Expression Regulation, Leukemic;Genes, p16;Genes, p53;Genes, ras;Humans;K562 Cells;Mice;Models, Genetic;Oligonucleotides, Antisense;Point Mutation;Promoter Regions, Genetic;Proteins;Proto-Oncogene Proteins p21(ras);Recombinant Fusion Proteins;Transfection;Tumor Stem Cell Assay;Tumor Suppressor Protein p14ARF;Tumor Suppressor Protein p53",
        "Doc_meshqualifiers":"physiology;physiology;cytology;metabolism;pharmacology;genetics;physiology;genetics;physiology;physiology;physiology",
        "_version_":1605765149656875008},
      {
        "Doc_abstract":"The G1 regulatory pathway involving p16, pRb and cdk4 in the cell cycle has been investigated in human chondrosarcoma. The protein expression of p16, pRb and cdk4 was analyzed by Western blot in cultured cells from eight chondrosarcomas and in two chondrosarcoma cell lines. Both cell lines and one other sample were negative for p16. Moreover, one of the cell lines was pRb-negative and showed a high expression of cdk4 as well. In the other cell line and in three other samples pRb of expected size were detected in addition to a shorter form of the protein. To further investigate the reasons for down-regulation of the p16 protein, the p16-coding gene CDKN2 was analyzed by polymerase chain reaction (PCR), methyl-specific PCR (MSP) and sequencing in all tumor samples as well as in corresponding tumor tissues from three of the samples. The p16-negative samples were all found to have homozygous deletion of CDKN2. Another sample showed partial gene methylation and a heterozygous position in codon 148 was detected in one sample. The same base substitution was also found in two of the tissue samples. Finally, cytogenetic analysis of the samples with homozygously deleted CDKN2 revealed multiple structural abnormalities in all three cases. In conclusion, the p16/pRb/cdk4 pathway may play an important role in the pathogenesis of some chondrosarcomas.",
        "Doc_title":"Alterations in the regulatory pathway involving p16, pRb and cdk4 in human chondrosarcoma.",
        "Journal":"Journal of orthopaedic research : official publication of the Orthopaedic Research Society",
        "Do_id":"11332612",
        "Doc_ChemicalList":"Cyclin-Dependent Kinase Inhibitor p16;Proto-Oncogene Proteins;Retinoblastoma Protein;CDK4 protein, human;Cyclin-Dependent Kinase 4;Cyclin-Dependent Kinases",
        "Doc_meshdescriptors":"Bone Neoplasms;Chondrosarcoma;Chromosome Aberrations;Cyclin-Dependent Kinase 4;Cyclin-Dependent Kinase Inhibitor p16;Cyclin-Dependent Kinases;Genes, p16;Humans;Proto-Oncogene Proteins;Retinoblastoma Protein;Tumor Cells, Cultured",
        "Doc_meshqualifiers":"chemistry;genetics;chemistry;genetics;analysis;analysis;analysis",
        "_version_":1605826783902433280},
      {
        "Doc_abstract":"p15(INK4b) and p16(INK4a) proteins are cell cycle regulators involved in the inhibition of G1 phase progression. High frequency of methylation of both genes has been reported in multiple myeloma (MM), but it remains to be determined how and when these alterations contribute to tumorigenesis. Monoclonal gammopathy of undetermined significance (MGUS) represents an early disease stage in a fraction of MMs. Plasma cells from 33 patients with MGUS and 33 patients with MM were isolated and analyzed for p15(INK4b) and p16(INK4a) methylation by methylation-specific polymerase chain reaction. Selective methylation was found in 19% for p16(INK4a), 36% for p15(INK4b), and 6.5% for both genes in MGUS, and frequencies were similar in MM suggesting that methylation of these genes is an early event, not associated with transition from MGUS to MM. p15(INK4b) and p16(INK4a) gene methylation might contribute to immortalization of plasma cells rather than malignant transformation in the natural history of MM.",
        "Doc_title":"p16(INK4a) and p15(INK4b) gene methylations in plasma cells from monoclonal gammopathy of undetermined significance.",
        "Journal":"Blood",
        "Do_id":"11418489",
        "Doc_ChemicalList":"CDKN2B protein, human;Carrier Proteins;Cell Cycle Proteins;Cyclin-Dependent Kinase Inhibitor p15;Cyclin-Dependent Kinase Inhibitor p16;Tumor Suppressor Proteins",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Bone Marrow Cells;Carrier Proteins;Cell Cycle Proteins;Cyclin-Dependent Kinase Inhibitor p15;Cyclin-Dependent Kinase Inhibitor p16;DNA Methylation;Female;Humans;Male;Middle Aged;Multiple Myeloma;Paraproteinemias;Plasma Cells;Tumor Suppressor Proteins",
        "Doc_meshqualifiers":"metabolism;pathology;genetics;genetics;genetics;pathology;genetics;pathology;metabolism;pathology",
        "_version_":1605908244919746560},
      {
        "Doc_abstract":"The tumor suppressor gene p16INK4A is a cyclin-dependent kinase inhibitor (CDKI) and an important cell cycle regulator. We have previously constructed a recombinant adenovirus which expresses p16 (Adp16) and shown that infection in a variety of human tumor cell lines with this recombinant virus results in high levels of p16INK4A protein expression resulting in cell cycle arrest and loss of cyclin-cdk activity. Furthermore, adenoviral-mediated overexpression of wild-type p16INK4A is more toxic in cancer cells which express mutant forms of p16INK4A compared to cancer cell lines containing endogenous wild-type p16. TUNEL assay and DAPI staining following infection of MDA-MB 231 breast cancer cells with Adp16 indicate that p16INK4A-mediated cytotoxicity was associated with apoptosis. This is supported by studies demonstrating a decrease in cpp32 and cyclinB1 protein levels and induction of poly (ADP-ribose) polymerase (PARP) cleavage following infection of MDA-MB-231 cells with Adp16. These results suggest that gene therapy using Adp16 may be a promising treatment option for human cancers containing alterations in p16 expression.",
        "Doc_title":"Induction of apoptosis in p16INK4A mutant cell lines by adenovirus-mediated overexpression of p16INK4A protein.",
        "Journal":"Cell death and differentiation",
        "Do_id":"10918444",
        "Doc_ChemicalList":"Carrier Proteins;Cyclin-Dependent Kinase Inhibitor p16;Poly(ADP-ribose) Polymerases;CASP3 protein, human;Caspase 3;Caspases",
        "Doc_meshdescriptors":"Adenoviridae;Apoptosis;Carrier Proteins;Caspase 3;Caspases;Cell Line;Cyclin-Dependent Kinase Inhibitor p16;Gene Expression;Genetic Vectors;Humans;Mutagenesis;Poly(ADP-ribose) Polymerases;Tumor Cells, Cultured",
        "Doc_meshqualifiers":"biosynthesis;genetics;metabolism;metabolism",
        "_version_":1605903429228560384}]
  }}
